{"doc_key": "23846525", "sentences": [["Acute", "hepatitis", "associated", "with", "clopidogrel", ":", "a", "case", "report", "and", "review", "of", "the", "literature", ".", "Drug", "-", "induced", "hepatotoxicity", "is", "a", "common", "cause", "of", "acute", "hepatitis", ",", "and", "the", "recognition", "of", "the", "responsible", "drug", "may", "be", "difficult", ".", "We", "describe", "a", "case", "of", "clopidogrel", "-", "related", "acute", "hepatitis", ".", "The", "diagnosis", "is", "strongly", "suggested", "by", "an", "accurate", "medical", "history", "and", "liver", "biopsy", ".", "Reports", "about", "cases", "of", "hepatotoxicity", "due", "to", "clopidogrel", "are", "increasing", "in", "the", "last", "few", "years", ",", "after", "the", "increased", "use", "of", "this", "drug", ".", "In", "conclusion", ",", "we", "believe", "that", "physicians", "should", "carefully", "consider", "the", "risk", "of", "drug", "-", "induced", "hepatic", "injury", "when", "clopidogrel", "is", "prescribed", "."]], "ner": [[[4, 4, "Chemical"], [43, 43, "Chemical"], [70, 70, "Chemical"], [106, 106, "Chemical"], [1, 1, "Disease"], [18, 18, "Disease"], [25, 25, "Disease"], [47, 47, "Disease"], [67, 67, "Disease"], [103, 104, "Disease"]]], "relations": [[[4, 4, 1, 1, "CID"], [4, 4, 18, 18, "CID"], [4, 4, 25, 25, "CID"], [4, 4, 47, 47, "CID"], [4, 4, 67, 67, "CID"], [4, 4, 103, 104, "CID"], [43, 43, 1, 1, "CID"], [43, 43, 18, 18, "CID"], [43, 43, 25, 25, "CID"], [43, 43, 47, 47, "CID"], [43, 43, 67, 67, "CID"], [43, 43, 103, 104, "CID"], [70, 70, 1, 1, "CID"], [70, 70, 18, 18, "CID"], [70, 70, 25, 25, "CID"], [70, 70, 47, 47, "CID"], [70, 70, 67, 67, "CID"], [70, 70, 103, 104, "CID"], [106, 106, 1, 1, "CID"], [106, 106, 18, 18, "CID"], [106, 106, 25, 25, "CID"], [106, 106, 47, 47, "CID"], [106, 106, 67, 67, "CID"], [106, 106, 103, 104, "CID"]]], "clusters": [], "translated": "与<0>氯吡格雷</0>相关的急性<4>肝炎</4>：病例报告及文献复习。药物引起的<5>肝毒性</5>是急性<6>肝炎</6>的常见原因，可能难以识别责任药物。我们描述了一例与<1>氯吡格雷</1>相关的急性<7>肝炎</7>。准确的病史和肝活检强烈提示该诊断。在过去几年中，随着使用<2>氯吡格雷</2>的增加，关于<8>肝毒性</8>的病例报告也越来越多。总之，我们认为医生在处方<3>氯吡格雷</3>时应仔细考虑药物引起的<9>肝损伤</9>的风险。", "revised": true}
{"doc_key": "439781", "sentences": [["Indomethacin", "induced", "hypotension", "in", "sodium", "and", "volume", "depleted", "rats", ".", "After", "a", "single", "oral", "dose", "of", "4", "mg", "/", "kg", "indomethacin", "(", "IDM", ")", "to", "sodium", "and", "volume", "depleted", "rats", "plasma", "renin", "activity", "(", "PRA", ")", "and", "systolic", "blood", "pressure", "fell", "significantly", "within", "four", "hours", ".", "In", "sodium", "repleted", "animals", "indomethacin", "did", "not", "change", "systolic", "blood", "pressure", "(", "BP", ")", "although", "plasma", "renin", "activity", "was", "decreased", ".", "Thus", ",", "indomethacin", "by", "inhibition", "of", "prostaglandin", "synthesis", "may", "diminish", "the", "blood", "pressure", "maintaining", "effect", "of", "the", "stimulated", "renin", "-", "angiotensin", "system", "in", "sodium", "and", "volume", "depletion", "."]], "ner": [[[0, 0, "Chemical"], [20, 20, "Chemical"], [22, 22, "Chemical"], [50, 50, "Chemical"], [69, 69, "Chemical"], [2, 2, "Disease"], [4, 4, "Chemical"], [25, 25, "Chemical"], [47, 47, "Chemical"], [90, 90, "Chemical"], [73, 73, "Chemical"], [87, 87, "Chemical"]]], "relations": [[[0, 0, 2, 2, "CID"], [20, 20, 2, 2, "CID"], [22, 22, 2, 2, "CID"], [50, 50, 2, 2, "CID"], [69, 69, 2, 2, "CID"]]], "clusters": [], "translated": "<0>吲哚美辛</0>在<6>钠</6>和容量耗竭的大鼠中诱导<5>低血压</5>。单次口服4mg/kg<1>吲哚美辛</1>（<2>IDM</2>）至<7>钠</7>和容量耗竭大鼠血浆肾素活性（PRA）和收缩压明显下降，在<8>钠</8>充盈动物中，<3>吲哚美辛</3>没有改变收缩压（BP）尽管血浆肾素活性降低。因此，<4>吲哚美辛</4>通过抑制<10>前列腺素</10>的合成可能降低<9>钠</9>和容量耗竭状态下刺激的肾素-<11>血管紧张素</11>系统的血压维持作用。", "revised": true}
{"doc_key": "22836123", "sentences": [["Late", "-", "onset", "scleroderma", "renal", "crisis", "induced", "by", "tacrolimus", "and", "prednisolone", ":", "a", "case", "report", ".", "Scleroderma", "renal", "crisis", "(", "SRC", ")", "is", "a", "rare", "complication", "of", "systemic", "sclerosis", "(", "SSc", ")", "but", "can", "be", "severe", "enough", "to", "require", "temporary", "or", "permanent", "renal", "replacement", "therapy", ".", "Moderate", "to", "high", "dose", "corticosteroid", "use", "is", "recognized", "as", "a", "major", "risk", "factor", "for", "SRC", ".", "Furthermore", ",", "there", "have", "been", "reports", "of", "thrombotic", "microangiopathy", "precipitated", "by", "cyclosporine", "in", "patients", "with", "SSc", ".", "In", "this", "article", ",", "we", "report", "a", "patient", "with", "SRC", "induced", "by", "tacrolimus", "and", "corticosteroids", ".", "The", "aim", "of", "this", "work", "is", "to", "call", "attention", "to", "the", "risk", "of", "tacrolimus", "use", "in", "patients", "with", "SSc", "."]], "ner": [[[8, 8, "Chemical"], [91, 91, "Chemical"], [108, 108, "Chemical"], [27, 28, "Disease"], [30, 30, "Disease"], [77, 77, "Disease"], [113, 113, "Disease"], [50, 50, "Chemical"], [93, 93, "Chemical"], [73, 73, "Chemical"], [69, 70, "Disease"], [3, 5, "Disease"], [16, 18, "Disease"], [20, 20, "Disease"], [60, 60, "Disease"], [88, 88, "Disease"], [10, 10, "Chemical"]]], "relations": [[[8, 8, 27, 28, "CID"], [8, 8, 30, 30, "CID"], [8, 8, 77, 77, "CID"], [8, 8, 113, 113, "CID"], [91, 91, 27, 28, "CID"], [91, 91, 30, 30, "CID"], [91, 91, 77, 77, "CID"], [91, 91, 113, 113, "CID"], [108, 108, 27, 28, "CID"], [108, 108, 30, 30, "CID"], [108, 108, 77, 77, "CID"], [108, 108, 113, 113, "CID"], [50, 50, 27, 28, "CID"], [50, 50, 30, 30, "CID"], [50, 50, 77, 77, "CID"], [50, 50, 113, 113, "CID"], [93, 93, 27, 28, "CID"], [93, 93, 30, 30, "CID"], [93, 93, 77, 77, "CID"], [93, 93, 113, 113, "CID"], [73, 73, 69, 70, "CID"]]], "clusters": [], "translated": "<0>他克莫司</0>和<16>泼尼松龙</16>诱发的迟发性<11>硬皮病肾危象</11>：病例报告。<12>硬皮病肾危象</12>（<13>SRC</13>）是<3>系统性硬化症</3>（<4>SSc</4>）的罕见并发症，但严重到足以需要临时或永久性肾脏替代治疗。中度至高剂量<7>皮质类固醇</7>的使用被认为是<14>SRC</14>的主要危险因素。此外，已有<5>SSc</5>患者<9>环孢素</9>诱发<10>血栓性微血管病</10>的报道。在这篇文章中，我们报告了<1>他克莫司</1>和<8>皮质类固醇</8>诱发的<15>SRC</15>患者。这项工作的目的是提醒人们注意<6>SSc</6>患者使用<2>他克莫司</2>的风险。", "revised": true}
{"doc_key": "8701013", "sentences": [["Famotidine", "-", "associated", "delirium", ".", "A", "series", "of", "six", "cases", ".", "Famotidine", "is", "a", "histamine", "H2", "-", "receptor", "antagonist", "used", "in", "inpatient", "settings", "for", "prevention", "of", "stress", "ulcers", "and", "is", "showing", "increasing", "popularity", "because", "of", "its", "low", "cost", ".", "Although", "all", "of", "the", "currently", "available", "H2", "-", "receptor", "antagonists", "have", "shown", "the", "propensity", "to", "cause", "delirium", ",", "only", "two", "previously", "reported", "cases", "have", "been", "associated", "with", "famotidine", ".", "The", "authors", "report", "on", "six", "cases", "of", "famotidine", "-", "associated", "delirium", "in", "hospitalized", "patients", "who", "cleared", "completely", "upon", "removal", "of", "famotidine", ".", "The", "pharmacokinetics", "of", "famotidine", "are", "reviewed", ",", "with", "no", "change", "in", "its", "metabolism", "in", "the", "elderly", "population", "seen", ".", "The", "implications", "of", "using", "famotidine", "in", "elderly", "persons", "are", "discussed", "."]], "ner": [[[0, 0, "Chemical"], [11, 11, "Chemical"], [66, 66, "Chemical"], [75, 75, "Chemical"], [88, 88, "Chemical"], [93, 93, "Chemical"], [113, 113, "Chemical"], [3, 3, "Disease"], [55, 55, "Disease"], [78, 78, "Disease"], [27, 27, "Disease"]]], "relations": [[[0, 0, 3, 3, "CID"], [0, 0, 55, 55, "CID"], [0, 0, 78, 78, "CID"], [11, 11, 3, 3, "CID"], [11, 11, 55, 55, "CID"], [11, 11, 78, 78, "CID"], [66, 66, 3, 3, "CID"], [66, 66, 55, 55, "CID"], [66, 66, 78, 78, "CID"], [75, 75, 3, 3, "CID"], [75, 75, 55, 55, "CID"], [75, 75, 78, 78, "CID"], [88, 88, 3, 3, "CID"], [88, 88, 55, 55, "CID"], [88, 88, 78, 78, "CID"], [93, 93, 3, 3, "CID"], [93, 93, 55, 55, "CID"], [93, 93, 78, 78, "CID"], [113, 113, 3, 3, "CID"], [113, 113, 55, 55, "CID"], [113, 113, 78, 78, "CID"]]], "clusters": [], "translated": " <0>法莫替丁</0> - 相关<7>谵妄</7>。一系列的六个案例。 <1>法莫替丁</1> 是一种组胺 H2 受体拮抗剂，用于住院患者预防应激性<10>溃疡</10>，并且由于成本低而越来越受欢迎。尽管目前可用的所有 H2-受体拮抗剂均显示出引起<8>谵妄</8>的倾向，但只有两例先前报道的病例与<2>法莫替丁</2>有关。作者报告了 6 例与<3>法莫替丁</3>相关的<9>谵妄</9>住院患者，这些患者在停用<4>法莫替丁</4>后完全消失。回顾了<5>法莫替丁</5>的药代动力学，未见其在老年人群中的代谢发生变化。讨论了在老年人中使用<6>法莫替丁</6>的意义。", "revised": true}
{"doc_key": "23535177", "sentences": [["Cerebellar", "sensory", "processing", "alterations", "impact", "motor", "cortical", "plasticity", "in", "Parkinson", "'s", "disease", ":", "clues", "from", "dyskinetic", "patients", ".", "The", "plasticity", "of", "primary", "motor", "cortex", "(", "M1", ")", "in", "patients", "with", "Parkinson", "'s", "disease", "(", "PD", ")", "and", "levodopa", "-", "induced", "dyskinesias", "(", "LIDs", ")", "is", "severely", "impaired", ".", "We", "recently", "reported", "in", "young", "healthy", "subjects", "that", "inhibitory", "cerebellar", "stimulation", "enhanced", "the", "sensorimotor", "plasticity", "of", "M1", "that", "was", "induced", "by", "paired", "associative", "stimulation", "(", "PAS", ")", ".", "This", "study", "demonstrates", "that", "the", "deficient", "sensorimotor", "M1", "plasticity", "in", "16", "patients", "with", "LIDs", "could", "be", "reinstated", "by", "a", "single", "session", "of", "real", "inhibitory", "cerebellar", "stimulation", "but", "not", "sham", "stimulation", ".", "This", "was", "evident", "only", "when", "a", "sensory", "component", "was", "involved", "in", "the", "induction", "of", "plasticity", ",", "indicating", "that", "cerebellar", "sensory", "processing", "function", "is", "involved", "in", "the", "resurgence", "of", "M1", "plasticity", ".", "The", "benefit", "of", "inhibitory", "cerebellar", "stimulation", "on", "LIDs", "is", "known", ".", "To", "explore", "whether", "this", "benefit", "is", "linked", "to", "the", "restoration", "of", "sensorimotor", "plasticity", "of", "M1", ",", "we", "conducted", "an", "additional", "study", "looking", "at", "changes", "in", "LIDs", "and", "PAS", "-", "induced", "plasticity", "after", "10", "sessions", "of", "either", "bilateral", ",", "real", "inhibitory", "cerebellar", "stimulation", "or", "sham", "stimulation", ".", "Only", "real", "and", "not", "sham", "stimulation", "had", "an", "antidyskinetic", "effect", "and", "it", "was", "paralleled", "by", "a", "resurgence", "in", "the", "sensorimotor", "plasticity", "of", "M1", ".", "These", "results", "suggest", "that", "alterations", "in", "cerebellar", "sensory", "processing", "function", ",", "occurring", "secondary", "to", "abnormal", "basal", "ganglia", "signals", "reaching", "it", ",", "may", "be", "an", "important", "element", "contributing", "to", "the", "maladaptive", "sensorimotor", "plasticity", "of", "M1", "and", "the", "emergence", "of", "abnormal", "involuntary", "movements", "."]], "ner": [[[37, 37, "Chemical"], [15, 15, "Disease"], [40, 40, "Disease"], [42, 42, "Disease"], [89, 89, "Disease"], [145, 145, "Disease"], [174, 174, "Disease"], [257, 259, "Disease"], [9, 11, "Disease"], [30, 32, "Disease"], [34, 34, "Disease"]]], "relations": [[[37, 37, 15, 15, "CID"], [37, 37, 40, 40, "CID"], [37, 37, 42, 42, "CID"], [37, 37, 89, 89, "CID"], [37, 37, 145, 145, "CID"], [37, 37, 174, 174, "CID"], [37, 37, 257, 259, "CID"]]], "clusters": [], "translated": "小脑感觉处理改变影响<8>帕金森病</8>的运动皮层可塑性：来自<1>运动障碍</1>患者的线索。 <9>帕金森病</9>（<10>PD</10>）和<0>左旋多巴</0>引起的<2>运动障碍</2>（<3>LIDs</3>）首发表现在初级运动皮层（M1）的可塑性上严重受损。我们最近在年轻的健康受试者中报告说，抑制性小脑刺激增强了配对联想刺激(PAS)诱导的M1的感觉运动可塑性。这项研究表明，<4>LIDs</4>患者的感觉运动M1可塑性缺陷可以通过单次真正的抑制性小脑刺激而不是假刺激恢复。只有在感觉诱导可塑性时才明显，表明小脑感觉处理功能参与了M1可塑性的复苏。抑制性小脑刺激对<5>LIDs</5>的效益已经被证实。为了展开这种效益是否与M1感觉运动可塑性的恢复有关，我们进行了一项研究来观察10次双侧、真正抑制性小脑刺激或假刺激后<LIDs>和PAS诱导的可塑性的变化。</LIDs>。只有真正刺激而非假刺激具有抗<6>运动障碍</6>的效果，并且与M1的感觉运动可塑性的复苏和解除病态运动并行。这些结果表明，小脑感觉处理功能的变化由于到达小脑的异常基底神经节信号可能是导致M1的适应不良感觉运动可塑性和<7>异常不自主运动</7>的重要因素。", "revised": true}
{"doc_key": "23871786", "sentences": [["Pubertal", "exposure", "to", "Bisphenol", "A", "increases", "anxiety", "-", "like", "behavior", "and", "decreases", "acetylcholinesterase", "activity", "of", "hippocampus", "in", "adult", "male", "mice", ".", "The", "negative", "effects", "of", "Bisphenol", "A", "(", "BPA", ")", "on", "neurodevelopment", "and", "behaviors", "have", "been", "well", "established", ".", "Acetylcholinesterase", "(", "AChE", ")", "is", "a", "regulatory", "enzyme", "which", "is", "involved", "in", "anxiety", "-", "like", "behavior", ".", "This", "study", "investigated", "behavioral", "phenotypes", "and", "AChE", "activity", "in", "male", "mice", "following", "BPA", "exposure", "during", "puberty", ".", "On", "postnatal", "day", "(", "PND", ")", "35", ",", "male", "mice", "were", "exposed", "to", "50mg", "BPA", "/", "kg", "diet", "per", "day", "for", "a", "period", "of", "35", "days", ".", "On", "PND71", ",", "a", "behavioral", "assay", "was", "performed", "using", "the", "elevated", "plus", "maze", "(", "EPM", ")", "and", "the", "light", "/", "dark", "test", ".", "In", "addition", ",", "AChE", "activity", "was", "measured", "in", "the", "prefrontal", "cortex", ",", "hypothalamus", ",", "cerebellum", "and", "hippocampus", ".", "Results", "from", "our", "behavioral", "phenotyping", "indicated", "that", "anxiety", "-", "like", "behavior", "was", "increased", "in", "mice", "exposed", "to", "BPA", ".", "AChE", "activity", "was", "significantly", "decreased", "in", "the", "hippocampus", "of", "mice", "with", "BPA", "compared", "to", "control", "mice", ",", "whereas", "no", "difference", "was", "found", "in", "the", "prefrontal", "cortex", ",", "hypothalamus", "and", "cerebellum", ".", "Our", "findings", "showed", "that", "pubertal", "BPA", "exposure", "increased", "anxiety", "-", "like", "behavior", ",", "which", "may", "be", "associated", "with", "decreased", "AChE", "activity", "of", "the", "hippocampus", "in", "adult", "male", "mice", ".", "Further", "studies", "are", "necessary", "to", "investigate", "the", "cholinergic", "signaling", "of", "the", "hippocampus", "in", "PBE", "induced", "anxiety", "-", "like", "behaviors", "."]], "ner": [[[3, 4, "Chemical"], [25, 26, "Chemical"], [28, 28, "Chemical"], [68, 68, "Chemical"], [87, 87, "Chemical"], [158, 158, "Chemical"], [171, 171, "Chemical"], [196, 196, "Chemical"], [6, 6, "Disease"], [51, 51, "Disease"], [148, 148, "Disease"], [199, 199, "Disease"], [235, 235, "Disease"]]], "relations": [[[3, 4, 6, 6, "CID"], [3, 4, 51, 51, "CID"], [3, 4, 148, 148, "CID"], [3, 4, 199, 199, "CID"], [3, 4, 235, 235, "CID"], [25, 26, 6, 6, "CID"], [25, 26, 51, 51, "CID"], [25, 26, 148, 148, "CID"], [25, 26, 199, 199, "CID"], [25, 26, 235, 235, "CID"], [28, 28, 6, 6, "CID"], [28, 28, 51, 51, "CID"], [28, 28, 148, 148, "CID"], [28, 28, 199, 199, "CID"], [28, 28, 235, 235, "CID"], [68, 68, 6, 6, "CID"], [68, 68, 51, 51, "CID"], [68, 68, 148, 148, "CID"], [68, 68, 199, 199, "CID"], [68, 68, 235, 235, "CID"], [87, 87, 6, 6, "CID"], [87, 87, 51, 51, "CID"], [87, 87, 148, 148, "CID"], [87, 87, 199, 199, "CID"], [87, 87, 235, 235, "CID"], [158, 158, 6, 6, "CID"], [158, 158, 51, 51, "CID"], [158, 158, 148, 148, "CID"], [158, 158, 199, 199, "CID"], [158, 158, 235, 235, "CID"], [171, 171, 6, 6, "CID"], [171, 171, 51, 51, "CID"], [171, 171, 148, 148, "CID"], [171, 171, 199, 199, "CID"], [171, 171, 235, 235, "CID"], [196, 196, 6, 6, "CID"], [196, 196, 51, 51, "CID"], [196, 196, 148, 148, "CID"], [196, 196, 199, 199, "CID"], [196, 196, 235, 235, "CID"]]], "clusters": [], "translated": "青春期接触<0>双酚A</0>会增加成年雄性小鼠的<8>焦虑</8>样行为并降低海马体的乙酰胆碱酯酶活性。<1>双酚A</1>(<2>BPA</2>)对神经发育和行为的负面影响已得到充分证实。乙酰胆碱酯酶(AChE)是一种参与<9>焦虑</9>样行为的调节酶。本研究调查了雄性小鼠在青春期接触<3>BPA</3>后的行为表型和AChE活性。在出生后第35天(PND)，雄性小鼠每天暴露于50mg<4>BPA</4>/kg饮食，持续35天。在PND71上，使用高架十字迷宫(EPM)和光/暗测试进行了行为分析。此外，还测量了前额皮质、下丘脑、小脑和海马体中的AChE活性。我们的行为表型分析结果表明，在暴露于<5>BPA</5>的小鼠中，<10>焦虑</10>样行为有所增加。与对照小鼠相比，<6>BPA</6>小鼠海马体中的AChE活性显着降低，而前额皮质、下丘脑和小脑则没有差异。我们的研究结果表明，青春期<7>BPA</7>暴露增加了<11>焦虑</11>样行为，这可能与成年雄性小鼠海马体AChE活性降低有关。需要进一步的研究来调查PBE诱导的<12>焦虑</12>样行为中海马体的胆碱能信号。", "revised": true}
{"doc_key": "24067251", "sentences": [["An", "investigation", "of", "the", "pattern", "of", "kidney", "injury", "in", "HIV", "-", "positive", "persons", "exposed", "to", "tenofovir", "disoproxil", "fumarate", ":", "an", "examination", "of", "a", "large", "population", "database", "(", "MHRA", "database", ")", ".", "The", "potential", "for", "tenofovir", "to", "cause", "a", "range", "of", "kidney", "syndromes", "has", "been", "established", "from", "mechanistic", "and", "randomised", "clinical", "trials", ".", "However", ",", "the", "exact", "pattern", "of", "kidney", "involvement", "is", "still", "uncertain", ".", "We", "undertook", "a", "descriptive", "analysis", "of", "Yellow", "Card", "records", "of", "407", "HIV", "-", "positive", "persons", "taking", "tenofovir", "disoproxil", "fumarate", "(", "TDF", ")", "as", "part", "of", "their", "antiretroviral", "therapy", "regimen", "and", "submitted", "to", "the", "Medicines", "and", "Healthcare", "Products", "Regulatory", "Agency", "(", "MHRA", ")", "with", "suspected", "kidney", "adverse", "effects", ".", "Reports", "that", "satisfy", "defined", "criteria", "were", "classified", "as", "acute", "kidney", "injury", ",", "kidney", "tubular", "dysfunction", "and", "Fanconi", "syndrome", ".", "Of", "the", "407", "Yellow", "Card", "records", "analysed", ",", "106", "satisfied", "criteria", "for", "TDF", "-", "related", "kidney", "disease", ",", "of", "which", "53", "(", "50", "%", ")", "had", "features", "of", "kidney", "tubular", "dysfunction", ",", "35", "(", "33", "%", ")", "were", "found", "to", "have", "features", "of", "glomerular", "dysfunction", "and", "18", "(", "17", "%", ")", "had", "Fanconi", "syndrome", ".", "The", "median", "TDF", "exposure", "was", "316", "days", "(", "interquartile", "range", "120", "-", "740", ")", ".", "The", "incidence", "of", "hospitalisation", "for", "TDF", "kidney", "adverse", "effects", "was", "high", ",", "particularly", "amongst", "patients", "with", "features", "of", "Fanconi", "syndrome", ".", "The", "pattern", "of", "kidney", "syndromes", "in", "this", "population", "series", "mirrors", "that", "reported", "in", "randomised", "clinical", "trials", ".", "Cessation", "of", "TDF", "was", "associated", "with", "complete", "restoration", "of", "kidney", "function", "in", "up", "half", "of", "the", "patients", "in", "this", "report", "."]], "ner": [[[15, 17, "Chemical"], [80, 82, "Chemical"], [84, 84, "Chemical"], [143, 143, "Chemical"], [188, 188, "Chemical"], [206, 206, "Chemical"], [241, 241, "Chemical"], [120, 122, "Disease"], [128, 129, "Disease"], [183, 184, "Disease"], [219, 220, "Disease"], [6, 7, "Disease"], [124, 126, "Disease"], [146, 147, "Disease"], [159, 161, "Disease"], [174, 175, "Disease"], [34, 34, "Chemical"]]], "relations": [[[15, 17, 120, 122, "CID"], [80, 82, 120, 122, "CID"], [84, 84, 120, 122, "CID"], [143, 143, 120, 122, "CID"], [188, 188, 120, 122, "CID"], [206, 206, 120, 122, "CID"], [241, 241, 120, 122, "CID"], [15, 17, 128, 129, "CID"], [15, 17, 183, 184, "CID"], [15, 17, 219, 220, "CID"], [80, 82, 128, 129, "CID"], [80, 82, 183, 184, "CID"], [80, 82, 219, 220, "CID"], [84, 84, 128, 129, "CID"], [84, 84, 183, 184, "CID"], [84, 84, 219, 220, "CID"], [143, 143, 128, 129, "CID"], [143, 143, 183, 184, "CID"], [143, 143, 219, 220, "CID"], [188, 188, 128, 129, "CID"], [188, 188, 183, 184, "CID"], [188, 188, 219, 220, "CID"], [206, 206, 128, 129, "CID"], [206, 206, 183, 184, "CID"], [206, 206, 219, 220, "CID"], [241, 241, 128, 129, "CID"], [241, 241, 183, 184, "CID"], [241, 241, 219, 220, "CID"]]], "clusters": [], "translated": "对暴露于 <0>富马酸替诺福韦二吡呋酯</0> 的 HIV 阳性者的 <11>肾损伤</11> 模式的调查：对大型人口数据库（MHRA 数据库）的检查。已确定<16>替诺福韦</16> 引起一系列肾脏综合征的潜在性，来自机械学和随机临床试验。然而，肾脏受累的确切模式仍不确定。我们对 407 名服用 <1>富马酸替诺福韦二吡呋酯</1>（<2>TDF</2>）的 HIV 阳性者的黄卡记录进行了描述性分析，并将其作为抗逆转录病毒治疗方案的一部分，并提交给了药物和保健产品监管机构（MHRA）怀疑对肾脏有不良影响。满足定义标准的报告被分类为<7>急性肾损伤</7>、<12>肾小管功能障碍</12>和<8>范可尼综合征</8>。在分析的 407 份黄卡记录中，106 份满足<3>TDF</3>相关<13>肾脏疾病</13>的标准，其中 53 份 (50%) 具有<14>肾小管功能障碍</14>的特征，发现35例（33%）具有<15>肾小球功能障碍</15>的特征，18例（17%）具有<9>范可尼综合征</9>。<4>TDF</4> 暴露的中位数为 316 天（四分位间距 120-740）。因 <5>TDF</5> 肾脏不良反应而住院的发生率很高，尤其是在具有<10>Fanconi综合征</10>特征的患者中。该人群系列中的肾脏综合征模式反映了随机临床试验中的报告。在本报告中，停止使用<6>TDF</6>与肾功能完全恢复相关，多达一半的患者。", "revised": true}
{"doc_key": "24068571", "sentences": [["Incidence", "of", "postoperative", "delirium", "is", "high", "even", "in", "a", "population", "without", "known", "risk", "factors", ".", "PURPOSE", ":", "Postoperative", "delirium", "is", "a", "recognized", "complication", "in", "populations", "at", "risk", ".", "The", "aim", "of", "this", "study", "is", "to", "assess", "the", "prevalence", "of", "early", "postoperative", "delirium", "in", "a", "population", "without", "known", "risk", "factors", "admitted", "to", "the", "ICU", "for", "postoperative", "monitoring", "after", "elective", "major", "surgery", ".", "The", "secondary", "outcome", "investigated", "is", "to", "identify", "eventual", "independent", "risk", "factors", "among", "demographic", "data", "and", "anesthetic", "drugs", "used", ".", "METHODS", ":", "An", "observational", ",", "prospective", "study", "was", "conducted", "on", "a", "consecutive", "cohort", "of", "patients", "admitted", "to", "our", "ICU", "within", "and", "for", "at", "least", "24", "h", "after", "major", "surgical", "procedures", ".", "Exclusion", "criteria", "were", "any", "preexisting", "predisposing", "factor", "for", "delirium", "or", "other", "potentially", "confounding", "neurological", "dysfunctions", ".", "Patients", "were", "assessed", "daily", "using", "the", "confusion", "assessment", "method", "for", "the", "ICU", "scale", "for", "3", "days", "after", "the", "surgical", "procedure", ".", "Early", "postoperative", "delirium", "incidence", "risk", "factors", "were", "then", "assessed", "through", "three", "different", "multiple", "regression", "models", ".", "RESULTS", ":", "According", "to", "the", "confusion", "assessment", "method", "for", "the", "ICU", "scale", ",", "28", "%", "of", "patients", "were", "diagnosed", "with", "early", "postoperative", "delirium", ".", "The", "use", "of", "thiopentone", "was", "significantly", "associated", "with", "an", "eight", "-", "fold", "-", "higher", "risk", "for", "delirium", "compared", "to", "propofol", "(", "57", ".", "1", "%", "vs", ".", "7", ".", "1", "%", ",", "RR", "=", "8", ".", "0", ",", "X2", "=", "4", ".", "256", ";", "df", "=", "1", ";", "0", ".", "05", "<", "p", "<", "0", ".", "02", ")", ".", "CONCLUSION", ":", "In", "this", "study", "early", "postoperative", "delirium", "was", "found", "to", "be", "a", "very", "common", "complication", "after", "major", "surgery", ",", "even", "in", "a", "population", "without", "known", "risk", "factors", ".", "Thiopentone", "was", "independently", "associated", "with", "an", "increase", "in", "its", "relative", "risk", "."]], "ner": [[[191, 191, "Chemical"], [276, 276, "Chemical"], [2, 3, "Disease"], [17, 18, "Disease"], [40, 41, "Disease"], [149, 150, "Disease"], [185, 186, "Disease"], [253, 254, "Disease"], [119, 119, "Disease"], [204, 204, "Disease"], [207, 207, "Chemical"], [124, 125, "Disease"], [133, 133, "Disease"]]], "relations": [[[191, 191, 2, 3, "CID"], [191, 191, 17, 18, "CID"], [191, 191, 40, 41, "CID"], [191, 191, 149, 150, "CID"], [191, 191, 185, 186, "CID"], [191, 191, 253, 254, "CID"], [276, 276, 2, 3, "CID"], [276, 276, 17, 18, "CID"], [276, 276, 40, 41, "CID"], [276, 276, 149, 150, "CID"], [276, 276, 185, 186, "CID"], [276, 276, 253, 254, "CID"], [191, 191, 119, 119, "CID"], [191, 191, 204, 204, "CID"], [276, 276, 119, 119, "CID"], [276, 276, 204, 204, "CID"]]], "clusters": [], "translated": "即使在没有已知危险因素的人群中，<2>术后谵妄</2>的发生率也很高。目的：<3>术后谵妄</3>是高危人群公认的并发症。本研究的目的是评估早期<4>术后谵妄</4>在无已知危险因素的人群中的患病率，该人群在择期大手术后进入 ICU 进行术后监测。调查的次要结果是确定人口统计数据和使用的麻醉药物之间的最终独立危险因素。方法：一项观察性、前瞻性研究是对在大手术后至少 24 小时内入住我们 ICU 的连续队列患者进行的。排除标准是任何预先存在的<8>谵妄</8>或其他可能混杂的<11>神经功能障碍</11>的诱发因素。手术后3天，每天使用ICU量表的<12>混淆</12>评估方法对患者进行评估。然后通过三种不同的多元回归模型评估了早期<5>术后谵妄</5>发生的危险因素。结果：根据ICU量表混淆评估法，28%的患者被诊断为早期<6>术后谵妄</6>。与<10>丙泊酚</10>相比，使用<0>硫喷妥酮</0>与<9>谵妄</9>的风险显着相关（57.1%对7.1%，RR=8.0，X2=4.256；df=1；0.05<p<0.02）。结论：在这项研究中，早期<7>术后谵妄</7>被发现是大手术后非常常见的并发症，即使在没有已知危险因素的人群中也是如此。<1>硫喷妥酮</1>与其相对风险的增加独立相关。", "revised": true}
{"doc_key": "23872883", "sentences": [["Biochemical", "effects", "of", "Solidago", "virgaurea", "extract", "on", "experimental", "cardiotoxicity", ".", "Cardiovascular", "diseases", "(", "CVDs", ")", "are", "the", "major", "health", "problem", "of", "advanced", "as", "well", "as", "developing", "countries", "of", "the", "world", ".", "The", "aim", "of", "the", "present", "study", "was", "to", "investigate", "the", "protective", "effect", "of", "the", "Solidago", "virgaurea", "extract", "on", "isoproterenol", "-", "induced", "cardiotoxicity", "in", "rats", ".", "The", "subcutaneous", "injection", "of", "isoproterenol", "(", "30", "mg", "/", "kg", ")", "into", "rats", "twice", "at", "an", "interval", "of", "24", "h", ",", "for", "two", "consecutive", "days", ",", "led", "to", "a", "significant", "increase", "in", "serum", "lactate", "dehydrogenase", ",", "creatine", "phosphokinase", ",", "alanine", "transaminase", ",", "aspartate", "transaminase", ",", "and", "angiotensin", "-", "converting", "enzyme", "activities", ",", "total", "cholesterol", ",", "triglycerides", ",", "free", "serum", "fatty", "acid", ",", "cardiac", "tissue", "malondialdehyde", "(", "MDA", ")", ",", "and", "nitric", "oxide", "levels", "and", "a", "significant", "decrease", "in", "levels", "of", "glutathione", "and", "superoxide", "dismutase", "in", "cardiac", "tissue", "as", "compared", "to", "the", "normal", "control", "group", "(", "P", "<", "0", ".", "05", ")", ".", "Pretreatment", "with", "S", ".", "virgaurea", "extract", "for", "5", "weeks", "at", "a", "dose", "of", "250", "mg", "/", "kg", "followed", "by", "isoproterenol", "injection", "significantly", "prevented", "the", "observed", "alterations", ".", "Captopril", "(", "50", "mg", "/", "kg", "/", "day", ",", "given", "orally", ")", ",", "an", "inhibitor", "of", "angiotensin", "-", "converting", "enzyme", "used", "as", "a", "standard", "cardioprotective", "drug", ",", "was", "used", "as", "a", "positive", "control", "in", "this", "study", ".", "The", "data", "of", "the", "present", "study", "suggest", "that", "S", ".", "virgaurea", "extract", "exerts", "its", "protective", "effect", "by", "decreasing", "MDA", "level", "and", "increasing", "the", "antioxidant", "status", "in", "isoproterenol", "-", "treated", "rats", ".", "The", "study", "emphasizes", "the", "beneficial", "action", "of", "S", ".", "virgaurea", "extract", "as", "a", "cardioprotective", "agent", "."]], "ner": [[[49, 49, "Chemical"], [60, 60, "Chemical"], [177, 177, "Chemical"], [248, 248, "Chemical"], [8, 8, "Disease"], [52, 52, "Disease"], [89, 89, "Chemical"], [92, 92, "Chemical"], [95, 95, "Chemical"], [98, 98, "Chemical"], [102, 102, "Chemical"], [201, 201, "Chemical"], [109, 109, "Chemical"], [111, 111, "Chemical"], [115, 116, "Chemical"], [120, 120, "Chemical"], [122, 122, "Chemical"], [240, 240, "Chemical"], [126, 127, "Chemical"], [136, 136, "Chemical"], [138, 138, "Chemical"], [185, 185, "Chemical"], [10, 11, "Disease"], [13, 13, "Disease"]]], "relations": [[[49, 49, 8, 8, "CID"], [49, 49, 52, 52, "CID"], [60, 60, 8, 8, "CID"], [60, 60, 52, 52, "CID"], [177, 177, 8, 8, "CID"], [177, 177, 52, 52, "CID"], [248, 248, 8, 8, "CID"], [248, 248, 52, 52, "CID"]]], "clusters": [], "translated": "一枝黄花提取物对实验性<4>心脏毒性</4>的生化作用。<22>心血管疾病</22>（<23>CVDs</23>）是世界发达国家和发展中国家面临的主要健康问题。本研究的目的是研究一枝黄花提取物对<0>异丙肾上腺素</0>诱导的大鼠<5>心脏毒性</5>的保护作用。大鼠皮下注射<1>异丙肾上腺素</1>（30 mg/kg），间隔24小时两次，连续2天，导致血清<6>乳酸脱氢酶</6>显着升高，<7>肌酸磷酸激酶</7>、<8>丙氨酸转氨酶</8>、<9>天冬氨酸转氨酶</9>和<10>血管紧张素转化酶</10>活性、总<12>胆固醇</12>、<13>甘油三酯</13>、游离血清<14>脂肪酸</14>、心脏组织中的<15>丙二醛</15>（<16>MDA</16>）和<18>一氧化氮</18>水平显着增加，而心脏组织中的<19>谷胱甘肽</19>和<20>超氧化物歧化酶</20>水平则显着降低（P<0.05）。用250mg/kg剂量的S. virgaurea提取物预处理5周，然后注射<2>异丙肾上腺素</2>可显著防止观察到的改变。<21>卡托普利</21>（50mg/kg/天，口服），一种<11>血管紧张素转化酶</11>抑制剂，被用作标准的心脏保护药物，在本研究中作为阳性对照。本研究的数据表明，S. virgaurea提取物通过降低<17>MDA</17>水平和增加<3>异丙肾上腺素</3>处理的大鼠的抗氧化状态发挥其保护作用。该研究强调了S. virgaurea提取物作为心脏保护剂的有益作用。", "revised": true}
{"doc_key": "23666265", "sentences": [["The", "function", "of", "P2X3", "receptor", "and", "NK1", "receptor", "antagonists", "on", "cyclophosphamide", "-", "induced", "cystitis", "in", "rats", ".", "PURPOSE", ":", "The", "purpose", "of", "the", "study", "is", "to", "explore", "the", "function", "of", "P2X3", "and", "NK1", "receptors", "antagonists", "on", "cyclophosphamide", "(", "CYP", ")", "-", "induced", "cystitis", "in", "rats", ".", "METHODS", ":", "Sixty", "female", "Sprague", "-", "Dawley", "(", "SD", ")", "rats", "were", "randomly", "divided", "into", "three", "groups", ".", "The", "rats", "in", "the", "control", "group", "were", "intraperitoneally", "(", "i", ".", "p", ".", ")", "injected", "with", "0", ".", "9", "%", "saline", "(", "4", "ml", "/", "kg", ")", ";", "the", "rats", "in", "the", "model", "group", "were", "i", ".", "p", ".", "injected", "with", "CYP", "(", "150", "mg", "/", "kg", ")", ";", "and", "the", "rats", "in", "the", "intervention", "group", "were", "i", ".", "p", ".", "injected", "with", "CYP", "with", "subsequently", "perfusion", "of", "bladder", "with", "P2X3", "and", "NK1", "receptors", "'", "antagonists", ",", "Suramin", "and", "GR", "82334", ".", "Spontaneous", "pain", "behaviors", "following", "the", "administration", "of", "CYP", "were", "observed", ".", "Urodynamic", "parameters", ",", "bladder", "pressure", "-", "volume", "curve", ",", "maximum", "voiding", "pressure", "(", "MVP", ")", ",", "and", "maximum", "cystometric", "capacity", "(", "MCC", ")", ",", "were", "recorded", ".", "Pathological", "changes", "in", "bladder", "tissue", "were", "observed", ".", "Immunofluorescence", "was", "used", "to", "detect", "the", "expression", "of", "P2X3", "and", "NK1", "receptors", "in", "bladder", ".", "RESULTS", ":", "Cyclophosphamide", "treatment", "increased", "the", "spontaneous", "pain", "behaviors", "scores", ".", "The", "incidence", "of", "bladder", "instability", "during", "urine", "storage", "period", "of", "model", "group", "was", "significantly", "higher", "than", "intervention", "group", "(", "X", "(", "2", ")", "=", "7", ".", "619", ",", "P", "=", "0", ".", "007", ")", "and", "control", "group", "(", "X", "(", "2", ")", "=", "13", ".", "755", ",", "P", "=", "0", ".", "000", ")", ".", "MCC", "in", "the", "model", "group", "was", "lower", "than", "the", "control", "and", "intervention", "groups", "(", "P", "<", "0", ".", "01", ")", ".", "Histological", "changes", "evident", "in", "model", "and", "intervention", "groups", "rats", "'", "bladder", "included", "edema", ",", "vasodilation", ",", "and", "infiltration", "of", "inflammatory", "cells", ".", "In", "model", "group", ",", "the", "expression", "of", "P2X3", "receptor", "increased", "in", "urothelium", "and", "suburothelium", ",", "and", "NK1", "receptor", "increased", "in", "suburothelium", ",", "while", "the", "expression", "of", "them", "in", "intervention", "group", "was", "lower", ".", "CONCLUSIONS", ":", "In", "CYP", "-", "induced", "cystitis", ",", "the", "expression", "of", "P2X3", "and", "NK1", "receptors", "increased", "in", "urothelium", "and", "/", "or", "suburothelium", ".", "Perfusion", "of", "bladder", "with", "P2X3", "and", "NK1", "receptors", "antagonists", "ameliorated", "the", "bladder", "function", "."]], "ner": [[[10, 10, "Chemical"], [36, 36, "Chemical"], [38, 38, "Chemical"], [105, 105, "Chemical"], [127, 127, "Chemical"], [153, 153, "Chemical"], [209, 209, "Chemical"], [351, 351, "Chemical"], [13, 13, "Disease"], [42, 42, "Disease"], [354, 354, "Disease"], [147, 147, "Disease"], [214, 214, "Disease"], [305, 305, "Disease"], [141, 141, "Chemical"], [143, 144, "Chemical"]]], "relations": [[[10, 10, 13, 13, "CID"], [10, 10, 42, 42, "CID"], [10, 10, 354, 354, "CID"], [36, 36, 13, 13, "CID"], [36, 36, 42, 42, "CID"], [36, 36, 354, 354, "CID"], [38, 38, 13, 13, "CID"], [38, 38, 42, 42, "CID"], [38, 38, 354, 354, "CID"], [105, 105, 13, 13, "CID"], [105, 105, 42, 42, "CID"], [105, 105, 354, 354, "CID"], [127, 127, 13, 13, "CID"], [127, 127, 42, 42, "CID"], [127, 127, 354, 354, "CID"], [153, 153, 13, 13, "CID"], [153, 153, 42, 42, "CID"], [153, 153, 354, 354, "CID"], [209, 209, 13, 13, "CID"], [209, 209, 42, 42, "CID"], [209, 209, 354, 354, "CID"], [351, 351, 13, 13, "CID"], [351, 351, 42, 42, "CID"], [351, 351, 354, 354, "CID"], [10, 10, 147, 147, "CID"], [10, 10, 214, 214, "CID"], [36, 36, 147, 147, "CID"], [36, 36, 214, 214, "CID"], [38, 38, 147, 147, "CID"], [38, 38, 214, 214, "CID"], [105, 105, 147, 147, "CID"], [105, 105, 214, 214, "CID"], [127, 127, 147, 147, "CID"], [127, 127, 214, 214, "CID"], [153, 153, 147, 147, "CID"], [153, 153, 214, 214, "CID"], [209, 209, 147, 147, "CID"], [209, 209, 214, 214, "CID"], [351, 351, 147, 147, "CID"], [351, 351, 214, 214, "CID"], [10, 10, 305, 305, "CID"], [36, 36, 305, 305, "CID"], [38, 38, 305, 305, "CID"], [105, 105, 305, 305, "CID"], [127, 127, 305, 305, "CID"], [153, 153, 305, 305, "CID"], [209, 209, 305, 305, "CID"], [351, 351, 305, 305, "CID"]]], "clusters": [], "translated": "P2X3受体和NK1受体拮抗剂对<0>环磷酰胺</0>诱导的大鼠<8>膀胱炎</8>的作用。目的：本研究旨在探讨P2X3和NK1受体拮抗剂对<1>环磷酰胺</1>（<2>CYP</2>）诱导的大鼠<9>膀胱炎</9>的作用。方法：60只雌性Sprague-Dawley (SD)大鼠随机分为三组。对照组大鼠腹腔 (i.p.) 注射0.9%生理盐水（4毫升/千克）；模型组大鼠为 i.p. 注射<3>CYP</3> (150 mg/kg)；干预组大鼠为i.p.注射<4>CYP</4>，随后用P2X3和NK1受体拮抗剂<14>Suramin</14>和<15>GR 82334</15>灌注膀胱。观察施用<5>CYP</5>后的自发性<11>疼痛</11>行为。记录尿流动力学参数、膀胱压力-容积曲线、最大排尿压力(MVP)和最大膀胱容量(MCC)。观察膀胱组织病理变化。免疫荧光法检测膀胱P2X3和NK1受体的表达。结果：<6>环磷酰胺</6>治疗增加了自发性<12>疼痛</12>行为评分。模型组储尿期膀胱不稳定发生率显着高于干预组(X(2)=7.619，P=0.007)和对照组(X(2)=13.755，P=0.000)。模型组MCC低于对照组和干预组(P<0.01)。模型组和干预组大鼠膀胱组织学变化明显，包括<13>水肿</13>、血管扩张和炎性细胞浸润。模型组尿路上皮和尿路上皮下P2X3受体表达增加，NK1受体在尿路上皮下层表达增加，而干预组则表达降低。结论：在<7>CYP</7>诱导的<10>膀胱炎</10>中，P2X3和NK1受体在尿路上皮和/或尿路上皮下层的表达增加。P2X3和NK1受体拮抗剂灌注膀胱可改善膀胱功能。", "revised": true}
{"doc_key": "24072398", "sentences": [["A", "single", "neurotoxic", "dose", "of", "methamphetamine", "induces", "a", "long", "-", "lasting", "depressive", "-", "like", "behaviour", "in", "mice", ".", "Methamphetamine", "(", "METH", ")", "triggers", "a", "disruption", "of", "the", "monoaminergic", "system", "and", "METH", "abuse", "leads", "to", "negative", "emotional", "states", "including", "depressive", "symptoms", "during", "drug", "withdrawal", ".", "However", ",", "it", "is", "currently", "unknown", "if", "the", "acute", "toxic", "dosage", "of", "METH", "also", "causes", "a", "long", "-", "lasting", "depressive", "phenotype", "and", "persistent", "monoaminergic", "deficits", ".", "Thus", ",", "we", "now", "assessed", "the", "depressive", "-", "like", "behaviour", "in", "mice", "at", "early", "and", "long", "-", "term", "periods", "following", "a", "single", "high", "METH", "dose", "(", "30", "mg", "/", "kg", ",", "i", ".", "p", ".", ")", ".", "METH", "did", "not", "alter", "the", "motor", "function", "and", "procedural", "memory", "of", "mice", "as", "assessed", "by", "swimming", "speed", "and", "escape", "latency", "to", "find", "the", "platform", "in", "a", "cued", "version", "of", "the", "water", "maze", "task", ".", "However", ",", "METH", "significantly", "increased", "the", "immobility", "time", "in", "the", "tail", "suspension", "test", "at", "3", "and", "49", "days", "post", "-", "administration", ".", "This", "depressive", "-", "like", "profile", "induced", "by", "METH", "was", "accompanied", "by", "a", "marked", "depletion", "of", "frontostriatal", "dopaminergic", "and", "serotonergic", "neurotransmission", ",", "indicated", "by", "a", "reduction", "in", "the", "levels", "of", "dopamine", ",", "DOPAC", "and", "HVA", ",", "tyrosine", "hydroxylase", "and", "serotonin", ",", "observed", "at", "both", "3", "and", "49", "days", "post", "-", "administration", ".", "In", "parallel", ",", "another", "neurochemical", "feature", "of", "depression", "-", "-", "astroglial", "dysfunction", "-", "-", "was", "unaffected", "in", "the", "cortex", "and", "the", "striatal", "levels", "of", "the", "astrocytic", "protein", "marker", ",", "glial", "fibrillary", "acidic", "protein", ",", "were", "only", "transiently", "increased", "at", "3", "days", ".", "These", "findings", "demonstrate", "for", "the", "first", "time", "that", "a", "single", "high", "dose", "of", "METH", "induces", "long", "-", "lasting", "depressive", "-", "like", "behaviour", "in", "mice", "associated", "with", "a", "persistent", "disruption", "of", "frontostriatal", "dopaminergic", "and", "serotonergic", "homoeostasis", "."]], "ner": [[[5, 5, "Chemical"], [18, 18, "Chemical"], [20, 20, "Chemical"], [30, 30, "Chemical"], [56, 56, "Chemical"], [93, 93, "Chemical"], [107, 107, "Chemical"], [143, 143, "Chemical"], [170, 170, "Chemical"], [269, 269, "Chemical"], [11, 11, "Disease"], [38, 39, "Disease"], [63, 63, "Disease"], [76, 76, "Disease"], [164, 164, "Disease"], [221, 221, "Disease"], [274, 274, "Disease"], [2, 2, "Disease"], [192, 192, "Chemical"], [194, 194, "Chemical"], [196, 196, "Chemical"], [198, 198, "Chemical"], [201, 201, "Chemical"]]], "relations": [[[5, 5, 11, 11, "CID"], [5, 5, 38, 39, "CID"], [5, 5, 63, 63, "CID"], [5, 5, 76, 76, "CID"], [5, 5, 164, 164, "CID"], [5, 5, 221, 221, "CID"], [5, 5, 274, 274, "CID"], [18, 18, 11, 11, "CID"], [18, 18, 38, 39, "CID"], [18, 18, 63, 63, "CID"], [18, 18, 76, 76, "CID"], [18, 18, 164, 164, "CID"], [18, 18, 221, 221, "CID"], [18, 18, 274, 274, "CID"], [20, 20, 11, 11, "CID"], [20, 20, 38, 39, "CID"], [20, 20, 63, 63, "CID"], [20, 20, 76, 76, "CID"], [20, 20, 164, 164, "CID"], [20, 20, 221, 221, "CID"], [20, 20, 274, 274, "CID"], [30, 30, 11, 11, "CID"], [30, 30, 38, 39, "CID"], [30, 30, 63, 63, "CID"], [30, 30, 76, 76, "CID"], [30, 30, 164, 164, "CID"], [30, 30, 221, 221, "CID"], [30, 30, 274, 274, "CID"], [56, 56, 11, 11, "CID"], [56, 56, 38, 39, "CID"], [56, 56, 63, 63, "CID"], [56, 56, 76, 76, "CID"], [56, 56, 164, 164, "CID"], [56, 56, 221, 221, "CID"], [56, 56, 274, 274, "CID"], [93, 93, 11, 11, "CID"], [93, 93, 38, 39, "CID"], [93, 93, 63, 63, "CID"], [93, 93, 76, 76, "CID"], [93, 93, 164, 164, "CID"], [93, 93, 221, 221, "CID"], [93, 93, 274, 274, "CID"], [107, 107, 11, 11, "CID"], [107, 107, 38, 39, "CID"], [107, 107, 63, 63, "CID"], [107, 107, 76, 76, "CID"], [107, 107, 164, 164, "CID"], [107, 107, 221, 221, "CID"], [107, 107, 274, 274, "CID"], [143, 143, 11, 11, "CID"], [143, 143, 38, 39, "CID"], [143, 143, 63, 63, "CID"], [143, 143, 76, 76, "CID"], [143, 143, 164, 164, "CID"], [143, 143, 221, 221, "CID"], [143, 143, 274, 274, "CID"], [170, 170, 11, 11, "CID"], [170, 170, 38, 39, "CID"], [170, 170, 63, 63, "CID"], [170, 170, 76, 76, "CID"], [170, 170, 164, 164, "CID"], [170, 170, 221, 221, "CID"], [170, 170, 274, 274, "CID"], [269, 269, 11, 11, "CID"], [269, 269, 38, 39, "CID"], [269, 269, 63, 63, "CID"], [269, 269, 76, 76, "CID"], [269, 269, 164, 164, "CID"], [269, 269, 221, 221, "CID"], [269, 269, 274, 274, "CID"]]], "clusters": [], "translated": "单次<17>神经毒性</17>剂量的<0>甲基苯丙胺</0>会在小鼠中诱导长期持续的<10>抑郁</10>样行为。<1>甲基苯丙胺</1>（<2>METH</2>）会触发单胺能系统的破坏，<3>METH</3>滥用会导致负面情绪状态，包括<11>抑郁症状</11>在停药期间。然而，目前尚不清楚急性毒性剂量的<4>METH</4>是否也会导致持久的<12>抑郁</12>表型和持续的单胺能缺陷。因此，我们现在评估了单次高剂量<5>METH</5>（30 mg/kg，i.p.）后小鼠早期和长期的<13>抑郁</13>样行为。<6>METH</6>没有改变小鼠的运动功能和程序记忆，这是通过游泳速度和逃避潜伏期评估的，在水迷宫任务的提示版本中找到平台。然而，<7>METH</7>显着增加了给药后3天和49天的悬尾试验中的不动时间。<14>抑郁</14>-样特征的诱导由<8>METH</8>附带额纹状体多巴胺能和血清素能神经递质的显著损伤，表现为<18>多巴胺</18>、<19>DOPAC</19>和<20>HVA</20>、<21>酪氨酸</21>羟化酶和<22>5-羟色胺</22>水平的下降，给药后3天和49天观察到。与此同时，<15>抑郁症</15>的另一个神经化学特征——星形胶质细胞功能障碍——在皮质中未受影响，星形胶质细胞蛋白标志物胶质纤维酸性蛋白的纹状体水平仅在第3天时短暂升高。这些发现首次表明，单次高剂量的<9>METH</9>会在小鼠中诱导长期的<16>抑郁</16>样行为，并与额纹状体多巴胺能和5-羟色胺能稳态的持续破坏有关。", "revised": true}
{"doc_key": "23864035", "sentences": [["Bortezomib", "and", "dexamethasone", "as", "salvage", "therapy", "in", "patients", "with", "relapsed", "/", "refractory", "multiple", "myeloma", ":", "analysis", "of", "long", "-", "term", "clinical", "outcomes", ".", "Bortezomib", "(", "bort", ")", "-", "dexamethasone", "(", "dex", ")", "is", "an", "effective", "therapy", "for", "relapsed", "/", "refractory", "(", "R", "/", "R", ")", "multiple", "myeloma", "(", "MM", ")", ".", "This", "retrospective", "study", "investigated", "the", "combination", "of", "bort", "(", "1", ".", "3", "mg", "/", "m", "(", "2", ")", "on", "days", "1", ",", "4", ",", "8", ",", "and", "11", "every", "3", "weeks", ")", "and", "dex", "(", "20", "mg", "on", "the", "day", "of", "and", "the", "day", "after", "bort", ")", "as", "salvage", "treatment", "in", "85", "patients", "with", "R", "/", "R", "MM", "after", "prior", "autologous", "stem", "cell", "transplantation", "or", "conventional", "chemotherapy", ".", "The", "median", "number", "of", "prior", "lines", "of", "therapy", "was", "2", ".", "Eighty", "-", "seven", "percent", "of", "the", "patients", "had", "received", "immunomodulatory", "drugs", "included", "in", "some", "line", "of", "therapy", "before", "bort", "-", "dex", ".", "The", "median", "number", "of", "bort", "-", "dex", "cycles", "was", "6", ",", "up", "to", "a", "maximum", "of", "12", "cycles", ".", "On", "an", "intention", "-", "to", "-", "treat", "basis", ",", "55", "%", "of", "the", "patients", "achieved", "at", "least", "partial", "response", ",", "including", "19", "%", "CR", "and", "35", "%", "achieved", "at", "least", "very", "good", "partial", "response", ".", "Median", "durations", "of", "response", ",", "time", "to", "next", "therapy", "and", "treatment", "-", "free", "interval", "were", "8", ",", "11", ".", "2", ",", "and", "5", ".", "1", "months", ",", "respectively", ".", "The", "most", "relevant", "adverse", "event", "was", "peripheral", "neuropathy", ",", "which", "occurred", "in", "78", "%", "of", "the", "patients", "(", "grade", "II", ",", "38", "%", ";", "grade", "III", ",", "21", "%", ")", "and", "led", "to", "treatment", "discontinuation", "in", "6", "%", ".", "With", "a", "median", "follow", "up", "of", "22", "months", ",", "median", "time", "to", "progression", ",", "progression", "-", "free", "survival", "(", "PFS", ")", "and", "overall", "survival", "(", "OS", ")", "were", "8", ".", "9", ",", "8", ".", "7", ",", "and", "22", "months", ",", "respectively", ".", "Prolonged", "PFS", "and", "OS", "were", "observed", "in", "patients", "achieving", "CR", "and", "receiving", "bort", "-", "dex", "a", "single", "line", "of", "prior", "therapy", ".", "Bort", "-", "dex", "was", "an", "effective", "salvage", "treatment", "for", "MM", "patients", ",", "particularly", "for", "those", "in", "first", "relapse", "."]], "ner": [[[0, 0, "Chemical"], [23, 23, "Chemical"], [25, 25, "Chemical"], [58, 58, "Chemical"], [96, 96, "Chemical"], [148, 148, "Chemical"], [156, 156, "Chemical"], [328, 328, "Chemical"], [338, 338, "Chemical"], [241, 242, "Disease"], [2, 2, "Chemical"], [28, 28, "Chemical"], [30, 30, "Chemical"], [84, 84, "Chemical"], [150, 150, "Chemical"], [158, 158, "Chemical"], [330, 330, "Chemical"], [340, 340, "Chemical"], [12, 13, "Disease"], [45, 46, "Disease"], [48, 48, "Disease"], [108, 108, "Disease"], [347, 347, "Disease"]]], "relations": [[[0, 0, 241, 242, "CID"], [23, 23, 241, 242, "CID"], [25, 25, 241, 242, "CID"], [58, 58, 241, 242, "CID"], [96, 96, 241, 242, "CID"], [148, 148, 241, 242, "CID"], [156, 156, 241, 242, "CID"], [328, 328, 241, 242, "CID"], [338, 338, 241, 242, "CID"], [2, 2, 241, 242, "CID"], [28, 28, 241, 242, "CID"], [30, 30, 241, 242, "CID"], [84, 84, 241, 242, "CID"], [150, 150, 241, 242, "CID"], [158, 158, 241, 242, "CID"], [330, 330, 241, 242, "CID"], [340, 340, 241, 242, "CID"]]], "clusters": [], "translated": "<0>硼替佐米</0>和<10>地塞米松</10>作为复发/难治性<18>多发性骨髓瘤</18>患者的挽救治疗：长期临床结果分析。 <1>硼替佐米</1>（<2>bort</2>）- <11>地塞米松</11>（<12>dex</12>）是治疗复发/难治性（R/R）<19>多发性骨髓瘤</19>（<20>MM</20>）的有效药物。这项回顾性研究调查了<3>bort</3>（每3周第1、4、8和11天1.3mg/m(2)）和<13>dex</13>（20mg在<4>bort</4>当天和之后的一天）作为补救治疗，用于85名R/R<21>MM</21>患者，这些患者在先前接受过自体干细胞移植或常规化疗。既往治疗线的中位数为2。87%的患者在<5>bort</5>-<14>dex</14>之前接受过免疫调节药物治疗。<6>bort</6>-<15>dex</15>循环的中位数为6，最多为12个循环。在意向性治疗的基础上，55%的患者至少达到部分缓解，包括19%的CR和35%的患者至少达到非常好的部分缓解。中位反应持续时间、下一次治疗时间和无治疗间隔时间分别为8、11.2和5.1个月。最相关的不良事件是<9>周围神经病变</9>，发生在78%的患者中（II级，38%；III级，21%），导致6%的患者停止治疗。在中位随访时间为22个月时，中位进展时间、无进展生存期（PFS）和总生存期（OS）分别为8.9、8.7和22个月。在达到CR并接受<7>bort</7>-<16>dex</16>单线既往治疗的患者中观察到延长的PFS和OS。<8>bort</8>-<17>dex</17>是<22>MM</22>患者的有效挽救治疗，尤其是对于那些首次复发的患者。", "revised": true}
{"doc_key": "23892921", "sentences": [["\"", "Real", "-", "world", "\"", "data", "on", "the", "efficacy", "and", "safety", "of", "lenalidomide", "and", "dexamethasone", "in", "patients", "with", "relapsed", "/", "refractory", "multiple", "myeloma", "who", "were", "treated", "according", "to", "the", "standard", "clinical", "practice", ":", "a", "study", "of", "the", "Greek", "Myeloma", "Study", "Group", ".", "Lenalidomide", "and", "dexamethasone", "(", "RD", ")", "is", "a", "standard", "of", "care", "for", "relapsed", "/", "refractory", "multiple", "myeloma", "(", "RRMM", ")", ",", "but", "there", "is", "limited", "published", "data", "on", "its", "efficacy", "and", "safety", "in", "the", "\"", "real", "world", "\"", "(", "RW", ")", ",", "according", "to", "the", "International", "Society", "of", "Pharmacoeconomics", "and", "Outcomes", "Research", "definition", ".", "We", "studied", "212", "RRMM", "patients", "who", "received", "RD", "in", "RW", ".", "Objective", "response", "(", ">", "PR", "(", "partial", "response", ")", ")", "rate", "was", "77", ".", "4", "%", "(", "complete", "response", "(", "CR", ")", ",", "20", ".", "2", "%", ")", ".", "Median", "time", "to", "first", "and", "best", "response", "was", "2", "and", "5", "months", ",", "respectively", ".", "Median", "time", "to", "CR", "when", "RD", "was", "given", "as", "2nd", "or", ">", "2", "(", "nd", ")", "-", "line", "treatment", "at", "4", "and", "11", "months", ",", "respectively", ".", "Quality", "of", "response", "was", "independent", "of", "previous", "lines", "of", "therapies", "or", "previous", "exposure", "to", "thalidomide", "or", "bortezomib", ".", "Median", "duration", "of", "response", "was", "34", ".", "4", "months", ",", "and", "it", "was", "higher", "in", "patients", "who", "received", "RD", "until", "progression", "(", "not", "reached", "versus", "19", "months", ",", "p", "<", "0", ".", "001", ")", ".", "Improvement", "of", "humoral", "immunity", "occurred", "in", "60", "%", "of", "responders", "(", "p", "<", "0", ".", "001", ")", "and", "in", "the", "majority", "of", "patients", "who", "achieved", "stable", "disease", ".", "Adverse", "events", "were", "reported", "in", "68", ".", "9", "%", "of", "patients", "(", "myelosuppression", "in", "49", ".", "4", "%", ")", "and", "12", ".", "7", "%", "of", "patients", "needed", "hospitalization", ".", "Peripheral", "neuropathy", "was", "observed", "only", "in", "2", ".", "5", "%", "of", "patients", "and", "deep", "vein", "thrombosis", "in", "5", ".", "7", "%", ".", "Dose", "reductions", "were", "needed", "in", "31", "%", "of", "patients", "and", "permanent", "discontinuation", "in", "38", ".", "9", "%", ".", "Median", "time", "to", "treatment", "discontinuation", "was", "16", ".", "8", "months", ".", "Performance", "status", "(", "PS", ")", "and", "initial", "lenalidomide", "dose", "predicted", "for", "treatment", "discontinuation", ".", "Extra", "-", "medullary", "relapses", "occurred", "in", "3", ".", "8", "%", "of", "patients", ".", "Our", "study", "confirms", "that", "RD", "is", "effective", "and", "safe", "in", "RRMM", "in", "the", "RW", ";", "it", "produces", "durable", "responses", "especially", "in", "patients", "who", "continue", "on", "treatment", "till", "progression", "and", "improves", "humoral", "immunity", "even", "in", "patients", "with", "stable", "disease", "."]], "ner": [[[12, 12, "Chemical"], [42, 42, "Chemical"], [46, 46, "Chemical"], [103, 103, "Chemical"], [156, 156, "Chemical"], [214, 214, "Chemical"], [346, 346, "Chemical"], [370, 370, "Chemical"], [271, 271, "Disease"], [288, 289, "Disease"], [301, 303, "Disease"], [14, 14, "Chemical"], [44, 44, "Chemical"], [21, 22, "Disease"], [38, 38, "Disease"], [57, 58, "Disease"], [60, 60, "Disease"], [99, 99, "Disease"], [376, 376, "Disease"], [192, 192, "Chemical"], [194, 194, "Chemical"]]], "relations": [[[12, 12, 271, 271, "CID"], [42, 42, 271, 271, "CID"], [46, 46, 271, 271, "CID"], [103, 103, 271, 271, "CID"], [156, 156, 271, 271, "CID"], [214, 214, 271, 271, "CID"], [346, 346, 271, 271, "CID"], [370, 370, 271, 271, "CID"], [12, 12, 288, 289, "CID"], [42, 42, 288, 289, "CID"], [46, 46, 288, 289, "CID"], [103, 103, 288, 289, "CID"], [156, 156, 288, 289, "CID"], [214, 214, 288, 289, "CID"], [346, 346, 288, 289, "CID"], [370, 370, 288, 289, "CID"], [12, 12, 301, 303, "CID"], [42, 42, 301, 303, "CID"], [46, 46, 301, 303, "CID"], [103, 103, 301, 303, "CID"], [156, 156, 301, 303, "CID"], [214, 214, 301, 303, "CID"], [346, 346, 301, 303, "CID"], [370, 370, 301, 303, "CID"], [14, 14, 271, 271, "CID"], [44, 44, 271, 271, "CID"], [14, 14, 288, 289, "CID"], [44, 44, 288, 289, "CID"], [14, 14, 301, 303, "CID"], [44, 44, 301, 303, "CID"]]], "clusters": [], "translated": "<0>来那度胺</0>和<11>地塞米松</11>治疗复发/难治性<13>多发性骨髓瘤</13>患者疗效和安全性的“真实世界”数据：标准临床实践：希腊<14>骨髓瘤</14>研究组的一项研究。 <1>来那度胺</1>和<12>地塞米松</12> (<2>RD</2>)是复发/难治性<15>多发性骨髓瘤</15> (<16>RRMM</16>)的标准治疗，但根据国际药物经济学和结果研究学会的定义，在“真实世界”(RW)中对其疗效和安全性公开的数据有限。我们研究了212名RW中接受<3>RD</3>治疗的<17>RRMM</17>患者。客观缓解 (>PR (部分缓解) )率为77.4 % (完全缓解(CR)，20.2 %)。首次和最佳缓解的中位时间为2个月和5个月，<4>RD</4>作为第2或> 2(nd)线治疗的CR中位时间分别为4个月和11个月。反应质量与之前的治疗方案或<19>沙利度胺</19>或<20>硼替佐米</20>的使用无关。反应持续时间中位数为34.4个月，并在接受<5>RD</5>治疗直到疾病进展的患者中更长(未到达而是19个月，P < 0.001)。在60%的患者中(应答者)和大多数稳态病情的患者中，体液免疫得到改善(p < 0.001)。68.9%的患者报告了不良事件，其中49.4%的患者有<8>骨髓抑制</8>，12.7%的患者需要住院治疗。<9>周围神经病变</9>仅在2.5%的患者中观察到，<10>深静脉血栓形成</10>在5.7%的患者中观察到。31%的患者需要减少剂量，38.9%的患者永久停药。至治疗停止的中位时间为16.8个月。体能状态(PS)和初始<6>来那度胺</6>的剂量预测了治疗的停止。发生3.8％的骨髓外复发。我们的研究证实，在RW的<18>RRMM</18>中，<7>RD</7>是有效而安全的，尤其是在继续治疗直至进展的患者中可产生持久反应，即使在疾病稳定的患者中也能提高体液免疫功能。", "revised": true}
{"doc_key": "23433219", "sentences": [["The", "risk", "and", "associated", "factors", "of", "methamphetamine", "psychosis", "in", "methamphetamine", "-", "dependent", "patients", "in", "Malaysia", ".", "OBJECTIVE", ":", "The", "objective", "of", "this", "study", "was", "to", "determine", "the", "risk", "of", "lifetime", "and", "current", "methamphetamine", "-", "induced", "psychosis", "in", "patients", "with", "methamphetamine", "dependence", ".", "The", "association", "between", "psychiatric", "co", "-", "morbidity", "and", "methamphetamine", "-", "induced", "psychosis", "was", "also", "studied", ".", "METHODS", ":", "This", "was", "a", "cross", "-", "sectional", "study", "conducted", "concurrently", "at", "a", "teaching", "hospital", "and", "a", "drug", "rehabilitation", "center", "in", "Malaysia", ".", "Patients", "with", "the", "diagnosis", "of", "methamphetamine", "based", "on", "DSM", "-", "IV", "were", "interviewed", "using", "the", "Mini", "International", "Neuropsychiatric", "Interview", "(", "M", ".", "I", ".", "N", ".", "I", ".", ")", "for", "methamphetamine", "-", "induced", "psychosis", "and", "other", "Axis", "I", "psychiatric", "disorders", ".", "The", "information", "on", "sociodemographic", "background", "and", "drug", "use", "history", "was", "obtained", "from", "interview", "or", "medical", "records", ".", "RESULTS", ":", "Of", "292", "subjects", ",", "47", ".", "9", "%", "of", "the", "subjects", "had", "a", "past", "history", "of", "psychotic", "symptoms", "and", "13", ".", "0", "%", "of", "the", "patients", "were", "having", "current", "psychotic", "symptoms", ".", "Co", "-", "morbid", "major", "depressive", "disorder", "(", "OR", "=", "7", ".", "18", ",", "95", "CI", "=", "2", ".", "612", "-", "19", ".", "708", ")", ",", "bipolar", "disorder", "(", "OR", "=", "13", ".", "807", ",", "95", "CI", "=", "5", ".", "194", "-", "36", ".", "706", ")", ",", "antisocial", "personality", "disorder", "(", "OR", "=", "12", ".", "619", ",", "95", "CI", "=", "6", ".", "702", "-", "23", ".", "759", ")", "and", "heavy", "methamphetamine", "uses", "were", "significantly", "associated", "with", "lifetime", "methamphetamine", "-", "induced", "psychosis", "after", "adjusted", "for", "other", "factors", ".", "Major", "depressive", "disorder", "(", "OR", "=", "2", ".", "870", ",", "CI", "=", "1", ".", "154", "-", "7", ".", "142", ")", "and", "antisocial", "personality", "disorder", "(", "OR", "=", "3", ".", "299", ",", "95", "CI", "=", "1", ".", "375", "-", "7", ".", "914", ")", "were", "the", "only", "factors", "associated", "with", "current", "psychosis", ".", "CONCLUSION", ":", "There", "was", "a", "high", "risk", "of", "psychosis", "in", "patients", "with", "methamphetamine", "dependence", ".", "It", "was", "associated", "with", "co", "-", "morbid", "affective", "disorder", ",", "antisocial", "personality", ",", "and", "heavy", "methamphetamine", "use", ".", "It", "is", "recommended", "that", "all", "cases", "of", "methamphetamine", "dependence", "should", "be", "screened", "for", "psychotic", "symptoms", "."]], "ner": [[[6, 6, "Chemical"], [9, 9, "Chemical"], [32, 32, "Chemical"], [39, 39, "Chemical"], [50, 50, "Chemical"], [86, 86, "Chemical"], [111, 111, "Chemical"], [242, 242, "Chemical"], [249, 249, "Chemical"], [322, 322, "Chemical"], [340, 340, "Chemical"], [350, 350, "Chemical"], [7, 7, "Disease"], [35, 35, "Disease"], [53, 53, "Disease"], [114, 114, "Disease"], [157, 158, "Disease"], [170, 171, "Disease"], [252, 252, "Disease"], [308, 308, "Disease"], [318, 318, "Disease"], [356, 357, "Disease"], [198, 199, "Disease"], [219, 221, "Disease"], [280, 282, "Disease"], [335, 336, "Disease"], [119, 120, "Disease"], [177, 178, "Disease"], [259, 261, "Disease"], [332, 333, "Disease"]]], "relations": [[[6, 6, 7, 7, "CID"], [6, 6, 35, 35, "CID"], [6, 6, 53, 53, "CID"], [6, 6, 114, 114, "CID"], [6, 6, 157, 158, "CID"], [6, 6, 170, 171, "CID"], [6, 6, 252, 252, "CID"], [6, 6, 308, 308, "CID"], [6, 6, 318, 318, "CID"], [6, 6, 356, 357, "CID"], [9, 9, 7, 7, "CID"], [9, 9, 35, 35, "CID"], [9, 9, 53, 53, "CID"], [9, 9, 114, 114, "CID"], [9, 9, 157, 158, "CID"], [9, 9, 170, 171, "CID"], [9, 9, 252, 252, "CID"], [9, 9, 308, 308, "CID"], [9, 9, 318, 318, "CID"], [9, 9, 356, 357, "CID"], [32, 32, 7, 7, "CID"], [32, 32, 35, 35, "CID"], [32, 32, 53, 53, "CID"], [32, 32, 114, 114, "CID"], [32, 32, 157, 158, "CID"], [32, 32, 170, 171, "CID"], [32, 32, 252, 252, "CID"], [32, 32, 308, 308, "CID"], [32, 32, 318, 318, "CID"], [32, 32, 356, 357, "CID"], [39, 39, 7, 7, "CID"], [39, 39, 35, 35, "CID"], [39, 39, 53, 53, "CID"], [39, 39, 114, 114, "CID"], [39, 39, 157, 158, "CID"], [39, 39, 170, 171, "CID"], [39, 39, 252, 252, "CID"], [39, 39, 308, 308, "CID"], [39, 39, 318, 318, "CID"], [39, 39, 356, 357, "CID"], [50, 50, 7, 7, "CID"], [50, 50, 35, 35, "CID"], [50, 50, 53, 53, "CID"], [50, 50, 114, 114, "CID"], [50, 50, 157, 158, "CID"], [50, 50, 170, 171, "CID"], [50, 50, 252, 252, "CID"], [50, 50, 308, 308, "CID"], [50, 50, 318, 318, "CID"], [50, 50, 356, 357, "CID"], [86, 86, 7, 7, "CID"], [86, 86, 35, 35, "CID"], [86, 86, 53, 53, "CID"], [86, 86, 114, 114, "CID"], [86, 86, 157, 158, "CID"], [86, 86, 170, 171, "CID"], [86, 86, 252, 252, "CID"], [86, 86, 308, 308, "CID"], [86, 86, 318, 318, "CID"], [86, 86, 356, 357, "CID"], [111, 111, 7, 7, "CID"], [111, 111, 35, 35, "CID"], [111, 111, 53, 53, "CID"], [111, 111, 114, 114, "CID"], [111, 111, 157, 158, "CID"], [111, 111, 170, 171, "CID"], [111, 111, 252, 252, "CID"], [111, 111, 308, 308, "CID"], [111, 111, 318, 318, "CID"], [111, 111, 356, 357, "CID"], [242, 242, 7, 7, "CID"], [242, 242, 35, 35, "CID"], [242, 242, 53, 53, "CID"], [242, 242, 114, 114, "CID"], [242, 242, 157, 158, "CID"], [242, 242, 170, 171, "CID"], [242, 242, 252, 252, "CID"], [242, 242, 308, 308, "CID"], [242, 242, 318, 318, "CID"], [242, 242, 356, 357, "CID"], [249, 249, 7, 7, "CID"], [249, 249, 35, 35, "CID"], [249, 249, 53, 53, "CID"], [249, 249, 114, 114, "CID"], [249, 249, 157, 158, "CID"], [249, 249, 170, 171, "CID"], [249, 249, 252, 252, "CID"], [249, 249, 308, 308, "CID"], [249, 249, 318, 318, "CID"], [249, 249, 356, 357, "CID"], [322, 322, 7, 7, "CID"], [322, 322, 35, 35, "CID"], [322, 322, 53, 53, "CID"], [322, 322, 114, 114, "CID"], [322, 322, 157, 158, "CID"], [322, 322, 170, 171, "CID"], [322, 322, 252, 252, "CID"], [322, 322, 308, 308, "CID"], [322, 322, 318, 318, "CID"], [322, 322, 356, 357, "CID"], [340, 340, 7, 7, "CID"], [340, 340, 35, 35, "CID"], [340, 340, 53, 53, "CID"], [340, 340, 114, 114, "CID"], [340, 340, 157, 158, "CID"], [340, 340, 170, 171, "CID"], [340, 340, 252, 252, "CID"], [340, 340, 308, 308, "CID"], [340, 340, 318, 318, "CID"], [340, 340, 356, 357, "CID"], [350, 350, 7, 7, "CID"], [350, 350, 35, 35, "CID"], [350, 350, 53, 53, "CID"], [350, 350, 114, 114, "CID"], [350, 350, 157, 158, "CID"], [350, 350, 170, 171, "CID"], [350, 350, 252, 252, "CID"], [350, 350, 308, 308, "CID"], [350, 350, 318, 318, "CID"], [350, 350, 356, 357, "CID"], [6, 6, 198, 199, "CID"], [9, 9, 198, 199, "CID"], [32, 32, 198, 199, "CID"], [39, 39, 198, 199, "CID"], [50, 50, 198, 199, "CID"], [86, 86, 198, 199, "CID"], [111, 111, 198, 199, "CID"], [242, 242, 198, 199, "CID"], [249, 249, 198, 199, "CID"], [322, 322, 198, 199, "CID"], [340, 340, 198, 199, "CID"], [350, 350, 198, 199, "CID"], [6, 6, 219, 221, "CID"], [6, 6, 280, 282, "CID"], [6, 6, 335, 336, "CID"], [9, 9, 219, 221, "CID"], [9, 9, 280, 282, "CID"], [9, 9, 335, 336, "CID"], [32, 32, 219, 221, "CID"], [32, 32, 280, 282, "CID"], [32, 32, 335, 336, "CID"], [39, 39, 219, 221, "CID"], [39, 39, 280, 282, "CID"], [39, 39, 335, 336, "CID"], [50, 50, 219, 221, "CID"], [50, 50, 280, 282, "CID"], [50, 50, 335, 336, "CID"], [86, 86, 219, 221, "CID"], [86, 86, 280, 282, "CID"], [86, 86, 335, 336, "CID"], [111, 111, 219, 221, "CID"], [111, 111, 280, 282, "CID"], [111, 111, 335, 336, "CID"], [242, 242, 219, 221, "CID"], [242, 242, 280, 282, "CID"], [242, 242, 335, 336, "CID"], [249, 249, 219, 221, "CID"], [249, 249, 280, 282, "CID"], [249, 249, 335, 336, "CID"], [322, 322, 219, 221, "CID"], [322, 322, 280, 282, "CID"], [322, 322, 335, 336, "CID"], [340, 340, 219, 221, "CID"], [340, 340, 280, 282, "CID"], [340, 340, 335, 336, "CID"], [350, 350, 219, 221, "CID"], [350, 350, 280, 282, "CID"], [350, 350, 335, 336, "CID"]]], "clusters": [], "translated": "马来西亚<1>甲基苯丙胺</1>依赖患者<0>甲基苯丙胺</0><12>精神病</12>的风险及相关因素。目的：本研究的目的是确定<3>甲基苯丙胺</3>依赖患者终生和当前<2>甲基苯丙胺</2>诱发的<13>精神病</13>的风险。还研究了精神病合并症与<4>甲基苯丙胺</4>引起的<14>精神病</14>之间的关系。方法：这是一项横断面研究，在马来西亚的一家教学医院和一家戒毒中心同时进行。根据 DSM-IV 诊断为<5>甲基苯丙胺</5>的患者使用迷你国际神经精神病学访谈 (M.I.N.I.)对<6>甲基苯丙胺</6>诱导的<15>精神病</15>和其他 Axis I<26>精神障碍</26>进行了访谈。有关社会人口学背景和药物使用史的信息是从面谈或医疗记录中获得的。结果：292 名受试者中，47.9%的受试者有<16>精神病症状</16>和13.0%的患者目前有<17>精神病症状</17>。合并重度<27>抑郁症</27>(OR = 7.18, 95 CI = 2.612-19.708)，<22>双相情感障碍</22> (OR = 13.807, 95 CI = 5.194-36.706)，<23>反社会人格障碍</23> (OR = 12.619, 95 CI = 6.702-23.759)和重<7>甲基苯丙胺</7>使用调整其他因素后，与终生<8>甲基苯丙胺</8>诱发的<18>精神病</18>显着相关。<28>重度抑郁症</28> (OR = 2.870, CI = 1.154-7.142)和<24>反社会人格障碍</24> (OR = 3.299, 95 CI = 1.375-7.914)是与当前<19>精神病</19>相关的唯一因素。结论：<9>甲基苯丙胺</9>依赖患者发生<20>精神病</20>的风险较高。它与共病<29>情感障碍</29>、<25>反社会人格</25>和重度<10>甲基苯丙胺</10>使用有关。建议对所有<11>甲基苯丙胺</11>依赖病例进行<21>精神病症状</21>筛查。", "revised": true}
{"doc_key": "23949582", "sentences": [["The", "cytogenetic", "action", "of", "ifosfamide", ",", "mesna", ",", "and", "their", "combination", "on", "peripheral", "rabbit", "lymphocytes", ":", "an", "in", "vivo", "/", "in", "vitro", "cytogenetic", "study", ".", "Ifosfamide", "(", "IFO", ")", "is", "an", "alkylating", "nitrogen", "mustard", ",", "administrated", "as", "an", "antineoplasmic", "agent", ".", "It", "is", "characterized", "by", "its", "intense", "urotoxic", "action", ",", "leading", "to", "hemorrhagic", "cystitis", ".", "This", "side", "effect", "of", "IFO", "raises", "the", "requirement", "for", "the", "co", "-", "administration", "with", "sodium", "2", "-", "sulfanylethanesulfonate", "(", "Mesna", ")", "aiming", "to", "avoid", "or", "minimize", "this", "effect", ".", "IFO", "and", "Mesna", "were", "administrated", "separately", "on", "rabbit", "'s", "lymphocytes", "in", "vivo", ",", "which", "were", "later", "developed", "in", "vitro", ".", "Cytogenetic", "markers", "for", "sister", "chromatid", "exchanges", "(", "SCEs", ")", ",", "proliferation", "rate", "index", "(", "PRI", ")", "and", "Mitotic", "Index", "were", "recorded", ".", "Mesna", "'s", "action", ",", "in", "conjunction", "with", "IFO", "reduces", "the", "frequency", "of", "SCEs", ",", "in", "comparison", "with", "the", "SCEs", "recordings", "obtained", "when", "IFO", "is", "administered", "alone", ".", "In", "addition", "to", "this", ",", "when", "high", "concentrations", "of", "Mesna", "were", "administered", "alone", "significant", "reductions", "of", "the", "PRI", "were", "noted", ",", "than", "with", "IFO", "acting", "at", "the", "same", "concentration", "on", "the", "lymphocytes", ".", "Mesna", "significantly", "reduces", "IFO", "'s", "genotoxicity", ",", "while", "when", "administered", "in", "high", "concentrations", "it", "acts", "in", "an", "inhibitory", "fashion", "on", "the", "cytostatic", "action", "of", "the", "drug", "."]], "ner": [[[4, 4, "Chemical"], [25, 25, "Chemical"], [27, 27, "Chemical"], [59, 59, "Chemical"], [84, 84, "Chemical"], [133, 133, "Chemical"], [148, 148, "Chemical"], [176, 176, "Chemical"], [189, 189, "Chemical"], [52, 53, "Disease"], [191, 191, "Disease"], [6, 6, "Chemical"], [69, 72, "Chemical"], [74, 74, "Chemical"], [86, 86, "Chemical"], [126, 126, "Chemical"], [162, 162, "Chemical"], [186, 186, "Chemical"], [32, 32, "Chemical"]]], "relations": [[[4, 4, 52, 53, "CID"], [25, 25, 52, 53, "CID"], [27, 27, 52, 53, "CID"], [59, 59, 52, 53, "CID"], [84, 84, 52, 53, "CID"], [133, 133, 52, 53, "CID"], [148, 148, 52, 53, "CID"], [176, 176, 52, 53, "CID"], [189, 189, 52, 53, "CID"]]], "clusters": [], "translated": "<0>异环磷酰胺</0>、<11>美司钠</11>及其联合用药对兔外周淋巴细胞的细胞遗传学作用：体内/体外细胞遗传学研究。<1>Ifosfamide</1>(<2>IFO</2>)是一种烷基化<18>氮</18>芥子气，用作抗肿瘤药。它的特点是具有强烈的尿毒作用，可导致<9>出血性膀胱炎</9>。<3>IFO</3>的这一副作用提出了与<12>2-硫烷基乙磺酸钠</12>(<13>美司钠</13>)联合用药的要求，旨在避免或尽量减少这种影响。<4>IFO</4>和<14>Mesna</14>分别给药于兔体内淋巴细胞，随后体外培养。记录了姐妹染色单体交换(<15>SCEs</15>)、<16>增殖率指数(PRI)</16>和<17>有丝分裂指数</17>的细胞遗传学标记。<15>美司钠</15>的作用与<5>IFO</5>相结合，与单独使用<6>IFO</6>时获得的<SCEs>记录相比，减少了<15>SCEs</15>的频率。除此之外，当单独使用高浓度的<16>Mesna</16>时，与作用于淋巴细胞的相同浓度的<7>IFO</7>相比，<16>PRI</16>显着降低。<17> Mesna</17>显着降低<8>IFO</8>的<10>遗传毒性</10>，而当以高浓度给药时，它以抑制方式抑制药物的细胞生长作用。", "revised": true}
{"doc_key": "24100257", "sentences": [["Takotsubo", "syndrome", "(", "or", "apical", "ballooning", "syndrome", ")", "secondary", "to", "Zolmitriptan", ".", "Takotsubo", "syndrome", "(", "TS", ")", ",", "also", "known", "as", "broken", "heart", "syndrome", ",", "is", "characterized", "by", "left", "ventricle", "apical", "ballooning", "with", "elevated", "cardiac", "biomarkers", "and", "electrocardiographic", "changes", "suggestive", "of", "an", "acute", "coronary", "syndrome", "(", "ie", ",", "ST", "-", "segment", "elevation", ",", "T", "wave", "inversions", ",", "and", "pathologic", "Q", "waves", ")", ".", "We", "report", "a", "case", "of", "54", "-", "year", "-", "old", "woman", "with", "medical", "history", "of", "mitral", "valve", "prolapse", "and", "migraines", ",", "who", "was", "admitted", "to", "the", "hospital", "for", "substernal", "chest", "pain", "and", "electrocardiogram", "demonstrated", "1", "/", "2", "mm", "ST", "-", "segment", "elevation", "in", "leads", "II", ",", "III", ",", "aVF", ",", "V5", ",", "and", "V6", "and", "positive", "troponin", "I", ".", "Emergent", "coronary", "angiogram", "revealed", "normal", "coronary", "arteries", "with", "moderately", "reduced", "left", "ventricular", "ejection", "fraction", "with", "wall", "motion", "abnormalities", "consistent", "with", "TS", ".", "Detailed", "history", "obtained", "retrospectively", "revealed", "that", "the", "patient", "took", "zolmitriptan", "sparingly", "only", "when", "she", "had", "migraines", ".", "But", "before", "this", "event", ",", "she", "was", "taking", "zolmitriptan", "2", "-", "3", "times", "daily", "for", "several", "days", "because", "of", "a", "persistent", "migraine", "headache", ".", "She", "otherwise", "reported", "that", "she", "is", "quite", "active", ",", "rides", "horses", ",", "and", "does", "show", "jumping", "without", "any", "limitations", "in", "her", "physical", "activity", ".", "There", "was", "no", "evidence", "of", "any", "recent", "stress", "or", "status", "migrainosus", ".", "Extensive", "literature", "search", "revealed", "multiple", "cases", "of", "coronary", "artery", "vasospasm", "secondary", "to", "zolmitriptan", ",", "but", "none", "of", "the", "cases", "were", "associated", "with", "TS", "."]], "ner": [[[10, 10, "Chemical"], [153, 153, "Chemical"], [169, 169, "Chemical"], [233, 233, "Chemical"], [0, 1, "Disease"], [4, 6, "Disease"], [12, 13, "Disease"], [15, 15, "Disease"], [21, 23, "Disease"], [142, 142, "Disease"], [243, 243, "Disease"], [228, 230, "Disease"], [42, 44, "Disease"], [78, 80, "Disease"], [82, 82, "Disease"], [159, 159, "Disease"], [182, 183, "Disease"], [218, 219, "Disease"], [92, 93, "Disease"]]], "relations": [[[10, 10, 0, 1, "CID"], [10, 10, 4, 6, "CID"], [10, 10, 12, 13, "CID"], [10, 10, 15, 15, "CID"], [10, 10, 21, 23, "CID"], [10, 10, 142, 142, "CID"], [10, 10, 243, 243, "CID"], [153, 153, 0, 1, "CID"], [153, 153, 4, 6, "CID"], [153, 153, 12, 13, "CID"], [153, 153, 15, 15, "CID"], [153, 153, 21, 23, "CID"], [153, 153, 142, 142, "CID"], [153, 153, 243, 243, "CID"], [169, 169, 0, 1, "CID"], [169, 169, 4, 6, "CID"], [169, 169, 12, 13, "CID"], [169, 169, 15, 15, "CID"], [169, 169, 21, 23, "CID"], [169, 169, 142, 142, "CID"], [169, 169, 243, 243, "CID"], [233, 233, 0, 1, "CID"], [233, 233, 4, 6, "CID"], [233, 233, 12, 13, "CID"], [233, 233, 15, 15, "CID"], [233, 233, 21, 23, "CID"], [233, 233, 142, 142, "CID"], [233, 233, 243, 243, "CID"], [10, 10, 228, 230, "CID"], [153, 153, 228, 230, "CID"], [169, 169, 228, 230, "CID"], [233, 233, 228, 230, "CID"]]], "clusters": [], "translated": "<4>Takotsubo综合征</4>（或<5>根尖气球样变综合征</5>）继发于<0>Zolmitriptan</0>。<6>Takotsubo综合征</6>（<7>TS</7>），也称为<8>心碎综合征</8>，其特征是左心室心尖球形扩张伴心脏生物标志物升高和心电图改变提示<12>急性冠脉综合征</12>（即ST段抬高，T波倒置和病理性Q波）。我们报告一例54岁女性，有<13>二尖瓣脱垂</13>和<14>偏头痛</14>病史，因胸骨后<18>胸痛</18>和心电图显示II、III、aVF、V5和V6导联ST段抬高1/2mm，肌钙蛋白I阳性。急诊冠状动脉造影显示冠状动脉正常，左心室射血分数中度降低，室壁运动异常符合<9>TS</9>。回顾性获得的详细病史显示，该患者仅在出现<15>偏头痛</15>时才少量服用<1>佐米曲普坦</1>。但在此事件之前，由于持续的<16>偏头痛</16>，她每天服用<2>佐米曲普坦</2>2-3次，连续几天。此外，她报告说她非常活跃，骑马，并在她的身体活动中不受任何限制地展示跳跃。没有任何近期压力或<17>偏头痛状态</17>的证据。广泛的文献检索显示多例<11>冠状动脉血管痉挛</11>继发于<3>佐米曲普坦</3>，但没有一例与<10>TS</10>相关。", "revised": true}
{"doc_key": "24091473", "sentences": [["Resuscitation", "with", "lipid", ",", "epinephrine", ",", "or", "both", "in", "levobupivacaine", "-", "induced", "cardiac", "toxicity", "in", "newborn", "piglets", ".", "BACKGROUND", ":", "The", "optimal", "dosing", "regimens", "of", "lipid", "emulsion", ",", "epinephrine", ",", "or", "both", "are", "not", "yet", "determined", "in", "neonates", "in", "cases", "of", "local", "anaesthetic", "systemic", "toxicity", "(", "LAST", ")", ".", "METHODS", ":", "Newborn", "piglets", "received", "levobupivacaine", "until", "cardiovascular", "collapse", "occurred", ".", "Standard", "cardiopulmonary", "resuscitation", "was", "started", "and", "electrocardiogram", "(", "ECG", ")", "was", "monitored", "for", "ventricular", "tachycardia", ",", "fibrillation", ",", "or", "QRS", "prolongation", ".", "Piglets", "were", "then", "randomly", "allocated", "to", "four", "groups", ":", "control", "(", "saline", ")", ",", "Intralipid", "(", ")", "alone", ",", "epinephrine", "alone", ",", "or", "a", "combination", "of", "Intralipd", "plus", "epinephrine", ".", "Resuscitation", "continued", "for", "30", "min", "or", "until", "there", "was", "a", "return", "of", "spontaneous", "circulation", "(", "ROSC", ")", "accompanied", "by", "a", "mean", "arterial", "pressure", "at", "or", "superior", "to", "the", "baseline", "pressure", "and", "normal", "sinus", "rhythm", "for", "a", "period", "of", "30", "min", ".", "RESULTS", ":", "ROSC", "was", "achieved", "in", "only", "one", "of", "the", "control", "piglets", "compared", "with", "most", "of", "the", "treated", "piglets", ".", "Mortality", "was", "not", "significantly", "different", "between", "the", "three", "treatment", "groups", ",", "but", "was", "significantly", "lower", "in", "all", "the", "treatment", "groups", "compared", "with", "control", ".", "The", "number", "of", "ECG", "abnormalities", "was", "zero", "in", "the", "Intralipid", "only", "group", ",", "but", "14", "and", "17", ",", "respectively", ",", "in", "the", "epinephrine", "and", "epinephrine", "plus", "lipid", "groups", "(", "P", "<", "0", ".", "05", ")", ".", "CONCLUSIONS", ":", "Lipid", "emulsion", "with", "or", "without", "epinephrine", ",", "or", "epinephrine", "alone", "were", "equally", "effective", "in", "achieving", "a", "return", "to", "spontaneous", "circulation", "in", "this", "model", "of", "LAST", ".", "Epinephrine", "alone", "or", "in", "combination", "with", "lipid", "was", "associated", "with", "an", "increased", "number", "of", "ECG", "abnormalities", "compared", "with", "lipid", "emulsion", "alone", "."]], "ner": [[[9, 9, "Chemical"], [54, 54, "Chemical"], [56, 57, "Disease"], [4, 4, "Chemical"], [28, 28, "Chemical"], [101, 101, "Chemical"], [110, 110, "Chemical"], [219, 219, "Chemical"], [221, 221, "Chemical"], [240, 240, "Chemical"], [243, 243, "Chemical"], [261, 261, "Chemical"], [12, 13, "Disease"], [44, 44, "Disease"], [73, 74, "Disease"], [76, 76, "Disease"]]], "relations": [[[9, 9, 56, 57, "CID"], [54, 54, 56, 57, "CID"]]], "clusters": [], "translated": "在新生仔猪<0>左布比卡因</0>诱导的<12>心脏毒性</12>中，使用脂质、<3>肾上腺素</3>或两者进行复苏。背景：脂肪乳剂、<4>肾上腺素</4>或两者的最佳给药方案尚未确定在新生儿局部麻醉剂全身性<13>毒性</13> (LAST) 病例中。方法：新生仔猪接受<1>左旋布比卡因</1>直至发生<2>心血管衰竭</2>。开始标准心肺复苏并监测心电图 (ECG) 是否有<14>室性心动过速</14>、<15>颤动</15>或 QRS 延长。然后将仔猪随机分配到四组：对照组（生理盐水）、单独使用Intralipid()、单独使用<5>肾上腺素</5>或Intralipd加<6>肾上腺素</6>的组合。复苏持续30分钟或直到自主循环(ROSC)恢复，平均动脉压等于或高于基线压和正常窦性心律30分钟。结果：与大多数接受治疗的仔猪相比，只有一只对照仔猪实现了ROSC。死亡率在三个治疗组之间没有显着差异，但与对照组相比，所有治疗组的死亡率均显着降低。仅Intralipid组ECG异常数为0，而<7>肾上腺素</7>和<8>肾上腺素</8>加脂质组分别为14和17(P<0.05)。结论：脂肪乳剂加或不加<9>肾上腺素</9>，或单独使用<10>肾上腺素</10>在该LAST模型中恢复自主循环同样有效。<11>肾上腺素</11>单独使用或与脂质联合使用与单独使用脂质乳剂相比心电图异常数量增加有关。", "revised": true}
{"doc_key": "24100055", "sentences": [["Incidence", "of", "heparin", "-", "induced", "thrombocytopenia", "type", "II", "and", "postoperative", "recovery", "of", "platelet", "count", "in", "liver", "graft", "recipients", ":", "a", "retrospective", "cohort", "analysis", ".", "BACKGROUND", ":", "Thrombocytopenia", "in", "patients", "with", "end", "-", "stage", "liver", "disease", "is", "a", "common", "disorder", "caused", "mainly", "by", "portal", "hypertension", ",", "low", "levels", "of", "thrombopoetin", ",", "and", "endotoxemia", ".", "The", "impact", "of", "immune", "-", "mediated", "heparin", "-", "induced", "thrombocytopenia", "type", "II", "(", "HIT", "type", "II", ")", "as", "a", "cause", "of", "thrombocytopenia", "after", "liver", "transplantation", "is", "not", "yet", "understood", ",", "with", "few", "literature", "citations", "reporting", "contradictory", "results", ".", "The", "aim", "of", "our", "study", "was", "to", "demonstrate", "the", "perioperative", "course", "of", "thrombocytopenia", "after", "liver", "transplantation", "and", "determine", "the", "occurrence", "of", "clinical", "HIT", "type", "II", ".", "METHOD", ":", "We", "retrospectively", "evaluated", "the", "medical", "records", "of", "205", "consecutive", "adult", "patients", "who", "underwent", "full", "-", "size", "liver", "transplantation", "between", "January", "2006", "and", "December", "2010", "due", "to", "end", "-", "stage", "or", "malignant", "liver", "disease", ".", "Preoperative", "platelet", "count", ",", "postoperative", "course", "of", "platelets", ",", "and", "clinical", "signs", "of", "HIT", "type", "II", "were", "analyzed", ".", "RESULTS", ":", "A", "total", "of", "155", "(", "75", ".", "6", "%", ")", "of", "205", "patients", "had", "thrombocytopenia", "before", "transplantation", ",", "significantly", "influenced", "by", "Model", "of", "End", "-", "Stage", "Liver", "Disease", "score", "and", "liver", "cirrhosis", ".", "The", "platelet", "count", "exceeded", "100", ",", "000", "/", "uL", "in", "most", "of", "the", "patients", "(", "n", "=", "193", ")", "at", "a", "medium", "of", "7", "d", ".", "Regarding", "HIT", "II", ",", "there", "were", "four", "(", "1", ".", "95", "%", ")", "patients", "with", "a", "background", "of", "HIT", "type", "II", ".", "CONCLUSIONS", ":", "The", "incidence", "of", "HIT", "in", "patients", "with", "end", "-", "stage", "hepatic", "failure", "is", ",", "with", "about", "1", ".", "95", "%", ",", "rare", ".", "For", "further", "reduction", "of", "HIT", "type", "II", ",", "the", "use", "of", "intravenous", "heparin", "should", "be", "avoided", "and", "the", "prophylactic", "anticoagulation", "should", "be", "performed", "with", "low", "-", "molecular", "-", "weight", "heparin", "after", "normalization", "of", "platelet", "count", "."]], "ner": [[[2, 2, "Chemical"], [59, 59, "Chemical"], [292, 292, "Chemical"], [309, 309, "Chemical"], [5, 7, "Disease"], [26, 26, "Disease"], [62, 64, "Disease"], [66, 68, "Disease"], [74, 74, "Disease"], [103, 103, "Disease"], [113, 115, "Disease"], [166, 168, "Disease"], [188, 188, "Disease"], [234, 235, "Disease"], [251, 253, "Disease"], [260, 260, "Disease"], [284, 286, "Disease"], [30, 34, "Disease"], [145, 151, "Disease"], [197, 201, "Disease"], [264, 268, "Disease"], [42, 43, "Disease"], [51, 51, "Disease"], [204, 205, "Disease"]]], "relations": [[[2, 2, 5, 7, "CID"], [2, 2, 26, 26, "CID"], [2, 2, 62, 64, "CID"], [2, 2, 66, 68, "CID"], [2, 2, 74, 74, "CID"], [2, 2, 103, 103, "CID"], [2, 2, 113, 115, "CID"], [2, 2, 166, 168, "CID"], [2, 2, 188, 188, "CID"], [2, 2, 234, 235, "CID"], [2, 2, 251, 253, "CID"], [2, 2, 260, 260, "CID"], [2, 2, 284, 286, "CID"], [59, 59, 5, 7, "CID"], [59, 59, 26, 26, "CID"], [59, 59, 62, 64, "CID"], [59, 59, 66, 68, "CID"], [59, 59, 74, 74, "CID"], [59, 59, 103, 103, "CID"], [59, 59, 113, 115, "CID"], [59, 59, 166, 168, "CID"], [59, 59, 188, 188, "CID"], [59, 59, 234, 235, "CID"], [59, 59, 251, 253, "CID"], [59, 59, 260, 260, "CID"], [59, 59, 284, 286, "CID"], [292, 292, 5, 7, "CID"], [292, 292, 26, 26, "CID"], [292, 292, 62, 64, "CID"], [292, 292, 66, 68, "CID"], [292, 292, 74, 74, "CID"], [292, 292, 103, 103, "CID"], [292, 292, 113, 115, "CID"], [292, 292, 166, 168, "CID"], [292, 292, 188, 188, "CID"], [292, 292, 234, 235, "CID"], [292, 292, 251, 253, "CID"], [292, 292, 260, 260, "CID"], [292, 292, 284, 286, "CID"], [309, 309, 5, 7, "CID"], [309, 309, 26, 26, "CID"], [309, 309, 62, 64, "CID"], [309, 309, 66, 68, "CID"], [309, 309, 74, 74, "CID"], [309, 309, 103, 103, "CID"], [309, 309, 113, 115, "CID"], [309, 309, 166, 168, "CID"], [309, 309, 188, 188, "CID"], [309, 309, 234, 235, "CID"], [309, 309, 251, 253, "CID"], [309, 309, 260, 260, "CID"], [309, 309, 284, 286, "CID"]]], "clusters": [], "translated": "<0>肝素</0>诱发的<4>II型血小板减少症</4>的发生率和肝移植受者术后血小板计数的恢复：一项回顾性队列分析。背景：在患有<17>终末期肝病</17>的患者中，<5>血小板减少症</5>是一种常见疾病，主要由于<21>门静脉高压症</21>、<22>内毒素血症</22>及血小板生成素水平低引起。对于肝移植后<8>血小板减少症</8>的原因，免疫介导的<1>肝素</1>诱导的<6>II型血小板减少症</6>（<7>II型HIT</7>）的影响尚未得到充分了解，只有极少的文献报道了相互矛盾的结果。本研究旨在研究肝移植后<9>血小板减少症</9>的围术期病情变化，并确定<10>Ⅱ型HIT</10>的临床发生情况。方法：我们回顾性分析了 205 名连续接受全尺寸肝移植的成年患者（2006年1月至2010年12月），因为患有<18>终末期或恶性肝病</18>。分析术前血小板计数、术后血小板变化过程及<11>Ⅱ型HIT</11>的临床表现。结果：共有 155 名（75 . 6 %）在移植前存在<12>血小板减少</12>，其中外科操作时<19>终末期肝病</19>评分和<23>肝硬化的影响</23>最大。大多数患者（n = 193）的血小板计数在 7 天内超过 100, 000 /μL。关于<13>Ⅱ型HIT</13>，有四名（1 . 95 %）患者有<14>Ⅱ型HIT</14>的背景。结论：在<20>终末期肝功能衰竭</20>患者中，<15>HIT</15>的发生率约为 1 . 95 %，非常罕见。为了进一步降低<16>II型HIT</16>的发生率，应避免使用静脉<2>肝素</2>，而采用低分子量<3>肝素</3>来进行预防性抗凝。同时，需在患者的<9>血小板减少症</9>恢复正常后进行此操作。", "revised": true}
{"doc_key": "24126708", "sentences": [["Association", "of", "common", "genetic", "variants", "of", "HOMER1", "gene", "with", "levodopa", "adverse", "effects", "in", "Parkinson", "'s", "disease", "patients", ".", "Levodopa", "is", "the", "most", "effective", "symptomatic", "therapy", "for", "Parkinson", "'s", "disease", ",", "but", "its", "chronic", "use", "could", "lead", "to", "chronic", "adverse", "outcomes", ",", "such", "as", "motor", "fluctuations", ",", "dyskinesia", "and", "visual", "hallucinations", ".", "HOMER1", "is", "a", "protein", "with", "pivotal", "function", "in", "glutamate", "transmission", ",", "which", "has", "been", "related", "to", "the", "pathogenesis", "of", "these", "complications", ".", "This", "study", "investigates", "whether", "polymorphisms", "in", "the", "HOMER1", "gene", "promoter", "region", "are", "associated", "with", "the", "occurrence", "of", "the", "chronic", "complications", "of", "levodopa", "therapy", ".", "A", "total", "of", "205", "patients", "with", "idiopathic", "Parkinson", "'s", "disease", "were", "investigated", ".", "Patients", "were", "genotyped", "for", "rs4704559", ",", "rs10942891", "and", "rs4704560", "by", "allelic", "discrimination", "with", "Taqman", "assays", ".", "The", "rs4704559", "G", "allele", "was", "associated", "with", "a", "lower", "prevalence", "of", "dyskinesia", "(", "prevalence", "ratio", "(", "PR", ")", "=", "0", ".", "615", ",", "95", "%", "confidence", "interval", "(", "CI", ")", "0", ".", "426", "-", "0", ".", "887", ",", "P", "=", "0", ".", "009", ")", "and", "visual", "hallucinations", "(", "PR", "=", "0", ".", "515", ",", "95", "%", "CI", "0", ".", "295", "-", "0", ".", "899", ",", "P", "=", "0", ".", "020", ")", ".", "Our", "data", "suggest", "that", "HOMER1", "rs4704559", "G", "allele", "has", "a", "protective", "role", "for", "the", "development", "of", "levodopa", "adverse", "effects", "."]], "ner": [[[9, 9, "Chemical"], [18, 18, "Chemical"], [94, 94, "Chemical"], [214, 214, "Chemical"], [46, 46, "Disease"], [137, 137, "Disease"], [48, 49, "Disease"], [171, 172, "Disease"], [13, 15, "Disease"], [26, 28, "Disease"], [103, 106, "Disease"], [59, 59, "Chemical"]]], "relations": [[[9, 9, 46, 46, "CID"], [9, 9, 137, 137, "CID"], [18, 18, 46, 46, "CID"], [18, 18, 137, 137, "CID"], [94, 94, 46, 46, "CID"], [94, 94, 137, 137, "CID"], [214, 214, 46, 46, "CID"], [214, 214, 137, 137, "CID"], [9, 9, 48, 49, "CID"], [9, 9, 171, 172, "CID"], [18, 18, 48, 49, "CID"], [18, 18, 171, 172, "CID"], [94, 94, 48, 49, "CID"], [94, 94, 171, 172, "CID"], [214, 214, 48, 49, "CID"], [214, 214, 171, 172, "CID"]]], "clusters": [], "translated": "HOMER1 基因常见遗传变异与<8>帕金森病</8>患者<0>左旋多巴</0>不良反应的关联。 <1>左旋多巴</1>是<9>帕金森病</9>最有效的对症疗法，但长期使用它可能导致慢性不良后果，例如<5>运动障碍</5>、<4>异动症</4>和<6>视觉幻觉</6>。HOMER1是一种在<11>谷氨酸</11>传递中起关键作用的蛋白质，与这些并发症的发病机制有关。本研究探讨了HOMER1基因启动子区域的多态性是否与<2>左旋多巴</2>治疗慢性并发症的发生有关。共有205名<10>特发性帕金森病</10>患者接受了调查。通过Taqman分析等位基因鉴别，对患者进行rs4704559、rs10942891和rs4704560的基因分型。rs4704559 G 等位基因与较低的<5>运动障碍</5>患病率相关（患病率(PR) = 0.615，95%置信区间(CI) 0.426-0.887，P = 0.009）和<7>视觉幻觉</7>（PR = 0.515，95% CI 0.295-0.899，P = 0.020）。我们的数据表明，HOMER1 rs4704559 G 等位基因对<3>左旋多巴</3>不良反应的发生具有保护作用。", "revised": true}
{"doc_key": "24234943", "sentences": [["Syndrome", "of", "inappropriate", "antidiuretic", "hormone", "secretion", "associated", "with", "desvenlafaxine", ".", "OBJECTIVE", ":", "To", "report", "a", "case", "of", "syndrome", "of", "inappropriate", "anti", "-", "diuretic", "hormone", "(", "SIADH", ")", "secretion", "associated", "with", "desvenlafaxine", ".", "CASE", "SUMMARY", ":", "A", "57", "-", "year", "old", "female", "with", "hyponatraemia", ".", "Her", "medications", "included", "desvenlafaxine", ",", "and", "symptoms", "included", "nausea", ",", "anxiety", "and", "confusion", ".", "The", "serum", "sodium", "at", "this", "time", "was", "120", "mmol", "/", "L", ",", "serum", "osmolality", "was", "263", "mosmol", "/", "kg", ",", "urine", "osmolality", "410", "mosmol", "/", "kg", "and", "urine", "sodium", "63", "mmol", "/", "L", ",", "consistent", "with", "a", "diagnosis", "of", "SIADH", ".", "Desvenlafaxine", "was", "ceased", "and", "fluid", "restriction", "implemented", ".", "After", "4", "days", "the", "sodium", "increased", "to", "128", "mmol", "/", "L", "and", "fluid", "restriction", "was", "relaxed", ".", "During", "her", "further", "3", "weeks", "inpatient", "admission", "the", "serum", "sodium", "ranged", "from", "134", "to", "137", "mmol", "/", "L", "during", "treatment", "with", "mirtazapine", ".", "DISCUSSION", ":", "SIADH", "has", "been", "widely", "reported", "with", "a", "range", "of", "antidepressants", ".", "This", "case", "report", "suggests", "that", "desvenlafaxine", "might", "cause", "clinically", "significant", "hyponatremia", ".", "CONCLUSIONS", ":", "Clinicians", "should", "be", "aware", "of", "the", "potential", "for", "antidepressants", "to", "cause", "hyponatremia", ",", "and", "take", "appropriate", "corrective", "action", "where", "necessary", "."]], "ner": [[[8, 8, "Chemical"], [30, 30, "Chemical"], [47, 47, "Chemical"], [99, 99, "Chemical"], [165, 165, "Chemical"], [0, 4, "Disease"], [17, 23, "Disease"], [25, 25, "Disease"], [97, 97, "Disease"], [149, 149, "Disease"], [42, 42, "Disease"], [170, 170, "Disease"], [185, 185, "Disease"], [52, 52, "Disease"], [54, 54, "Disease"], [56, 56, "Disease"], [60, 60, "Chemical"], [86, 86, "Chemical"], [111, 111, "Chemical"], [133, 133, "Chemical"], [145, 145, "Chemical"]]], "relations": [[[8, 8, 0, 4, "CID"], [8, 8, 17, 23, "CID"], [8, 8, 25, 25, "CID"], [8, 8, 97, 97, "CID"], [8, 8, 149, 149, "CID"], [30, 30, 0, 4, "CID"], [30, 30, 17, 23, "CID"], [30, 30, 25, 25, "CID"], [30, 30, 97, 97, "CID"], [30, 30, 149, 149, "CID"], [47, 47, 0, 4, "CID"], [47, 47, 17, 23, "CID"], [47, 47, 25, 25, "CID"], [47, 47, 97, 97, "CID"], [47, 47, 149, 149, "CID"], [99, 99, 0, 4, "CID"], [99, 99, 17, 23, "CID"], [99, 99, 25, 25, "CID"], [99, 99, 97, 97, "CID"], [99, 99, 149, 149, "CID"], [165, 165, 0, 4, "CID"], [165, 165, 17, 23, "CID"], [165, 165, 25, 25, "CID"], [165, 165, 97, 97, "CID"], [165, 165, 149, 149, "CID"], [8, 8, 42, 42, "CID"], [8, 8, 170, 170, "CID"], [8, 8, 185, 185, "CID"], [30, 30, 42, 42, "CID"], [30, 30, 170, 170, "CID"], [30, 30, 185, 185, "CID"], [47, 47, 42, 42, "CID"], [47, 47, 170, 170, "CID"], [47, 47, 185, 185, "CID"], [99, 99, 42, 42, "CID"], [99, 99, 170, 170, "CID"], [99, 99, 185, 185, "CID"], [165, 165, 42, 42, "CID"], [165, 165, 170, 170, "CID"], [165, 165, 185, 185, "CID"], [8, 8, 52, 52, "CID"], [30, 30, 52, 52, "CID"], [47, 47, 52, 52, "CID"], [99, 99, 52, 52, "CID"], [165, 165, 52, 52, "CID"], [8, 8, 54, 54, "CID"], [30, 30, 54, 54, "CID"], [47, 47, 54, 54, "CID"], [99, 99, 54, 54, "CID"], [165, 165, 54, 54, "CID"], [8, 8, 56, 56, "CID"], [30, 30, 56, 56, "CID"], [47, 47, 56, 56, "CID"], [99, 99, 56, 56, "CID"], [165, 165, 56, 56, "CID"]]], "clusters": [], "translated": "<5>抗利尿激素异常</5>分泌综合征与<0>去甲文拉法辛</0>有关。目的：报道一例与<1>去甲文拉法辛</1>相关的<6>抗利尿激素异常</6> (<7>SIADH</7>) 分泌综合征 1 例。病例概要：一名 57 岁的女性，患有<10>低钠血症</10>。她服用的药物包括<2>去甲文拉法辛</2>，症状包括<13>恶心</13>、<14>焦虑</14> 和<15>意识模糊</15>。此时血清<16>钠</16>为 120 mmol/L，血清渗透压为 263 mosmol/kg，尿渗透压为 410 mosmol/kg，尿<17>钠</17>为 63 mmol/L，符合<8>SIADH</8>的诊断。<3>去甲文拉法辛</3>被停用并实施液体限制。四天后，<18>钠</18>升至 128 mmol/L并放宽了液体限制。在她入院后的三周内，接受 <20>米氮平</20> 治疗期间，血清<19>钠</19>的范围为 134 至 137 mmol/L。讨论：<9>SIADH</9>已被广泛报道与一系列抗抑郁药有关。该病例报告表明，<4>去甲文拉法辛</4>可能会导致具有临床意义的<11>低钠血症</11>。结论：临床医生应意识到抗抑郁药可能引起<12>低钠血症</12>，并在必要时采取适当的纠正措施。", "revised": true}
{"doc_key": "24283660", "sentences": [["Tacrolimus", "-", "related", "seizure", "after", "pediatric", "liver", "transplantation", "-", "-", "a", "single", "-", "center", "experience", ".", "To", "identify", "the", "risk", "factors", "for", "new", "-", "onset", "seizures", "after", "pediatric", "LT", "and", "to", "assess", "their", "clinical", "implications", "and", "long", "-", "term", "prognosis", ".", "The", "clinical", "and", "laboratory", "data", "of", "27", "consecutive", "children", "who", "underwent", "LT", "from", "January", "2007", "to", "December", "2010", "in", "our", "center", "were", "analyzed", "retrospectively", ".", "Patients", "were", "divided", "into", "seizures", "group", "and", "a", "non", "-", "seizures", "group", ".", "Pre", "-", "operative", ",", "intra", "-", "operative", ",", "and", "post", "-", "operative", "data", "were", "collected", ".", "Seizures", "occurred", "in", "four", "children", ",", "an", "incidence", "of", "14", ".", "8", "%", ".", "All", "exhibited", "generalized", "tonic", "-", "clonic", "seizures", "within", "the", "first", "two", "wk", "after", "LT", ".", "Univariate", "analysis", "showed", "that", "the", "risk", "factors", "associated", "with", "seizures", "after", "pediatric", "LT", "included", "gender", ",", "pediatric", "end", "-", "stage", "liver", "disease", "score", "before", "surgery", ",", "Child", "-", "Pugh", "score", "before", "surgery", ",", "serum", "total", "bilirubin", "after", "surgery", ",", "and", "trough", "TAC", "level", ".", "Multivariate", "analysis", "showed", "that", "trough", "TAC", "level", "was", "the", "only", "independent", "risk", "factor", "associated", "with", "the", "seizures", ".", "All", "children", "who", "experienced", "seizures", "survived", "with", "good", "graft", "function", "and", "remained", "seizure", "-", "free", "without", "anti", "-", "epileptic", "drugs", "over", "a", "mean", "follow", "-", "up", "period", "of", "33", ".", "7", "+", "14", ".", "6", "months", ".", "High", "trough", "TAC", "level", "was", "the", "predominant", "factor", "that", "contributed", "to", "seizures", "in", "the", "early", "post", "-", "operative", "period", "after", "pediatric", "LT", ".", "High", "PELD", "and", "Child", "-", "Pugh", "scores", "before", "LT", "and", "high", "post", "-", "operative", "serum", "Tbil", "may", "be", "contributory", "risk", "factors", "for", "TAC", "-", "related", "seizures", "."]], "ner": [[[0, 0, "Chemical"], [165, 165, "Chemical"], [173, 173, "Chemical"], [225, 225, "Chemical"], [268, 268, "Chemical"], [3, 3, "Disease"], [25, 25, "Disease"], [70, 70, "Disease"], [76, 76, "Disease"], [95, 95, "Disease"], [133, 133, "Disease"], [184, 184, "Disease"], [190, 190, "Disease"], [198, 198, "Disease"], [234, 234, "Disease"], [271, 271, "Disease"], [112, 115, "Disease"], [141, 145, "Disease"], [204, 204, "Disease"], [159, 159, "Chemical"]]], "relations": [[[0, 0, 3, 3, "CID"], [0, 0, 25, 25, "CID"], [0, 0, 70, 70, "CID"], [0, 0, 76, 76, "CID"], [0, 0, 95, 95, "CID"], [0, 0, 133, 133, "CID"], [0, 0, 184, 184, "CID"], [0, 0, 190, 190, "CID"], [0, 0, 198, 198, "CID"], [0, 0, 234, 234, "CID"], [0, 0, 271, 271, "CID"], [165, 165, 3, 3, "CID"], [165, 165, 25, 25, "CID"], [165, 165, 70, 70, "CID"], [165, 165, 76, 76, "CID"], [165, 165, 95, 95, "CID"], [165, 165, 133, 133, "CID"], [165, 165, 184, 184, "CID"], [165, 165, 190, 190, "CID"], [165, 165, 198, 198, "CID"], [165, 165, 234, 234, "CID"], [165, 165, 271, 271, "CID"], [173, 173, 3, 3, "CID"], [173, 173, 25, 25, "CID"], [173, 173, 70, 70, "CID"], [173, 173, 76, 76, "CID"], [173, 173, 95, 95, "CID"], [173, 173, 133, 133, "CID"], [173, 173, 184, 184, "CID"], [173, 173, 190, 190, "CID"], [173, 173, 198, 198, "CID"], [173, 173, 234, 234, "CID"], [173, 173, 271, 271, "CID"], [225, 225, 3, 3, "CID"], [225, 225, 25, 25, "CID"], [225, 225, 70, 70, "CID"], [225, 225, 76, 76, "CID"], [225, 225, 95, 95, "CID"], [225, 225, 133, 133, "CID"], [225, 225, 184, 184, "CID"], [225, 225, 190, 190, "CID"], [225, 225, 198, 198, "CID"], [225, 225, 234, 234, "CID"], [225, 225, 271, 271, "CID"], [268, 268, 3, 3, "CID"], [268, 268, 25, 25, "CID"], [268, 268, 70, 70, "CID"], [268, 268, 76, 76, "CID"], [268, 268, 95, 95, "CID"], [268, 268, 133, 133, "CID"], [268, 268, 184, 184, "CID"], [268, 268, 190, 190, "CID"], [268, 268, 198, 198, "CID"], [268, 268, 234, 234, "CID"], [268, 268, 271, 271, "CID"]]], "clusters": [], "translated": "小儿肝移植后<0>他克莫司</0>相关<5>癫痫发作</5> - 单中心经验。确定儿童 LT 后新发<6>癫痫发作</6>的危险因素，并评估其临床意义和长期预后。回顾性分析 2007 年 1 月至 2010 年 12 月在我中心接受肝移植的 27 例连续患儿的临床和实验室资料。患者分为<7>发作</7>组和非<8>发作</8>组。收集术前、术中和术后数据。<9>癫痫发作</9>发生在 4 名儿童中，发病率为 14.8%。在 LT 后的前两周内，所有患者均表现出全身性<16>强直-阵挛发作</16>。单因素分析显示，儿童肝移植后发生<10>癫痫</10>的危险因素包括性别、儿童<17>终末期肝病</17>术前评分、术前 Child-Pugh 评分、血清总<19>胆红素</19>和谷<1>TAC</1>水平。多变量分析表明，谷<2>TAC</2>水平是与<11>癫痫发作</11>相关的唯一独立危险因素。所有经历过<12>癫痫发作</12>的儿童都存活下来，移植物功能良好，并且在平均 33 年的随访期内保持<13>癫痫发作</13> - 没有抗<18>癫痫</18>药物。高谷<3>TAC</3>水平是导致儿童 LT 术后早期<14>癫痫发作</14>的主要因素。LT 前高 PELD 和 Child-Pugh 评分以及高术后血清 Tbil 可能是<4>TAC</4>相关<15>癫痫发作</15>的促成危险因素。", "revised": true}
{"doc_key": "24040781", "sentences": [["An", "unexpected", "diagnosis", "in", "a", "renal", "-", "transplant", "patient", "with", "proteinuria", "treated", "with", "everolimus", ":", "AL", "amyloidosis", ".", "Proteinuria", "is", "an", "expected", "complication", "in", "transplant", "patients", "treated", "with", "mammalian", "target", "of", "rapamycin", "inhibitors", "(", "mTOR", "-", "i", ")", ".", "However", ",", "clinical", "suspicion", "should", "always", "be", "supported", "by", "histological", "evidence", "in", "order", "to", "investigate", "potential", "alternate", "diagnoses", "such", "as", "acute", "or", "chronic", "rejection", ",", "interstitial", "fibrosis", "and", "tubular", "atrophy", ",", "or", "recurrent", "or", "de", "novo", "glomerulopathy", ".", "In", "this", "case", "we", "report", "the", "unexpected", "diagnosis", "of", "amyloidosis", "in", "a", "renal", "-", "transplant", "patient", "with", "pre", "-", "transplant", "monoclonal", "gammapathy", "of", "undetermined", "significance", "who", "developed", "proteinuria", "after", "conversion", "from", "tacrolimus", "to", "everolimus", "."]], "ner": [[[13, 13, "Chemical"], [110, 110, "Chemical"], [10, 10, "Disease"], [18, 18, "Disease"], [104, 104, "Disease"], [15, 15, "Disease"], [16, 16, "Disease"], [86, 86, "Disease"], [31, 31, "Chemical"], [108, 108, "Chemical"], [65, 65, "Disease"], [68, 68, "Disease"], [75, 75, "Disease"]]], "relations": [[[13, 13, 10, 10, "CID"], [13, 13, 18, 18, "CID"], [13, 13, 104, 104, "CID"], [110, 110, 10, 10, "CID"], [110, 110, 18, 18, "CID"], [110, 110, 104, 104, "CID"], [13, 13, 15, 15, "CID"], [13, 13, 16, 16, "CID"], [13, 13, 86, 86, "CID"], [110, 110, 15, 15, "CID"], [110, 110, 16, 16, "CID"], [110, 110, 86, 86, "CID"]]], "clusters": [], "translated": "<0>依维莫司</0>治疗<2>蛋白尿</2>肾移植患者的意外诊断：<5>AL</5><6>淀粉样变性</6>。<3>蛋白尿</3>是接受哺乳动物<8>雷帕霉素</8>靶点抑制剂(mTOR-i)治疗的移植患者的预期并发症。然而，临床怀疑应始终得到组织学证据的支持，以便调查潜在的替代诊断，例如急性或慢性排斥反应、间质<10>纤维化</10>和肾小管<11>萎缩</11>，或复发或新发<12>肾小球病</12>。在本案例中，我们报告了一名肾移植患者意外诊断出<7>淀粉样变性</7>，该患者患有移植前意义未明的单克隆丙种球蛋白病，在从<9>他克莫司</9>转化后出现<4>蛋白尿</4>，转化后使用的药物为<1>依维莫司</1>。", "revised": true}
{"doc_key": "24190587", "sentences": [["Basal", "functioning", "of", "the", "hypothalamic", "-", "pituitary", "-", "adrenal", "(", "HPA", ")", "axis", "and", "psychological", "distress", "in", "recreational", "ecstasy", "polydrug", "users", ".", "RATIONALE", ":", "Ecstasy", "(", "MDMA", ")", "is", "a", "psychostimulant", "drug", "which", "is", "increasingly", "associated", "with", "psychobiological", "dysfunction", ".", "While", "some", "recent", "studies", "suggest", "acute", "changes", "in", "neuroendocrine", "function", ",", "less", "is", "known", "about", "long", "-", "term", "changes", "in", "HPA", "functionality", "in", "recreational", "users", ".", "OBJECTIVES", ":", "The", "current", "study", "is", "the", "first", "to", "explore", "the", "effects", "of", "ecstasy", "-", "polydrug", "use", "on", "psychological", "distress", "and", "basal", "functioning", "of", "the", "HPA", "axis", "through", "assessing", "the", "secretion", "of", "cortisol", "across", "the", "diurnal", "period", ".", "METHOD", ":", "Seventy", "-", "six", "participants", "(", "21", "nonusers", ",", "29", "light", "ecstasy", "-", "polydrug", "users", ",", "26", "heavy", "ecstasy", "-", "polydrug", "users", ")", "completed", "a", "substance", "use", "inventory", "and", "measures", "of", "psychological", "distress", "at", "baseline", ",", "then", "two", "consecutive", "days", "of", "cortisol", "sampling", "(", "on", "awakening", ",", "30", "min", "post", "awakening", ",", "between", "1400", "and", "1600", "hours", "and", "pre", "bedtime", ")", ".", "On", "day", "2", ",", "participants", "also", "attended", "the", "laboratory", "to", "complete", "a", "20", "-", "min", "multitasking", "stressor", ".", "RESULTS", ":", "Both", "user", "groups", "exhibited", "significantly", "greater", "levels", "of", "anxiety", "and", "depression", "than", "nonusers", ".", "On", "day", "1", ",", "all", "participants", "exhibited", "a", "typical", "cortisol", "profile", ",", "though", "light", "users", "had", "significantly", "elevated", "levels", "pre", "-", "bed", ".", "On", "day", "2", ",", "heavy", "users", "demonstrated", "elevated", "levels", "upon", "awakening", "and", "all", "ecstasy", "-", "polydrug", "users", "demonstrated", "elevated", "pre", "-", "bed", "levels", "compared", "to", "non", "-", "users", ".", "Significant", "between", "group", "differences", "were", "also", "observed", "in", "afternoon", "cortisol", "levels", "and", "in", "overall", "cortisol", "secretion", "across", "the", "day", ".", "CONCLUSIONS", ":", "The", "increases", "in", "anxiety", "and", "depression", "are", "in", "line", "with", "previous", "observations", "in", "recreational", "ecstasy", "-", "polydrug", "users", ".", "Dysregulated", "diurnal", "cortisol", "may", "be", "indicative", "of", "inappropriate", "anticipation", "of", "forthcoming", "demands", "and", "hypersecretion", "may", "lead", "to", "the", "increased", "psychological", "and", "physical", "morbidity", "associated", "with", "heavy", "recreational", "use", "of", "ecstasy", "."]], "ner": [[[18, 18, "Chemical"], [24, 24, "Chemical"], [26, 26, "Chemical"], [79, 79, "Chemical"], [116, 116, "Chemical"], [123, 123, "Chemical"], [237, 237, "Chemical"], [289, 289, "Chemical"], [323, 323, "Chemical"], [197, 197, "Disease"], [280, 280, "Disease"], [37, 38, "Disease"], [195, 195, "Disease"], [278, 278, "Disease"], [98, 98, "Chemical"], [146, 146, "Chemical"], [210, 210, "Chemical"], [262, 262, "Chemical"], [267, 267, "Chemical"], [296, 296, "Chemical"]]], "relations": [[[18, 18, 197, 197, "CID"], [18, 18, 280, 280, "CID"], [24, 24, 197, 197, "CID"], [24, 24, 280, 280, "CID"], [26, 26, 197, 197, "CID"], [26, 26, 280, 280, "CID"], [79, 79, 197, 197, "CID"], [79, 79, 280, 280, "CID"], [116, 116, 197, 197, "CID"], [116, 116, 280, 280, "CID"], [123, 123, 197, 197, "CID"], [123, 123, 280, 280, "CID"], [237, 237, 197, 197, "CID"], [237, 237, 280, 280, "CID"], [289, 289, 197, 197, "CID"], [289, 289, 280, 280, "CID"], [323, 323, 197, 197, "CID"], [323, 323, 280, 280, "CID"]]], "clusters": [], "translated": "下丘脑-垂体-肾上腺 (HPA) 轴的基础功能和娱乐性<0>摇头丸</0>多药使用者的心理压力。理由：<1>摇头丸</1> (<2>MDMA</2>)是一种精神兴奋剂，与<11>心理生物学功能障碍</11>的联系越来越紧密。虽然最近的一些研究表明神经内分泌功能发生了急剧变化，但人们对休闲用户 HPA 功能的长期变化知之甚少。目的：目前的研究首次通过评估<14>皮质醇</14>的昼夜分泌来探索<3>摇头丸</3>-多种药物使用对心理困扰和 HPA 轴基础功能的影响<div><0>时期</0>。</div>方法：76 名参与者（21 名非吸毒者，29 名轻度<4>摇头丸</4>-多种吸毒者，26 名重度<5>摇头丸</5>-多种吸毒者）在基线时完成了物质使用清单和心理困扰测量，然后连续两天<15>皮质醇</15>采样（觉醒时，觉醒后 30 分钟，1400 至 1600 小时和睡前）。在第 2 天，参与者还参加了实验室以完成 20 分钟的多任务压力源。结果：与非用户相比，两个用户组都表现出明显更高水平的<12>焦虑</12>和<9>抑郁</9>。在第 1 天，所有参与者都表现出典型的<16>皮质醇</16>特征，但轻度使用者的睡前水平显着升高。在第 2 天，重度吸毒者在醒来时表现出升高的水平，并且所有<6>摇头丸</6>-多种吸毒者在睡前表现出升高的水平，与非吸毒者相比。在下午<17>皮质醇</17>水平和全天的总体<18>皮质醇</18>分泌中也观察到组间显着差异。结论：<13>焦虑</13>和<10>抑郁</10>的增加与之前在消遣性<7>摇头丸</7>-多种药物使用者中的观察结果一致。失调的昼夜<19>皮质醇</19>可能表明对即将到来的需求的不适当预期，分泌过多可能导致与大量娱乐性使用<8>摇头丸</8>相关的心理和身体发病率增加。", "revised": true}
{"doc_key": "24114426", "sentences": [["Depression", ",", "impulsiveness", ",", "sleep", ",", "and", "memory", "in", "past", "and", "present", "polydrug", "users", "of", "3", ",", "4", "-", "methylenedioxymethamphetamine", "(", "MDMA", ",", "ecstasy", ")", ".", "RATIONALE", ":", "Ecstasy", "(", "3", ",", "4", "-", "methylenedioxymethamphetamine", ",", "MDMA", ")", "is", "a", "worldwide", "recreational", "drug", "of", "abuse", ".", "Unfortunately", ",", "the", "results", "from", "human", "research", "investigating", "its", "psychological", "effects", "have", "been", "inconsistent", ".", "OBJECTIVES", ":", "The", "present", "study", "aimed", "to", "be", "the", "largest", "to", "date", "in", "sample", "size", "and", "5HT", "-", "related", "behaviors", ";", "the", "first", "to", "compare", "present", "ecstasy", "users", "with", "past", "users", "after", "an", "abstinence", "of", "4", "or", "more", "years", ",", "and", "the", "first", "to", "include", "robust", "controls", "for", "other", "recreational", "substances", ".", "METHODS", ":", "A", "sample", "of", "997", "participants", "(", "52", "%", "male", ")", "was", "recruited", "to", "four", "control", "groups", "(", "non", "-", "drug", "(", "ND", ")", ",", "alcohol", "/", "nicotine", "(", "AN", ")", ",", "cannabis", "/", "alcohol", "/", "nicotine", "(", "CAN", ")", ",", "non", "-", "ecstasy", "polydrug", "(", "PD", ")", ")", ",", "and", "two", "ecstasy", "polydrug", "groups", "(", "present", "(", "MDMA", ")", "and", "past", "users", "(", "EX", "-", "MDMA", ")", ".", "Participants", "completed", "a", "drug", "history", "questionnaire", ",", "Beck", "Depression", "Inventory", ",", "Barratt", "Impulsiveness", "Scale", ",", "Pittsburgh", "Sleep", "Quality", "Index", ",", "and", "Wechsler", "Memory", "Scale", "-", "Revised", "which", ",", "in", "total", ",", "provided", "13", "psychometric", "measures", ".", "RESULTS", ":", "While", "the", "CAN", "and", "PD", "groups", "tended", "to", "record", "greater", "deficits", "than", "the", "non", "-", "drug", "controls", ",", "the", "MDMA", "and", "EX", "-", "MDMA", "groups", "recorded", "greater", "deficits", "than", "all", "the", "control", "groups", "on", "ten", "of", "the", "13", "psychometric", "measures", ".", "Strikingly", ",", "despite", "prolonged", "abstinence", "(", "mean", ",", "4", ".", "98", ";", "range", ",", "4", "-", "9", "years", ")", ",", "past", "ecstasy", "users", "showed", "few", "signs", "of", "recovery", ".", "Compared", "with", "present", "ecstasy", "users", ",", "the", "past", "users", "showed", "no", "change", "for", "ten", "measures", ",", "increased", "impairment", "for", "two", "measures", ",", "and", "improvement", "on", "just", "one", "measure", ".", "CONCLUSIONS", ":", "Given", "this", "record", "of", "impaired", "memory", "and", "clinically", "significant", "levels", "of", "depression", ",", "impulsiveness", ",", "and", "sleep", "disturbance", ",", "the", "prognosis", "for", "the", "current", "generation", "of", "ecstasy", "users", "is", "a", "major", "cause", "for", "concern", "."]], "ner": [[[15, 19, "Chemical"], [21, 21, "Chemical"], [23, 23, "Chemical"], [28, 28, "Chemical"], [30, 34, "Chemical"], [36, 36, "Chemical"], [87, 87, "Chemical"], [157, 157, "Chemical"], [166, 166, "Chemical"], [172, 172, "Chemical"], [180, 180, "Chemical"], [240, 240, "Chemical"], [244, 244, "Chemical"], [283, 283, "Chemical"], [294, 294, "Chemical"], [348, 348, "Chemical"], [0, 0, "Disease"], [191, 191, "Disease"], [333, 333, "Disease"], [2, 2, "Disease"], [195, 195, "Disease"], [335, 335, "Disease"], [338, 339, "Disease"], [139, 139, "Chemical"], [143, 143, "Chemical"], [148, 148, "Chemical"], [152, 152, "Chemical"], [223, 223, "Chemical"], [141, 141, "Chemical"], [150, 150, "Chemical"], [146, 146, "Chemical"], [326, 327, "Disease"]]], "relations": [[[15, 19, 0, 0, "CID"], [15, 19, 191, 191, "CID"], [15, 19, 333, 333, "CID"], [21, 21, 0, 0, "CID"], [21, 21, 191, 191, "CID"], [21, 21, 333, 333, "CID"], [23, 23, 0, 0, "CID"], [23, 23, 191, 191, "CID"], [23, 23, 333, 333, "CID"], [28, 28, 0, 0, "CID"], [28, 28, 191, 191, "CID"], [28, 28, 333, 333, "CID"], [30, 34, 0, 0, "CID"], [30, 34, 191, 191, "CID"], [30, 34, 333, 333, "CID"], [36, 36, 0, 0, "CID"], [36, 36, 191, 191, "CID"], [36, 36, 333, 333, "CID"], [87, 87, 0, 0, "CID"], [87, 87, 191, 191, "CID"], [87, 87, 333, 333, "CID"], [157, 157, 0, 0, "CID"], [157, 157, 191, 191, "CID"], [157, 157, 333, 333, "CID"], [166, 166, 0, 0, "CID"], [166, 166, 191, 191, "CID"], [166, 166, 333, 333, "CID"], [172, 172, 0, 0, "CID"], [172, 172, 191, 191, "CID"], [172, 172, 333, 333, "CID"], [180, 180, 0, 0, "CID"], [180, 180, 191, 191, "CID"], [180, 180, 333, 333, "CID"], [240, 240, 0, 0, "CID"], [240, 240, 191, 191, "CID"], [240, 240, 333, 333, "CID"], [244, 244, 0, 0, "CID"], [244, 244, 191, 191, "CID"], [244, 244, 333, 333, "CID"], [283, 283, 0, 0, "CID"], [283, 283, 191, 191, "CID"], [283, 283, 333, 333, "CID"], [294, 294, 0, 0, "CID"], [294, 294, 191, 191, "CID"], [294, 294, 333, 333, "CID"], [348, 348, 0, 0, "CID"], [348, 348, 191, 191, "CID"], [348, 348, 333, 333, "CID"], [15, 19, 2, 2, "CID"], [15, 19, 195, 195, "CID"], [15, 19, 335, 335, "CID"], [21, 21, 2, 2, "CID"], [21, 21, 195, 195, "CID"], [21, 21, 335, 335, "CID"], [23, 23, 2, 2, "CID"], [23, 23, 195, 195, "CID"], [23, 23, 335, 335, "CID"], [28, 28, 2, 2, "CID"], [28, 28, 195, 195, "CID"], [28, 28, 335, 335, "CID"], [30, 34, 2, 2, "CID"], [30, 34, 195, 195, "CID"], [30, 34, 335, 335, "CID"], [36, 36, 2, 2, "CID"], [36, 36, 195, 195, "CID"], [36, 36, 335, 335, "CID"], [87, 87, 2, 2, "CID"], [87, 87, 195, 195, "CID"], [87, 87, 335, 335, "CID"], [157, 157, 2, 2, "CID"], [157, 157, 195, 195, "CID"], [157, 157, 335, 335, "CID"], [166, 166, 2, 2, "CID"], [166, 166, 195, 195, "CID"], [166, 166, 335, 335, "CID"], [172, 172, 2, 2, "CID"], [172, 172, 195, 195, "CID"], [172, 172, 335, 335, "CID"], [180, 180, 2, 2, "CID"], [180, 180, 195, 195, "CID"], [180, 180, 335, 335, "CID"], [240, 240, 2, 2, "CID"], [240, 240, 195, 195, "CID"], [240, 240, 335, 335, "CID"], [244, 244, 2, 2, "CID"], [244, 244, 195, 195, "CID"], [244, 244, 335, 335, "CID"], [283, 283, 2, 2, "CID"], [283, 283, 195, 195, "CID"], [283, 283, 335, 335, "CID"], [294, 294, 2, 2, "CID"], [294, 294, 195, 195, "CID"], [294, 294, 335, 335, "CID"], [348, 348, 2, 2, "CID"], [348, 348, 195, 195, "CID"], [348, 348, 335, 335, "CID"], [15, 19, 338, 339, "CID"], [21, 21, 338, 339, "CID"], [23, 23, 338, 339, "CID"], [28, 28, 338, 339, "CID"], [30, 34, 338, 339, "CID"], [36, 36, 338, 339, "CID"], [87, 87, 338, 339, "CID"], [157, 157, 338, 339, "CID"], [166, 166, 338, 339, "CID"], [172, 172, 338, 339, "CID"], [180, 180, 338, 339, "CID"], [240, 240, 338, 339, "CID"], [244, 244, 338, 339, "CID"], [283, 283, 338, 339, "CID"], [294, 294, 338, 339, "CID"], [348, 348, 338, 339, "CID"]]], "clusters": [], "translated": " <16>抑郁</16>，<19>冲动</19>，睡眠和记忆在过去和现在的聚众物品使用<0>3，4-亚甲二氧甲基苯丙胺</0>（<1>MDMA</1>，<2>狂喜</2>）。理由：<3> 摇头丸 </3>（<4> 3,4-亚甲二氧甲基苯丙胺 </4>，<5> MDMA </5>）是一种全球范围内滥用的娱乐性药物。不幸的是，调查其心理影响的人类研究结果并不一致。目的：本研究旨在成为迄今为止样本量和 5HT 相关行为最大的研究，第一个将现在的<6> 摇头丸 </6>使用者与戒烟四年或以上的既往使用者进行比较，以及第一个对其他娱乐性物质进行严格控制。方法：997 名参与者（52% 男性）被招募到四个对照组（非药物（ND）、<23>酒精</23> / <28>尼古丁</28>（<24> AN </24>）、<30>大麻</30> / <25>酒精</25> / <29>尼古丁</29>（<26> CAN </26>），非<7>摇头丸</7> 聚众药物（PD）和两个<8> 狂喜 </8>聚众药物组（现在的（<9> MDMA </9>）和过去的使用者（EX-<10> MDMA </10>）。参与者完成了药物史问卷、Beck<17>抑郁</17>量表、Barratt<20>冲动</20>量表、匹兹堡睡眠质量指数和韦氏记忆量表-修订版，总共提供了13项心理测量指标。结果：虽然<27> CAN </27>和PD组倾向于记录比非药物控制组更大的缺陷，但<11> MDMA </11>和EX-<12> MDMA </12>组在13个心理测量指标中的十个指标上的缺陷比所有控制组都要大。引人注目的是，尽管戒烟时间延长（平均4.98年，范围为4-9年），过去的<13>摇头丸</13>使用者几乎没有恢复的迹象。与现在的<14> 狂喜 </14>使用者相比，过去的使用者十个指标没有变化，两个指标减值增加，只有一个指标有改善。结论：考虑到<31>记忆障碍</31>和临床上显著的<18> 抑郁 </18>、<21>冲动</21>和<22>睡眠障碍</22>，当前这一代<15>狂喜</15>使用者的预后是一个令人担忧的主要问题。", "revised": true}
{"doc_key": "24158386", "sentences": [["GEM", "-", "P", "chemotherapy", "is", "active", "in", "the", "treatment", "of", "relapsed", "Hodgkin", "lymphoma", ".", "Hodgkin", "lymphoma", "(", "HL", ")", "is", "a", "relatively", "chemosensitive", "malignancy", ".", "However", ",", "for", "those", "who", "relapse", ",", "high", "-", "dose", "chemotherapy", "with", "autologous", "stem", "cell", "transplant", "is", "the", "treatment", "of", "choice", "which", "relies", "on", "adequate", "disease", "control", "with", "salvage", "chemotherapy", ".", "Regimens", "commonly", "used", "often", "require", "inpatient", "administration", "and", "can", "be", "difficult", "to", "deliver", "due", "to", "toxicity", ".", "Gemcitabine", "and", "cisplatin", "have", "activity", "in", "HL", ",", "non", "-", "overlapping", "toxicity", "with", "first", "-", "line", "chemotherapeutics", ",", "and", "may", "be", "delivered", "in", "an", "outpatient", "setting", ".", "In", "this", "retrospective", "single", "-", "centre", "analysis", ",", "patients", "with", "relapsed", "or", "refractory", "HL", "treated", "with", "gemcitabine", "1", ",", "000", "mg", "/", "m", "(", "2", ")", "day", "(", "D", ")", "1", ",", "D8", "and", "D15", ";", "methylprednisolone", "1", ",", "000", "mg", "D1", "-", "5", ";", "and", "cisplatin", "100", "mg", "/", "m", "(", "2", ")", "D15", ",", "every", "28", "days", "(", "GEM", "-", "P", ")", "were", "included", ".", "Demographic", ",", "survival", ",", "response", "and", "toxicity", "data", "were", "recorded", ".", "Forty", "-", "one", "eligible", "patients", "were", "identified", ":", "median", "age", "27", ".", "One", "hundred", "and", "twenty", "-", "two", "cycles", "of", "GEM", "-", "P", "were", "administered", "in", "total", "(", "median", "3", "cycles", ";", "range", "1", "-", "6", ")", ".", "Twenty", "of", "41", "(", "48", "%", ")", "patients", "received", "GEM", "-", "P", "as", "second", "-", "line", "treatment", "and", "11", "/", "41", "(", "27", "%", ")", "as", "third", "-", "line", "therapy", ".", "Overall", "response", "rate", "(", "ORR", ")", "to", "GEM", "-", "P", "in", "the", "entire", "cohort", "was", "80", "%", "(", "complete", "response", "(", "CR", ")", "37", "%", ",", "partial", "response", "44", "%", ")", "with", "14", "/", "15", "CR", "confirmed", "as", "a", "metabolic", "CR", "on", "PET", "and", "ORR", "of", "85", "%", "in", "the", "20", "second", "-", "line", "patients", ".", "The", "most", "common", "grade", "3", "/", "4", "toxicities", "were", "haematological", ":", "neutropenia", "54", "%", "and", "thrombocytopenia", "51", "%", ".", "Median", "follow", "-", "up", "from", "the", "start", "of", "GEM", "-", "P", "was", "4", ".", "5", "years", ".", "Following", "GEM", "-", "P", ",", "5", "-", "year", "progression", "-", "free", "survival", "was", "46", "%", "(", "95", "%", "confidence", "interval", "(", "CI", ")", ",", "30", "-", "62", "%", ")", "and", "5", "-", "year", "overall", "survival", "was", "59", "%", "(", "95", "%", "CI", ",", "43", "-", "74", "%", ")", ".", "Fourteen", "of", "41", "patients", "proceeded", "directly", "to", "autologous", "transplant", ".", "GEM", "-", "P", "is", "a", "salvage", "chemotherapy", "with", "relatively", "high", "response", "rates", ",", "leading", "to", "successful", "transplantation", "in", "appropriate", "patients", ",", "in", "the", "treatment", "of", "relapsed", "or", "refractory", "HL", "."]], "ner": [[[0, 0, "Chemical"], [73, 73, "Chemical"], [116, 116, "Chemical"], [160, 160, "Chemical"], [198, 198, "Chemical"], [225, 225, "Chemical"], [254, 254, "Chemical"], [330, 330, "Chemical"], [340, 340, "Chemical"], [398, 398, "Chemical"], [314, 314, "Disease"], [318, 318, "Disease"], [136, 136, "Chemical"], [11, 12, "Disease"], [14, 15, "Disease"], [17, 17, "Disease"], [79, 79, "Disease"], [113, 113, "Disease"], [426, 426, "Disease"], [23, 23, "Disease"], [71, 71, "Disease"], [84, 84, "Disease"], [173, 173, "Disease"], [310, 310, "Disease"], [75, 75, "Chemical"], [146, 146, "Chemical"]]], "relations": [[[0, 0, 314, 314, "CID"], [73, 73, 314, 314, "CID"], [116, 116, 314, 314, "CID"], [160, 160, 314, 314, "CID"], [198, 198, 314, 314, "CID"], [225, 225, 314, 314, "CID"], [254, 254, 314, 314, "CID"], [330, 330, 314, 314, "CID"], [340, 340, 314, 314, "CID"], [398, 398, 314, 314, "CID"], [0, 0, 318, 318, "CID"], [73, 73, 318, 318, "CID"], [116, 116, 318, 318, "CID"], [160, 160, 318, 318, "CID"], [198, 198, 318, 318, "CID"], [225, 225, 318, 318, "CID"], [254, 254, 318, 318, "CID"], [330, 330, 318, 318, "CID"], [340, 340, 318, 318, "CID"], [398, 398, 318, 318, "CID"], [136, 136, 314, 314, "CID"], [136, 136, 318, 318, "CID"]]], "clusters": [], "translated": " <0>GEM</0>-P化疗对复发性<13>霍奇金淋巴瘤</13>的治疗有积极作用。<14>霍奇金淋巴瘤</14>（<15>HL</15>）是一种相对化疗敏感的<19>恶性肿瘤</19>。然而，对于那些复发的患者，高剂量化疗和自体干细胞移植是治疗的选择，这取决于充分的疾病控制和挽救性化疗。常用的方案通常需要住院给药，并且由于<20>毒性</20>可能难以实施。<1>吉西他滨</1>和<24>顺铂</24>在<16>HL</16>中具有活性，与一线化疗药物不重叠<21>毒性</21>，并且可以递送在门诊环境中。在这项回顾性单中心分析中，复发或难治性<17>HL</17>患者接受<2>吉西他滨</2> 1,000 mg/m(2)天(D)1、D8和D15治疗；<12>甲基强的松龙</12> 1,000 mg D1-5；和<25>顺铂</25>100 mg/m(2)D15，每28天一次(<3>GEM</3>-P)。记录了人口统计、生存、反应和<22>毒性</22>数据。确定了41名符合条件的患者：中位年龄27岁。<4>GEM</4>-P总共给药122个周期（中位数3个周期；范围1-6）。41名患者中有20名(48%)接受了<5>GEM</5>-P作为二线治疗，11/41(27%)名患者接受了三线治疗。整个队列中<6>GEM</6>-P的总体缓解率(ORR)为80%（完全缓解(CR)37%，部分缓解44%），其中14/15 CR被PET确认为代谢CR，20名二线患者的ORR为85%。最常见的3/4级<23>毒性</23>是血液学方面的：<10>中性粒细胞减少症</10>54%和<11>血小板减少症</11>51%。从<7>GEM</7>-P开始的中位随访时间为4.5年。随<8>GEM</8>-P后，5年无进展生存率为46%（95%置信区间(CI)，30-62%），5年总生存率为59%（95%CI，43-74%）。41名患者中有14名直接进行了自体移植。<9>GEM</9>-P是一种具有相对较高反应率的挽救性化疗，可在合适的患者中成功移植，用于治疗复发或难治性<18>HL</18>。", "revised": true}
{"doc_key": "24132704", "sentences": [["Crocin", "improves", "lipid", "dysregulation", "in", "subacute", "diazinon", "exposure", "through", "ERK1", "/", "2", "pathway", "in", "rat", "liver", ".", "INTRODUCTION", ":", "Diazinon", "Yis", "one", "of", "the", "most", "broadly", "used", "organophosphorus", "insecticides", "in", "agriculture", ".", "It", "has", "been", "shown", "that", "exposure", "to", "diazinon", "may", "interfere", "with", "lipid", "metabolism", ".", "Moreover", ",", "the", "hypolipidemic", "effect", "of", "crocin", "has", "been", "established", ".", "Earlier", "studies", "revealed", "the", "major", "role", "of", "Extracellular", "signal", "-", "regulated", "kinase", "(", "ERK", ")", "pathways", "in", "low", "-", "density", "lipoprotein", "receptor", "(", "LDLr", ")", "expression", ".", "The", "aim", "of", "this", "study", "was", "to", "evaluate", "changes", "in", "the", "regulation", "of", "lipid", "metabolism", ",", "ERK", "and", "LDLr", "expression", "in", "the", "liver", "of", "rats", "exposed", "to", "subacute", "diazinon", ".", "Furthermore", "ameliorating", "effect", "of", "crocin", "on", "diazinon", "induced", "disturbed", "cholesterol", "homeostasis", "was", "studied", ".", "METHODS", ":", "24", "Rats", "were", "divided", "into", "4", "groups", "and", "received", "following", "treatments", "for", "4", "weeks", ";", "Corn", "oil", "(", "control", ")", ",", "diazinon", "(", "15mg", "/", "kg", "per", "day", ",", "orally", ")", "and", "crocin", "(", "12", ".", "5", "and", "25mg", "/", "kg", "per", "day", ",", "intraperitoneally", ")", "in", "combination", "with", "diazinon", "(", "15", "mg", "/", "kg", ")", ".", "The", "levels", "of", "cholesterol", ",", "triglyceride", "and", "LDL", "in", "blood", "of", "rats", "were", "analyzed", ".", "Moreover", "mRNA", "levels", "of", "LDLr", "and", "ERK1", "/", "2", "as", "well", "as", "protein", "levels", "of", "total", "and", "activated", "forms", "of", "ERK1", "/", "2", "in", "rat", "liver", "were", "evaluated", "by", "Western", "blotting", "and", "quantitative", "real", "time", "polymerase", "chain", "reaction", "analysis", ".", "RESULTS", ":", "Our", "data", "showed", "that", "subacute", "exposure", "to", "diazinon", "significantly", "increased", "concentrations", "of", "cholesterol", ",", "triglyceride", "and", "LDL", ".", "Moreover", "diazinon", "decreased", "ERK1", "/", "2", "protein", "phosphorylation", "and", "LDLr", "transcript", ".", "Crocin", "reduced", "inhibition", "of", "ERK", "activation", "and", "diazinon", "-", "induced", "hyperlipemia", "and", "increased", "levels", "of", "LDLr", "transcript", ".", "CONCLUSIONS", ":", "Crocin", "may", "be", "considered", "as", "a", "novel", "protective", "agent", "in", "diazinon", "-", "induced", "hyperlipemia", "through", "modulating", "of", "ERK", "pathway", "and", "increase", "of", "LDLr", "expression", "."]], "ner": [[[6, 6, "Chemical"], [19, 19, "Chemical"], [39, 39, "Chemical"], [112, 112, "Chemical"], [120, 120, "Chemical"], [151, 151, "Chemical"], [179, 179, "Chemical"], [251, 251, "Chemical"], [263, 263, "Chemical"], [281, 281, "Chemical"], [304, 304, "Chemical"], [284, 284, "Disease"], [307, 307, "Disease"], [0, 0, "Chemical"], [52, 52, "Chemical"], [118, 118, "Chemical"], [162, 162, "Chemical"], [274, 274, "Chemical"], [294, 294, "Chemical"], [27, 27, "Chemical"], [123, 123, "Chemical"], [190, 190, "Chemical"], [256, 256, "Chemical"], [192, 192, "Chemical"], [258, 258, "Chemical"]]], "relations": [[[6, 6, 284, 284, "CID"], [6, 6, 307, 307, "CID"], [19, 19, 284, 284, "CID"], [19, 19, 307, 307, "CID"], [39, 39, 284, 284, "CID"], [39, 39, 307, 307, "CID"], [112, 112, 284, 284, "CID"], [112, 112, 307, 307, "CID"], [120, 120, 284, 284, "CID"], [120, 120, 307, 307, "CID"], [151, 151, 284, 284, "CID"], [151, 151, 307, 307, "CID"], [179, 179, 284, 284, "CID"], [179, 179, 307, 307, "CID"], [251, 251, 284, 284, "CID"], [251, 251, 307, 307, "CID"], [263, 263, 284, 284, "CID"], [263, 263, 307, 307, "CID"], [281, 281, 284, 284, "CID"], [281, 281, 307, 307, "CID"], [304, 304, 284, 284, "CID"], [304, 304, 307, 307, "CID"]]], "clusters": [], "translated": " <13>藏红花素</13>通过大鼠肝脏中的ERK1/2通路改善亚急性<0>二嗪磷</0>暴露的脂质失调。简介：<1>二嗪农</1>是农业中使用最广泛的<19>有机磷</19>杀虫剂之一。已经表明，接触<2>二嗪磷</2>可能会干扰脂质代谢。此外，<14>藏红花素</14>的降血脂作用已得到证实。早期的研究揭示了细胞外信号调节激酶（ERK）通路在低密度脂蛋白受体（LDLr）表达中的主要作用。本研究的目的是评估暴露于亚急性<3>二嗪磷</3>的大鼠肝脏中脂质代谢、ERK和LDLr表达的调节变化。此外，还研究了<15>藏红花素</15>对<4>二嗪磷</4>诱导的<20>胆固醇</20>体内平衡的改善作用。\n方法：24只大鼠分为4组，连续4周进行以下治疗；玉米油（对照）、<5>二嗪农</5>（每天15毫克/千克，口服）和<16>藏红花素</16>（每天12.5和25毫克/千克，腹膜内注射）与<6>二嗪磷</6>（15毫克/千克）。分析大鼠血液中<21>胆固醇</21>、<23>甘油三酯</23>和低密度脂蛋白的含量。此外，通过蛋白质印迹和定量实时聚合酶链反应分析评估了大鼠肝脏中LDLr和ERK1/2的mRNA水平以及ERK1/2的总蛋白水平和激活形式的蛋白水平。\n结果：我们的数据表明，<7>二嗪磷</7>的亚急性暴露显着增加了<22>胆固醇</22>、<24>甘油三酯</24>和低密度脂蛋白的浓度。此外，<8>二嗪磷</8>降低ERK1/2蛋白磷酸化和LDLr转录。 <17>藏红花素</17>减少了对ERK激活和<9>二嗪磷</9>诱导的<11>高脂血症</11>的抑制，并增加了LDLr转录物的水平。\n结论：<18>藏红花素</18>可通过调节ERK通路和增加LDLr表达，作为一种新型的保护剂来预防<10>二嗪磷</10>诱导的<12>高脂血症</12>。", "revised": true}
{"doc_key": "24275640", "sentences": [["Oxidative", "stress", "on", "cardiotoxicity", "after", "treatment", "with", "single", "and", "multiple", "doses", "of", "doxorubicin", ".", "The", "mechanism", "of", "doxorubicin", "(", "DOX", ")", "-", "induced", "cardiotoxicity", "remains", "controversial", ".", "Wistar", "rats", "(", "n", "=", "66", ")", "received", "DOX", "injections", "intraperitoneally", "and", "were", "randomly", "assigned", "to", "2", "experimental", "protocols", ":", "(", "1", ")", "rats", "were", "killed", "before", "(", "-", "24", "h", ",", "n", "=", "8", ")", "and", "24", "h", "after", "(", "+", "24", "h", ",", "n", "=", "8", ")", "a", "single", "dose", "of", "DOX", "(", "4", "mg", "/", "kg", "body", "weight", ")", "to", "determine", "the", "DOX", "acute", "effect", "and", "(", "2", ")", "rats", "(", "n", "=", "58", ")", "received", "4", "injections", "of", "DOX", "(", "4", "mg", "/", "kg", "body", "weight", "/", "week", ")", "and", "were", "killed", "before", "the", "first", "injection", "(", "M0", ")", "and", "1", "week", "after", "each", "injection", "(", "M1", ",", "M2", ",", "M3", ",", "and", "M4", ")", "to", "determine", "the", "chronological", "effects", ".", "Animals", "used", "at", "M0", "(", "n", "=", "8", ")", "were", "also", "used", "at", "moment", "-", "24", "h", "of", "acute", "study", ".", "Cardiac", "total", "antioxidant", "performance", "(", "TAP", ")", ",", "DNA", "damage", ",", "and", "morphology", "analyses", "were", "carried", "out", "at", "each", "time", "point", ".", "Single", "dose", "of", "DOX", "was", "associated", "with", "increased", "cardiac", "disarrangement", ",", "necrosis", ",", "and", "DNA", "damage", "(", "strand", "breaks", "(", "SBs", ")", "and", "oxidized", "pyrimidines", ")", "and", "decreased", "TAP", ".", "The", "chronological", "study", "showed", "an", "effect", "of", "a", "cumulative", "dose", "on", "body", "weight", "(", "R", "=", "-", "0", ".", "99", ",", "p", "=", "0", ".", "011", ")", ",", "necrosis", "(", "R", "=", "1", ".", "00", ",", "p", "=", "0", ".", "004", ")", ",", "TAP", "(", "R", "=", "0", ".", "95", ",", "p", "=", "0", ".", "049", ")", ",", "and", "DNA", "SBs", "(", "R", "=", "-", "0", ".", "95", ",", "p", "=", "0", ".", "049", ")", ".", "DNA", "SBs", "damage", "was", "negatively", "associated", "with", "TAP", "(", "R", "=", "-", "0", ".", "98", ",", "p", "=", "0", ".", "018", ")", ",", "and", "necrosis", "(", "R", "=", "-", "0", ".", "97", ",", "p", "=", "0", ".", "027", ")", ".", "Our", "results", "suggest", "that", "oxidative", "damage", "is", "associated", "with", "acute", "cardiotoxicity", "induced", "by", "a", "single", "dose", "of", "DOX", "only", ".", "Increased", "resistance", "to", "the", "oxidative", "stress", "is", "plausible", "for", "the", "multiple", "dose", "of", "DOX", ".", "Thus", ",", "different", "mechanisms", "may", "be", "involved", "in", "acute", "toxicity", "versus", "chronic", "toxicity", "."]], "ner": [[[12, 12, "Chemical"], [17, 17, "Chemical"], [19, 19, "Chemical"], [35, 35, "Chemical"], [80, 80, "Chemical"], [92, 92, "Chemical"], [109, 109, "Chemical"], [198, 198, "Chemical"], [358, 358, "Chemical"], [374, 374, "Chemical"], [3, 3, "Disease"], [23, 23, "Disease"], [351, 351, "Disease"], [206, 206, "Disease"], [253, 253, "Disease"], [325, 325, "Disease"], [203, 204, "Disease"], [385, 385, "Disease"], [388, 388, "Disease"]]], "relations": [[[12, 12, 3, 3, "CID"], [12, 12, 23, 23, "CID"], [12, 12, 351, 351, "CID"], [17, 17, 3, 3, "CID"], [17, 17, 23, 23, "CID"], [17, 17, 351, 351, "CID"], [19, 19, 3, 3, "CID"], [19, 19, 23, 23, "CID"], [19, 19, 351, 351, "CID"], [35, 35, 3, 3, "CID"], [35, 35, 23, 23, "CID"], [35, 35, 351, 351, "CID"], [80, 80, 3, 3, "CID"], [80, 80, 23, 23, "CID"], [80, 80, 351, 351, "CID"], [92, 92, 3, 3, "CID"], [92, 92, 23, 23, "CID"], [92, 92, 351, 351, "CID"], [109, 109, 3, 3, "CID"], [109, 109, 23, 23, "CID"], [109, 109, 351, 351, "CID"], [198, 198, 3, 3, "CID"], [198, 198, 23, 23, "CID"], [198, 198, 351, 351, "CID"], [358, 358, 3, 3, "CID"], [358, 358, 23, 23, "CID"], [358, 358, 351, 351, "CID"], [374, 374, 3, 3, "CID"], [374, 374, 23, 23, "CID"], [374, 374, 351, 351, "CID"], [12, 12, 206, 206, "CID"], [12, 12, 253, 253, "CID"], [12, 12, 325, 325, "CID"], [17, 17, 206, 206, "CID"], [17, 17, 253, 253, "CID"], [17, 17, 325, 325, "CID"], [19, 19, 206, 206, "CID"], [19, 19, 253, 253, "CID"], [19, 19, 325, 325, "CID"], [35, 35, 206, 206, "CID"], [35, 35, 253, 253, "CID"], [35, 35, 325, 325, "CID"], [80, 80, 206, 206, "CID"], [80, 80, 253, 253, "CID"], [80, 80, 325, 325, "CID"], [92, 92, 206, 206, "CID"], [92, 92, 253, 253, "CID"], [92, 92, 325, 325, "CID"], [109, 109, 206, 206, "CID"], [109, 109, 253, 253, "CID"], [109, 109, 325, 325, "CID"], [198, 198, 206, 206, "CID"], [198, 198, 253, 253, "CID"], [198, 198, 325, 325, "CID"], [358, 358, 206, 206, "CID"], [358, 358, 253, 253, "CID"], [358, 358, 325, 325, "CID"], [374, 374, 206, 206, "CID"], [374, 374, 253, 253, "CID"], [374, 374, 325, 325, "CID"]]], "clusters": [], "translated": "单剂量和多剂量<0>多柔比星</0>治疗后氧化应激对<10>心脏毒性</10>的影响。 <1>阿霉素</1> (<2>DOX</2>) 引起<11>心脏毒性</11>的机制仍存在争议。Wistar大鼠 (n=66) 接受<3>DOX</3>腹膜内注射，并随机分配到 2 个实验方案：(1) 大鼠在前 (-24小时, n=8) 和后24小时 (+24h, n=8) 单剂量<4>DOX</4> (4 mg/kg 体重) 确定<5>DOX</5>急性效应和 (2)大鼠 (n=58) 接受 4 次注射<6>DOX</6> (4 mg/kg 体重/周)，并在第一次注射前 (M0) 和每次注射后 1 周 (M1, M2, M3和M4) 处死，以确定时序效应。在 M0 (n = 8) 时使用的动物也用于急性研究的 24 小时时刻。在每个时间点进行心脏总抗氧化性能 (TAP)、DNA 损伤和形态学分析。单剂量<7>DOX</7> 与<16>心脏紊乱</16>、<13>坏死</13>和DNA损伤（链断裂 (SBs) 和氧化嘧啶）增加以及TAP降低有关。按时间顺序排列的研究显示了累积剂量对体重的影响 (R = -0.99，p = 0.011)，<14>坏死</14> (R = 1 . 00，p = 0 . 004)，TAP (R = 0.95，p = 0.049)和DNA SBs (R = -0.95，p = 0.049)。DNA SBs损伤与TAP (R = -0.98，p = 0.018)和<15>坏死</15> (R = -0.97，p = 0.027)呈负相关。我们的结果表明，氧化损伤仅与单剂量<8>DOX</8>诱导的急性<12>心脏毒性</12>相关。多次服用<9>DOX</9>可能会增加对氧化应激的抵抗力。因此，急性<17>毒性</17>与慢性<18>毒性</18>可能涉及不同的机制。", "revised": true}
{"doc_key": "23952588", "sentences": [["Risk", "factors", "and", "predictors", "of", "levodopa", "-", "induced", "dyskinesia", "among", "multiethnic", "Malaysians", "with", "Parkinson", "'s", "disease", ".", "Chronic", "pulsatile", "levodopa", "therapy", "for", "Parkinson", "'s", "disease", "(", "PD", ")", "leads", "to", "the", "development", "of", "motor", "fluctuations", "and", "dyskinesia", ".", "We", "studied", "the", "prevalence", "and", "predictors", "of", "levodopa", "-", "induced", "dyskinesia", "among", "multiethnic", "Malaysian", "patients", "with", "PD", ".", "METHODS", ":", "This", "is", "a", "cross", "-", "sectional", "study", "involving", "95", "patients", "with", "PD", "on", "uninterrupted", "levodopa", "therapy", "for", "at", "least", "6", "months", ".", "The", "instrument", "used", "was", "the", "UPDRS", "questionnaires", ".", "The", "predictors", "of", "dyskinesia", "were", "determined", "using", "multivariate", "logistic", "regression", "analysis", ".", "RESULTS", ":", "The", "mean", "age", "was", "65", ".", "6", "+", "8", ".", "5", "years", ".", "The", "mean", "onset", "age", "was", "58", ".", "5", "+", "9", ".", "8", "years", ".", "The", "median", "disease", "duration", "was", "6", "(", "7", ")", "years", ".", "Dyskinesia", "was", "present", "in", "44", "%", "(", "n", "=", "42", ")", "with", "median", "levodopa", "therapy", "of", "3", "years", ".", "There", "were", "64", ".", "3", "%", "Chinese", ",", "31", "%", "Malays", ",", "and", "3", ".", "7", "%", "Indians", "and", "other", "ethnic", "groups", ".", "Eighty", "-", "one", "percent", "of", "patients", "with", "dyskinesia", "had", "clinical", "fluctuations", ".", "Patients", "with", "dyskinesia", "had", "lower", "onset", "age", "(", "p", "<", "0", ".", "001", ")", ",", "longer", "duration", "of", "levodopa", "therapy", "(", "p", "<", "0", ".", "001", ")", ",", "longer", "disease", "duration", "(", "p", "<", "0", ".", "001", ")", ",", "higher", "total", "daily", "levodopa", "dose", "(", "p", "<", "0", ".", "001", ")", ",", "and", "higher", "total", "UPDRS", "scores", "(", "p", "=", "0", ".", "005", ")", "than", "patients", "without", "dyskinesia", ".", "The", "three", "significant", "predictors", "of", "dyskinesia", "were", "duration", "of", "levodopa", "therapy", ",", "onset", "age", ",", "and", "total", "daily", "levodopa", "dose", ".", "CONCLUSIONS", ":", "The", "prevalence", "of", "levodopa", "-", "induced", "dyskinesia", "in", "our", "patients", "was", "44", "%", ".", "The", "most", "significant", "predictors", "were", "duration", "of", "levodopa", "therapy", ",", "total", "daily", "levodopa", "dose", ",", "and", "onset", "age", "."]], "ner": [[[5, 5, "Chemical"], [19, 19, "Chemical"], [45, 45, "Chemical"], [72, 72, "Chemical"], [153, 153, "Chemical"], [212, 212, "Chemical"], [236, 236, "Chemical"], [272, 272, "Chemical"], [281, 281, "Chemical"], [289, 289, "Chemical"], [307, 307, "Chemical"], [312, 312, "Chemical"], [8, 8, "Disease"], [36, 36, "Disease"], [48, 48, "Disease"], [91, 91, "Disease"], [140, 140, "Disease"], [189, 189, "Disease"], [196, 196, "Disease"], [261, 261, "Disease"], [268, 268, "Disease"], [292, 292, "Disease"], [13, 15, "Disease"], [22, 24, "Disease"], [26, 26, "Disease"], [54, 54, "Disease"], [69, 69, "Disease"]]], "relations": [[[5, 5, 8, 8, "CID"], [5, 5, 36, 36, "CID"], [5, 5, 48, 48, "CID"], [5, 5, 91, 91, "CID"], [5, 5, 140, 140, "CID"], [5, 5, 189, 189, "CID"], [5, 5, 196, 196, "CID"], [5, 5, 261, 261, "CID"], [5, 5, 268, 268, "CID"], [5, 5, 292, 292, "CID"], [19, 19, 8, 8, "CID"], [19, 19, 36, 36, "CID"], [19, 19, 48, 48, "CID"], [19, 19, 91, 91, "CID"], [19, 19, 140, 140, "CID"], [19, 19, 189, 189, "CID"], [19, 19, 196, 196, "CID"], [19, 19, 261, 261, "CID"], [19, 19, 268, 268, "CID"], [19, 19, 292, 292, "CID"], [45, 45, 8, 8, "CID"], [45, 45, 36, 36, "CID"], [45, 45, 48, 48, "CID"], [45, 45, 91, 91, "CID"], [45, 45, 140, 140, "CID"], [45, 45, 189, 189, "CID"], [45, 45, 196, 196, "CID"], [45, 45, 261, 261, "CID"], [45, 45, 268, 268, "CID"], [45, 45, 292, 292, "CID"], [72, 72, 8, 8, "CID"], [72, 72, 36, 36, "CID"], [72, 72, 48, 48, "CID"], [72, 72, 91, 91, "CID"], [72, 72, 140, 140, "CID"], [72, 72, 189, 189, "CID"], [72, 72, 196, 196, "CID"], [72, 72, 261, 261, "CID"], [72, 72, 268, 268, "CID"], [72, 72, 292, 292, "CID"], [153, 153, 8, 8, "CID"], [153, 153, 36, 36, "CID"], [153, 153, 48, 48, "CID"], [153, 153, 91, 91, "CID"], [153, 153, 140, 140, "CID"], [153, 153, 189, 189, "CID"], [153, 153, 196, 196, "CID"], [153, 153, 261, 261, "CID"], [153, 153, 268, 268, "CID"], [153, 153, 292, 292, "CID"], [212, 212, 8, 8, "CID"], [212, 212, 36, 36, "CID"], [212, 212, 48, 48, "CID"], [212, 212, 91, 91, "CID"], [212, 212, 140, 140, "CID"], [212, 212, 189, 189, "CID"], [212, 212, 196, 196, "CID"], [212, 212, 261, 261, "CID"], [212, 212, 268, 268, "CID"], [212, 212, 292, 292, "CID"], [236, 236, 8, 8, "CID"], [236, 236, 36, 36, "CID"], [236, 236, 48, 48, "CID"], [236, 236, 91, 91, "CID"], [236, 236, 140, 140, "CID"], [236, 236, 189, 189, "CID"], [236, 236, 196, 196, "CID"], [236, 236, 261, 261, "CID"], [236, 236, 268, 268, "CID"], [236, 236, 292, 292, "CID"], [272, 272, 8, 8, "CID"], [272, 272, 36, 36, "CID"], [272, 272, 48, 48, "CID"], [272, 272, 91, 91, "CID"], [272, 272, 140, 140, "CID"], [272, 272, 189, 189, "CID"], [272, 272, 196, 196, "CID"], [272, 272, 261, 261, "CID"], [272, 272, 268, 268, "CID"], [272, 272, 292, 292, "CID"], [281, 281, 8, 8, "CID"], [281, 281, 36, 36, "CID"], [281, 281, 48, 48, "CID"], [281, 281, 91, 91, "CID"], [281, 281, 140, 140, "CID"], [281, 281, 189, 189, "CID"], [281, 281, 196, 196, "CID"], [281, 281, 261, 261, "CID"], [281, 281, 268, 268, "CID"], [281, 281, 292, 292, "CID"], [289, 289, 8, 8, "CID"], [289, 289, 36, 36, "CID"], [289, 289, 48, 48, "CID"], [289, 289, 91, 91, "CID"], [289, 289, 140, 140, "CID"], [289, 289, 189, 189, "CID"], [289, 289, 196, 196, "CID"], [289, 289, 261, 261, "CID"], [289, 289, 268, 268, "CID"], [289, 289, 292, 292, "CID"], [307, 307, 8, 8, "CID"], [307, 307, 36, 36, "CID"], [307, 307, 48, 48, "CID"], [307, 307, 91, 91, "CID"], [307, 307, 140, 140, "CID"], [307, 307, 189, 189, "CID"], [307, 307, 196, 196, "CID"], [307, 307, 261, 261, "CID"], [307, 307, 268, 268, "CID"], [307, 307, 292, 292, "CID"], [312, 312, 8, 8, "CID"], [312, 312, 36, 36, "CID"], [312, 312, 48, 48, "CID"], [312, 312, 91, 91, "CID"], [312, 312, 140, 140, "CID"], [312, 312, 189, 189, "CID"], [312, 312, 196, 196, "CID"], [312, 312, 261, 261, "CID"], [312, 312, 268, 268, "CID"], [312, 312, 292, 292, "CID"]]], "clusters": [], "translated": "<0>左旋多巴</0>的危险因素和预测因素 - 在患有<22>帕金森病</22>的多民族马来西亚人中诱发<12>运动障碍</12>。慢性脉冲<1>左旋多巴</1> 疗法治疗<23>帕金森病</23>(<24>PD</24>)会导致运动波动和<13>运动障碍</13>的发展。我们研究了患有<25>PD</25>的马来西亚多民族患者中<2>左旋多巴</2>诱发的<14>运动障碍</14>的患病率和预测因子。方法：这是一项横断面研究，涉及95名<26>PD</26>患者，这些患者接受了至少6个月的不间断<3>左旋多巴</3>治疗。使用的工具是UPDRS问卷。预测<15>运动障碍</15>的因素是使用多变量逻辑回归分析确定的。结果：平均年龄为65.6+8.5岁，平均发病年龄为58.5+9.8岁。中位病程为6(7)年。患有<16>运动障碍</16>的患者占44%(n=42)，<4>左旋多巴</4>治疗中位数为3年。其中有64.3%是华人，31%是马来人，3.7%是印度人和其他族裔。81%的<17>运动障碍 </17>患者有临床波动。患有<18>运动障碍</18>的患者比没有<19>运动障碍</19>的患者发病年龄更低(p < 0 . 001)，<5>左旋多巴</5>治疗时间更长(p < 0 . 001)，病程更长(p < 0 . 001),每日总<6>左旋多巴</6>剂量更高(p < 0 . 001)以及总UPDRS评分更高(p = 0 . 005)。预测<20>运动障碍</20>的三个显著因素是<7> 左旋多巴</7>治疗持续时间、发病年龄和每日总<8>左旋多巴</8>剂量。结论：我们患者中<9>左旋多巴</9>引起的<21>运动障碍</21>的患病率为44%。最显著的预测因素是<10>左旋多巴</10>治疗持续时间、每日总<11>左旋多巴</11>剂量和发病年龄。", "revised": true}
{"doc_key": "24209900", "sentences": [["Ifosfamide", "related", "encephalopathy", ":", "the", "need", "for", "a", "timely", "EEG", "evaluation", ".", "BACKGROUND", ":", "Ifosfamide", "is", "an", "alkylating", "agent", "useful", "in", "the", "treatment", "of", "a", "wide", "range", "of", "cancers", "including", "sarcomas", ",", "lymphoma", ",", "gynecologic", "and", "testicular", "cancers", ".", "Encephalopathy", "has", "been", "reported", "in", "10", "-", "40", "%", "of", "patients", "receiving", "high", "-", "dose", "IV", "ifosfamide", ".", "OBJECTIVE", ":", "To", "highlight", "the", "role", "of", "electroencephalogram", "(", "EEG", ")", "in", "the", "early", "detection", "and", "management", "of", "ifosfamide", "related", "encephalopathy", ".", "METHODS", ":", "Retrospective", "chart", "review", "including", "clinical", "data", "and", "EEG", "recordings", "was", "done", "on", "five", "patients", ",", "admitted", "to", "MD", "Anderson", "Cancer", "Center", "between", "years", "2009", "and", "2012", ",", "who", "developed", "ifosfamide", "related", "acute", "encephalopathy", ".", "RESULTS", ":", "All", "five", "patients", "experienced", "symptoms", "of", "encephalopathy", "soon", "after", "(", "within", "12", "h", "-", "2", "days", ")", "receiving", "ifosfamide", ".", "Two", "patients", "developed", "generalized", "convulsions", "while", "one", "patient", "developed", "continuous", "non", "-", "convulsive", "status", "epilepticus", "(", "NCSE", ")", "that", "required", "ICU", "admission", "and", "intubation", ".", "Initial", "EEG", "showed", "epileptiform", "discharges", "in", "three", "patients", ";", "run", "of", "triphasic", "waves", "in", "one", "patient", "and", "moderate", "degree", "diffuse", "generalized", "slowing", ".", "Mixed", "pattern", "with", "the", "presence", "of", "both", "sharps", "and", "triphasic", "waves", "were", "also", "noted", ".", "Repeat", "EEGs", "within", "24_h", "of", "symptom", "onset", "showed", "marked", "improvement", "that", "was", "correlated", "with", "clinical", "improvement", ".", "CONCLUSIONS", ":", "Severity", "of", "ifosfamide", "related", "encephalopathy", "correlates", "with", "EEG", "changes", ".", "We", "suggest", "a", "timely", "EEG", "evaluation", "for", "patients", "receiving", "ifosfamide", "who", "develop", "features", "of", "encephalopathy", "."]], "ner": [[[0, 0, "Chemical"], [14, 14, "Chemical"], [55, 55, "Chemical"], [75, 75, "Chemical"], [110, 110, "Chemical"], [135, 135, "Chemical"], [221, 221, "Chemical"], [238, 238, "Chemical"], [141, 141, "Disease"], [147, 151, "Disease"], [153, 153, "Disease"], [2, 2, "Disease"], [39, 39, "Disease"], [77, 77, "Disease"], [113, 113, "Disease"], [123, 123, "Disease"], [223, 223, "Disease"], [243, 243, "Disease"], [28, 28, "Disease"], [34, 37, "Disease"], [100, 100, "Disease"], [30, 30, "Disease"], [32, 32, "Disease"]]], "relations": [[[0, 0, 141, 141, "CID"], [14, 14, 141, 141, "CID"], [55, 55, 141, 141, "CID"], [75, 75, 141, 141, "CID"], [110, 110, 141, 141, "CID"], [135, 135, 141, 141, "CID"], [221, 221, 141, 141, "CID"], [238, 238, 141, 141, "CID"], [0, 0, 147, 151, "CID"], [0, 0, 153, 153, "CID"], [14, 14, 147, 151, "CID"], [14, 14, 153, 153, "CID"], [55, 55, 147, 151, "CID"], [55, 55, 153, 153, "CID"], [75, 75, 147, 151, "CID"], [75, 75, 153, 153, "CID"], [110, 110, 147, 151, "CID"], [110, 110, 153, 153, "CID"], [135, 135, 147, 151, "CID"], [135, 135, 153, 153, "CID"], [221, 221, 147, 151, "CID"], [221, 221, 153, 153, "CID"], [238, 238, 147, 151, "CID"], [238, 238, 153, 153, "CID"]]], "clusters": [], "translated": "<0> 异环磷酰胺 </0> 相关 <11> 脑病 </11>：需要及时进行脑电图评估。背景： <1> 异环磷酰胺 </1> 是一种烷基化剂，可用于治疗多种 <18> 癌症 </18>，包括 <21> 肉瘤 </21>、<22> 淋巴瘤 </22>、<19> 妇科和睾丸癌 </19>。 <12> 脑病 </12> 据报道，有 10-40% 的接受静脉高剂量 <2> 异环磷酰胺 </2> 患者发生该病。目的：强调脑电图（EEG）在 <3> 异环磷酰胺 </3> 相关 <13> 脑病 </13> 早期发现和管理中的作用。方法：对 2009 年至 2012 年间被收治到 MD 安德森 <20> 癌症 </20> 中心的五名患者进行了回顾性病历筛查，其中包括临床数据和 EEG 记录，这些患者发生了 <4> 异环磷酰胺 </4> 相关急性 <14> 脑病 </14>。结果：所有的五名患者，在接受 <5> 异环磷酰胺 </5> 治疗后很快（12h-2d）出现了<15> 脑病 </15> 症状。两名患者出现了一般性<8> 抽搐 </8>，一名患者发生了需要 ICU 入住和插管的<9> 非惊厥性癫痫持续状态 </9>（<10> NCSE </10>）。初始 EEG 显示三位患者出现了癫痫样放电；一位患者出现了三相波并表现为中度全身弥漫性减速。还提到出现了锐波和三相波的混合模式。症状出现后 24h 之内重复的 EEG 检查显示出明显改善，与临床功能改善相关。结论： <6> 异环磷酰胺 </6> 相关 <16> 脑病 </16> 的严重程度与 EEG 变化相关。我们建议对已收到 <7> 异环磷酰胺 </7> 治疗且出现<17> 脑病 </17>特征的患者进行及时的脑电图评估。", "revised": true}
{"doc_key": "24451297", "sentences": [["Drug", "-", "Induced", "Acute", "Liver", "Injury", "Within", "12", "Hours", "After", "Fluvastatin", "Therapy", ".", "Although", "statins", "are", "generally", "well", "-", "tolerated", "drugs", ",", "recent", "cases", "of", "drug", "-", "induced", "liver", "injury", "associated", "with", "their", "use", "have", "been", "reported", ".", "A", "52", "-", "year", "-", "old", "Chinese", "man", "reported", "with", "liver", "damage", ",", "which", "appeared", "12", "hours", "after", "beginning", "treatment", "with", "fluvastatin", ".", "Patient", "presented", "with", "complaints", "of", "increasing", "nausea", ",", "anorexia", ",", "and", "upper", "abdominal", "pain", ".", "His", "laboratory", "values", "showed", "elevated", "creatine", "kinase", "and", "transaminases", ".", "Testing", "for", "autoantibodies", "was", "also", "negative", ".", "The", "liver", "biochemistries", "eventually", "normalized", "within", "3", "weeks", "of", "stopping", "the", "fluvastatin", ".", "Therefore", ",", "when", "prescribing", "statins", ",", "the", "possibility", "of", "hepatic", "damage", "should", "be", "taken", "into", "account", "."]], "ner": [[[10, 10, "Chemical"], [59, 59, "Chemical"], [104, 104, "Chemical"], [0, 5, "Disease"], [25, 29, "Disease"], [48, 49, "Disease"], [115, 116, "Disease"], [67, 67, "Disease"], [69, 69, "Disease"], [73, 74, "Disease"], [14, 14, "Chemical"], [81, 81, "Chemical"]]], "relations": [[[10, 10, 0, 5, "CID"], [10, 10, 25, 29, "CID"], [10, 10, 48, 49, "CID"], [10, 10, 115, 116, "CID"], [59, 59, 0, 5, "CID"], [59, 59, 25, 29, "CID"], [59, 59, 48, 49, "CID"], [59, 59, 115, 116, "CID"], [104, 104, 0, 5, "CID"], [104, 104, 25, 29, "CID"], [104, 104, 48, 49, "CID"], [104, 104, 115, 116, "CID"], [10, 10, 67, 67, "CID"], [59, 59, 67, 67, "CID"], [104, 104, 67, 67, "CID"], [10, 10, 69, 69, "CID"], [59, 59, 69, 69, "CID"], [104, 104, 69, 69, "CID"], [10, 10, 73, 74, "CID"], [59, 59, 73, 74, "CID"], [104, 104, 73, 74, "CID"]]], "clusters": [], "translated": "<3>药物引起的急性肝损伤</3><0>氟伐他汀</0>治疗后12小时内。虽然<10>他汀类药物</10>通常是耐受性良好的药物，但最近报告了与其使用相关的<4>药物性肝损伤</4>病例。一名52岁的中国男性报告在开始使用<1>氟伐他汀</1>治疗12小时后出现<5>肝损伤</5>。患者主诉越来越严重的<7>恶心</7>、<8>厌食</8>和上<9>腹痛</9>。他的化验值显示<11>肌酸</11>激酶和转氨酶升高。自身抗体检测也呈阴性。在停止使用<2>氟伐他汀</2>后3周内，肝脏生化指标最终恢复正常。因此，在开他汀类药物时，应考虑<6>肝损伤</6>的可能性。", "revised": true}
{"doc_key": "24434397", "sentences": [["Tranexamic", "acid", "overdosage", "-", "induced", "generalized", "seizure", "in", "renal", "failure", ".", "We", "report", "a", "45", "-", "year", "-", "old", "lady", "with", "chronic", "kidney", "disease", "stage", "4", "due", "to", "chronic", "tubulointerstial", "disease", ".", "She", "was", "admitted", "to", "our", "center", "for", "severe", "anemia", "due", "to", "menorrhagia", "and", "deterioration", "of", "renal", "function", ".", "She", "was", "infused", "three", "units", "of", "packed", "cells", "during", "a", "session", "of", "hemodialysis", ".", "Tranexamic", "acid", "(", "TNA", ")", "1", "g", "8", "-", "hourly", "was", "administered", "to", "her", "to", "control", "bleeding", "per", "vaginum", ".", "Two", "hours", "after", "the", "sixth", "dose", "of", "TNA", ",", "she", "had", "an", "episode", "of", "generalized", "tonic", "clonic", "convulsions", ".", "TNA", "was", "discontinued", ".", "Investigations", "of", "the", "patient", "revealed", "no", "biochemical", "or", "structural", "central", "nervous", "system", "abnormalities", "that", "could", "have", "provoked", "the", "convulsions", ".", "She", "did", "not", "require", "any", "further", "dialytic", "support", ".", "She", "had", "no", "further", "episodes", "of", "convulsion", "till", "dis", "-", "charge", "and", "during", "the", "two", "months", "of", "follow", "-", "up", ".", "Thus", ",", "the", "precipitating", "cause", "of", "convulsions", "was", "believed", "to", "be", "an", "overdose", "of", "TNA", "."]], "ner": [[[0, 1, "Chemical"], [64, 65, "Chemical"], [67, 67, "Chemical"], [91, 91, "Chemical"], [103, 103, "Chemical"], [171, 171, "Chemical"], [99, 101, "Disease"], [6, 6, "Disease"], [125, 125, "Disease"], [142, 142, "Disease"], [163, 163, "Disease"], [8, 9, "Disease"], [45, 48, "Disease"], [21, 23, "Disease"], [29, 30, "Disease"], [40, 40, "Disease"], [43, 43, "Disease"], [80, 80, "Disease"], [117, 119, "Disease"], [169, 169, "Disease"]]], "relations": [[[0, 1, 99, 101, "CID"], [64, 65, 99, 101, "CID"], [67, 67, 99, 101, "CID"], [91, 91, 99, 101, "CID"], [103, 103, 99, 101, "CID"], [171, 171, 99, 101, "CID"]]], "clusters": [], "translated": " <0>氨甲环酸</0> 药物过量引起的全身性<7>癫痫发作</7> - <11>肾功能衰竭</11>。我们报告一位45岁的女士因慢性<14>肾小管间质疾病</14>而患有<13>慢性肾脏病</13> 4期。由于<16>月经过多</16>和<12>肾功能恶化</12>，她因严重<15>贫血</15>入院。在一次血液透析期间，她被注入了三个单位的浓缩细胞。<1>氨甲环酸</1> (<2>TNA</2>) 1克，8小时一次，以控制阴道<17>出血</17>。在第6剂<3>TNA</3>两小时后，她出现了全身性<6>强直阵挛性抽搐</6>。<4>TNA</4>已停产。对患者的调查显示，没有可能引发<8>抽搐</8>的生化或结构性中枢<18>神经系统异常</18>。她不需要任何进一步的透析支持。直到出院和两个月的随访期间，她都没有再发生<9>惊厥</9>。因此，<5>TNA</5>的<19>过量</19>被认为是<10>抽搐</10>的诱发原因。", "revised": true}
{"doc_key": "24571687", "sentences": [["Vasovagal", "syncope", "and", "severe", "bradycardia", "following", "intranasal", "dexmedetomidine", "for", "pediatric", "procedural", "sedation", ".", "We", "report", "syncope", "and", "bradycardia", "in", "an", "11", "-", "year", "-", "old", "girl", "following", "administration", "of", "intranasal", "dexmedetomidine", "for", "sedation", "for", "a", "voiding", "cystourethrogram", ".", "Following", "successful", "completion", "of", "VCUG", "and", "a", "60", "-", "min", "recovery", "period", ",", "the", "patient", "'s", "level", "of", "consciousness", "and", "vital", "signs", "returned", "to", "presedation", "levels", ".", "Upon", "leaving", "the", "sedation", "area", ",", "the", "patient", "collapsed", ",", "with", "no", "apparent", "inciting", "event", ".", "The", "patient", "quickly", "regained", "consciousness", "and", "no", "injury", "occurred", ".", "The", "primary", "abnormality", "found", "was", "persistent", "bradycardia", ",", "and", "she", "was", "admitted", "to", "the", "hospital", "for", "telemetric", "observation", ".", "The", "bradycardia", "lasted", "~2", "h", ",", "and", "further", "cardiac", "workup", "revealed", "no", "underlying", "abnormality", ".", "Unanticipated", "and", "previously", "unreported", "outcomes", "may", "be", "witnessed", "as", "we", "expand", "the", "use", "of", "certain", "sedatives", "to", "alternative", "routes", "of", "administration", "."]], "ner": [[[7, 7, "Chemical"], [30, 30, "Chemical"], [0, 1, "Disease"], [4, 4, "Disease"], [17, 17, "Disease"], [97, 97, "Disease"], [111, 111, "Disease"], [15, 15, "Disease"]]], "relations": [[[7, 7, 0, 1, "CID"], [30, 30, 0, 1, "CID"], [7, 7, 4, 4, "CID"], [7, 7, 17, 17, "CID"], [7, 7, 97, 97, "CID"], [7, 7, 111, 111, "CID"], [30, 30, 4, 4, "CID"], [30, 30, 17, 17, "CID"], [30, 30, 97, 97, "CID"], [30, 30, 111, 111, "CID"]]], "clusters": [], "translated": " <2>血管迷走性晕厥</2> 和严重的<3>心动过缓</3> 鼻内<0>右美托咪定</0>用于儿科程序镇静。我们报告了一名11岁女孩因排尿性膀胱尿道造影使用鼻内<1>右美托咪定</1>进行镇静后出现<7>晕厥</7>和<4>心动过缓</4>。在成功完成 VCUG 和 60 分钟的恢复期后，患者的意识水平和生命体征恢复到镇静前水平。离开镇静区后，病人倒下了，没有明显的刺激事件。患者很快苏醒，没有受伤。发现的主要异常是持续性<5>心动过缓</5>，她被收入院进行遥测观察。<6>心动过缓</6>持续了约2小时，进一步的心脏检查未发现潜在异常。当我们将某些镇静剂的使用扩展到其他给药途径时，可能会看到意想不到和以前未报告的结果。", "revised": true}
{"doc_key": "24459006", "sentences": [["Fluconazole", "associated", "agranulocytosis", "and", "thrombocytopenia", ".", "CASE", ":", "We", "describe", "a", "second", "case", "of", "fluconazole", "associated", "agranulocytosis", "with", "thrombocytopenia", "and", "recovery", "upon", "discontinuation", "of", "therapy", ".", "The", "patient", "began", "to", "have", "changes", "in", "white", "blood", "cells", "and", "platelets", "within", "48", "h", "of", "administration", "of", "fluconazole", "and", "began", "to", "recover", "with", "48", "h", "of", "discontinuation", ".", "This", "case", "highlights", "that", "drug", "-", "induced", "blood", "dyscrasias", "can", "occur", "unexpectedly", "as", "a", "result", "of", "treatment", "with", "a", "commonly", "used", "drug", "thought", "to", "be", "\"", "safe", "\"", ".", "CONCLUSION", ":", "According", "to", "Naranjo", "'s", "algorithm", "the", "likelihood", "that", "our", "patient", "'s", "agranulocytosis", "and", "thrombocytopenia", "occurred", "as", "a", "result", "of", "therapy", "with", "fluconazole", "is", "probable", ",", "with", "a", "total", "of", "six", "points", ".", "We", "feel", "that", "the", "weight", "of", "the", "overall", "evidence", "of", "this", "evidence", "is", "strong", ".", "In", "particular", "the", "temporal", "relationship", "of", "bone", "marrow", "suppression", "to", "the", "initiation", "of", "fluconazole", "and", "the", "abatement", "of", "symptoms", "that", "rapidly", "reversed", "immediately", "following", "discontinuation", "."]], "ner": [[[0, 0, "Chemical"], [14, 14, "Chemical"], [44, 44, "Chemical"], [107, 107, "Chemical"], [146, 146, "Chemical"], [2, 2, "Disease"], [16, 16, "Disease"], [97, 97, "Disease"], [4, 4, "Disease"], [18, 18, "Disease"], [99, 99, "Disease"], [62, 63, "Disease"], [139, 141, "Disease"]]], "relations": [[[0, 0, 2, 2, "CID"], [0, 0, 16, 16, "CID"], [0, 0, 97, 97, "CID"], [14, 14, 2, 2, "CID"], [14, 14, 16, 16, "CID"], [14, 14, 97, 97, "CID"], [44, 44, 2, 2, "CID"], [44, 44, 16, 16, "CID"], [44, 44, 97, 97, "CID"], [107, 107, 2, 2, "CID"], [107, 107, 16, 16, "CID"], [107, 107, 97, 97, "CID"], [146, 146, 2, 2, "CID"], [146, 146, 16, 16, "CID"], [146, 146, 97, 97, "CID"], [0, 0, 4, 4, "CID"], [0, 0, 18, 18, "CID"], [0, 0, 99, 99, "CID"], [14, 14, 4, 4, "CID"], [14, 14, 18, 18, "CID"], [14, 14, 99, 99, "CID"], [44, 44, 4, 4, "CID"], [44, 44, 18, 18, "CID"], [44, 44, 99, 99, "CID"], [107, 107, 4, 4, "CID"], [107, 107, 18, 18, "CID"], [107, 107, 99, 99, "CID"], [146, 146, 4, 4, "CID"], [146, 146, 18, 18, "CID"], [146, 146, 99, 99, "CID"]]], "clusters": [], "translated": " <0>氟康唑</0> 相关 <5>粒细胞缺乏症</5> 和 <8>血小板减少症</8>。案例:我们描述了第二例 <1>氟康唑</1> 相关 <6>粒细胞缺乏症</6> 伴有 <9>血小板减少症</9> 并在停止治疗后恢复。患者服用 <2>氟康唑</2> 后48小时内白细胞和血小板开始出现变化，停药48小时后开始恢复。该病例强调了药物引起的 <11>血液恶液质</11> 可能由于使用被认为“安全”的常用药物治疗而意外发生。结论:根据 Naranjo 的算法，我们的患者 <7>粒细胞缺乏症</7> 和 <10>血小板减少症</10> 发生的可能性是 <3>氟康唑</3> 治疗的结果，一共六点。我们觉得这个证据的整体证据权重是很强的。特别是 <12>骨髓抑制</12> 与开始使用 <4>氟康唑</4> 的时间关系以及停药后立即迅速逆转的症状减轻。", "revised": true}
{"doc_key": "24341598", "sentences": [["Comparison", "of", "effects", "of", "isotonic", "sodium", "chloride", "with", "diltiazem", "in", "prevention", "of", "contrast", "-", "induced", "nephropathy", ".", "INTRODUCTION", "AND", "OBJECTIVE", ":", "Contrast", "-", "induced", "nephropathy", "(", "CIN", ")", "significantly", "increases", "the", "morbidity", "and", "mortality", "of", "patients", ".", "The", "aim", "of", "this", "study", "is", "to", "investigate", "and", "compare", "the", "protective", "effects", "of", "isotonic", "sodium", "chloride", "with", "sodium", "bicarbonate", "infusion", "and", "isotonic", "sodium", "chloride", "infusion", "with", "diltiazem", ",", "a", "calcium", "channel", "blocker", ",", "in", "preventing", "CIN", ".", "MATERIALS", "AND", "METHODS", ":", "Our", "study", "included", "patients", "who", "were", "administered", "30", "-", "60", "mL", "of", "iodinated", "contrast", "agent", "for", "percutaneous", "coronary", "angiography", "(", "PCAG", ")", ",", "all", "with", "creatinine", "values", "between", "1", ".", "1", "and", "3", ".", "1", "mg", "/", "dL", ".", "Patients", "were", "divided", "into", "three", "groups", "and", "each", "group", "had", "20", "patients", ".", "The", "first", "group", "of", "patients", "was", "administered", "isotonic", "sodium", "chloride", ";", "the", "second", "group", "was", "administered", "a", "solution", "that", "of", "5", "%", "dextrose", "and", "sodium", "bicarbonate", ",", "while", "the", "third", "group", "was", "administered", "isotonic", "sodium", "chloride", "before", "and", "after", "the", "contrast", "injection", ".", "The", "third", "group", "received", "an", "additional", "injection", "of", "diltiazem", "the", "day", "before", "and", "first", "2", "days", "after", "the", "contrast", "injection", ".", "All", "of", "the", "patients", "'", "plasma", "blood", "urea", "nitrogen", "(", "BUN", ")", "and", "creatinine", "levels", "were", "measured", "on", "the", "second", "and", "seventh", "day", "after", "the", "administration", "of", "intravenous", "contrast", "material", ".", "RESULTS", ":", "The", "basal", "creatinine", "levels", "were", "similar", "for", "all", "three", "groups", "(", "p", ">", "0", ".", "05", ")", ".", "Among", "a", "total", "of", "60", "patients", "included", "in", "the", "study", ",", "16", "patients", "developed", "acute", "renal", "failure", "(", "ARF", ")", "on", "the", "second", "day", "after", "contrast", "material", "was", "injected", "(", "26", ".", "6", "%", ")", ".", "The", "number", "of", "patients", "who", "developed", "ARF", "on", "the", "second", "day", "after", "the", "injection", "in", "the", "first", "group", "was", "five", "(", "25", "%", ")", ",", "in", "the", "second", "group", "was", "six", "(", "30", "%", ")", "and", "the", "third", "group", "was", "five", "(", "25", "%", ")", "(", "p", ">", "0", ".", "05", ")", ".", "CONCLUSION", ":", "There", "was", "no", "significant", "difference", "between", "isotonic", "sodium", "chloride", ",", "sodium", "bicarbonate", "and", "isotonic", "sodium", "chloride", "with", "diltiazem", "application", "in", "prevention", "of", "CIN", "."]], "ner": [[[12, 12, "Chemical"], [21, 21, "Chemical"], [92, 92, "Chemical"], [171, 171, "Chemical"], [192, 192, "Chemical"], [223, 223, "Chemical"], [271, 271, "Chemical"], [260, 262, "Disease"], [264, 264, "Disease"], [288, 288, "Disease"], [5, 6, "Chemical"], [52, 53, "Chemical"], [60, 61, "Chemical"], [139, 140, "Chemical"], [165, 166, "Chemical"], [344, 345, "Chemical"], [351, 352, "Chemical"], [15, 15, "Disease"], [24, 24, "Disease"], [8, 8, "Chemical"], [64, 64, "Chemical"], [182, 182, "Chemical"], [354, 354, "Chemical"], [55, 56, "Chemical"], [155, 156, "Chemical"], [347, 348, "Chemical"], [67, 67, "Chemical"], [104, 104, "Chemical"], [208, 208, "Chemical"], [230, 230, "Chemical"], [153, 153, "Chemical"], [201, 203, "Chemical"], [205, 205, "Chemical"]]], "relations": [[[12, 12, 260, 262, "CID"], [12, 12, 264, 264, "CID"], [12, 12, 288, 288, "CID"], [21, 21, 260, 262, "CID"], [21, 21, 264, 264, "CID"], [21, 21, 288, 288, "CID"], [92, 92, 260, 262, "CID"], [92, 92, 264, 264, "CID"], [92, 92, 288, 288, "CID"], [171, 171, 260, 262, "CID"], [171, 171, 264, 264, "CID"], [171, 171, 288, 288, "CID"], [192, 192, 260, 262, "CID"], [192, 192, 264, 264, "CID"], [192, 192, 288, 288, "CID"], [223, 223, 260, 262, "CID"], [223, 223, 264, 264, "CID"], [223, 223, 288, 288, "CID"], [271, 271, 260, 262, "CID"], [271, 271, 264, 264, "CID"], [271, 271, 288, 288, "CID"]]], "clusters": [], "translated": "比较等渗<10>氯化钠</10>与<19>地尔硫卓</19>预防<0>造影剂</0>诱发的<17>肾病</17>的效果。引言与目的：<1>造影剂</1>诱发的<18>肾病</18> (CIN) 显着增加患者的发病率和死亡率。本研究的目的是调查和比较等渗<11>氯化钠</11>与<23>碳酸氢钠</23>输液和等渗<12>氯化钠</12>输液与<20>地尔硫卓</20>，一种<26>钙</26>通道阻滞剂，用于预防CIN。材料和方法：我们的研究包括接受30 - 60 mL碘化<2>造影剂</2>经皮冠状动脉造影术(PCAG)的患者，所有患者的<27>肌酐</27>值都在1.1和3.1毫克/分升。患者分为三组，每组20例。第一组患者给予等渗<13>氯化钠</13>，第二组给予5%<30>葡萄糖</30>和<24>碳酸氢钠</24>的溶液，而第三组给予等渗<14>氯化钠</14>前后<3>造影剂</3>注入。第三组在<4>造影剂</4>注射前一天和后头2天接受额外注射<21>地尔硫卓</21>。所有患者的血浆<31>血尿素氮</31> (<32>BUN</32>)和<28>肌酐</28>水平均在静脉注射<5>造影剂</5>材质后的第二和第七天测量。结果：所有三组的基础<29>肌酐</29>水平相似（p > 0.05）。在研究中的60名患者中，有16名患者在注射<6>造影剂</6>材料后的第二天发生了<7>急性肾功能衰竭</7> (<8>ARF</8>) (26.6%)。第一组注射后第二天发生<9>ARF</9>的患者人数为5 (25%)，第二组为6 (30%)，第三组为5 (25%) (p > 0.05)。结论：等渗<15>氯化钠</15>、<25>碳酸氢钠</25>和等渗<16>氯化钠</16>与<22>地尔硫卓</22>应用无显着差异，用于预防CIN。", "revised": true}
{"doc_key": "24088636", "sentences": [["Linezolid", "-", "induced", "optic", "neuropathy", ".", "Many", "systemic", "antimicrobials", "have", "been", "implicated", "to", "cause", "ocular", "adverse", "effects", ".", "This", "is", "especially", "relevant", "in", "multidrug", "therapy", "where", "more", "than", "one", "drug", "can", "cause", "a", "similar", "ocular", "adverse", "effect", ".", "We", "describe", "a", "case", "of", "progressive", "loss", "of", "vision", "associated", "with", "linezolid", "therapy", ".", "A", "45", "-", "year", "-", "old", "male", "patient", "who", "was", "on", "treatment", "with", "multiple", "second", "-", "line", "anti", "-", "tuberculous", "drugs", "including", "linezolid", "and", "ethambutol", "for", "extensively", "drug", "-", "resistant", "tuberculosis", "(", "XDR", "-", "TB", ")", "presented", "to", "us", "with", "painless", "progressive", "loss", "of", "vision", "in", "both", "eyes", ".", "Color", "vision", "was", "defective", "and", "fundus", "examination", "revealed", "optic", "disc", "edema", "in", "both", "eyes", ".", "Ethambutol", "-", "induced", "toxic", "optic", "neuropathy", "was", "suspected", "and", "tablet", "ethambutol", "was", "withdrawn", ".", "Deterioration", "of", "vision", "occurred", "despite", "withdrawal", "of", "ethambutol", ".", "Discontinuation", "of", "linezolid", "resulted", "in", "marked", "improvement", "of", "vision", ".", "Our", "report", "emphasizes", "the", "need", "for", "monitoring", "of", "visual", "function", "in", "patients", "on", "long", "-", "term", "linezolid", "treatment", "."]], "ner": [[[0, 0, "Chemical"], [49, 49, "Chemical"], [74, 74, "Chemical"], [141, 141, "Chemical"], [165, 165, "Chemical"], [3, 4, "Disease"], [119, 121, "Disease"], [109, 111, "Disease"], [44, 46, "Disease"], [94, 96, "Disease"], [78, 82, "Disease"], [84, 86, "Disease"], [130, 132, "Disease"], [76, 76, "Chemical"], [116, 116, "Chemical"], [126, 126, "Chemical"], [137, 137, "Chemical"]]], "relations": [[[0, 0, 3, 4, "CID"], [0, 0, 119, 121, "CID"], [49, 49, 3, 4, "CID"], [49, 49, 119, 121, "CID"], [74, 74, 3, 4, "CID"], [74, 74, 119, 121, "CID"], [141, 141, 3, 4, "CID"], [141, 141, 119, 121, "CID"], [165, 165, 3, 4, "CID"], [165, 165, 119, 121, "CID"], [0, 0, 109, 111, "CID"], [49, 49, 109, 111, "CID"], [74, 74, 109, 111, "CID"], [141, 141, 109, 111, "CID"], [165, 165, 109, 111, "CID"]]], "clusters": [], "translated": " <0>利奈唑胺</0> - 诱发<5>视神经病变</5>。许多全身性抗微生物药物与引起眼部不良反应有关。这在多药治疗中尤为重要，因为不止一种药物会引起类似的眼部不良反应。我们描述了一例与<1>利奈唑胺</1>治疗相关的进行性<8>视力丧失</8>。45岁男性患者因<10>广泛耐药结核病</10>正在接受多种二线抗结核药物治疗，包括<2>利奈唑胺</2>和<13>乙胺丁醇</13> （<11>XDR-TB</11>）。他向我们展示了双眼无痛进行性<9>视力丧失</9>。色觉有缺陷，眼底检查发现双眼<7>视盘水肿</7>。被怀疑<14>乙胺丁醇</14>引起的<6>中毒性视神经病变</6>，并撤回了<15>乙胺丁醇</15>片剂。尽管停用了<16>乙胺丁醇</16>，<12>视力恶化</12>。而停用<3>利奈唑胺</3>后视力明显改善。我们的报告强调了对接受长期<4>利奈唑胺</4>治疗的患者进行视功能监测的必要性。", "revised": true}
{"doc_key": "24554916", "sentences": [["Cholestatic", "presentation", "of", "yellow", "phosphorus", "poisoning", ".", "Yellow", "phosphorus", ",", "a", "component", "of", "certain", "pesticide", "pastes", "and", "fireworks", ",", "is", "well", "known", "to", "cause", "hepatotoxicity", ".", "Poisoning", "with", "yellow", "phosphorus", "classically", "manifests", "with", "acute", "hepatitis", "leading", "to", "acute", "liver", "failure", "which", "may", "need", "liver", "transplantation", ".", "We", "present", "a", "case", "of", "yellow", "phosphorus", "poisoning", "in", "which", "a", "patient", "presented", "with", "florid", "clinical", "features", "of", "cholestasis", "highlighting", "the", "fact", "that", "cholestasis", "can", "rarely", "be", "a", "presenting", "feature", "of", "yellow", "phosphorus", "hepatotoxicity", "."]], "ner": [[[4, 4, "Chemical"], [8, 8, "Chemical"], [29, 29, "Chemical"], [52, 52, "Chemical"], [78, 78, "Chemical"], [0, 0, "Disease"], [64, 64, "Disease"], [69, 69, "Disease"], [33, 34, "Disease"], [37, 39, "Disease"], [5, 5, "Disease"], [26, 26, "Disease"], [53, 53, "Disease"], [24, 24, "Disease"], [79, 79, "Disease"]]], "relations": [[[4, 4, 0, 0, "CID"], [4, 4, 64, 64, "CID"], [4, 4, 69, 69, "CID"], [8, 8, 0, 0, "CID"], [8, 8, 64, 64, "CID"], [8, 8, 69, 69, "CID"], [29, 29, 0, 0, "CID"], [29, 29, 64, 64, "CID"], [29, 29, 69, 69, "CID"], [52, 52, 0, 0, "CID"], [52, 52, 64, 64, "CID"], [52, 52, 69, 69, "CID"], [78, 78, 0, 0, "CID"], [78, 78, 64, 64, "CID"], [78, 78, 69, 69, "CID"], [4, 4, 33, 34, "CID"], [8, 8, 33, 34, "CID"], [29, 29, 33, 34, "CID"], [52, 52, 33, 34, "CID"], [78, 78, 33, 34, "CID"], [4, 4, 37, 39, "CID"], [8, 8, 37, 39, "CID"], [29, 29, 37, 39, "CID"], [52, 52, 37, 39, "CID"], [78, 78, 37, 39, "CID"]]], "clusters": [], "translated": "<5>胆汁淤积</5>黄<0>磷</0><10>中毒</10>的表现。黄<1>磷</1>是某些杀虫膏和烟花的成分，众所周知会导致<13>肝毒性</13>。黄<2>磷</2><11>中毒</11>典型表现为<8>急性肝炎</8>，导致<9>急性肝衰竭</9>，可能需要肝移植。我们介绍了一个黄<3>磷</3><12>中毒</12>病例，其中一名患者表现出<6>胆汁淤积</6>的丰富临床特征，强调了<7>胆汁淤积</7>很少是黄<4>磷</4><14>肝毒性</14>的表现特征。", "revised": true}
{"doc_key": "24582773", "sentences": [["Paradoxical", "severe", "agitation", "induced", "by", "add", "-", "on", "high", "-", "doses", "quetiapine", "in", "schizo", "-", "affective", "disorder", ".", "We", "report", "the", "case", "of", "a", "35", "-", "year", "-", "old", "patient", "suffering", "from", "schizo", "-", "affective", "disorder", "since", "the", "age", "of", "19", "years", ",", "treated", "by", "a", "combination", "of", "first", "-", "generation", "antipsychotics", ",", "zuclopenthixol", "(", "100", "mg", "/", "day", ")", "and", "lithium", "(", "1200", "mg", "/", "day", ")", "(", "serum", "lithium", "=", "0", ".", "85", "mEq", "/", "l", ")", ".", "This", "patient", "had", "no", "associated", "personality", "disorder", "(", "particularly", "no", "antisocial", "disorder", ")", "and", "no", "substance", "abuse", "disorder", ".", "Within", "the", "48", "h", "following", "the", "gradual", "introduction", "of", "quetiapine", "(", "up", "to", "600", "mg", "/", "day", ")", ",", "the", "patient", "presented", "severe", "agitation", "without", "an", "environmental", "explanation", ",", "contrasting", "with", "the", "absence", "of", "a", "history", "of", "aggressiveness", "or", "personality", "disorder", ".", "The", "diagnoses", "of", "manic", "shift", "and", "akathisia", "were", "dismissed", ".", "The", "withdrawal", "and", "the", "gradual", "reintroduction", "of", "quetiapine", "2", "weeks", "later", ",", "which", "led", "to", "another", "severe", "agitation", ",", "enabled", "us", "to", "attribute", "the", "agitation", "specifically", "to", "quetiapine", "."]], "ner": [[[11, 11, "Chemical"], [108, 108, "Chemical"], [158, 158, "Chemical"], [178, 178, "Chemical"], [2, 2, "Disease"], [122, 122, "Disease"], [168, 168, "Disease"], [175, 175, "Disease"], [53, 53, "Chemical"], [61, 61, "Chemical"], [70, 70, "Chemical"], [13, 16, "Disease"], [32, 35, "Disease"], [85, 86, "Disease"], [136, 136, "Disease"], [138, 139, "Disease"], [90, 91, "Disease"], [95, 97, "Disease"], [144, 144, "Disease"], [147, 147, "Disease"]]], "relations": [[[11, 11, 2, 2, "CID"], [11, 11, 122, 122, "CID"], [11, 11, 168, 168, "CID"], [11, 11, 175, 175, "CID"], [108, 108, 2, 2, "CID"], [108, 108, 122, 122, "CID"], [108, 108, 168, 168, "CID"], [108, 108, 175, 175, "CID"], [158, 158, 2, 2, "CID"], [158, 158, 122, 122, "CID"], [158, 158, 168, 168, "CID"], [158, 158, 175, 175, "CID"], [178, 178, 2, 2, "CID"], [178, 178, 122, 122, "CID"], [178, 178, 168, 168, "CID"], [178, 178, 175, 175, "CID"]]], "clusters": [], "translated": "<11>精神分裂症</11>中附加高剂量<0>喹硫平</0>引起矛盾的严重<4>激越</4>。我们报告了一名35岁的患者从19岁开始患有<12>分裂性情感障碍</12>的病例，接受了第一代抗精神病药<8>珠氯噻醇</8>的联合治疗（100毫克/天）和<9>锂</9>（1200毫克/天）（血清<10>锂</10>=0.85mEq/l）。该患者没有相关的<13>人格障碍</13>（特别是没有<16>反社会障碍</16>）和<17>药物滥用障碍</17>。在逐渐引入<1>喹硫平</1>（高达600mg/天）后的48小时内，患者出现严重的<5>激越</5>，这与没有<14>攻击性</14>或<15>人格障碍</15>的病史形成对比，没有环境原因。 <18>躁狂</18>转移和<19>静坐不能</19>的诊断被驳回。2周后停用和逐渐重新引入<2>喹硫平</2>导致了另一次严重的<6>躁动</6>，使我们能够将<7>激越</7>具体归因于<3>喹硫平</3>。", "revised": true}
{"doc_key": "24345882", "sentences": [["Neurocognitive", "and", "neuroradiologic", "central", "nervous", "system", "late", "effects", "in", "children", "treated", "on", "Pediatric", "Oncology", "Group", "(", "POG", ")", "P9605", "(", "standard", "risk", ")", "and", "P9201", "(", "lesser", "risk", ")", "acute", "lymphoblastic", "leukemia", "protocols", "(", "ACCL0131", ")", ":", "a", "methotrexate", "consequence", "?", "A", "report", "from", "the", "Children", "'s", "Oncology", "Group", ".", "Concerns", "about", "long", "-", "term", "methotrexate", "(", "MTX", ")", "neurotoxicity", "in", "the", "1990s", "led", "to", "modifications", "in", "intrathecal", "(", "IT", ")", "therapy", ",", "leucovorin", "rescue", ",", "and", "frequency", "of", "systemic", "MTX", "administration", "in", "children", "with", "acute", "lymphoblastic", "leukemia", ".", "In", "this", "study", ",", "neurocognitive", "outcomes", "and", "neuroradiologic", "evidence", "of", "leukoencephalopathy", "were", "compared", "in", "children", "treated", "with", "intense", "central", "nervous", "system", "(", "CNS", ")", "-", "directed", "therapy", "(", "P9605", ")", "versus", "those", "receiving", "fewer", "CNS", "-", "directed", "treatment", "days", "during", "intensive", "consolidation", "(", "P9201", ")", ".", "A", "total", "of", "66", "children", "from", "16", "Pediatric", "Oncology", "Group", "institutions", "with", "\"", "standard", "-", "risk", "\"", "acute", "lymphoblastic", "leukemia", ",", "1", ".", "00", "to", "9", ".", "99", "years", "at", "diagnosis", ",", "without", "evidence", "of", "CNS", "leukemia", "at", "diagnosis", "were", "enrolled", "on", "ACCL0131", ":", "28", "from", "P9201", "and", "38", "from", "P9605", ".", "Magnetic", "resonance", "imaging", "scans", "and", "standard", "neuropsychological", "tests", "were", "performed", ">", "2", ".", "6", "years", "after", "the", "end", "of", "treatment", ".", "Significantly", "more", "P9605", "patients", "developed", "leukoencephalopathy", "compared", "with", "P9201", "patients", "(", "68", "%", ",", "95", "%", "confidence", "interval", "49", "%", "-", "83", "%", "vs", ".", "22", "%", ",", "95", "%", "confidence", "interval", "5", "%", "-", "44", "%", ";", "P", "=", "0", ".", "001", ")", "identified", "as", "late", "as", "7", ".", "7", "years", "after", "the", "end", "of", "treatment", ".", "Overall", ",", "40", "%", "of", "patients", "scored", "<", "85", "on", "either", "Verbal", "or", "Performance", "IQ", ".", "Children", "on", "both", "studies", "had", "significant", "attention", "problems", ",", "but", "P9605", "children", "scored", "below", "average", "on", "more", "neurocognitive", "measures", "than", "those", "treated", "on", "P9201", "(", "82", "%", ",", "14", "/", "17", "measures", "vs", ".", "24", "%", ",", "4", "/", "17", "measures", ")", ".", "This", "supports", "ongoing", "concerns", "about", "intensive", "MTX", "exposure", "as", "a", "major", "contributor", "to", "CNS", "late", "effects", "."]], "ner": [[[38, 38, "Chemical"], [55, 55, "Chemical"], [57, 57, "Chemical"], [80, 80, "Chemical"], [331, 331, "Chemical"], [99, 99, "Disease"], [213, 213, "Disease"], [288, 289, "Disease"], [29, 31, "Disease"], [85, 87, "Disease"], [152, 154, "Disease"], [59, 59, "Disease"], [171, 171, "Disease"]]], "relations": [[[38, 38, 99, 99, "CID"], [38, 38, 213, 213, "CID"], [55, 55, 99, 99, "CID"], [55, 55, 213, 213, "CID"], [57, 57, 99, 99, "CID"], [57, 57, 213, 213, "CID"], [80, 80, 99, 99, "CID"], [80, 80, 213, 213, "CID"], [331, 331, 99, 99, "CID"], [331, 331, 213, 213, "CID"], [38, 38, 288, 289, "CID"], [55, 55, 288, 289, "CID"], [57, 57, 288, 289, "CID"], [80, 80, 288, 289, "CID"], [331, 331, 288, 289, "CID"]]], "clusters": [], "translated": "接受儿科肿瘤组 (POG) P9605（标准风险）和 P9201（较低风险）<8>急性淋巴细胞白血病</8>方案 (ACCL0131)治疗的儿童的神经认知和神经放射学中枢神经系统迟发效应：a<0>甲氨蝶呤</0>后果？来自儿童肿瘤学小组的报告。1990年代对长期<1>甲氨蝶呤</1> ( <2>MTX</2> )<11>神经毒性</11> 的担忧导致鞘内 (IT)治疗、亚叶酸补救和<3>全身性MTX</3>给药在患有<9>急性淋巴细胞白血病</9>的儿童中进行了修改。在这项研究中，神经认知结果和<5>白质脑病</5>的神经放射学证据在接受强化中枢神经系统 (CNS)定向治疗 (P9605)与强化巩固期间接受较少CNS定向治疗天数的儿童中进行了比较(P9201)。共有来自16个儿科肿瘤组机构的66名患有“标准风险”的<10>急性淋巴细胞白血病</10>的儿童，1.00到9.99年诊断，诊断时无<12>CNS白血病</12>证据，被纳入ACCL0131：28例来自P9201，38例来自P9605。在治疗结束2.6年后进行磁共振成像扫描和标准神经心理学测试。最晚在治疗结束7.7年后，显着更多P9605患者发生<6>白质脑病</6> (68%, 95%置信区间 49% - 83%对比22%, 95%置信区间 5% - 44%; P = 0.001)。总体而言，40%的患者在语言或行为智商上的得分低于85。两项研究中的儿童都有明显的<7>注意力问题</7>，但P9605儿童在神经认知测量方面的得分低于接受P9201治疗的儿童的平均水平(82%，14 / 17 项测量与24%，4 / 17 项测量)。这支持了对作为 CNS迟发效应的主要贡献者的密集<4>MTX</4>暴露的持续关注。", "revised": true}
{"doc_key": "24284476", "sentences": [["The", "flavonoid", "apigenin", "delays", "forgetting", "of", "passive", "avoidance", "conditioning", "in", "rats", ".", "The", "present", "experiments", "were", "performed", "to", "study", "the", "effect", "of", "the", "flavonoid", "apigenin", "(", "20", "mg", "/", "kg", "intraperitoneally", "(", "i", ".", "p", ".", ")", ",", "1", "h", "before", "acquisition", ")", ",", "on", "24", "h", "retention", "performance", "and", "forgetting", "of", "a", "step", "-", "through", "passive", "avoidance", "task", ",", "in", "young", "male", "Wistar", "rats", ".", "There", "were", "no", "differences", "between", "saline", "-", "and", "apigenin", "-", "treated", "groups", "in", "the", "24", "h", "retention", "trial", ".", "Furthermore", ",", "apigenin", "did", "not", "prevent", "the", "amnesia", "induced", "by", "scopolamine", "(", "1mg", "/", "kg", ",", "i", ".", "p", ".", ",", "30", "min", "before", "the", "acquisition", ")", ".", "The", "saline", "-", "and", "apigenin", "-", "treated", "rats", "that", "did", "not", "step", "through", "into", "the", "dark", "compartment", "during", "the", "cut", "-", "off", "time", "(", "540", "s", ")", "were", "retested", "weekly", "for", "up", "to", "eight", "weeks", ".", "In", "the", "saline", "treated", "group", ",", "the", "first", "significant", "decline", "in", "passive", "avoidance", "response", "was", "observed", "at", "four", "weeks", ",", "and", "complete", "memory", "loss", "was", "found", "five", "weeks", "after", "the", "acquisition", "of", "the", "passive", "avoidance", "task", ".", "At", "the", "end", "of", "the", "experimental", "period", ",", "60", "%", "of", "the", "animals", "treated", "with", "apigenin", "still", "did", "not", "step", "through", ".", "These", "data", "suggest", "that", "1", ")", "apigenin", "delays", "the", "long", "-", "term", "forgetting", "but", "did", "not", "modulate", "the", "24", "h", "retention", "of", "fear", "memory", "and", "2", ")", "the", "obtained", "beneficial", "effect", "of", "apigenin", "on", "the", "passive", "avoidance", "conditioning", "is", "mediated", "by", "mechanisms", "that", "do", "not", "implicate", "its", "action", "on", "the", "muscarinic", "cholinergic", "system", "."]], "ner": [[[95, 95, "Chemical"], [92, 92, "Disease"], [1, 1, "Chemical"], [23, 23, "Chemical"], [171, 172, "Disease"], [2, 2, "Chemical"], [24, 24, "Chemical"], [74, 74, "Chemical"], [87, 87, "Chemical"], [117, 117, "Chemical"], [201, 201, "Chemical"], [214, 214, "Chemical"], [240, 240, "Chemical"]]], "relations": [[[95, 95, 92, 92, "CID"]]], "clusters": [], "translated": "<2>类黄酮</2> <5>芹菜素</5>延缓大鼠被动回避条件反射的遗忘。本实验旨在研究<3>类黄酮</3> <6>芹菜素</6>（20 mg/kg腹膜内注射（i.p.），采集前1小时），对24小时保留的影响。在年轻的雄性Wistar大鼠中执行和遗忘逐步被动回避任务。在24小时保留试验中，生理盐水和<7>芹菜素</7>处理组之间没有差异。此外，<8>芹菜素</8>不能预防<1>遗忘</1>，它是由<0>东莨菪碱</0>（1mg/kg，i.p.，采集前30分钟）引起的。在截止时间（540秒）内没有进入黑暗的生理盐水和<9>芹菜素</9>处理的大鼠在长达八周的时间内每周重新测试一次。生理盐水治疗组在4周时观察到被动回避反应首次显着下降，在获得被动回避任务5周后发现完全的<4>记忆丧失</4>。实验结束时，60%的用<10>芹菜素</10>处理的动物仍未通过。这些数据表明1)<11>芹菜素</11>延缓长期遗忘，但不会调节恐惧记忆的24小时保留；2)<12>芹菜素</12>对被动的有益影响条件反射是通过不涉及其对毒蕈碱胆碱能系统的作用机制介导的。", "revised": true}
{"doc_key": "24641119", "sentences": [["Baboon", "syndrome", "induced", "by", "ketoconazole", ".", "A", "27", "-", "year", "-", "old", "male", "patient", "presented", "with", "a", "maculopapular", "eruption", "on", "the", "flexural", "areas", "and", "buttocks", "after", "using", "oral", "ketoconazole", ".", "The", "patient", "was", "diagnosed", "with", "drug", "-", "induced", "baboon", "syndrome", "based", "on", "his", "history", ",", "which", "included", "prior", "sensitivity", "to", "topical", "ketoconazole", ",", "a", "physical", "examination", ",", "and", "histopathological", "findings", ".", "Baboon", "syndrome", "is", "a", "drug", "-", "or", "contact", "allergen", "-", "related", "maculopapular", "eruption", "that", "typically", "involves", "the", "flexural", "and", "gluteal", "areas", ".", "To", "the", "best", "of", "our", "knowledge", ",", "this", "is", "the", "first", "reported", "case", "of", "ketoconazole", "-", "induced", "baboon", "syndrome", "in", "the", "English", "literature", "."]], "ner": [[[4, 4, "Chemical"], [28, 28, "Chemical"], [51, 51, "Chemical"], [97, 97, "Chemical"], [17, 18, "Disease"], [72, 73, "Disease"]]], "relations": [[[4, 4, 17, 18, "CID"], [4, 4, 72, 73, "CID"], [28, 28, 17, 18, "CID"], [28, 28, 72, 73, "CID"], [51, 51, 17, 18, "CID"], [51, 51, 72, 73, "CID"], [97, 97, 17, 18, "CID"], [97, 97, 72, 73, "CID"]]], "clusters": [], "translated": "<0>酮康唑</0>致狒狒综合征。一名 27 岁的男性患者在口服<1>酮康唑</1>后出现弯曲区域和臀部的<4>斑丘疹</4>。根据患者的病史（包括之前对局部<2>酮康唑</2>的敏感性）、体检和组织病理学结果，该患者被诊断为药物性狒狒综合征。狒狒综合征是一种与药物或接触性过敏原相关的<5>斑丘疹</5>，通常累及弯曲和臀部区域。据我们所知，这是英文文献中首次报道<3>酮康唑</3>诱发的狒狒综合征。", "revised": true}
{"doc_key": "24587916", "sentences": [["Antioxidant", "effects", "of", "bovine", "lactoferrin", "on", "dexamethasone", "-", "induced", "hypertension", "in", "rat", ".", "Dexamethasone", "-", "(", "Dex", "-", ")", "induced", "hypertension", "is", "associated", "with", "enhanced", "oxidative", "stress", ".", "Lactoferrin", "(", "LF", ")", "is", "an", "iron", "-", "binding", "glycoprotein", "with", "antihypertensive", "properties", ".", "In", "this", "study", ",", "we", "investigated", "the", "effect", "of", "chronic", "administration", "of", "LF", "on", "oxidative", "stress", "and", "hypertension", "upon", "Dex", "administration", ".", "Male", "Wistar", "rats", "were", "treated", "by", "Dex", "(", "30", "u", "g", "/", "kg", "/", "day", "subcutaneously", ")", "or", "saline", "for", "14", "days", ".", "Oral", "bovine", "LF", "(", "30", ",", "100", ",", "300", "mg", "/", "kg", ")", "was", "given", "from", "day", "8", "to", "14", "in", "a", "reversal", "study", ".", "In", "a", "prevention", "study", ",", "rats", "received", "4", "days", "of", "LF", "treatment", "followed", "by", "Dex", "and", "continued", "during", "the", "test", "period", ".", "Systolic", "blood", "pressure", "(", "SBP", ")", "was", "measured", "using", "tail", "-", "cuff", "method", ".", "Thymus", "weight", "was", "used", "as", "a", "marker", "of", "glucocorticoid", "activity", ".", "Plasma", "hydrogen", "peroxide", "(", "H2O2", ")", "concentration", "and", "ferric", "reducing", "antioxidant", "power", "(", "FRAP", ")", "value", "were", "determined", ".", "Dexamethasone", "significantly", "increased", "SBP", "and", "plasma", "H2O2", "level", "and", "decreased", "thymus", "and", "body", "weights", ".", "LF", "lowered", "(", "P", "<", "0", ".", "01", ")", "and", "dose", "dependently", "prevented", "(", "P", "<", "0", ".", "001", ")", "Dex", "-", "induced", "hypertension", ".", "LF", "prevented", "body", "weight", "loss", "and", "significantly", "reduced", "the", "elevated", "plasma", "H2O2", "and", "increased", "FRAP", "values", ".", "Chronic", "administration", "of", "LF", "strongly", "reduced", "the", "blood", "pressure", "and", "production", "of", "ROS", "and", "improved", "antioxidant", "capacity", "in", "Dex", "-", "induced", "hypertension", ",", "suggesting", "the", "role", "of", "inhibition", "of", "oxidative", "stress", "as", "another", "mechanism", "of", "antihypertensive", "action", "of", "LF", "."]], "ner": [[[6, 6, "Chemical"], [13, 13, "Chemical"], [16, 16, "Chemical"], [61, 61, "Chemical"], [70, 70, "Chemical"], [126, 126, "Chemical"], [178, 178, "Chemical"], [213, 213, "Chemical"], [253, 253, "Chemical"], [9, 9, "Disease"], [20, 20, "Disease"], [59, 59, "Disease"], [216, 216, "Disease"], [256, 256, "Disease"], [221, 222, "Disease"], [34, 34, "Chemical"], [160, 161, "Chemical"], [163, 163, "Chemical"], [184, 184, "Chemical"], [229, 229, "Chemical"]]], "relations": [[[6, 6, 9, 9, "CID"], [6, 6, 20, 20, "CID"], [6, 6, 59, 59, "CID"], [6, 6, 216, 216, "CID"], [6, 6, 256, 256, "CID"], [13, 13, 9, 9, "CID"], [13, 13, 20, 20, "CID"], [13, 13, 59, 59, "CID"], [13, 13, 216, 216, "CID"], [13, 13, 256, 256, "CID"], [16, 16, 9, 9, "CID"], [16, 16, 20, 20, "CID"], [16, 16, 59, 59, "CID"], [16, 16, 216, 216, "CID"], [16, 16, 256, 256, "CID"], [61, 61, 9, 9, "CID"], [61, 61, 20, 20, "CID"], [61, 61, 59, 59, "CID"], [61, 61, 216, 216, "CID"], [61, 61, 256, 256, "CID"], [70, 70, 9, 9, "CID"], [70, 70, 20, 20, "CID"], [70, 70, 59, 59, "CID"], [70, 70, 216, 216, "CID"], [70, 70, 256, 256, "CID"], [126, 126, 9, 9, "CID"], [126, 126, 20, 20, "CID"], [126, 126, 59, 59, "CID"], [126, 126, 216, 216, "CID"], [126, 126, 256, 256, "CID"], [178, 178, 9, 9, "CID"], [178, 178, 20, 20, "CID"], [178, 178, 59, 59, "CID"], [178, 178, 216, 216, "CID"], [178, 178, 256, 256, "CID"], [213, 213, 9, 9, "CID"], [213, 213, 20, 20, "CID"], [213, 213, 59, 59, "CID"], [213, 213, 216, 216, "CID"], [213, 213, 256, 256, "CID"], [253, 253, 9, 9, "CID"], [253, 253, 20, 20, "CID"], [253, 253, 59, 59, "CID"], [253, 253, 216, 216, "CID"], [253, 253, 256, 256, "CID"], [6, 6, 221, 222, "CID"], [13, 13, 221, 222, "CID"], [16, 16, 221, 222, "CID"], [61, 61, 221, 222, "CID"], [70, 70, 221, 222, "CID"], [126, 126, 221, 222, "CID"], [178, 178, 221, 222, "CID"], [213, 213, 221, 222, "CID"], [253, 253, 221, 222, "CID"]]], "clusters": [], "translated": "牛乳铁蛋白对<0>地塞米松</0>-诱导的大鼠<10>高血压</10>的抗氧化作用。<1>地塞米松</1>（<2>Dex</2>）-诱发的<9>高血压</9>与氧化应激增强有关。乳铁蛋白（LF）是一种<15>铁</15>结合糖蛋白，具有抗高血压作用。在这项研究中，我们研究了长期服用LF对氧化应激和<11>高血压</11>对<3>Dex</3>给药的影响。雄性Wistar大鼠用<4>Dex</4>（30ug/kg/天皮下注射）或生理盐水处理14天。在逆转研究中，从第8天到第14天口服牛LF（30、100、300毫克/千克）。在一项预防研究中，大鼠接受了4天的LF治疗，随后接受了<5>Dex</5>治疗，并在试验期间继续进行。收缩压（SBP）采用尾套法测量。胸腺重量被用作糖皮质激素活性的标志。测定血浆<16>过氧化氢</16>（<17>H2O2</17>）浓度和铁还原抗氧化能力（FRAP）值。<6>地塞米松</6>显着增加SBP和血浆<18>H2O2</18>水平，降低胸腺和体重。LF降低（P < 0.01）和剂量依赖性预防（P < 0.001）<7>Dex</7>引起的<12>高血压</12>。LF防止<14>体重减轻</14>，显着降低升高的血浆<19>H2O2</19>并增加FRAP值。长期服用LF可显着降低血压和ROS的产生，并改善<8>Dex</8>引起的<13>高血压</13>中的抗氧化能力，表明抑制氧化应激的作用是LF另一种抗高血压机制的作用。", "revised": true}
{"doc_key": "24658375", "sentences": [["All", "-", "trans", "retinoic", "acid", "-", "induced", "inflammatory", "myositis", "in", "a", "patient", "with", "acute", "promyelocytic", "leukemia", ".", "All", "-", "trans", "retinoic", "acid", "(", "ATRA", ")", ",", "a", "component", "of", "standard", "therapy", "for", "acute", "promyelocytic", "leukemia", "(", "APL", ")", ",", "is", "associated", "with", "potentially", "serious", "but", "treatable", "adverse", "effects", "involving", "numerous", "organ", "systems", ",", "including", "rare", "skeletal", "muscle", "involvement", ".", "Only", "a", "handful", "of", "cases", "of", "ATRA", "-", "induced", "myositis", "in", "children", "have", "been", "reported", ",", "and", "none", "in", "the", "radiology", "literature", ".", "We", "present", "such", "a", "case", "in", "a", "15", "-", "year", "-", "old", "boy", "with", "APL", ",", "where", "recognition", "of", "imaging", "findings", "played", "a", "crucial", "role", "in", "making", "the", "diagnosis", "and", "facilitated", "prompt", ",", "effective", "treatment", "."]], "ner": [[[0, 4, "Chemical"], [17, 21, "Chemical"], [23, 23, "Chemical"], [65, 65, "Chemical"], [8, 8, "Disease"], [68, 68, "Disease"], [13, 15, "Disease"], [32, 34, "Disease"], [36, 36, "Disease"], [96, 96, "Disease"]]], "relations": [[[0, 4, 8, 8, "CID"], [0, 4, 68, 68, "CID"], [17, 21, 8, 8, "CID"], [17, 21, 68, 68, "CID"], [23, 23, 8, 8, "CID"], [23, 23, 68, 68, "CID"], [65, 65, 8, 8, "CID"], [65, 65, 68, 68, "CID"]]], "clusters": [], "translated": "<0>全反式维甲酸</0>引起的炎症<4>肌炎</4>在一名<6>急性早幼粒细胞白血病</6>患者中出现。 <1>全反式维甲酸</1>（<2>ATRA</2>），<7>急性早幼粒细胞白血病</7>（<8>APL</8>）标准疗法的组成部分，与涉及许多器官系统的潜在严重但可治疗的副作用有关，包括罕见的骨骼肌受累。只有少数儿童出现由<3>ATRA</3> 诱发的<5>肌炎</5> 病例被报道，放射学文献中没有。我们介绍了一名患有<9>APL</9>的 15 岁男孩的病例，影像学检查结果的识别在做出诊断和促进及时有效的治疗方面发挥了关键作用。", "revised": true}
{"doc_key": "24653743", "sentences": [["A", "Case", "of", "Sudden", "Cardiac", "Death", "due", "to", "Pilsicainide", "-", "Induced", "Torsades", "de", "Pointes", ".", "An", "84", "-", "year", "-", "old", "male", "received", "oral", "pilsicainide", ",", "a", "pure", "sodium", "channel", "blocker", "with", "slow", "recovery", "kinetics", ",", "to", "convert", "his", "paroxysmal", "atrial", "fibrillation", "to", "a", "sinus", "rhythm", ";", "the", "patient", "developed", "sudden", "cardiac", "death", "two", "days", "later", ".", "The", "Holter", "electrocardiogram", ",", "which", "was", "worn", "by", "chance", ",", "revealed", "torsade", "de", "pointes", "with", "gradually", "prolonged", "QT", "intervals", ".", "This", "drug", "is", "rapidly", "absorbed", "from", "the", "gastrointestinal", "tract", ",", "and", "most", "of", "it", "is", "excreted", "from", "the", "kidney", ".", "Although", "the", "patient", "'s", "renal", "function", "was", "not", "highly", "impaired", "and", "the", "dose", "of", "pilsicainide", "was", "low", ",", "the", "plasma", "concentration", "of", "pilsicainide", "may", "have", "been", "high", ",", "which", "can", "produce", "torsades", "de", "pointes", "in", "the", "octogenarian", ".", "Although", "the", "oral", "administration", "of", "class", "IC", "drugs", ",", "including", "pilsicainide", ",", "is", "effective", "to", "terminate", "atrial", "fibrillation", ",", "careful", "consideration", "must", "be", "taken", "before", "giving", "these", "drugs", "to", "octogenarians", "."]], "ner": [[[8, 8, "Chemical"], [24, 24, "Chemical"], [111, 111, "Chemical"], [119, 119, "Chemical"], [145, 145, "Chemical"], [3, 5, "Disease"], [50, 52, "Disease"], [11, 13, "Disease"], [68, 70, "Disease"], [128, 130, "Disease"], [28, 28, "Chemical"], [40, 41, "Disease"], [151, 152, "Disease"]]], "relations": [[[8, 8, 3, 5, "CID"], [8, 8, 50, 52, "CID"], [24, 24, 3, 5, "CID"], [24, 24, 50, 52, "CID"], [111, 111, 3, 5, "CID"], [111, 111, 50, 52, "CID"], [119, 119, 3, 5, "CID"], [119, 119, 50, 52, "CID"], [145, 145, 3, 5, "CID"], [145, 145, 50, 52, "CID"], [8, 8, 11, 13, "CID"], [8, 8, 68, 70, "CID"], [8, 8, 128, 130, "CID"], [24, 24, 11, 13, "CID"], [24, 24, 68, 70, "CID"], [24, 24, 128, 130, "CID"], [111, 111, 11, 13, "CID"], [111, 111, 68, 70, "CID"], [111, 111, 128, 130, "CID"], [119, 119, 11, 13, "CID"], [119, 119, 68, 70, "CID"], [119, 119, 128, 130, "CID"], [145, 145, 11, 13, "CID"], [145, 145, 68, 70, "CID"], [145, 145, 128, 130, "CID"]]], "clusters": [], "translated": "一例<5>心脏猝死</5>由于<0>匹西卡尼</0>-诱发<7>尖端扭转型室性心动过速</7>。一位84岁的男性接受了口服<1>pilsicainide</1>，一种恢复动力学缓慢的纯<10>钠</10>通道阻滞剂，将他的阵发性<11>心房颤动</11>转化为窦性心律；两天后，患者<6>心源性猝死</6>。偶然佩戴的Holter心电图显示<8>尖端扭转型室性心动过速</8>，QT间期逐渐延长。本药经胃肠道吸收迅速，大部分经肾脏排泄。虽然患者的肾功能没有严重受损并且<2>pilsicainide</2>的剂量很低，但<3>pilsicainide</3>的血浆浓度可能已经很高，可以产生<9>扭转型室性心动过速</9>在八十多岁的老人中发生。尽管口服IC类药物（包括<4>匹西卡尼</4>）可有效终止<12>心房颤动</12>，但在将这些药物用于八十多岁的老人之前必须慎重考虑。", "revised": true}
{"doc_key": "24464946", "sentences": [["Two", "-", "dimensional", "speckle", "tracking", "echocardiography", "combined", "with", "high", "-", "sensitive", "cardiac", "troponin", "T", "in", "early", "detection", "and", "prediction", "of", "cardiotoxicity", "during", "epirubicine", "-", "based", "chemotherapy", ".", "AIMS", ":", "To", "investigate", "whether", "alterations", "of", "myocardial", "strain", "and", "high", "-", "sensitive", "cardiac", "troponin", "T", "(", "cTnT", ")", "could", "predict", "future", "cardiac", "dysfunction", "in", "patients", "after", "epirubicin", "exposure", ".", "METHODS", ":", "Seventy", "-", "five", "patients", "with", "non", "-", "Hodgkin", "lymphoma", "treated", "with", "epirubicin", "were", "studied", ".", "Blood", "collection", "and", "echocardiography", "were", "performed", "at", "baseline", ",", "1", "day", "after", "the", "third", "cycle", ",", "and", "1", "day", "after", "completion", "of", "chemotherapy", ".", "Patients", "were", "studied", "using", "echocardiography", "during", "follow", "-", "up", ".", "Global", "longitudinal", "(", "GLS", ")", ",", "circumferential", "(", "GCS", ")", ",", "and", "radial", "strain", "(", "GRS", ")", "were", "calculated", "using", "speckle", "tracking", "echocardiography", ".", "Left", "ventricular", "ejection", "fraction", "was", "analysed", "by", "real", "-", "time", "3D", "echocardiography", ".", "Cardiotoxicity", "was", "defined", "as", "a", "reduction", "of", "the", "LVEF", "of", ">", "5", "%", "to", "<", "55", "%", "with", "symptoms", "of", "heart", "failure", "or", "an", "asymptomatic", "reduction", "of", "the", "LVEF", "of", ">", "10", "%", "to", "<", "55", "%", ".", "RESULTS", ":", "Fourteen", "patients", "(", "18", ".", "67", "%", ")", "developed", "cardiotoxicity", "after", "treatment", ".", "GLS", "(", "-", "18", ".", "48", "+", "1", ".", "72", "%", "vs", ".", "-", "15", ".", "96", "+", "1", ".", "6", "%", ")", ",", "GCS", "(", "-", "20", ".", "93", "+", "2", ".", "86", "%", "vs", ".", "-", "19", ".", "20", "+", "3", ".", "21", "%", ")", ",", "and", "GRS", "(", "39", ".", "23", "+", "6", ".", "44", "%", "vs", ".", "34", ".", "98", "+", "6", ".", "2", "%", ")", "were", "markedly", "reduced", "and", "cTnT", "was", "elevated", "from", "0", ".", "0010", "+", "0", ".", "0020", "to", "0", ".", "0073", "+", "0", ".", "0038", "ng", "/", "mL", "(", "P", "all", "<", "0", ".", "01", ")", "at", "the", "completion", "of", "chemotherapy", "compared", "with", "baseline", "values", ".", "A", ">", "15", ".", "9", "%", "decrease", "in", "GLS", "[", "sensitivity", ",", "86", "%", ";", "specificity", ",", "75", "%", ";", "area", "under", "the", "curve", "(", "AUC", ")", "=", "0", ".", "815", ";", "P", "=", "0", ".", "001", "]", "and", "a", ">", "0", ".", "004", "ng", "/", "mL", "elevation", "in", "cTnT", "(", "sensitivity", ",", "79", "%", ";", "specificity", ",", "64", "%", ";", "AUC", "=", "0", ".", "757", ";", "P", "=", "0", ".", "005", ")", "from", "baseline", "to", "the", "third", "cycle", "of", "chemotherapy", "predicted", "later", "cardiotoxicity", ".", "The", "decrease", "in", "GLS", "remained", "the", "only", "independent", "predictor", "of", "cardiotoxicity", "(", "P", "=", "0", ".", "000", ")", ".", "CONCLUSIONS", ":", "GLS", "combined", "with", "cTnT", "may", "provide", "a", "reliable", "and", "non", "-", "invasive", "method", "to", "predict", "cardiac", "dysfunction", "in", "patients", "receiving", "anthracycline", "-", "based", "chemotherapy", "."]], "ner": [[[22, 22, "Chemical"], [54, 54, "Chemical"], [70, 70, "Chemical"], [20, 20, "Disease"], [145, 145, "Disease"], [194, 194, "Disease"], [395, 395, "Disease"], [407, 407, "Disease"], [165, 166, "Disease"], [438, 438, "Chemical"], [34, 35, "Disease"], [49, 50, "Disease"], [433, 434, "Disease"], [64, 67, "Disease"]]], "relations": [[[22, 22, 20, 20, "CID"], [22, 22, 145, 145, "CID"], [22, 22, 194, 194, "CID"], [22, 22, 395, 395, "CID"], [22, 22, 407, 407, "CID"], [54, 54, 20, 20, "CID"], [54, 54, 145, 145, "CID"], [54, 54, 194, 194, "CID"], [54, 54, 395, 395, "CID"], [54, 54, 407, 407, "CID"], [70, 70, 20, 20, "CID"], [70, 70, 145, 145, "CID"], [70, 70, 194, 194, "CID"], [70, 70, 395, 395, "CID"], [70, 70, 407, 407, "CID"], [22, 22, 165, 166, "CID"], [54, 54, 165, 166, "CID"], [70, 70, 165, 166, "CID"]]], "clusters": [], "translated": "二维斑点追踪超声心动图联合高敏心肌肌钙蛋白 T 在以 <0> 表柔比星 </0> 为基础的化疗期间早期检测和预测 <3> 心脏毒性 </3>。目的：研究 <10> 心肌应变 </10> 和高敏心肌肌钙蛋白 T (cTnT) 的改变是否可以预测患者在接受 <1> 表柔比星 </1> 后未来的 <11> 心功能不全 </11> 。方法：对 75 例接受 <2> 表柔比星 </2> 治疗的 <13> 非霍奇金淋巴瘤 </13>患者进行了研究。在基线、第三个周期后 1 天和化疗完成后 1 天进行血液采集和超声心动图检查。在随访期间使用超声心动图对患者进行研究。使用散斑追踪超声心动图计算整体纵向 (GLS)、周向 (GCS) 和径向应变 (GRS)。通过实时 3D 超声心动图分析左心室射血分数。 <4> 心脏毒性 </4>定义为 LVEF 降低 > 5% 至 <55% 并伴有 <8> 心力衰竭 </8> 症状或 LVEF 无症状降低 > 10% 至 <55%。结果：14 例患者 (18.67%) 在治疗后出现 <5> 心脏毒性 </5>。 GLS (-18.48+1.72% 对比 -15.96+1.6%)，GCS (-20.93+2.86% 对比 -19.20+3.21%) 和 GRS (39.23+6.44% 对比 34.98+6.2%) 显着减少，cTnT 从 0.0010+0.0020 ng/mL 到 0.0073+0.0038 ng/mL (P all <0.01) 在化疗完成时与基线值相比。一个 >15.9% 的 GLS 降低 [灵敏度，86%; 特异性, 75%; 曲线下面积 (AUC) = 0.815; P = 0.001] 和 >0.004 ng/mL 的 cTnT 升高（敏感性，79%; 特异性，64%; AUC = 0.757; P = 0.005）从基线到化疗的第三个周期可以预测后来的 <6> 心脏毒性 </6>。 GLS 的降低仍然是 <7> 心脏毒性 </7> 的唯一独立预测因子 (P = 0.000)。结论：GLS 联合 cTnT 可为接受 <9> 蒽环类药物 </9>化疗的患者提供可靠、无创的预测方法预测未来的 <12> 心功能不全 </12>。", "revised": true}
{"doc_key": "24309294", "sentences": [["Cholecystokinin", "-", "octapeptide", "restored", "morphine", "-", "induced", "hippocampal", "long", "-", "term", "potentiation", "impairment", "in", "rats", ".", "Cholecystokinin", "-", "octapeptide", "(", "CCK", "-", "8", ")", ",", "which", "is", "a", "typical", "brain", "-", "gut", "peptide", ",", "exerts", "a", "wide", "range", "of", "biological", "activities", "on", "the", "central", "nervous", "system", ".", "We", "have", "previously", "reported", "that", "CCK", "-", "8", "significantly", "alleviated", "morphine", "-", "induced", "amnesia", "and", "reversed", "spine", "density", "decreases", "in", "the", "CA1", "region", "of", "the", "hippocampus", "in", "morphine", "-", "treated", "animals", ".", "Here", ",", "we", "investigated", "the", "effects", "of", "CCK", "-", "8", "on", "long", "-", "term", "potentiation", "(", "LTP", ")", "in", "the", "lateral", "perforant", "path", "(", "LPP", ")", "-", "granule", "cell", "synapse", "of", "rat", "dentate", "gyrus", "(", "DG", ")", "in", "acute", "saline", "or", "morphine", "-", "treated", "rats", ".", "Population", "spikes", "(", "PS", ")", ",", "which", "were", "evoked", "by", "stimulation", "of", "the", "LPP", ",", "were", "recorded", "in", "the", "DG", "region", ".", "Acute", "morphine", "(", "30mg", "/", "kg", ",", "s", ".", "c", ".", ")", "treatment", "significantly", "attenuated", "hippocampal", "LTP", "and", "CCK", "-", "8", "(", "1ug", ",", "i", ".", "c", ".", "v", ".", ")", "restored", "the", "amplitude", "of", "PS", "that", "was", "attenuated", "by", "morphine", "injection", ".", "Furthermore", ",", "microinjection", "of", "CCK", "-", "8", "(", "0", ".", "1", "and", "1ug", ",", "i", ".", "c", ".", "v", ".", ")", "also", "significantly", "augmented", "hippocampal", "LTP", "in", "saline", "-", "treated", "(", "1ml", "/", "kg", ",", "s", ".", "c", ".", ")", "rats", ".", "Pre", "-", "treatment", "of", "the", "CCK2", "receptor", "antagonist", "L", "-", "365", ",", "260", "(", "10ug", ",", "i", ".", "c", ".", "v", ")", "reversed", "the", "effects", "of", "CCK", "-", "8", ",", "but", "the", "CCK1", "receptor", "antagonist", "L", "-", "364", ",", "718", "(", "10ug", ",", "i", ".", "c", ".", "v", ")", "did", "not", ".", "The", "present", "results", "demonstrate", "that", "CCK", "-", "8", "attenuates", "the", "effect", "of", "morphine", "on", "hippocampal", "LTP", "through", "CCK2", "receptors", "and", "suggest", "an", "ameliorative", "function", "of", "CCK", "-", "8", "on", "morphine", "-", "induced", "memory", "impairment", "."]], "ner": [[[4, 4, "Chemical"], [57, 57, "Chemical"], [74, 74, "Chemical"], [120, 120, "Chemical"], [148, 148, "Chemical"], [187, 187, "Chemical"], [296, 296, "Chemical"], [313, 313, "Chemical"], [60, 60, "Disease"], [0, 2, "Chemical"], [16, 18, "Chemical"], [20, 22, "Chemical"], [52, 54, "Chemical"], [86, 88, "Chemical"], [165, 167, "Chemical"], [194, 196, "Chemical"], [258, 260, "Chemical"], [289, 291, "Chemical"], [309, 311, "Chemical"], [316, 317, "Disease"]]], "relations": [[[4, 4, 60, 60, "CID"], [57, 57, 60, 60, "CID"], [74, 74, 60, 60, "CID"], [120, 120, 60, 60, "CID"], [148, 148, 60, 60, "CID"], [187, 187, 60, 60, "CID"], [296, 296, 60, 60, "CID"], [313, 313, 60, 60, "CID"]]], "clusters": [], "translated": " <9>缩胆囊素-八肽</9>恢复<0>吗啡</0> -诱导的大鼠海马长时程增强损伤。 <10>缩胆囊素八肽</10>（<11>CCK-8</11>），是一种典型的脑肠肽，对中枢神经系统具有广泛的生物学活性。我们之前曾报道过，<12> CCK-8 </12>显着减轻了<1>吗啡</1> -引起的<8>健忘症</8>并逆转了<2>吗啡</2>治疗动物时海马CA1区的脊柱密度下降。在这里，我们研究了<13> CCK-8 </13>对急性盐水或<3>吗啡</3>治疗的大鼠齿状回（DG）中侧孔径通路（LPP）-颗粒细胞突触中长时程增强（LTP）的影响。记录DG区域为LPP刺激引起的群体峰（PS）信号。急性<4>吗啡</4>（30mg/kg，s.c.）处理显着减弱了海马LTP，<14> CCK-8 </14>（1ug，i.c.v.）恢复了由<5>吗啡</5>注射减弱的PS振幅。此外，微量注射<15> CCK-8 </15>（0.1和1ug，i.c.v.）还显着增加了盐水处理（1ml/kg，s.c.）大鼠的海马LTP。CCK2受体拮抗剂L-365，260（10ug，i.c.v.）可预处理逆转<16> CCK-8 </16>的作用，但CCK1受体拮抗剂L-364，718（10ug，i.c.v）不能。目前的结果表明，<17> CCK-8 </17>通过CCK2受体减弱了<6>吗啡</6>对海马LTP的影响，并表明<18> CCK-8 </18>对<7>吗啡</7> -引起的<19>记忆障碍</19>有改善作用。", "revised": true}
{"doc_key": "24618873", "sentences": [["Cerebellar", "and", "oculomotor", "dysfunction", "induced", "by", "rapid", "infusion", "of", "pethidine", ".", "Pethidine", "is", "an", "opioid", "that", "gains", "its", "popularity", "for", "the", "effective", "pain", "control", "through", "acting", "on", "the", "opioid", "-", "receptors", ".", "However", ",", "rapid", "pain", "relief", "sometimes", "brings", "about", "unfavourable", "side", "effects", "that", "largely", "limit", "its", "clinical", "utility", ".", "Common", "side", "effects", "include", "nausea", ",", "vomiting", "and", "hypotension", ".", "In", "patients", "with", "impaired", "renal", "and", "liver", "function", ",", "and", "those", "who", "need", "long", "-", "term", "pain", "control", ",", "pethidine", "may", "cause", "excitatory", "central", "nervous", "system", "(", "CNS", ")", "effects", "through", "its", "neurotoxic", "metabolite", ",", "norpethidine", ",", "resulting", "in", "irritability", "and", "seizure", "attack", ".", "On", "the", "contrary", ",", "though", "not", "clinically", "apparent", ",", "pethidine", "potentially", "causes", "inhibitory", "impacts", "on", "the", "CNS", "and", "impairs", "normal", "cerebellar", "and", "oculomotor", "function", "in", "the", "short", "term", ".", "In", "this", "case", "report", ",", "we", "highlight", "opioid", "'s", "inhibitory", "side", "effects", "on", "the", "cerebellar", "structure", "that", "causes", "dysmetria", ",", "dysarthria", ",", "reduced", "smooth", "pursuit", "gain", "and", "decreased", "saccadic", "velocity", "."]], "ner": [[[9, 9, "Chemical"], [11, 11, "Chemical"], [79, 79, "Chemical"], [113, 113, "Chemical"], [54, 54, "Disease"], [56, 56, "Disease"], [58, 58, "Disease"], [151, 151, "Disease"], [153, 153, "Disease"], [95, 95, "Chemical"], [101, 101, "Disease"], [0, 3, "Disease"], [22, 22, "Disease"], [35, 35, "Disease"], [76, 76, "Disease"], [63, 67, "Disease"], [92, 92, "Disease"], [99, 99, "Disease"]]], "relations": [[[9, 9, 54, 54, "CID"], [11, 11, 54, 54, "CID"], [79, 79, 54, 54, "CID"], [113, 113, 54, 54, "CID"], [9, 9, 56, 56, "CID"], [11, 11, 56, 56, "CID"], [79, 79, 56, 56, "CID"], [113, 113, 56, 56, "CID"], [9, 9, 58, 58, "CID"], [11, 11, 58, 58, "CID"], [79, 79, 58, 58, "CID"], [113, 113, 58, 58, "CID"], [9, 9, 151, 151, "CID"], [11, 11, 151, 151, "CID"], [79, 79, 151, 151, "CID"], [113, 113, 151, 151, "CID"], [9, 9, 153, 153, "CID"], [11, 11, 153, 153, "CID"], [79, 79, 153, 153, "CID"], [113, 113, 153, 153, "CID"], [95, 95, 101, 101, "CID"]]], "clusters": [], "translated": "<11>快速输注</11><0>哌替啶</0>引起的<11>小脑和动眼神经功能障碍</11>。<1>哌替啶</1>是一种阿片类药物，通过作用于阿片受体，因有效地控制<12>疼痛</12>而广受欢迎。然而，快速<13>疼痛</13>缓解有时会带来不利的副作用，这在很大程度上限制了其临床应用。常见的副作用包括<4>恶心</4>、<5>呕吐</5>和<6>低血压</6>。对于<15>肝肾功能受损</15>，以及需要长期控制<14>疼痛</14>的患者，<2>哌替啶</2>可能会引起中枢神经系统兴奋性（CNS），通过其<16>神经毒性</16>代谢物<9>去甲哌替啶</9>发挥作用，导致<17>易怒</17>和<10>癫痫发作</10>。相反，<3>哌替啶</3>虽然在临床上不明显，但可能会对中枢神经系统产生抑制作用，并在短期内损害正常的小脑和动眼神经功能。在本病例报告中，我们强调了阿片类药物对小脑结构的抑制性副作用，该副作用会导致<7>辨距障碍</7>、<8>构音障碍</8>，平滑追踪增益降低和扫视速度降低。", "revised": true}
{"doc_key": "24665854", "sentences": [["Valproate", "-", "induced", "hyperammonemic", "encephalopathy", "in", "a", "renal", "transplanted", "patient", ".", "Neurological", "complications", "after", "renal", "transplantation", "constitute", "an", "important", "cause", "of", "morbidity", "and", "mortality", ".", "Their", "differential", "diagnosis", "is", "difficult", "and", "essential", "for", "subsequent", "patient", "'s", "management", ".", "Valproate", "-", "induced", "hyperammonemic", "encephalopathy", "is", "an", "uncommon", "but", "serious", "effect", "of", "valproate", "treatment", ".", "Here", ",", "we", "describe", "the", "case", "of", "a", "15", "-", "year", "-", "old", "girl", "who", "was", "on", "a", "long", "-", "term", "therapy", "with", "valproate", "due", "to", "epilepsy", "and", "revealed", "impaired", "consciousness", "with", "hyperammonemia", "12", "days", "after", "renal", "transplantation", ".", "After", "withdraw", "of", "valproate", ",", "patients", "'", "symptoms", "resolved", "within", "24", "h", ".", "Clinicians", "should", "increase", "their", "awareness", "for", "potential", "complication", "of", "valproate", ",", "especially", "in", "transplanted", "patients", "."]], "ner": [[[0, 0, "Chemical"], [38, 38, "Chemical"], [50, 50, "Chemical"], [76, 76, "Chemical"], [95, 95, "Chemical"], [114, 114, "Chemical"], [3, 3, "Disease"], [41, 41, "Disease"], [85, 85, "Disease"], [82, 83, "Disease"], [4, 4, "Disease"], [42, 42, "Disease"], [11, 12, "Disease"], [79, 79, "Disease"]]], "relations": [[[0, 0, 3, 3, "CID"], [0, 0, 41, 41, "CID"], [0, 0, 85, 85, "CID"], [38, 38, 3, 3, "CID"], [38, 38, 41, 41, "CID"], [38, 38, 85, 85, "CID"], [50, 50, 3, 3, "CID"], [50, 50, 41, 41, "CID"], [50, 50, 85, 85, "CID"], [76, 76, 3, 3, "CID"], [76, 76, 41, 41, "CID"], [76, 76, 85, 85, "CID"], [95, 95, 3, 3, "CID"], [95, 95, 41, 41, "CID"], [95, 95, 85, 85, "CID"], [114, 114, 3, 3, "CID"], [114, 114, 41, 41, "CID"], [114, 114, 85, 85, "CID"], [0, 0, 82, 83, "CID"], [38, 38, 82, 83, "CID"], [50, 50, 82, 83, "CID"], [76, 76, 82, 83, "CID"], [95, 95, 82, 83, "CID"], [114, 114, 82, 83, "CID"]]], "clusters": [], "translated": " <0>丙戊酸盐</0>诱导的<6>高氨血症</6> <10>脑病</10>在肾移植患者中出现。 在肾移植后的<12>神经系统并发症</12>是导致发病率和死亡率升高的重要原因。鉴别诊断极其困难，但对患者的后续管理至关重要。 <1>丙戊酸盐</1>诱导的<7>高氨血症</7> <11>脑病</11>是<2>丙戊酸盐</2>治疗的罕见但严重后果。在这里，我们描述了一名15岁女孩的病例，她因为<13>癫痫症</13>而接受长期的<3>丙戊酸盐</3>治疗，在肾移植后12天出现<8>高氨血症</8> 和<9>意识障碍</9>。停止使用<4>丙戊酸盐</4>后，患者症状在24小时内得到缓解。临床医生应该提高对<5>丙戊酸盐</5>潜在并发症的认识，尤其是对于移植患者。", "revised": true}
{"doc_key": "24588023", "sentences": [["The", "association", "between", "tranexamic", "acid", "and", "convulsive", "seizures", "after", "cardiac", "surgery", ":", "a", "multivariate", "analysis", "in", "11", "529", "patients", ".", "Because", "of", "a", "lack", "of", "contemporary", "data", "regarding", "seizures", "after", "cardiac", "surgery", ",", "we", "undertook", "a", "retrospective", "analysis", "of", "prospectively", "collected", "data", "from", "11", "529", "patients", "in", "whom", "cardiopulmonary", "bypass", "was", "used", "from", "January", "2004", "to", "December", "2010", ".", "A", "convulsive", "seizure", "was", "defined", "as", "a", "transient", "episode", "of", "disturbed", "brain", "function", "characterised", "by", "abnormal", "involuntary", "motor", "movements", ".", "Multivariate", "regression", "analysis", "was", "performed", "to", "identify", "independent", "predictors", "of", "postoperative", "seizures", ".", "A", "total", "of", "100", "(", "0", ".", "9", "%", ")", "patients", "developed", "postoperative", "convulsive", "seizures", ".", "Generalised", "and", "focal", "seizures", "were", "identified", "in", "68", "and", "32", "patients", ",", "respectively", ".", "The", "median", "(", "IQR", "[", "range", "]", ")", "time", "after", "surgery", "when", "the", "seizure", "occurred", "was", "7", "(", "6", "-", "12", "[", "1", "-", "216", "]", ")", "h", "and", "8", "(", "6", "-", "11", "[", "4", "-", "18", "]", ")", "h", ",", "respectively", ".", "Epileptiform", "findings", "on", "electroencephalography", "were", "seen", "in", "19", "patients", ".", "Independent", "predictors", "of", "postoperative", "seizures", "included", "age", ",", "female", "sex", ",", "redo", "cardiac", "surgery", ",", "calcification", "of", "ascending", "aorta", ",", "congestive", "heart", "failure", ",", "deep", "hypothermic", "circulatory", "arrest", ",", "duration", "of", "aortic", "cross", "-", "clamp", "and", "tranexamic", "acid", ".", "When", "tested", "in", "a", "multivariate", "regression", "analysis", ",", "tranexamic", "acid", "was", "a", "strong", "independent", "predictor", "of", "seizures", "(", "OR", "14", ".", "3", ",", "95", "%", "CI", "5", ".", "5", "-", "36", ".", "7", ";", "p", "<", "0", ".", "001", ")", ".", "Patients", "with", "convulsive", "seizures", "had", "2", ".", "5", "times", "higher", "in", "-", "hospital", "mortality", "rates", "and", "twice", "the", "length", "of", "hospital", "stay", "compared", "with", "patients", "without", "convulsive", "seizures", ".", "Mean", "(", "IQR", "[", "range", "]", ")", "length", "of", "stay", "in", "the", "intensive", "care", "unit", "was", "115", "(", "49", "-", "228", "[", "32", "-", "481", "]", ")", "h", "in", "patients", "with", "convulsive", "seizures", "compared", "with", "26", "(", "22", "-", "69", "[", "14", "-", "1080", "]", ")", "h", "in", "patients", "without", "seizures", "(", "p", "<", "0", ".", "001", ")", ".", "Convulsive", "seizures", "are", "a", "serious", "postoperative", "complication", "after", "cardiac", "surgery", ".", "As", "tranexamic", "acid", "is", "the", "only", "modifiable", "factor", ",", "its", "administration", ",", "particularly", "in", "doses", "exceeding", "80", "mg", ".", "kg", "(", "-", "1", ")", ",", "should", "be", "weighed", "against", "the", "risk", "of", "postoperative", "seizures", "."]], "ner": [[[3, 4, "Chemical"], [212, 213, "Chemical"], [223, 224, "Chemical"], [356, 357, "Chemical"], [6, 6, "Disease"], [7, 7, "Disease"], [28, 28, "Disease"], [60, 60, "Disease"], [61, 61, "Disease"], [90, 90, "Disease"], [105, 105, "Disease"], [106, 106, "Disease"], [108, 111, "Disease"], [135, 135, "Disease"], [180, 180, "Disease"], [231, 231, "Disease"], [258, 258, "Disease"], [259, 259, "Disease"], [282, 282, "Disease"], [283, 283, "Disease"], [316, 316, "Disease"], [317, 317, "Disease"], [335, 335, "Disease"], [344, 344, "Disease"], [345, 345, "Disease"], [388, 388, "Disease"], [74, 77, "Disease"], [196, 198, "Disease"], [201, 201, "Disease"], [349, 350, "Disease"]]], "relations": [[[3, 4, 6, 6, "CID"], [3, 4, 7, 7, "CID"], [3, 4, 28, 28, "CID"], [3, 4, 60, 60, "CID"], [3, 4, 61, 61, "CID"], [3, 4, 90, 90, "CID"], [3, 4, 105, 105, "CID"], [3, 4, 106, 106, "CID"], [3, 4, 108, 111, "CID"], [3, 4, 135, 135, "CID"], [3, 4, 180, 180, "CID"], [3, 4, 231, 231, "CID"], [3, 4, 258, 258, "CID"], [3, 4, 259, 259, "CID"], [3, 4, 282, 282, "CID"], [3, 4, 283, 283, "CID"], [3, 4, 316, 316, "CID"], [3, 4, 317, 317, "CID"], [3, 4, 335, 335, "CID"], [3, 4, 344, 344, "CID"], [3, 4, 345, 345, "CID"], [3, 4, 388, 388, "CID"], [212, 213, 6, 6, "CID"], [212, 213, 7, 7, "CID"], [212, 213, 28, 28, "CID"], [212, 213, 60, 60, "CID"], [212, 213, 61, 61, "CID"], [212, 213, 90, 90, "CID"], [212, 213, 105, 105, "CID"], [212, 213, 106, 106, "CID"], [212, 213, 108, 111, "CID"], [212, 213, 135, 135, "CID"], [212, 213, 180, 180, "CID"], [212, 213, 231, 231, "CID"], [212, 213, 258, 258, "CID"], [212, 213, 259, 259, "CID"], [212, 213, 282, 282, "CID"], [212, 213, 283, 283, "CID"], [212, 213, 316, 316, "CID"], [212, 213, 317, 317, "CID"], [212, 213, 335, 335, "CID"], [212, 213, 344, 344, "CID"], [212, 213, 345, 345, "CID"], [212, 213, 388, 388, "CID"], [223, 224, 6, 6, "CID"], [223, 224, 7, 7, "CID"], [223, 224, 28, 28, "CID"], [223, 224, 60, 60, "CID"], [223, 224, 61, 61, "CID"], [223, 224, 90, 90, "CID"], [223, 224, 105, 105, "CID"], [223, 224, 106, 106, "CID"], [223, 224, 108, 111, "CID"], [223, 224, 135, 135, "CID"], [223, 224, 180, 180, "CID"], [223, 224, 231, 231, "CID"], [223, 224, 258, 258, "CID"], [223, 224, 259, 259, "CID"], [223, 224, 282, 282, "CID"], [223, 224, 283, 283, "CID"], [223, 224, 316, 316, "CID"], [223, 224, 317, 317, "CID"], [223, 224, 335, 335, "CID"], [223, 224, 344, 344, "CID"], [223, 224, 345, 345, "CID"], [223, 224, 388, 388, "CID"], [356, 357, 6, 6, "CID"], [356, 357, 7, 7, "CID"], [356, 357, 28, 28, "CID"], [356, 357, 60, 60, "CID"], [356, 357, 61, 61, "CID"], [356, 357, 90, 90, "CID"], [356, 357, 105, 105, "CID"], [356, 357, 106, 106, "CID"], [356, 357, 108, 111, "CID"], [356, 357, 135, 135, "CID"], [356, 357, 180, 180, "CID"], [356, 357, 231, 231, "CID"], [356, 357, 258, 258, "CID"], [356, 357, 259, 259, "CID"], [356, 357, 282, 282, "CID"], [356, 357, 283, 283, "CID"], [356, 357, 316, 316, "CID"], [356, 357, 317, 317, "CID"], [356, 357, 335, 335, "CID"], [356, 357, 344, 344, "CID"], [356, 357, 345, 345, "CID"], [356, 357, 388, 388, "CID"]]], "clusters": [], "translated": "心脏手术后<0>氨甲环酸</0>与<4>惊厥</4><5>癫痫发作</5>之间的关联：11 529 名患者的多变量分析。由于缺乏有关心脏手术后<6>癫痫发作</6>的当代数据，我们对2004年1月至2010年12月期间接受体外循环的11 529名患者的前瞻性收集数据进行了回顾性分析。<7>惊厥</7><8>癫痫发作</8>被定义为以<26>异常不自主运动</26>为特征的大脑功能紊乱的短暂发作。进行多变量回归分析以确定术后<9>癫痫发作</9>的独立预测因子。共有100名(0.9%)患者出现术后<10>惊厥</10><11>癫痫发作</11>。<12>全身性和局灶性癫痫发作</12>分别在68名和32名患者中被发现。术后发生<13>癫痫发作</13>的中位时间（IQR[范围]）分别为7(6-12 [1-216])小时和8(6-11 [4-18])小时。19例患者脑电图有癫痫样表现。术后<14>癫痫发作</14>的独立预测因素包括年龄、女性、再次心脏手术、升主动脉钙化、<27>充血性心力衰竭</27>、深度<28>低温</28>停循环、主动脉钳夹和<1>氨甲环酸</1>的持续时间。当在多变量回归分析中进行测试时，<2>氨甲环酸</2>是<15>癫痫发作</15>的强独立预测因子（OR 14.3，95% CI 5.5-36.7；p < 0.001）。<16>惊厥</16><17>癫痫发作</17>患者住院死亡率高2.5倍，住院时间长2倍与没有<18>惊厥</18><19>癫痫发作</19>的患者相比。<20>惊厥</20><21>癫痫发作</21>的患者在重症监护室的平均（IQR[范围]）逗留时间为 115(49-228 [32-481]) h，而没有<22>癫痫发作</22>的患者为26(22-69 [14-1080]) h(p <0.001)。<23>惊厥</23><24>癫痫发作</24>是心脏手术后严重的<29>术后并发症</29>。由于<3>氨甲环酸</3>是唯一可改变的因素，其给药，特别是剂量超过80毫克时。 kg(-1)，应权衡术后<25>癫痫发作</25>的风险。", "revised": true}
{"doc_key": "24333387", "sentences": [["Glial", "activation", "and", "post", "-", "synaptic", "neurotoxicity", ":", "the", "key", "events", "in", "Streptozotocin", "(", "ICV", ")", "induced", "memory", "impairment", "in", "rats", ".", "In", "the", "present", "study", "the", "role", "of", "glial", "activation", "and", "post", "synaptic", "toxicity", "in", "ICV", "Streptozotocin", "(", "STZ", ")", "induced", "memory", "impaired", "rats", "was", "explored", ".", "In", "experiment", "set", "up", "1", ":", "Memory", "deficit", "was", "found", "in", "Morris", "water", "maze", "test", "on", "14", "-", "16", "days", "after", "STZ", "(", "ICV", ";", "3mg", "/", "Kg", ")", "administration", ".", "STZ", "causes", "increased", "expression", "of", "GFAP", ",", "CD11b", "and", "TNF", "-", "a", "indicating", "glial", "activation", "and", "neuroinflammation", ".", "STZ", "also", "significantly", "increased", "the", "level", "of", "ROS", ",", "nitrite", ",", "Ca", "(", "2", "+", ")", "and", "reduced", "the", "mitochondrial", "activity", "in", "synaptosomal", "preparation", "illustrating", "free", "radical", "generation", "and", "excitotoxicity", ".", "Increased", "expression", "and", "activity", "of", "Caspase", "-", "3", "was", "also", "observed", "in", "STZ", "treated", "rat", "which", "specify", "apoptotic", "cell", "death", "in", "hippocampus", "and", "cortex", ".", "STZ", "treatment", "showed", "decrease", "expression", "of", "post", "synaptic", "markers", "CaMKIIa", "and", "PSD", "-", "95", ",", "while", ",", "expression", "of", "pre", "synaptic", "markers", "(", "synaptophysin", "and", "SNAP", "-", "25", ")", "remains", "unaltered", "indicating", "selective", "post", "synaptic", "neurotoxicity", ".", "Oral", "treatment", "with", "Memantine", "(", "10mg", "/", "kg", ")", "and", "Ibuprofen", "(", "50", "mg", "/", "kg", ")", "daily", "for", "13", "days", "attenuated", "STZ", "induced", "glial", "activation", ",", "apoptotic", "cell", "death", "and", "post", "synaptic", "neurotoxicity", "in", "rat", "brain", ".", "Further", ",", "in", "experiment", "set", "up", "2", ":", "where", "memory", "function", "was", "not", "affected", "i", ".", "e", ".", "7", "-", "9", "days", "after", "STZ", "treatment", ".", "The", "level", "of", "GFAP", ",", "CD11b", ",", "TNF", "-", "a", ",", "ROS", "and", "nitrite", "levels", "were", "increased", ".", "On", "the", "other", "hand", ",", "apoptotic", "marker", ",", "synaptic", "markers", ",", "mitochondrial", "activity", "and", "Ca", "(", "2", "+", ")", "levels", "remained", "unaffected", ".", "Collective", "data", "indicates", "that", "neuroinflammatory", "process", "and", "oxidative", "stress", "occurs", "earlier", "to", "apoptosis", "and", "does", "not", "affect", "memory", "function", ".", "Present", "study", "clearly", "suggests", "that", "glial", "activation", "and", "post", "synaptic", "neurotoxicity", "are", "the", "key", "factors", "in", "STZ", "induced", "memory", "impairment", "and", "neuronal", "cell", "death", "."]], "ner": [[[12, 12, "Chemical"], [37, 37, "Chemical"], [39, 39, "Chemical"], [69, 69, "Chemical"], [79, 79, "Chemical"], [97, 97, "Chemical"], [140, 140, "Chemical"], [153, 153, "Chemical"], [212, 212, "Chemical"], [251, 251, "Chemical"], [331, 331, "Chemical"], [17, 18, "Disease"], [42, 43, "Disease"], [54, 55, "Disease"], [333, 334, "Disease"], [95, 95, "Disease"], [299, 299, "Disease"], [6, 6, "Disease"], [188, 188, "Disease"], [223, 223, "Disease"], [325, 325, "Disease"], [106, 106, "Chemical"], [267, 267, "Chemical"], [108, 108, "Chemical"], [286, 286, "Chemical"], [193, 193, "Chemical"], [200, 200, "Chemical"], [34, 34, "Disease"], [126, 126, "Disease"]]], "relations": [[[12, 12, 17, 18, "CID"], [12, 12, 42, 43, "CID"], [12, 12, 54, 55, "CID"], [12, 12, 333, 334, "CID"], [37, 37, 17, 18, "CID"], [37, 37, 42, 43, "CID"], [37, 37, 54, 55, "CID"], [37, 37, 333, 334, "CID"], [39, 39, 17, 18, "CID"], [39, 39, 42, 43, "CID"], [39, 39, 54, 55, "CID"], [39, 39, 333, 334, "CID"], [69, 69, 17, 18, "CID"], [69, 69, 42, 43, "CID"], [69, 69, 54, 55, "CID"], [69, 69, 333, 334, "CID"], [79, 79, 17, 18, "CID"], [79, 79, 42, 43, "CID"], [79, 79, 54, 55, "CID"], [79, 79, 333, 334, "CID"], [97, 97, 17, 18, "CID"], [97, 97, 42, 43, "CID"], [97, 97, 54, 55, "CID"], [97, 97, 333, 334, "CID"], [140, 140, 17, 18, "CID"], [140, 140, 42, 43, "CID"], [140, 140, 54, 55, "CID"], [140, 140, 333, 334, "CID"], [153, 153, 17, 18, "CID"], [153, 153, 42, 43, "CID"], [153, 153, 54, 55, "CID"], [153, 153, 333, 334, "CID"], [212, 212, 17, 18, "CID"], [212, 212, 42, 43, "CID"], [212, 212, 54, 55, "CID"], [212, 212, 333, 334, "CID"], [251, 251, 17, 18, "CID"], [251, 251, 42, 43, "CID"], [251, 251, 54, 55, "CID"], [251, 251, 333, 334, "CID"], [331, 331, 17, 18, "CID"], [331, 331, 42, 43, "CID"], [331, 331, 54, 55, "CID"], [331, 331, 333, 334, "CID"], [12, 12, 95, 95, "CID"], [12, 12, 299, 299, "CID"], [37, 37, 95, 95, "CID"], [37, 37, 299, 299, "CID"], [39, 39, 95, 95, "CID"], [39, 39, 299, 299, "CID"], [69, 69, 95, 95, "CID"], [69, 69, 299, 299, "CID"], [79, 79, 95, 95, "CID"], [79, 79, 299, 299, "CID"], [97, 97, 95, 95, "CID"], [97, 97, 299, 299, "CID"], [140, 140, 95, 95, "CID"], [140, 140, 299, 299, "CID"], [153, 153, 95, 95, "CID"], [153, 153, 299, 299, "CID"], [212, 212, 95, 95, "CID"], [212, 212, 299, 299, "CID"], [251, 251, 95, 95, "CID"], [251, 251, 299, 299, "CID"], [331, 331, 95, 95, "CID"], [331, 331, 299, 299, "CID"]]], "clusters": [], "translated": "胶质细胞激活和突触后<17>神经毒性</17>：<0>链脲佐菌素</0> （ICV）诱导大鼠<11>记忆障碍</11>的关键事件。在本研究中，神经胶质细胞激活和突触后<27>毒性</27>在ICV<1>链脲佐菌素</1>（<2>STZ</2>）诱导的<12>记忆障碍</12>中的作用大鼠进行了探索。实验设置1：<3>STZ</3>（ICV；3mg/Kg）给药后14-16天Morris水迷宫试验发现<13>记忆力减退</13>。<4>STZ</4> 导致GFAP、CD11b和TNF-a的表达增加，表明神经胶质细胞激活和<15>神经炎症</15>。<5>STZ</5> 还显着增加ROS、<21>亚硝酸盐</21>、<23>Ca</23>(2+)的水平，并降低突触体制备中的线粒体活性，说明自由基的产生和<28>兴奋毒性</28>。在<6>STZ</6>处理的大鼠中也观察到Caspase-3的表达和活性增加，这表明海马和皮质中的凋亡细胞死亡。<7>STZ</7>治疗显示突触后标志物CaMKIIa和PSD-95的表达减少，而突触前标志物（突触素和SNAP-25）的表达保持不变，表明选择性突触后<18>神经毒性</18>。每天口服<25>美金刚</25>（10mg/kg）和<26>布洛芬</26>（50mg/kg），持续13天，减弱<8>STZ</8>诱导的胶质细胞活化，凋亡细胞大鼠脑中的死亡和突触后<19>神经毒性</19>。此外，在实验设置2中：记忆功能未受影响i.e.7-9天后<9>STZ</9>治疗。GFAP、CD11b、TNF-a、ROS和<22>亚硝酸盐</22>水平升高。另一方面，凋亡标志物、突触标志物、线粒体活性和<24>Ca</24>(2+)水平未受影响。综合数据表明，<16>神经炎症</16>过程和氧化应激发生在细胞凋亡之前，并且不影响记忆功能。目前的研究清楚地表明，神经胶质细胞激活和突触后<20>神经毒性</20>是<10>STZ</10>诱导的<14>记忆障碍</14>和神经元细胞死亡的关键因素。", "revised": true}
{"doc_key": "24709919", "sentences": [["Effects", "of", "ginsenosides", "on", "opioid", "-", "induced", "hyperalgesia", "in", "mice", ".", "Opioid", "-", "induced", "hyperalgesia", "(", "OIH", ")", "is", "characterized", "by", "nociceptive", "sensitization", "caused", "by", "the", "cessation", "of", "chronic", "opioid", "use", ".", "OIH", "can", "limit", "the", "clinical", "use", "of", "opioid", "analgesics", "and", "complicate", "withdrawal", "from", "opioid", "addiction", ".", "In", "this", "study", ",", "we", "investigated", "the", "effects", "of", "Re", ",", "Rg1", ",", "and", "Rb1", "ginsenosides", ",", "the", "bioactive", "components", "of", "ginseng", ",", "on", "OIH", ".", "OIH", "was", "achieved", "in", "mice", "after", "subcutaneous", "administration", "of", "morphine", "for", "7", "consecutive", "days", "three", "times", "per", "day", ".", "During", "withdrawal", "(", "days", "8", "and", "9", ")", ",", "these", "mice", "were", "administered", "Re", ",", "Rg1", ",", "or", "Rb1", "intragastrically", "two", "times", "per", "day", ".", "On", "the", "test", "day", "(", "day", "10", ")", ",", "mice", "were", "subjected", "to", "the", "thermal", "sensitivity", "test", "and", "the", "acetic", "acid", "-", "induced", "writhing", "test", ".", "Re", "(", "300", "mg", "/", "kg", ")", "inhibited", "OIH", "in", "both", "the", "thermal", "sensitivity", "test", "and", "the", "acetic", "acid", "-", "induced", "writhing", "test", ".", "However", ",", "the", "Rg1", "and", "Rb1", "ginsenosides", "failed", "to", "prevent", "OIH", "in", "either", "test", ".", "Furthermore", ",", "Rg1", "showed", "a", "tendency", "to", "aggravate", "OIH", "in", "the", "acetic", "acid", "-", "induced", "writhing", "test", ".", "Our", "data", "suggested", "that", "the", "ginsenoside", "Re", ",", "but", "not", "Rg1", "or", "Rb1", ",", "may", "contribute", "toward", "reversal", "of", "OIH", "."]], "ner": [[[83, 83, "Chemical"], [7, 7, "Disease"], [14, 14, "Disease"], [16, 16, "Disease"], [32, 32, "Disease"], [72, 72, "Disease"], [74, 74, "Disease"], [152, 152, "Disease"], [178, 178, "Disease"], [191, 191, "Disease"], [220, 220, "Disease"], [2, 2, "Chemical"], [45, 46, "Disease"], [57, 63, "Chemical"], [106, 106, "Chemical"], [144, 144, "Chemical"], [206, 207, "Chemical"], [108, 108, "Chemical"], [171, 174, "Chemical"], [185, 185, "Chemical"], [211, 211, "Chemical"], [111, 111, "Chemical"], [213, 213, "Chemical"], [137, 138, "Chemical"], [161, 162, "Chemical"], [194, 195, "Chemical"]]], "relations": [[[83, 83, 7, 7, "CID"], [83, 83, 14, 14, "CID"], [83, 83, 16, 16, "CID"], [83, 83, 32, 32, "CID"], [83, 83, 72, 72, "CID"], [83, 83, 74, 74, "CID"], [83, 83, 152, 152, "CID"], [83, 83, 178, 178, "CID"], [83, 83, 191, 191, "CID"], [83, 83, 220, 220, "CID"]]], "clusters": [], "translated": "<11>人参皂甙</11>对小鼠阿片类药物<1>痛觉过敏</1>的影响。阿片类药物诱发的<2>痛觉过敏</2>（<3>OIH</3>）的特点是长期停止使用阿片类药物引起的伤害性敏感。<4>OIH</4>可以限制阿片类镇痛药的临床使用，并使<12>阿片类药物成瘾</12>的戒断复杂化。在这项研究中，我们研究了人参的生物活性成分<13>Re、Rg1和Rb1人参皂苷</13>对<5>OIH</5>的影响。<6>OIH</6>小鼠皮下注射<0>吗啡</0>，连续7天，每天3次。在停药期间（第8天和第9天），这些小鼠每天两次胃内给药<14>Re</14>、<17>Rg1</17>或<21>Rb1</21>。试验日（第10天）小鼠进行热敏试验和<23>醋酸</23>致扭体试验。<15>Re</15>（300 mg/kg）在热敏感性试验和<24>乙酸</24>诱导的扭体试验中均抑制<7>OIH</7>。然而，<18>Rg1和Rb1人参皂苷</18>在这两项试验中均未能预防<8>OIH</8>。此外，<19>Rg1</19>在<25>醋酸</25>致扭体试验中有加重<9>OIH</9>的倾向。我们的数据表明：<16>人参皂苷Re</16>而非<20>Rg1</20>或<22>Rb1</22>可能有助于逆转<10>OIH</10>。", "revised": true}
{"doc_key": "24664478", "sentences": [["Nelarabine", "neurotoxicity", "with", "concurrent", "intrathecal", "chemotherapy", ":", "Case", "report", "and", "review", "of", "literature", ".", "Severe", "nelarabine", "neurotoxicity", "in", "a", "patient", "who", "received", "concurrent", "intrathecal", "(", "IT", ")", "chemotherapy", "is", "reported", ".", "A", "37", "-", "year", "-", "old", "Caucasian", "woman", "with", "a", "history", "of", "T", "-", "cell", "lymphoblastic", "lymphoma", "was", "admitted", "for", "relapsed", "disease", ".", "She", "was", "originally", "treated", "with", "induction", "chemotherapy", "followed", "by", "an", "autologous", "transplant", ".", "She", "developed", "relapsed", "disease", "10", "months", "later", "with", "leukemic", "involvement", ".", "She", "was", "re", "-", "induced", "with", "nelarabine", "1500", "mg", "/", "m", "(", "2", ")", "on", "days", "1", ",", "3", ",", "and", "5", "with", "1", "dose", "of", "IT", "cytarabine", "100", "mg", "on", "day", "2", "as", "central", "nervous", "system", "(", "CNS", ")", "prophylaxis", ".", "At", "the", "time", "of", "treatment", ",", "she", "was", "on", "continuous", "renal", "replacement", "therapy", "due", "to", "sequelae", "of", "tumor", "lysis", "syndrome", "(", "TLS", ")", ".", "She", "tolerated", "therapy", "well", ",", "entered", "a", "complete", "remission", ",", "and", "recovered", "her", "renal", "function", ".", "She", "received", "a", "second", "cycle", "of", "nelarabine", "without", "additional", "IT", "prophylaxis", "one", "month", "later", ".", "A", "week", "after", "this", "second", "cycle", ",", "she", "noted", "numbness", "in", "her", "lower", "extremities", ".", "Predominantly", "sensory", ",", "though", "also", "motor", "and", "autonomic", ",", "peripheral", "neuropathy", "started", "in", "her", "feet", ",", "ascended", "proximally", "to", "the", "mid", "-", "thoracic", "region", ",", "and", "eventually", "included", "her", "distal", "upper", "extremities", ".", "A", "magnetic", "resonance", "imaging", "(", "MRI", ")", "of", "her", "spine", "demonstrated", "changes", "from", "C2", "to", "C6", "consistent", "with", "subacute", "combined", "degeneration", ".", "Nelarabine", "was", "felt", "to", "be", "the", "cause", "of", "her", "symptoms", ".", "Her", "neuropathy", "stabilized", "and", "showed", "slight", "improvement", "and", "ultimately", "received", "an", "unrelated", ",", "reduced", "-", "intensity", "allogeneic", "transplant", "while", "in", "complete", "remission", ",", "but", "relapsed", "disease", "10", "weeks", "later", ".", "She", "is", "currently", "being", "treated", "with", "best", "supportive", "care", ".", "To", "our", "knowledge", ",", "this", "is", "the", "first", "published", "case", "report", "of", "severe", "neurotoxicity", "caused", "by", "nelarabine", "in", "a", "patient", "who", "received", "concurrent", "IT", "chemotherapy", "."]], "ner": [[[0, 0, "Chemical"], [15, 15, "Chemical"], [84, 84, "Chemical"], [166, 166, "Chemical"], [245, 245, "Chemical"], [312, 312, "Chemical"], [199, 200, "Disease"], [1, 1, "Disease"], [16, 16, "Disease"], [309, 309, "Disease"], [43, 47, "Disease"], [75, 75, "Disease"], [137, 139, "Disease"], [141, 141, "Disease"], [257, 257, "Disease"], [105, 105, "Chemical"]]], "relations": [[[0, 0, 199, 200, "CID"], [15, 15, 199, 200, "CID"], [84, 84, 199, 200, "CID"], [166, 166, 199, 200, "CID"], [245, 245, 199, 200, "CID"], [312, 312, 199, 200, "CID"]]], "clusters": [], "translated": " <0>奈拉滨</0><7>神经毒性</7>同时进行鞘内化疗：病例报告和文献复习。据报道，一名接受同步鞘内 (IT) 化疗的患者出现了严重的<1>奈拉滨</1><8>神经毒性</8>。一名有<10>T 细胞淋巴母细胞淋巴瘤</10>病史的37岁白人女性因疾病复发入院。她最初接受了诱导化疗，随后进行了自体移植。10个月后她出现疾病复发，并伴有<11>白血病</11>。她在第1、3和5天用<2>奈拉滨</2> 1500 mg / m(2)再次诱导，第2天用1剂IT<15>阿糖胞苷</15> 100 mg作为中枢神经系统(CNS)预防。治疗时，由于<12>肿瘤溶解综合征</12>(<13>TLS</13>)的后遗症，她正在接受持续的肾脏替代治疗。她对治疗的耐受性良好，进入了完全缓解期，并恢复了肾功能。一个月后，她接受了第二个周期的<3>奈拉滨</3>治疗，但未进行额外的IT预防。第二个周期后一周，她发现下肢麻木。主要是感觉，虽然也有运动和自主神经，<6>周围神经病变</6>从她的脚开始，向近端上升到中胸区域，并最终包括她的上肢远端。她脊柱的磁共振成像(MRI)显示C2到C6的变化与亚急性联合退化一致。<4>奈拉滨</4>被认为是她症状的原因。她的<14>神经病变</14>稳定下来并略有好转，最终接受了无关的、强度降低的同种异体移植，同时完全缓解，但10周后疾病复发。她目前正在接受最好的支持治疗。据我们所知，这是第一例已发表的关于<5>奈拉滨</5>在同时接受IT化疗的患者中引起严重<9>神经毒性</9>的病例报告。", "revised": true}
{"doc_key": "24438483", "sentences": [["Pre", "-", "treatment", "of", "bupivacaine", "-", "induced", "cardiovascular", "depression", "using", "different", "lipid", "formulations", "of", "propofol", ".", "BACKGROUND", ":", "Pre", "-", "treatment", "with", "lipid", "emulsions", "has", "been", "shown", "to", "increase", "lethal", "doses", "of", "bupivacaine", ",", "and", "the", "lipid", "content", "of", "propofol", "may", "alleviate", "bupivacaine", "-", "induced", "cardiotoxicity", ".", "The", "aim", "of", "this", "study", "is", "to", "investigate", "the", "effects", "of", "propofol", "in", "intralipid", "or", "medialipid", "emulsions", "on", "bupivacaine", "-", "induced", "cardiotoxicity", ".", "METHODS", ":", "Rats", "were", "anaesthetised", "with", "ketamine", "and", "were", "given", "0", ".", "5", "mg", "/", "kg", "/", "min", "propofol", "in", "intralipid", "(", "Group", "P", ")", ",", "propofol", "in", "medialipid", "(", "Group", "L", ")", ",", "or", "saline", "(", "Group", "C", ")", "over", "20", "min", ".", "Thereafter", ",", "2", "mg", "/", "kg", "/", "min", "bupivacaine", "0", ".", "5", "%", "was", "infused", ".", "We", "recorded", "time", "to", "first", "dysrhythmia", "occurrence", ",", "respective", "times", "to", "25", "%", "and", "50", "%", "reduction", "of", "the", "heart", "rate", "(", "HR", ")", "and", "mean", "arterial", "pressure", ",", "and", "time", "to", "asystole", "and", "total", "amount", "of", "bupivacaine", "consumption", ".", "Blood", "and", "tissue", "samples", "were", "collected", "following", "asystole", ".", "RESULTS", ":", "The", "time", "to", "first", "dysrhythmia", "occurrence", ",", "time", "to", "25", "%", "and", "50", "%", "reductions", "in", "HR", ",", "and", "time", "to", "asystole", "were", "longer", "in", "Group", "P", "than", "the", "other", "groups", ".", "The", "cumulative", "bupivacaine", "dose", "given", "at", "those", "time", "points", "was", "higher", "in", "Group", "P", ".", "Plasma", "bupivacaine", "levels", "were", "significantly", "lower", "in", "Group", "P", "than", "in", "Group", "C", ".", "Bupivacaine", "levels", "in", "the", "brain", "and", "heart", "were", "significantly", "lower", "in", "Group", "P", "and", "Group", "L", "than", "in", "Group", "C", ".", "CONCLUSION", ":", "We", "conclude", "that", "pre", "-", "treatment", "with", "propofol", "in", "intralipid", ",", "compared", "with", "propofol", "in", "medialipid", "or", "saline", ",", "delayed", "the", "onset", "of", "bupivacaine", "-", "induced", "cardiotoxic", "effects", "as", "well", "as", "reduced", "plasma", "bupivacaine", "levels", ".", "Further", "studies", "are", "needed", "to", "explore", "tissue", "bupivacaine", "levels", "of", "propofol", "in", "medialipid", "and", "adapt", "these", "results", "to", "clinical", "practice", "."]], "ner": [[[4, 4, "Chemical"], [32, 32, "Chemical"], [42, 42, "Chemical"], [65, 65, "Chemical"], [122, 122, "Chemical"], [167, 167, "Chemical"], [215, 215, "Chemical"], [229, 229, "Chemical"], [242, 242, "Chemical"], [288, 288, "Chemical"], [298, 298, "Chemical"], [308, 308, "Chemical"], [45, 45, "Disease"], [68, 68, "Disease"], [291, 291, "Disease"], [162, 162, "Disease"], [177, 177, "Disease"], [202, 202, "Disease"], [7, 8, "Disease"], [135, 135, "Disease"], [185, 185, "Disease"], [14, 14, "Chemical"], [39, 39, "Chemical"], [58, 58, "Chemical"], [88, 88, "Chemical"], [96, 96, "Chemical"], [272, 272, "Chemical"], [278, 278, "Chemical"], [311, 311, "Chemical"], [76, 76, "Chemical"]]], "relations": [[[4, 4, 45, 45, "CID"], [4, 4, 68, 68, "CID"], [4, 4, 291, 291, "CID"], [32, 32, 45, 45, "CID"], [32, 32, 68, 68, "CID"], [32, 32, 291, 291, "CID"], [42, 42, 45, 45, "CID"], [42, 42, 68, 68, "CID"], [42, 42, 291, 291, "CID"], [65, 65, 45, 45, "CID"], [65, 65, 68, 68, "CID"], [65, 65, 291, 291, "CID"], [122, 122, 45, 45, "CID"], [122, 122, 68, 68, "CID"], [122, 122, 291, 291, "CID"], [167, 167, 45, 45, "CID"], [167, 167, 68, 68, "CID"], [167, 167, 291, 291, "CID"], [215, 215, 45, 45, "CID"], [215, 215, 68, 68, "CID"], [215, 215, 291, 291, "CID"], [229, 229, 45, 45, "CID"], [229, 229, 68, 68, "CID"], [229, 229, 291, 291, "CID"], [242, 242, 45, 45, "CID"], [242, 242, 68, 68, "CID"], [242, 242, 291, 291, "CID"], [288, 288, 45, 45, "CID"], [288, 288, 68, 68, "CID"], [288, 288, 291, 291, "CID"], [298, 298, 45, 45, "CID"], [298, 298, 68, 68, "CID"], [298, 298, 291, 291, "CID"], [308, 308, 45, 45, "CID"], [308, 308, 68, 68, "CID"], [308, 308, 291, 291, "CID"], [4, 4, 162, 162, "CID"], [4, 4, 177, 177, "CID"], [4, 4, 202, 202, "CID"], [32, 32, 162, 162, "CID"], [32, 32, 177, 177, "CID"], [32, 32, 202, 202, "CID"], [42, 42, 162, 162, "CID"], [42, 42, 177, 177, "CID"], [42, 42, 202, 202, "CID"], [65, 65, 162, 162, "CID"], [65, 65, 177, 177, "CID"], [65, 65, 202, 202, "CID"], [122, 122, 162, 162, "CID"], [122, 122, 177, 177, "CID"], [122, 122, 202, 202, "CID"], [167, 167, 162, 162, "CID"], [167, 167, 177, 177, "CID"], [167, 167, 202, 202, "CID"], [215, 215, 162, 162, "CID"], [215, 215, 177, 177, "CID"], [215, 215, 202, 202, "CID"], [229, 229, 162, 162, "CID"], [229, 229, 177, 177, "CID"], [229, 229, 202, 202, "CID"], [242, 242, 162, 162, "CID"], [242, 242, 177, 177, "CID"], [242, 242, 202, 202, "CID"], [288, 288, 162, 162, "CID"], [288, 288, 177, 177, "CID"], [288, 288, 202, 202, "CID"], [298, 298, 162, 162, "CID"], [298, 298, 177, 177, "CID"], [298, 298, 202, 202, "CID"], [308, 308, 162, 162, "CID"], [308, 308, 177, 177, "CID"], [308, 308, 202, 202, "CID"]]], "clusters": [], "translated": "<0>布比卡因</0>诱导的<18>心血管抑制</18>使用<21>异丙酚</21>的不同脂质制剂进行预处理。背景：已证明用脂肪乳剂预处理会增加<1>布比卡因</1>的致死剂量，而<22>异丙酚</22>的脂质含量可能会减轻<2>布比卡因</2>引起的<12>心脏毒性</12>。本研究旨在探讨<23>异丙酚</23>脂肪乳剂或中脂肪乳剂对<3>布比卡因</3>引起的<13>心脏毒性</13>的影响。方法：用<29>氯胺酮</29>麻醉大鼠并给予0.5 mg/kg/min<24>异丙酚</24>脂肪乳（Group P），<25>异丙酚</25>中脂肪乳（Group L）或生理盐水（Group C）20min。此后，注入2mg/kg/min<4>布比卡因</4> 0.5%。我们记录了第一次<19>心律失常</19>发生的时间，各组目标时间至心率（HR）下降25%和50%以及平均动脉压下降25%和50%的时间，<15>心搏停止</15>时间和总<5>布比卡因</5>用量。<16>心搏停止</16>后采集血液和组织样品。结果：与其他组相比，P组首次出现<20>心律失常</20>的时间、HR降低25%和50%的时间以及<17>心搏停止</17>的时间均较长，这些时间点P组累计给予的<6>布比卡因</6>用量较高。P组血浆<7>布比卡因</7>水平显著低于C组。P组和L组脑和心脏<8>布比卡因</8>水平也显著低于C组。结论：我们得出结论，与<27>异丙酚</27>中脂比或生理盐水相比，用<26>异丙酚</26>脂肪乳预处理可以延迟<9>布比卡因</9>诱导的<14>心脏毒性</14>作用并降低血浆<10>布比卡因</10>水平。需要进一步研究中脂<28>异丙酚</28>对组织<11>布比卡因</11>水平的影响，并将这些结果应用于临床实践。", "revised": true}
{"doc_key": "24675088", "sentences": [["An", "integrated", "characterization", "of", "serological", ",", "pathological", ",", "and", "functional", "events", "in", "doxorubicin", "-", "induced", "cardiotoxicity", ".", "Many", "efficacious", "cancer", "treatments", "cause", "significant", "cardiac", "morbidity", ",", "yet", "biomarkers", "or", "functional", "indices", "of", "early", "damage", ",", "which", "would", "allow", "monitoring", "and", "intervention", ",", "are", "lacking", ".", "In", "this", "study", ",", "we", "have", "utilized", "a", "rat", "model", "of", "progressive", "doxorubicin", "(", "DOX", ")", "-", "induced", "cardiomyopathy", ",", "applying", "multiple", "approaches", ",", "including", "cardiac", "magnetic", "resonance", "imaging", "(", "MRI", ")", ",", "to", "provide", "the", "most", "comprehensive", "characterization", "to", "date", "of", "the", "timecourse", "of", "serological", ",", "pathological", ",", "and", "functional", "events", "underlying", "this", "toxicity", ".", "Hannover", "Wistar", "rats", "were", "dosed", "with", "1", ".", "25", "mg", "/", "kg", "DOX", "weekly", "for", "8", "weeks", "followed", "by", "a", "4", "week", "off", "-", "dosing", "\"", "recovery", "\"", "period", ".", "Electron", "microscopy", "of", "the", "myocardium", "revealed", "subcellular", "degeneration", "and", "marked", "mitochondrial", "changes", "after", "a", "single", "dose", ".", "Histopathological", "analysis", "revealed", "progressive", "cardiomyocyte", "degeneration", ",", "hypertrophy", "/", "cytomegaly", ",", "and", "extensive", "vacuolation", "after", "two", "doses", ".", "Extensive", "replacement", "fibrosis", "(", "quantified", "by", "Sirius", "red", "staining", ")", "developed", "during", "the", "off", "-", "dosing", "period", ".", "Functional", "indices", "assessed", "by", "cardiac", "MRI", "(", "including", "left", "ventricular", "ejection", "fraction", "(", "LVEF", ")", ",", "cardiac", "output", ",", "and", "E", "/", "A", "ratio", ")", "declined", "progressively", ",", "reaching", "statistical", "significance", "after", "two", "doses", "and", "culminating", "in", "\"", "clinical", "\"", "LV", "dysfunction", "by", "12", "weeks", ".", "Significant", "increases", "in", "peak", "myocardial", "contrast", "enhancement", "and", "serological", "cardiac", "troponin", "I", "(", "cTnI", ")", "emerged", "after", "eight", "doses", ",", "importantly", "preceding", "the", "LVEF", "decline", "to", "<", "50", "%", ".", "Troponin", "I", "levels", "positively", "correlated", "with", "delayed", "and", "peak", "gadolinium", "contrast", "enhancement", ",", "histopathological", "grading", ",", "and", "diastolic", "dysfunction", ".", "In", "summary", ",", "subcellular", "cardiomyocyte", "degeneration", "was", "the", "earliest", "marker", ",", "followed", "by", "progressive", "functional", "decline", "and", "histopathological", "manifestations", ".", "Myocardial", "contrast", "enhancement", "and", "elevations", "in", "cTnI", "occurred", "later", ".", "However", ",", "all", "indices", "predated", "\"", "clinical", "\"", "LV", "dysfunction", "and", "thus", "warrant", "further", "evaluation", "as", "predictive", "biomarkers", "."]], "ner": [[[12, 12, "Chemical"], [57, 57, "Chemical"], [59, 59, "Chemical"], [113, 113, "Chemical"], [63, 63, "Disease"], [168, 168, "Disease"], [224, 225, "Disease"], [318, 319, "Disease"], [15, 15, "Disease"], [19, 19, "Disease"], [99, 99, "Disease"], [137, 138, "Disease"], [152, 153, "Disease"], [284, 285, "Disease"], [155, 155, "Disease"], [277, 278, "Disease"], [269, 269, "Chemical"]]], "relations": [[[12, 12, 63, 63, "CID"], [57, 57, 63, 63, "CID"], [59, 59, 63, 63, "CID"], [113, 113, 63, 63, "CID"], [12, 12, 168, 168, "CID"], [57, 57, 168, 168, "CID"], [59, 59, 168, 168, "CID"], [113, 113, 168, 168, "CID"], [12, 12, 224, 225, "CID"], [12, 12, 318, 319, "CID"], [57, 57, 224, 225, "CID"], [57, 57, 318, 319, "CID"], [59, 59, 224, 225, "CID"], [59, 59, 318, 319, "CID"], [113, 113, 224, 225, "CID"], [113, 113, 318, 319, "CID"]]], "clusters": [], "translated": "<0>多柔比星</0>诱导的<8>心脏毒性</8>的血清学、病理学和功能事件的综合表征。许多有效的<9>癌症</9>治疗会导致显着的心脏病发病率，但缺乏可以进行监测和干预的早期损伤的生物标志物或功能指标。在这项研究中，我们利用了进行性<1>多柔比星</1>（<2>DOX</2>）诱导的<4>心肌病</4>大鼠模型，应用多种方法，包括心脏磁共振成像（MRI），以提供迄今为止最全面的表征此<10>毒性</10>的血清学、病理学和功能事件的时程。给Hannover Wistar大鼠每周一次1.25mg/kg的<3>DOX</3>，持续8周，然后是4周的停药“恢复”期。心肌的电子显微镜显示<11>亚细胞变性</11>，并在单次给药后显着改变线粒体。组织病理学分析显示进行性<12>心肌细胞变性</12>、<14>肥大</14>/<14>胞肥大，</14>以及两次给药后广泛的空泡形成。在停药期间发生了广泛的<5>纤维化</5>（通过天狼星红染色定量）。通过心脏MRI评估的功能指标（包括左心室射血分数（LVEF）、心输出量和E/A比率）逐渐下降，在两次给药后达到统计学显着性，并最终导致“临床”<6>LV功能障碍</6> 12周。八次给药后，心肌对比增强峰值和血清学心肌肌钙蛋白I（cTnI）显着增加，重要的是在LVEF下降<50%之前。肌钙蛋白I水平与延迟和峰值<16>钆</16>对比增强、组织病理学分级和<15>舒张功能障碍</15>呈正相关。综上所述，亚细胞<13>心肌细胞变性</13>是最早的标志物，其次是进行性功能减退和组织病理学表现。心肌对比增强和cTnI升高发生较晚。然而，所有指标都早于“临床”<7>左室功能障碍</7>，因此需要作为预测性生物标志物进行进一步评估。", "revised": true}
{"doc_key": "24691439", "sentences": [["Ocular", "-", "specific", "ER", "stress", "reduction", "rescues", "glaucoma", "in", "murine", "glucocorticoid", "-", "induced", "glaucoma", ".", "Administration", "of", "glucocorticoids", "induces", "ocular", "hypertension", "in", "some", "patients", ".", "If", "untreated", ",", "these", "patients", "can", "develop", "a", "secondary", "glaucoma", "that", "resembles", "primary", "open", "-", "angle", "glaucoma", "(", "POAG", ")", ".", "The", "underlying", "pathology", "of", "glucocorticoid", "-", "induced", "glaucoma", "is", "not", "fully", "understood", ",", "due", "in", "part", "to", "lack", "of", "an", "appropriate", "animal", "model", ".", "Here", ",", "we", "developed", "a", "murine", "model", "of", "glucocorticoid", "-", "induced", "glaucoma", "that", "exhibits", "glaucoma", "features", "that", "are", "observed", "in", "patients", ".", "Treatment", "of", "WT", "mice", "with", "topical", "ocular", "0", ".", "1", "%", "dexamethasone", "led", "to", "elevation", "of", "intraocular", "pressure", "(", "IOP", ")", ",", "functional", "and", "structural", "loss", "of", "retinal", "ganglion", "cells", ",", "and", "axonal", "degeneration", ",", "resembling", "glucocorticoid", "-", "induced", "glaucoma", "in", "human", "patients", ".", "Furthermore", ",", "dexamethasone", "-", "induced", "ocular", "hypertension", "was", "associated", "with", "chronic", "ER", "stress", "of", "the", "trabecular", "meshwork", "(", "TM", ")", ".", "Similar", "to", "patients", ",", "withdrawal", "of", "dexamethasone", "treatment", "reduced", "elevated", "IOP", "and", "ER", "stress", "in", "this", "animal", "model", ".", "Dexamethasone", "induced", "the", "transcriptional", "factor", "CHOP", ",", "a", "marker", "for", "chronic", "ER", "stress", ",", "in", "the", "anterior", "segment", "tissues", ",", "and", "Chop", "deletion", "reduced", "ER", "stress", "in", "these", "tissues", "and", "prevented", "dexamethasone", "-", "induced", "ocular", "hypertension", ".", "Furthermore", ",", "reduction", "of", "ER", "stress", "in", "the", "TM", "with", "sodium", "4", "-", "phenylbutyrate", "prevented", "dexamethasone", "-", "induced", "ocular", "hypertension", "in", "WT", "mice", ".", "Our", "data", "indicate", "that", "ER", "stress", "contributes", "to", "glucocorticoid", "-", "induced", "ocular", "hypertension", "and", "suggest", "that", "reducing", "ER", "stress", "has", "potential", "as", "a", "therapeutic", "strategy", "for", "treating", "glucocorticoid", "-", "induced", "glaucoma", "."]], "ner": [[[103, 103, "Chemical"], [138, 138, "Chemical"], [163, 163, "Chemical"], [176, 176, "Chemical"], [207, 207, "Chemical"], [228, 228, "Chemical"], [7, 7, "Disease"], [13, 13, "Disease"], [34, 34, "Disease"], [53, 53, "Disease"], [81, 81, "Disease"], [84, 84, "Disease"], [131, 131, "Disease"], [267, 267, "Disease"], [19, 20, "Disease"], [141, 142, "Disease"], [210, 211, "Disease"], [231, 232, "Disease"], [248, 249, "Disease"], [124, 125, "Disease"], [223, 226, "Chemical"], [37, 41, "Disease"], [43, 43, "Disease"], [119, 120, "Disease"]]], "relations": [[[103, 103, 7, 7, "CID"], [103, 103, 13, 13, "CID"], [103, 103, 34, 34, "CID"], [103, 103, 53, 53, "CID"], [103, 103, 81, 81, "CID"], [103, 103, 84, 84, "CID"], [103, 103, 131, 131, "CID"], [103, 103, 267, 267, "CID"], [138, 138, 7, 7, "CID"], [138, 138, 13, 13, "CID"], [138, 138, 34, 34, "CID"], [138, 138, 53, 53, "CID"], [138, 138, 81, 81, "CID"], [138, 138, 84, 84, "CID"], [138, 138, 131, 131, "CID"], [138, 138, 267, 267, "CID"], [163, 163, 7, 7, "CID"], [163, 163, 13, 13, "CID"], [163, 163, 34, 34, "CID"], [163, 163, 53, 53, "CID"], [163, 163, 81, 81, "CID"], [163, 163, 84, 84, "CID"], [163, 163, 131, 131, "CID"], [163, 163, 267, 267, "CID"], [176, 176, 7, 7, "CID"], [176, 176, 13, 13, "CID"], [176, 176, 34, 34, "CID"], [176, 176, 53, 53, "CID"], [176, 176, 81, 81, "CID"], [176, 176, 84, 84, "CID"], [176, 176, 131, 131, "CID"], [176, 176, 267, 267, "CID"], [207, 207, 7, 7, "CID"], [207, 207, 13, 13, "CID"], [207, 207, 34, 34, "CID"], [207, 207, 53, 53, "CID"], [207, 207, 81, 81, "CID"], [207, 207, 84, 84, "CID"], [207, 207, 131, 131, "CID"], [207, 207, 267, 267, "CID"], [228, 228, 7, 7, "CID"], [228, 228, 13, 13, "CID"], [228, 228, 34, 34, "CID"], [228, 228, 53, 53, "CID"], [228, 228, 81, 81, "CID"], [228, 228, 84, 84, "CID"], [228, 228, 131, 131, "CID"], [228, 228, 267, 267, "CID"], [103, 103, 19, 20, "CID"], [103, 103, 141, 142, "CID"], [103, 103, 210, 211, "CID"], [103, 103, 231, 232, "CID"], [103, 103, 248, 249, "CID"], [138, 138, 19, 20, "CID"], [138, 138, 141, 142, "CID"], [138, 138, 210, 211, "CID"], [138, 138, 231, 232, "CID"], [138, 138, 248, 249, "CID"], [163, 163, 19, 20, "CID"], [163, 163, 141, 142, "CID"], [163, 163, 210, 211, "CID"], [163, 163, 231, 232, "CID"], [163, 163, 248, 249, "CID"], [176, 176, 19, 20, "CID"], [176, 176, 141, 142, "CID"], [176, 176, 210, 211, "CID"], [176, 176, 231, 232, "CID"], [176, 176, 248, 249, "CID"], [207, 207, 19, 20, "CID"], [207, 207, 141, 142, "CID"], [207, 207, 210, 211, "CID"], [207, 207, 231, 232, "CID"], [207, 207, 248, 249, "CID"], [228, 228, 19, 20, "CID"], [228, 228, 141, 142, "CID"], [228, 228, 210, 211, "CID"], [228, 228, 231, 232, "CID"], [228, 228, 248, 249, "CID"], [103, 103, 124, 125, "CID"], [138, 138, 124, 125, "CID"], [163, 163, 124, 125, "CID"], [176, 176, 124, 125, "CID"], [207, 207, 124, 125, "CID"], [228, 228, 124, 125, "CID"]]], "clusters": [], "translated": "眼特异性 ER 应激减少可挽救小鼠糖皮质激素诱导的<7>青光眼</7>中的<6>青光眼</6>。一些患者使用糖皮质激素会引起<14>高眼压</14>。如果不治疗，这些患者会发展为类似于<21>原发性开角型青光眼</21> (<22>POAG</22>)的<8>继发性青光眼</8>。糖皮质激素诱发的<9>青光眼</9>的潜在病理学尚不完全清楚，部分原因是缺乏合适的动物模型。在这里，我们开发了一种糖皮质激素诱导的<10>青光眼</10>小鼠模型，该模型表现出在患者身上观察到的<11>青光眼</11>特征。用局部眼部0.1%<0>地塞米松</0>治疗 WT 小鼠，导致眼内压 (IOP) 升高，<23>视网膜神经节</23>细胞的功能和结构丧失，以及<19>轴突变性</19>，类似于糖皮质激素在人类患者中诱发的<12>青光眼</12>。此外，<1>地塞米松</1>诱导的<15>高眼压</15>与小梁网(TM)的慢性内质网应激有关。与患者相似，停止<2>地塞米松</2>治疗可降低该动物模型升高的眼压和内质网应激。<3>地塞米松</3>在眼前节组织中诱导转录因子 CHOP，这是慢性 ER 应激的标志物，并且 Chop 缺失降低了这些组织中的 ER 应激并阻止了<4>地塞米松</4>诱导的<16>高眼压症</16>。此外，用<20>4-苯基丁酸钠</20>降低 TM 中的内质网应激可预防<5>地塞米松</5>诱导的<17>高眼压</17>小鼠。我们的数据表明，内质网应激会导致糖皮质激素引起的<18>高眼压症</18>，并表明降低内质网应激可能成为治疗糖皮质激素引起的<13>青光眼</13>的一种治疗策略。", "revised": true}
{"doc_key": "24729111", "sentences": [["Amiodarone", "-", "induced", "myxoedema", "coma", ".", "A", "62", "-", "year", "-", "old", "man", "was", "found", "to", "have", "bradycardia", ",", "hypothermia", "and", "respiratory", "failure", "3", "weeks", "after", "initiation", "of", "amiodarone", "therapy", "for", "atrial", "fibrillation", ".", "Thyroid", "-", "stimulating", "hormone", "was", "found", "to", "be", "168", "uIU", "/", "mL", "(", "nl", ".", "0", ".", "3", "-", "5", "uIU", "/", "mL", ")", "and", "free", "thyroxine", "(", "FT4", ")", "was", "<", "0", ".", "2", "ng", "/", "dL", "(", "nl", ".", "0", ".", "8", "-", "1", ".", "8", "ng", "/", "dL", ")", ".", "He", "received", "intravenous", "fluids", ",", "vasopressor", "therapy", "and", "stress", "dose", "steroids", ";", "he", "was", "intubated", "and", "admitted", "to", "the", "intensive", "care", "unit", ".", "He", "received", "500", "ug", "of", "intravenous", "levothyroxine", "in", "the", "first", "18", "h", "of", "therapy", ",", "and", "150", "ug", "intravenous", "daily", "thereafter", ".", "Haemodynamic", "improvement", ",", "along", "with", "complete", "recovery", "of", "mental", "status", ",", "occurred", "after", "48", "h", ".", "Twelve", "hours", "after", "the", "initiation", "of", "therapy", ",", "FT4", "was", "0", ".", "96", "ng", "/", "dL", ".", "The", "patient", "was", "maintained", "on", "levothyroxine", "175", "(", "g", "POorally", "daily", ".", "A", "thyroid", "ultrasound", "showed", "diffuse", "heterogeneity", ".", "The", "24", "hour", "excretion", "of", "iodine", "was", "3657", "(", "mcg", "(", "25", "-", "756", "(", "mcg", ")", ".", "The", "only", "two", "cases", "of", "amiodarone", "-", "induced", "myxoedema", "coma", "in", "the", "literature", "report", "patient", "death", "despite", "supportive", "therapy", "and", "thyroid", "hormone", "replacement", ".", "This", "case", "represents", "the", "most", "thoroughly", "investigated", "case", "of", "amiodarone", "-", "induced", "myxoedema", "coma", "with", "a", "history", "significant", "for", "subclinical", "thyroid", "disease", "."]], "ner": [[[0, 0, "Chemical"], [28, 28, "Chemical"], [207, 207, "Chemical"], [235, 235, "Chemical"], [3, 4, "Disease"], [210, 211, "Disease"], [238, 239, "Disease"], [17, 17, "Disease"], [19, 19, "Disease"], [21, 22, "Disease"], [31, 32, "Disease"], [246, 247, "Disease"], [60, 60, "Chemical"], [116, 116, "Chemical"], [170, 170, "Chemical"], [97, 97, "Chemical"], [189, 189, "Chemical"]]], "relations": [[[0, 0, 3, 4, "CID"], [0, 0, 210, 211, "CID"], [0, 0, 238, 239, "CID"], [28, 28, 3, 4, "CID"], [28, 28, 210, 211, "CID"], [28, 28, 238, 239, "CID"], [207, 207, 3, 4, "CID"], [207, 207, 210, 211, "CID"], [207, 207, 238, 239, "CID"], [235, 235, 3, 4, "CID"], [235, 235, 210, 211, "CID"], [235, 235, 238, 239, "CID"], [0, 0, 17, 17, "CID"], [28, 28, 17, 17, "CID"], [207, 207, 17, 17, "CID"], [235, 235, 17, 17, "CID"], [0, 0, 19, 19, "CID"], [28, 28, 19, 19, "CID"], [207, 207, 19, 19, "CID"], [235, 235, 19, 19, "CID"], [0, 0, 21, 22, "CID"], [28, 28, 21, 22, "CID"], [207, 207, 21, 22, "CID"], [235, 235, 21, 22, "CID"]]], "clusters": [], "translated": " <0>胺碘酮</0> - 诱发<4>粘液水肿昏迷</4>。一名 62 岁男性在开始<1>胺碘酮</1>治疗 3 周后被发现有<7>心动过缓</7>、<8>体温过低</8>和<9>呼吸衰竭</9>，治疗<10>心房颤动</10>。发现促甲状腺激素为 168 uIU/mL (nl. 0 . 3 - 5 uIU/mL)，游离<12>甲状腺素</12> (FT4) <0.2纳克/分升（nl.0.8-1.8纳克/分升）。他接受了静脉输液、升压药治疗和应激剂量<15>类固醇</15>；他被插管并住进了重症监护室。治疗的前 18 小时他接受了 500 微克<13>左旋甲状腺素</13> 静脉注射，此后每天静脉注射 150 微克。48 小时后血液动力学得到改善，精神状态完全恢复。治疗开始后 12 小时，FT4 为 0.96 纳克/分升。患者每天口服<14>左旋甲状腺素</14> 175 (g PO)。甲状腺超声显示弥漫性异质性。24小时排泄量为<16>碘</16> 3657 (mcg) （25-756mcg）。文献中只有两例<2>胺碘酮</2> - 诱发<5>粘液水肿昏迷</5>患者尽管接受了支持疗法和甲状腺激素替代治疗仍死亡。该病例代表了对<3>胺碘酮</3> - 诱发的<6>粘液水肿昏迷</6>最彻底调查的病例，具有明显的亚临床<11>甲状腺疾病</11>病史。", "revised": true}
{"doc_key": "24717468", "sentences": [["A", "comparison", "of", "severe", "hemodynamic", "disturbances", "between", "dexmedetomidine", "and", "propofol", "for", "sedation", "in", "neurocritical", "care", "patients", ".", "OBJECTIVE", ":", "Dexmedetomidine", "and", "propofol", "are", "commonly", "used", "sedatives", "in", "neurocritical", "care", "as", "they", "allow", "for", "frequent", "neurologic", "examinations", ".", "However", ",", "both", "agents", "are", "associated", "with", "significant", "hemodynamic", "side", "effects", ".", "The", "primary", "objective", "of", "this", "study", "is", "to", "compare", "the", "prevalence", "of", "severe", "hemodynamic", "effects", "in", "neurocritical", "care", "patients", "receiving", "dexmedetomidine", "and", "propofol", ".", "DESIGN", ":", "Multicenter", ",", "retrospective", ",", "propensity", "-", "matched", "cohort", "study", ".", "SETTING", ":", "Neurocritical", "care", "units", "at", "two", "academic", "medical", "centers", "with", "dedicated", "neurocritical", "care", "teams", "and", "board", "-", "certified", "neurointensivists", ".", "PATIENTS", ":", "Neurocritical", "care", "patients", "admitted", "between", "July", "2009", "and", "September", "2012", "were", "evaluated", "and", "then", "matched", "1", ":", "1", "based", "on", "propensity", "scoring", "of", "baseline", "characteristics", ".", "INTERVENTIONS", ":", "Continuous", "sedation", "with", "dexmedetomidine", "or", "propofol", ".", "MEASUREMENTS", "AND", "MAIN", "RESULTS", ":", "A", "total", "of", "342", "patients", "(", "105", "dexmedetomidine", "and", "237", "propofol", ")", "were", "included", "in", "the", "analysis", ",", "with", "190", "matched", "(", "95", "in", "each", "group", ")", "by", "propensity", "score", ".", "The", "primary", "outcome", "of", "this", "study", "was", "a", "composite", "of", "severe", "hypotension", "(", "mean", "arterial", "pressure", "<", "60", "mm", "Hg", ")", "and", "bradycardia", "(", "heart", "rate", "<", "50", "beats", "/", "min", ")", "during", "sedative", "infusion", ".", "No", "difference", "in", "the", "primary", "composite", "outcome", "in", "both", "the", "unmatched", "(", "30", "%", "vs", "30", "%", ",", "p", "=", "0", ".", "94", ")", "or", "matched", "cohorts", "(", "28", "%", "vs", "34", "%", ",", "p", "=", "0", ".", "35", ")", "could", "be", "found", ".", "When", "analyzed", "separately", ",", "no", "differences", "could", "be", "found", "in", "the", "prevalence", "of", "severe", "hypotension", "or", "bradycardia", "in", "either", "the", "unmatched", "or", "matched", "cohorts", ".", "CONCLUSIONS", ":", "Severe", "hypotension", "and", "bradycardia", "occur", "at", "similar", "prevalence", "in", "neurocritical", "care", "patients", "who", "receive", "dexmedetomidine", "or", "propofol", ".", "Providers", "should", "similarly", "consider", "the", "likelihood", "of", "hypotension", "or", "bradycardia", "before", "starting", "either", "sedative", "."]], "ner": [[[7, 7, "Chemical"], [19, 19, "Chemical"], [69, 69, "Chemical"], [139, 139, "Chemical"], [155, 155, "Chemical"], [300, 300, "Chemical"], [190, 190, "Disease"], [273, 273, "Disease"], [287, 287, "Disease"], [311, 311, "Disease"], [201, 201, "Disease"], [275, 275, "Disease"], [289, 289, "Disease"], [313, 313, "Disease"], [9, 9, "Chemical"], [21, 21, "Chemical"], [71, 71, "Chemical"], [141, 141, "Chemical"], [158, 158, "Chemical"], [302, 302, "Chemical"]]], "relations": [[[7, 7, 190, 190, "CID"], [7, 7, 273, 273, "CID"], [7, 7, 287, 287, "CID"], [7, 7, 311, 311, "CID"], [19, 19, 190, 190, "CID"], [19, 19, 273, 273, "CID"], [19, 19, 287, 287, "CID"], [19, 19, 311, 311, "CID"], [69, 69, 190, 190, "CID"], [69, 69, 273, 273, "CID"], [69, 69, 287, 287, "CID"], [69, 69, 311, 311, "CID"], [139, 139, 190, 190, "CID"], [139, 139, 273, 273, "CID"], [139, 139, 287, 287, "CID"], [139, 139, 311, 311, "CID"], [155, 155, 190, 190, "CID"], [155, 155, 273, 273, "CID"], [155, 155, 287, 287, "CID"], [155, 155, 311, 311, "CID"], [300, 300, 190, 190, "CID"], [300, 300, 273, 273, "CID"], [300, 300, 287, 287, "CID"], [300, 300, 311, 311, "CID"], [7, 7, 201, 201, "CID"], [7, 7, 275, 275, "CID"], [7, 7, 289, 289, "CID"], [7, 7, 313, 313, "CID"], [19, 19, 201, 201, "CID"], [19, 19, 275, 275, "CID"], [19, 19, 289, 289, "CID"], [19, 19, 313, 313, "CID"], [69, 69, 201, 201, "CID"], [69, 69, 275, 275, "CID"], [69, 69, 289, 289, "CID"], [69, 69, 313, 313, "CID"], [139, 139, 201, 201, "CID"], [139, 139, 275, 275, "CID"], [139, 139, 289, 289, "CID"], [139, 139, 313, 313, "CID"], [155, 155, 201, 201, "CID"], [155, 155, 275, 275, "CID"], [155, 155, 289, 289, "CID"], [155, 155, 313, 313, "CID"], [300, 300, 201, 201, "CID"], [300, 300, 275, 275, "CID"], [300, 300, 289, 289, "CID"], [300, 300, 313, 313, "CID"], [9, 9, 190, 190, "CID"], [9, 9, 273, 273, "CID"], [9, 9, 287, 287, "CID"], [9, 9, 311, 311, "CID"], [21, 21, 190, 190, "CID"], [21, 21, 273, 273, "CID"], [21, 21, 287, 287, "CID"], [21, 21, 311, 311, "CID"], [71, 71, 190, 190, "CID"], [71, 71, 273, 273, "CID"], [71, 71, 287, 287, "CID"], [71, 71, 311, 311, "CID"], [141, 141, 190, 190, "CID"], [141, 141, 273, 273, "CID"], [141, 141, 287, 287, "CID"], [141, 141, 311, 311, "CID"], [158, 158, 190, 190, "CID"], [158, 158, 273, 273, "CID"], [158, 158, 287, 287, "CID"], [158, 158, 311, 311, "CID"], [302, 302, 190, 190, "CID"], [302, 302, 273, 273, "CID"], [302, 302, 287, 287, "CID"], [302, 302, 311, 311, "CID"], [9, 9, 201, 201, "CID"], [9, 9, 275, 275, "CID"], [9, 9, 289, 289, "CID"], [9, 9, 313, 313, "CID"], [21, 21, 201, 201, "CID"], [21, 21, 275, 275, "CID"], [21, 21, 289, 289, "CID"], [21, 21, 313, 313, "CID"], [71, 71, 201, 201, "CID"], [71, 71, 275, 275, "CID"], [71, 71, 289, 289, "CID"], [71, 71, 313, 313, "CID"], [141, 141, 201, 201, "CID"], [141, 141, 275, 275, "CID"], [141, 141, 289, 289, "CID"], [141, 141, 313, 313, "CID"], [158, 158, 201, 201, "CID"], [158, 158, 275, 275, "CID"], [158, 158, 289, 289, "CID"], [158, 158, 313, 313, "CID"], [302, 302, 201, 201, "CID"], [302, 302, 275, 275, "CID"], [302, 302, 289, 289, "CID"], [302, 302, 313, 313, "CID"]]], "clusters": [], "translated": "<0>右美托咪定</0>和<14>丙泊酚</14>在神经重症监护患者镇静中严重血流动力学紊乱的比较。目的：<1>右美托咪定</1>和<15>丙泊酚</15>是神经重症监护中常用的镇静剂，因为它们可以进行频繁的神经系统检查。然而，这两种药物都与显着的血液动力学副作用有关。本研究的主要目的是比较接受<2>右美托咪定</2>和<16>丙泊酚</16>的神经重症监护患者严重血流动力学影响的发生率。设计：多中心、回顾性、倾向匹配队列研究。地点：两个学术医疗中心的神经重症监护病房，配备专门的神经重症监护团队和董事会认证的神经重症监护医师。患者：对 2009 年 7 月至 2012 年 9 月期间入院的神经重症监护患者进行评估，然后根据基线特征的倾向评分进行1:1匹配。干预措施：用<3>右美托咪定</3>或<17>丙泊酚</17>持续镇静。测量和主要结果：共有342名患者（105名<4>右美托咪定</4>和237名<18>丙泊酚</18>）被纳入分析，其中190名患者（每组95名）通过倾向评分匹配。该研究的主要结果是镇静剂输注期间严重<6>低血压</6>（平均动脉压<60mmHg）和<10>心动过缓</10>（心率<50次/分钟）的复合结果。在未匹配的（30%对30%，p=0.94）或匹配的队列（28%对34%，p=0.35）中，主要复合结果没有差异。单独分析时，未匹配或匹配队列中严重<7>低血压</7>或<11>心动过缓</11>的患病率没有差异。结论：在接受<5>右美托咪定</5>或<19>丙泊酚</19>的神经重症监护患者中，严重<8>低血压</8>和<12>心动过缓</12>的发生率相似。在开始镇静之前，提供者应同样考虑<9>低血压</9>或<13>心动过缓</13>的可能性。", "revised": true}
{"doc_key": "24671324", "sentences": [["Necrotising", "fasciitis", "after", "bortezomib", "and", "dexamethasone", "-", "containing", "regimen", "in", "an", "elderly", "patient", "of", "Waldenstrom", "macroglobulinaemia", ".", "Bortezomib", "and", "high", "-", "dose", "dexamethasone", "-", "containing", "regimens", "are", "considered", "to", "be", "generally", "tolerable", "with", "few", "severe", "bacterial", "infections", "in", "patients", "with", "B", "-", "cell", "malignancies", ".", "However", ",", "information", "is", "limited", "concerning", "the", "safety", "of", "the", "regimen", "in", "elderly", "patients", ".", "We", "report", "a", "case", "of", "a", "76", "-", "year", "-", "old", "man", "with", "Waldenstrom", "macroglobulinaemia", "who", "suffered", "necrotising", "fasciitis", "without", "neutropenia", "after", "the", "combination", "treatment", "with", "bortezomib", ",", "high", "-", "dose", "dexamethasone", "and", "rituximab", ".", "Despite", "immediate", "intravenous", "antimicrobial", "therapy", ",", "he", "succumbed", "23", "h", "after", "the", "onset", ".", "Physicians", "should", "recognise", "the", "possibility", "of", "fatal", "bacterial", "infections", "related", "to", "bortezomib", "plus", "high", "-", "dose", "dexamethasone", "in", "elderly", "patients", ",", "and", "we", "believe", "this", "case", "warrants", "further", "investigation", "."]], "ner": [[[3, 3, "Chemical"], [17, 17, "Chemical"], [86, 86, "Chemical"], [120, 120, "Chemical"], [0, 1, "Disease"], [77, 78, "Disease"], [5, 5, "Chemical"], [22, 22, "Chemical"], [91, 91, "Chemical"], [125, 125, "Chemical"], [14, 15, "Disease"], [73, 74, "Disease"], [35, 36, "Disease"], [116, 117, "Disease"], [43, 43, "Disease"], [80, 80, "Disease"]]], "relations": [[[3, 3, 0, 1, "CID"], [3, 3, 77, 78, "CID"], [17, 17, 0, 1, "CID"], [17, 17, 77, 78, "CID"], [86, 86, 0, 1, "CID"], [86, 86, 77, 78, "CID"], [120, 120, 0, 1, "CID"], [120, 120, 77, 78, "CID"], [5, 5, 0, 1, "CID"], [5, 5, 77, 78, "CID"], [22, 22, 0, 1, "CID"], [22, 22, 77, 78, "CID"], [91, 91, 0, 1, "CID"], [91, 91, 77, 78, "CID"], [125, 125, 0, 1, "CID"], [125, 125, 77, 78, "CID"]]], "clusters": [], "translated": "一名患有<10>华氏巨球蛋白血症</10>的老年患者在<0>硼替佐米</0>和<6>地塞米松</6>含方案后出现<4>坏死性筋膜炎</4>。 <1>硼替佐米</1>和高剂量<7>地塞米松</7>方案被认为是普遍耐受的，在B细胞<14>恶性肿瘤</14>患者中很少有严重的<12>细菌感染</12>。然而，有关该方案在老年患者中的安全性的信息有限。我们报告了一例患有<11>华氏巨球蛋白血症</11>的76岁男性，他在与<2>硼替佐米</2>、大剂量<8>地塞米松</8>和利妥昔单抗联合治疗后出现了<5>坏死性筋膜炎</5>而没有<15>中性粒细胞减少症</15>. 尽管立即进行了静脉内抗菌治疗，他还是在发病23小时后死亡。医生应该认识到与<3>硼替佐米</3>加高剂量<9>地塞米松</9>相关的致命性<13>细菌感染</13>在老年患者中的可能性，我们认为该病例值得进一步调查。", "revised": true}
{"doc_key": "24684312", "sentences": [["Intradermal", "glutamate", "and", "capsaicin", "injections", ":", "intra", "-", "and", "interindividual", "variability", "of", "provoked", "hyperalgesia", "and", "allodynia", ".", "Intradermal", "injections", "of", "glutamate", "and", "capsaicin", "are", "attractive", "to", "use", "in", "human", "experimental", "pain", "models", "because", "hyperalgesia", "and", "allodynia", "mimic", "isolated", "aspects", "of", "clinical", "pain", "disorders", ".", "The", "aim", "of", "the", "present", "study", "was", "to", "investigate", "the", "reproducibility", "of", "these", "models", ".", "Twenty", "healthy", "male", "volunteers", "(", "mean", "age", "24", "years", ";", "range", "18", "-", "38", "years", ")", "received", "intradermal", "injections", "of", "glutamate", "and", "capsaicin", "in", "the", "volar", "forearm", ".", "Magnitudes", "of", "secondary", "pinprick", "hyperalgesia", "and", "brush", "-", "evoked", "allodynia", "were", "investigated", "using", "von", "Frey", "filaments", "(", "gauges", "10", ",", "15", ",", "60", "and", "100", "g", ")", "and", "brush", "strokes", ".", "Areas", "of", "secondary", "hyperalgesia", "and", "allodynia", "were", "quantified", "immediately", "after", "injection", "and", "after", "15", ",", "30", "and", "60", "min", ".", "Two", "identical", "experiments", "separated", "by", "at", "least", "7", "days", "were", "performed", ".", "Reproducibility", "across", "and", "within", "volunteers", "(", "inter", "-", "and", "intra", "-", "individual", "variation", ",", "respectively", ")", "was", "assessed", "using", "intraclass", "correlation", "coefficient", "(", "ICC", ")", "and", "coefficient", "of", "variation", "(", "CV", ")", ".", "Secondary", "pinprick", "hyperalgesia", "was", "observed", "as", "a", "marked", "increase", "in", "the", "visual", "analogue", "scale", "(", "VAS", ")", "response", "to", "von", "Frey", "gauges", "60", "and", "100", "g", "(", "P", "<", "0", ".", "001", ")", "after", "glutamate", "injection", ".", "For", "capsaicin", ",", "secondary", "pinprick", "hyperalgesia", "was", "detected", "with", "all", "von", "Frey", "gauges", "(", "P", "<", "0", ".", "001", ")", ".", "Glutamate", "evoked", "reproducible", "VAS", "response", "to", "all", "von", "Frey", "gauges", "(", "ICC", ">", "0", ".", "60", ")", "and", "brush", "strokes", "(", "ICC", ">", "0", ".", "83", ")", ".", "Capsaicin", "injection", "was", "reproducible", "for", "secondary", "hyperalgesia", "(", "ICC", ">", "0", ".", "70", ")", "and", "allodynia", "(", "ICC", ">", "0", ".", "71", ")", ".", "Intra", "-", "individual", "variability", "was", "generally", "lower", "for", "the", "VAS", "response", "to", "von", "Frey", "and", "brush", "compared", "with", "areas", "of", "secondary", "hyperalgesia", "and", "allodynia", ".", "In", "conclusion", ",", "glutamate", "and", "capsaicin", "yield", "reproducible", "hyperalgesic", "and", "allodynic", "responses", ",", "and", "the", "present", "model", "is", "well", "suited", "for", "basic", "research", ",", "as", "well", "as", "for", "assessing", "the", "modulation", "of", "central", "phenomena", "."]], "ner": [[[3, 3, "Chemical"], [22, 22, "Chemical"], [81, 81, "Chemical"], [221, 221, "Chemical"], [269, 269, "Chemical"], [323, 323, "Chemical"], [13, 13, "Disease"], [15, 15, "Disease"], [33, 33, "Disease"], [35, 35, "Disease"], [91, 91, "Disease"], [96, 96, "Disease"], [120, 121, "Disease"], [123, 123, "Disease"], [185, 185, "Disease"], [225, 225, "Disease"], [274, 275, "Disease"], [284, 284, "Disease"], [313, 314, "Disease"], [316, 316, "Disease"], [326, 326, "Disease"], [328, 328, "Disease"], [1, 1, "Chemical"], [20, 20, "Chemical"], [79, 79, "Chemical"], [217, 217, "Chemical"], [241, 241, "Chemical"], [321, 321, "Chemical"], [30, 30, "Disease"], [41, 42, "Disease"]]], "relations": [[[3, 3, 13, 13, "CID"], [3, 3, 15, 15, "CID"], [3, 3, 33, 33, "CID"], [3, 3, 35, 35, "CID"], [3, 3, 91, 91, "CID"], [3, 3, 96, 96, "CID"], [3, 3, 120, 121, "CID"], [3, 3, 123, 123, "CID"], [3, 3, 185, 185, "CID"], [3, 3, 225, 225, "CID"], [3, 3, 274, 275, "CID"], [3, 3, 284, 284, "CID"], [3, 3, 313, 314, "CID"], [3, 3, 316, 316, "CID"], [3, 3, 326, 326, "CID"], [3, 3, 328, 328, "CID"], [22, 22, 13, 13, "CID"], [22, 22, 15, 15, "CID"], [22, 22, 33, 33, "CID"], [22, 22, 35, 35, "CID"], [22, 22, 91, 91, "CID"], [22, 22, 96, 96, "CID"], [22, 22, 120, 121, "CID"], [22, 22, 123, 123, "CID"], [22, 22, 185, 185, "CID"], [22, 22, 225, 225, "CID"], [22, 22, 274, 275, "CID"], [22, 22, 284, 284, "CID"], [22, 22, 313, 314, "CID"], [22, 22, 316, 316, "CID"], [22, 22, 326, 326, "CID"], [22, 22, 328, 328, "CID"], [81, 81, 13, 13, "CID"], [81, 81, 15, 15, "CID"], [81, 81, 33, 33, "CID"], [81, 81, 35, 35, "CID"], [81, 81, 91, 91, "CID"], [81, 81, 96, 96, "CID"], [81, 81, 120, 121, "CID"], [81, 81, 123, 123, "CID"], [81, 81, 185, 185, "CID"], [81, 81, 225, 225, "CID"], [81, 81, 274, 275, "CID"], [81, 81, 284, 284, "CID"], [81, 81, 313, 314, "CID"], [81, 81, 316, 316, "CID"], [81, 81, 326, 326, "CID"], [81, 81, 328, 328, "CID"], [221, 221, 13, 13, "CID"], [221, 221, 15, 15, "CID"], [221, 221, 33, 33, "CID"], [221, 221, 35, 35, "CID"], [221, 221, 91, 91, "CID"], [221, 221, 96, 96, "CID"], [221, 221, 120, 121, "CID"], [221, 221, 123, 123, "CID"], [221, 221, 185, 185, "CID"], [221, 221, 225, 225, "CID"], [221, 221, 274, 275, "CID"], [221, 221, 284, 284, "CID"], [221, 221, 313, 314, "CID"], [221, 221, 316, 316, "CID"], [221, 221, 326, 326, "CID"], [221, 221, 328, 328, "CID"], [269, 269, 13, 13, "CID"], [269, 269, 15, 15, "CID"], [269, 269, 33, 33, "CID"], [269, 269, 35, 35, "CID"], [269, 269, 91, 91, "CID"], [269, 269, 96, 96, "CID"], [269, 269, 120, 121, "CID"], [269, 269, 123, 123, "CID"], [269, 269, 185, 185, "CID"], [269, 269, 225, 225, "CID"], [269, 269, 274, 275, "CID"], [269, 269, 284, 284, "CID"], [269, 269, 313, 314, "CID"], [269, 269, 316, 316, "CID"], [269, 269, 326, 326, "CID"], [269, 269, 328, 328, "CID"], [323, 323, 13, 13, "CID"], [323, 323, 15, 15, "CID"], [323, 323, 33, 33, "CID"], [323, 323, 35, 35, "CID"], [323, 323, 91, 91, "CID"], [323, 323, 96, 96, "CID"], [323, 323, 120, 121, "CID"], [323, 323, 123, 123, "CID"], [323, 323, 185, 185, "CID"], [323, 323, 225, 225, "CID"], [323, 323, 274, 275, "CID"], [323, 323, 284, 284, "CID"], [323, 323, 313, 314, "CID"], [323, 323, 316, 316, "CID"], [323, 323, 326, 326, "CID"], [323, 323, 328, 328, "CID"]]], "clusters": [], "translated": "皮内<22>谷氨酸</22>和<0>辣椒素</0>注射：引发的<6>痛觉过敏</6>和<7>异常性疼痛</7>的个体内和个体间差异。<23>谷氨酸</23>和<1>辣椒素</1>的皮内注射在人类实验<28>疼痛</28>模型中的应用很有吸引力，因为<8>痛觉过敏</8>和<9>异常性疼痛</9>模仿临床<29>疼痛障碍</29>的孤立方面。本研究的目的是调查这些模型的可重复性。20名健康男性志愿者（平均年龄 24 岁；范围 18-38 岁）在前臂掌侧皮内注射<24>谷氨酸</24>和<2>辣椒素</2>。使用 von Frey 细丝（规格 10、15、60 和 100 g）和刷子笔触研究了继发性针刺<10>痛觉过敏</10>和刷子诱发的<11>异常性疼痛</11>的程度。<12>继发性痛觉过敏</12>和<13>异常性疼痛</13>的面积在注射后立即和15、30和60分钟后进行量化。进行了两个相隔至少7天的相同实验。使用组内相关系数（ICC）和变异系数（CV）评估志愿者之间和志愿者内部的再现性（分别为个体间和个体内的差异）。在<25>谷氨酸</25>注射后，观察到继发性针刺<14>痛觉过敏</14>视觉模拟量表（VAS）对von Frey量表60和100 g （P < 0.001）的反应显着增加。对于<3>辣椒素</3>，所有von Frey量表均检测到继发性针刺<15>痛觉过敏</15>（P < 0.001）。<26>谷氨酸</26>诱发了对所有von Frey量表（ICC > 0.60）和笔触（ICC > 0.83）的可重复VAS反应。<4>辣椒素</4>注射对<16>继发性痛觉过敏（ICC > 0.70）</16>和<17>异常性疼痛（ICC > 0.71）</17>具有可重复性。与<18>继发性痛觉过敏</18>和<19>异常性疼痛</19>区域相比，VAS对von Frey和刷子的反应的个体内变异性通常较低。总之，<27>谷氨酸</27>和<5>辣椒素</5>产生可重现的<20>痛觉过敏</20>和<21>异常性疼痛</21>反应，本模型非常适合基本研究，以及评估中枢现象的调制。", "revised": true}
{"doc_key": "24733133", "sentences": [["Use", "of", "argatroban", "and", "catheter", "-", "directed", "thrombolysis", "with", "alteplase", "in", "an", "oncology", "patient", "with", "heparin", "-", "induced", "thrombocytopenia", "with", "thrombosis", ".", "PURPOSE", ":", "The", "case", "of", "an", "oncology", "patient", "who", "developed", "heparin", "-", "induced", "thrombocytopenia", "with", "thrombosis", "(", "HITT", ")", "and", "was", "treated", "with", "argatroban", "plus", "catheter", "-", "directed", "thrombolysis", "(", "CDT", ")", "with", "alteplase", "is", "presented", ".", "SUMMARY", ":", "A", "63", "-", "year", "-", "old", "Caucasian", "man", "with", "renal", "amyloidosis", "undergoing", "peripheral", "blood", "stem", "cell", "collection", "for", "an", "autologous", "stem", "cell", "transplant", "developed", "extensive", "bilateral", "upper", "-", "extremity", "deep", "venous", "thrombosis", "(", "DVT", ")", "and", "pulmonary", "embolism", "secondary", "to", "heparin", "-", "induced", "thrombocytopenia", ".", "A", "continuous", "i", ".", "v", ".", "infusion", "of", "argatroban", "was", "initiated", ",", "and", "the", "patient", "was", "managed", "on", "the", "general", "medical", "floor", ".", "After", "one", "week", "of", "therapy", ",", "he", "was", "transferred", "to", "the", "intensive", "care", "unit", "with", "cardiopulmonary", "compromise", "related", "to", "superior", "vena", "cava", "(", "SVC", ")", "syndrome", ".", "A", "percutaneous", "mechanical", "thrombectomy", "and", "CDT", "with", "alteplase", "were", "attempted", ",", "but", "the", "procedure", "was", "aborted", "due", "to", "epistaxis", ".", "The", "epistaxis", "resolved", "the", "next", "day", ",", "and", "the", "patient", "was", "restarted", "on", "argatroban", ".", "A", "second", "percutaneous", "mechanical", "thrombectomy", "was", "performed", "six", "days", "later", "and", "resulted", "in", "partial", "revascularization", "of", "the", "SVC", "and", "central", "veins", ".", "Postthrombectomy", "continuous", "CDT", "with", "alteplase", "was", "commenced", "while", "argatroban", "was", "withheld", ",", "and", "complete", "patency", "of", "the", "SVC", "and", "central", "veins", "was", "achieved", "after", "three", "days", "of", "therapy", ".", "Alteplase", "was", "discontinued", ",", "and", "the", "patient", "was", "reinitiated", "on", "argatroban", ";", "ultimately", ",", "he", "was", "transitioned", "to", "warfarin", "for", "long", "-", "term", "anticoagulation", ".", "Although", "the", "patient", "recovered", ",", "he", "experienced", "permanent", "vision", "and", "hearing", "loss", ",", "as", "well", "as", "end", "-", "stage", "renal", "disease", ".", "CONCLUSION", ":", "A", "63", "-", "year", "-", "old", "man", "with", "renal", "amyloidosis", "and", "SVC", "syndrome", "secondary", "to", "HITT", "was", "successfully", "treated", "with", "argatroban", "and", "CDT", "with", "alteplase", "."]], "ner": [[[15, 15, "Chemical"], [32, 32, "Chemical"], [101, 101, "Chemical"], [18, 18, "Disease"], [35, 35, "Disease"], [39, 39, "Disease"], [104, 104, "Disease"], [306, 306, "Disease"], [94, 94, "Disease"], [97, 98, "Disease"], [2, 2, "Chemical"], [45, 45, "Chemical"], [114, 114, "Chemical"], [189, 189, "Chemical"], [221, 221, "Chemical"], [252, 252, "Chemical"], [311, 311, "Chemical"], [7, 7, "Disease"], [50, 50, "Disease"], [20, 20, "Disease"], [37, 37, "Disease"], [71, 71, "Disease"], [300, 300, "Disease"], [87, 92, "Disease"], [148, 154, "Disease"], [302, 303, "Disease"], [174, 174, "Disease"], [177, 177, "Disease"], [275, 278, "Disease"], [283, 287, "Disease"], [260, 260, "Chemical"]]], "relations": [[[15, 15, 18, 18, "CID"], [15, 15, 35, 35, "CID"], [15, 15, 39, 39, "CID"], [15, 15, 104, 104, "CID"], [15, 15, 306, 306, "CID"], [32, 32, 18, 18, "CID"], [32, 32, 35, 35, "CID"], [32, 32, 39, 39, "CID"], [32, 32, 104, 104, "CID"], [32, 32, 306, 306, "CID"], [101, 101, 18, 18, "CID"], [101, 101, 35, 35, "CID"], [101, 101, 39, 39, "CID"], [101, 101, 104, 104, "CID"], [101, 101, 306, 306, "CID"], [15, 15, 94, 94, "CID"], [32, 32, 94, 94, "CID"], [101, 101, 94, 94, "CID"], [15, 15, 97, 98, "CID"], [32, 32, 97, 98, "CID"], [101, 101, 97, 98, "CID"]]], "clusters": [], "translated": "<10>阿加曲班</10>和导管导向<17>溶栓</17>与阿替普酶在<0>肝素</0>-诱发的<3>血小板减少症</3>伴随<19>血栓形成</19>的肿瘤患者中的应用。目的：介绍了一名肿瘤患者发生<1>肝素</1>-诱发的<4>血小板减少症</4>并伴有<20>血栓形成</20> (<5>HITT</5>) 并接受治疗的情况，使用<11>阿加曲班</11>加阿替普酶的导管定向<18>溶栓</18> (CDT)。摘要：一名患有肾<21>淀粉样变性</21>的63岁白人男性在接受外周血干细胞采集以进行自体干细胞移植时发生广泛的双侧<23>上肢深静脉血栓形成</23> (<8>DVT</8>) 和<9>肺栓塞</9>继发于<2>肝素</2>-诱发的<6>血小板减少</6>。一个连续的 i.v. 输注<12>阿加曲班</12>，患者在普通医疗楼层接受治疗。治疗一周后，他因发生<24>上腔静脉 (SVC) 综合征</24>相关的心肺损害被转移到重症监护病房。尝试了经皮机械血栓切除术和阿替普酶CDT，但由于<26>鼻出血</26>手术中止。 <27>鼻出血</27>第二天消失，患者重新开始服用<13>阿加曲班</13>。 6 天后进行了第二次经皮机械血栓切除术，导致SVC和中央静脉部分血运重建。血栓切除术后开始使用阿替普酶连续CDT，同时停用<14>阿加曲班</14>，治疗三天后上腔静脉和中央静脉完全通畅。停用阿替普酶，患者重新开始服用<15>阿加曲班</15>；最终，他转为<30>华法林</30>进行长期抗凝治疗。虽然患者康复了，但他经历了永久性<28>视力和听力损失</28>，以及<29>终末期肾病</29>。结论：成功地使用<16>阿加曲班</16>和CDT与阿替普酶治疗了一名63岁男性，他发生了<7>HITT</7>继发肾<22>淀粉样变性</22>和<25>SVC综合征</25>。", "revised": true}
{"doc_key": "24742750", "sentences": [["Availability", "of", "human", "induced", "pluripotent", "stem", "cell", "-", "derived", "cardiomyocytes", "in", "assessment", "of", "drug", "potential", "for", "QT", "prolongation", ".", "Field", "potential", "duration", "(", "FPD", ")", "in", "human", "-", "induced", "pluripotent", "stem", "cell", "-", "derived", "cardiomyocytes", "(", "hiPS", "-", "CMs", ")", ",", "which", "can", "express", "QT", "interval", "in", "an", "electrocardiogram", ",", "is", "reported", "to", "be", "a", "useful", "tool", "to", "predict", "K", "(", "+", ")", "channel", "and", "Ca", "(", "2", "+", ")", "channel", "blocker", "effects", "on", "QT", "interval", ".", "However", ",", "there", "is", "no", "report", "showing", "that", "this", "technique", "can", "be", "used", "to", "predict", "multichannel", "blocker", "potential", "for", "QT", "prolongation", ".", "The", "aim", "of", "this", "study", "is", "to", "show", "that", "FPD", "from", "MEA", "(", "Multielectrode", "array", ")", "of", "hiPS", "-", "CMs", "can", "detect", "QT", "prolongation", "induced", "by", "multichannel", "blockers", ".", "hiPS", "-", "CMs", "were", "seeded", "onto", "MEA", "and", "FPD", "was", "measured", "for", "2min", "every", "10min", "for", "30min", "after", "drug", "exposure", "for", "the", "vehicle", "and", "each", "drug", "concentration", ".", "IKr", "and", "IKs", "blockers", "concentration", "-", "dependently", "prolonged", "corrected", "FPD", "(", "FPDc", ")", ",", "whereas", "Ca", "(", "2", "+", ")", "channel", "blockers", "concentration", "-", "dependently", "shortened", "FPDc", ".", "Also", ",", "the", "multichannel", "blockers", "Amiodarone", ",", "Paroxetine", ",", "Terfenadine", "and", "Citalopram", "prolonged", "FPDc", "in", "a", "concentration", "dependent", "manner", ".", "Finally", ",", "the", "IKr", "blockers", ",", "Terfenadine", "and", "Citalopram", ",", "which", "are", "reported", "to", "cause", "Torsade", "de", "Pointes", "(", "TdP", ")", "in", "clinical", "practice", ",", "produced", "early", "afterdepolarization", "(", "EAD", ")", ".", "hiPS", "-", "CMs", "using", "MEA", "system", "and", "FPDc", "can", "predict", "the", "effects", "of", "drug", "candidates", "on", "QT", "interval", ".", "This", "study", "also", "shows", "that", "this", "assay", "can", "help", "detect", "EAD", "for", "drugs", "with", "TdP", "potential", "."]], "ner": [[[193, 193, "Chemical"], [210, 210, "Chemical"], [219, 221, "Disease"], [223, 223, "Disease"], [269, 269, "Disease"], [195, 195, "Chemical"], [212, 212, "Chemical"], [59, 59, "Chemical"], [16, 17, "Disease"], [96, 97, "Disease"], [121, 122, "Disease"], [65, 65, "Chemical"], [171, 171, "Chemical"], [189, 189, "Chemical"], [191, 191, "Chemical"]]], "relations": [[[193, 193, 219, 221, "CID"], [193, 193, 223, 223, "CID"], [193, 193, 269, 269, "CID"], [210, 210, 219, 221, "CID"], [210, 210, 223, 223, "CID"], [210, 210, 269, 269, "CID"], [195, 195, 219, 221, "CID"], [195, 195, 223, 223, "CID"], [195, 195, 269, 269, "CID"], [212, 212, 219, 221, "CID"], [212, 212, 223, 223, "CID"], [212, 212, 269, 269, "CID"]]], "clusters": [], "translated": "人诱导多能干细胞衍生心肌细胞在评估<8> QT延长 </8>药物潜力中的可用性。人诱导的多能干细胞来源的心肌细胞(hiPS - CMs)中的场电位持续时间(FPD)，可以在心电图中表达QT间期，据报道是预测<7> K </7>(+)通道和<11> Ca </11>(2+)通道阻滞剂对QT间期的影响。然而，没有报告表明该技术可用于预测<9> QT延长 </9>的多通道阻滞剂潜力。本研究的目的是表明来自hiPS-CMs的MEA（多电极阵列）的FPD可以检测多通道阻滞剂诱导的<10> QT延长 </10>。将hiPS-CM接种到MEA上，并在药物暴露后每10分钟测量FPD，持续30分钟。IKr和IKs阻滞剂浓度依赖性地延长校正的FPD(FPDc)，而<12> Ca </12>(2+)通道阻滞剂浓度依赖性地缩短FPDc。此外，多通道阻滞剂<13> Amiodarone </13>、<14> Paroxetine </14>、<0> Terfenadine </0>和<5> Citalopram </5>以浓度依赖性方式延长了FPDc。最后，据报道，IKr阻滞剂<1> Terfenadine </1>和<6> Citalopram </6>会导致<2> Torsade de Pointes </2>(<3> TdP </3>)室性心动过速在临床实践中，产生了早期后除极(EAD)。使用MEA系统和FPDc的hiPS-CMs可以预测候选药物对QT间期的影响。该研究还表明，该测定可以帮助检测具有<4> TdP </4>潜力的药物的EAD。", "revised": true}
{"doc_key": "24816962", "sentences": [["Metronidazole", "-", "induced", "encephalopathy", ":", "an", "uncommon", "scenario", ".", "Metronidazole", "can", "produce", "neurological", "complications", "although", "it", "is", "not", "a", "common", "scenario", ".", "We", "present", "a", "case", "where", "a", "patient", "developed", "features", "of", "encephalopathy", "following", "prolonged", "metronidazole", "intake", ".", "Magnetic", "resonance", "imaging", "(", "MRI", ")", "brain", "showed", "abnormal", "signal", "intensity", "involving", "both", "dentate", "nuclei", "of", "cerebellum", "and", "splenium", "of", "corpus", "callosum", ".", "The", "diagnosis", "of", "metronidazole", "toxicity", "was", "made", "by", "the", "MRI", "findings", "and", "supported", "clinically", "."]], "ner": [[[0, 0, "Chemical"], [9, 9, "Chemical"], [35, 35, "Chemical"], [64, 64, "Chemical"], [3, 3, "Disease"], [32, 32, "Disease"], [65, 65, "Disease"]]], "relations": [[[0, 0, 3, 3, "CID"], [0, 0, 32, 32, "CID"], [9, 9, 3, 3, "CID"], [9, 9, 32, 32, "CID"], [35, 35, 3, 3, "CID"], [35, 35, 32, 32, "CID"], [64, 64, 3, 3, "CID"], [64, 64, 32, 32, "CID"]]], "clusters": [], "translated": "<0>甲硝唑</0>引起的<4>脑病</4>：一种不常见的情况。 <1>甲硝唑 </1>可产生神经系统并发症，但这种情况并不常见。我们介绍了一个案例，其中一名患者在长期服用<2>甲硝唑</2>后出现了<5>脑病</5>的特征。大脑磁共振成像(MRI)显示异常信号强度，涉及小脑齿状核和胼胝体压部。<3>甲硝唑</3><6>毒性</6>的诊断是根据MRI表现做出的，并有临床支持。", "revised": true}
{"doc_key": "24881749", "sentences": [["Neuroleptic", "malignant", "syndrome", "induced", "by", "combination", "therapy", "with", "tetrabenazine", "and", "tiapride", "in", "a", "Japanese", "patient", "with", "Huntington", "'s", "disease", "at", "the", "terminal", "stage", "of", "recurrent", "breast", "cancer", ".", "We", "herein", "describe", "the", "case", "of", "an", "81", "-", "year", "-", "old", "Japanese", "woman", "with", "neuroleptic", "malignant", "syndrome", "that", "occurred", "36", "days", "after", "the", "initiation", "of", "combination", "therapy", "with", "tiapride", "(", "75", "mg", "/", "day", ")", "and", "tetrabenazine", "(", "12", ".", "5", "mg", "/", "day", ")", "for", "Huntington", "'s", "disease", ".", "The", "patient", "had", "been", "treated", "with", "tiapride", "or", "tetrabenazine", "alone", "without", "any", "adverse", "effects", "before", "the", "administration", "of", "the", "combination", "therapy", ".", "She", "also", "had", "advanced", "breast", "cancer", "when", "the", "combination", "therapy", "was", "initiated", ".", "To", "the", "best", "of", "our", "knowledge", ",", "the", "occurrence", "of", "neuroleptic", "malignant", "syndrome", "due", "to", "combination", "therapy", "with", "tetrabenazine", "and", "tiapride", "has", "not", "been", "previously", "reported", ".", "Tetrabenazine", "should", "be", "administered", "very", "carefully", "in", "combination", "with", "other", "neuroleptic", "drugs", ",", "particularly", "in", "patients", "with", "a", "worsening", "general", "condition", "."]], "ner": [[[8, 8, "Chemical"], [65, 65, "Chemical"], [87, 87, "Chemical"], [132, 132, "Chemical"], [141, 141, "Chemical"], [0, 2, "Disease"], [43, 45, "Disease"], [124, 126, "Disease"], [10, 10, "Chemical"], [57, 57, "Chemical"], [85, 85, "Chemical"], [134, 134, "Chemical"], [151, 152, "Chemical"], [16, 18, "Disease"], [75, 77, "Disease"], [25, 26, "Disease"], [105, 106, "Disease"]]], "relations": [[[8, 8, 0, 2, "CID"], [8, 8, 43, 45, "CID"], [8, 8, 124, 126, "CID"], [65, 65, 0, 2, "CID"], [65, 65, 43, 45, "CID"], [65, 65, 124, 126, "CID"], [87, 87, 0, 2, "CID"], [87, 87, 43, 45, "CID"], [87, 87, 124, 126, "CID"], [132, 132, 0, 2, "CID"], [132, 132, 43, 45, "CID"], [132, 132, 124, 126, "CID"], [141, 141, 0, 2, "CID"], [141, 141, 43, 45, "CID"], [141, 141, 124, 126, "CID"], [10, 10, 0, 2, "CID"], [10, 10, 43, 45, "CID"], [10, 10, 124, 126, "CID"], [57, 57, 0, 2, "CID"], [57, 57, 43, 45, "CID"], [57, 57, 124, 126, "CID"], [85, 85, 0, 2, "CID"], [85, 85, 43, 45, "CID"], [85, 85, 124, 126, "CID"], [134, 134, 0, 2, "CID"], [134, 134, 43, 45, "CID"], [134, 134, 124, 126, "CID"]]], "clusters": [], "translated": "<0>丁苯那嗪</0>与<8>噻必利</8>联合治疗1例日本<13>亨廷顿病</13>复发性<15>乳腺癌</15>终末期患者的<5>抗精神病药恶性综合征</5>。我们在此描述了一名 81 岁的日本女性，在开始使用<9>泰必利</9>治疗 36 天后发生<6>抗精神病药物恶性综合征</6>的病例，治疗中同时使用<1>丁苯那嗪</1>（12. 5 毫克/天）用于<14>亨廷顿舞蹈病</14>。该患者在联合治疗前曾单独接受<10>泰必利</10>或<2>丁苯那嗪</2>治疗，无任何不良反应。当联合治疗开始时，她还患有晚期<16>乳腺癌</16>。据我们所知，<3>丁苯那嗪</3>和<11>泰必利</11>的联合治疗导致<7>抗精神病药恶性综合征</7>的发生以前没有报道。<4>丁苯那嗪</4>与其他<12>抗精神病药</12>联合使用时应非常小心，尤其是在一般情况恶化的患者中。", "revised": true}
{"doc_key": "24897009", "sentences": [["Optochiasmatic", "and", "peripheral", "neuropathy", "due", "to", "ethambutol", "overtreatment", ".", "Ethambutol", "is", "known", "to", "cause", "optic", "neuropathy", "and", ",", "more", "rarely", ",", "axonal", "polyneuropathy", ".", "We", "characterize", "the", "clinical", ",", "neurophysiological", ",", "and", "neuroimaging", "findings", "in", "a", "72", "-", "year", "-", "old", "man", "who", "developed", "visual", "loss", "and", "paresthesias", "after", "11", "weeks", "of", "exposure", "to", "a", "supratherapeutic", "dose", "of", "ethambutol", ".", "This", "case", "demonstrates", "the", "selective", "vulnerability", "of", "the", "anterior", "visual", "pathways", "and", "peripheral", "nerves", "to", "ethambutol", "toxicity", "."]], "ner": [[[6, 6, "Chemical"], [9, 9, "Chemical"], [58, 58, "Chemical"], [75, 75, "Chemical"], [14, 15, "Disease"], [22, 22, "Disease"], [44, 45, "Disease"], [47, 47, "Disease"], [2, 3, "Disease"], [76, 76, "Disease"]]], "relations": [[[6, 6, 14, 15, "CID"], [9, 9, 14, 15, "CID"], [58, 58, 14, 15, "CID"], [75, 75, 14, 15, "CID"], [6, 6, 22, 22, "CID"], [9, 9, 22, 22, "CID"], [58, 58, 22, 22, "CID"], [75, 75, 22, 22, "CID"], [6, 6, 44, 45, "CID"], [9, 9, 44, 45, "CID"], [58, 58, 44, 45, "CID"], [75, 75, 44, 45, "CID"], [6, 6, 47, 47, "CID"], [9, 9, 47, 47, "CID"], [58, 58, 47, 47, "CID"], [75, 75, 47, 47, "CID"]]], "clusters": [], "translated": "由于<0>乙胺丁醇</0>过度治疗导致的视交叉和<8>周围神经病变</8>。<1>乙胺丁醇</1>已知会引起<4>视神经病变</4>以及更为罕见的轴索性<5>多发性神经病变</5>。我们描述了一名72岁男性的临床、神经生理学和神经影像学发现的特征，该男性在暴露于超治疗剂量<2>乙胺丁醇</2>11周后出现<6>视力丧失</6>和<7>感觉异常</7>。该病例表明前视觉通路和周围神经对<3>乙胺丁醇</3><9>毒性</9>的选择性脆弱性。", "revised": true}
{"doc_key": "24753331", "sentences": [["Dermal", "developmental", "toxicity", "of", "N", "-", "phenylimide", "herbicides", "in", "rats", ".", "BACKGROUND", ":", "S", "-", "53482", "and", "S", "-", "23121", "are", "N", "-", "phenylimide", "herbicides", "and", "produced", "embryolethality", ",", "teratogenicity", "(", "mainly", "ventricular", "septal", "defects", "and", "wavy", "ribs", ")", ",", "and", "growth", "retardation", "in", "rats", "in", "conventional", "oral", "developmental", "toxicity", "studies", ".", "Our", "objective", "in", "this", "study", "was", "to", "investigate", "whether", "the", "compounds", "induce", "developmental", "toxicity", "via", "the", "dermal", "route", ",", "which", "is", "more", "relevant", "to", "occupational", "exposure", ",", "hence", "better", "addressing", "human", "health", "risks", ".", "METHODS", ":", "S", "-", "53482", "was", "administered", "dermally", "to", "rats", "at", "30", ",", "100", ",", "and", "300", "mg", "/", "kg", "during", "organogenesis", ",", "and", "S", "-", "23121", "was", "administered", "at", "200", ",", "400", ",", "and", "800", "mg", "/", "kg", "(", "the", "maximum", "applicable", "dose", "level", ")", ".", "Fetuses", "were", "obtained", "by", "a", "Cesarean", "section", "and", "examined", "for", "external", ",", "visceral", ",", "and", "skeletal", "alterations", ".", "RESULTS", ":", "Dermal", "exposure", "of", "rats", "to", "S", "-", "53482", "at", "300", "mg", "/", "kg", "produced", "patterns", "of", "developmental", "toxicity", "similar", "to", "those", "resulting", "from", "oral", "exposure", ".", "Toxicity", "included", "embryolethality", ",", "teratogenicity", ",", "and", "growth", "retardation", ".", "Dermal", "administration", "of", "S", "-", "23121", "at", "800", "mg", "/", "kg", "resulted", "in", "an", "increased", "incidence", "of", "embryonic", "death", "and", "ventricular", "septal", "defect", ",", "but", "retarded", "fetal", "growth", "was", "not", "observed", "as", "it", "was", "following", "oral", "exposure", "to", "S", "-", "23121", ".", "CONCLUSIONS", ":", "Based", "on", "the", "results", ",", "S", "-", "53482", "and", "S", "-", "23121", "were", "teratogenic", "when", "administered", "dermally", "to", "pregnant", "rats", "as", "were", "the", "compounds", "administered", "orally", ".", "Thus", ",", "investigation", "of", "the", "mechanism", "and", "its", "human", "relevancy", "become", "more", "important", "."]], "ner": [[[13, 15, "Chemical"], [88, 90, "Chemical"], [158, 160, "Chemical"], [238, 240, "Chemical"], [27, 27, "Disease"], [181, 181, "Disease"], [206, 207, "Disease"], [29, 29, "Disease"], [183, 183, "Disease"], [246, 246, "Disease"], [32, 34, "Disease"], [209, 211, "Disease"], [41, 42, "Disease"], [186, 187, "Disease"], [17, 19, "Chemical"], [110, 112, "Chemical"], [192, 194, "Chemical"], [227, 229, "Chemical"], [242, 244, "Chemical"], [2, 2, "Disease"], [49, 49, "Disease"], [65, 65, "Disease"], [170, 170, "Disease"], [179, 179, "Disease"]]], "relations": [[[13, 15, 27, 27, "CID"], [13, 15, 181, 181, "CID"], [13, 15, 206, 207, "CID"], [88, 90, 27, 27, "CID"], [88, 90, 181, 181, "CID"], [88, 90, 206, 207, "CID"], [158, 160, 27, 27, "CID"], [158, 160, 181, 181, "CID"], [158, 160, 206, 207, "CID"], [238, 240, 27, 27, "CID"], [238, 240, 181, 181, "CID"], [238, 240, 206, 207, "CID"], [13, 15, 29, 29, "CID"], [13, 15, 183, 183, "CID"], [13, 15, 246, 246, "CID"], [88, 90, 29, 29, "CID"], [88, 90, 183, 183, "CID"], [88, 90, 246, 246, "CID"], [158, 160, 29, 29, "CID"], [158, 160, 183, 183, "CID"], [158, 160, 246, 246, "CID"], [238, 240, 29, 29, "CID"], [238, 240, 183, 183, "CID"], [238, 240, 246, 246, "CID"], [13, 15, 32, 34, "CID"], [13, 15, 209, 211, "CID"], [88, 90, 32, 34, "CID"], [88, 90, 209, 211, "CID"], [158, 160, 32, 34, "CID"], [158, 160, 209, 211, "CID"], [238, 240, 32, 34, "CID"], [238, 240, 209, 211, "CID"], [13, 15, 41, 42, "CID"], [13, 15, 186, 187, "CID"], [88, 90, 41, 42, "CID"], [88, 90, 186, 187, "CID"], [158, 160, 41, 42, "CID"], [158, 160, 186, 187, "CID"], [238, 240, 41, 42, "CID"], [238, 240, 186, 187, "CID"], [17, 19, 27, 27, "CID"], [17, 19, 181, 181, "CID"], [17, 19, 206, 207, "CID"], [110, 112, 27, 27, "CID"], [110, 112, 181, 181, "CID"], [110, 112, 206, 207, "CID"], [192, 194, 27, 27, "CID"], [192, 194, 181, 181, "CID"], [192, 194, 206, 207, "CID"], [227, 229, 27, 27, "CID"], [227, 229, 181, 181, "CID"], [227, 229, 206, 207, "CID"], [242, 244, 27, 27, "CID"], [242, 244, 181, 181, "CID"], [242, 244, 206, 207, "CID"], [17, 19, 29, 29, "CID"], [17, 19, 183, 183, "CID"], [17, 19, 246, 246, "CID"], [110, 112, 29, 29, "CID"], [110, 112, 183, 183, "CID"], [110, 112, 246, 246, "CID"], [192, 194, 29, 29, "CID"], [192, 194, 183, 183, "CID"], [192, 194, 246, 246, "CID"], [227, 229, 29, 29, "CID"], [227, 229, 183, 183, "CID"], [227, 229, 246, 246, "CID"], [242, 244, 29, 29, "CID"], [242, 244, 183, 183, "CID"], [242, 244, 246, 246, "CID"], [17, 19, 32, 34, "CID"], [17, 19, 209, 211, "CID"], [110, 112, 32, 34, "CID"], [110, 112, 209, 211, "CID"], [192, 194, 32, 34, "CID"], [192, 194, 209, 211, "CID"], [227, 229, 32, 34, "CID"], [227, 229, 209, 211, "CID"], [242, 244, 32, 34, "CID"], [242, 244, 209, 211, "CID"], [17, 19, 41, 42, "CID"], [17, 19, 186, 187, "CID"], [110, 112, 41, 42, "CID"], [110, 112, 186, 187, "CID"], [192, 194, 41, 42, "CID"], [192, 194, 186, 187, "CID"], [227, 229, 41, 42, "CID"], [227, 229, 186, 187, "CID"], [242, 244, 41, 42, "CID"], [242, 244, 186, 187, "CID"]]], "clusters": [], "translated": "N-苯酰亚胺除草剂对大鼠的<19>皮肤发育毒性</19>。背景：<0>S-53482</0>和<14>S-23121</14>是N-苯酰亚胺类除草剂，具有<4>胚胎致死性</4>、<7>致畸性</7>（主要是<10>室间隔缺损</10>和波状肋骨），以及<12>生长迟缓</12>，在大鼠中的常规口服<20>发育毒性</20>研究中被观察到。我们的目的是调查这些化合物是否通过皮肤途径引起<21>发育毒性</21>，这与职业暴露更相关，因此更好地预测人类健康风险。方法：<1>S-53482</1>在器官形成期间以30、100和300 mg/kg经皮给予大鼠，<15>S-23121</15>在最大的适用剂量水平下以200、400和800 mg/kg经皮给予大鼠。通过剖宫产获得胎儿，检查外部、内脏和骨骼异常。结果：大鼠皮肤向<2>S-53482</2>暴露300 mg/kg产生的<22>发育毒性</22>模式与口服暴露相似。<23>毒性</23>包括<5>胚胎致死性</5>、<8>致畸性</8>和<13>生长迟缓</13>。在皮肤给予<16>S-23121</16>800 mg/kg下，<6>胚胎死亡</6>和<11>室间隔缺损</11>的发生率增加，但相较于口服<17>S-23121</17>不会导致胎儿生长迟缓。结论：根据这些结果，<3>S-53482</3>和<18>S-23121</18>在妊娠大鼠中均通过皮肤途径或口服引起<9>致畸作用</9>。因此，该机制及其对人类健康的重要性需要进一步研究。", "revised": true}
{"doc_key": "24614773", "sentences": [["Normoammonemic", "encephalopathy", ":", "solely", "valproate", "induced", "or", "multiple", "mechanisms", "?", "A", "77", "-", "year", "-", "old", "woman", "presented", "with", "subacute", "onset", "progressive", "confusion", ",", "aggression", ",", "auditory", "hallucinations", "and", "delusions", ".", "In", "the", "preceding", "months", ",", "the", "patient", "had", "a", "number", "of", "admissions", "with", "transient", "unilateral", "hemiparesis", "with", "facial", "droop", ",", "and", "had", "been", "started", "on", "valproate", "for", "presumed", "hemiplegic", "migraine", ".", "Valproate", "was", "withdrawn", "soon", "after", "admission", "and", "her", "cognitive", "abilities", "have", "gradually", "improved", "over", "3", "months", "of", "follow", "-", "up", ".", "Valproate", "levels", "taken", "prior", "to", "withdrawal", "were", "subtherapeutic", "and", "the", "patient", "was", "normoammonaemic", ".", "EEG", "undertaken", "during", "inpatient", "stay", "showed", "changes", "consistent", "with", "encephalopathy", ",", "and", "low", "titre", "N", "-", "methyl", "-", "D", "-", "aspartate", "(", "NMDA", ")", "receptor", "antibodies", "were", "present", "in", "this", "patient", ".", "The", "possible", "aetiologies", "of", "valproate", "-", "induced", "encephalopathy", "and", "NMDA", "receptor", "-", "associated", "encephalitis", "present", "a", "diagnostic", "dilemma", ".", "We", "present", "a", "putative", "combinatorial", "hypothesis", "to", "explain", "this", "patient", "'s", "symptoms", "."]], "ner": [[[4, 4, "Chemical"], [56, 56, "Chemical"], [62, 62, "Chemical"], [83, 83, "Chemical"], [133, 133, "Chemical"], [22, 22, "Disease"], [26, 27, "Disease"], [29, 29, "Disease"], [1, 1, "Disease"], [106, 106, "Disease"], [136, 136, "Disease"], [111, 117, "Chemical"], [119, 119, "Chemical"], [138, 138, "Chemical"], [24, 24, "Disease"], [46, 46, "Disease"], [59, 60, "Disease"], [142, 142, "Disease"]]], "relations": [[[4, 4, 22, 22, "CID"], [56, 56, 22, 22, "CID"], [62, 62, 22, 22, "CID"], [83, 83, 22, 22, "CID"], [133, 133, 22, 22, "CID"], [4, 4, 26, 27, "CID"], [56, 56, 26, 27, "CID"], [62, 62, 26, 27, "CID"], [83, 83, 26, 27, "CID"], [133, 133, 26, 27, "CID"], [4, 4, 29, 29, "CID"], [56, 56, 29, 29, "CID"], [62, 62, 29, 29, "CID"], [83, 83, 29, 29, "CID"], [133, 133, 29, 29, "CID"]]], "clusters": [], "translated": "正常氨血症<8>脑病</8>：单独<0>丙戊酸钠</0>诱发还是多种机制？一名 77 岁的女性因亚急性起病进行性<5>意识模糊</5>、<14>攻击性</14>、<6>幻听</6>和<7>妄想</7>就诊。在之前的几个月中，患者因短暂的单侧<15>偏瘫</15>伴有面部下垂而多次入院，并已开始使用<1>丙戊酸盐</1>治疗推测的<16>偏瘫性偏头痛</16>。<2>丙戊酸钠</2>入院后很快停药，随访3个月认知能力逐渐改善。<3>丙戊酸盐</3>水平低于治疗水平，停药前患者血氨正常。住院期间进行的脑电图显示与<9>脑病</9>一致的变化，并且该患者具有低滴度的<11>N-甲基-D-天冬氨酸</11><12>NMDA</12>受体抗体。 <4>丙戊酸盐</4>诱发的<10>脑病</10>和<13>NMDA受体</13>相关的<17>脑炎</17>的可能病因给诊断带来了难题。我们提出了一个推定的组合假设来解释该患者的症状。", "revised": true}
{"doc_key": "24894748", "sentences": [["A", "metoprolol", "-", "terbinafine", "combination", "induced", "bradycardia", ".", "To", "report", "a", "sinus", "bradycardia", "induced", "by", "metoprolol", "and", "terbinafine", "drug", "-", "drug", "interaction", "and", "its", "management", ".", "A", "63", "year", "-", "old", "Caucasian", "man", "on", "metoprolol", "200", "mg", "/", "day", "for", "stable", "coronary", "artery", "disease", "was", "prescribed", "a", "90", "-", "day", "course", "of", "oral", "terbinafine", "250", "mg", "/", "day", "for", "onychomycosis", ".", "On", "the", "49th", "day", "of", "terbinafine", "therapy", ",", "he", "was", "brought", "to", "the", "emergency", "room", "for", "a", "decrease", "of", "his", "global", "health", "status", ",", "confusion", "and", "falls", ".", "The", "electrocardiogram", "revealed", "a", "37", "beats", "/", "min", "sinus", "bradycardia", ".", "A", "score", "of", "7", "on", "the", "Naranjo", "adverse", "drug", "reaction", "probability", "scale", "indicates", "a", "probable", "relationship", "between", "the", "patient", "'s", "sinus", "bradycardia", "and", "the", "drug", "interaction", "between", "metoprolol", "and", "terbinafine", ".", "The", "heart", "rate", "ameliorated", "first", "with", "a", "decrease", "in", "the", "dose", "of", "metoprolol", ".", "It", "was", "subsequently", "changed", "to", "bisoprolol", "and", "the", "heart", "rate", "remained", "normal", ".", "By", "inhibiting", "the", "cytochrome", "P450", "2D6", ",", "terbinafine", "had", "decreased", "metoprolol", "'s", "clearance", ",", "leading", "in", "metoprolol", "accumulation", "which", "has", "resulted", "in", "clinically", "significant", "sinus", "bradycardia", "."]], "ner": [[[1, 1, "Chemical"], [15, 15, "Chemical"], [34, 34, "Chemical"], [127, 127, "Chemical"], [143, 143, "Chemical"], [168, 168, "Chemical"], [174, 174, "Chemical"], [6, 6, "Disease"], [3, 3, "Chemical"], [17, 17, "Chemical"], [53, 53, "Chemical"], [66, 66, "Chemical"], [129, 129, "Chemical"], [165, 165, "Chemical"], [11, 12, "Disease"], [97, 98, "Disease"], [120, 121, "Disease"], [182, 183, "Disease"], [41, 43, "Disease"], [59, 59, "Disease"], [85, 85, "Disease"], [107, 109, "Disease"], [150, 150, "Chemical"]]], "relations": [[[1, 1, 6, 6, "CID"], [15, 15, 6, 6, "CID"], [34, 34, 6, 6, "CID"], [127, 127, 6, 6, "CID"], [143, 143, 6, 6, "CID"], [168, 168, 6, 6, "CID"], [174, 174, 6, 6, "CID"], [3, 3, 6, 6, "CID"], [17, 17, 6, 6, "CID"], [53, 53, 6, 6, "CID"], [66, 66, 6, 6, "CID"], [129, 129, 6, 6, "CID"], [165, 165, 6, 6, "CID"]]], "clusters": [], "translated": "<0>美托洛尔</0>-<8>特比萘芬</8>合用诱发<7>心动过缓</7>。报道一例<1>美托洛尔</1>和<9>特比萘芬</9>药物相互作用所致<14>窦性心动过缓</14>及其处理。一名63岁的白人男子服用<2>美托洛尔</2> 200毫克/天治疗稳定的<18>冠状动脉疾病</18>并被规定口服<10>特比萘芬</10> 250毫克/天90天疗程治疗<19>甲癣</19>。在<11>特比萘芬</11>治疗的第49天，他因全身健康状况下降、<20>意识模糊</20>和跌倒而被送往急诊室。心电图显示37次/分<15>窦性心动过缓</15>。Naranjo<21>药物不良反应</21>概率量表得分为7表明患者的<16>窦性心动过缓</16>与<3>美托洛尔</3>和<12>特比萘芬</12>药物相互作用可能存在关系。随着<4>美托洛尔</4>剂量的减少，心率首先得到改善。随后改为<22>比索洛尔</22>，心率保持正常。通过抑制细胞色素P450 2D6，<13>特比萘芬</13>降低了<5>美托洛尔</5>的清除率，导致<6>美托洛尔</6>积聚，从而导致具有临床意义的 <17>窦性心动过缓</17>。", "revised": true}
{"doc_key": "24812279", "sentences": [["P53", "inhibition", "exacerbates", "late", "-", "stage", "anthracycline", "cardiotoxicity", ".", "AIMS", ":", "Doxorubicin", "(", "DOX", ")", "is", "an", "effective", "anti", "-", "cancer", "therapeutic", ",", "but", "is", "associated", "with", "both", "acute", "and", "late", "-", "stage", "cardiotoxicity", ".", "Children", "are", "particularly", "sensitive", "to", "DOX", "-", "induced", "heart", "failure", ".", "Here", ",", "the", "impact", "of", "p53", "inhibition", "on", "acute", "vs", ".", "late", "-", "stage", "DOX", "cardiotoxicity", "was", "examined", "in", "a", "juvenile", "model", ".", "METHODS", "AND", "RESULTS", ":", "Two", "-", "week", "-", "old", "MHC", "-", "CB7", "mice", "(", "which", "express", "dominant", "-", "interfering", "p53", "in", "cardiomyocytes", ")", "and", "their", "non", "-", "transgenic", "(", "NON", "-", "TXG", ")", "littermates", "received", "weekly", "DOX", "injections", "for", "5", "weeks", "(", "25", "mg", "/", "kg", "cumulative", "dose", ")", ".", "One", "week", "after", "the", "last", "DOX", "treatment", "(", "acute", "stage", ")", ",", "MHC", "-", "CB7", "mice", "exhibited", "improved", "cardiac", "function", "and", "lower", "levels", "of", "cardiomyocyte", "apoptosis", "when", "compared", "with", "the", "NON", "-", "TXG", "mice", ".", "Surprisingly", ",", "by", "13", "weeks", "following", "the", "last", "DOX", "treatment", "(", "late", "stage", ")", ",", "MHC", "-", "CB7", "exhibited", "a", "progressive", "decrease", "in", "cardiac", "function", "and", "higher", "rates", "of", "cardiomyocyte", "apoptosis", "when", "compared", "with", "NON", "-", "TXG", "mice", ".", "p53", "inhibition", "blocked", "transient", "DOX", "-", "induced", "STAT3", "activation", "in", "MHC", "-", "CB7", "mice", ",", "which", "was", "associated", "with", "enhanced", "induction", "of", "the", "DNA", "repair", "proteins", "Ku70", "and", "Ku80", ".", "Mice", "with", "cardiomyocyte", "-", "restricted", "deletion", "of", "STAT3", "exhibited", "worse", "cardiac", "function", ",", "higher", "levels", "of", "cardiomyocyte", "apoptosis", ",", "and", "a", "greater", "induction", "of", "Ku70", "and", "Ku80", "in", "response", "to", "DOX", "treatment", "during", "the", "acute", "stage", "when", "compared", "with", "control", "animals", ".", "CONCLUSION", ":", "These", "data", "support", "a", "model", "wherein", "a", "p53", "-", "dependent", "cardioprotective", "pathway", ",", "mediated", "via", "STAT3", "activation", ",", "mitigates", "DOX", "-", "induced", "myocardial", "stress", "during", "drug", "delivery", ".", "Furthermore", ",", "these", "data", "suggest", "an", "explanation", "as", "to", "how", "p53", "inhibition", "can", "result", "in", "cardioprotection", "during", "drug", "treatment", "and", ",", "paradoxically", ",", "enhanced", "cardiotoxicity", "long", "after", "the", "cessation", "of", "drug", "treatment", "."]], "ner": [[[11, 11, "Chemical"], [13, 13, "Chemical"], [40, 40, "Chemical"], [60, 60, "Chemical"], [105, 105, "Chemical"], [124, 124, "Chemical"], [162, 162, "Chemical"], [197, 197, "Chemical"], [253, 253, "Chemical"], [286, 286, "Chemical"], [43, 44, "Disease"], [6, 6, "Chemical"], [7, 7, "Disease"], [33, 33, "Disease"], [61, 61, "Disease"], [319, 319, "Disease"], [20, 20, "Disease"]]], "relations": [[[11, 11, 43, 44, "CID"], [13, 13, 43, 44, "CID"], [40, 40, 43, 44, "CID"], [60, 60, 43, 44, "CID"], [105, 105, 43, 44, "CID"], [124, 124, 43, 44, "CID"], [162, 162, 43, 44, "CID"], [197, 197, 43, 44, "CID"], [253, 253, 43, 44, "CID"], [286, 286, 43, 44, "CID"]]], "clusters": [], "translated": "P53 抑制加剧晚期<11>蒽环类药物</11><12>心脏毒性</12>。目的：<0>阿霉素</0>（<1>DOX</1>）是一种有效的抗<16>癌症</16>治疗剂，但与急性和晚期<13>心脏毒性</13>有关。儿童对<2>DOX</2>诱发的<10>心力衰竭</10>特别敏感。在这里，p53抑制对急性vs.晚期<3>DOX</3><14>心脏毒性</14>的影响在青少年模型中进行了检查。方法和结果：两周大的MHC-CB7小鼠（在心肌细胞中表达显性干扰性p53）和它们的非转基因(NON-TXG)同窝小鼠每周接受<4>DOX</4>注射，持续5周(25mg/kg累积剂量)。最后一次<5>DOX</5>治疗(急性期)一周后，MHC-CB7小鼠表现出改善的心脏功能和较低水平的心肌细胞凋亡，与NON-TXG小鼠相比。令人惊讶的是，在最后一次<6>DOX</6>治疗(晚期)后13周，MHC-CB7表现出心脏功能进行性下降和心肌细胞凋亡率更高，与非TXG小鼠相比。p53抑制阻断了MHC-CB7小鼠中瞬时<7>DOX</7>诱导的STAT3激活，这与DNA修复蛋白Ku70和Ku80的诱导增强有关。具有心肌细胞限制性STAT3缺失的小鼠与对照动物相比，在急性期表现出更差的心脏功能、更高水平的心肌细胞凋亡以及更大的Ku70和Ku80诱导以响应<8>DOX</8>处理。结论：这些数据支持一种模型，其中通过STAT 3激活介导的p53依赖性心脏保护途径减轻药物输送过程中<9>DOX</9>诱导的心肌应激。此外，这些数据还解释了p53抑制如何在药物治疗期间产生心脏保护作用，并且矛盾的是，在药物治疗停止后很长一段时间内<15>心脏毒性</15>增强。", "revised": true}
{"doc_key": "24840785", "sentences": [["Aconitine", "-", "induced", "Ca2", "+", "overload", "causes", "arrhythmia", "and", "triggers", "apoptosis", "through", "p38", "MAPK", "signaling", "pathway", "in", "rats", ".", "Aconitine", "is", "a", "major", "bioactive", "diterpenoid", "alkaloid", "with", "high", "content", "derived", "from", "herbal", "aconitum", "plants", ".", "Emerging", "evidence", "indicates", "that", "voltage", "-", "dependent", "Na", "(", "+", ")", "channels", "have", "pivotal", "roles", "in", "the", "cardiotoxicity", "of", "aconitine", ".", "However", ",", "no", "reports", "are", "available", "on", "the", "role", "of", "Ca", "(", "2", "+", ")", "in", "aconitine", "poisoning", ".", "In", "this", "study", ",", "we", "explored", "the", "importance", "of", "pathological", "Ca", "(", "2", "+", ")", "signaling", "in", "aconitine", "poisoning", "in", "vitro", "and", "in", "vivo", ".", "We", "found", "that", "Ca", "(", "2", "+", ")", "overload", "lead", "to", "accelerated", "beating", "rhythm", "in", "adult", "rat", "ventricular", "myocytes", "and", "caused", "arrhythmia", "in", "conscious", "freely", "moving", "rats", ".", "To", "investigate", "effects", "of", "aconitine", "on", "myocardial", "injury", ",", "we", "performed", "cytotoxicity", "assay", "in", "neonatal", "rat", "ventricular", "myocytes", "(", "NRVMs", ")", ",", "as", "well", "as", "measured", "lactate", "dehydrogenase", "level", "in", "the", "culture", "medium", "of", "NRVMs", "and", "activities", "of", "serum", "cardiac", "enzymes", "in", "rats", ".", "The", "results", "showed", "that", "aconitine", "resulted", "in", "myocardial", "injury", "and", "reduced", "NRVMs", "viability", "dose", "-", "dependently", ".", "To", "confirm", "the", "pro", "-", "apoptotic", "effects", ",", "we", "performed", "flow", "cytometric", "detection", ",", "cardiac", "histology", ",", "transmission", "electron", "microscopy", "and", "terminal", "deoxynucleotidyl", "transferase", "-", "mediated", "dUTP", "-", "biotin", "nick", "end", "labeling", "assay", ".", "The", "results", "showed", "that", "aconitine", "stimulated", "apoptosis", "time", "-", "dependently", ".", "The", "expression", "analysis", "of", "Ca", "(", "2", "+", ")", "handling", "proteins", "demonstrated", "that", "aconitine", "promoted", "Ca", "(", "2", "+", ")", "overload", "through", "the", "expression", "regulation", "of", "Ca", "(", "2", "+", ")", "handling", "proteins", ".", "The", "expression", "analysis", "of", "apoptosis", "-", "related", "proteins", "revealed", "that", "pro", "-", "apoptotic", "protein", "expression", "was", "upregulated", ",", "and", "anti", "-", "apoptotic", "protein", "BCL", "-", "2", "expression", "was", "downregulated", ".", "Furthermore", ",", "increased", "phosphorylation", "of", "MAPK", "family", "members", ",", "especially", "the", "P", "-", "P38", "/", "P38", "ratio", "was", "found", "in", "cardiac", "tissues", ".", "Hence", ",", "our", "results", "suggest", "that", "aconitine", "significantly", "aggravates", "Ca", "(", "2", "+", ")", "overload", "and", "causes", "arrhythmia", "and", "finally", "promotes", "apoptotic", "development", "via", "phosphorylation", "of", "P38", "mitogen", "-", "activated", "protein", "kinase", "."]], "ner": [[[0, 0, "Chemical"], [19, 19, "Chemical"], [54, 54, "Chemical"], [72, 72, "Chemical"], [92, 92, "Chemical"], [132, 132, "Chemical"], [176, 176, "Chemical"], [227, 227, "Chemical"], [247, 247, "Chemical"], [327, 327, "Chemical"], [7, 7, "Disease"], [121, 121, "Disease"], [338, 338, "Disease"], [52, 52, "Disease"], [73, 73, "Disease"], [93, 93, "Disease"], [134, 135, "Disease"], [179, 180, "Disease"], [139, 139, "Disease"], [3, 3, "Chemical"], [66, 66, "Chemical"], [85, 85, "Chemical"], [103, 103, "Chemical"], [238, 238, "Chemical"], [249, 249, "Chemical"], [260, 260, "Chemical"], [330, 330, "Chemical"], [42, 42, "Chemical"], [154, 154, "Chemical"], [217, 217, "Chemical"]]], "relations": [[[0, 0, 7, 7, "CID"], [0, 0, 121, 121, "CID"], [0, 0, 338, 338, "CID"], [19, 19, 7, 7, "CID"], [19, 19, 121, 121, "CID"], [19, 19, 338, 338, "CID"], [54, 54, 7, 7, "CID"], [54, 54, 121, 121, "CID"], [54, 54, 338, 338, "CID"], [72, 72, 7, 7, "CID"], [72, 72, 121, 121, "CID"], [72, 72, 338, 338, "CID"], [92, 92, 7, 7, "CID"], [92, 92, 121, 121, "CID"], [92, 92, 338, 338, "CID"], [132, 132, 7, 7, "CID"], [132, 132, 121, 121, "CID"], [132, 132, 338, 338, "CID"], [176, 176, 7, 7, "CID"], [176, 176, 121, 121, "CID"], [176, 176, 338, 338, "CID"], [227, 227, 7, 7, "CID"], [227, 227, 121, 121, "CID"], [227, 227, 338, 338, "CID"], [247, 247, 7, 7, "CID"], [247, 247, 121, 121, "CID"], [247, 247, 338, 338, "CID"], [327, 327, 7, 7, "CID"], [327, 327, 121, 121, "CID"], [327, 327, 338, 338, "CID"], [0, 0, 52, 52, "CID"], [19, 19, 52, 52, "CID"], [54, 54, 52, 52, "CID"], [72, 72, 52, 52, "CID"], [92, 92, 52, 52, "CID"], [132, 132, 52, 52, "CID"], [176, 176, 52, 52, "CID"], [227, 227, 52, 52, "CID"], [247, 247, 52, 52, "CID"], [327, 327, 52, 52, "CID"], [0, 0, 73, 73, "CID"], [0, 0, 93, 93, "CID"], [19, 19, 73, 73, "CID"], [19, 19, 93, 93, "CID"], [54, 54, 73, 73, "CID"], [54, 54, 93, 93, "CID"], [72, 72, 73, 73, "CID"], [72, 72, 93, 93, "CID"], [92, 92, 73, 73, "CID"], [92, 92, 93, 93, "CID"], [132, 132, 73, 73, "CID"], [132, 132, 93, 93, "CID"], [176, 176, 73, 73, "CID"], [176, 176, 93, 93, "CID"], [227, 227, 73, 73, "CID"], [227, 227, 93, 93, "CID"], [247, 247, 73, 73, "CID"], [247, 247, 93, 93, "CID"], [327, 327, 73, 73, "CID"], [327, 327, 93, 93, "CID"]]], "clusters": [], "translated": "<0>乌头碱</0> -诱导的<19>Ca2</19>+超载引起<10>心律失常</10>和通过p38 MAPK信号通路触发大鼠细胞凋亡。 <1>乌头碱</1>是一种主要的生物活性二萜类生物碱，含量高，来源于草本植物乌头。新出现的证据表明，电压依赖性<27>Na</27>(+ )通道在 <2>乌头碱</2> 的<13>心脏毒性</13>中具有关键作用。但目前尚无关于<20>Ca</20>(2+)在<3>乌头碱</3><14>中毒</14>中作用的报道。在本研究中，我们探讨了病理性<21>Ca</21>(2+)信号通路在体外和体内<4>乌头碱</4><15>中毒</15>中的重要性。我们发现<22>Ca</22>(2+)超载导致成年大鼠心室肌细胞跳动节律加快，并引起有意识的自由活动大鼠<11>心律失常</11>。为了研究<5>乌头碱</5>对<16>心肌损伤</16>的影响，我们在新生大鼠心室肌细胞（NRVMs）中进行了<18>细胞毒性</18>试验，并测量了 NRVMs培养基中<28>乳酸脱氢酶</28>水平以及大鼠血清心肌酶的活性。结果表明，<6>乌头碱</6>导致<17>心肌损伤</17>，并呈剂量依赖性降低 NRVMs 活力。为证实其促凋亡作用，我们进行了流式细胞仪检测、心脏组织学，透射电镜以及末端脱氧核苷酸转移酶介导的dUTP-<29>生物素</29>缺口末端标记实验。结果表明，<7>乌头碱</7>时间依赖性地刺激细胞凋亡。 <23> Ca </23> (2+) 处理蛋白的表达分析表明，<8>乌头碱</8>通过<25>Ca</25>(2+)处理蛋白质的调节促进了<24>Ca</24>(2+)过载。凋亡相关蛋白表达分析显示表达促凋亡蛋白上调，抗凋亡蛋白BCL-2表达下调。此外，在心脏组织中发现 MAPK 家族成员的磷酸化增加，尤其是 P-P38/P38 比率。因此，我们的结果表明，<9>乌头碱</9>显著加重<26>Ca</26>(2+)超载并导致<12>心律失常</12>，最终通过P38 MAPK信号通路促进细胞凋亡的发展。", "revised": true}
{"doc_key": "24802403", "sentences": [["Metformin", "protects", "against", "seizures", ",", "learning", "and", "memory", "impairments", "and", "oxidative", "damage", "induced", "by", "pentylenetetrazole", "-", "induced", "kindling", "in", "mice", ".", "Cognitive", "impairment", ",", "the", "most", "common", "and", "severe", "comorbidity", "of", "epilepsy", ",", "greatly", "diminishes", "the", "quality", "of", "life", ".", "However", ",", "current", "therapeutic", "interventions", "for", "epilepsy", "can", "also", "cause", "untoward", "cognitive", "effects", ".", "Thus", ",", "there", "is", "an", "urgent", "need", "for", "new", "kinds", "of", "agents", "targeting", "both", "seizures", "and", "cognition", "deficits", ".", "Oxidative", "stress", "is", "considered", "to", "play", "an", "important", "role", "in", "epileptogenesis", "and", "cognitive", "deficits", ",", "and", "antioxidants", "have", "a", "putative", "antiepileptic", "potential", ".", "Metformin", ",", "the", "most", "commonly", "prescribed", "antidiabetic", "oral", "drug", ",", "has", "antioxidant", "properties", ".", "This", "study", "was", "designed", "to", "evaluate", "the", "ameliorative", "effects", "of", "metformin", "on", "seizures", ",", "cognitive", "impairment", "and", "brain", "oxidative", "stress", "markers", "observed", "in", "pentylenetetrazole", "-", "induced", "kindling", "animals", ".", "Male", "C57BL", "/", "6", "mice", "were", "administered", "with", "subconvulsive", "dose", "of", "pentylenetetrazole", "(", "37", "mg", "/", "kg", ",", "i", ".", "p", ".", ")", "every", "other", "day", "for", "14", "injections", ".", "Metformin", "was", "injected", "intraperitoneally", "in", "dose", "of", "200mg", "/", "kg", "along", "with", "alternate", "-", "day", "PTZ", ".", "We", "found", "that", "metformin", "suppressed", "the", "progression", "of", "kindling", ",", "ameliorated", "the", "cognitive", "impairment", "and", "decreased", "brain", "oxidative", "stress", ".", "Thus", "the", "present", "study", "concluded", "that", "metformin", "may", "be", "a", "potential", "agent", "for", "the", "treatment", "of", "epilepsy", "as", "well", "as", "a", "protective", "medicine", "against", "cognitive", "impairment", "induced", "by", "seizures", "."]], "ner": [[[14, 14, "Chemical"], [133, 133, "Chemical"], [150, 150, "Chemical"], [184, 184, "Chemical"], [3, 3, "Disease"], [68, 68, "Disease"], [122, 122, "Disease"], [234, 234, "Disease"], [5, 8, "Disease"], [21, 22, "Disease"], [70, 71, "Disease"], [85, 86, "Disease"], [124, 125, "Disease"], [198, 199, "Disease"], [230, 231, "Disease"], [0, 0, "Chemical"], [96, 96, "Chemical"], [120, 120, "Chemical"], [169, 169, "Chemical"], [189, 189, "Chemical"], [212, 212, "Chemical"], [31, 31, "Disease"], [46, 46, "Disease"], [222, 222, "Disease"]]], "relations": [[[14, 14, 3, 3, "CID"], [14, 14, 68, 68, "CID"], [14, 14, 122, 122, "CID"], [14, 14, 234, 234, "CID"], [133, 133, 3, 3, "CID"], [133, 133, 68, 68, "CID"], [133, 133, 122, 122, "CID"], [133, 133, 234, 234, "CID"], [150, 150, 3, 3, "CID"], [150, 150, 68, 68, "CID"], [150, 150, 122, 122, "CID"], [150, 150, 234, 234, "CID"], [184, 184, 3, 3, "CID"], [184, 184, 68, 68, "CID"], [184, 184, 122, 122, "CID"], [184, 184, 234, 234, "CID"], [14, 14, 5, 8, "CID"], [133, 133, 5, 8, "CID"], [150, 150, 5, 8, "CID"], [184, 184, 5, 8, "CID"], [14, 14, 21, 22, "CID"], [14, 14, 70, 71, "CID"], [14, 14, 85, 86, "CID"], [14, 14, 124, 125, "CID"], [14, 14, 198, 199, "CID"], [14, 14, 230, 231, "CID"], [133, 133, 21, 22, "CID"], [133, 133, 70, 71, "CID"], [133, 133, 85, 86, "CID"], [133, 133, 124, 125, "CID"], [133, 133, 198, 199, "CID"], [133, 133, 230, 231, "CID"], [150, 150, 21, 22, "CID"], [150, 150, 70, 71, "CID"], [150, 150, 85, 86, "CID"], [150, 150, 124, 125, "CID"], [150, 150, 198, 199, "CID"], [150, 150, 230, 231, "CID"], [184, 184, 21, 22, "CID"], [184, 184, 70, 71, "CID"], [184, 184, 85, 86, "CID"], [184, 184, 124, 125, "CID"], [184, 184, 198, 199, "CID"], [184, 184, 230, 231, "CID"]]], "clusters": [], "translated": "<15>二甲双胍</15>防止<4>癫痫发作</4>、<8>学习和记忆障碍</8>以及由<0>戊四唑</0>诱导的小鼠点燃引起的氧化损伤。<9>认知障碍</9>是<21>癫痫</21>最常见和最严重的合并症，大大降低了生活质量。然而，目前针对<22>癫痫</22>的治疗干预也会导致不良的认知影响。因此，迫切需要针对<5>癫痫发作</5>和<10>认知缺陷</10>的新型药物。氧化应激被认为在癫痫发生和<11>认知缺陷</11>中发挥重要作用，并且抗氧化剂具有公认的抗癫痫潜力。<16>二甲双胍</16>是最常用的抗糖尿病口服药物，具有抗氧化特性。本研究旨在评估<17>二甲双胍</17>对<6>癫痫发作</6>、<12>认知障碍</12>和在<1>戊四唑</1>诱导点燃动物中观察到的脑氧化应激标志物的改善作用。雄性C57BL/6小鼠隔日给予亚惊厥剂量的<2>戊四唑</2>(37 mg/kg，i.p.)，共注射14次。<18>二甲双胍</18>以200mg/kg的剂量腹腔注射，同时隔日<3>戊四唑</3>。我们发现<19>二甲双胍</19>抑制了点燃的进程，改善了<13>认知障碍</13>并降低了脑氧化应激。因此，本研究得出结论，<20>二甲双胍</20>可能是治疗<23>癫痫</23>的潜在药物，也是预防由<7>癫痫发作</7>引起的<14>认知障碍</14>的药物。", "revised": true}
{"doc_key": "24535067", "sentences": [["Prevention", "of", "etomidate", "-", "induced", "myoclonus", ":", "which", "is", "superior", ":", "Fentanyl", ",", "midazolam", ",", "or", "a", "combination", "?", "A", "Retrospective", "comparative", "study", ".", "BACKGROUND", ":", "In", "this", "retrospective", "comparative", "study", ",", "we", "aimed", "to", "compare", "the", "effectiveness", "of", "fentanyl", ",", "midazolam", ",", "and", "a", "combination", "of", "fentanyl", "and", "midazolam", "to", "prevent", "etomidate", "-", "induced", "myoclonus", ".", "MATERIAL", "AND", "METHODS", ":", "This", "study", "was", "performed", "based", "on", "anesthesia", "records", ".", "Depending", "on", "the", "drugs", "that", "would", "be", "given", "before", "the", "induction", "of", "anesthesia", "with", "etomidate", ",", "the", "patients", "were", "separated", "into", "4", "groups", ":", "no", "pretreatment", "(", "Group", "NP", ")", ",", "fentanyl", "1", "ug", ".", "kg", "-", "1", "(", "Group", "F", ")", ",", "midazolam", "0", ".", "03", "mg", ".", "kg", "-", "1", "(", "Group", "M", ")", ",", "and", "midazolam", "0", ".", "015", "mg", ".", "kg", "-", "1", "+", "fentanyl", "0", ".", "5", "ug", ".", "kg", "-", "1", "(", "Group", "FM", ")", ".", "Patients", "who", "received", "the", "same", "anesthetic", "procedure", "were", "selected", ":", "2", "minutes", "after", "intravenous", "injections", "of", "the", "pretreatment", "drugs", ",", "anesthesia", "is", "induced", "with", "0", ".", "3", "mg", ".", "kg", "-", "1", "etomidate", "injected", "intravenously", "over", "a", "period", "of", "20", "-", "30", "seconds", ".", "Myoclonic", "movements", "are", "evaluated", ",", "which", "were", "observed", "and", "graded", "according", "to", "clinical", "severity", "during", "the", "2", "minutes", "after", "etomidate", "injection", ".", "The", "severity", "of", "pain", "due", "to", "etomidate", "injection", ",", "mean", "arterial", "pressure", ",", "heart", "rate", ",", "and", "adverse", "effects", "were", "also", "evaluated", ".", "RESULTS", ":", "Study", "results", "showed", "that", "myoclonus", "incidence", "was", "85", "%", ",", "40", "%", ",", "70", "%", ",", "and", "25", "%", "in", "Group", "NP", ",", "Group", "F", ",", "Group", "M", ",", "and", "Group", "FM", ",", "respectively", ",", "and", "were", "significantly", "lower", "in", "Group", "F", "and", "Group", "FM", ".", "CONCLUSIONS", ":", "We", "conclude", "that", "pretreatment", "with", "fentanyl", "or", "combination", "of", "fentanyl", "and", "midazolam", "was", "effective", "in", "preventing", "etomidate", "-", "induced", "myoclonus", "."]], "ner": [[[2, 2, "Chemical"], [52, 52, "Chemical"], [84, 84, "Chemical"], [184, 184, "Chemical"], [215, 215, "Chemical"], [224, 224, "Chemical"], [307, 307, "Chemical"], [5, 5, "Disease"], [55, 55, "Disease"], [247, 247, "Disease"], [310, 310, "Disease"], [196, 197, "Disease"], [221, 221, "Disease"], [11, 11, "Chemical"], [39, 39, "Chemical"], [47, 47, "Chemical"], [101, 101, "Chemical"], [138, 138, "Chemical"], [296, 296, "Chemical"], [300, 300, "Chemical"], [13, 13, "Chemical"], [41, 41, "Chemical"], [49, 49, "Chemical"], [113, 113, "Chemical"], [128, 128, "Chemical"], [302, 302, "Chemical"]]], "relations": [[[2, 2, 5, 5, "CID"], [2, 2, 55, 55, "CID"], [2, 2, 247, 247, "CID"], [2, 2, 310, 310, "CID"], [52, 52, 5, 5, "CID"], [52, 52, 55, 55, "CID"], [52, 52, 247, 247, "CID"], [52, 52, 310, 310, "CID"], [84, 84, 5, 5, "CID"], [84, 84, 55, 55, "CID"], [84, 84, 247, 247, "CID"], [84, 84, 310, 310, "CID"], [184, 184, 5, 5, "CID"], [184, 184, 55, 55, "CID"], [184, 184, 247, 247, "CID"], [184, 184, 310, 310, "CID"], [215, 215, 5, 5, "CID"], [215, 215, 55, 55, "CID"], [215, 215, 247, 247, "CID"], [215, 215, 310, 310, "CID"], [224, 224, 5, 5, "CID"], [224, 224, 55, 55, "CID"], [224, 224, 247, 247, "CID"], [224, 224, 310, 310, "CID"], [307, 307, 5, 5, "CID"], [307, 307, 55, 55, "CID"], [307, 307, 247, 247, "CID"], [307, 307, 310, 310, "CID"]]], "clusters": [], "translated": "预防<0>依托咪酯</0>引起的<7>肌阵挛</7>:<13>芬太尼</13>、<20>咪达唑仑</20>或联合用药哪个更好？一项回顾性比较研究。背景：在这项回顾性比较研究中，我们旨在比较<14>芬太尼</14>、<21>咪达唑仑</21>以及<15>芬太尼</15>和<22>咪达唑仑联合用药的有效性</22>，预防<1>依托咪酯</1>诱发的<8>肌阵挛</8>。材料和方法：这项研究是根据麻醉记录进行的。根据<2>依托咪酯</2>麻醉诱导前给予的药物，患者分为4组：无预处理（Group NP），<16>芬太尼</16>1ug/kg-1 (Group F)，<23>咪达唑仑</23>0.03mg/kg-1 (Group M)，和<24>咪达唑仑</24>0.015mg/kg-1+<17>芬太尼</17>0.5ug/kg-1 (Group FM)。选择接受相同麻醉程序的患者：静脉注射预处理药物后2分钟，以0.3mg/kg-1<3>依托咪酯</3>静脉内注射20-30秒。<11>评估肌阵挛运动</11>，在注射<4>依托咪酯</4>后的2分钟内根据临床严重程度观察并分级。还评估了<5>依托咪酯</5>注射引起的<12>疼痛</12>的严重程度、平均动脉压、心率和不良反应。结果：研究结果显示，<9>肌阵挛</9>发生率在Group NP、Group F、Group M、Group FM分别为85%、40%、70%、25%，显着低于对照组F和Group FM。结论：我们得出结论，<18>芬太尼</18>或联合用药<19>芬太尼</19>和<25>咪达唑仑</25>可有效预防<6>依托咪酯</6>诱导的<10>肌阵挛</10>。", "revised": true}
{"doc_key": "24220752", "sentences": [["Incidence", "of", "contrast", "-", "induced", "nephropathy", "in", "hospitalised", "patients", "with", "cancer", ".", "OBJECTIVES", ":", "To", "determine", "the", "frequency", "of", "and", "possible", "factors", "related", "to", "contrast", "-", "induced", "nephropathy", "(", "CIN", ")", "in", "hospitalised", "patients", "with", "cancer", ".", "METHODS", ":", "Ninety", "adult", "patients", "were", "enrolled", ".", "Patients", "with", "risk", "factors", "for", "acute", "renal", "failure", "were", "excluded", ".", "Blood", "samples", "were", "examined", "the", "day", "before", "contrast", "-", "enhanced", "computed", "tomography", "(", "CT", ")", "and", "serially", "for", "3", "days", "thereafter", ".", "CIN", "was", "defined", "as", "an", "increase", "in", "serum", "creatinine", "(", "Cr", ")", "of", "0", ".", "5", "mg", "/", "dl", "or", "more", ",", "or", "elevation", "of", "Cr", "to", "25", "%", "over", "baseline", ".", "Relationships", "between", "CIN", "and", "possible", "risk", "factors", "were", "investigated", ".", "RESULTS", ":", "CIN", "was", "detected", "in", "18", "/", "90", "(", "20", "%", ")", "patients", ".", "CIN", "developed", "in", "25", ".", "5", "%", "patients", "who", "underwent", "chemotherapy", "and", "in", "11", "%", "patients", "who", "did", "not", "(", "P", "=", "0", ".", "1", ")", ".", "CIN", "more", "frequently", "developed", "in", "patients", "who", "had", "undergone", "CT", "within", "45", "days", "after", "the", "last", "chemotherapy", "(", "P", "=", "0", ".", "005", ")", ";", "it", "was", "also", "an", "independent", "risk", "factor", "(", "P", "=", "0", ".", "017", ")", ".", "CIN", "was", "significantly", "more", "after", "treatment", "with", "bevacizumab", "/", "irinotecan", "(", "P", "=", "0", ".", "021", ")", "and", "in", "patients", "with", "hypertension", "(", "P", "=", "0", ".", "044", ")", ".", "CONCLUSIONS", ":", "The", "incidence", "of", "CIN", "after", "CT", "in", "hospitalised", "oncological", "patients", "was", "20", "%", ".", "CIN", "developed", "4", ".", "5", "-", "times", "more", "frequently", "in", "patients", "with", "cancer", "who", "had", "undergone", "recent", "chemotherapy", ".", "Hypertension", "and", "the", "combination", "of", "bevacizumab", "/", "irinotecan", "may", "be", "additional", "risk", "factors", "for", "CIN", "development", ".", "KEY", "POINTS", ":", ".", "Contrast", "-", "induced", "nephropathy", "(", "CIN", ")", "is", "a", "concern", "for", "oncological", "patients", "undergoing", "CT", ".", ".", "CIN", "occurs", "more", "often", "when", "CT", "is", "performed", "<", "45", "days", "after", "chemotherapy", ".", ".", "Hypertension", "and", "treatment", "with", "bevacizumab", "appear", "to", "be", "additional", "risk", "factors", "."]], "ner": [[[2, 2, "Chemical"], [24, 24, "Chemical"], [63, 63, "Chemical"], [288, 288, "Chemical"], [5, 5, "Disease"], [27, 27, "Disease"], [291, 291, "Disease"], [211, 211, "Chemical"], [274, 274, "Chemical"], [10, 10, "Disease"], [35, 35, "Disease"], [260, 260, "Disease"], [50, 52, "Disease"], [223, 223, "Disease"], [267, 267, "Disease"], [320, 320, "Disease"], [86, 86, "Chemical"], [88, 88, "Chemical"], [103, 103, "Chemical"]]], "relations": [[[2, 2, 5, 5, "CID"], [2, 2, 27, 27, "CID"], [2, 2, 291, 291, "CID"], [24, 24, 5, 5, "CID"], [24, 24, 27, 27, "CID"], [24, 24, 291, 291, "CID"], [63, 63, 5, 5, "CID"], [63, 63, 27, 27, "CID"], [63, 63, 291, 291, "CID"], [288, 288, 5, 5, "CID"], [288, 288, 27, 27, "CID"], [288, 288, 291, 291, "CID"], [211, 211, 5, 5, "CID"], [211, 211, 27, 27, "CID"], [211, 211, 291, 291, "CID"], [274, 274, 5, 5, "CID"], [274, 274, 27, 27, "CID"], [274, 274, 291, 291, "CID"]]], "clusters": [], "translated": "<9>癌症</9>住院患者<0>造影剂</0>诱发的<4>肾病</4>发生率。目的：确定因<10>癌症</10>住院的患者<1>造影剂</1>诱发的<5>CIN</5>的发生率和可能的相关因素。方法：纳入了90名成年患者。排除有<12>急性肾功能衰竭</12>危险因素的患者。在<2>造影剂</2>增强型计算机断层扫描（CT）前一天检查血样，并在之后连续检查3天。CIN定义为血清<16>肌酐</16>（<17>Cr</17>）增加0.5mg/dl或更多，或<18>Cr</18>高于基线25%。调查了CIN与可能的危险因素之间的关系。结果：CIN在18/90（20%）患者中检出。 CIN发生于25.5%接受过化疗的患者和11%未接受化疗的患者（P=0.1）。在最后一次化疗后45天内接受过CT的患者更容易发生CIN（P=0.005）；它也是一个独立的危险因素（P=0.017）。贝伐珠单抗/<7>伊立替康</7>治疗后（P=0.021）和<13>高血压</13>患者（P=0.044），CIN明显增多。结论：住院肿瘤患者CT后CIN的发生率为20%。化疗后45天内接受CT的<11>癌症</11>患者中CIN发生频率高出4.5倍。<14>高血压</14>和贝伐珠单抗/<8>伊立替康</8>的组合可能是CIN发展的额外危险因素。关键点：1.<3>造影剂</3>诱发的<6>CIN</6>是接受CT的肿瘤患者关注的问题。2.当在化疗后45天以内进行CT时，CIN更常发生。3.<15>高血压</15>和贝伐珠单抗治疗似乎是额外的危险因素。", "revised": true}
{"doc_key": "24727461", "sentences": [["Hydroxytyrosol", "ameliorates", "oxidative", "stress", "and", "mitochondrial", "dysfunction", "in", "doxorubicin", "-", "induced", "cardiotoxicity", "in", "rats", "with", "breast", "cancer", ".", "Oxidative", "stress", "is", "involved", "in", "several", "processes", "including", "cancer", ",", "aging", "and", "cardiovascular", "disease", ",", "and", "has", "been", "shown", "to", "potentiate", "the", "therapeutic", "effect", "of", "drugs", "such", "as", "doxorubicin", ".", "Doxorubicin", "causes", "significant", "cardiotoxicity", "characterized", "by", "marked", "increases", "in", "oxidative", "stress", "and", "mitochondrial", "dysfunction", ".", "Herein", ",", "we", "investigate", "whether", "doxorubicin", "-", "associated", "chronic", "cardiac", "toxicity", "can", "be", "ameliorated", "with", "the", "antioxidant", "hydroxytyrosol", "in", "rats", "with", "breast", "cancer", ".", "Thirty", "-", "six", "rats", "bearing", "breast", "tumors", "induced", "chemically", "were", "divided", "into", "4", "groups", ":", "control", ",", "hydroxytyrosol", "(", "0", ".", "5mg", "/", "kg", ",", "5days", "/", "week", ")", ",", "doxorubicin", "(", "1mg", "/", "kg", "/", "week", ")", ",", "and", "doxorubicin", "plus", "hydroxytyrosol", ".", "Cardiac", "disturbances", "at", "the", "cellular", "and", "mitochondrial", "level", ",", "mitochondrial", "electron", "transport", "chain", "complexes", "I", "-", "IV", "and", "apoptosis", "-", "inducing", "factor", ",", "and", "oxidative", "stress", "markers", "have", "been", "analyzed", ".", "Hydroxytyrosol", "improved", "the", "cardiac", "disturbances", "enhanced", "by", "doxorubicin", "by", "significantly", "reducing", "the", "percentage", "of", "altered", "mitochondria", "and", "oxidative", "damage", ".", "These", "results", "suggest", "that", "hydroxytyrosol", "improve", "the", "mitochondrial", "electron", "transport", "chain", ".", "This", "study", "demonstrates", "that", "hydroxytyrosol", "protect", "rat", "heart", "damage", "provoked", "by", "doxorubicin", "decreasing", "oxidative", "damage", "and", "mitochondrial", "alterations", "."]], "ner": [[[8, 8, "Chemical"], [46, 46, "Chemical"], [48, 48, "Chemical"], [68, 68, "Chemical"], [117, 117, "Chemical"], [127, 127, "Chemical"], [169, 169, "Chemical"], [205, 205, "Chemical"], [131, 132, "Disease"], [165, 166, "Disease"], [201, 202, "Disease"], [0, 0, "Chemical"], [80, 80, "Chemical"], [104, 104, "Chemical"], [129, 129, "Chemical"], [162, 162, "Chemical"], [186, 186, "Chemical"], [198, 198, "Chemical"], [5, 6, "Disease"], [60, 61, "Disease"], [11, 11, "Disease"], [51, 51, "Disease"], [72, 73, "Disease"], [15, 16, "Disease"], [84, 85, "Disease"], [92, 93, "Disease"], [26, 26, "Disease"], [30, 31, "Disease"]]], "relations": [[[8, 8, 131, 132, "CID"], [8, 8, 165, 166, "CID"], [8, 8, 201, 202, "CID"], [46, 46, 131, 132, "CID"], [46, 46, 165, 166, "CID"], [46, 46, 201, 202, "CID"], [48, 48, 131, 132, "CID"], [48, 48, 165, 166, "CID"], [48, 48, 201, 202, "CID"], [68, 68, 131, 132, "CID"], [68, 68, 165, 166, "CID"], [68, 68, 201, 202, "CID"], [117, 117, 131, 132, "CID"], [117, 117, 165, 166, "CID"], [117, 117, 201, 202, "CID"], [127, 127, 131, 132, "CID"], [127, 127, 165, 166, "CID"], [127, 127, 201, 202, "CID"], [169, 169, 131, 132, "CID"], [169, 169, 165, 166, "CID"], [169, 169, 201, 202, "CID"], [205, 205, 131, 132, "CID"], [205, 205, 165, 166, "CID"], [205, 205, 201, 202, "CID"]]], "clusters": [], "translated": "<11>羟基酪醇</11> 改善氧化应激和 <18>线粒体功能障碍</18> 在 <0>多柔比星</0> - 诱导的 <20>心脏毒性</20> 中的作用，以及大鼠携带 <23>乳腺癌</23>。氧化应激参与多个过程，包括 <26>癌症</26>、衰老和 <27>心血管疾病</27>，已经表明可以增强药物，例如 <1>阿霉素</1>的治疗效果。 <2>多柔比星</2>导致显着的 <21>心脏毒性</21>，其特征是显着增加氧化应激和 <19>线粒体功能障碍</19>。在此，我们研究了是否可以使用抗氧化剂 <12>羟基酪醇</12> 改善与 <3>多柔比星</3> 相关的慢性 <22>心脏毒性</22> 在携带 <24>乳腺癌</24> 的大鼠中。将 36 只荷载 <25>乳腺肿瘤</25> 的化学诱导大鼠分为 4 组: 对照组，<13>羟基酪醇</13>（0.5mg/kg，5天/周），<4>多柔比星</4>（1mg/kg/周）和 <5>多柔比星</5>加<14>羟基酪醇</14>。分析了细胞和线粒体水平、线粒体电子传递链复合物I-IV和细胞凋亡诱导因子以及氧化应激标志物的 <8>心脏障碍</8>。<15>羟基酪醇</15>通过显着降低 <6>多柔比星</6>增强的 <9>心脏紊乱</9> 中改变的线粒体和氧化损伤的百分比来改善这些结果表明，<16>羟基酪醇</16>可以改善线粒体电子传递链。该研究表明，<17>羟基酪醇</17>可以保护携带 <23>乳腺癌</23> 的大鼠免受由 <7>阿霉素</7> 引起的 <10>心脏损伤</10>，减少氧化损伤和线粒体变化。", "revised": true}
{"doc_key": "24902786", "sentences": [["Testosterone", "ameliorates", "streptozotocin", "-", "induced", "memory", "impairment", "in", "male", "rats", ".", "AIM", ":", "To", "study", "the", "effects", "of", "testosterone", "on", "streptozotocin", "(", "STZ", ")", "-", "induced", "memory", "impairment", "in", "male", "rats", ".", "METHODS", ":", "Adult", "male", "Wistar", "rats", "were", "intracerebroventricularly", "(", "icv", ")", "infused", "with", "STZ", "(", "750", "ug", ")", "on", "d", "1", "and", "d", "3", ",", "and", "a", "passive", "avoidance", "task", "was", "assessed", "2", "weeks", "after", "the", "first", "injection", "of", "STZ", ".", "Castration", "surgery", "was", "performed", "in", "another", "group", "of", "rats", ",", "and", "the", "passive", "avoidance", "task", "was", "assessed", "4", "weeks", "after", "the", "operation", ".", "Testosterone", "(", "1", "mg", ".", "kg", "(", "-", "1", ")", ".", "d", "(", "-", "1", ")", ",", "sc", ")", ",", "the", "androgen", "receptor", "antagonist", "flutamide", "(", "10", "mg", ".", "kg", "(", "-", "1", ")", ".", "d", "(", "-", "1", ")", ",", "ip", ")", ",", "the", "estrogen", "receptor", "antagonist", "tamoxifen", "(", "1", "mg", ".", "kg", "(", "-", "1", ")", ".", "d", "(", "-", "1", ")", ",", "ip", ")", "or", "the", "aromatase", "inhibitor", "letrozole", "(", "4", "mg", ".", "kg", "(", "-", "1", ")", ".", "d", "(", "-", "1", ")", ",", "ip", ")", "were", "administered", "for", "6", "d", "after", "the", "first", "injection", "of", "STZ", ".", "RESULTS", ":", "STZ", "administration", "and", "castration", "markedly", "decreased", "both", "STL1", "(", "the", "short", "memory", ")", "and", "STL2", "(", "the", "long", "memory", ")", "in", "passive", "avoidance", "tests", ".", "Testosterone", "replacement", "almost", "restored", "the", "STL1", "and", "STL2", "in", "castrated", "rats", ",", "and", "significantly", "prolonged", "the", "STL1", "and", "STL2", "in", "STZ", "-", "treated", "rats", ".", "Administration", "of", "flutamide", ",", "letrozole", "or", "tamoxifen", "significantly", "impaired", "the", "memory", "in", "intact", "rats", ",", "and", "significantly", "attenuated", "the", "testosterone", "replacement", "in", "improving", "STZ", "-", "and", "castration", "-", "induced", "memory", "impairment", ".", "CONCLUSION", ":", "Testosterone", "administration", "ameliorates", "STZ", "-", "and", "castration", "-", "induced", "memory", "impairment", "in", "male", "Wistar", "rats", "."]], "ner": [[[2, 2, "Chemical"], [20, 20, "Chemical"], [22, 22, "Chemical"], [45, 45, "Chemical"], [71, 71, "Chemical"], [196, 196, "Chemical"], [200, 200, "Chemical"], [245, 245, "Chemical"], [273, 273, "Chemical"], [287, 287, "Chemical"], [5, 6, "Disease"], [26, 27, "Disease"], [258, 260, "Disease"], [279, 280, "Disease"], [293, 294, "Disease"], [120, 120, "Chemical"], [252, 252, "Chemical"], [144, 144, "Chemical"], [256, 256, "Chemical"], [167, 167, "Chemical"], [254, 254, "Chemical"], [0, 0, "Chemical"], [18, 18, "Chemical"], [96, 96, "Chemical"], [225, 225, "Chemical"], [269, 269, "Chemical"], [284, 284, "Chemical"], [117, 117, "Chemical"], [141, 141, "Chemical"]]], "relations": [[[2, 2, 5, 6, "CID"], [2, 2, 26, 27, "CID"], [2, 2, 258, 260, "CID"], [2, 2, 279, 280, "CID"], [2, 2, 293, 294, "CID"], [20, 20, 5, 6, "CID"], [20, 20, 26, 27, "CID"], [20, 20, 258, 260, "CID"], [20, 20, 279, 280, "CID"], [20, 20, 293, 294, "CID"], [22, 22, 5, 6, "CID"], [22, 22, 26, 27, "CID"], [22, 22, 258, 260, "CID"], [22, 22, 279, 280, "CID"], [22, 22, 293, 294, "CID"], [45, 45, 5, 6, "CID"], [45, 45, 26, 27, "CID"], [45, 45, 258, 260, "CID"], [45, 45, 279, 280, "CID"], [45, 45, 293, 294, "CID"], [71, 71, 5, 6, "CID"], [71, 71, 26, 27, "CID"], [71, 71, 258, 260, "CID"], [71, 71, 279, 280, "CID"], [71, 71, 293, 294, "CID"], [196, 196, 5, 6, "CID"], [196, 196, 26, 27, "CID"], [196, 196, 258, 260, "CID"], [196, 196, 279, 280, "CID"], [196, 196, 293, 294, "CID"], [200, 200, 5, 6, "CID"], [200, 200, 26, 27, "CID"], [200, 200, 258, 260, "CID"], [200, 200, 279, 280, "CID"], [200, 200, 293, 294, "CID"], [245, 245, 5, 6, "CID"], [245, 245, 26, 27, "CID"], [245, 245, 258, 260, "CID"], [245, 245, 279, 280, "CID"], [245, 245, 293, 294, "CID"], [273, 273, 5, 6, "CID"], [273, 273, 26, 27, "CID"], [273, 273, 258, 260, "CID"], [273, 273, 279, 280, "CID"], [273, 273, 293, 294, "CID"], [287, 287, 5, 6, "CID"], [287, 287, 26, 27, "CID"], [287, 287, 258, 260, "CID"], [287, 287, 279, 280, "CID"], [287, 287, 293, 294, "CID"], [120, 120, 5, 6, "CID"], [120, 120, 26, 27, "CID"], [120, 120, 258, 260, "CID"], [120, 120, 279, 280, "CID"], [120, 120, 293, 294, "CID"], [252, 252, 5, 6, "CID"], [252, 252, 26, 27, "CID"], [252, 252, 258, 260, "CID"], [252, 252, 279, 280, "CID"], [252, 252, 293, 294, "CID"], [144, 144, 5, 6, "CID"], [144, 144, 26, 27, "CID"], [144, 144, 258, 260, "CID"], [144, 144, 279, 280, "CID"], [144, 144, 293, 294, "CID"], [256, 256, 5, 6, "CID"], [256, 256, 26, 27, "CID"], [256, 256, 258, 260, "CID"], [256, 256, 279, 280, "CID"], [256, 256, 293, 294, "CID"], [167, 167, 5, 6, "CID"], [167, 167, 26, 27, "CID"], [167, 167, 258, 260, "CID"], [167, 167, 279, 280, "CID"], [167, 167, 293, 294, "CID"], [254, 254, 5, 6, "CID"], [254, 254, 26, 27, "CID"], [254, 254, 258, 260, "CID"], [254, 254, 279, 280, "CID"], [254, 254, 293, 294, "CID"]]], "clusters": [], "translated": "<21>睾酮</21>改善<0>链脲佐菌素</0>诱导的<10>记忆障碍</10>雄性大鼠。目的：研究<22>睾酮</22>对<1>链脲佐菌素</1>（<2>STZ</2>）所致<11>记忆障碍</11>雄性大鼠的影响。方法：成年雄性Wistar大鼠在第1天和第3天脑室内(icv)输注<3>STZ</3>（750 ug），并在第一次注射<4>STZ</4>后2周评估被动回避任务。另一组大鼠行去势手术，术后4周评估被动回避任务。<23>睾酮</23>（1mg.kg(-1).d(-1),sc），<27>雄激素</27>受体拮抗剂<15>氟他胺</15>（10mg.kg(-1).d(-1),ip），<28>雌激素</28>受体拮抗剂<17>他莫昔芬</17>（1mg.kg(-1).d(-1),ip）或芳香化酶抑制剂<19>来曲唑</19>（4mg.kg(-1).d(-1),ip）在第一次注射<5>STZ</5>后给药6d。结果：<6>STZ</6>给药和去势显着降低了被动回避测试中的STL1（短记忆）和STL2（长记忆）。<24>睾酮</24>替代疗法几乎恢复了去势大鼠的STL1和STL2，并显着延长了<7>STZ</7>治疗大鼠的STL1和STL2。<16>氟他胺</16>、<20>来曲唑</20>或<18>他莫昔芬</18>显着<12>损害完整大鼠的记忆</12>，并显着减弱了<25>睾酮</25>替代改善<8>STZ</8>-和阉割引起的<13>记忆障碍</13>。结论：<26>睾酮</26>给药可改善雄性Wistar大鼠<9>STZ</9>和去势诱导的<14>记忆障碍</14>。", "revised": true}
{"doc_key": "24595967", "sentences": [["Dysfunctional", "overnight", "memory", "consolidation", "in", "ecstasy", "users", ".", "Sleep", "plays", "an", "important", "role", "in", "the", "consolidation", "and", "integration", "of", "memory", "in", "a", "process", "called", "overnight", "memory", "consolidation", ".", "Previous", "studies", "indicate", "that", "ecstasy", "users", "have", "marked", "and", "persistent", "neurocognitive", "and", "sleep", "-", "related", "impairments", ".", "We", "extend", "past", "research", "by", "examining", "overnight", "memory", "consolidation", "among", "regular", "ecstasy", "users", "(", "n", "=", "12", ")", "and", "drug", "naive", "healthy", "controls", "(", "n", "=", "26", ")", ".", "Memory", "recall", "of", "word", "pairs", "was", "evaluated", "before", "and", "after", "a", "period", "of", "sleep", ",", "with", "and", "without", "interference", "prior", "to", "testing", ".", "In", "addition", ",", "we", "assessed", "neurocognitive", "performances", "across", "tasks", "of", "learning", ",", "memory", "and", "executive", "functioning", ".", "Ecstasy", "users", "demonstrated", "impaired", "overnight", "memory", "consolidation", ",", "a", "finding", "that", "was", "more", "pronounced", "following", "associative", "interference", ".", "Additionally", ",", "ecstasy", "users", "demonstrated", "impairments", "on", "tasks", "recruiting", "frontostriatal", "and", "hippocampal", "neural", "circuitry", ",", "in", "the", "domains", "of", "proactive", "interference", "memory", ",", "long", "-", "term", "memory", ",", "encoding", ",", "working", "memory", "and", "complex", "planning", ".", "We", "suggest", "that", "ecstasy", "-", "associated", "dysfunction", "in", "fronto", "-", "temporal", "circuitry", "may", "underlie", "overnight", "consolidation", "memory", "impairments", "in", "regular", "ecstasy", "users", "."]], "ner": [[[5, 5, "Chemical"], [32, 32, "Chemical"], [56, 56, "Chemical"], [114, 114, "Chemical"], [134, 134, "Chemical"], [171, 171, "Chemical"], [188, 188, "Chemical"], [0, 2, "Disease"], [117, 119, "Disease"], [184, 185, "Disease"], [40, 43, "Disease"]]], "relations": [[[5, 5, 0, 2, "CID"], [5, 5, 117, 119, "CID"], [5, 5, 184, 185, "CID"], [32, 32, 0, 2, "CID"], [32, 32, 117, 119, "CID"], [32, 32, 184, 185, "CID"], [56, 56, 0, 2, "CID"], [56, 56, 117, 119, "CID"], [56, 56, 184, 185, "CID"], [114, 114, 0, 2, "CID"], [114, 114, 117, 119, "CID"], [114, 114, 184, 185, "CID"], [134, 134, 0, 2, "CID"], [134, 134, 117, 119, "CID"], [134, 134, 184, 185, "CID"], [171, 171, 0, 2, "CID"], [171, 171, 117, 119, "CID"], [171, 171, 184, 185, "CID"], [188, 188, 0, 2, "CID"], [188, 188, 117, 119, "CID"], [188, 188, 184, 185, "CID"], [5, 5, 40, 43, "CID"], [32, 32, 40, 43, "CID"], [56, 56, 40, 43, "CID"], [114, 114, 40, 43, "CID"], [134, 134, 40, 43, "CID"], [171, 171, 40, 43, "CID"], [188, 188, 40, 43, "CID"]]], "clusters": [], "translated": " <7>功能失调的夜间记忆</7>巩固<0>摇头丸</0>用户。睡眠对记忆的巩固和整合起着重要作用，这一过程称为夜间记忆巩固。以前的研究表明，<1>摇头丸</1>使用者有显着和持续的神经认知和<10>睡眠相关障碍</10>。我们通过检查经常服用<2>摇头丸</2>的人 (n = 12) 和未接触过药物的健康对照者 (n = 26) 之间的夜间记忆巩固来扩展过去的研究。单词对的记忆回忆在一段时间的睡眠之前和之后进行评估，在测试之前有和没有干扰。此外，我们评估了跨学习、记忆和执行功能任务的神经认知表现。<3>摇头丸</3>用户表现出<8>夜间记忆受损</8>巩固，这一发现在联想干扰后更为明显。此外，<4>摇头丸</4>使用者在募集额纹状体和海马神经回路的任务中表现出劣势，这些任务包括前瞻性干扰记忆、长期记忆、编码、工作记忆和复杂的规划。我们认为，<5>摇头丸</5>相关的前额-颞回路功能障碍可能是经常服用<6>摇头丸</6>的夜间记忆巩固<9>记忆障碍</9>的基础。", "revised": true}
{"doc_key": "24927617", "sentences": [["Rhabdomyolysis", "in", "a", "hepatitis", "C", "virus", "infected", "patient", "treated", "with", "telaprevir", "and", "simvastatin", ".", "A", "46", "-", "year", "old", "man", "with", "a", "chronic", "hepatitis", "C", "virus", "infection", "received", "triple", "therapy", "with", "ribavirin", ",", "pegylated", "interferon", "and", "telaprevir", ".", "The", "patient", "also", "received", "simvastatin", ".", "One", "month", "after", "starting", "the", "antiviral", "therapy", ",", "the", "patient", "was", "admitted", "to", "the", "hospital", "because", "he", "developed", "rhabdomyolysis", ".", "At", "admission", "simvastatin", "and", "all", "antiviral", "drugs", "were", "discontinued", "because", "toxicity", "due", "to", "a", "drug", "-", "drug", "interaction", "was", "suspected", ".", "The", "creatine", "kinase", "peaked", "at", "62", ",", "246", "IU", "/", "L", "and", "the", "patient", "was", "treated", "with", "intravenous", "normal", "saline", ".", "The", "patient", "'s", "renal", "function", "remained", "unaffected", ".", "Fourteen", "days", "after", "hospitalization", ",", "creatine", "kinase", "level", "had", "returned", "to", "230", "IU", "/", "L", "and", "the", "patient", "was", "discharged", ".", "Telaprevir", "was", "considered", "the", "probable", "causative", "agent", "of", "an", "interaction", "with", "simvastatin", "according", "to", "the", "Drug", "Interaction", "Probability", "Scale", ".", "The", "interaction", "is", "due", "to", "inhibition", "of", "CYP3A4", "-", "mediated", "simvastatin", "clearance", ".", "Simvastatin", "plasma", "concentration", "increased", "30", "times", "in", "this", "patient", "and", "statin", "induced", "muscle", "toxicity", "is", "related", "to", "the", "concentration", "of", "the", "statin", "in", "blood", ".", "In", "conclusion", ",", "with", "this", "case", "we", "illustrate", "that", "telaprevir", "as", "well", "as", "statins", "are", "susceptible", "to", "clinical", "relevant", "drug", "-", "drug", "interactions", "."]], "ner": [[[10, 10, "Chemical"], [36, 36, "Chemical"], [135, 135, "Chemical"], [202, 202, "Chemical"], [0, 0, "Disease"], [62, 62, "Disease"], [12, 12, "Chemical"], [42, 42, "Chemical"], [66, 66, "Chemical"], [146, 146, "Chemical"], [165, 165, "Chemical"], [168, 168, "Chemical"], [178, 178, "Chemical"], [189, 189, "Chemical"], [206, 206, "Chemical"], [180, 181, "Disease"], [31, 31, "Chemical"], [33, 34, "Chemical"], [86, 86, "Chemical"], [119, 119, "Chemical"], [3, 6, "Disease"], [23, 26, "Disease"], [74, 74, "Disease"]]], "relations": [[[10, 10, 0, 0, "CID"], [10, 10, 62, 62, "CID"], [36, 36, 0, 0, "CID"], [36, 36, 62, 62, "CID"], [135, 135, 0, 0, "CID"], [135, 135, 62, 62, "CID"], [202, 202, 0, 0, "CID"], [202, 202, 62, 62, "CID"], [12, 12, 0, 0, "CID"], [12, 12, 62, 62, "CID"], [42, 42, 0, 0, "CID"], [42, 42, 62, 62, "CID"], [66, 66, 0, 0, "CID"], [66, 66, 62, 62, "CID"], [146, 146, 0, 0, "CID"], [146, 146, 62, 62, "CID"], [165, 165, 0, 0, "CID"], [165, 165, 62, 62, "CID"], [168, 168, 0, 0, "CID"], [168, 168, 62, 62, "CID"], [178, 178, 0, 0, "CID"], [178, 178, 62, 62, "CID"], [189, 189, 0, 0, "CID"], [189, 189, 62, 62, "CID"], [206, 206, 0, 0, "CID"], [206, 206, 62, 62, "CID"], [12, 12, 180, 181, "CID"], [42, 42, 180, 181, "CID"], [66, 66, 180, 181, "CID"], [146, 146, 180, 181, "CID"], [165, 165, 180, 181, "CID"], [168, 168, 180, 181, "CID"], [178, 178, 180, 181, "CID"], [189, 189, 180, 181, "CID"], [206, 206, 180, 181, "CID"]]], "clusters": [], "translated": "<4>横纹肌溶解症</4>在一名接受<0>特拉匹韦</0>和<6>辛伐他汀</6>治疗的<20>丙型肝炎病毒感染</20>患者中发生。一名患有慢性<21>丙型肝炎病毒感染</21>的46岁男性接受了<16>利巴韦林</16>、<17>聚乙二醇干扰素</17>和<1>特拉匹韦</1>的三联疗法。患者还接受了<7>辛伐他汀</7>。开始抗病毒治疗1个月后，患者因<5>横纹肌溶解症</5>入院。入院时<8>辛伐他汀</8>和所有抗病毒药物均已停用，因为怀疑由药物相互作用引起<22>毒性</22>。 <18>肌酸</18>激酶峰值为62,246 IU/L，患者接受静脉正常盐水。患者的肾功能未受影响。住院14天后，<19>肌酸</19>激酶水平恢复至230 IU/L，患者出院。<2>特拉匹韦</2>根据药物相互作用概率量表，被认为是与<9>辛伐他汀</9>相互作用的可能致病剂。这种相互作用是由于抑制CYP3A4介导的<10>辛伐他汀</10>清除。<11>辛伐他汀</11>患者血药浓度增加30倍，<12>他汀</12>类引起的<15>肌肉毒性</15>与<13>他汀</13>类在血液中的浓度有关。总之，通过这个案例，我们说明了<3>特拉匹韦</3>以及<14>他汀类药物</14>对临床相关的药物相互作用敏感。", "revised": true}
{"doc_key": "24842192", "sentences": [["Chronic", "treatment", "with", "metformin", "suppresses", "toll", "-", "like", "receptor", "4", "signaling", "and", "attenuates", "left", "ventricular", "dysfunction", "following", "myocardial", "infarction", ".", "Acute", "treatment", "with", "metformin", "has", "a", "protective", "effect", "in", "myocardial", "infarction", "by", "suppression", "of", "inflammatory", "responses", "due", "to", "activation", "of", "AMP", "-", "activated", "protein", "kinase", "(", "AMPK", ")", ".", "In", "the", "present", "study", ",", "the", "effect", "of", "chronic", "pre", "-", "treatment", "with", "metformin", "on", "cardiac", "dysfunction", "and", "toll", "-", "like", "receptor", "4", "(", "TLR4", ")", "activities", "following", "myocardial", "infarction", "and", "their", "relation", "with", "AMPK", "were", "assessed", ".", "Male", "Wistar", "rats", "were", "randomly", "assigned", "to", "one", "of", "5", "groups", "(", "n", "=", "6", ")", ":", "normal", "control", "and", "groups", "were", "injected", "isoproterenol", "after", "chronic", "pre", "-", "treatment", "with", "0", ",", "25", ",", "50", ",", "or", "100mg", "/", "kg", "of", "metformin", "twice", "daily", "for", "14", "days", ".", "Isoproterenol", "(", "100mg", "/", "kg", ")", "was", "injected", "subcutaneously", "on", "the", "13th", "and", "14th", "days", "to", "induce", "acute", "myocardial", "infarction", ".", "Isoproterenol", "alone", "decreased", "left", "ventricular", "systolic", "pressure", "and", "myocardial", "contractility", "indexed", "as", "LVdp", "/", "dtmax", "and", "LVdp", "/", "dtmin", ".", "The", "left", "ventricular", "dysfunction", "was", "significantly", "lower", "in", "the", "groups", "treated", "with", "25", "and", "50mg", "/", "kg", "of", "metformin", ".", "Metfromin", "markedly", "lowered", "isoproterenol", "-", "induced", "elevation", "in", "the", "levels", "of", "TLR4", "mRNA", ",", "myeloid", "differentiation", "protein", "88", "(", "MyD88", ")", ",", "tumor", "necrosis", "factor", "-", "alpha", "(", "TNF", "-", "a", ")", ",", "and", "interleukin", "6", "(", "IL", "-", "6", ")", "in", "the", "heart", "tissues", ".", "Similar", "changes", "were", "also", "seen", "in", "the", "serum", "levels", "of", "TNF", "-", "a", "and", "IL", "-", "6", ".", "However", ",", "the", "lower", "doses", "of", "25", "and", "50mg", "/", "kg", "were", "more", "effective", "than", "100mg", "/", "kg", ".", "Phosphorylated", "AMPKa", "(", "p", "-", "AMPK", ")", "in", "the", "myocardium", "was", "significantly", "elevated", "by", "25mg", "/", "kg", "of", "metformin", ",", "slightly", "by", "50mg", "/", "kg", ",", "but", "not", "by", "100mg", "/", "kg", ".", "Chronic", "pre", "-", "treatment", "with", "metformin", "reduces", "post", "-", "myocardial", "infarction", "cardiac", "dysfunction", "and", "suppresses", "inflammatory", "responses", ",", "possibly", "through", "inhibition", "of", "TLR4", "activities", ".", "This", "mechanism", "can", "be", "considered", "as", "a", "target", "to", "protect", "infarcted", "myocardium", "."]], "ner": [[[110, 110, "Chemical"], [135, 135, "Chemical"], [156, 156, "Chemical"], [199, 199, "Chemical"], [13, 15, "Disease"], [177, 179, "Disease"], [17, 18, "Disease"], [29, 30, "Disease"], [77, 78, "Disease"], [152, 154, "Disease"], [321, 322, "Disease"], [3, 3, "Chemical"], [23, 23, "Chemical"], [62, 62, "Chemical"], [128, 128, "Chemical"], [194, 194, "Chemical"], [297, 297, "Chemical"], [317, 317, "Chemical"], [64, 65, "Disease"], [218, 218, "Disease"], [219, 219, "Disease"], [40, 40, "Chemical"]]], "relations": [[[110, 110, 13, 15, "CID"], [110, 110, 177, 179, "CID"], [135, 135, 13, 15, "CID"], [135, 135, 177, 179, "CID"], [156, 156, 13, 15, "CID"], [156, 156, 177, 179, "CID"], [199, 199, 13, 15, "CID"], [199, 199, 177, 179, "CID"], [110, 110, 17, 18, "CID"], [110, 110, 29, 30, "CID"], [110, 110, 77, 78, "CID"], [110, 110, 152, 154, "CID"], [110, 110, 321, 322, "CID"], [135, 135, 17, 18, "CID"], [135, 135, 29, 30, "CID"], [135, 135, 77, 78, "CID"], [135, 135, 152, 154, "CID"], [135, 135, 321, 322, "CID"], [156, 156, 17, 18, "CID"], [156, 156, 29, 30, "CID"], [156, 156, 77, 78, "CID"], [156, 156, 152, 154, "CID"], [156, 156, 321, 322, "CID"], [199, 199, 17, 18, "CID"], [199, 199, 29, 30, "CID"], [199, 199, 77, 78, "CID"], [199, 199, 152, 154, "CID"], [199, 199, 321, 322, "CID"]]], "clusters": [], "translated": "<11>二甲双胍</11> 的长期治疗可抑制 Toll 样受体 4 信号传导并减轻<4>左心室功能障碍</4>继<6>心肌梗死</6>后。<12>二甲双胍</12>急性治疗通过抑制<21>AMP</21>活化蛋白激酶（AMPK）激活引起的炎症反应，对<7>心肌梗死</7>具有保护作用。在本研究中，<13>二甲双胍</13>慢性预处理对<18>心功能不全</18>和<8>心肌梗死</8>后 Toll 样受体 4（TLR4）活性的影响，并评估了它们与 AMPK 的关系。雄性 Wistar 大鼠被随机分配到 5 组中的一组（n = 6）：正常对照组和各组在用 0、25、50或100mg/kg的<14>二甲双胍</14>进行慢性预处理后注射<0>异丙肾上腺素</0>每天两次，持续 14 天。<1>第13、14天皮下注射异丙肾上腺素</1>（100mg/kg），诱发<9>急性心肌梗死</9>。<2>异丙肾上腺素</2>单独降低左心室收缩压和心肌收缩力，指数为 LVdp/dtmax 和 LVdp/dtmin。<5>左心室功能障碍</5>在用25和50mg/kg的<15>二甲双胍</15>治疗的组中显着降低。二甲双胍明显降低<3>异丙肾上腺素</3>诱导的 TLR4 mRNA、骨髓分化蛋白88（MyD88）、<19>肿瘤</19><20>坏死</20>因子-α（TNF-a）和白细胞介素6（IL-6）在心脏组织中。TNF-a和IL-6的血清水平也有类似的变化。然而，25和50mg/kg的较低剂量比100mg/kg更有效。<16>二甲双胍</16>25mg/kg时心肌中磷酸化AMPKa（p-AMPK）显着升高，50mg/kg略有升高，但100mg/kg不会升高。使用<17>二甲双胍</17>进行慢性预治疗可减少<10>心肌梗塞</10>后的心功能障碍并抑制炎症反应，这可能是通过抑制 TLR4 活性实现的。该机制可作为保护梗死心肌的靶点。", "revised": true}
{"doc_key": "24923469", "sentences": [["Standard", "operating", "procedures", "for", "antibiotic", "therapy", "and", "the", "occurrence", "of", "acute", "kidney", "injury", ":", "a", "prospective", ",", "clinical", ",", "non", "-", "interventional", ",", "observational", "study", ".", "INTRODUCTION", ":", "Acute", "kidney", "injury", "(", "AKI", ")", "occurs", "in", "7", "%", "of", "hospitalized", "and", "66", "%", "of", "Intensive", "Care", "Unit", "(", "ICU", ")", "patients", ".", "It", "increases", "mortality", ",", "hospital", "length", "of", "stay", ",", "and", "costs", ".", "The", "aim", "of", "this", "study", "was", "to", "investigate", ",", "whether", "there", "is", "an", "association", "between", "adherence", "to", "guidelines", "(", "standard", "operating", "procedures", "(", "SOP", ")", ")", "for", "potentially", "nephrotoxic", "antibiotics", "and", "the", "occurrence", "of", "AKI", ".", "METHODS", ":", "This", "study", "was", "carried", "out", "as", "a", "prospective", ",", "clinical", ",", "non", "-", "interventional", ",", "observational", "study", ".", "Data", "collection", "was", "performed", "over", "a", "total", "of", "170", "days", "in", "three", "ICUs", "at", "Charite", "-", "Universitaetsmedizin", "Berlin", ".", "A", "total", "of", "675", "patients", "were", "included", ";", "163", "of", "these", "had", "therapy", "with", "vancomycin", ",", "gentamicin", ",", "or", "tobramycin", ";", "were", ">", "18", "years", ";", "and", "treated", "in", "the", "ICU", "for", ">", "24", "hours", ".", "Patients", "with", "an", "adherence", "to", "SOP", ">", "70", "%", "were", "classified", "into", "the", "high", "adherence", "group", "(", "HAG", ")", "and", "patients", "with", "an", "adherence", "of", "<", "70", "%", "into", "the", "low", "adherence", "group", "(", "LAG", ")", ".", "AKI", "was", "defined", "according", "to", "RIFLE", "criteria", ".", "Adherence", "to", "SOPs", "was", "evaluated", "by", "retrospective", "expert", "audit", ".", "Development", "of", "AKI", "was", "compared", "between", "groups", "with", "exact", "Chi2", "-", "test", "and", "multivariate", "logistic", "regression", "analysis", "(", "two", "-", "sided", "P", "<", "0", ".", "05", ")", ".", "RESULTS", ":", "LAG", "consisted", "of", "75", "patients", "(", "46", "%", ")", "versus", "88", "HAG", "patients", "(", "54", "%", ")", ".", "AKI", "occurred", "significantly", "more", "often", "in", "LAG", "with", "36", "%", "versus", "21", "%", "in", "HAG", "(", "P", "=", "0", ".", "035", ")", ".", "Basic", "characteristics", "were", "comparable", ",", "except", "an", "increased", "rate", "of", "soft", "tissue", "infections", "in", "LAG", ".", "Multivariate", "analysis", "revealed", "an", "odds", "ratio", "of", "2", ".", "5", "-", "fold", "for", "LAG", "to", "develop", "AKI", "compared", "with", "HAG", "(", "95", "%", "confidence", "interval", "1", ".", "195", "to", "5", ".", "124", ",", "P", "=", "0", ".", "039", ")", ".", "CONCLUSION", ":", "Low", "adherence", "to", "SOPs", "for", "potentially", "nephrotoxic", "antibiotics", "was", "associated", "with", "a", "higher", "occurrence", "of", "AKI", ".", "TRIAL", "REGISTRATION", ":", "Current", "Controlled", "Trials", "ISRCTN54598675", ".", "Registered", "17", "August", "2007", "."]], "ner": [[[153, 153, "Chemical"], [10, 12, "Disease"], [28, 30, "Disease"], [32, 32, "Disease"], [98, 98, "Disease"], [212, 212, "Disease"], [232, 232, "Disease"], [278, 278, "Disease"], [333, 333, "Disease"], [374, 374, "Disease"], [155, 155, "Chemical"], [158, 158, "Chemical"], [92, 92, "Disease"], [365, 365, "Disease"], [313, 313, "Disease"]]], "relations": [[[153, 153, 10, 12, "CID"], [153, 153, 28, 30, "CID"], [153, 153, 32, 32, "CID"], [153, 153, 98, 98, "CID"], [153, 153, 212, 212, "CID"], [153, 153, 232, 232, "CID"], [153, 153, 278, 278, "CID"], [153, 153, 333, 333, "CID"], [153, 153, 374, 374, "CID"], [155, 155, 10, 12, "CID"], [155, 155, 28, 30, "CID"], [155, 155, 32, 32, "CID"], [155, 155, 98, 98, "CID"], [155, 155, 212, 212, "CID"], [155, 155, 232, 232, "CID"], [155, 155, 278, 278, "CID"], [155, 155, 333, 333, "CID"], [155, 155, 374, 374, "CID"], [158, 158, 10, 12, "CID"], [158, 158, 28, 30, "CID"], [158, 158, 32, 32, "CID"], [158, 158, 98, 98, "CID"], [158, 158, 212, 212, "CID"], [158, 158, 232, 232, "CID"], [158, 158, 278, 278, "CID"], [158, 158, 333, 333, "CID"], [158, 158, 374, 374, "CID"]]], "clusters": [], "translated": "抗生素治疗的标准操作程序和<1>急性肾损伤</1>的发生：一项前瞻性、临床、非干预、观察性研究。简介：<2>急性肾损伤</2> (<3>AKI</3>) 发生在7%的住院患者和66%的重症监护病房(ICU)患者中。它会增加死亡率、住院时间和费用。本研究的目的是调查遵守潜在<12>肾毒性</12>抗生素指南（标准操作程序(SOP)）与<4>AKI</4>的发生之间是否存在关联。方法：本研究是一项前瞻性、临床、非干预性观察性研究。在Charite-Universitaetsmedizin Berlin的三个ICU中进行了总共170天的数据收集。共纳入675例患者；其中163人接受了<0>万古霉素</0>、<10>庆大霉素</10>或<11>妥布霉素</11>治疗；>18岁；并在ICU治疗>24小时。SOP依从性>70%的患者分为高依从性组(HAG)，依从性<70%的患者分为低依从性组(LAG)。<5>AKI</5>是根据RIFLE标准定义的。通过回顾性专家审核评估对SOP的遵守情况。比较组间<6>AKI</6>的发生情况，采用精确Chi2检验和多因素logistic回归分析(双侧P<0.05)。结果：LAG由75名患者(46%)和88名HAG患者(54%)组成。<7>AKI</7>在LAG中的发生率明显更高，为36%，而在HAG中为21%(P=0.035)。除了LAG中软组织<14>感染</14>的发生率增加外，基本特征相似。多变量分析显示优势比为2.5，LAG发生<8>AKI</8>的概率是HAG的5倍(95%置信区间1.195至5.124，P=0.039)。结论：对潜在<13>肾毒性</13>抗生素的SOP依从性低与<9>AKI</9>发生率较高相关。试验注册：电流控制试验ISRCTN54598675。2007年8月17日注册。", "revised": true}
{"doc_key": "25031906", "sentences": [["Is", "Dysguesia", "Going", "to", "be", "a", "Rare", "or", "a", "Common", "Side", "-", "effect", "of", "Amlodipine", "?", "A", "very", "rare", "side", "-", "effect", "of", "amlodipine", "is", "dysguesia", ".", "A", "review", "of", "the", "literature", "produced", "only", "one", "case", ".", "We", "report", "a", "case", "about", "a", "female", "with", "essential", "hypertension", "on", "drug", "treatment", "with", "amlodipine", "developed", "loss", "of", "taste", "sensation", ".", "Condition", "moderately", "improved", "on", "stoppage", "of", "the", "drug", "for", "25", "days", ".", "We", "conclude", "that", "amlodipine", "can", "cause", "dysguesia", ".", "Here", ",", "we", "describe", "the", "clinical", "presentation", "and", "review", "the", "relevant", "literature", "on", "amlodipine", "and", "dysguesia", "."]], "ner": [[[14, 14, "Chemical"], [23, 23, "Chemical"], [51, 51, "Chemical"], [73, 73, "Chemical"], [91, 91, "Chemical"], [1, 1, "Disease"], [25, 25, "Disease"], [76, 76, "Disease"], [93, 93, "Disease"], [46, 46, "Disease"], [53, 56, "Disease"]]], "relations": [[[14, 14, 1, 1, "CID"], [14, 14, 25, 25, "CID"], [14, 14, 76, 76, "CID"], [14, 14, 93, 93, "CID"], [23, 23, 1, 1, "CID"], [23, 23, 25, 25, "CID"], [23, 23, 76, 76, "CID"], [23, 23, 93, 93, "CID"], [51, 51, 1, 1, "CID"], [51, 51, 25, 25, "CID"], [51, 51, 76, 76, "CID"], [51, 51, 93, 93, "CID"], [73, 73, 1, 1, "CID"], [73, 73, 25, 25, "CID"], [73, 73, 76, 76, "CID"], [73, 73, 93, 93, "CID"], [91, 91, 1, 1, "CID"], [91, 91, 25, 25, "CID"], [91, 91, 76, 76, "CID"], [91, 91, 93, 93, "CID"]]], "clusters": [], "translated": "<5>消化不良</5>是<0>氨氯地平</0>的罕见或常见副作用吗？<1>氨氯地平</1>的一个非常罕见的副作用是<6>味觉丧失</6>。对文献的回顾只产生了一个案例。我们报告了一名患有原发性<9>高血压</9>的女性在接受<2>氨氯地平</2>药物治疗后出现<10>味觉丧失</10>的病例。停药25天，病情稍有好转。我们得出结论，<3>氨氯地平</3>可引起<7>味觉障碍</7>。在这里，我们描述了临床表现并回顾了关于<4>氨氯地平</4>和<8>味觉障碍</8>的相关文献。", "revised": true}
{"doc_key": "24971338", "sentences": [["Conversion", "to", "sirolimus", "ameliorates", "cyclosporine", "-", "induced", "nephropathy", "in", "the", "rat", ":", "focus", "on", "serum", ",", "urine", ",", "gene", ",", "and", "protein", "renal", "expression", "biomarkers", ".", "Protocols", "of", "conversion", "from", "cyclosporin", "A", "(", "CsA", ")", "to", "sirolimus", "(", "SRL", ")", "have", "been", "widely", "used", "in", "immunotherapy", "after", "transplantation", "to", "prevent", "CsA", "-", "induced", "nephropathy", ",", "but", "the", "molecular", "mechanisms", "underlying", "these", "protocols", "remain", "nuclear", ".", "This", "study", "aimed", "to", "identify", "the", "molecular", "pathways", "and", "putative", "biomarkers", "of", "CsA", "-", "to", "-", "SRL", "conversion", "in", "a", "rat", "model", ".", "Four", "animal", "groups", "(", "n", "=", "6", ")", "were", "tested", "during", "9", "weeks", ":", "control", ",", "CsA", ",", "SRL", ",", "and", "conversion", "(", "CsA", "for", "3", "weeks", "followed", "by", "SRL", "for", "6", "weeks", ")", ".", "Classical", "and", "emergent", "serum", ",", "urinary", ",", "and", "kidney", "tissue", "(", "gene", "and", "protein", "expression", ")", "markers", "were", "assessed", ".", "Renal", "lesions", "were", "analyzed", "in", "hematoxylin", "and", "eosin", ",", "periodic", "acid", "-", "Schiff", ",", "and", "Masson", "'s", "trichrome", "stains", ".", "SRL", "-", "treated", "rats", "presented", "proteinuria", "and", "NGAL", "(", "serum", "and", "urinary", ")", "as", "the", "best", "markers", "of", "renal", "impairment", ".", "Short", "CsA", "treatment", "presented", "slight", "or", "even", "absent", "kidney", "lesions", "and", "TGF", "-", "b", ",", "NF", "-", "kb", ",", "mTOR", ",", "PCNA", ",", "TP53", ",", "KIM", "-", "1", ",", "and", "CTGF", "as", "relevant", "gene", "and", "protein", "changes", ".", "Prolonged", "CsA", "exposure", "aggravated", "renal", "damage", ",", "without", "clear", "changes", "on", "the", "traditional", "markers", ",", "but", "with", "changes", "in", "serums", "TGF", "-", "b", "and", "IL", "-", "7", ",", "TBARs", "clearance", ",", "and", "kidney", "TGF", "-", "b", "and", "mTOR", ".", "Conversion", "to", "SRL", "prevented", "CsA", "-", "induced", "renal", "damage", "evolution", "(", "absent", "/", "mild", "grade", "lesions", ")", ",", "while", "NGAL", "(", "serum", "versus", "urine", ")", "seems", "to", "be", "a", "feasible", "biomarker", "of", "CsA", "replacement", "to", "SRL", "."]], "ner": [[[2, 2, "Chemical"], [36, 36, "Chemical"], [38, 38, "Chemical"], [81, 81, "Chemical"], [106, 106, "Chemical"], [117, 117, "Chemical"], [163, 163, "Chemical"], [263, 263, "Chemical"], [296, 296, "Chemical"], [168, 168, "Disease"], [4, 4, "Chemical"], [30, 31, "Chemical"], [33, 33, "Chemical"], [50, 50, "Chemical"], [77, 77, "Chemical"], [104, 104, "Chemical"], [111, 111, "Chemical"], [185, 185, "Chemical"], [223, 223, "Chemical"], [265, 265, "Chemical"], [293, 293, "Chemical"], [7, 7, "Disease"], [53, 53, "Disease"], [143, 144, "Disease"], [181, 182, "Disease"], [192, 193, "Disease"], [226, 227, "Disease"], [268, 269, "Disease"], [148, 148, "Chemical"], [150, 150, "Chemical"]]], "relations": [[[2, 2, 168, 168, "CID"], [36, 36, 168, 168, "CID"], [38, 38, 168, 168, "CID"], [81, 81, 168, 168, "CID"], [106, 106, 168, 168, "CID"], [117, 117, 168, 168, "CID"], [163, 163, 168, 168, "CID"], [263, 263, 168, 168, "CID"], [296, 296, 168, 168, "CID"], [4, 4, 7, 7, "CID"], [4, 4, 53, 53, "CID"], [4, 4, 143, 144, "CID"], [4, 4, 181, 182, "CID"], [4, 4, 192, 193, "CID"], [4, 4, 226, 227, "CID"], [4, 4, 268, 269, "CID"], [30, 31, 7, 7, "CID"], [30, 31, 53, 53, "CID"], [30, 31, 143, 144, "CID"], [30, 31, 181, 182, "CID"], [30, 31, 192, 193, "CID"], [30, 31, 226, 227, "CID"], [30, 31, 268, 269, "CID"], [33, 33, 7, 7, "CID"], [33, 33, 53, 53, "CID"], [33, 33, 143, 144, "CID"], [33, 33, 181, 182, "CID"], [33, 33, 192, 193, "CID"], [33, 33, 226, 227, "CID"], [33, 33, 268, 269, "CID"], [50, 50, 7, 7, "CID"], [50, 50, 53, 53, "CID"], [50, 50, 143, 144, "CID"], [50, 50, 181, 182, "CID"], [50, 50, 192, 193, "CID"], [50, 50, 226, 227, "CID"], [50, 50, 268, 269, "CID"], [77, 77, 7, 7, "CID"], [77, 77, 53, 53, "CID"], [77, 77, 143, 144, "CID"], [77, 77, 181, 182, "CID"], [77, 77, 192, 193, "CID"], [77, 77, 226, 227, "CID"], [77, 77, 268, 269, "CID"], [104, 104, 7, 7, "CID"], [104, 104, 53, 53, "CID"], [104, 104, 143, 144, "CID"], [104, 104, 181, 182, "CID"], [104, 104, 192, 193, "CID"], [104, 104, 226, 227, "CID"], [104, 104, 268, 269, "CID"], [111, 111, 7, 7, "CID"], [111, 111, 53, 53, "CID"], [111, 111, 143, 144, "CID"], [111, 111, 181, 182, "CID"], [111, 111, 192, 193, "CID"], [111, 111, 226, 227, "CID"], [111, 111, 268, 269, "CID"], [185, 185, 7, 7, "CID"], [185, 185, 53, 53, "CID"], [185, 185, 143, 144, "CID"], [185, 185, 181, 182, "CID"], [185, 185, 192, 193, "CID"], [185, 185, 226, 227, "CID"], [185, 185, 268, 269, "CID"], [223, 223, 7, 7, "CID"], [223, 223, 53, 53, "CID"], [223, 223, 143, 144, "CID"], [223, 223, 181, 182, "CID"], [223, 223, 192, 193, "CID"], [223, 223, 226, 227, "CID"], [223, 223, 268, 269, "CID"], [265, 265, 7, 7, "CID"], [265, 265, 53, 53, "CID"], [265, 265, 143, 144, "CID"], [265, 265, 181, 182, "CID"], [265, 265, 192, 193, "CID"], [265, 265, 226, 227, "CID"], [265, 265, 268, 269, "CID"], [293, 293, 7, 7, "CID"], [293, 293, 53, 53, "CID"], [293, 293, 143, 144, "CID"], [293, 293, 181, 182, "CID"], [293, 293, 192, 193, "CID"], [293, 293, 226, 227, "CID"], [293, 293, 268, 269, "CID"]]], "clusters": [], "translated": "转化为 <0>西罗莫司</0> 可改善 <10>环孢菌素</10> 诱导的大鼠 <21>肾病</21>：关注血清、尿液、基因和蛋白质肾表达生物标志物。 <11>环孢菌素A</11>（<12>CsA</12>）转化为 <1>西罗莫司</1>（<2>SRL</2>）的方案已广泛应用于移植后的免疫治疗以预防 <13>CsA</13> 诱发的 <22>肾病</22>，但这些方案背后的分子机制仍然是核心的。本研究旨在确定大鼠模型中 <14>CsA</14> 至 <3>SRL</3> 转化的分子途径和推定的生物标志物。在 9 周内测试了四个动物组（n = 6）：对照组、<15>CsA</15>、<4>SRL</4> 和转化组（<16>CsA</16>，持续 3 周，随后 <5>SRL</5> 6 周）。评估了经典和新出现的血清、尿液和肾组织 （基因和蛋白质表达）标志物。 <23>肾脏病变</23> 在 <28>苏木精</28> 和 <29>伊红</29> 、高碘酸席夫和马松三色染色中进行了分析。 <6>SRL</6>- 治疗的大鼠呈现出 <9>蛋白尿</9> 和 NGAL（血清和尿液）作为 <24>肾功能损害</24> 的最佳标志。短期 <17>CsA</17> 治疗呈现轻微或甚至没有 <25>肾脏病变</25> 和 TGF-b、NF-kb、mTOR、PCNA、TP53、KIM-1 和 CTGF 作为相关基因和蛋白变化。长期 <18>CsA</18> 暴露加重 <26>肾损害</26>，传统标志物无明显变化，但血清 TGF-b 和 IL-7、TBARs 清除率、肾 TGF-b 均有变化。转换为 <7>SRL</7> 可防止 <19>CsA</19> 诱导的 <27>肾损伤</27> 演变（无/轻度病变），而 NGAL（血清与尿液）似乎是一种 <20>CsA</20> 替代 <8>SRL</8> 的可行生物标志物。", "revised": true}
{"doc_key": "24911645", "sentences": [["Behavioral", "and", "neurochemical", "studies", "in", "mice", "pretreated", "with", "garcinielliptone", "FC", "in", "pilocarpine", "-", "induced", "seizures", ".", "Garcinielliptone", "FC", "(", "GFC", ")", "isolated", "from", "hexanic", "fraction", "seed", "extract", "of", "species", "Platonia", "insignis", "Mart", ".", "It", "is", "widely", "used", "in", "folk", "medicine", "to", "treat", "skin", "diseases", "in", "both", "humans", "and", "animals", "as", "well", "as", "the", "seed", "decoction", "has", "been", "used", "to", "treat", "diarrheas", "and", "inflammatory", "diseases", ".", "However", ",", "there", "is", "no", "research", "on", "GFC", "effects", "in", "the", "central", "nervous", "system", "of", "rodents", ".", "The", "present", "study", "aimed", "to", "evaluate", "the", "GFC", "effects", "at", "doses", "of", "25", ",", "50", "or", "75", "mg", "/", "kg", "on", "seizure", "parameters", "to", "determine", "their", "anticonvulsant", "activity", "and", "its", "effects", "on", "amino", "acid", "(", "r", "-", "aminobutyric", "acid", "(", "GABA", ")", ",", "glutamine", ",", "aspartate", "and", "glutathione", ")", "levels", "as", "well", "as", "on", "acetylcholinesterase", "(", "AChE", ")", "activity", "in", "mice", "hippocampus", "after", "seizures", ".", "GFC", "produced", "an", "increased", "latency", "to", "first", "seizure", ",", "at", "doses", "25mg", "/", "kg", "(", "20", ".", "12", "+", "2", ".", "20", "min", ")", ",", "50mg", "/", "kg", "(", "20", ".", "95", "+", "2", ".", "21", "min", ")", "or", "75", "mg", "/", "kg", "(", "23", ".", "43", "+", "1", ".", "99", "min", ")", "when", "compared", "with", "seized", "mice", ".", "In", "addition", ",", "GABA", "content", "of", "mice", "hippocampus", "treated", "with", "GFC75", "plus", "P400", "showed", "an", "increase", "of", "46", ".", "90", "%", "when", "compared", "with", "seized", "mice", ".", "In", "aspartate", ",", "glutamine", "and", "glutamate", "levels", "detected", "a", "decrease", "of", "5", ".", "21", "%", ",", "13", ".", "55", "%", "and", "21", ".", "80", "%", ",", "respectively", "in", "mice", "hippocampus", "treated", "with", "GFC75", "plus", "P400", "when", "compared", "with", "seized", "mice", ".", "Hippocampus", "mice", "treated", "with", "GFC75", "plus", "P400", "showed", "an", "increase", "in", "AChE", "activity", "(", "63", ".", "30", "%", ")", "when", "compared", "with", "seized", "mice", ".", "The", "results", "indicate", "that", "GFC", "can", "exert", "anticonvulsant", "activity", "and", "reduce", "the", "frequency", "of", "installation", "of", "pilocarpine", "-", "induced", "status", "epilepticus", ",", "as", "demonstrated", "by", "increase", "in", "latency", "to", "first", "seizure", "and", "decrease", "in", "mortality", "rate", "of", "animals", ".", "In", "conclusion", ",", "our", "data", "suggest", "that", "GFC", "may", "influence", "in", "epileptogenesis", "and", "promote", "anticonvulsant", "actions", "in", "pilocarpine", "model", "by", "modulating", "the", "GABA", "and", "glutamate", "contents", "and", "of", "AChE", "activity", "in", "seized", "mice", "hippocampus", ".", "This", "compound", "may", "be", "useful", "to", "produce", "neuronal", "protection", "and", "it", "can", "be", "considered", "as", "an", "anticonvulsant", "agent", "."]], "ner": [[[11, 11, "Chemical"], [315, 315, "Chemical"], [355, 355, "Chemical"], [14, 14, "Disease"], [103, 103, "Disease"], [145, 145, "Disease"], [154, 154, "Disease"], [329, 329, "Disease"], [318, 319, "Disease"], [8, 9, "Chemical"], [16, 17, "Chemical"], [19, 19, "Chemical"], [72, 72, "Chemical"], [89, 89, "Chemical"], [147, 147, "Chemical"], [303, 303, "Chemical"], [345, 345, "Chemical"], [42, 43, "Disease"], [60, 60, "Disease"], [62, 63, "Disease"], [114, 115, "Chemical"], [117, 120, "Chemical"], [122, 122, "Chemical"], [209, 209, "Chemical"], [360, 360, "Chemical"], [125, 125, "Chemical"], [236, 236, "Chemical"], [238, 238, "Chemical"], [362, 362, "Chemical"], [127, 127, "Chemical"], [234, 234, "Chemical"], [129, 129, "Chemical"]]], "relations": [[[11, 11, 14, 14, "CID"], [11, 11, 103, 103, "CID"], [11, 11, 145, 145, "CID"], [11, 11, 154, 154, "CID"], [11, 11, 329, 329, "CID"], [315, 315, 14, 14, "CID"], [315, 315, 103, 103, "CID"], [315, 315, 145, 145, "CID"], [315, 315, 154, 154, "CID"], [315, 315, 329, 329, "CID"], [355, 355, 14, 14, "CID"], [355, 355, 103, 103, "CID"], [355, 355, 145, 145, "CID"], [355, 355, 154, 154, "CID"], [355, 355, 329, 329, "CID"], [11, 11, 318, 319, "CID"], [315, 315, 318, 319, "CID"], [355, 355, 318, 319, "CID"]]], "clusters": [], "translated": "在<0>毛果芸香碱</0>诱导的<3>癫痫发作</3>中用<9>藤黄酮 FC</9>预处理小鼠的行为和神经化学研究。<10>Garcinielliptone FC</10>（<11>GFC</11>）从Platonia insignis Mart种的己烷部分种子提取物中分离。它在民间医学中被广泛用于治疗人和动物的<17>皮肤病</17>，其种子煎剂已被用于治疗<18>腹泻</18>和<19>炎症性疾病</19>。但目前尚无对啮齿类动物中枢神经系统影响的<12>GFC</12>研究。本研究旨在评估剂量为25、50或75 mg/kg的<13>GFC</13>对<4>癫痫发作</4>参数的影响，以确定其抗惊厥活性及其对<20>氨基酸</20>（<21>r-氨基丁酸</21>（<22>GABA</22>）、<25>谷氨酰胺</25>、<29>天冬氨酸</29>和<31>谷胱甘肽</31>）水平以及<5>癫痫发作</5>后小鼠海马中乙酰胆碱酯酶(AChE)活性。 <14>GFC</14>导致首次<6>癫痫发作</6>的潜伏期增加，剂量为25mg/kg（20.12+2.20分钟）、50mg/kg（20.95+2.21分钟）或75mg/kg(23.43+1.99分钟)与被抓获的小鼠相比。此外，用GFC75加P400处理的小鼠海马<23>GABA</23>含量增加了46.90%与抓获的老鼠相比。在<30>天冬氨酸</30>、<26>谷氨酰胺</26>和<27>谷氨酸</27>水平检测到降低了5.21%、13.55%和21.80%，与被捕获的小鼠相比，用GFC75加P400处理的小鼠海马分别为5.21%、13.55%和21.80%。与被抓获的小鼠相比，用GFC75加P400处理的海马小鼠显示AChE活性增加（63.30%）。结果表明，<15>GFC</15>可以发挥抗惊厥作用，降低<1>毛果芸香碱</1>诱发的<8>癫痫持续状态</8>的安装频率，表现为潜伏期增加第一<7>发作</7>动物死亡率下降。总之，我们的数据表明，<16>GFC</16>可能通过调节<24>GABA</24>和<28>谷氨酸</28>的含量和AChE活性在<2>毛果芸香碱</2>模型中影响癫痫发生并促进抗惊厥作用。该化合物可用于产生神经元保护作用，可被视为抗惊厥剂。", "revised": true}
{"doc_key": "25041770", "sentences": [["Rhabdomyolysis", "in", "association", "with", "simvastatin", "and", "dosage", "increment", "in", "clarithromycin", ".", "Clarithromycin", "is", "the", "most", "documented", "cytochrome", "P450", "3A4", "(", "CYP3A4", ")", "inhibitor", "to", "cause", "an", "adverse", "interaction", "with", "simvastatin", ".", "This", "particular", "case", "is", "of", "interest", "as", "rhabdomyolysis", "only", "occurred", "after", "an", "increase", "in", "the", "dose", "of", "clarithromycin", ".", "The", "patient", "developed", "raised", "cardiac", "biomarkers", "without", "any", "obvious", "cardiac", "issues", ",", "a", "phenomenon", "that", "has", "been", "linked", "to", "rhabdomyolysis", "previously", ".", "To", "date", ",", "there", "has", "been", "no", "reported", "effect", "of", "rhabdomyolysis", "on", "the", "structure", "and", "function", "of", "cardiac", "muscle", ".", "Clinicians", "need", "to", "be", "aware", "of", "prescribing", "concomitant", "medications", "that", "increase", "the", "risk", "of", "myopathy", "or", "inhibit", "the", "CYP3A4", "enzyme", ".", "Our", "case", "suggests", "that", "troponin", "elevation", "could", "be", "associated", "with", "statin", "induced", "rhabdomyolysis", ",", "which", "may", "warrant", "further", "studies", "."]], "ner": [[[4, 4, "Chemical"], [29, 29, "Chemical"], [123, 123, "Chemical"], [0, 0, "Disease"], [38, 38, "Disease"], [69, 69, "Disease"], [82, 82, "Disease"], [125, 125, "Disease"], [9, 9, "Chemical"], [11, 11, "Chemical"], [48, 48, "Chemical"], [106, 106, "Disease"]]], "relations": [[[4, 4, 0, 0, "CID"], [4, 4, 38, 38, "CID"], [4, 4, 69, 69, "CID"], [4, 4, 82, 82, "CID"], [4, 4, 125, 125, "CID"], [29, 29, 0, 0, "CID"], [29, 29, 38, 38, "CID"], [29, 29, 69, 69, "CID"], [29, 29, 82, 82, "CID"], [29, 29, 125, 125, "CID"], [123, 123, 0, 0, "CID"], [123, 123, 38, 38, "CID"], [123, 123, 69, 69, "CID"], [123, 123, 82, 82, "CID"], [123, 123, 125, 125, "CID"], [9, 9, 0, 0, "CID"], [9, 9, 38, 38, "CID"], [9, 9, 69, 69, "CID"], [9, 9, 82, 82, "CID"], [9, 9, 125, 125, "CID"], [11, 11, 0, 0, "CID"], [11, 11, 38, 38, "CID"], [11, 11, 69, 69, "CID"], [11, 11, 82, 82, "CID"], [11, 11, 125, 125, "CID"], [48, 48, 0, 0, "CID"], [48, 48, 38, 38, "CID"], [48, 48, 69, 69, "CID"], [48, 48, 82, 82, "CID"], [48, 48, 125, 125, "CID"]]], "clusters": [], "translated": "<3>横纹肌溶解症</3>与<0>辛伐他汀</0>和<8>克拉霉素</8>的剂量增加有关。 <9>克拉霉素</9>是记录最多的细胞色素P450 3A4 (CYP3A4)抑制剂，可引起与<1>辛伐他汀</1>的不良相互作用。这个特殊病例很有趣，因为<4>横纹肌溶解症</4>仅在增加剂量后的<10>克拉霉素</10>发生。该患者的心脏生物标志物升高，但没有任何明显的心脏问题，这种现象以前与<5>横纹肌溶解症</5>有关。迄今为止，尚无报道<6>横纹肌溶解</6>对心肌结构和功能的影响。临床医生需要注意同时开出会增加<11>肌无力</11>或抑制CYP3A4酶风险的药物。我们的病例表明，肌钙蛋白升高可能与<2>他汀类药物</2>引起的<7>横纹肌溶解</7>有关，这可能值得进一步研究。", "revised": true}
{"doc_key": "24739405", "sentences": [["Effects", "of", "dehydroepiandrosterone", "in", "amphetamine", "-", "induced", "schizophrenia", "models", "in", "mice", ".", "OBJECTIVE", ":", "To", "examine", "the", "effects", "of", "dehydroepiandrosterone", "(", "DHEA", ")", "on", "animal", "models", "of", "schizophrenia", ".", "METHODS", ":", "Seventy", "Swiss", "albino", "female", "mice", "(", "25", "-", "35", "g", ")", "were", "divided", "into", "4", "groups", ":", "amphetamine", "-", "free", "(", "control", ")", ",", "amphetamine", ",", "50", ",", "and", "100", "mg", "/", "kg", "DHEA", ".", "The", "DHEA", "was", "administered", "intraperitoneally", "(", "ip", ")", "for", "5", "days", ".", "Amphetamine", "(", "3", "mg", "/", "kg", "ip", ")", "induced", "hyper", "locomotion", ",", "apomorphine", "(", "1", ".", "5", "mg", "/", "kg", "subcutaneously", "[", "sc", "]", ")", "induced", "climbing", ",", "and", "haloperidol", "(", "1", ".", "5", "mg", "/", "kg", "sc", ")", "induced", "catalepsy", "tests", "were", "used", "as", "animal", "models", "of", "schizophrenia", ".", "The", "study", "was", "conducted", "at", "the", "Animal", "Experiment", "Laboratories", ",", "Department", "of", "Pharmacology", ",", "Medical", "School", ",", "Eskisehir", "Osmangazi", "University", ",", "Eskisehir", ",", "Turkey", "between", "March", "and", "May", "2012", ".", "Statistical", "analysis", "was", "carried", "out", "using", "Kruskal", "-", "Wallis", "test", "for", "hyper", "locomotion", ",", "and", "one", "-", "way", "ANOVA", "for", "climbing", "and", "catalepsy", "tests", ".", "RESULTS", ":", "In", "the", "amphetamine", "-", "induced", "locomotion", "test", ",", "there", "were", "significant", "increases", "in", "all", "movements", "compared", "with", "the", "amphetamine", "-", "free", "group", ".", "Both", "DHEA", "50", "mg", "/", "kg", "(", "p", "<", "0", ".", "05", ")", ",", "and", "100", "mg", "/", "kg", "(", "p", "<", "0", ".", "01", ")", "significantly", "decreased", "all", "movements", "compared", "with", "the", "amphetamine", "-", "induced", "locomotion", "group", ".", "There", "was", "a", "significant", "difference", "between", "groups", "in", "the", "haloperidol", "-", "induced", "catalepsy", "test", "(", "p", "<", "0", ".", "05", ")", ".", "There", "was", "no", "significant", "difference", "between", "groups", "in", "terms", "of", "total", "climbing", "time", "in", "the", "apomorphine", "-", "induced", "climbing", "test", "(", "p", ">", "0", ".", "05", ")", ".", "CONCLUSION", ":", "We", "observed", "that", "DHEA", "reduced", "locomotor", "activity", "and", "increased", "catalepsy", "at", "both", "doses", ",", "while", "it", "had", "no", "effect", "on", "climbing", "behavior", ".", "We", "suggest", "that", "DHEA", "displays", "typical", "neuroleptic", "-", "like", "effects", ",", "and", "may", "be", "used", "in", "the", "treatment", "of", "schizophrenia", "."]], "ner": [[[4, 4, "Chemical"], [48, 48, "Chemical"], [55, 55, "Chemical"], [78, 78, "Chemical"], [187, 187, "Chemical"], [203, 203, "Chemical"], [241, 241, "Chemical"], [7, 7, "Disease"], [27, 27, "Disease"], [126, 126, "Disease"], [341, 341, "Disease"], [90, 90, "Chemical"], [284, 284, "Chemical"], [107, 107, "Chemical"], [256, 256, "Chemical"], [118, 118, "Disease"], [180, 180, "Disease"], [259, 259, "Disease"], [308, 308, "Disease"], [2, 2, "Chemical"], [19, 19, "Chemical"], [21, 21, "Chemical"], [64, 64, "Chemical"], [67, 67, "Chemical"], [209, 209, "Chemical"], [302, 302, "Chemical"], [325, 325, "Chemical"], [87, 87, "Disease"], [169, 169, "Disease"]]], "relations": [[[4, 4, 7, 7, "CID"], [4, 4, 27, 27, "CID"], [4, 4, 126, 126, "CID"], [4, 4, 341, 341, "CID"], [48, 48, 7, 7, "CID"], [48, 48, 27, 27, "CID"], [48, 48, 126, 126, "CID"], [48, 48, 341, 341, "CID"], [55, 55, 7, 7, "CID"], [55, 55, 27, 27, "CID"], [55, 55, 126, 126, "CID"], [55, 55, 341, 341, "CID"], [78, 78, 7, 7, "CID"], [78, 78, 27, 27, "CID"], [78, 78, 126, 126, "CID"], [78, 78, 341, 341, "CID"], [187, 187, 7, 7, "CID"], [187, 187, 27, 27, "CID"], [187, 187, 126, 126, "CID"], [187, 187, 341, 341, "CID"], [203, 203, 7, 7, "CID"], [203, 203, 27, 27, "CID"], [203, 203, 126, 126, "CID"], [203, 203, 341, 341, "CID"], [241, 241, 7, 7, "CID"], [241, 241, 27, 27, "CID"], [241, 241, 126, 126, "CID"], [241, 241, 341, 341, "CID"], [90, 90, 7, 7, "CID"], [90, 90, 27, 27, "CID"], [90, 90, 126, 126, "CID"], [90, 90, 341, 341, "CID"], [284, 284, 7, 7, "CID"], [284, 284, 27, 27, "CID"], [284, 284, 126, 126, "CID"], [284, 284, 341, 341, "CID"], [107, 107, 7, 7, "CID"], [107, 107, 27, 27, "CID"], [107, 107, 126, 126, "CID"], [107, 107, 341, 341, "CID"], [256, 256, 7, 7, "CID"], [256, 256, 27, 27, "CID"], [256, 256, 126, 126, "CID"], [256, 256, 341, 341, "CID"], [107, 107, 118, 118, "CID"], [107, 107, 180, 180, "CID"], [107, 107, 259, 259, "CID"], [107, 107, 308, 308, "CID"], [256, 256, 118, 118, "CID"], [256, 256, 180, 180, "CID"], [256, 256, 259, 259, "CID"], [256, 256, 308, 308, "CID"]]], "clusters": [], "translated": "<19>脱氢表雄酮</19>在<0>苯丙胺</0>诱导的<7>精神分裂症</7>小鼠模型中的影响。目的：研究<20>脱氢表雄酮</20>（<21>DHEA</21>）对<8>精神分裂症</8>动物模型的影响。方法：将70只瑞士白化雌性小鼠(25-35g)分为4组：<1>安非他命</1>-无(对照)、<2>安非他命</2>、50和100mg/kg<22>DHEA</22>。<23>DHEA</23>每天经腹膜注射5天。 <3>安非他命</3> (3mg/kgip)诱导<27>运动亢进</27>，<11>阿哌吗啡</11>(1.5mg/kg皮下注射[sc])诱发攀爬行为，以及<13>氟哌啶醇</13>(1.5mg/kgsc)诱发<15>强直症</15>试验作为<9>精神分裂症</9>动物模型。该研究于2012年3月至5月在土耳其Eskisehir的Eskisehir Osmangazi大学医学院药理学系动物实验实验室进行。使用Kruskal-Wallis检验对<28>运动亢进</28>进行统计分析，对攀爬和<16>强直症</16>检验进行单向方差分析。结果：在<4>安非他命</4>诱导的运动试验中，与<5>安非他命</5>无组相比，所有运动均显着增加。<24>DHEA</24> 50mg/kg (p < 0.05)和100mg/kg(p < 0.01)与<6>安非他命</6>诱导的运动组相比，显着减少了所有运动。在<14>氟哌啶醇</14>诱发的<17>强直症</17>试验中，各组间差异显着(p < 0.05)。在<12>阿哌吗啡</12>诱导的攀爬试验中，各组间总攀爬时间无显着差异(p > 0.05)。结论：我们观察到，<25>DHEA</25>在两种剂量下均降低了运动活性并增加了<18>强直症</18>，但对攀爬行为没有影响。我们认为<26>DHEA</26>显示出典型的抗精神病药样作用，可用于治疗<10>精神分裂症</10>。", "revised": true}
{"doc_key": "24975837", "sentences": [["Kinin", "B2", "receptor", "deletion", "and", "blockage", "ameliorates", "cisplatin", "-", "induced", "acute", "renal", "injury", ".", "Cisplatin", "treatment", "has", "been", "adopted", "in", "some", "chemotherapies", ";", "however", ",", "this", "drug", "can", "induce", "acute", "kidney", "injury", "due", "its", "ability", "to", "negatively", "affect", "renal", "function", ",", "augment", "serum", "levels", "of", "creatinine", "and", "urea", ",", "increase", "the", "acute", "tubular", "necrosis", "score", "and", "up", "-", "regulate", "cytokines", "(", "e", ".", "g", ".", ",", "IL", "-", "1b", "and", "TNF", "-", "a", ")", ".", "The", "kinin", "B2", "receptor", "has", "been", "associated", "with", "the", "inflammation", "process", ",", "as", "well", "as", "the", "regulation", "of", "cytokine", "expression", ",", "and", "its", "deletion", "resulted", "in", "an", "improvement", "in", "the", "diabetic", "nephropathy", "status", ".", "To", "examine", "the", "role", "of", "the", "kinin", "B2", "receptor", "in", "cisplatin", "-", "induced", "acute", "kidney", "injury", ",", "kinin", "B2", "receptor", "knockout", "mice", "were", "challenged", "with", "cisplatin", ".", "Additionally", ",", "WT", "mice", "were", "treated", "with", "a", "B2", "receptor", "antagonist", "after", "cisplatin", "administration", ".", "B2", "receptor", "-", "deficient", "mice", "were", "less", "sensitive", "to", "this", "drug", "than", "the", "WT", "mice", ",", "as", "shown", "by", "reduced", "weight", "loss", ",", "better", "preservation", "of", "kidney", "function", ",", "down", "regulation", "of", "inflammatory", "cytokines", "and", "less", "acute", "tubular", "necrosis", ".", "Moreover", ",", "treatment", "with", "the", "kinin", "B2", "receptor", "antagonist", "effectively", "reduced", "the", "levels", "of", "serum", "creatinine", "and", "blood", "urea", "after", "cisplatin", "administration", ".", "Thus", ",", "our", "data", "suggest", "that", "the", "kinin", "B2", "receptor", "is", "involved", "in", "cisplatin", "-", "induced", "acute", "kidney", "injury", "by", "mediating", "the", "necrotic", "process", "and", "the", "expression", "of", "inflammatory", "cytokines", ",", "thus", "resulting", "in", "declined", "renal", "function", ".", "These", "results", "highlight", "the", "kinin", "B2", "receptor", "antagonist", "treatment", "in", "amelioration", "of", "nephrotoxicity", "induced", "by", "cisplatin", "therapy", "."]], "ner": [[[7, 7, "Chemical"], [14, 14, "Chemical"], [119, 119, "Chemical"], [134, 134, "Chemical"], [148, 148, "Chemical"], [211, 211, "Chemical"], [227, 227, "Chemical"], [267, 267, "Chemical"], [10, 12, "Disease"], [29, 31, "Disease"], [122, 124, "Disease"], [230, 232, "Disease"], [51, 53, "Disease"], [187, 189, "Disease"], [171, 172, "Disease"], [84, 84, "Disease"], [105, 106, "Disease"], [236, 236, "Disease"], [264, 264, "Disease"], [45, 45, "Chemical"], [206, 206, "Chemical"], [47, 47, "Chemical"], [209, 209, "Chemical"]]], "relations": [[[7, 7, 10, 12, "CID"], [7, 7, 29, 31, "CID"], [7, 7, 122, 124, "CID"], [7, 7, 230, 232, "CID"], [14, 14, 10, 12, "CID"], [14, 14, 29, 31, "CID"], [14, 14, 122, 124, "CID"], [14, 14, 230, 232, "CID"], [119, 119, 10, 12, "CID"], [119, 119, 29, 31, "CID"], [119, 119, 122, 124, "CID"], [119, 119, 230, 232, "CID"], [134, 134, 10, 12, "CID"], [134, 134, 29, 31, "CID"], [134, 134, 122, 124, "CID"], [134, 134, 230, 232, "CID"], [148, 148, 10, 12, "CID"], [148, 148, 29, 31, "CID"], [148, 148, 122, 124, "CID"], [148, 148, 230, 232, "CID"], [211, 211, 10, 12, "CID"], [211, 211, 29, 31, "CID"], [211, 211, 122, 124, "CID"], [211, 211, 230, 232, "CID"], [227, 227, 10, 12, "CID"], [227, 227, 29, 31, "CID"], [227, 227, 122, 124, "CID"], [227, 227, 230, 232, "CID"], [267, 267, 10, 12, "CID"], [267, 267, 29, 31, "CID"], [267, 267, 122, 124, "CID"], [267, 267, 230, 232, "CID"], [7, 7, 51, 53, "CID"], [7, 7, 187, 189, "CID"], [14, 14, 51, 53, "CID"], [14, 14, 187, 189, "CID"], [119, 119, 51, 53, "CID"], [119, 119, 187, 189, "CID"], [134, 134, 51, 53, "CID"], [134, 134, 187, 189, "CID"], [148, 148, 51, 53, "CID"], [148, 148, 187, 189, "CID"], [211, 211, 51, 53, "CID"], [211, 211, 187, 189, "CID"], [227, 227, 51, 53, "CID"], [227, 227, 187, 189, "CID"], [267, 267, 51, 53, "CID"], [267, 267, 187, 189, "CID"], [7, 7, 171, 172, "CID"], [14, 14, 171, 172, "CID"], [119, 119, 171, 172, "CID"], [134, 134, 171, 172, "CID"], [148, 148, 171, 172, "CID"], [211, 211, 171, 172, "CID"], [227, 227, 171, 172, "CID"], [267, 267, 171, 172, "CID"]]], "clusters": [], "translated": "激肽 B2 受体缺失和阻断可改善<0>顺铂</0>诱导的<8>急性肾损伤</8>。 <1>顺铂</1>治疗已被部分化疗所采用；然而，这种药物可引起<9>急性肾损伤</9>，因为它能够对肾功能产生负面影响，增加<19>肌酐</19>和<21>尿素</21>的血清水平，增加<12>急性肾小管坏死</12>评分和上调细胞因子（例如，IL-1b和TNF-a）。激肽 B2 受体与<15>炎症</15>过程以及细胞因子表达的调节有关，其缺失导致<16>糖尿病肾病</16>状态的改善。为了检查激肽 B2 受体在<2>顺铂</2>诱导的<10>急性肾损伤</10>中的作用，用<3>顺铂</3>攻击激肽 B2 受体敲除小鼠。此外，<4>顺铂</4>后给 WT 小鼠用 B2 受体拮抗剂治疗。 B2 受体缺陷小鼠对这种药物的敏感性低于 WT 小鼠，如<14>体重减轻</14>、肾功能更好地保存、炎性细胞因子下调和<13>急性肾小管坏死</13>。此外，使用<5>顺铂</5>后，用激肽B2受体拮抗剂治疗可有效降低血清<20>肌酐</20>和血液<22>尿素</22>的水平。因此，我们的数据表明激肽B2受体通过介导<17>坏死</17>过程和炎症表达参与<6>顺铂</6>诱导的<11>急性肾损伤</11>，从而导致肾功能下降。这些结果强调了激肽 B2 受体拮抗剂治疗可改善<7>顺铂</7>治疗引起的<18>肾毒性</18>。", "revised": true}
{"doc_key": "25006369", "sentences": [["Optimal", "precurarizing", "dose", "of", "rocuronium", "to", "decrease", "fasciculation", "and", "myalgia", "following", "succinylcholine", "administration", ".", "BACKGROUND", ":", "Succinylcholine", "commonly", "produces", "frequent", "adverse", "effects", ",", "including", "muscle", "fasciculation", "and", "myalgia", ".", "The", "current", "study", "identified", "the", "optimal", "dose", "of", "rocuronium", "to", "prevent", "succinylcholine", "-", "induced", "fasciculation", "and", "myalgia", "and", "evaluated", "the", "influence", "of", "rocuronium", "on", "the", "speed", "of", "onset", "produced", "by", "succinylcholine", ".", "METHODS", ":", "This", "randomized", ",", "double", "-", "blinded", "study", "was", "conducted", "in", "100", "patients", "randomly", "allocated", "into", "five", "groups", "of", "20", "patients", "each", ".", "Patients", "were", "randomized", "to", "receive", "0", ".", "02", ",", "0", ".", "03", ",", "0", ".", "04", ",", "0", ".", "05", "and", "0", ".", "06", "mg", "/", "kg", "rocuronium", "as", "a", "precurarizing", "dose", ".", "Neuromuscular", "monitoring", "after", "each", "precurarizing", "dose", "was", "recorded", "from", "the", "adductor", "pollicis", "muscle", "using", "acceleromyography", "with", "train", "-", "of", "-", "four", "stimulation", "of", "the", "ulnar", "nerve", ".", "All", "patients", "received", "succinylcholine", "1", ".", "5", "mg", "/", "kg", "at", "2", "minutes", "after", "the", "precurarization", ",", "and", "were", "assessed", "the", "incidence", "and", "severity", "of", "fasciculations", ",", "while", "myalgia", "was", "assessed", "at", "24", "hours", "after", "surgery", ".", "RESULTS", ":", "The", "incidence", "and", "severity", "of", "visible", "muscle", "fasciculation", "was", "significantly", "less", "with", "increasing", "the", "amount", "of", "precurarizing", "dose", "of", "rocuronium", "(", "P", "<", "0", ".", "001", ")", ".", "Those", "of", "myalgia", "tend", "to", "decrease", "according", "to", "increasing", "the", "amount", "of", "precurarizing", "dose", "of", "rocuronium", ",", "but", "there", "was", "no", "significance", "(", "P", "=", "0", ".", "072", ")", ".", "The", "onset", "time", "of", "succinylcholine", "was", "significantly", "longer", "with", "increasing", "the", "amount", "of", "precurarizing", "dose", "of", "rocuronium", "(", "P", "<", "0", ".", "001", ")", ".", "CONCLUSIONS", ":", "Precurarization", "with", "0", ".", "04", "mg", "/", "kg", "rocuronium", "was", "the", "optimal", "dose", "considering", "the", "reduction", "in", "the", "incidence", "and", "severity", "of", "fasciculation", "and", "myalgia", "with", "acceptable", "onset", "time", ",", "and", "the", "safe", "and", "effective", "precurarization", "."]], "ner": [[[11, 11, "Chemical"], [16, 16, "Chemical"], [40, 40, "Chemical"], [59, 59, "Chemical"], [148, 148, "Chemical"], [246, 246, "Chemical"], [7, 7, "Disease"], [24, 25, "Disease"], [43, 43, "Disease"], [170, 170, "Disease"], [190, 191, "Disease"], [291, 291, "Disease"], [9, 9, "Disease"], [27, 27, "Disease"], [45, 45, "Disease"], [173, 173, "Disease"], [214, 214, "Disease"], [293, 293, "Disease"], [4, 4, "Chemical"], [37, 37, "Chemical"], [51, 51, "Chemical"], [112, 112, "Chemical"], [203, 203, "Chemical"], [227, 227, "Chemical"], [258, 258, "Chemical"], [277, 277, "Chemical"]]], "relations": [[[11, 11, 7, 7, "CID"], [11, 11, 24, 25, "CID"], [11, 11, 43, 43, "CID"], [11, 11, 170, 170, "CID"], [11, 11, 190, 191, "CID"], [11, 11, 291, 291, "CID"], [16, 16, 7, 7, "CID"], [16, 16, 24, 25, "CID"], [16, 16, 43, 43, "CID"], [16, 16, 170, 170, "CID"], [16, 16, 190, 191, "CID"], [16, 16, 291, 291, "CID"], [40, 40, 7, 7, "CID"], [40, 40, 24, 25, "CID"], [40, 40, 43, 43, "CID"], [40, 40, 170, 170, "CID"], [40, 40, 190, 191, "CID"], [40, 40, 291, 291, "CID"], [59, 59, 7, 7, "CID"], [59, 59, 24, 25, "CID"], [59, 59, 43, 43, "CID"], [59, 59, 170, 170, "CID"], [59, 59, 190, 191, "CID"], [59, 59, 291, 291, "CID"], [148, 148, 7, 7, "CID"], [148, 148, 24, 25, "CID"], [148, 148, 43, 43, "CID"], [148, 148, 170, 170, "CID"], [148, 148, 190, 191, "CID"], [148, 148, 291, 291, "CID"], [246, 246, 7, 7, "CID"], [246, 246, 24, 25, "CID"], [246, 246, 43, 43, "CID"], [246, 246, 170, 170, "CID"], [246, 246, 190, 191, "CID"], [246, 246, 291, 291, "CID"], [11, 11, 9, 9, "CID"], [11, 11, 27, 27, "CID"], [11, 11, 45, 45, "CID"], [11, 11, 173, 173, "CID"], [11, 11, 214, 214, "CID"], [11, 11, 293, 293, "CID"], [16, 16, 9, 9, "CID"], [16, 16, 27, 27, "CID"], [16, 16, 45, 45, "CID"], [16, 16, 173, 173, "CID"], [16, 16, 214, 214, "CID"], [16, 16, 293, 293, "CID"], [40, 40, 9, 9, "CID"], [40, 40, 27, 27, "CID"], [40, 40, 45, 45, "CID"], [40, 40, 173, 173, "CID"], [40, 40, 214, 214, "CID"], [40, 40, 293, 293, "CID"], [59, 59, 9, 9, "CID"], [59, 59, 27, 27, "CID"], [59, 59, 45, 45, "CID"], [59, 59, 173, 173, "CID"], [59, 59, 214, 214, "CID"], [59, 59, 293, 293, "CID"], [148, 148, 9, 9, "CID"], [148, 148, 27, 27, "CID"], [148, 148, 45, 45, "CID"], [148, 148, 173, 173, "CID"], [148, 148, 214, 214, "CID"], [148, 148, 293, 293, "CID"], [246, 246, 9, 9, "CID"], [246, 246, 27, 27, "CID"], [246, 246, 45, 45, "CID"], [246, 246, 173, 173, "CID"], [246, 246, 214, 214, "CID"], [246, 246, 293, 293, "CID"]]], "clusters": [], "translated": "<18>罗库溴铵</18> 的最佳预麻痹剂量可减少 <0>琥珀胆碱</0> 后的<6>肌束震颤</6>和<12>肌痛</12>。背景：<1>琥珀胆碱</1>通常会产生频繁的副作用，包括<7>肌肉束颤</7>和<13>肌痛</13>。目前的研究确定了<19>罗库溴铵</19>预防<2>琥珀酰胆碱</2>引起的<8>肌束震颤</8>和<14>肌痛</14>的最佳剂量，并评估了<20>罗库溴铵</20>对<3>琥珀胆碱</3>产生的起效速度的影响。方法：这项随机、双盲研究在100名患者中进行，随机分为五组，每组20名患者。患者随机接受0.02、0.03、0.04、0.05和0.06mg/kg <21>罗库溴铵</21>作为预固化剂量。使用加速肌动描记法和尺神经四列刺激法记录每次预麻痹剂量后的神经肌肉监测，记录拇收肌。所有患者均接受<4>琥珀胆碱</4> 1.5mg/kg于预固化后2分钟注射，评估<9>肌束震颤</9>的发生率和严重程度，术后24小时评估<15>肌痛</15>。结果：可见<10>肌束震颤</10>的发生率和严重程度随着<22>罗库溴铵</22>预固化剂量的增加而显着降低(P<0.001)。<16>肌痛</16>随<23>罗库溴铵</23>预固化剂量的增加而减轻，但无显着性意义(P=0.072)。随着<24>罗库溴铵</24>预固化剂量的增加，<5>琥珀胆碱</5>的起效时间明显延长(P<0.001)。结论：预固化用0.04mg/kg <25>罗库溴铵</25>是最佳剂量，因为它可以降低<11>肌束震颤</11>和<17>肌痛</17>的发生率和严重程度，并且起效时间可以接受，是一种安全有效的precurarization。", "revised": true}
{"doc_key": "25071004", "sentences": [["Delayed", "anemia", "after", "treatment", "with", "injectable", "artesunate", "in", "the", "Democratic", "Republic", "of", "the", "Congo", ":", "a", "manageable", "issue", ".", "Cases", "of", "delayed", "hemolytic", "anemia", "have", "been", "described", "after", "treatment", "with", "injectable", "artesunate", ",", "the", "current", "World", "Health", "Organization", "(", "WHO", ")", "-", "recommended", "first", "-", "line", "drug", "for", "the", "treatment", "of", "severe", "malaria", ".", "A", "total", "of", "350", "patients", "(", "215", "[", "61", ".", "4", "%", "]", "<", "5", "years", "of", "age", "and", "135", "[", "38", ".", "6", "%", "]", ">", "5", "years", "of", "age", ")", "were", "followed", "-", "up", "after", "treatment", "with", "injectable", "artesunate", "for", "severe", "malaria", "in", "hospitals", "and", "health", "centers", "of", "the", "Democratic", "Republic", "of", "the", "Congo", ".", "Complete", "series", "of", "hemoglobin", "(", "Hb", ")", "measurements", "were", "available", "for", "201", "patients", ".", "A", "decrease", "in", "Hb", "levels", "between", "2", "and", "5", "g", "/", "dL", "was", "detected", "in", "23", "(", "11", ".", "4", "%", ")", "patients", "during", "the", "follow", "-", "up", "period", ".", "For", "five", "patients", ",", "Hb", "levels", "decreased", "below", "5", "g", "/", "dL", "during", "at", "least", "one", "follow", "-", "up", "visit", ".", "All", "cases", "of", "delayed", "anemia", "were", "clinically", "manageable", "and", "resolved", "within", "one", "month", "."]], "ner": [[[6, 6, "Chemical"], [31, 31, "Chemical"], [94, 94, "Chemical"], [22, 23, "Disease"], [1, 1, "Disease"], [180, 180, "Disease"], [52, 52, "Disease"], [97, 97, "Disease"]]], "relations": [[[6, 6, 22, 23, "CID"], [31, 31, 22, 23, "CID"], [94, 94, 22, 23, "CID"]]], "clusters": [], "translated": "在刚果民主共和国用可注射的<0>青蒿琥酯</0>治疗后迟发性<4>贫血</4>：一个可控的问题。注射用<1>青蒿琥酯</1>治疗后发生迟发性<3>溶血性贫血</3>的病例已有报道，青蒿琥酯是目前世界卫生组织（WHO）推荐的一线药物治疗重症<6>疟疾</6>。共有350名患者（215 [61.4%]<5岁和135 [38.6%]>5岁）在治疗重症<7>疟疾</7>后接受了注射用<2>青蒿琥酯</2>的随访，在刚果民主共和国的医院和保健中心进行。对201名患者进行了完整系列的血红蛋白（Hb）测量。在随访期间，有23名（11.4%）患者的Hb水平降低了2到5 g/dL。在至少一次随访期间，有5名患者的Hb水平降至5 g/dL以下。所有迟发性<5>贫血</5>病例均在临床上可控制，并在一个月内得到解决。", "revised": true}
{"doc_key": "24999722", "sentences": [["Safety", "and", "efficacy", "of", "fluocinolone", "acetonide", "intravitreal", "implant", "(", "0", ".", "59", "mg", ")", "in", "birdshot", "retinochoroidopathy", ".", "PURPOSE", ":", "To", "report", "the", "treatment", "outcomes", "of", "the", "fluocinolone", "acetonide", "intravitreal", "implant", "(", "0", ".", "59", "mg", ")", "in", "patients", "with", "birdshot", "retinochoroidopathy", "whose", "disease", "is", "refractory", "or", "intolerant", "to", "conventional", "immunomodulatory", "therapy", ".", "METHODS", ":", "A", "retrospective", "case", "series", "involving", "11", "birdshot", "retinochoroidopathy", "patients", "(", "11", "eyes", ")", ".", "Eleven", "patients", "(", "11", "eyes", ")", "underwent", "surgery", "for", "fluocinolone", "acetonide", "implant", "(", "0", ".", "59", "mg", ")", ".", "Treatment", "outcomes", "of", "interest", "were", "noted", "at", "baseline", ",", "before", "fluocinolone", "acetonide", "implant", ",", "and", "then", "at", "6", "months", ",", "1", "year", ",", "2", "years", ",", "3", "years", ",", "and", "beyond", "3", "years", ".", "Disease", "activity", "markers", ",", "including", "signs", "of", "ocular", "inflammation", ",", "evidence", "of", "retinal", "vasculitis", ",", "Swedish", "interactive", "threshold", "algorithm", "-", "short", "wavelength", "automated", "perimetry", "Humphrey", "visual", "field", "analysis", ",", "electroretinographic", "parameters", ",", "and", "optical", "coherence", "tomography", "were", "recorded", ".", "Data", "on", "occurrence", "of", "cataract", "and", "raised", "intraocular", "pressure", "were", "collected", "in", "all", "eyes", ".", "RESULTS", ":", "Intraocular", "inflammation", "was", "present", "in", "54", ".", "5", ",", "9", ".", "9", ",", "11", ".", "1", ",", "and", "0", "%", "of", "patients", "at", "baseline", ",", "6", "months", ",", "1", "year", ",", "2", "years", ",", "3", "years", ",", "and", "beyond", "3", "years", "after", "receiving", "the", "implant", ",", "respectively", ".", "Active", "vasculitis", "was", "noted", "in", "36", ".", "3", "%", "patients", "at", "baseline", "and", "0", "%", "at", "3", "years", "of", "follow", "-", "up", ".", "More", "than", "20", "%", "(", "47", ".", "61", "-", "67", ".", "2", "%", ")", "reduction", "in", "central", "retinal", "thickness", "was", "noted", "in", "all", "patients", "with", "cystoid", "macular", "edema", "at", "6", "months", ",", "1", "year", ",", "2", "years", ",", "and", "3", "years", "postimplant", ".", "At", "baseline", ",", "54", ".", "5", "%", "patients", "were", "on", "immunomodulatory", "agents", ".", "This", "percentage", "decreased", "to", "45", ".", "45", ",", "44", ".", "4", ",", "and", "14", ".", "28", "%", "at", "1", "year", ",", "2", "years", ",", "and", "3", "years", "postimplant", ",", "respectively", ".", "Adverse", "events", "included", "increased", "intraocular", "pressure", "(", "54", ".", "5", "%", ")", "and", "cataract", "formation", "(", "100", "%", ")", ".", "CONCLUSION", ":", "The", "data", "suggest", "that", "fluocinolone", "acetonide", "implant", "(", "0", ".", "59", "mg", ")", "helps", "to", "control", "inflammation", "in", "otherwise", "treatment", "-", "refractory", "cases", "of", "birdshot", "retinochoroidopathy", ".", "It", "is", "associated", "with", "significant", "side", "effects", "of", "cataract", "and", "ocular", "hypertension", "requiring", "treatment", "."]], "ner": [[[4, 5, "Chemical"], [27, 28, "Chemical"], [78, 79, "Chemical"], [98, 99, "Chemical"], [362, 363, "Chemical"], [165, 165, "Disease"], [349, 349, "Disease"], [393, 393, "Disease"], [167, 169, "Disease"], [339, 341, "Disease"], [395, 396, "Disease"], [15, 16, "Disease"], [40, 41, "Disease"], [61, 62, "Disease"], [382, 383, "Disease"], [130, 130, "Disease"], [179, 179, "Disease"], [374, 374, "Disease"], [134, 135, "Disease"], [227, 227, "Disease"], [274, 276, "Disease"]]], "relations": [[[4, 5, 165, 165, "CID"], [4, 5, 349, 349, "CID"], [4, 5, 393, 393, "CID"], [27, 28, 165, 165, "CID"], [27, 28, 349, 349, "CID"], [27, 28, 393, 393, "CID"], [78, 79, 165, 165, "CID"], [78, 79, 349, 349, "CID"], [78, 79, 393, 393, "CID"], [98, 99, 165, 165, "CID"], [98, 99, 349, 349, "CID"], [98, 99, 393, 393, "CID"], [362, 363, 165, 165, "CID"], [362, 363, 349, 349, "CID"], [362, 363, 393, 393, "CID"], [4, 5, 167, 169, "CID"], [4, 5, 339, 341, "CID"], [4, 5, 395, 396, "CID"], [27, 28, 167, 169, "CID"], [27, 28, 339, 341, "CID"], [27, 28, 395, 396, "CID"], [78, 79, 167, 169, "CID"], [78, 79, 339, 341, "CID"], [78, 79, 395, 396, "CID"], [98, 99, 167, 169, "CID"], [98, 99, 339, 341, "CID"], [98, 99, 395, 396, "CID"], [362, 363, 167, 169, "CID"], [362, 363, 339, 341, "CID"], [362, 363, 395, 396, "CID"]]], "clusters": [], "translated": "<0>醋酸氟轻松</0>玻璃体内植入物（0.59 mg）在<11>鸟弹样视网膜脉络膜病变</11>中的安全性和有效性。目的：报告<1> 醋酸氟轻松 </1>玻璃体内植入物（0.59毫克）对难以治疗或无法耐受常规免疫调节治疗的<12> 鸟弹样视网膜脉络膜病变 </12>患者的治疗效果。方法：回顾性病例系列涉及11例<13>鸟弹样视网膜脉络膜病变</13>患者（11只眼）。这些患者接受了<2>醋酸氟轻松</2>（0.59毫克）植入剂手术。在基线、<3>植入剂</3>之前，以及植入剂术后6个月、1年、2年、3年和3年以上记录了治疗结果。记录疾病活动的指标，包括眼部<15>炎症</15>的体征，<18>视网膜血管炎</18>的证据，瑞典交互式阈值算法-短波长自动视野计汉弗莱视野分析，视网膜电图参数以及光学相干断层扫描等。收集所有眼中<5>白内障</5>和<8>高眼压</8>的发生情况数据。结果：54.5％、9.9％、11.1%、0%的患者在接受植入剂后的基线、6个月、1年、2年、3年和3年以上出现眼内<16>炎症</16>。36.3％的患者基线时出现活动性<19>血管炎</19>，3年随访时无病例。在6个月、1年、2年和3年术后，所有患有<20>黄斑囊样水肿</20>的患者中，中央视网膜厚度均减少了超过20％（47.61-67.2％）。在基线时，54.5％的患者使用免疫调节药物，这个百分比分别在植入剂后的1年、2年和3年降至45.45％、44.4％、14.28％。不良事件包括<9>眼内高压</9>（54.5％）和<6>白内障</6>形成（100％）。结论：数据表明，<4>醋酸氟轻松</4>植入剂（0.59毫克）有助于控制<17>炎症</17>，在其他治疗难以治疗的<14>鸟弹样视网膜脉络膜病变</14>患者中有显著的副作用，需要治疗的包括<7>白内障</7>和<10>高眼压</10>。", "revised": true}
{"doc_key": "25096313", "sentences": [["Lateral", "antebrachial", "cutaneous", "neuropathy", "after", "steroid", "injection", "at", "lateral", "epicondyle", ".", "BACKGROUND", "AND", "OBJECTIVES", ":", "This", "report", "aimed", "to", "present", "a", "case", "of", "lateral", "antebrachial", "cutaneous", "neuropathy", "(", "LACNP", ")", "that", "occurred", "after", "a", "steroid", "injection", "in", "the", "lateral", "epicondyle", "to", "treat", "lateral", "epicondylitis", "in", "a", "40", "-", "year", "-", "old", "woman", ".", "MATERIAL", "AND", "METHOD", ":", "A", "40", "-", "year", "-", "old", "woman", "presented", "with", "decreased", "sensation", "and", "paresthesia", "over", "her", "right", "lateral", "forearm", ";", "the", "paresthesia", "had", "occurred", "after", "a", "steroid", "injection", "in", "the", "right", "lateral", "epicondyle", "3", "months", "before", ".", "Her", "sensation", "of", "light", "touch", "and", "pain", "was", "diminished", "over", "the", "lateral", "side", "of", "the", "right", "forearm", "and", "wrist", "area", ".", "RESULTS", ":", "The", "sensory", "action", "potential", "amplitude", "of", "the", "right", "lateral", "antebrachial", "cutaneous", "nerve", "(", "LACN", ")", "(", "6", ".", "2", "uV", ")", "was", "lower", "than", "that", "of", "the", "left", "(", "13", ".", "1", "uV", ")", ".", "The", "difference", "of", "amplitude", "between", "both", "sides", "was", "significant", "because", "there", "was", "more", "than", "a", "50", "%", "reduction", ".", "She", "was", "diagnosed", "with", "right", "LACNP", "(", "mainly", "axonal", "involvement", ")", "on", "the", "basis", "of", "the", "clinical", "manifestation", "and", "the", "electrodiagnostic", "findings", ".", "Her", "symptoms", "improved", "through", "physical", "therapy", "but", "persisted", "to", "some", "degree", ".", "CONCLUSION", ":", "This", "report", "describes", "the", "case", "of", "a", "woman", "with", "LACNP", "that", "developed", "after", "a", "steroid", "injection", "for", "the", "treatment", "of", "lateral", "epicondylitis", ".", "An", "electrodiagnostic", "study", ",", "including", "a", "nerve", "conduction", "study", "of", "the", "LACN", ",", "was", "helpful", "to", "diagnose", "right", "LACNP", "and", "to", "find", "the", "passage", "of", "the", "LACN", "on", "the", "lateral", "epicondyle", "."]], "ner": [[[5, 5, "Chemical"], [34, 34, "Chemical"], [82, 82, "Chemical"], [221, 221, "Chemical"], [69, 69, "Disease"], [77, 77, "Disease"], [3, 3, "Disease"], [26, 26, "Disease"], [42, 43, "Disease"], [227, 228, "Disease"], [99, 99, "Disease"]]], "relations": [[[5, 5, 69, 69, "CID"], [5, 5, 77, 77, "CID"], [34, 34, 69, 69, "CID"], [34, 34, 77, 77, "CID"], [82, 82, 69, 69, "CID"], [82, 82, 77, 77, "CID"], [221, 221, 69, 69, "CID"], [221, 221, 77, 77, "CID"]]], "clusters": [], "translated": "在外上髁注射<0>类固醇</0>后，外侧前臂皮肤<6>神经病变</6>。背景和目的：本报告旨在介绍一例在外上髁<1>类固醇</1>注射治疗<8>外上髁炎</8>后发生的外侧前臂皮肤<7>神经病变</7>（LACNP）。材料和方法：一位40岁的女性就诊时，她的右前臂感觉减退，<4>感觉异常</4>；<5>感觉异常</5>是在3个月前在右侧外上髁注射<2>类固醇</2>后发生的。她的右前臂外侧和手腕区域的轻触感和<10>疼痛</10>减弱了。结果：右侧前臂外侧皮神经(LACN)的感觉动作电位幅度(6.2uV)低于左侧(13.1uV)。两侧的振幅差异很大，因为减少了50%以上。根据临床表现和电诊断结果诊断为右侧LACNP（主要是轴突受累）。她的症状通过物理治疗得到改善，但在一定程度上仍然存在。结论：本报告描述了一名患有LACNP的女性病例，该病例在注射<3>类固醇</3>治疗<9>外上髁炎</9>后发生。电诊断研究，包括LACN的神经传导研究，有助于诊断右侧LACNP和发现LACN在外上髁上的通道。", "revised": true}
{"doc_key": "25951420", "sentences": [["Associations", "of", "Ozone", "and", "PM2", ".", "5", "Concentrations", "With", "Parkinson", "'s", "Disease", "Among", "Participants", "in", "the", "Agricultural", "Health", "Study", ".", "OBJECTIVE", ":", "This", "study", "describes", "associations", "of", "ozone", "and", "fine", "particulate", "matter", "with", "Parkinson", "'s", "disease", "observed", "among", "farmers", "in", "North", "Carolina", "and", "Iowa", ".", "METHODS", ":", "We", "used", "logistic", "regression", "to", "determine", "the", "associations", "of", "these", "pollutants", "with", "self", "-", "reported", ",", "doctor", "-", "diagnosed", "Parkinson", "'s", "disease", ".", "Daily", "predicted", "pollutant", "concentrations", "were", "used", "to", "derive", "surrogates", "of", "long", "-", "term", "exposure", "and", "link", "them", "to", "study", "participants", "'", "geocoded", "addresses", ".", "RESULTS", ":", "We", "observed", "positive", "associations", "of", "Parkinson", "'s", "disease", "with", "ozone", "(", "odds", "ratio", "=", "1", ".", "39", ";", "95", "%", "CI", ":", "0", ".", "98", "to", "1", ".", "98", ")", "and", "fine", "particulate", "matter", "(", "odds", "ratio", "=", "1", ".", "34", ";", "95", "%", "CI", ":", "0", ".", "93", "to", "1", ".", "93", ")", "in", "North", "Carolina", "but", "not", "in", "Iowa", ".", "CONCLUSIONS", ":", "The", "plausibility", "of", "an", "effect", "of", "ambient", "concentrations", "of", "these", "pollutants", "on", "Parkinson", "'s", "disease", "risk", "is", "supported", "by", "experimental", "data", "demonstrating", "damage", "to", "dopaminergic", "neurons", "at", "relevant", "concentrations", ".", "Additional", "studies", "are", "needed", "to", "address", "uncertainties", "related", "to", "confounding", "and", "to", "examine", "temporal", "aspects", "of", "the", "associations", "we", "observed", "."]], "ner": [[[2, 2, "Chemical"], [27, 27, "Chemical"], [105, 105, "Chemical"], [9, 11, "Disease"], [33, 35, "Disease"], [66, 68, "Disease"], [101, 103, "Disease"], [172, 174, "Disease"], [30, 31, "Chemical"], [128, 129, "Chemical"]]], "relations": [[[2, 2, 9, 11, "CID"], [2, 2, 33, 35, "CID"], [2, 2, 66, 68, "CID"], [2, 2, 101, 103, "CID"], [2, 2, 172, 174, "CID"], [27, 27, 9, 11, "CID"], [27, 27, 33, 35, "CID"], [27, 27, 66, 68, "CID"], [27, 27, 101, 103, "CID"], [27, 27, 172, 174, "CID"], [105, 105, 9, 11, "CID"], [105, 105, 33, 35, "CID"], [105, 105, 66, 68, "CID"], [105, 105, 101, 103, "CID"], [105, 105, 172, 174, "CID"], [30, 31, 9, 11, "CID"], [30, 31, 33, 35, "CID"], [30, 31, 66, 68, "CID"], [30, 31, 101, 103, "CID"], [30, 31, 172, 174, "CID"], [128, 129, 9, 11, "CID"], [128, 129, 33, 35, "CID"], [128, 129, 66, 68, "CID"], [128, 129, 101, 103, "CID"], [128, 129, 172, 174, "CID"]]], "clusters": [], "translated": "<0>臭氧</0>与PM2.5的关联。农业健康研究参与者中<3>帕金森病</3>的浓度。目标：本研究描述了在北卡罗来纳州和爱荷华州的农民中观察到的<1>臭氧</1>和<8>细颗粒物</8>与<4>帕金森病</4>之间的关联。方法：我们使用逻辑回归来确定这些污染物与自我报告的、医生诊断的<5>帕金森病</5>之间的关联。每天预测的污染物浓度被用来推导出长期暴露的替代物，并将它们与研究参与者的地理编码地址联系起来。结果：我们观察到<6>帕金森病</6>与<2>臭氧</2>呈正相关（比值比 = 1 . 39 ； 95 % CI ： 0 . 98 至 1 . 98 ）和<9>精细颗粒物</9>（比值比 = 1. 34；95% CI：0. 93 至 1. 93）在北卡罗来纳州，但在爱荷华州没有。结论：这些污染物的环境浓度对<7>帕金森病</7>风险的影响的合理性得到证明在相关浓度下对多巴胺能神经元造成损害的实验数据的支持。需要更多的研究来解决与混杂相关的不确定性，并检查我们观察到的关联的时间方面。", "revised": true}
{"doc_key": "25054547", "sentences": [["Characterization", "of", "a", "novel", "BCHE", "\"", "silent", "\"", "allele", ":", "point", "mutation", "(", "p", ".", "Val204Asp", ")", "causes", "loss", "of", "activity", "and", "prolonged", "apnea", "with", "suxamethonium", ".", "Butyrylcholinesterase", "deficiency", "is", "characterized", "by", "prolonged", "apnea", "after", "the", "use", "of", "muscle", "relaxants", "(", "suxamethonium", "or", "mivacurium", ")", "in", "patients", "who", "have", "mutations", "in", "the", "BCHE", "gene", ".", "Here", ",", "we", "report", "a", "case", "of", "prolonged", "neuromuscular", "block", "after", "administration", "of", "suxamethonium", "leading", "to", "the", "discovery", "of", "a", "novel", "BCHE", "variant", "(", "c", ".", "695T", ">", "A", ",", "p", ".", "Val204Asp", ")", ".", "Inhibition", "studies", ",", "kinetic", "analysis", "and", "molecular", "dynamics", "were", "undertaken", "to", "understand", "how", "this", "mutation", "disrupts", "the", "catalytic", "triad", "and", "determines", "a", "\"", "silent", "\"", "phenotype", ".", "Low", "activity", "of", "patient", "plasma", "butyrylcholinesterase", "with", "butyrylthiocholine", "(", "BTC", ")", "and", "benzoylcholine", ",", "and", "values", "of", "dibucaine", "and", "fluoride", "numbers", "fit", "with", "heterozygous", "atypical", "silent", "genotype", ".", "Electrophoretic", "analysis", "of", "plasma", "BChE", "of", "the", "proband", "and", "his", "mother", "showed", "that", "patient", "has", "a", "reduced", "amount", "of", "tetrameric", "enzyme", "in", "plasma", "and", "that", "minor", "fast", "-", "moving", "BChE", "components", ":", "monomer", ",", "dimer", ",", "and", "monomer", "-", "albumin", "conjugate", "are", "missing", ".", "Kinetic", "analysis", "showed", "that", "the", "p", ".", "Val204Asp", "/", "p", ".", "Asp70Gly", "-", "p", ".", "Ala539Thr", "BChE", "displays", "a", "pure", "Michaelian", "behavior", "with", "BTC", "as", "the", "substrate", ".", "Both", "catalytic", "parameters", "Km", "=", "265", "uM", "for", "BTC", ",", "two", "times", "higher", "than", "that", "of", "the", "atypical", "enzyme", ",", "and", "a", "low", "Vmax", "are", "consistent", "with", "the", "absence", "of", "activity", "against", "suxamethonium", ".", "Molecular", "dynamic", "(", "MD", ")", "simulations", "showed", "that", "the", "overall", "effect", "of", "the", "mutation", "p", ".", "Val204Asp", "is", "disruption", "of", "hydrogen", "bonding", "between", "Gln223", "and", "Glu441", ",", "leading", "Ser198", "and", "His438", "to", "move", "away", "from", "each", "other", "with", "subsequent", "disruption", "of", "the", "catalytic", "triad", "functionality", "regardless", "of", "the", "type", "of", "substrate", ".", "MD", "also", "showed", "that", "the", "enzyme", "volume", "is", "increased", ",", "suggesting", "a", "pre", "-", "denaturation", "state", ".", "This", "fits", "with", "the", "reduced", "concentration", "of", "p", ".", "Ala204Asp", "/", "p", ".", "Asp70Gly", "-", "p", ".", "Ala539Thr", "tetrameric", "enzyme", "in", "the", "plasma", "and", "non", "-", "detectable", "fast", "moving", "-", "bands", "on", "electrophoresis", "gels", "."]], "ner": [[[25, 25, "Chemical"], [41, 41, "Chemical"], [68, 68, "Chemical"], [249, 249, "Chemical"], [23, 23, "Disease"], [33, 33, "Disease"], [43, 43, "Chemical"], [27, 28, "Disease"], [124, 124, "Chemical"], [126, 126, "Chemical"], [212, 212, "Chemical"], [225, 225, "Chemical"], [129, 129, "Chemical"], [134, 134, "Chemical"], [136, 136, "Chemical"], [271, 271, "Chemical"]]], "relations": [[[25, 25, 23, 23, "CID"], [25, 25, 33, 33, "CID"], [41, 41, 23, 23, "CID"], [41, 41, 33, 33, "CID"], [68, 68, 23, 23, "CID"], [68, 68, 33, 33, "CID"], [249, 249, 23, 23, "CID"], [249, 249, 33, 33, "CID"], [43, 43, 23, 23, "CID"], [43, 43, 33, 33, "CID"], [25, 25, 27, 28, "CID"], [41, 41, 27, 28, "CID"], [68, 68, 27, 28, "CID"], [249, 249, 27, 28, "CID"], [43, 43, 27, 28, "CID"]]], "clusters": [], "translated": "新型 <7>BCHE“沉默”</7> 等位基因的特征：点突变 (p. Val204Asp) 导致活性丧失和<4>呼吸暂停</4> 延长与<0>琥珀胆碱</0>。 <7>丁酰胆碱酯酶缺乏症</7>的特征是使用肌肉松弛剂（<1>琥珀胆碱</1>或<6>米库氯铵</6>）后长期<5>呼吸暂停</5>，在<7>BCHE基因突变</7>患者中产生。在这里，我们报告了一例服用<2>琥珀胆碱</2>后神经肌肉阻滞时间延长的病例，导致发现了一种新的<7>BCHE变体</7>（c.695T > A，p.Val204Asp）。进行了抑制研究、动力学分析和分子动力学，以了解这种突变如何破坏催化三联体并确定“沉默”表型。患者血浆丁酰胆碱酯酶与<8>丁酰硫代胆碱</8> (<9>BTC</9>)和<12>苯甲酰胆碱</12>的低活性，以及<13>地布卡因</13>和<14>氟化物</14>的值符合杂合非典型沉默基因型。先证者及其母亲的血浆BChE电泳分析表明，患者血浆中的四聚体酶量减少，并且缺少少量快速移动的BChE成分：单体、二聚体和单体-白蛋白结合物。动力学分析表明，p. Val204Asp/p. Asp70Gly-p. Ala539Thr BChE以<10>BTC</10>为底物表现出纯迈克尔行为。两个催化参数Km = 265 uM对<11>BTC</11>，是非典型酶的两倍，低Vmax与不存在针对<3>琥珀胆碱</3>的活性一致。分子动力学(MD)模拟显示突变p.Val204Asp破坏了Gln223和Glu441之间的<15>氢键</15>，导致Ser198和His438相互远离，随后破坏了催化三联体功能，而不管底物的类型如何。MD还显示酶体积增加，表明处于预变性状态。这符合p.Ala204Asp/p.Asp70Gly-p.Ala539Thr四聚体酶的浓度降低和血浆中不可检测的快速移动条带。", "revised": true}
{"doc_key": "26002693", "sentences": [["1", ",", "3", "-", "Butadiene", ",", "CML", "and", "the", "t", "(", "9", ":", "22", ")", "translocation", ":", "A", "reality", "check", ".", "UNASSIGNED", ":", "Epidemiological", "studies", "of", "1", ",", "3", "-", "butadiene", "have", "suggest", "that", "exposures", "to", "humans", "are", "associated", "with", "chronic", "myeloid", "leukemia", "(", "CML", ")", ".", "CML", "has", "a", "well", "-", "documented", "association", "with", "ionizing", "radiation", ",", "but", "reports", "of", "associations", "with", "chemical", "exposures", "have", "been", "questioned", ".", "Ionizing", "radiation", "is", "capable", "of", "inducing", "the", "requisite", "CML", "-", "associated", "t", "(", "9", ":", "22", ")", "translocation", "(", "Philadelphia", "chromosome", ")", "in", "appropriate", "cells", "in", "vitro", "but", ",", "thus", "far", ",", "chemicals", "have", "not", "shown", "this", "capacity", ".", "We", "have", "proposed", "that", "1", ",", "3", "-", "butadiene", "metabolites", "be", "so", "tested", "as", "a", "reality", "check", "on", "the", "epidemiological", "reports", ".", "In", "order", "to", "conduct", "reliable", "testing", "in", "this", "regard", ",", "it", "is", "essential", "that", "a", "positive", "control", "for", "induction", "be", "available", ".", "We", "have", "used", "ionizing", "radiation", "to", "develop", "such", "a", "control", ".", "Results", "described", "here", "demonstrate", "that", "this", "agent", "does", "in", "fact", "induce", "pathogenic", "t", "(", "9", ":", "22", ")", "translocations", "in", "a", "human", "myeloid", "cell", "line", "in", "vitro", ",", "but", "does", "so", "at", "low", "frequencies", ".", "Conditions", "that", "will", "be", "required", "for", "studies", "of", "1", ",", "3", "-", "butadiene", "are", "discussed", "."]], "ner": [[[0, 4, "Chemical"], [26, 30, "Chemical"], [112, 116, "Chemical"], [206, 210, "Chemical"], [88, 89, "Disease"], [6, 6, "Disease"], [40, 42, "Disease"], [44, 44, "Disease"], [47, 47, "Disease"], [77, 77, "Disease"]]], "relations": [[[0, 4, 88, 89, "CID"], [26, 30, 88, 89, "CID"], [112, 116, 88, 89, "CID"], [206, 210, 88, 89, "CID"]]], "clusters": [], "translated": " \n<0>1, 3-丁二烯</0>、<5>慢性粒细胞白血病</5>和t(9:22)易位：现实检验。未分配：流行病学研究表明，人类接触<1>1, 3-丁二烯</1>与<6>慢性粒细胞白血病</6>（<7>CML</7>）有关。<8>CML</8>与电离辐射有充分的关联，但有关与化学暴露关联的报道受到质疑。电离辐射能够在适当的体外细胞中诱导必需的<9>CML</9>-相关的t(9:22)易位（<4>费城染色体</4>），但迄今为止，化学物质尚未显示这种能力。我们建议对<2>1, 3-丁二烯</2>代谢物进行这样的测试，作为对流行病学报告的真实性检验。为了在这方面进行可靠的测试，必须提供用于诱导的阳性对照。我们已经使用电离辐射来开发这样的控制。此处描述的结果表明，该试剂确实在体外诱导人骨髓细胞系中的致病性t(9:22)易位，但频率较低。讨论了<3>1, 3-丁二烯</3>研究所需的条件。", "revised": true}
{"doc_key": "920167", "sentences": [["Fetal", "risks", "due", "to", "warfarin", "therapy", "during", "pregnancy", ".", "Two", "mothers", "with", "heart", "valve", "prosthesis", "were", "treated", "with", "warfarin", "during", "pregnancy", ".", "In", "the", "first", "case", "a", "caesarean", "section", "was", "done", "one", "week", "after", "replacement", "of", "warfarin", "with", "heparin", ".", "The", "baby", "died", "of", "cerebral", "and", "pulmonary", "hemorrhage", ".", "The", "second", "mother", "had", "a", "male", "infant", "by", "caesarean", "section", ".", "The", "baby", "showed", "warfarin", "-", "induced", "embryopathy", "with", "nasal", "hypoplasia", "and", "stippled", "epiphyses", "(", "chondrodysplasia", "punctata", ")", ".", "Nasal", "hypoplasia", "with", "or", "without", "stippled", "epiphyses", "has", "now", "been", "reported", "in", "11", "infants", "born", "to", "mothers", "treated", "with", "warfarin", "during", "the", "first", "trimester", ",", "and", "a", "causal", "association", "is", "probable", ".", "In", "view", "of", "the", "risks", "to", "both", "mother", "and", "fetus", "in", "women", "with", "prosthetic", "cardiac", "valves", "it", "is", "recommended", "that", "therapeutic", "abortion", "be", "advised", "as", "the", "first", "alternative", "."]], "ner": [[[4, 4, "Chemical"], [18, 18, "Chemical"], [36, 36, "Chemical"], [63, 63, "Chemical"], [97, 97, "Chemical"], [44, 47, "Disease"], [71, 72, "Disease"], [74, 75, "Disease"], [83, 84, "Disease"], [66, 66, "Disease"], [38, 38, "Chemical"]]], "relations": [[[4, 4, 44, 47, "CID"], [18, 18, 44, 47, "CID"], [36, 36, 44, 47, "CID"], [63, 63, 44, 47, "CID"], [97, 97, 44, 47, "CID"], [4, 4, 71, 72, "CID"], [4, 4, 74, 75, "CID"], [4, 4, 83, 84, "CID"], [18, 18, 71, 72, "CID"], [18, 18, 74, 75, "CID"], [18, 18, 83, 84, "CID"], [36, 36, 71, 72, "CID"], [36, 36, 74, 75, "CID"], [36, 36, 83, 84, "CID"], [63, 63, 71, 72, "CID"], [63, 63, 74, 75, "CID"], [63, 63, 83, 84, "CID"], [97, 97, 71, 72, "CID"], [97, 97, 74, 75, "CID"], [97, 97, 83, 84, "CID"]]], "clusters": [], "translated": "怀孕期间 <0>华法林</0>治疗对胎儿造成的风险。两名植入心脏瓣膜假体的母亲在怀孕期间接受了<1>华法林</1>治疗。在第一个案例中，在用<10>肝素</10>替代<2>华法林</2>一周后进行了剖腹产手术。<5>婴儿</5>死于<5>脑出血和肺出血</5>。第二位母亲剖腹产男婴。该婴儿表现出<3>华法林</3>诱发的<9>胚胎病</9>伴有鼻发育不全和<6>点状骨骺</6>（<7>点状软骨发育不良</7>）。已报道在妊娠早期接受<4>华法林</4>治疗的母亲所生的11名婴儿中，有或没有<8>点状骨骺</8>的鼻发育不全，并且可能存在因果关系。鉴于人工心脏瓣膜对母亲和胎儿的风险，建议将治疗性流产作为第一选择。", "revised": true}
{"doc_key": "24778426", "sentences": [["Rates", "of", "Renal", "Toxicity", "in", "Cancer", "Patients", "Receiving", "Cisplatin", "With", "and", "Without", "Mannitol", ".", "BACKGROUND", ":", "Cisplatin", "is", "a", "widely", "used", "antineoplastic", ".", "One", "of", "the", "major", "complications", "of", "cisplatin", "use", "is", "dose", "-", "limiting", "nephrotoxicity", ".", "There", "are", "many", "strategies", "to", "prevent", "this", "toxicity", ",", "including", "the", "use", "of", "mannitol", "as", "a", "nephroprotectant", "in", "combination", "with", "hydration", ".", "OBJECTIVE", ":", "We", "aimed", "to", "evaluate", "the", "rates", "of", "cisplatin", "-", "induced", "nephrotoxicity", "in", "cancer", "patients", "receiving", "single", "-", "agent", "cisplatin", "with", "and", "without", "mannitol", ".", "METHODS", ":", "This", "single", "-", "center", "retrospective", "analysis", "was", "a", "quasi", "experiment", "created", "by", "the", "national", "mannitol", "shortage", ".", "Data", "were", "collected", "on", "adult", "cancer", "patients", "receiving", "single", "-", "agent", "cisplatin", "as", "an", "outpatient", "from", "January", "2011", "to", "September", "2012", ".", "The", "primary", "outcome", "was", "acute", "kidney", "injury", "(", "AKI", ")", ".", "RESULTS", ":", "We", "evaluated", "143", "patients", "who", "received", "single", "-", "agent", "cisplatin", ";", "97", ".", "2", "%", "of", "patients", "had", "head", "and", "neck", "cancer", "as", "their", "primary", "malignancy", ".", "Patients", "who", "did", "not", "receive", "mannitol", "were", "more", "likely", "to", "develop", "nephrotoxicity", ":", "odds", "ratio", "[", "OR", "]", "=", "2", ".", "646", "(", "95", "%", "CI", "=", "1", ".", "008", ",", "6", ".", "944", ";", "P", "=", "0", ".", "048", ")", ".", "Patients", "who", "received", "the", "100", "mg", "/", "m", "(", "2", ")", "dosing", "and", "patients", "who", "had", "a", "history", "of", "hypertension", "also", "had", "a", "higher", "likelihood", "of", "developing", "nephrotoxicity", ":", "OR", "=", "11", ".", "494", "(", "95", "%", "CI", "=", "4", ".", "149", ",", "32", ".", "258", ";", "P", "<", "0", ".", "0001", ")", "and", "OR", "=", "3", ".", "219", "(", "95", "%", "CI", "=", "1", ".", "228", ",", "8", ".", "439", ";", "P", "=", "0", ".", "017", ")", ",", "respectively", ".", "CONCLUSIONS", ":", "When", "limited", "quantities", "of", "mannitol", "are", "available", ",", "it", "should", "preferentially", "be", "given", "to", "patients", "at", "particularly", "high", "risk", "of", "nephrotoxicity", ".", "Our", "analysis", "suggests", "that", "those", "patients", "receiving", "the", "dosing", "schedule", "of", "100", "mg", "/", "m", "(", "2", ")", "cisplatin", "every", "3", "weeks", "and", "those", "with", "hypertension", "are", "at", "the", "greatest", "risk", "of", "nephrotoxicity", "and", "would", "benefit", "from", "the", "addition", "of", "mannitol", "."]], "ner": [[[8, 8, "Chemical"], [16, 16, "Chemical"], [29, 29, "Chemical"], [68, 68, "Chemical"], [79, 79, "Chemical"], [115, 115, "Chemical"], [148, 148, "Chemical"], [331, 331, "Chemical"], [130, 132, "Disease"], [134, 134, "Disease"], [2, 3, "Disease"], [35, 35, "Disease"], [71, 71, "Disease"], [177, 177, "Disease"], [235, 235, "Disease"], [311, 311, "Disease"], [345, 345, "Disease"], [12, 12, "Chemical"], [50, 50, "Chemical"], [83, 83, "Chemical"], [101, 101, "Chemical"], [171, 171, "Chemical"], [295, 295, "Chemical"], [353, 353, "Chemical"], [5, 5, "Disease"], [73, 73, "Disease"], [109, 109, "Disease"], [164, 164, "Disease"], [44, 44, "Disease"], [157, 160, "Disease"], [227, 227, "Disease"], [338, 338, "Disease"]]], "relations": [[[8, 8, 130, 132, "CID"], [8, 8, 134, 134, "CID"], [16, 16, 130, 132, "CID"], [16, 16, 134, 134, "CID"], [29, 29, 130, 132, "CID"], [29, 29, 134, 134, "CID"], [68, 68, 130, 132, "CID"], [68, 68, 134, 134, "CID"], [79, 79, 130, 132, "CID"], [79, 79, 134, 134, "CID"], [115, 115, 130, 132, "CID"], [115, 115, 134, 134, "CID"], [148, 148, 130, 132, "CID"], [148, 148, 134, 134, "CID"], [331, 331, 130, 132, "CID"], [331, 331, 134, 134, "CID"]]], "clusters": [], "translated": "<10>肾毒性</10>在<24>癌症</24>患者接受有和没有<17>甘露醇</17>的<0>顺铂</0>治疗中的发生率。背景：<1>顺铂</1>是一种使用广泛的抗肿瘤药物。使用<2>顺铂</2>的主要并发症之一是剂量限制性<11>肾毒性</11>。有许多策略可以防止这种<28>毒性</28>，包括使用<18>甘露醇</18>作为肾保护剂并结合水合作用。目的：我们旨在评估接受单药<4>顺铂</4>治疗的<25>癌症</25>患者中<3>顺铂</3>诱导的<12>肾毒性</12>发生率，并且在没有<19>甘露醇</19>的情况下进行评估。方法：本单中心回顾性分析是针对全国<20>甘露醇</20>紧缺问题而创设的类实验。收集了2011年1月至2012年9月接受单药<5>顺铂</5>作为门诊治疗的成年<26>癌症</26>患者的数据。主要结局为<8>急性肾损伤</8> (<9>AKI</9>)。结果：我们评估了143名接受单药<6>顺铂</6>治疗的患者；97.2%的患者以<29>头颈癌</29>为主要<27>恶性肿瘤</27>。未接受<21>甘露醇</21>的患者更可能发生<13>肾毒性</13>：优势比[OR]=2.646 (95%CI=1.008,6.944;P=0.048)。接受100mg/m(2)剂量的患者和有<30>高血压</30>病史的患者也有更高的发生<14>肾毒性</14>可能性：OR=11.494 (95%CI=4.149,32.258;P<0.0001)和OR=3.219 (95%CI=1.228,8.439;P=0.017)，分别。结论：当可用量有限的<22>甘露醇</22>时，应优先给予<15>肾毒性</15>风险特别高的患者。我们的分析表明，接受每3周100mg/m(2)<7>顺铂</7>给药方案的患者和患有<31>高血压</31>的患者发生<16>肾毒性的风险最大</16>，并且会受益于添加<23>甘露醇</23>。", "revised": true}
{"doc_key": "25119790", "sentences": [["Curcumin", "prevents", "maleate", "-", "induced", "nephrotoxicity", ":", "relation", "to", "hemodynamic", "alterations", ",", "oxidative", "stress", ",", "mitochondrial", "oxygen", "consumption", "and", "activity", "of", "respiratory", "complex", "I", ".", "The", "potential", "protective", "effect", "of", "the", "dietary", "antioxidant", "curcumin", "(", "120", "mg", "/", "Kg", "/", "day", "for", "6", "days", ")", "against", "the", "renal", "injury", "induced", "by", "maleate", "was", "evaluated", ".", "Tubular", "proteinuria", "and", "oxidative", "stress", "were", "induced", "by", "a", "single", "injection", "of", "maleate", "(", "400", "mg", "/", "kg", ")", "in", "rats", ".", "Maleate", "-", "induced", "renal", "injury", "included", "increase", "in", "renal", "vascular", "resistance", "and", "in", "the", "urinary", "excretion", "of", "total", "protein", ",", "glucose", ",", "sodium", ",", "neutrophil", "gelatinase", "-", "associated", "lipocalin", "(", "NGAL", ")", "and", "N", "-", "acetyl", "b", "-", "D", "-", "glucosaminidase", "(", "NAG", ")", ",", "upregulation", "of", "kidney", "injury", "molecule", "(", "KIM", ")", "-", "1", ",", "decrease", "in", "renal", "blood", "flow", "and", "claudin", "-", "2", "expression", "besides", "of", "necrosis", "and", "apoptosis", "of", "tubular", "cells", "on", "24", "h", ".", "Oxidative", "stress", "was", "determined", "by", "measuring", "the", "oxidation", "of", "lipids", "and", "proteins", "and", "diminution", "in", "renal", "Nrf2", "levels", ".", "Studies", "were", "also", "conducted", "in", "renal", "epithelial", "LLC", "-", "PK1", "cells", "and", "in", "mitochondria", "isolated", "from", "kidneys", "of", "all", "the", "experimental", "groups", ".", "Maleate", "induced", "cell", "damage", "and", "reactive", "oxygen", "species", "(", "ROS", ")", "production", "in", "LLC", "-", "PK1", "cells", "in", "culture", ".", "In", "addition", ",", "maleate", "treatment", "reduced", "oxygen", "consumption", "in", "ADP", "-", "stimulated", "mitochondria", "and", "diminished", "respiratory", "control", "index", "when", "using", "malate", "/", "glutamate", "as", "substrate", ".", "The", "activities", "of", "both", "complex", "I", "and", "aconitase", "were", "also", "diminished", ".", "All", "the", "above", "-", "described", "alterations", "were", "prevented", "by", "curcumin", ".", "It", "is", "concluded", "that", "curcumin", "is", "able", "to", "attenuate", "in", "vivo", "maleate", "-", "induced", "nephropathy", "and", "in", "vitro", "cell", "damage", ".", "The", "in", "vivo", "protection", "was", "associated", "to", "the", "prevention", "of", "oxidative", "stress", "and", "preservation", "of", "mitochondrial", "oxygen", "consumption", "and", "activity", "of", "respiratory", "complex", "I", ",", "and", "the", "in", "vitro", "protection", "was", "associated", "to", "the", "prevention", "of", "ROS", "production", "."]], "ner": [[[2, 2, "Chemical"], [51, 51, "Chemical"], [67, 67, "Chemical"], [77, 77, "Chemical"], [197, 197, "Chemical"], [220, 220, "Chemical"], [277, 277, "Chemical"], [5, 5, "Disease"], [47, 48, "Disease"], [80, 81, "Disease"], [124, 125, "Disease"], [280, 280, "Disease"], [56, 56, "Disease"], [145, 145, "Disease"], [0, 0, "Chemical"], [33, 33, "Chemical"], [264, 264, "Chemical"], [270, 270, "Chemical"], [16, 16, "Chemical"], [203, 203, "Chemical"], [223, 223, "Chemical"], [303, 303, "Chemical"], [97, 97, "Chemical"], [99, 99, "Chemical"], [226, 226, "Chemical"], [237, 237, "Chemical"], [239, 239, "Chemical"]]], "relations": [[[2, 2, 5, 5, "CID"], [2, 2, 47, 48, "CID"], [2, 2, 80, 81, "CID"], [2, 2, 124, 125, "CID"], [2, 2, 280, 280, "CID"], [51, 51, 5, 5, "CID"], [51, 51, 47, 48, "CID"], [51, 51, 80, 81, "CID"], [51, 51, 124, 125, "CID"], [51, 51, 280, 280, "CID"], [67, 67, 5, 5, "CID"], [67, 67, 47, 48, "CID"], [67, 67, 80, 81, "CID"], [67, 67, 124, 125, "CID"], [67, 67, 280, 280, "CID"], [77, 77, 5, 5, "CID"], [77, 77, 47, 48, "CID"], [77, 77, 80, 81, "CID"], [77, 77, 124, 125, "CID"], [77, 77, 280, 280, "CID"], [197, 197, 5, 5, "CID"], [197, 197, 47, 48, "CID"], [197, 197, 80, 81, "CID"], [197, 197, 124, 125, "CID"], [197, 197, 280, 280, "CID"], [220, 220, 5, 5, "CID"], [220, 220, 47, 48, "CID"], [220, 220, 80, 81, "CID"], [220, 220, 124, 125, "CID"], [220, 220, 280, 280, "CID"], [277, 277, 5, 5, "CID"], [277, 277, 47, 48, "CID"], [277, 277, 80, 81, "CID"], [277, 277, 124, 125, "CID"], [277, 277, 280, 280, "CID"], [2, 2, 56, 56, "CID"], [51, 51, 56, 56, "CID"], [67, 67, 56, 56, "CID"], [77, 77, 56, 56, "CID"], [197, 197, 56, 56, "CID"], [220, 220, 56, 56, "CID"], [277, 277, 56, 56, "CID"], [2, 2, 145, 145, "CID"], [51, 51, 145, 145, "CID"], [67, 67, 145, 145, "CID"], [77, 77, 145, 145, "CID"], [197, 197, 145, 145, "CID"], [220, 220, 145, 145, "CID"], [277, 277, 145, 145, "CID"]]], "clusters": [], "translated": "<14>姜黄素</14>预防<0>马来酸盐</0>诱导的<7>肾毒性</7>：与血液动力学改变、氧化应激、线粒体<18>氧气</18>消耗和呼吸活性的关系。评估了膳食抗氧化剂<15>姜黄素</15>（120 mg/Kg/天，连续6天）对<1>马来酸盐</1>诱导的<8>肾损伤</8>的潜在保护作用。给大鼠单次注射<2>马来酸盐</2> (400 mg/kg)，诱导管状<12>蛋白尿</12>和氧化应激。<3>马来酸盐</3>-诱导的<9>肾损伤</9>包括增加肾血管阻力和总蛋白、<22>葡萄糖</22>、<23>钠</23>的尿排泄，中性粒细胞明胶酶相关脂质运载蛋白 (NGAL)和N-乙酰基b-D-氨基葡萄糖苷酶 (NAG)，<10>肾损伤</10>分子 (KIM)-1上调，肾血流量和claudin-2减少。24 h肾小管细胞不仅有<13>坏死</13>，而且还有细胞凋亡。氧化应激通过测量脂质和蛋白质的氧化以及肾脏Nrf2水平的降低来确定。还在肾上皮LLC-PK1细胞和从所有实验组的肾脏分离的线粒体中进行了研究。<4>马来酸盐</4>在培养的LLC-PK1细胞中诱导细胞损伤和活性<19>氧</19>物质(ROS)的产生。此外，<5>马来酸盐</5>处理减少了<24>ADP</24>刺激下<20>氧气</20>消耗-使用<25>苹果酸盐</25>时，降低了呼吸控制指数/ <26>谷氨酸</26>为底物。复合物I和顺乌头酸酶的活性也降低了。所有上述变化均被<16>姜黄素</16>防止。结论是<17>姜黄素</17>能够减轻体内<6>马来酸盐</6>诱导的<11>肾病</11>和体外细胞损伤。体内保护作用与防止氧化应激、维持线粒体<21>氧</21>消耗和呼吸复合物I活性有关，体外保护作用与防止ROS产生有关。", "revised": true}
{"doc_key": "25907210", "sentences": [["Incidence", "of", "solid", "tumours", "among", "pesticide", "applicators", "exposed", "to", "the", "organophosphate", "insecticide", "diazinon", "in", "the", "Agricultural", "Health", "Study", ":", "an", "updated", "analysis", ".", "OBJECTIVE", ":", "Diazinon", ",", "a", "common", "organophosphate", "insecticide", "with", "genotoxic", "properties", ",", "was", "previously", "associated", "with", "lung", "cancer", "in", "the", "Agricultural", "Health", "Study", "(", "AHS", ")", "cohort", ",", "but", "few", "other", "epidemiological", "studies", "have", "examined", "diazinon", "-", "associated", "cancer", "risk", ".", "We", "used", "updated", "diazinon", "exposure", "and", "cancer", "incidence", "information", "to", "evaluate", "solid", "tumour", "risk", "in", "the", "AHS", ".", "METHODS", ":", "Male", "pesticide", "applicators", "in", "Iowa", "and", "North", "Carolina", "reported", "lifetime", "diazinon", "use", "at", "enrolment", "(", "1993", "-", "1997", ")", "and", "follow", "-", "up", "(", "1998", "-", "2005", ")", ";", "cancer", "incidence", "was", "assessed", "through", "2010", "(", "North", "Carolina", ")", "/", "2011", "(", "Iowa", ")", ".", "Among", "applicators", "with", "usage", "information", "sufficient", "to", "evaluate", "exposure", "-", "response", "patterns", ",", "we", "used", "Poisson", "regression", "to", "estimate", "adjusted", "rate", "ratios", "(", "RRs", ")", "and", "95", "%", "CI", "for", "cancer", "sites", "with", ">", "10", "exposed", "cases", "for", "both", "lifetime", "(", "LT", ")", "exposure", "days", "and", "intensity", "-", "weighted", "(", "IW", ")", "lifetime", "exposure", "days", "(", "accounting", "for", "factors", "impacting", "exposure", ")", ".", "RESULTS", ":", "We", "observed", "elevated", "lung", "cancer", "risks", "(", "N", "=", "283", ")", "among", "applicators", "with", "the", "greatest", "number", "of", "LT", "(", "RR", "=", "1", ".", "60", ";", "95", "%", "CI", "1", ".", "11", "to", "2", ".", "31", ";", "Ptrend", "=", "0", ".", "02", ")", "and", "IW", "days", "of", "diazinon", "use", "(", "RR", "=", "1", ".", "41", ";", "95", "%", "CI", "0", ".", "98", "to", "2", ".", "04", ";", "Ptrend", "=", "0", ".", "08", ")", ".", "Kidney", "cancer", "(", "N", "=", "94", ")", "risks", "were", "non", "-", "significantly", "elevated", "(", "RRLT", "days", "=", "1", ".", "77", ";", "95", "%", "CI", "0", ".", "90", "to", "3", ".", "51", ";", "Ptrend", "=", "0", ".", "09", ";", "RRIW", "days", "1", ".", "37", ";", "95", "%", "CI", "0", ".", "64", "to", "2", ".", "92", ";", "Ptrend", "=", "0", ".", "50", ")", ",", "as", "were", "risks", "for", "aggressive", "prostate", "cancer", "(", "N", "=", "656", ")", ".", "CONCLUSIONS", ":", "Our", "updated", "evaluation", "of", "diazinon", "provides", "additional", "evidence", "of", "an", "association", "with", "lung", "cancer", "risk", ".", "Newly", "identified", "links", "to", "kidney", "cancer", "and", "associations", "with", "aggressive", "prostate", "cancer", "require", "further", "evaluation", "."]], "ner": [[[12, 12, "Chemical"], [25, 25, "Chemical"], [58, 58, "Chemical"], [67, 67, "Chemical"], [94, 94, "Chemical"], [241, 241, "Chemical"], [349, 349, "Chemical"], [39, 40, "Disease"], [197, 198, "Disease"], [357, 358, "Disease"], [10, 10, "Chemical"], [29, 29, "Chemical"], [3, 3, "Disease"], [61, 61, "Disease"], [70, 70, "Disease"], [76, 76, "Disease"], [113, 113, "Disease"], [159, 159, "Disease"], [268, 269, "Disease"], [365, 366, "Disease"], [335, 336, "Disease"], [371, 372, "Disease"]]], "relations": [[[12, 12, 39, 40, "CID"], [12, 12, 197, 198, "CID"], [12, 12, 357, 358, "CID"], [25, 25, 39, 40, "CID"], [25, 25, 197, 198, "CID"], [25, 25, 357, 358, "CID"], [58, 58, 39, 40, "CID"], [58, 58, 197, 198, "CID"], [58, 58, 357, 358, "CID"], [67, 67, 39, 40, "CID"], [67, 67, 197, 198, "CID"], [67, 67, 357, 358, "CID"], [94, 94, 39, 40, "CID"], [94, 94, 197, 198, "CID"], [94, 94, 357, 358, "CID"], [241, 241, 39, 40, "CID"], [241, 241, 197, 198, "CID"], [241, 241, 357, 358, "CID"], [349, 349, 39, 40, "CID"], [349, 349, 197, 198, "CID"], [349, 349, 357, 358, "CID"]]], "clusters": [], "translated": "农业健康研究中接触 <10> 有机磷 </10> 杀虫剂 <0> 二嗪农 </0> 的农药施药者的实体 <12> 肿瘤 </12> 发病率：最新分析。目的： <1> 二嗪农 </1> 是一种常见的 <11> 有机磷 </11> 杀虫剂，具有遗传毒性，在农业健康研究（AHS）队列中与 <7> 肺癌 </7> 相关，但很少有其他流行病学研究检查过 <2> 二嗪农 </2> 相关的 <13> 癌症 </13> 风险。我们使用更新的 <3> 二嗪农 </3> 暴露和 <14> 癌症 </14> 发病率信息来评估 AHS 中的实体 <15> 肿瘤 </15> 风险。方法：在 Iowa 和 North Carolina 的男性农药施药者报告了入伍时（1993-1997）和随访时（1998-2005）的终身 <4> 二嗪农 </4> 使用情况；通过2010年（North Carolina）/2011年（Iowa）评估了 <16> 癌症 </16> 发病率。在具有足以评估暴露-反应模式的施药者中，我们使用泊松回归分析来估计调整后的比率（RRs）和95% CI，对于两种暴露时间（LT）和强度加权（IW）终身暴露时间（考虑到影响暴露的因素）均具有>10个暴露病例的 <17> 癌症 </17> 部位进行分析。结果：我们观察到最多 LT （RR = 1.60；95% CI 1.11至2.31；Ptrend = 0.02）和最大 IW 天数下的<5> 二嗪农 </5> 使用（RR = 1.41；95% CI 0.98至2.04；Ptrend = 0.08）增加的 <8> 肺癌 </8> 风险（N = 283）。<18> 肾癌 </18>（N = 94）风险升高但不明显（RRLT 天数=1.77；95% CI 0.90至3.51；Ptrend=0.09；RRIW 天数=1.37；95% CI 0.64至2.92；Ptrend=0.50），侵袭性 <20> 前列腺癌 </20> 风险（N = 656）也没有明显增加。结论：我们对 <6> 二嗪农 </6> 的最新评估提供了与 <9> 肺癌 </9> 风险相关的额外证据。需要进一步评估新发现的与 <19> 肾癌 </19> 的关联以及与侵袭性 <21> 前列腺癌 </21> 的关联。", "revised": true}
{"doc_key": "25986755", "sentences": [["Low", "functional", "programming", "of", "renal", "AT2R", "mediates", "the", "developmental", "origin", "of", "glomerulosclerosis", "in", "adult", "offspring", "induced", "by", "prenatal", "caffeine", "exposure", ".", "UNASSIGNED", ":", "Our", "previous", "study", "has", "indicated", "that", "prenatal", "caffeine", "exposure", "(", "PCE", ")", "could", "induce", "intrauterine", "growth", "retardation", "(", "IUGR", ")", "of", "offspring", ".", "Recent", "research", "suggested", "that", "IUGR", "is", "a", "risk", "factor", "for", "glomerulosclerosis", ".", "However", ",", "whether", "PCE", "could", "induce", "glomerulosclerosis", "and", "its", "underlying", "mechanisms", "remain", "unknown", ".", "This", "study", "aimed", "to", "demonstrate", "the", "induction", "to", "glomerulosclerosis", "in", "adult", "offspring", "by", "PCE", "and", "its", "intrauterine", "programming", "mechanisms", ".", "A", "rat", "model", "of", "IUGR", "was", "established", "by", "PCE", ",", "male", "fetuses", "and", "adult", "offspring", "at", "the", "age", "of", "postnatal", "week", "24", "were", "euthanized", ".", "The", "results", "revealed", "that", "the", "adult", "offspring", "kidneys", "in", "the", "PCE", "group", "exhibited", "glomerulosclerosis", "as", "well", "as", "interstitial", "fibrosis", ",", "accompanied", "by", "elevated", "levels", "of", "serum", "creatinine", "and", "urine", "protein", ".", "Renal", "angiotensin", "II", "receptor", "type", "2", "(", "AT2R", ")", "gene", "expression", "in", "adult", "offspring", "was", "reduced", "by", "PCE", ",", "whereas", "the", "renal", "angiotensin", "II", "receptor", "type", "1a", "(", "AT1aR", ")", "/", "AT2R", "expression", "ratio", "was", "increased", ".", "The", "fetal", "kidneys", "in", "the", "PCE", "group", "displayed", "an", "enlarged", "Bowman", "'s", "space", "and", "a", "shrunken", "glomerular", "tuft", ",", "accompanied", "by", "a", "reduced", "cortex", "width", "and", "an", "increase", "in", "the", "nephrogenic", "zone", "/", "cortical", "zone", "ratio", ".", "Observation", "by", "electronic", "microscope", "revealed", "structural", "damage", "of", "podocytes", ";", "the", "reduced", "expression", "level", "of", "podocyte", "marker", "genes", ",", "nephrin", "and", "podocin", ",", "was", "also", "detected", "by", "q", "-", "PCR", ".", "Moreover", ",", "AT2R", "gene", "and", "protein", "expressions", "in", "fetal", "kidneys", "were", "inhibited", "by", "PCE", ",", "associated", "with", "the", "repression", "of", "the", "gene", "expression", "of", "glial", "-", "cell", "-", "line", "-", "derived", "neurotrophic", "factor", "(", "GDNF", ")", "/", "tyrosine", "kinase", "receptor", "(", "c", "-", "Ret", ")", "signaling", "pathway", ".", "These", "results", "demonstrated", "that", "PCE", "could", "induce", "dysplasia", "of", "fetal", "kidneys", "as", "well", "as", "glomerulosclerosis", "of", "adult", "offspring", ",", "and", "the", "low", "functional", "programming", "of", "renal", "AT2R", "might", "mediate", "the", "developmental", "origin", "of", "adult", "glomerulosclerosis", "."]], "ner": [[[18, 18, "Chemical"], [30, 30, "Chemical"], [37, 39, "Disease"], [41, 41, "Disease"], [50, 50, "Disease"], [96, 96, "Disease"], [134, 135, "Disease"], [308, 311, "Disease"], [11, 11, "Disease"], [56, 56, "Disease"], [64, 64, "Disease"], [80, 80, "Disease"], [130, 130, "Disease"], [315, 315, "Disease"], [335, 335, "Disease"], [143, 143, "Chemical"], [149, 150, "Chemical"], [170, 171, "Chemical"], [290, 290, "Chemical"]]], "relations": [[[18, 18, 37, 39, "CID"], [18, 18, 41, 41, "CID"], [18, 18, 50, 50, "CID"], [18, 18, 96, 96, "CID"], [30, 30, 37, 39, "CID"], [30, 30, 41, 41, "CID"], [30, 30, 50, 50, "CID"], [30, 30, 96, 96, "CID"], [18, 18, 134, 135, "CID"], [30, 30, 134, 135, "CID"], [18, 18, 308, 311, "CID"], [30, 30, 308, 311, "CID"]]], "clusters": [], "translated": "肾脏 AT2R 的低功能编程介导了由产前<0>咖啡因</0>暴露诱导的成年后代<8>肾小球硬化</8>的发育起源。未指定：我们之前的研究表明，产前<1>咖啡因</1>暴露（PCE）可导致后代<2>宫内发育迟缓</2>（<3>IUGR</3>）。最近的研究表明，<4>IUGR</4>是<9>肾小球硬化</9>的危险因素。然而，是否PCE可诱发<10>肾小球硬化</10>及其机制尚不清楚。本研究旨在证明PCE及其宫内编程机制对成年后代<11>肾小球硬化</11>的诱导作用。采用PCE法建立<5>IUGR</5>大鼠模型，对出生后24周龄的雄性胎儿及成年子代实施安乐死。结果显示，PCE组成年子代肾脏出现<12>肾小球硬化</12>和<6>间质纤维化</6>，伴有血清<15>肌酐</15>和尿液蛋白质水平升高。成年后代的肾<16>血管紧张素II</16>受体2型（AT2R）基因表达被PCE降低，而肾<17>血管紧张素II</17>受体1a型（AT1aR）/AT2R表达比则增加。PCE组胎儿肾脏表现为增大的Bowman氏空间和缩小的肾小球丛，伴有皮质宽度减小和肾源区/皮质区比率增加。电镜观察可见足细胞结构损伤；q-PCR检测到足细胞标记基因nephrin 和podocin 的表达水平的下降。此外，PCE抑制了胎儿肾脏中AT2R基因和蛋白的表达，伴随着神经胶质细胞衍生的神经营养因子(GDNF)/<18>酪氨酸激酶受体</18>(c-Ret)信号通路的基因表达受到抑制。这些结果表明，PCE可诱导<7>胎儿肾脏发育不良</7>以及成年后代<13>肾小球硬化</13>，而肾脏AT2R的低功能编程可能介导了成年<14>肾小球硬化</14>的发育起源。", "revised": true}
{"doc_key": "25084821", "sentences": [["Quetiapine", "-", "induced", "neutropenia", "in", "a", "bipolar", "patient", "with", "hepatocellular", "carcinoma", ".", "OBJECTIVE", ":", "Quetiapine", "is", "a", "dibenzothiazepine", "derivative", ",", "similar", "to", "clozapine", ",", "which", "has", "the", "highest", "risk", "of", "causing", "blood", "dyscrasias", ",", "especially", "neutropenia", ".", "There", "are", "some", "case", "reports", "about", "this", "side", "effect", "of", "quetiapine", ",", "but", "possible", "risk", "factors", "are", "seldom", "discussed", "and", "identified", ".", "A", "case", "of", "a", "patient", "with", "hepatocellular", "carcinoma", "that", "developed", "neutropenia", "after", "treatment", "with", "quetiapine", "is", "described", "here", ".", "CASE", "REPORT", ":", "A", "62", "-", "year", "-", "old", "Taiwanese", "widow", "with", "bipolar", "disorder", "was", "diagnosed", "with", "hepatocellular", "carcinoma", "at", "age", "60", ".", "She", "developed", "leucopenia", "after", "being", "treated", "with", "quetiapine", ".", "After", "quetiapine", "was", "discontinued", ",", "her", "white", "blood", "cell", "count", "returned", "to", "normal", ".", "CONCLUSIONS", ":", "Although", "neutropenia", "is", "not", "a", "common", "side", "effect", "of", "quetiapine", ",", "physicians", "should", "be", "cautious", "about", "its", "presentation", "and", "associated", "risk", "factors", ".", "Hepatic", "dysfunction", "may", "be", "one", "of", "the", "possible", "risk", "factors", ",", "and", "concomitant", "fever", "may", "be", "a", "diagnostic", "marker", "for", "adverse", "reaction", "to", "quetiapine", "."]], "ner": [[[0, 0, "Chemical"], [14, 14, "Chemical"], [47, 47, "Chemical"], [73, 73, "Chemical"], [108, 108, "Chemical"], [111, 111, "Chemical"], [135, 135, "Chemical"], [172, 172, "Chemical"], [3, 3, "Disease"], [35, 35, "Disease"], [69, 69, "Disease"], [127, 127, "Disease"], [103, 103, "Disease"], [162, 162, "Disease"], [6, 6, "Disease"], [90, 91, "Disease"], [9, 10, "Disease"], [65, 66, "Disease"], [95, 96, "Disease"], [31, 32, "Disease"], [149, 150, "Disease"], [22, 22, "Chemical"]]], "relations": [[[0, 0, 3, 3, "CID"], [0, 0, 35, 35, "CID"], [0, 0, 69, 69, "CID"], [0, 0, 127, 127, "CID"], [14, 14, 3, 3, "CID"], [14, 14, 35, 35, "CID"], [14, 14, 69, 69, "CID"], [14, 14, 127, 127, "CID"], [47, 47, 3, 3, "CID"], [47, 47, 35, 35, "CID"], [47, 47, 69, 69, "CID"], [47, 47, 127, 127, "CID"], [73, 73, 3, 3, "CID"], [73, 73, 35, 35, "CID"], [73, 73, 69, 69, "CID"], [73, 73, 127, 127, "CID"], [108, 108, 3, 3, "CID"], [108, 108, 35, 35, "CID"], [108, 108, 69, 69, "CID"], [108, 108, 127, 127, "CID"], [111, 111, 3, 3, "CID"], [111, 111, 35, 35, "CID"], [111, 111, 69, 69, "CID"], [111, 111, 127, 127, "CID"], [135, 135, 3, 3, "CID"], [135, 135, 35, 35, "CID"], [135, 135, 69, 69, "CID"], [135, 135, 127, 127, "CID"], [172, 172, 3, 3, "CID"], [172, 172, 35, 35, "CID"], [172, 172, 69, 69, "CID"], [172, 172, 127, 127, "CID"], [0, 0, 103, 103, "CID"], [14, 14, 103, 103, "CID"], [47, 47, 103, 103, "CID"], [73, 73, 103, 103, "CID"], [108, 108, 103, 103, "CID"], [111, 111, 103, 103, "CID"], [135, 135, 103, 103, "CID"], [172, 172, 103, 103, "CID"], [0, 0, 162, 162, "CID"], [14, 14, 162, 162, "CID"], [47, 47, 162, 162, "CID"], [73, 73, 162, 162, "CID"], [108, 108, 162, 162, "CID"], [111, 111, 162, 162, "CID"], [135, 135, 162, 162, "CID"], [172, 172, 162, 162, "CID"]]], "clusters": [], "translated": " <0>喹硫平</0> - 在<14>双相</14><16>肝细胞癌</16>患者中诱导<8>中性粒细胞减少</8>。目的：<1>喹硫平</1>是一种二苯并硫氮杂类衍生物，与<21>氯氮平</21>相似，引起<19>血液恶液质</19>的风险最高，尤其是<9>中性粒细胞减少</9>。关于<2>喹硫平</2>的这种副作用有一些病例报告，但很少讨论和确定可能的危险因素。此处描述了一名<17>肝细胞癌</17>患者在接受<3>喹硫平</3>治疗后出现<10>中性粒细胞减少症</10>的病例。病例报告：一位患有<15>双相情感障碍</15>的62岁台湾寡妇在60岁时被诊断出患有<18>肝细胞癌</18>。在接受<4>喹硫平</4>治疗后，她出现了<12>白细胞减少症</12>。停用<5>喹硫平</5>后，她的白细胞计数恢复正常。结论：虽然<11>中性粒细胞减少</11>不是<6>喹硫平</6>的常见副作用，但医生应对其表现和相关危险因素保持谨慎。<20>肝功能障碍</20>可能是可能的危险因素之一，伴随的<13>发热</13>可能是<7>喹硫平</7>不良反应的诊断标志。", "revised": true}
{"doc_key": "26033014", "sentences": [["Cancer", "incidence", "and", "metolachlor", "use", "in", "the", "Agricultural", "Health", "Study", ":", "An", "update", ".", "UNASSIGNED", ":", "Metolachlor", ",", "a", "widely", "used", "herbicide", ",", "is", "classified", "as", "a", "Group", "C", "carcinogen", "by", "the", "U", ".", "S", ".", "Environmental", "Protection", "Agency", "based", "on", "increased", "liver", "neoplasms", "in", "female", "rats", ".", "Epidemiologic", "studies", "of", "the", "health", "effects", "of", "metolachlor", "have", "been", "limited", ".", "The", "Agricultural", "Health", "Study", "(", "AHS", ")", "is", "a", "prospective", "cohort", "study", "including", "licensed", "private", "and", "commercial", "pesticide", "applicators", "in", "Iowa", "and", "North", "Carolina", "enrolled", "1993", "-", "1997", ".", "We", "evaluated", "cancer", "incidence", "through", "2010", "/", "2011", "(", "NC", "/", "IA", ")", "for", "49", ",", "616", "applicators", ",", "53", "%", "of", "whom", "reported", "ever", "using", "metolachlor", ".", "We", "used", "Poisson", "regression", "to", "evaluate", "relations", "between", "two", "metrics", "of", "metolachlor", "use", "(", "lifetime", "days", ",", "intensity", "-", "weighted", "lifetime", "days", ")", "and", "cancer", "incidence", ".", "We", "saw", "no", "association", "between", "metolachlor", "use", "and", "incidence", "of", "all", "cancers", "combined", "(", "n", "=", "5", ",", "701", "with", "a", "5", "-", "year", "lag", ")", "or", "most", "site", "-", "specific", "cancers", ".", "For", "liver", "cancer", ",", "in", "analyses", "restricted", "to", "exposed", "workers", ",", "elevations", "observed", "at", "higher", "categories", "of", "use", "were", "not", "statistically", "significant", ".", "However", ",", "trends", "for", "both", "lifetime", "and", "intensity", "-", "weighted", "lifetime", "days", "of", "metolachor", "use", "were", "positive", "and", "statistically", "significant", "with", "an", "unexposed", "reference", "group", ".", "A", "similar", "pattern", "was", "observed", "for", "follicular", "cell", "lymphoma", ",", "but", "no", "other", "lymphoma", "subtypes", ".", "An", "earlier", "suggestion", "of", "increased", "lung", "cancer", "risk", "at", "high", "levels", "of", "metolachlor", "use", "in", "this", "cohort", "was", "not", "confirmed", "in", "this", "update", ".", "This", "suggestion", "of", "an", "association", "between", "metolachlor", "and", "liver", "cancer", "among", "pesticide", "applicators", "is", "a", "novel", "finding", "and", "echoes", "observation", "of", "increased", "liver", "neoplasms", "in", "some", "animal", "studies", ".", "However", ",", "our", "findings", "for", "both", "liver", "cancer", "and", "follicular", "cell", "lymphoma", "warrant", "follow", "-", "up", "to", "better", "differentiate", "effects", "of", "metolachlor", "use", "from", "other", "factors", "."]], "ner": [[[3, 3, "Chemical"], [16, 16, "Chemical"], [55, 55, "Chemical"], [115, 115, "Chemical"], [128, 128, "Chemical"], [149, 149, "Chemical"], [213, 213, "Chemical"], [254, 254, "Chemical"], [272, 272, "Chemical"], [316, 316, "Chemical"], [42, 43, "Disease"], [178, 179, "Disease"], [274, 275, "Disease"], [288, 289, "Disease"], [301, 302, "Disease"], [232, 234, "Disease"], [0, 0, "Disease"], [91, 91, "Disease"], [141, 141, "Disease"], [155, 155, "Disease"], [175, 175, "Disease"], [239, 239, "Disease"], [306, 306, "Disease"], [247, 248, "Disease"]]], "relations": [[[3, 3, 42, 43, "CID"], [3, 3, 178, 179, "CID"], [3, 3, 274, 275, "CID"], [3, 3, 288, 289, "CID"], [3, 3, 301, 302, "CID"], [16, 16, 42, 43, "CID"], [16, 16, 178, 179, "CID"], [16, 16, 274, 275, "CID"], [16, 16, 288, 289, "CID"], [16, 16, 301, 302, "CID"], [55, 55, 42, 43, "CID"], [55, 55, 178, 179, "CID"], [55, 55, 274, 275, "CID"], [55, 55, 288, 289, "CID"], [55, 55, 301, 302, "CID"], [115, 115, 42, 43, "CID"], [115, 115, 178, 179, "CID"], [115, 115, 274, 275, "CID"], [115, 115, 288, 289, "CID"], [115, 115, 301, 302, "CID"], [128, 128, 42, 43, "CID"], [128, 128, 178, 179, "CID"], [128, 128, 274, 275, "CID"], [128, 128, 288, 289, "CID"], [128, 128, 301, 302, "CID"], [149, 149, 42, 43, "CID"], [149, 149, 178, 179, "CID"], [149, 149, 274, 275, "CID"], [149, 149, 288, 289, "CID"], [149, 149, 301, 302, "CID"], [213, 213, 42, 43, "CID"], [213, 213, 178, 179, "CID"], [213, 213, 274, 275, "CID"], [213, 213, 288, 289, "CID"], [213, 213, 301, 302, "CID"], [254, 254, 42, 43, "CID"], [254, 254, 178, 179, "CID"], [254, 254, 274, 275, "CID"], [254, 254, 288, 289, "CID"], [254, 254, 301, 302, "CID"], [272, 272, 42, 43, "CID"], [272, 272, 178, 179, "CID"], [272, 272, 274, 275, "CID"], [272, 272, 288, 289, "CID"], [272, 272, 301, 302, "CID"], [316, 316, 42, 43, "CID"], [316, 316, 178, 179, "CID"], [316, 316, 274, 275, "CID"], [316, 316, 288, 289, "CID"], [316, 316, 301, 302, "CID"], [3, 3, 232, 234, "CID"], [16, 16, 232, 234, "CID"], [55, 55, 232, 234, "CID"], [115, 115, 232, 234, "CID"], [128, 128, 232, 234, "CID"], [149, 149, 232, 234, "CID"], [213, 213, 232, 234, "CID"], [254, 254, 232, 234, "CID"], [272, 272, 232, 234, "CID"], [316, 316, 232, 234, "CID"]]], "clusters": [], "translated": " <16>癌症</16>发病率和<0>异丙甲草胺</0>在农业健康研究中的使用：更新。未指定：<1>异丙甲草胺</1>，是一种广泛使用的除草剂，被美国列为C组致癌物。年代。环境保护局基于雌性大鼠<10>肝肿瘤</10>的增加。流行病学研究表明<2>异丙甲草胺</2>对健康的影响有限。农业健康研究（AHS）是一项前瞻性队列研究，包括 1993 年至 1997 年在爱荷华州和北卡罗来纳州注册的获得许可的私人和商业杀虫剂施药者。我们评估了49,616名施药者在2010/2011年(NC/IA)期间的<17>癌症</17>发病率，其中53% 的人报告曾使用过 <3> 异丙甲草胺 </3>。我们使用泊松回归来评估<4>异丙甲草胺</4>使用（生命周期天数、强度加权生命周期天数）和<18>癌症</18>发病率这两个指标之间的关系。我们发现<5>异丙甲草胺</5>使用与所有<19>癌症</19>组合(n=5,701有5年滞后)或大多数特定部位的<20>癌症</20>无关。对于<11>肝癌</11>，在仅限于暴露工人的分析中，在更高类别的使用中观察到的升高没有统计学意义。然而，<6>异丙甲草胺</6>使用的寿命和强度加权寿命天数的趋势是积极的，并且与未暴露的参照组相比具有统计学意义。在<15>滤泡细胞淋巴瘤</15>中观察到类似的模式，但在其他<21>淋巴瘤</21>亚型中没有观察到。本次更新并未证实早先关于该队列中高水平使用<7>异丙甲草胺</7>会增加<23>肺癌</23>风险的建议。农药施用者中，<8>异丙甲草胺</8>与<12>肝癌</12>之间存在关联的这一建议是一项新发现，与一些动物研究中观察到的<13>肝肿瘤</13>增加相呼应。然而，我们对<14>肝癌</14>和滤泡细胞<22>淋巴瘤</22>的研究结果需要进行随访，以更好地区分<9>异丙甲草胺</9>使用的影响与其他因素。", "revised": true}
{"doc_key": "1451544", "sentences": [["Isradipine", "treatment", "for", "hypertension", "in", "general", "practice", "in", "Hong", "Kong", ".", "A", "6", "-", "week", "open", "study", "of", "the", "introduction", "of", "isradipine", "treatment", "was", "conducted", "in", "general", "practice", "in", "Hong", "Kong", ".", "303", "Chinese", "patients", "with", "mild", "to", "moderate", "hypertension", "entered", "the", "study", ".", "Side", "effects", "were", "reported", "in", "21", "%", "of", "patients", "and", "caused", "withdrawal", "from", "the", "study", "in", "3", "patients", ".", "The", "main", "side", "-", "effects", "were", "headache", ",", "dizziness", ",", "palpitation", "and", "flushing", "and", "these", "were", "not", "more", "frequent", "than", "reported", "in", "other", "studies", "with", "isradipine", "or", "with", "placebo", ".", "Supine", "blood", "pressure", "was", "reduced", "(", "P", "less", "than", "0", ".", "01", ")", "from", "170", "+", "/", "-", "20", "/", "102", "+", "/", "-", "6", "mmHg", "to", "153", "+", "/", "-", "19", "/", "92", "+", "/", "-", "8", ",", "147", "+", "/", "-", "18", "/", "88", "+", "/", "-", "7", "and", "144", "+", "/", "-", "14", "/", "87", "+", "/", "-", "6", "mmHg", "at", "2", ",", "4", "and", "6", "weeks", "respectively", "in", "evaluable", "patients", ".", "Similar", "reductions", "occurred", "in", "standing", "blood", "pressure", "and", "there", "was", "no", "evidence", "of", "postural", "hypotension", ".", "Normalization", "and", "responder", "rates", "at", "6", "weeks", "were", "86", "%", "and", "69", "%", "respectively", ".", "Dosage", "was", "increased", "from", "2", ".", "5", "mg", "b", ".", "d", ".", "to", "5", "mg", "b", ".", "d", ".", "at", "4", "weeks", "in", "patients", "with", "diastolic", "blood", "pressure", "greater", "than", "90", "mmHg", "and", "their", "further", "response", "was", "greater", "than", "those", "remaining", "on", "2", ".", "5", "mg", "b", ".", "d", "."]], "ner": [[[0, 0, "Chemical"], [21, 21, "Chemical"], [88, 88, "Chemical"], [69, 69, "Disease"], [71, 71, "Disease"], [75, 75, "Disease"], [3, 3, "Disease"], [39, 39, "Disease"], [181, 182, "Disease"]]], "relations": [[[0, 0, 69, 69, "CID"], [21, 21, 69, 69, "CID"], [88, 88, 69, 69, "CID"], [0, 0, 71, 71, "CID"], [21, 21, 71, 71, "CID"], [88, 88, 71, 71, "CID"], [0, 0, 75, 75, "CID"], [21, 21, 75, 75, "CID"], [88, 88, 75, 75, "CID"]]], "clusters": [], "translated": " <0>伊拉地平</0>治疗<6>高血压</6>在香港的一般实践中。一项为期 6 周的关于引入<1>伊拉地平</1>治疗的开放性研究在香港的全科诊所进行。303名患有轻度至中度<7>高血压</7>的中国患者进入了研究。21% 的患者报告了副作用，并导致3名患者退出研究。主要副作用是<3>头痛</3>、<4>头晕</4>、心悸和<5>潮红</5>，这些副作用并不比其他<2>伊拉地平</2>研究报告的更频繁或安慰剂。仰卧位血压从170 +/- 20 / 102 +/- 6 mmHg降低(P 小于 0 . 01)至153 +/-19 / 92 +/- 8、147 +/- 18 / 88 +/- 7和144 +/- 14 / 87 +/- 6 毫米汞柱分别在2、4和6周可评估的患者。站立时血压也有类似的下降，并且没有<8>体位性低血压</8>的证据。6周时的正常化率和应答率分别为86%和69%。剂量从2.5 毫克 b.d.至5 毫克 b.d.在舒张压大于90 mmHg的患者中4周时，他们的进一步反应大于2.5 毫克 b.d.。", "revised": true}
{"doc_key": "25006961", "sentences": [["Absence", "of", "PKC", "-", "alpha", "attenuates", "lithium", "-", "induced", "nephrogenic", "diabetes", "insipidus", ".", "Lithium", ",", "an", "effective", "antipsychotic", ",", "induces", "nephrogenic", "diabetes", "insipidus", "(", "NDI", ")", "in", "40", "%", "of", "patients", ".", "The", "decreased", "capacity", "to", "concentrate", "urine", "is", "likely", "due", "to", "lithium", "acutely", "disrupting", "the", "cAMP", "pathway", "and", "chronically", "reducing", "urea", "transporter", "(", "UT", "-", "A1", ")", "and", "water", "channel", "(", "AQP2", ")", "expression", "in", "the", "inner", "medulla", ".", "Targeting", "an", "alternative", "signaling", "pathway", ",", "such", "as", "PKC", "-", "mediated", "signaling", ",", "may", "be", "an", "effective", "method", "of", "treating", "lithium", "-", "induced", "polyuria", ".", "PKC", "-", "alpha", "null", "mice", "(", "PKCa", "KO", ")", "and", "strain", "-", "matched", "wild", "type", "(", "WT", ")", "controls", "were", "treated", "with", "lithium", "for", "0", ",", "3", "or", "5", "days", ".", "WT", "mice", "had", "increased", "urine", "output", "and", "lowered", "urine", "osmolality", "after", "3", "and", "5", "days", "of", "treatment", "whereas", "PKCa", "KO", "mice", "had", "no", "change", "in", "urine", "output", "or", "concentration", ".", "Western", "blot", "analysis", "revealed", "that", "AQP2", "expression", "in", "medullary", "tissues", "was", "lowered", "after", "3", "and", "5", "days", "in", "WT", "mice", ";", "however", ",", "AQP2", "was", "unchanged", "in", "PKCa", "KO", ".", "Similar", "results", "were", "observed", "with", "UT", "-", "A1", "expression", ".", "Animals", "were", "also", "treated", "with", "lithium", "for", "6", "weeks", ".", "Lithium", "-", "treated", "WT", "mice", "had", "19", "-", "fold", "increased", "urine", "output", "whereas", "treated", "PKCa", "KO", "animals", "had", "a", "4", "-", "fold", "increase", "in", "output", ".", "AQP2", "and", "UT", "-", "A1", "expression", "was", "lowered", "in", "6", "week", "lithium", "-", "treated", "WT", "animals", "whereas", "in", "treated", "PKCa", "KO", "mice", ",", "AQP2", "was", "only", "reduced", "by", "2", "-", "fold", "and", "UT", "-", "A1", "expression", "was", "unaffected", ".", "Urinary", "sodium", ",", "potassium", "and", "calcium", "were", "elevated", "in", "lithium", "-", "fed", "WT", "but", "not", "in", "lithium", "-", "fed", "PKCa", "KO", "mice", ".", "Our", "data", "show", "that", "ablation", "of", "PKCa", "preserves", "AQP2", "and", "UT", "-", "A1", "protein", "expression", "and", "localization", "in", "lithium", "-", "induced", "NDI", ",", "and", "prevents", "the", "development", "of", "the", "severe", "polyuria", "associated", "with", "lithium", "therapy", "."]], "ner": [[[6, 6, "Chemical"], [13, 13, "Chemical"], [42, 42, "Chemical"], [90, 90, "Chemical"], [117, 117, "Chemical"], [201, 201, "Chemical"], [206, 206, "Chemical"], [243, 243, "Chemical"], [280, 280, "Chemical"], [287, 287, "Chemical"], [312, 312, "Chemical"], [327, 327, "Chemical"], [9, 11, "Disease"], [20, 22, "Disease"], [24, 24, "Disease"], [315, 315, "Disease"], [93, 93, "Disease"], [324, 324, "Disease"], [46, 46, "Chemical"], [51, 51, "Chemical"], [272, 272, "Chemical"], [274, 274, "Chemical"], [276, 276, "Chemical"]]], "relations": [[[6, 6, 9, 11, "CID"], [6, 6, 20, 22, "CID"], [6, 6, 24, 24, "CID"], [6, 6, 315, 315, "CID"], [13, 13, 9, 11, "CID"], [13, 13, 20, 22, "CID"], [13, 13, 24, 24, "CID"], [13, 13, 315, 315, "CID"], [42, 42, 9, 11, "CID"], [42, 42, 20, 22, "CID"], [42, 42, 24, 24, "CID"], [42, 42, 315, 315, "CID"], [90, 90, 9, 11, "CID"], [90, 90, 20, 22, "CID"], [90, 90, 24, 24, "CID"], [90, 90, 315, 315, "CID"], [117, 117, 9, 11, "CID"], [117, 117, 20, 22, "CID"], [117, 117, 24, 24, "CID"], [117, 117, 315, 315, "CID"], [201, 201, 9, 11, "CID"], [201, 201, 20, 22, "CID"], [201, 201, 24, 24, "CID"], [201, 201, 315, 315, "CID"], [206, 206, 9, 11, "CID"], [206, 206, 20, 22, "CID"], [206, 206, 24, 24, "CID"], [206, 206, 315, 315, "CID"], [243, 243, 9, 11, "CID"], [243, 243, 20, 22, "CID"], [243, 243, 24, 24, "CID"], [243, 243, 315, 315, "CID"], [280, 280, 9, 11, "CID"], [280, 280, 20, 22, "CID"], [280, 280, 24, 24, "CID"], [280, 280, 315, 315, "CID"], [287, 287, 9, 11, "CID"], [287, 287, 20, 22, "CID"], [287, 287, 24, 24, "CID"], [287, 287, 315, 315, "CID"], [312, 312, 9, 11, "CID"], [312, 312, 20, 22, "CID"], [312, 312, 24, 24, "CID"], [312, 312, 315, 315, "CID"], [327, 327, 9, 11, "CID"], [327, 327, 20, 22, "CID"], [327, 327, 24, 24, "CID"], [327, 327, 315, 315, "CID"], [6, 6, 93, 93, "CID"], [6, 6, 324, 324, "CID"], [13, 13, 93, 93, "CID"], [13, 13, 324, 324, "CID"], [42, 42, 93, 93, "CID"], [42, 42, 324, 324, "CID"], [90, 90, 93, 93, "CID"], [90, 90, 324, 324, "CID"], [117, 117, 93, 93, "CID"], [117, 117, 324, 324, "CID"], [201, 201, 93, 93, "CID"], [201, 201, 324, 324, "CID"], [206, 206, 93, 93, "CID"], [206, 206, 324, 324, "CID"], [243, 243, 93, 93, "CID"], [243, 243, 324, 324, "CID"], [280, 280, 93, 93, "CID"], [280, 280, 324, 324, "CID"], [287, 287, 93, 93, "CID"], [287, 287, 324, 324, "CID"], [312, 312, 93, 93, "CID"], [312, 312, 324, 324, "CID"], [327, 327, 93, 93, "CID"], [327, 327, 324, 324, "CID"]]], "clusters": [], "translated": "PKC-α 的缺失减弱了<0>锂</0>诱导的<12>肾性尿崩症</12>。<1>锂</1>是一种有效的抗精神病药，可在40%的患者中诱发<13>肾性尿崩症</13>（<14>NDI</14>）。尿液浓缩能力下降可能是由于<2>锂</2>急性破坏<18>cAMP</18>通路和长期减少<19>尿素</19>转运蛋白 (UT-A1)和水通道(AQP2)在内髓质中表达。针对替代信号通路，如PKC介导的信号通路，可能是治疗<3>锂</3>诱导的<16>多尿</16>的有效方法。PKC-α缺失小鼠(PKCa KO)和品系匹配的野生型(WT)对照用<4>锂</4>处理0、3或5天。在治疗3天和5天后，WT小鼠的尿量增加，尿液渗透压降低，而PKCa KO小鼠的尿量或浓度没有变化。Western blot分析表明，WT小鼠在3天和5天后髓质组织中的AQP2表达降低；然而，AQP2在PKCa KO中没有变化。UT-A1表达也观察到类似的结果。动物也接受了<5>锂</5>治疗6周。<6>锂</6>治疗的WT小鼠的尿量增加了19倍，而PKCa KO动物的尿量增加了4倍。AQP2和UT-A1表达在6周<7>锂</7>治疗的WT动物中降低，而在治疗的PKCa KO小鼠中，AQP2仅降低2倍，而UT-A1表达不受影响。尿<20>钠</20>、<21>钾</21>和<22>钙</22>在<8>锂</8>中升高-喂食WT但在<9>锂</9>-喂食PKCa KO小鼠。我们的数据表明，PKCa的消融保留了AQP2和UT-A1蛋白在<10>锂</10>诱导的<15>NDI</15>中的表达和定位，并防止了严重的<17>多尿</17>与<11>锂</11>疗法相关。", "revised": true}
{"doc_key": "753803", "sentences": [["Experimental", "progressive", "muscular", "dystrophy", "and", "its", "treatment", "with", "high", "doses", "anabolizing", "agents", ".", "We", "are", "still", "a", "long", "way", "from", "discovering", "an", "unequivocal", "pathogenetic", "interpretation", "of", "progressive", "muscular", "dystrophy", "in", "man", ".", "Noteworthy", "efforts", "have", "been", "made", "in", "the", "experimental", "field", ";", "a", "recessive", "autosomic", "form", "found", "in", "the", "mouse", "seems", "to", "bear", "the", "closest", "resemblance", "to", "the", "human", "form", "from", "the", "genetic", "point", "of", "view", ".", "Myopathy", "due", "to", "lack", "of", "vitamin", "E", "and", "myopathy", "induced", "by", "certain", "viruses", "have", "much", "in", "common", "anatomically", "and", "pathologically", "with", "the", "human", "form", ".", "The", "authors", "induced", "myodystrophy", "in", "the", "rat", "by", "giving", "it", "a", "diet", "lacking", "in", "vitamin", "E", ".", "The", "pharmacological", "characteristics", "of", "vitamin", "E", "and", "the", "degenerative", "changes", "brought", "about", "by", "its", "deficiency", ",", "especially", "in", "the", "muscles", ",", "are", "illustrated", ".", "It", "is", "thus", "confirmed", "that", "the", "histological", "characteristics", "of", "myopathic", "rat", "muscle", "induced", "experimentally", "are", "extraordinarily", "similar", "to", "those", "of", "human", "myopathy", "as", "confirmed", "during", "biopsies", "performed", "at", "the", "Orthopaedic", "Traumatological", "Centre", ",", "Florence", ".", "The", "encouraging", "results", "obtained", "in", "various", "authoratative", "departments", "in", "myopathic", "patients", "by", "using", "anabolizing", "steroids", "have", "encouraged", "the", "authors", "to", "investigate", "the", "beneficial", "effects", "of", "one", "anabolizing", "agent", "(", "Dianabol", ",", "CIBA", ")", "at", "high", "doses", "in", "rats", "rendered", "myopathic", "by", "a", "diet", "deficient", "in", "vitamin", "E", ".", "In", "this", "way", "they", "obtained", "appreciable", "changes", "in", "body", "weight", "(", "increased", "from", "50", "to", "70", "g", "after", "forty", "days", "at", "a", "dose", "of", "5", "mg", "per", "day", "of", "anabolizing", "agent", ")", ",", "but", "most", "of", "all", "they", "found", "histological", "changes", "due", "to", "\"", "regenerative", "\"", "changes", "in", "the", "muscle", "tissue", ",", "which", "however", "maintained", "its", "myopathic", "characteristics", "in", "the", "control", "animals", "that", "were", "not", "treated", "with", "the", "anabolizing", "agent", ".", "The", "authors", "conclude", "by", "affirming", "the", "undoubted", "efficacy", "of", "the", "anabolizing", "steroids", "in", "experimental", "myopathic", "disease", ",", "but", "they", "have", "reservations", "as", "to", "the", "transfer", "of", "the", "results", "into", "the", "human", "field", ",", "where", "high", "dosage", "can", "not", "be", "carried", "out", "continuously", "because", "of", "the", "effects", "of", "the", "drug", "on", "virility", ";", "because", "the", "tissue", "injury", "too", "often", "occurs", "at", "an", "irreversible", "stage", "vis", "-", "a", "-", "vis", "the", "\"", "regeneration", "\"", "of", "the", "muscle", "tissue", ";", "and", "finally", "because", "the", "dystrophic", "injurious", "agent", "is", "certainly", "not", "the", "lack", "of", "vitamin", "E", "but", "something", "as", "yet", "unknown", "."]], "ner": [[[72, 73, "Chemical"], [106, 107, "Chemical"], [113, 114, "Chemical"], [213, 214, "Chemical"], [377, 378, "Chemical"], [2, 3, "Disease"], [27, 28, "Disease"], [95, 95, "Disease"], [197, 197, "Chemical"], [182, 182, "Chemical"], [298, 298, "Chemical"], [67, 67, "Disease"], [75, 75, "Disease"], [142, 142, "Disease"], [154, 154, "Disease"], [177, 177, "Disease"], [207, 207, "Disease"], [272, 272, "Disease"], [301, 302, "Disease"]]], "relations": [[[72, 73, 2, 3, "CID"], [72, 73, 27, 28, "CID"], [72, 73, 95, 95, "CID"], [106, 107, 2, 3, "CID"], [106, 107, 27, 28, "CID"], [106, 107, 95, 95, "CID"], [113, 114, 2, 3, "CID"], [113, 114, 27, 28, "CID"], [113, 114, 95, 95, "CID"], [213, 214, 2, 3, "CID"], [213, 214, 27, 28, "CID"], [213, 214, 95, 95, "CID"], [377, 378, 2, 3, "CID"], [377, 378, 27, 28, "CID"], [377, 378, 95, 95, "CID"], [197, 197, 2, 3, "CID"], [197, 197, 27, 28, "CID"], [197, 197, 95, 95, "CID"]]], "clusters": [], "translated": "实验性进行性 <5>肌营养不良症</5>及其用高剂量合成代谢剂的治疗。我们距离发现人类进行性<6>肌营养不良症</6>的明确发病机制还有很长的路要走。在实验领域做出了显着的努力；从遗传学的角度来看，在老鼠身上发现的一种隐性常染色体形式似乎与人类最相似。<11>肌病</11>由于缺乏<0>维生素E</0>和某些病毒引起的<12>肌病</12>在解剖学和病理学上与人类形态有很多共同点。作者通过给大鼠喂食缺乏<1>维生素 E</1>的食物，诱发了大鼠的<7>肌营养不良</7>。阐述了<2>维生素E</2>的药理特性及其缺乏引起的退行性变化，尤其是肌肉退行性变化。因此证实，实验诱导的<13>肌病</13>大鼠肌肉的组织学特征与人类<14>肌病</14>的组织学特征非常相似，这在佛罗伦萨骨科创伤中心进行的活组织检查中得到证实。<15>肌病</15>患者使用合成代谢<9>类固醇</9>在各个权威部门获得的令人鼓舞的结果鼓励作者研究一种合成代谢剂的有益作用(<8>大力补</8>，CIBA)在大鼠中因缺乏<3>维生素E</3>的饮食而导致<16>肌营养不良</16>。通过这种方式，他们获得了明显的体重变化(每天服用5毫克的合成代谢剂，40天后体重从50克增加到70克)，但最重要的是，他们发现了由于肌肉“再生”变化引起的组织学变化。组织，然而在未用合成代谢剂处理的对照动物中保持其<17>肌营养不良症</17>特征。作者最后肯定了合成代谢类固醇<10>类固醇</10>在实验性<18>肌营养不良症</18>中的无可置疑的功效，但他们对将结果转移到高剂量的人体领域持保留态度因药物影响性功能而不能连续进行；因为组织损伤往往发生在不可逆转的阶段，相对于肌肉组织的“再生”；最后，因为营养不良的致病因素当然不是缺乏<4>维生素E</4>，而是一些未知的东西。", "revised": true}
{"doc_key": "26115410", "sentences": [["Mechanisms", "Underlying", "Latent", "Disease", "Risk", "Associated", "with", "Early", "-", "Life", "Arsenic", "Exposure", ":", "Current", "Research", "Trends", "and", "Scientific", "Gaps", ".", "BACKGROUND", ":", "Millions", "of", "individuals", "worldwide", ",", "particularly", "those", "living", "in", "rural", "and", "developing", "areas", ",", "are", "exposed", "to", "harmful", "levels", "of", "inorganic", "arsenic", "(", "iAs", ")", "in", "their", "drinking", "water", ".", "Inorganic", "As", "exposure", "during", "key", "developmental", "periods", "is", "associated", "with", "a", "variety", "of", "adverse", "health", "effects", "including", "those", "that", "are", "evident", "in", "adulthood", ".", "There", "is", "considerable", "interest", "in", "identifying", "the", "molecular", "mechanisms", "that", "relate", "early", "-", "life", "iAs", "exposure", "to", "the", "development", "of", "these", "latent", "diseases", ",", "particularly", "in", "relationship", "to", "cancer", ".", "OBJECTIVES", ":", "This", "work", "summarizes", "research", "on", "the", "molecular", "mechanisms", "that", "underlie", "the", "increased", "risk", "of", "cancer", "development", "in", "adulthood", "that", "is", "associated", "with", "early", "-", "life", "iAs", "exposure", ".", "DISCUSSION", ":", "Epigenetic", "reprogramming", "that", "imparts", "functional", "changes", "in", "gene", "expression", ",", "the", "development", "of", "cancer", "stem", "cells", ",", "and", "immunomodulation", "are", "plausible", "underlying", "mechanisms", "by", "which", "early", "-", "life", "iAs", "exposure", "elicits", "latent", "carcinogenic", "effects", ".", "CONCLUSIONS", ":", "Evidence", "is", "mounting", "that", "relates", "early", "-", "life", "iAs", "exposure", "and", "cancer", "development", "later", "in", "life", ".", "Future", "research", "should", "include", "animal", "studies", "that", "address", "mechanistic", "hypotheses", "and", "studies", "of", "human", "populations", "that", "integrate", "early", "-", "life", "exposure", ",", "molecular", "alterations", ",", "and", "latent", "disease", "outcomes", "."]], "ner": [[[42, 43, "Chemical"], [45, 45, "Chemical"], [52, 53, "Chemical"], [90, 90, "Chemical"], [133, 133, "Chemical"], [166, 166, "Chemical"], [183, 183, "Chemical"], [104, 104, "Disease"], [122, 122, "Disease"], [151, 151, "Disease"], [186, 186, "Disease"], [10, 10, "Chemical"]]], "relations": [[[42, 43, 104, 104, "CID"], [42, 43, 122, 122, "CID"], [42, 43, 151, 151, "CID"], [42, 43, 186, 186, "CID"], [45, 45, 104, 104, "CID"], [45, 45, 122, 122, "CID"], [45, 45, 151, 151, "CID"], [45, 45, 186, 186, "CID"], [52, 53, 104, 104, "CID"], [52, 53, 122, 122, "CID"], [52, 53, 151, 151, "CID"], [52, 53, 186, 186, "CID"], [90, 90, 104, 104, "CID"], [90, 90, 122, 122, "CID"], [90, 90, 151, 151, "CID"], [90, 90, 186, 186, "CID"], [133, 133, 104, 104, "CID"], [133, 133, 122, 122, "CID"], [133, 133, 151, 151, "CID"], [133, 133, 186, 186, "CID"], [166, 166, 104, 104, "CID"], [166, 166, 122, 122, "CID"], [166, 166, 151, 151, "CID"], [166, 166, 186, 186, "CID"], [183, 183, 104, 104, "CID"], [183, 183, 122, 122, "CID"], [183, 183, 151, 151, "CID"], [183, 183, 186, 186, "CID"]]], "clusters": [], "translated": "与生命早期<11>砷</11> 暴露相关的潜在疾病风险的机制：当前的研究趋势和科学差距。背景：全世界数以百万计的人，尤其是生活在农村和发展中地区的人，在饮用水中暴露于有害水平的<0>无机砷</0> (<1>iAs</1>)。 <2>无机砷</2>暴露在关键发育时期会导致多种不良健康影响，包括那些在成年期就很明显的影响。人们对确定与生命早期<3> iAs </3> 暴露与这些潜在疾病的发展相关的分子机制非常感兴趣，特别是与<7>癌症</7>的关系。目标：这项工作总结了与<4>生命早期iAs暴露</4>相关的成年期<8>癌症</8>发展风险增加的分子机制研究。讨论：使基因表达发生功能性变化的表观遗传重编程，<9>癌症</9>干细胞的发展和免疫调节是早期<5>iAs</5>暴露引起潜在致癌效应的潜在机制。结论：越来越多的证据表明，<6>生命早期iAs暴露</6>与生命后期<10>癌症</10>的发展有关。未来的研究应包括动物研究来解决机理假设和人群研究，其整合早期生命暴露、分子改变和潜在疾病结果。", "revised": true}
{"doc_key": "2782734", "sentences": [["Tachyphylaxis", "to", "systemic", "but", "not", "to", "airway", "responses", "during", "prolonged", "therapy", "with", "high", "dose", "inhaled", "salbutamol", "in", "asthmatics", ".", "High", "doses", "of", "inhaled", "salbutamol", "produce", "substantial", "improvements", "in", "airway", "response", "in", "patients", "with", "asthma", ",", "and", "are", "associated", "with", "dose", "-", "dependent", "systemic", "beta", "-", "adrenoceptor", "responses", ".", "The", "purpose", "of", "the", "present", "study", "was", "to", "investigate", "whether", "tachyphylaxis", "occurs", "during", "prolonged", "treatment", "with", "high", "dose", "inhaled", "salbutamol", ".", "Twelve", "asthmatic", "patients", "(", "FEV1", ",", "81", "+", "/", "-", "4", "%", "predicted", ")", ",", "requiring", "only", "occasional", "inhaled", "beta", "-", "agonists", "as", "their", "sole", "therapy", ",", "were", "given", "a", "14", "-", "day", "treatment", "with", "high", "dose", "inhaled", "salbutamol", "(", "HDS", ")", ",", "4", ",", "000", "micrograms", "daily", ",", "low", "dose", "inhaled", "salbutamol", "(", "LDS", ")", ",", "800", "micrograms", "daily", ",", "or", "placebo", "(", "PI", ")", "by", "metered", "-", "dose", "inhaler", "in", "a", "double", "-", "blind", ",", "randomized", "crossover", "design", ".", "During", "the", "14", "-", "day", "run", "-", "in", "and", "during", "washout", "periods", ",", "inhaled", "beta", "-", "agonists", "were", "withheld", "and", "ipratropium", "bromide", "was", "substituted", "for", "rescue", "purposes", ".", "At", "the", "end", "of", "each", "14", "-", "day", "treatment", ",", "a", "dose", "-", "response", "curve", "(", "DRC", ")", "was", "performed", ",", "and", "airway", "(", "FEV1", ",", "FEF25", "-", "75", ")", "chronotropic", "(", "HR", ")", ",", "tremor", ",", "and", "metabolic", "(", "K", ",", "Glu", ")", "responses", "were", "measured", "at", "each", "step", "(", "from", "100", "to", "4", ",", "000", "micrograms", ")", ".", "Treatment", "had", "no", "significant", "effect", "on", "baseline", "values", ".", "There", "were", "dose", "-", "dependent", "increases", "in", "FEV1", "and", "FEF25", "-", "75", "(", "p", "less", "than", "0", ".", "001", ")", ",", "and", "pretreatment", "with", "HDS", "did", "not", "displace", "the", "DRC", "to", "the", "right", ".", "DRC", "for", "HR", "(", "p", "less", "than", "0", ".", "001", ")", ",", "K", "(", "p", "less", "than", "0", ".", "001", ")", ",", "and", "Glu", "(", "p", "less", "than", "0", ".", "005", ")", "were", "attenuated", "after", "treatment", "with", "HDS", "compared", "with", "PI", ".", "There", "were", "also", "differences", "between", "HDS", "and", "LDS", "for", "HR", "(", "p", "less", "than", "0", ".", "001", ")", "and", "Glu", "(", "p", "less", "than", "0", ".", "05", ")", "responses", ".", "Frequency", "and", "severity", "of", "subjective", "adverse", "effects", "were", "also", "reduced", "after", "HDS", ":", "tremor", "(", "p", "less", "than", "0", ".", "001", ")", ",", "palpitations", "(", "p", "less", "than", "0", ".", "001", ")", ".", "(", "ABSTRACT", "TRUNCATED", "AT", "250", "WORDS", ")"]], "ner": [[[15, 15, "Chemical"], [23, 23, "Chemical"], [67, 67, "Chemical"], [107, 107, "Chemical"], [121, 121, "Chemical"], [213, 213, "Disease"], [366, 366, "Disease"], [17, 17, "Disease"], [33, 33, "Disease"], [70, 70, "Disease"], [170, 171, "Chemical"], [218, 218, "Chemical"], [293, 293, "Chemical"], [220, 220, "Chemical"], [304, 304, "Chemical"], [342, 342, "Chemical"]]], "relations": [[[15, 15, 213, 213, "CID"], [15, 15, 366, 366, "CID"], [23, 23, 213, 213, "CID"], [23, 23, 366, 366, "CID"], [67, 67, 213, 213, "CID"], [67, 67, 366, 366, "CID"], [107, 107, 213, 213, "CID"], [107, 107, 366, 366, "CID"], [121, 121, 213, 213, "CID"], [121, 121, 366, 366, "CID"]]], "clusters": [], "translated": "在 <7>哮喘患者 </7>中长期吸入高剂量<0>沙丁胺醇</0>期间，对全身反应的快速耐受性而非气道反应。吸入高剂量的<1>沙丁胺醇</1>可显着改善<8>哮喘 </8>患者的气道反应，并且与剂量依赖性全身β-肾上腺素能受体反应有关。本研究的目的是调查在长期吸入高剂量<2>沙丁胺醇</2>期间是否会发生快速耐受。十二名<9>哮喘</9>患者（FEV1，81+/-4%预测值），仅偶尔需要吸入β-受体激动剂作为唯一治疗，接受了为期14天的高剂量吸入<3>沙丁胺醇</3>（HDS），4,000微克每天，低剂量吸入<4>沙丁胺醇</4>（LDS），每天800微克，或通过定量吸入器在双盲、随机交叉中使用安慰剂(PI)设计。在为期14天的磨合期和清除期，吸入β-受体激动剂被停用，<10>异丙托溴铵</10>被替代以用于抢救目的。在每个14天治疗结束时，进行剂量反应曲线(DRC)和气道(FEV1，FEF25-75)变时性(HR)，<5>震颤</5>，和代谢(<11>K</11>，<13>Glu</13>)反应在每个步骤中都被测量（从100到4,000微克）。治疗对基线值没有显着影响。FEV1和FEF25-75呈剂量依赖性增加(p小于0.001)，HDS预处理并未使DRC向右移位。HR(p小于0.001)、<12>K</12>(p小于0.001)和<14>Glu</14>(p小于0.005)的DRC在治疗后减弱与HDS与PI相比。HDS和LDS对HR(p小于0.001)和<15>Glu</15>(p小于0.05)的反应也存在差异。HDS后主观不良反应的频率和严重程度也有所降低：<6>震颤</6>(p小于0.001)、心悸(p小于0.001)。（摘要被截断为250个单词）", "revised": true}
{"doc_key": "19681452", "sentences": [["Bilateral", "haemorrhagic", "infarction", "of", "the", "globus", "pallidus", "after", "cocaine", "and", "alcohol", "intoxication", ".", "Cocaine", "is", "a", "risk", "factor", "for", "both", "ischemic", "and", "haemorrhagic", "stroke", ".", "We", "present", "the", "case", "of", "a", "31", "-", "year", "-", "old", "man", "with", "bilateral", "ischemia", "of", "the", "globus", "pallidus", "after", "excessive", "alcohol", "and", "intranasal", "cocaine", "use", ".", "Drug", "-", "related", "globus", "pallidus", "infarctions", "are", "most", "often", "associated", "with", "heroin", ".", "Bilateral", "basal", "ganglia", "infarcts", "after", "the", "use", "of", "cocaine", ",", "without", "concurrent", "heroin", "use", ",", "have", "never", "been", "reported", ".", "In", "our", "patient", ",", "transient", "cardiac", "arrhythmia", "or", "respiratory", "dysfunction", "related", "to", "cocaine", "and", "/", "or", "ethanol", "use", "were", "the", "most", "likely", "causes", "of", "cerebral", "hypoperfusion", "."]], "ner": [[[63, 63, "Chemical"], [77, 77, "Chemical"], [1, 6, "Disease"], [55, 57, "Disease"], [66, 68, "Disease"], [8, 8, "Chemical"], [13, 13, "Chemical"], [49, 49, "Chemical"], [73, 73, "Chemical"], [97, 97, "Chemical"], [39, 43, "Disease"], [10, 10, "Chemical"], [46, 46, "Chemical"], [101, 101, "Chemical"], [20, 23, "Disease"], [90, 91, "Disease"], [93, 94, "Disease"]]], "relations": [[[63, 63, 1, 6, "CID"], [63, 63, 55, 57, "CID"], [63, 63, 66, 68, "CID"], [77, 77, 1, 6, "CID"], [77, 77, 55, 57, "CID"], [77, 77, 66, 68, "CID"], [8, 8, 39, 43, "CID"], [13, 13, 39, 43, "CID"], [49, 49, 39, 43, "CID"], [73, 73, 39, 43, "CID"], [97, 97, 39, 43, "CID"], [10, 10, 20, 23, "CID"], [46, 46, 20, 23, "CID"], [101, 101, 20, 23, "CID"]]], "clusters": [], "translated": " <5>可卡因</5>和<11>酒精</11>中毒后双侧<2>苍白球出血性梗塞</2>。<6>可卡因</6>是<14>缺血性和出血性中风</14>的危险因素。我们介绍了一名31岁男性在过量<12>酒精</12>和鼻内<7>可卡因</7>使用后出现双侧<10>苍白球缺血</10>的病例。与药物有关的<3>苍白球梗塞</3>最常与<0>海洛因</0>有关。使用<8>可卡因</8>后未同时使用<1>海洛因</1>的双侧<4>基底神经节梗死</4>，从未见报道。在我们的患者中，与<9>可卡因</9>和/或<13>乙醇</13>使用相关的短暂性<15>心律失常</15>或<16>呼吸功能障碍</16>最有可能是脑灌注不足的原因。", "revised": true}
{"doc_key": "7248895", "sentences": [["Invasive", "carcinoma", "of", "the", "renal", "pelvis", "following", "cyclophosphamide", "therapy", "for", "nonmalignant", "disease", ".", "A", "47", "-", "year", "-", "old", "woman", "with", "right", "hydroureteronephrosis", "due", "to", "ureterovesical", "junction", "obstruction", "had", "gross", "hematuria", "after", "being", "treated", "for", "five", "years", "wtih", "cyclophosphamide", "for", "cerebral", "vasculitis", ".", "A", "right", "nephroureterectomy", "was", "required", "for", "control", "of", "bleeding", ".", "The", "pathology", "specimen", "contained", "clinically", "occult", "invasive", "carcinoma", "of", "the", "renal", "pelvis", ".", "Although", "the", "ability", "of", "cyclophosphamide", "to", "cause", "hemorrhagic", "cystitis", "and", "urine", "cytologic", "abnormalities", "indistinguishable", "from", "high", "grade", "carcinoma", "is", "well", "known", ",", "it", "is", "less", "widely", "appreciated", "that", "it", "is", "also", "associated", "with", "carcinoma", "of", "the", "urinary", "tract", ".", "Twenty", "carcinomas", "of", "the", "urinary", "bladder", "and", "one", "carcinoma", "of", "the", "prostate", "have", "been", "reported", "in", "association", "with", "its", "use", ".", "The", "present", "case", "is", "the", "first", "carcinoma", "of", "the", "renal", "pelvis", "reported", "in", "association", "with", "cyclophosphamide", "treatment", ".", "It", "is", "the", "third", "urinary", "tract", "cancer", "reported", "in", "association", "with", "cyclophosphamide", "treatment", "for", "nonmalignant", "disease", ".", "The", "association", "of", "the", "tumor", "with", "preexisting", "hydroureteronephrosis", "suggests", "that", "stasis", "prolonged", "and", "intensified", "exposure", "of", "upper", "urinary", "tract", "epithelium", "to", "cyclophosphamide", ".", "Patients", "who", "are", "candidates", "for", "long", "-", "term", "cyclophosphamide", "treatment", "should", "be", "routinely", "evaluated", "for", "obstructive", "uropathy", "."]], "ner": [[[7, 7, "Chemical"], [38, 38, "Chemical"], [70, 70, "Chemical"], [141, 141, "Chemical"], [155, 155, "Chemical"], [182, 182, "Chemical"], [192, 192, "Chemical"], [30, 30, "Disease"], [83, 83, "Disease"], [106, 110, "Disease"], [1, 5, "Disease"], [60, 64, "Disease"], [132, 136, "Disease"], [22, 22, "Disease"], [168, 168, "Disease"], [40, 41, "Disease"], [51, 51, "Disease"], [73, 74, "Disease"], [99, 103, "Disease"], [148, 150, "Disease"], [113, 116, "Disease"], [165, 165, "Disease"]]], "relations": [[[7, 7, 30, 30, "CID"], [38, 38, 30, 30, "CID"], [70, 70, 30, 30, "CID"], [141, 141, 30, 30, "CID"], [155, 155, 30, 30, "CID"], [182, 182, 30, 30, "CID"], [192, 192, 30, 30, "CID"], [7, 7, 83, 83, "CID"], [38, 38, 83, 83, "CID"], [70, 70, 83, 83, "CID"], [141, 141, 83, 83, "CID"], [155, 155, 83, 83, "CID"], [182, 182, 83, 83, "CID"], [192, 192, 83, 83, "CID"], [7, 7, 106, 110, "CID"], [38, 38, 106, 110, "CID"], [70, 70, 106, 110, "CID"], [141, 141, 106, 110, "CID"], [155, 155, 106, 110, "CID"], [182, 182, 106, 110, "CID"], [192, 192, 106, 110, "CID"]]], "clusters": [], "translated": "浸润性<10>肾盂癌</10>因非恶性疾病接受<0>环磷酰胺</0>治疗后。一位 47 岁的女性因输尿管膀胱连接部梗阻而患有右侧<13>输尿管肾积水</13>，在使用<1>环磷酰胺</1>治疗<15>脑血管炎</15>5 年后出现肉眼<7>血尿</7>。需要进行右肾输尿管切除术以控制<16>出血</16>。病理标本含有临床上隐匿性浸润性<11>肾盂癌</11>。虽然<2>环磷酰胺</2>引起<17>出血性膀胱炎</17>和与高级别<8>癌</8>无法区分的尿液细胞学异常的能力是众所周知的，但人们不太了解它也与<18>泌尿道癌</18>有关。已有20例<9>膀胱癌</9>和1例<20>前列腺癌</20>与其使用有关。本病例是第一例报道的与<3>环磷酰胺</3>治疗相关的<12>肾盂癌</12>。这是第三例与<4>环磷酰胺</4>治疗非恶性疾病相关的<19>尿路癌症</19>报道。<21>肿瘤</21>与先前存在的<14>输尿管肾积水</14>的关联表明，淤滞延长并加强了上尿路上皮对<5>环磷酰胺</5>的暴露。适合长期<6>环磷酰胺</6>治疗的患者应常规评估是否存在梗阻性尿路病变。", "revised": true}
{"doc_key": "12678199", "sentences": [["Amiodarone", "-", "induced", "torsade", "de", "pointes", "during", "bladder", "irrigation", ":", "an", "unusual", "presentation", "-", "-", "a", "case", "report", ".", "The", "authors", "present", "a", "case", "of", "early", "(", "within", "4", "days", ")", "development", "of", "torsade", "de", "pointes", "(", "TdP", ")", "associated", "with", "oral", "amiodarone", "therapy", ".", "Consistent", "with", "other", "reports", "this", "case", "of", "TdP", "occurred", "in", "the", "context", "of", "multiple", "exacerbating", "factors", "including", "hypokalemia", "and", "digoxin", "excess", ".", "Transient", "prolongation", "of", "the", "QT", "during", "bladder", "irrigation", "prompted", "the", "episode", "of", "TdP", ".", "It", "is", "well", "known", "that", "bradycardia", "exacerbates", "acquired", "TdP", ".", "The", "authors", "speculate", "that", "the", "increased", "vagal", "tone", "during", "bladder", "irrigation", ",", "a", "vagal", "maneuver", ",", "in", "the", "context", "of", "amiodarone", "therapy", "resulted", "in", "amiodarone", "-", "induced", "proarrhythmia", ".", "In", "the", "absence", "of", "amiodarone", "therapy", ",", "a", "second", "bladder", "irrigation", "did", "not", "induce", "TdP", "despite", "hypokalemia", "and", "hypomagnesemia", "."]], "ner": [[[0, 0, "Chemical"], [42, 42, "Chemical"], [111, 111, "Chemical"], [115, 115, "Chemical"], [124, 124, "Chemical"], [3, 5, "Disease"], [33, 35, "Disease"], [37, 37, "Disease"], [52, 52, "Disease"], [79, 79, "Disease"], [89, 89, "Disease"], [134, 134, "Disease"], [62, 62, "Disease"], [136, 136, "Disease"], [86, 86, "Disease"], [138, 138, "Disease"], [64, 64, "Chemical"]]], "relations": [[[0, 0, 3, 5, "CID"], [0, 0, 33, 35, "CID"], [0, 0, 37, 37, "CID"], [0, 0, 52, 52, "CID"], [0, 0, 79, 79, "CID"], [0, 0, 89, 89, "CID"], [0, 0, 134, 134, "CID"], [42, 42, 3, 5, "CID"], [42, 42, 33, 35, "CID"], [42, 42, 37, 37, "CID"], [42, 42, 52, 52, "CID"], [42, 42, 79, 79, "CID"], [42, 42, 89, 89, "CID"], [42, 42, 134, 134, "CID"], [111, 111, 3, 5, "CID"], [111, 111, 33, 35, "CID"], [111, 111, 37, 37, "CID"], [111, 111, 52, 52, "CID"], [111, 111, 79, 79, "CID"], [111, 111, 89, 89, "CID"], [111, 111, 134, 134, "CID"], [115, 115, 3, 5, "CID"], [115, 115, 33, 35, "CID"], [115, 115, 37, 37, "CID"], [115, 115, 52, 52, "CID"], [115, 115, 79, 79, "CID"], [115, 115, 89, 89, "CID"], [115, 115, 134, 134, "CID"], [124, 124, 3, 5, "CID"], [124, 124, 33, 35, "CID"], [124, 124, 37, 37, "CID"], [124, 124, 52, 52, "CID"], [124, 124, 79, 79, "CID"], [124, 124, 89, 89, "CID"], [124, 124, 134, 134, "CID"]]], "clusters": [], "translated": " <0>胺碘酮</0> - 在膀胱冲洗过程中诱发<5>尖端扭转型室速</5>：一个不寻常的表现 - 一个病例报告。作者介绍了与口服<1>胺碘酮</1>治疗相关的早期（4天内）<6>尖端扭转型室速</6> (<7>TdP</7>)的病例。与其他报告一致，这例<TdP><8>尖端扭转型室速</8></TdP>发生在多种加重因素的背景下，包括<12>低钾血症</12>和<16>地高辛</16>过量。膀胱冲洗期间QT的短暂延长促使<9>尖端扭转型室速</9>的发作。众所周知，<14>心动过缓</14>会加剧获得性<10>尖端扭转型室速</10>。作者推测，在<2>胺碘酮</2>治疗的情况下，膀胱冲洗过程中迷走神经张力增加是一种迷走神经运动，导致<3>胺碘酮</3>诱发心律失常。在没有<4>胺碘酮</4>治疗的情况下，尽管有<13>低钾血症</13>和<15>低镁血症</15>，但第二次膀胱冲洗不会诱发<11>尖端扭转型室速</11>。", "revised": true}
{"doc_key": "17721298", "sentences": [["Corneal", "ulcers", "associated", "with", "aerosolized", "crack", "cocaine", "use", ".", "PURPOSE", ":", "We", "report", "4", "cases", "of", "corneal", "ulcers", "associated", "with", "drug", "abuse", ".", "The", "pathogenesis", "of", "these", "ulcers", "and", "management", "of", "these", "patients", "are", "also", "reviewed", ".", "METHODS", ":", "Review", "of", "all", "cases", "of", "corneal", "ulcers", "associated", "with", "drug", "abuse", "seen", "at", "our", "institution", "from", "July", "2006", "to", "December", "2006", ".", "RESULTS", ":", "Four", "patients", "with", "corneal", "ulcers", "associated", "with", "crack", "cocaine", "use", "were", "reviewed", ".", "All", "corneal", "ulcers", "were", "cultured", ",", "and", "the", "patients", "were", "admitted", "to", "the", "hospital", "for", "intensive", "topical", "antibiotic", "treatment", ".", "Each", "patient", "received", "comprehensive", "health", "care", ",", "including", "medical", "and", "substance", "abuse", "consultations", ".", "Streptococcal", "organisms", "were", "found", "in", "3", "cases", "and", "Capnocytophaga", "and", "Brevibacterium", "casei", "in", "1", "patient", ".", "The", "infections", "responded", "to", "antibiotic", "treatment", ".", "Two", "patients", "needed", "a", "lateral", "tarsorrhaphy", "for", "persistent", "epithelial", "defects", ".", "CONCLUSIONS", ":", "Aerosolized", "crack", "cocaine", "use", "can", "be", "associated", "with", "the", "development", "of", "corneal", "ulcers", ".", "Drug", "abuse", "provides", "additional", "challenges", "for", "management", ".", "Not", "only", "treatment", "of", "their", "infections", "but", "also", "the", "overall", "poor", "health", "of", "the", "patients", "and", "increased", "risk", "of", "noncompliance", "need", "to", "be", "addressed", ".", "Comprehensive", "care", "may", "provide", "the", "patient", "the", "opportunity", "to", "discontinue", "their", "substance", "abuse", ",", "improve", "their", "overall", "health", ",", "and", "prevent", "future", "corneal", "complications", "."]], "ner": [[[5, 6, "Chemical"], [70, 71, "Chemical"], [147, 148, "Chemical"], [0, 1, "Disease"], [16, 17, "Disease"], [44, 45, "Disease"], [66, 67, "Disease"], [77, 78, "Disease"], [157, 158, "Disease"], [20, 21, "Disease"], [48, 49, "Disease"], [106, 107, "Disease"], [160, 161, "Disease"], [204, 205, "Disease"], [27, 27, "Disease"], [127, 127, "Disease"], [173, 173, "Disease"]]], "relations": [[[5, 6, 0, 1, "CID"], [5, 6, 16, 17, "CID"], [5, 6, 44, 45, "CID"], [5, 6, 66, 67, "CID"], [5, 6, 77, 78, "CID"], [5, 6, 157, 158, "CID"], [70, 71, 0, 1, "CID"], [70, 71, 16, 17, "CID"], [70, 71, 44, 45, "CID"], [70, 71, 66, 67, "CID"], [70, 71, 77, 78, "CID"], [70, 71, 157, 158, "CID"], [147, 148, 0, 1, "CID"], [147, 148, 16, 17, "CID"], [147, 148, 44, 45, "CID"], [147, 148, 66, 67, "CID"], [147, 148, 77, 78, "CID"], [147, 148, 157, 158, "CID"]]], "clusters": [], "translated": " <3>角膜溃疡</3>与雾化<0>快克可卡因</0>使用有关。目的：我们报告了 4 例与<9>药物滥用</9>相关的<4>角膜溃疡</4>。还回顾了这些<14>溃疡</14>的发病机制和这些患者的治疗。方法：回顾 2006 年 7 月至 2006 年 12 月期间在我们机构就诊的与<10>药物滥用</10>相关的所有<5>角膜溃疡</5>病例。结果：对 4 名<6>角膜溃疡</6>与<1>快克可卡因</1>使用相关的患者进行了回顾。所有<7>角膜溃疡</7>均进行了培养，患者入院进行强化外用抗生素治疗。每位患者都接受了全面的医疗保健，包括医疗和<11>药物滥用</11>咨询。链球菌3例和干酪球菌和短小杆菌1例。<15>感染</15>对抗生素治疗有反应。两名患者因持续性上皮缺损而需要进行侧方睑缝合术。结论：雾化<2>快克可卡因</2>的使用可能与<8>角膜溃疡</8>的发展有关。<12>药物滥用</12>给管理带来了额外的挑战。不仅要治疗他们的<16>感染</16>，还要解决患者整体健康状况不佳和不依从性增加的风险问题。综合护理可为患者提供停止<13>药物滥用</13>、改善整体健康状况并预防未来角膜并发症的机会。", "revised": true}
{"doc_key": "17554526", "sentences": [["Impaired", "fear", "recognition", "in", "regular", "recreational", "cocaine", "users", ".", "INTRODUCTION", ":", "The", "ability", "to", "read", "facial", "expressions", "is", "essential", "for", "normal", "human", "social", "interaction", ".", "The", "aim", "of", "the", "present", "study", "was", "to", "conduct", "the", "first", "investigation", "of", "facial", "expression", "recognition", "performance", "in", "recreational", "cocaine", "users", ".", "MATERIALS", "AND", "METHODS", ":", "Three", "groups", ",", "comprised", "of", "21", "cocaine", "naive", "participants", "(", "CN", ")", ",", "30", "occasional", "cocaine", "(", "OC", ")", ",", "and", "48", "regular", "recreational", "cocaine", "(", "RC", ")", "users", ",", "were", "compared", ".", "An", "emotional", "facial", "expression", "(", "EFE", ")", "task", "consisting", "of", "a", "male", "and", "female", "face", "expressing", "six", "basic", "emotions", "(", "happiness", ",", "surprise", ",", "sadness", ",", "anger", ",", "fear", ",", "and", "disgust", ")", "was", "administered", ".", "Mean", "percent", "accuracy", "and", "latencies", "for", "correct", "responses", "across", "eight", "presentations", "of", "each", "basic", "emotion", "were", "derived", ".", "Participants", "were", "also", "assessed", "with", "the", "\"", "Eyes", "task", "\"", "to", "investigate", "their", "ability", "to", "recognize", "more", "complex", "emotional", "states", "and", "the", "Symptom", "CheckList", "-", "90", "-", "Revised", "to", "measure", "psychopathology", ".", "RESULTS", ":", "There", "were", "no", "group", "differences", "in", "psychopathology", "or", "\"", "eyes", "task", "\"", "performance", ",", "but", "the", "RC", "group", ",", "who", "otherwise", "had", "similar", "illicit", "substance", "use", "histories", "to", "the", "OC", "group", ",", "exhibited", "impaired", "fear", "recognition", "accuracy", "compared", "to", "the", "OC", "and", "CN", "groups", ".", "The", "RC", "group", "also", "correctly", "identified", "anger", ",", "fear", ",", "happiness", ",", "and", "surprise", ",", "more", "slowly", "than", "CN", ",", "but", "not", "OC", "participants", ".", "The", "OC", "group", "was", "slower", "than", "CN", "when", "correctly", "identifying", "disgust", ".", "The", "selective", "deficit", "in", "fear", "recognition", "accuracy", "manifested", "by", "the", "RC", "group", "can", "not", "be", "explained", "by", "the", "subacute", "effects", "of", "cocaine", ",", "or", "ecstasy", ",", "because", "recent", "and", "less", "recent", "users", "of", "these", "drugs", "within", "this", "group", "were", "similarly", "impaired", ".", "Possible", "parallels", "between", "RC", "users", "and", "psychopaths", "with", "respect", "to", "impaired", "fear", "recognition", ",", "amygdala", "dysfunction", ",", "and", "etiology", "are", "discussed", "."]], "ner": [[[6, 6, "Chemical"], [44, 44, "Chemical"], [57, 57, "Chemical"], [66, 66, "Chemical"], [75, 75, "Chemical"], [275, 275, "Chemical"], [0, 2, "Disease"], [205, 207, "Disease"], [256, 259, "Disease"], [306, 308, "Disease"], [278, 278, "Chemical"], [302, 302, "Disease"]]], "relations": [[[6, 6, 0, 2, "CID"], [6, 6, 205, 207, "CID"], [6, 6, 256, 259, "CID"], [6, 6, 306, 308, "CID"], [44, 44, 0, 2, "CID"], [44, 44, 205, 207, "CID"], [44, 44, 256, 259, "CID"], [44, 44, 306, 308, "CID"], [57, 57, 0, 2, "CID"], [57, 57, 205, 207, "CID"], [57, 57, 256, 259, "CID"], [57, 57, 306, 308, "CID"], [66, 66, 0, 2, "CID"], [66, 66, 205, 207, "CID"], [66, 66, 256, 259, "CID"], [66, 66, 306, 308, "CID"], [75, 75, 0, 2, "CID"], [75, 75, 205, 207, "CID"], [75, 75, 256, 259, "CID"], [75, 75, 306, 308, "CID"], [275, 275, 0, 2, "CID"], [275, 275, 205, 207, "CID"], [275, 275, 256, 259, "CID"], [275, 275, 306, 308, "CID"]]], "clusters": [], "translated": "<6>受损的恐惧识别</6>在经常娱乐<0>可卡因</0>用户中。简介：阅读面部表情的能力对于正常的人类社会互动至关重要。本研究的目的是对消遣性<1>可卡因</1>使用者的面部表情识别性能进行首次调查。材料和方法：三组，包括21名<2>可卡因</2>天真的参与者(CN)，30名偶尔<3>可卡因</3>(OC)和48名经常消遣的<4>可卡因</4>(RC)用户，进行比较。进行了情绪面部表情(EFE)任务，该任务由表达六种基本情绪（快乐、惊讶、悲伤、愤怒、恐惧和厌恶）的男性和女性面部组成。得出了对每种基本情绪的八次呈现的正确反应的平均准确度和延迟百分比。参与者还接受了“眼睛任务”的评估，以调查他们识别更复杂情绪状态的能力，并使用症状检查表-90-修订版来衡量精神病理学。结果：在精神病理学或“眼睛任务”表现方面没有组间差异，但RC组与OC组在其他方面有相似的非法物质使用历史，与OC相比，表现出<7>恐惧识别受损</7>准确性，而CN组则表现正常。RC组也正确识别愤怒、恐惧、快乐和惊讶，比CN慢，但不是OC参与者。OC组在正确识别厌恶时比CN慢。RC组表现出的选择性<8>恐惧识别缺陷</8>不能用<5>可卡因</5>或<10>摇头丸</10>的亚急性效应来解释，因为最近和该组中最近较少使用这些药物的人同样受到损害。讨论了RC用户和<11>精神病患者</11>在<9>恐惧识别受损</9>、杏仁核功能障碍和病因方面可能存在的相似之处。", "revised": true}
{"doc_key": "25080425", "sentences": [["Regulation", "of", "signal", "transducer", "and", "activator", "of", "transcription", "3", "and", "apoptotic", "pathways", "by", "betaine", "attenuates", "isoproterenol", "-", "induced", "acute", "myocardial", "injury", "in", "rats", ".", "The", "present", "study", "was", "designed", "to", "investigate", "the", "cardioprotective", "effects", "of", "betaine", "on", "acute", "myocardial", "ischemia", "induced", "experimentally", "in", "rats", "focusing", "on", "regulation", "of", "signal", "transducer", "and", "activator", "of", "transcription", "3", "(", "STAT3", ")", "and", "apoptotic", "pathways", "as", "the", "potential", "mechanism", "underlying", "the", "drug", "effect", ".", "Male", "Sprague", "Dawley", "rats", "were", "treated", "with", "betaine", "(", "100", ",", "200", ",", "and", "400", "mg", "/", "kg", ")", "orally", "for", "40", "days", ".", "Acute", "myocardial", "ischemic", "injury", "was", "induced", "in", "rats", "by", "subcutaneous", "injection", "of", "isoproterenol", "(", "85", "mg", "/", "kg", ")", ",", "for", "two", "consecutive", "days", ".", "Serum", "cardiac", "marker", "enzyme", ",", "histopathological", "variables", "and", "expression", "of", "protein", "levels", "were", "analyzed", ".", "Oral", "administration", "of", "betaine", "(", "200", "and", "400", "mg", "/", "kg", ")", "significantly", "reduced", "the", "level", "of", "cardiac", "marker", "enzyme", "in", "the", "serum", "and", "prevented", "left", "ventricular", "remodeling", ".", "Western", "blot", "analysis", "showed", "that", "isoproterenol", "-", "induced", "phosphorylation", "of", "STAT3", "was", "maintained", "or", "further", "enhanced", "by", "betaine", "treatment", "in", "myocardium", ".", "Furthermore", ",", "betaine", "(", "200", "and", "400", "mg", "/", "kg", ")", "treatment", "increased", "the", "ventricular", "expression", "of", "Bcl", "-", "2", "and", "reduced", "the", "level", "of", "Bax", ",", "therefore", "causing", "a", "significant", "increase", "in", "the", "ratio", "of", "Bcl", "-", "2", "/", "Bax", ".", "The", "protective", "role", "of", "betaine", "on", "myocardial", "damage", "was", "further", "confirmed", "by", "histopathological", "examination", ".", "In", "summary", ",", "our", "results", "showed", "that", "betaine", "pretreatment", "attenuated", "isoproterenol", "-", "induced", "acute", "myocardial", "ischemia", "via", "the", "regulation", "of", "STAT3", "and", "apoptotic", "pathways", "."]], "ner": [[[15, 15, "Chemical"], [106, 106, "Chemical"], [168, 168, "Chemical"], [252, 252, "Chemical"], [38, 39, "Disease"], [95, 97, "Disease"], [256, 257, "Disease"], [160, 161, "Disease"], [13, 13, "Chemical"], [35, 35, "Chemical"], [77, 77, "Chemical"], [137, 137, "Chemical"], [180, 180, "Chemical"], [187, 187, "Chemical"], [231, 231, "Chemical"], [249, 249, "Chemical"], [19, 20, "Disease"], [233, 234, "Disease"]]], "relations": [[[15, 15, 38, 39, "CID"], [15, 15, 95, 97, "CID"], [15, 15, 256, 257, "CID"], [106, 106, 38, 39, "CID"], [106, 106, 95, 97, "CID"], [106, 106, 256, 257, "CID"], [168, 168, 38, 39, "CID"], [168, 168, 95, 97, "CID"], [168, 168, 256, 257, "CID"], [252, 252, 38, 39, "CID"], [252, 252, 95, 97, "CID"], [252, 252, 256, 257, "CID"], [15, 15, 160, 161, "CID"], [106, 106, 160, 161, "CID"], [168, 168, 160, 161, "CID"], [252, 252, 160, 161, "CID"]]], "clusters": [], "translated": "<8>甜菜碱</8>对信号转导和转录激活因子3 (STAT3)以及细胞凋亡途径的调节减轻了<0>异丙肾上腺素</0>诱导的大鼠急性<16>心肌损伤</16>。本研究旨在研究<9>甜菜碱</9>对实验诱导的大鼠急性<4>心肌缺血</4>的心脏保护作用，重点关注STAT3的调节和细胞凋亡通路，作为药物作用的潜在机制。雄性Sprague Dawley大鼠口服<10>甜菜碱</10>(100、200和400mg/kg)，持续40天。连续两天皮下注射<1>异丙肾上腺素</1>(85mg/kg)，诱发急性<5>心肌缺血损伤</5>。分析了血清心肌标志物酶、组织病理学变量和蛋白表达水平。口服<11>甜菜碱</11>(200和400mg/kg)明显降低血清心脏标志物酶的水平，并预防了左<7>心室重构</7>。Western blot分析显示，在心肌中，<2>异丙肾上腺素</2>诱导的STAT3磷酸化得以维持或进一步增强，经过<12>甜菜碱</12>处理后。此外，<13>甜菜碱</13>(200和400mg/kg)处理可增加Bcl-2的心室表达，降低Bax的表达水平，因此使Bcl-2/Bax比值显著升高。组织病理学检查进一步证实了<14>甜菜碱</14>对<17>心肌损伤</17>的保护作用。总之，本研究结果表明，<15>甜菜碱</15>预处理可通过调节STAT3和细胞凋亡途径减轻<3>异丙肾上腺素</3>诱导的急性<6>心肌缺血</6>。", "revised": true}
{"doc_key": "20009434", "sentences": [["Acute", "renal", "failure", "after", "high", "-", "dose", "methotrexate", "therapy", "in", "a", "patient", "with", "ileostomy", ".", "High", "-", "dose", "methotrexate", "(", "HD", "-", "MTX", ")", "is", "an", "important", "treatment", "for", "Burkitt", "lymphoma", ",", "but", "can", "cause", "hepatic", "and", "renal", "toxicity", "when", "its", "clearance", "is", "delayed", ".", "We", "report", "a", "case", "of", "acute", "renal", "failure", "after", "HD", "-", "MTX", "therapy", "in", "a", "patient", "with", "ileostomy", ",", "The", "patient", "was", "a", "3", "-", "year", "-", "old", "boy", "who", "had", "received", "a", "living", "-", "related", "liver", "transplantation", "for", "congenital", "biliary", "atresia", ".", "At", "day", "833", "after", "the", "transplantation", ",", "he", "was", "diagnosed", "with", "PTLD", "(", "post", "-", "transplantation", "lymphoproliferative", "disorder", ",", "Burkitt", "-", "type", "malignant", "lymphoma", ")", ".", "During", "induction", "therapy", ",", "he", "suffered", "ileal", "perforation", "and", "ileostomy", "was", "performed", ".", "Subsequent", "HD", "-", "MTX", "therapy", "caused", "acute", "renal", "failure", "that", "required", "continuous", "hemodialysis", ".", "We", "supposed", "that", "intravascular", "hypovolemia", "due", "to", "substantial", "drainage", "from", "the", "ileostoma", "caused", "acute", "prerenal", "failure", ".", "After", "recovery", "of", "his", "renal", "function", ",", "we", "could", "safely", "treat", "the", "patient", "with", "HD", "-", "MTX", "therapy", "by", "controlling", "drainage", "from", "ileostoma", "with", "total", "parenteral", "nutrition", "."]], "ner": [[[7, 7, "Chemical"], [18, 18, "Chemical"], [22, 22, "Chemical"], [56, 56, "Chemical"], [130, 130, "Chemical"], [174, 174, "Chemical"], [0, 2, "Disease"], [50, 52, "Disease"], [133, 135, "Disease"], [29, 30, "Disease"], [107, 111, "Disease"], [35, 38, "Disease"], [85, 86, "Disease"], [99, 99, "Disease"], [101, 105, "Disease"], [145, 145, "Disease"]]], "relations": [[[7, 7, 0, 2, "CID"], [7, 7, 50, 52, "CID"], [7, 7, 133, 135, "CID"], [18, 18, 0, 2, "CID"], [18, 18, 50, 52, "CID"], [18, 18, 133, 135, "CID"], [22, 22, 0, 2, "CID"], [22, 22, 50, 52, "CID"], [22, 22, 133, 135, "CID"], [56, 56, 0, 2, "CID"], [56, 56, 50, 52, "CID"], [56, 56, 133, 135, "CID"], [130, 130, 0, 2, "CID"], [130, 130, 50, 52, "CID"], [130, 130, 133, 135, "CID"], [174, 174, 0, 2, "CID"], [174, 174, 50, 52, "CID"], [174, 174, 133, 135, "CID"]]], "clusters": [], "translated": "<6> 急性肾功能衰竭 </6> 高剂量 <0> 甲氨蝶呤 </0> 治疗后，回肠造口术患者出现。大剂量 <1> 甲氨蝶呤 </1>（HD-<2> MTX </2>）是治疗<9> 伯基特淋巴瘤 </9>的重要药物，但当其清除受阻时，会导致<11> 肝肾毒性 </11>。我们报道了一例回肠造口术患者接受 HD-<3> MTX </3>治疗后出现<7> 急性肾功能衰竭 </7>的病例。该患者是一名3岁男孩，他接受了与活体相关的治疗肝移植治疗先天性<12> 胆道闭锁 </12>。移植后第833天，他被诊断为<13> PTLD </13>（<14>移植后淋巴组织增生性疾病 </14>，<10> Burkitt型恶性淋巴瘤 </10>）。诱导治疗期间发生回肠穿孔，行回肠造口术。随后的 HD-<4> MTX </4>治疗导致<8> 急性肾功能衰竭 </8>，需要持续进行血液透析。我们假设回肠造口大量引流导致血管内<15> 低血容量 </15>，最终导致急性肾前性衰竭。在他的肾功能恢复后，我们通过全胃肠外营养控制回肠造口的引流，安全地用HD-<5> MTX </5>治疗患者。", "revised": true}
{"doc_key": "6728873", "sentences": [["Interstrain", "variation", "in", "acute", "toxic", "response", "to", "caffeine", "among", "inbred", "mice", ".", "Acute", "toxic", "dosage", "-", "dependent", "behavioral", "effects", "of", "caffeine", "were", "compared", "in", "adult", "males", "from", "seven", "inbred", "mouse", "strains", "(", "A", "/", "J", ",", "BALB", "/", "cJ", ",", "CBA", "/", "J", ",", "C3H", "/", "HeJ", ",", "C57BL", "/", "6J", ",", "DBA", "/", "2J", ",", "SWR", "/", "J", ")", ".", "C57BL", "/", "6J", ",", "chosen", "as", "a", "\"", "prototypic", "\"", "mouse", "strain", ",", "was", "used", "to", "determine", "behavioral", "responses", "to", "a", "broad", "range", "(", "5", "-", "500", "mg", "/", "kg", ")", "of", "caffeine", "doses", ".", "Five", "phenotypic", "characteristics", "-", "-", "locomotor", "activity", ",", "righting", "ability", ",", "clonic", "seizure", "induction", ",", "stress", "-", "induced", "lethality", ",", "death", "without", "external", "stress", "-", "-", "were", "scored", "at", "various", "caffeine", "doses", "in", "drug", "-", "naive", "animals", "under", "empirically", "optimized", ",", "rigidly", "constant", "experimental", "conditions", ".", "Mice", "(", "n", "=", "12", "for", "each", "point", ")", "received", "single", "IP", "injections", "of", "a", "fixed", "volume", "/", "g", "body", "weight", "of", "physiological", "saline", "carrier", "with", "or", "without", "caffeine", "in", "doses", "ranging", "from", "125", "-", "500", "mg", "/", "kg", ".", "Loss", "of", "righting", "ability", "was", "scored", "at", "1", ",", "3", ",", "5", "min", "post", "dosing", "and", "at", "5", "min", "intervals", "thereafter", "for", "20", "min", ".", "In", "the", "same", "animals", "the", "occurrence", "of", "clonic", "seizures", "was", "scored", "as", "to", "time", "of", "onset", "and", "severity", "for", "20", "min", "after", "drug", "administration", ".", "When", "these", "proceeded", "to", "tonic", "seizures", ",", "death", "occurred", "in", "less", "than", "20", "min", ".", "Animals", "surviving", "for", "20", "min", "were", "immediately", "stressed", "by", "a", "swim", "test", "in", "25", "degrees", "C", "water", ",", "and", "death", "-", "producing", "tonic", "seizures", "were", "scored", "for", "2", "min", ".", "In", "other", "animals", "locomotor", "activity", "was", "measured", "15", "or", "60", "min", "after", "caffeine", "administration", ".", "By", "any", "single", "behavioral", "criterion", "or", "a", "combination", "of", "these", "criteria", ",", "marked", "differences", "in", "response", "to", "toxic", "caffeine", "doses", "were", "observed", "between", "strains", ".", "These", "results", "indicate", "that", "behavioral", "toxicity", "testing", "of", "alkylxanthines", "in", "a", "single", "mouse", "strain", "may", "be", "misleading", "and", "suggest", "that", "toxic", "responses", "of", "the", "central", "nervous", "system", "to", "this", "class", "of", "compounds", "are", "genetically", "influenced", "in", "mammals", "."]], "ner": [[[7, 7, "Chemical"], [20, 20, "Chemical"], [93, 93, "Chemical"], [126, 126, "Chemical"], [170, 170, "Chemical"], [289, 289, "Chemical"], [310, 310, "Chemical"], [107, 108, "Disease"], [214, 215, "Disease"], [236, 237, "Disease"], [269, 270, "Disease"], [322, 322, "Disease"]]], "relations": [[[7, 7, 107, 108, "CID"], [7, 7, 214, 215, "CID"], [7, 7, 236, 237, "CID"], [7, 7, 269, 270, "CID"], [20, 20, 107, 108, "CID"], [20, 20, 214, 215, "CID"], [20, 20, 236, 237, "CID"], [20, 20, 269, 270, "CID"], [93, 93, 107, 108, "CID"], [93, 93, 214, 215, "CID"], [93, 93, 236, 237, "CID"], [93, 93, 269, 270, "CID"], [126, 126, 107, 108, "CID"], [126, 126, 214, 215, "CID"], [126, 126, 236, 237, "CID"], [126, 126, 269, 270, "CID"], [170, 170, 107, 108, "CID"], [170, 170, 214, 215, "CID"], [170, 170, 236, 237, "CID"], [170, 170, 269, 270, "CID"], [289, 289, 107, 108, "CID"], [289, 289, 214, 215, "CID"], [289, 289, 236, 237, "CID"], [289, 289, 269, 270, "CID"], [310, 310, 107, 108, "CID"], [310, 310, 214, 215, "CID"], [310, 310, 236, 237, "CID"], [310, 310, 269, 270, "CID"]]], "clusters": [], "translated": "近交系小鼠对<0>咖啡因</0>的急性毒性反应的品系间差异。在来自七种近交系小鼠品系（A/J、BALB/cJ、CBA/J、C3H/HeJ、C57BL/6J、DBA/2J）的成年雄性小鼠中比较了<1>咖啡因</1>的急性毒性剂量依赖性行为效应，C57BL/6J被选为“原型”小鼠品系，用于确定对宽范围（5-500mg/kg）的<2>咖啡因</2>剂量的行为反应。五种表型特征 - 运动活性、翻正能力、<7>阵挛发作</7>诱导、应激诱导的致死率、无外部应激的死亡 - 在未用药的动物在经验优化的、严格恒定的实验条件下对不同的<3>咖啡因</3>剂量进行评分。小鼠（每个点n = 12）接受单次IP注射固定体积/ g体重的生理盐水载体，有或没有<4>咖啡因</4>，剂量范围为125-500mg/kg。在给药后1、3、5分钟以及此后的20分钟内每隔5分钟对失去翻正能力进行评分。在相同的动物中，<8>阵挛发作</8>的发生在给药后20分钟内根据发作时间和严重程度进行评分。当这些发展为<9>强直性癫痫发作</9>时，死亡发生在不到20分钟内。存活20分钟的动物立即在25摄氏度的水中进行游泳测试，并对导致死亡的<10>强直发作</10>进行2分钟的评分。在其他动物中，在<5>咖啡因</5>给药后15或60分钟测量运动活动。通过任何单一的行为标准或这些标准的组合，在菌株之间观察到对毒性<6>咖啡因</6>剂量的反应存在显着差异。这些结果表明，在单个小鼠品系中对烷基黄嘌呤进行的行为<11>毒性</11>测试可能会产生误导，并表明中枢神经系统对此类化合物的毒性反应在哺乳动物中受到遗传影响。", "revised": true}
{"doc_key": "15696449", "sentences": [["Acute", "renal", "insufficiency", "after", "high", "-", "dose", "melphalan", "in", "patients", "with", "primary", "systemic", "amyloidosis", "during", "stem", "cell", "transplantation", ".", "BACKGROUND", ":", "Patients", "with", "primary", "systemic", "amyloidosis", "(", "AL", ")", "have", "a", "poor", "prognosis", ".", "Median", "survival", "time", "from", "standard", "treatments", "is", "only", "17", "months", ".", "High", "-", "dose", "intravenous", "melphalan", "followed", "by", "peripheral", "blood", "stem", "cell", "transplant", "(", "PBSCT", ")", "appears", "to", "be", "the", "most", "promising", "therapy", ",", "but", "treatment", "mortality", "can", "be", "high", ".", "The", "authors", "have", "noted", "the", "development", "of", "acute", "renal", "insufficiency", "immediately", "after", "melphalan", "conditioning", ".", "This", "study", "was", "undertaken", "to", "further", "examine", "its", "risk", "factors", "and", "impact", "on", "posttransplant", "mortality", ".", "METHODS", ":", "Consecutive", "AL", "patients", "who", "underwent", "PBSCT", "were", "studied", "retrospectively", ".", "Acute", "renal", "insufficiency", "(", "ARI", ")", "after", "high", "-", "dose", "melphalan", "was", "defined", "by", "a", "minimum", "increase", "of", "0", ".", "5", "mg", "/", "dL", "(", "44", "micromol", "/", "L", ")", "in", "the", "serum", "creatinine", "level", "that", "is", "greater", "than", "50", "%", "of", "baseline", "immediately", "after", "conditioning", ".", "Urine", "sediment", "score", "was", "the", "sum", "of", "the", "individual", "types", "of", "sediment", "identified", "on", "urine", "microscopy", ".", "RESULTS", ":", "Of", "the", "80", "patients", "studied", ",", "ARI", "developed", "in", "18", ".", "8", "%", "of", "the", "patients", "after", "high", "-", "dose", "melphalan", ".", "Univariate", "analysis", "identified", "age", ",", "hypoalbuminemia", ",", "heavy", "proteinuria", ",", "diuretic", "use", ",", "and", "urine", "sediment", "score", "(", ">", "3", ")", "as", "risk", "factors", ".", "Age", "and", "urine", "sediment", "score", "remained", "independently", "significant", "risk", "factors", "in", "the", "multivariate", "analysis", ".", "Patients", "who", "had", "ARI", "after", "high", "-", "dose", "melphalan", "underwent", "dialysis", "more", "often", "(", "P", "=", "0", ".", "007", ")", ",", "and", "had", "a", "worse", "1", "-", "year", "survival", "(", "P", "=", "0", ".", "03", ")", ".", "CONCLUSION", ":", "The", "timing", "of", "renal", "injury", "strongly", "suggests", "melphalan", "as", "the", "causative", "agent", ".", "Ongoing", "tubular", "injury", "may", "be", "a", "prerequisite", "for", "renal", "injury", "by", "melphalan", "as", "evidenced", "by", "the", "active", "urinary", "sediment", ".", "Development", "of", "ARI", "adversely", "affected", "the", "outcome", "after", "PBSCT", ".", "Effective", "preventive", "measures", "may", "help", "decrease", "the", "treatment", "mortality", "of", "PBSCT", "in", "AL", "patients", "."]], "ner": [[[7, 7, "Chemical"], [49, 49, "Chemical"], [87, 87, "Chemical"], [128, 128, "Chemical"], [204, 204, "Chemical"], [254, 254, "Chemical"], [292, 292, "Chemical"], [309, 309, "Chemical"], [0, 2, "Disease"], [82, 84, "Disease"], [118, 120, "Disease"], [122, 122, "Disease"], [190, 190, "Disease"], [249, 249, "Disease"], [288, 289, "Disease"], [306, 307, "Disease"], [320, 320, "Disease"], [151, 151, "Chemical"], [11, 13, "Disease"], [23, 25, "Disease"], [27, 27, "Disease"], [109, 109, "Disease"], [340, 340, "Disease"], [211, 211, "Disease"], [214, 214, "Disease"]]], "relations": [[[7, 7, 0, 2, "CID"], [7, 7, 82, 84, "CID"], [7, 7, 118, 120, "CID"], [7, 7, 122, 122, "CID"], [7, 7, 190, 190, "CID"], [7, 7, 249, 249, "CID"], [7, 7, 288, 289, "CID"], [7, 7, 306, 307, "CID"], [7, 7, 320, 320, "CID"], [49, 49, 0, 2, "CID"], [49, 49, 82, 84, "CID"], [49, 49, 118, 120, "CID"], [49, 49, 122, 122, "CID"], [49, 49, 190, 190, "CID"], [49, 49, 249, 249, "CID"], [49, 49, 288, 289, "CID"], [49, 49, 306, 307, "CID"], [49, 49, 320, 320, "CID"], [87, 87, 0, 2, "CID"], [87, 87, 82, 84, "CID"], [87, 87, 118, 120, "CID"], [87, 87, 122, 122, "CID"], [87, 87, 190, 190, "CID"], [87, 87, 249, 249, "CID"], [87, 87, 288, 289, "CID"], [87, 87, 306, 307, "CID"], [87, 87, 320, 320, "CID"], [128, 128, 0, 2, "CID"], [128, 128, 82, 84, "CID"], [128, 128, 118, 120, "CID"], [128, 128, 122, 122, "CID"], [128, 128, 190, 190, "CID"], [128, 128, 249, 249, "CID"], [128, 128, 288, 289, "CID"], [128, 128, 306, 307, "CID"], [128, 128, 320, 320, "CID"], [204, 204, 0, 2, "CID"], [204, 204, 82, 84, "CID"], [204, 204, 118, 120, "CID"], [204, 204, 122, 122, "CID"], [204, 204, 190, 190, "CID"], [204, 204, 249, 249, "CID"], [204, 204, 288, 289, "CID"], [204, 204, 306, 307, "CID"], [204, 204, 320, 320, "CID"], [254, 254, 0, 2, "CID"], [254, 254, 82, 84, "CID"], [254, 254, 118, 120, "CID"], [254, 254, 122, 122, "CID"], [254, 254, 190, 190, "CID"], [254, 254, 249, 249, "CID"], [254, 254, 288, 289, "CID"], [254, 254, 306, 307, "CID"], [254, 254, 320, 320, "CID"], [292, 292, 0, 2, "CID"], [292, 292, 82, 84, "CID"], [292, 292, 118, 120, "CID"], [292, 292, 122, 122, "CID"], [292, 292, 190, 190, "CID"], [292, 292, 249, 249, "CID"], [292, 292, 288, 289, "CID"], [292, 292, 306, 307, "CID"], [292, 292, 320, 320, "CID"], [309, 309, 0, 2, "CID"], [309, 309, 82, 84, "CID"], [309, 309, 118, 120, "CID"], [309, 309, 122, 122, "CID"], [309, 309, 190, 190, "CID"], [309, 309, 249, 249, "CID"], [309, 309, 288, 289, "CID"], [309, 309, 306, 307, "CID"], [309, 309, 320, 320, "CID"]]], "clusters": [], "translated": "干细胞移植期间<18>原发性系统性淀粉样变性</18>患者大剂量<0>马法兰</0>后<8>急性肾功能不全</8>。背景：<19>原发性系统性淀粉样变性</19>（<20>AL</20>）患者预后较差。标准治疗的中位生存时间仅为 17 个月。大剂量静脉注射<1>美法仑</1>，然后进行外周血干细胞移植 (PBSCT) 似乎是最有希望的治疗方法，但治疗死亡率可能很高。作者注意到<9>急性肾功能不全</9>在<2>马法兰</2>调节后立即发生。进行这项研究是为了进一步检查其风险因素和对移植后死亡率的影响。方法：对接受 PBSCT 的连续<21>AL</21>患者进行回顾性研究。<10>急性肾功能不全</10>(<11>ARI</11>)在高剂量<3>美法仑</3>后定义为最小增加0.5 mg/dL (44 μmol/L)血清<17>肌酐</17>水平在调节后立即大于基线的 50% 。尿沉渣评分是尿液显微镜检查确定的各种类型沉渣的总和。结果：在所研究的80名患者中，有18名发生了<12>ARI</12>，即8%的患者接受高剂量<4>美法仑</4>后。单变量分析将年龄、<23>低白蛋白血症</23>、重度<24>蛋白尿</24>、使用利尿剂和尿沉渣评分(>3)确定为危险因素。在多变量分析中，年龄和尿沉渣评分仍然是独立的显着危险因素。大剂量<5>美法仑</5>后发生<13>ARI</13>的患者接受透析的频率更高(P=0.007)，并且1年生存率更差(P=0.03)。结论：<14>肾损伤</14>的发生时间强烈提示<6>美法仑</6>为致病因子。持续的肾小管损伤可能是<7>马法兰</7>引起的<15>肾损伤</15>的先决条件，如活性尿沉渣所示。<16>ARI</16>的发展对PBSCT后的结果产生不利影响。有效的预防措施可能有助于降低<22>AL</22>患者PBSCT的治疗死亡率。", "revised": true}
{"doc_key": "11423811", "sentences": [["A", "pilot", "study", "to", "assess", "the", "safety", "of", "dobutamine", "stress", "echocardiography", "in", "the", "emergency", "department", "evaluation", "of", "cocaine", "-", "associated", "chest", "pain", ".", "STUDY", "OBJECTIVE", ":", "Chest", "pain", "in", "the", "setting", "of", "cocaine", "use", "poses", "a", "diagnostic", "dilemma", ".", "Dobutamine", "stress", "echocardiography", "(", "DSE", ")", "is", "a", "widely", "available", "and", "sensitive", "test", "for", "evaluating", "cardiac", "ischemia", ".", "Because", "of", "the", "theoretical", "concern", "regarding", "administration", "of", "dobutamine", "in", "the", "setting", "of", "cocaine", "use", ",", "we", "conducted", "a", "pilot", "study", "to", "assess", "the", "safety", "of", "DSE", "in", "emergency", "department", "patients", "with", "cocaine", "-", "associated", "chest", "pain", ".", "METHODS", ":", "A", "prospective", "case", "series", "was", "conducted", "in", "the", "intensive", "diagnostic", "and", "treatment", "unit", "in", "the", "ED", "of", "an", "urban", "tertiary", "-", "care", "teaching", "hospital", ".", "Patients", "were", "eligible", "for", "DSE", "if", "they", "had", "used", "cocaine", "within", "24", "hours", "preceding", "the", "onset", "of", "chest", "pain", "and", "had", "a", "normal", "ECG", "and", "tropinin", "I", "level", ".", "Patients", "exhibiting", "signs", "of", "continuing", "cocaine", "toxicity", "were", "excluded", "from", "the", "study", ".", "All", "patients", "were", "admitted", "to", "the", "hospital", "for", "serial", "testing", "after", "the", "DSE", "testing", "in", "the", "intensive", "diagnostic", "and", "treatment", "unit", ".", "RESULTS", ":", "Twenty", "-", "four", "patients", "were", "enrolled", ".", "Two", "patients", "had", "inadequate", "resting", "images", ",", "one", "DSE", "was", "terminated", "because", "of", "inferior", "hypokinesis", ",", "another", "DSE", "was", "terminated", "because", "of", "a", "rate", "-", "related", "atrial", "conduction", "deficit", ",", "and", "1", "patient", "did", "not", "reach", "the", "target", "heart", "rate", ".", "Thus", ",", "19", "patients", "completed", "a", "DSE", "and", "reached", "their", "target", "heart", "rates", ".", "None", "of", "the", "patients", "experienced", "signs", "of", "exaggerated", "adrenergic", "response", ",", "which", "was", "defined", "as", "a", "systolic", "blood", "pressure", "of", "greater", "than", "200", "mm", "Hg", "or", "the", "occurrence", "of", "tachydysrhythmias", "(", "excluding", "sinus", "tachycardia", ")", ".", "Further", "suggesting", "lack", "of", "exaggerated", "adrenergic", "response", ",", "13", "(", "65", "%", ")", "of", "20", "patients", "required", "supplemental", "atropine", "to", "reach", "their", "target", "heart", "rates", ".", "CONCLUSION", ":", "No", "exaggerated", "adrenergic", "response", "was", "detected", "when", "dobutamine", "was", "administered", "to", "patients", "with", "cocaine", "-", "related", "chest", "pain", "."]], "ner": [[[17, 17, "Chemical"], [32, 32, "Chemical"], [70, 70, "Chemical"], [89, 89, "Chemical"], [131, 131, "Chemical"], [156, 156, "Chemical"], [327, 327, "Chemical"], [20, 21, "Disease"], [26, 27, "Disease"], [92, 93, "Disease"], [139, 140, "Disease"], [330, 331, "Disease"], [8, 8, "Chemical"], [39, 39, "Chemical"], [65, 65, "Chemical"], [321, 321, "Chemical"], [55, 55, "Disease"], [157, 157, "Disease"], [209, 209, "Disease"], [282, 283, "Disease"], [304, 304, "Chemical"]]], "relations": [[[17, 17, 20, 21, "CID"], [17, 17, 26, 27, "CID"], [17, 17, 92, 93, "CID"], [17, 17, 139, 140, "CID"], [17, 17, 330, 331, "CID"], [32, 32, 20, 21, "CID"], [32, 32, 26, 27, "CID"], [32, 32, 92, 93, "CID"], [32, 32, 139, 140, "CID"], [32, 32, 330, 331, "CID"], [70, 70, 20, 21, "CID"], [70, 70, 26, 27, "CID"], [70, 70, 92, 93, "CID"], [70, 70, 139, 140, "CID"], [70, 70, 330, 331, "CID"], [89, 89, 20, 21, "CID"], [89, 89, 26, 27, "CID"], [89, 89, 92, 93, "CID"], [89, 89, 139, 140, "CID"], [89, 89, 330, 331, "CID"], [131, 131, 20, 21, "CID"], [131, 131, 26, 27, "CID"], [131, 131, 92, 93, "CID"], [131, 131, 139, 140, "CID"], [131, 131, 330, 331, "CID"], [156, 156, 20, 21, "CID"], [156, 156, 26, 27, "CID"], [156, 156, 92, 93, "CID"], [156, 156, 139, 140, "CID"], [156, 156, 330, 331, "CID"], [327, 327, 20, 21, "CID"], [327, 327, 26, 27, "CID"], [327, 327, 92, 93, "CID"], [327, 327, 139, 140, "CID"], [327, 327, 330, 331, "CID"]]], "clusters": [], "translated": "评估<12>多巴酚丁胺</12>负荷超声心动图在急诊科评估<0>可卡因</0>- 相关<7>胸痛</7>安全性的初步研究。 研究目的：在<1>可卡因</1>使用情况下发生的<8>胸痛</8>存在一定的诊断难度。 <13>多巴酚丁胺</13>负荷超声心动图（DSE）是一种广泛使用且敏感的测试，用于评估心脏<16>缺血</16>。由于在使用<2>可卡因</2>的情况下给予<14>多巴酚丁胺</14>存在一定的理论上的问题，我们进行了一项初步研究来评估在急诊科患者中应用DSE对<3>可卡因</3>- 相关的<9>胸痛</9>的安全性。 方法：在一所城市三级教学医院急诊室的重症诊疗室进行了前瞻性病例研究。如果患者在<10>胸痛</10>发作前24小时内使用过<4>可卡因</4>并且心电图和肌钙蛋白I水平正常，则患者符合DSE检查的条件。表现出持续<5>可卡因</5><17>毒性</17>迹象的患者被排除在研究之外。所有患者在重症诊疗室进行DSE检测后入院进行系列检测。 结果：共招募了24名患者。其中2名患者的休息图像不清晰，1名患者因下壁<18>运动功能减退</18>而中止DSE检查，1名患者因心率相关心房传导障碍而中止DSE检查，1名患者未能达到目标心率。因此，共有19名患者完成了DSE检查并且达到了他们的目标心率。没有患者出现过度的肾上腺能反应的迹象，肾上腺能反应过度的表现是指患者的收缩压超过200mm Hg或出现快速性心律失常（除了<19>窦性心动过速</19>）。另外，结果显示，在20名患者中，有13名（65％）需要补充<20>阿托品</20>才能达到目标心率，这进一步表明没有出现过度的肾上腺反应。结论：当<6>可卡因</6>- 相关的<11>胸痛</11>患者接受<15>多巴酚丁胺</15>治疗时，未发现肾上腺素反应过度的情况。", "revised": true}
{"doc_key": "44072", "sentences": [["On", "the", "antiarrhythmic", "activity", "of", "one", "N", "-", "substituted", "piperazine", "derivative", "of", "trans", "-", "2", "-", "amino", "-", "3", "-", "hydroxy", "-", "1", ",", "2", ",", "3", ",", "4", "-", "tetrahydroanaphthalene", ".", "The", "antiarrhythmic", "activity", "of", "the", "compound", "N", "-", "(", "trans", "-", "3", "-", "hydroxy", "-", "1", ",", "2", ",", "3", ",", "4", "-", "tetrahydro", "-", "2", "-", "naphthyl", ")", "-", "N", "-", "(", "3", "-", "oxo", "-", "3", "-", "phenyl", "-", "2", "-", "methylpropyl", ")", "-", "piperazine", "hydrochloride", ",", "referred", "to", "as", "P11", ",", "is", "studied", "on", "anaesthesized", "cats", "and", "Wistar", "albino", "rats", ",", "as", "well", "as", "on", "non", "-", "anaesthesized", "rabbits", ".", "Four", "types", "of", "experimental", "arrhythmia", "are", "used", "-", "-", "with", "BaCl2", ",", "with", "chloroform", "-", "adrenaline", ",", "with", "strophantine", "G", "and", "with", "aconitine", ".", "The", "compound", "P11", "is", "introduced", "in", "doses", "of", "0", ".", "25", "and", "0", ".", "50", "mg", "/", "kg", "intravenously", "and", "10", "mg", "/", "kg", "orally", ".", "The", "compound", "manifests", "antiarrhythmic", "activity", "in", "all", "models", "of", "experimental", "arrhythmia", "used", ",", "causing", "greatest", "inhibition", "on", "the", "arrhythmia", "induced", "by", "chloroform", "-", "adrenaline", "(", "in", "90", "per", "cent", ")", "and", "with", "BaCl2", "(", "in", "84", "per", "cent", ")", ".", "The", "results", "obtained", "are", "associated", "with", "the", "beta", "-", "adrenoblocking", "and", "with", "the", "membrane", "-", "stabilizing", "action", "of", "the", "compound", "."]], "ner": [[[115, 115, "Chemical"], [187, 187, "Chemical"], [109, 109, "Disease"], [165, 165, "Disease"], [173, 173, "Disease"], [118, 118, "Chemical"], [176, 176, "Chemical"], [120, 120, "Chemical"], [178, 178, "Chemical"], [123, 124, "Chemical"], [127, 127, "Chemical"], [9, 9, "Chemical"], [38, 79, "Chemical"], [84, 84, "Chemical"], [131, 131, "Chemical"]]], "relations": [[[115, 115, 109, 109, "CID"], [115, 115, 165, 165, "CID"], [115, 115, 173, 173, "CID"], [187, 187, 109, 109, "CID"], [187, 187, 165, 165, "CID"], [187, 187, 173, 173, "CID"], [118, 118, 109, 109, "CID"], [118, 118, 165, 165, "CID"], [118, 118, 173, 173, "CID"], [176, 176, 109, 109, "CID"], [176, 176, 165, 165, "CID"], [176, 176, 173, 173, "CID"], [120, 120, 109, 109, "CID"], [120, 120, 165, 165, "CID"], [120, 120, 173, 173, "CID"], [178, 178, 109, 109, "CID"], [178, 178, 165, 165, "CID"], [178, 178, 173, 173, "CID"], [123, 124, 109, 109, "CID"], [123, 124, 165, 165, "CID"], [123, 124, 173, 173, "CID"], [127, 127, 109, 109, "CID"], [127, 127, 165, 165, "CID"], [127, 127, 173, 173, "CID"]]], "clusters": [], "translated": "反式-2-氨基-3-羟基-1,2,3,4-四氢萘的一种N-取代<11>哌嗪</11>衍生物的抗心律失常活性研究。化合物<12>N-(trans-3-hydroxy-1,2,3,4-tetrahydro-2-naphthyl)-N-(3-oxo-3-phenyl-2-methylpropyl)盐酸盐</12>，称为<13>P11</13>，在麻醉的猫和Wistar白化大鼠以及未麻醉的兔子身上进行了研究。使用四种类型的实验性<2>心律失常</2> - - <0>BaCl2</0>，<5>氯仿</5>-<7>肾上腺素</7>，<9>斯特罗芬G</9>和<10>乌头碱</10>。化合物<14>P11</14>的引入剂量为0.25和0.50 mg/kg静脉内和10 mg/kg口服。该化合物在所有使用的实验模型的<3>心律失常</3>中均表现出抗心律失常活性，对<1>BaCl2</1>（84%）和<6>氯仿</6>-<8>肾上腺素</8>引起的<4>心律失常</4>具有最大的抑制作用（90%）。获得的结果与化合物的β肾上腺素阻断作用和膜稳定作用有关。", "revised": true}
{"doc_key": "573555", "sentences": [["Long", "-", "term", "propranolol", "therapy", "in", "pregnancy", ":", "maternal", "and", "fetal", "outcome", ".", "Propranolol", ",", "a", "beta", "-", "adrenergic", "blocking", "agent", ",", "has", "found", "an", "important", "position", "in", "the", "practice", "of", "medicine", ".", "Its", "use", "in", "pregnancy", ",", "however", ",", "is", "an", "open", "question", "as", "a", "number", "of", "detrimental", "side", "effects", "have", "been", "reported", "in", "the", "fetus", "and", "neonate", ".", "Ten", "patients", "and", "12", "pregnancies", "are", "reported", "where", "chronic", "propranolol", "has", "been", "administered", ".", "Five", "patients", "with", "serial", "pregnancies", "with", "and", "without", "propranolol", "therapy", "are", "also", "examined", ".", "Maternal", ",", "fetal", ",", "and", "neonatal", "complications", "are", "examined", ".", "An", "attempt", "is", "made", "to", "differentiate", "drug", "-", "related", "complications", "from", "maternal", "disease", "-", "-", "related", "complications", ".", "We", "conclude", "that", "previously", "reported", "hypoglycemia", ",", "hyperbilirubinemia", ",", "polycythemia", ",", "neonatal", "apnea", ",", "and", "bradycardia", "are", "not", "invariable", "and", "can", "not", "be", "statistically", "correlated", "with", "chronic", "propranolol", "therapy", ".", "Growth", "retardation", ",", "however", ",", "appears", "to", "be", "significant", "in", "both", "of", "our", "series", "."]], "ner": [[[3, 3, "Chemical"], [13, 13, "Chemical"], [69, 69, "Chemical"], [82, 82, "Chemical"], [143, 143, "Chemical"], [146, 147, "Disease"], [121, 121, "Disease"], [123, 123, "Disease"], [125, 125, "Disease"], [127, 128, "Disease"], [131, 131, "Disease"]]], "relations": [[[3, 3, 146, 147, "CID"], [13, 13, 146, 147, "CID"], [69, 69, 146, 147, "CID"], [82, 82, 146, 147, "CID"], [143, 143, 146, 147, "CID"]]], "clusters": [], "translated": "妊娠期长期 <0>普萘洛尔</0> 治疗：母婴结局。<1>普萘洛尔</1>是一种β-肾上腺素能受体阻滞剂，在医学实践中占有重要地位。然而，它在怀孕期间的使用是一个悬而未决的问题，因为据报道，它对胎儿和新生儿有许多有害的副作用。据报道，有10名患者和12名孕妇长期服用<2>普萘洛尔</2>。还检查了五名接受和未接受<3>普萘洛尔</3>治疗的连续妊娠患者。检查母体、胎儿和新生儿并发症。试图将药物相关并发症与母体疾病相关并发症区分开来。我们得出结论，之前报告的<6>低血糖</6>、<7>高胆红素血症</7>、<8>红细胞增多症</8>、<9>新生儿呼吸暂停</9>和<10>心动过缓</10> 不是一成不变的，也不能与慢性<4>普萘洛尔</4>治疗有统计学相关性。<5>生长迟缓</5>，然而，在我们的两个系列中似乎都很重要。", "revised": true}
{"doc_key": "24928523", "sentences": [["Combination", "of", "bortezomib", ",", "thalidomide", ",", "and", "dexamethasone", "(", "VTD", ")", "as", "a", "consolidation", "therapy", "after", "autologous", "stem", "cell", "transplantation", "for", "symptomatic", "multiple", "myeloma", "in", "Japanese", "patients", ".", "Consolidation", "therapy", "for", "patients", "with", "multiple", "myeloma", "(", "MM", ")", "has", "been", "widely", "adopted", "to", "improve", "treatment", "response", "following", "autologous", "stem", "cell", "transplantation", ".", "In", "this", "study", ",", "we", "retrospectively", "analyzed", "the", "safety", "and", "efficacy", "of", "combination", "regimen", "of", "bortezomib", ",", "thalidomide", ",", "and", "dexamethasone", "(", "VTD", ")", "as", "consolidation", "therapy", "in", "24", "Japanese", "patients", "with", "newly", "diagnosed", "MM", ".", "VTD", "consisted", "of", "bortezomib", "at", "a", "dose", "of", "1", ".", "3", "mg", "/", "m", "(", "2", ")", "and", "dexamethasone", "at", "a", "dose", "of", "40", "mg", "/", "day", "on", "days", "1", ",", "8", ",", "15", ",", "and", "22", "of", "a", "35", "-", "day", "cycle", ",", "with", "daily", "oral", "thalidomide", "at", "a", "dose", "of", "100", "mg", "/", "day", ".", "Grade", "3", "-", "4", "neutropenia", "and", "thrombocytopenia", "were", "documented", "in", "four", "and", "three", "patients", "(", "17", "and", "13", "%", ")", ",", "respectively", ",", "but", "drug", "dose", "reduction", "due", "to", "cytopenia", "was", "not", "required", "in", "any", "case", ".", "Peripheral", "neuropathy", "was", "common", "(", "63", "%", ")", ",", "but", "severe", "grade", "3", "-", "4", "peripheral", "neuropathy", "was", "not", "observed", ".", "Very", "good", "partial", "response", "or", "better", "response", "(", ">", "VGPR", ")", "rates", "before", "and", "after", "consolidation", "therapy", "were", "54", "and", "79", "%", ",", "respectively", ".", "Patients", "had", "a", "significant", "probability", "of", "improving", "from", "<", "VGPR", "before", "consolidation", "therapy", "to", ">", "VGPR", "after", "consolidation", "therapy", "(", "p", "=", "0", ".", "041", ")", ".", "The", "VTD", "regimen", "may", "be", "safe", "and", "effective", "as", "a", "consolidation", "therapy", "in", "the", "treatment", "of", "MM", "in", "Japanese", "population", "."]], "ner": [[[2, 2, "Chemical"], [67, 67, "Chemical"], [91, 91, "Chemical"], [149, 149, "Disease"], [151, 151, "Disease"], [182, 183, "Disease"], [197, 198, "Disease"], [4, 4, "Chemical"], [69, 69, "Chemical"], [135, 135, "Chemical"], [7, 7, "Chemical"], [72, 72, "Chemical"], [106, 106, "Chemical"], [22, 23, "Disease"], [33, 34, "Disease"], [36, 36, "Disease"], [86, 86, "Disease"], [174, 174, "Disease"]]], "relations": [[[2, 2, 149, 149, "CID"], [67, 67, 149, 149, "CID"], [91, 91, 149, 149, "CID"], [2, 2, 151, 151, "CID"], [67, 67, 151, 151, "CID"], [91, 91, 151, 151, "CID"], [2, 2, 182, 183, "CID"], [2, 2, 197, 198, "CID"], [67, 67, 182, 183, "CID"], [67, 67, 197, 198, "CID"], [91, 91, 182, 183, "CID"], [91, 91, 197, 198, "CID"], [4, 4, 149, 149, "CID"], [69, 69, 149, 149, "CID"], [135, 135, 149, 149, "CID"], [4, 4, 151, 151, "CID"], [69, 69, 151, 151, "CID"], [135, 135, 151, 151, "CID"], [4, 4, 182, 183, "CID"], [4, 4, 197, 198, "CID"], [69, 69, 182, 183, "CID"], [69, 69, 197, 198, "CID"], [135, 135, 182, 183, "CID"], [135, 135, 197, 198, "CID"], [7, 7, 149, 149, "CID"], [72, 72, 149, 149, "CID"], [106, 106, 149, 149, "CID"], [7, 7, 151, 151, "CID"], [72, 72, 151, 151, "CID"], [106, 106, 151, 151, "CID"], [7, 7, 182, 183, "CID"], [7, 7, 197, 198, "CID"], [72, 72, 182, 183, "CID"], [72, 72, 197, 198, "CID"], [106, 106, 182, 183, "CID"], [106, 106, 197, 198, "CID"]]], "clusters": [], "translated": "联合使用<0>硼替佐米</0>、<7>沙利度胺</7>和<10>地塞米松</10>（VTD）作为自体干细胞移植后症状性<13>多发性骨髓瘤</13>的巩固治疗在日本患者中。 <14>多发性骨髓瘤</14>（<15>MM</15>）患者的巩固治疗已被广泛采用，以改善自体干细胞移植后的治疗反应。在本研究中，我们回顾性分析了<1>硼替佐米</1>、<8>沙利度胺</8>和<11>地塞米松</11>（VTD）联合方案作为巩固治疗在24例日本新确诊<16>MM</16>患者中的安全性和有效性。VTD由剂量为1.3 mg/m²的<2>硼替佐米</2>和剂量为40 mg/天的<12>地塞米松</12>组成，在35天周期的第1、8、15和22天，每天口服剂量为100 mg/天的<9>沙利度胺</9>。 4名患者（17%）出现3-4级的<3>中性粒细胞减少症</3>，3名患者（13%）出现3-4级的<4>血小板减少症</4>，但在任何情况下都不需要因为<17>血细胞减少症</17>而减少药物剂量。虽然<5>周围神经病变</5>很常见（63%），但严重的3 - 4级<6>周围神经病变</6>未被观察到。巩固治疗前后，非常好的部分反应或更好的反应（>VGPR）率分别为54%和79%。患者从巩固治疗前的<VGPR改善到巩固治疗后的>VGPR的可能性很大（p=0.041）。VTD方案可能对治疗日本人群中的MM具有安全有效性。", "revised": true}
{"doc_key": "89511", "sentences": [["Prevention", "and", "treatment", "of", "endometrial", "disease", "in", "climacteric", "women", "receiving", "oestrogen", "therapy", ".", "The", "treatment", "regimens", "are", "described", "in", "74", "patients", "with", "endometrial", "disease", "among", "850", "climacteric", "women", "receiving", "oestrogen", "therapy", ".", "Cystic", "hyperplasia", "was", "associated", "with", "unopposed", "oestrogen", "therapy", "without", "progestagen", ".", "Two", "courses", "of", "21", "days", "of", "5", "mg", "norethisterone", "daily", "caused", "reversion", "to", "normal", "in", "all", "57", "cases", "of", "cystic", "hyperplasia", "and", "6", "of", "the", "8", "cases", "of", "atypical", "hyperplasia", ".", "4", "cases", "of", "endometrial", "carcinoma", "referred", "from", "elsewhere", "demonstrated", "the", "problems", "of", "inappropriate", "and", "unsupervised", "unopposed", "oestrogen", "therapy", "and", "the", "difficulty", "in", "distinguishing", "severe", "hyperplasia", "from", "malignancy", ".", "Cyclical", "low", "-", "dose", "oestrogen", "therapy", "with", "7", "-", "-", "13", "days", "of", "progestagen", "does", "not", "seem", "to", "increase", "the", "risk", "of", "endometrial", "hyperplasia", "or", "carcinoma", "."]], "ner": [[[10, 10, "Chemical"], [29, 29, "Chemical"], [38, 38, "Chemical"], [90, 90, "Chemical"], [106, 106, "Chemical"], [33, 33, "Disease"], [63, 63, "Disease"], [72, 72, "Disease"], [98, 98, "Disease"], [4, 5, "Disease"], [22, 23, "Disease"], [41, 41, "Chemical"], [115, 115, "Chemical"], [51, 51, "Chemical"], [77, 78, "Disease"], [100, 100, "Disease"], [124, 125, "Disease"], [127, 127, "Disease"]]], "relations": [[[10, 10, 33, 33, "CID"], [10, 10, 63, 63, "CID"], [10, 10, 72, 72, "CID"], [10, 10, 98, 98, "CID"], [29, 29, 33, 33, "CID"], [29, 29, 63, 63, "CID"], [29, 29, 72, 72, "CID"], [29, 29, 98, 98, "CID"], [38, 38, 33, 33, "CID"], [38, 38, 63, 63, "CID"], [38, 38, 72, 72, "CID"], [38, 38, 98, 98, "CID"], [90, 90, 33, 33, "CID"], [90, 90, 63, 63, "CID"], [90, 90, 72, 72, "CID"], [90, 90, 98, 98, "CID"], [106, 106, 33, 33, "CID"], [106, 106, 63, 63, "CID"], [106, 106, 72, 72, "CID"], [106, 106, 98, 98, "CID"]]], "clusters": [], "translated": "接受<0>雌激素</0>治疗的更年期妇女<9>子宫内膜疾病</9>的防治。描述了850名接受<1>雌激素</1>治疗的更年期女性中74名<10>子宫内膜疾病</10>患者的治疗方案。囊性<5>增生</5>与没有<11>孕激素</11>的<2>无对抗雌激素</2>治疗相关。每天5毫克<13>炔诺酮</13>的两个疗程21天，使所有57例囊性<6>增生</6>和8例非典型<7>增生</7>中的6例恢复正常。异地转诊的<14>子宫内膜癌</14>的4例显示了无监督的<3>无对抗雌激素</3>治疗不当和<8>重度增生</8>与<15>恶性肿瘤鉴别困难</15>的问题。周期性低剂量<4>雌激素</4>治疗7-13天<12>孕激素</12>似乎不会增加<16>子宫内膜增生</16>或<17>癌的风险</17>。", "revised": true}
{"doc_key": "3711722", "sentences": [["Human", "and", "canine", "ventricular", "vasoactive", "intestinal", "polypeptide", ":", "decrease", "with", "heart", "failure", ".", "Vasoactive", "intestinal", "polypeptide", "(", "VIP", ")", "is", "a", "systemic", "and", "coronary", "vasodilator", "that", "may", "have", "positive", "inotropic", "properties", ".", "Myocardial", "levels", "of", "VIP", "were", "assayed", "before", "and", "after", "the", "development", "of", "heart", "failure", "in", "two", "canine", "models", ".", "In", "the", "first", ",", "cobalt", "cardiomyopathy", "was", "induced", "in", "eight", "dogs", ";", "VIP", "(", "by", "radioimmunoassay", ")", "decreased", "from", "35", "+", "/", "-", "11", "pg", "/", "mg", "protein", "(", "mean", "+", "/", "-", "SD", ")", "to", "5", "+", "/", "-", "4", "pg", "/", "mg", "protein", "(", "P", "less", "than", "0", ".", "05", ")", ".", "In", "six", "dogs", "with", "doxorubicin", "-", "induced", "heart", "failure", ",", "VIP", "decreased", "from", "31", "+", "/", "-", "7", "to", "11", "+", "/", "-", "4", "pg", "/", "mg", "protein", "(", "P", "less", "than", "0", ".", "05", ")", ".", "In", "addition", ",", "VIP", "content", "of", "left", "ventricular", "muscle", "of", "resected", "failing", "hearts", "in", "10", "patients", "receiving", "a", "heart", "transplant", "was", "compared", "with", "the", "papillary", "muscles", "in", "14", "patients", "(", "five", "with", "rheumatic", "disease", ",", "nine", "with", "myxomatous", "degeneration", ")", "receiving", "mitral", "valve", "prostheses", ".", "The", "lowest", "myocardial", "VIP", "concentration", "was", "found", "in", "the", "hearts", "of", "patients", "with", "coronary", "disease", "(", "one", "patient", "receiving", "a", "transplant", "and", "three", "receiving", "mitral", "prostheses", ")", "(", "6", ".", "3", "+", "/", "-", "1", ".", "9", "pg", "/", "mg", "protein", ")", ".", "The", "other", "patients", "undergoing", "transplantation", "had", "an", "average", "ejection", "fraction", "of", "17", "%", "+", "/", "-", "6", "%", "and", "a", "VIP", "level", "of", "8", ".", "8", "+", "/", "-", "3", ".", "9", "pg", "/", "mg", "protein", ".", "The", "hearts", "without", "coronary", "artery", "disease", "(", "average", "ejection", "fraction", "of", "this", "group", "62", "%", "+", "/", "-", "10", "%", ")", "had", "a", "VIP", "concentration", "of", "14", ".", "1", "+", "/", "-", "7", ".", "9", "pg", "/", "mg", "protein", ",", "and", "this", "was", "greater", "than", "in", "hearts", "of", "the", "patients", "with", "coronary", "disease", "and", "the", "hearts", "of", "patients", "receiving", "a", "transplant", "(", "P", "less", "than", "0", ".", "05", ")", ".", "Myocardial", "catecholamines", "were", "also", "determined", "in", "14", "subjects", ";", "a", "weak", "correlation", "(", "r", "=", "0", ".", "57", ",", "P", "less", "than", "0", ".", "05", ")", "between", "the", "tissue", "concentrations", "of", "VIP", "and", "norepinephrine", "was", "noted", ".", "(", "ABSTRACT", "TRUNCATED", "AT", "250", "WORDS", ")"]], "ner": [[[109, 109, "Chemical"], [10, 11, "Disease"], [44, 45, "Disease"], [112, 113, "Disease"], [55, 55, "Chemical"], [56, 56, "Disease"], [338, 338, "Chemical"], [370, 370, "Chemical"], [174, 175, "Disease"], [200, 201, "Disease"], [318, 319, "Disease"], [270, 272, "Disease"]]], "relations": [[[109, 109, 10, 11, "CID"], [109, 109, 44, 45, "CID"], [109, 109, 112, 113, "CID"], [55, 55, 56, 56, "CID"]]], "clusters": [], "translated": "人和犬心室血管活性肠多肽：随着<1>心力衰竭</1>而减少。血管活性肠多肽(VIP)是一种全身血管和冠状血管扩张剂，可能具有正性肌力特性。在两种犬类模型中，检测了<2>心力衰竭</2>发生前后 VIP 的心肌水平。首先，在八只狗中诱发<4>钴</4><5>心肌病</5>；VIP(通过放射免疫测定)从35+/-11 pg/mg蛋白质(平均值+/-SD)降至5+/-4 pg/mg蛋白质(P小于0.05)。在六只因<0>阿霉素</0>引发的<3>心力衰竭</3>狗中，VIP浓度从31+/-7降至11+/-4 pg/mg蛋白质(P小于0.05)。此外，将接受心脏移植的10个切除衰竭心脏的左心室肌的VIP含量与接受二尖瓣假体治疗或手术的14位患者（其中五人患有<8>风湿病</8>，九人患有粘液样变）的乳头肌进行了比较。在患者中，所有<9>冠心病</9>者的心脏（其中一名接受移植，另外三名接受二尖瓣假体）的VIP含量最低，仅为6.3+/-1.9 pg/mg蛋白质。接受移植的其他患者，平均射血分数为17%+/-6%，VIP水平为8.8+/-3.9 pg/mg蛋白质。无<11>冠状动脉疾病</11>患者（平均射血分数为62%+/-10%），VIP浓度为14.1+/-7.9 pg/mg蛋白质，高于有<10>冠心病</10>患者和接受移植患者的心脏(P小于0.05)。此外，对14个受试者的心肌<6>儿茶酚胺</6>也进行了测定；发现VIP与<7>去甲肾上腺素</7>的组织浓度呈弱相关性(r=0.57，P小于0.05)。（摘要被截断为250个单词）", "revised": true}
{"doc_key": "20595935", "sentences": [["Verapamil", "stimulation", "test", "in", "hyperprolactinemia", ":", "loss", "of", "prolactin", "response", "in", "anatomic", "or", "functional", "stalk", "effect", ".", "AIM", ":", "Verapamil", "stimulation", "test", "was", "previously", "investigated", "as", "a", "tool", "for", "differential", "diagnosis", "of", "hyperprolactinemia", ",", "but", "with", "conflicting", "results", ".", "Macroprolactinemia", "was", "never", "considered", "in", "those", "previous", "studies", ".", "Here", ",", "we", "aimed", "to", "re", "-", "investigate", "the", "diagnostic", "value", "of", "verapamil", "in", "a", "population", "who", "were", "all", "screened", "for", "macroprolactinemia", ".", "Prolactin", "responses", "to", "verapamil", "in", "65", "female", "patients", "(", "age", ":", "29", ".", "9", "+", "/", "-", "8", ".", "1", "years", ")", "with", "hyperprolactinemia", "were", "tested", "in", "a", "descriptive", ",", "matched", "case", "-", "control", "study", ".", "METHODS", ":", "Verapamil", "80", "mg", ",", "p", ".", "o", ".", "was", "administered", ",", "and", "then", "PRL", "levels", "were", "measured", "at", "8th", "and", "16th", "hours", ",", "by", "immunometric", "chemiluminescence", ".", "Verapamil", "responsiveness", "was", "determined", "by", "peak", "percent", "change", "in", "basal", "prolactin", "levels", "(", "PRL", ")", ".", "RESULTS", ":", "Verapamil", "significantly", "increased", "PRL", "levels", "in", "healthy", "controls", "(", "N", ".", "8", ",", "PRL", ":", "183", "%", ")", ",", "macroprolactinoma", "(", "N", ".", "8", ",", "PRL", ":", "7", "%", ")", ",", "microprolactinoma", "(", "N", ".", "19", ",", "PRL", ":", "21", "%", ")", ",", "macroprolactinemia", "(", "N", ".", "23", ",", "PRL", ":", "126", "%", ")", ",", "but", "not", "in", "pseudoprolactinoma", "(", "N", ".", "8", ",", "PRL", ":", "0", ".", "8", "%", ")", ",", "and", "risperidone", "-", "induced", "hyperprolactinemia", "(", "N", ".", "7", ",", "PRL", ":", "3", "%", ")", ".", "ROC", "curve", "analysis", "revealed", "that", "unresponsiveness", "to", "verapamil", "defined", "as", "PRL", "<", "7", "%", ",", "discriminated", "anatomical", "or", "functional", "stalk", "effect", "(", "sensitivity", ":", "74", "%", ",", "specificity", ":", "73", "%", ",", "AUC", ":", "0", ".", "855", "+", "/", "-", "0", ".", "04", ",", "P", "<", "0", ".", "001", ",", "CI", ":", "0", ".", "768", "-", "0", ".", "942", ")", "associated", "with", "pseudoprolactinoma", "or", "risperidone", "-", "induced", "hyperprolactinemia", ",", "respectively", ".", "CONCLUSION", ":", "Verapamil", "responsiveness", "is", "not", "a", "reliable", "finding", "for", "the", "differential", "diagnosis", "of", "hyperprolactinemia", ".", "However", ",", "verapamil", "unresponsiveness", "discriminates", "stalk", "effect", "(", "i", ".", "e", ".", ",", "anatomically", "or", "functionally", "inhibited", "dopaminergic", "tonus", ")", "from", "other", "causes", "of", "hyperprolactinemia", "with", "varying", "degrees", "of", "responsiveness", "."]], "ner": [[[227, 227, "Chemical"], [306, 306, "Chemical"], [4, 4, "Disease"], [32, 32, "Disease"], [94, 94, "Disease"], [230, 230, "Disease"], [309, 309, "Disease"], [327, 327, "Disease"], [353, 353, "Disease"], [0, 0, "Chemical"], [19, 19, "Chemical"], [60, 60, "Chemical"], [74, 74, "Chemical"], [109, 109, "Chemical"], [136, 136, "Chemical"], [154, 154, "Chemical"], [249, 249, "Chemical"], [315, 315, "Chemical"], [331, 331, "Chemical"], [39, 39, "Disease"], [69, 69, "Disease"], [173, 173, "Disease"], [185, 185, "Disease"], [197, 197, "Disease"]]], "relations": [[[227, 227, 4, 4, "CID"], [227, 227, 32, 32, "CID"], [227, 227, 94, 94, "CID"], [227, 227, 230, 230, "CID"], [227, 227, 309, 309, "CID"], [227, 227, 327, 327, "CID"], [227, 227, 353, 353, "CID"], [306, 306, 4, 4, "CID"], [306, 306, 32, 32, "CID"], [306, 306, 94, 94, "CID"], [306, 306, 230, 230, "CID"], [306, 306, 309, 309, "CID"], [306, 306, 327, 327, "CID"], [306, 306, 353, 353, "CID"]]], "clusters": [], "translated": " <9>维拉帕米</9>在<2>高催乳素血症</2>中的刺激试验：解剖或功能性梗效应中催乳素反应丧失。 目的：<10>维拉帕米</10>兴奋试验曾作为<3>高催乳素血症</3>的鉴别诊断工具进行研究，但结果相互矛盾。 <19>巨泌乳素血症</19>在之前的研究中从未被考虑过。在这里，我们的目的是重新研究<11>维拉帕米</11>在所有接受<20>巨泌乳素血症</20>筛查的人群中的诊断价值。对65名<4>高催乳素血症</4>女性患者（年龄：29.9+/-8.1岁）进行了<12>维拉帕米</12>的催乳素反应描述性匹配病例-对照研究。方法：<13>维拉帕米</13> 80mg，p.o.给药，然后在第8小时和第16小时通过免疫化学发光法测量PRL水平。<14>维拉帕米</14>反应性由基础催乳素水平(PRL)的峰值百分比变化决定。结果：<15>维拉帕米</15>显着增加了健康对照组(N. 8, PRL:183%)、<21>巨泌乳素瘤</21>(N. 8, PRL:7%)、<22>微小泌乳素瘤</22>(N.19, PRL:21%)、<23>巨泌乳素血症</23>(N.23, PRL:126%)，但不在假性泌乳素瘤( N.8, PRL:0.8% )和<0>利培酮</0>诱导的<5>高催乳素血症</5>(N.7, PRL:3%)中。ROC曲线分析显示，对<16>维拉帕米</16>无反应定义为PRL<7%，区分解剖或功能性茎效应(敏感性:74%，特异性:73%，AUC:0.855+/-0.04, P<0.001, CI:0.768-0.942)分别与假性催乳素瘤或<1>利培酮</1>诱发的<6>高催乳素血症</6>有关。结论：<17>维拉帕米</17>反应性不是<7>高泌乳素血症</7>鉴别诊断的可靠依据。然而，<18>维拉帕米</18>反应迟钝可将茎效应(即解剖学或功能上抑制的多巴胺能张力)与具有不同反应程度的<8>高泌乳素血症</8>的其他原因区分开来。", "revised": true}
{"doc_key": "612112", "sentences": [["Total", "intravenous", "anesthesia", "with", "etomidate", ".", "III", ".", "Some", "observations", "in", "adults", ".", "An", "investigation", "was", "undertaken", "to", "determine", "the", "dosage", "of", "etomidate", "required", "to", "maintain", "sleep", "in", "adults", "undergoing", "surgery", "under", "regional", "local", "anesthesia", ".", "Premedication", "of", "diazepam", "10", "mg", "and", "atropine", "0", ".", "5", "mg", "was", "given", ",", "and", "sleep", "was", "induced", "and", "maintained", "by", "intermittent", "intravenous", "injections", "of", "etomidate", "0", ".", "1", "/", "mg", "/", "kg", ",", "given", "whenever", "the", "patient", "would", "open", "his", "eyes", "on", "request", ".", "A", "mean", "overall", "dose", "of", "etomidate", "17", ".", "4", "microgram", "/", "kg", "/", "min", ".", "was", "required", "to", "maintain", "sleep", ",", "but", "great", "individual", "variation", "occurred", ",", "with", "older", "patients", "requiring", "less", "drug", ".", "The", "investigation", "was", "discontinued", "after", "18", "patients", "because", "of", "the", "frequency", "and", "intensity", "of", "side", "-", "effects", ",", "particularly", "pain", "and", "myoclonia", ",", "which", "caused", "the", "technique", "to", "be", "abandoned", "in", "two", "cases", ".", "It", "is", "considered", "unlikely", "that", "etomidate", "will", "prove", "to", "be", "the", "hypnotic", "of", "choice", "for", "a", "totally", "intravenous", "anesthetic", "technique", "in", "adults", "because", "of", "the", "high", "incidence", "of", "myoclonia", "after", "prolonged", "administration", ".", "In", "several", "patients", "uncontrollable", "muscle", "movements", "persisted", "for", "many", "minutes", "after", "complete", "recovery", "of", "consciousness", "."]], "ner": [[[4, 4, "Chemical"], [22, 22, "Chemical"], [61, 61, "Chemical"], [86, 86, "Chemical"], [154, 154, "Chemical"], [134, 134, "Disease"], [136, 136, "Disease"], [177, 177, "Disease"], [38, 38, "Chemical"], [42, 42, "Chemical"]]], "relations": [[[4, 4, 134, 134, "CID"], [22, 22, 134, 134, "CID"], [61, 61, 134, 134, "CID"], [86, 86, 134, 134, "CID"], [154, 154, 134, 134, "CID"], [4, 4, 136, 136, "CID"], [4, 4, 177, 177, "CID"], [22, 22, 136, 136, "CID"], [22, 22, 177, 177, "CID"], [61, 61, 136, 136, "CID"], [61, 61, 177, 177, "CID"], [86, 86, 136, 136, "CID"], [86, 86, 177, 177, "CID"], [154, 154, 136, 136, "CID"], [154, 154, 177, 177, "CID"]]], "clusters": [], "translated": "<0>依托咪酯</0>全静脉麻醉。三、成人的一些观察。进行了一项调查，以确定在区域局部麻醉下接受手术的成人维持睡眠所需的<1>依托咪酯</1>剂量。术前用药<8>地西泮</8>10mg和<9>阿托品</9>0.5mg，诱导和维持睡眠的方式是间歇静脉注射<2>依托咪酯</2>0.1mg/kg，每当患者根据要求睁开眼睛时给予。平均总剂量为<3>依托咪酯</3>17.4微克/公斤/分钟。需要维持睡眠，但个体差异很大，老年患者需要的药物较少。在18名患者之后停止了调查，因为副作用的频率和强度，特别是<5>疼痛</5>和<6>肌阵挛</6>，这导致该技术被2例患者放弃。由于长期给药后<7>肌阵挛</7>的发生率很高，因此<4>依托咪酯</4>不太可能被证明是成人全静脉内麻醉技术的首选催眠药。在一些患者中，无法控制的肌肉运动在意识完全恢复后仍持续了数分钟。", "revised": true}
{"doc_key": "689020", "sentences": [["A", "method", "for", "the", "measurement", "of", "tremor", ",", "and", "a", "comparison", "of", "the", "effects", "of", "tocolytic", "beta", "-", "mimetics", ".", "A", "method", "permitting", "measurement", "of", "finger", "tremor", "as", "a", "displacement", "-", "time", "curve", "is", "described", ",", "using", "a", "test", "system", "with", "simple", "amplitude", "calibration", ".", "The", "coordinates", "of", "the", "inversion", "points", "of", "the", "displacement", "-", "time", "curves", "were", "transferred", "through", "graphical", "input", "equipment", "to", "punched", "tape", ".", "By", "means", "of", "a", "computer", "program", ",", "periods", "and", "amplitudes", "of", "tremor", "oscillations", "were", "calculated", "and", "classified", ".", "The", "event", "frequency", "for", "each", "class", "of", "periods", "and", "amplitudes", "was", "determined", ".", "The", "actions", "of", "fenoterol", "-", "hydrobromide", ",", "ritodrin", "-", "HCl", "and", "placebo", "given", "to", "10", "healthy", "subjects", "by", "intravenous", "infusion", "in", "a", "double", "-", "blind", "crossover", "study", "were", "tested", "by", "this", "method", ".", "At", "therapeutic", "doses", "both", "substances", "raised", "the", "mean", "tremor", "amplitude", "to", "about", "three", "times", "the", "control", "level", ".", "At", "the", "same", "time", ",", "the", "mean", "period", "within", "each", "class", "of", "amplitudes", "shortened", "by", "10", "-", "-", "20", "ms", ",", "whereas", "the", "mean", "periods", "calculated", "from", "all", "oscillations", "together", "did", "not", "change", "significantly", ".", "After", "the", "end", "of", "fenoterol", "-", "hydrobromide", "infusion", ",", "tremor", "amplitudes", "decreased", "significantly", "faster", "than", "those", "following", "ritodrin", "-", "HCl", "infusion", "."]], "ner": [[[101, 103, "Chemical"], [188, 190, "Chemical"], [6, 6, "Disease"], [26, 26, "Disease"], [78, 78, "Disease"], [139, 139, "Disease"], [193, 193, "Disease"], [105, 107, "Chemical"], [201, 203, "Chemical"]]], "relations": [[[101, 103, 6, 6, "CID"], [101, 103, 26, 26, "CID"], [101, 103, 78, 78, "CID"], [101, 103, 139, 139, "CID"], [101, 103, 193, 193, "CID"], [188, 190, 6, 6, "CID"], [188, 190, 26, 26, "CID"], [188, 190, 78, 78, "CID"], [188, 190, 139, 139, "CID"], [188, 190, 193, 193, "CID"], [105, 107, 6, 6, "CID"], [105, 107, 26, 26, "CID"], [105, 107, 78, 78, "CID"], [105, 107, 139, 139, "CID"], [105, 107, 193, 193, "CID"], [201, 203, 6, 6, "CID"], [201, 203, 26, 26, "CID"], [201, 203, 78, 78, "CID"], [201, 203, 139, 139, "CID"], [201, 203, 193, 193, "CID"]]], "clusters": [], "translated": "一种测量<2>震颤</2>的方法，以及对宫缩抑制剂β-模拟物作用的比较。描述了一种允许测量手指<3>震颤</3>的方法，该方法使用具有简单振幅校准的测试系统。位移-时间曲线的反演点坐标通过图形输入设备输入到穿孔带上。通过计算机程序，计算和分类了<4>震颤</4>振荡的周期和振幅。确定每一类周期和振幅的事件频率。采用该方法对10名健康受试者静脉滴注<0>非诺特罗-氢溴酸盐</0>、<7>利托君盐酸盐</7>和安慰剂的作用进行了双盲交叉试验。在治疗剂量下，这两种物质都将平均<5>震颤</5>振幅提高到控制水平的三倍左右。同时，每类振幅的平均周期缩短了10-20 ms，而所有振荡共同计算的平均周期变化不大。<1>非诺特罗-氢溴酸盐</1>滴注结束后，<6>震颤</6>振幅下降明显快于<8>利托君盐酸盐</8>滴注。", "revised": true}
{"doc_key": "35781", "sentences": [["Central", "action", "of", "narcotic", "analgesics", ".", "Part", "IV", ".", "Noradrenergic", "influences", "on", "the", "activity", "of", "analgesics", "in", "rats", ".", "The", "effect", "of", "clonidine", ",", "naphazoline", "and", "xylometazoline", "on", "analgesia", "induced", "by", "morphine", ",", "codeine", ",", "fentanyl", "and", "pentazocine", ",", "and", "on", "cataleptic", "effect", "of", "morphine", ",", "codine", "and", "fentanyl", "was", "studied", "in", "rats", ".", "The", "biochemical", "assays", "on", "the", "influence", "of", "four", "analgesics", "on", "the", "brain", "concentration", "and", "turnover", "of", "noradrenaline", "(", "NA", ")", "were", "also", "performed", ".", "It", "was", "found", "that", "three", "drugs", "stimulating", "central", "NA", "receptors", "failed", "to", "affect", "the", "analgesic", "ED50", "of", "all", "antinociceptive", "agents", "and", "they", "enhanced", "catalepsy", "induced", "by", "morphine", "and", "fentanyl", ".", "Codeine", "catalepsy", "was", "increased", "by", "clonidine", "and", "decreased", "by", "naphazoline", "and", "xylometazoline", ".", "The", "brain", "concentration", "of", "NA", "was", "not", "changed", "by", "morphine", "and", "fentanyl", ",", "but", "one", "of", "the", "doses", "of", "codeine", "(", "45", "mg", "/", "kg", ")", "slightly", "enhanced", "it", ".", "Pentazocine", "dose", "-", "dependently", "decreased", "the", "brain", "level", "of", "NA", ".", "The", "rate", "of", "NA", "turnover", "was", "not", "altered", "by", "analgesics", "except", "for", "the", "higher", "dose", "of", "fentanyl", "(", "0", ".", "2", "mg", "/", "kg", ")", "following", "which", "the", "disappearance", "of", "NA", "from", "the", "brain", "was", "diminished", ".", "The", "results", "are", "discussed", "in", "the", "light", "of", "various", "and", "non", "-", "uniform", "data", "from", "the", "literature", ".", "It", "is", "suggested", "that", "in", "rats", "the", "brain", "NA", "plays", "a", "less", "important", "function", "than", "the", "other", "monoamines", "in", "the", "behavioural", "activity", "of", "potent", "analgesics", "."]], "ner": [[[22, 22, "Chemical"], [113, 113, "Chemical"], [41, 41, "Disease"], [101, 101, "Disease"], [109, 109, "Disease"], [24, 24, "Chemical"], [117, 117, "Chemical"], [26, 26, "Chemical"], [119, 119, "Chemical"], [31, 31, "Chemical"], [44, 44, "Chemical"], [104, 104, "Chemical"], [130, 130, "Chemical"], [33, 33, "Chemical"], [46, 46, "Chemical"], [108, 108, "Chemical"], [140, 140, "Chemical"], [35, 35, "Chemical"], [48, 48, "Chemical"], [106, 106, "Chemical"], [132, 132, "Chemical"], [178, 178, "Chemical"], [37, 37, "Chemical"], [151, 151, "Chemical"], [70, 70, "Chemical"], [72, 72, "Chemical"], [86, 86, "Chemical"], [125, 125, "Chemical"], [160, 160, "Chemical"], [165, 165, "Chemical"], [192, 192, "Chemical"], [225, 225, "Chemical"], [234, 234, "Chemical"]]], "relations": [[[22, 22, 41, 41, "CID"], [22, 22, 101, 101, "CID"], [22, 22, 109, 109, "CID"], [113, 113, 41, 41, "CID"], [113, 113, 101, 101, "CID"], [113, 113, 109, 109, "CID"], [24, 24, 41, 41, "CID"], [24, 24, 101, 101, "CID"], [24, 24, 109, 109, "CID"], [117, 117, 41, 41, "CID"], [117, 117, 101, 101, "CID"], [117, 117, 109, 109, "CID"], [26, 26, 41, 41, "CID"], [26, 26, 101, 101, "CID"], [26, 26, 109, 109, "CID"], [119, 119, 41, 41, "CID"], [119, 119, 101, 101, "CID"], [119, 119, 109, 109, "CID"], [31, 31, 41, 41, "CID"], [31, 31, 101, 101, "CID"], [31, 31, 109, 109, "CID"], [44, 44, 41, 41, "CID"], [44, 44, 101, 101, "CID"], [44, 44, 109, 109, "CID"], [104, 104, 41, 41, "CID"], [104, 104, 101, 101, "CID"], [104, 104, 109, 109, "CID"], [130, 130, 41, 41, "CID"], [130, 130, 101, 101, "CID"], [130, 130, 109, 109, "CID"], [33, 33, 41, 41, "CID"], [33, 33, 101, 101, "CID"], [33, 33, 109, 109, "CID"], [46, 46, 41, 41, "CID"], [46, 46, 101, 101, "CID"], [46, 46, 109, 109, "CID"], [108, 108, 41, 41, "CID"], [108, 108, 101, 101, "CID"], [108, 108, 109, 109, "CID"], [140, 140, 41, 41, "CID"], [140, 140, 101, 101, "CID"], [140, 140, 109, 109, "CID"], [35, 35, 41, 41, "CID"], [35, 35, 101, 101, "CID"], [35, 35, 109, 109, "CID"], [48, 48, 41, 41, "CID"], [48, 48, 101, 101, "CID"], [48, 48, 109, 109, "CID"], [106, 106, 41, 41, "CID"], [106, 106, 101, 101, "CID"], [106, 106, 109, 109, "CID"], [132, 132, 41, 41, "CID"], [132, 132, 101, 101, "CID"], [132, 132, 109, 109, "CID"], [178, 178, 41, 41, "CID"], [178, 178, 101, 101, "CID"], [178, 178, 109, 109, "CID"]]], "clusters": [], "translated": "麻醉镇痛药的中枢作用。第四部分。去甲肾上腺素能对大鼠镇痛药活性的影响。<0>可乐定</0>、<5>萘甲唑啉</5>和<7>赛洛唑啉</7>对<9>吗啡</9>、<13>可待因</13>、<17>芬太尼</17>和<22>喷他佐辛</22> 诱导的镇痛作用，以及<2>强直</2>引发的<10>吗啡</10>、<14>可待因</14>和<18>芬太尼</18>作用于大鼠身上的影响被研究。还进行了四种镇痛药对<24>去甲肾上腺素</24> (<25>NA</25>) 脑浓度和周转影响的生化测定。结果发现，三种刺激中枢<26>NA</26> 受体的药物未能影响所有抗伤害药的镇痛ED50，它们增强了<11>吗啡</11>和<19>芬太尼</19>引起的<3>强直症</3>。 <15>可待因</15>的<4>强直症</4>因<1>可乐定</1>增加而因<6>萘甲唑啉</6>和<8>赛洛唑啉</8>而减少。大脑中的<27>NA</27>浓度没有被<12>吗啡</12>和<20>芬太尼</20>改变，但是<16>可待因 </16>的一种剂量（45mg/kg）略有增加。<23>喷他佐辛</23> 剂量依赖性地降低了<28> NA </28>的大脑水平。除了较高剂量的<21>芬太尼</21> (0.2mg/kg)之外，<29> NA</29>周转率没有被镇痛药改变，该剂量下<30>NA</30>从大脑中消失速度减慢。<br>根据文献中各种不统一的数据对结果进行了讨论。表明在大鼠中，<31>NA</31>在强效镇痛药的行为活动中发挥的作用不如其他<32>单胺</32>重要。", "revised": true}
{"doc_key": "611664", "sentences": [["Use", "of", "propranolol", "in", "the", "treatment", "of", "idiopathic", "orthostatic", "hypotension", ".", "Five", "patients", "with", "idiopathic", "orthostatic", "hypotension", "who", "had", "physiologic", "and", "biochemical", "evidence", "of", "severe", "autonomic", "dysfunction", "were", "included", "in", "the", "study", ".", "They", "all", "exhibited", "markedly", "reduced", "plasma", "catecholamines", "and", "plasma", "renin", "activity", "in", "both", "recumbent", "and", "upright", "positions", "and", "had", "marked", "hypersensitivity", "to", "the", "pressor", "effects", "of", "infused", "norepinephrine", ".", "Treatment", "with", "propanolol", "administered", "intravenously", "(", "1", "-", "5", "mg", ")", "produced", "increases", "in", "supine", "and", "upright", "blood", "pressure", "in", "4", "of", "the", "5", "individuals", "with", "rises", "ranging", "from", "11", "/", "6", "to", "22", "/", "11", "mmHg", ".", "Chronic", "oral", "administration", "of", "propranolol", "(", "40", "-", "160", "mg", "/", "day", ")", "also", "elevated", "the", "blood", "pressures", "of", "these", "individuals", "with", "increases", "in", "the", "order", "of", "20", "-", "35", "/", "15", "-", "25", "mmg", "being", "observed", ".", "In", "1", "patient", ",", "marked", "hypertension", "was", "induced", "by", "propranolol", "and", "the", "drug", "had", "to", "be", "withdrawn", ".", "It", "otherwise", "was", "well", "tolerated", "and", "no", "important", "side", "effects", "were", "observed", ".", "Treatment", "has", "been", "continued", "in", "3", "individuals", "for", "6", "-", "13", "months", "with", "persistence", "of", "the", "pressor", "effect", ",", "although", "there", "appears", "to", "have", "been", "some", "decrease", "in", "the", "degree", "of", "response", "with", "time", ".", "Hemodynamic", "measurements", "in", "1", "of", "the", "patients", "demonstrated", "an", "increase", "in", "total", "peripheral", "resistance", "and", "essentially", "no", "change", "in", "cardiac", "output", "following", "propranolol", "therapy", ".", "The", "studies", "suggest", "that", "propranolol", "is", "a", "useful", "drug", "in", "selected", "patients", "with", "severe", "idiopathic", "orthostatic", "hypotension", "."]], "ner": [[[2, 2, "Chemical"], [64, 64, "Chemical"], [104, 104, "Chemical"], [147, 147, "Chemical"], [226, 226, "Chemical"], [233, 233, "Chemical"], [143, 143, "Disease"], [7, 9, "Disease"], [14, 16, "Disease"], [243, 245, "Disease"], [53, 53, "Disease"], [39, 39, "Chemical"], [60, 60, "Chemical"]]], "relations": [[[2, 2, 143, 143, "CID"], [64, 64, 143, 143, "CID"], [104, 104, 143, 143, "CID"], [147, 147, 143, 143, "CID"], [226, 226, 143, 143, "CID"], [233, 233, 143, 143, "CID"]]], "clusters": [], "translated": "<0>心得安</0> 在 <7>特发性体位性低血压</7> 治疗中的应用。5名 <8>特发性直立性低血压</8> 患者被纳入研究，这些患者具有严重自主神经功能障碍的生理生化证据。他们都表现出在卧位和直立位时血浆 <11>儿茶酚胺</11> 和血浆肾素活性显着降低，并且对输注的 <12>去甲肾上腺素</12> 的升压作用显着 <10>超敏反应</10>。静脉注射 <1>心得安</1> （1-5mg）后，5名患者中有4名的仰卧位和直立位血压升高，升高范围为11/6 至 22/11mmHg。长期口服 <2>普萘洛尔</2>（40-160mg/天）也使这些个体的血压升高，观察到的血压升高量级为20-35/15-25毫米。1例因 <3>普萘洛尔</3> 诱发显着 <6>高血压</6> 而不得不停药。它在其他方面的耐受性良好，没有观察到重要的副作用。 3名患者的治疗持续了6-13个月，升压效应持续存在，尽管随着时间的推移反应程度似乎有所下降。1名患者的血流动力学测量表明，在 <4>普萘洛尔</4> 治疗后，总外周阻力增加，心输出量基本没有变化。研究表明，<5>普萘洛尔</5> 对于某些严重 <9>特发性直立性低血压</9> 患者是一种有用的药物。", "revised": true}
{"doc_key": "48835", "sentences": [["Modification", "by", "propranolol", "of", "cardiovascular", "effects", "of", "induced", "hypoglycaemia", ".", "The", "cardiovascular", "effects", "of", "hypoglycaemia", ",", "with", "and", "without", "beta", "-", "blockade", ",", "were", "compared", "in", "fourteen", "healthy", "men", ".", "Eight", "received", "insulin", "alone", ",", "and", "eight", ",", "including", "two", "of", "the", "original", "insulin", "-", "only", "group", ",", "were", "given", "propranolol", "and", "insulin", ".", "In", "the", "insulin", "-", "group", "the", "period", "of", "hypoglycaemia", "was", "associated", "with", "an", "increase", "in", "heart", "-", "rate", "and", "a", "fall", "in", "diastolic", "blood", "-", "pressure", ".", "In", "the", "propranolol", "-", "insulin", "group", "there", "was", "a", "significant", "fall", "in", "heart", "-", "rate", "in", "most", "subjects", "and", "an", "increase", "in", "diastolic", "pressure", ".", "Typical", "S", "-", "T", "/", "T", "changes", "occurred", "in", "the", "insulin", "-", "group", "but", "in", "none", "of", "the", "propranolol", "-", "insulin", "group", ".", "Hypertension", "in", "diabetics", "prone", "to", "hypoglycaemia", "attacks", "should", "not", "be", "treated", "with", "beta", "-", "blockers", "because", "these", "drugs", "may", "cause", "a", "sharp", "rise", "in", "blood", "-", "pressure", "in", "such", "patients", "."]], "ner": [[[2, 2, "Chemical"], [50, 50, "Chemical"], [83, 83, "Chemical"], [124, 124, "Chemical"], [129, 129, "Disease"], [8, 8, "Disease"], [14, 14, "Disease"], [62, 62, "Disease"], [134, 134, "Disease"], [131, 131, "Disease"]]], "relations": [[[2, 2, 129, 129, "CID"], [50, 50, 129, 129, "CID"], [83, 83, 129, 129, "CID"], [124, 124, 129, 129, "CID"]]], "clusters": [], "translated": "<0>普萘洛尔</0>对诱导<5>低血糖</5>的心血管作用的修饰。在 14 名健康男性中比较了<6>低血糖症</6>的心血管影响，使用和不使用β-阻滞剂。8 名仅接受胰岛素治疗，8 名（包括最初仅接受胰岛素治疗组的两名）接受<1>普萘洛尔</1>和胰岛素治疗。在胰岛素组中，<7>低血糖</7>期与心率加快和舒张压下降有关。在<2>普萘洛尔</2>-胰岛素组中，大多数受试者的心率显着下降，舒张压升高。典型的S-T/T变化发生在胰岛素组，但<3>普萘洛尔</3>-胰岛素组均未发生。<4>高血压</4> <9>糖尿病患者</9>容易发生<8>低血糖</8>发作不应使用β-受体阻滞剂治疗，因为这些药物可能会导致患者血压急剧升高。", "revised": true}
{"doc_key": "20431083", "sentences": [["Antithrombotic", "drug", "use", ",", "cerebral", "microbleeds", ",", "and", "intracerebral", "hemorrhage", ":", "a", "systematic", "review", "of", "published", "and", "unpublished", "studies", ".", "BACKGROUND", "AND", "PURPOSE", ":", "Cerebral", "microbleeds", "(", "MB", ")", "are", "potential", "risk", "factors", "for", "intracerebral", "hemorrhage", "(", "ICH", ")", ",", "but", "it", "is", "unclear", "if", "they", "are", "a", "contraindication", "to", "using", "antithrombotic", "drugs", ".", "Insights", "could", "be", "gained", "by", "pooling", "data", "on", "MB", "frequency", "stratified", "by", "antithrombotic", "use", "in", "cohorts", "with", "ICH", "and", "ischemic", "stroke", "(", "IS", ")", "/", "transient", "ischemic", "attack", "(", "TIA", ")", ".", "METHODS", ":", "We", "performed", "a", "systematic", "review", "of", "published", "and", "unpublished", "data", "from", "cohorts", "with", "stroke", "or", "TIA", "to", "compare", "the", "presence", "of", "MB", "in", ":", "(", "1", ")", "antithrombotic", "users", "vs", "nonantithrombotic", "users", "with", "ICH", ";", "(", "2", ")", "antithrombotic", "users", "vs", "nonusers", "with", "IS", "/", "TIA", ";", "and", "(", "3", ")", "ICH", "vs", "ischemic", "events", "stratified", "by", "antithrombotic", "use", ".", "We", "also", "analyzed", "published", "and", "unpublished", "follow", "-", "up", "data", "to", "determine", "the", "risk", "of", "ICH", "in", "antithrombotic", "users", "with", "MB", ".", "RESULTS", ":", "In", "a", "pooled", "analysis", "of", "1460", "ICH", "and", "3817", "IS", "/", "TIA", ",", "MB", "were", "more", "frequent", "in", "ICH", "vs", "IS", "/", "TIA", "in", "all", "treatment", "groups", ",", "but", "the", "excess", "increased", "from", "2", ".", "8", "(", "odds", "ratio", ";", "range", ",", "2", ".", "3", "-", "3", ".", "5", ")", "in", "nonantithrombotic", "users", "to", "5", ".", "7", "(", "range", ",", "3", ".", "4", "-", "9", ".", "7", ")", "in", "antiplatelet", "users", "and", "8", ".", "0", "(", "range", ",", "3", ".", "5", "-", "17", ".", "8", ")", "in", "warfarin", "users", "(", "P", "difference", "=", "0", ".", "01", ")", ".", "There", "was", "also", "an", "excess", "of", "MB", "in", "warfarin", "users", "vs", "nonusers", "with", "ICH", "(", "OR", ",", "2", ".", "7", ";", "95", "%", "CI", ",", "1", ".", "6", "-", "4", ".", "4", ";", "P", "<", "0", ".", "001", ")", "but", "none", "in", "warfarin", "users", "with", "IS", "/", "TIA", "(", "OR", ",", "1", ".", "3", ";", "95", "%", "CI", ",", "0", ".", "9", "-", "1", ".", "7", ";", "P", "=", "0", ".", "33", ";", "P", "difference", "=", "0", ".", "01", ")", ".", "There", "was", "a", "smaller", "excess", "of", "MB", "in", "antiplatelet", "users", "vs", "nonusers", "with", "ICH", "(", "OR", ",", "1", ".", "7", ";", "95", "%", "CI", ",", "1", ".", "3", "-", "2", ".", "3", ";", "P", "<", "0", ".", "001", ")", ",", "but", "findings", "were", "similar", "for", "antiplatelet", "users", "with", "IS", "/", "TIA", "(", "OR", ",", "1", ".", "4", ";", "95", "%", "CI", ",", "1", ".", "2", "-", "1", ".", "7", ";", "P", "<", "0", ".", "001", ";", "P", "difference", "=", "0", ".", "25", ")", ".", "In", "pooled", "follow", "-", "up", "data", "for", "768", "antithrombotic", "users", ",", "presence", "of", "MB", "at", "baseline", "was", "associated", "with", "a", "substantially", "increased", "risk", "of", "subsequent", "ICH", "(", "OR", ",", "12", ".", "1", ";", "95", "%", "CI", ",", "3", ".", "4", "-", "42", ".", "5", ";", "P", "<", "0", ".", "001", ")", ".", "CONCLUSIONS", ":", "The", "excess", "of", "MB", "in", "warfarin", "users", "with", "ICH", "compared", "to", "other", "groups", "suggests", "that", "MB", "increase", "the", "risk", "of", "warfarin", "-", "associated", "ICH", ".", "Limited", "prospective", "data", "corroborate", "these", "findings", ",", "but", "larger", "prospective", "studies", "are", "urgently", "required", "."]], "ner": [[[259, 259, "Chemical"], [278, 278, "Chemical"], [312, 312, "Chemical"], [494, 494, "Chemical"], [509, 509, "Chemical"], [8, 9, "Disease"], [34, 35, "Disease"], [37, 37, "Disease"], [71, 71, "Disease"], [121, 121, "Disease"], [139, 139, "Disease"], [163, 163, "Disease"], [178, 178, "Disease"], [190, 190, "Disease"], [283, 283, "Disease"], [364, 364, "Disease"], [460, 460, "Disease"], [497, 497, "Disease"], [512, 512, "Disease"], [73, 74, "Disease"], [76, 76, "Disease"], [131, 131, "Disease"], [181, 181, "Disease"], [192, 192, "Disease"], [315, 315, "Disease"], [399, 399, "Disease"], [79, 81, "Disease"], [83, 83, "Disease"], [103, 103, "Disease"], [133, 133, "Disease"], [183, 183, "Disease"], [194, 194, "Disease"], [317, 317, "Disease"], [401, 401, "Disease"], [101, 101, "Disease"], [141, 141, "Disease"]]], "relations": [[[259, 259, 8, 9, "CID"], [259, 259, 34, 35, "CID"], [259, 259, 37, 37, "CID"], [259, 259, 71, 71, "CID"], [259, 259, 121, 121, "CID"], [259, 259, 139, 139, "CID"], [259, 259, 163, 163, "CID"], [259, 259, 178, 178, "CID"], [259, 259, 190, 190, "CID"], [259, 259, 283, 283, "CID"], [259, 259, 364, 364, "CID"], [259, 259, 460, 460, "CID"], [259, 259, 497, 497, "CID"], [259, 259, 512, 512, "CID"], [278, 278, 8, 9, "CID"], [278, 278, 34, 35, "CID"], [278, 278, 37, 37, "CID"], [278, 278, 71, 71, "CID"], [278, 278, 121, 121, "CID"], [278, 278, 139, 139, "CID"], [278, 278, 163, 163, "CID"], [278, 278, 178, 178, "CID"], [278, 278, 190, 190, "CID"], [278, 278, 283, 283, "CID"], [278, 278, 364, 364, "CID"], [278, 278, 460, 460, "CID"], [278, 278, 497, 497, "CID"], [278, 278, 512, 512, "CID"], [312, 312, 8, 9, "CID"], [312, 312, 34, 35, "CID"], [312, 312, 37, 37, "CID"], [312, 312, 71, 71, "CID"], [312, 312, 121, 121, "CID"], [312, 312, 139, 139, "CID"], [312, 312, 163, 163, "CID"], [312, 312, 178, 178, "CID"], [312, 312, 190, 190, "CID"], [312, 312, 283, 283, "CID"], [312, 312, 364, 364, "CID"], [312, 312, 460, 460, "CID"], [312, 312, 497, 497, "CID"], [312, 312, 512, 512, "CID"], [494, 494, 8, 9, "CID"], [494, 494, 34, 35, "CID"], [494, 494, 37, 37, "CID"], [494, 494, 71, 71, "CID"], [494, 494, 121, 121, "CID"], [494, 494, 139, 139, "CID"], [494, 494, 163, 163, "CID"], [494, 494, 178, 178, "CID"], [494, 494, 190, 190, "CID"], [494, 494, 283, 283, "CID"], [494, 494, 364, 364, "CID"], [494, 494, 460, 460, "CID"], [494, 494, 497, 497, "CID"], [494, 494, 512, 512, "CID"], [509, 509, 8, 9, "CID"], [509, 509, 34, 35, "CID"], [509, 509, 37, 37, "CID"], [509, 509, 71, 71, "CID"], [509, 509, 121, 121, "CID"], [509, 509, 139, 139, "CID"], [509, 509, 163, 163, "CID"], [509, 509, 178, 178, "CID"], [509, 509, 190, 190, "CID"], [509, 509, 283, 283, "CID"], [509, 509, 364, 364, "CID"], [509, 509, 460, 460, "CID"], [509, 509, 497, 497, "CID"], [509, 509, 512, 512, "CID"]]], "clusters": [], "translated": "抗血栓药物的使用、脑微出血和<5>脑出血</5>：对已发表和未发表研究的系统评价。背景与目的：脑微出血(MB)是<6>脑出血</6>(<7>ICH</7>)的潜在危险因素，但尚不清楚是否为使用抗血栓药物的禁忌证。通过合并<8>ICH</8> 和<19>缺血性卒中</19>(<20>IS</20>)/<26>短暂性缺血发作</26>(<27>TIA</27>)队列中抗血栓药物使用分层的MB频率数据，可以获得见解。方法：我们对发表和未发表的<34>卒中</34>或<28>TIA</28>队列的数据进行了系统审查，以比较：(1) 患有<9> ICH</9>抗血栓药物使用者与非使用者；(2) 抗血栓药物使用者与非使用者对<21>IS</21>/<29>TIA</29>的影响；以及 (3)按抗血栓治疗分层<10>ICH</10>与<35>缺血性</35>事件。我们还分析了已发表和未发表的随访数据，以确定患有MB的抗血栓药物使用者发生<11>ICH</11>的风险。结果：在对1460例<12> ICH</12> 和3817例<22>IS</22>/<30>TIA</30>的汇总分析中，MB在<13>ICH</13>与<23>IS</23>/<31>TIA</31>的所有治疗组中都更为频繁，但是沉重负担却分别从非抗血栓使用组的2.8（比值比；范围2.3-3.5）增加到抗血小板使用组的5.7(范围3.4-9.7)，在<0>华法林</0>使用组为8.0 (范围3.5-17.8)(P差别=0.01)。在<1>华法林</1>使用组中，MB也比未使用<14>ICH</14>药的组更多(OR,2.7; 95% CI,1.6-4.4; P<0.001),但在<2>华法林</2>使用组中，<24>IS</24>/<32>TIA</32>组在所有治疗组中都更多(MB 与未使用者无差别，OR, 1.3；95% CI,0.9-1.7; P=0.33;P差别=0.01)。抗血小板使用组MB数量较少但与未使用者相比仍更多(<15>ICH</15>组OR,1.7; 95% CI,1.3-2.3; P<0.001)，但是对于<25>IS</25>/<33>TIA</33>的抗血小板使用组结果类似(OR,1.4; 95% CI, 1.2-1.7; P<0.001; P差别=0.25)。在对768名抗血栓药物使用者进行的汇总随访数据中，基线时存在MB与随后发生<16>ICH</16>的风险明显相关(OR,12.1; 95% CI, 3.4-42.5; P<0.001)。结论：得出<3>华法林</3>使用组发生<17>ICH</17>较其他组更多的结论表明MB增加了<4>华法林</4>-相关<18>ICH</18>的风险。有限的前瞻性数据证实了这些发现，但需要更大规模的前瞻性研究来证实。", "revised": true}
{"doc_key": "816141", "sentences": [["Cephalothin", "-", "induced", "immune", "hemolytic", "anemia", ".", "A", "patient", "with", "renal", "disease", "developed", "Coombs", "-", "positive", "hemolytic", "anemia", "while", "receiving", "cephalothin", "therapy", ".", "An", "anti", "-", "cephalothin", "IgG", "antibody", "was", "detected", "in", "the", "patient", "'s", "serum", "and", "in", "the", "eluates", "from", "her", "erythrocytes", ".", "In", "addition", ",", "nonimmunologic", "binding", "of", "normal", "and", "patient", "'s", "serum", "proteins", "to", "her", "own", "and", "cephalothin", "-", "coated", "normal", "red", "cells", "was", "demonstrated", ".", "Skin", "tests", "and", "in", "vitro", "lymphocyte", "stimulation", "revealed", "that", "the", "patient", "was", "sensitized", "to", "cephalothin", "and", "also", "to", "ampicillin", ".", "Careful", "investigation", "of", "drug", "-", "induced", "hemolytic", "anemias", "reveals", "the", "complexity", "of", "the", "immune", "mechanisms", "involved", "."]], "ner": [[[0, 0, "Chemical"], [20, 20, "Chemical"], [26, 26, "Chemical"], [60, 60, "Chemical"], [83, 83, "Chemical"], [4, 5, "Disease"], [16, 17, "Disease"], [95, 96, "Disease"], [10, 11, "Disease"], [87, 87, "Chemical"]]], "relations": [[[0, 0, 4, 5, "CID"], [0, 0, 16, 17, "CID"], [0, 0, 95, 96, "CID"], [20, 20, 4, 5, "CID"], [20, 20, 16, 17, "CID"], [20, 20, 95, 96, "CID"], [26, 26, 4, 5, "CID"], [26, 26, 16, 17, "CID"], [26, 26, 95, 96, "CID"], [60, 60, 4, 5, "CID"], [60, 60, 16, 17, "CID"], [60, 60, 95, 96, "CID"], [83, 83, 4, 5, "CID"], [83, 83, 16, 17, "CID"], [83, 83, 95, 96, "CID"]]], "clusters": [], "translated": "<0>头孢磷脂</0>-诱导的免疫性<5>溶血性贫血</5>。一位<8>肾病</8>患者在接受<1>头孢噻吩</1>治疗时出现了Coombs阳性<6>溶血性贫血</6>。在患者的血清和红细胞洗脱液中检测到抗<2>头孢噻吩</2> IgG 抗体。此外，证明了正常和患者血清蛋白与她自己的和<3>头孢磷脂</3>包被的正常红细胞的非免疫结合。皮肤试验和体外淋巴细胞刺激显示患者对<4>头孢噻吩</4>和<9>氨苄西林</9>敏感。对药物引起的<7>溶血性贫血</7>的仔细研究揭示了所涉及的免疫机制的复杂性。", "revised": true}
{"doc_key": "891494", "sentences": [["Phenytoin", "encephalopathy", "as", "probable", "idiosyncratic", "reaction", ":", "case", "report", ".", "A", "case", "of", "phenytoin", "(", "DPH", ")", "encephalopathy", "with", "increasing", "seizures", "and", "EEG", "and", "mental", "changes", "is", "described", ".", "Despite", "adequate", "oral", "dosage", "of", "DPH", "(", "5", "mg", "/", "kg", "/", "daily", ")", "the", "plasma", "level", "was", "very", "low", "(", "2", ".", "8", "microgramg", "/", "ml", ")", ".", "The", "encephalopathy", "was", "probably", "an", "idiosyncratic", "and", "not", "toxic", "or", "allergic", "reaction", ".", "In", "fact", "the", "concentration", "of", "free", "DPH", "was", "normal", ",", "the", "patient", "presented", "a", "retarded", "morbilliform", "rash", "during", "DPH", "treatment", ",", "the", "protidogram", "was", "normal", ",", "and", "an", "intradermic", "DPH", "injection", "had", "no", "local", "effect", ".", "The", "authors", "conclude", "that", "in", "a", "patient", "starting", "DPH", "treatment", "an", "unexpected", "increase", "in", "seizures", ",", "with", "EEG", "and", "mental", "changes", "occurring", "simultaneously", ",", "should", "alert", "the", "physician", "to", "the", "possible", "need", "for", "eliminating", "DPH", "from", "the", "therapeutic", "regimen", ",", "even", "if", "plasma", "concentrations", "are", "low", "."]], "ner": [[[0, 0, "Chemical"], [13, 13, "Chemical"], [15, 15, "Chemical"], [34, 34, "Chemical"], [77, 77, "Chemical"], [89, 89, "Chemical"], [100, 100, "Chemical"], [115, 115, "Chemical"], [141, 141, "Chemical"], [1, 1, "Disease"], [17, 17, "Disease"], [59, 59, "Disease"], [20, 20, "Disease"], [121, 121, "Disease"], [87, 87, "Disease"]]], "relations": [[[0, 0, 1, 1, "CID"], [0, 0, 17, 17, "CID"], [0, 0, 59, 59, "CID"], [13, 13, 1, 1, "CID"], [13, 13, 17, 17, "CID"], [13, 13, 59, 59, "CID"], [15, 15, 1, 1, "CID"], [15, 15, 17, 17, "CID"], [15, 15, 59, 59, "CID"], [34, 34, 1, 1, "CID"], [34, 34, 17, 17, "CID"], [34, 34, 59, 59, "CID"], [77, 77, 1, 1, "CID"], [77, 77, 17, 17, "CID"], [77, 77, 59, 59, "CID"], [89, 89, 1, 1, "CID"], [89, 89, 17, 17, "CID"], [89, 89, 59, 59, "CID"], [100, 100, 1, 1, "CID"], [100, 100, 17, 17, "CID"], [100, 100, 59, 59, "CID"], [115, 115, 1, 1, "CID"], [115, 115, 17, 17, "CID"], [115, 115, 59, 59, "CID"], [141, 141, 1, 1, "CID"], [141, 141, 17, 17, "CID"], [141, 141, 59, 59, "CID"]]], "clusters": [], "translated": " <0>苯妥英</0> <9>脑病</9> 作为可能的特异性反应：病例报告。描述了<1>苯妥英</1>（<2>DPH</2>）<10>脑病</10>伴有<12>癫痫发作</12>和脑电图及精神改变的病例。尽管<3>DPH</3>的口服剂量足够（5毫克/千克/天），血浆水平却很低（2.8微克/毫升）。<11>脑病</11>可能是一种特异质反应，并非毒性或过敏反应。实际上，游离<4>DPH</4>浓度正常，患者在<5>DPH</5>治疗期间出现麻疹样<14>皮疹</14>，protidogram正常，皮内注射的<6>DPH</6>没有局部作用。作者得出结论，在开始<7>DPH</7>治疗的患者中，意外的<13>癫痫发作</13>增加，脑电图和精神变化同时发生，应该提醒医生可能需要消除自治疗方案中的<8>DPH</8>，即使血浆浓度很低。", "revised": true}
{"doc_key": "256433", "sentences": [["Continuous", "infusion", "tobramycin", "combined", "with", "carbenicillin", "for", "infections", "in", "cancer", "patients", ".", "The", "cure", "rate", "of", "infections", "in", "cancer", "patients", "is", "adversely", "affected", "by", "neutropenia", "(", "less", "than", "1", ",", "000", "/", "mm3", ")", ".", "In", "particular", ",", "patients", "with", "severe", "neutropenia", "(", "less", "than", "100", "/", "mm3", ")", "have", "shown", "a", "poor", "response", "to", "antibiotics", ".", "To", "overcome", "the", "adverse", "effects", "of", "neutropenia", ",", "tobramycin", "was", "given", "by", "continuous", "infusion", "and", "combined", "with", "intermittent", "carbenicillin", ".", "Tobramycin", "was", "given", "to", "a", "total", "daily", "dose", "of", "300", "mg", "/", "m2", "and", "carbenicillin", "was", "given", "at", "a", "dose", "of", "5", "gm", "every", "four", "hours", ".", "There", "were", "125", "infectious", "episodes", "in", "116", "cancer", "patients", "receiving", "myelosuppressive", "chemotherapy", ".", "The", "overall", "cure", "rate", "was", "70", "%", ".", "Pneumonia", "was", "the", "most", "common", "infection", "and", "61", "%", "of", "59", "episodes", "were", "cured", ".", "Gram", "-", "negative", "bacilli", "were", "the", "most", "common", "causative", "organisms", "and", "69", "%", "of", "these", "infections", "were", "cured", ".", "The", "most", "common", "pathogen", "was", "Klebsiella", "pneumoniae", "and", "this", ",", "together", "with", "Escherichia", "coli", "and", "Pseudomonas", "aeruginosa", ",", "accounted", "for", "74", "%", "of", "all", "gram", "-", "negative", "bacillary", "infections", ".", "Response", "was", "not", "influenced", "by", "the", "initial", "neutrophil", "count", ",", "with", "a", "62", "%", "cure", "rate", "for", "39", "episodes", "associated", "with", "severe", "neutropenia", ".", "However", ",", "failure", "of", "the", "neutrophil", "count", "to", "increase", "during", "therapy", "adversely", "affected", "response", ".", "Azotemia", "was", "the", "major", "side", "effect", "recognized", ",", "and", "it", "occurred", "in", "11", "%", "of", "episodes", ".", "Major", "azotemia", "(", "serum", "creatinine", "greater", "than", "2", ".", "5", "mg", "/", "dl", "or", "BUN", "greater", "than", "50", "mg", "/", "dl", ")", "occurred", "in", "only", "2", "%", ".", "Azotemia", "was", "not", "related", "to", "duration", "of", "therapy", "or", "serum", "tobramycin", "concentration", ".", "This", "antibiotic", "regimen", "showed", "both", "therapeutic", "efficacy", "and", "acceptable", "renal", "toxicity", "for", "these", "patients", "."]], "ner": [[[2, 2, "Chemical"], [65, 65, "Chemical"], [77, 77, "Chemical"], [283, 283, "Chemical"], [228, 228, "Disease"], [246, 246, "Disease"], [273, 273, "Disease"], [5, 5, "Chemical"], [75, 75, "Chemical"], [91, 91, "Chemical"], [7, 7, "Disease"], [16, 16, "Disease"], [130, 130, "Disease"], [155, 155, "Disease"], [9, 9, "Disease"], [18, 18, "Disease"], [111, 111, "Disease"], [24, 24, "Disease"], [41, 41, "Disease"], [63, 63, "Disease"], [211, 211, "Disease"], [125, 125, "Disease"], [165, 165, "Disease"], [183, 187, "Disease"], [295, 296, "Disease"], [249, 249, "Chemical"]]], "relations": [[[2, 2, 228, 228, "CID"], [2, 2, 246, 246, "CID"], [2, 2, 273, 273, "CID"], [65, 65, 228, 228, "CID"], [65, 65, 246, 246, "CID"], [65, 65, 273, 273, "CID"], [77, 77, 228, 228, "CID"], [77, 77, 246, 246, "CID"], [77, 77, 273, 273, "CID"], [283, 283, 228, 228, "CID"], [283, 283, 246, 246, "CID"], [283, 283, 273, 273, "CID"], [5, 5, 228, 228, "CID"], [5, 5, 246, 246, "CID"], [5, 5, 273, 273, "CID"], [75, 75, 228, 228, "CID"], [75, 75, 246, 246, "CID"], [75, 75, 273, 273, "CID"], [91, 91, 228, 228, "CID"], [91, 91, 246, 246, "CID"], [91, 91, 273, 273, "CID"]]], "clusters": [], "translated": "持续输注<0>妥布霉素</0>联合<7>羧苄青霉素</7>治疗<14>癌症</14>患者的<10>感染</10>。 <11>感染</11> 在<15>癌症</15>患者中的治愈率受到<17>中性粒细胞减少</17>（小于1,000/mm3）的不利影响。特别是患有严重<18>中性粒细胞减少症</18>（小于100/mm3）的患者对抗生素反应不佳。为克服<19>中性粒细胞减少</19>的不良反应，采用<1>妥布霉素</1>连续滴注联合间断<8>羧苄青霉素</8>。 <2>妥布霉素</2> 的日总剂量为 300 mg/m2，<9>羧苄青霉素</9> 的剂量为每4小时5 gm。接受骨髓抑制化疗的 116 例<16>癌症</16>患者共发生 125 次<10>感染</10>。总治愈率为 70%。 <21>肺炎</21>是最常见的<12>感染</12>，59 例中有 61% 治愈。革兰氏阴性杆菌是最常见的致病微生物，这些<13>感染</13>中有 69% 得到治愈。最常见的病原体是肺炎克雷伯菌<22>，</22>与大肠杆菌和铜绿假单胞菌一起，占所有<23>革兰氏阴性杆菌感染</23> 的 74%。反应不受初始中性粒细胞计数的影响，39 例严重<20>中性粒细胞减少</20>的治愈率为62%。然而，在治疗期间嗜中性粒细胞计数未能增加会对反应产生不利影响。<4>氮质血症</4>是公认的主要副作用，发生在 11% 的发作中。严重<5>氮质血症</5>（血清<25>肌酐</25>大于 2.5 mg/dl或BUN大于50 mg/dl）的发生率仅为 2%。 <6>氮质血症</6>与治疗时间或血清<3>妥布霉素</3>浓度无关。这种抗生素方案对这些患者显示出治疗效果和可接受的<24>肾毒性</24>。", "revised": true}
{"doc_key": "733189", "sentences": [["Bilateral", "retinal", "artery", "and", "choriocapillaris", "occlusion", "following", "the", "injection", "of", "long", "-", "acting", "corticosteroid", "suspensions", "in", "combination", "with", "other", "drugs", ":", "I", ".", "Clinical", "studies", ".", "Two", "well", "-", "documented", "cases", "of", "bilateral", "retinal", "artery", "and", "choriocapillaris", "occlusions", "with", "blindness", "following", "head", "and", "neck", "soft", "-", "tissue", "injection", "with", "methylprednisolone", "acetate", "in", "combination", "with", "lidocaine", ",", "epinephrine", ",", "or", "penicillin", "are", "reported", ".", "One", "case", "had", "only", "a", "unilateral", "injection", ".", "The", "acute", "observations", "included", "hazy", "sensorium", ",", "superior", "gaze", "palsy", ",", "pupillary", "abnormalities", ",", "and", "conjunctival", "hemorrhages", "with", "edema", ".", "Follow", "-", "up", "changes", "showed", "marked", "visual", "loss", ",", "constricted", "visual", "fields", ",", "optic", "nerve", "pallor", ",", "vascular", "attenuation", ",", "and", "chorioretinal", "atrophy", ".", "The", "literature", "is", "reviewed", ",", "and", "possible", "causes", "are", "discussed", "."]], "ner": [[[49, 50, "Chemical"], [1, 5, "Disease"], [33, 37, "Disease"], [13, 13, "Chemical"], [54, 54, "Chemical"], [56, 56, "Chemical"], [59, 59, "Chemical"], [39, 39, "Disease"], [80, 80, "Disease"], [82, 83, "Disease"], [87, 87, "Disease"], [89, 89, "Disease"], [97, 98, "Disease"], [112, 113, "Disease"]]], "relations": [[[49, 50, 1, 5, "CID"], [49, 50, 33, 37, "CID"]]], "clusters": [], "translated": "注射长效<3>皮质类固醇</3>混悬液联合其他药物后双侧<1>视网膜动脉和脉络膜毛细血管闭塞</1>：I.临床研究。两例记录完备的双侧<2>视网膜动脉和脉络膜毛细血管阻塞</2>伴有<7>失明</7>的头颈部软组织注射<0>醋酸甲泼尼龙</0>与<4>利多卡因</4>、<5>肾上腺素</5>或<6>青霉素</6>均有报道。1例仅单侧注射。急性观察包括模糊感觉、上凝视<8>麻痹</8>、<9>瞳孔异常</9>和结膜<10>出血</10>伴有<11>水肿</11>。随访变化显示显着<12>视力丧失</12>、视野缩小、视神经苍白、血管变细和<13>脉络膜视网膜萎缩</13>。回顾了文献，并讨论了可能的原因。", "revised": true}
{"doc_key": "1117341", "sentences": [["Hyperglycemic", "effect", "of", "amino", "compounds", "structurally", "related", "to", "caproate", "in", "rats", ".", "The", "chronic", "feeding", "of", "small", "amounts", "(", "0", ".", "3", "-", "3", "%", "of", "diet", "weight", ")", "of", "certain", "amino", "derivatives", "of", "caproate", "resulted", "in", "hyperglycemia", ",", "an", "elevated", "glucose", "tolerance", "curve", "and", ",", "occasionally", ",", "glucosuria", ".", "Effective", "compounds", "included", "norleucine", ",", "norvaline", ",", "glutamate", ",", "epsilon", "-", "aminocaproate", ",", "methionine", ",", "and", "leucine", "."]], "ner": [[[3, 3, "Chemical"], [31, 31, "Chemical"], [0, 0, "Disease"], [37, 37, "Disease"], [8, 8, "Chemical"], [34, 34, "Chemical"], [41, 41, "Chemical"], [57, 57, "Chemical"], [63, 63, "Chemical"], [48, 48, "Disease"]]], "relations": [[[3, 3, 0, 0, "CID"], [3, 3, 37, 37, "CID"], [31, 31, 0, 0, "CID"], [31, 31, 37, 37, "CID"]]], "clusters": [], "translated": "与<4>己酸盐</4>结构相关的<0>氨基</0>化合物对大鼠<2>高血糖</2>的影响。长期少量（0.3-3%的饮食重量）的某些<1>氨基</1>衍生物<5>己酸盐</5>导致<3>高血糖</3>、<6>葡萄糖</6>耐受曲线升高，偶尔出现<9>糖尿</9>。有效化合物包括正诺白氨酸、正缬氨酸、<7>谷氨酸</7>、ε-氨基己酸盐、<8>蛋氨酸</8>和正亮氨酸。", "revised": true}
{"doc_key": "895432", "sentences": [["Effects", "of", "exercise", "on", "the", "severity", "of", "isoproterenol", "-", "induced", "myocardial", "infarction", ".", "The", "effect", "of", "exercise", "on", "the", "severity", "of", "isoproterenol", "-", "induced", "myocardial", "infarction", "was", "studied", "in", "male", "rats", ".", "Ninety", "-", "three", "rats", "were", "randomly", "divided", "into", "three", "groups", ".", "The", "exercise", "-", "isoproterenol", "(", "E", "-", "1", ")", "and", "exercise", "control", "(", "EC", ")", "groups", "exercised", "daily", "for", "thirty", "days", "on", "a", "treadmill", "at", "1", "mph", ",", "2", "%", "grade", "while", "animals", "of", "the", "sedentary", "-", "isoproterenol", "(", "S", "-", "I", ")", "group", "remained", "sedentary", ".", "Eight", "animals", "were", "assigned", "to", "the", "sedentary", "control", "(", "SC", ")", "group", "which", "remained", "sedentary", "throughout", "the", "experimental", "period", ".", "Forty", "-", "eight", "hours", "after", "the", "final", "exercise", "period", ",", "S", "-", "I", "and", "E", "-", "I", "animals", "received", "a", "single", "subcutaneous", "injection", "of", "isoproterenol", "(", "250", "mg", "/", "kg", "body", "weight", ")", ".", "Animals", "of", "the", "S", "-", "I", "group", "exhibited", "significantly", "(", "Pp", "less", "than", "0", ".", "05", ")", "greater", "mortality", "from", "the", "effects", "of", "isoproterenol", "than", "animals", "of", "the", "E", "-", "I", "group", ".", "Serum", "CPK", "activity", "for", "E", "-", "I", "animals", "was", "significantly", "(", "p", "less", "than", "0", ".", "05", ")", "greater", "than", "for", "animals", "in", "the", "S", "-", "I", "and", "EC", "groups", "twenty", "hours", "following", "isoproterenol", "injection", ".", "No", "statistically", "significant", "differences", "were", "observed", "between", "the", "two", "isoproterenol", "treated", "groups", "for", "severity", "of", "the", "induced", "lesions", ",", "changes", "in", "heart", "weight", ",", "or", "heart", "weight", "to", "body", "weight", "ratios", ".", "The", "results", "indicated", "that", "exercise", "reduced", "the", "mortality", "associated", "with", "the", "effects", "of", "large", "dosages", "of", "isoproterenol", "but", "had", "little", "on", "the", "severity", "of", "the", "infarction", "."]], "ner": [[[7, 7, "Chemical"], [21, 21, "Chemical"], [46, 46, "Chemical"], [80, 80, "Chemical"], [134, 134, "Chemical"], [167, 167, "Chemical"], [210, 210, "Chemical"], [222, 222, "Chemical"], [261, 261, "Chemical"], [10, 11, "Disease"], [24, 25, "Disease"], [270, 270, "Disease"]]], "relations": [[[7, 7, 10, 11, "CID"], [7, 7, 24, 25, "CID"], [21, 21, 10, 11, "CID"], [21, 21, 24, 25, "CID"], [46, 46, 10, 11, "CID"], [46, 46, 24, 25, "CID"], [80, 80, 10, 11, "CID"], [80, 80, 24, 25, "CID"], [134, 134, 10, 11, "CID"], [134, 134, 24, 25, "CID"], [167, 167, 10, 11, "CID"], [167, 167, 24, 25, "CID"], [210, 210, 10, 11, "CID"], [210, 210, 24, 25, "CID"], [222, 222, 10, 11, "CID"], [222, 222, 24, 25, "CID"], [261, 261, 10, 11, "CID"], [261, 261, 24, 25, "CID"]]], "clusters": [], "translated": "运动对<0>异丙肾上腺素</0>诱发<9>心肌梗死</9>严重程度的影响。在雄性大鼠中研究了运动对<1>异丙肾上腺素</1>诱发的<10>心肌梗死</10>严重程度的影响。93只大鼠随机分为三组。运动-<2>异丙肾上腺素</2> (E-1)和运动控制(EC)组每天在跑步机上以1 mph、2 %等级每天运动30天，而久坐不动的动物-<3>异丙肾上腺素</3>(S-I)组保持久坐不动。八只动物被分配到久坐不动的对照组(SC)，该组在整个实验期间都保持久坐不动。最后一次运动后48小时，S-I和E-I动物接受单次皮下注射<4>异丙肾上腺素</4> (250 mg/kg体重)。由于<5>异丙肾上腺素</5>的作用，S-I组动物的死亡率显着高于E-I组动物(Pp小于0.05)。在 <6>异丙肾上腺素</6>注射后二十小时，E-I组动物的血清CPK活性显着(p小于0.05)高于S-I和EC组动物。两个<7>异丙肾上腺素</7>治疗组在诱发损伤的严重程度、心脏重量的变化或心脏重量与体重的比率方面没有观察到统计学上的显着差异。结果表明，运动降低了与大剂量<8>异丙肾上腺素</8>相关的死亡率，但对<11>梗死的严重程度影响不大</11>。", "revised": true}
{"doc_key": "946593", "sentences": [["Paraplegia", "following", "intrathecal", "methotrexate", ":", "report", "of", "a", "case", "and", "review", "of", "the", "literature", ".", "A", "patient", "who", "developed", "paraplegia", "following", "the", "intrathecal", "instillation", "of", "methotrexate", "is", "discribed", ".", "The", "ten", "previously", "reported", "cases", "of", "this", "unusual", "complication", "are", "reviewed", ".", "The", "following", "factors", "appear", "to", "predispose", "to", "the", "development", "of", "this", "complication", ":", "abnormal", "cerebrospinal", "dynamics", "related", "to", "the", "presence", "of", "central", "nervous", "system", "leukemia", ",", "and", "epidural", "cerebrospinal", "leakage", ";", "elevated", "cerebrospinal", "fluid", "methothexate", "concentration", "related", "to", "abnormal", "cerebrospinal", "fluid", "dynamics", "and", "to", "inappropriately", "high", "methotrexate", "doses", "based", "on", "body", "surface", "area", "calculations", "in", "older", "children", "and", "adults", ";", "the", "presence", "of", "neurotoxic", "preservatives", "in", "commercially", "available", "methotrexate", "preparations", "and", "diluents", ";", "and", "the", "use", "of", "methotrexate", "diluents", "of", "unphysiologic", "pH", ",", "ionic", "content", "and", "osmolarity", ".", "The", "role", "of", "methotrexate", "contaminants", ",", "local", "folate", "deficiency", ",", "and", "cranial", "irradiation", "in", "the", "pathogenesis", "of", "intrathecal", "methotrexate", "toxicity", "is", "unclear", ".", "The", "incidence", "of", "neurotoxicity", "may", "be", "reduced", "by", "employing", "lower", "doses", "of", "methotrexate", "in", "the", "presence", "of", "central", "nervous", "system", "leukemia", ",", "in", "older", "children", "and", "adults", ",", "and", "in", "the", "presence", "of", "epidural", "leakage", ".", "Only", "preservative", "-", "free", "methotrexate", "in", "Elliott", "'s", "B", "Solution", "at", "a", "concentration", "of", "not", "more", "than", "1", "mg", "/", "ml", "should", "be", "used", "for", "intrathecal", "administration", ".", "Periodic", "monitoring", "of", "cerebruspinal", "fluid", "methotrexate", "levels", "may", "be", "predictive", "of", "the", "development", "of", "serious", "neurotoxicity", "."]], "ner": [[[3, 3, "Chemical"], [25, 25, "Chemical"], [75, 75, "Chemical"], [87, 87, "Chemical"], [109, 109, "Chemical"], [118, 118, "Chemical"], [132, 132, "Chemical"], [147, 147, "Chemical"], [164, 164, "Chemical"], [192, 192, "Chemical"], [221, 221, "Chemical"], [0, 0, "Disease"], [19, 19, "Disease"], [62, 65, "Disease"], [169, 172, "Disease"], [104, 104, "Disease"], [155, 155, "Disease"], [231, 231, "Disease"], [136, 137, "Disease"], [148, 148, "Disease"]]], "relations": [[[3, 3, 0, 0, "CID"], [3, 3, 19, 19, "CID"], [25, 25, 0, 0, "CID"], [25, 25, 19, 19, "CID"], [75, 75, 0, 0, "CID"], [75, 75, 19, 19, "CID"], [87, 87, 0, 0, "CID"], [87, 87, 19, 19, "CID"], [109, 109, 0, 0, "CID"], [109, 109, 19, 19, "CID"], [118, 118, 0, 0, "CID"], [118, 118, 19, 19, "CID"], [132, 132, 0, 0, "CID"], [132, 132, 19, 19, "CID"], [147, 147, 0, 0, "CID"], [147, 147, 19, 19, "CID"], [164, 164, 0, 0, "CID"], [164, 164, 19, 19, "CID"], [192, 192, 0, 0, "CID"], [192, 192, 19, 19, "CID"], [221, 221, 0, 0, "CID"], [221, 221, 19, 19, "CID"]]], "clusters": [], "translated": " <11>截瘫</11>鞘内注射<0>甲氨蝶呤</0>后：病例报告和文献复习。描述了一名在鞘内滴注<1>甲氨蝶呤</1>后出现<12>截瘫</12>的患者。回顾了先前报告的十例这种不寻常的并发症。以下因素似乎易导致这种并发症的发生: 与<13>中枢神经系统白血病</13>相关的脑脊髓动力学异常，以及硬膜外脑脊髓漏；脑脊液<2>甲氨蝶呤</2>浓度升高与脑脊液动力学异常有关，并且根据年龄较大的儿童和成人的体表面积计算，与不适当的高<3>甲氨蝶呤</3>剂量有关；市售<4>甲氨蝶呤</4>制剂和稀释剂中的<15>神经毒性</15>防腐剂的存在；以及使用非生理pH值、离子含量和渗透压的<5>甲氨蝶呤</5>稀释剂。<6>甲氨蝶呤</6>污染物、局部<18>叶酸缺乏</18>和颅内照射在鞘内注射<7>甲氨蝶呤</7><19>毒性</19>中的作用尚不清楚。在存在<14>中枢神经系统白血病</14>、年龄较大的儿童和成人中，使用较低剂量的<8>甲氨蝶呤</8>可降低<16>神经毒性</16>的发生率，以及存在硬膜外渗漏。只有浓度不超过 1mg/ml 的Elliott B溶液中不含防腐剂的<9>甲氨蝶呤</9>才可用于鞘内给药。定期监测脑脊液<10>甲氨蝶呤</10>水平可预测严重<17>神经毒性</17>的发展。", "revised": true}
{"doc_key": "1289188", "sentences": [["Acute", "renal", "failure", "occurring", "during", "intravenous", "desferrioxamine", "therapy", ":", "recovery", "after", "haemodialysis", ".", "A", "patient", "with", "transfusion", "-", "dependent", "thalassemia", "was", "undergoing", "home", "intravenous", "desferrioxamine", "(", "DFX", ")", "treatment", "by", "means", "of", "a", "totally", "implanted", "system", "because", "of", "his", "poor", "compliance", "with", "the", "nightly", "subcutaneous", "therapy", ".", "Due", "to", "an", "accidental", "malfunctioning", "of", "the", "infusion", "pump", ",", "the", "patient", "was", "inadvertently", "administered", "a", "toxic", "dosage", "of", "the", "drug", "which", "caused", "renal", "insufficiency", ".", "Given", "the", "progressive", "deterioration", "of", "the", "symptoms", "and", "of", "the", "laboratory", "values", ",", "despite", "adequate", "medical", "treatment", ",", "a", "decision", "was", "made", "to", "introduce", "haemodialytical", "therapy", "in", "order", "to", "remove", "the", "drug", "and", "therapy", "reduce", "the", "nephrotoxicity", ".", "From", "the", "results", "obtained", ",", "haemodialysis", "can", "therefore", "be", "suggested", "as", "a", "useful", "therapy", "in", "rare", "cases", "of", "progressive", "acute", "renal", "failure", "caused", "by", "desferrioxamine", "."]], "ner": [[[6, 6, "Chemical"], [24, 24, "Chemical"], [26, 26, "Chemical"], [135, 135, "Chemical"], [70, 71, "Disease"], [0, 2, "Disease"], [130, 132, "Disease"], [19, 19, "Disease"], [109, 109, "Disease"]]], "relations": [[[6, 6, 70, 71, "CID"], [24, 24, 70, 71, "CID"], [26, 26, 70, 71, "CID"], [135, 135, 70, 71, "CID"]]], "clusters": [], "translated": "<5>急性肾功能衰竭</5>发生在静脉<0>去铁胺</0>治疗期间：血液透析后恢复。一名输血依赖型<7>地中海贫血</7>患者正在接受家庭内全植入系统的静脉注射<1>去铁胺</1>（<2>DFX</2>）治疗，因为夜间皮下注射治疗的依从性较差。由于输注泵的意外故障，患者意外接受了药物的有毒剂量，导致<4>肾功能不全</4>。考虑到症状和实验室值的进行性恶化，尽管进行了充分的药物治疗，还是决定采用血液透析疗法以去除药物并减轻<8>肾毒性</8>。因此，从获得的结果来看，血液透析可作为一种用于治疗由<3>去铁胺</3>引起的罕见的进行性<6>急性肾功能衰竭</6>的有用疗法。", "revised": true}
{"doc_key": "1280054", "sentences": [["Fatal", "myeloencephalopathy", "due", "to", "intrathecal", "vincristine", "administration", ".", "Vincristine", "was", "accidentally", "given", "intrathecally", "to", "a", "child", "with", "leukaemia", ",", "producing", "sensory", "and", "motor", "dysfunction", "followed", "by", "encephalopathy", "and", "death", ".", "Separate", "times", "for", "administering", "vincristine", "and", "intrathecal", "therapy", "is", "recommended", "."]], "ner": [[[5, 5, "Chemical"], [8, 8, "Chemical"], [34, 34, "Chemical"], [1, 1, "Disease"], [26, 26, "Disease"], [20, 23, "Disease"], [17, 17, "Disease"]]], "relations": [[[5, 5, 1, 1, "CID"], [5, 5, 26, 26, "CID"], [8, 8, 1, 1, "CID"], [8, 8, 26, 26, "CID"], [34, 34, 1, 1, "CID"], [34, 34, 26, 26, "CID"], [5, 5, 20, 23, "CID"], [8, 8, 20, 23, "CID"], [34, 34, 20, 23, "CID"]]], "clusters": [], "translated": "由于鞘内注射<0>长春新碱</0>引起的致命性<3>脊髓脑病</3>。<1>长春新碱</1>意外鞘内注射给一名<6>白血病</6>患儿，导致<5>感觉和运动功能障碍</5>，继而<4>脑病</4>死亡。推荐<2>长春新碱</2>给药和鞘内给药分开进行。", "revised": true}
{"doc_key": "1360900", "sentences": [["Ethacrynic", "acid", "-", "induced", "convulsions", "and", "brain", "neurotransmitters", "in", "mice", ".", "Intracerebroventricular", "injection", "of", "ethacrynic", "acid", "(", "50", "%", "convulsive", "dose", ";", "50", "micrograms", "/", "mouse", ")", "accelerated", "the", "synthesis", "/", "turnover", "of", "5", "-", "hydroxytryptamine", "(", "5", "-", "HT", ")", "but", "suppressed", "the", "synthesis", "of", "gamma", "-", "aminobutyric", "acid", "and", "acetylcholine", "in", "mouse", "brain", ".", "These", "effects", "were", "completely", "antagonized", "by", "pretreatment", "with", "a", "glutamate", "/", "N", "-", "methyl", "-", "D", "-", "aspartate", "antagonist", ",", "aminophosphonovaleric", "acid", ".", "In", "ethacrynic", "acid", "-", "induced", "convulsions", ",", "these", "neurotransmitter", "systems", "may", "be", "differentially", "modulated", ",", "probably", "through", "activation", "of", "glutaminergic", "neurons", "in", "the", "brain", "."]], "ner": [[[0, 1, "Chemical"], [14, 15, "Chemical"], [80, 81, "Chemical"], [4, 4, "Disease"], [19, 19, "Disease"], [84, 84, "Disease"], [33, 35, "Chemical"], [37, 39, "Chemical"], [46, 49, "Chemical"], [51, 51, "Chemical"], [65, 65, "Chemical"], [67, 73, "Chemical"]]], "relations": [[[0, 1, 4, 4, "CID"], [0, 1, 19, 19, "CID"], [0, 1, 84, 84, "CID"], [14, 15, 4, 4, "CID"], [14, 15, 19, 19, "CID"], [14, 15, 84, 84, "CID"], [80, 81, 4, 4, "CID"], [80, 81, 19, 19, "CID"], [80, 81, 84, 84, "CID"]]], "clusters": [], "translated": "<0>依他尼酸</0> - 诱导小鼠<3>惊厥</3>和脑神经递质。脑室内注射<1>依他尼酸</1>（50%<4>惊厥</4>剂量；50微克/小鼠）加速<6>5-羟色胺</6>（<7>5-HT</7>），但抑制小鼠脑内<8>γ-氨基丁酸</8>和<9>乙酰胆碱</9>的合成。这些作用被 <10>谷氨酸</10>/<11>N-甲基-D-天冬氨酸</11>拮抗剂氨基膦戊酸预处理完全拮抗。在<2>依他尼酸</2> 诱导的<5>抽搐</5>中，这些神经递质系统可能受到差异调节，可能是通过激活大脑中的谷氨酰胺能神经元。", "revised": true}
{"doc_key": "1395192", "sentences": [["Recurrent", "myocardial", "infarction", "in", "a", "postpartum", "patient", "receiving", "bromocriptine", ".", "Myocardial", "infarction", "in", "puerperium", "is", "infrequently", "reported", ".", "Spasm", ",", "coronary", "dissection", ",", "or", "atheromatous", "etiology", "has", "been", "described", ".", "Bromocriptine", "has", "been", "implicated", "in", "several", "previous", "case", "reports", "of", "myocardial", "infarction", "in", "the", "puerperium", ".", "Our", "case", "(", "including", "an", "inadvertent", "rechallenge", ")", "suggests", "such", "a", "relationship", ".", "Although", "generally", "regarded", "as", "\"", "safe", ",", "\"", "possible", "serious", "cardiac", "effects", "of", "bromocriptine", "should", "be", "acknowledged", "."]], "ner": [[[8, 8, "Chemical"], [30, 30, "Chemical"], [72, 72, "Chemical"], [1, 2, "Disease"], [10, 11, "Disease"], [40, 41, "Disease"], [18, 18, "Disease"]]], "relations": [[[8, 8, 1, 2, "CID"], [8, 8, 10, 11, "CID"], [8, 8, 40, 41, "CID"], [30, 30, 1, 2, "CID"], [30, 30, 10, 11, "CID"], [30, 30, 40, 41, "CID"], [72, 72, 1, 2, "CID"], [72, 72, 10, 11, "CID"], [72, 72, 40, 41, "CID"]]], "clusters": [], "translated": "接受<0>溴隐亭</0>治疗的产后患者复发性<3>心肌梗死</3>。 <4>产褥期心肌梗塞</4>罕见报道。 <6>痉挛</6>、冠状动脉夹层或动脉粥样硬化的病因已有描述。<1>溴隐亭</1>与之前的几例产褥期<5>心肌梗死</5>病例报告有关。我们的案例（包括无意中的重新质疑）表明了这种关系。尽管通常被认为是“安全的”，但应该承认<2>溴隐亭</2>可能对心脏产生严重影响。", "revised": true}
{"doc_key": "1280707", "sentences": [["Progesterone", "potentiation", "of", "bupivacaine", "arrhythmogenicity", "in", "pentobarbital", "-", "anesthetized", "rats", "and", "beating", "rat", "heart", "cell", "cultures", ".", "The", "effects", "of", "progesterone", "treatment", "on", "bupivacaine", "arrhythmogenicity", "in", "beating", "rat", "heart", "myocyte", "cultures", "and", "on", "anesthetized", "rats", "were", "determined", ".", "After", "determining", "the", "bupivacaine", "AD50", "(", "the", "concentration", "of", "bupivacaine", "that", "caused", "50", "%", "of", "all", "beating", "rat", "heart", "myocyte", "cultures", "to", "become", "arrhythmic", ")", ",", "we", "determined", "the", "effect", "of", "1", "-", "hour", "progesterone", "HCl", "exposure", "on", "myocyte", "contractile", "rhythm", ".", "Each", "concentration", "of", "progesterone", "(", "6", ".", "25", ",", "12", ".", "5", ",", "25", ",", "and", "50", "micrograms", "/", "ml", ")", "caused", "a", "significant", "and", "concentration", "-", "dependent", "reduction", "in", "the", "AD50", "for", "bupivacaine", ".", "Estradiol", "treatment", "also", "increased", "the", "arrhythmogenicity", "of", "bupivacaine", "in", "myocyte", "cultures", ",", "but", "was", "only", "one", "fourth", "as", "potent", "as", "progesterone", ".", "Neither", "progesterone", "nor", "estradiol", "effects", "on", "bupivacaine", "arrhythmogenicity", "were", "potentiated", "by", "epinephrine", ".", "Chronic", "progesterone", "pretreatment", "(", "5", "mg", "/", "kg", "/", "day", "for", "21", "days", ")", "caused", "a", "significant", "increase", "in", "bupivacaine", "arrhythmogenicity", "in", "intact", "pentobarbital", "-", "anesthetized", "rats", ".", "There", "was", "a", "significant", "decrease", "in", "the", "time", "to", "onset", "of", "arrhythmia", "as", "compared", "with", "control", "nonprogesterone", "-", "treated", "rats", "(", "6", ".", "2", "+", "/", "-", "1", ".", "3", "vs", ".", "30", ".", "8", "+", "/", "-", "2", ".", "5", "min", ",", "mean", "+", "/", "-", "SE", ")", ".", "The", "results", "of", "this", "study", "indicate", "that", "progesterone", "can", "potentiate", "bupivacaine", "arrhythmogenicity", "both", "in", "vivo", "and", "in", "vitro", ".", "Potentiation", "of", "bupivacaine", "arrhythmia", "in", "myocyte", "cultures", "suggests", "that", "this", "effect", "is", "at", "least", "partly", "mediated", "at", "the", "myocyte", "level", "."]], "ner": [[[0, 0, "Chemical"], [20, 20, "Chemical"], [72, 72, "Chemical"], [83, 83, "Chemical"], [135, 135, "Chemical"], [138, 138, "Chemical"], [151, 151, "Chemical"], [235, 235, "Chemical"], [61, 61, "Disease"], [189, 189, "Disease"], [250, 250, "Disease"], [3, 3, "Chemical"], [23, 23, "Chemical"], [41, 41, "Chemical"], [47, 47, "Chemical"], [113, 113, "Chemical"], [122, 122, "Chemical"], [143, 143, "Chemical"], [169, 169, "Chemical"], [238, 238, "Chemical"], [249, 249, "Chemical"], [115, 115, "Chemical"], [140, 140, "Chemical"], [6, 6, "Chemical"], [173, 173, "Chemical"], [73, 73, "Chemical"], [148, 148, "Chemical"]]], "relations": [[[0, 0, 61, 61, "CID"], [0, 0, 189, 189, "CID"], [0, 0, 250, 250, "CID"], [20, 20, 61, 61, "CID"], [20, 20, 189, 189, "CID"], [20, 20, 250, 250, "CID"], [72, 72, 61, 61, "CID"], [72, 72, 189, 189, "CID"], [72, 72, 250, 250, "CID"], [83, 83, 61, 61, "CID"], [83, 83, 189, 189, "CID"], [83, 83, 250, 250, "CID"], [135, 135, 61, 61, "CID"], [135, 135, 189, 189, "CID"], [135, 135, 250, 250, "CID"], [138, 138, 61, 61, "CID"], [138, 138, 189, 189, "CID"], [138, 138, 250, 250, "CID"], [151, 151, 61, 61, "CID"], [151, 151, 189, 189, "CID"], [151, 151, 250, 250, "CID"], [235, 235, 61, 61, "CID"], [235, 235, 189, 189, "CID"], [235, 235, 250, 250, "CID"], [3, 3, 61, 61, "CID"], [3, 3, 189, 189, "CID"], [3, 3, 250, 250, "CID"], [23, 23, 61, 61, "CID"], [23, 23, 189, 189, "CID"], [23, 23, 250, 250, "CID"], [41, 41, 61, 61, "CID"], [41, 41, 189, 189, "CID"], [41, 41, 250, 250, "CID"], [47, 47, 61, 61, "CID"], [47, 47, 189, 189, "CID"], [47, 47, 250, 250, "CID"], [113, 113, 61, 61, "CID"], [113, 113, 189, 189, "CID"], [113, 113, 250, 250, "CID"], [122, 122, 61, 61, "CID"], [122, 122, 189, 189, "CID"], [122, 122, 250, 250, "CID"], [143, 143, 61, 61, "CID"], [143, 143, 189, 189, "CID"], [143, 143, 250, 250, "CID"], [169, 169, 61, 61, "CID"], [169, 169, 189, 189, "CID"], [169, 169, 250, 250, "CID"], [238, 238, 61, 61, "CID"], [238, 238, 189, 189, "CID"], [238, 238, 250, 250, "CID"], [249, 249, 61, 61, "CID"], [249, 249, 189, 189, "CID"], [249, 249, 250, 250, "CID"], [115, 115, 61, 61, "CID"], [115, 115, 189, 189, "CID"], [115, 115, 250, 250, "CID"], [140, 140, 61, 61, "CID"], [140, 140, 189, 189, "CID"], [140, 140, 250, 250, "CID"]]], "clusters": [], "translated": "<0>黄体酮</0>增强<11>布比卡因</11>在<23>戊巴比妥</23>中的致心律失常性-麻醉大鼠和跳动的大鼠心脏细胞培养物。确定了<1>黄体酮</1>治疗对跳动大鼠心肌细胞培养物和麻醉大鼠的<12>布比卡因</12>致心律失常性的影响。在确定了<13>布比卡因</13>AD50（<14>布比卡因</14>的浓度导致50%所有跳动的大鼠心肌细胞培养物变得<8>心律失常</8>），我们确定了1小时<2>黄体酮</2><25>HCl</25>暴露对肌细胞收缩节律的影响。<3>黄体酮</3>的每个浓度（6.25、12.5、25和50微克/毫升）都会导致<15>布比卡因</15>的AD50浓度依赖性显着降低。<21>雌二醇</21>治疗还增加了肌细胞培养物中<16>布比卡因</16>的致心律失常性，但其效力仅为<4>黄体酮</4>的四分之一。<5>孕酮</5>和<22>雌二醇</22>对<17>布比卡因</17>致心律失常性的影响被<26>肾上腺素</26>增强。慢性<6>孕酮</6>预处理（5mg/千克/天，持续21天）导致<24>戊巴比妥</24>麻醉大鼠的<18>布比卡因</18>致心律失常性显着增加。与对照组非黄体酮治疗大鼠相比，<9>心律失常</9>发作时间显着减少（6.2+/-1.3对比30.8+/-2.5分钟，均值+/-标准误差）。本研究结果表明，<7>孕酮</7>可增强<19>布比卡因</19>在体内和体外的致心律失常性。<20>布比卡因</20><10>心律失常</10>在肌细胞培养物中的增强表明这种作用至少部分是在肌细胞水平上介导的。", "revised": true}
{"doc_key": "2983630", "sentences": [["Increased", "anxiogenic", "effects", "of", "caffeine", "in", "panic", "disorders", ".", "The", "effects", "of", "oral", "administration", "of", "caffeine", "(", "10", "mg", "/", "kg", ")", "on", "behavioral", "ratings", ",", "somatic", "symptoms", ",", "blood", "pressure", "and", "plasma", "levels", "of", "3", "-", "methoxy", "-", "4", "-", "hydroxyphenethyleneglycol", "(", "MHPG", ")", "and", "cortisol", "were", "determined", "in", "17", "healthy", "subjects", "and", "21", "patients", "meeting", "DSM", "-", "III", "criteria", "for", "agoraphobia", "with", "panic", "attacks", "or", "panic", "disorder", ".", "Caffeine", "produced", "significantly", "greater", "increases", "in", "subject", "-", "rated", "anxiety", ",", "nervousness", ",", "fear", ",", "nausea", ",", "palpitations", ",", "restlessness", ",", "and", "tremors", "in", "the", "patients", "compared", "with", "healthy", "subjects", ".", "In", "the", "patients", ",", "but", "not", "the", "healthy", "subjects", ",", "these", "symptoms", "were", "significantly", "correlated", "with", "plasma", "caffeine", "levels", ".", "Seventy", "-", "one", "percent", "of", "the", "patients", "reported", "that", "the", "behavioral", "effects", "of", "caffeine", "were", "similar", "to", "those", "experienced", "during", "panic", "attacks", ".", "Caffeine", "did", "not", "alter", "plasma", "MHPG", "levels", "in", "either", "the", "healthy", "subjects", "or", "patients", ".", "Caffeine", "increased", "plasma", "cortisol", "levels", "equally", "in", "the", "patient", "and", "healthy", "groups", ".", "Because", "caffeine", "is", "an", "adenosine", "receptor", "antagonist", ",", "these", "results", "suggest", "that", "some", "panic", "disorder", "patients", "may", "have", "abnormalities", "in", "neuronal", "systems", "involving", "adenosine", ".", "Patients", "with", "anxiety", "disorders", "may", "benefit", "by", "avoiding", "caffeine", "-", "containing", "foods", "and", "beverages", "."]], "ner": [[[4, 4, "Chemical"], [15, 15, "Chemical"], [70, 70, "Chemical"], [118, 118, "Chemical"], [134, 134, "Chemical"], [144, 144, "Chemical"], [159, 159, "Chemical"], [173, 173, "Chemical"], [205, 205, "Chemical"], [79, 79, "Disease"], [199, 200, "Disease"], [85, 85, "Disease"], [92, 92, "Disease"], [6, 7, "Disease"], [64, 65, "Disease"], [67, 68, "Disease"], [141, 142, "Disease"], [185, 186, "Disease"], [62, 62, "Disease"], [89, 89, "Disease"], [190, 193, "Disease"], [35, 41, "Chemical"], [43, 43, "Chemical"], [149, 149, "Chemical"], [46, 46, "Chemical"], [162, 162, "Chemical"], [176, 176, "Chemical"], [195, 195, "Chemical"]]], "relations": [[[4, 4, 79, 79, "CID"], [4, 4, 199, 200, "CID"], [15, 15, 79, 79, "CID"], [15, 15, 199, 200, "CID"], [70, 70, 79, 79, "CID"], [70, 70, 199, 200, "CID"], [118, 118, 79, 79, "CID"], [118, 118, 199, 200, "CID"], [134, 134, 79, 79, "CID"], [134, 134, 199, 200, "CID"], [144, 144, 79, 79, "CID"], [144, 144, 199, 200, "CID"], [159, 159, 79, 79, "CID"], [159, 159, 199, 200, "CID"], [173, 173, 79, 79, "CID"], [173, 173, 199, 200, "CID"], [205, 205, 79, 79, "CID"], [205, 205, 199, 200, "CID"], [4, 4, 85, 85, "CID"], [15, 15, 85, 85, "CID"], [70, 70, 85, 85, "CID"], [118, 118, 85, 85, "CID"], [134, 134, 85, 85, "CID"], [144, 144, 85, 85, "CID"], [159, 159, 85, 85, "CID"], [173, 173, 85, 85, "CID"], [205, 205, 85, 85, "CID"], [4, 4, 92, 92, "CID"], [15, 15, 92, 92, "CID"], [70, 70, 92, 92, "CID"], [118, 118, 92, 92, "CID"], [134, 134, 92, 92, "CID"], [144, 144, 92, 92, "CID"], [159, 159, 92, 92, "CID"], [173, 173, 92, 92, "CID"], [205, 205, 92, 92, "CID"]]], "clusters": [], "translated": "<0>咖啡因</0>对<13>恐慌症</13>的焦虑作用增加。口服<1>咖啡因</1>（10 mg / kg）对行为评分、躯体症状、血压和<21>3-甲氧基-4-羟基苯乙二醇</21>（<22>MHPG</22>）和<24>皮质醇</24>在17名健康受试者和21名符合DSM-III标准的<18>广场恐惧症</18>伴有<14>惊恐发作</14>或<15>恐慌症</15>中进行了测定。 <2>咖啡因</2>产生的<9>焦虑</9>、紧张、<11>恶心</11>、心悸、<12>震颤</12>、<19>烦躁</19>等症状在患者中显著增加，相较于健康受试者。在患者中，而非健康受试者，这些症状与血浆<3>咖啡因</3>水平显著相关。百分之七十一的患者报告说，<4>咖啡因</4>的行为影响与<16>惊恐发作</16>期间体验到的相似。在健康受试者和患者中，<5>咖啡因</5>不会改变血浆<23>MHPG</23>水平。患者和健康组中，<6>咖啡因</6>将血浆<25>皮质醇</25>水平同等增加。这些结果表明，因为<7>咖啡因</7>是<26>腺苷</26>受体拮抗剂，<17>恐慌症</17>患者中可能存在涉及<27>腺苷</27>的<20>神经系统异常</20>。患有<10>焦虑症</10>的患者可能因避免含有<8>咖啡因</8>的食品和饮料而受益。", "revised": true}
{"doc_key": "146391", "sentences": [["Pure", "red", "cell", "aplasia", ",", "toxic", "dermatitis", "and", "lymphadenopathy", "in", "a", "patient", "taking", "diphenylhydantoin", ".", "A", "patient", "taking", "diphenylhydantoin", "for", "3", "weeks", "developed", "a", "generalized", "skin", "rash", ",", "lymphadenopathy", "and", "pure", "red", "cell", "aplasia", ".", "After", "withdrawal", "of", "the", "pharmacon", "all", "symptoms", "disappeared", "spontaneously", ".", "Skin", "rash", "is", "a", "well", "-", "known", "complication", "of", "diphenylhydantoin", "treatment", "as", "is", "benign", "and", "malignant", "lymphadenopathy", ".", "Pure", "red", "cell", "aplasia", "associated", "with", "diphenylhydantoin", "medication", "has", "been", "reported", "in", "3", "patients", ".", "The", "exact", "mechanism", "by", "which", "diphenylhydantoin", "exerts", "its", "toxic", "effects", "is", "not", "known", ".", "In", "this", "patient", "the", "time", "relation", "between", "the", "ingestion", "of", "diphenylhydantoin", "and", "the", "occurrence", "of", "the", "skin", "rash", ",", "lymphadenopathy", "and", "pure", "red", "cell", "aplasia", "is", "very", "suggestive", "of", "a", "direct", "connection", "."]], "ner": [[[13, 13, "Chemical"], [18, 18, "Chemical"], [54, 54, "Chemical"], [69, 69, "Chemical"], [83, 83, "Chemical"], [102, 102, "Chemical"], [0, 3, "Disease"], [30, 33, "Disease"], [63, 66, "Disease"], [113, 116, "Disease"], [5, 6, "Disease"], [8, 8, "Disease"], [28, 28, "Disease"], [61, 61, "Disease"], [111, 111, "Disease"], [25, 26, "Disease"], [45, 46, "Disease"], [108, 109, "Disease"]]], "relations": [[[13, 13, 0, 3, "CID"], [13, 13, 30, 33, "CID"], [13, 13, 63, 66, "CID"], [13, 13, 113, 116, "CID"], [18, 18, 0, 3, "CID"], [18, 18, 30, 33, "CID"], [18, 18, 63, 66, "CID"], [18, 18, 113, 116, "CID"], [54, 54, 0, 3, "CID"], [54, 54, 30, 33, "CID"], [54, 54, 63, 66, "CID"], [54, 54, 113, 116, "CID"], [69, 69, 0, 3, "CID"], [69, 69, 30, 33, "CID"], [69, 69, 63, 66, "CID"], [69, 69, 113, 116, "CID"], [83, 83, 0, 3, "CID"], [83, 83, 30, 33, "CID"], [83, 83, 63, 66, "CID"], [83, 83, 113, 116, "CID"], [102, 102, 0, 3, "CID"], [102, 102, 30, 33, "CID"], [102, 102, 63, 66, "CID"], [102, 102, 113, 116, "CID"], [13, 13, 5, 6, "CID"], [18, 18, 5, 6, "CID"], [54, 54, 5, 6, "CID"], [69, 69, 5, 6, "CID"], [83, 83, 5, 6, "CID"], [102, 102, 5, 6, "CID"], [13, 13, 8, 8, "CID"], [13, 13, 28, 28, "CID"], [13, 13, 61, 61, "CID"], [13, 13, 111, 111, "CID"], [18, 18, 8, 8, "CID"], [18, 18, 28, 28, "CID"], [18, 18, 61, 61, "CID"], [18, 18, 111, 111, "CID"], [54, 54, 8, 8, "CID"], [54, 54, 28, 28, "CID"], [54, 54, 61, 61, "CID"], [54, 54, 111, 111, "CID"], [69, 69, 8, 8, "CID"], [69, 69, 28, 28, "CID"], [69, 69, 61, 61, "CID"], [69, 69, 111, 111, "CID"], [83, 83, 8, 8, "CID"], [83, 83, 28, 28, "CID"], [83, 83, 61, 61, "CID"], [83, 83, 111, 111, "CID"], [102, 102, 8, 8, "CID"], [102, 102, 28, 28, "CID"], [102, 102, 61, 61, "CID"], [102, 102, 111, 111, "CID"]]], "clusters": [], "translated": "<6>纯红细胞再生障碍</6>，<10>中毒性皮炎</10>和<11>淋巴结肿大</11>患者服用<0>苯内酰脲</0>。一名服用<1>苯妥英钠</1> 3周的患者出现全身性<15>皮疹</15>、<12>淋巴结肿大</12>和<7>纯红细胞再生障碍</7>。停药后所有症状自然消失。 <16>皮疹</16>是<2>苯妥英钠</2>治疗的众所周知的并发症，良性和恶性<13>淋巴结肿大</13>也是如此。<8>纯红细胞再生障碍</8>与<3>苯妥英钠</3>药物相关已在3名患者中报告。<4>苯妥英钠</4>发挥其毒性作用的确切机制尚不清楚。在该患者中，摄入<5>苯妥英钠</5>与发生<17>皮疹</17>、<14>淋巴结肿大</14>和<9>纯红细胞再生障碍</9>非常暗示直接连接。", "revised": true}
{"doc_key": "1424076", "sentences": [["Syndrome", "of", "inappropriate", "secretion", "of", "antidiuretic", "hormone", "after", "infusional", "vincristine", ".", "A", "77", "-", "year", "-", "old", "woman", "with", "refractory", "multiple", "myeloma", "was", "treated", "with", "a", "4", "-", "day", "continuous", "intravenous", "infusion", "of", "vincristine", "and", "doxorubicin", "and", "4", "days", "of", "oral", "dexamethasone", ".", "Nine", "days", "after", "her", "second", "cycle", "she", "presented", "with", "lethargy", "and", "weakness", "associated", "with", "hyponatremia", ".", "Evaluation", "revealed", "the", "syndrome", "of", "inappropriate", "secretion", "of", "antidiuretic", "hormone", ",", "which", "was", "attributed", "to", "the", "vincristine", "infusion", ".", "After", "normal", "serum", "sodium", "levels", "returned", ",", "further", "doxorubicin", "and", "dexamethasone", "chemotherapy", "without", "vincristine", "did", "not", "produce", "this", "complication", "."]], "ner": [[[9, 9, "Chemical"], [33, 33, "Chemical"], [75, 75, "Chemical"], [91, 91, "Chemical"], [0, 6, "Disease"], [62, 68, "Disease"], [35, 35, "Chemical"], [86, 86, "Chemical"], [41, 41, "Chemical"], [88, 88, "Chemical"], [81, 81, "Chemical"], [20, 21, "Disease"], [52, 52, "Disease"], [54, 54, "Disease"], [57, 57, "Disease"]]], "relations": [[[9, 9, 0, 6, "CID"], [9, 9, 62, 68, "CID"], [33, 33, 0, 6, "CID"], [33, 33, 62, 68, "CID"], [75, 75, 0, 6, "CID"], [75, 75, 62, 68, "CID"], [91, 91, 0, 6, "CID"], [91, 91, 62, 68, "CID"]]], "clusters": [], "translated": "输注<0>长春新碱</0>后<4>抗利尿激素分泌不当综合征</4>。一位患有难治性<11>多发性骨髓瘤</11>的77 岁女性接受了为期4天的连续静脉输注<1>长春新碱</1>和<6>多柔比星</6>以及4天的口服<8>地塞米松</8>。在她的第二个周期后第9天，她出现了<12>嗜睡</12>和<13>虚弱</13>，并伴有<14>低钠血症</14>。评估显示<5>抗利尿激素异常分泌综合征</5>，与输注的<2>长春新碱</2>有关。血清<10>钠</10>水平恢复正常后，进一步的化疗，包括<7>多柔比星</7>和<9>地塞米松</9>，不含<3>长春新碱</3>，未产生该并发症。", "revised": true}
{"doc_key": "851038", "sentences": [["Kaliuretic", "effect", "of", "L", "-", "dopa", "treatment", "in", "parkinsonian", "patients", ".", "Hypokalemia", ",", "sometimes", "severe", ",", "was", "observed", "in", "some", "L", "-", "dopa", "-", "treated", "parkinsonian", "patients", ".", "The", "influence", "of", "L", "-", "dopa", "on", "the", "renal", "excretion", "of", "potassium", "was", "studied", "in", "3", "patients", "with", "hypokalemia", "and", "in", "5", "normokalemic", "patients", "by", "determination", "of", "renal", "plasma", "flow", ",", "glomerular", "filtration", "rate", ",", "plasma", "concentration", "of", "potassium", "and", "sodium", "as", "well", "as", "urinary", "excretion", "of", "potassium", ",", "sodium", "and", "aldosterone", ".", "L", "-", "Dopa", "intake", "was", "found", "to", "cause", "an", "increased", "excretion", "of", "potassium", ",", "and", "sometimes", "also", "of", "sodium", ",", "in", "the", "hypokalemic", "but", "not", "in", "the", "normokalemic", "patients", ".", "This", "effect", "on", "the", "renal", "function", "could", "be", "prohibited", "by", "the", "administration", "of", "a", "peripheral", "dopa", "decarbodylase", "inhibitor", ".", "It", "is", "not", "known", "why", "this", "effect", "occurred", "in", "some", "individuals", "but", "not", "in", "others", ",", "but", "our", "results", "indicate", "a", "correlation", "between", "aldosterone", "production", "and", "this", "renal", "effect", "of", "L", "-", "dopa", "."]], "ner": [[[3, 5, "Chemical"], [20, 22, "Chemical"], [31, 33, "Chemical"], [81, 83, "Chemical"], [160, 162, "Chemical"], [11, 11, "Disease"], [46, 46, "Disease"], [8, 8, "Disease"], [25, 25, "Disease"], [39, 39, "Chemical"], [66, 66, "Chemical"], [75, 75, "Chemical"], [93, 93, "Chemical"], [68, 68, "Chemical"], [77, 77, "Chemical"], [99, 99, "Chemical"], [79, 79, "Chemical"], [153, 153, "Chemical"]]], "relations": [[[3, 5, 11, 11, "CID"], [3, 5, 46, 46, "CID"], [20, 22, 11, 11, "CID"], [20, 22, 46, 46, "CID"], [31, 33, 11, 11, "CID"], [31, 33, 46, 46, "CID"], [81, 83, 11, 11, "CID"], [81, 83, 46, 46, "CID"], [160, 162, 11, 11, "CID"], [160, 162, 46, 46, "CID"]]], "clusters": [], "translated": "<0>左旋多巴</0>治疗<7>帕金森病</7>患者的利尿作用。<5>低钾血症</5>，有时很严重，在一些接受<1>左旋多巴</1>治疗的<8>帕金森病</8>患者中观察到。在3名<6>低钾血症</6>患者和5名正常血钾患者中研究了<2>左旋多巴</2>对<9>钾</9>肾排泄的影响，包括血流量、肾小球滤过率、<10>钾</10>和<13>钠</13>的血浆浓度，以及<11>钾</11>、<14>钠</14>和<16>醛固酮</16>的尿排泄。研究发现<3>左旋多巴</3>的摄入会导致<12>钾</12>的排泄增加，有时还会导致<15>钠</15>的排泄增加，但这种情况只出现在低钾血症患者中而正常血钾患者中没有。这种对肾功能的影响可以通过使用外周多巴脱碳酶抑制剂来抑制。尚不清楚为什么这种影响只发生在某些人身上而其他人却没有，但我们的结果表明 <17>醛固酮</17>的产生与<4> 左旋多巴 </4> 的肾效应之间存在相关性。", "revised": true}
{"doc_key": "1359137", "sentences": [["Neuroleptic", "-", "associated", "hyperprolactinemia", ".", "Can", "it", "be", "treated", "with", "bromocriptine", "?", "Six", "stable", "psychiatric", "outpatients", "with", "hyperprolactinemia", "and", "amenorrhea", "/", "oligomenorrhea", "associated", "with", "their", "neuroleptic", "medications", "were", "treated", "with", "bromocriptine", ".", "Daily", "dosages", "of", "5", "-", "10", "mg", "corrected", "the", "hyperprolactinemia", "and", "restored", "menstruation", "in", "four", "of", "the", "six", "patients", ".", "One", "woman", ",", "however", ",", "developed", "worsened", "psychiatric", "symptoms", "while", "taking", "bromocriptine", ",", "and", "it", "was", "discontinued", ".", "Thus", ",", "three", "of", "six", "patients", "had", "their", "menstrual", "irregularity", "successfully", "corrected", "with", "bromocriptine", ".", "This", "suggests", "that", "bromocriptine", "should", "be", "further", "evaluated", "as", "potential", "therapy", "for", "neuroleptic", "-", "associated", "hyperprolactinemia", "and", "amenorrhea", "/", "galactorrhea", "."]], "ner": [[[0, 0, "Chemical"], [25, 26, "Chemical"], [97, 97, "Chemical"], [3, 3, "Disease"], [17, 17, "Disease"], [41, 41, "Disease"], [100, 100, "Disease"], [19, 19, "Disease"], [102, 102, "Disease"], [21, 21, "Disease"], [10, 10, "Chemical"], [30, 30, "Chemical"], [63, 63, "Chemical"], [83, 83, "Chemical"], [88, 88, "Chemical"], [59, 60, "Disease"], [104, 104, "Disease"]]], "relations": [[[0, 0, 3, 3, "CID"], [0, 0, 17, 17, "CID"], [0, 0, 41, 41, "CID"], [0, 0, 100, 100, "CID"], [25, 26, 3, 3, "CID"], [25, 26, 17, 17, "CID"], [25, 26, 41, 41, "CID"], [25, 26, 100, 100, "CID"], [97, 97, 3, 3, "CID"], [97, 97, 17, 17, "CID"], [97, 97, 41, 41, "CID"], [97, 97, 100, 100, "CID"], [0, 0, 19, 19, "CID"], [0, 0, 102, 102, "CID"], [25, 26, 19, 19, "CID"], [25, 26, 102, 102, "CID"], [97, 97, 19, 19, "CID"], [97, 97, 102, 102, "CID"], [0, 0, 21, 21, "CID"], [25, 26, 21, 21, "CID"], [97, 97, 21, 21, "CID"], [10, 10, 59, 60, "CID"], [30, 30, 59, 60, "CID"], [63, 63, 59, 60, "CID"], [83, 83, 59, 60, "CID"], [88, 88, 59, 60, "CID"]]], "clusters": [], "translated": " <0>抗精神病药</0>-相关<3>高催乳素血症</3>。可以用<10>溴隐亭</10>治疗吗？六名稳定的精神科门诊患者<4>高催乳素血症</4>和<7>闭经</7>/<9>月经稀发</9>与他们的<1>抗精神病药</1>相关的<11>溴隐亭治疗</11>。每天服用5-10毫克的剂量可以纠正<5>高泌乳素血症</5>并使4名患者恢复月经。然而，一名妇女在服用<12>溴隐亭</12>期间出现了恶化的<15>精神症状</15>，因此停药。因此，六名患者中的三名使用<13>溴隐亭</13>成功纠正了月经不调。这表明<14>溴隐亭</14>应作为<2>抗精神病药</2>相关的<6>高催乳素血症</6>和<8>闭经</8>/<16>溢乳</16>的潜在疗法进行进一步评估。", "revised": true}
{"doc_key": "18341442", "sentences": [["Levetiracetam", "as", "an", "adjunct", "to", "phenobarbital", "treatment", "in", "cats", "with", "suspected", "idiopathic", "epilepsy", ".", "OBJECTIVE", ":", "To", "assess", "pharmacokinetics", ",", "efficacy", ",", "and", "tolerability", "of", "oral", "levetiracetam", "administered", "as", "an", "adjunct", "to", "phenobarbital", "treatment", "in", "cats", "with", "poorly", "controlled", "suspected", "idiopathic", "epilepsy", ".", "DESIGN", "-", "Open", "-", "label", ",", "noncomparative", "clinical", "trial", ".", "ANIMALS", ":", "12", "cats", "suspected", "to", "have", "idiopathic", "epilepsy", "that", "was", "poorly", "controlled", "with", "phenobarbital", "or", "that", "had", "unacceptable", "adverse", "effects", "when", "treated", "with", "phenobarbital", ".", "PROCEDURES", ":", "Cats", "were", "treated", "with", "levetiracetam", "(", "20", "mg", "/", "kg", "[", "9", ".", "1", "mg", "/", "lb", "]", ",", "PO", ",", "q", "8", "h", ")", ".", "After", "a", "minimum", "of", "1", "week", "of", "treatment", ",", "serum", "levetiracetam", "concentrations", "were", "measured", "before", "and", "2", ",", "4", ",", "and", "6", "hours", "after", "drug", "administration", ",", "and", "maximum", "and", "minimum", "serum", "concentrations", "and", "elimination", "half", "-", "life", "were", "calculated", ".", "Seizure", "frequencies", "before", "and", "after", "initiation", "of", "levetiracetam", "treatment", "were", "compared", ",", "and", "adverse", "effects", "were", "recorded", ".", "RESULTS", ":", "Median", "maximum", "serum", "levetiracetam", "concentration", "was", "25", ".", "5", "microg", "/", "mL", ",", "median", "minimum", "serum", "levetiracetam", "concentration", "was", "8", ".", "3", "microg", "/", "mL", ",", "and", "median", "elimination", "half", "-", "life", "was", "2", ".", "9", "hours", ".", "Median", "seizure", "frequency", "prior", "to", "treatment", "with", "levetiracetam", "(", "2", ".", "1", "seizures", "/", "mo", ")", "was", "significantly", "higher", "than", "median", "seizure", "frequency", "after", "initiation", "of", "levetiracetam", "treatment", "(", "0", ".", "42", "seizures", "/", "mo", ")", ",", "and", "7", "of", "10", "cats", "were", "classified", "as", "having", "responded", "to", "levetiracetam", "treatment", "(", "ie", ",", "reduction", "in", "seizure", "frequency", "of", ">", "or", "=", "50", "%", ")", ".", "Two", "cats", "had", "transient", "lethargy", "and", "inappetence", ".", "CONCLUSIONS", "AND", "CLINICAL", "RELEVANCE", ":", "Results", "suggested", "that", "levetiracetam", "is", "well", "tolerated", "in", "cats", "and", "may", "be", "useful", "as", "an", "adjunct", "to", "phenobarbital", "treatment", "in", "cats", "with", "idiopathic", "epilepsy", "."]], "ner": [[[0, 0, "Chemical"], [26, 26, "Chemical"], [85, 85, "Chemical"], [117, 117, "Chemical"], [155, 155, "Chemical"], [171, 171, "Chemical"], [184, 184, "Chemical"], [213, 213, "Chemical"], [232, 232, "Chemical"], [254, 254, "Chemical"], [287, 287, "Chemical"], [275, 275, "Disease"], [11, 12, "Disease"], [40, 41, "Disease"], [60, 61, "Disease"], [306, 307, "Disease"], [148, 148, "Disease"], [207, 207, "Disease"], [218, 218, "Disease"], [227, 227, "Disease"], [238, 238, "Disease"], [261, 261, "Disease"], [5, 5, "Chemical"], [32, 32, "Chemical"], [67, 67, "Chemical"], [77, 77, "Chemical"], [301, 301, "Chemical"]]], "relations": [[[0, 0, 275, 275, "CID"], [26, 26, 275, 275, "CID"], [85, 85, 275, 275, "CID"], [117, 117, 275, 275, "CID"], [155, 155, 275, 275, "CID"], [171, 171, 275, 275, "CID"], [184, 184, 275, 275, "CID"], [213, 213, 275, 275, "CID"], [232, 232, 275, 275, "CID"], [254, 254, 275, 275, "CID"], [287, 287, 275, 275, "CID"]]], "clusters": [], "translated": " <0>左乙拉西坦</0> 作为 <22>苯巴比妥</22> 治疗疑似<12>特发性癫痫</12>的猫的辅助药物。目的：评估口服<1>左乙拉西坦</1>作为<23>苯巴比妥</23>治疗控制不佳的疑似<13>特发性癫痫</13>猫的辅助治疗对药代动力学、疗效和耐受性的影响。设计——开放标签、非比较性临床试验。动物：12只疑似患有<14>特发性癫痫</14>的猫，这些猫用<24>苯巴比妥</24>控制不佳，或在用<25>苯巴比妥</25>治疗期间出现了无法接受的不良反应。程序：使用<2>左乙拉西坦</2>（20毫克/千克[9.1毫克/磅]，口服，每8小时1次）治疗猫。治疗至少1周后，在用药前和用药后2、4、6小时测定血清中的<3>左乙拉西坦</3>浓度，计算血清中的最大和最小浓度以及清除半衰期。比较<4>左乙拉西坦</4>治疗前和治疗后的<16>癫痫发作</16>频率，并记录不良反应。结果：最大血清<5>左乙拉西坦</5>浓度中位数为25.5微克/毫升，最小血清<6>左乙拉西坦</6>浓度中位数为8.3微克/毫升，消除半衰期中位数为2.9小时。治疗以<7>左乙拉西坦</7>开始前的中位<17>发作</17>频率（2.1<18>次发作</18>/月）明显高于<8>左乙拉西坦</8>治疗开始后的中位<19>发作</19>频率（0.42<20>次发作</20>/月），10只猫中有7只被认为对<9>左乙拉西坦</9>的治疗产生了反应（即<21>发作</21>的频率减少了>或=50%）。两只猫有短暂的<11>嗜睡</11>和食欲不振。结论和临床相关性：结果表明，在猫中，<10>左乙拉西坦</10>耐受性良好，可作为<26>苯巴比妥</26>治疗<15>特发性癫痫</15>的辅助药物。", "revised": true}
{"doc_key": "1556529", "sentences": [["Zidovudine", "-", "induced", "hepatitis", ".", "A", "case", "of", "acute", "hepatitis", "induced", "by", "zidovudine", "in", "a", "38", "-", "year", "-", "old", "patient", "with", "AIDS", "is", "presented", ".", "The", "mechanism", "whereby", "the", "hepatitis", "was", "induced", "is", "not", "known", ".", "However", ",", "the", "patient", "tolerated", "well", "an", "alternative", "reverse", "transcriptase", "inhibitor", ",", "2", "'", "3", "'", "dideoxyinosine", ".", "Physicians", "caring", "for", "patients", "with", "AIDS", "should", "be", "aware", "of", "this", "hitherto", "rarely", "reported", "complication", "."]], "ner": [[[0, 0, "Chemical"], [12, 12, "Chemical"], [3, 3, "Disease"], [9, 9, "Disease"], [30, 30, "Disease"], [22, 22, "Disease"], [60, 60, "Disease"], [49, 53, "Chemical"]]], "relations": [[[0, 0, 3, 3, "CID"], [0, 0, 9, 9, "CID"], [0, 0, 30, 30, "CID"], [12, 12, 3, 3, "CID"], [12, 12, 9, 9, "CID"], [12, 12, 30, 30, "CID"]]], "clusters": [], "translated": "<0>齐多夫定</0>-诱发<2>肝炎</2>。报告一例38岁<5>艾滋病</5>患者，因使用<1>齐多夫定</1>而诱发急性<3>肝炎</3>。目前尚不清楚导致<4>肝炎</4>发生的机制。然而，患者对另一种逆转录酶抑制剂<7>2'3'双脱氧肌苷</7>的耐受性良好。照顾<6>艾滋病</6>患者的医生应该意识到这一迄今为止很少报道的并发症。", "revised": true}
{"doc_key": "1563460", "sentences": [["Thoracic", "hematomyelia", "secondary", "to", "coumadin", "anticoagulant", "therapy", ":", "a", "case", "report", ".", "A", "case", "of", "thoracic", "hematomyelia", "secondary", "to", "anticoagulant", "therapy", "is", "presented", ".", "Clinical", "features", ",", "similar", "to", "2", "other", "previously", "reported", "cases", ",", "are", "discussed", ".", "A", "high", "index", "of", "suspicion", "may", "lead", "to", "a", "quick", "diagnostic", "procedure", "and", "successful", "decompressive", "surgery", "."]], "ner": [[[4, 4, "Chemical"], [0, 1, "Disease"], [15, 16, "Disease"]]], "relations": [[[4, 4, 0, 1, "CID"], [4, 4, 15, 16, "CID"]]], "clusters": [], "translated": "<1>胸腔积血</1><0>继发于香豆素</0>抗凝治疗：一例报告。报告一例继发于抗凝治疗的<2>胸腔脊髓血肿</2>。讨论了与之前报道的其他2例病例相似的临床特征。高度怀疑可能导致快速诊断程序和成功的减压手术。", "revised": true}
{"doc_key": "1449452", "sentences": [["Heart", "failure", ":", "to", "digitalise", "or", "not", "?", "The", "view", "against", ".", "Despite", "extensive", "clinical", "experience", "the", "role", "of", "digoxin", "is", "still", "not", "well", "defined", ".", "In", "patients", "with", "atrial", "fibrillation", "digoxin", "is", "beneficial", "for", "ventricular", "rate", "control", ".", "For", "patients", "in", "sinus", "rhythm", "and", "heart", "failure", "the", "situation", "is", "less", "clear", ".", "Digoxin", "has", "a", "narrow", "therapeutic", ":", "toxic", "ratio", "and", "concentrations", "are", "affected", "by", "a", "number", "of", "drugs", ".", "Also", ",", "digoxin", "has", "undesirable", "effects", "such", "as", "increasing", "peripheral", "resistance", "and", "myocardial", "demands", ",", "and", "causing", "arrhythmias", ".", "There", "is", "a", "paucity", "of", "data", "from", "well", "-", "designed", "trials", ".", "The", "trials", "that", "are", "available", "are", "generally", "small", "with", "limitations", "in", "design", "and", "these", "show", "variation", "in", "patient", "benefit", ".", "More", "convincing", "evidence", "is", "required", "showing", "that", "digoxin", "improves", "symptoms", "or", "exercise", "capacity", ".", "Furthermore", ",", "no", "trial", "has", "had", "sufficient", "power", "to", "evaluate", "mortality", ".", "Pooled", "analysis", "of", "the", "effects", "of", "other", "inotropic", "drugs", "shows", "an", "excess", "mortality", "and", "there", "is", "a", "possibility", "that", "digoxin", "may", "increase", "mortality", "after", "myocardial", "infarction", "(", "MI", ")", ".", "Angiotensin", "-", "converting", "enzyme", "(", "ACE", ")", "inhibitors", "should", "be", "used", "first", "as", "they", "are", "safer", ",", "do", "not", "require", "blood", "level", "monitoring", ",", "modify", "progression", "of", "disease", ",", "relieve", "symptoms", ",", "improve", "exercise", "tolerance", "and", "reduce", "mortality", ".", "Caution", "should", "be", "exercised", "in", "using", "digoxin", "until", "large", "mortality", "trials", "are", "completed", "showing", "either", "benefit", "or", "harm", ".", "Until", "then", "digoxin", "should", "be", "considered", "a", "third", "-", "line", "therapy", "."]], "ner": [[[19, 19, "Chemical"], [31, 31, "Chemical"], [53, 53, "Chemical"], [73, 73, "Chemical"], [129, 129, "Chemical"], [167, 167, "Chemical"], [223, 223, "Chemical"], [238, 238, "Chemical"], [88, 88, "Disease"], [0, 1, "Disease"], [45, 46, "Disease"], [178, 178, "Chemical"], [29, 30, "Disease"], [172, 173, "Disease"], [175, 175, "Disease"]]], "relations": [[[19, 19, 88, 88, "CID"], [31, 31, 88, 88, "CID"], [53, 53, 88, 88, "CID"], [73, 73, 88, 88, "CID"], [129, 129, 88, 88, "CID"], [167, 167, 88, 88, "CID"], [223, 223, 88, 88, "CID"], [238, 238, 88, 88, "CID"]]], "clusters": [], "translated": " <9>心力衰竭</9>：数字化与否？反对的观点。尽管有丰富的临床经验，<0>地高辛</0>的作用仍未明确。在<12>房颤</12>患者中，<1>地高辛</1>有利于控制心室率。对于窦性心律和<10>心力衰竭</10>的患者，情况不太清楚。<2> 地高辛 </2>具有狭窄的治疗：毒性比和浓度受许多药物的影响。此外，<3>地高辛</3>具有不良作用，例如增加外周阻力和心肌需求，并引起<8>心律失常</8>。来自设计良好的试验的数据很少。可用的试验通常规模较小，设计有局限性，而且这些试验显示出患者获益的差异。需要更有说服力的证据表明<4> 地高辛 </4>改善症状或运动能力。此外，没有任何试验具有足够的效力来评估死亡率。对其他正性肌力药物作用的汇总分析显示死亡率过高，<5>地高辛</5>可能会增加 <13>心肌梗死</13> ( <14>MI</14> ) 后的死亡率。 <11> 血管紧张素 </11>- 转换酶（ACE）抑制剂应该首先使用，因为它们更安全，不需要监测血药浓度，可以改变疾病的进展，缓解症状，提高运动耐量，降低死亡率。应谨慎使用<6> 地高辛 </6>，直到大型死亡率试验完成，显示其益处或危害。在那之前，<7>地高辛</7>应该被认为是一种三线疗法。", "revised": true}
{"doc_key": "448423", "sentences": [["Recurrent", "subarachnoid", "hemorrhage", "associated", "with", "aminocaproic", "acid", "therapy", "and", "acute", "renal", "artery", "thrombosis", ".", "Case", "report", ".", "Epsilon", "aminocaproic", "acid", "(", "EACA", ")", "has", "been", "used", "to", "prevent", "rebleeding", "in", "patients", "with", "subarachnoid", "hemorrhage", "(", "SAH", ")", ".", "Although", "this", "agent", "does", "decrease", "the", "frequency", "of", "rebleeding", ",", "several", "reports", "have", "described", "thrombotic", "complications", "of", "EACA", "therapy", ".", "These", "complications", "have", "included", "clinical", "deterioration", "and", "intracranial", "vascular", "thrombosis", "in", "patients", "with", "SAH", ",", "arteriolar", "and", "capillary", "fibrin", "thrombi", "in", "patients", "with", "fibrinolytic", "syndromes", "treated", "with", "EACA", ",", "or", "other", "thromboembolic", "phenomena", ".", "Since", "intravascular", "fibrin", "thrombi", "are", "often", "observed", "in", "patients", "with", "fibrinolytic", "disorders", ",", "EACA", "should", "not", "be", "implicated", "in", "the", "pathogenesis", "of", "fibrin", "thrombi", "in", "patients", "with", "disseminated", "intravascular", "coagulation", "or", "other", "\"", "consumption", "coagulopathies", ".", "\"", "This", "report", "describes", "subtotal", "infarction", "of", "the", "kidney", "due", "to", "thrombosis", "of", "a", "normal", "renal", "artery", ".", "This", "occlusion", "occurred", "after", "EACA", "therapy", "in", "a", "patient", "with", "SAH", "and", "histopathological", "documentation", "of", "recurrent", "SAH", ".", "The", "corresponding", "clinical", "event", "was", "characterized", "by", "marked", "hypertension", "and", "abrupt", "neurological", "deterioration", "."]], "ner": [[[17, 19, "Chemical"], [21, 21, "Chemical"], [55, 55, "Chemical"], [85, 85, "Chemical"], [105, 105, "Chemical"], [150, 150, "Chemical"], [1, 2, "Disease"], [32, 33, "Disease"], [35, 35, "Disease"], [71, 71, "Disease"], [156, 156, "Disease"], [162, 162, "Disease"], [9, 12, "Disease"], [139, 144, "Disease"], [52, 52, "Disease"], [77, 77, "Disease"], [95, 95, "Disease"], [115, 115, "Disease"], [65, 67, "Disease"], [172, 172, "Disease"], [5, 6, "Chemical"], [89, 90, "Disease"], [119, 121, "Disease"], [125, 126, "Disease"], [133, 133, "Disease"]]], "relations": [[[17, 19, 1, 2, "CID"], [17, 19, 32, 33, "CID"], [17, 19, 35, 35, "CID"], [17, 19, 71, 71, "CID"], [17, 19, 156, 156, "CID"], [17, 19, 162, 162, "CID"], [21, 21, 1, 2, "CID"], [21, 21, 32, 33, "CID"], [21, 21, 35, 35, "CID"], [21, 21, 71, 71, "CID"], [21, 21, 156, 156, "CID"], [21, 21, 162, 162, "CID"], [55, 55, 1, 2, "CID"], [55, 55, 32, 33, "CID"], [55, 55, 35, 35, "CID"], [55, 55, 71, 71, "CID"], [55, 55, 156, 156, "CID"], [55, 55, 162, 162, "CID"], [85, 85, 1, 2, "CID"], [85, 85, 32, 33, "CID"], [85, 85, 35, 35, "CID"], [85, 85, 71, 71, "CID"], [85, 85, 156, 156, "CID"], [85, 85, 162, 162, "CID"], [105, 105, 1, 2, "CID"], [105, 105, 32, 33, "CID"], [105, 105, 35, 35, "CID"], [105, 105, 71, 71, "CID"], [105, 105, 156, 156, "CID"], [105, 105, 162, 162, "CID"], [150, 150, 1, 2, "CID"], [150, 150, 32, 33, "CID"], [150, 150, 35, 35, "CID"], [150, 150, 71, 71, "CID"], [150, 150, 156, 156, "CID"], [150, 150, 162, 162, "CID"], [17, 19, 9, 12, "CID"], [17, 19, 139, 144, "CID"], [21, 21, 9, 12, "CID"], [21, 21, 139, 144, "CID"], [55, 55, 9, 12, "CID"], [55, 55, 139, 144, "CID"], [85, 85, 9, 12, "CID"], [85, 85, 139, 144, "CID"], [105, 105, 9, 12, "CID"], [105, 105, 139, 144, "CID"], [150, 150, 9, 12, "CID"], [150, 150, 139, 144, "CID"], [17, 19, 52, 52, "CID"], [17, 19, 77, 77, "CID"], [17, 19, 95, 95, "CID"], [17, 19, 115, 115, "CID"], [21, 21, 52, 52, "CID"], [21, 21, 77, 77, "CID"], [21, 21, 95, 95, "CID"], [21, 21, 115, 115, "CID"], [55, 55, 52, 52, "CID"], [55, 55, 77, 77, "CID"], [55, 55, 95, 95, "CID"], [55, 55, 115, 115, "CID"], [85, 85, 52, 52, "CID"], [85, 85, 77, 77, "CID"], [85, 85, 95, 95, "CID"], [85, 85, 115, 115, "CID"], [105, 105, 52, 52, "CID"], [105, 105, 77, 77, "CID"], [105, 105, 95, 95, "CID"], [105, 105, 115, 115, "CID"], [150, 150, 52, 52, "CID"], [150, 150, 77, 77, "CID"], [150, 150, 95, 95, "CID"], [150, 150, 115, 115, "CID"], [17, 19, 65, 67, "CID"], [21, 21, 65, 67, "CID"], [55, 55, 65, 67, "CID"], [85, 85, 65, 67, "CID"], [105, 105, 65, 67, "CID"], [150, 150, 65, 67, "CID"], [17, 19, 172, 172, "CID"], [21, 21, 172, 172, "CID"], [55, 55, 172, 172, "CID"], [85, 85, 172, 172, "CID"], [105, 105, 172, 172, "CID"], [150, 150, 172, 172, "CID"]]], "clusters": [], "translated": "与<20>氨基己酸</20>治疗和<12>急性肾动脉血栓形成</12>相关的复发性<6>蛛网膜下腔出血</6>。案例报告。 <0>epsilon氨基己酸</0>（<1>EACA</1>）已被用于预防<7>蛛网膜下腔出血</7>（<8>SAH</8>）患者的再出血。虽然该药物确实降低了再出血的频率，但一些报告描述了<2>EACA</2>治疗的<14>血栓形成</14>并发症。这些并发症包括<9>SAH</9>患者的临床恶化和<18>颅内血管血栓形成</18>，<15>纤溶综合征</15>患者的小动脉和毛细血管纤维蛋白<3>EACA</3>治疗后的血栓，或其他<21>血栓栓塞现象</21>。由于血管内纤维蛋白<16>血栓</16>经常在纤维蛋白溶解障碍患者中观察到，故<4>EACA</4>不应与<22>弥散性血管内凝血</22>或其他“<23>消耗性凝血病</23>”患者的纤维蛋白<17>血栓</17>的发病机制有关。该报告描述了由于<13>肾动脉血栓形成</13>导致的肾脏次全<24>梗死</24>。这种闭塞发生在<10>SAH</10>患者<5>EACA</5>治疗后，组织病理学证明患者存在复发性<11>SAH</11>。相应的临床事件的特征是明显的<19>高血压</19>和突然的神经功能恶化。", "revised": true}
{"doc_key": "1420650", "sentences": [["Asterixis", "induced", "by", "carbamazepine", "therapy", ".", "There", "are", "very", "few", "reports", "about", "asterixis", "as", "a", "side", "effect", "of", "treatment", "with", "psychopharmacologic", "agents", ".", "In", "this", "report", "we", "present", "four", "patients", "treated", "with", "a", "combination", "of", "different", "psychotropic", "drugs", ",", "in", "whom", "asterixis", "was", "triggered", "either", "by", "adding", "carbamazepine", "(", "CBZ", ")", "to", "a", "treatment", "regimen", ",", "or", "by", "increasing", "its", "dosage", ".", "Neither", "dosage", "nor", "serum", "levels", "of", "CBZ", "were", "in", "a", "higher", "range", ".", "We", "consider", "asterixis", "to", "be", "an", "easily", "overlooked", "sign", "of", "neurotoxicity", ",", "which", "may", "occur", "even", "at", "low", "or", "moderate", "dosage", "levels", ",", "if", "certain", "drugs", "as", "lithium", "or", "clozapine", "are", "used", "in", "combination", "with", "CBZ", "."]], "ner": [[[102, 102, "Chemical"], [0, 0, "Disease"], [12, 12, "Disease"], [41, 41, "Disease"], [77, 77, "Disease"], [104, 104, "Chemical"], [3, 3, "Chemical"], [47, 47, "Chemical"], [49, 49, "Chemical"], [68, 68, "Chemical"], [110, 110, "Chemical"], [85, 85, "Disease"]]], "relations": [[[102, 102, 0, 0, "CID"], [102, 102, 12, 12, "CID"], [102, 102, 41, 41, "CID"], [102, 102, 77, 77, "CID"], [104, 104, 0, 0, "CID"], [104, 104, 12, 12, "CID"], [104, 104, 41, 41, "CID"], [104, 104, 77, 77, "CID"]]], "clusters": [], "translated": " <1>扑翼样震颤</1>由<6>卡马西平</6>治疗引起。关于<2>扑翼样震颤</2>作为精神药理学药物治疗的副作用的报道非常少。在这份报告中，我们介绍了四名接受不同精神药物联合治疗的患者，其中<3>扑翼样震颤</3>是通过将<7>卡马西平</7> (<8>CBZ</8>)添加到一种治疗方案中或增加其剂量引起的。 <9>CBZ</9> 的剂量和血清水平均不在较高范围内。我们认为<4>扑翼样震颤</4>是一个容易被忽视的<11>神经毒性</11>征兆，如果某些药物，如<0>锂</0>或<5>氯氮平</5>与<10>CBZ</10>联合使用。", "revised": true}
{"doc_key": "9578276", "sentences": [["Ascending", "dose", "tolerance", "study", "of", "intramuscular", "carbetocin", "administered", "after", "normal", "vaginal", "birth", ".", "OBJECTIVE", ":", "To", "determine", "the", "maximum", "tolerated", "dose", "(", "MTD", ")", "of", "carbetocin", "(", "a", "long", "-", "acting", "synthetic", "analogue", "of", "oxytocin", ")", ",", "when", "administered", "immediately", "after", "vaginal", "delivery", "at", "term", ".", "MATERIALS", "AND", "METHODS", ":", "Carbetocin", "was", "given", "as", "an", "intramuscular", "injection", "immediately", "after", "the", "birth", "of", "the", "infant", "in", "45", "healthy", "women", "with", "normal", "singleton", "pregnancies", "who", "delivered", "vaginally", "at", "term", ".", "Dosage", "groups", "of", "15", ",", "30", ",", "50", ",", "75", ",", "100", ",", "125", ",", "150", ",", "175", "or", "200", "microg", "carbetocin", "were", "assigned", "to", "blocks", "of", "three", "women", "according", "to", "the", "continual", "reassessment", "method", "(", "CRM", ")", ".", "RESULTS", ":", "All", "dosage", "groups", "consisted", "of", "three", "women", ",", "except", "those", "with", "100", "microg", "(", "n", "=", "6", ")", "and", "200", "microg", "(", "n", "=", "18", ")", ".", "Recorded", "were", "dose", "-", "limiting", "adverse", "events", ":", "hyper", "-", "or", "hypotension", "(", "three", ")", ",", "severe", "abdominal", "pain", "(", "0", ")", ",", "vomiting", "(", "0", ")", "and", "retained", "placenta", "(", "four", ")", ".", "Serious", "adverse", "events", "occurred", "in", "seven", "women", ":", "six", "cases", "with", "blood", "loss", ">", "or", "=", "1000", "ml", ",", "four", "cases", "of", "manual", "placenta", "removal", ",", "five", "cases", "of", "additional", "oxytocics", "administration", "and", "five", "cases", "of", "blood", "transfusion", ".", "Maximum", "blood", "loss", "was", "greatest", "at", "the", "upper", "and", "lower", "dose", "levels", ",", "and", "lowest", "in", "the", "70", "-", "125", "microg", "dose", "range", ".", "Four", "out", "of", "six", "cases", "with", "blood", "loss", ">", "or", "=", "1000", "ml", "occurred", "in", "the", "200", "microg", "group", ".", "The", "majority", "of", "additional", "administration", "of", "oxytocics", "(", "4", "/", "5", ")", "and", "blood", "transfusion", "(", "3", "/", "5", ")", "occurred", "in", "the", "dose", "groups", "of", "200", "microg", ".", "All", "retained", "placentae", "were", "found", "in", "the", "group", "of", "200", "microg", ".", "CONCLUSION", ":", "The", "MTD", "was", "calculated", "to", "be", "at", "200", "microg", "carbetocin", "."]], "ner": [[[6, 6, "Chemical"], [25, 25, "Chemical"], [50, 50, "Chemical"], [99, 99, "Chemical"], [315, 315, "Chemical"], [154, 157, "Disease"], [163, 164, "Disease"], [169, 169, "Disease"], [174, 175, "Disease"], [191, 192, "Disease"], [220, 221, "Disease"], [249, 250, "Disease"], [34, 34, "Chemical"]]], "relations": [[[6, 6, 154, 157, "CID"], [25, 25, 154, 157, "CID"], [50, 50, 154, 157, "CID"], [99, 99, 154, 157, "CID"], [315, 315, 154, 157, "CID"], [6, 6, 163, 164, "CID"], [25, 25, 163, 164, "CID"], [50, 50, 163, 164, "CID"], [99, 99, 163, 164, "CID"], [315, 315, 163, 164, "CID"], [6, 6, 169, 169, "CID"], [25, 25, 169, 169, "CID"], [50, 50, 169, 169, "CID"], [99, 99, 169, 169, "CID"], [315, 315, 169, 169, "CID"], [6, 6, 174, 175, "CID"], [25, 25, 174, 175, "CID"], [50, 50, 174, 175, "CID"], [99, 99, 174, 175, "CID"], [315, 315, 174, 175, "CID"], [6, 6, 191, 192, "CID"], [6, 6, 220, 221, "CID"], [6, 6, 249, 250, "CID"], [25, 25, 191, 192, "CID"], [25, 25, 220, 221, "CID"], [25, 25, 249, 250, "CID"], [50, 50, 191, 192, "CID"], [50, 50, 220, 221, "CID"], [50, 50, 249, 250, "CID"], [99, 99, 191, 192, "CID"], [99, 99, 220, 221, "CID"], [99, 99, 249, 250, "CID"], [315, 315, 191, 192, "CID"], [315, 315, 220, 221, "CID"], [315, 315, 249, 250, "CID"]]], "clusters": [], "translated": "正常阴道分娩后肌肉注射<0>卡贝缩宫素</0>的递增剂量耐受性研究。目的：确定足月阴道分娩后立即服用<1>卡贝缩宫素</1>（<12>催产素</12>的长效合成类似物）的最大耐受剂量 (MTD)。材料和方法：<2>卡贝缩宫素</2>在婴儿出生后立即给予45名正常单胎妊娠且足月阴道分娩的健康女性进行肌肉注射。根据连续再评估方法 (CRM)，将15、30、50、75、100、125、150、175或200微克<3>卡贝缩宫素</3>的剂量组分配给三名女性。结果：除了服用100微克(n=6)和200微克(n=18)的女性外，所有剂量组均由三名女性组成。记录的是剂量限制性不良事件：<5>高血压或低血压</5>（三），严重<6>腹痛</6>（0），<7>呕吐</7>（0）和<8>胎盘滞留</8>（四）。7名妇女发生严重不良事件：6例<9>失血</9> ≥1000毫升，4例人工取出胎盘，5例额外给予催产剂和5例输血。最大<10>失血量</10>在高剂量和低剂量水平下最大，在70-125微克剂量范围内最低。<11>失血</11> ≥1000毫升的6例病例中有4例发生在200微克组。大多数额外施用催产剂 (4/5) 和输血 (3/5) 发生在200微克的剂量组中。所有胎盘残留均在200微克组中发现。结论：MTD计算为200微克<4>卡贝缩宫素</4>。", "revised": true}
{"doc_key": "1655018", "sentences": [["Hepatocellular", "carcinoma", "in", "Fanconi", "'s", "anemia", "treated", "with", "androgen", "and", "corticosteroid", ".", "The", "case", "of", "an", "11", "-", "year", "-", "old", "boy", "is", "reported", "who", "was", "known", "to", "have", "Fanconi", "'s", "anemia", "for", "3", "years", "and", "was", "treated", "with", "androgens", ",", "corticosteroids", "and", "transfusions", ".", "Two", "weeks", "before", "his", "death", "he", "was", "readmitted", "because", "of", "aplastic", "crisis", "with", "septicemia", "and", "marked", "abnormalities", "in", "liver", "function", "and", "died", "of", "hemorrhagic", "bronchopneumonia", ".", "At", "autopsy", "peliosis", "and", "multiple", "hepatic", "tumors", "were", "found", "which", "histologically", "proved", "to", "be", "well", "-", "differentiated", "hepatocellular", "carcinoma", ".", "This", "case", "contributes", "to", "the", "previous", "observations", "that", "non", "-", "metastasizing", "hepatic", "neoplasms", "and", "peliosis", "can", "develop", "in", "patients", "with", "androgen", "-", "and", "corticosteroid", "-", "treated", "Fanconi", "'s", "anemia", "."]], "ner": [[[8, 8, "Chemical"], [39, 39, "Chemical"], [111, 111, "Chemical"], [0, 1, "Disease"], [88, 89, "Disease"], [10, 10, "Chemical"], [41, 41, "Chemical"], [114, 114, "Chemical"], [73, 73, "Disease"], [105, 105, "Disease"], [3, 5, "Disease"], [29, 31, "Disease"], [117, 119, "Disease"], [58, 58, "Disease"], [68, 69, "Disease"], [76, 77, "Disease"], [102, 103, "Disease"]]], "relations": [[[8, 8, 0, 1, "CID"], [8, 8, 88, 89, "CID"], [39, 39, 0, 1, "CID"], [39, 39, 88, 89, "CID"], [111, 111, 0, 1, "CID"], [111, 111, 88, 89, "CID"], [10, 10, 0, 1, "CID"], [10, 10, 88, 89, "CID"], [41, 41, 0, 1, "CID"], [41, 41, 88, 89, "CID"], [114, 114, 0, 1, "CID"], [114, 114, 88, 89, "CID"], [8, 8, 73, 73, "CID"], [8, 8, 105, 105, "CID"], [39, 39, 73, 73, "CID"], [39, 39, 105, 105, "CID"], [111, 111, 73, 73, "CID"], [111, 111, 105, 105, "CID"], [10, 10, 73, 73, "CID"], [10, 10, 105, 105, "CID"], [41, 41, 73, 73, "CID"], [41, 41, 105, 105, "CID"], [114, 114, 73, 73, "CID"], [114, 114, 105, 105, "CID"]]], "clusters": [], "translated": "<3>肝细胞癌</3> 在 <10>范可尼贫血</10> 患者中应用 <0>雄激素</0> 和 <5>皮质类固醇</5> 治疗的病例。报道了一名 11 岁男孩的病例，他已知患有 <11>范可尼贫血</11> 3 年，并接受了 <1>雄激素</1>、<6>皮质类固醇</6>和输血。在他去世前两周，他因再生障碍性危象和<13>败血症</13>以及肝功能明显异常而再次入院，并死于<14>出血性支气管肺炎</14>。尸检发现<8>紫癜</8>和多个<15>肝肿瘤</15>，组织学证实为分化良好的<4>肝细胞癌</4>。该病例有助于先前的观察，即非转移性<16>肝肿瘤</16>和<9>紫癜</9>可在应用<2>雄激素</2>-和<7>皮质类固醇</7>治疗的<12>范可尼贫血</12>患者中发展。", "revised": true}
{"doc_key": "1361574", "sentences": [["Pharmacology", "of", "gamma", "-", "aminobutyric", "acidA", "receptor", "complex", "after", "the", "in", "vivo", "administration", "of", "the", "anxioselective", "and", "anticonvulsant", "beta", "-", "carboline", "derivative", "abecarnil", ".", "In", "rodents", ",", "the", "effect", "of", "the", "beta", "-", "carboline", "derivative", "isopropyl", "-", "6", "-", "benzyloxy", "-", "4", "-", "methoxymethyl", "-", "beta", "-", "carboline", "-", "3", "-", "carboxylate", "(", "abecarrnil", ")", ",", "a", "new", "ligand", "for", "benzodiazepine", "receptors", "possessing", "anxiolytic", "and", "anticonvulsant", "properties", ",", "was", "evaluated", "on", "the", "function", "of", "central", "gamma", "-", "aminobutyric", "acid", "(", "GABA", ")", "A", "receptor", "complex", ",", "both", "in", "vitro", "and", "in", "vivo", ".", "Added", "in", "vitro", "to", "rat", "cortical", "membrane", "preparation", ",", "abecarnil", "increased", "[", "3H", "]", "GABA", "binding", ",", "enhanced", "muscimol", "-", "stimulated", "36Cl", "-", "uptake", "and", "reduced", "the", "binding", "of", "t", "-", "[", "35S", "]", "butylbicyclophosphorothionate", "(", "[", "35S", "]", "TBPS", ")", ".", "These", "effects", "were", "similar", "to", "those", "induced", "by", "diazepam", ",", "whereas", "the", "partial", "agonist", "Ro", "16", "-", "6028", "(", "tert", "-", "butyl", "-", "(", "S", ")", "-", "8", "-", "bromo", "-", "11", ",", "12", ",", "13", ",", "13a", "-", "tetrahydro", "-", "9", "-", "oxo", "-", "9H", "-", "imidazo", "[", "1", ",", "5", "-", "a", "]", "-", "pyrrolo", "-", "[", "2", ",", "1", "-", "c", "]", "[", "1", ",", "4", "]", "benzodiazepine", "-", "1", "-", "carboxylate", ")", "showed", "very", "weak", "efficacy", "in", "these", "biochemical", "tests", ".", "After", "i", ".", "p", ".", "injection", "to", "rats", ",", "abecarnil", "and", "diazepam", "decreased", "in", "a", "time", "-", "dependent", "and", "dose", "-", "related", "(", "0", ".", "25", "-", "20", "mg", "/", "kg", "i", ".", "p", ".", ")", "manner", "[", "35S", "]", "TBPS", "binding", "measured", "ex", "vivo", "in", "the", "cerebral", "cortex", ".", "Moreover", ",", "both", "drugs", "at", "the", "dose", "of", "0", ".", "5", "mg", "/", "kg", "antagonized", "completely", "the", "convulsant", "activity", "and", "the", "increase", "of", "[", "35S", "]", "TBPS", "binding", "induced", "by", "isoniazide", "(", "350", "mg", "/", "kg", "s", ".", "c", ".", ")", "as", "well", "as", "the", "increase", "of", "[", "35S", "]", "TBPS", "binding", "induced", "by", "foot", "-", "shock", "stress", ".", "To", "better", "correlate", "the", "biochemical", "and", "the", "pharmacological", "effects", ",", "we", "studied", "the", "action", "of", "abecarnil", "on", "[", "35S", "]", "TBPS", "binding", ",", "exploratory", "motility", "and", "on", "isoniazid", "-", "induced", "biochemical", "and", "pharmacological", "effects", "in", "mice", ".", "In", "these", "animals", ",", "abecarnil", "produced", "a", "paralleled", "dose", "-", "dependent", "(", "0", ".", "05", "-", "1", "mg", "/", "kg", "i", ".", "p", ".", ")", "reduction", "of", "both", "motor", "behavior", "and", "cortical", "[", "35S", "]", "TBPS", "binding", ".", "Moreover", ",", "0", ".", "05", "mg", "/", "kg", "of", "this", "beta", "-", "carboline", "reduced", "markedly", "the", "increase", "of", "[", "35S", "]", "TBPS", "binding", "and", "the", "convulsions", "induced", "by", "isoniazid", "(", "200", "mg", "/", "kg", "s", ".", "c", ".", ")", ".", "(", "ABSTRACT", "TRUNCATED", "AT", "250", "WORDS", ")"]], "ner": [[[300, 300, "Chemical"], [356, 356, "Chemical"], [432, 432, "Chemical"], [429, 429, "Disease"], [2, 5, "Chemical"], [75, 78, "Chemical"], [80, 80, "Chemical"], [107, 107, "Chemical"], [18, 20, "Chemical"], [31, 33, "Chemical"], [414, 416, "Chemical"], [22, 22, "Chemical"], [35, 51, "Chemical"], [53, 53, "Chemical"], [102, 102, "Chemical"], [229, 229, "Chemical"], [344, 344, "Chemical"], [370, 370, "Chemical"], [60, 60, "Chemical"], [111, 111, "Chemical"], [122, 127, "Chemical"], [129, 132, "Chemical"], [257, 260, "Chemical"], [293, 296, "Chemical"], [317, 320, "Chemical"], [346, 349, "Chemical"], [422, 425, "Chemical"], [143, 143, "Chemical"], [231, 231, "Chemical"], [149, 152, "Chemical"], [154, 209, "Chemical"]]], "relations": [[[300, 300, 429, 429, "CID"], [356, 356, 429, 429, "CID"], [432, 432, 429, 429, "CID"]]], "clusters": [], "translated": "<4> γ-氨基丁酸A </4> 受体复合物在体内给予抗焦虑和抗惊厥药<8> β-咔啉 </8> 衍生物<11> 阿贝卡尼 </11> 后的药理学。在啮齿动物中，<9>β-咔啉 </9> 衍生物<12> 异丙基-6-苄氧基-4-甲氧基甲基-β-咔啉-3-羧酸酯</12> （<13>abecarrnil</13>）是一种新的<18>苯并二氮卓</18> 受体配体，具有抗焦虑和抗惊厥作用，评估了中枢<5> γ-氨基丁酸</5>（<6> GABA </6>）的功能体外和体内的受体复合物。在体外添加到大鼠皮质膜制剂中，<14> abecarnil </14> 增加[3H]<7> GABA </7> 结合，增强 <19> muscimol </19> - 刺激 36Cl - 摄取并降低结合 <20>t-[35S]丁基二环硫代磷酸盐</20>（<21>[35S]TBPS </21>）。这些作用与<27> 地西泮 </27> 诱导的作用相似，而部分激动剂<29> Ro 16-6028 </29> （<30> tert - butyl - (S) - 8 - bromo-11,12,13,13a-四氢 - 9 - 氧代 - 9H - 咪唑并[1,5-a]-吡咯并-[2,1-c][1,4]苯并二氮卓-1-羧酸盐</30>）表现出非常弱的在这些生化测试中的疗效。在i.p.给大鼠注射<15> abecarnil </15>和 <28> 地西泮 </28>以时间依赖性和剂量相关的方式降低(0.25-20 mg/kg i.p.)<22> [35S] TBPS </22>结合在大脑皮层中离体测量。而且，两种药物的剂量均为0.5 mg/kg 完全拮抗<0>异烟肼</0> （350 mg/kg s.c.）引起的惊厥活性和<23> [35S] TBPS </23>结合的增加以及增加<24> [35S] TBPS </24>由足震应力引起的结合。为了更好地关联生化和药理作用，我们研究了<16> abecarnil </16>对<25> [35S] TBPS </25> 结合、探索运动和对<1>异烟肼</1> - 对小鼠产生生化和药理作用。在这些动物中，<17> abecarnil </17> 产生平行的剂量依赖性（0.05-1 mg/kg i.p.）运动行为和皮质 [35S] TBPS结合减少。而且，0.05 mg/kg的这种<10> β-咔啉</10> 显着减少<26> [35S] TBPS </26>结合的增加和<3>抽搐</3>由<2>异烟肼</2> (200 mg/kg s.c.)。 （摘要被截断为250个单词）", "revised": true}
{"doc_key": "978847", "sentences": [["Centrally", "mediated", "cardiovascular", "effects", "of", "intracisternal", "application", "of", "carbachol", "in", "anesthetized", "rats", ".", "The", "pressor", "response", "to", "the", "intracisternal", "(", "i", ".", "c", ".", ")", "injection", "of", "carbachol", "(", "1", "mug", ")", "in", "anesthetized", "rats", "was", "analyzed", ".", "This", "response", "was", "significantly", "reduced", "by", "the", "intravenous", "(", "i", ".", "v", ".", ")", "injection", "of", "guanethidine", "(", "5", "mg", ")", ",", "hexamethonium", "(", "10", "mg", ")", "or", "phentolamine", "(", "5", "mg", ")", ",", "and", "conversely", ",", "potentiated", "by", "i", ".", "v", ".", "desmethylimipramine", "(", "0", ".", "3", "mg", ")", ",", "while", "propranolol", "(", "0", ".", "5", "mg", ")", "i", ".", "v", ".", "selectively", "inhibited", "the", "enlargement", "of", "pulse", "pressure", "and", "the", "tachycardia", "following", "i", ".", "c", ".", "carbachol", "(", "1", "mug", ")", ".", "On", "the", "other", "hand", ",", "the", "pressor", "response", "to", "i", ".", "c", ".", "carbachol", "(", "1", "mug", ")", "was", "almost", "completely", "blocked", "by", "i", ".", "c", ".", "atropine", "(", "3", "mug", ")", "or", "hexamethonium", "(", "500", "mug", ")", ",", "and", "significantly", "reduced", "by", "i", ".", "c", ".", "chlorpromazine", "(", "50", "mug", ")", "but", "significantly", "potentiated", "by", "i", ".", "c", ".", "desmethylimipramine", "(", "30", "mug", ")", ".", "The", "pressor", "response", "to", "i", ".", "c", ".", "carbachol", "(", "1", "mug", ")", "remained", "unchanged", "after", "sectioning", "of", "the", "bilateral", "cervical", "vagal", "nerves", "but", "disappeared", "after", "sectioning", "of", "the", "spinal", "cord", "(", "C7", "-", "C8", ")", ".", "From", "the", "above", "result", "it", "is", "suggested", "that", "the", "pressor", "response", "to", "i", ".", "c", ".", "carbachol", "ortral", "and", "peripheral", "adrenergic", "mechanisms", ",", "and", "that", "the", "sympathetic", "trunk", "is", "the", "main", "pathway", "."]], "ner": [[[8, 8, "Chemical"], [27, 27, "Chemical"], [116, 116, "Chemical"], [135, 135, "Chemical"], [196, 196, "Chemical"], [241, 241, "Chemical"], [104, 107, "Disease"], [110, 110, "Disease"], [81, 81, "Chemical"], [182, 182, "Chemical"], [54, 54, "Chemical"], [60, 60, "Chemical"], [155, 155, "Chemical"], [66, 66, "Chemical"], [90, 90, "Chemical"], [149, 149, "Chemical"], [169, 169, "Chemical"]]], "relations": [[[8, 8, 104, 107, "CID"], [27, 27, 104, 107, "CID"], [116, 116, 104, 107, "CID"], [135, 135, 104, 107, "CID"], [196, 196, 104, 107, "CID"], [241, 241, 104, 107, "CID"], [8, 8, 110, 110, "CID"], [27, 27, 110, 110, "CID"], [116, 116, 110, 110, "CID"], [135, 135, 110, 110, "CID"], [196, 196, 110, 110, "CID"], [241, 241, 110, 110, "CID"], [81, 81, 104, 107, "CID"], [182, 182, 104, 107, "CID"]]], "clusters": [], "translated": "对麻醉大鼠脑池内应用<0>卡巴胆碱</0>的中枢介导的心血管作用。分析了麻醉大鼠脑池内（i.c.）注射<1>卡巴胆碱</1>（1杯）后的升压反应。静脉内（i.v.）注射<10>胍乙啶</10>（5mg）、<11>六甲铵</11>（10mg）或<13>酚妥拉明</13>（5mg）可显着降低这种反应（5毫克），相反，由i.v. <8>去甲丙咪嗪</8>（0.3mg）而加强，而i.v. <14>普萘洛尔</14>（0.5mg）选择性抑制i.c.<2>卡巴胆碱</2>（1杯）后的<6>脉压增高</6>和<7>心动过速</7>。另一方面，<3>卡巴胆碱</3>（1杯）对升压的反应几乎完全被i.c. <15>阿托品</15>（3杯）或<12>六甲铵</12>（500杯）挡住，且被i.c. <16>氯丙嗪</16>（50杯）显着降低，但被i.c. <9>去甲丙咪嗪</9>（30杯）显着增强。在切断双侧颈迷走神经后，i.c. <4>卡巴胆碱</4>（1杯）的升压反应保持不变，但在切断脊髓（C7-C8）后消失。从上面的结果可以看出，升压反应对i.c. <5>卡巴胆碱</5>既经过中枢又经过周围肾上腺素能机制，并认为交感神经干是主要途径。", "revised": true}
{"doc_key": "1905439", "sentences": [["Delirium", "in", "an", "elderly", "woman", "possibly", "associated", "with", "administration", "of", "misoprostol", ".", "Misoprostol", "has", "been", "associated", "with", "adverse", "reactions", ",", "including", "gastrointestinal", "symptoms", ",", "gynecologic", "problems", ",", "and", "headache", ".", "Changes", "in", "mental", "status", ",", "however", ",", "have", "not", "been", "reported", ".", "We", "present", "a", "case", "in", "which", "an", "89", "-", "year", "-", "old", "woman", "in", "a", "long", "-", "term", "care", "facility", "became", "confused", "after", "the", "initiation", "of", "misoprostol", "therapy", ".", "The", "patient", "'s", "change", "in", "mental", "status", "was", "first", "reported", "nine", "days", "after", "the", "initiation", "of", "therapy", ".", "Her", "delirium", "significantly", "improved", "after", "misoprostol", "was", "discontinued", "and", "her", "mental", "status", "returned", "to", "normal", "within", "a", "week", ".", "Because", "no", "other", "factors", "related", "to", "this", "patient", "changed", "significantly", ",", "the", "delirium", "experienced", "by", "this", "patient", "possibly", "resulted", "from", "misoprostol", "therapy", "."]], "ner": [[[10, 10, "Chemical"], [12, 12, "Chemical"], [68, 68, "Chemical"], [94, 94, "Chemical"], [128, 128, "Chemical"], [0, 0, "Disease"], [90, 90, "Disease"], [120, 120, "Disease"], [28, 28, "Disease"]]], "relations": [[[10, 10, 0, 0, "CID"], [10, 10, 90, 90, "CID"], [10, 10, 120, 120, "CID"], [12, 12, 0, 0, "CID"], [12, 12, 90, 90, "CID"], [12, 12, 120, 120, "CID"], [68, 68, 0, 0, "CID"], [68, 68, 90, 90, "CID"], [68, 68, 120, 120, "CID"], [94, 94, 0, 0, "CID"], [94, 94, 90, 90, "CID"], [94, 94, 120, 120, "CID"], [128, 128, 0, 0, "CID"], [128, 128, 90, 90, "CID"], [128, 128, 120, 120, "CID"]]], "clusters": [], "translated": "<5>老年妇女的谵妄</5>可能与服用<0>米索前列醇</0>有关。 <1>米索前列醇</1>与不良反应有关，包括胃肠道症状、妇科问题和<8>头痛</8>。然而，精神状态的变化尚未见报道。我们介绍了一个案例，一位在长期护理机构中的89岁女性在开始<2>米索前列醇</2>治疗后变得神志不清。患者精神状态的变化在治疗开始后9天首次报告。停用<3>米索前列醇</3>后，<6>谵妄</6>明显好转，精神状态在一周内恢复正常。由于与该患者相关的其他因素无明显变化，该患者出现的<7>谵妄</7>可能是<4>米索前列醇</4>治疗所致。", "revised": true}
{"doc_key": "1858969", "sentences": [["Five", "cases", "of", "encephalitis", "during", "treatment", "of", "loiasis", "with", "diethylcarbamazine", ".", "Five", "cases", "of", "encephalitis", "following", "treatment", "with", "diethylcarbamazine", "(", "DEC", ")", "were", "observed", "in", "Congolese", "patients", "with", "Loa", "loa", "filariasis", ".", "Two", "cases", "had", "a", "fatal", "outcome", "and", "one", "resulted", "in", "severe", "sequelae", ".", "The", "notable", "fact", "was", "that", "this", "complication", "occurred", "in", "three", "patients", "hospitalized", "before", "treatment", "began", ",", "with", "whom", "particularly", "strict", "therapeutic", "precautions", "were", "taken", ",", "i", ".", "e", ".", ",", "initial", "dose", "less", "than", "10", "mg", "of", "DEC", ",", "very", "gradual", "dose", "increases", ",", "and", "associated", "anti", "-", "allergic", "treatment", ".", "This", "type", "of", "drug", "-", "induced", "complication", "may", "not", "be", "that", "uncommon", "in", "highly", "endemic", "regions", ".", "It", "occurs", "primarily", ",", "but", "not", "exclusively", ",", "in", "subjects", "presenting", "with", "a", "high", "microfilarial", "load", ".", "The", "relationship", "between", "the", "occurrence", "of", "encephalitis", "and", "the", "decrease", "in", "microfilaremia", "is", "evident", ".", "The", "pathophysiological", "mechanisms", "are", "discussed", "in", "the", "light", "of", "these", "observations", "and", "the", "few", "other", "comments", "on", "this", "subject", "published", "in", "the", "literature", "."]], "ner": [[[9, 9, "Chemical"], [18, 18, "Chemical"], [20, 20, "Chemical"], [82, 82, "Chemical"], [3, 3, "Disease"], [14, 14, "Disease"], [136, 136, "Disease"], [7, 7, "Disease"], [30, 30, "Disease"]]], "relations": [[[9, 9, 3, 3, "CID"], [9, 9, 14, 14, "CID"], [9, 9, 136, 136, "CID"], [18, 18, 3, 3, "CID"], [18, 18, 14, 14, "CID"], [18, 18, 136, 136, "CID"], [20, 20, 3, 3, "CID"], [20, 20, 14, 14, "CID"], [20, 20, 136, 136, "CID"], [82, 82, 3, 3, "CID"], [82, 82, 14, 14, "CID"], [82, 82, 136, 136, "CID"]]], "clusters": [], "translated": "<0>二乙基卡马嗪</0>治疗<7>罗阿斯病</7>期间发生<4>脑炎</4>5例。在刚果Loa loa <8>丝虫病</8>患者中，观察到使用<1>二乙基卡马嗪</1>（<2>DEC</2>）治疗后发生5例<5>脑炎</5>。两例导致死亡，一例导致严重的后遗症。值得注意的事实是，这种并发症发生在三名治疗开始前住院的患者身上。对他们采取了特别严格的治疗预防措施，即初始剂量小于10mg的<3>DEC</3>，逐渐增加剂量，并进行相关的抗过敏治疗。这种药物引起的并发症在高流行地区可能并不少见。它主要（但不限于）发生在具有高微丝蚴负荷的受试者中。<6>脑炎</6>的发生与微丝蚴血症的减少之间的关系是显而易见的。病理生理机制是根据这些观察结果和文献中发表的关于该主题的少数其他评论进行讨论的。", "revised": true}
{"doc_key": "931801", "sentences": [["Effect", "of", "D", "-", "Glucarates", "on", "basic", "antibiotic", "-", "induced", "renal", "damage", "in", "rats", ".", "Dehydrated", "rats", "regularly", "develop", "acute", "renal", "failure", "following", "single", "injection", "of", "aminoglycoside", "antibiotics", "combined", "with", "dextran", "or", "of", "antibiotics", "only", ".", "Oral", "administration", "of", "2", ",", "5", "-", "di", "-", "O", "-", "acetyl", "-", "D", "-", "glucaro", "-", "1", ",", "4", "-", "6", ",", "3", "-", "dilactone", "protected", "rats", "against", "renal", "failure", "induced", "by", "kanamycin", "-", "dextran", ".", "The", "protective", "effect", "was", "prevalent", "among", "D", "-", "glucarates", ",", "and", "also", "to", "other", "saccharic", "acid", ",", "hexauronic", "acids", "and", "hexaaldonic", "acids", ",", "although", "to", "a", "lesser", "degree", ",", "but", "not", "to", "a", "hexaaldose", ",", "sugar", "alcohols", ",", "substances", "inthe", "TCA", "cycle", "and", "other", "acidic", "compounds", ".", "D", "-", "Glucarates", "were", "effective", "against", "renal", "damage", "induced", "by", "peptide", "antibiotics", "as", "well", "as", "various", "aminoglycoside", "antibitocis", ".", "Dose", "-", "responses", "were", "observed", "in", "the", "protective", "effect", "of", "D", "-", "Glucarates", ".", "With", "a", "D", "-", "glucarate", "of", "a", "fixed", "size", "of", "dose", ",", "approximately", "the", "same", "degree", "of", "protection", "was", "obtained", "against", "renal", "damages", "induced", "by", "different", "basic", "antibiotics", "despite", "large", "disparities", "in", "administration", "doses", "of", "different", "antibiotics", ".", "D", "-", "Glucarates", "had", "the", "ability", "to", "prevent", "renal", "damage", "but", "not", "to", "cure", "it", ".", "Rats", "excreted", "acidic", "urine", "when", "they", "were", "spared", "from", "renal", "lesions", "by", "monosaccharides", ".", "The", "reduction", "effect", "of", "D", "-", "glucarates", "against", "nephrotoxicity", "of", "basic", "antibiotics", "was", "discussed", "."]], "ner": [[[26, 26, "Chemical"], [136, 136, "Chemical"], [19, 21, "Disease"], [69, 69, "Chemical"], [2, 4, "Chemical"], [79, 81, "Chemical"], [87, 88, "Chemical"], [120, 122, "Chemical"], [149, 151, "Chemical"], [155, 157, "Chemical"], [191, 193, "Chemical"], [225, 227, "Chemical"], [10, 11, "Disease"], [126, 127, "Disease"], [174, 175, "Disease"], [199, 200, "Disease"], [216, 217, "Disease"], [229, 229, "Disease"], [15, 15, "Disease"], [65, 66, "Disease"], [39, 61, "Chemical"], [90, 91, "Chemical"], [108, 109, "Chemical"], [113, 113, "Chemical"], [219, 219, "Chemical"]]], "relations": [[[26, 26, 19, 21, "CID"], [136, 136, 19, 21, "CID"], [69, 69, 19, 21, "CID"]]], "clusters": [], "translated": "<4>D-葡萄糖酸盐</4>对碱性抗生素引起的大鼠<12>肾损伤</12>的影响。<18>脱水</18>大鼠在单次注射<0>氨基糖苷类</0>抗生素联合葡聚糖或仅注射抗生素后，经常发生<2>急性肾功能衰竭</2>。口服<20>2,5-di-O-acetyl-D-glucaro-1,4-6,3-dilactone</20>保护大鼠免受<19>肾功能衰竭</19>诱导的<3>卡那霉素</3>-葡聚糖。保护作用普遍存在于<5>D-葡糖二酸盐</5>，以及其他<6>多糖酸</6>、<21>己糖醛酸</21>和六醛糖酸中，尽管程度较轻，但不包括六醛糖、<22>糖醇</22>、<23>三羧酸</23>循环中的物质和其他酸性化合物。<7>D-葡萄糖酸盐</7>对肽类抗生素和各种<1>氨基糖苷类</1>抗生素引起的<13>肾损伤</13>均有效。在<8>D-葡萄糖酸盐</8>的保护作用中观察到剂量反应。使用固定剂量的<9>D-葡萄糖二酸盐</9>，尽管不同抗生素的给药剂量差异很大，但对不同碱性抗生素引起的<14>肾损伤</14>的保护作用大致相同。 <10>D-葡萄糖酸盐</10>具有预防<15>肾损伤</15>但不能治愈的能力。大鼠因<24>单糖</24>而免于<16>肾损伤</16>时排泄酸性尿液。探讨了<11>D-葡萄糖二酸盐</11>对碱性抗生素<17>肾毒性</17>的减轻作用。", "revised": true}
{"doc_key": "1779253", "sentences": [["Topical", "0", ".", "025", "%", "capsaicin", "in", "chronic", "post", "-", "herpetic", "neuralgia", ":", "efficacy", ",", "predictors", "of", "response", "and", "long", "-", "term", "course", ".", "In", "order", "to", "evaluate", "the", "efficacy", ",", "time", "-", "course", "of", "action", "and", "predictors", "of", "response", "to", "topical", "capsaicin", ",", "39", "patients", "with", "chronic", "post", "-", "herpetic", "neuralgia", "(", "PHN", ")", ",", "median", "duration", "24", "months", ",", "were", "treated", "with", "0", ".", "025", "%", "capsaicin", "cream", "for", "8", "weeks", ".", "During", "therapy", "the", "patients", "rated", "their", "pain", "on", "a", "visual", "analogue", "scale", "(", "VAS", ")", "and", "a", "verbal", "outcome", "scale", ".", "A", "follow", "-", "up", "investigation", "was", "performed", "10", "-", "12", "months", "after", "study", "onset", "on", "the", "patients", "who", "had", "improved", ".", "Nineteen", "patients", "(", "48", ".", "7", "%", ")", "substantially", "improved", "after", "the", "8", "-", "week", "trial", ";", "5", "(", "12", ".", "8", "%", ")", "discontinued", "therapy", "due", "to", "side", "-", "effects", "such", "as", "intolerable", "capsaicin", "-", "induced", "burning", "sensations", "(", "4", ")", "or", "mastitis", "(", "1", ")", ";", "15", "(", "38", ".", "5", "%", ")", "reported", "no", "benefit", ".", "The", "decrease", "in", "VAS", "ratings", "was", "significant", "after", "2", "weeks", "of", "continuous", "application", ".", "Of", "the", "responders", "72", ".", "2", "%", "were", "still", "improved", "at", "the", "follow", "-", "up", ";", "only", "one", "-", "third", "of", "them", "had", "continued", "application", "irregularly", ".", "Treatment", "effect", "was", "not", "dependent", "on", "patient", "'s", "age", ",", "duration", "or", "localization", "of", "PHN", "(", "trigeminal", "involvement", "was", "excluded", ")", ",", "sensory", "disturbance", "or", "pain", "character", ".", "Treatment", "response", "was", "not", "correlated", "with", "the", "incidence", ",", "time", "-", "course", "or", "severity", "of", "capsaicin", "-", "induced", "burning", ".", "If", "confirmed", "in", "controlled", "trials", ",", "the", "long", "-", "term", "results", "of", "this", "open", ",", "non", "-", "randomized", "study", "might", "indicate", "that", "the", "analgesic", "effect", "of", "capsaicin", "in", "PHN", "is", "mediated", "by", "both", "interference", "with", "neuropeptide", "metabolism", "and", "morphological", "changes", "(", "perhaps", "degeneration", ")", "of", "nociceptive", "afferents", "."]], "ner": [[[5, 5, "Chemical"], [42, 42, "Chemical"], [68, 68, "Chemical"], [150, 150, "Chemical"], [259, 259, "Chemical"], [290, 290, "Chemical"], [80, 80, "Disease"], [241, 241, "Disease"], [159, 159, "Disease"], [8, 11, "Disease"], [48, 51, "Disease"], [53, 53, "Disease"], [230, 230, "Disease"], [292, 292, "Disease"]]], "relations": [[[5, 5, 80, 80, "CID"], [5, 5, 241, 241, "CID"], [42, 42, 80, 80, "CID"], [42, 42, 241, 241, "CID"], [68, 68, 80, 80, "CID"], [68, 68, 241, 241, "CID"], [150, 150, 80, 80, "CID"], [150, 150, 241, 241, "CID"], [259, 259, 80, 80, "CID"], [259, 259, 241, 241, "CID"], [290, 290, 80, 80, "CID"], [290, 290, 241, 241, "CID"], [5, 5, 159, 159, "CID"], [42, 42, 159, 159, "CID"], [68, 68, 159, 159, "CID"], [150, 150, 159, 159, "CID"], [259, 259, 159, 159, "CID"], [290, 290, 159, 159, "CID"]]], "clusters": [], "translated": "局部0.025%<0>辣椒素</0>治疗慢性<9>带状疱疹后神经痛</9>：疗效、反应预测因子和长期病程。为了评估疗效、作用时程和对局部<1>辣椒素</1>反应的预测因子，39例慢性<10>带状疱疹后神经痛</10>（<11>PHN</11>）患者，中位持续时间为24个月，均接受0.025%<2>辣椒素</2>霜 8周。在治疗期间，患者根据视觉模拟量表（VAS）和语言结果量表对他们的<6>疼痛</6>进行评分。在研究开始后10-12个月对病情有所改善的患者进行了随访调查。19名患者（48.7%）在8周试验后明显好转；5（12.8%）因无法忍受<3>辣椒素</3>引起的烧灼感（4）或<8>乳腺炎</8>（1）等副作用而停止治疗；15人（38.5%）报告没有获益。连续应用2周后VAS评分下降显着。响应者72.2%随访仍有好转；只有三分之一的人不定期继续申请。治疗效果不依赖于患者的年龄、病程或<12>PHN</12>的定位（排除三叉神经受累）、感觉障碍或<7>疼痛</7>特征。治疗反应与<4>辣椒素</4>引起的烧灼感的发生率、时程或严重程度无关。如果在对照试验中得到证实，这个开放的、非随机研究的长期结果可能表明<5>辣椒素</5>对<13>PHN</13>的镇痛作用是通过干扰神经肽介导的伤害性传入神经的新陈代谢和形态变化（可能退化）。", "revised": true}
{"doc_key": "1837756", "sentences": [["Serotonin", "reuptake", "inhibitors", ",", "paranoia", ",", "and", "the", "ventral", "basal", "ganglia", ".", "Antidepressants", "have", "previously", "been", "associated", "with", "paranoid", "reactions", "in", "psychiatric", "patients", ".", "Five", "cases", "of", "paranoid", "exacerbation", "with", "the", "serotonin", "reuptake", "inhibitors", "fluoxetine", "and", "amitriptyline", "are", "reported", "here", ".", "Elements", "common", "to", "these", "cases", "included", "a", "history", "of", "paranoid", "symptomatology", "and", "the", "concomitant", "occurrence", "of", "depressive", "and", "psychotic", "symptoms", ".", "Complicated", "depressive", "disorders", "(", "including", "atypicality", "of", "course", "and", "symptomatology", ",", "chronicity", ",", "psychosis", ",", "bipolarity", ",", "and", "secondary", "onset", "in", "the", "course", "of", "a", "primary", "psychosis", ")", "may", "present", "particular", "vulnerability", "to", "paranoid", "exacerbations", "associated", "with", "serotonin", "reuptake", "inhibitors", ".", "Although", "the", "pharmacology", "and", "neurobiology", "of", "paranoia", "remain", "cryptic", ",", "several", "mechanisms", ",", "including", "5HT3", "receptor", "-", "mediated", "dopamine", "release", ",", "beta", "-", "noradrenergic", "receptor", "downregulation", ",", "or", "GABAB", "receptor", "upregulation", "acting", "in", "the", "vicinity", "of", "the", "ventral", "basal", "ganglia", "(", "possibly", "in", "lateral", "orbitofrontal", "or", "anterior", "cingulate", "circuits", ")", ",", "might", "apply", "to", "this", "phenomenon", ".", "These", "cases", "call", "attention", "to", "possible", "paranoid", "exacerbations", "with", "serotonin", "reuptake", "blockers", "in", "select", "patients", "and", "raise", "neurobiological", "considerations", "regarding", "paranoia", "."]], "ner": [[[34, 34, "Chemical"], [4, 4, "Disease"], [18, 18, "Disease"], [27, 27, "Disease"], [50, 50, "Disease"], [95, 95, "Disease"], [109, 109, "Disease"], [166, 166, "Disease"], [180, 180, "Disease"], [36, 36, "Chemical"], [0, 0, "Chemical"], [31, 31, "Chemical"], [99, 99, "Chemical"], [169, 169, "Chemical"], [57, 60, "Disease"], [63, 64, "Disease"], [75, 75, "Disease"], [88, 88, "Disease"], [121, 121, "Chemical"]]], "relations": [[[34, 34, 4, 4, "CID"], [34, 34, 18, 18, "CID"], [34, 34, 27, 27, "CID"], [34, 34, 50, 50, "CID"], [34, 34, 95, 95, "CID"], [34, 34, 109, 109, "CID"], [34, 34, 166, 166, "CID"], [34, 34, 180, 180, "CID"], [36, 36, 4, 4, "CID"], [36, 36, 18, 18, "CID"], [36, 36, 27, 27, "CID"], [36, 36, 50, 50, "CID"], [36, 36, 95, 95, "CID"], [36, 36, 109, 109, "CID"], [36, 36, 166, 166, "CID"], [36, 36, 180, 180, "CID"]]], "clusters": [], "translated": " <10>血清素</10> 再摄取抑制剂，<1>偏执狂</1>，和腹侧基底神经节。抗抑郁药以前曾与精神病患者的<2>偏执</2>反应有关。此处报告了5例<3>偏执狂</3>因<11>5-羟色胺</11>再摄取抑制剂<0>氟西汀</0>和<9>阿米替林</9>而加重的病例。这些病例的共同要素包括<4>偏执狂</4>病史和同时出现<14>抑郁和精神病症状</14>。复杂的<15>抑郁症</15>（包括病程和症状的非典型性、慢性病、<16>精神病</16>、双相情感障碍和原发性<17>精神病</17>过程中的继发性发作）可能对与<12>血清素</12>再摄取抑制剂相关的<5>偏执狂</5>恶化表现出特别的脆弱性。虽然<6>偏执狂</6>的药理学和神经生物学仍然是个谜，但有几种机制，包括5HT3 受体介导的<18>多巴胺</18>释放、β-去甲肾上腺素能受体下调或作用于附近的GABAB受体上调腹侧基底神经节（可能在外侧眶额或前扣带回路中）可能适用于这种现象。这些病例提请注意在特定患者中使用<13>血清素</13>再摄取阻滞剂可能导致<7>偏执狂</7>恶化，并提出关于<8>偏执狂</8>的神经生物学考虑。", "revised": true}
{"doc_key": "2083961", "sentences": [["Acute", "renal", "failure", "due", "to", "rifampicin", ".", "A", "23", "-", "year", "-", "old", "male", "patient", "with", "bacteriologically", "proven", "pulmonary", "tuberculosis", "was", "treated", "with", "the", "various", "regimens", "of", "antituberculosis", "drugs", "for", "nearly", "15", "months", ".", "Rifampicin", "was", "administered", "thrice", "as", "one", "of", "the", "3", "-", "4", "drug", "regimen", "and", "each", "time", "he", "developed", "untoward", "side", "effects", "like", "nausea", ",", "vomiting", "and", "fever", "with", "chills", "and", "rigors", ".", "The", "last", "such", "episode", "was", "of", "acute", "renal", "failure", "at", "which", "stage", "the", "patient", "was", "seen", "by", "the", "authors", "of", "this", "report", ".", "The", "patient", ",", "however", ",", "made", "a", "full", "recovery", "."]], "ner": [[[5, 5, "Chemical"], [34, 34, "Chemical"], [0, 2, "Disease"], [18, 19, "Disease"], [56, 56, "Disease"], [58, 58, "Disease"], [60, 60, "Disease"]]], "relations": [[[5, 5, 0, 2, "CID"], [34, 34, 0, 2, "CID"]]], "clusters": [], "translated": "<2>急性肾功能衰竭</2>由于<0>利福平</0>。一名23岁的男性患者经细菌学证实为<3>肺结核</3>，接受了近15个月的各种抗结核药物治疗。<1>利福平</1>作为3-4药物治疗方案中的一种给药三次，每次他都会出现不良副作用，如<4>恶心</4>、<5>呕吐</5>和<6>发热</6>伴有寒战和寒战。最后一次这样的发作是急性肾功能衰竭，在该阶段患者由本文作者进行就诊。然而，患者最终完全康复。", "revised": true}
{"doc_key": "1615846", "sentences": [["Gemfibrozil", "-", "lovastatin", "therapy", "for", "primary", "hyperlipoproteinemias", ".", "The", "specific", "aim", "of", "this", "retrospective", ",", "observational", "study", "was", "to", "assess", "safety", "and", "efficacy", "of", "long", "-", "term", "(", "21", "months", "/", "patient", ")", ",", "open", "-", "label", ",", "gemfibrozil", "-", "lovastatin", "treatment", "in", "80", "patients", "with", "primary", "mixed", "hyperlipidemia", "(", "68", "%", "of", "whom", "had", "atherosclerotic", "vascular", "disease", ")", ".", "Because", "ideal", "lipid", "targets", "were", "not", "reached", "(", "low", "-", "density", "lipoprotein", "(", "LDL", ")", "cholesterol", "less", "than", "130", "mg", "/", "dl", ",", "high", "-", "density", "lipoprotein", "(", "HDL", ")", "cholesterol", "greater", "than", "35", "mg", "/", "dl", ",", "or", "total", "cholesterol", "/", "HDL", "cholesterol", "less", "than", "4", ".", "5", "mg", "/", "dl", ")", "with", "diet", "plus", "a", "single", "drug", ",", "gemfibrozil", "(", "1", ".", "2", "g", "/", "day", ")", "-", "lovastatin", "(", "primarily", "20", "or", "40", "mg", ")", "treatment", "was", "given", ".", "Follow", "-", "up", "visits", "were", "scheduled", "with", "2", "-", "drug", "therapy", "every", "6", "to", "8", "weeks", ",", "an", "average", "of", "10", ".", "3", "visits", "per", "patient", ",", "with", "741", "batteries", "of", "6", "liver", "function", "tests", "and", "714", "creatine", "phosphokinase", "levels", "measured", ".", "Only", "1", "of", "the", "4", ",", "446", "liver", "function", "tests", "(", "0", ".", "02", "%", ")", ",", "a", "gamma", "glutamyl", "transferase", ",", "was", "greater", "than", "or", "equal", "to", "3", "times", "the", "upper", "normal", "limit", ".", "Of", "the", "714", "creatine", "phosphokinase", "levels", ",", "9", "%", "were", "high", ";", "only", "1", "(", "0", ".", "1", "%", ")", "was", "greater", "than", "or", "equal", "to", "3", "times", "the", "upper", "normal", "limit", ".", "With", "2", "-", "drug", "therapy", ",", "mean", "total", "cholesterol", "decreased", "22", "%", "from", "255", "to", "200", "mg", "/", "dl", ",", "triglyceride", "levels", "decreased", "35", "%", "from", "236", "to", "154", "mg", "/", "dl", ",", "LDL", "cholesterol", "decreased", "26", "%", "from", "176", "to", "131", "mg", "/", "dl", ",", "and", "the", "total", "cholesterol", "/", "HDL", "cholesterol", "ratio", "decreased", "24", "%", "from", "7", ".", "1", "to", "5", ".", "4", ",", "all", "p", "less", "than", "or", "equal", "to", "0", ".", "0001", ".", "Myositis", ",", "attributable", "to", "the", "drug", "combination", "and", "symptomatic", "enough", "to", "discontinue", "it", ",", "occurred", "in", "3", "%", "of", "patients", ",", "and", "in", "1", "%", "with", "concurrent", "high", "creatine", "phosphokinase", "(", "769", "U", "/", "liter", ")", ";", "no", "patients", "had", "rhabdomyolysis", "or", "myoglobinuria", ".", "(", "ABSTRACT", "TRUNCATED", "AT", "250", "WORDS", ")"]], "ner": [[[0, 0, "Chemical"], [38, 38, "Chemical"], [120, 120, "Chemical"], [329, 329, "Disease"], [2, 2, "Chemical"], [40, 40, "Chemical"], [130, 130, "Chemical"], [6, 6, "Disease"], [48, 48, "Disease"], [55, 57, "Disease"], [369, 369, "Disease"], [371, 371, "Disease"], [75, 75, "Chemical"], [90, 90, "Chemical"], [100, 100, "Chemical"], [103, 103, "Chemical"], [260, 260, "Chemical"], [286, 286, "Chemical"], [301, 301, "Chemical"], [304, 304, "Chemical"], [179, 179, "Chemical"], [222, 222, "Chemical"], [357, 357, "Chemical"], [272, 272, "Chemical"]]], "relations": [[[0, 0, 329, 329, "CID"], [38, 38, 329, 329, "CID"], [120, 120, 329, 329, "CID"], [2, 2, 329, 329, "CID"], [40, 40, 329, 329, "CID"], [130, 130, 329, 329, "CID"]]], "clusters": [], "translated": " <0>吉非罗齐</0> - <4>洛伐他汀</4>治疗原发性<7>高脂蛋白血症</7>。这项回顾性、观察性研究的具体目的是评估长期（21个月/患者）、开放标签、<1>吉非罗齐</1> - <5>洛伐他汀</5>治疗80名患者的安全性和有效性。在主要混合型<8>高脂血症</8>患者中（其中68%患有<9>动脉粥样硬化性血管疾病</9>），因未达到理想的脂质目标（低密度脂蛋白（LDL）<12>胆固醇</12>低于130毫克/分升，高密度脂蛋白（HDL）<13>胆固醇</13>大于35毫克/分升，或总<14>胆固醇</14>/ HDL <15>胆固醇</15>比小于4.5毫克/分升），使用饮食及单一药物治疗后，接受<2>吉非罗齐</2>（1.2克/天） - <6>洛伐他汀</6>（主要20或40毫克）治疗。每位患者进行平均10.3次随访，每6至8周使用2-药物治疗。患者共接受741次肝功能测试和714次<20>肌酸</20>磷酸激酶水平测量。在4446项肝功能检查中，只有1项（0.02%）γ谷氨酰转移酶大于或等于正常上限3倍。在714项<21>肌酸</21>磷酸激酶水平中，9%为高水平，只有1（0.1%）大于或等于正常上限3倍。 通过2-药物治疗，平均总<16>胆固醇</16>降低22%，从255降低至200毫克/分升，<23>甘油三酯</23>水平降低35%，从236降低至154毫克/分升，LDL <17>胆固醇</17>降低26%，从176降低至131 mg/dl，总<18>胆固醇</18>/HDL <19>胆固醇</19>比率降低24%，从7降至5.4，所有p值均小于或等于0.0001。 <3>肌炎</3>，可归因于药物组合且症状足以停药，发生在3%的患者中，并发生在1%并发高<22>肌酸</22>磷酸激酶（769 U/升）；没有患者出现<10>横纹肌溶解症</10>或<11>肌红蛋白尿</11>。（摘要截断在250词）", "revised": true}
{"doc_key": "1943082", "sentences": [["Hepatocellular", "oxidant", "stress", "following", "intestinal", "ischemia", "-", "reperfusion", "injury", ".", "Reperfusion", "of", "ischemic", "intestine", "results", "in", "acute", "liver", "dysfunction", "characterized", "by", "hepatocellular", "enzyme", "release", "into", "plasma", ",", "reduction", "in", "bile", "flow", "rate", ",", "and", "neutrophil", "sequestration", "within", "the", "liver", ".", "The", "pathophysiology", "underlying", "this", "acute", "hepatic", "injury", "is", "unknown", ".", "This", "study", "was", "undertaken", "to", "determine", "whether", "oxidants", "are", "associated", "with", "the", "hepatic", "injury", "and", "to", "determine", "the", "relative", "value", "of", "several", "indirect", "methods", "of", "assessing", "oxidant", "exposure", "in", "vivo", ".", "Rats", "were", "subjected", "to", "a", "standardized", "intestinal", "ischemia", "-", "reperfusion", "injury", ".", "Hepatic", "tissue", "was", "assayed", "for", "lipid", "peroxidation", "products", "and", "oxidized", "and", "reduced", "glutathione", ".", "There", "was", "no", "change", "in", "hepatic", "tissue", "total", "glutathione", "following", "intestinal", "ischemia", "-", "reperfusion", "injury", ".", "Oxidized", "glutathione", "(", "GSSG", ")", "increased", "significantly", "following", "30", "and", "60", "min", "of", "reperfusion", ".", "There", "was", "no", "increase", "in", "any", "of", "the", "products", "of", "lipid", "peroxidation", "associated", "with", "this", "injury", ".", "An", "increase", "in", "GSSG", "within", "hepatic", "tissue", "during", "intestinal", "reperfusion", "suggests", "exposure", "of", "hepatocytes", "to", "an", "oxidant", "stress", ".", "The", "lack", "of", "a", "significant", "increase", "in", "products", "of", "lipid", "peroxidation", "suggests", "that", "the", "oxidant", "stress", "is", "of", "insufficient", "magnitude", "to", "result", "in", "irreversible", "injury", "to", "hepatocyte", "cell", "membranes", ".", "These", "data", "also", "suggest", "that", "the", "measurement", "of", "tissue", "GSSG", "may", "be", "a", "more", "sensitive", "indicator", "of", "oxidant", "stress", "than", "measurement", "of", "products", "of", "lipid", "peroxidation", "."]], "ner": [[[102, 105, "Chemical"], [123, 124, "Chemical"], [126, 126, "Chemical"], [158, 158, "Chemical"], [213, 213, "Chemical"], [7, 8, "Disease"], [90, 91, "Disease"], [120, 121, "Disease"], [5, 5, "Disease"], [12, 12, "Disease"], [88, 88, "Disease"], [118, 118, "Disease"], [115, 115, "Chemical"], [17, 18, "Disease"], [45, 46, "Disease"], [62, 63, "Disease"]]], "relations": [[[102, 105, 7, 8, "CID"], [102, 105, 90, 91, "CID"], [102, 105, 120, 121, "CID"], [123, 124, 7, 8, "CID"], [123, 124, 90, 91, "CID"], [123, 124, 120, 121, "CID"], [126, 126, 7, 8, "CID"], [126, 126, 90, 91, "CID"], [126, 126, 120, 121, "CID"], [158, 158, 7, 8, "CID"], [158, 158, 90, 91, "CID"], [158, 158, 120, 121, "CID"], [213, 213, 7, 8, "CID"], [213, 213, 90, 91, "CID"], [213, 213, 120, 121, "CID"]]], "clusters": [], "translated": "肠<8>缺血</8>-<5>再灌注损伤</5>后的肝细胞氧化应激。<9>缺血性</9>肠的再灌注导致急性<13>肝功能障碍</13>，其特征是肝细胞酶释放到血浆中、胆汁流速降低以及肝脏内的中性粒细胞隔离。这种急性<14>肝损伤</14>的病理生理学尚不清楚。本研究旨在确定氧化剂是否与<15>肝损伤</15>相关，并确定评估体内氧化剂暴露的几种间接方法的相对价值。对大鼠进行标准化肠道<10>缺血</10>-<6>再灌注损伤</6>。测定肝组织的脂质过氧化产物和<0>氧化和还原型谷胱甘肽</0>。肠<11>缺血</11>-<7>再灌注损伤</7>后，肝组织总<12>谷胱甘肽</12>无变化。<1>氧化型谷胱甘肽</1>（<2>GSSG</2>）在再灌注30和60分钟后显着增加。与这种损伤相关的任何脂质过氧化产物都没有增加。肠道再灌注期间肝组织内<3>GSSG</3>的增加表明肝细胞暴露于氧化应激。脂质过氧化产物没有显着增加表明氧化应激的强度不足以导致对肝细胞细胞膜的不可逆损伤。这些数据还表明，组织<4>GSSG</4>的测量可能是比脂质过氧化产物的测量更敏感的氧化应激指标。", "revised": true}
{"doc_key": "2131034", "sentences": [["Severe", "polyneuropathy", "and", "motor", "loss", "after", "intrathecal", "thiotepa", "combination", "chemotherapy", ":", "description", "of", "two", "cases", ".", "Two", "cases", "of", "severe", "delayed", "neurologic", "toxicity", "related", "to", "the", "administration", "of", "intrathecal", "(", "IT", ")", "combination", "chemotherapy", "including", "thiotepa", "(", "TSPA", ")", "are", "presented", ".", "Both", "cases", "developed", "axonal", "neuropathy", "with", "motor", "predominance", "in", "the", "lower", "extremities", "1", "and", "6", "months", "after", "IT", "chemotherapy", "was", "administered", ".", "Neurologic", "toxicities", "have", "been", "described", "with", "IT", "-", "methotrexate", ",", "IT", "-", "cytosine", "arabinoside", "and", "IT", "-", "TSPA", ".", "To", "our", "knowledge", ",", "however", ",", "axonal", "neuropathy", "following", "administration", "of", "these", "three", "agents", "has", "not", "been", "previously", "described", ".", "In", "spite", "of", "the", "fact", "that", "TSPA", "is", "a", "useful", "IT", "agent", ",", "its", "combination", "with", "MTX", ",", "ara", "-", "C", "and", "radiotherapy", "could", "cause", "severe", "neurotoxicity", ".", "This", "unexpected", "complication", "indicates", "the", "need", "for", "further", "toxicology", "research", "on", "IT", "-", "TSPA", "."]], "ner": [[[7, 7, "Chemical"], [35, 35, "Chemical"], [37, 37, "Chemical"], [81, 81, "Chemical"], [109, 109, "Chemical"], [144, 144, "Chemical"], [1, 1, "Disease"], [72, 72, "Chemical"], [119, 119, "Chemical"], [76, 77, "Chemical"], [121, 123, "Chemical"], [21, 22, "Disease"], [64, 65, "Disease"], [129, 129, "Disease"], [45, 46, "Disease"], [89, 90, "Disease"]]], "relations": [[[7, 7, 1, 1, "CID"], [35, 35, 1, 1, "CID"], [37, 37, 1, 1, "CID"], [81, 81, 1, 1, "CID"], [109, 109, 1, 1, "CID"], [144, 144, 1, 1, "CID"], [72, 72, 1, 1, "CID"], [119, 119, 1, 1, "CID"], [76, 77, 1, 1, "CID"], [121, 123, 1, 1, "CID"], [7, 7, 21, 22, "CID"], [7, 7, 64, 65, "CID"], [7, 7, 129, 129, "CID"], [35, 35, 21, 22, "CID"], [35, 35, 64, 65, "CID"], [35, 35, 129, 129, "CID"], [37, 37, 21, 22, "CID"], [37, 37, 64, 65, "CID"], [37, 37, 129, 129, "CID"], [81, 81, 21, 22, "CID"], [81, 81, 64, 65, "CID"], [81, 81, 129, 129, "CID"], [109, 109, 21, 22, "CID"], [109, 109, 64, 65, "CID"], [109, 109, 129, 129, "CID"], [144, 144, 21, 22, "CID"], [144, 144, 64, 65, "CID"], [144, 144, 129, 129, "CID"], [72, 72, 21, 22, "CID"], [72, 72, 64, 65, "CID"], [72, 72, 129, 129, "CID"], [119, 119, 21, 22, "CID"], [119, 119, 64, 65, "CID"], [119, 119, 129, 129, "CID"], [76, 77, 21, 22, "CID"], [76, 77, 64, 65, "CID"], [76, 77, 129, 129, "CID"], [121, 123, 21, 22, "CID"], [121, 123, 64, 65, "CID"], [121, 123, 129, 129, "CID"]]], "clusters": [], "translated": "鞘内注射<0>噻替哌</0>联合化疗后重度<6>多发性神经病</6>及运动功能丧失2例。报告了两例与鞘内 (IT) 联合化疗（包括<1>噻替哌</1> (<2>TSPA</2>) 相关的严重迟发性<11>神经系统毒性</11>。两例均在IT化疗后 1 个月和 6 个月出现<14>轴索性神经病变</14>，下肢运动为主。<12> 神经毒性</12>已被描述为IT-<7>甲氨蝶呤</7>、IT-<9>阿糖胞苷</9>和IT-<3>TSA</3>。然而，据我们所知，服用这三种药物后<15>轴索性神经病</15>的情况以前没有描述过。尽管<4>TSPA</4>是一种有用的IT剂，但它与<8>MTX</8>、<10>ara-C</10>和放射疗法的组合可能导致严重的<13>神经毒性</13>。这种意想不到的并发症表明需要对 IT-<5>TSPA</5>进行进一步的毒理学研究。", "revised": true}
{"doc_key": "2021990", "sentences": [["Diphenhydramine", "prevents", "the", "haemodynamic", "changes", "of", "cimetidine", "in", "ICU", "patients", ".", "Cimetidine", ",", "a", "histamine", "2", "(", "H2", ")", "antagonist", ",", "produces", "a", "decrease", "in", "arterial", "pressure", "due", "to", "vasodilatation", ",", "especially", "in", "critically", "ill", "patients", ".", "This", "may", "be", "because", "cimetidine", "acts", "as", "a", "histamine", "agonist", ".", "We", ",", "therefore", ",", "investigated", "the", "effects", "of", "the", "histamine", "1", "(", "H1", ")", "receptor", "antagonist", ",", "diphenhydramine", ",", "on", "the", "haemodynamic", "changes", "observed", "after", "cimetidine", "in", "ICU", "patients", ".", "Each", "patient", "was", "studied", "on", "two", "separate", "days", ".", "In", "a", "random", "fashion", ",", "they", "received", "cimetidine", "200", "mg", "iv", "on", "one", "day", ",", "and", "on", "the", "other", ",", "a", "pretreatment", "of", "diphenhydramine", "40", "mg", "iv", "with", "cimetidine", "200", "mg", "iv", ".", "In", "the", "non", "-", "pretreatment", "group", ",", "mean", "arterial", "pressure", "(", "MAP", ")", "decreased", "from", "107", ".", "4", "+", "/", "-", "8", ".", "4", "mmHg", "to", "86", ".", "7", "+", "/", "-", "11", ".", "4", "mmHg", "(", "P", "less", "than", "0", ".", "01", ")", "two", "minutes", "after", "cimetidine", ".", "Also", ",", "systemic", "vascular", "resistance", "(", "SVR", ")", "decreased", "during", "the", "eight", "-", "minute", "observation", "period", "(", "P", "less", "than", "0", ".", "01", ")", ".", "In", "contrast", ",", "in", "the", "pretreatment", "group", ",", "little", "haemodynamic", "change", "was", "seen", ".", "We", "conclude", "that", "an", "H1", "antagonist", "may", "be", "useful", "in", "preventing", "hypotension", "caused", "by", "iv", "cimetidine", ",", "since", "the", "vasodilating", "activity", "of", "cimetidine", "is", "mediated", ",", "in", "part", ",", "through", "the", "H1", "receptor", "."]], "ner": [[[6, 6, "Chemical"], [11, 11, "Chemical"], [41, 41, "Chemical"], [73, 73, "Chemical"], [94, 94, "Chemical"], [115, 115, "Chemical"], [167, 167, "Chemical"], [223, 223, "Chemical"], [230, 230, "Chemical"], [219, 219, "Disease"], [0, 0, "Chemical"], [65, 65, "Chemical"], [110, 110, "Chemical"], [14, 14, "Chemical"], [45, 45, "Chemical"], [57, 57, "Chemical"]]], "relations": [[[6, 6, 219, 219, "CID"], [11, 11, 219, 219, "CID"], [41, 41, 219, 219, "CID"], [73, 73, 219, 219, "CID"], [94, 94, 219, 219, "CID"], [115, 115, 219, 219, "CID"], [167, 167, 219, 219, "CID"], [223, 223, 219, 219, "CID"], [230, 230, 219, 219, "CID"]]], "clusters": [], "translated": " <10>苯海拉明</10>预防 ICU 患者 <0>西咪替丁</0> 的血流动力学变化。 <1>西咪替丁</1>，一种 <13>组胺</13> 2 (H2) 拮抗剂，由于血管舒张而降低动脉压，特别是在危重病人中。这可能是因为 <2>西咪替丁</2> 作为 <14>组胺</14> 激动剂起作用。因此，我们研究了 <15>组胺</15> 1 (H1) 受体拮抗剂 <11>苯海拉明</11> 对 ICU 患者 <3>西咪替丁</3> 后观察到的血流动力学变化的影响。在不同的两天对每位患者进行研究。以随机方式，他们一天接受 <12>苯海拉明</12> 40 mg iv 和 <5> 西咪替丁 </5> 的预处理 200 毫克静脉注射，另一天接受 <4> 西咪替丁 </4> 200 mg 静脉注射。在非预处理组中，平均动脉压 (MAP) 从 107.4 +/- 8.4 毫米汞柱下降至 86.7 +/- 11.4 毫米汞柱（P小于0.01）两分钟后 <6>西咪替丁</6>。此外，全身血管阻力 (SVR) 在 8 分钟的观察期内下降 (P小于0.01)。相反，在预处理组中，血流动力学变化很小。我们得出结论，H1 拮抗剂可能有助于预防由静脉注射 <7>西咪替丁</7> 引起的 <9>低血压</9>，因为<8>西咪替丁</8>的血管舒张活性部分是通过 H1 受体介导的。", "revised": true}
{"doc_key": "2239937", "sentences": [["Etiology", "of", "hypercalcemia", "in", "hemodialysis", "patients", "on", "calcium", "carbonate", "therapy", ".", "Fourteen", "of", "39", "dialysis", "patients", "(", "36", "%", ")", "became", "hypercalcemic", "after", "switching", "to", "calcium", "carbonate", "as", "their", "principal", "phosphate", "binder", ".", "In", "order", "to", "identify", "risk", "factors", "associated", "with", "the", "development", "of", "hypercalcemia", ",", "indirect", "parameters", "of", "intestinal", "calcium", "reabsorption", "and", "bone", "turnover", "rate", "in", "these", "14", "patients", "were", "compared", "with", "results", "in", "14", "eucalcemic", "patients", "matched", "for", "age", ",", "sex", ",", "length", "of", "time", "on", "dialysis", ",", "and", "etiology", "of", "renal", "disease", ".", "In", "addition", "to", "experiencing", "hypercalcemic", "episodes", "with", "peak", "calcium", "values", "of", "2", ".", "7", "to", "3", ".", "8", "mmol", "/", "L", "(", "10", ".", "7", "to", "15", ".", "0", "mg", "/", "dL", ")", ",", "patients", "in", "the", "hypercalcemic", "group", "exhibited", "a", "significant", "increase", "in", "the", "mean", "calcium", "concentration", "obtained", "during", "6", "months", "before", "the", "switch", ",", "compared", "with", "the", "mean", "value", "obtained", "during", "the", "7", "months", "of", "observation", "after", "the", "switch", "(", "2", ".", "4", "+", "/", "-", "0", ".", "03", "to", "2", ".", "5", "+", "/", "-", "0", ".", "03", "mmol", "/", "L", "[", "9", ".", "7", "+", "/", "-", "0", ".", "2", "to", "10", ".", "2", "+", "/", "-", "0", ".", "1", "mg", "/", "dL", "]", ",", "P", "=", "0", ".", "006", ")", ".", "In", "contrast", ",", "eucalcemic", "patients", "exhibited", "no", "change", "in", "mean", "calcium", "values", "over", "the", "same", "time", "period", "(", "2", ".", "3", "+", "/", "-", "0", ".", "05", "to", "2", ".", "3", "+", "/", "-", "0", ".", "05", "mmol", "/", "L", "[", "9", ".", "2", "+", "/", "-", "0", ".", "2", "to", "9", ".", "2", "+", "/", "-", "0", ".", "2", "mg", "/", "dL", "]", ")", ".", "CaCO3", "dosage", ",", "calculated", "dietary", "calcium", "intake", ",", "and", "circulating", "levels", "of", "vitamin", "D", "metabolites", "were", "similar", "in", "both", "groups", ".", "Physical", "activity", "index", "and", "predialysis", "serum", "bicarbonate", "levels", "also", "were", "similar", "in", "both", "groups", ".", "However", ",", "there", "was", "a", "significant", "difference", "in", "parameters", "reflecting", "bone", "turnover", "rates", "between", "groups", ".", "(", "ABSTRACT", "TRUNCATED", "AT", "250", "WORDS", ")"]], "ner": [[[7, 8, "Chemical"], [25, 26, "Chemical"], [278, 278, "Chemical"], [2, 2, "Disease"], [21, 21, "Disease"], [44, 44, "Disease"], [90, 90, "Disease"], [123, 123, "Disease"], [30, 30, "Chemical"], [50, 50, "Chemical"], [94, 94, "Chemical"], [132, 132, "Chemical"], [222, 222, "Chemical"], [283, 283, "Chemical"], [290, 291, "Chemical"], [305, 305, "Chemical"], [83, 84, "Disease"]]], "relations": [[[7, 8, 2, 2, "CID"], [7, 8, 21, 21, "CID"], [7, 8, 44, 44, "CID"], [7, 8, 90, 90, "CID"], [7, 8, 123, 123, "CID"], [25, 26, 2, 2, "CID"], [25, 26, 21, 21, "CID"], [25, 26, 44, 44, "CID"], [25, 26, 90, 90, "CID"], [25, 26, 123, 123, "CID"], [278, 278, 2, 2, "CID"], [278, 278, 21, 21, "CID"], [278, 278, 44, 44, "CID"], [278, 278, 90, 90, "CID"], [278, 278, 123, 123, "CID"]]], "clusters": [], "translated": "接受<0>碳酸钙</0>治疗的血液透析患者<3>高钙血症</3>的病因。39名透析患者中有14名（36%）在改用<1>碳酸钙</1>作为主要的<8>磷酸盐</8>结合剂后出现了<4>高钙血症</4>。为了确定与<5>高钙血症</5>发展相关的危险因素，将这14名患者的肠道<9>钙</9>重吸收和骨转换率的间接参数与14名正常钙血症患者的结果进行了比较，这些患者的年龄、性别、透析时间长短和<16>肾脏疾病</16>的病因相匹配。除了经历<6>高血钙</6>发作，峰值<10>钙</10>值为2.7至3.8毫摩尔/升（10.7至15.0毫克/分升），<7>高钙血症</7>组的患者在转换治疗前6个月期间获得的平均<11>钙</11>浓度显着增加，与转换后7个月观察期间获得的平均值相比（2.4+/-0.03至2.5+/-0.03毫摩尔/升[9.7+/-0.2至10.2+/-0.1毫克/分升]，P=0.006）。相比之下，正常钙血症患者在同一时间段内的平均<12>钙</12>值没有变化（2.3+/-0.05至2.3+/-0.05毫摩尔/升[9.2+/-0.2至9.2+/-0.2毫克/分升]）。<2>CaCO3</2>剂量、计算的膳食<13>钙</13>摄入量和<14>维生素D</14>代谢物的循环水平在两组中相似。两组的体力活动指数和透析前血清<15>碳酸氢盐</15>水平也相似。然而，反映骨转换率的参数在组间存在显着差异。（摘要被截断为250个单词）", "revised": true}
{"doc_key": "2358093", "sentences": [["The", "long", "-", "term", "safety", "of", "danazol", "in", "women", "with", "hereditary", "angioedema", ".", "Although", "the", "short", "-", "term", "safety", "(", "less", "than", "or", "equal", "to", "6", "months", ")", "of", "danazol", "has", "been", "established", "in", "a", "variety", "of", "settings", ",", "no", "information", "exists", "as", "to", "its", "long", "-", "term", "safety", ".", "We", "therefore", "investigated", "the", "long", "-", "term", "safety", "of", "danazol", "by", "performing", "a", "retrospective", "chart", "review", "of", "60", "female", "patients", "with", "hereditary", "angioedema", "treated", "with", "danazol", "for", "a", "continuous", "period", "of", "6", "months", "or", "longer", ".", "The", "mean", "age", "of", "the", "patients", "was", "35", ".", "2", "years", "and", "the", "mean", "duration", "of", "therapy", "was", "59", ".", "7", "months", ".", "Virtually", "all", "patients", "experienced", "one", "or", "more", "adverse", "reactions", ".", "Menstrual", "abnormalities", "(", "79", "%", ")", ",", "weight", "gain", "(", "60", "%", ")", ",", "muscle", "cramps", "/", "myalgias", "(", "40", "%", ")", ",", "and", "transaminase", "elevations", "(", "40", "%", ")", "were", "the", "most", "common", "adverse", "reactions", ".", "The", "drug", "was", "discontinued", "due", "to", "adverse", "reactions", "in", "8", "patients", ".", "No", "patient", "has", "died", "or", "suffered", "any", "apparent", "long", "-", "term", "sequelae", "that", "were", "directly", "attributable", "to", "the", "drug", ".", "We", "conclude", "that", ",", "despite", "a", "relatively", "high", "incidence", "of", "adverse", "reactions", ",", "danazol", "has", "proven", "to", "be", "remarkably", "safe", "over", "the", "long", "-", "term", "in", "this", "group", "of", "patients", "."]], "ner": [[[6, 6, "Chemical"], [29, 29, "Chemical"], [59, 59, "Chemical"], [75, 75, "Chemical"], [201, 201, "Chemical"], [119, 120, "Disease"], [126, 127, "Disease"], [133, 134, "Disease"], [10, 11, "Disease"], [71, 72, "Disease"], [136, 136, "Disease"]]], "relations": [[[6, 6, 119, 120, "CID"], [29, 29, 119, 120, "CID"], [59, 59, 119, 120, "CID"], [75, 75, 119, 120, "CID"], [201, 201, 119, 120, "CID"], [6, 6, 126, 127, "CID"], [29, 29, 126, 127, "CID"], [59, 59, 126, 127, "CID"], [75, 75, 126, 127, "CID"], [201, 201, 126, 127, "CID"], [6, 6, 133, 134, "CID"], [29, 29, 133, 134, "CID"], [59, 59, 133, 134, "CID"], [75, 75, 133, 134, "CID"], [201, 201, 133, 134, "CID"]]], "clusters": [], "translated": "<0>达那唑</0>对患有<8>遗传性血管性水肿</8>的女性的长期安全性。尽管<1>达那唑</1>的短期安全性（小于或等于6个月）已在多种情况下得到证实，但尚无关于其长期安全性的信息。因此，我们通过对60名患有<9>遗传性血管性水肿</9>的女性患者进行回顾性图表审查，调查了<2>达那唑</2>的长期安全性，这些患者接受了<3>达那唑</3>连续治疗期限为6个月或更长。患者的平均年龄为35.2年，平均治疗时间为59.7个月。几乎所有患者都经历过一种或多种不良反应。<5>月经异常</5>（79%），<6>体重增加</6>（60%），<7>肌肉痉挛</7> / <10>肌痛</10>（40%）和转氨酶升高（40%）是最常见的不良反应。8例患者因不良反应停药。没有患者死亡或遭受直接归因于该药物的任何明显的长期后遗症。我们的结论是，尽管不良反应的发生率相对较高，<4>达那唑</4>已被证明在该组患者中长期使用非常安全。", "revised": true}
{"doc_key": "2217015", "sentences": [["Mefenamic", "acid", "-", "induced", "neutropenia", "and", "renal", "failure", "in", "elderly", "females", "with", "hypothyroidism", ".", "We", "report", "mefenamic", "acid", "-", "induced", "non", "-", "oliguric", "renal", "failure", "and", "severe", "neutropenia", "occurring", "simultaneously", "in", "two", "elderly", "females", ".", "The", "neutropenia", "was", "due", "to", "maturation", "arrest", "of", "the", "myeloid", "series", "in", "one", "patient", ".", "Both", "patients", "were", "also", "hypothyroid", ",", "but", "it", "is", "not", "clear", "whether", "this", "was", "a", "predisposing", "factor", "to", "the", "development", "of", "these", "adverse", "reactions", ".", "However", ",", "it", "would", "seem", "prudent", "not", "to", "use", "mefenamic", "acid", "in", "hypothyroid", "patients", "until", "the", "hypothyroidism", "has", "been", "corrected", "."]], "ner": [[[0, 1, "Chemical"], [16, 17, "Chemical"], [84, 85, "Chemical"], [4, 4, "Disease"], [27, 27, "Disease"], [36, 36, "Disease"], [6, 7, "Disease"], [23, 24, "Disease"], [12, 12, "Disease"], [54, 54, "Disease"], [87, 87, "Disease"], [91, 91, "Disease"]]], "relations": [[[0, 1, 4, 4, "CID"], [0, 1, 27, 27, "CID"], [0, 1, 36, 36, "CID"], [16, 17, 4, 4, "CID"], [16, 17, 27, 27, "CID"], [16, 17, 36, 36, "CID"], [84, 85, 4, 4, "CID"], [84, 85, 27, 27, "CID"], [84, 85, 36, 36, "CID"], [0, 1, 6, 7, "CID"], [0, 1, 23, 24, "CID"], [16, 17, 6, 7, "CID"], [16, 17, 23, 24, "CID"], [84, 85, 6, 7, "CID"], [84, 85, 23, 24, "CID"]]], "clusters": [], "translated": " <0>甲芬那酸</0> - 诱发<3>中性粒细胞减少症</3>和<6>肾功能衰竭</6> 老年女性<8>甲状腺功能减退症</8>。我们报道了<1>甲芬那酸</1>诱发的非少尿性<7>肾功能衰竭</7>和严重的<4>中性粒细胞减少症</4>同时发生在两名老年女性身上。<5>中性粒细胞减少症</5>是由于一名患者的骨髓系列成熟停滞所致。两名患者也都患有<9>甲状腺功能减退症</9>，但尚不清楚这是否是发生这些不良反应的诱发因素。然而，在<11>甲状腺功能减退症</11>得到纠正之前，不对<10>甲状腺功能减退症</10>患者使用<2>甲芬那酸</2>似乎是谨慎的做法。", "revised": true}
{"doc_key": "2173761", "sentences": [["Effects", "of", "cromakalim", "and", "pinacidil", "on", "large", "epicardial", "and", "small", "coronary", "arteries", "in", "conscious", "dogs", ".", "The", "effects", "of", "i", ".", "v", ".", "bolus", "administration", "of", "cromakalim", "(", "1", "-", "10", "micrograms", "/", "kg", ")", "and", "pinacidil", "(", "3", "-", "100", "micrograms", "/", "kg", ")", "on", "large", "(", "circumflex", "artery", ")", "and", "small", "coronary", "arteries", "and", "on", "systemic", "hemodynamics", "were", "investigated", "in", "chronically", "instrumented", "conscious", "dogs", "and", "compared", "to", "those", "of", "nitroglycerin", "(", "0", ".", "03", "-", "10", "micrograms", "/", "kg", ")", ".", "Nitroglycerin", ",", "up", "to", "0", ".", "3", "micrograms", "/", "kg", ",", "selectively", "increased", "circumflex", "artery", "diameter", "(", "CxAD", ")", "without", "simultaneously", "affecting", "any", "other", "cardiac", "or", "systemic", "hemodynamic", "parameter", ".", "In", "contrast", ",", "cromakalim", "and", "pinacidil", "at", "all", "doses", "and", "nitroglycerin", "at", "doses", "higher", "than", "0", ".", "3", "micrograms", "/", "kg", "simultaneously", "and", "dose", "-", "dependently", "increased", "CxAD", ",", "coronary", "blood", "flow", "and", "heart", "rate", "and", "decreased", "coronary", "vascular", "resistance", "and", "aortic", "pressure", ".", "Cromakalim", "was", "approximately", "8", "-", "to", "9", ".", "5", "-", "fold", "more", "potent", "than", "pinacidil", "in", "increasing", "CxAD", ".", "Vasodilation", "of", "large", "and", "small", "coronary", "vessels", "and", "hypotension", "induced", "by", "cromakalim", "and", "pinacidil", "were", "not", "affected", "by", "prior", "combined", "beta", "adrenergic", "and", "muscarinic", "receptors", "blockade", "but", "drug", "-", "induced", "tachycardia", "was", "abolished", ".", "When", "circumflex", "artery", "blood", "flow", "was", "maintained", "constant", ",", "the", "increases", "in", "CxAD", "induced", "by", "cromakalim", "(", "10", "micrograms", "/", "kg", ")", ",", "pinacidil", "(", "30", "micrograms", "/", "kg", ")", "and", "nitroglycerin", "(", "10", "micrograms", "/", "kg", ")", "were", "reduced", "by", "68", "+", "/", "-", "7", ",", "54", "+", "/", "-", "9", "and", "1", "+", "/", "-", "1", "%", ",", "respectively", ".", "Thus", ",", "whereas", "nitroglycerin", "preferentially", "and", "flow", "-", "independently", "dilates", "large", "coronary", "arteries", ",", "cromakalim", "and", "pinacidil", "dilate", "both", "large", "and", "small", "coronary", "arteries", "and", "this", "effect", "is", "not", "dependent", "upon", "the", "simultaneous", "beta", "adrenoceptors", "-", "mediated", "rise", "in", "myocardial", "metabolic", "demand", ".", "Finally", ",", "two", "mechanisms", "at", "least", ",", "direct", "vasodilation", "and", "flow", "dependency", ",", "are", "involved", "in", "the", "cromakalim", "-", "and", "pinacidil", "-", "induced", "increase", "in", "CxAD", "."]], "ner": [[[2, 2, "Chemical"], [26, 26, "Chemical"], [116, 116, "Chemical"], [157, 157, "Chemical"], [187, 187, "Chemical"], [225, 225, "Chemical"], [286, 286, "Chemical"], [332, 332, "Chemical"], [184, 184, "Disease"], [206, 206, "Disease"], [4, 4, "Chemical"], [36, 36, "Chemical"], [118, 118, "Chemical"], [171, 171, "Chemical"], [189, 189, "Chemical"], [233, 233, "Chemical"], [288, 288, "Chemical"], [335, 335, "Chemical"], [71, 71, "Chemical"], [83, 83, "Chemical"], [123, 123, "Chemical"], [241, 241, "Chemical"], [275, 275, "Chemical"], [196, 201, "Chemical"]]], "relations": [[[2, 2, 184, 184, "CID"], [26, 26, 184, 184, "CID"], [116, 116, 184, 184, "CID"], [157, 157, 184, 184, "CID"], [187, 187, 184, 184, "CID"], [225, 225, 184, 184, "CID"], [286, 286, 184, 184, "CID"], [332, 332, 184, 184, "CID"], [2, 2, 206, 206, "CID"], [26, 26, 206, 206, "CID"], [116, 116, 206, 206, "CID"], [157, 157, 206, 206, "CID"], [187, 187, 206, 206, "CID"], [225, 225, 206, 206, "CID"], [286, 286, 206, 206, "CID"], [332, 332, 206, 206, "CID"], [4, 4, 184, 184, "CID"], [36, 36, 184, 184, "CID"], [118, 118, 184, 184, "CID"], [171, 171, 184, 184, "CID"], [189, 189, 184, 184, "CID"], [233, 233, 184, 184, "CID"], [288, 288, 184, 184, "CID"], [335, 335, 184, 184, "CID"], [4, 4, 206, 206, "CID"], [36, 36, 206, 206, "CID"], [118, 118, 206, 206, "CID"], [171, 171, 206, 206, "CID"], [189, 189, 206, 206, "CID"], [233, 233, 206, 206, "CID"], [288, 288, 206, 206, "CID"], [335, 335, 206, 206, "CID"]]], "clusters": [], "translated": " <0>克洛卡林</0> 和 <10>吡那地尔</10> 对有意识的狗的大心外膜和小冠状动脉的影响。 <1>克洛卡林</1> (1-10微克/公斤) 和<11>吡那地尔</11> (3-100微克/公斤) 对大冠状动脉（回旋支）和小冠状动脉以及全身血流动力学的推注给药在长期仪器清醒的狗中进行了调查，并与<18>硝酸甘油</18>（0.03-10微克/千克）进行了比较。<19>硝酸甘油</19>，至0.3微克/千克，选择性地增加回旋支动脉直径（CxAD），而不会同时影响任何其他心脏或全身血液动力学参数。相比之下，所有剂量的<2>克洛卡林</2> 和<12>吡那地尔</12> 以及剂量高于0.3的<20>硝酸甘油</20> 同时、剂量依赖性地增加 CxAD、冠状动脉血流量和心率并降低冠状血管阻力和主动脉压力。<3>克洛卡林</3> 在增加 CxAD 方面大约比<13>吡那地尔</13> 强 5 倍。由<4>克洛卡林</4> 和<14>吡那地尔</14> 引起的大小冠状血管血管舒张和<8>低血压</8> 不受先前联合<23>β肾上腺素能和毒蕈碱受体阻断的影响</23>，但药物引起的<9>心动过速</9> 被废除。当回旋支动脉血流量保持恒定时，<5>克洛卡林</5> （10微克/千克）、<15>吡那地尔</15> （30微克/千克）和<21>硝酸甘油</21> （10微克/千克）所引起的CxAD升高分别减少了68+/-7、54+/-9和1+/-1%。因此，虽然<22>硝酸甘油</22> 优先且与流量无关地扩张大冠状动脉，但<6>克洛卡林</6> 和<16>吡那地尔</16> 可扩张大冠状动脉和小冠状动脉，且这种作用不依赖于同时 β肾上腺素能受体介导的心肌代谢需求的增加。最后，<7>克洛卡林</7> 和<17>吡那地尔</17> 诱导的CxAD增加至少涉及两种机制，即直接血管舒张和血流依赖。", "revised": true}
{"doc_key": "1158089", "sentences": [["Fatty", "liver", "induced", "by", "tetracycline", "in", "the", "rat", ".", "Dose", "-", "response", "relationships", "and", "effect", "of", "sex", ".", "Dose", "-", "response", "relationships", ",", "biochemical", "mechanisms", ",", "and", "sex", "differences", "in", "the", "experimental", "fatty", "liver", "induced", "by", "tetracycline", "were", "studied", "in", "the", "intact", "rat", "and", "with", "the", "isolated", "perfused", "rat", "liver", "in", "vitro", ".", "In", "the", "intact", "male", "and", "female", "rat", ",", "no", "direct", "relationship", "was", "observed", "between", "dose", "of", "tetracycline", "and", "hepatic", "accumulation", "of", "triglyceride", ".", "With", "provision", "of", "adequate", "oleic", "acid", "as", "a", "substrate", "for", "the", "isolated", "perfused", "liver", ",", "a", "direct", "relationship", "was", "observed", "between", "dose", "of", "tetracycline", "and", "both", "accumulation", "of", "triglyceride", "in", "the", "liver", "and", "depression", "of", "output", "of", "triglyceride", "by", "livers", "from", "male", "and", "female", "rats", ".", "Marked", "differences", "were", "observed", "between", "female", "and", "male", "rats", "with", "regard", "to", "base", "line", "(", "control", ")", "hepatic", "concentration", "of", "triglyceride", "and", "output", "of", "triglyceride", ".", "Accumulation", "of", "hepatic", "triglyceride", ",", "as", "a", "per", "cent", "of", "control", "values", ",", "in", "response", "to", "graded", "doses", "of", "tetracycline", ",", "did", "not", "differ", "significantly", "between", "male", ",", "female", "and", "pregnant", "rat", "livers", ".", "However", ",", "livers", "from", "female", ",", "and", "especially", "pregnant", "female", "rats", ",", "were", "strikingly", "resistant", "to", "the", "effects", "of", "tetracycline", "on", "depression", "of", "output", "of", "triglyceride", "under", "these", "experimental", "conditions", ".", "These", "differences", "between", "the", "sexes", "could", "not", "be", "related", "to", "altered", "disposition", "of", "tetracycline", "or", "altered", "uptake", "of", "oleic", "acid", ".", "Depressed", "hepatic", "secretion", "of", "triglyceride", "accounted", "only", "for", "30", "to", "50", "%", "of", "accumulated", "hepatic", "triglyceride", ",", "indicating", "that", "additional", "mechanisms", "must", "be", "involved", "in", "the", "production", "of", "the", "triglyceride", "-", "rich", "fatty", "liver", "in", "response", "to", "tetracycline", "."]], "ner": [[[4, 4, "Chemical"], [36, 36, "Chemical"], [69, 69, "Chemical"], [99, 99, "Chemical"], [167, 167, "Chemical"], [201, 201, "Chemical"], [226, 226, "Chemical"], [271, 271, "Chemical"], [0, 1, "Disease"], [32, 33, "Disease"], [266, 267, "Disease"], [74, 74, "Chemical"], [104, 104, "Chemical"], [113, 113, "Chemical"], [142, 142, "Chemical"], [146, 146, "Chemical"], [151, 151, "Chemical"], [207, 207, "Chemical"], [238, 238, "Chemical"], [249, 249, "Chemical"], [263, 263, "Chemical"], [80, 81, "Chemical"], [231, 232, "Chemical"], [109, 109, "Disease"], [203, 203, "Disease"]]], "relations": [[[4, 4, 0, 1, "CID"], [4, 4, 32, 33, "CID"], [4, 4, 266, 267, "CID"], [36, 36, 0, 1, "CID"], [36, 36, 32, 33, "CID"], [36, 36, 266, 267, "CID"], [69, 69, 0, 1, "CID"], [69, 69, 32, 33, "CID"], [69, 69, 266, 267, "CID"], [99, 99, 0, 1, "CID"], [99, 99, 32, 33, "CID"], [99, 99, 266, 267, "CID"], [167, 167, 0, 1, "CID"], [167, 167, 32, 33, "CID"], [167, 167, 266, 267, "CID"], [201, 201, 0, 1, "CID"], [201, 201, 32, 33, "CID"], [201, 201, 266, 267, "CID"], [226, 226, 0, 1, "CID"], [226, 226, 32, 33, "CID"], [226, 226, 266, 267, "CID"], [271, 271, 0, 1, "CID"], [271, 271, 32, 33, "CID"], [271, 271, 266, 267, "CID"]]], "clusters": [], "translated": " <0>四环素</0>诱导大鼠<8>脂肪肝</8>。剂量反应关系和性别的影响。在完整大鼠和体外离体灌注大鼠肝脏中研究了<1>四环素</1>诱导的实验性<9>脂肪肝</9>的剂量反应关系、生化机制和性别差异。在完整的雄性和雌性大鼠中，未观察到<2>四环素</2>的剂量与肝脏蓄积<11>甘油三酯</11>之间存在直接关系。通过提供足够的<21>油酸</21>作为离体灌注肝脏的底物，观察到<3>四环素</3>的剂量与肝脏<12>甘油三酯</12>的积累之间存在直接关系，并且会<23>抑制</23>雄性和雌性大鼠肝脏的<13>甘油三酯</13>输出。在<14>甘油三酯</14>的基线（对照）肝脏浓度和<15>甘油三酯</15>的输出方面，观察到雌性和雄性大鼠之间存在显着差异。响应分级剂量的<4>四环素</4>，在雄性、雌性和怀孕大鼠肝脏之间未观察到肝脏<16>甘油三酯</16>的积累存在显着差异。然而，在这些实验中，雌性，尤其是妊娠雌性大鼠的肝脏对<5>四环素</5>对于<24>抑制</24><17>甘油三酯</17>的输出具有显著的抵抗力。性别之间的这些差异与<6>四环素</6>的处置改变或<22>油酸</22>的摄取改变无关。只有肝脏<18>甘油三酯</18>受到抑制，占肝脏<19>甘油三酯</19>累积量的30%至50%，表明在对<7>四环素</7>的反应中存在其他机制，包括肝脏产生富含<20>甘油三酯</20>的<10>脂肪肝</10>。", "revised": true}
{"doc_key": "2383364", "sentences": [["Patient", "tolerance", "study", "of", "topical", "chlorhexidine", "diphosphanilate", ":", "a", "new", "topical", "agent", "for", "burns", ".", "Effective", "topical", "antimicrobial", "agents", "decrease", "infection", "and", "mortality", "in", "burn", "patients", ".", "Chlorhexidine", "phosphanilate", "(", "CHP", ")", ",", "a", "new", "broad", "-", "spectrum", "antimicrobial", "agent", ",", "has", "been", "evaluated", "as", "a", "topical", "burn", "wound", "dressing", "in", "cream", "form", ",", "but", "preliminary", "clinical", "trials", "reported", "that", "it", "was", "painful", "upon", "application", ".", "This", "study", "compared", "various", "concentrations", "of", "CHP", "to", "determine", "if", "a", "tolerable", "concentration", "could", "be", "identified", "with", "retention", "of", "antimicrobial", "efficacy", ".", "Twenty", "-", "nine", "burn", "patients", ",", "each", "with", "two", "similar", "burns", "which", "could", "be", "separately", "treated", ",", "were", "given", "pairs", "of", "treatments", "at", "successive", "12", "-", "h", "intervals", "over", "a", "3", "-", "day", "period", ".", "One", "burn", "site", "was", "treated", "with", "each", "of", "four", "different", "CHP", "concentrations", ",", "from", "0", ".", "25", "per", "cent", "to", "2", "per", "cent", ",", "their", "vehicle", ",", "and", "1", "per", "cent", "silver", "sulphadiazine", "(", "AgSD", ")", "cream", ",", "an", "antimicrobial", "agent", "frequently", "used", "for", "topical", "treatment", "of", "burn", "wounds", ".", "The", "other", "site", "was", "always", "treated", "with", "AgSD", "cream", ".", "There", "was", "a", "direct", "relationship", "between", "CHP", "concentration", "and", "patients", "'", "ratings", "of", "pain", "on", "an", "analogue", "scale", ".", "The", "0", ".", "25", "per", "cent", "CHP", "cream", "was", "closest", "to", "AgSD", "in", "pain", "tolerance", ";", "however", ",", "none", "of", "the", "treatments", "differed", "statistically", "from", "AgSD", "or", "from", "each", "other", ".", "In", "addition", ",", "ease", "of", "application", "of", "CHP", "creams", "was", "less", "satisfactory", "than", "that", "of", "AgSD", ".", "It", "was", "concluded", "that", "formulations", "at", "or", "below", "0", ".", "5", "per", "cent", "CHP", "may", "prove", "acceptable", "for", "wound", "care", ",", "but", "the", "vehicle", "system", "needs", "pharmaceutical", "improvement", "to", "render", "it", "more", "tolerable", "and", "easier", "to", "use", "."]], "ner": [[[5, 6, "Chemical"], [27, 28, "Chemical"], [30, 30, "Chemical"], [72, 72, "Chemical"], [133, 133, "Chemical"], [189, 189, "Chemical"], [208, 208, "Chemical"], [240, 240, "Chemical"], [263, 263, "Chemical"], [196, 196, "Disease"], [215, 215, "Disease"], [13, 13, "Disease"], [24, 24, "Disease"], [47, 47, "Disease"], [91, 91, "Disease"], [98, 98, "Disease"], [124, 124, "Disease"], [170, 170, "Disease"], [20, 20, "Disease"], [154, 155, "Chemical"], [157, 157, "Chemical"], [180, 180, "Chemical"], [213, 213, "Chemical"], [227, 227, "Chemical"], [248, 248, "Chemical"]]], "relations": [[[5, 6, 196, 196, "CID"], [5, 6, 215, 215, "CID"], [27, 28, 196, 196, "CID"], [27, 28, 215, 215, "CID"], [30, 30, 196, 196, "CID"], [30, 30, 215, 215, "CID"], [72, 72, 196, 196, "CID"], [72, 72, 215, 215, "CID"], [133, 133, 196, 196, "CID"], [133, 133, 215, 215, "CID"], [189, 189, 196, 196, "CID"], [189, 189, 215, 215, "CID"], [208, 208, 196, 196, "CID"], [208, 208, 215, 215, "CID"], [240, 240, 196, 196, "CID"], [240, 240, 215, 215, "CID"], [263, 263, 196, 196, "CID"], [263, 263, 215, 215, "CID"]]], "clusters": [], "translated": "外用<0>二膦酸氯己定</0>的患者耐受性研究：一种新的<11>烧伤外用剂</11>。有效的外用抗菌药物可降低<12>烧伤</12>患者的<18>感染</18>和死亡率。<1>氯己定磷苯甲酸酯</1>（<2>CHP</2>），一种新型广谱抗菌剂，已被评估为局部<13>烧伤</13>伤口敷料的霜剂形式，但初步临床试验报告说使用时会很痛。本研究比较了各种浓度的<3>CHP</3>，以确定是否可以确定可耐受的浓度并保持抗菌功效。29名<14>烧伤</14>患者，每名患者有两处类似的<15>烧伤</15>，可以单独治疗，在3天的时间内以连续12小时的间隔进行成对治疗。一处<16>烧伤</16>使用不同的<4>CHP</4>浓度，从0.25%至2%，以及它们的载体，还使用一种经常用于<17>烧伤</17>伤口的局部治疗药物——1%<19>磺胺嘧啶银</19>（<20>AgSD</20>）乳膏。另一处总是用<21>AgSD</21>乳膏处理。<5>CHP</5>浓度与患者在模拟量表上对<9>疼痛</9>的评分之间存在直接关系。0.25%的<6>CHP</6>乳膏在<10>疼痛</10>耐受性方面最接近<22>AgSD</22>，然而，没有一种处理与<23>AgSD</23>或彼此之间有统计学差异。此外，<7>CHP</7>乳膏的易用性不如<24>AgSD</24>。得出的结论是，配方为0.5%或以下的<8>CHP</8>可能被证明可用于伤口护理，但载体系统需要药物改进以使其更容易耐受和更易于使用。", "revised": true}
{"doc_key": "1756784", "sentences": [["Damage", "of", "substantia", "nigra", "pars", "reticulata", "during", "pilocarpine", "-", "induced", "status", "epilepticus", "in", "the", "rat", ":", "immunohistochemical", "study", "of", "neurons", ",", "astrocytes", "and", "serum", "-", "protein", "extravasation", ".", "The", "substantia", "nigra", "has", "a", "gating", "function", "controlling", "the", "spread", "of", "epileptic", "seizure", "activity", ".", "Additionally", ",", "in", "models", "of", "prolonged", "status", "epilepticus", "the", "pars", "reticulata", "of", "substantia", "nigra", "(", "SNR", ")", "suffers", "from", "a", "massive", "lesion", "which", "may", "arise", "from", "a", "massive", "metabolic", "derangement", "and", "hyperexcitation", "developing", "in", "the", "activated", "SNR", ".", "In", "this", "study", ",", "status", "epilepticus", "was", "induced", "by", "systemic", "injection", "of", "pilocarpine", "in", "rats", ".", "The", "neuropathology", "of", "SNR", "was", "investigated", "using", "immunohistochemical", "techniques", "with", "the", "major", "emphasis", "on", "the", "time", "-", "course", "of", "changes", "in", "neurons", "and", "astrocytes", ".", "Animals", "surviving", "20", ",", "30", ",", "40", ",", "60", "min", ",", "2", ",", "3", ",", "6", "hours", ",", "1", ",", "2", ",", "and", "3", "days", "after", "induction", "of", "status", "epilepticus", "were", "perfusion", "-", "fixed", ",", "and", "brains", "processed", "for", "immunohistochemical", "staining", "of", "SNR", ".", "Nissl", "-", "staining", "and", "antibodies", "against", "the", "neuron", "-", "specific", "calcium", "-", "binding", "protein", ",", "parvalbumin", ",", "served", "to", "detect", "neuronal", "damage", "in", "SNR", ".", "Antibodies", "against", "the", "astroglia", "-", "specific", "cytoskeletal", "protein", ",", "glial", "fibrillary", "acidic", "protein", "(", "GFAP", ")", ",", "and", "against", "the", "glial", "calcium", "-", "binding", "protein", ",", "S", "-", "100", "protein", ",", "were", "used", "to", "assess", "the", "status", "of", "astrocytes", ".", "Immunohistochemical", "staining", "for", "serum", "-", "albumin", "and", "immunoglobulins", "in", "brain", "tissue", "was", "taken", "as", "indicator", "of", "blood", "-", "brain", "barrier", "disturbances", "and", "vasogenic", "edema", "formation", ".", "Immunohistochemical", "staining", "indicated", "loss", "of", "GFAP", "-", "staining", "already", "at", "30", "min", "after", "induction", "of", "seizures", "in", "an", "oval", "focus", "situated", "in", "the", "center", "of", "SNR", "while", "sparing", "medial", "and", "lateral", "aspects", ".", "At", "1", "h", "there", "was", "additional", "vacuolation", "in", "S", "-", "100", "protein", "staining", ".", "By", "2", "hours", ",", "parvalbumin", "-", "staining", "changed", "in", "the", "central", "SNR", "indicating", "neuronal", "damage", ",", "and", "Nissl", "-", "staining", "visualized", "some", "neuronal", "distortion", ".", "Staining", "for", "serum", "-", "proteins", "occurred", "in", "a", "patchy", "manner", "throughout", "the", "forebrain", "during", "the", "first", "hours", ".", "By", "6", "h", ",", "vasogenic", "edema", "covered", "the", "lesioned", "SNR", ".", "By", "24", "h", ",", "glial", "and", "neuronal", "markers", "indicated", "a", "massive", "lesion", "in", "the", "center", "of", "SNR", ".", "By", "48", "-", "72", "h", ",", "astrocytes", "surrounding", "the", "lesion", "increased", "in", "size", ",", "and", "polymorphic", "phagocytotic", "cells", "invaded", "the", "damaged", "area", ".", "In", "a", "further", "group", "of", "animals", "surviving", "1", "to", "5", "days", ",", "conventional", "paraffin", "-", "sections", "confirmed", "the", "neuronal", "and", "glial", "damage", "of", "SNR", ".", "Additional", "pathology", "of", "similar", "quality", "was", "found", "in", "the", "globus", "pallidus", ".", "Since", "astrocytes", "were", "always", "damaged", "in", "parallel", "with", "neurons", "in", "SNR", "it", "is", "proposed", "that", "the", "anatomical", "and", "functional", "interrelationship", "between", "neurons", "and", "astrocytes", "is", "particularly", "tight", "in", "SNR", ".", "Both", "cell", "elements", "may", "suffer", "in", "common", "from", "metabolic", "disturbance", "and", "neurotransmitter", "dysfunction", "as", "occur", "during", "massive", "status", "epilepticus", "."]], "ner": [[[7, 7, "Chemical"], [93, 93, "Chemical"], [0, 5, "Disease"], [355, 356, "Disease"], [420, 422, "Disease"], [10, 11, "Disease"], [48, 50, "Disease"], [85, 86, "Disease"], [150, 151, "Disease"], [483, 484, "Disease"], [477, 478, "Disease"], [176, 176, "Chemical"], [212, 212, "Chemical"], [39, 40, "Disease"], [71, 72, "Disease"], [186, 187, "Disease"], [317, 318, "Disease"], [253, 254, "Disease"], [351, 352, "Disease"], [272, 272, "Disease"]]], "relations": [[[7, 7, 0, 5, "CID"], [7, 7, 355, 356, "CID"], [7, 7, 420, 422, "CID"], [93, 93, 0, 5, "CID"], [93, 93, 355, 356, "CID"], [93, 93, 420, 422, "CID"], [7, 7, 10, 11, "CID"], [7, 7, 48, 50, "CID"], [7, 7, 85, 86, "CID"], [7, 7, 150, 151, "CID"], [7, 7, 483, 484, "CID"], [93, 93, 10, 11, "CID"], [93, 93, 48, 50, "CID"], [93, 93, 85, 86, "CID"], [93, 93, 150, 151, "CID"], [93, 93, 483, 484, "CID"], [7, 7, 477, 478, "CID"], [93, 93, 477, 478, "CID"]]], "clusters": [], "translated": "<0>毛果芸香碱</0>诱发大鼠<5>癫痫持续状态</5>时的<2>黑质网状部损伤</2>：神经元、星形胶质细胞和血清蛋白外渗的免疫组织化学研究。黑质具有控制<13>癫痫发作</13>活动扩散的门控功能。此外，在<6>长期癫痫持续状态</6>的模型中，黑质网状部(SNR)遭受巨大的损伤，这可能是由大量的<14>代谢紊乱</14>和激活过度兴奋引起的信噪比。本研究通过全身注射<1>毛果芸香碱</1>诱导大鼠<7>癫痫持续状态</7>。使用免疫组化技术研究了 SNR 的神经病理学，重点是神经元和星形胶质细胞随时间变化的过程。在<8>癫痫持续状态</8>诱导后存活20, 30, 40,60分钟, 2, 3, 6小时, 1, 2和3天的动物被灌注固定，并对大脑进行 SNR 免疫组化染色处理。Nissl染色和针对神经元特异性<11>钙</11>结合蛋白小清蛋白的抗体用于检测 SNR 中的<15>神经元损伤</15>。针对星形胶质细胞特异性细胞骨架蛋白、胶质纤维酸性蛋白(GFAP)和针对胶质细胞<12>钙</12>结合蛋白S-100蛋白的抗体被用于评估星形胶质细胞的状态。脑组织血清白蛋白和免疫球蛋白的免疫组织化学染色作为血脑屏障障碍和<17>血管源性水肿</17>形成的指标。免疫组织化学染色表明，在位于SNR中心的椭圆形病灶中诱导<19>癫痫发作</19>后30分钟时，GFAP染色已经丢失，同时不影响内侧和外侧。1小时后，S-100蛋白染色出现额外的空泡形成。2小时后，小白蛋白染色在中央SNR中发生变化，表明<16>神经元损伤</16>，尼氏染色显示一些神经元畸变。在最初的几个小时内，血清蛋白染色以斑驳的方式出现在整个前脑中。到6小时时，<18>血管源性水肿</18>覆盖了<3>受损的 SNR</3>。到24小时，胶质细胞和神经元标记物表明SNR中心有一个巨大的损伤。至48-72小时，病灶周围星形胶质细胞体积增大，多形性吞噬细胞侵入病灶。在另一组存活1至5天的动物中，常规石蜡切片证实了SNR的<4>神经元和神经胶质损伤</4>。在苍白球中发现了其他类似性质的病理。由于星形胶质细胞在SNR中总是与神经元平行受损，因此提出神经元和星形胶质细胞之间的解剖学和功能相互关系在SNR中特别紧密。两种细胞成分可能共同遭受代谢紊乱和<10>神经递质功能障碍</10>，如在大量<9>癫痫持续状态</9>期间发生的那样。", "revised": true}
{"doc_key": "2484903", "sentences": [["Unusual", "complications", "of", "antithyroid", "drug", "therapy", ":", "four", "case", "reports", "and", "review", "of", "literature", ".", "Two", "cases", "of", "propylthiouracil", "-", "associated", "acute", "hepatitis", ",", "one", "case", "of", "fatal", "methimazole", "-", "associated", "hepatocellular", "necrosis", "and", "one", "case", "of", "propylthiouracil", "-", "associated", "lupus", "-", "like", "syndrome", "are", "described", ".", "The", "literature", "related", "to", "antithyroid", "drug", "side", "effects", "and", "the", "mechanisms", "for", "their", "occurrence", "are", "reviewed", "and", "the", "efficacy", "and", "complications", "of", "thyroidectomy", "and", "radioiodine", "compared", "to", "those", "of", "antithyroid", "drugs", ".", "It", "is", "concluded", "that", "in", "most", "circumstances", "131I", "is", "the", "therapy", "of", "choice", "for", "hyperthyroidism", "."]], "ner": [[[18, 18, "Chemical"], [37, 37, "Chemical"], [22, 22, "Disease"], [40, 43, "Disease"], [28, 28, "Chemical"], [31, 32, "Disease"], [93, 93, "Disease"]]], "relations": [[[18, 18, 22, 22, "CID"], [37, 37, 22, 22, "CID"], [18, 18, 40, 43, "CID"], [37, 37, 40, 43, "CID"], [28, 28, 31, 32, "CID"]]], "clusters": [], "translated": "抗甲状腺药物治疗的不寻常并发症：四例报告和文献复习。两例<0>丙基硫氧嘧啶</0> - 相关的急性<2>肝炎</2>，一例致命的<4>甲巯咪唑</4> - 相关的<5>肝细胞坏死</5>和一例<1>丙基硫氧嘧啶</1>相关的<3>狼疮样综合征</3>被描述。综述了有关抗甲状腺药物副作用及其发生机制的文献，并比较了甲状腺切除术和放射性碘治疗与抗甲状腺药物的疗效和并发症。得出的结论是，在大多数情况下，<6>131I</6>是甲状腺功能亢进症的首选疗法。", "revised": true}
{"doc_key": "2429800", "sentences": [["Histamine", "antagonists", "and", "d", "-", "tubocurarine", "-", "induced", "hypotension", "in", "cardiac", "surgical", "patients", ".", "Hemodynamic", "effects", "and", "histamine", "release", "by", "bolus", "injection", "of", "0", ".", "35", "mg", "/", "kg", "of", "d", "-", "tubocurarine", "were", "studied", "in", "24", "patients", ".", "H1", "-", "and", "H2", "-", "histamine", "antagonists", "or", "placebo", "were", "given", "before", "dosing", "with", "d", "-", "tubocurarine", "in", "a", "randomized", "double", "-", "blind", "fashion", "to", "four", "groups", ":", "group", "1", "-", "-", "placebo", ";", "group", "2", "-", "-", "cimetidine", ",", "4", "mg", "/", "kg", ",", "plus", "placebo", ";", "group", "3", "-", "-", "chlorpheniramine", ",", "0", ".", "1", "mg", "/", "kg", ",", "plus", "placebo", ";", "and", "group", "4", "-", "-", "cimetidine", "plus", "chlorpheniramine", ".", "Histamine", "release", "occurred", "in", "most", "patients", ",", "the", "highest", "level", "2", "minutes", "after", "d", "-", "tubocurarine", "dosing", ".", "Group", "1", "had", "a", "moderate", "negative", "correlation", "between", "plasma", "histamine", "change", "and", "systemic", "vascular", "resistance", "(", "r", "=", "0", ".", "58", ";", "P", "less", "than", "0", ".", "05", ")", "not", "present", "in", "group", "4", ".", "Prior", "dosing", "with", "antagonists", "partially", "prevented", "the", "fall", "in", "systemic", "vascular", "resistance", ".", "These", "data", "demonstrate", "that", "the", "hemodynamic", "changes", "associated", "with", "d", "-", "tubocurarine", "dosing", "are", "only", "partially", "explained", "by", "histamine", "release", ".", "Thus", "prior", "dosing", "with", "H1", "-", "and", "H2", "-", "antagonists", "provides", "only", "partial", "protection", "."]], "ner": [[[3, 5, "Chemical"], [30, 32, "Chemical"], [53, 55, "Chemical"], [125, 127, "Chemical"], [187, 189, "Chemical"], [8, 8, "Disease"], [0, 0, "Chemical"], [17, 17, "Chemical"], [44, 44, "Chemical"], [112, 112, "Chemical"], [139, 139, "Chemical"], [196, 196, "Chemical"], [77, 77, "Chemical"], [108, 108, "Chemical"], [91, 91, "Chemical"], [110, 110, "Chemical"]]], "relations": [[[3, 5, 8, 8, "CID"], [30, 32, 8, 8, "CID"], [53, 55, 8, 8, "CID"], [125, 127, 8, 8, "CID"], [187, 189, 8, 8, "CID"]]], "clusters": [], "translated": " <6>组胺</6>拮抗剂和<0>d-筒箭毒碱</0><5>引起的低血压</5>：心脏外科患者肺部>。在24名患者中研究了以0.35 mg/kg <1>d-筒箭毒碱</1> bolus injection诱导的血流动力学效应和<7>组胺</7>释放。在随机双盲方式下，先给予 H1-和H2-<8>组胺</8>拮抗剂或安慰剂，再服用<2>d-筒箭毒碱</2>，分为四组：第1组——安慰剂；第2组——<12>西咪替丁</12>，4 mg/kg，加安慰剂;第3组——<14>扑尔敏</14>，0.1 mg/kg，加安慰剂;第4组——<13>西咪替丁</13>加<15>扑尔敏</15>。在<3>d-筒箭毒碱</3>注射后2分钟，大多数患者发生<9>组胺</9>释放。第1组血浆<10>组胺</10>变化和全身血管阻力呈中度负相关(r= 0.58; P小于0.05)，第4组没有这种相关性。先用拮抗剂部分预防了全身血管阻力下降。这些数据表明，由<11>组胺</11>释放的<4>d-筒箭毒碱</4>给药相应的血流动力学变化只有部分解释。因此，预先服用H1-和H2-<6>组胺</6>拮抗剂只提供部分保护。", "revised": true}
{"doc_key": "2453942", "sentences": [["Convulsant", "effect", "of", "lindane", "and", "regional", "brain", "concentration", "of", "GABA", "and", "dopamine", ".", "Lindane", "(", "gamma", "-", "hexachlorocyclohexane", ")", "is", "an", "organochlorine", "insecticide", "with", "known", "neurotoxic", "effects", ".", "Its", "mechanism", "of", "action", "is", "not", "well", "understood", "although", "it", "has", "been", "proposed", "that", "lindane", "acts", "as", "a", "non", "-", "competitive", "antagonist", "at", "the", "gamma", "-", "aminobutyric", "acid", "(", "GABA", ")", "-", "A", "receptor", ".", "We", "studied", "the", "effect", "of", "lindane", "(", "150", "mg", "/", "kg", ")", "on", "the", "GABAergic", "and", "dopaminergic", "systems", "by", "measuring", "the", "concentration", "of", "GABA", ",", "dopamine", "and", "its", "metabolites", "in", "7", "brain", "areas", "at", "the", "onset", "of", "seizures", ".", "All", "animals", "suffered", "tonic", "convulsions", "at", "18", ".", "3", "+", "/", "-", "1", ".", "4", "min", "after", "lindane", "administration", ".", "The", "concentration", "of", "GABA", "was", "only", "slightly", "but", "significantly", "decreased", "in", "the", "colliculi", "without", "modifications", "in", "the", "other", "areas", ".", "The", "concentration", "of", "dopamine", "was", "increased", "in", "the", "mesencephalon", "and", "that", "of", "its", "metabolite", "DOPAC", "was", "also", "increased", "in", "the", "mesencephalon", "and", "the", "striatum", "."]], "ner": [[[3, 3, "Chemical"], [13, 13, "Chemical"], [15, 17, "Chemical"], [42, 42, "Chemical"], [68, 68, "Chemical"], [119, 119, "Chemical"], [100, 100, "Disease"], [106, 106, "Disease"], [25, 25, "Disease"], [9, 9, "Chemical"], [52, 55, "Chemical"], [57, 57, "Chemical"], [86, 86, "Chemical"], [125, 125, "Chemical"], [11, 11, "Chemical"], [88, 88, "Chemical"], [145, 145, "Chemical"], [156, 156, "Chemical"]]], "relations": [[[3, 3, 100, 100, "CID"], [3, 3, 106, 106, "CID"], [13, 13, 100, 100, "CID"], [13, 13, 106, 106, "CID"], [15, 17, 100, 100, "CID"], [15, 17, 106, 106, "CID"], [42, 42, 100, 100, "CID"], [42, 42, 106, 106, "CID"], [68, 68, 100, 100, "CID"], [68, 68, 106, 106, "CID"], [119, 119, 100, 100, "CID"], [119, 119, 106, 106, "CID"]]], "clusters": [], "translated": "<0>林丹</0>的惊厥作用和<9>GABA</9>和<14>多巴胺</14>的局部脑浓度。<1>林丹</1>（<2>γ-六氯环己烷</2>）是一种有机氯杀虫剂，具有已知的<8>神经毒性</8>作用。虽然有人提出<3>林丹</3>作为非竞争性拮抗剂作用于<10>γ-氨基丁酸</10>（<11>GABA</11>）-A受体。我们通过测量<12>GABA</12>、<15>多巴胺</15>及其代谢物的浓度，研究了<4>林丹</4>（150mg/kg）对GABA能和多巴胺能系统的影响在<6>癫痫发作</6>开始时的 7 个脑区。所有动物在<5>林丹</5>给药后的 18.3+/-1.4 分钟出现强直<7>抽搐</7>。丘中<13>GABA</13>的浓度仅轻微但显着降低，而其他区域没有变化。中脑中<16>多巴胺</16>的浓度升高，其代谢产物<17>DOPAC</17>在中脑和纹状体中的浓度也升高。", "revised": true}
{"doc_key": "1522360", "sentences": [["Intravascular", "hemolysis", "and", "acute", "renal", "failure", "following", "intermittent", "rifampin", "therapy", ".", "Renal", "failure", "is", "a", "rare", "complication", "associated", "with", "the", "use", "of", "rifampin", ".", "Intravascular", "hemolysis", "leading", "to", "acute", "renal", "failure", "following", "rifampin", "therapy", "is", "extremely", "rare", ".", "Two", "patients", "with", "leprosy", "who", "developed", "hemolysis", "and", "acute", "renal", "failure", "following", "rifampin", "are", "reported", "."]], "ner": [[[8, 8, "Chemical"], [22, 22, "Chemical"], [32, 32, "Chemical"], [50, 50, "Chemical"], [1, 1, "Disease"], [25, 25, "Disease"], [44, 44, "Disease"], [3, 5, "Disease"], [28, 30, "Disease"], [46, 48, "Disease"], [11, 12, "Disease"], [41, 41, "Disease"]]], "relations": [[[8, 8, 1, 1, "CID"], [8, 8, 25, 25, "CID"], [8, 8, 44, 44, "CID"], [22, 22, 1, 1, "CID"], [22, 22, 25, 25, "CID"], [22, 22, 44, 44, "CID"], [32, 32, 1, 1, "CID"], [32, 32, 25, 25, "CID"], [32, 32, 44, 44, "CID"], [50, 50, 1, 1, "CID"], [50, 50, 25, 25, "CID"], [50, 50, 44, 44, "CID"], [8, 8, 3, 5, "CID"], [8, 8, 28, 30, "CID"], [8, 8, 46, 48, "CID"], [22, 22, 3, 5, "CID"], [22, 22, 28, 30, "CID"], [22, 22, 46, 48, "CID"], [32, 32, 3, 5, "CID"], [32, 32, 28, 30, "CID"], [32, 32, 46, 48, "CID"], [50, 50, 3, 5, "CID"], [50, 50, 28, 30, "CID"], [50, 50, 46, 48, "CID"]]], "clusters": [], "translated": "间歇性<0>利福平</0>治疗后血管内<4>溶血</4>和<7>急性肾功能衰竭</7>。 <10>肾衰竭</10>是一种与使用<1>利福平</1> 相关的罕见并发症。 <2>利福平</2>治疗后血管内<5>溶血</5>导致<8>急性肾功能衰竭</8>的情况极为罕见。据报道，两名<11>麻风病</11>患者在服用<3>利福平</3>后出现了<6>溶血</6>和<9>急性肾功能衰竭</9>。", "revised": true}
{"doc_key": "2765447", "sentences": [["Convulsion", "following", "intravenous", "fluorescein", "angiography", ".", "Tonic", "-", "clonic", "seizures", "followed", "intravenous", "fluorescein", "injection", "for", "fundus", "angiography", "in", "a", "47", "-", "year", "-", "old", "male", ".", "Despite", "precautions", "this", "adverse", "reaction", "recurred", "on", "re", "-", "exposure", "to", "intravenous", "fluorescein", "."]], "ner": [[[3, 3, "Chemical"], [12, 12, "Chemical"], [38, 38, "Chemical"], [6, 9, "Disease"], [0, 0, "Disease"]]], "relations": [[[3, 3, 6, 9, "CID"], [12, 12, 6, 9, "CID"], [38, 38, 6, 9, "CID"]]], "clusters": [], "translated": " <4>抽搐</4> 静脉注射<0>荧光素</0>血管造影后。 <3>强直阵挛发作</3> 随着47岁男性静脉注射<1>荧光素</1>进行眼底血管造影后出现。尽管采取预防措施，但这种不良反应在再次接受静脉注射<2>荧光素</2>时再次发生了。", "revised": true}
{"doc_key": "2614930", "sentences": [["Nifedipine", "induced", "bradycardia", "in", "a", "patient", "with", "autonomic", "neuropathy", ".", "An", "80", "year", "old", "diabetic", "male", "with", "evidence", "of", "peripheral", "and", "autonomic", "neuropathy", "was", "admitted", "with", "chest", "pain", ".", "He", "was", "found", "to", "have", "atrial", "flutter", "at", "a", "ventricular", "rate", "of", "70", "/", "min", "which", "slowed", "down", "to", "30", "-", "40", "/", "min", "when", "nifedipine", "(", "60", "mg", ")", "in", "3", "divided", "doses", ",", "during", "which", "he", "was", "paced", "at", "a", "rate", "of", "70", "/", "min", ".", "This", "is", "inconsistent", "with", "the", "well", "-", "established", "finding", "that", "nifedipine", "induces", "tachycardia", "in", "normally", "innervated", "hearts", ".", "However", ",", "in", "hearts", "deprived", "of", "compensatory", "sympathetic", "drive", ",", "it", "may", "lead", "to", "bradycardia", "."]], "ner": [[[0, 0, "Chemical"], [54, 54, "Chemical"], [87, 87, "Chemical"], [2, 2, "Disease"], [109, 109, "Disease"], [89, 89, "Disease"], [7, 8, "Disease"], [19, 22, "Disease"], [14, 14, "Disease"], [26, 27, "Disease"], [34, 35, "Disease"]]], "relations": [[[0, 0, 2, 2, "CID"], [0, 0, 109, 109, "CID"], [54, 54, 2, 2, "CID"], [54, 54, 109, 109, "CID"], [87, 87, 2, 2, "CID"], [87, 87, 109, 109, "CID"], [0, 0, 89, 89, "CID"], [54, 54, 89, 89, "CID"], [87, 87, 89, 89, "CID"]]], "clusters": [], "translated": " <0>硝苯地平</0>在<6>自主神经病变</6>患者中诱发<3>心动过缓</3>。一名 80 岁<8>糖尿病患者</8>男性，有<7>周围神经和自主神经病变</7>的证据，因<9>胸痛</9>入院。他被发现有<10>心房扑动</10>心室率为70次/分钟，当<1>硝苯地平</1>（60mg）分3次给药时，心室率减慢至30-40次/分钟，期间他以70次/分钟的速度进行配速。这与<2>硝苯地平</2>在正常受神经支配的心脏中诱发<5>心动过速</5>的公认发现不一致。然而，在被剥夺代偿性交感神经驱动的心脏中，它可能导致<4>心动过缓</4>。", "revised": true}
{"doc_key": "2818777", "sentences": [["Phenytoin", "induced", "fatal", "hepatic", "injury", ".", "A", "61", "year", "old", "female", "developed", "fatal", "hepatic", "failure", "after", "phenytoin", "administration", ".", "A", "typical", "multisystem", "clinical", "pattern", "precedes", "the", "manifestations", "of", "hepatic", "injury", ".", "The", "hematologic", ",", "biochemical", "and", "pathologic", "features", "indicate", "a", "mixed", "hepatocellular", "damage", "due", "to", "drug", "hypersensitivity", ".", "In", "a", "patient", "receiving", "phenytoin", "who", "presents", "a", "viral", "-", "like", "illness", ",", "early", "recognition", "and", "discontinuation", "of", "the", "drug", "are", "mandatory", "."]], "ner": [[[0, 0, "Chemical"], [16, 16, "Chemical"], [52, 52, "Chemical"], [13, 14, "Disease"], [45, 46, "Disease"], [3, 4, "Disease"], [28, 29, "Disease"], [41, 42, "Disease"]]], "relations": [[[0, 0, 13, 14, "CID"], [16, 16, 13, 14, "CID"], [52, 52, 13, 14, "CID"], [0, 0, 45, 46, "CID"], [16, 16, 45, 46, "CID"], [52, 52, 45, 46, "CID"]]], "clusters": [], "translated": " <0>苯妥英钠</0>致死性<5>肝损伤</5>。一名61岁的女性在服用<1>苯妥英</1>后发生致命性<3>肝功能衰竭</3>。典型的多系统临床模式先于<6>肝损伤</6>的表现。血液学、生化和病理学特征表明由于<4>药物超敏反应</4>引起的混合<7>肝细胞损伤</7>。对于接受<2>苯妥英</2>并出现病毒样疾病的患者，必须及早发现并停药。", "revised": true}
{"doc_key": "2400986", "sentences": [["Dose", "-", "dependent", "neurotoxicity", "of", "high", "-", "dose", "busulfan", "in", "children", ":", "a", "clinical", "and", "pharmacological", "study", ".", "Busulfan", "is", "known", "to", "be", "neurotoxic", "in", "animals", "and", "humans", ",", "but", "its", "acute", "neurotoxicity", "remains", "poorly", "characterized", "in", "children", ".", "We", "report", "here", "a", "retrospective", "study", "of", "123", "children", "(", "median", "age", ",", "6", ".", "5", "years", ")", "receiving", "high", "-", "dose", "busulfan", "in", "combined", "chemotherapy", "before", "bone", "marrow", "transplantation", "for", "malignant", "solid", "tumors", ",", "brain", "tumors", "excluded", ".", "Busulfan", "was", "given", "p", ".", "o", ".", ",", "every", "6", "hours", "for", "16", "doses", "over", "4", "days", ".", "Two", "total", "doses", "were", "consecutively", "used", ":", "16", "mg", "/", "kg", ",", "then", "600", "mg", "/", "m2", ".", "The", "dose", "calculation", "on", "the", "basis", "of", "body", "surface", "area", "results", "in", "higher", "doses", "in", "young", "children", "than", "in", "older", "patients", "(", "16", "to", "28", "mg", "/", "kg", ")", ".", "Ninety", "-", "six", "patients", "were", "not", "given", "anticonvulsive", "prophylaxis", ";", "7", "(", "7", ".", "5", "%", ")", "developed", "seizures", "during", "the", "4", "days", "of", "the", "busulfan", "course", "or", "within", "24", "h", "after", "the", "last", "dosing", ".", "When", "the", "total", "busulfan", "dose", "was", "taken", "into", "account", ",", "there", "was", "a", "significant", "difference", "in", "terms", "of", "neurotoxicity", "incidence", "among", "patients", "under", "16", "mg", "/", "kg", "(", "1", "of", "57", ",", "1", ".", "7", "%", ")", "and", "patients", "under", "600", "mg", "/", "m2", "(", "6", "of", "39", ",", "15", ".", "4", "%", ")", "(", "P", "less", "than", "0", ".", "02", ")", ".", "Twenty", "-", "seven", "patients", "were", "given", "a", "600", "-", "mg", "/", "m2", "busulfan", "total", "dose", "with", "continuous", "i", ".", "v", ".", "infusion", "of", "clonazepam", ";", "none", "had", "any", "neurological", "symptoms", ".", "Busulfan", "levels", "were", "measured", "by", "a", "gas", "chromatographic", "-", "mass", "spectrometry", "assay", "in", "the", "plasma", "and", "cerebrospinal", "fluid", "of", "9", "children", "without", "central", "nervous", "system", "disease", "under", "600", "mg", "/", "m2", "busulfan", "with", "clonazepam", ":", "busulfan", "cerebrospinal", "fluid", ":", "plasma", "ratio", "was", "1", ".", "39", ".", "This", "was", "significantly", "different", "(", "P", "less", "than", "0", ".", "02", ")", "from", "the", "cerebrospinal", "fluid", ":", "plasma", "ratio", "previously", "defined", "in", "children", "receiving", "a", "16", "-", "mg", "/", "kg", "total", "dose", "of", "busulfan", ".", "This", "study", "shows", "that", "busulfan", "neurotoxicity", "is", "dose", "-", "dependent", "in", "children", "and", "efficiently", "prevented", "by", "clonazepam", ".", "A", "busulfan", "dose", "calculated", "on", "the", "basis", "of", "body", "surface", "area", ",", "resulting", "in", "higher", "doses", "in", "young", "children", ",", "was", "followed", "by", "increased", "neurotoxicity", ",", "close", "to", "neurotoxicity", "incidence", "observed", "in", "adults", ".", "Since", "plasma", "pharmacokinetic", "studies", "showed", "a", "faster", "busulfan", "clearance", "in", "children", "than", "in", "adults", ",", "this", "new", "dose", "may", "approximate", "more", "closely", "the", "adult", "systemic", "exposure", "obtained", "after", "the", "usual", "16", "-", "mg", "/", "kg", "total", "dose", ",", "with", "potential", "inferences", "in", "terms", "of", "anticancer", "or", "myeloablative", "effects", ".", "The", "busulfan", "dose", "in", "children", "and", "infants", "undergoing", "bone", "marrow", "transplantation", "should", "be", "reconsidered", "on", "the", "basis", "of", "pharmacokinetic", "studies", "."]], "ner": [[[8, 8, "Chemical"], [18, 18, "Chemical"], [61, 61, "Chemical"], [78, 78, "Chemical"], [169, 169, "Chemical"], [183, 183, "Chemical"], [255, 255, "Chemical"], [274, 274, "Chemical"], [305, 305, "Chemical"], [309, 309, "Chemical"], [353, 353, "Chemical"], [359, 359, "Chemical"], [374, 374, "Chemical"], [414, 414, "Chemical"], [457, 457, "Chemical"], [162, 162, "Disease"], [3, 3, "Disease"], [23, 23, "Disease"], [32, 32, "Disease"], [198, 198, "Disease"], [360, 360, "Disease"], [397, 397, "Disease"], [401, 401, "Disease"], [266, 266, "Chemical"], [307, 307, "Chemical"], [371, 371, "Chemical"], [72, 72, "Disease"], [74, 75, "Disease"], [271, 272, "Disease"], [296, 299, "Disease"]]], "relations": [[[8, 8, 162, 162, "CID"], [18, 18, 162, 162, "CID"], [61, 61, 162, 162, "CID"], [78, 78, 162, 162, "CID"], [169, 169, 162, 162, "CID"], [183, 183, 162, 162, "CID"], [255, 255, 162, 162, "CID"], [274, 274, 162, 162, "CID"], [305, 305, 162, 162, "CID"], [309, 309, 162, 162, "CID"], [353, 353, 162, 162, "CID"], [359, 359, 162, 162, "CID"], [374, 374, 162, 162, "CID"], [414, 414, 162, 162, "CID"], [457, 457, 162, 162, "CID"]]], "clusters": [], "translated": "高剂量<0>白消安</0>对儿童的剂量依赖性<16>神经毒性</16>：一项临床和药理学研究。 <1>白消安</1>已知对动物和人类具有<17>神经毒性</17>，但其急性<18>神经毒性</18>在儿童中的特征仍不明确。我们在这里报告了一项回顾性研究，对 123 名儿童（中位年龄 6.5 岁）在骨髓移植前接受大剂量<2>白消安</2>联合化疗治疗恶性实体<26>肿瘤</26>，<27>脑肿瘤</27>除外。 <3>白消安</3>被给予p.o.，在4天内每6小时服用16剂。连续使用两个总剂量：16 mg/kg，然后是600 mg/m2。基于体表面积的剂量计算导致年幼儿童的剂量高于年长患者（16至28 mg/kg）。96例患者未给予抗惊厥预防；7例（7.5%）在<4>白消安</4>疗程的4天内或最后一次给药后24小时内发生了<15>癫痫发作</15>。当考虑总<5>白消安</5>剂量时，<19>神经毒性</19>发生率在低于16 mg/kg的患者中存在显着差异（57人中有1人，1.7%）和低于600 mg/m2的患者（39人中有6人，15.4%）（P小于0.02）。27名患者接受了600 mg/m2 <6>白消安</6>总剂量连续i.v.输注<23>氯硝西泮</23>；没有人有任何<28>神经系统症状</28>。 <7>白消安</7>水平通过气相色谱-质谱法测定9名无<29>中枢神经系统疾病</29>的儿童血浆和脑脊液中浓度低于600 mg/m2<8>白消安</8>与<24>氯硝西泮</24>：<9>白消安</9>脑脊液：血浆比为1.39。这与脑脊液显着不同（P小于0.02）：先前定义的接受16 mg/kg总剂量<10>白消安</10>的儿童的血浆比率。本研究表明，<11>白消安</11><20>神经毒性</20>在儿童中呈剂量依赖性，<25>氯硝西泮</25>可有效预防。根据体表面积计算的<12>白消安</12>剂量，导致幼儿剂量较高，随后<21>神经毒性</21>增加，接近成人中观察到的<22>神经毒性</22>发病率。由于血浆药代动力学研究表明，<13>白消安</13>在儿童中的清除速度比在成人中快，因此这一新剂量可能更接近于通常16 mg/kg总剂量后获得的成人全身暴露量，并可能推论为抗癌或清髓作用。接受骨髓移植的儿童和婴儿的<14>白消安</14>剂量应根据药代动力学研究重新考虑。", "revised": true}
{"doc_key": "2650911", "sentences": [["Autoradiographic", "evidence", "of", "estrogen", "binding", "sites", "in", "nuclei", "of", "diethylstilbesterol", "induced", "hamster", "renal", "carcinomas", ".", "Estrogen", "binding", "sites", "were", "demonstrated", "by", "autoradiography", "in", "one", "transplantable", "and", "five", "primary", "diethylstilbesterol", "induced", "renal", "carcinomas", "in", "three", "hamsters", ".", "Radiolabelling", ",", "following", "the", "in", "vivo", "injection", "of", "3H", "-", "17", "beta", "estradiol", ",", "was", "increased", "only", "over", "the", "nuclei", "of", "tumor", "cells", ";", "stereologic", "analysis", "revealed", "a", "4", ".", "5", "-", "to", "6", ".", "7", "-", "times", "higher", "concentration", "of", "reduced", "silver", "grains", "over", "nuclei", "than", "cytoplasm", "of", "these", "cells", ".", "Despite", "rapid", "tubular", "excretion", "of", "estradiol", "which", "peaked", "in", "less", "than", "1", "h", ",", "the", "normal", "cells", "did", "not", "appear", "to", "bind", "the", "ligand", ".", "This", "is", "the", "first", "published", "report", "documenting", "the", "preferential", "in", "vivo", "binding", "of", "estrogen", "to", "nuclei", "of", "cells", "in", "estrogen", "induced", "hamster", "renal", "carcinomas", "."]], "ner": [[[9, 9, "Chemical"], [28, 28, "Chemical"], [12, 13, "Disease"], [30, 31, "Disease"], [135, 136, "Disease"], [3, 3, "Chemical"], [15, 15, "Chemical"], [126, 126, "Chemical"], [132, 132, "Chemical"], [57, 57, "Disease"], [48, 48, "Chemical"], [93, 93, "Chemical"], [78, 78, "Chemical"]]], "relations": [[[9, 9, 12, 13, "CID"], [9, 9, 30, 31, "CID"], [9, 9, 135, 136, "CID"], [28, 28, 12, 13, "CID"], [28, 28, 30, 31, "CID"], [28, 28, 135, 136, "CID"]]], "clusters": [], "translated": "<5>雌激素</5> 细胞核中 <0>己烯雌酚</0> 诱导仓鼠<2>肾癌</2>结合位点的放射自显影证据。通过放射自显影，在三只仓鼠中的一只可移植和五只原发性<1>二乙基己烯甾醇</1>诱导的<3>肾癌</3>中证实了<6>雌激素</6>结合位点。体内注射3H-17β<10>雌二醇</10>后，放射性标记仅在<9>肿瘤</9>细胞的细胞核上增加；体视学分析显示在这些细胞的细胞核中，还原<12>银</12>颗粒的浓度比细胞质高4.5-6.7倍。尽管<11>雌二醇</11>的肾小管快速排泄在不到1小时内达到峰值，但正常细胞似乎并未与配体结合。这是第一份报道，证实 <7>雌激素</7> 体内优先在<8>雌激素</8>诱导的仓鼠<4>肾癌</4>细胞核中结合的报告。", "revised": true}
{"doc_key": "1735570", "sentences": [["Chronic", "lesion", "of", "rostral", "ventrolateral", "medulla", "in", "spontaneously", "hypertensive", "rats", ".", "We", "studied", "the", "effects", "of", "chronic", "selective", "neuronal", "lesion", "of", "rostral", "ventrolateral", "medulla", "on", "mean", "arterial", "pressure", ",", "heart", "rate", ",", "and", "neurogenic", "tone", "in", "conscious", ",", "unrestrained", "spontaneously", "hypertensive", "rats", ".", "The", "lesions", "were", "placed", "via", "bilateral", "microinjections", "of", "30", "nmol", "/", "200", "nl", "N", "-", "methyl", "-", "D", "-", "aspartic", "acid", ".", "The", "restimulation", "of", "this", "area", "with", "N", "-", "methyl", "-", "D", "-", "aspartic", "acid", "15", "days", "postlesion", "failed", "to", "produce", "a", "pressor", "response", ".", "One", "day", "postlesion", ",", "the", "resting", "mean", "arterial", "pressure", "was", "significantly", "decreased", "in", "lesioned", "rats", "when", "compared", "with", "sham", "rats", "(", "100", "+", "/", "-", "7", "versus", "173", "+", "/", "-", "4", "mm", "Hg", ",", "p", "less", "than", "0", ".", "05", ")", ".", "Fifteen", "days", "later", ",", "the", "lesioned", "group", "still", "showed", "values", "significantly", "lower", "than", "the", "sham", "group", "(", "150", "+", "/", "-", "6", "versus", "167", "+", "/", "-", "5", "mm", "Hg", ",", "p", "less", "than", "0", ".", "05", ")", ".", "No", "significant", "heart", "rate", "differences", "were", "observed", "between", "the", "sham", "and", "lesioned", "groups", ".", "The", "ganglionic", "blocker", "trimethaphan", "(", "5", "mg", "/", "kg", "i", ".", "v", ".", ")", "caused", "similar", "reductions", "in", "mean", "arterial", "pressure", "in", "both", "lesioned", "and", "sham", "groups", ".", "The", "trimethaphan", "-", "induced", "hypotension", "was", "accompanied", "by", "a", "significant", "bradycardia", "in", "lesioned", "rats", "(", "-", "32", "+", "/", "-", "13", "beats", "per", "minute", ")", "but", "a", "tachycardia", "in", "sham", "rats", "(", "+", "33", "+", "/", "-", "12", "beats", "per", "minute", ")", "1", "day", "postlesion", ".", "Therefore", ",", "rostral", "ventrolateral", "medulla", "neurons", "appear", "to", "play", "a", "significant", "role", "in", "maintaining", "hypertension", "in", "conscious", "spontaneously", "hypertensive", "rats", ".", "Spinal", "or", "suprabulbar", "structures", "could", "be", "responsible", "for", "the", "gradual", "recovery", "of", "the", "hypertension", "in", "the", "lesioned", "rats", "."]], "ner": [[[188, 188, "Chemical"], [214, 214, "Chemical"], [217, 217, "Disease"], [240, 240, "Disease"], [56, 63, "Chemical"], [71, 78, "Chemical"], [8, 8, "Disease"], [40, 40, "Disease"], [273, 273, "Disease"], [277, 277, "Disease"], [293, 293, "Disease"], [223, 223, "Disease"]]], "relations": [[[188, 188, 217, 217, "CID"], [214, 214, 217, 217, "CID"], [188, 188, 240, 240, "CID"], [214, 214, 240, 240, "CID"]]], "clusters": [], "translated": "自发性<6>高血压</6>大鼠延髓头侧腹外侧慢性损伤。我们研究了延髓头侧腹外侧慢性选择性神经元损伤对有意识、不受约束的自发性<7>高血压</7>大鼠的平均动脉压、心率和神经源性张力的影响。通过双侧显微注射 30 nmol / 200 nl <4>N-甲基-D-天冬氨酸</4> 放置病灶。损伤后15天用 <5>N-甲基-D-天冬氨酸</5> 再刺激该区域未能产生升压反应。损伤一天后，与假大鼠相比，损伤大鼠的静息平均动脉压显着降低（100+/-7对173+/-4mmHg，p小于0.05）。15天后，损伤组的值仍显着低于假手术组（150+/-6对167+/-5mmHg，p小于0.05）。在假手术组和损伤组之间没有观察到显着的心率差异。神经节阻滞剂<0>trimethaphan</0>（5mg/kg i.v.）在损伤组和假手术组中引起了类似的平均动脉压降低。<1>trimethaphan</1>-引起的<2>低血压</2>在受损大鼠中伴有显着的<11>心动过缓</11>（-32+/-13次/分钟），但损伤后1天假大鼠<3>心动过速</3>（每分钟+33+/-12次）。因此，延髓头侧腹外侧神经元似乎在维持有意识的自发性<9>高血压</9>大鼠的<8>高血压</8>方面发挥重要作用。脊柱或球上结构可能是损伤大鼠<10>高血压</10>逐渐恢复的原因。", "revised": true}
{"doc_key": "2904523", "sentences": [["Support", "for", "adrenaline", "-", "hypertension", "hypothesis", ":", "18", "hour", "pressor", "effect", "after", "6", "hours", "adrenaline", "infusion", ".", "In", "a", "double", "blind", ",", "crossover", "study", "6", "h", "infusions", "of", "adrenaline", "(", "15", "ng", "/", "kg", "/", "min", ";", "1", "ng", "=", "5", ".", "458", "pmol", ")", ",", "noradrenaline", "(", "30", "ng", "/", "kg", "/", "min", ";", "1", "ng", "=", "5", ".", "911", "pmol", ")", ",", "and", "a", "5", "%", "dextrose", "solution", "(", "5", ".", "4", "ml", "/", "h", ")", ",", "were", "given", "to", "ten", "healthy", "volunteers", "in", "random", "order", "2", "weeks", "apart", ".", "By", "means", "of", "intra", "-", "arterial", "ambulatory", "monitoring", "the", "haemodynamic", "effects", "were", "followed", "for", "18", "h", "after", "the", "infusions", "were", "stopped", ".", "Adrenaline", ",", "but", "not", "noradrenaline", ",", "caused", "a", "delayed", "and", "protracted", "pressor", "effect", ".", "Over", "the", "total", "postinfusion", "period", "systolic", "and", "diastolic", "arterial", "pressure", "were", "6", "(", "SEM", "2", ")", "%", "and", "7", "(", "2", ")", "%", ",", "respectively", ",", "higher", "than", "after", "dextrose", "infusion", "(", "ANOVA", ",", "p", "less", "than", "0", ".", "001", ")", ".", "Thus", ",", "\"", "stress", "\"", "levels", "of", "adrenaline", "(", "230", "pg", "/", "ml", ")", "for", "6", "h", "cause", "a", "delayed", "and", "protracted", "pressor", "effect", ".", "These", "findings", "are", "strong", "support", "for", "the", "adrenaline", "-", "hypertension", "hypothesis", "in", "man", "."]], "ner": [[[2, 2, "Chemical"], [14, 14, "Chemical"], [28, 28, "Chemical"], [114, 114, "Chemical"], [177, 177, "Chemical"], [202, 202, "Chemical"], [4, 4, "Disease"], [204, 204, "Disease"], [46, 46, "Chemical"], [118, 118, "Chemical"], [68, 68, "Chemical"], [157, 157, "Chemical"]]], "relations": [[[2, 2, 4, 4, "CID"], [2, 2, 204, 204, "CID"], [14, 14, 4, 4, "CID"], [14, 14, 204, 204, "CID"], [28, 28, 4, 4, "CID"], [28, 28, 204, 204, "CID"], [114, 114, 4, 4, "CID"], [114, 114, 204, 204, "CID"], [177, 177, 4, 4, "CID"], [177, 177, 204, 204, "CID"], [202, 202, 4, 4, "CID"], [202, 202, 204, 204, "CID"]]], "clusters": [], "translated": "支持<0>肾上腺素</0> - <6>高血压</6>假说：<1>肾上腺素</1>输注6小时后18小时升压作用。在一项双盲交叉研究中，输注6小时的<2>肾上腺素</2>（15 ng/kg/分钟；1 ng=5.458 pmol），<8>去甲肾上腺素</8>（30 ng/kg/min;1 ng=5.911 pmol）和5%的<10>葡萄糖</10>溶液（5.4ml/h），间隔2周随机给予10名健康志愿者。通过动脉内动态监测，在输注停止后的18小时内跟踪血液动力学效应。<3>肾上腺素</3>，但不是<9>去甲肾上腺素</9>，引起延迟和持久的升压作用。在整个输注后期间，动脉收缩压和舒张压分别为6(S EM 2)%和7(2)%，高于<11>葡萄糖</11>输注后（方差分析，p小于0.001）。因此，<4>肾上腺素</4>(230 pg/ml)的“压力”水平持续6小时会导致延迟和持久的升压效应。这些发现有力地支持了人类<5>肾上腺素</5>-<7>高血压</7>假说。", "revised": true}
{"doc_key": "2931989", "sentences": [["Adverse", "ocular", "reactions", "possibly", "associated", "with", "isotretinoin", ".", "A", "total", "of", "261", "adverse", "ocular", "reactions", "occurred", "in", "237", "patients", "who", "received", "isotretinoin", ",", "a", "commonly", "used", "drug", "in", "the", "treatment", "of", "severe", "cystic", "acne", ".", "Blepharoconjunctivitis", ",", "subjective", "complaints", "of", "dry", "eyes", ",", "blurred", "vision", ",", "contact", "lens", "intolerance", ",", "and", "photodermatitis", "are", "reversible", "side", "effects", ".", "More", "serious", "ocular", "adverse", "reactions", "include", "papilledema", ",", "pseudotumor", "cerebri", ",", "and", "white", "or", "gray", "subepithelial", "corneal", "opacities", ";", "all", "of", "these", "are", "reversible", "if", "the", "drug", "is", "discontinued", ".", "Reported", "cases", "of", "decreased", "dark", "adaptation", "are", "under", "investigation", ".", "Isotretinoin", "is", "contraindicated", "in", "pregnancy", "because", "of", "the", "many", "reported", "congenital", "abnormalities", "after", "maternal", "use", "(", "including", "microphthalmos", ",", "orbital", "hypertelorism", ",", "and", "optic", "nerve", "hypoplasia", ")", "."]], "ner": [[[6, 6, "Chemical"], [21, 21, "Chemical"], [97, 97, "Chemical"], [35, 35, "Disease"], [40, 41, "Disease"], [43, 44, "Disease"], [51, 51, "Disease"], [63, 63, "Disease"], [65, 66, "Disease"], [73, 74, "Disease"], [33, 33, "Disease"], [107, 108, "Disease"], [114, 114, "Disease"], [117, 117, "Disease"], [120, 122, "Disease"]]], "relations": [[[6, 6, 35, 35, "CID"], [21, 21, 35, 35, "CID"], [97, 97, 35, 35, "CID"], [6, 6, 40, 41, "CID"], [21, 21, 40, 41, "CID"], [97, 97, 40, 41, "CID"], [6, 6, 43, 44, "CID"], [21, 21, 43, 44, "CID"], [97, 97, 43, 44, "CID"], [6, 6, 51, 51, "CID"], [21, 21, 51, 51, "CID"], [97, 97, 51, 51, "CID"], [6, 6, 63, 63, "CID"], [21, 21, 63, 63, "CID"], [97, 97, 63, 63, "CID"], [6, 6, 65, 66, "CID"], [21, 21, 65, 66, "CID"], [97, 97, 65, 66, "CID"], [6, 6, 73, 74, "CID"], [21, 21, 73, 74, "CID"], [97, 97, 73, 74, "CID"]]], "clusters": [], "translated": "可能与<0>异维A酸</0>有关的不良眼部反应。237名接受<1>异维A酸</1>治疗的重度囊性<10>痤疮</10>常用药物的患者共发生261次眼部不良反应。 <3>睑结膜炎</3>、<4>眼干燥</4>、<5>视力模糊</5>、隐形眼镜不耐受和<6>光敏性皮炎</6>的主观主诉是可逆的副作用。更严重的眼部不良反应包括<7>视乳头水肿</7>、<8>假性脑瘤</8>、白色或灰色上皮下<9>角膜混浊</9>；如果停药，所有这些都是可逆的。已报告的暗适应下降病例正在调查中。<2>异维甲酸</2>禁用于妊娠期，因为有许多报告称，母亲使用后会出现<11>先天性异常</11>（包括<12>小眼症</12>、眼眶<13>间距过宽</13>以及<14>视神经发育不全</14>）。", "revised": true}
{"doc_key": "2320485", "sentences": [["Methyldopa", "-", "induced", "hemolytic", "anemia", "in", "a", "15", "year", "old", "presenting", "as", "near", "-", "syncope", ".", "Methyldopa", "is", "an", "antihypertensive", "medication", "which", "is", "available", "generically", "and", "under", "the", "trade", "name", "Aldomet", "that", "is", "widely", "prescribed", "in", "the", "adult", "population", "and", "infrequently", "used", "in", "children", ".", "Methyldopa", "causes", "an", "autoimmune", "hemolytic", "anemia", "in", "a", "small", "percentage", "of", "patients", "who", "take", "the", "drug", ".", "We", "report", "a", "case", "of", "methyldopa", "-", "induced", "hemolytic", "anemia", "in", "a", "15", "-", "year", "-", "old", "boy", "who", "presented", "to", "the", "emergency", "department", "with", "near", "-", "syncope", ".", "The", "boy", "had", "been", "treated", "with", "intravenous", "methyldopa", "during", "a", "trauma", "admission", "seven", "weeks", "prior", "to", "presentation", ".", "Evaluation", "revealed", "a", "hemoglobin", "of", "three", "grams", ",", "3", "+", "Coombs", "'", "test", "with", "polyspecific", "anti", "-", "human", "globulin", "and", "monospecific", "IgG", "reagents", ",", "and", "a", "warm", "reacting", "autoantibody", ".", "Transfusion", "and", "corticosteroid", "therapy", "resulted", "in", "a", "complete", "recovery", "of", "the", "patient", ".", "Emergency", "physicians", "treating", "children", "must", "be", "aware", "of", "this", "syndrome", "in", "order", "to", "diagnose", "and", "treat", "it", "correctly", ".", "A", "brief", "review", "of", "autoimmune", "and", "drug", "-", "induced", "hemolytic", "anemias", "is", "provided", "."]], "ner": [[[0, 0, "Chemical"], [16, 16, "Chemical"], [30, 30, "Chemical"], [45, 45, "Chemical"], [67, 67, "Chemical"], [98, 98, "Chemical"], [3, 4, "Disease"], [70, 71, "Disease"], [180, 181, "Disease"], [14, 14, "Disease"], [89, 89, "Disease"], [48, 50, "Disease"], [84, 85, "Disease"], [101, 101, "Disease"], [141, 141, "Chemical"]]], "relations": [[[0, 0, 3, 4, "CID"], [0, 0, 70, 71, "CID"], [0, 0, 180, 181, "CID"], [16, 16, 3, 4, "CID"], [16, 16, 70, 71, "CID"], [16, 16, 180, 181, "CID"], [30, 30, 3, 4, "CID"], [30, 30, 70, 71, "CID"], [30, 30, 180, 181, "CID"], [45, 45, 3, 4, "CID"], [45, 45, 70, 71, "CID"], [45, 45, 180, 181, "CID"], [67, 67, 3, 4, "CID"], [67, 67, 70, 71, "CID"], [67, 67, 180, 181, "CID"], [98, 98, 3, 4, "CID"], [98, 98, 70, 71, "CID"], [98, 98, 180, 181, "CID"]]], "clusters": [], "translated": " <0>甲基多巴</0> - 诱发<6>溶血性贫血</6>，一名 15 岁患者呈现为接近 -<9>晕厥</9>。 <1>甲基多巴</1>是一种抗高血压药物，它的商品名是<2>Aldomet</2>，在成人中广泛使用，但很少用于儿童。 <3>甲基多巴</3>引起 <11>自身免疫性溶血性贫血</11>在服药患者中的比例很小。我们报告了一例<4>甲基多巴</4> - 诱发<7>溶血性贫血</7>的一名 15 岁男孩，他到<12>急诊科</12>就诊，因为出现接近 -<10>晕厥</10>。这名男孩在就诊前 7 周因<13>外伤</13>入院，期间接受了静脉注射<5>甲基多巴</5>治疗。评估显示血红蛋白为 3 克，使用多特异性抗人球蛋白和单特异性 IgG 试剂进行3+ Coombs试验，以及一种温反应性自身抗体。输血和<14>皮质类固醇</14>治疗使患者完全康复。治疗儿童的急诊医师必须了解这种综合征，才能正确诊断和治疗。提供了自身免疫性和药物引起的<8>溶血性贫血</8>的简要回顾。", "revised": true}
{"doc_key": "3083835", "sentences": [["Penicillin", "anaphylaxis", ".", "A", "case", "of", "oral", "penicillin", "anaphylaxis", "is", "described", ",", "and", "the", "terminology", ",", "occurrence", ",", "clinical", "manifestations", ",", "pathogenesis", ",", "prevention", ",", "and", "treatment", "of", "anaphylaxis", "are", "reviewed", ".", "Emergency", "physicians", "should", "be", "aware", "of", "oral", "penicillin", "anaphylaxis", "in", "order", "to", "prevent", "its", "occurrence", "by", "prescribing", "the", "antibiotic", "judiciously", "and", "knowledgeably", "and", "to", "offer", "optimal", "medical", "therapy", "once", "this", "life", "-", "threatening", "reaction", "has", "begun", "."]], "ner": [[[0, 0, "Chemical"], [7, 7, "Chemical"], [39, 39, "Chemical"], [1, 1, "Disease"], [8, 8, "Disease"], [28, 28, "Disease"], [40, 40, "Disease"]]], "relations": [[[0, 0, 1, 1, "CID"], [0, 0, 8, 8, "CID"], [0, 0, 28, 28, "CID"], [0, 0, 40, 40, "CID"], [7, 7, 1, 1, "CID"], [7, 7, 8, 8, "CID"], [7, 7, 28, 28, "CID"], [7, 7, 40, 40, "CID"], [39, 39, 1, 1, "CID"], [39, 39, 8, 8, "CID"], [39, 39, 28, 28, "CID"], [39, 39, 40, 40, "CID"]]], "clusters": [], "translated": "<0>青霉素</0><3>过敏反应</3>。叙述口服<1>青霉素</1><4>过敏反应</4>一例，对<5>过敏反应</5>的术语、发生、临床表现、发病机制、预防和治疗进行综述。急诊医师应了解口服<2>青霉素</2><6>过敏反应</6>，以便通过明智而知情地开处抗生素来预防其发生，并在这种危及生命的反应开始时提供最佳的医疗治疗。", "revised": true}
{"doc_key": "2625524", "sentences": [["The", "effect", "of", "haloperidol", "in", "cocaine", "and", "amphetamine", "intoxication", ".", "The", "effectiveness", "of", "haloperidol", "pretreatment", "in", "preventing", "the", "toxic", "effects", "of", "high", "doses", "of", "amphetamine", "and", "cocaine", "was", "studied", "in", "rats", ".", "In", "this", "model", ",", "toxic", "effects", "were", "induced", "by", "intraperitoneal", "(", "i", ".", "p", ".", ")", "injection", "of", "amphetamine", "75", "mg", "/", "kg", "(", "100", "%", "death", "rate", ")", "or", "cocaine", "70", "mg", "/", "kg", "(", "82", "%", "death", "rate", ")", ".", "Haloperidol", "failed", "to", "prevent", "amphetamine", "-", "induced", "seizures", ",", "but", "did", "lower", "the", "mortality", "rate", "at", "most", "doses", "tested", ".", "Haloperidol", "decreased", "the", "incidence", "of", "cocaine", "-", "induced", "seizures", "at", "the", "two", "highest", "doses", ",", "but", "the", "lowering", "of", "the", "mortality", "rate", "did", "not", "reach", "statistical", "significance", "at", "any", "dose", ".", "These", "data", "suggest", "a", "protective", "role", "for", "the", "central", "dopamine", "blocker", "haloperidol", "against", "death", "from", "high", "-", "dose", "amphetamine", "exposure", "without", "reducing", "the", "incidence", "of", "seizures", ".", "In", "contrast", ",", "haloperidol", "demonstrated", "an", "ability", "to", "reduce", "cocaine", "-", "induced", "seizures", "without", "significantly", "reducing", "mortality", "."]], "ner": [[[5, 5, "Chemical"], [26, 26, "Chemical"], [62, 62, "Chemical"], [99, 99, "Chemical"], [161, 161, "Chemical"], [81, 81, "Disease"], [102, 102, "Disease"], [150, 150, "Disease"], [164, 164, "Disease"], [7, 7, "Chemical"], [24, 24, "Chemical"], [50, 50, "Chemical"], [78, 78, "Chemical"], [143, 143, "Chemical"], [3, 3, "Chemical"], [13, 13, "Chemical"], [74, 74, "Chemical"], [94, 94, "Chemical"], [136, 136, "Chemical"], [155, 155, "Chemical"], [134, 134, "Chemical"]]], "relations": [[[5, 5, 81, 81, "CID"], [5, 5, 102, 102, "CID"], [5, 5, 150, 150, "CID"], [5, 5, 164, 164, "CID"], [26, 26, 81, 81, "CID"], [26, 26, 102, 102, "CID"], [26, 26, 150, 150, "CID"], [26, 26, 164, 164, "CID"], [62, 62, 81, 81, "CID"], [62, 62, 102, 102, "CID"], [62, 62, 150, 150, "CID"], [62, 62, 164, 164, "CID"], [99, 99, 81, 81, "CID"], [99, 99, 102, 102, "CID"], [99, 99, 150, 150, "CID"], [99, 99, 164, 164, "CID"], [161, 161, 81, 81, "CID"], [161, 161, 102, 102, "CID"], [161, 161, 150, 150, "CID"], [161, 161, 164, 164, "CID"], [7, 7, 81, 81, "CID"], [7, 7, 102, 102, "CID"], [7, 7, 150, 150, "CID"], [7, 7, 164, 164, "CID"], [24, 24, 81, 81, "CID"], [24, 24, 102, 102, "CID"], [24, 24, 150, 150, "CID"], [24, 24, 164, 164, "CID"], [50, 50, 81, 81, "CID"], [50, 50, 102, 102, "CID"], [50, 50, 150, 150, "CID"], [50, 50, 164, 164, "CID"], [78, 78, 81, 81, "CID"], [78, 78, 102, 102, "CID"], [78, 78, 150, 150, "CID"], [78, 78, 164, 164, "CID"], [143, 143, 81, 81, "CID"], [143, 143, 102, 102, "CID"], [143, 143, 150, 150, "CID"], [143, 143, 164, 164, "CID"]]], "clusters": [], "translated": "<14>氟哌啶醇</14>对<0>可卡因</0>和<9>苯丙胺</9>中毒的影响。在大鼠中研究了<15>氟哌啶醇</15>预处理在预防高剂量<10>苯丙胺</10>和<1>可卡因</1>的毒性作用方面的有效性。在此模型中，通过腹膜内(i.p.)注射<11>苯丙胺</11>75 mg/kg（100%死亡率）或<2>可卡因</2>70 mg/kg（82%的死亡率）。<16>氟哌啶醇</16>未能预防<12>苯丙胺</12>引起的<5>癫痫发作</5>，但在大多数测试剂量下确实降低了死亡率。<17>氟哌啶醇</17>降低了<3>可卡因</3>诱发的<6>癫痫发作</6>的发生率，但并未在任何剂量下显著降低死亡率。这些数据表明中枢<20>多巴胺</20>阻滞剂<18>氟哌啶醇</18>对高剂量<13>安非他明</13>暴露的死亡具有保护作用，而不会降低<7>癫痫发作的发生率</7>。相比之下，<19>氟哌啶醇</19>显示能够减少<4>可卡因</4>引起的<8>癫痫发作</8>，而不会显著降低死亡率。", "revised": true}
{"doc_key": "2710809", "sentences": [["Bradycardia", "due", "to", "biperiden", ".", "In", "a", "38", "-", "year", "-", "old", "male", "patient", "suffering", "from", "a", "severe", "postzosteric", "trigeminal", "neuralgia", ",", "intravenous", "application", "of", "10", "mg", "biperiden", "lactate", "led", "to", "a", "long", "-", "lasting", "paradoxical", "reaction", "characterized", "by", "considerable", "bradycardia", ",", "dysarthria", ",", "and", "dysphagia", ".", "The", "heart", "rate", "was", "back", "to", "normal", "within", "12", "hours", "upon", "administration", "of", "orciprenaline", "under", "cardiac", "monitoring", "in", "an", "intensive", "care", "unit", ".", "Bradycardia", "induced", "by", "biperiden", "is", "attributed", "to", "the", "speed", "of", "injection", "and", "to", "a", "dose", "-", "related", "dual", "effect", "of", "atropine", "-", "like", "drugs", "on", "muscarine", "receptors", "."]], "ner": [[[3, 3, "Chemical"], [73, 73, "Chemical"], [0, 0, "Disease"], [40, 40, "Disease"], [70, 70, "Disease"], [42, 42, "Disease"], [45, 45, "Disease"], [27, 28, "Chemical"], [60, 60, "Chemical"], [90, 90, "Chemical"], [95, 95, "Chemical"], [18, 18, "Disease"], [19, 20, "Disease"]]], "relations": [[[3, 3, 0, 0, "CID"], [3, 3, 40, 40, "CID"], [3, 3, 70, 70, "CID"], [73, 73, 0, 0, "CID"], [73, 73, 40, 40, "CID"], [73, 73, 70, 70, "CID"], [3, 3, 42, 42, "CID"], [73, 73, 42, 42, "CID"], [3, 3, 45, 45, "CID"], [73, 73, 45, 45, "CID"]]], "clusters": [], "translated": " <2>心动过缓</2>由于<0>比哌立登</0>。在一名患有严重<11>带状疱疹后遗症</11><12>三叉神经痛</12>的38岁男性患者中，静脉注射10 mg<7>比哌立登乳酸盐</7>导致长期-持久的反常反应，其特征是严重的<3>心动过缓</3>、<5>构音障碍</5>和<6>吞咽困难</6>。在重症监护病房的心脏监测下，服用<8>orciprenaline</8>后12小时内心率恢复正常。<4>心动过缓</4>由<1>比哌立登</1>引起，归因于注射速度和剂量相关双重作用的<9>阿托品类药物</9>对<10>毒蕈碱</10>受体。", "revised": true}
{"doc_key": "1423336", "sentences": [["Pharmacodynamics", "of", "the", "hypotensive", "effect", "of", "levodopa", "in", "parkinsonian", "patients", ".", "Blood", "pressure", "effects", "of", "i", ".", "v", ".", "levodopa", "were", "examined", "in", "parkinsonian", "patients", "with", "stable", "and", "fluctuating", "responses", "to", "levodopa", ".", "The", "magnitude", "of", "the", "hypotensive", "effect", "of", "levodopa", "was", "concentration", "dependent", "and", "was", "fit", "to", "an", "Emax", "model", "in", "fluctuating", "responders", ".", "Stable", "responders", "demonstrated", "a", "small", "hypotensive", "response", ".", "Baseline", "blood", "pressures", "were", "higher", "in", "fluctuating", "patients", ";", "a", "higher", "baseline", "blood", "pressure", "correlated", "with", "greater", "hypotensive", "effects", ".", "Antiparkinsonian", "effects", "of", "levodopa", "temporally", "correlated", "with", "blood", "pressure", "changes", ".", "Phenylalanine", ",", "a", "large", "neutral", "amino", "acid", "(", "LNAA", ")", "competing", "with", "levodopa", "for", "transport", "across", "the", "blood", "-", "brain", "barrier", ",", "reduced", "the", "hypotensive", "and", "antiparkinsonian", "effects", "of", "levodopa", ".", "We", "conclude", "that", "levodopa", "has", "a", "central", "hypotensive", "action", "that", "parallels", "the", "motor", "effects", "in", "fluctuating", "patients", ".", "The", "hypotensive", "effect", "appears", "to", "be", "related", "to", "the", "higher", "baseline", "blood", "pressure", "we", "observed", "in", "fluctuating", "patients", "relative", "to", "stable", "patients", "."]], "ner": [[[6, 6, "Chemical"], [19, 19, "Chemical"], [31, 31, "Chemical"], [40, 40, "Chemical"], [86, 86, "Chemical"], [106, 106, "Chemical"], [123, 123, "Chemical"], [128, 128, "Chemical"], [3, 3, "Disease"], [37, 37, "Disease"], [60, 60, "Disease"], [80, 80, "Disease"], [118, 118, "Disease"], [132, 132, "Disease"], [144, 144, "Disease"], [94, 94, "Chemical"], [99, 100, "Chemical"], [8, 8, "Disease"], [23, 23, "Disease"]]], "relations": [[[6, 6, 3, 3, "CID"], [6, 6, 37, 37, "CID"], [6, 6, 60, 60, "CID"], [6, 6, 80, 80, "CID"], [6, 6, 118, 118, "CID"], [6, 6, 132, 132, "CID"], [6, 6, 144, 144, "CID"], [19, 19, 3, 3, "CID"], [19, 19, 37, 37, "CID"], [19, 19, 60, 60, "CID"], [19, 19, 80, 80, "CID"], [19, 19, 118, 118, "CID"], [19, 19, 132, 132, "CID"], [19, 19, 144, 144, "CID"], [31, 31, 3, 3, "CID"], [31, 31, 37, 37, "CID"], [31, 31, 60, 60, "CID"], [31, 31, 80, 80, "CID"], [31, 31, 118, 118, "CID"], [31, 31, 132, 132, "CID"], [31, 31, 144, 144, "CID"], [40, 40, 3, 3, "CID"], [40, 40, 37, 37, "CID"], [40, 40, 60, 60, "CID"], [40, 40, 80, 80, "CID"], [40, 40, 118, 118, "CID"], [40, 40, 132, 132, "CID"], [40, 40, 144, 144, "CID"], [86, 86, 3, 3, "CID"], [86, 86, 37, 37, "CID"], [86, 86, 60, 60, "CID"], [86, 86, 80, 80, "CID"], [86, 86, 118, 118, "CID"], [86, 86, 132, 132, "CID"], [86, 86, 144, 144, "CID"], [106, 106, 3, 3, "CID"], [106, 106, 37, 37, "CID"], [106, 106, 60, 60, "CID"], [106, 106, 80, 80, "CID"], [106, 106, 118, 118, "CID"], [106, 106, 132, 132, "CID"], [106, 106, 144, 144, "CID"], [123, 123, 3, 3, "CID"], [123, 123, 37, 37, "CID"], [123, 123, 60, 60, "CID"], [123, 123, 80, 80, "CID"], [123, 123, 118, 118, "CID"], [123, 123, 132, 132, "CID"], [123, 123, 144, 144, "CID"], [128, 128, 3, 3, "CID"], [128, 128, 37, 37, "CID"], [128, 128, 60, 60, "CID"], [128, 128, 80, 80, "CID"], [128, 128, 118, 118, "CID"], [128, 128, 132, 132, "CID"], [128, 128, 144, 144, "CID"]]], "clusters": [], "translated": "<0>左旋多巴</0>对<17>帕金森病</17>患者的<8>降压</8>作用的药效学。i.v. <1>左旋多巴</1>的血压影响在对<2>左旋多巴</2>反应稳定和波动的<18>帕金森病</18>患者中进行了研究。 <3>左旋多巴</3> 的<9>降压</9>作用大小是浓度依赖性的，并且符合波动反应者的Emax模型。稳定反应者显示出较小的<10>降压</10>反应。波动患者的基线血压较高；较高的基线血压与较大的<11>降压</11>效应相关。<4>左旋多巴</4>的抗帕金森病效应在时间上与血压变化相关。<15>苯丙氨酸</15>，一种竞争<5>左旋多巴</5>穿过血脑屏障转运的大中性<16>氨基酸</16>（LNAA），降低了<6>左旋多巴</6>的<12>降压</12>和抗帕金森病作用。我们得出结论，<7>左旋多巴</7>具有与波动反应者运动效应相似的中枢性<13>降压</13>作用。<14>降压</14>效应似乎与我们在波动患者中观察到的相对于稳定患者的较高基线血压有关。", "revised": true}
{"doc_key": "2884595", "sentences": [["Treatment", "of", "lethal", "pertussis", "vaccine", "reaction", "with", "histamine", "H1", "antagonists", ".", "We", "studied", "mortality", "after", "pertussis", "immunization", "in", "the", "mouse", ".", "Without", "treatment", ",", "73", "of", "92", "animals", "(", "80", "%", ")", "died", "after", "injection", "of", "bovine", "serum", "albumin", "(", "BSA", ")", "on", "day", "+", "7", "of", "pertussis", "immunization", ".", "After", "pretreatment", "with", "3", "mg", "of", "cyproheptadine", ",", "2", "mg", "mianserin", ",", "or", "2", "mg", "chlorpheniramine", ",", "only", "5", "of", "105", "animals", "(", "5", "%", ")", "died", "after", "receiving", "BSA", "on", "day", "+", "7", "(", "p", "less", "than", "0", ".", "001", ")", ".", "Blockade", "of", "histamine", "H1", "receptors", "may", "reduce", "mortality", "in", "pertussis", "immunization", "-", "induced", "encephalopathy", "in", "mice", "."]], "ner": [[[3, 4, "Chemical"], [106, 106, "Disease"], [15, 15, "Disease"], [47, 47, "Disease"], [102, 102, "Disease"], [7, 7, "Chemical"], [95, 95, "Chemical"], [56, 56, "Chemical"], [60, 60, "Chemical"], [65, 65, "Chemical"]]], "relations": [[[3, 4, 106, 106, "CID"]]], "clusters": [], "translated": "用<5>组胺</5> H1拮抗剂治疗致死性<0>百日咳疫苗</0>反应。我们研究了小鼠<2>百日咳</2>免疫接种后的死亡率。在 <3>百日咳</3> 免疫第+7天注射牛血清白蛋白（BSA）后，92只动物中有73只（80%）未经治疗死亡。在用3毫克<7>赛庚啶</7>、2毫克<8>米安色林</8>或2毫克<9>扑尔敏</9>预处理后，105只动物中只有5只（5%）在接受 BSA on day + 7 治疗后死亡 (p < 0.001)。阻断<6>组胺</6> H1受体可降低<4>百日咳</4>免疫诱导的<1>脑病</1>小鼠的死亡率。", "revised": true}
{"doc_key": "3084231", "sentences": [["Reversible", "valproic", "acid", "-", "induced", "dementia", ":", "a", "case", "report", ".", "Reversible", "valproic", "acid", "-", "induced", "dementia", "was", "documented", "in", "a", "21", "-", "year", "-", "old", "man", "with", "epilepsy", "who", "had", "a", "3", "-", "year", "history", "of", "insidious", "progressive", "decline", "in", "global", "cognitive", "abilities", "documented", "by", "serial", "neuropsychological", "studies", ".", "Repeat", "neuropsychological", "testing", "7", "weeks", "after", "discontinuation", "of", "the", "drug", "revealed", "dramatic", "improvement", "in", "IQ", ",", "memory", ",", "naming", ",", "and", "other", "tasks", "commensurate", "with", "clinical", "recovery", "in", "his", "intellectual", "capacity", ".", "Possible", "pathophysiological", "mechanisms", "which", "may", "have", "been", "operative", "in", "this", "case", "include", ":", "a", "direct", "central", "nervous", "system", "(", "CNS", ")", "toxic", "effect", "of", "valproic", "acid", ";", "a", "paradoxical", "epileptogenic", "effect", "secondary", "to", "the", "drug", ";", "and", "an", "indirect", "CNS", "toxic", "effect", "mediated", "through", "valproic", "acid", "-", "induced", "hyperammonemia", "."]], "ner": [[[1, 2, "Chemical"], [12, 13, "Chemical"], [106, 107, "Chemical"], [126, 127, "Chemical"], [5, 5, "Disease"], [16, 16, "Disease"], [130, 130, "Disease"], [28, 28, "Disease"]]], "relations": [[[1, 2, 5, 5, "CID"], [1, 2, 16, 16, "CID"], [12, 13, 5, 5, "CID"], [12, 13, 16, 16, "CID"], [106, 107, 5, 5, "CID"], [106, 107, 16, 16, "CID"], [126, 127, 5, 5, "CID"], [126, 127, 16, 16, "CID"], [1, 2, 130, 130, "CID"], [12, 13, 130, 130, "CID"], [106, 107, 130, 130, "CID"], [126, 127, 130, 130, "CID"]]], "clusters": [], "translated": "可逆性 <0>丙戊酸</0> 诱发的<4>痴呆</4>：病例报告。可逆性<1>丙戊酸</1>诱发的 <5>痴呆</5> 记录在一名患有<7>癫痫症</7>的21岁男性身上，他有3年的隐匿性进行性衰退病史，在系列神经心理学研究中记录了全球认知能力的下降。停药7周后重复进行神经心理学测试，结果显示智商、记忆力、命名和其他任务有了显着改善，与智力的临床恢复相称。在这种情况下可能起作用的可能病理生理机制包括：<2>丙戊酸</2>的直接中枢神经系统(CNS)毒性作用；继发于药物的矛盾的致癫痫作用；以及通过<3>丙戊酸</3>介导的间接中枢神经系统毒性作用- 诱导<6>高氨血症</6>。", "revised": true}
{"doc_key": "1564030", "sentences": [["Mania", "associated", "with", "fluoxetine", "treatment", "in", "adolescents", ".", "Fluoxetine", ",", "a", "selective", "serotonin", "reuptake", "inhibitor", ",", "is", "gaining", "increased", "acceptance", "in", "the", "treatment", "of", "adolescent", "depression", ".", "Generally", "safe", "and", "well", "tolerated", "by", "adults", ",", "fluoxetine", "has", "been", "reported", "to", "induce", "mania", ".", "The", "cases", "of", "five", "depressed", "adolescents", ",", "14", "-", "16", "years", "of", "age", ",", "who", "developed", "mania", "during", "pharmacotherapy", "with", "fluoxetine", ",", "are", "reported", "here", ".", "Apparent", "risk", "factors", "for", "the", "development", "of", "mania", "or", "hypomania", "during", "fluoxetine", "pharmacotherapy", "in", "this", "population", "were", "the", "combination", "of", "attention", "-", "deficit", "hyperactivity", "disorder", "and", "affective", "instability", ";", "major", "depression", "with", "psychotic", "features", ";", "a", "family", "history", "of", "affective", "disorder", ",", "especially", "bipolar", "disorder", ";", "and", "a", "diagnosis", "of", "bipolar", "disorder", ".", "Further", "study", "is", "needed", "to", "determine", "the", "optimal", "dosage", "and", "to", "identify", "risk", "factors", "that", "increase", "individual", "vulnerability", "to", "fluoxetine", "induced", "mania", "in", "adolescents", "."]], "ner": [[[3, 3, "Chemical"], [8, 8, "Chemical"], [35, 35, "Chemical"], [63, 63, "Chemical"], [80, 80, "Chemical"], [141, 141, "Chemical"], [0, 0, "Disease"], [41, 41, "Disease"], [59, 59, "Disease"], [76, 76, "Disease"], [78, 78, "Disease"], [112, 113, "Disease"], [119, 120, "Disease"], [143, 143, "Disease"], [12, 12, "Chemical"], [25, 25, "Disease"], [47, 47, "Disease"], [99, 99, "Disease"], [89, 93, "Disease"], [101, 101, "Disease"], [108, 109, "Disease"]]], "relations": [[[3, 3, 0, 0, "CID"], [3, 3, 41, 41, "CID"], [3, 3, 59, 59, "CID"], [3, 3, 76, 76, "CID"], [3, 3, 78, 78, "CID"], [3, 3, 112, 113, "CID"], [3, 3, 119, 120, "CID"], [3, 3, 143, 143, "CID"], [8, 8, 0, 0, "CID"], [8, 8, 41, 41, "CID"], [8, 8, 59, 59, "CID"], [8, 8, 76, 76, "CID"], [8, 8, 78, 78, "CID"], [8, 8, 112, 113, "CID"], [8, 8, 119, 120, "CID"], [8, 8, 143, 143, "CID"], [35, 35, 0, 0, "CID"], [35, 35, 41, 41, "CID"], [35, 35, 59, 59, "CID"], [35, 35, 76, 76, "CID"], [35, 35, 78, 78, "CID"], [35, 35, 112, 113, "CID"], [35, 35, 119, 120, "CID"], [35, 35, 143, 143, "CID"], [63, 63, 0, 0, "CID"], [63, 63, 41, 41, "CID"], [63, 63, 59, 59, "CID"], [63, 63, 76, 76, "CID"], [63, 63, 78, 78, "CID"], [63, 63, 112, 113, "CID"], [63, 63, 119, 120, "CID"], [63, 63, 143, 143, "CID"], [80, 80, 0, 0, "CID"], [80, 80, 41, 41, "CID"], [80, 80, 59, 59, "CID"], [80, 80, 76, 76, "CID"], [80, 80, 78, 78, "CID"], [80, 80, 112, 113, "CID"], [80, 80, 119, 120, "CID"], [80, 80, 143, 143, "CID"], [141, 141, 0, 0, "CID"], [141, 141, 41, 41, "CID"], [141, 141, 59, 59, "CID"], [141, 141, 76, 76, "CID"], [141, 141, 78, 78, "CID"], [141, 141, 112, 113, "CID"], [141, 141, 119, 120, "CID"], [141, 141, 143, 143, "CID"]]], "clusters": [], "translated": "<6>躁狂症</6>与青少年<0>氟西汀</0>治疗相关。<1>氟西汀</1>是一种选择性<14>5-羟色胺</14>再摄取抑制剂，在治疗青少年<15>抑郁症</15>方面获得越来越多的认可。通常安全且成人耐受性良好，<2>氟西汀</2>已被报道可诱发<7>躁狂症</7>。此处报告了5名年龄在14-16岁之间的<16>抑郁</16>青少年，在<3>氟西汀</3>药物治疗期间出现<8>躁狂</8>的病例。在该人群中，<4>氟西汀</4>药物治疗期间发生<9>躁狂</9>或<10>轻躁狂</10>的明显危险因素是<18>注意力缺陷多动障碍</18>和情感不稳定；具有<19>精神病特征</19>的重度<17>抑郁症</17>；家族史中存在<20>情感障碍</20>，尤其是<11>双相情感障碍</11>；以及被诊断为<12>双相情感障碍</12>。需要进一步研究以确定最佳剂量，并确定增加个体对<5>氟西汀</5>诱发<13>躁狂</13>的青少年易感性的风险因素。", "revised": true}
{"doc_key": "2933998", "sentences": [["Procaterol", "and", "terbutaline", "in", "bronchial", "asthma", ".", "A", "double", "-", "blind", ",", "placebo", "-", "controlled", ",", "cross", "-", "over", "study", ".", "Procaterol", ",", "a", "new", "beta", "-", "2", "adrenoceptor", "stimulant", ",", "was", "studied", "in", "a", "double", "-", "blind", ",", "placebo", "-", "controlled", ",", "cross", "-", "over", "trial", "in", "patients", "with", "bronchial", "asthma", ".", "Oral", "procaterol", "50", "micrograms", "b", ".", "d", ".", ",", "procaterol", "100", "micrograms", "b", ".", "d", ".", ",", "and", "terbutaline", "5", "mg", "t", ".", "i", ".", "d", ".", ",", "were", "compared", "when", "given", "randomly", "in", "1", "-", "week", "treatment", "periods", ".", "The", "best", "clinical", "effect", "was", "found", "with", "terbutaline", ".", "Both", "anti", "-", "asthmatic", "and", "tremorgenic", "effects", "of", "procaterol", "were", "dose", "-", "related", ".", "Procaterol", "appeared", "effective", "in", "the", "doses", "tested", ",", "and", "a", "twice", "daily", "regimen", "would", "appear", "to", "be", "suitable", "with", "this", "drug", "."]], "ner": [[[0, 0, "Chemical"], [21, 21, "Chemical"], [54, 54, "Chemical"], [62, 62, "Chemical"], [110, 110, "Chemical"], [116, 116, "Chemical"], [107, 107, "Disease"], [4, 5, "Disease"], [50, 51, "Disease"], [105, 105, "Disease"], [2, 2, "Chemical"], [71, 71, "Chemical"], [100, 100, "Chemical"]]], "relations": [[[0, 0, 107, 107, "CID"], [21, 21, 107, 107, "CID"], [54, 54, 107, 107, "CID"], [62, 62, 107, 107, "CID"], [110, 110, 107, 107, "CID"], [116, 116, 107, 107, "CID"]]], "clusters": [], "translated": "<0>丙卡特罗</0>和<10>特布他林</10>治疗<7>支气管哮喘</7>。一项双盲、安慰剂对照、交叉研究。<1>丙卡特罗</1>，是一种新的β-2肾上腺素能受体兴奋剂，在一项针对<8>支气管哮喘</8>患者的双盲、安慰剂对照、交叉试验中进行了研究。口服<2>丙卡特罗</2> 50微克 b. d.，<3>丙卡特罗</3> 100微克 b. d.，和<11>特布他林</11> 5mg t. i. d.，在1周的治疗期间随机给予时进行比较。<12>特布他林</12>的临床效果最好。抗<9>哮喘</9>和产生<6>震颤</6>的<4>丙卡特罗</4>的效应均与剂量相关。<5>丙卡特罗</5>在测试的剂量下似乎有效，每天两次的方案似乎适合这种药物。", "revised": true}
{"doc_key": "3125850", "sentences": [["Increase", "in", "intragastric", "pressure", "during", "suxamethonium", "-", "induced", "muscle", "fasciculations", "in", "children", ":", "inhibition", "by", "alfentanil", ".", "Changes", "in", "intragastric", "pressure", "after", "the", "administration", "of", "suxamethonium", "1", ".", "5", "mg", "kg", "-", "1", "i", ".", "v", ".", "were", "studied", "in", "32", "children", "(", "mean", "age", "6", ".", "9", "yr", ")", "pretreated", "with", "either", "physiological", "saline", "or", "alfentanil", "50", "micrograms", "kg", "-", "1", ".", "Anaesthesia", "was", "induced", "with", "thiopentone", "5", "mg", "kg", "-", "1", ".", "The", "incidence", "and", "intensity", "of", "muscle", "fasciculations", "caused", "by", "suxamethonium", "were", "significantly", "greater", "in", "the", "control", "than", "in", "the", "alfentanil", "group", ".", "The", "intragastric", "pressure", "during", "muscle", "fasciculations", "was", "significantly", "higher", "in", "the", "control", "group", "(", "16", "+", "/", "-", "0", ".", "7", "(", "SEM", ")", "cm", "H2O", ")", "than", "in", "the", "alfentanil", "group", "(", "7", ".", "7", "+", "/", "-", "1", ".", "5", "(", "SEM", ")", "cm", "H2O", ")", ".", "The", "increase", "in", "intragastric", "pressure", "was", "directly", "related", "to", "the", "intensity", "of", "muscle", "fasciculations", "(", "regression", "line", ":", "y", "=", "0", ".", "5", "+", "4", ".", "78x", "with", "r", "of", "0", ".", "78", ")", ".", "It", "is", "concluded", "that", "intragastric", "pressure", "increases", "significantly", "during", "muscle", "fasciculations", "caused", "by", "suxamethonium", "in", "healthy", "children", ".", "Alfentanil", "50", "micrograms", "kg", "-", "1", "effectively", "inhibits", "the", "incidence", "and", "intensity", "of", "suxamethonium", "-", "induced", "muscle", "fasciculations", ";", "moreover", ",", "intragastric", "pressure", "remains", "at", "its", "control", "value", "."]], "ner": [[[5, 5, "Chemical"], [25, 25, "Chemical"], [83, 83, "Chemical"], [193, 193, "Chemical"], [211, 211, "Chemical"], [8, 9, "Disease"], [79, 80, "Disease"], [100, 101, "Disease"], [157, 158, "Disease"], [189, 190, "Disease"], [214, 215, "Disease"], [15, 15, "Chemical"], [56, 56, "Chemical"], [93, 93, "Chemical"], [126, 126, "Chemical"], [198, 198, "Chemical"], [67, 67, "Chemical"], [121, 121, "Chemical"], [142, 142, "Chemical"]]], "relations": [[[5, 5, 8, 9, "CID"], [5, 5, 79, 80, "CID"], [5, 5, 100, 101, "CID"], [5, 5, 157, 158, "CID"], [5, 5, 189, 190, "CID"], [5, 5, 214, 215, "CID"], [25, 25, 8, 9, "CID"], [25, 25, 79, 80, "CID"], [25, 25, 100, 101, "CID"], [25, 25, 157, 158, "CID"], [25, 25, 189, 190, "CID"], [25, 25, 214, 215, "CID"], [83, 83, 8, 9, "CID"], [83, 83, 79, 80, "CID"], [83, 83, 100, 101, "CID"], [83, 83, 157, 158, "CID"], [83, 83, 189, 190, "CID"], [83, 83, 214, 215, "CID"], [193, 193, 8, 9, "CID"], [193, 193, 79, 80, "CID"], [193, 193, 100, 101, "CID"], [193, 193, 157, 158, "CID"], [193, 193, 189, 190, "CID"], [193, 193, 214, 215, "CID"], [211, 211, 8, 9, "CID"], [211, 211, 79, 80, "CID"], [211, 211, 100, 101, "CID"], [211, 211, 157, 158, "CID"], [211, 211, 189, 190, "CID"], [211, 211, 214, 215, "CID"]]], "clusters": [], "translated": "<0>琥珀胆碱</0>引起儿童<5>肌束震颤</5>时胃内压升高：<11>阿芬太尼</11>抑制。<1>琥珀胆碱</1>引起的<6>肌束震颤</6>的发生率和强度在对照组中明显高于<13>阿芬太尼</13>组。对32名儿童（平均年龄6.9岁）进行了研究，这些儿童使用生理盐水或<12>阿芬太尼</12>50微克kg-1进行预处理。用<16>硫喷妥酮</16>5mgkg-1诱导麻醉。<2>琥珀胆碱</2>引起的<7>肌束震颤</7>期间的胃内压（16+/-0.7(SEM) cm <17>H2O</17>）在<14>阿芬太尼</14>组（7.7+/-1.5(SEM) cm <18>H2O</18>）明显降低。胃内压力的增加与<8>肌束震颤</8>的强度直接相关（回归线：y=0.5+4.78x，r为0.78）。结论是，在健康儿童中，<3>琥珀胆碱</3>引起的<9>肌束震颤</9>时胃内压力显着升高。<15>阿芬太尼</15>50微克kg-1有效抑制<4>琥珀胆碱</4>诱发的<10>肌束震颤</10>的发生率和强度，而且胃内压力保持在其控制值。", "revised": true}
{"doc_key": "3191389", "sentences": [["Differential", "effects", "of", "non", "-", "steroidal", "anti", "-", "inflammatory", "drugs", "on", "seizures", "produced", "by", "pilocarpine", "in", "rats", ".", "The", "muscarinic", "cholinergic", "agonist", "pilocarpine", "induces", "in", "rats", "seizures", "and", "status", "epilepticus", "followed", "by", "widespread", "damage", "to", "the", "forebrain", ".", "The", "present", "study", "was", "designed", "to", "investigate", "the", "effect", "of", "5", "non", "-", "steroidal", "anti", "-", "inflammatory", "drugs", ",", "sodium", "salicylate", ",", "phenylbutazone", ",", "indomethacin", ",", "ibuprofen", "and", "mefenamic", "acid", ",", "on", "seizures", "produced", "by", "pilocarpine", ".", "Pretreatment", "of", "rats", "with", "sodium", "salicylate", ",", "ED50", "103", "mg", "/", "kg", "(", "60", "-", "174", ")", ",", "and", "phenylbutazone", ",", "59", "mg", "/", "kg", "(", "50", "-", "70", ")", "converted", "the", "non", "-", "convulsant", "dose", "of", "pilocarpine", ",", "200", "mg", "/", "kg", ",", "to", "a", "convulsant", "one", ".", "Indomethacin", ",", "1", "-", "10", "mg", "/", "kg", ",", "and", "ibuprofen", ",", "10", "-", "100", "mg", "/", "kg", ",", "failed", "to", "modulate", "seizures", "produced", "by", "pilocarpine", ".", "Mefenamic", "acid", ",", "26", "(", "22", "-", "30", ")", "mg", "/", "kg", ",", "prevented", "seizures", "and", "protected", "rats", "from", "seizure", "-", "related", "brain", "damage", "induced", "by", "pilocarpine", ",", "380", "mg", "/", "kg", ".", "These", "results", "indicate", "that", "non", "-", "steroidal", "anti", "-", "inflammatory", "drugs", "differentially", "modulate", "the", "threshold", "for", "pilocarpine", "-", "induced", "seizures", "."]], "ner": [[[14, 14, "Chemical"], [22, 22, "Chemical"], [73, 73, "Chemical"], [112, 112, "Chemical"], [149, 149, "Chemical"], [177, 177, "Chemical"], [200, 200, "Chemical"], [11, 11, "Disease"], [26, 26, "Disease"], [70, 70, "Disease"], [146, 146, "Disease"], [165, 165, "Disease"], [170, 170, "Disease"], [203, 203, "Disease"], [57, 58, "Chemical"], [79, 80, "Chemical"], [60, 60, "Chemical"], [94, 94, "Chemical"], [28, 29, "Disease"], [62, 62, "Chemical"], [124, 124, "Chemical"], [64, 64, "Chemical"], [134, 134, "Chemical"], [66, 67, "Chemical"], [151, 152, "Chemical"], [173, 174, "Disease"]]], "relations": [[[14, 14, 11, 11, "CID"], [14, 14, 26, 26, "CID"], [14, 14, 70, 70, "CID"], [14, 14, 146, 146, "CID"], [14, 14, 165, 165, "CID"], [14, 14, 170, 170, "CID"], [14, 14, 203, 203, "CID"], [22, 22, 11, 11, "CID"], [22, 22, 26, 26, "CID"], [22, 22, 70, 70, "CID"], [22, 22, 146, 146, "CID"], [22, 22, 165, 165, "CID"], [22, 22, 170, 170, "CID"], [22, 22, 203, 203, "CID"], [73, 73, 11, 11, "CID"], [73, 73, 26, 26, "CID"], [73, 73, 70, 70, "CID"], [73, 73, 146, 146, "CID"], [73, 73, 165, 165, "CID"], [73, 73, 170, 170, "CID"], [73, 73, 203, 203, "CID"], [112, 112, 11, 11, "CID"], [112, 112, 26, 26, "CID"], [112, 112, 70, 70, "CID"], [112, 112, 146, 146, "CID"], [112, 112, 165, 165, "CID"], [112, 112, 170, 170, "CID"], [112, 112, 203, 203, "CID"], [149, 149, 11, 11, "CID"], [149, 149, 26, 26, "CID"], [149, 149, 70, 70, "CID"], [149, 149, 146, 146, "CID"], [149, 149, 165, 165, "CID"], [149, 149, 170, 170, "CID"], [149, 149, 203, 203, "CID"], [177, 177, 11, 11, "CID"], [177, 177, 26, 26, "CID"], [177, 177, 70, 70, "CID"], [177, 177, 146, 146, "CID"], [177, 177, 165, 165, "CID"], [177, 177, 170, 170, "CID"], [177, 177, 203, 203, "CID"], [200, 200, 11, 11, "CID"], [200, 200, 26, 26, "CID"], [200, 200, 70, 70, "CID"], [200, 200, 146, 146, "CID"], [200, 200, 165, 165, "CID"], [200, 200, 170, 170, "CID"], [200, 200, 203, 203, "CID"], [57, 58, 11, 11, "CID"], [57, 58, 26, 26, "CID"], [57, 58, 70, 70, "CID"], [57, 58, 146, 146, "CID"], [57, 58, 165, 165, "CID"], [57, 58, 170, 170, "CID"], [57, 58, 203, 203, "CID"], [79, 80, 11, 11, "CID"], [79, 80, 26, 26, "CID"], [79, 80, 70, 70, "CID"], [79, 80, 146, 146, "CID"], [79, 80, 165, 165, "CID"], [79, 80, 170, 170, "CID"], [79, 80, 203, 203, "CID"], [60, 60, 11, 11, "CID"], [60, 60, 26, 26, "CID"], [60, 60, 70, 70, "CID"], [60, 60, 146, 146, "CID"], [60, 60, 165, 165, "CID"], [60, 60, 170, 170, "CID"], [60, 60, 203, 203, "CID"], [94, 94, 11, 11, "CID"], [94, 94, 26, 26, "CID"], [94, 94, 70, 70, "CID"], [94, 94, 146, 146, "CID"], [94, 94, 165, 165, "CID"], [94, 94, 170, 170, "CID"], [94, 94, 203, 203, "CID"], [14, 14, 28, 29, "CID"], [22, 22, 28, 29, "CID"], [73, 73, 28, 29, "CID"], [112, 112, 28, 29, "CID"], [149, 149, 28, 29, "CID"], [177, 177, 28, 29, "CID"], [200, 200, 28, 29, "CID"]]], "clusters": [], "translated": "非甾体类抗炎药对<0>毛果芸香碱</0>大鼠<7>癫痫发作</7>的不同作用。毒蕈碱胆碱能激动剂<1>毛果芸香碱</1>在大鼠中诱导<8>癫痫发作</8>和<18>癫痫持续状态</18>，随后对前脑造成广泛损伤。本研究旨在研究5种非甾体类抗炎药<14>水杨酸钠</14>、<16>保泰松</16>、<19>消炎痛</19>、<21>布洛芬</21>和<23>甲芬那酸</23>对<2>毛果芸香碱</2>产生的<9>癫痫发作</9>的影响。用<15>水杨酸钠</15> ED50 103 mg/kg (60-174) 和<17>保泰松</17> 59 mg/kg (50-70) 预处理大鼠，转化为非惊厥剂量<3>毛果芸香碱</3>，200 mg/kg，至惊厥一剂。 <20>吲哚美辛</20> 1-10 mg/kg 和<22>布洛芬</22> 10-100 mg/kg 未能调节<4>毛果芸香碱</4>产生的<10>癫痫发作</10>。 <24>甲芬那酸</24>，26 (22-30) mg/kg，预防<11>癫痫发作</11>并保护大鼠免受<12>癫痫发作</12>相关的<25>脑损伤</25>由<5>毛果芸香碱</5>诱导，380 mg/kg。这些结果表明，非甾体类抗炎药对<6>毛果芸香碱</6>诱导的<13>癫痫发作</13>的阈值有不同的调节作用。", "revised": true}
{"doc_key": "3109094", "sentences": [["Electron", "microscopic", "investigations", "of", "the", "cyclophosphamide", "-", "induced", "lesions", "of", "the", "urinary", "bladder", "of", "the", "rat", "and", "their", "prevention", "by", "mesna", ".", "Fully", "developed", "cyclophosphamide", "-", "induced", "cystitis", "is", "characterized", "by", "nearly", "complete", "detachment", "of", "the", "urothelium", ",", "severe", "submucosal", "edema", "owing", "to", "damage", "to", "the", "microvascular", "bed", "and", "focal", "muscle", "necroses", ".", "The", "initial", "response", "to", "the", "primary", "attack", "by", "the", "cyclophosphamide", "metabolites", "seems", "to", "be", "fragmentation", "of", "the", "luminal", "membrane", ".", "This", "damages", "the", "cellular", "barrier", "against", "the", "hypertonic", "urine", ".", "Subsequent", "breaks", "in", "the", "lateral", "cell", "membranes", "of", "the", "superficial", "cells", "and", "in", "all", "the", "plasma", "membranes", "of", "the", "intermediate", "and", "basal", "cells", ",", "intercellular", "and", "intracellular", "edema", "and", "disintegration", "of", "the", "desmosomes", "and", "hemidesmosomes", "lead", "to", "progressive", "degeneration", "and", "detachment", "of", "the", "epithelial", "cells", "with", "exposure", "and", "splitting", "of", "the", "basal", "membrane", ".", "The", "morphological", "changes", "of", "the", "endothelial", "cells", ",", "which", "become", "more", "pronounced", "in", "the", "later", "stages", "of", "the", "experiment", ",", "the", "involvement", "of", "blood", "vessels", "regardless", "of", "their", "diameter", "and", "the", "location", "-", "dependent", "extent", "of", "the", "damage", "indicate", "a", "direct", "type", "of", "damage", "which", "is", "preceded", "by", "a", "mediator", "-", "induced", "increase", "in", "permeability", ",", "the", "morphological", "correlate", "of", "which", "is", "the", "formation", "of", "gaps", "in", "the", "interendothelial", "cell", "connections", "on", "the", "venules", ".", "These", "changes", "can", "be", "effectively", "prevented", "by", "mesna", ".", "The", "only", "sign", "of", "a", "possible", "involvement", "is", "the", "increase", "in", "the", "number", "of", "specific", "granules", "with", "a", "presumed", "lysosomal", "function", "in", "the", "superficial", "cells", "."]], "ner": [[[5, 5, "Chemical"], [24, 24, "Chemical"], [62, 62, "Chemical"], [8, 12, "Disease"], [27, 27, "Disease"], [40, 40, "Disease"], [110, 110, "Disease"], [51, 51, "Disease"], [20, 20, "Chemical"], [219, 219, "Chemical"], [70, 70, "Chemical"]]], "relations": [[[5, 5, 8, 12, "CID"], [24, 24, 8, 12, "CID"], [62, 62, 8, 12, "CID"]]], "clusters": [], "translated": " <0>环磷酰胺</0>致大鼠膀胱<3>损伤</3>的电镜观察及<8>美司钠</8>的预防。完全发展的<1>环磷酰胺</1> -诱导的<4>膀胱炎</4>的特征是由于微血管床和局灶性肌肉的损伤，尿路上皮几乎完全脱离，严重的粘膜下<5>水肿</5>，因为管腔膜的破裂，胞外液渗入，引起局灶性<7>坏死</7>。 <2>环磷酰胺</2>代谢物对初级攻击的最初反应似乎是<10>管腔</10>膜的碎裂。这会破坏细胞对高渗尿的屏障。表层细胞的质膜和中间和基底细胞的所有质膜随后断裂，细胞内和细胞间发生<6>水肿</6>，细胞核弥漫性变性，细胞脱落形成空泡，间质充血，上皮底膜分解并裂开。在实验的后期阶段，内皮细胞的形态学变化及不同位置的血管受累程度的评估表明了一种介导体诱导的血管通透性增加和直接损伤，而毛细血管和静脉的损害程度不同。这些变化可以通过使用<9>美司钠</9>有效地预防。有可能参与的唯一迹象是在表皮细胞中特异性有假定溶酶体功能颗粒的数量增加。", "revised": true}
{"doc_key": "3289726", "sentences": [["Acute", "neurologic", "dysfunction", "after", "high", "-", "dose", "etoposide", "therapy", "for", "malignant", "glioma", ".", "Etoposide", "(", "VP", "-", "16", "-", "213", ")", "has", "been", "used", "in", "the", "treatment", "of", "many", "solid", "tumors", "and", "hematologic", "malignancies", ".", "When", "used", "in", "high", "doses", "and", "in", "conjunction", "with", "autologous", "bone", "marrow", "transplantation", ",", "this", "agent", "has", "activity", "against", "several", "treatment", "-", "resistant", "cancers", "including", "malignant", "glioma", ".", "In", "six", "of", "eight", "patients", "(", "75", "%", ")", "who", "we", "treated", "for", "recurrent", "or", "resistant", "glioma", ",", "sudden", "severe", "neurologic", "deterioration", "occurred", ".", "This", "developed", "a", "median", "of", "9", "days", "after", "initiation", "of", "high", "-", "dose", "etoposide", "therapy", ".", "Significant", "clinical", "manifestations", "have", "included", "confusion", ",", "papilledema", ",", "somnolence", ",", "exacerbation", "of", "motor", "deficits", ",", "and", "sharp", "increase", "in", "seizure", "activity", ".", "These", "abnormalities", "resolved", "rapidly", "after", "initiation", "of", "high", "-", "dose", "intravenous", "dexamethasone", "therapy", ".", "In", "all", "patients", ",", "computerized", "tomographic", "(", "CT", ")", "brain", "scans", "demonstrated", "stability", "in", "tumor", "size", "and", "peritumor", "edema", "when", "compared", "with", "pretransplant", "scans", ".", "This", "complication", "appears", "to", "represent", "a", "significant", "new", "toxicity", "of", "high", "-", "dose", "etoposide", "therapy", "for", "malignant", "glioma", "."]], "ner": [[[7, 7, "Chemical"], [13, 13, "Chemical"], [15, 19, "Chemical"], [100, 100, "Chemical"], [178, 178, "Chemical"], [108, 108, "Disease"], [110, 110, "Disease"], [123, 123, "Disease"], [0, 2, "Disease"], [83, 84, "Disease"], [137, 137, "Chemical"], [10, 11, "Disease"], [60, 61, "Disease"], [79, 79, "Disease"], [181, 182, "Disease"], [30, 30, "Disease"], [58, 58, "Disease"], [154, 154, "Disease"], [32, 33, "Disease"], [112, 112, "Disease"], [158, 158, "Disease"], [173, 173, "Disease"]]], "relations": [[[7, 7, 108, 108, "CID"], [13, 13, 108, 108, "CID"], [15, 19, 108, 108, "CID"], [100, 100, 108, 108, "CID"], [178, 178, 108, 108, "CID"], [7, 7, 110, 110, "CID"], [13, 13, 110, 110, "CID"], [15, 19, 110, 110, "CID"], [100, 100, 110, 110, "CID"], [178, 178, 110, 110, "CID"], [7, 7, 123, 123, "CID"], [13, 13, 123, 123, "CID"], [15, 19, 123, 123, "CID"], [100, 100, 123, 123, "CID"], [178, 178, 123, 123, "CID"]]], "clusters": [], "translated": "<11>恶性胶质瘤</11>大剂量<0>依托泊苷</0>治疗后出现<8>急性神经功能障碍</8>。<1>依托泊苷</1>（<2>VP-16-213</2>）已被用于治疗许多实体<15>肿瘤</15>和<18>血液系统恶性肿瘤</18>。当以高剂量使用并与自体骨髓移植结合使用时，该药物对多种治疗耐药的<16>癌症</16>（包括<12>恶性神经胶质瘤</12>）具有活性。在接受我们治疗的复发性或耐药性<13>神经胶质瘤</13>的8名患者中，有6名（75%）发生了突然的严重<9>神经功能恶化</9>。这在开始高剂量<3>依托泊苷</3>治疗后的中位时间为9天。重要的临床表现包括<5>意识模糊</5>、<6>视乳头水肿</6>、<7>癫痫发作</7>活动急剧增加、<19>嗜睡</19>和运动障碍加重。这些异常在开始大剂量静脉注射<10>地塞米松</10>治疗后迅速消失。在所有患者中，计算机断层扫描 (CT) 脑部扫描显示<17>肿瘤</17>大小和肿瘤周围<20>水肿</20>稳定，与移植前扫描相比。这种并发症似乎代表了高剂量<4>依托泊苷</4>治疗<14>恶性神经胶质瘤</14>的显着新<21>毒性</21>。", "revised": true}
{"doc_key": "3297909", "sentences": [["Progressive", "bile", "duct", "injury", "after", "thiabendazole", "administration", ".", "A", "27", "-", "yr", "-", "old", "man", "developed", "jaundice", "2", "wk", "after", "exposure", "to", "thiabendazole", ".", "Cholestasis", "persisted", "for", "3", "yr", ",", "at", "which", "time", "a", "liver", "transplant", "was", "performed", ".", "Two", "liver", "biopsy", "specimens", "and", "the", "hepatectomy", "specimen", "were", "remarkable", "for", "almost", "complete", "disappearance", "of", "interlobular", "bile", "ducts", ".", "Prominent", "fibrosis", "and", "hepatocellular", "regeneration", "were", "also", "present", ";", "however", ",", "the", "lobular", "architecture", "was", "preserved", ".", "This", "case", "represents", "an", "example", "of", "\"", "idiosyncratic", "\"", "drug", "-", "induced", "liver", "damage", "in", "which", "the", "primary", "target", "of", "injury", "is", "the", "bile", "duct", ".", "An", "autoimmune", "pathogenesis", "of", "the", "bile", "duct", "destruction", "is", "suggested", "."]], "ner": [[[5, 5, "Chemical"], [22, 22, "Chemical"], [24, 24, "Disease"], [84, 88, "Disease"], [1, 3, "Disease"], [106, 108, "Disease"], [16, 16, "Disease"], [59, 59, "Disease"]]], "relations": [[[5, 5, 24, 24, "CID"], [22, 22, 24, 24, "CID"], [5, 5, 84, 88, "CID"], [22, 22, 84, 88, "CID"]]], "clusters": [], "translated": "<0>噻苯达唑</0>给药后进行性<4>胆管损伤</4>。一名27岁男子在接触<1>噻苯达唑</1>后2周出现<6>黄疸</6>。持续3年的<2>胆汁淤积</2>后，接受了肝移植手术。两份肝活检标本和肝切除标本的小叶间胆管几乎完全消失。还出现了显著的<7>纤维化</7>和肝细胞再生，然而小叶结构得以保留。该病例是“特异质”<3>药物性肝损伤</3>的一个例子，其中损伤的主要目标是胆管。该病例提出了自身免疫发病机制与 <5> 胆管破坏 </5> 的关联。", "revised": true}
{"doc_key": "2553470", "sentences": [["Anticonvulsant", "actions", "of", "MK", "-", "801", "on", "the", "lithium", "-", "pilocarpine", "model", "of", "status", "epilepticus", "in", "rats", ".", "MK", "-", "801", ",", "a", "noncompetitive", "N", "-", "methyl", "-", "D", "-", "aspartate", "(", "NMDA", ")", "receptor", "antagonist", ",", "was", "tested", "for", "anticonvulsant", "effects", "in", "rats", "using", "two", "seizure", "models", ",", "coadministration", "of", "lithium", "and", "pilocarpine", "and", "administration", "of", "a", "high", "dose", "of", "pilocarpine", "alone", ".", "Three", "major", "results", "are", "reported", ".", "First", ",", "pretreatment", "with", "MK", "-", "801", "produced", "an", "effective", "and", "dose", "-", "dependent", "anticonvulsant", "action", "with", "the", "lithium", "-", "pilocarpine", "model", "but", "not", "with", "rats", "treated", "with", "pilocarpine", "alone", ",", "suggesting", "that", "different", "biochemical", "mechanisms", "control", "seizures", "in", "these", "two", "models", ".", "Second", ",", "the", "anticonvulsant", "effect", "of", "MK", "-", "801", "in", "the", "lithium", "-", "pilocarpine", "model", "only", "occurred", "after", "initial", "periods", "of", "seizure", "activity", ".", "This", "observation", "is", "suggested", "to", "be", "an", "in", "vivo", "demonstration", "of", "the", "conclusion", "derived", "from", "in", "vitro", "experiments", "that", "MK", "-", "801", "binding", "requires", "agonist", "-", "induced", "opening", "of", "the", "channel", "sites", "of", "the", "NMDA", "receptor", ".", "Third", ",", "although", "it", "is", "relatively", "easy", "to", "block", "seizures", "induced", "by", "lithium", "and", "pilocarpine", "by", "administration", "of", "anticonvulsants", "prior", "to", "pilocarpine", ",", "it", "is", "more", "difficult", "to", "terminate", "ongoing", "status", "epilepticus", "and", "block", "the", "lethality", "of", "the", "seizures", ".", "Administration", "of", "MK", "-", "801", "30", "or", "60", "min", "after", "pilocarpine", ",", "i", ".", "e", ".", ",", "during", "status", "epilepticus", ",", "gradually", "reduced", "electrical", "and", "behavioral", "seizure", "activity", "and", "greatly", "enhanced", "the", "survival", "rate", ".", "These", "results", "suggest", "that", "activation", "of", "NMDA", "receptors", "plays", "an", "important", "role", "in", "status", "epilepticus", "and", "brain", "damage", "in", "the", "lithium", "-", "pilocarpine", "model", ".", "This", "was", "further", "supported", "by", "results", "showing", "that", "nonconvulsive", "doses", "of", "NMDA", "and", "pilocarpine", "were", "synergistic", ",", "resulting", "in", "status", "epilepticus", "and", "subsequent", "mortality", "."]], "ner": [[[8, 8, "Chemical"], [51, 51, "Chemical"], [88, 88, "Chemical"], [124, 124, "Chemical"], [186, 186, "Chemical"], [269, 269, "Chemical"], [13, 14, "Disease"], [204, 205, "Disease"], [232, 233, "Disease"], [262, 263, "Disease"], [293, 294, "Disease"], [10, 10, "Chemical"], [53, 53, "Chemical"], [61, 61, "Chemical"], [90, 90, "Chemical"], [98, 98, "Chemical"], [126, 126, "Chemical"], [188, 188, "Chemical"], [195, 195, "Chemical"], [224, 224, "Chemical"], [271, 271, "Chemical"], [287, 287, "Chemical"], [3, 5, "Chemical"], [18, 20, "Chemical"], [74, 76, "Chemical"], [119, 121, "Chemical"], [156, 158, "Chemical"], [216, 218, "Chemical"], [46, 46, "Disease"], [107, 107, "Disease"], [134, 134, "Disease"], [183, 183, "Disease"], [212, 212, "Disease"], [240, 240, "Disease"], [265, 266, "Disease"], [24, 30, "Chemical"], [32, 32, "Chemical"], [171, 171, "Chemical"], [255, 255, "Chemical"], [285, 285, "Chemical"]]], "relations": [[[8, 8, 13, 14, "CID"], [8, 8, 204, 205, "CID"], [8, 8, 232, 233, "CID"], [8, 8, 262, 263, "CID"], [8, 8, 293, 294, "CID"], [51, 51, 13, 14, "CID"], [51, 51, 204, 205, "CID"], [51, 51, 232, 233, "CID"], [51, 51, 262, 263, "CID"], [51, 51, 293, 294, "CID"], [88, 88, 13, 14, "CID"], [88, 88, 204, 205, "CID"], [88, 88, 232, 233, "CID"], [88, 88, 262, 263, "CID"], [88, 88, 293, 294, "CID"], [124, 124, 13, 14, "CID"], [124, 124, 204, 205, "CID"], [124, 124, 232, 233, "CID"], [124, 124, 262, 263, "CID"], [124, 124, 293, 294, "CID"], [186, 186, 13, 14, "CID"], [186, 186, 204, 205, "CID"], [186, 186, 232, 233, "CID"], [186, 186, 262, 263, "CID"], [186, 186, 293, 294, "CID"], [269, 269, 13, 14, "CID"], [269, 269, 204, 205, "CID"], [269, 269, 232, 233, "CID"], [269, 269, 262, 263, "CID"], [269, 269, 293, 294, "CID"], [10, 10, 13, 14, "CID"], [10, 10, 204, 205, "CID"], [10, 10, 232, 233, "CID"], [10, 10, 262, 263, "CID"], [10, 10, 293, 294, "CID"], [53, 53, 13, 14, "CID"], [53, 53, 204, 205, "CID"], [53, 53, 232, 233, "CID"], [53, 53, 262, 263, "CID"], [53, 53, 293, 294, "CID"], [61, 61, 13, 14, "CID"], [61, 61, 204, 205, "CID"], [61, 61, 232, 233, "CID"], [61, 61, 262, 263, "CID"], [61, 61, 293, 294, "CID"], [90, 90, 13, 14, "CID"], [90, 90, 204, 205, "CID"], [90, 90, 232, 233, "CID"], [90, 90, 262, 263, "CID"], [90, 90, 293, 294, "CID"], [98, 98, 13, 14, "CID"], [98, 98, 204, 205, "CID"], [98, 98, 232, 233, "CID"], [98, 98, 262, 263, "CID"], [98, 98, 293, 294, "CID"], [126, 126, 13, 14, "CID"], [126, 126, 204, 205, "CID"], [126, 126, 232, 233, "CID"], [126, 126, 262, 263, "CID"], [126, 126, 293, 294, "CID"], [188, 188, 13, 14, "CID"], [188, 188, 204, 205, "CID"], [188, 188, 232, 233, "CID"], [188, 188, 262, 263, "CID"], [188, 188, 293, 294, "CID"], [195, 195, 13, 14, "CID"], [195, 195, 204, 205, "CID"], [195, 195, 232, 233, "CID"], [195, 195, 262, 263, "CID"], [195, 195, 293, 294, "CID"], [224, 224, 13, 14, "CID"], [224, 224, 204, 205, "CID"], [224, 224, 232, 233, "CID"], [224, 224, 262, 263, "CID"], [224, 224, 293, 294, "CID"], [271, 271, 13, 14, "CID"], [271, 271, 204, 205, "CID"], [271, 271, 232, 233, "CID"], [271, 271, 262, 263, "CID"], [271, 271, 293, 294, "CID"], [287, 287, 13, 14, "CID"], [287, 287, 204, 205, "CID"], [287, 287, 232, 233, "CID"], [287, 287, 262, 263, "CID"], [287, 287, 293, 294, "CID"]]], "clusters": [], "translated": "<22>MK-801</22> 对 <0>锂</0> - <11>毛果芸香碱</11> 大鼠 <6>癫痫持续状态</6> 模型的抗惊厥作用。  <23>MK-801</23>，一种非竞争性 <35>N-甲基-D-天冬氨酸</35> (<36>NMDA</36>) 受体拮抗剂，使用两种<28>癫痫发作</28>模型：用 <1>锂</1> 和 <12>毛果芸香碱</12> 共同给药和单独使用高剂量的 <13>毛果芸香碱</13>。报告了三个主要结果。首先，用<24>MK-801</24>预处理在<2>锂</2> - <14>毛果芸香碱</14>模型中产生了有效的剂量依赖性抗惊厥作用，但在用 <15>毛果芸香碱</15> 单独给药的大鼠上未观察到该作用，表明不同的生化机制控制这两种模型的<29>癫痫发作</29>。其次，在<3>锂</3> - <16>毛果芸香碱</16> 模型中，<25>MK-801</25>的抗惊厥作用仅出现在<30>癫痫发作</30>的初始活动阶段。该观察结果被认为是体内实验的结论的体内证明，即<26>MK-801</26>结合需要激动剂诱导的<37>NMDA</37>受体通道位点的开放。第三，虽然在<18>毛果芸香碱</18>给予抗惊厥药可以相对容易地阻止由<4>锂</4>和<17>毛果芸香碱</17>引起的<31>癫痫发作</31>，但终止正在进行的<7>癫痫持续状态</7>和阻止<32>癫痫发作</32>的致死性更为困难。在<19>毛果芸香碱</19>后30或60分钟施用<27>MK-801</27>，即在<8>癫痫持续状态</8>期间，可以逐渐减少电子和行为<33>癫痫发作</33>活动，并显著提高存活率。这些结果表明，在<5>锂</5> - <20>毛果芸香碱</20> 模型中，<38>NMDA</38>受体的活化在<9> 癫痫持续状态</9> 和<34>脑损伤</34>中起重要作用。而且，该结果有进一步的支持，显示了在非癫痫剂量的<39>NMDA</39>和<21>毛果芸香碱</21>具有协同作用时可能导致<10>癫痫持续状态</10>和随后的死亡。", "revised": true}
{"doc_key": "3088653", "sentences": [["Reversal", "of", "scopolamine", "-", "induced", "amnesia", "of", "passive", "avoidance", "by", "pre", "-", "and", "post", "-", "training", "naloxone", ".", "In", "a", "series", "of", "five", "experiments", ",", "the", "modulating", "role", "of", "naloxone", "on", "a", "scopolamine", "-", "induced", "retention", "deficit", "in", "a", "passive", "avoidance", "paradigm", "was", "investigated", "in", "mice", ".", "Scopolamine", ",", "but", "not", "methyl", "scopolamine", "(", "1", "and", "3", "mg", "/", "kg", ")", ",", "induced", "an", "amnesia", "as", "measured", "by", "latency", "and", "duration", "parameters", ".", "Naloxone", "(", "0", ".", "3", ",", "1", ",", "3", ",", "and", "10", "mg", "/", "kg", ")", "injected", "prior", "to", "training", "attenuated", "the", "retention", "deficit", "with", "a", "peak", "of", "activity", "at", "3", "mg", "/", "kg", ".", "The", "effect", "of", "naloxone", "could", "be", "antagonized", "with", "morphine", "(", "1", ",", "3", ",", "and", "10", "mg", "/", "kg", ")", ",", "demonstrating", "the", "opioid", "specificity", "of", "the", "naloxone", "effect", ".", "Post", "-", "training", "administration", "of", "naloxone", "(", "3", "mg", "/", "kg", ")", "as", "a", "single", "or", "as", "a", "split", "dose", "also", "attenuated", "the", "scopolamine", "-", "induced", "amnesia", ".", "Control", "experiments", "indicated", "that", "neither", "an", "increase", "in", "pain", "sensitivity", "(", "pre", "-", "training", "naloxone", ")", "nor", "an", "induced", "aversive", "state", "(", "post", "-", "training", "naloxone", ")", "appear", "to", "be", "responsible", "for", "the", "influence", "of", "naloxone", "on", "the", "scopolamine", "-", "induced", "retention", "deficit", ".", "These", "results", "extend", "previous", "findings", "implicating", "a", "cholinergic", "-", "opioid", "interaction", "in", "memory", "processes", ".", "A", "possible", "mechanism", "for", "this", "interaction", "involving", "the", "septo", "-", "hippocampal", "cholinergic", "pathway", "is", "discussed", "."]], "ner": [[[2, 2, "Chemical"], [32, 32, "Chemical"], [47, 47, "Chemical"], [161, 161, "Chemical"], [204, 204, "Chemical"], [5, 5, "Disease"], [64, 64, "Disease"], [164, 164, "Disease"], [35, 36, "Disease"], [95, 96, "Disease"], [207, 208, "Disease"], [174, 174, "Disease"], [16, 16, "Chemical"], [29, 29, "Chemical"], [73, 73, "Chemical"], [111, 111, "Chemical"], [135, 135, "Chemical"], [143, 143, "Chemical"], [180, 180, "Chemical"], [191, 191, "Chemical"], [201, 201, "Chemical"], [51, 52, "Chemical"], [116, 116, "Chemical"]]], "relations": [[[2, 2, 5, 5, "CID"], [2, 2, 64, 64, "CID"], [2, 2, 164, 164, "CID"], [32, 32, 5, 5, "CID"], [32, 32, 64, 64, "CID"], [32, 32, 164, 164, "CID"], [47, 47, 5, 5, "CID"], [47, 47, 64, 64, "CID"], [47, 47, 164, 164, "CID"], [161, 161, 5, 5, "CID"], [161, 161, 64, 64, "CID"], [161, 161, 164, 164, "CID"], [204, 204, 5, 5, "CID"], [204, 204, 64, 64, "CID"], [204, 204, 164, 164, "CID"]]], "clusters": [], "translated": "通过训练前和训练后<12>纳洛酮</12>逆转<0>东莨菪碱</0>诱导的<5>遗忘</5>被动回避。在一系列的五个实验中，在小鼠中研究了<13>纳洛酮</13>对<1>东莨菪碱</1>诱导的<8>滞留缺陷</8>的调节作用。 <2>东莨菪碱</2>，而不是<21>甲基东莨菪碱</21>（1 和 3 mg/kg），可诱发<6>健忘症</6>，这是通过潜伏期和持续时间参数来衡量的。 <14>纳洛酮</14>（0.3、1、3和10 mg/kg）注射到训练前可减轻<9>记忆力不足</9>，活动峰值为3 mg/kg。对于<15>纳洛酮</15>的作用，可以通过<22>吗啡</22>（1、3、10 mg/kg）进行拮抗，证明了<16>纳洛酮</16>作用的阿片受体特异性。训练后单独或者分次注射<17>纳洛酮</17>（3 mg/kg），同样可以减轻<3>东莨菪碱</3>引起的<7>健忘</7>。对照实验表明，无论是增加<11>疼痛</11>敏感性（训练前<18>纳洛酮</18>），还是诱发厌恶状态（训练后<19>纳洛酮</19>），都不会导致<20>纳洛酮</20>对<4>东莨菪碱</4>引起的<10>滞留缺陷</10>影响的增加。这些结果扩展了先前的研究结果，揭示了胆碱能-阿片相互作用的在记忆过程中的作用。探讨了一种可能涉及隔海马胆碱能通路的相互作用机制。", "revised": true}
{"doc_key": "3383127", "sentences": [["Hypotension", "as", "a", "manifestation", "of", "cardiotoxicity", "in", "three", "patients", "receiving", "cisplatin", "and", "5", "-", "fluorouracil", ".", "Cardiac", "symptoms", ",", "including", "hypotension", ",", "developed", "in", "three", "patients", "with", "advanced", "colorectal", "carcinoma", "while", "being", "treated", "with", "cisplatin", "(", "CDDP", ")", "and", "5", "-", "fluorouracil", "(", "5", "-", "FU", ")", ".", "In", "two", "patients", ",", "hypotension", "was", "associated", "with", "severe", "left", "ventricular", "dysfunction", ".", "All", "three", "patients", "required", "therapy", "discontinuation", ".", "Cardiac", "enzymes", "remained", "normal", "despite", "transient", "electrocardiographic", "(", "EKG", ")", "changes", ".", "The", "presentation", "and", "cardiac", "evaluation", "(", "hemodynamic", ",", "echocardiographic", ",", "and", "scintigraphic", ")", "of", "these", "patients", "suggest", "new", "manifestations", "of", "5", "-", "FU", "cardiotoxicity", "that", "may", "be", "influenced", "by", "CDDP", ".", "The", "possible", "pathophysiologic", "mechanisms", "are", "discussed", "."]], "ner": [[[10, 10, "Chemical"], [34, 34, "Chemical"], [36, 36, "Chemical"], [109, 109, "Chemical"], [0, 0, "Disease"], [20, 20, "Disease"], [52, 52, "Disease"], [12, 14, "Chemical"], [39, 41, "Chemical"], [43, 45, "Chemical"], [100, 102, "Chemical"], [57, 59, "Disease"], [5, 5, "Disease"], [103, 103, "Disease"], [28, 29, "Disease"]]], "relations": [[[10, 10, 0, 0, "CID"], [10, 10, 20, 20, "CID"], [10, 10, 52, 52, "CID"], [34, 34, 0, 0, "CID"], [34, 34, 20, 20, "CID"], [34, 34, 52, 52, "CID"], [36, 36, 0, 0, "CID"], [36, 36, 20, 20, "CID"], [36, 36, 52, 52, "CID"], [109, 109, 0, 0, "CID"], [109, 109, 20, 20, "CID"], [109, 109, 52, 52, "CID"], [12, 14, 0, 0, "CID"], [12, 14, 20, 20, "CID"], [12, 14, 52, 52, "CID"], [39, 41, 0, 0, "CID"], [39, 41, 20, 20, "CID"], [39, 41, 52, 52, "CID"], [43, 45, 0, 0, "CID"], [43, 45, 20, 20, "CID"], [43, 45, 52, 52, "CID"], [100, 102, 0, 0, "CID"], [100, 102, 20, 20, "CID"], [100, 102, 52, 52, "CID"], [10, 10, 57, 59, "CID"], [34, 34, 57, 59, "CID"], [36, 36, 57, 59, "CID"], [109, 109, 57, 59, "CID"], [12, 14, 57, 59, "CID"], [39, 41, 57, 59, "CID"], [43, 45, 57, 59, "CID"], [100, 102, 57, 59, "CID"]]], "clusters": [], "translated": "<4>低血压</4>作为<12>心脏毒性</12>的表现在三名接受<0>顺铂</0>和<7>5-氟尿嘧啶</7>的患者中。三名晚期<14>结直肠癌</14>患者在接受<1>顺铂</1> (<2>CDDP</2>)治疗期间出现心脏症状，包括<5>低血压</5>，<8>5-氟尿嘧啶</8>（<9>5-FU</9>）。在两名患者中，<6>低血压</6>与严重的<11>左心室功能不全</11>有关。所有三名患者都需要停止治疗。尽管有短暂的心电图(EKG)变化，心肌酶仍保持正常。这些患者的表现和心脏评估（血流动力学、超声心动图和闪烁显像）表明<10>5-FU</10><13>心脏毒性</13>的新表现可能受<3>CDDP</3>影响。讨论了可能的病理生理机制。", "revised": true}
{"doc_key": "3409843", "sentences": [["Fatal", "aplastic", "anemia", "in", "a", "patient", "treated", "with", "carbamazepine", ".", "A", "case", "of", "fatal", "aplastic", "anemia", "due", "to", "carbamazepine", "treatment", "in", "an", "epileptic", "woman", "is", "reported", ".", "Despite", "concerns", "of", "fatal", "bone", "marrow", "toxicity", "due", "to", "carbamazepine", ",", "this", "is", "only", "the", "fourth", "documented", "and", "published", "report", ".", "Carbamazepine", "is", "a", "safe", "drug", ",", "but", "physicians", "and", "patients", "should", "be", "aware", "of", "the", "exceedingly", "rare", "but", "potentially", "fatal", "side", "effects", ",", "better", "prevented", "by", "clinical", "than", "by", "laboratory", "monitoring", "."]], "ner": [[[8, 8, "Chemical"], [18, 18, "Chemical"], [36, 36, "Chemical"], [48, 48, "Chemical"], [1, 2, "Disease"], [14, 15, "Disease"], [22, 22, "Disease"], [31, 33, "Disease"]]], "relations": [[[8, 8, 1, 2, "CID"], [8, 8, 14, 15, "CID"], [18, 18, 1, 2, "CID"], [18, 18, 14, 15, "CID"], [36, 36, 1, 2, "CID"], [36, 36, 14, 15, "CID"], [48, 48, 1, 2, "CID"], [48, 48, 14, 15, "CID"]]], "clusters": [], "translated": "用<0>卡马西平</0>治疗的患者发生致命性<4>再生障碍性贫血</4>。据报道，一名<6>癫痫</6>妇女因治疗中的<1>卡马西平</1>导致致命性<5>再生障碍性贫血</5>。尽管担心<2>卡马西平</2>会导致致命的<7>骨髓毒性</7>，但这只是第四份已记录和发表的报告。<3>卡马西平</3>是一种安全的药物，但医生和患者应该意识到这种极其罕见但可能致命的副作用，最好通过临床检查而非实验室检测进行预防。", "revised": true}
{"doc_key": "3375885", "sentences": [["Hyperkalemia", "induced", "by", "indomethacin", "and", "naproxen", "and", "reversed", "by", "fludrocortisone", ".", "We", "have", "described", "a", "patient", "with", "severe", "rheumatoid", "arthritis", "and", "a", "history", "of", "mefenamic", "acid", "nephropathy", "in", "whom", "hyperkalemia", "and", "inappropriate", "hypoaldosteronism", "were", "caused", "by", "both", "indomethacin", "and", "naproxen", ",", "without", "major", "decline", "in", "renal", "function", ".", "It", "is", "likely", "that", "preexisting", "renal", "disease", "predisposed", "this", "patient", "to", "type", "IV", "renal", "tubular", "acidosis", "with", "prostaglandin", "synthetase", "inhibitors", ".", "Because", "he", "was", "unable", "to", "discontinue", "nonsteroidal", "anti", "-", "inflammatory", "drug", "therapy", ",", "fludrocortisone", "was", "added", ",", "correcting", "the", "hyperkalemia", "and", "allowing", "indomethacin", "therapy", "to", "be", "continued", "safely", "."]], "ner": [[[3, 3, "Chemical"], [37, 37, "Chemical"], [91, 91, "Chemical"], [0, 0, "Disease"], [29, 29, "Disease"], [88, 88, "Disease"], [5, 5, "Chemical"], [39, 39, "Chemical"], [32, 32, "Disease"], [59, 63, "Disease"], [24, 25, "Chemical"], [26, 26, "Disease"], [53, 54, "Disease"], [9, 9, "Chemical"], [82, 82, "Chemical"], [65, 65, "Chemical"], [18, 19, "Disease"]]], "relations": [[[3, 3, 0, 0, "CID"], [3, 3, 29, 29, "CID"], [3, 3, 88, 88, "CID"], [37, 37, 0, 0, "CID"], [37, 37, 29, 29, "CID"], [37, 37, 88, 88, "CID"], [91, 91, 0, 0, "CID"], [91, 91, 29, 29, "CID"], [91, 91, 88, 88, "CID"], [5, 5, 0, 0, "CID"], [5, 5, 29, 29, "CID"], [5, 5, 88, 88, "CID"], [39, 39, 0, 0, "CID"], [39, 39, 29, 29, "CID"], [39, 39, 88, 88, "CID"], [3, 3, 32, 32, "CID"], [3, 3, 59, 63, "CID"], [37, 37, 32, 32, "CID"], [37, 37, 59, 63, "CID"], [91, 91, 32, 32, "CID"], [91, 91, 59, 63, "CID"], [5, 5, 32, 32, "CID"], [5, 5, 59, 63, "CID"], [39, 39, 32, 32, "CID"], [39, 39, 59, 63, "CID"], [24, 25, 26, 26, "CID"], [24, 25, 53, 54, "CID"]]], "clusters": [], "translated": " \n<3>高钾血症</3>由<0>吲哚美辛</0>和<6>萘普生</6>诱导，并被<13>氟氢可的松</13>逆转。我们描述了一名患有严重<16>类风湿性关节炎</16>和<10>甲芬那酸</10><11>肾病</11>病史的患者，其中<4>高钾血症</4>和不适当的<8>醛固酮减少症</8>均由<1>吲哚美辛</1>和<7>萘普生</7>引起，肾功能无明显下降。使用<15>前列腺素</15>合成酶抑制剂时，很可能先前存在的<12>肾脏疾病</12>使该患者易患<9>IV型肾小管酸中毒</9>。由于他无法停止非甾体类抗炎药治疗，加用了<14>氟氢可的松</14>，纠正了<5>高钾血症</5>并使<2>吲哚美辛</2>治疗得以安全继续进行。", "revised": true}
{"doc_key": "2907577", "sentences": [["Effect", "of", "alkylxanthines", "on", "gentamicin", "-", "induced", "acute", "renal", "failure", "in", "the", "rat", ".", "Adenosine", "antagonists", "have", "been", "previously", "shown", "to", "be", "of", "benefit", "in", "some", "ischaemic", "and", "nephrotoxic", "models", "of", "acute", "renal", "failure", "(", "ARF", ")", ".", "In", "the", "present", "study", ",", "the", "effects", "of", "three", "alkylxanthines", "with", "different", "potencies", "as", "adenosine", "antagonists", "8", "-", "phenyltheophylline", ",", "theophylline", "and", "enprofylline", ",", "were", "examined", "in", "rats", "developing", "acute", "renal", "failure", "after", "4", "daily", "injections", "of", "gentamicin", "(", "200", "mg", "kg", "-", "1", ")", ".", "Renal", "function", "was", "assessed", "by", "biochemical", "(", "plasma", "urea", "and", "creatinine", ")", ",", "functional", "(", "urine", "analysis", "and", "[", "3H", "]", "inulin", "and", "[", "14C", "]", "p", "-", "aminohippuric", "acid", "clearances", ")", "and", "morphological", "(", "degree", "of", "necrosis", ")", "indices", ".", "The", "various", "drug", "treatments", "produced", "improvements", "in", "some", ",", "but", "not", "all", ",", "measurements", "of", "renal", "function", ".", "However", ",", "any", "improvement", "produced", "by", "drug", "treatment", "was", "largely", "a", "result", "of", "a", "beneficial", "effect", "exerted", "by", "its", "vehicle", "(", "polyethylene", "glycol", "and", "NaOH", ")", ".", "The", "lack", "of", "any", "consistent", "protective", "effect", "noted", "with", "the", "alkylxanthines", "tested", "in", "the", "present", "study", "indicates", "that", "adenosine", "plays", "little", ",", "if", "any", ",", "pathophysiological", "role", "in", "gentamicin", "-", "induced", "ARF", "."]], "ner": [[[4, 4, "Chemical"], [75, 75, "Chemical"], [198, 198, "Chemical"], [7, 9, "Disease"], [31, 33, "Disease"], [35, 35, "Disease"], [67, 69, "Disease"], [201, 201, "Disease"], [26, 26, "Disease"], [28, 28, "Disease"], [121, 121, "Disease"], [14, 14, "Chemical"], [52, 52, "Chemical"], [188, 188, "Chemical"], [54, 56, "Chemical"], [58, 58, "Chemical"], [60, 60, "Chemical"], [92, 92, "Chemical"], [94, 94, "Chemical"], [110, 113, "Chemical"], [164, 165, "Chemical"], [167, 167, "Chemical"]]], "relations": [[[4, 4, 7, 9, "CID"], [4, 4, 31, 33, "CID"], [4, 4, 35, 35, "CID"], [4, 4, 67, 69, "CID"], [4, 4, 201, 201, "CID"], [75, 75, 7, 9, "CID"], [75, 75, 31, 33, "CID"], [75, 75, 35, 35, "CID"], [75, 75, 67, 69, "CID"], [75, 75, 201, 201, "CID"], [198, 198, 7, 9, "CID"], [198, 198, 31, 33, "CID"], [198, 198, 35, 35, "CID"], [198, 198, 67, 69, "CID"], [198, 198, 201, 201, "CID"]]], "clusters": [], "translated": "烷基黄嘌呤对<0>庆大霉素</0>诱导的大鼠<3>急性肾功能衰竭</3>的影响。 <11>腺苷</11>拮抗剂先前已被证明对<4>急性肾功能衰竭</4>的一些<8>缺血性</8>和<9>肾毒性</9>模型有益（<5>ARF</5>） 。在本研究中，三种具有不同效力的烷基黄嘌呤作为<12>腺苷</12>拮抗剂<14>8-苯基茶碱</14>，<15>茶碱</15>和<16>恩丙茶碱</16>，在每天注射4次<1>庆大霉素</1>（200 mg kg-1）后发生<6>急性肾功能衰竭</6>的大鼠中进行检查。肾功能通过生化（血浆<17>尿素</17>和<18>肌酐</18>）、功能（尿液分析和[3H]菊粉和[14C]<19>对氨基马尿酸</19>间隙）和形态学（<10>坏死程度</10>）指标。各种药物治疗改善了一些但不是全部的肾功能测量值。然而，药物治疗产生的任何改善主要是其载体（<20>聚乙二醇</20>和<21>NaOH</21>）发挥有益作用的结果。本研究中所测试的烷基黄嘌呤缺乏任何一致的保护作用表明<13>腺苷</13>在<2>庆大霉素</2>诱导的<7>ARF</7>中几乎没有病理生理学作用，如果有的话。", "revised": true}
{"doc_key": "3339945", "sentences": [["Theophylline", "neurotoxicity", "in", "pregnant", "rats", ".", "The", "purpose", "of", "this", "investigation", "was", "to", "determine", "whether", "the", "neurotoxicity", "of", "theophylline", "is", "altered", "in", "advanced", "pregnancy", ".", "Sprague", "-", "Dawley", "rats", "that", "were", "20", "days", "pregnant", "and", "nonpregnant", "rats", "of", "the", "same", "age", "and", "strain", "received", "infusions", "of", "aminophylline", "until", "onset", "of", "maximal", "seizures", "which", "occurred", "after", "28", "and", "30", "minutes", "respectively", ".", "Theophylline", "concentrations", "at", "this", "endpoint", "in", "serum", "(", "total", ")", "and", "CSF", "were", "similar", "but", "serum", "(", "free", ")", "and", "brain", "concentrations", "were", "slightly", "different", "in", "pregnant", "rats", ".", "Theophylline", "serum", "protein", "binding", "determined", "by", "equilibrium", "dialysis", "was", "lower", "in", "pregnant", "rats", ".", "Fetal", "serum", "concentrations", "at", "onset", "of", "seizures", "in", "the", "mother", "were", "similar", "to", "maternal", "brain", "and", "CSF", "concentrations", "and", "correlated", "significantly", "with", "the", "former", ".", "It", "is", "concluded", "that", "advanced", "pregnancy", "has", "a", "negligible", "effect", "on", "the", "neurotoxic", "response", "to", "theophylline", "in", "rats", "."]], "ner": [[[46, 46, "Chemical"], [51, 51, "Disease"], [110, 110, "Disease"], [0, 0, "Chemical"], [18, 18, "Chemical"], [61, 61, "Chemical"], [90, 90, "Chemical"], [144, 144, "Chemical"], [1, 1, "Disease"], [16, 16, "Disease"], [141, 141, "Disease"]]], "relations": [[[46, 46, 51, 51, "CID"], [46, 46, 110, 110, "CID"]]], "clusters": [], "translated": "<3>茶碱</3> <8>对孕鼠的神经毒性</8>。本次调查的目的是确定<4>茶碱</4>的<9>神经毒性</9>在妊娠晚期是否发生改变。怀孕20天的Sprague-Dawley大鼠和相同年龄和品系的未怀孕大鼠接受<0>氨茶碱</0>输注，直到分别在28分钟和30分钟后出现最大<1>癫痫发作</1>。 <5>茶碱</5>在该终点在血清（总）和脑脊液中的浓度相似，但血清（游离）和脑浓度在怀孕大鼠中略有不同。 <6>茶碱</6>经由平衡透析测定的血清蛋白结合在怀孕大鼠中较低。母亲开展<2>癫痫发作</2>的同时，胎儿血清浓度与母体脑和脑脊液浓度相似，并与前者显着相关。结论是，晚期怀孕对大鼠<7>茶碱 </7>的<10>神经毒性</10>反应的影响可忽略不计。", "revised": true}
{"doc_key": "3323259", "sentences": [["Differential", "effects", "of", "1", ",", "4", "-", "dihydropyridine", "calcium", "channel", "blockers", ":", "therapeutic", "implications", ".", "Increasing", "recognition", "of", "the", "importance", "of", "calcium", "in", "the", "pathogenesis", "of", "cardiovascular", "disease", "has", "stimulated", "research", "into", "the", "use", "of", "calcium", "channel", "blocking", "agents", "for", "treatment", "of", "a", "variety", "of", "cardiovascular", "diseases", ".", "The", "favorable", "efficacy", "and", "tolerability", "profiles", "of", "these", "agents", "make", "them", "attractive", "therapeutic", "modalities", ".", "Clinical", "applications", "of", "calcium", "channel", "blockers", "parallel", "their", "tissue", "selectivity", ".", "In", "contrast", "to", "verapamil", "and", "diltiazem", ",", "which", "are", "roughly", "equipotent", "in", "their", "actions", "on", "the", "heart", "and", "vascular", "smooth", "muscle", ",", "the", "dihydropyridine", "calcium", "channel", "blockers", "are", "a", "group", "of", "potent", "peripheral", "vasodilator", "agents", "that", "exert", "minimal", "electrophysiologic", "effects", "on", "cardiac", "nodal", "or", "conduction", "tissue", ".", "As", "the", "first", "dihydropyridine", "available", "for", "use", "in", "the", "United", "States", ",", "nifedipine", "controls", "angina", "and", "hypertension", "with", "minimal", "depression", "of", "cardiac", "function", ".", "Additional", "members", "of", "this", "group", "of", "calcium", "channel", "blockers", "have", "been", "studied", "for", "a", "variety", "of", "indications", "for", "which", "they", "may", "offer", "advantages", "over", "current", "therapy", ".", "Once", "or", "twice", "daily", "dosage", "possible", "with", "nitrendipine", "and", "nisoldipine", "offers", "a", "convenient", "administration", "schedule", ",", "which", "encourages", "patient", "compliance", "in", "long", "-", "term", "therapy", "of", "hypertension", ".", "The", "coronary", "vasodilating", "properties", "of", "nisoldipine", "have", "led", "to", "the", "investigation", "of", "this", "agent", "for", "use", "in", "angina", ".", "Selectivity", "for", "the", "cerebrovascular", "bed", "makes", "nimodipine", "potentially", "useful", "in", "the", "treatment", "of", "subarachnoid", "hemorrhage", ",", "migraine", "headache", ",", "dementia", ",", "and", "stroke", ".", "In", "general", ",", "the", "dihydropyridine", "calcium", "channel", "blockers", "are", "usually", "well", "tolerated", ",", "with", "headache", ",", "facial", "flushing", ",", "palpitations", ",", "edema", ",", "nausea", ",", "anorexia", ",", "and", "dizziness", "being", "the", "more", "common", "adverse", "effects", "."]], "ner": [[[8, 10, "Chemical"], [35, 38, "Chemical"], [66, 68, "Chemical"], [98, 100, "Chemical"], [151, 153, "Chemical"], [248, 250, "Chemical"], [257, 257, "Disease"], [260, 260, "Disease"], [264, 264, "Disease"], [266, 266, "Disease"], [268, 268, "Disease"], [271, 271, "Disease"], [3, 7, "Chemical"], [97, 97, "Chemical"], [124, 124, "Chemical"], [247, 247, "Chemical"], [26, 27, "Disease"], [45, 46, "Disease"], [135, 135, "Disease"], [217, 217, "Disease"], [137, 137, "Disease"], [198, 198, "Disease"], [232, 233, "Disease"], [235, 236, "Disease"], [238, 238, "Disease"], [241, 241, "Disease"], [21, 21, "Chemical"], [77, 77, "Chemical"], [79, 79, "Chemical"], [133, 133, "Chemical"], [179, 179, "Chemical"], [181, 181, "Chemical"], [205, 205, "Chemical"], [225, 225, "Chemical"]]], "relations": [[[8, 10, 257, 257, "CID"], [35, 38, 257, 257, "CID"], [66, 68, 257, 257, "CID"], [98, 100, 257, 257, "CID"], [151, 153, 257, 257, "CID"], [248, 250, 257, 257, "CID"], [8, 10, 260, 260, "CID"], [35, 38, 260, 260, "CID"], [66, 68, 260, 260, "CID"], [98, 100, 260, 260, "CID"], [151, 153, 260, 260, "CID"], [248, 250, 260, 260, "CID"], [8, 10, 264, 264, "CID"], [35, 38, 264, 264, "CID"], [66, 68, 264, 264, "CID"], [98, 100, 264, 264, "CID"], [151, 153, 264, 264, "CID"], [248, 250, 264, 264, "CID"], [8, 10, 266, 266, "CID"], [35, 38, 266, 266, "CID"], [66, 68, 266, 266, "CID"], [98, 100, 266, 266, "CID"], [151, 153, 266, 266, "CID"], [248, 250, 266, 266, "CID"], [8, 10, 268, 268, "CID"], [35, 38, 268, 268, "CID"], [66, 68, 268, 268, "CID"], [98, 100, 268, 268, "CID"], [151, 153, 268, 268, "CID"], [248, 250, 268, 268, "CID"], [8, 10, 271, 271, "CID"], [35, 38, 271, 271, "CID"], [66, 68, 271, 271, "CID"], [98, 100, 271, 271, "CID"], [151, 153, 271, 271, "CID"], [248, 250, 271, 271, "CID"]]], "clusters": [], "translated": "<12>1,4-二氢吡啶</12> <0>钙通道阻滞剂</0>的不同作用：治疗意义。越来越多的人认识到<26>钙</26>在<16>心血管疾病</16>的发病机制中的重要性，这刺激了对使用<1>钙通道阻滞剂</1>治疗多种<17>心血管疾病</17>的研究。这些药物的良好功效和耐受性使它们成为有吸引力的治疗方式。临床应用<2>钙通道阻滞剂</2>与其组织选择性平行。与 <27>维拉帕米</27> 和 <28>地尔硫卓</28> 不同，它们对心脏和血管平滑肌的作用大致相同。而<13>二氢吡啶</13> <3>钙通道阻滞剂</3> 是一组强效的外周血管扩张剂，对心脏结节或传导组织的电生理效应最小。作为第一种在美国使用的 <14>二氢吡啶</14>，<29>硝苯地平</29> 可以控制<18>心绞痛</18>和<20>高血压</20>，并仅对心脏功能有最小的影响。这组<4>钙通道阻滞剂 </4> 的其他成员已经针对多种适应症进行了研究，它们可能比当前的治疗方案有更多的优势。比如每天一次或两次给药的 <30>尼群地平</30> 和 <31>尼索地平</31>提供了方便的给药时间表，鼓励患者在<21>高血压</21>的长期治疗中依从性。 <32>尼索地平</32> 的冠状血管扩张特性使其用于<19>心绞痛</19>的研究。而选择性作用于脑血管的<33>尼莫地平</33> 可以潜在地用于治疗<22>蛛网膜下腔出血</22>、<23>偏头痛</23>、<24>痴呆</24> 和<25>中风</25>。一般来说，<15>二氢吡啶</15> <5>钙通道阻滞剂</5> 通常耐受性良好，常见的副作用包括<6>头痛</6>、面部<7>潮红</7>、心悸、<8>水肿</8>、<9>恶心</9>、<10>厌食</10>和<11>头晕</11>。", "revised": true}
{"doc_key": "3323599", "sentences": [["The", "enhancement", "of", "aminonucleoside", "nephrosis", "by", "the", "co", "-", "administration", "of", "protamine", ".", "An", "experimental", "model", "of", "focal", "segmental", "glomerular", "sclerosis", "(", "FSGS", ")", "was", "developed", "in", "rats", "by", "the", "combined", "administration", "of", "puromycin", "-", "aminonucleoside", "(", "AMNS", ")", "and", "protamine", "sulfate", "(", "PS", ")", ".", "Male", "Sprague", "-", "Dawley", "rats", ",", "uninephrectomized", "three", "weeks", "before", ",", "received", "daily", "injections", "of", "subcutaneous", "AMNS", "(", "1", "mg", "/", "100", "g", "body", "wt", ")", "and", "intravenous", "PS", "(", "2", "separated", "doses", "of", "2", ".", "5", "mg", "/", "100", "g", "body", "wt", ")", "for", "four", "days", ".", "The", "series", "of", "injections", "were", "repeated", "another", "three", "times", "at", "10", "day", "intervals", ".", "The", "animals", "were", "sacrificed", "on", "days", "24", ",", "52", ",", "and", "80", ".", "They", "developed", "nephrotic", "syndrome", "and", "finally", "renal", "failure", ".", "The", "time", "-", "course", "curve", "of", "creatinine", "clearance", "dropped", "and", "showed", "significant", "difference", "(", "P", "less", "than", "0", ".", "01", ")", "from", "that", "of", "each", "control", "group", ",", "such", "as", ",", "AMNS", "alone", ",", "PS", "alone", "or", "saline", "injected", ".", "Their", "glomeruli", "showed", "changes", "of", "progressive", "FSGS", ".", "The", "ultrastructural", "studies", "in", "the", "initial", "stage", "revealed", "significant", "lack", "of", "particles", "of", "perfused", "ruthenium", "red", "on", "the", "lamina", "rara", "externa", "and", "marked", "changes", "in", "epithelial", "cell", "cytoplasm", ".", "Therefore", ",", "it", "is", "suggested", "that", "the", "administration", "of", "PS", "enhances", "the", "toxicity", "of", "AMNS", "on", "the", "glomerulus", "and", "readily", "produces", "progressive", "FSGS", "in", "rats", "resulting", "in", "the", "end", "-", "stage", "renal", "disease", "."]], "ner": [[[3, 3, "Chemical"], [33, 35, "Chemical"], [37, 37, "Chemical"], [62, 62, "Chemical"], [161, 161, "Chemical"], [221, 221, "Chemical"], [17, 20, "Disease"], [22, 22, "Disease"], [176, 176, "Disease"], [229, 229, "Disease"], [123, 124, "Disease"], [235, 239, "Disease"], [4, 4, "Disease"], [127, 128, "Disease"], [219, 219, "Disease"], [40, 41, "Chemical"], [43, 43, "Chemical"], [74, 74, "Chemical"], [164, 164, "Chemical"], [216, 216, "Chemical"], [136, 136, "Chemical"], [192, 192, "Chemical"]]], "relations": [[[3, 3, 17, 20, "CID"], [3, 3, 22, 22, "CID"], [3, 3, 176, 176, "CID"], [3, 3, 229, 229, "CID"], [33, 35, 17, 20, "CID"], [33, 35, 22, 22, "CID"], [33, 35, 176, 176, "CID"], [33, 35, 229, 229, "CID"], [37, 37, 17, 20, "CID"], [37, 37, 22, 22, "CID"], [37, 37, 176, 176, "CID"], [37, 37, 229, 229, "CID"], [62, 62, 17, 20, "CID"], [62, 62, 22, 22, "CID"], [62, 62, 176, 176, "CID"], [62, 62, 229, 229, "CID"], [161, 161, 17, 20, "CID"], [161, 161, 22, 22, "CID"], [161, 161, 176, 176, "CID"], [161, 161, 229, 229, "CID"], [221, 221, 17, 20, "CID"], [221, 221, 22, 22, "CID"], [221, 221, 176, 176, "CID"], [221, 221, 229, 229, "CID"], [3, 3, 123, 124, "CID"], [33, 35, 123, 124, "CID"], [37, 37, 123, 124, "CID"], [62, 62, 123, 124, "CID"], [161, 161, 123, 124, "CID"], [221, 221, 123, 124, "CID"], [3, 3, 235, 239, "CID"], [33, 35, 235, 239, "CID"], [37, 37, 235, 239, "CID"], [62, 62, 235, 239, "CID"], [161, 161, 235, 239, "CID"], [221, 221, 235, 239, "CID"]]], "clusters": [], "translated": "鱼精蛋白联合给药对<0>氨基核苷</0><12>肾病</12>的增强作用。<6>局灶节段性肾小球硬化</6>（<7>FSGS</7>）大鼠实验模型是通过<1>嘌呤霉素-氨基核苷</1>（<2>AMNS</2>）和<15>硫酸鱼精蛋白</15>（<16>PS</16>）共同注射产生的。雄性Sprague-Dawley大鼠，未进行肾脏切除手术，持续四天每天接受皮下注射<3>AMNS</3>（1毫克/100克体重）和2次分开剂量2.5毫克/100克体重的静脉注射<17>PS</17>。每组注射间隔10天，该系列注射再重复3次。在第24、52、80天时动物被人道处死，它们均患有<10>肾病综合征</10>，并最终导致<13>肾功能衰竭</13>。这时，<20>肌酐</20>清除率的时间-进程曲线显示出与对照组-仅接受<4>AMNS</4>、<18>PS</18>单独或注射生理盐水组存在明显的差异（P <0.01）。它们的肾小球表现出进行性<8>FSGS</8>的变化。初期的超微结构研究表明，外层稀薄层明显缺乏灌注<21>钌</21>红颗粒，上皮细胞胞质发生明显变化，因此提示给予<19>PS</19>的注射可增强<5>AMNS</5>对肾小球的<14>毒性</14>，使之容易在大鼠中引起进行性<9>FSGS</9>，最终导致<11>终末期肾病</11>。", "revised": true}
{"doc_key": "3423103", "sentences": [["Participation", "of", "a", "bulbospinal", "serotonergic", "pathway", "in", "the", "rat", "brain", "in", "clonidine", "-", "induced", "hypotension", "and", "bradycardia", ".", "The", "effects", "of", "microinjection", "of", "clonidine", "(", "1", "-", "10", "micrograms", "in", "1", "microliter", ")", "into", "a", "region", "adjacent", "to", "the", "ventrolateral", "surface", "of", "the", "medulla", "oblongata", "on", "cardiovascular", "function", "were", "assessed", "in", "urethane", "-", "anesthetized", "rats", ".", "Intramedullary", "administration", "of", "clonidine", ",", "but", "not", "saline", "vehicle", ",", "caused", "a", "dose", "-", "dependent", "decrease", "in", "both", "the", "mean", "arterial", "pressure", "and", "the", "heart", "rate", ".", "The", "clonidine", "-", "induced", "hypotension", "was", "antagonized", "by", "prior", "spinal", "transection", ",", "but", "not", "bilateral", "vagotomy", ".", "On", "the", "other", "hand", ",", "the", "clonidine", "-", "induced", "bradycardia", "was", "antagonized", "by", "prior", "bilateral", "vagotomy", ",", "but", "not", "spinal", "transection", ".", "Furthermore", ",", "selective", "destruction", "of", "the", "spinal", "5", "-", "HT", "nerves", ",", "produced", "by", "bilateral", "spinal", "injection", "of", "5", ",", "7", "-", "dihydroxytryptamine", ",", "reduced", "the", "magnitude", "of", "the", "vasodepressor", "or", "the", "bradycardiac", "responses", "to", "clonidine", "microinjected", "into", "the", "area", "near", "the", "ventrolateral", "surface", "of", "the", "medulla", "oblongata", "in", "rats", ".", "The", "data", "indicate", "that", "a", "bulbospinal", "serotonergic", "pathway", "is", "involved", "in", "development", "of", "clonidine", "-", "induced", "hypotension", "and", "bradycardia", ".", "The", "induced", "hypotension", "is", "brought", "about", "by", "a", "decrease", "in", "sympathetic", "efferent", "activity", ",", "whereas", "the", "induced", "bradycardia", "was", "due", "to", "an", "increase", "in", "vagal", "efferent", "activity", "."]], "ner": [[[11, 11, "Chemical"], [23, 23, "Chemical"], [59, 59, "Chemical"], [84, 84, "Chemical"], [106, 106, "Chemical"], [157, 157, "Chemical"], [186, 186, "Chemical"], [14, 14, "Disease"], [87, 87, "Disease"], [189, 189, "Disease"], [195, 195, "Disease"], [16, 16, "Disease"], [109, 109, "Disease"], [154, 154, "Disease"], [191, 191, "Disease"], [210, 210, "Disease"], [51, 51, "Chemical"], [129, 131, "Chemical"], [140, 144, "Chemical"]]], "relations": [[[11, 11, 14, 14, "CID"], [11, 11, 87, 87, "CID"], [11, 11, 189, 189, "CID"], [11, 11, 195, 195, "CID"], [23, 23, 14, 14, "CID"], [23, 23, 87, 87, "CID"], [23, 23, 189, 189, "CID"], [23, 23, 195, 195, "CID"], [59, 59, 14, 14, "CID"], [59, 59, 87, 87, "CID"], [59, 59, 189, 189, "CID"], [59, 59, 195, 195, "CID"], [84, 84, 14, 14, "CID"], [84, 84, 87, 87, "CID"], [84, 84, 189, 189, "CID"], [84, 84, 195, 195, "CID"], [106, 106, 14, 14, "CID"], [106, 106, 87, 87, "CID"], [106, 106, 189, 189, "CID"], [106, 106, 195, 195, "CID"], [157, 157, 14, 14, "CID"], [157, 157, 87, 87, "CID"], [157, 157, 189, 189, "CID"], [157, 157, 195, 195, "CID"], [186, 186, 14, 14, "CID"], [186, 186, 87, 87, "CID"], [186, 186, 189, 189, "CID"], [186, 186, 195, 195, "CID"], [11, 11, 16, 16, "CID"], [11, 11, 109, 109, "CID"], [11, 11, 154, 154, "CID"], [11, 11, 191, 191, "CID"], [11, 11, 210, 210, "CID"], [23, 23, 16, 16, "CID"], [23, 23, 109, 109, "CID"], [23, 23, 154, 154, "CID"], [23, 23, 191, 191, "CID"], [23, 23, 210, 210, "CID"], [59, 59, 16, 16, "CID"], [59, 59, 109, 109, "CID"], [59, 59, 154, 154, "CID"], [59, 59, 191, 191, "CID"], [59, 59, 210, 210, "CID"], [84, 84, 16, 16, "CID"], [84, 84, 109, 109, "CID"], [84, 84, 154, 154, "CID"], [84, 84, 191, 191, "CID"], [84, 84, 210, 210, "CID"], [106, 106, 16, 16, "CID"], [106, 106, 109, 109, "CID"], [106, 106, 154, 154, "CID"], [106, 106, 191, 191, "CID"], [106, 106, 210, 210, "CID"], [157, 157, 16, 16, "CID"], [157, 157, 109, 109, "CID"], [157, 157, 154, 154, "CID"], [157, 157, 191, 191, "CID"], [157, 157, 210, 210, "CID"], [186, 186, 16, 16, "CID"], [186, 186, 109, 109, "CID"], [186, 186, 154, 154, "CID"], [186, 186, 191, 191, "CID"], [186, 186, 210, 210, "CID"]]], "clusters": [], "translated": "在 <0>可乐定</0> 诱导的 <7>低血压</7> 和 <11>心动过缓</11> 中参与大鼠大脑中的球蛋白血清素能通路。将 <1>可乐定</1>（1 微升中 1-10 微克）显微注射到靠近延髓腹外侧表面的区域对心血管功能的影响在 <16>氨基甲酸乙酯</16> 麻醉老鼠中进行了评估。髓内给药 <2>可乐定</2>，但不是盐水载体，导致平均动脉压和心率均呈剂量依赖性降低。 <3>可乐定</3> 引起的 <8>低血压</8> 被先前的脊柱横断所拮抗，但不是双侧迷走神经切断术。另一方面，<4>可乐定</4> 诱发的 <12>心动过缓</12> 被先前的双侧迷走神经切断术而不是脊柱横断术所拮抗。此外，通过双侧脊髓注射 <18>5,7-二羟色胺</18> 选择性破坏脊髓 <17>5-HT</17> 神经，降低了血管降压药或 <13>心动过缓的反应</13> 对<5>可乐定</5> 显微注射到大鼠延髓腹外侧表面附近区域的强度。数据表明球脊髓 5-羟色胺能通路参与 <6>可乐定</6> 诱导的 <9>低血压</9> 和 <14>心动过缓</14> 的发展。诱发的 <10>低血压</10> 是由交感神经传出活动减少引起的，而诱发的 <15>心动过缓</15> 是由于迷走神经传出活动增加所致。", "revised": true}
{"doc_key": "3475563", "sentences": [["Rechallenge", "of", "patients", "who", "developed", "oral", "candidiasis", "or", "hoarseness", "with", "beclomethasone", "dipropionate", ".", "Of", "158", "asthmatic", "patients", "who", "were", "placed", "on", "inhaled", "beclomethasone", ",", "15", "(", "9", ".", "5", "%", ")", "developed", "either", "hoarseness", "(", "8", ")", ",", "oral", "thrush", "(", "6", ")", ",", "or", "both", "(", "1", ")", ".", "When", "their", "adverse", "reactions", "subsided", ",", "seven", "of", "these", "15", "patients", "were", "rechallenged", "with", "inhaled", "beclomethasone", ".", "These", "included", "five", "cases", "who", "developed", "hoarseness", "and", "three", "who", "developed", "Candidiasis", ".", "One", "patient", "had", "both", ".", "Oral", "thrush", "did", "not", "recur", ",", "but", "60", "%", "(", "3", "/", "5", ")", "of", "patients", "with", "hoarseness", "had", "recurrence", ".", "We", "conclude", "that", "patients", "may", "be", "restarted", "on", "inhaled", "beclomethasone", "when", "clinically", "indicated", ";", "however", ",", "because", "of", "the", "high", "recurrence", "rate", ",", "patients", "who", "develop", "hoarseness", "should", "not", "be", "re", "-", "challenged", ".", "Concomitant", "use", "of", "oral", "prednisone", "and", "topical", "beclomethasone", "may", "increase", "the", "risk", "of", "developing", "hoarseness", "or", "candidiasis", "."]], "ner": [[[10, 11, "Chemical"], [22, 22, "Chemical"], [65, 65, "Chemical"], [115, 115, "Chemical"], [147, 147, "Chemical"], [5, 6, "Disease"], [39, 39, "Disease"], [86, 86, "Disease"], [8, 8, "Disease"], [33, 33, "Disease"], [73, 73, "Disease"], [102, 102, "Disease"], [132, 132, "Disease"], [154, 154, "Disease"], [144, 144, "Chemical"], [15, 15, "Disease"], [78, 78, "Disease"], [156, 156, "Disease"]]], "relations": [[[10, 11, 5, 6, "CID"], [10, 11, 39, 39, "CID"], [10, 11, 86, 86, "CID"], [22, 22, 5, 6, "CID"], [22, 22, 39, 39, "CID"], [22, 22, 86, 86, "CID"], [65, 65, 5, 6, "CID"], [65, 65, 39, 39, "CID"], [65, 65, 86, 86, "CID"], [115, 115, 5, 6, "CID"], [115, 115, 39, 39, "CID"], [115, 115, 86, 86, "CID"], [147, 147, 5, 6, "CID"], [147, 147, 39, 39, "CID"], [147, 147, 86, 86, "CID"], [10, 11, 8, 8, "CID"], [10, 11, 33, 33, "CID"], [10, 11, 73, 73, "CID"], [10, 11, 102, 102, "CID"], [10, 11, 132, 132, "CID"], [10, 11, 154, 154, "CID"], [22, 22, 8, 8, "CID"], [22, 22, 33, 33, "CID"], [22, 22, 73, 73, "CID"], [22, 22, 102, 102, "CID"], [22, 22, 132, 132, "CID"], [22, 22, 154, 154, "CID"], [65, 65, 8, 8, "CID"], [65, 65, 33, 33, "CID"], [65, 65, 73, 73, "CID"], [65, 65, 102, 102, "CID"], [65, 65, 132, 132, "CID"], [65, 65, 154, 154, "CID"], [115, 115, 8, 8, "CID"], [115, 115, 33, 33, "CID"], [115, 115, 73, 73, "CID"], [115, 115, 102, 102, "CID"], [115, 115, 132, 132, "CID"], [115, 115, 154, 154, "CID"], [147, 147, 8, 8, "CID"], [147, 147, 33, 33, "CID"], [147, 147, 73, 73, "CID"], [147, 147, 102, 102, "CID"], [147, 147, 132, 132, "CID"], [147, 147, 154, 154, "CID"]]], "clusters": [], "translated": "对发生<5>口腔念珠菌病</5>或<8>声音嘶哑</8>的患者再次服用<0>二丙酸倍氯米松</0>。在158名<15>哮喘患者</15>接受吸入性<1> 倍氯米松</1>治疗后，有15名 (9.5%) 出现了<9>声音嘶哑</9> (8)，口腔<6>画眉</6> (6)，或两者兼而有之 (1)。当他们的不良反应消退时，这15名患者中有7名再次接受吸入性<2>倍氯米松</2>治疗。其中包括出现<10> 声音嘶哑</10> 的五例和出现<16>念珠菌病</16>的三例。一名患者两者都有。口腔<7>鹅口疮</7>未复发，但出现<11>声音嘶哑</11>的患者中有60% (3/5) 复发。我们得出结论，当有临床指征时，患者可以重新开始吸入<3>倍氯米松</3>；但是，由于复发率高，出现<12>声音嘶哑</12>的患者不应再接受挑战。同时使用口服<14>泼尼松</14>和局部<4>倍氯米松</4>可能会增加发生<13>声音嘶哑</13>或<17>念珠菌病</17>的风险。", "revised": true}
{"doc_key": "3538855", "sentences": [["Studies", "of", "risk", "factors", "for", "aminoglycoside", "nephrotoxicity", ".", "The", "epidemiology", "of", "aminoglycoside", "-", "induced", "nephrotoxicity", "is", "not", "fully", "understood", ".", "Experimental", "studies", "in", "healthy", "human", "volunteers", "indicate", "aminoglycosides", "cause", "proximal", "tubular", "damage", "in", "most", "patients", ",", "but", "rarely", ",", "if", "ever", ",", "cause", "glomerular", "or", "tubular", "dysfunction", ".", "Clinical", "trials", "of", "aminoglycosides", "in", "seriously", "ill", "patients", "indicate", "that", "the", "relative", "risk", "for", "developing", "acute", "renal", "failure", "during", "therapy", "ranges", "from", "8", "to", "10", "and", "that", "the", "attributable", "risk", "is", "70", "%", "to", "80", "%", ".", "Further", "analysis", "of", "these", "data", "suggests", "that", "the", "duration", "of", "therapy", ",", "plasma", "aminoglycoside", "levels", ",", "liver", "disease", ",", "advanced", "age", ",", "high", "initial", "estimated", "creatinine", "clearance", "and", ",", "possibly", ",", "female", "gender", "all", "increase", "the", "risk", "for", "nephrotoxicity", ".", "Other", "causes", "of", "acute", "renal", "failure", ",", "such", "as", "shock", ",", "appear", "to", "have", "an", "additive", "effect", ".", "Predictive", "models", "have", "been", "developed", "from", "these", "analyses", "that", "should", "be", "useful", "for", "identifying", "patients", "at", "high", "risk", ".", "These", "models", "may", "also", "be", "useful", "in", "developing", "insights", "into", "the", "pathophysiology", "of", "aminoglycoside", "-", "induced", "nephrotoxicity", "."]], "ner": [[[5, 5, "Chemical"], [11, 11, "Chemical"], [27, 27, "Chemical"], [51, 51, "Chemical"], [98, 98, "Chemical"], [175, 175, "Chemical"], [6, 6, "Disease"], [14, 14, "Disease"], [43, 46, "Disease"], [123, 123, "Disease"], [178, 178, "Disease"], [63, 65, "Disease"], [128, 130, "Disease"], [101, 102, "Disease"], [134, 134, "Disease"], [110, 110, "Chemical"]]], "relations": [[[5, 5, 6, 6, "CID"], [5, 5, 14, 14, "CID"], [5, 5, 43, 46, "CID"], [5, 5, 123, 123, "CID"], [5, 5, 178, 178, "CID"], [11, 11, 6, 6, "CID"], [11, 11, 14, 14, "CID"], [11, 11, 43, 46, "CID"], [11, 11, 123, 123, "CID"], [11, 11, 178, 178, "CID"], [27, 27, 6, 6, "CID"], [27, 27, 14, 14, "CID"], [27, 27, 43, 46, "CID"], [27, 27, 123, 123, "CID"], [27, 27, 178, 178, "CID"], [51, 51, 6, 6, "CID"], [51, 51, 14, 14, "CID"], [51, 51, 43, 46, "CID"], [51, 51, 123, 123, "CID"], [51, 51, 178, 178, "CID"], [98, 98, 6, 6, "CID"], [98, 98, 14, 14, "CID"], [98, 98, 43, 46, "CID"], [98, 98, 123, 123, "CID"], [98, 98, 178, 178, "CID"], [175, 175, 6, 6, "CID"], [175, 175, 14, 14, "CID"], [175, 175, 43, 46, "CID"], [175, 175, 123, 123, "CID"], [175, 175, 178, 178, "CID"]]], "clusters": [], "translated": "<0>氨基糖苷类</0> <6>肾毒性</6>危险因素研究。<1>氨基糖苷类</1>引起的<7>肾毒性</7>的流行病学尚不完全清楚。在健康人类志愿者中进行的实验研究表明，<2>氨基糖苷类</2>会导致大多数患者的近端肾小管损伤，但很少（如果有的话）会导致<8>肾小球或肾小管功能障碍</8>。在重病患者中的临床试验表明，<3>氨基糖苷类药物</3>治疗期间发生<11>急性肾功能衰竭</11>的相对风险为8至10，归因风险为70%至80%。对这些数据的进一步分析表明，治疗持续时间、血浆<4>氨基糖苷类</4>水平、<13>肝脏疾病</13>、高龄、高初始估计<15>肌酐</15>清除率和可能是女性都会增加<9>肾毒性</9>的风险。<12>急性肾功能衰竭</12>的其他原因，例如<14>休克</14>，似乎具有叠加效应。已从这些分析中发展出预测模型，应有助于识别高危患者。这些模型也可用于深入了解<5>氨基糖苷类</5>诱导<10>肾毒性</10>的病理生理学。", "revised": true}
{"doc_key": "3439580", "sentences": [["Hypertension", "in", "neuroblastoma", "induced", "by", "imipramine", ".", "Hypertension", "is", "a", "well", "-", "known", "finding", "in", "some", "patients", "with", "neuroblastoma", ".", "However", ",", "it", "has", "not", "previously", "been", "described", "in", "association", "with", "the", "use", "of", "Imipramine", ".", "We", "report", "the", "occurrence", "of", "severe", "hypertension", "(", "blood", "pressure", "190", "/", "160", ")", "in", "a", "4", "-", "year", "-", "old", "girl", "with", "neuroblastoma", "who", "was", "given", "Imipramine", "to", "control", "a", "behavior", "disorder", ".", "It", "was", "determined", "later", "that", "this", "patient", "'s", "tumor", "was", "recurring", "at", "the", "time", "of", "her", "hypertensive", "episode", ".", "Since", "she", "had", "no", "blood", "pressure", "elevation", "at", "initial", "diagnosis", "and", "none", "following", "discontinuation", "of", "the", "Imipramine", "(", "when", "she", "was", "in", "florid", "relapse", ")", ",", "we", "believe", "that", "this", "drug", "rather", "than", "her", "underlying", "disease", "alone", "caused", "her", "hypertension", ".", "The", "mechanism", "for", "this", "reaction", "is", "believed", "to", "be", "increased", "levels", "of", "vasoactive", "catecholamines", "due", "to", "interference", "of", "their", "physiologic", "inactivation", "by", "Imipramine", ".", "From", "this", "experience", ",", "we", "urge", "extreme", "caution", "in", "the", "use", "of", "tricyclic", "antidepressants", "in", "children", "with", "active", "neuroblastoma", "."]], "ner": [[[5, 5, "Chemical"], [34, 34, "Chemical"], [63, 63, "Chemical"], [105, 105, "Chemical"], [152, 152, "Chemical"], [0, 0, "Disease"], [7, 7, "Disease"], [42, 42, "Disease"], [86, 86, "Disease"], [128, 128, "Disease"], [143, 143, "Chemical"], [2, 2, "Disease"], [18, 18, "Disease"], [59, 59, "Disease"], [172, 172, "Disease"], [67, 68, "Disease"], [78, 78, "Disease"]]], "relations": [[[5, 5, 0, 0, "CID"], [5, 5, 7, 7, "CID"], [5, 5, 42, 42, "CID"], [5, 5, 86, 86, "CID"], [5, 5, 128, 128, "CID"], [34, 34, 0, 0, "CID"], [34, 34, 7, 7, "CID"], [34, 34, 42, 42, "CID"], [34, 34, 86, 86, "CID"], [34, 34, 128, 128, "CID"], [63, 63, 0, 0, "CID"], [63, 63, 7, 7, "CID"], [63, 63, 42, 42, "CID"], [63, 63, 86, 86, "CID"], [63, 63, 128, 128, "CID"], [105, 105, 0, 0, "CID"], [105, 105, 7, 7, "CID"], [105, 105, 42, 42, "CID"], [105, 105, 86, 86, "CID"], [105, 105, 128, 128, "CID"], [152, 152, 0, 0, "CID"], [152, 152, 7, 7, "CID"], [152, 152, 42, 42, "CID"], [152, 152, 86, 86, "CID"], [152, 152, 128, 128, "CID"]]], "clusters": [], "translated": " \n<5>高血压</5>在<11>神经母细胞瘤</11>中由<0>丙咪嗪</0>诱发。<6>高血压</6>是一些<12>神经母细胞瘤</12>患者的众所周知的发现。然而，以前没有描述过它与<1>丙咪嗪</1>的使用有关。我们报告了一名患有<13>神经母细胞瘤</13>的4岁女孩的严重<7>高血压</7>（血压190/160）的发生，她服用了<2>丙咪嗪</2>以控制<15>行为障碍</15>。后来确定该患者的<16>肿瘤</16>在她<8>高血压</8>发作时复发。由于她在初步诊断时没有血压升高并且在停用<3>丙咪嗪</3>后也没有升高（当时她处于严重复发状态），我们认为是这种药物而不是她的基础疾病单独导致了她的<9>高血压</9>。该反应的机制被认为是血管活性<10>儿茶酚胺</10>的水平增加，因为<4>丙咪嗪</4>干扰了它们的生理失活。根据这一经验，我们敦促在患有活动性<14>神经母细胞瘤</14>的儿童中使用三环类抗抑郁药时要格外谨慎。", "revised": true}
{"doc_key": "3685052", "sentences": [["Flurothyl", "seizure", "thresholds", "in", "mice", "treated", "neonatally", "with", "a", "single", "injection", "of", "monosodium", "glutamate", "(", "MSG", ")", ":", "evaluation", "of", "experimental", "parameters", "in", "flurothyl", "seizure", "testing", ".", "Monosodium", "glutamate", "(", "MSG", ")", "administration", "to", "neonatal", "rodents", "produces", "convulsions", "and", "results", "in", "numerous", "biochemical", "and", "behavioral", "deficits", ".", "These", "studies", "were", "undertaken", "to", "determine", "if", "neonatal", "administration", "of", "MSG", "produced", "permanent", "alterations", "in", "seizure", "susceptibility", ",", "since", "previous", "investigations", "were", "inconclusive", ".", "A", "flurothyl", "ether", "seizure", "screening", "technique", "was", "used", "to", "evaluate", "seizure", "susceptibility", "in", "adult", "mice", "that", "received", "neonatal", "injections", "of", "MSG", "(", "4", "mg", "/", "g", "and", "1", "mg", "/", "g", ")", ".", "MSG", "treatment", "resulted", "in", "significant", "reductions", "in", "whole", "brain", "weight", "but", "did", "not", "alter", "seizure", "threshold", ".", "A", "naloxone", "(", "5", "mg", "/", "kg", ")", "challenge", "was", "also", "ineffective", "in", "altering", "the", "seizure", "thresholds", "of", "either", "control", "of", "MSG", "-", "treated", "mice", ".", "Flurothyl", "ether", "produced", "hypothermia", "which", "was", "correlated", "with", "the", "duration", "of", "flurothyl", "exposure", ";", "however", ",", "the", "relationship", "of", "hypothermia", "to", "seizure", "induction", "was", "unclear", ".", "Flurothyl", "seizure", "testing", "proved", "to", "be", "a", "rapid", "and", "reliable", "technique", "with", "which", "to", "evaluate", "seizure", "susceptibility", "."]], "ner": [[[0, 0, "Chemical"], [23, 23, "Chemical"], [72, 72, "Chemical"], [147, 147, "Chemical"], [158, 158, "Chemical"], [173, 173, "Chemical"], [150, 150, "Disease"], [166, 166, "Disease"], [1, 1, "Disease"], [24, 24, "Disease"], [37, 37, "Disease"], [62, 62, "Disease"], [74, 74, "Disease"], [81, 81, "Disease"], [118, 118, "Disease"], [136, 136, "Disease"], [168, 168, "Disease"], [174, 174, "Disease"], [188, 188, "Disease"], [12, 13, "Chemical"], [15, 15, "Chemical"], [27, 28, "Chemical"], [30, 30, "Chemical"], [57, 57, "Chemical"], [91, 91, "Chemical"], [104, 104, "Chemical"], [142, 142, "Chemical"], [73, 73, "Chemical"], [148, 148, "Chemical"], [122, 122, "Chemical"]]], "relations": [[[0, 0, 150, 150, "CID"], [0, 0, 166, 166, "CID"], [23, 23, 150, 150, "CID"], [23, 23, 166, 166, "CID"], [72, 72, 150, 150, "CID"], [72, 72, 166, 166, "CID"], [147, 147, 150, 150, "CID"], [147, 147, 166, 166, "CID"], [158, 158, 150, 150, "CID"], [158, 158, 166, 166, "CID"], [173, 173, 150, 150, "CID"], [173, 173, 166, 166, "CID"]]], "clusters": [], "translated": " <0>氟嘧啶</0><8>癫痫发作</8>新生小鼠单次注射<19>味精</19>（<20>MSG</20>）的阈值：实验参数的评估在<1>氟嘧啶</1><9>癫痫发作</9>检测中。<21>单钠谷氨酸</21>（<22>味精</22>）对新生啮齿动物的给药会产生<10>抽搐</10>并导致许多生化和行为缺陷。开展这些研究是为了确定新生儿服用<23>MSG</23>是否会对<11>癫痫发作</11>易感性产生永久性改变，因为之前的研究尚无定论。<2>氟嘧啶</2><27>乙醚</27><12>癫痫发作</12>筛选技术用于评估接受新生儿注射<24>MSG</24>（4毫克/克和1毫克/克）的成年小鼠的<13>癫痫发作</13>易感性。<25>MSG</25>治疗导致全脑重量显着降低，但没有改变<14>癫痫发作</14>阈值。<29>纳洛酮</29>（5毫克/千克）对改变<15>癫痫发作</15>阈值的<26>MSG</26>治疗小鼠和对照组均无效。<3>氟嘧啶</3><28>乙醚</28>产生<6>体温过低</6>，这与<4>氟嘧啶</4>暴露的持续时间相关；然而，<7>体温过低</7>与<16>癫痫发作</16>诱导的关系尚不清楚。<5>氟嘧啶</5><17>癫痫发作</17>测试被证明是一种快速可靠的技术，可用于评估<18>癫痫发作</18>易感性。", "revised": true}
{"doc_key": "3812624", "sentences": [["Two", "cases", "of", "downbeat", "nystagmus", "and", "oscillopsia", "associated", "with", "carbamazepine", ".", "Downbeat", "nystagmus", "is", "often", "associated", "with", "structural", "lesions", "at", "the", "craniocervical", "junction", ",", "but", "has", "occasionally", "been", "reported", "as", "a", "manifestation", "of", "metabolic", "imbalance", "or", "drug", "intoxication", ".", "We", "recorded", "the", "eye", "movements", "of", "two", "patients", "with", "reversible", "downbeat", "nystagmus", "related", "to", "carbamazepine", "therapy", ".", "The", "nystagmus", "of", "both", "patients", "resolved", "after", "reduction", "of", "the", "serum", "carbamazepine", "levels", ".", "Neuroradiologic", "investigations", "including", "magnetic", "resonance", "imaging", "scans", "in", "both", "patients", "showed", "no", "evidence", "of", "intracranial", "abnormality", ".", "In", "patients", "with", "downbeat", "nystagmus", "who", "are", "taking", "anticonvulsant", "medications", ",", "consideration", "should", "be", "given", "to", "reduction", "in", "dose", "before", "further", "investigation", "is", "undertaken", "."]], "ner": [[[9, 9, "Chemical"], [53, 53, "Chemical"], [67, 67, "Chemical"], [6, 6, "Disease"], [3, 4, "Disease"], [11, 12, "Disease"], [49, 50, "Disease"], [57, 57, "Disease"], [90, 91, "Disease"]]], "relations": [[[9, 9, 6, 6, "CID"], [53, 53, 6, 6, "CID"], [67, 67, 6, 6, "CID"]]], "clusters": [], "translated": "<0>卡马西平</0>相关<4>下跳性眼球震颤</4>和<3>震颤</3>2例。 <5>下跳性眼球震颤</5>常与颅颈交界处的结构性病变有关，但偶有报道为代谢失衡或药物中毒的表现。我们记录了两名与<1>卡马西平</1>治疗相关的可逆性<6>下跳性眼球震颤</6>患者的眼球运动。两名患者的<7>眼球震颤</7>在血清<2>卡马西平</2>水平降低后得到缓解。对这两名患者进行的包括磁共振成像扫描在内的神经放射学检查均未显示颅内异常的证据。对于正在服用抗惊厥药物的<8>下跳性眼球震颤</8>患者，在进行进一步检查之前应考虑减少剂量。", "revised": true}
{"doc_key": "3831029", "sentences": [["Improvement", "by", "denopamine", "(", "TA", "-", "064", ")", "of", "pentobarbital", "-", "induced", "cardiac", "failure", "in", "the", "dog", "heart", "-", "lung", "preparation", ".", "The", "efficacy", "of", "denopamine", ",", "an", "orally", "active", "beta", "1", "-", "adrenoceptor", "agonist", ",", "in", "improving", "cardiac", "failure", "was", "assessed", "in", "dog", "heart", "-", "lung", "preparations", ".", "Cardiac", "functions", "depressed", "by", "pentobarbital", "(", "118", "+", "/", "-", "28", "mg", ";", "mean", "value", "+", "/", "-", "SD", ")", "such", "that", "cardiac", "output", "and", "maximum", "rate", "of", "rise", "of", "left", "ventricular", "pressure", "(", "LV", "dP", "/", "dt", "max", ")", "had", "been", "reduced", "by", "about", "35", "%", "and", "26", "%", "of", "the", "respective", "controls", "were", "improved", "by", "denopamine", "(", "10", "-", "300", "micrograms", ")", "in", "a", "dose", "-", "dependent", "manner", ".", "With", "100", "micrograms", "denopamine", ",", "almost", "complete", "restoration", "of", "cardiac", "performance", "was", "attained", ",", "associated", "with", "a", "slight", "increase", "in", "heart", "rate", ".", "No", "arrhythmias", "were", "induced", "by", "these", "doses", "of", "denopamine", ".", "The", "results", "warrant", "clinical", "trials", "of", "denopamine", "in", "the", "treatment", "of", "cardiac", "failure", "."]], "ner": [[[9, 9, "Chemical"], [53, 53, "Chemical"], [12, 13, "Disease"], [38, 39, "Disease"], [164, 165, "Disease"], [2, 2, "Chemical"], [4, 6, "Chemical"], [25, 25, "Chemical"], [106, 106, "Chemical"], [123, 123, "Chemical"], [151, 151, "Chemical"], [159, 159, "Chemical"], [144, 144, "Disease"]]], "relations": [[[9, 9, 12, 13, "CID"], [9, 9, 38, 39, "CID"], [9, 9, 164, 165, "CID"], [53, 53, 12, 13, "CID"], [53, 53, 38, 39, "CID"], [53, 53, 164, 165, "CID"]]], "clusters": [], "translated": "<5>地诺胺</5>（<6>TA-064</6>）对<0>戊巴比妥</0>所致<2>心力衰竭</2>犬心肺制剂的改善作用。评估了以口服活性β1肾上腺素能受体激动剂<7>地诺胺</7>改善<3>心力衰竭</3>的有效性，应用于犬心肺制剂中。<1>戊巴比妥</1>（118+/-28mg;平均值+/-SD）抑制了心脏功能，使心输出量和左心室压力的最大上升率(LV dP/dt max)降低了约35%和26%。这些由<8>地诺胺</8>（10-300微克）在剂量依赖的方式下得到了改善。使用100微克的<9>地诺胺</9>，心脏功能几乎完全恢复，并伴有轻微的心率增加，这些剂量的<10>去巴胺</10>没有引起<12>心律失常</12>。这些结果支持了在治疗<4>心力衰竭</4>时进行<11>地诺胺</11>的临床试验。", "revised": true}
{"doc_key": "3533179", "sentences": [["Cyclophosphamide", "cardiotoxicity", ":", "an", "analysis", "of", "dosing", "as", "a", "risk", "factor", ".", "Patients", "who", "undergo", "bone", "marrow", "transplantation", "are", "generally", "immunosuppressed", "with", "a", "dose", "of", "cyclophosphamide", "(", "CYA", ")", "which", "is", "usually", "calculated", "based", "on", "the", "patient", "'s", "weight", ".", "At", "these", "high", "doses", "of", "CYA", ",", "serious", "cardiotoxicity", "may", "occur", ",", "but", "definitive", "risk", "factors", "for", "the", "development", "of", "such", "cardiotoxicity", "have", "not", "been", "described", ".", "Since", "chemotherapeutic", "agent", "toxicity", "generally", "correlates", "with", "dose", "per", "body", "surface", "area", ",", "we", "retrospectively", "calculated", "the", "dose", "of", "CYA", "in", "patients", "transplanted", "at", "our", "institution", "to", "determine", "whether", "the", "incidence", "of", "CYA", "cardiotoxicity", "correlated", "with", "the", "dose", "per", "body", "surface", "area", ".", "Eighty", "patients", "who", "were", "to", "receive", "CYA", "50", "mg", "/", "kg", "/", "d", "for", "four", "days", "as", "preparation", "for", "marrow", "grafting", "underwent", "a", "total", "of", "84", "transplants", "for", "aplastic", "anemia", ",", "Wiskott", "-", "Aldrich", "syndrome", ",", "or", "severe", "combined", "immunodeficiency", "syndrome", ".", "Fourteen", "of", "84", "(", "17", "%", ")", "patients", "had", "symptoms", "and", "signs", "consistent", "with", "CYA", "cardiotoxicity", "within", "ten", "days", "of", "receiving", "1", "to", "4", "doses", "of", "CYA", ".", "Six", "of", "the", "14", "patients", "died", "with", "congestive", "heart", "failure", ".", "The", "dose", "of", "CYA", "per", "body", "surface", "area", "was", "calculated", "for", "all", "patients", "and", "the", "patients", "were", "divided", "into", "two", "groups", "based", "on", "daily", "CYA", "dose", ":", "Group", "1", ",", "CYA", "less", "than", "or", "equal", "to", "1", ".", "55", "g", "/", "m2", "/", "d", ";", "Group", "2", ",", "CYA", "greater", "than", "1", ".", "55", "g", "/", "m2", "/", "d", ".", "Cardiotoxicity", "that", "was", "thought", "to", "be", "related", "to", "CYA", "occurred", "in", "1", "/", "32", "(", "3", "%", ")", "of", "patients", "in", "Group", "1", "and", "in", "13", "/", "52", "(", "25", "%", ")", "patients", "in", "Group", "2", "(", "P", "less", "than", "0", ".", "025", ")", ".", "Congestive", "heart", "failure", "caused", "or", "contributed", "to", "death", "in", "0", "/", "32", "patients", "in", "Group", "1", "v", "6", "/", "52", "(", "12", "%", ")", "of", "patients", "in", "Group", "2", "(", "P", "less", "than", "0", ".", "25", ")", ".", "There", "was", "no", "difference", "in", "the", "rate", "of", "engraftment", "of", "evaluable", "patients", "in", "the", "two", "groups", "(", "P", "greater", "than", "0", ".", "5", ")", ".", "We", "conclude", "that", "the", "CYA", "cardiotoxicity", "correlates", "with", "CYA", "dosage", "as", "calculated", "by", "body", "surface", "area", ",", "and", "that", "patients", "with", "aplastic", "anemia", "and", "immunodeficiencies", "can", "be", "effectively", "prepared", "for", "bone", "marrow", "grafting", "at", "a", "CYA", "dose", "of", "1", ".", "55", "g", "/", "m2", "/", "d", "for", "four", "days", "with", "a", "lower", "incidence", "of", "cardiotoxicity", "than", "patients", "whose", "CYA", "dosage", "is", "calculated", "based", "on", "weight", ".", "This", "study", "reaffirms", "the", "principle", "that", "drug", "toxicity", "correlates", "with", "dose", "per", "body", "surface", "area", "."]], "ner": [[[0, 0, "Chemical"], [25, 25, "Chemical"], [27, 27, "Chemical"], [45, 45, "Chemical"], [86, 86, "Chemical"], [99, 99, "Chemical"], [116, 116, "Chemical"], [166, 166, "Chemical"], [178, 178, "Chemical"], [194, 194, "Chemical"], [215, 215, "Chemical"], [221, 221, "Chemical"], [239, 239, "Chemical"], [259, 259, "Chemical"], [363, 363, "Chemical"], [367, 367, "Chemical"], [394, 394, "Chemical"], [417, 417, "Chemical"], [187, 189, "Disease"], [296, 298, "Disease"], [1, 1, "Disease"], [48, 48, "Disease"], [61, 61, "Disease"], [100, 100, "Disease"], [167, 167, "Disease"], [251, 251, "Disease"], [364, 364, "Disease"], [413, 413, "Disease"], [70, 70, "Disease"], [432, 432, "Disease"], [138, 139, "Disease"], [380, 381, "Disease"], [141, 144, "Disease"], [147, 150, "Disease"], [383, 383, "Disease"]]], "relations": [[[0, 0, 187, 189, "CID"], [0, 0, 296, 298, "CID"], [25, 25, 187, 189, "CID"], [25, 25, 296, 298, "CID"], [27, 27, 187, 189, "CID"], [27, 27, 296, 298, "CID"], [45, 45, 187, 189, "CID"], [45, 45, 296, 298, "CID"], [86, 86, 187, 189, "CID"], [86, 86, 296, 298, "CID"], [99, 99, 187, 189, "CID"], [99, 99, 296, 298, "CID"], [116, 116, 187, 189, "CID"], [116, 116, 296, 298, "CID"], [166, 166, 187, 189, "CID"], [166, 166, 296, 298, "CID"], [178, 178, 187, 189, "CID"], [178, 178, 296, 298, "CID"], [194, 194, 187, 189, "CID"], [194, 194, 296, 298, "CID"], [215, 215, 187, 189, "CID"], [215, 215, 296, 298, "CID"], [221, 221, 187, 189, "CID"], [221, 221, 296, 298, "CID"], [239, 239, 187, 189, "CID"], [239, 239, 296, 298, "CID"], [259, 259, 187, 189, "CID"], [259, 259, 296, 298, "CID"], [363, 363, 187, 189, "CID"], [363, 363, 296, 298, "CID"], [367, 367, 187, 189, "CID"], [367, 367, 296, 298, "CID"], [394, 394, 187, 189, "CID"], [394, 394, 296, 298, "CID"], [417, 417, 187, 189, "CID"], [417, 417, 296, 298, "CID"]]], "clusters": [], "translated": " <0>环磷酰胺</0> <20>心脏毒性</20>：作为危险因素的剂量分析。接受骨髓移植的患者通常使用一定剂量的<1>环磷酰胺</1> (<2>CYA</2>) 进行免疫抑制，剂量通常根据患者的体重计算。 在这些高剂量的 <3>CYA</3> 下，可能会发生严重的 <21>心脏毒性</21>，但尚未描述发生此类 <22>心脏毒性</22> 的明确危险因素。由于化疗药物<28>毒性</28>通常与单位体表面积的剂量相关，我们回顾性地计算了在我们机构移植的患者中<4>CYA</4>的剂量以确定 <5>CYA</5> <23>心脏毒性</23> 与单位体表面积的剂量相关。接受 <6> CYA </6> 50 mg/kg/d 四天作为骨髓移植准备的80名患者因<30>再生障碍性贫血</30>接受了总共84次移植，<32>Wiskott-奥尔德里奇综合征</32>，或<33>严重联合免疫缺陷综合征</33>。84名患者中有14名（17%）在接受1至4剂<8>CYA</8>治疗后的10天内出现与 <7>CYA</7> <24>心脏毒性</24>一致的症状和体征。14名患者中有6名死于<18>充血性心力衰竭</18>。计算所有患者每单位体表面积的<9>CYA</9>剂量，并根据每日<10>CYA</10>剂量将患者分为两组：第1组，<11>CYA</11>小于或等于1.55克/平方米/天；第2组，<12>CYA</12>大于1.55克/平方米/天。被认为与<13>CYA</13>相关的<25>心脏毒性</25>发生在第1组中的1/32 (3%)患者和第2组中的13/52 (25%)患者中 (P小于0.025)。<19>充血性心力衰竭</19>在第1组中有0/32名患者死亡，而在第2组中有6/52 (12%)名患者死亡（P小于0.25）。两组可评估患者的植入率无差异（P大于0.5）。我们得出结论，<14>CYA</14> <26>心脏毒性</26> 与按体表面积计算的<15>CYA</15>剂量相关，<31>再生障碍性贫血</31>患者和<34>免疫缺陷</34>可以有效地为骨髓移植做好准备，<16>CYA</16>剂量为1.55克/平方米/天连续四天，<27>心脏毒性</27>的发生率低于根据体重计算<17>CYA</17>剂量的患者。该研究重申了药物<29>毒性</29>与单位体表面积剂量相关的原则。", "revised": true}
{"doc_key": "3832950", "sentences": [["Clonazepam", "monotherapy", "for", "epilepsy", "in", "childhood", ".", "Sixty", "patients", "(", "age", "-", "range", "one", "month", "to", "14", "years", ")", "with", "other", "types", "of", "epilepsy", "than", "infantile", "spasms", "were", "treated", "with", "clonazepam", ".", "Disappearance", "of", "seizures", "and", "normalization", "of", "abnormal", "EEG", "with", "disappearance", "of", "seizures", "were", "recognized", "in", "77", "%", "and", "50", "%", ",", "respectively", ".", "Seizures", "disappeared", "in", "71", "%", "of", "the", "patients", "with", "generalized", "seizures", "and", "89", "%", "of", "partial", "seizures", ".", "Improvement", "of", "abnormal", "EEG", "was", "noticed", "in", "76", "%", "of", "diffuse", "paroxysms", "and", "in", "67", "%", "of", "focal", "paroxysms", ".", "In", "excellent", "cases", ",", "mean", "effective", "dosages", "were", "0", ".", "086", "+", "/", "-", "0", ".", "021", "mg", "/", "kg", "/", "day", "in", "infants", "and", "0", ".", "057", "+", "/", "-", "0", ".", "022", "mg", "/", "kg", "/", "day", "in", "schoolchildren", ",", "this", "difference", "was", "statistically", "significant", "(", "p", "less", "than", "0", ".", "005", ")", ".", "The", "incidence", "of", "side", "effects", "such", "as", "drowsiness", "and", "ataxia", "was", "only", "5", "%", "."]], "ner": [[[0, 0, "Chemical"], [30, 30, "Chemical"], [156, 156, "Disease"], [158, 158, "Disease"], [3, 3, "Disease"], [23, 23, "Disease"], [25, 26, "Disease"], [34, 34, "Disease"], [43, 43, "Disease"], [55, 55, "Disease"], [65, 65, "Disease"], [71, 71, "Disease"]]], "relations": [[[0, 0, 156, 156, "CID"], [30, 30, 156, 156, "CID"], [0, 0, 158, 158, "CID"], [30, 30, 158, 158, "CID"]]], "clusters": [], "translated": " <0>氯硝西泮</0>单一疗法治疗<4>儿童癫痫</4>。60名患有其他类型<5>癫痫</5>（而非<6>婴儿痉挛症</6>）的患者（年龄范围为1个月至14岁），接受了<1>氯硝西泮</1>治疗。在77%的患者中，<7>癫痫发作</7>消失；在50%的患者中，异常脑电图正常化且<8>癫痫发作</8>消失。在71%的全身性<10>癫痫发作</10>患者和89%的部分性<11>癫痫发作</11>患者中，<9>癫痫发作</9>消失。在76%的弥漫性发作和67%的局灶性发作中，观察到异常脑电图改善。在极好的情况下，平均有效剂量为0.086 +/- 0.021毫克/千克/天的婴儿和0.057 +/- 0.022毫克/千克/天的学龄儿童，这种差异具有统计学意义（p小于0.005）。副作用如<2>嗜睡</2>和<3>共济失调</3>的发生率仅为5%。", "revised": true}
{"doc_key": "3833372", "sentences": [["Postmarketing", "study", "of", "timolol", "-", "hydrochlorothiazide", "antihypertensive", "therapy", ".", "A", "postmarketing", "surveillance", "study", "was", "conducted", "to", "determine", "the", "safety", "and", "efficacy", "of", "a", "fixed", "-", "ratio", "combination", "containing", "10", "mg", "of", "timolol", "maleate", "and", "25", "mg", "of", "hydrochlorothiazide", ",", "administered", "twice", "daily", "for", "one", "month", "to", "hypertensive", "patients", ".", "Data", "on", "9", ",", "037", "patients", "were", "collected", "by", "1", ",", "455", "participating", "physicians", ".", "Mean", "systolic", "blood", "pressure", "decreased", "25", "mmHg", "and", "mean", "diastolic", "blood", "pressure", "declined", "15", "mmHg", "after", "one", "month", "of", "timolol", "-", "hydrochlorothiazide", "therapy", "(", "P", "less", "than", "0", ".", "01", ",", "both", "comparisons", ")", ".", "Age", ",", "race", ",", "and", "sex", "appeared", "to", "have", "no", "influence", "on", "the", "decrease", "in", "blood", "pressure", ".", "The", "antihypertensive", "effect", "of", "the", "drug", "was", "greater", "in", "patients", "with", "more", "severe", "hypertension", ".", "Overall", ",", "1", ",", "453", "patients", "experienced", "a", "total", "of", "2", ",", "658", "adverse", "events", ",", "the", "most", "common", "being", "fatigue", ",", "dizziness", ",", "and", "weakness", ".", "Treatment", "in", "590", "patients", "was", "discontinued", "because", "of", "adverse", "events", "."]], "ner": [[[3, 3, "Chemical"], [31, 32, "Chemical"], [83, 83, "Chemical"], [152, 152, "Disease"], [154, 154, "Disease"], [157, 157, "Disease"], [5, 5, "Chemical"], [37, 37, "Chemical"], [85, 85, "Chemical"], [46, 46, "Disease"], [130, 130, "Disease"]]], "relations": [[[3, 3, 152, 152, "CID"], [31, 32, 152, 152, "CID"], [83, 83, 152, 152, "CID"], [3, 3, 154, 154, "CID"], [31, 32, 154, 154, "CID"], [83, 83, 154, 154, "CID"], [3, 3, 157, 157, "CID"], [31, 32, 157, 157, "CID"], [83, 83, 157, 157, "CID"], [5, 5, 152, 152, "CID"], [37, 37, 152, 152, "CID"], [85, 85, 152, 152, "CID"], [5, 5, 154, 154, "CID"], [37, 37, 154, 154, "CID"], [85, 85, 154, 154, "CID"], [5, 5, 157, 157, "CID"], [37, 37, 157, 157, "CID"], [85, 85, 157, 157, "CID"]]], "clusters": [], "translated": "<0>噻吗洛尔</0> - <6>氢氯噻嗪</6>抗高血压治疗的上市后研究。进行了一项上市后监测研究，以确定包含 10 mg 马来酸<1>噻吗洛尔</1>和25 mg<7>氢氯噻嗪</7>的固定比例组合的安全性和有效性，每天给药两次，持续一个月<9>高血压</9>患者。1,455名参与医师收集了9,037名患者的数据。平均收缩压下降25 mmHg，平均舒张压下降15 mmHg（<2>P均小于0.01，两项比较</2>）<2>噻吗洛尔</2>-<8>氢氯噻嗪</8>治疗一个月后。年龄、种族和性别似乎对血压下降没有影响。对于更严重的<10>高血压</10>患者，药物的降压作用更大。总体而言，1,453名患者共经历了2,658次不良事件，最常见的是<3>疲劳</3>、<4>头晕</4>和<5>虚弱</5>。590名患者因不良事件停止治疗。", "revised": true}
{"doc_key": "3895875", "sentences": [["Prophylactic", "lidocaine", "in", "the", "early", "phase", "of", "suspected", "myocardial", "infarction", ".", "Four", "hundred", "two", "patients", "with", "suspected", "myocardial", "infarction", "seen", "within", "6", "hours", "of", "the", "onset", "of", "symptoms", "entered", "a", "double", "-", "blind", "randomized", "trial", "of", "lidocaine", "vs", "placebo", ".", "During", "the", "1", "hour", "after", "administration", "of", "the", "drug", "the", "incidence", "of", "ventricular", "fibrillation", "or", "sustained", "ventricular", "tachycardia", "among", "the", "204", "patients", "with", "acute", "myocardial", "infarction", "was", "low", ",", "1", ".", "5", "%", ".", "Lidocaine", ",", "given", "in", "a", "300", "mg", "dose", "intramuscularly", "followed", "by", "100", "mg", "intravenously", ",", "did", "not", "prevent", "sustained", "ventricular", "tachycardia", ",", "although", "there", "was", "a", "significant", "reduction", "in", "the", "number", "of", "patients", "with", "warning", "arrhythmias", "between", "15", "and", "45", "minutes", "after", "the", "administration", "of", "lidocaine", "(", "p", "less", "than", "0", ".", "05", ")", ".", "The", "average", "plasma", "lidocaine", "level", "10", "minutes", "after", "administration", "for", "patients", "without", "a", "myocardial", "infarction", "was", "significantly", "higher", "than", "that", "for", "patients", "with", "an", "acute", "infarction", ".", "The", "mean", "plasma", "lidocaine", "level", "of", "patients", "on", "beta", "-", "blocking", "agents", "was", "no", "different", "from", "that", "in", "patients", "not", "on", "beta", "blocking", "agents", ".", "During", "the", "1", "-", "hour", "study", "period", ",", "the", "incidence", "of", "central", "nervous", "system", "side", "effects", "was", "significantly", "greater", "in", "the", "lidocaine", "group", ",", "hypotension", "occurred", "in", "11", "patients", ",", "nine", "of", "whom", "had", "received", "lidocaine", ",", "and", "four", "patients", "died", "from", "asystole", ",", "three", "of", "whom", "had", "had", "lidocaine", ".", "We", "can", "not", "advocate", "the", "administration", "of", "lidocaine", "prophylactically", "in", "the", "early", "hours", "of", "suspected", "myocardial", "infarction", "."]], "ner": [[[1, 1, "Chemical"], [36, 36, "Chemical"], [74, 74, "Chemical"], [119, 119, "Chemical"], [132, 132, "Chemical"], [159, 159, "Chemical"], [202, 202, "Chemical"], [216, 216, "Chemical"], [230, 230, "Chemical"], [239, 239, "Chemical"], [205, 205, "Disease"], [8, 9, "Disease"], [17, 18, "Disease"], [64, 65, "Disease"], [142, 143, "Disease"], [247, 248, "Disease"], [52, 53, "Disease"], [56, 57, "Disease"], [93, 94, "Disease"], [109, 109, "Disease"], [154, 154, "Disease"], [223, 223, "Disease"]]], "relations": [[[1, 1, 205, 205, "CID"], [36, 36, 205, 205, "CID"], [74, 74, 205, 205, "CID"], [119, 119, 205, 205, "CID"], [132, 132, 205, 205, "CID"], [159, 159, 205, 205, "CID"], [202, 202, 205, 205, "CID"], [216, 216, 205, 205, "CID"], [230, 230, 205, 205, "CID"], [239, 239, 205, 205, "CID"]]], "clusters": [], "translated": "疑似<11>心肌梗死</11>早期预防性<0>利多卡因</0>。在出现症状后 6 小时内出现疑似<12>心肌梗死</12>的四百二名患者参加了<1>利多卡因</1>与安慰剂的双盲随机试验。在给药后 1 小时内，204例急性<13>心肌梗死</13>患者<16>室颤</16>或持续<17>室性心动过速</17>的发生率较低，1.5%。<2>利多卡因</2>，以300 mg剂量肌肉注射，随后100 mg静脉注射，并不能预防持续性<18>室性心动过速</18>，尽管出现警告<19>心律失常</19>的患者数量显着减少（p小于0.05），在<3>利多卡因</3>给药后15到45分钟之间。未发生<14>心肌梗死</14>的患者给药后10分钟的平均血浆<4>利多卡因</4>水平显着高于急性<20>心肌梗死</20>患者。使用β受体阻滞剂的患者的平均血浆<5>利多卡因</5>水平与未使用β受体阻滞剂的患者没有差异。在1小时的研究期间，<6>利多卡因</6>组中枢神经系统副作用的发生率明显更高，11名患者出现<10>低血压</10>，其中9名接受了<7>利多卡因</7>，4名患者死于<21>心搏停止</21>，其中3名曾服用过<8>利多卡因</8>。我们不能提倡在疑似<15>心肌梗死</15>的早期预防性使用<9>利多卡因</9>。", "revised": true}
{"doc_key": "3746148", "sentences": [["Non", "-", "invasive", "detection", "of", "coronary", "artery", "disease", "by", "body", "surface", "electrocardiographic", "mapping", "after", "dipyridamole", "infusion", ".", "Electrocardiographic", "changes", "after", "dipyridamole", "infusion", "(", "0", ".", "568", "mg", "/", "kg", "/", "4", "min", ")", "were", "studied", "in", "41", "patients", "with", "coronary", "artery", "disease", "and", "compared", "with", "those", "after", "submaximal", "treadmill", "exercise", "by", "use", "of", "the", "body", "surface", "mapping", "technique", ".", "Patients", "were", "divided", "into", "three", "groups", ";", "19", "patients", "without", "myocardial", "infarction", "(", "non", "-", "MI", "group", ")", ",", "14", "with", "anterior", "infarction", "(", "ANT", "-", "MI", ")", "and", "eight", "with", "inferior", "infarction", "(", "INF", "-", "MI", ")", ".", "Eighty", "-", "seven", "unipolar", "electrocardiograms", "(", "ECGs", ")", "distributed", "over", "the", "entire", "thoracic", "surface", "were", "simultaneously", "recorded", ".", "After", "dipyridamole", ",", "ischemic", "ST", "-", "segment", "depression", "(", "0", ".", "05", "mV", "or", "more", ")", "was", "observed", "in", "84", "%", "of", "the", "non", "-", "MI", "group", ",", "29", "%", "of", "the", "ANT", "-", "MI", "group", ",", "63", "%", "of", "the", "INF", "-", "MI", "group", "and", "61", "%", "of", "the", "total", "population", ".", "Exercise", "-", "induced", "ST", "depression", "was", "observed", "in", "84", "%", "of", "the", "non", "-", "MI", "group", ",", "43", "%", "of", "the", "ANT", "-", "MI", "group", ",", "38", "%", "of", "the", "INF", "-", "MI", "group", "and", "61", "%", "of", "the", "total", ".", "For", "individual", "patients", ",", "there", "were", "no", "obvious", "differences", "between", "the", "body", "surface", "distribution", "of", "ST", "depression", "in", "both", "tests", ".", "The", "increase", "in", "pressure", "rate", "product", "after", "dipyridamole", "was", "significantly", "less", "than", "that", "during", "the", "treadmill", "exercise", ".", "The", "data", "suggest", "that", "the", "dipyridamole", "-", "induced", "myocardial", "ischemia", "is", "caused", "by", "the", "inhomogenous", "distribution", "of", "myocardial", "blood", "flow", ".", "We", "conclude", "that", "the", "dipyridamole", "ECG", "test", "is", "as", "useful", "as", "the", "exercise", "ECG", "test", "for", "the", "assessment", "of", "coronary", "artery", "disease", "."]], "ner": [[[14, 14, "Chemical"], [20, 20, "Chemical"], [117, 117, "Chemical"], [238, 238, "Chemical"], [254, 254, "Chemical"], [274, 274, "Chemical"], [257, 258, "Disease"], [5, 7, "Disease"], [39, 41, "Disease"], [289, 291, "Disease"], [69, 70, "Disease"], [74, 74, "Disease"], [141, 141, "Disease"], [183, 183, "Disease"], [80, 81, "Disease"], [83, 85, "Disease"], [148, 150, "Disease"], [190, 192, "Disease"], [90, 91, "Disease"], [93, 95, "Disease"], [157, 159, "Disease"], [199, 201, "Disease"], [119, 119, "Disease"], [123, 123, "Disease"], [173, 173, "Disease"], [226, 226, "Disease"]]], "relations": [[[14, 14, 257, 258, "CID"], [20, 20, 257, 258, "CID"], [117, 117, 257, 258, "CID"], [238, 238, 257, 258, "CID"], [254, 254, 257, 258, "CID"], [274, 274, 257, 258, "CID"]]], "clusters": [], "translated": "<0>双嘧达莫</0>输注后体表心电图无创检测<7>冠心病</7>。对41名<8>冠状动脉疾病</8>患者研究了<1>双嘧达莫</1>输注 (0.568 mg/kg/4min)后的心电图变化，并与使用亚极量跑台运动后的心电图变化进行了比较体表测绘技术。患者被分为三组；19例无<10>心肌梗死</10>（非<11>MI</11>组），14例有<14>前壁梗死</14>（<15>ANT-MI</15>）和8例患有<18>下壁梗死</18>（<19>INF-MI</19>）。同时记录了分布在整个胸腔表面的87个单极心电图 (ECGs)。<2>双嘧达莫</2>后，在84%的非<12>MI</12>组、29%的<16>ANT-MI</16>组、63%的<20>INF-MI</20>组和总人口的61%中观察到<22>缺血性</22>ST段<23>压低</23>（0.05mV或更多）。运动引起的ST<24>压低</24>在非<13>MI</13>组84%、<17>ANT-MI</17>组43%、<21>INF-MI</21>组38%，总人口的61%。对于个别患者，两种试验ST<25>压低</25>的体表分布无明显差异。 <3>双嘧达莫</3>后，压力率乘积的增加明显小于跑台运动时。资料提示，<4>双嘧达莫</4>引起的<6>心肌缺血</6>是由心肌血流分布不均所致。我们得出结论，<5>双嘧达莫</5>心电图测试与运动心电图测试一样可用于评估<9>冠状动脉疾病</9>。", "revised": true}
{"doc_key": "3798047", "sentences": [["Bradycardia", "after", "high", "-", "dose", "intravenous", "methylprednisolone", "therapy", ".", "In", "5", "consecutive", "patients", "with", "rheumatoid", "arthritis", "who", "received", "intravenous", "high", "-", "dose", "methylprednisolone", "(", "MP", ")", "therapy", "(", "1", "g", "daily", "for", "2", "or", "3", "consecutive", "days", ")", ",", "a", "decline", "in", "pulse", "rate", "was", "observed", ",", "most", "pronounced", "on", "day", "4", ".", "In", "one", "of", "the", "5", "patients", "the", "bradycardia", "was", "associated", "with", "complaints", "of", "substernal", "pressure", ".", "Reversal", "to", "normal", "heart", "rate", "was", "found", "on", "day", "7", ".", "Electrocardiographic", "registrations", "showed", "sinus", "bradycardia", "in", "all", "cases", ".", "No", "significant", "changes", "in", "plasma", "concentrations", "of", "electrolytes", "were", "found", ".", "Careful", "observation", "of", "patients", "receiving", "high", "-", "dose", "MP", "is", "recommended", ".", "High", "-", "dose", "MP", "may", "be", "contraindicated", "in", "patients", "with", "known", "heart", "disease", "."]], "ner": [[[6, 6, "Chemical"], [22, 22, "Chemical"], [24, 24, "Chemical"], [108, 108, "Chemical"], [115, 115, "Chemical"], [0, 0, "Disease"], [60, 60, "Disease"], [14, 15, "Disease"], [83, 84, "Disease"], [123, 124, "Disease"]]], "relations": [[[6, 6, 0, 0, "CID"], [6, 6, 60, 60, "CID"], [22, 22, 0, 0, "CID"], [22, 22, 60, 60, "CID"], [24, 24, 0, 0, "CID"], [24, 24, 60, 60, "CID"], [108, 108, 0, 0, "CID"], [108, 108, 60, 60, "CID"], [115, 115, 0, 0, "CID"], [115, 115, 60, 60, "CID"]]], "clusters": [], "translated": " <5>心动过缓</5>  after high - dose intravenous <0>甲泼尼龙</0> therapy . 连续 5 名<7>类风湿性关节炎</7> 患者接受静脉内高剂量<1>甲基泼尼松龙 </1>( <2>MP</2>) 治疗（每天 1 克，连续 2 或 3 天） ，观察到脉率下降，在第 4 天最为明显。 5 名患者中有一名<6>心动过缓</6>与抱怨胸骨下压力有关。第 7 天发现心率恢复正常。所有病例的心电图记录均显示<8>窦性心动过缓</8>。未发现血浆电解质浓度有明显变化。建议仔细观察接受高剂量<3>MP</3>的患者。已知<9>心脏病</9> 的患者可能禁用高剂量<4>MP</4>。", "revised": true}
{"doc_key": "4010471", "sentences": [["Relationship", "between", "nicotine", "-", "induced", "seizures", "and", "hippocampal", "nicotinic", "receptors", ".", "A", "controversy", "has", "existed", "for", "several", "years", "concerning", "the", "physiological", "relevance", "of", "the", "nicotinic", "receptor", "measured", "by", "alpha", "-", "bungarotoxin", "binding", ".", "Using", "mice", "derived", "from", "a", "classical", "F2", "and", "backcross", "genetic", "design", ",", "a", "relationship", "between", "nicotine", "-", "induced", "seizures", "and", "alpha", "-", "bungarotoxin", "nicotinic", "receptor", "concentration", "was", "found", ".", "Mice", "sensitive", "to", "the", "convulsant", "effects", "of", "nicotine", "had", "greater", "alpha", "-", "bungarotoxin", "binding", "in", "the", "hippocampus", "than", "seizure", "insensitive", "mice", ".", "The", "binding", "sites", "from", "seizure", "sensitive", "and", "resistant", "mice", "were", "equally", "affected", "by", "treatment", "with", "dithiothreitol", ",", "trypsin", "or", "heat", ".", "Thus", "it", "appears", "that", "the", "difference", "between", "seizure", "sensitive", "and", "insensitive", "animals", "may", "be", "due", "to", "a", "difference", "in", "hippocampal", "nicotinic", "receptor", "concentration", "as", "measured", "with", "alpha", "-", "bungarotoxin", "binding", "."]], "ner": [[[2, 2, "Chemical"], [48, 48, "Chemical"], [69, 69, "Chemical"], [5, 5, "Disease"], [51, 51, "Disease"], [80, 80, "Disease"], [88, 88, "Disease"], [112, 112, "Disease"], [99, 99, "Chemical"]]], "relations": [[[2, 2, 5, 5, "CID"], [2, 2, 51, 51, "CID"], [2, 2, 80, 80, "CID"], [2, 2, 88, 88, "CID"], [2, 2, 112, 112, "CID"], [48, 48, 5, 5, "CID"], [48, 48, 51, 51, "CID"], [48, 48, 80, 80, "CID"], [48, 48, 88, 88, "CID"], [48, 48, 112, 112, "CID"], [69, 69, 5, 5, "CID"], [69, 69, 51, 51, "CID"], [69, 69, 80, 80, "CID"], [69, 69, 88, 88, "CID"], [69, 69, 112, 112, "CID"]]], "clusters": [], "translated": "<0>尼古丁</0>诱发的<3>发作</3>与海马烟碱受体的关系。关于通过α-金环蛇毒素结合测量的烟碱受体的生理相关性，多年来一直存在争议。使用源自经典F2和回交遗传设计的小鼠，发现了<1>尼古丁</1>诱导的<4>癫痫发作</4>与α-金环蛇毒素烟碱受体浓度之间的关系。与<5>不敏感</5>的小鼠相比，在海马体中对<2>尼古丁</2>的惊厥作用敏感的小鼠与α-金环蛇毒素结合更多。<6>敏感</6>和耐药小鼠的结合位点同样受到<8>二硫苏糖醇</8>、胰蛋白酶或热处理的影响。因此，<7>敏感</7>和<7>不敏感</7>动物之间的差异似乎是由于海马烟碱受体浓度的差异（用α-金环蛇毒素结合测量）。", "revised": true}
{"doc_key": "3990093", "sentences": [["Mesangial", "function", "and", "glomerular", "sclerosis", "in", "rats", "with", "aminonucleoside", "nephrosis", ".", "The", "possible", "relationship", "between", "mesangial", "dysfunction", "and", "development", "of", "glomerular", "sclerosis", "was", "studied", "in", "the", "puromycin", "aminonucleoside", "(", "PAN", ")", "model", ".", "Five", "male", "Wistar", "rats", "received", "repeated", "subcutaneous", "PAN", "injections", ";", "five", "controls", "received", "saline", "only", ".", "After", "4", "weeks", "the", "PAN", "rats", "were", "severely", "proteinuric", "(", "190", "+", "/", "-", "80", "mg", "/", "24", "hr", ")", ",", "and", "all", "rats", "were", "given", "colloidal", "carbon", "(", "CC", ")", "intravenously", ".", "At", "5", "months", "glomerular", "sclerosis", "was", "found", "in", "7", ".", "6", "+", "/", "-", "3", ".", "4", "%", "of", "the", "glomeruli", "of", "PAN", "rats", ";", "glomeruli", "of", "the", "controls", "were", "normal", ".", "Glomeruli", "of", "PAN", "rats", "contained", "significantly", "more", "CC", "than", "glomeruli", "of", "controls", ".", "Glomeruli", "with", "sclerosis", "contained", "significantly", "more", "CC", "than", "non", "-", "sclerotic", "glomeruli", "in", "the", "same", "kidneys", ".", "CC", "was", "preferentially", "localized", "within", "the", "sclerotic", "areas", "of", "the", "affected", "glomeruli", ".", "Since", "mesangial", "CC", "clearance", "from", "the", "mesangium", "did", "not", "change", "during", "chronic", "PAN", "treatment", ",", "we", "conclude", "that", "this", "preferential", "CC", "localization", "within", "the", "lesions", "is", "caused", "by", "an", "increased", "CC", "uptake", "shortly", "after", "injection", "in", "apparent", "vulnerable", "areas", "where", "sclerosis", "will", "develop", "subsequently", ".", "Cluster", "analysis", "showed", "a", "random", "distribution", "of", "lesions", "in", "the", "PAN", "glomeruli", "in", "concordance", "with", "the", "random", "localization", "of", "mesangial", "areas", "with", "dysfunction", "in", "this", "model", ".", "Similar", "to", "the", "remnant", "kidney", "model", "in", "PAN", "nephrosis", "the", "development", "of", "glomerular", "sclerosis", "may", "be", "related", "to", "\"", "mesangial", "overloading", ".", "\""]], "ner": [[[8, 8, "Chemical"], [26, 27, "Chemical"], [29, 29, "Chemical"], [40, 40, "Chemical"], [53, 53, "Chemical"], [104, 104, "Chemical"], [116, 116, "Chemical"], [169, 169, "Chemical"], [212, 212, "Chemical"], [236, 236, "Chemical"], [57, 57, "Disease"], [3, 4, "Disease"], [15, 16, "Disease"], [20, 21, "Disease"], [85, 86, "Disease"], [241, 242, "Disease"], [76, 76, "Chemical"], [9, 9, "Disease"], [237, 237, "Disease"], [129, 129, "Disease"], [197, 197, "Disease"]]], "relations": [[[8, 8, 57, 57, "CID"], [26, 27, 57, 57, "CID"], [29, 29, 57, 57, "CID"], [40, 40, 57, 57, "CID"], [53, 53, 57, 57, "CID"], [104, 104, 57, 57, "CID"], [116, 116, 57, 57, "CID"], [169, 169, 57, 57, "CID"], [212, 212, 57, 57, "CID"], [236, 236, 57, 57, "CID"]]], "clusters": [], "translated": "<0>氨基核苷</0><17>肾病</17>大鼠系膜功能与<11>肾小球硬化</11>。在<1>嘌呤霉素氨基核苷</1>（<2>PAN</2>）模型中研究<12>系膜功能障碍</12>与<13>肾小球硬化</13>的可能关系。五只雄性 Wistar大鼠接受反复皮下<3>PAN</3>注射；五名对照组只接受生理盐水。4周后，<4>PAN</4>大鼠出现严重的<10>蛋白尿</10>（190 + / - 80 mg / 24小时），所有大鼠均给予胶体<16>碳</16>（CC）静脉注射。在5个月时，在<5>PAN</5>大鼠的肾小球中发现<14>肾小球硬化</14>占7.6 + / - 3.4％，对照组的肾小球正常。<6>PAN</6>大鼠的肾小球含有明显更多的CC比对照组的肾小球。在相同的肾脏中，<19>硬化</19>的肾小球含有明显更多的CC比非硬化的肾小球。CC优先位于受影响肾小球的硬化区内。由于在慢性<7>PAN</7>治疗期间系膜CC从系膜清除没有改变，我们得出结论，这种CC在病变内的优先定位是由于注射后不久在明显易受伤害的区域<20>的CC摄取增加引起的，随后会发生硬化</20>。聚类分析显示<8>PAN</8>肾小球中病变的随机分布与该模型中具有功能障碍的系膜区域的随机定位一致。与<9>PAN</9><18>肾病</18>的残肾模型类似，<15>肾小球硬化</15>的发展可能与“系膜超负荷”有关。", "revised": true}
{"doc_key": "4082466", "sentences": [["Morphine", "-", "induced", "seizures", "in", "newborn", "infants", ".", "Two", "neonates", "suffered", "from", "generalized", "seizures", "during", "the", "course", "of", "intravenous", "morphine", "sulfate", "for", "post", "-", "operative", "analgesia", ".", "They", "received", "morphine", "in", "doses", "of", "32", "micrograms", "/", "kg", "/", "hr", "and", "40", "micrograms", "/", "kg", "/", "hr", "larger", "than", "a", "group", "of", "10", "neonates", "who", "received", "6", "-", "24", "micrograms", "/", "kg", "/", "hr", "and", "had", "no", "seizures", ".", "Plasma", "concentrations", "of", "morphine", "in", "these", "neonates", "was", "excessive", "(", "60", "and", "90", "mg", "/", "ml", ")", ".", "Other", "known", "reasons", "for", "seizures", "were", "ruled", "out", "and", "the", "convulsions", "stopped", "a", "few", "hours", "after", "cessation", "of", "morphine", "and", "did", "not", "reoccur", "in", "the", "subsequent", "8", "months", ".", "It", "is", "suggested", "that", "post", "-", "operative", "intravenous", "morphine", "should", "not", "exceed", "20", "micrograms", "/", "kg", "/", "ml", "in", "neonates", "."]], "ner": [[[0, 0, "Chemical"], [19, 20, "Chemical"], [29, 29, "Chemical"], [71, 71, "Chemical"], [104, 104, "Chemical"], [123, 123, "Chemical"], [3, 3, "Disease"], [13, 13, "Disease"], [66, 66, "Disease"], [90, 90, "Disease"], [96, 96, "Disease"]]], "relations": [[[0, 0, 3, 3, "CID"], [0, 0, 13, 13, "CID"], [0, 0, 66, 66, "CID"], [0, 0, 90, 90, "CID"], [0, 0, 96, 96, "CID"], [19, 20, 3, 3, "CID"], [19, 20, 13, 13, "CID"], [19, 20, 66, 66, "CID"], [19, 20, 90, 90, "CID"], [19, 20, 96, 96, "CID"], [29, 29, 3, 3, "CID"], [29, 29, 13, 13, "CID"], [29, 29, 66, 66, "CID"], [29, 29, 90, 90, "CID"], [29, 29, 96, 96, "CID"], [71, 71, 3, 3, "CID"], [71, 71, 13, 13, "CID"], [71, 71, 66, 66, "CID"], [71, 71, 90, 90, "CID"], [71, 71, 96, 96, "CID"], [104, 104, 3, 3, "CID"], [104, 104, 13, 13, "CID"], [104, 104, 66, 66, "CID"], [104, 104, 90, 90, "CID"], [104, 104, 96, 96, "CID"], [123, 123, 3, 3, "CID"], [123, 123, 13, 13, "CID"], [123, 123, 66, 66, "CID"], [123, 123, 90, 90, "CID"], [123, 123, 96, 96, "CID"]]], "clusters": [], "translated": " <0>吗啡</0>引起的新生儿<6>癫痫发作</6>。2例新生儿在术后静脉<1>硫酸吗啡</1>镇痛过程中出现全身性<7>惊厥</7>。他们接受<2>吗啡</2>，剂量分别为 32 微克/千克/小时和 40 微克/千克/小时，比一组 10 名接受 6 - 24 微克/千克/小时且没有<8>发作的新生儿要大</8>。这些新生儿中<3>吗啡</3>的血浆浓度过高（60和90 mg/ml）。<9>癫痫发作</9>的其他已知原因被排除，<10>惊厥</10>在停止使用<4>吗啡</4>后几小时停止，并且在随后的8个月内没有再次发生。建议新生儿术后静脉<5>吗啡</5>不超过20微克/公斤/毫升。", "revised": true}
{"doc_key": "3155884", "sentences": [["Acute", "insulin", "treatment", "normalizes", "the", "resistance", "to", "the", "cardiotoxic", "effect", "of", "isoproterenol", "in", "streptozotocin", "diabetic", "rats", ".", "A", "morphometric", "study", "of", "isoproterenol", "induced", "myocardial", "fibrosis", ".", "The", "acute", "effect", "of", "insulin", "treatment", "on", "the", "earlier", "reported", "protective", "effect", "of", "streptozotocin", "diabetes", "against", "the", "cardiotoxic", "effect", "of", "high", "doses", "of", "isoproterenol", "(", "ISO", ")", "was", "investigated", "in", "rats", ".", "Thirty", "to", "135", "min", "after", "the", "injection", "of", "crystalline", "insulin", ",", "ISO", "was", "given", "subcutaneously", "and", "when", "ISO", "induced", "fibrosis", "in", "the", "myocardium", "was", "morphometrically", "analyzed", "7", "days", "later", ",", "a", "highly", "significant", "correlation", "(", "r", "=", "0", ".", "83", ",", "2", "p", "=", "0", ".", "006", ")", "to", "the", "slope", "of", "the", "fall", "in", "blood", "glucose", "after", "insulin", "treatment", "appeared", ".", "The", "myocardial", "content", "of", "catecholamines", "was", "estimated", "in", "these", "8", "day", "diabetic", "rats", ".", "The", "norepinephrine", "content", "was", "significantly", "increased", "while", "epinephrine", "remained", "unchanged", ".", "An", "enhanced", "sympathetic", "nervous", "system", "activity", "with", "a", "consequent", "down", "regulation", "of", "the", "myocardial", "beta", "-", "adrenergic", "receptors", "could", ",", "therefore", ",", "explain", "this", "catecholamine", "resistance", ".", "The", "rapid", "reversion", "after", "insulin", "treatment", "excludes", "the", "possibility", "that", "streptozotocin", "in", "itself", "causes", "the", "ISO", "resistance", "and", "points", "towards", "a", "direct", "insulin", "effect", "on", "myocardial", "catecholamine", "sensitivity", "in", "diabetic", "rats", ".", "The", "phenomenon", "described", "might", "elucidate", "pathogenetic", "mechanisms", "behind", "toxic", "myocardial", "cell", "degeneration", "and", "may", "possibly", "have", "relevance", "for", "acute", "cardiovascular", "complications", "in", "diabetic", "patients", "."]], "ner": [[[11, 11, "Chemical"], [21, 21, "Chemical"], [49, 49, "Chemical"], [51, 51, "Chemical"], [69, 69, "Chemical"], [75, 75, "Chemical"], [187, 187, "Chemical"], [24, 24, "Disease"], [77, 77, "Disease"], [13, 13, "Chemical"], [39, 39, "Chemical"], [182, 182, "Chemical"], [14, 14, "Disease"], [40, 40, "Disease"], [131, 131, "Disease"], [201, 201, "Disease"], [226, 226, "Disease"], [8, 8, "Disease"], [43, 43, "Disease"], [114, 114, "Chemical"], [124, 124, "Chemical"], [169, 169, "Chemical"], [198, 198, "Chemical"], [135, 135, "Chemical"], [141, 141, "Chemical"]]], "relations": [[[11, 11, 24, 24, "CID"], [11, 11, 77, 77, "CID"], [21, 21, 24, 24, "CID"], [21, 21, 77, 77, "CID"], [49, 49, 24, 24, "CID"], [49, 49, 77, 77, "CID"], [51, 51, 24, 24, "CID"], [51, 51, 77, 77, "CID"], [69, 69, 24, 24, "CID"], [69, 69, 77, 77, "CID"], [75, 75, 24, 24, "CID"], [75, 75, 77, 77, "CID"], [187, 187, 24, 24, "CID"], [187, 187, 77, 77, "CID"], [13, 13, 14, 14, "CID"], [13, 13, 40, 40, "CID"], [13, 13, 131, 131, "CID"], [13, 13, 201, 201, "CID"], [13, 13, 226, 226, "CID"], [39, 39, 14, 14, "CID"], [39, 39, 40, 40, "CID"], [39, 39, 131, 131, "CID"], [39, 39, 201, 201, "CID"], [39, 39, 226, 226, "CID"], [182, 182, 14, 14, "CID"], [182, 182, 40, 40, "CID"], [182, 182, 131, 131, "CID"], [182, 182, 201, 201, "CID"], [182, 182, 226, 226, "CID"]]], "clusters": [], "translated": "急性胰岛素治疗可使<9>链脲佐菌素</9> <12>糖尿病</12>大鼠对<0>异丙肾上腺素</0>的<17>心脏毒性</17>作用的抵抗力正常化。 <1>异丙肾上腺素</1>致心肌<7>纤维化</7>的形态学研究。胰岛素治疗对早期报道的<10>链脲佐菌素</10><13>糖尿病</13>对高剂量<2>异丙肾上腺素</2> (<3>ISO</3>) <18>心脏毒性</18>的保护作用的急性作用在大鼠中进行了研究。注射结晶胰岛素后30至135分钟，皮下注射<4>ISO</4>，并在7天后对<5>ISO</5>诱导的心肌<8>纤维化</8>进行形态学分析，与胰岛素治疗后血糖<19>葡萄糖</19>下降的斜率存在高度显着相关性(r = 0.83, 2p = 0.006)。在这些8天的<14>糖尿病</14>大鼠中估计了心肌<20>儿茶酚胺</20>的含量。 <23>去甲肾上腺素</23>含量显着增加，而<24>肾上腺素</24>没有变化。因此，增强的交感神经系统活动以及随之而来的心肌β-肾上腺素能受体的下调可以解释这种<21>儿茶酚胺</21>抗性。胰岛素治疗后的快速逆转排除了<11>链脲佐菌素</11>本身引起<6>ISO</6>抵抗的可能性，并指出胰岛素对<15>糖尿病</15>大鼠心肌<22>儿茶酚胺</22>敏感性的直接影响。所描述的现象可能会阐明毒性心肌细胞变性背后的发病机制，并且可能与<16>糖尿病</16>患者的急性心血管并发症有关。", "revised": true}
{"doc_key": "3987172", "sentences": [["Propranolol", "antagonism", "of", "phenylpropanolamine", "-", "induced", "hypertension", ".", "Phenylpropanolamine", "(", "PPA", ")", "overdose", "can", "cause", "severe", "hypertension", ",", "intracerebral", "hemorrhage", ",", "and", "death", ".", "We", "studied", "the", "efficacy", "and", "safety", "of", "propranolol", "in", "the", "treatment", "of", "PPA", "-", "induced", "hypertension", ".", "Subjects", "received", "propranolol", "either", "by", "mouth", "for", "48", "hours", "before", "PPA", "or", "as", "a", "rapid", "intravenous", "infusion", "after", "PPA", ".", "PPA", ",", "75", "mg", "alone", ",", "increased", "blood", "pressure", "(", "31", "+", "/", "-", "14", "mm", "Hg", "systolic", ",", "20", "+", "/", "-", "5", "mm", "Hg", "diastolic", ")", ",", "and", "propranolol", "pretreatment", "antagonized", "this", "increase", "(", "12", "+", "/", "-", "10", "mm", "Hg", "systolic", ",", "10", "+", "/", "-", "7", "mm", "Hg", "diastolic", ")", ".", "Intravenous", "propranolol", "after", "PPA", "also", "decreased", "blood", "pressure", ".", "Left", "ventricular", "function", "(", "assessed", "by", "echocardiography", ")", "showed", "that", "PPA", "increased", "the", "stroke", "volume", "30", "%", "(", "from", "62", ".", "5", "+", "/", "-", "20", ".", "9", "to", "80", ".", "8", "+", "/", "-", "22", ".", "4", "ml", ")", ",", "the", "ejection", "fraction", "9", "%", "(", "from", "64", "%", "+", "/", "-", "10", "%", "to", "70", "%", "+", "/", "-", "7", "%", ")", ",", "and", "cardiac", "output", "14", "%", "(", "from", "3", ".", "6", "+", "/", "-", "0", ".", "6", "to", "4", ".", "1", "+", "/", "-", "1", ".", "0", "L", "/", "min", ")", ".", "Intravenous", "propranolol", "reversed", "these", "effects", ".", "Systemic", "vascular", "resistance", "was", "increased", "by", "PPA", "28", "%", "(", "from", "1710", "+", "/", "-", "200", "to", "2190", "+", "/", "-", "700", "dyne", "X", "sec", "/", "cm5", ")", "and", "was", "further", "increased", "by", "propranolol", "22", "%", "(", "to", "2660", "+", "/", "-", "1200", "dyne", "X", "sec", "/", "cm5", ")", ".", "We", "conclude", "that", "PPA", "increases", "blood", "pressure", "by", "increasing", "systemic", "vascular", "resistance", "and", "cardiac", "output", ",", "and", "that", "propranolol", "antagonizes", "this", "increase", "by", "reversing", "the", "effect", "of", "PPA", "on", "cardiac", "output", ".", "That", "propranolol", "antagonizes", "the", "pressor", "effect", "of", "PPA", "is", "in", "contrast", "to", "the", "interaction", "in", "which", "propranolol", "enhances", "the", "pressor", "effect", "of", "norepinephrine", ".", "This", "is", "probably", "because", "PPA", "has", "less", "beta", "2", "activity", "than", "does", "norepinephrine", "."]], "ner": [[[3, 3, "Chemical"], [8, 8, "Chemical"], [10, 10, "Chemical"], [36, 36, "Chemical"], [51, 51, "Chemical"], [59, 59, "Chemical"], [61, 61, "Chemical"], [119, 119, "Chemical"], [135, 135, "Chemical"], [233, 233, "Chemical"], [280, 280, "Chemical"], [304, 304, "Chemical"], [316, 316, "Chemical"], [337, 337, "Chemical"], [6, 6, "Disease"], [16, 16, "Disease"], [39, 39, "Disease"], [0, 0, "Chemical"], [31, 31, "Chemical"], [43, 43, "Chemical"], [91, 91, "Chemical"], [117, 117, "Chemical"], [222, 222, "Chemical"], [260, 260, "Chemical"], [295, 295, "Chemical"], [310, 310, "Chemical"], [325, 325, "Chemical"], [12, 12, "Disease"], [18, 19, "Disease"], [138, 138, "Disease"], [331, 331, "Chemical"], [345, 345, "Chemical"]]], "relations": [[[3, 3, 6, 6, "CID"], [3, 3, 16, 16, "CID"], [3, 3, 39, 39, "CID"], [8, 8, 6, 6, "CID"], [8, 8, 16, 16, "CID"], [8, 8, 39, 39, "CID"], [10, 10, 6, 6, "CID"], [10, 10, 16, 16, "CID"], [10, 10, 39, 39, "CID"], [36, 36, 6, 6, "CID"], [36, 36, 16, 16, "CID"], [36, 36, 39, 39, "CID"], [51, 51, 6, 6, "CID"], [51, 51, 16, 16, "CID"], [51, 51, 39, 39, "CID"], [59, 59, 6, 6, "CID"], [59, 59, 16, 16, "CID"], [59, 59, 39, 39, "CID"], [61, 61, 6, 6, "CID"], [61, 61, 16, 16, "CID"], [61, 61, 39, 39, "CID"], [119, 119, 6, 6, "CID"], [119, 119, 16, 16, "CID"], [119, 119, 39, 39, "CID"], [135, 135, 6, 6, "CID"], [135, 135, 16, 16, "CID"], [135, 135, 39, 39, "CID"], [233, 233, 6, 6, "CID"], [233, 233, 16, 16, "CID"], [233, 233, 39, 39, "CID"], [280, 280, 6, 6, "CID"], [280, 280, 16, 16, "CID"], [280, 280, 39, 39, "CID"], [304, 304, 6, 6, "CID"], [304, 304, 16, 16, "CID"], [304, 304, 39, 39, "CID"], [316, 316, 6, 6, "CID"], [316, 316, 16, 16, "CID"], [316, 316, 39, 39, "CID"], [337, 337, 6, 6, "CID"], [337, 337, 16, 16, "CID"], [337, 337, 39, 39, "CID"]]], "clusters": [], "translated": "<17>普萘洛尔</17>对<0>苯丙醇胺</0>诱发的<14>高血压</14>的拮抗作用。<1>苯丙醇胺</1>（<2>PPA</2>）<27>过量</27>可引起严重的<15>高血压</15>，<28>脑出血</28>，甚至死亡。我们研究了<18>普萘洛尔</18>治疗<3>PPA</3>诱发的<16>高血压</16>的有效性和安全性。受试者接受<19>普萘洛尔</19>在<4>PPA</4>之前口服48小时或在<5>PPA</5>之后快速静脉输注。<6>PPA</6>，单独使用75 mg，血压升高（收缩压31+/- 14mmHg，舒张压20+/-5mmHg），<20>普萘洛尔</20>预处理拮抗这种升高（12+/-10 mmHg收缩压，10+/-7 mmHg舒张压）。静脉注射<21>普萘洛尔</21>在<7>PPA</7>后也可降低血压。左心室功能（通过超声心动图评估）显示<8>PPA</8>增加了<29>中风量</29>30%（从62.5+/-20.9到80.8+/-22.4 ml），射血分数9%（从64%+/-10%到70%+/-7%），心输出量14%（从3.6+/-0.6到4.1+/-1.0 L/min）。静脉注射<22>普萘洛尔</22>逆转了这些影响。全身血管阻力增加<9>PPA</9>28%（从1710+/-200到2190+/-700 dyne X sec/cm5），并进一步增加<23>普萘洛尔</23>22%（至2660+/-1200 dyne X sec/cm5） 。我们得出结论，<10>PPA</10>通过增加全身血管阻力和心输出量来增加血压，并且<24>普萘洛尔</24>通过逆转<11>PPA</11>对心输出量的影响拮抗这种升高。<25>普萘洛尔</25>拮抗<12>PPA</12>的升压作用与<26>普萘洛尔</26>增强<30>去甲肾上腺素</30>的升压作用的相互作用相反。这可能是因为<13>PPA</13>的β2活性低于<31>去甲肾上腺素</31>。", "revised": true}
{"doc_key": "6453500", "sentences": [["Toxic", "hepatitis", "induced", "by", "disulfiram", "in", "a", "non", "-", "alcoholic", ".", "A", "reversible", "toxic", "liver", "damage", "was", "observed", "in", "a", "non", "-", "alcoholic", "woman", "treated", "with", "disulfiram", ".", "The", "causative", "relationship", "was", "proven", "by", "challenge", "."]], "ner": [[[4, 4, "Chemical"], [26, 26, "Chemical"], [0, 1, "Disease"], [13, 15, "Disease"]]], "relations": [[[4, 4, 0, 1, "CID"], [4, 4, 13, 15, "CID"], [26, 26, 0, 1, "CID"], [26, 26, 13, 15, "CID"]]], "clusters": [], "translated": "<2>中毒性肝炎</2>由<0>双硫仑</0>在非酒精中诱发。在接受<1>双硫仑</1>治疗的非酒精女性中观察到可逆的<3>中毒性肝损伤</3>。因果关系被证明。", "revised": true}
{"doc_key": "3074291", "sentences": [["Comparison", "of", "the", "effect", "of", "oxitropium", "bromide", "and", "of", "slow", "-", "release", "theophylline", "on", "nocturnal", "asthma", ".", "The", "effects", "of", "a", "new", "inhaled", "antimuscarinic", "drug", ",", "oxitropium", "bromide", ",", "and", "of", "a", "slow", "-", "release", "theophylline", "preparation", "upon", "nocturnal", "asthma", "were", "compared", "in", "a", "placebo", "-", "controlled", "double", "-", "blind", "study", ".", "Two", "samples", "were", "studied", ":", "12", "patients", "received", "oxitropium", "at", "600", "micrograms", "(", "6", "subjects", ")", "or", "at", "400", "micrograms", "t", ".", "i", ".", "d", ".", "(", "6", "subjects", ")", "whereas", "11", "received", "theophylline", "at", "300", "mg", "b", ".", "i", ".", "d", ".", "Morning", "dipping", ",", "assessed", "by", "the", "fall", "in", "peak", "flow", "overnight", ",", "was", "significantly", "reduced", "in", "the", "periods", "when", "either", "active", "drug", "was", "taken", ",", "whereas", "no", "difference", "was", "noticed", "during", "the", "placebo", "administration", ".", "No", "significant", "difference", "was", "noticed", "between", "results", "obtained", "with", "either", "active", "drug", ",", "as", "well", "as", "with", "either", "dosage", "of", "oxitropium", ".", "No", "subject", "reported", "side", "effects", "of", "oxitropium", ",", "as", "compared", "to", "three", "subjects", "reporting", "nausea", ",", "vomiting", "and", "tremors", "after", "theophylline", ".", "Oxitropium", "proves", "to", "be", "a", "valuable", "alternative", "to", "theophylline", "in", "nocturnal", "asthma", ",", "since", "it", "is", "equally", "potent", ",", "safer", "and", "does", "not", "require", "the", "titration", "of", "dosage", "."]], "ner": [[[12, 12, "Chemical"], [35, 35, "Chemical"], [85, 85, "Chemical"], [172, 172, "Chemical"], [182, 182, "Chemical"], [166, 166, "Disease"], [168, 168, "Disease"], [170, 170, "Disease"], [5, 6, "Chemical"], [26, 27, "Chemical"], [60, 60, "Chemical"], [150, 150, "Chemical"], [158, 158, "Chemical"], [174, 174, "Chemical"], [15, 15, "Disease"], [39, 39, "Disease"], [185, 185, "Disease"]]], "relations": [[[12, 12, 166, 166, "CID"], [35, 35, 166, 166, "CID"], [85, 85, 166, 166, "CID"], [172, 172, 166, 166, "CID"], [182, 182, 166, 166, "CID"], [12, 12, 168, 168, "CID"], [35, 35, 168, 168, "CID"], [85, 85, 168, 168, "CID"], [172, 172, 168, 168, "CID"], [182, 182, 168, 168, "CID"], [12, 12, 170, 170, "CID"], [35, 35, 170, 170, "CID"], [85, 85, 170, 170, "CID"], [172, 172, 170, 170, "CID"], [182, 182, 170, 170, "CID"]]], "clusters": [], "translated": "<8>氧托溴铵</8>与缓释<0>茶碱</0>对夜间<14>哮喘</14>的疗效比较。一种新的吸入性抗毒蕈碱药<9>氧托溴铵</9>和缓释<1>茶碱</1>制剂对夜间<15>哮喘</15>的作用在安慰剂中进行了比较-对照双盲研究。研究了两个样本：12名患者接受了600微克（6名受试者）或400微克t。i。d.的<10>氧托溴铵</10>，而11名接受了300 mg b。i。d.的<2>茶碱</2>。通过夜间峰值流量下降来评估的早晨浸渍显着减少，而在安慰剂给药期间没有发现差异。使用任何一种活性药物以及任何一剂量的<11>氧托溴铵</11>获得的结果均未发现显着差异。与<5>恶心</5>、<6>呕吐</6>和<7>震颤</7>相比，<12>氧托溴铵</12>的三名受试者没有报告副作用，而在服用<3>茶碱</3>之后则有三名受试者报告了副作用。<13>氧托溴铵</13>被证明是一种可替代<4>茶碱</4>治疗夜间<16>哮喘</16>的有价值替代品，因为它同样有效、更安全并且不需要逐渐增加剂量。", "revised": true}
{"doc_key": "3708328", "sentences": [["Susceptibility", "to", "seizures", "produced", "by", "pilocarpine", "in", "rats", "after", "microinjection", "of", "isoniazid", "or", "gamma", "-", "vinyl", "-", "GABA", "into", "the", "substantia", "nigra", ".", "Pilocarpine", ",", "given", "intraperitoneally", "to", "rats", ",", "reproduces", "the", "neuropathological", "sequelae", "of", "temporal", "lobe", "epilepsy", "and", "provides", "a", "relevant", "animal", "model", "for", "studying", "mechanisms", "of", "buildup", "of", "convulsive", "activity", "and", "pathways", "operative", "in", "the", "generalization", "and", "propagation", "of", "seizures", "within", "the", "forebrain", ".", "In", "the", "present", "study", ",", "the", "effects", "of", "manipulating", "the", "activity", "of", "the", "gamma", "-", "aminobutyric", "acid", "(", "GABA", ")", "-", "mediated", "synaptic", "inhibition", "within", "the", "substantia", "nigra", "on", "seizures", "produced", "by", "pilocarpine", "in", "rats", ",", "were", "investigated", ".", "In", "animals", "pretreated", "with", "microinjections", "of", "isoniazid", ",", "150", "micrograms", ",", "an", "inhibitor", "of", "activity", "of", "the", "GABA", "-", "synthesizing", "enzyme", ",", "L", "-", "glutamic", "acid", "decarboxylase", ",", "into", "the", "substantia", "nigra", "pars", "reticulata", "(", "SNR", ")", ",", "bilaterally", ",", "non", "-", "convulsant", "doses", "of", "pilocarpine", ",", "100", "and", "200", "mg", "/", "kg", ",", "resulted", "in", "severe", "motor", "limbic", "seizures", "and", "status", "epilepticus", ".", "Electroencephalographic", "and", "behavioral", "monitoring", "revealed", "a", "profound", "reduction", "of", "the", "threshold", "for", "pilocarpine", "-", "induced", "convulsions", ".", "Morphological", "analysis", "of", "frontal", "forebrain", "sections", "with", "light", "microscopy", "revealed", "seizure", "-", "related", "damage", "to", "the", "hippocampal", "formation", ",", "thalamus", ",", "amygdala", ",", "olfactory", "cortex", ",", "substantia", "nigra", "and", "neocortex", ",", "which", "is", "typically", "observed", "with", "pilocarpine", "in", "doses", "exceeding", "350", "mg", "/", "kg", ".", "Bilateral", "intrastriatal", "injections", "of", "isoniazid", "did", "not", "augment", "seizures", "produced", "by", "pilocarpine", ",", "200", "mg", "/", "kg", ".", "Application", "of", "an", "irreversible", "inhibitor", "of", "GABA", "transaminase", ",", "gamma", "-", "vinyl", "-", "GABA", "(", "D", ",", "L", "-", "4", "-", "amino", "-", "hex", "-", "5", "-", "enoic", "acid", ")", ",", "5", "micrograms", ",", "into", "the", "SNR", ",", "bilaterally", ",", "suppressed", "the", "appearance", "of", "electrographic", "and", "behavioral", "seizures", "produced", "by", "pilocarpine", ",", "380", "mg", "/", "kg", ".", "This", "treatment", "was", "also", "sufficient", "to", "protect", "animals", "from", "the", "occurrence", "of", "brain", "damage", ".", "Microinjections", "of", "gamma", "-", "vinyl", "-", "GABA", ",", "5", "micrograms", ",", "into", "the", "dorsal", "striatum", ",", "bilaterally", ",", "failed", "to", "prevent", "the", "development", "of", "convulsions", "produced", "by", "pilocarpine", ",", "380", "mg", "/", "kg", ".", "The", "results", "demonstrate", "that", "the", "threshold", "for", "pilocarpine", "-", "induced", "seizures", "in", "rats", "is", "subjected", "to", "the", "regulation", "of", "the", "GABA", "-", "mediated", "synaptic", "inhibition", "within", "the", "substantia", "nigra", "."]], "ner": [[[5, 5, "Chemical"], [23, 23, "Chemical"], [98, 98, "Chemical"], [150, 150, "Chemical"], [181, 181, "Chemical"], [222, 222, "Chemical"], [242, 242, "Chemical"], [299, 299, "Chemical"], [348, 348, "Chemical"], [362, 362, "Chemical"], [2, 2, "Disease"], [50, 50, "Disease"], [61, 61, "Disease"], [95, 95, "Disease"], [164, 164, "Disease"], [184, 184, "Disease"], [196, 196, "Disease"], [239, 239, "Disease"], [296, 296, "Disease"], [345, 345, "Disease"], [365, 365, "Disease"], [11, 11, "Chemical"], [111, 111, "Chemical"], [235, 235, "Chemical"], [13, 17, "Chemical"], [258, 262, "Chemical"], [264, 277, "Chemical"], [323, 327, "Chemical"], [79, 82, "Chemical"], [84, 84, "Chemical"], [122, 122, "Chemical"], [255, 255, "Chemical"], [375, 375, "Chemical"], [127, 130, "Chemical"], [35, 37, "Disease"], [166, 167, "Disease"], [318, 319, "Disease"]]], "relations": [[[5, 5, 2, 2, "CID"], [5, 5, 50, 50, "CID"], [5, 5, 61, 61, "CID"], [5, 5, 95, 95, "CID"], [5, 5, 164, 164, "CID"], [5, 5, 184, 184, "CID"], [5, 5, 196, 196, "CID"], [5, 5, 239, 239, "CID"], [5, 5, 296, 296, "CID"], [5, 5, 345, 345, "CID"], [5, 5, 365, 365, "CID"], [23, 23, 2, 2, "CID"], [23, 23, 50, 50, "CID"], [23, 23, 61, 61, "CID"], [23, 23, 95, 95, "CID"], [23, 23, 164, 164, "CID"], [23, 23, 184, 184, "CID"], [23, 23, 196, 196, "CID"], [23, 23, 239, 239, "CID"], [23, 23, 296, 296, "CID"], [23, 23, 345, 345, "CID"], [23, 23, 365, 365, "CID"], [98, 98, 2, 2, "CID"], [98, 98, 50, 50, "CID"], [98, 98, 61, 61, "CID"], [98, 98, 95, 95, "CID"], [98, 98, 164, 164, "CID"], [98, 98, 184, 184, "CID"], [98, 98, 196, 196, "CID"], [98, 98, 239, 239, "CID"], [98, 98, 296, 296, "CID"], [98, 98, 345, 345, "CID"], [98, 98, 365, 365, "CID"], [150, 150, 2, 2, "CID"], [150, 150, 50, 50, "CID"], [150, 150, 61, 61, "CID"], [150, 150, 95, 95, "CID"], [150, 150, 164, 164, "CID"], [150, 150, 184, 184, "CID"], [150, 150, 196, 196, "CID"], [150, 150, 239, 239, "CID"], [150, 150, 296, 296, "CID"], [150, 150, 345, 345, "CID"], [150, 150, 365, 365, "CID"], [181, 181, 2, 2, "CID"], [181, 181, 50, 50, "CID"], [181, 181, 61, 61, "CID"], [181, 181, 95, 95, "CID"], [181, 181, 164, 164, "CID"], [181, 181, 184, 184, "CID"], [181, 181, 196, 196, "CID"], [181, 181, 239, 239, "CID"], [181, 181, 296, 296, "CID"], [181, 181, 345, 345, "CID"], [181, 181, 365, 365, "CID"], [222, 222, 2, 2, "CID"], [222, 222, 50, 50, "CID"], [222, 222, 61, 61, "CID"], [222, 222, 95, 95, "CID"], [222, 222, 164, 164, "CID"], [222, 222, 184, 184, "CID"], [222, 222, 196, 196, "CID"], [222, 222, 239, 239, "CID"], [222, 222, 296, 296, "CID"], [222, 222, 345, 345, "CID"], [222, 222, 365, 365, "CID"], [242, 242, 2, 2, "CID"], [242, 242, 50, 50, "CID"], [242, 242, 61, 61, "CID"], [242, 242, 95, 95, "CID"], [242, 242, 164, 164, "CID"], [242, 242, 184, 184, "CID"], [242, 242, 196, 196, "CID"], [242, 242, 239, 239, "CID"], [242, 242, 296, 296, "CID"], [242, 242, 345, 345, "CID"], [242, 242, 365, 365, "CID"], [299, 299, 2, 2, "CID"], [299, 299, 50, 50, "CID"], [299, 299, 61, 61, "CID"], [299, 299, 95, 95, "CID"], [299, 299, 164, 164, "CID"], [299, 299, 184, 184, "CID"], [299, 299, 196, 196, "CID"], [299, 299, 239, 239, "CID"], [299, 299, 296, 296, "CID"], [299, 299, 345, 345, "CID"], [299, 299, 365, 365, "CID"], [348, 348, 2, 2, "CID"], [348, 348, 50, 50, "CID"], [348, 348, 61, 61, "CID"], [348, 348, 95, 95, "CID"], [348, 348, 164, 164, "CID"], [348, 348, 184, 184, "CID"], [348, 348, 196, 196, "CID"], [348, 348, 239, 239, "CID"], [348, 348, 296, 296, "CID"], [348, 348, 345, 345, "CID"], [348, 348, 365, 365, "CID"], [362, 362, 2, 2, "CID"], [362, 362, 50, 50, "CID"], [362, 362, 61, 61, "CID"], [362, 362, 95, 95, "CID"], [362, 362, 164, 164, "CID"], [362, 362, 184, 184, "CID"], [362, 362, 196, 196, "CID"], [362, 362, 239, 239, "CID"], [362, 362, 296, 296, "CID"], [362, 362, 345, 345, "CID"], [362, 362, 365, 365, "CID"]]], "clusters": [], "translated": "大鼠黑质显微注射<21>异烟肼</21>或<24>γ-乙烯基-GABA</24>后对<0>毛果芸香碱</0>产生的<10>癫痫发作</10>的易感性。 <1>毛果芸香碱</1>，给予大鼠腹膜内注射，重现了<34>颞叶癫痫</34>的神经病理学后遗症，并为研究<11>惊厥</11>活动的形成机制提供了相关的动物模型，通路在前脑内<12>癫痫发作</12>的泛化和传播中起作用。在本研究中，操纵<28>γ-氨基丁酸</28>(<29>GABA</29>)介导的黑质内突触抑制对<2>毛果芸香碱</2>在大鼠中产生的<13>癫痫发作</13>的影响进行了研究。在用<22>异烟肼</22>150微克预处理的动物中，进入动物体内黑质网状部(SNR)的<30>GABA</30>-合成酶、<33>L-谷氨酸</33>脱羧酶的活性抑制剂，双侧注射，非惊厥诱导剂量<3>毛果芸香碱</3>，100和200毫克/千克，导致严重的运动边缘<14>癫痫发作</14>和<35>状态癫痫发作</35>。脑电图和行为监测显示<4>毛果芸香碱</4>诱发的<15>惊厥</15>的阈值显着降低。用光学显微镜对额前脑切片进行的形态学分析显示，<16>癫痫发作</16>与海马结构、丘脑、杏仁核、嗅觉皮层、黑质和新皮层相关的损伤，通常用<5>毛果芸香碱</5>观察到的剂量超过350毫克/千克。双侧纹状体内注射<23>异烟肼</23>不增加<6>毛果芸香碱</6>产生的<17>癫痫发作</17>，200毫克/千克。将<31>GABA</31>转氨酶不可逆抑制剂的应用<25>γ-乙烯基-GABA</25>(<26>D,L-4-氨基-己-5-烯酸</26>),5微克，双侧显微注射到SNR，可以抑制由<7>毛果芸香碱</7>产生的电图和行为<18>癫痫发作</18>，380毫克/千克。这种处理也足以保护动物免受<36>脑损伤</36>的发生。将5微克<27>γ-乙烯基-GABA</27>显微注射到双侧背侧纹状体中未能阻止<8>毛果芸香碱</8>产生的<19>惊厥</19>的发展，380毫克/千克。结果表明，大鼠<9>毛果芸香碱</9>诱导的<20>癫痫发作</20>的阈值受黑质内 <32>GABA</32>介导的突触抑制的调节。", "revised": true}
{"doc_key": "6316193", "sentences": [["Structure", "-", "activity", "and", "dose", "-", "effect", "relationships", "of", "the", "antagonism", "of", "picrotoxin", "-", "induced", "seizures", "by", "cholecystokinin", ",", "fragments", "and", "analogues", "of", "cholecystokinin", "in", "mice", ".", "Intraperitoneal", "administration", "of", "cholecystokinin", "octapeptide", "sulphate", "ester", "(", "CCK", "-", "8", "-", "SE", ")", "and", "nonsulphated", "cholecystokinin", "octapeptide", "(", "CCK", "-", "8", "-", "NS", ")", "enhanced", "the", "latency", "of", "seizures", "induced", "by", "picrotoxin", "in", "mice", ".", "Experiments", "with", "N", "-", "and", "C", "-", "terminal", "fragments", "revealed", "that", "the", "C", "-", "terminal", "tetrapeptide", "(", "CCK", "-", "5", "-", "8", ")", "was", "the", "active", "centre", "of", "the", "CCK", "octapeptide", "molecule", ".", "The", "analogues", "CCK", "-", "8", "-", "SE", "and", "CCK", "-", "8", "-", "NS", "(", "dose", "range", "0", ".", "2", "-", "6", ".", "4", "mumol", "/", "kg", ")", "and", "caerulein", "dose", "range", "0", ".", "1", "-", "0", ".", "8", "mumol", "/", "kg", ")", "showed", "bell", "-", "shaped", "dose", "-", "effect", "curves", ",", "with", "the", "greatest", "maximum", "inhibition", "for", "CCK", "-", "8", "-", "NS", ".", "The", "peptide", "CCK", "-", "5", "-", "8", "had", "weak", "anticonvulsant", "activity", "in", "comparison", "to", "the", "octapeptides", ",", "3", ".", "2", "mumol", "/", "kg", "and", "larger", "doses", "of", "the", "reference", "drug", ",", "diazepam", ",", "totally", "prevented", "picrotoxin", "-", "induced", "seizures", "and", "mortality", ".", "The", "maximum", "effect", "of", "the", "peptides", "tested", "was", "less", "than", "that", "of", "diazepam", ".", "Experiments", "with", "analogues", "and", "derivatives", "of", "CCK", "-", "5", "-", "8", "demonstrated", "that", "the", "effectiveness", "of", "the", "beta", "-", "alanyl", "derivatives", "of", "CCK", "-", "5", "-", "8", "were", "enhanced", "and", "that", "they", "were", "equipotent", "with", "CCK", "-", "8", "-", "SE", ".", "Of", "the", "CCK", "-", "2", "-", "8", "analogues", ",", "Ser", "(", "SO3H", ")", "7", "-", "Ac", "-", "CCK", "-", "2", "-", "8", "-", "SE", "and", "Thr", "(", "SO3H", ")", "7", "-", "Ac", "-", "CCK", "-", "2", "-", "8", "-", "SE", "and", "Hyp", "(", "SO3H", ")", "-", "Ac", "-", "CCK", "-", "2", "-", "8", "-", "SE", "were", "slightly", "more", "active", "than", "CCK", "-", "8", "-", "SE", "."]], "ner": [[[12, 12, "Chemical"], [59, 59, "Chemical"], [194, 194, "Chemical"], [15, 15, "Disease"], [56, 56, "Disease"], [197, 197, "Disease"], [17, 17, "Chemical"], [23, 23, "Chemical"], [30, 31, "Chemical"], [35, 37, "Chemical"], [43, 44, "Chemical"], [46, 48, "Chemical"], [98, 100, "Chemical"], [104, 106, "Chemical"], [153, 155, "Chemical"], [250, 252, "Chemical"], [316, 318, "Chemical"], [124, 124, "Chemical"], [190, 190, "Chemical"], [213, 213, "Chemical"]]], "relations": [[[12, 12, 15, 15, "CID"], [12, 12, 56, 56, "CID"], [12, 12, 197, 197, "CID"], [59, 59, 15, 15, "CID"], [59, 59, 56, 56, "CID"], [59, 59, 197, 197, "CID"], [194, 194, 15, 15, "CID"], [194, 194, 56, 56, "CID"], [194, 194, 197, 197, "CID"]]], "clusters": [], "translated": "<0> 印防己毒素 </0> 的拮抗作用的结构-活性和剂量-效应关系 - 通过 <6>缩胆囊素</6>、<7>缩胆囊素</7> 的片段和类似物诱导<3>癫痫发作</3>在小鼠中。<8>胆囊收缩素八肽</8>硫酸酯(<9>CCK-8</9>-SE)和非硫酸化<10>胆囊收缩素八肽</10> (<11>CCK-8</11>-NS)可延长小鼠<1>印防己毒素</1>引起的<4>癫痫发作</4>潜伏期。N端和C端片段实验表明，C端四肽(CCK-5-8)是CCK八肽分子的活性中心。类似物<12>CCK-8</12>-SE和<13>CCK-8</13>-NS(剂量范围0.2-6.4 mumol/kg)和<17>降钙素</17>(剂量范围0.1-0.8 mumol/kg)呈钟形量效曲线，对<14>CCK-8</14>-NS的抑制作用最大。与八肽相比，CCK-5-8肽具有较弱的抗惊厥活性，3.2 μmol/kg和更大剂量的参考药物<18>地西泮</18>完全阻止了<2>印防己毒素</2>引起的<5>癫痫发作</5>和死亡率。所测试的肽的最大作用小于<19>地西泮</19>。用CCK-5-8的类似物和衍生物进行的实验表明，CCK-5-8的β-丙氨酰衍生物的有效性得到增强，并且与<15>CCK-8</15>-SE等效。在CCK-2-8类似物中，Ser(SO3H)7-Ac-CCK-2-8-SE和Thr(SO3H)7-Ac-CCK-2-8-SE和Hyp(SO3H)-Ac-CCK-2-8-SE比<16>CCK-8</16>-SE活性稍高。", "revised": true}
{"doc_key": "6517710", "sentences": [["Atrial", "thrombosis", "involving", "the", "heart", "of", "F", "-", "344", "rats", "ingesting", "quinacrine", "hydrochloride", ".", "Quinacrine", "hydrochloride", "is", "toxic", "for", "the", "heart", "of", "F", "-", "344", "rats", ".", "Rats", "treated", "with", "500", "ppm", "quinacrine", "hydrochloride", "in", "the", "diet", "all", "developed", "a", "high", "incidence", "of", "left", "atrial", "thrombosis", ".", "The", "lesion", "was", "associated", "with", "cardiac", "hypertrophy", "and", "dilatation", "and", "focal", "myocardial", "degeneration", ".", "Rats", "died", "from", "cardiac", "hypertrophy", "with", "severe", "acute", "and", "chronic", "congestion", "of", "the", "lungs", ",", "liver", ",", "and", "other", "organs", ".", "Seventy", "percent", "of", "rats", "given", "250", "ppm", "quinacrine", "hydrochloride", "and", "1", ",", "000", "ppm", "sodium", "nitrite", "simultaneously", "in", "the", "diet", "had", "thrombosis", "of", "the", "atria", "of", "the", "heart", ",", "while", "untreated", "control", "rats", "in", "this", "laboratory", "did", "not", "have", "atrial", "thrombosis", ".", "Sodium", "nitrite", "in", "combination", "with", "quinacrine", "hydrochloride", "appeared", "to", "have", "no", "additional", "effect", "."]], "ner": [[[11, 12, "Chemical"], [14, 15, "Chemical"], [32, 33, "Chemical"], [89, 90, "Chemical"], [129, 130, "Chemical"], [0, 1, "Disease"], [44, 45, "Disease"], [121, 122, "Disease"], [52, 53, "Disease"], [64, 65, "Disease"], [96, 97, "Chemical"], [124, 125, "Chemical"], [58, 59, "Disease"], [103, 103, "Disease"]]], "relations": [[[11, 12, 0, 1, "CID"], [11, 12, 44, 45, "CID"], [11, 12, 121, 122, "CID"], [14, 15, 0, 1, "CID"], [14, 15, 44, 45, "CID"], [14, 15, 121, 122, "CID"], [32, 33, 0, 1, "CID"], [32, 33, 44, 45, "CID"], [32, 33, 121, 122, "CID"], [89, 90, 0, 1, "CID"], [89, 90, 44, 45, "CID"], [89, 90, 121, 122, "CID"], [129, 130, 0, 1, "CID"], [129, 130, 44, 45, "CID"], [129, 130, 121, 122, "CID"], [11, 12, 52, 53, "CID"], [11, 12, 64, 65, "CID"], [14, 15, 52, 53, "CID"], [14, 15, 64, 65, "CID"], [32, 33, 52, 53, "CID"], [32, 33, 64, 65, "CID"], [89, 90, 52, 53, "CID"], [89, 90, 64, 65, "CID"], [129, 130, 52, 53, "CID"], [129, 130, 64, 65, "CID"]]], "clusters": [], "translated": "<5>心房血栓形成</5>累及 F-344 大鼠摄入<0>盐酸奎纳克林</0>的心脏。 <1>盐酸奎纳克林</1>对 F-344 大鼠的心脏有毒性。以 500 ppm 的剂量在饮食中加入<2>盐酸奎纳克林</2>的大鼠均发生左<6>心房血栓形成</6>的高发生率。该病变伴有<8>心肌肥厚</8>和扩张以及局灶性<12>心肌变性</12>。大鼠死亡原因是<9>心脏肥大</9>和严重的急性和慢性肺、肝和其他器官充血。在饮食中同时给予 250 ppm 的<3>盐酸奎纳克林</3>和 1,000 ppm 的<10>亚硝酸钠</10>，其大鼠中有 70% 的心房发生<13>血栓形成</13>，而在该实验室未处理的对照大鼠中并没有<7>心房血栓形成</7>。联合使用的<11>亚硝酸钠</11>和<4>盐酸奎纳克林</4>似乎没有额外的效果。", "revised": true}
{"doc_key": "3925479", "sentences": [["Evidence", "for", "a", "cholinergic", "role", "in", "haloperidol", "-", "induced", "catalepsy", ".", "Experiments", "in", "mice", "tested", "previous", "evidence", "that", "activation", "of", "cholinergic", "systems", "promotes", "catalepsy", "and", "that", "cholinergic", "mechanisms", "need", "to", "be", "intact", "for", "full", "expression", "of", "neuroleptic", "-", "induced", "catalepsy", ".", "Large", "doses", "of", "the", "cholinomimetic", ",", "pilocarpine", ",", "could", "induce", "catalepsy", "when", "peripheral", "cholinergic", "receptors", "were", "blocked", ".", "Low", "doses", "of", "pilocarpine", "caused", "a", "pronounced", "enhancement", "of", "the", "catalepsy", "that", "was", "induced", "by", "the", "dopaminergic", "blocker", ",", "haloperidol", ".", "A", "muscarinic", "receptor", "blocker", ",", "atropine", ",", "disrupted", "haloperidol", "-", "induced", "catalepsy", ".", "Intracranial", "injection", "of", "an", "acetylcholine", "-", "synthesis", "inhibitor", ",", "hemicholinium", ",", "prevented", "the", "catalepsy", "that", "is", "usually", "induced", "by", "haloperidol", ".", "These", "findings", "suggest", "the", "hypothesis", "that", "the", "catalepsy", "that", "is", "produced", "by", "neuroleptics", "such", "as", "haloperidol", "is", "actually", "mediated", "by", "intrinsic", "central", "cholinergic", "systems", ".", "Alternatively", ",", "activation", "of", "central", "cholinergic", "systems", "could", "promote", "catalepsy", "by", "suppression", "of", "dopaminergic", "systems", "."]], "ner": [[[6, 6, "Chemical"], [78, 78, "Chemical"], [88, 88, "Chemical"], [112, 112, "Chemical"], [129, 129, "Chemical"], [9, 9, "Disease"], [23, 23, "Disease"], [39, 39, "Disease"], [51, 51, "Disease"], [69, 69, "Disease"], [91, 91, "Disease"], [106, 106, "Disease"], [121, 121, "Disease"], [148, 148, "Disease"], [47, 47, "Chemical"], [62, 62, "Chemical"], [36, 36, "Chemical"], [126, 126, "Chemical"], [85, 85, "Chemical"], [97, 97, "Chemical"], [102, 102, "Chemical"]]], "relations": [[[6, 6, 9, 9, "CID"], [6, 6, 23, 23, "CID"], [6, 6, 39, 39, "CID"], [6, 6, 51, 51, "CID"], [6, 6, 69, 69, "CID"], [6, 6, 91, 91, "CID"], [6, 6, 106, 106, "CID"], [6, 6, 121, 121, "CID"], [6, 6, 148, 148, "CID"], [78, 78, 9, 9, "CID"], [78, 78, 23, 23, "CID"], [78, 78, 39, 39, "CID"], [78, 78, 51, 51, "CID"], [78, 78, 69, 69, "CID"], [78, 78, 91, 91, "CID"], [78, 78, 106, 106, "CID"], [78, 78, 121, 121, "CID"], [78, 78, 148, 148, "CID"], [88, 88, 9, 9, "CID"], [88, 88, 23, 23, "CID"], [88, 88, 39, 39, "CID"], [88, 88, 51, 51, "CID"], [88, 88, 69, 69, "CID"], [88, 88, 91, 91, "CID"], [88, 88, 106, 106, "CID"], [88, 88, 121, 121, "CID"], [88, 88, 148, 148, "CID"], [112, 112, 9, 9, "CID"], [112, 112, 23, 23, "CID"], [112, 112, 39, 39, "CID"], [112, 112, 51, 51, "CID"], [112, 112, 69, 69, "CID"], [112, 112, 91, 91, "CID"], [112, 112, 106, 106, "CID"], [112, 112, 121, 121, "CID"], [112, 112, 148, 148, "CID"], [129, 129, 9, 9, "CID"], [129, 129, 23, 23, "CID"], [129, 129, 39, 39, "CID"], [129, 129, 51, 51, "CID"], [129, 129, 69, 69, "CID"], [129, 129, 91, 91, "CID"], [129, 129, 106, 106, "CID"], [129, 129, 121, 121, "CID"], [129, 129, 148, 148, "CID"], [47, 47, 9, 9, "CID"], [47, 47, 23, 23, "CID"], [47, 47, 39, 39, "CID"], [47, 47, 51, 51, "CID"], [47, 47, 69, 69, "CID"], [47, 47, 91, 91, "CID"], [47, 47, 106, 106, "CID"], [47, 47, 121, 121, "CID"], [47, 47, 148, 148, "CID"], [62, 62, 9, 9, "CID"], [62, 62, 23, 23, "CID"], [62, 62, 39, 39, "CID"], [62, 62, 51, 51, "CID"], [62, 62, 69, 69, "CID"], [62, 62, 91, 91, "CID"], [62, 62, 106, 106, "CID"], [62, 62, 121, 121, "CID"], [62, 62, 148, 148, "CID"]]], "clusters": [], "translated": "<0>氟哌啶醇</0> 诱发的<5>强直性昏厥</5>中胆碱能作用的证据。小鼠实验测试了先前的证据，即胆碱能系统的激活会促进<6>强直性昏厥</6>并且胆碱能机制需要完好无损才能完全表达<16>抗精神病药</16>-诱发<7>强直性昏厥</7>。当外周胆碱能受体被阻断时，大剂量的拟胆碱药<14>毛果芸香碱</14>可诱发<8>强直性昏厥</8>。低剂量的<15>毛果芸香碱</15>引起明显增强的<9>强直性昏厥</9>是由多巴胺能阻滞剂<1>氟哌啶醇</1>引起的。毒蕈碱受体阻滞剂<18>阿托品</18>可破坏<2>氟哌啶醇</2>-诱导的<10>强直性昏厥</10>。颅内注射<19>乙酰胆碱</19>-合成抑制剂<20>半胆碱</20>可预防通常由<3>氟哌啶醇</3>诱发的<11>强直性昏厥</11>。这些发现表明，<17>抗精神病药</17>（例如<4>氟哌啶醇</4>）产生的<12>强直性昏厥</12>实际上是由内在中枢胆碱能系统介导的假设。或者，中枢胆碱能系统的激活可以通过抑制多巴胺能系统促进<13>强直性昏厥</13>。", "revised": true}
{"doc_key": "6529939", "sentences": [["Alternating", "sinus", "rhythm", "and", "intermittent", "sinoatrial", "block", "induced", "by", "propranolol", ".", "Alternating", "sinus", "rhythm", "and", "intermittent", "sinoatrial", "(", "S", "-", "A", ")", "block", "was", "observed", "in", "a", "57", "-", "year", "-", "old", "woman", ",", "under", "treatment", "for", "angina", "with", "80", "mg", "propranolol", "daily", ".", "The", "electrocardiogram", "showed", "alternation", "of", "long", "and", "short", "P", "-", "P", "intervals", "and", "occasional", "pauses", ".", "These", "pauses", "were", "always", "preceded", "by", "the", "short", "P", "-", "P", "intervals", "and", "were", "usually", "followed", "by", "one", "or", "two", "P", "-", "P", "intervals", "of", "0", ".", "92", "-", "0", ".", "95", "s", "representing", "the", "basic", "sinus", "cycle", ".", "Following", "these", "basic", "sinus", "cycles", ",", "alternating", "rhythm", "started", "with", "the", "longer", "P", "-", "P", "interval", ".", "The", "long", "P", "-", "P", "intervals", "ranged", "between", "1", ".", "04", "-", "1", ".", "12", "s", "and", "the", "short", "P", "-", "P", "intervals", "between", "0", ".", "80", "-", "0", ".", "84", "s", ",", "respectively", ".", "The", "duration", "of", "the", "pauses", "were", "equal", "or", "almost", "equal", "to", "one", "short", "plus", "one", "long", "P", "-", "P", "interval", "or", "to", "twice", "the", "basic", "sinus", "cycle", ".", "In", "one", "recording", "a", "short", "period", "of", "regular", "sinus", "rhythm", "with", "intermittent", "2", "/", "1", "S", "-", "A", "block", "was", "observed", ".", "This", "short", "period", "of", "sinus", "rhythm", "was", "interrupted", "by", "sudden", "prolongation", "of", "the", "P", "-", "P", "interval", "starting", "the", "alternative", "rhythm", ".", "There", "were", "small", "changes", "in", "the", "shape", "of", "the", "P", "waves", "and", "P", "-", "R", "intervals", ".", "S", "-", "A", "conduction", "through", "two", "pathways", ",", "the", "first", "with", "2", "/", "1", "block", "the", "second", "having", "0", ".", "12", "-", "0", ".", "14", "s", "longer", "conduction", "time", "and", "with", "occasional", "2", "/", "1", "block", "was", "proposed", "for", "the", "explanation", "of", "the", "alternating", "P", "-", "P", "interval", "and", "other", "electrocardiographic", "features", "seen", ".", "Atropine", "1", "mg", "given", "intravenously", "resulted", "in", "shortening", "of", "all", "P", "-", "P", "intervals", "without", "changing", "the", "rhythm", ".", "The", "abnormal", "rhythm", "disappeared", "with", "the", "withdrawal", "of", "propranolol", "and", "when", "the", "drug", "was", "restarted", "a", "2", "/", "1", "S", "-", "A", "block", "was", "seen", ".", "This", "was", "accepted", "as", "evidence", "for", "propranolol", "being", "the", "cause", "of", "this", "conduction", "disorder", "."]], "ner": [[[9, 9, "Chemical"], [41, 41, "Chemical"], [321, 321, "Chemical"], [345, 345, "Chemical"], [0, 2, "Disease"], [11, 13, "Disease"], [105, 106, "Disease"], [5, 6, "Disease"], [16, 22, "Disease"], [194, 197, "Disease"], [332, 335, "Disease"], [294, 294, "Chemical"], [37, 37, "Disease"], [351, 352, "Disease"]]], "relations": [[[9, 9, 0, 2, "CID"], [9, 9, 11, 13, "CID"], [9, 9, 105, 106, "CID"], [41, 41, 0, 2, "CID"], [41, 41, 11, 13, "CID"], [41, 41, 105, 106, "CID"], [321, 321, 0, 2, "CID"], [321, 321, 11, 13, "CID"], [321, 321, 105, 106, "CID"], [345, 345, 0, 2, "CID"], [345, 345, 11, 13, "CID"], [345, 345, 105, 106, "CID"], [9, 9, 5, 6, "CID"], [9, 9, 16, 22, "CID"], [9, 9, 194, 197, "CID"], [9, 9, 332, 335, "CID"], [41, 41, 5, 6, "CID"], [41, 41, 16, 22, "CID"], [41, 41, 194, 197, "CID"], [41, 41, 332, 335, "CID"], [321, 321, 5, 6, "CID"], [321, 321, 16, 22, "CID"], [321, 321, 194, 197, "CID"], [321, 321, 332, 335, "CID"], [345, 345, 5, 6, "CID"], [345, 345, 16, 22, "CID"], [345, 345, 194, 197, "CID"], [345, 345, 332, 335, "CID"]]], "clusters": [], "translated": "<0>普萘洛尔</0>引起的<4>交替窦性心律</4>和间歇性<7>窦房传导阻滞</7>。<5>交替性窦性心律</5>和间歇性<8>窦房(S-A)传导阻滞</8>在一位57岁的女性身上观察到，她因<12>心绞痛</12>接受80mg<1>普萘洛尔</1>每天治疗。心电图显示 P-P 间期长短交替，偶有停顿。这些停顿之前总是有短的 P-P 间隔，通常紧随其后的是一个或两个 P-P 间隔为 0.92-0.95 秒代表基本的窦性循环。在这些基本的窦性周期之后，<6>交替节律</6>以较长的 P-P 间期开始。长 P-P 间隔介于1.04-1.12秒和0.80-0.84秒，分别。停顿的持续时间等于或几乎等于一短加一长 P-P 间隔或基本窦性周期的两倍。在一个记录中，观察到短时间的正常窦性心律伴间歇性2/1<9>S-A阻滞</9>。这段短暂的窦性心律被开始交替心律的 P-P 间期的突然延长所打断。P波和P-R间期的形状有微小变化。S-A传导通过两条路径，第一条以2/1阻断，第二条以0.12-0.14秒延长的传导时间和偶尔出现2/1阻滞被用于解释观察到的交替的 P-P 间期和心电图的其他特征。<11>阿托品</11>1mg静脉注射缩短了所有的 P-P 间期而不改变节律。停用<2>普萘洛尔</2>后异常节律消失，重新开始用药时出现2/1<10>S-A阻滞</10>。这被接受作为<3>普萘洛尔</3>导致此<13>传导障碍</13>的证据。", "revised": true}
{"doc_key": "6615679", "sentences": [["Intraoperative", "bradycardia", "and", "hypotension", "associated", "with", "timolol", "and", "pilocarpine", "eye", "drops", ".", "A", "69", "-", "yr", "-", "old", "man", ",", "who", "was", "concurrently", "being", "treated", "with", "pilocarpine", "nitrate", "and", "timolol", "maleate", "eye", "drops", ",", "developed", "a", "bradycardia", "and", "became", "hypotensive", "during", "halothane", "anaesthesia", ".", "Both", "timolol", "and", "pilocarpine", "were", "subsequently", "identified", "in", "a", "24", "-", "h", "collection", "of", "urine", ".", "Timolol", "(", "but", "not", "pilocarpine", ")", "was", "detected", "in", "a", "sample", "of", "plasma", "removed", "during", "surgery", ";", "the", "plasma", "concentration", "of", "timolol", "(", "2", ".", "6", "ng", "ml", "-", "1", ")", "was", "consistent", "with", "partial", "beta", "-", "adrenoceptor", "blockade", ".", "It", "is", "postulated", "that", "this", "action", "may", "have", "been", "enhanced", "during", "halothane", "anaesthesia", "with", "resultant", "bradycardia", "and", "hypotension", ".", "Pilocarpine", "may", "have", "had", "a", "contributory", "effect", "."]], "ner": [[[6, 6, "Chemical"], [29, 30, "Chemical"], [45, 45, "Chemical"], [60, 60, "Chemical"], [81, 81, "Chemical"], [1, 1, "Disease"], [36, 36, "Disease"], [115, 115, "Disease"], [8, 8, "Chemical"], [26, 27, "Chemical"], [47, 47, "Chemical"], [64, 64, "Chemical"], [119, 119, "Chemical"], [3, 3, "Disease"], [39, 39, "Disease"], [117, 117, "Disease"], [41, 41, "Chemical"], [111, 111, "Chemical"]]], "relations": [[[6, 6, 1, 1, "CID"], [6, 6, 36, 36, "CID"], [6, 6, 115, 115, "CID"], [29, 30, 1, 1, "CID"], [29, 30, 36, 36, "CID"], [29, 30, 115, 115, "CID"], [45, 45, 1, 1, "CID"], [45, 45, 36, 36, "CID"], [45, 45, 115, 115, "CID"], [60, 60, 1, 1, "CID"], [60, 60, 36, 36, "CID"], [60, 60, 115, 115, "CID"], [81, 81, 1, 1, "CID"], [81, 81, 36, 36, "CID"], [81, 81, 115, 115, "CID"], [8, 8, 1, 1, "CID"], [8, 8, 36, 36, "CID"], [8, 8, 115, 115, "CID"], [26, 27, 1, 1, "CID"], [26, 27, 36, 36, "CID"], [26, 27, 115, 115, "CID"], [47, 47, 1, 1, "CID"], [47, 47, 36, 36, "CID"], [47, 47, 115, 115, "CID"], [64, 64, 1, 1, "CID"], [64, 64, 36, 36, "CID"], [64, 64, 115, 115, "CID"], [119, 119, 1, 1, "CID"], [119, 119, 36, 36, "CID"], [119, 119, 115, 115, "CID"], [6, 6, 3, 3, "CID"], [6, 6, 39, 39, "CID"], [6, 6, 117, 117, "CID"], [29, 30, 3, 3, "CID"], [29, 30, 39, 39, "CID"], [29, 30, 117, 117, "CID"], [45, 45, 3, 3, "CID"], [45, 45, 39, 39, "CID"], [45, 45, 117, 117, "CID"], [60, 60, 3, 3, "CID"], [60, 60, 39, 39, "CID"], [60, 60, 117, 117, "CID"], [81, 81, 3, 3, "CID"], [81, 81, 39, 39, "CID"], [81, 81, 117, 117, "CID"], [8, 8, 3, 3, "CID"], [8, 8, 39, 39, "CID"], [8, 8, 117, 117, "CID"], [26, 27, 3, 3, "CID"], [26, 27, 39, 39, "CID"], [26, 27, 117, 117, "CID"], [47, 47, 3, 3, "CID"], [47, 47, 39, 39, "CID"], [47, 47, 117, 117, "CID"], [64, 64, 3, 3, "CID"], [64, 64, 39, 39, "CID"], [64, 64, 117, 117, "CID"], [119, 119, 3, 3, "CID"], [119, 119, 39, 39, "CID"], [119, 119, 117, 117, "CID"]]], "clusters": [], "translated": "术中<5>心动过缓</5>和<13>低血压</13>与<0>噻吗洛尔</0>和<8>毛果芸香碱</8>滴眼液有关。一名 69 岁的男性同时接受<9>硝酸毛果芸香碱</9>和<1>马来酸噻吗洛尔</1>滴眼液治疗，出现了<6>心动过缓</6>并成为<14>低血压</14>在<16>氟烷</16>麻醉期间。 <2>噻吗洛尔</2>和<10>毛果芸香碱</10>随后在24小时的尿液收集中被鉴定出来。<3>噻吗洛尔</3>（但不是<11>毛果芸香碱</11>）在手术期间取出的血浆样本中被检测到；<4>噻吗洛尔</4>的血浆浓度（2.6 ng ml-1）与部分β-肾上腺素能受体阻滞剂一致。据推测，这种作用在<17>氟烷</17>麻醉期间可能会增强，从而导致了<7>心动过缓 </7>和<15>低血压</15>。<12>毛果芸香碱</12>可能有一定的促进作用。", "revised": true}
{"doc_key": "6299641", "sentences": [["Evidence", "for", "cardiac", "beta", "2", "-", "adrenoceptors", "in", "man", ".", "We", "compared", "the", "effects", "of", "single", "doses", "of", "50", "mg", "atenolol", "(", "cardioselective", ")", ",", "40", "mg", "propranolol", "(", "nonselective", ")", ",", "and", "placebo", "on", "both", "exercise", "-", "and", "isoproterenol", "-", "induced", "tachycardia", "in", "two", "experiments", "involving", "nine", "normal", "subjects", ".", "Maximal", "exercise", "heart", "rate", "was", "reduced", "from", "187", "+", "/", "-", "4", "(", "SEM", ")", "after", "placebo", "to", "146", "+", "/", "-", "7", "bpm", "after", "atenolol", "and", "138", "+", "/", "-", "6", "bpm", "after", "propranolol", ",", "but", "there", "were", "no", "differences", "between", "the", "drugs", ".", "The", "effects", "on", "isoproterenol", "tachycardia", "were", "determined", "before", "and", "after", "atropine", "(", "0", ".", "04", "mg", "/", "kg", "IV", ")", ".", "Isoproterenol", "sensitivity", "was", "determined", "as", "the", "intravenous", "dose", "that", "increased", "heart", "rate", "by", "25", "bpm", "(", "CD25", ")", "and", "this", "was", "increased", "from", "1", ".", "8", "+", "/", "-", "0", ".", "3", "micrograms", "after", "placebo", "to", "38", ".", "9", "+", "/", "-", "8", ".", "3", "micrograms", "after", "propranolol", "and", "8", ".", "3", "+", "/", "-", "1", ".", "7", "micrograms", "after", "atenolol", ".", "The", "difference", "in", "the", "effects", "of", "the", "two", "was", "significant", ".", "After", "atropine", "the", "CD25", "was", "unchanged", "after", "placebo", "(", "2", ".", "3", "+", "/", "-", "0", ".", "3", "micrograms", ")", "and", "atenolol", "(", "7", ".", "7", "+", "/", "-", "1", ".", "3", "micrograms", ")", ";", "it", "was", "reduced", "after", "propranolol", "(", "24", ".", "8", "+", "/", "-", "5", ".", "0", "micrograms", ")", ",", "but", "remained", "different", "from", "atenolol", ".", "This", "change", "with", "propranolol", "sensitivity", "was", "calculated", "as", "the", "apparent", "Ka", ",", "this", "was", "unchanged", "by", "atropine", "(", "11", ".", "7", "+", "/", "-", "2", ".", "1", "and", "10", ".", "1", "+", "/", "-", "2", ".", "5", "ml", "/", "ng", ")", ".", "These", "data", "are", "consistent", "with", "the", "hypothesis", "that", "exercise", "-", "induced", "tachycardia", "results", "largely", "from", "beta", "1", "-", "receptor", "activation", "that", "is", "blocked", "by", "both", "cardioselective", "and", "nonselective", "drugs", ",", "whereas", "isoproterenol", "activates", "both", "beta", "1", "-", "and", "beta", "2", "-", "receptors", "so", "that", "after", "cardioselective", "blockade", "there", "remains", "a", "beta", "2", "-", "component", "that", "can", "be", "blocked", "with", "a", "nonselective", "drug", ".", "While", "there", "appear", "to", "be", "beta", "2", "-", "receptors", "in", "the", "human", "heart", ",", "their", "physiologic", "or", "pathologic", "roles", "remain", "to", "be", "defined", "."]], "ner": [[[39, 39, "Chemical"], [99, 99, "Chemical"], [117, 117, "Chemical"], [322, 322, "Chemical"], [42, 42, "Disease"], [100, 100, "Disease"], [302, 302, "Disease"], [20, 20, "Chemical"], [76, 76, "Chemical"], [177, 177, "Chemical"], [211, 211, "Chemical"], [247, 247, "Chemical"], [27, 27, "Chemical"], [85, 85, "Chemical"], [164, 164, "Chemical"], [229, 229, "Chemical"], [252, 252, "Chemical"], [106, 106, "Chemical"], [191, 191, "Chemical"], [265, 265, "Chemical"]]], "relations": [[[39, 39, 42, 42, "CID"], [39, 39, 100, 100, "CID"], [39, 39, 302, 302, "CID"], [99, 99, 42, 42, "CID"], [99, 99, 100, 100, "CID"], [99, 99, 302, 302, "CID"], [117, 117, 42, 42, "CID"], [117, 117, 100, 100, "CID"], [117, 117, 302, 302, "CID"], [322, 322, 42, 42, "CID"], [322, 322, 100, 100, "CID"], [322, 322, 302, 302, "CID"]]], "clusters": [], "translated": "人类心脏 β2-肾上腺素能受体的证据。我们比较了单剂量 50 mg <7>阿替洛尔</7>（心脏选择性）、40 mg <12>普萘洛尔</12>（非选择性）和安慰剂对运动和<0>异丙肾上腺素</0>诱发的<4>心动过速</4>的影响，在涉及9名正常受试者的两个实验中。最大运动心率从安慰剂组后的187 +/- 4 (SEM) 降低到<8>阿替洛尔</8>后的146 +/- 7 bpm和<13>普萘洛尔</13>后的138 +/- 6 bpm，但药物之间没有区别。<1>异丙肾上腺素</1><5>心动过速</5>的影响在<17>阿托品</17>（0.04mg/kg IV）前后测定。<2>异丙肾上腺素</2>敏感性被确定为使心率增加25 bpm (CD25) 的静脉内剂量，并且该剂量从安慰剂后的1.8 +/- 0.3微克至<14>普萘洛尔</14>后的38.9 +/- 8.3微克和<9>阿替洛尔</9>后的8.3 +/- 1.7微克。两者的效果差异显着。<18>阿托品</18>后CD25在安慰剂（2.3 +/- 0.3微克）和<10>阿替洛尔</10>（7.7 +/- 1.3微克）后没有变化；<15>普萘洛尔</15>后有所降低（24.8 +/- 5.0微克），但与<11>阿替洛尔</11>仍不同。<16>普萘洛尔</16>敏感性的这种变化被计算为表观Ka，<19>阿托品</19>没有改变（11.7 +/- 2.1和10.1 +/- 2.5毫升/纳克）。这些数据与以下假设一致：运动引起的<6>心动过速</6>主要是由β1受体激活引起的，该受体被心脏选择性和非选择性药物阻断，而<3>异丙肾上腺素</3>激活β1和β2受体，因此在心脏选择性阻滞后，仍然存在可用非选择性药物阻断的beta 2 -成分。虽然人类心脏中似乎存在β2受体，但它们的生理或病理作用仍有待确定。", "revised": true}
{"doc_key": "4631913", "sentences": [["Effect", "of", "vincristine", "sulfate", "on", "Pseudomonas", "infections", "in", "monkeys", ".", "In", "rhesus", "monkeys", ",", "intravenous", "challenge", "with", "0", ".", "6", "x", "10", "(", "10", ")", "to", "2", ".", "2", "x", "10", "(", "10", ")", "Pseudomonas", "aeruginosa", "organisms", "caused", "acute", "illness", "of", "4", "to", "5", "days", "'", "duration", "with", "spontaneous", "recovery", "in", "13", "of", "15", "monkeys", ";", "blood", "cultures", "became", "negative", "3", "to", "17", "days", "after", "challenge", ".", "Leukocytosis", "was", "observed", "in", "all", "monkeys", ".", "Intravenous", "or", "intratracheal", "inoculation", "of", "2", ".", "0", "to", "2", ".", "5", "mg", "of", "vincristine", "sulfate", "was", "followed", "by", "leukopenia", "in", "4", "to", "5", "days", ".", "Intravenous", "inoculation", "of", "4", ".", "2", "x", "10", "(", "10", ")", "to", "7", ".", "8", "x", "10", "(", "10", ")", "pyocin", "type", "6", "Pseudomonas", "organisms", "in", "monkeys", "given", "vincristine", "sulfate", "4", "days", "previously", "resulted", "in", "fatal", "infection", "in", "11", "of", "14", "monkeys", ",", "whereas", "none", "of", "four", "receiving", "Pseudomonas", "alone", "died", ".", "These", "studies", "suggest", "that", "an", "antimetabolite", "-", "induced", "leukopenia", "predisposes", "to", "severe", "Pseudomonas", "sepsis", "and", "that", "such", "monkeys", "may", "serve", "as", "a", "biological", "model", "for", "study", "of", "comparative", "efficacy", "of", "antimicrobial", "agents", "."]], "ner": [[[2, 3, "Chemical"], [88, 89, "Chemical"], [128, 129, "Chemical"], [5, 6, "Disease"], [93, 93, "Disease"], [160, 160, "Disease"], [165, 165, "Disease"], [67, 67, "Disease"], [136, 136, "Disease"]]], "relations": [[[2, 3, 5, 6, "CID"], [88, 89, 5, 6, "CID"], [128, 129, 5, 6, "CID"], [2, 3, 93, 93, "CID"], [2, 3, 160, 160, "CID"], [88, 89, 93, 93, "CID"], [88, 89, 160, 160, "CID"], [128, 129, 93, 93, "CID"], [128, 129, 160, 160, "CID"], [2, 3, 165, 165, "CID"], [88, 89, 165, 165, "CID"], [128, 129, 165, 165, "CID"]]], "clusters": [], "translated": "<0>硫酸长春新碱</0>对猴子<3>假单胞菌感染</3>的影响。在恒河猴中，用0.6x10(10)至2.2x10(10)个铜绿假单胞菌生物体导致持续4至5天的急性疾病，13只猴子自愈，而其他猴子则 spontaneous recovery；攻击后3至17天，血培养呈阴性。所有猴子中都出现了<7>白细胞增多</7>现象。接种2.0到2.5毫克的<1>硫酸长春新碱</1>，在4至5天内，会出现<4>白细胞减少</4>现象。静脉接种4.2x10(10)至7.8x10(10)个假单胞菌6型绿脓菌菌株时，4天前接种<2>硫酸长春新碱</2>的猴子中11只猴子致命<8>感染</8>，而接受假单胞菌的四只猴子没有一只死亡。这些研究表明，抗代谢物诱导的<5>白细胞减少症</5>易患严重的假单胞菌<6>败血症</6>，而这些猴子可以作为研究抗菌药物疗效比较的生物模型。", "revised": true}
{"doc_key": "6627074", "sentences": [["Succinylcholine", "apnoea", ":", "attempted", "reversal", "with", "anticholinesterases", ".", "Anticholinesterases", "were", "administered", "in", "an", "attempt", "to", "antagonize", "prolonged", "neuromuscular", "blockade", "following", "the", "administration", "of", "succinylcholine", "in", "a", "patient", "later", "found", "to", "be", "homozygous", "for", "atypical", "plasma", "cholinesterase", ".", "Edrophonium", "10", "mg", ",", "given", "74", "min", "after", "succinylcholine", ",", "when", "train", "-", "of", "-", "four", "stimulation", "was", "characteristic", "of", "phase", "II", "block", ",", "produced", "partial", "antagonism", "which", "was", "not", "sustained", ".", "Repeated", "doses", "of", "edrophonium", "to", "70", "mg", "and", "neostigmine", "to", "2", ".", "5", "mg", "did", "not", "antagonize", "or", "augment", "the", "block", ".", "Spontaneous", "respiration", "recommenced", "200", "min", "after", "succinylcholine", "administration", ".", "It", "is", "concluded", "that", "anticholinesterases", "are", "only", "partially", "effective", "in", "restoring", "neuromuscular", "function", "in", "succinylcholine", "apnoea", "despite", "muscle", "twitch", "activity", "typical", "of", "phase", "II", "block", "."]], "ner": [[[0, 0, "Chemical"], [23, 23, "Chemical"], [45, 45, "Chemical"], [97, 97, "Chemical"], [114, 114, "Chemical"], [1, 1, "Disease"], [115, 115, "Disease"], [17, 18, "Disease"], [37, 37, "Chemical"], [72, 72, "Chemical"], [77, 77, "Chemical"]]], "relations": [[[0, 0, 1, 1, "CID"], [0, 0, 115, 115, "CID"], [23, 23, 1, 1, "CID"], [23, 23, 115, 115, "CID"], [45, 45, 1, 1, "CID"], [45, 45, 115, 115, "CID"], [97, 97, 1, 1, "CID"], [97, 97, 115, 115, "CID"], [114, 114, 1, 1, "CID"], [114, 114, 115, 115, "CID"]]], "clusters": [], "translated": " <0>琥珀胆碱</0> <5>呼吸暂停</5>：尝试用抗胆碱酯酶逆转。抗胆碱酯酶在<4>琥珀酰胆碱</4><6>呼吸暂停</6>中仅部分有效恢复神经肌肉功能，尽管II期阻滞典型的肌肉抽搐活动。在该患者接受<1>琥珀酰胆碱</1>后，给予抗胆碱酯酶以对抗长时间<7>神经肌肉阻滞</7>，此患者被发现是非典型的血浆胆碱酯酶纯合子。接受<2>琥珀酰胆碱</2>74分钟后，当train-of-four刺激表现为II期阻滞时，给予<8>Edrophonium</8> 10 mg ，产生了部分拮抗作用，但是不持续。多次重复给予<9>edrophonium</9>至70mg和<10>新斯的明</10>至2.5mg均未拮抗或增强神经肌肉阻滞。自<3>琥珀胆碱</3>给予之后200分钟，自主呼吸恢复。", "revised": true}
{"doc_key": "6585590", "sentences": [["Antitumor", "effect", ",", "cardiotoxicity", ",", "and", "nephrotoxicity", "of", "doxorubicin", "in", "the", "IgM", "solid", "immunocytoma", "-", "bearing", "LOU", "/", "M", "/", "WSL", "rat", ".", "Antitumor", "activity", ",", "cardiotoxicity", ",", "and", "nephrotoxicity", "induced", "by", "doxorubicin", "were", "studied", "in", "LOU", "/", "M", "/", "WSL", "inbred", "rats", "each", "bearing", "a", "transplantable", "solid", "IgM", "immunocytoma", ".", "Animals", "with", "a", "tumor", "(", "diameter", ",", "15", ".", "8", "+", "/", "-", "3", ".", "3", "mm", ")", "were", "treated", "with", "iv", "injections", "of", "doxorubicin", "on", "5", "consecutive", "days", ",", "followed", "by", "1", "weekly", "injection", "for", "7", "weeks", "(", "dose", "range", ",", "0", ".", "015", "-", "4", ".", "0", "mg", "/", "kg", "body", "wt", ")", ".", "Tumor", "regression", "was", "observed", "with", "0", ".", "5", "mg", "doxorubicin", "/", "kg", ".", "Complete", "disappearance", "of", "the", "tumor", "was", "induced", "with", "1", ".", "0", "mg", "doxorubicin", "/", "kg", ".", "Histologic", "evidence", "of", "cardiotoxicity", "scored", "as", "grade", "III", "was", "only", "observed", "at", "a", "dose", "of", "1", ".", "0", "mg", "doxorubicin", "/", "kg", ".", "Light", "microscopic", "evidence", "of", "renal", "damage", "was", "seen", "above", "a", "dose", "of", "0", ".", "5", "mg", "doxorubicin", "/", "kg", ",", "which", "resulted", "in", "albuminuria", "and", "very", "low", "serum", "albumin", "levels", ".", "In", "the", "group", "that", "received", "1", ".", "0", "mg", "doxorubicin", "/", "kg", ",", "the", "serum", "albumin", "level", "decreased", "from", "33", ".", "6", "+", "/", "-", "4", ".", "1", "to", "1", ".", "5", "+", "/", "-", "0", ".", "5", "g", "/", "liter", ".", "Ascites", "and", "hydrothorax", "were", "observed", "simultaneously", ".", "The", "same", "experiments", "were", "performed", "with", "non", "-", "tumor", "-", "bearing", "rats", ",", "in", "which", "no", "major", "differences", "were", "observed", ".", "In", "conclusion", ",", "antitumor", "activity", ",", "cardiotoxicity", ",", "and", "nephrotoxicity", "were", "studied", "simultaneously", "in", "the", "same", "LOU", "/", "M", "/", "WSL", "rat", ".", "Albuminuria", "due", "to", "renal", "damage", "led", "to", "extremely", "low", "serum", "albumin", "levels", ",", "so", "ascites", "and", "hydrothorax", "were", "not", "necessarily", "a", "consequence", "of", "the", "observed", "cardiomyopathy", "."]], "ner": [[[8, 8, "Chemical"], [32, 32, "Chemical"], [75, 75, "Chemical"], [116, 116, "Chemical"], [132, 132, "Chemical"], [155, 155, "Chemical"], [175, 175, "Chemical"], [199, 199, "Chemical"], [182, 182, "Disease"], [283, 283, "Disease"], [232, 232, "Disease"], [297, 297, "Disease"], [234, 234, "Disease"], [299, 299, "Disease"], [3, 3, "Disease"], [26, 26, "Disease"], [139, 139, "Disease"], [266, 266, "Disease"], [6, 6, "Disease"], [29, 29, "Disease"], [163, 164, "Disease"], [269, 269, "Disease"], [286, 287, "Disease"], [54, 54, "Disease"], [107, 107, "Disease"], [124, 124, "Disease"], [247, 247, "Disease"], [308, 308, "Disease"]]], "relations": [[[8, 8, 182, 182, "CID"], [8, 8, 283, 283, "CID"], [32, 32, 182, 182, "CID"], [32, 32, 283, 283, "CID"], [75, 75, 182, 182, "CID"], [75, 75, 283, 283, "CID"], [116, 116, 182, 182, "CID"], [116, 116, 283, 283, "CID"], [132, 132, 182, 182, "CID"], [132, 132, 283, 283, "CID"], [155, 155, 182, 182, "CID"], [155, 155, 283, 283, "CID"], [175, 175, 182, 182, "CID"], [175, 175, 283, 283, "CID"], [199, 199, 182, 182, "CID"], [199, 199, 283, 283, "CID"], [8, 8, 232, 232, "CID"], [8, 8, 297, 297, "CID"], [32, 32, 232, 232, "CID"], [32, 32, 297, 297, "CID"], [75, 75, 232, 232, "CID"], [75, 75, 297, 297, "CID"], [116, 116, 232, 232, "CID"], [116, 116, 297, 297, "CID"], [132, 132, 232, 232, "CID"], [132, 132, 297, 297, "CID"], [155, 155, 232, 232, "CID"], [155, 155, 297, 297, "CID"], [175, 175, 232, 232, "CID"], [175, 175, 297, 297, "CID"], [199, 199, 232, 232, "CID"], [199, 199, 297, 297, "CID"], [8, 8, 234, 234, "CID"], [8, 8, 299, 299, "CID"], [32, 32, 234, 234, "CID"], [32, 32, 299, 299, "CID"], [75, 75, 234, 234, "CID"], [75, 75, 299, 299, "CID"], [116, 116, 234, 234, "CID"], [116, 116, 299, 299, "CID"], [132, 132, 234, 234, "CID"], [132, 132, 299, 299, "CID"], [155, 155, 234, 234, "CID"], [155, 155, 299, 299, "CID"], [175, 175, 234, 234, "CID"], [175, 175, 299, 299, "CID"], [199, 199, 234, 234, "CID"], [199, 199, 299, 299, "CID"]]], "clusters": [], "translated": "<0>多柔比星</0>对携带IgM固体免疫细胞瘤LOU/M/WSL大鼠的抗肿瘤作用、<14>心脏毒性</14>和<18>肾毒性</18>进行了研究。在LOU/M/WSL近交系大鼠中研究了由<1>阿霉素</1>诱导的抗肿瘤活性、<15>心脏毒性</15>和<19>肾毒性</19>，每只大鼠均携带可移植的固体IgM免疫细胞瘤。患有<23>肿瘤</23>（直径，15.8+/-3.3 mm）的动物连续5天静脉注射<2>多柔比星</2>，随后每周注射1次7周（剂量范围，0.015-4.0毫克/千克体重）。观察到在0.5毫克<3>多柔比星</3>/千克剂量下，<24>肿瘤</24>消退。使用1.0毫克<4>多柔比星</4>/千克即可完全消除<25>肿瘤</25>。仅在1.0毫克<5>多柔比星</5>/千克剂量下观察到评分为III级的<16>心脏毒性</16>。在使用0.5毫克<6>多柔比星</6>/千克以上的剂量下，可看到有光学显微镜证据的<20>肾损伤</20>。这导致了<8>白蛋白尿</8>和极低的血清白蛋白水平。在接受1.0毫克<7>阿霉素</7>/千克的组中，血清白蛋白水平从33.6+/-4.1降至1.5+/-0.5 g/升。同时观察到<10>腹水</10>和<12>胸水</12>。对于未携带<26>肿瘤</26>的大鼠进行了相同的实验，未观察到任何重大差异。总之，在同一只LOU/M/WSL大鼠中同时研究了抗肿瘤活性、<17>心脏毒性</17>和<21>肾毒性</21>。由于<22>肾损害</22>引起的<9>白蛋白尿</9>导致血清白蛋白水平极低，所以<11>腹水</11>和<13>胸水</13>不一定是观察到的<27>心肌病</27>的后果。", "revised": true}
{"doc_key": "6884395", "sentences": [["Nontraumatic", "dissecting", "aneurysm", "of", "the", "basilar", "artery", ".", "A", "case", "of", "nontraumatic", "dissecting", "aneurysm", "of", "the", "basilar", "artery", "in", "association", "with", "hypertension", ",", "smoke", ",", "and", "oral", "contraceptives", "is", "reported", "in", "a", "young", "female", "patient", "with", "a", "locked", "-", "in", "syndrome", "."]], "ner": [[[26, 27, "Chemical"], [1, 2, "Disease"], [12, 13, "Disease"], [21, 21, "Disease"], [37, 40, "Disease"]]], "relations": [[[26, 27, 1, 2, "CID"], [26, 27, 12, 13, "CID"]]], "clusters": [], "translated": "基底动脉的非创伤性<1>夹层动脉瘤</1>。一例非创伤性<2>基底动脉夹层动脉瘤</2>与<3>高血压</3>、吸烟和<0>口服避孕药</0>相关的一例年轻女性患者报告<4>闭锁综合症</4>。", "revised": true}
{"doc_key": "6673474", "sentences": [["Hemodynamics", "and", "myocardial", "metabolism", "under", "deliberate", "hypotension", ".", "An", "experimental", "study", "in", "dogs", ".", "Coronary", "blood", "flow", ",", "cardiac", "work", "and", "metabolism", "were", "studied", "in", "dogs", "under", "sodium", "nitroprusside", "(", "SNP", ")", "and", "trimetaphan", "(", "TMP", ")", "deliberate", "hypotension", "(", "20", "%", "and", "40", "%", "mean", "pressure", "decrease", "from", "baseline", ")", ".", "Regarding", "the", "effects", "of", "drug", "-", "induced", "hypotension", "on", "coronary", "blood", "flow", ",", "aortic", "and", "coronary", "sinus", "metabolic", "data", "(", "pH", ",", "pO2", ",", "pCO2", ")", "we", "could", "confirm", "that", "nitroprusside", "hypotension", "could", "be", "safely", "used", "to", "30", "%", "mean", "blood", "pressure", "decrease", "from", "control", ",", "trimetaphan", "hypotension", "to", "20", "%", "mean", "blood", "pressure", "decrease", ".", "Cardiac", "work", "was", "significantly", "reduced", "during", "SNP", "hypotension", ".", "Myocardial", "O2", "consumption", "and", "O2", "availability", "were", "directly", "dependent", "on", "the", "coronary", "perfusion", ".", "Careful", "invasive", "monitoring", "of", "the", "blood", "pressure", ",", "blood", "gases", "and", "of", "the", "ECG", "ST", "-", "T", "segment", "is", "mandatory", "."]], "ner": [[[27, 28, "Chemical"], [30, 30, "Chemical"], [82, 82, "Chemical"], [114, 114, "Chemical"], [6, 6, "Disease"], [38, 38, "Disease"], [59, 59, "Disease"], [83, 83, "Disease"], [99, 99, "Disease"], [115, 115, "Disease"], [33, 33, "Chemical"], [35, 35, "Chemical"], [98, 98, "Chemical"], [118, 118, "Chemical"], [121, 121, "Chemical"]]], "relations": [[[27, 28, 6, 6, "CID"], [27, 28, 38, 38, "CID"], [27, 28, 59, 59, "CID"], [27, 28, 83, 83, "CID"], [27, 28, 99, 99, "CID"], [27, 28, 115, 115, "CID"], [30, 30, 6, 6, "CID"], [30, 30, 38, 38, "CID"], [30, 30, 59, 59, "CID"], [30, 30, 83, 83, "CID"], [30, 30, 99, 99, "CID"], [30, 30, 115, 115, "CID"], [82, 82, 6, 6, "CID"], [82, 82, 38, 38, "CID"], [82, 82, 59, 59, "CID"], [82, 82, 83, 83, "CID"], [82, 82, 99, 99, "CID"], [82, 82, 115, 115, "CID"], [114, 114, 6, 6, "CID"], [114, 114, 38, 38, "CID"], [114, 114, 59, 59, "CID"], [114, 114, 83, 83, "CID"], [114, 114, 99, 99, "CID"], [114, 114, 115, 115, "CID"], [33, 33, 6, 6, "CID"], [33, 33, 38, 38, "CID"], [33, 33, 59, 59, "CID"], [33, 33, 83, 83, "CID"], [33, 33, 99, 99, "CID"], [33, 33, 115, 115, "CID"], [35, 35, 6, 6, "CID"], [35, 35, 38, 38, "CID"], [35, 35, 59, 59, "CID"], [35, 35, 83, 83, "CID"], [35, 35, 99, 99, "CID"], [35, 35, 115, 115, "CID"], [98, 98, 6, 6, "CID"], [98, 98, 38, 38, "CID"], [98, 98, 59, 59, "CID"], [98, 98, 83, 83, "CID"], [98, 98, 99, 99, "CID"], [98, 98, 115, 115, "CID"]]], "clusters": [], "translated": "故意<4>低血压</4>下的血流动力学和心肌代谢。狗的实验研究。在<0>硝普钠</0>（<1>SNP</1>）和<10>曲美他芬</10>（<11>TMP</11>）故意<5>低血压</5>（平均压力从基线下降20%和40%）。关于药物引起的<6>低血压</6>对冠状动脉血流、主动脉和冠状窦代谢数据（pH、pO2、pCO2）的影响，我们可以确认<2>硝普钠</2><7>低血压</7>可安全用于控制平均血压下降30%，<12>曲美他芬</12><8>低血压</8>平均血压下降20%。 <3>SNP</3><9>低血压</9>期间心脏做功显着降低。心肌<13>O2</13>消耗和<14>O2</14>可用性直接取决于冠状动脉灌注。必须对血压、血气和ECG ST-T 段进行仔细的有创监测。", "revised": true}
{"doc_key": "6687006", "sentences": [["Evidence", "for", "a", "selective", "brain", "noradrenergic", "involvement", "in", "the", "locomotor", "stimulant", "effects", "of", "amphetamine", "in", "the", "rat", ".", "Male", "rats", "received", "the", "noradrenaline", "neurotoxin", "DSP4", "(", "50", "mg", "/", "kg", ")", "7", "days", "prior", "to", "injection", "of", "D", "-", "amphetamine", "(", "10", "or", "40", "mumol", "/", "kg", "i", ".", "p", ".", ")", ".", "The", "hyperactivity", "induced", "by", "D", "-", "amphetamine", "(", "10", "mumol", "/", "kg", ")", "was", "significantly", "reduced", "by", "DSP4", "pretreatment", ".", "However", ",", "the", "increased", "rearings", "and", "the", "amphetamine", "-", "induced", "stereotypies", "were", "not", "blocked", "by", "pretreatment", "with", "DSP4", ".", "The", "reduction", "of", "amphetamine", "hyperactivity", "induced", "by", "DSP4", "was", "blocked", "by", "pretreatment", "with", "the", "noradrenaline", "-", "uptake", "blocking", "agent", ",", "desipramine", ",", "which", "prevents", "the", "neurotoxic", "action", "of", "DSP4", ".", "The", "present", "results", "suggest", "a", "selective", "involvement", "of", "central", "noradrenergic", "neurones", "in", "the", "locomotor", "stimulant", "effect", "of", "amphetamine", "in", "the", "rat", "."]], "ner": [[[37, 39, "Chemical"], [57, 59, "Chemical"], [54, 54, "Disease"], [96, 96, "Disease"], [13, 13, "Chemical"], [80, 80, "Chemical"], [95, 95, "Chemical"], [139, 139, "Chemical"], [83, 83, "Disease"], [117, 117, "Disease"], [22, 22, "Chemical"], [106, 106, "Chemical"], [24, 24, "Chemical"], [70, 70, "Chemical"], [90, 90, "Chemical"], [99, 99, "Chemical"], [120, 120, "Chemical"], [112, 112, "Chemical"]]], "relations": [[[37, 39, 54, 54, "CID"], [37, 39, 96, 96, "CID"], [57, 59, 54, 54, "CID"], [57, 59, 96, 96, "CID"]]], "clusters": [], "translated": "选择性的大脑去甲肾上腺素能参与 <4>苯丙胺</4>在大鼠中的运动兴奋作用的证据。雄性大鼠接受 <10>去甲肾上腺素</10>神经毒素<12>DSP4</12>（50 mg/kg）注射前7天<0>D-安非他明</0>（10或40 mumol/kg i.p.）。<1>D-苯丙胺</1>（10 mumol/kg）诱导的<2>多动</2>经 <13>DSP4</13> 预处理后显着降低。然而，饲养增加和<5>苯丙胺</5>诱导的<8>刻板印象</8>未被 <14>DSP4</14> 预处理所阻止。 <15>DSP4</15> 诱导的<6>苯丙胺</6> <3>多动性</3> 的减少被可以预防<16>DSP4</16>神经毒性作用的<9>神经毒素</9>抑制剂，<11>去甲肾上腺素</11>-摄取阻断剂<17>地昔帕明</17>预处理所阻断。目前的结果表明，中枢的去甲肾上腺素能神经元选择性地参与<7>安非他明</7>在大鼠中的运动兴奋作用。", "revised": true}
{"doc_key": "6695685", "sentences": [["Accelerated", "junctional", "rhythms", "during", "oral", "verapamil", "therapy", ".", "This", "study", "examined", "the", "frequency", "of", "atrioventricular", "(", "AV", ")", "dissociation", "and", "accelerated", "junctional", "rhythms", "in", "59", "patients", "receiving", "oral", "verapamil", ".", "Accelerated", "junctional", "rhythms", "and", "AV", "dissociation", "were", "frequent", "in", "patients", "with", "supraventricular", "tachyarrhythmias", ",", "particularly", "AV", "nodal", "reentry", ".", "Verapamil", "administration", "to", "these", "patients", "led", "to", "an", "asymptomatic", "increase", "in", "activity", "of", "these", "junctional", "pacemakers", ".", "In", "patients", "with", "various", "chest", "pain", "syndromes", ",", "verapamil", "neither", "increased", "the", "frequency", "of", "junctional", "rhythms", "nor", "suppressed", "their", "role", "as", "escape", "rhythms", "under", "physiologically", "appropriate", "circumstances", "."]], "ner": [[[5, 5, "Chemical"], [28, 28, "Chemical"], [49, 49, "Chemical"], [74, 74, "Chemical"], [0, 2, "Disease"], [20, 22, "Disease"], [30, 32, "Disease"], [41, 42, "Disease"], [70, 71, "Disease"]]], "relations": [[[5, 5, 0, 2, "CID"], [5, 5, 20, 22, "CID"], [5, 5, 30, 32, "CID"], [28, 28, 0, 2, "CID"], [28, 28, 20, 22, "CID"], [28, 28, 30, 32, "CID"], [49, 49, 0, 2, "CID"], [49, 49, 20, 22, "CID"], [49, 49, 30, 32, "CID"], [74, 74, 0, 2, "CID"], [74, 74, 20, 22, "CID"], [74, 74, 30, 32, "CID"]]], "clusters": [], "translated": "口服<0>维拉帕米</0>治疗期间<4>加速连接节律</4>。这项研究检查了59名接受口服<1>维拉帕米</1>治疗的患者的房室(AV)分离频率和<5>加速连接节律</5>。在<7>室上性心动过速</7>患者中，<6>加速交界节律</6>和房室分离很常见，特别是房室结折返。在这些患者中，<2>维拉帕米</2>的使用导致这些连接起搏器的活动无症状增加。在患有各种<8>胸痛</8>综合征的患者中，<3>维拉帕米</3>既没有增加连接性节律的频率，也没有抑制它们在生理上适当的情况下作为逃逸节律的作用。", "revised": true}
{"doc_key": "2718706", "sentences": [["Deliberate", "hypotension", "induced", "by", "labetalol", "with", "halothane", ",", "enflurane", "or", "isoflurane", "for", "middle", "-", "ear", "surgery", ".", "The", "feasibility", "of", "using", "labetalol", ",", "an", "alpha", "-", "and", "beta", "-", "adrenergic", "blocking", "agent", ",", "as", "a", "hypotensive", "agent", "in", "combination", "with", "inhalation", "anaesthetics", "(", "halothane", ",", "enflurane", "or", "isoflurane", ")", "was", "studied", "in", "23", "adult", "patients", "undergoing", "middle", "-", "ear", "surgery", ".", "The", "mean", "arterial", "pressure", "was", "decreased", "from", "86", "+", "/", "-", "5", "(", "s", ".", "e", ".", "mean", ")", "mmHg", "to", "52", "+", "/", "-", "1", "mmHg", "(", "11", ".", "5", "+", "/", "-", "0", ".", "7", "to", "6", ".", "9", "+", "/", "-", "0", ".", "1", "kPa", ")", "for", "98", "+", "/", "-", "10", "min", "in", "the", "halothane", "(", "H", ")", "group", ",", "from", "79", "+", "/", "-", "5", "to", "53", "+", "/", "-", "1", "mmHg", "(", "10", ".", "5", "+", "/", "-", "0", ".", "7", "to", "7", ".", "1", "+", "/", "-", "0", ".", "1", "kPa", ")", "for", "129", "+", "/", "-", "11", "min", "in", "the", "enflurane", "(", "E", ")", "group", ",", "and", "from", "80", "+", "/", "-", "4", "to", "49", "+", "/", "-", "1", "mmHg", "(", "10", ".", "7", "+", "/", "-", "0", ".", "5", "to", "6", ".", "5", "+", "/", "-", "0", ".", "1", "kPa", ")", "for", "135", "+", "/", "-", "15", "min", "in", "the", "isoflurane", "(", "I", ")", "group", ".", "The", "mean", "H", "concentration", "during", "hypotension", "in", "the", "inspiratory", "gas", "was", "0", ".", "7", "+", "/", "-", "0", ".", "1", "vol", "%", ",", "the", "mean", "E", "concentration", "1", ".", "6", "+", "/", "-", "0", ".", "2", "vol", "%", ",", "and", "the", "mean", "I", "concentration", "1", ".", "0", "+", "/", "-", "0", ".", "1", "vol", "%", ".", "In", "addition", ",", "the", "patients", "received", "fentanyl", "and", "d", "-", "tubocurarine", ".", "The", "initial", "dose", "of", "labetalol", "for", "lowering", "blood", "pressure", "was", "similar", ",", "0", ".", "52", "-", "0", ".", "59", "mg", "/", "kg", ",", "in", "all", "the", "groups", ".", "During", "hypotension", ",", "the", "heart", "rate", "was", "stable", "without", "tachy", "-", "or", "bradycardia", ".", "The", "operating", "conditions", "regarding", "bleeding", "were", "estimated", "in", "a", "double", "-", "blind", "manner", ",", "and", "did", "not", "differ", "significantly", "between", "the", "groups", ".", "During", "hypotension", ",", "the", "serum", "creatinine", "concentration", "rose", "significantly", "in", "all", "groups", "from", "the", "values", "before", "hypotension", "and", "returned", "postoperatively", "to", "the", "initial", "level", "in", "the", "other", "groups", ",", "except", "the", "isoflurane", "group", ".", "After", "hypotension", "there", "was", "no", "rebound", "phenomenon", "in", "either", "blood", "pressure", "or", "heart", "rate", ".", "These", "results", "indicate", "that", "labetalol", "induces", "easily", "adjustable", "hypotension", "without", "compensatory", "tachycardia", "and", "rebound", "hypertension", "."]], "ner": [[[4, 4, "Chemical"], [21, 21, "Chemical"], [298, 298, "Chemical"], [412, 412, "Chemical"], [1, 1, "Disease"], [35, 35, "Disease"], [231, 231, "Disease"], [323, 323, "Disease"], [360, 360, "Disease"], [375, 375, "Disease"], [394, 394, "Disease"], [416, 416, "Disease"], [6, 6, "Chemical"], [43, 43, "Chemical"], [119, 119, "Chemical"], [121, 121, "Chemical"], [228, 228, "Chemical"], [8, 8, "Chemical"], [45, 45, "Chemical"], [169, 169, "Chemical"], [171, 171, "Chemical"], [251, 251, "Chemical"], [10, 10, "Chemical"], [47, 47, "Chemical"], [220, 220, "Chemical"], [222, 222, "Chemical"], [268, 268, "Chemical"], [390, 390, "Chemical"], [288, 288, "Chemical"], [290, 292, "Chemical"], [364, 364, "Chemical"], [331, 334, "Disease"], [419, 419, "Disease"], [340, 340, "Disease"], [422, 422, "Disease"]]], "relations": [[[4, 4, 1, 1, "CID"], [4, 4, 35, 35, "CID"], [4, 4, 231, 231, "CID"], [4, 4, 323, 323, "CID"], [4, 4, 360, 360, "CID"], [4, 4, 375, 375, "CID"], [4, 4, 394, 394, "CID"], [4, 4, 416, 416, "CID"], [21, 21, 1, 1, "CID"], [21, 21, 35, 35, "CID"], [21, 21, 231, 231, "CID"], [21, 21, 323, 323, "CID"], [21, 21, 360, 360, "CID"], [21, 21, 375, 375, "CID"], [21, 21, 394, 394, "CID"], [21, 21, 416, 416, "CID"], [298, 298, 1, 1, "CID"], [298, 298, 35, 35, "CID"], [298, 298, 231, 231, "CID"], [298, 298, 323, 323, "CID"], [298, 298, 360, 360, "CID"], [298, 298, 375, 375, "CID"], [298, 298, 394, 394, "CID"], [298, 298, 416, 416, "CID"], [412, 412, 1, 1, "CID"], [412, 412, 35, 35, "CID"], [412, 412, 231, 231, "CID"], [412, 412, 323, 323, "CID"], [412, 412, 360, 360, "CID"], [412, 412, 375, 375, "CID"], [412, 412, 394, 394, "CID"], [412, 412, 416, 416, "CID"], [6, 6, 1, 1, "CID"], [6, 6, 35, 35, "CID"], [6, 6, 231, 231, "CID"], [6, 6, 323, 323, "CID"], [6, 6, 360, 360, "CID"], [6, 6, 375, 375, "CID"], [6, 6, 394, 394, "CID"], [6, 6, 416, 416, "CID"], [43, 43, 1, 1, "CID"], [43, 43, 35, 35, "CID"], [43, 43, 231, 231, "CID"], [43, 43, 323, 323, "CID"], [43, 43, 360, 360, "CID"], [43, 43, 375, 375, "CID"], [43, 43, 394, 394, "CID"], [43, 43, 416, 416, "CID"], [119, 119, 1, 1, "CID"], [119, 119, 35, 35, "CID"], [119, 119, 231, 231, "CID"], [119, 119, 323, 323, "CID"], [119, 119, 360, 360, "CID"], [119, 119, 375, 375, "CID"], [119, 119, 394, 394, "CID"], [119, 119, 416, 416, "CID"], [121, 121, 1, 1, "CID"], [121, 121, 35, 35, "CID"], [121, 121, 231, 231, "CID"], [121, 121, 323, 323, "CID"], [121, 121, 360, 360, "CID"], [121, 121, 375, 375, "CID"], [121, 121, 394, 394, "CID"], [121, 121, 416, 416, "CID"], [228, 228, 1, 1, "CID"], [228, 228, 35, 35, "CID"], [228, 228, 231, 231, "CID"], [228, 228, 323, 323, "CID"], [228, 228, 360, 360, "CID"], [228, 228, 375, 375, "CID"], [228, 228, 394, 394, "CID"], [228, 228, 416, 416, "CID"], [8, 8, 1, 1, "CID"], [8, 8, 35, 35, "CID"], [8, 8, 231, 231, "CID"], [8, 8, 323, 323, "CID"], [8, 8, 360, 360, "CID"], [8, 8, 375, 375, "CID"], [8, 8, 394, 394, "CID"], [8, 8, 416, 416, "CID"], [45, 45, 1, 1, "CID"], [45, 45, 35, 35, "CID"], [45, 45, 231, 231, "CID"], [45, 45, 323, 323, "CID"], [45, 45, 360, 360, "CID"], [45, 45, 375, 375, "CID"], [45, 45, 394, 394, "CID"], [45, 45, 416, 416, "CID"], [169, 169, 1, 1, "CID"], [169, 169, 35, 35, "CID"], [169, 169, 231, 231, "CID"], [169, 169, 323, 323, "CID"], [169, 169, 360, 360, "CID"], [169, 169, 375, 375, "CID"], [169, 169, 394, 394, "CID"], [169, 169, 416, 416, "CID"], [171, 171, 1, 1, "CID"], [171, 171, 35, 35, "CID"], [171, 171, 231, 231, "CID"], [171, 171, 323, 323, "CID"], [171, 171, 360, 360, "CID"], [171, 171, 375, 375, "CID"], [171, 171, 394, 394, "CID"], [171, 171, 416, 416, "CID"], [251, 251, 1, 1, "CID"], [251, 251, 35, 35, "CID"], [251, 251, 231, 231, "CID"], [251, 251, 323, 323, "CID"], [251, 251, 360, 360, "CID"], [251, 251, 375, 375, "CID"], [251, 251, 394, 394, "CID"], [251, 251, 416, 416, "CID"], [10, 10, 1, 1, "CID"], [10, 10, 35, 35, "CID"], [10, 10, 231, 231, "CID"], [10, 10, 323, 323, "CID"], [10, 10, 360, 360, "CID"], [10, 10, 375, 375, "CID"], [10, 10, 394, 394, "CID"], [10, 10, 416, 416, "CID"], [47, 47, 1, 1, "CID"], [47, 47, 35, 35, "CID"], [47, 47, 231, 231, "CID"], [47, 47, 323, 323, "CID"], [47, 47, 360, 360, "CID"], [47, 47, 375, 375, "CID"], [47, 47, 394, 394, "CID"], [47, 47, 416, 416, "CID"], [220, 220, 1, 1, "CID"], [220, 220, 35, 35, "CID"], [220, 220, 231, 231, "CID"], [220, 220, 323, 323, "CID"], [220, 220, 360, 360, "CID"], [220, 220, 375, 375, "CID"], [220, 220, 394, 394, "CID"], [220, 220, 416, 416, "CID"], [222, 222, 1, 1, "CID"], [222, 222, 35, 35, "CID"], [222, 222, 231, 231, "CID"], [222, 222, 323, 323, "CID"], [222, 222, 360, 360, "CID"], [222, 222, 375, 375, "CID"], [222, 222, 394, 394, "CID"], [222, 222, 416, 416, "CID"], [268, 268, 1, 1, "CID"], [268, 268, 35, 35, "CID"], [268, 268, 231, 231, "CID"], [268, 268, 323, 323, "CID"], [268, 268, 360, 360, "CID"], [268, 268, 375, 375, "CID"], [268, 268, 394, 394, "CID"], [268, 268, 416, 416, "CID"], [390, 390, 1, 1, "CID"], [390, 390, 35, 35, "CID"], [390, 390, 231, 231, "CID"], [390, 390, 323, 323, "CID"], [390, 390, 360, 360, "CID"], [390, 390, 375, 375, "CID"], [390, 390, 394, 394, "CID"], [390, 390, 416, 416, "CID"]]], "clusters": [], "translated": "<0>拉贝洛尔</0>联合<12>氟烷</12>、<17>安氟烷</17>或<22>异氟烷</22>引起的故意<4>低血压</4>治疗中耳外科手术。使用<1>拉贝洛尔</1>，一种α-和β-肾上腺素能阻滞剂，作为<5>降压药</5>与吸入麻醉剂（<13>氟烷</13>，<18>安氟烷</18>或<23>异氟烷</23>）在23名接受中耳手术的成年患者中进行了研究。平均动脉压从86+/-5（s.e.平均值）mmHg降至52+/-1mmHg（11.5+/-0.7至6.9+/-0.1kPa）<14>氟烷</14>（<15>H</15>）组98+/-10分钟，从79+/-5至53+/-1mmHg（10.5+/-0.7至7.1+/-0.1kPa）在<19>安氟烷</19>（<20>E</20>）组中持续129+/-11分钟，从80+/-4至49+/-1mmHg（10.7+/-0.5至6.5+/-0.1kPa）在<24>异氟醚</24>（<25>I</25>）组中持续135+/-15分钟。<6>低血压</6>期间吸入气体的平均<16>H</16>浓度为0.7+/-0.1体积％，平均<21>E</21>浓度1.6+/-0.2体积％，平均<26>I</26>浓度1.0+/-0.1体积％。此外，患者接受<28>芬太尼</28>和<29>d-筒箭毒碱</29>治疗。<2>拉贝洛尔</2>的初始降压剂量相似，为0.52-0.59mg/kg，在所有组中。<7>低血压</7>期间，心率稳定，无<31>心动过速或心动过缓</31>。关于<33>出血</33>的操作条件以双盲方式进行评估，各组之间没有显着差异。<8>低血压</8>期间，各组血清<30>肌酐</30>浓度均较<9>低血压</9>前显着升高，其余各组术后恢复至初始水平，<27>异氟醚</27>组除外。<10>低血压</10>后血压、心率均无反弹现象。这些结果表明<3>拉贝洛尔</3>可引起易于调节的<11>低血压</11>而无代偿性<32>心动过速</32>和反跳性<34>高血压</34>。", "revised": true}
{"doc_key": "6106951", "sentences": [["Central", "excitatory", "actions", "of", "flurazepam", ".", "Toxic", "actions", "of", "flurazepam", "(", "FZP", ")", "were", "studied", "in", "cats", ",", "mice", "and", "rats", ".", "High", "doses", "caused", "an", "apparent", "central", "excitation", ",", "most", "clearly", "seen", "as", "clonic", "convulsions", ",", "superimposed", "on", "general", "depression", ".", "Following", "a", "lethal", "dose", ",", "death", "was", "always", "associated", "with", "convulsions", ".", "Comparing", "the", "relative", "sensitivity", "to", "central", "depression", "and", "excitation", "revealed", "that", "rats", "were", "least", "likely", "to", "have", "convulsions", "at", "doses", "that", "did", "not", "first", "cause", "loss", "of", "consciousness", ",", "while", "cats", "most", "clearly", "showed", "marked", "central", "excitatory", "actions", ".", "Signs", "of", "FZP", "toxocity", "in", "cats", "included", "excessive", "salivation", ",", "extreme", "apprehensive", "behavior", ",", "retching", ",", "muscle", "tremors", "and", "convulsions", ".", "An", "interaction", "between", "FZP", "and", "pentylenetetrazol", "(", "PTZ", ")", "was", "shown", "by", "pretreating", "mice", "with", "FZP", "before", "PTZ", "challenge", ".", "As", "a", "function", "of", "dose", ",", "FZP", "first", "protected", "against", "convulsions", "and", "death", ".", "At", "higher", "doses", ",", "however", ",", "convulsions", "again", "emerged", ".", "These", "doses", "of", "FZP", "were", "lower", "than", "those", "that", "would", "alone", "cause", "convulsions", ".", "These", "results", "may", "be", "relevant", "to", "the", "use", "of", "FZP", "in", "clinical", "situations", "in", "which", "there", "is", "increased", "neural", "excitability", ",", "such", "as", "epilepsy", "or", "sedative", "-", "hypnotic", "drug", "withdrawal", "."]], "ner": [[[4, 4, "Chemical"], [9, 9, "Chemical"], [11, 11, "Chemical"], [95, 95, "Chemical"], [117, 117, "Chemical"], [129, 129, "Chemical"], [140, 140, "Chemical"], [161, 161, "Chemical"], [181, 181, "Chemical"], [35, 35, "Disease"], [52, 52, "Disease"], [71, 71, "Disease"], [112, 112, "Disease"], [144, 144, "Disease"], [154, 154, "Disease"], [170, 170, "Disease"], [119, 119, "Chemical"], [121, 121, "Chemical"], [131, 131, "Chemical"], [40, 40, "Disease"], [60, 60, "Disease"], [79, 81, "Disease"], [96, 96, "Disease"], [101, 101, "Disease"], [109, 110, "Disease"], [195, 195, "Disease"]]], "relations": [[[4, 4, 35, 35, "CID"], [4, 4, 52, 52, "CID"], [4, 4, 71, 71, "CID"], [4, 4, 112, 112, "CID"], [4, 4, 144, 144, "CID"], [4, 4, 154, 154, "CID"], [4, 4, 170, 170, "CID"], [9, 9, 35, 35, "CID"], [9, 9, 52, 52, "CID"], [9, 9, 71, 71, "CID"], [9, 9, 112, 112, "CID"], [9, 9, 144, 144, "CID"], [9, 9, 154, 154, "CID"], [9, 9, 170, 170, "CID"], [11, 11, 35, 35, "CID"], [11, 11, 52, 52, "CID"], [11, 11, 71, 71, "CID"], [11, 11, 112, 112, "CID"], [11, 11, 144, 144, "CID"], [11, 11, 154, 154, "CID"], [11, 11, 170, 170, "CID"], [95, 95, 35, 35, "CID"], [95, 95, 52, 52, "CID"], [95, 95, 71, 71, "CID"], [95, 95, 112, 112, "CID"], [95, 95, 144, 144, "CID"], [95, 95, 154, 154, "CID"], [95, 95, 170, 170, "CID"], [117, 117, 35, 35, "CID"], [117, 117, 52, 52, "CID"], [117, 117, 71, 71, "CID"], [117, 117, 112, 112, "CID"], [117, 117, 144, 144, "CID"], [117, 117, 154, 154, "CID"], [117, 117, 170, 170, "CID"], [129, 129, 35, 35, "CID"], [129, 129, 52, 52, "CID"], [129, 129, 71, 71, "CID"], [129, 129, 112, 112, "CID"], [129, 129, 144, 144, "CID"], [129, 129, 154, 154, "CID"], [129, 129, 170, 170, "CID"], [140, 140, 35, 35, "CID"], [140, 140, 52, 52, "CID"], [140, 140, 71, 71, "CID"], [140, 140, 112, 112, "CID"], [140, 140, 144, 144, "CID"], [140, 140, 154, 154, "CID"], [140, 140, 170, 170, "CID"], [161, 161, 35, 35, "CID"], [161, 161, 52, 52, "CID"], [161, 161, 71, 71, "CID"], [161, 161, 112, 112, "CID"], [161, 161, 144, 144, "CID"], [161, 161, 154, 154, "CID"], [161, 161, 170, 170, "CID"], [181, 181, 35, 35, "CID"], [181, 181, 52, 52, "CID"], [181, 181, 71, 71, "CID"], [181, 181, 112, 112, "CID"], [181, 181, 144, 144, "CID"], [181, 181, 154, 154, "CID"], [181, 181, 170, 170, "CID"], [119, 119, 35, 35, "CID"], [119, 119, 52, 52, "CID"], [119, 119, 71, 71, "CID"], [119, 119, 112, 112, "CID"], [119, 119, 144, 144, "CID"], [119, 119, 154, 154, "CID"], [119, 119, 170, 170, "CID"], [121, 121, 35, 35, "CID"], [121, 121, 52, 52, "CID"], [121, 121, 71, 71, "CID"], [121, 121, 112, 112, "CID"], [121, 121, 144, 144, "CID"], [121, 121, 154, 154, "CID"], [121, 121, 170, 170, "CID"], [131, 131, 35, 35, "CID"], [131, 131, 52, 52, "CID"], [131, 131, 71, 71, "CID"], [131, 131, 112, 112, "CID"], [131, 131, 144, 144, "CID"], [131, 131, 154, 154, "CID"], [131, 131, 170, 170, "CID"]]], "clusters": [], "translated": "<0>氟西泮</0>的中枢兴奋作用。在猫、小鼠和大鼠中研究了<1>flurazepam</1> (<2>FZP</2>) 的毒性作用。高剂量引起明显的中枢兴奋，最明显的表现为阵挛性<9>抽搐</9>，叠加在一般性<19>抑郁症</19>上。服用致死剂量后，死亡总是伴随着<10>抽搐</10>。比较对中枢<20>抑郁</20>和兴奋的相对敏感性表明，在未首先引起<21>意识丧失</21>的剂量下，大鼠发生<11>抽搐</11>的可能性最小，而猫最清楚地表现出明显的中枢兴奋作用。猫<3>FZP</3>的<22>毒性</22>迹象包括过度<23>流涎</23>、极度恐惧行为、干呕、<24>肌肉震颤</24>和<12>抽搐</12>。在小鼠中表明了<4>FZP</4>和<16>戊二十四酸片</16>(<17>PTZ</17>)之间的相互作用通过预处理小鼠<5>FZP</5>在<18>PTZ</18>之前进行挑战，作为剂量函数，<6>FZP</6>首先保护免受<13>抽搐</13>和死亡。然而，在更高的剂量下，<14>抽搐</14>再次出现。这些<7>FZP</7>的剂量低于单独引起<15>抽搐</15>的剂量。这些结果可能与<8>FZP</8>在神经兴奋性增加的临床情况下的使用有关，例如<25>癫痫</25>或镇静催眠药物戒断。", "revised": true}
{"doc_key": "6321816", "sentences": [["Vasopressin", "as", "a", "possible", "contributor", "to", "hypertension", ".", "The", "role", "of", "vasopressin", "as", "a", "pressor", "agent", "to", "the", "hypertensive", "process", "was", "examined", ".", "Vasopressin", "plays", "a", "major", "role", "in", "the", "pathogenesis", "of", "DOCA", "-", "salt", "hypertension", ",", "since", "the", "elevation", "of", "blood", "pressure", "was", "not", "substantial", "in", "the", "rats", "with", "lithium", "-", "treated", "diabetes", "insipidus", "after", "DOCA", "-", "salt", "treatment", ".", "Administration", "of", "DDAVP", "which", "has", "antidiuretic", "action", "but", "minimal", "vasopressor", "effect", "failed", "to", "increase", "blood", "pressure", "to", "the", "levels", "observed", "after", "administration", "of", "AVP", ".", "Furthermore", ",", "the", "pressor", "action", "of", "vasopressin", "appears", "to", "be", "important", "in", "the", "development", "of", "this", "model", "of", "hypertension", ",", "since", "the", "enhanced", "pressor", "responsiveness", "to", "the", "hormone", "was", "observed", "in", "the", "initial", "stage", "of", "hypertension", ".", "Increased", "secretion", "of", "vasopressin", "from", "neurohypophysis", "also", "promotes", "the", "function", "of", "the", "hormone", "as", "a", "pathogenetic", "factor", "in", "hypertension", ".", "An", "unproportional", "release", "of", "vasopressin", "compared", "to", "plasma", "osmolality", "may", "be", "induced", "by", "the", "absence", "of", "an", "adjusting", "control", "of", "angiotensin", "II", "forming", "and", "receptor", "binding", "capacity", "for", "sodium", "balance", "in", "the", "brain", ".", "However", ",", "the", "role", "of", "vasopressin", "remains", "to", "be", "determined", "in", "human", "essential", "hypertension", "."]], "ner": [[[32, 32, "Chemical"], [56, 56, "Chemical"], [6, 6, "Disease"], [18, 18, "Disease"], [35, 35, "Disease"], [104, 104, "Disease"], [121, 121, "Disease"], [141, 141, "Disease"], [190, 190, "Disease"], [50, 50, "Chemical"], [53, 54, "Disease"], [0, 0, "Chemical"], [11, 11, "Chemical"], [23, 23, "Chemical"], [92, 92, "Chemical"], [126, 126, "Chemical"], [147, 147, "Chemical"], [182, 182, "Chemical"], [63, 63, "Chemical"], [163, 163, "Chemical"], [171, 171, "Chemical"]]], "relations": [[[32, 32, 6, 6, "CID"], [32, 32, 18, 18, "CID"], [32, 32, 35, 35, "CID"], [32, 32, 104, 104, "CID"], [32, 32, 121, 121, "CID"], [32, 32, 141, 141, "CID"], [32, 32, 190, 190, "CID"], [56, 56, 6, 6, "CID"], [56, 56, 18, 18, "CID"], [56, 56, 35, 35, "CID"], [56, 56, 104, 104, "CID"], [56, 56, 121, 121, "CID"], [56, 56, 141, 141, "CID"], [56, 56, 190, 190, "CID"], [50, 50, 53, 54, "CID"]]], "clusters": [], "translated": "<11>血管加压素</11> 可能导致<2>高血压</2>。研究了<12>加压素</12> 作为<3>高血压</3>过程的升压剂的作用。<13>血管加压素</13>在<0>DOCA</0>-盐<4>高血压</4>的发病机制中起主要作用，因为在<b><9>锂</9></b>-治疗过的<10>尿崩症</10>大鼠中，血压没有显著升高，而在<b><1>DOCA</1></b>-盐治疗后显著升高。具有抗利尿作用但血管加压作用最小的<18>DDAVP</18>给药未能将血压升高至给药AVP后观察到的水平。此外，<14>加压素</14>的升压作用似乎在该<b><5>高血压</5></b>模型的发展中很重要，因为在<b><6>高血压</6></b>的初期观察到激素引起的升压反应增强。神经垂体分泌的<15>加压素</15>也促进该激素作为<b><7>高血压</7></b>致病因素的作用。与血浆渗透压相比，<16>加压素</16>的不成比例释放可能是由于大脑中对<b><19>血管紧张素</19></b>II形成和<b><20>钠</20></b>受体结合容量的调节控制缺失引起的。然而，在人类原发性<b><8>高血压</8></b>中，<17>加压素</17>的作用尚待进一步确定。", "revised": true}
{"doc_key": "6305660", "sentences": [["Hormones", "and", "risk", "of", "breast", "cancer", ".", "This", "paper", "reports", "the", "results", "of", "a", "study", "of", "50", "menopausal", "women", "receiving", "hormonal", "replacement", "therapy", ".", "The", "majority", "(", "29", ")", "had", "surgical", "menopause", ";", "their", "mean", "age", "was", "45", ".", "7", "years", ".", "It", "was", "hypothesized", "that", "progestins", "could", "equilibrate", "the", "effects", "of", "the", "estrogenic", "stimulation", "on", "the", "mammary", "and", "endometrial", "target", "tissues", "of", "women", "on", "hormonal", "replacement", "therapy", ".", "The", "treatment", "schedule", "consisted", "of", "conjugated", "estrogens", "(", "Premarin", ")", "1", ".", "25", "mg", "/", "day", "for", "21", "days", "and", "Medroxyprogesterone", "acetate", "10", "mg", "/", "day", "for", "10", "days", "in", "each", "month", ".", "The", "mean", "treatment", "period", "was", "18", "months", ".", "During", "the", "follow", "-", "up", "period", ",", "attention", "was", "paid", "to", "breast", "modifications", "as", "evidenced", "by", "symptomatology", ",", "physical", "examination", ",", "and", "plate", "thermography", ".", "Mastodynia", "was", "reported", "by", "21", "patients", ",", "and", "physical", "examination", "revealed", "a", "light", "increase", "in", "breast", "firmness", "in", "12", "women", "and", "a", "moderate", "increase", "in", "breast", "nodularity", "in", "2", "women", ".", "Themography", "confirmed", "the", "existence", "of", "an", "excessive", "breast", "stimulation", "in", "1", "women", "who", "complained", "of", "moderate", "mastodynia", "and", "in", "5", "of", "the", "7", "women", "who", "complained", "of", "severe", "mastodynia", ".", "Normalization", "was", "obtained", "by", "halving", "the", "estrogen", "dose", ".", "These", "results", "suggest", "that", "hormonal", "replacement", "therapy", "can", "be", "safely", "prescribed", "if", "the", "following", "criteria", "are", "satisfied", ":", "1", ")", "preliminary", "evaluation", "of", "patients", "from", "a", "clinical", ",", "metabolic", ",", "cytologic", ",", "and", "mammographic", "perspective", ";", "2", ")", "cyclic", "treatment", "schedule", ",", "with", "a", "progestative", "phase", "of", "10", "days", ";", "and", "3", ")", "periodic", "complete", "follow", "-", "up", ",", "with", "accurate", "thermographic", "evaluation", "of", "the", "breast", "target", "tissues", "."]], "ner": [[[74, 75, "Chemical"], [77, 77, "Chemical"], [135, 135, "Disease"], [182, 182, "Disease"], [194, 194, "Disease"], [89, 90, "Chemical"], [46, 46, "Chemical"], [4, 5, "Disease"], [202, 202, "Chemical"]]], "relations": [[[74, 75, 135, 135, "CID"], [74, 75, 182, 182, "CID"], [74, 75, 194, 194, "CID"], [77, 77, 135, 135, "CID"], [77, 77, 182, 182, "CID"], [77, 77, 194, 194, "CID"], [89, 90, 135, 135, "CID"], [89, 90, 182, 182, "CID"], [89, 90, 194, 194, "CID"]]], "clusters": [], "translated": "激素与<7>乳腺癌</7>的风险。本文报告了一项针对 50 名接受激素替代疗法的绝经期妇女的研究结果。大多数人（29 人）经历了手术绝经；他们的平均年龄是 45 岁。7年。据推测，<6>孕激素</6>可以平衡雌激素刺激对接受激素替代疗法的女性乳腺和子宫内膜靶组织的影响。治疗方案包括<0>结合雌激素</0>（<1>倍美力</1>）1.25 毫克/天，连续 21 天，<5>醋酸甲羟孕酮</5> 10 毫克/天，连续 10 天，每月一次。平均治疗期为 18 个月。在随访期间，注意通过症状学、身体检查和平板热成像证明的乳房改变。<2>乳房痛</2>有 21 名患者报告，体格检查显示 12 名女性乳房硬度轻度增加，2 名女性乳房结节性中度增加。热成像证实 1 名主诉中度<3>乳房痛</3>的女性和主诉重度<4>乳房痛</4>的 7 名女性中的5 名存在过度乳房刺激。通过将<8>雌激素</8>剂量减半获得正常化。这些结果表明，如果满足以下标准，则可以安全地开出激素替代疗法：1）从临床、代谢、细胞学和乳腺X线摄影的角度对患者进行初步评估；2）周期性治疗方案，孕期10天；和3）定期完整的随访，对乳房目标组织进行准确的热成像评估。", "revised": true}
{"doc_key": "6893265", "sentences": [["Propylthiouracil", "-", "induced", "hepatic", "damage", ".", "Two", "cases", "of", "propylthiouracil", "-", "induced", "liver", "damage", "have", "been", "observed", ".", "The", "first", "case", "is", "of", "an", "acute", "type", "of", "damage", ",", "proven", "by", "rechallenge", ";", "the", "second", "presents", "a", "clinical", "and", "histologic", "picture", "resembling", "chronic", "active", "hepatitis", ",", "with", "spontaneous", "remission", "."]], "ner": [[[0, 0, "Chemical"], [9, 9, "Chemical"], [3, 4, "Disease"], [12, 13, "Disease"], [42, 44, "Disease"]]], "relations": [[[0, 0, 3, 4, "CID"], [0, 0, 12, 13, "CID"], [9, 9, 3, 4, "CID"], [9, 9, 12, 13, "CID"], [0, 0, 42, 44, "CID"], [9, 9, 42, 44, "CID"]]], "clusters": [], "translated": "<0>丙基硫氧嘧啶</0>引起的<2>肝损伤</2>。已观察到两例<1>丙基硫氧嘧啶</1><3>引起的肝损伤</3>。第一个案例是急性损伤，通过再次挑战得到证实；第二种表现出类似于<4>慢性活动性肝炎</4>的临床和组织学表现，并有自发缓解。", "revised": true}
{"doc_key": "6806735", "sentences": [["Treatment", "of", "ovarian", "cancer", "with", "a", "combination", "of", "cis", "-", "platinum", ",", "adriamycin", ",", "cyclophosphamide", "and", "hexamethylmelamine", ".", "During", "the", "last", "2", "1", "/", "2", "years", ",", "38", "patients", "with", "ovarian", "cancer", "were", "treated", "with", "a", "combination", "of", "cisplatinum", "(", "CPDD", ")", ",", "50", "mg", "/", "m2", ",", "adriamycin", ",", "30", "mg", "/", "m2", ",", "cyclophosphamide", ",", "300", "mg", "/", "m2", ",", "on", "day", "1", ";", "and", "hexamethylmelamine", "(", "HMM", ")", ",", "6", "mg", "/", "kg", "daily", ",", "for", "14", "days", ".", "Each", "course", "was", "repeated", "monthly", ".", "2", "patients", "had", "stage", "II", ",", "14", "stage", "III", "and", "22", "stage", "IV", "disease", ".", "14", "of", "the", "38", "patients", "were", "previously", "treated", "with", "chemotherapy", ",", "1", "with", "radiation", ",", "6", "with", "both", "chemotherapy", "and", "radiation", ",", "and", "17", "did", "not", "have", "any", "treatment", "before", "CPDD", "combination", ".", "31", "of", "the", "38", "cases", "(", "81", ".", "5", "%", ")", "demonstrated", "objective", "responses", "lasting", "for", "2", "months", "or", "more", ".", "These", "responses", "were", "partial", "in", "19", "and", "complete", "in", "12", "cases", ".", "Hematologic", "toxicity", "was", "moderate", "and", "with", "reversible", "anemia", "developing", "in", "71", "%", "of", "patients", ".", "Gastrointestinal", "side", "effects", "from", "CPDD", "were", "universal", ".", "HMM", "gastrointestinal", "toxicity", "necessitated", "discontinuation", "of", "the", "drug", "in", "5", "patients", ".", "Severe", "nephrotoxicity", "was", "observed", "in", "2", "patients", "but", "was", "reversible", ".", "There", "were", "no", "drug", "-", "related", "deaths", "."]], "ner": [[[40, 40, "Chemical"], [133, 133, "Chemical"], [188, 188, "Chemical"], [176, 176, "Disease"], [193, 194, "Disease"], [205, 205, "Disease"], [8, 10, "Chemical"], [38, 38, "Chemical"], [2, 3, "Disease"], [30, 31, "Disease"], [12, 12, "Chemical"], [48, 48, "Chemical"], [14, 14, "Chemical"], [55, 55, "Chemical"], [16, 16, "Chemical"], [67, 67, "Chemical"], [69, 69, "Chemical"], [192, 192, "Chemical"], [169, 170, "Disease"]]], "relations": [[[40, 40, 176, 176, "CID"], [133, 133, 176, 176, "CID"], [188, 188, 176, 176, "CID"], [40, 40, 193, 194, "CID"], [133, 133, 193, 194, "CID"], [188, 188, 193, 194, "CID"], [40, 40, 205, 205, "CID"], [133, 133, 205, 205, "CID"], [188, 188, 205, 205, "CID"]]], "clusters": [], "translated": " <8>卵巢癌</8>联合<6>顺铂</6>、<10>阿霉素</10>、<12>环磷酰胺</12>和<14>六甲基三聚氰胺</14>。在过去的 2 1 / 2 年中，38 名<9>卵巢癌</9>患者接受了<7>顺铂</7>（<0>CPDD</0>）50 mg/m2联合治疗，<11>阿霉素</11>，30 mg/m2，<13>环磷酰胺</13>，300 mg/m2，第1天；<15>六甲基三聚氰胺</15>（<16>HMM</16>），每日6mg/kg，连续14天。每个课程每月重复一次。II期2例，III期14例，IV期22例。38例患者中14例既往接受过化疗，1例接受过放疗，6例同时接受过化疗和放疗，17例在<1>CPDD</1>联合治疗前未接受过任何治疗。38例中有31例（81.5%）表现出持续2个月或更长时间的客观反应。这些反应在19例中是部分的，在12例中是完整的。<18>血液学毒性</18>为中度，71%的患者出现可逆性<3>贫血</3>。 <2>CPDD</2>的胃肠道副作用很普遍。<4>胃肠道毒性</4><17>HMM</17>使5名患者需要停药。在2名患者中观察到严重的<5>肾毒性</5>但是可逆的。没有与药物有关的死亡。", "revised": true}
{"doc_key": "6985498", "sentences": [["Hepatitis", "and", "renal", "tubular", "acidosis", "after", "anesthesia", "with", "methoxyflurane", ".", "A", "69", "-", "year", "-", "old", "man", "operated", "for", "acute", "cholecystitis", "under", "methoxyflurane", "anesthesia", "developed", "postoperatively", "a", "hepatic", "insufficiency", "syndrome", "and", "renal", "tubular", "acidosis", ".", "Massive", "bleeding", "appeared", "during", "surgery", "which", "lasted", "for", "six", "hours", ".", "Postoperative", "evolution", "under", "supportive", "therapy", "was", "favourable", ".", "Complete", "recovery", "was", "confirmed", "by", "repeated", "controls", "performed", "over", "a", "period", "of", "one", "year", "after", "surgery", "."]], "ner": [[[8, 8, "Chemical"], [22, 22, "Chemical"], [0, 0, "Disease"], [2, 4, "Disease"], [31, 33, "Disease"], [19, 20, "Disease"], [27, 29, "Disease"], [36, 36, "Disease"]]], "relations": [[[8, 8, 0, 0, "CID"], [22, 22, 0, 0, "CID"], [8, 8, 2, 4, "CID"], [8, 8, 31, 33, "CID"], [22, 22, 2, 4, "CID"], [22, 22, 31, 33, "CID"]]], "clusters": [], "translated": "<2>肝炎</2>和<3>肾小管性酸中毒</3><0>甲氧氟烷</0>麻醉后。一名 69 岁男性因<5>急性胆囊炎</5>在<1>甲氧氟烷</1>麻醉下进行手术，术后出现<6>肝功能不全综合征</6>和<4>肾小管酸中毒</4>。手术过程中出现大量<7>出血</7>，持续了六个小时。支持治疗下术后进展良好。手术后一年内进行的重复控制证实了完全康复。", "revised": true}
{"doc_key": "7121659", "sentences": [["Antirifampicin", "antibodies", "in", "acute", "rifampicin", "-", "associated", "renal", "failure", ".", "5", "patients", "with", "acute", "renal", "failure", "(", "3", "with", "thrombopenia", "and", "hemolysis", ")", "induced", "by", "the", "reintroduction", "of", "rifampicin", "are", "described", ".", "No", "correlation", "was", "found", "between", "the", "severity", "of", "clinical", "manifestations", "and", "the", "total", "dose", "taken", "by", "the", "patients", ".", "In", "all", "but", "1", "patient", ",", "antirifampicin", "antibodies", "were", "detected", ".", "Antibodies", "suggested", "to", "be", "of", "the", "IgM", "class", "were", "detected", "in", "all", "3", "patients", "with", "hematological", "disorders", ".", "The", "pattern", "of", "non", "-", "specific", "acute", "tubular", "necrosis", "found", "in", "the", "2", "biopsied", "patients", ",", "indistinguishable", "from", "that", "of", "ischemic", "origin", ",", "raised", "the", "possibility", "of", "a", "vascular", "-", "mediated", "damage", ".", "In", "3", "patients", ",", "the", "possibility", "of", "a", "triggering", "immunoallergic", "mechanism", "is", "discussed", "."]], "ner": [[[4, 4, "Chemical"], [28, 28, "Chemical"], [19, 19, "Disease"], [21, 21, "Disease"], [86, 88, "Disease"], [7, 8, "Disease"], [13, 15, "Disease"], [77, 78, "Disease"]]], "relations": [[[4, 4, 19, 19, "CID"], [28, 28, 19, 19, "CID"], [4, 4, 21, 21, "CID"], [28, 28, 21, 21, "CID"], [4, 4, 86, 88, "CID"], [28, 28, 86, 88, "CID"]]], "clusters": [], "translated": "急性<0>利福平</0><5>肾功能衰竭</5>中的抗利福平抗体。5例<1>利福平</1>引起<6>急性肾功能衰竭</6>（3例<2>血小板减少</2>和<3>溶血</3>）。患者服用的总剂量与临床表现的严重程度之间未发现相关性。除1名患者外，所有患者均检测到抗利福平抗体。所有3名患有<7>血液病</7>的患者中均检测到属于IgM类的抗体。在活检的2名患者中发现的非特异性<4>急性肾小管坏死</4>与缺血性起源难以区分，这增加了血管介导损伤的可能性。在3名患者中，讨论了触发免疫过敏机制的可能性。", "revised": true}
{"doc_key": "7018927", "sentences": [["Pituitary", "response", "to", "luteinizing", "hormone", "-", "releasing", "hormone", "during", "haloperidol", "-", "induced", "hyperprolactinemia", ".", "The", "effects", "of", "a", "6", "-", "hour", "infusion", "with", "haloperidol", "on", "serum", "prolactin", "and", "luteinizing", "hormone", "(", "LH", ")", "levels", "was", "studied", "in", "a", "group", "of", "male", "subjects", ".", "Five", "hours", "after", "starting", "the", "infusions", ",", "a", "study", "of", "the", "pituitary", "responses", "to", "LH", "-", "releasing", "hormone", "(", "LH", "-", "RH", ")", "was", "carried", "out", ".", "Control", "patients", "received", "infusions", "of", "0", ".", "9", "%", "NaCl", "solution", ".", "During", "the", "course", "of", "haloperidol", "infusions", ",", "significant", "hyperprolactinemia", "was", "found", ",", "together", "with", "an", "abolished", "pituitary", "response", "to", "LH", "-", "RH", ",", "as", "compared", "with", "responses", "of", "control", "subjects", "."]], "ner": [[[9, 9, "Chemical"], [23, 23, "Chemical"], [86, 86, "Chemical"], [12, 12, "Disease"], [90, 90, "Disease"], [79, 79, "Chemical"]]], "relations": [[[9, 9, 12, 12, "CID"], [9, 9, 90, 90, "CID"], [23, 23, 12, 12, "CID"], [23, 23, 90, 90, "CID"], [86, 86, 12, 12, "CID"], [86, 86, 90, 90, "CID"]]], "clusters": [], "translated": "<0>氟哌啶醇</0>诱导的<3>高催乳素血症</3>期间垂体对促黄体激素释放激素的反应。在一组男性受试者中研究了输注<1>氟哌啶醇</1> 6 小时对血清催乳素和黄体生成素 (LH) 水平的影响。开始输注 5 小时后，进行了垂体对 LH 释放激素 (<3>LH-RH</3>) 反应的研究。对照患者接受 0 . 9%<5>NaCl</5>溶液。在<2>氟哌啶醇</2>输注过程中，发现显着的<4>高催乳素血症</4> ，以及对<LH-RH>的垂体反应消失，与对照受试者的反应相比。", "revised": true}
{"doc_key": "3864191", "sentences": [["Salicylate", "nephropathy", "in", "the", "Gunn", "rat", ":", "potential", "role", "of", "prostaglandins", ".", "We", "examined", "the", "potential", "role", "of", "prostaglandins", "in", "the", "development", "of", "analgesic", "nephropathy", "in", "the", "Gunn", "strain", "of", "rat", ".", "The", "homozygous", "Gunn", "rats", "have", "unconjugated", "hyperbilirubinemia", "due", "to", "the", "absence", "of", "glucuronyl", "transferase", ",", "leading", "to", "marked", "bilirubin", "deposition", "in", "renal", "medulla", "and", "papilla", ".", "These", "rats", "are", "also", "highly", "susceptible", "to", "develop", "papillary", "necrosis", "with", "analgesic", "administration", ".", "We", "used", "homozygous", "(", "jj", ")", "and", "phenotypically", "normal", "heterozygous", "(", "jJ", ")", "animals", ".", "Four", "groups", "of", "rats", "(", "n", "=", "7", ")", "were", "studied", ":", "jj", "and", "jJ", "rats", "treated", "either", "with", "aspirin", "300", "mg", "/", "kg", "every", "other", "day", "or", "sham", "-", "treated", ".", "After", "one", "week", ",", "slices", "of", "cortex", ",", "outer", "and", "inner", "medulla", "from", "one", "kidney", "were", "incubated", "in", "buffer", "and", "prostaglandin", "synthesis", "was", "determined", "by", "radioimmunoassay", ".", "The", "other", "kidney", "was", "examined", "histologically", ".", "A", "marked", "corticomedullary", "gradient", "of", "prostaglandin", "synthesis", "was", "observed", "in", "all", "groups", ".", "PGE2", "synthesis", "was", "significantly", "higher", "in", "outer", "medulla", ",", "but", "not", "cortex", "or", "inner", "medulla", ",", "of", "jj", "(", "38", "+", "/", "-", "6", "ng", "/", "mg", "prot", ")", "than", "jJ", "rats", "(", "15", "+", "/", "-", "3", ")", "(", "p", "less", "than", "0", ".", "01", ")", ".", "Aspirin", "treatment", "reduced", "PGE2", "synthesis", "in", "all", "regions", ",", "but", "outer", "medullary", "PGE2", "remained", "higher", "in", "jj", "(", "18", "+", "/", "-", "3", ")", "than", "jJ", "rats", "(", "9", "+", "/", "-", "2", ")", "(", "p", "less", "than", "0", ".", "05", ")", ".", "PGF2", "alpha", "was", "also", "significantly", "higher", "in", "the", "outer", "medulla", "of", "jj", "rats", "with", "and", "without", "aspirin", "administration", "(", "p", "less", "than", "0", ".", "05", ")", ".", "The", "changes", "in", "renal", "prostaglandin", "synthesis", "were", "accompanied", "by", "evidence", "of", "renal", "damage", "in", "aspirin", "-", "treated", "jj", "but", "not", "jJ", "rats", "as", "evidenced", "by", ":", "increased", "incidence", "and", "severity", "of", "hematuria", "(", "p", "less", "than", "0", ".", "01", ")", ";", "increased", "serum", "creatinine", "(", "p", "less", "than", "0", ".", "05", ")", ";", "and", "increase", "in", "outer", "medullary", "histopathologic", "lesions", "(", "p", "less", "than", "0", ".", "005", "compared", "to", "either", "sham", "-", "treated", "jj", "or", "aspirin", "-", "treated", "jJ", ")", ".", "These", "results", "suggest", "that", "enhanced", "prostaglandin", "synthesis", "contributes", "to", "maintenance", "of", "renal", "function", "and", "morphological", "integrity", ",", "and", "that", "inhibition", "of", "prostaglandin", "synthesis", "may", "lead", "to", "pathological", "renal", "medullary", "lesions", "and", "deterioration", "of", "renal", "function", "."]], "ner": [[[106, 106, "Chemical"], [214, 214, "Chemical"], [273, 273, "Chemical"], [298, 298, "Chemical"], [359, 359, "Chemical"], [1, 1, "Disease"], [24, 24, "Disease"], [295, 296, "Disease"], [396, 399, "Disease"], [0, 0, "Chemical"], [38, 38, "Disease"], [66, 67, "Disease"], [315, 315, "Disease"], [391, 394, "Disease"], [10, 10, "Chemical"], [18, 18, "Chemical"], [139, 139, "Chemical"], [158, 158, "Chemical"], [288, 288, "Chemical"], [370, 370, "Chemical"], [386, 386, "Chemical"], [50, 50, "Chemical"], [166, 166, "Chemical"], [217, 217, "Chemical"], [226, 226, "Chemical"], [257, 258, "Chemical"], [327, 327, "Chemical"]]], "relations": [[[106, 106, 1, 1, "CID"], [106, 106, 24, 24, "CID"], [106, 106, 295, 296, "CID"], [106, 106, 396, 399, "CID"], [214, 214, 1, 1, "CID"], [214, 214, 24, 24, "CID"], [214, 214, 295, 296, "CID"], [214, 214, 396, 399, "CID"], [273, 273, 1, 1, "CID"], [273, 273, 24, 24, "CID"], [273, 273, 295, 296, "CID"], [273, 273, 396, 399, "CID"], [298, 298, 1, 1, "CID"], [298, 298, 24, 24, "CID"], [298, 298, 295, 296, "CID"], [298, 298, 396, 399, "CID"], [359, 359, 1, 1, "CID"], [359, 359, 24, 24, "CID"], [359, 359, 295, 296, "CID"], [359, 359, 396, 399, "CID"]]], "clusters": [], "translated": " <9>水杨酸盐</9> <5>肾病</5>在Gunn大鼠中：<14>前列腺素</14>的潜在作用。我们检查了<15>前列腺素</15>在大鼠Gunn品系中镇痛剂<6>肾病</6>发展中的潜在作用。纯合子Gunn大鼠因缺乏葡萄糖醛酸转移酶而出现非结合<10>高胆红素血症</10>，导致<21>胆红素</21>显着沉积于肾髓质和肾乳头。这些大鼠也极易发生<11>乳头状坏死</11>镇痛给药。我们使用纯合子(jj)和表型正常的杂合子(jJ)动物。对四组大鼠(n=7)进行了研究：jj和jJ大鼠每隔一天接受<0>阿司匹林</0>300mg/kg治疗或假治疗。一周后，将来自一个肾脏的皮质、外层和内层髓质切片在缓冲液中孵育，并通过放射免疫测定法测定<16>前列腺素</16>的合成。对另一个肾脏进行了组织学检查。在所有组中均观察到显着的<17>前列腺素</17>合成皮质髓质梯度。<22>PGE2</22>合成在jj (38+/-6ng/mg蛋白) 的外髓质中明显高于jJ大鼠(15+/-3) (p<0.01)。<1>阿司匹林</1>治疗减少了所有区域的<23>PGE2</23>合成，但外髓<24>PGE2</24>在jj(18+/-3)中仍然高于jJ大鼠(9+/-2) (p<0.05)。<25>PGF2α</25>在服用和未服用<2>阿司匹林</2>的jj大鼠的外髓质中也显着升高(p<0.05)。肾脏<18>前列腺素</18>合成的变化伴随着<3>阿司匹林</3>治疗的jj大鼠<7>肾损伤</7>的证据，但不是jJ大鼠，证据是：发病率增加和<12>血尿</12>的严重程度(p<0.01)；增加血清<26>肌酐</26>(p<0.05);和外髓组织病理学损伤的增加(与假治疗的jj或<4>阿司匹林</4>治疗的jJ相比，p<0.005)。这些结果表明，增强的<19>前列腺素</19>合成有助于维持肾功能和形态完整性，而抑制<20>前列腺素</20>合成可能导致<13>病理性肾髓质损伤</13>和<8>肾功能恶化</8>。", "revised": true}
{"doc_key": "7315949", "sentences": [["Medial", "changes", "in", "arterial", "spasm", "induced", "by", "L", "-", "norepinephrine", ".", "In", "normal", "rats", ",", "the", "media", "of", "small", "arteries", "(", "0", ".", "4", "-", "-", "0", ".", "2", "mm", "in", "diameter", ")", "previously", "was", "shown", "to", "contain", "intracellular", "vacuoles", ",", "identified", "ultrastructurally", "as", "herniations", "of", "one", "smooth", "muscle", "cell", "into", "another", ".", "The", "hypothesis", "that", "intense", "vasoconstriction", "would", "increase", "the", "number", "of", "such", "vacuoles", "has", "been", "tested", ".", "In", "the", "media", "of", "the", "saphenous", "artery", "and", "its", "distal", "branch", ",", "vasoconstriction", "induced", "by", "L", "-", "norepinephrine", "produced", "many", "cell", "-", "to", "-", "cell", "hernias", "within", "15", "minutes", ".", "At", "1", "day", "their", "number", "was", "reduced", "to", "about", "1", "/", "10", "of", "the", "original", "number", ".", "By", "7", "days", "the", "vessel", "was", "almost", "restored", "to", "normal", ".", "Triple", "stimulation", "over", "1", "day", "induced", "more", "severe", "changes", "in", "the", "media", ".", "These", "findings", "suggest", "that", "smooth", "muscle", "cells", "are", "susceptible", "to", "damage", "in", "the", "course", "of", "their", "specific", "function", ".", "The", "experimental", "data", "are", "discussed", "in", "relation", "to", "medial", "changes", "observed", "in", "other", "instances", "of", "arterial", "spasm", ".", "Endothelial", "changes", "that", "developed", "in", "the", "same", "experimental", "model", "were", "described", "in", "a", "previous", "paper", "."]], "ner": [[[7, 9, "Chemical"], [84, 86, "Chemical"], [4, 4, "Disease"], [175, 175, "Disease"], [94, 94, "Disease"]]], "relations": [[[7, 9, 4, 4, "CID"], [7, 9, 175, 175, "CID"], [84, 86, 4, 4, "CID"], [84, 86, 175, 175, "CID"]]], "clusters": [], "translated": "对<0>L-去甲肾上腺素</0>引起的动脉<2>痉挛</2>的内侧变化。在正常大鼠中，小动脉中膜（直径 0.4 - 0.2 毫米）以前显示含有细胞内液泡，在超微结构上被确定为一个平滑肌细胞向另一个平滑肌细胞的突出。强烈的血管收缩会增加这种液泡数量的假设已经过检验。在隐动脉及其远端分支的中层，<1>L-去甲肾上腺素</1>引起的血管收缩在15分钟内产生了许多细胞间<4>疝</4>。在第1天，他们的数量减少到原来数量的十分之一。到7天时，血管几乎恢复正常。超过1天的三重刺激在媒介中引起了更严重的变化。这些发现表明，平滑肌细胞在其特定功能的过程中容易受到损伤。讨论了与在其他动脉<3>痉挛</3>实例中观察到的内侧变化相关的实验数据。在之前的一篇论文中描述了在同一实验模型中发生的内皮细胞变化。", "revised": true}
{"doc_key": "7176945", "sentences": [["Post", "-", "suxamethonium", "pains", "in", "Nigerian", "surgical", "patients", ".", "Contrary", "to", "an", "earlier", "report", "by", "Coxon", ",", "scoline", "pain", "occurs", "in", "African", "negroes", ".", "Its", "incidence", "was", "determined", "in", "a", "prospective", "study", "involving", "a", "total", "of", "100", "Nigerian", "patients", "(", "50", "out", "-", "patients", "and", "50", "in", "-", "patients", ")", ".", "About", "62", "%", "of", "the", "out", "-", "patients", "developed", "scoline", "pain", "as", "compared", "with", "about", "26", "%", "among", "the", "in", "-", "patients", ".", "The", "abolition", "of", "muscle", "fasciculations", "(", "by", "0", ".", "075mg", "/", "kg", "dose", "of", "Fazadinium", ")", "did", "not", "influence", "the", "occurrence", "of", "scoline", "pain", ".", "Neither", "the", "type", "of", "induction", "agent", "(", "Althesin", "or", "Thiopentone", ")", "nor", "the", "salt", "preparation", "of", "suxamethonium", "used", "(", "chloride", "or", "bromide", ")", ",", "affected", "the", "incidence", "of", "scoline", "pain", "."]], "ner": [[[2, 2, "Chemical"], [17, 17, "Chemical"], [60, 60, "Chemical"], [96, 96, "Chemical"], [115, 115, "Chemical"], [127, 127, "Chemical"], [3, 3, "Disease"], [18, 18, "Disease"], [61, 61, "Disease"], [97, 97, "Disease"], [128, 128, "Disease"], [78, 78, "Disease"], [88, 88, "Chemical"], [106, 106, "Chemical"], [108, 108, "Chemical"], [118, 118, "Chemical"], [120, 120, "Chemical"]]], "relations": [[[2, 2, 3, 3, "CID"], [2, 2, 18, 18, "CID"], [2, 2, 61, 61, "CID"], [2, 2, 97, 97, "CID"], [2, 2, 128, 128, "CID"], [17, 17, 3, 3, "CID"], [17, 17, 18, 18, "CID"], [17, 17, 61, 61, "CID"], [17, 17, 97, 97, "CID"], [17, 17, 128, 128, "CID"], [60, 60, 3, 3, "CID"], [60, 60, 18, 18, "CID"], [60, 60, 61, 61, "CID"], [60, 60, 97, 97, "CID"], [60, 60, 128, 128, "CID"], [96, 96, 3, 3, "CID"], [96, 96, 18, 18, "CID"], [96, 96, 61, 61, "CID"], [96, 96, 97, 97, "CID"], [96, 96, 128, 128, "CID"], [115, 115, 3, 3, "CID"], [115, 115, 18, 18, "CID"], [115, 115, 61, 61, "CID"], [115, 115, 97, 97, "CID"], [115, 115, 128, 128, "CID"], [127, 127, 3, 3, "CID"], [127, 127, 18, 18, "CID"], [127, 127, 61, 61, "CID"], [127, 127, 97, 97, "CID"], [127, 127, 128, 128, "CID"], [2, 2, 78, 78, "CID"], [17, 17, 78, 78, "CID"], [60, 60, 78, 78, "CID"], [96, 96, 78, 78, "CID"], [115, 115, 78, 78, "CID"], [127, 127, 78, 78, "CID"]]], "clusters": [], "translated": "尼日利亚手术患者<0>琥珀胆碱</0><6>疼痛</6>后。与Coxon早先的报告相反，<1>scoline</1><7>疼痛</7>发生在非洲黑人身上。它的发病率是在一项涉及总共100名尼日利亚患者（50名门诊患者和50名住院患者）的前瞻性研究中确定的。大约62%的门诊患者出现了<2>scoline</2><8>疼痛</8>，而住院患者中这一比例约为26%。肌肉<11>肌束震颤</11>的消除（按0.075mg/kg剂量的<12>法扎定</12>）不影响<3>司可碱</3><9>疼痛</9>。既没有使用诱导剂的类型（<13>Althesin</13>或<14>Thiopentone</14>），也没有使用<4>琥珀胆碱</4>的盐制剂（<15>氯化物</15>或<16>溴化物</16>），影响<5>scoline</5><10>疼痛</10>的发生。", "revised": true}
{"doc_key": "7173007", "sentences": [["Comparative", "study", ":", "Endografine", "(", "diatrizoate", ")", ",", "Vasurix", "polyvidone", "(", "acetrizoate", ")", ",", "Dimer", "-", "X", "(", "iocarmate", ")", "and", "Hexabrix", "(", "ioxaglate", ")", "in", "hysterosalpingography", ".", "Side", "effects", "of", "hysterosalpingography", "with", "Dimer", "-", "X", ",", "Hexabrix", ",", "Vasurix", "polyvidone", "and", "Endografine", "in", "142", "consecutive", "patients", ",", "receiving", "one", "of", "the", "four", "tested", "media", "were", "evaluated", "from", "replies", "to", "postal", "questionnaires", ".", "The", "Dimer", "-", "X", "group", "had", "a", "higher", "incidence", "of", "nausea", "and", "dizziness", ".", "The", "Endografine", "group", "had", "a", "higher", "incidence", "of", "abdominal", "pain", ".", "These", "differences", "occur", "especially", "in", "the", "age", "groups", "under", "30", "years", ".", "Hexabrix", "and", "Vasurix", "polyvidone", "are", "considered", "the", "best", "contrast", "media", "for", "hysterosalpingography", "and", "perhaps", "because", "of", "its", "low", "toxicity", "Hexabrix", "should", "be", "preferred", "."]], "ner": [[[3, 3, "Chemical"], [42, 42, "Chemical"], [78, 78, "Chemical"], [85, 86, "Disease"], [14, 16, "Chemical"], [18, 18, "Chemical"], [33, 35, "Chemical"], [64, 66, "Chemical"], [73, 73, "Disease"], [75, 75, "Disease"], [118, 118, "Disease"], [5, 5, "Chemical"], [8, 9, "Chemical"], [11, 11, "Chemical"], [39, 40, "Chemical"], [102, 103, "Chemical"], [21, 21, "Chemical"], [23, 23, "Chemical"], [37, 37, "Chemical"], [100, 100, "Chemical"], [119, 119, "Chemical"], [108, 109, "Chemical"]]], "relations": [[[3, 3, 85, 86, "CID"], [42, 42, 85, 86, "CID"], [78, 78, 85, 86, "CID"], [14, 16, 73, 73, "CID"], [18, 18, 73, 73, "CID"], [33, 35, 73, 73, "CID"], [64, 66, 73, 73, "CID"], [14, 16, 75, 75, "CID"], [18, 18, 75, 75, "CID"], [33, 35, 75, 75, "CID"], [64, 66, 75, 75, "CID"]]], "clusters": [], "translated": "比较研究：<0>Endografine</0>（<11>二碘酸 </11>），<12>Vasurix polyvidone</12>（<13>乙酰二碘酸盐</13>），<4>Dimer-X</4>（<5>碘喹酯</5>）和<16>Hexabrix</16>（<17>碘酸六甲酯</17>）在子宫输卵管造影中。 <6>Dimer-X</6>、 <18>Hexabrix</18>、<14>Vasurix polyvidone</14>和<1>Endografine</1>四种造影剂的输卵管造影在连续评估了 142位接受四种测试媒体之一的病人的邮寄问卷所得的响应后，副作用被评估。 <7>Dimer-X</7>组出现<8>恶心</8>和<9>头晕</9>发生率较高。 <2>Endografine</2>组出现<3>腹痛</3>的发生率较高。这些差异尤其在30岁以下的年龄组中出现。 <19> Hexabrix </19>和<15> Vasurix polyvidone </15> 被认为是用于子宫输卵管造影的最佳<21>造影剂</21>，可能是因为其低<10>毒性</10>，所以<20>Hexabrix</20>应该是首选。", "revised": true}
{"doc_key": "6985297", "sentences": [["Studies", "on", "the", "bradycardia", "induced", "by", "bepridil", ".", "Bepridil", ",", "a", "novel", "active", "compound", "for", "prophylactic", "treatment", "of", "anginal", "attacks", ",", "induced", "persistent", "bradycardia", "and", "a", "non", "-", "specific", "anti", "-", "tachycardial", "effect", ",", "the", "mechanisms", "of", "which", "were", "investigated", "in", "vitro", "and", "in", "vivo", ".", "In", "vitro", "perfusion", "of", "bepridil", "in", "the", "life", "-", "support", "medium", "for", "isolated", "sino", "-", "atrial", "tissue", "from", "rabbit", "heart", ",", "caused", "a", "reduction", "in", "action", "potential", "(", "AP", ")", "spike", "frequency", "(", "recorded", "by", "KCl", "microelectrodes", ")", "starting", "at", "doses", "of", "5", "X", "10", "(", "-", "6", ")", "M", ".", "This", "effect", "was", "dose", "-", "dependent", "up", "to", "concentrations", "of", "5", "X", "10", "(", "-", "5", ")", "M", ",", "whereupon", "blockade", "of", "sinus", "activity", "set", "in", ".", "Bepridil", "at", "a", "dose", "of", "5", "X", "10", "(", "-", "6", ")", "M", ",", "induced", "a", "concomitant", "reduction", "in", "AP", "amplitude", "(", "falling", "from", "71", "+", "/", "-", "8", "mV", "to", "47", "+", "/", "-", "6", "mV", ")", ",", "maximum", "systolic", "depolarization", "velocity", "(", "phase", "0", ")", "which", "fell", "from", "1", ".", "85", "+", "/", "-", "0", ".", "35", "V", "/", "s", "to", "0", ".", "84", "+", "/", "-", "0", ".", "28", "V", "/", "s", ",", "together", "with", "maximum", "diastolic", "depolarization", "velocity", "(", "phase", "4", ")", "which", "fell", "from", "38", "+", "/", "-", "3", "mV", "/", "s", "to", "24", "+", "/", "-", "5", "mV", "/", "s", ".", "In", "vivo", "injection", "of", "bepridil", "at", "a", "dose", "of", "5", "mg", "/", "kg", "(", "i", ".", "v", ".", ")", "into", "6", "anaesthetized", "dogs", "which", "had", "undergone", "ablation", "of", "all", "the", "extrinsic", "cardiac", "afferent", "nerve", "supply", ",", "together", "with", "a", "bilateral", "medullo", "-", "adrenalectomy", ",", "caused", "a", "marked", "reduction", "in", "heart", "rate", "which", "fell", "from", "98", ".", "7", "+", "/", "-", "4", ".", "2", "beats", "/", "min", "to", "76", "+", "/", "-", "5", ".", "3", "beats", "/", "min", "sustained", "for", "more", "than", "45", "min", ".", "It", "is", "concluded", "that", "bepridil", "reduces", "heart", "rate", "by", "acting", "directly", "on", "the", "sinus", "node", ".", "This", "effect", ",", "which", "results", "in", "a", "flattening", "of", "the", "phase", "0", "and", "phase", "4", "slope", ",", "together", "with", "a", "longer", "AP", "duration", ",", "may", "be", "due", "to", "an", "increase", "in", "the", "time", "constants", "of", "slow", "inward", "ionic", "currents", "(", "already", "demonstrated", "elsewhere", ")", ",", "but", "also", "to", "an", "increased", "time", "constant", "for", "deactivation", "of", "the", "outward", "potassium", "current", "(", "Ip", ")", "."]], "ner": [[[6, 6, "Chemical"], [8, 8, "Chemical"], [50, 50, "Chemical"], [124, 124, "Chemical"], [235, 235, "Chemical"], [319, 319, "Chemical"], [3, 3, "Disease"], [23, 23, "Disease"], [81, 81, "Chemical"], [388, 388, "Chemical"], [18, 19, "Disease"], [31, 31, "Disease"]]], "relations": [[[6, 6, 3, 3, "CID"], [6, 6, 23, 23, "CID"], [8, 8, 3, 3, "CID"], [8, 8, 23, 23, "CID"], [50, 50, 3, 3, "CID"], [50, 50, 23, 23, "CID"], [124, 124, 3, 3, "CID"], [124, 124, 23, 23, "CID"], [235, 235, 3, 3, "CID"], [235, 235, 23, 23, "CID"], [319, 319, 3, 3, "CID"], [319, 319, 23, 23, "CID"]]], "clusters": [], "translated": "<0>苄普地尔</0>致<6>心动过缓</6>的研究。<1>苄普地尔</1>，一种用于预防性治疗<10>心绞痛发作</10>的新型活性化合物，可诱发持续性<7>心动过缓</7>和非特异性抗<11>心动过速</11>效应，其机制在体外和体内进行了研究。离体兔心脏窦房组织在维持生命的介质中加入<2>苄普地尔</2>，可在剂量为5 X 10 (-6) M 时引起动作电位(AP)尖峰频率（由<8> KCl </8>微电极记录）降低。这种效应是剂量依赖性的，浓度高达 5 X 10 (-5) M，窦性活动受阻。<3>苄普地尔</3>在剂量为5 X 10 (-6) M 时，同时诱导AP振幅降低（从71 +/- 8 mV 降至47 +/- 6 mV）、最大收缩去极化速度（阶段0）降低（从1.85 +/- 0.35 V/s 降至0.84 +/- 0.28 V/s），以及最大舒张期去极化速度（阶段4）降低（从38 +/- 3 mV/s 降至24 +/- 5 mV/s）。将<4>苄普地尔</4>以5 mg/kg (i.v.)的剂量注入6只已经切断所有外源性心脏传入神经，并进行了双侧髓质肾上腺切除术的麻醉狗体内，可导致心率明显降低，从98.7 +/- 4.2 次/分 降至76 +/- 5.3 次/分，持续45分钟以上。结论为<5>苄普地尔</5>通过直接作用于窦房结来降低心率，这种效应导致阶段0和阶段4斜率变平，同时AP持续时间变长，这可能是由于缓慢内向离子电流的时间常数增加(已在其他地方证实） ，也可能是由于外向<9>钾</9>电流失活的时间常数(Ip)增加。", "revised": true}
{"doc_key": "7369302", "sentences": [["Abnormalities", "of", "the", "pupil", "and", "visual", "-", "evoked", "potential", "in", "quinine", "amblyopia", ".", "Total", "blindness", "with", "a", "transient", "tonic", "pupillary", "response", ",", "denervation", "supersensitivity", ",", "and", "abnormal", "visual", "-", "evoked", "potentials", "developed", "in", "a", "54", "-", "year", "-", "old", "man", "after", "the", "use", "of", "quinine", "sulfate", "for", "leg", "cramps", ".", "He", "later", "recovered", "normal", "visual", "acuity", ".", "A", "transient", "tonic", "pupillary", "response", ",", "denervation", "supersensitivity", ",", "and", "abnormal", "visual", "-", "evoked", "potentials", "in", "quinine", "toxicity", ",", "to", "our", "knowledge", ",", "have", "not", "been", "previously", "reported", "."]], "ner": [[[10, 10, "Chemical"], [44, 45, "Chemical"], [73, 73, "Chemical"], [11, 11, "Disease"], [14, 14, "Disease"], [18, 19, "Disease"], [59, 60, "Disease"], [47, 48, "Disease"], [74, 74, "Disease"]]], "relations": [[[10, 10, 11, 11, "CID"], [44, 45, 11, 11, "CID"], [73, 73, 11, 11, "CID"], [10, 10, 14, 14, "CID"], [44, 45, 14, 14, "CID"], [73, 73, 14, 14, "CID"], [10, 10, 18, 19, "CID"], [10, 10, 59, 60, "CID"], [44, 45, 18, 19, "CID"], [44, 45, 59, 60, "CID"], [73, 73, 18, 19, "CID"], [73, 73, 59, 60, "CID"]]], "clusters": [], "translated": "<0>奎宁</0><3>弱视</3>及<0>视觉诱发电位</0>异常，<2>奎宁</2><8>毒性</8>中出现完全<4>失明</4>，伴有短暂的<5>强直性瞳孔</5>反应和去神经超敏反应。一名 54 岁男性在使用<1>硫酸奎宁</1>治疗<7>腿抽筋</7>后出现上述症状。他后来恢复了正常的视力。据我们所知，奎宁毒性中的短暂<6>强直性瞳孔</6>反应、去神经超敏反应和异常<0>视觉诱发电位</0>以前未见报道。", "revised": true}
{"doc_key": "6310832", "sentences": [["Early", "infections", "in", "kidney", ",", "heart", ",", "and", "liver", "transplant", "recipients", "on", "cyclosporine", ".", "Eighty", "-", "one", "renal", ",", "seventeen", "heart", ",", "and", "twenty", "-", "four", "liver", "transplant", "patients", "were", "followed", "for", "infection", ".", "Seventeen", "renal", "patients", "received", "azathioprine", "(", "Aza", ")", "and", "prednisone", "as", "part", "of", "a", "randomized", "trial", "of", "immunosuppression", "with", "21", "cyclosporine", "-", "and", "-", "prednisone", "-", "treated", "renal", "transplant", "patients", ".", "All", "others", "received", "cyclosporine", "and", "prednisone", ".", "The", "randomized", "Aza", "patients", "had", "more", "overall", "infections", "(", "P", "less", "than", "0", ".", "05", ")", "and", "more", "nonviral", "infections", "(", "P", "less", "than", "0", ".", "02", ")", "than", "the", "randomized", "cyclosporine", "patients", ".", "Heart", "and", "liver", "patients", "had", "more", "infections", "than", "cyclosporine", "renal", "patients", "but", "fewer", "infections", "than", "the", "Aza", "renal", "patients", ".", "There", "were", "no", "infectious", "deaths", "in", "renal", "transplant", "patients", "on", "cyclosporine", "or", "Aza", ",", "but", "infection", "played", "a", "major", "role", "in", "3", "out", "of", "6", "cardiac", "transplant", "deaths", "and", "in", "8", "out", "of", "9", "liver", "transplant", "deaths", ".", "Renal", "patients", "on", "cyclosporine", "had", "the", "fewest", "bacteremias", ".", "Analysis", "of", "site", "of", "infection", "showed", "a", "preponderance", "of", "abdominal", "infections", "in", "liver", "patients", ",", "intrathoracic", "infections", "in", "heart", "patients", ",", "and", "urinary", "tract", "infections", "in", "renal", "patients", ".", "Pulmonary", "infections", "were", "less", "common", "in", "cyclosporine", "-", "treated", "renal", "patients", "than", "in", "Aza", "-", "treated", "patients", "(", "P", "less", "than", "0", ".", "05", ")", ".", "Aza", "patients", "had", "significantly", "more", "staphylococcal", "infections", "than", "all", "other", "transplant", "groups", "(", "P", "less", "than", "0", ".", "005", ")", ",", "and", "systemic", "fungal", "infections", "occurred", "only", "in", "the", "liver", "transplant", "group", ".", "Cytomegalovirus", "(", "CMV", ")", "shedding", "or", "serological", "rises", "in", "antibody", "titer", ",", "or", "both", "occurred", "in", "78", "%", "of", "cyclosporine", "patients", "and", "76", "%", "of", "Aza", "patients", ".", "Of", "the", "cyclosporine", "patients", ",", "15", "%", "had", "symptoms", "related", "to", "CMV", "infection", ".", "Serological", "evidence", "for", "Epstein", "Barr", "Virus", "infection", "was", "found", "in", "20", "%", "of", "65", "cyclosporine", "patients", "studied", ".", "Three", "had", "associated", "symptoms", ",", "and", "one", "developed", "a", "lymphoma", "."]], "ner": [[[12, 12, "Chemical"], [54, 54, "Chemical"], [68, 68, "Chemical"], [103, 103, "Chemical"], [114, 114, "Chemical"], [136, 136, "Chemical"], [167, 167, "Chemical"], [208, 208, "Chemical"], [280, 280, "Chemical"], [291, 291, "Chemical"], [317, 317, "Chemical"], [1, 1, "Disease"], [32, 32, "Disease"], [79, 79, "Disease"], [91, 91, "Disease"], [112, 112, "Disease"], [119, 119, "Disease"], [141, 141, "Disease"], [177, 177, "Disease"], [189, 189, "Disease"], [203, 203, "Disease"], [38, 38, "Chemical"], [40, 40, "Chemical"], [74, 74, "Chemical"], [122, 122, "Chemical"], [138, 138, "Chemical"], [215, 215, "Chemical"], [228, 228, "Chemical"], [286, 286, "Chemical"], [43, 43, "Chemical"], [58, 58, "Chemical"], [70, 70, "Chemical"], [171, 171, "Disease"], [182, 183, "Disease"], [195, 197, "Disease"], [233, 234, "Disease"], [251, 252, "Disease"], [300, 301, "Disease"], [306, 309, "Disease"], [330, 330, "Disease"]]], "relations": [[[12, 12, 1, 1, "CID"], [12, 12, 32, 32, "CID"], [12, 12, 79, 79, "CID"], [12, 12, 91, 91, "CID"], [12, 12, 112, 112, "CID"], [12, 12, 119, 119, "CID"], [12, 12, 141, 141, "CID"], [12, 12, 177, 177, "CID"], [12, 12, 189, 189, "CID"], [12, 12, 203, 203, "CID"], [54, 54, 1, 1, "CID"], [54, 54, 32, 32, "CID"], [54, 54, 79, 79, "CID"], [54, 54, 91, 91, "CID"], [54, 54, 112, 112, "CID"], [54, 54, 119, 119, "CID"], [54, 54, 141, 141, "CID"], [54, 54, 177, 177, "CID"], [54, 54, 189, 189, "CID"], [54, 54, 203, 203, "CID"], [68, 68, 1, 1, "CID"], [68, 68, 32, 32, "CID"], [68, 68, 79, 79, "CID"], [68, 68, 91, 91, "CID"], [68, 68, 112, 112, "CID"], [68, 68, 119, 119, "CID"], [68, 68, 141, 141, "CID"], [68, 68, 177, 177, "CID"], [68, 68, 189, 189, "CID"], [68, 68, 203, 203, "CID"], [103, 103, 1, 1, "CID"], [103, 103, 32, 32, "CID"], [103, 103, 79, 79, "CID"], [103, 103, 91, 91, "CID"], [103, 103, 112, 112, "CID"], [103, 103, 119, 119, "CID"], [103, 103, 141, 141, "CID"], [103, 103, 177, 177, "CID"], [103, 103, 189, 189, "CID"], [103, 103, 203, 203, "CID"], [114, 114, 1, 1, "CID"], [114, 114, 32, 32, "CID"], [114, 114, 79, 79, "CID"], [114, 114, 91, 91, "CID"], [114, 114, 112, 112, "CID"], [114, 114, 119, 119, "CID"], [114, 114, 141, 141, "CID"], [114, 114, 177, 177, "CID"], [114, 114, 189, 189, "CID"], [114, 114, 203, 203, "CID"], [136, 136, 1, 1, "CID"], [136, 136, 32, 32, "CID"], [136, 136, 79, 79, "CID"], [136, 136, 91, 91, "CID"], [136, 136, 112, 112, "CID"], [136, 136, 119, 119, "CID"], [136, 136, 141, 141, "CID"], [136, 136, 177, 177, "CID"], [136, 136, 189, 189, "CID"], [136, 136, 203, 203, "CID"], [167, 167, 1, 1, "CID"], [167, 167, 32, 32, "CID"], [167, 167, 79, 79, "CID"], [167, 167, 91, 91, "CID"], [167, 167, 112, 112, "CID"], [167, 167, 119, 119, "CID"], [167, 167, 141, 141, "CID"], [167, 167, 177, 177, "CID"], [167, 167, 189, 189, "CID"], [167, 167, 203, 203, "CID"], [208, 208, 1, 1, "CID"], [208, 208, 32, 32, "CID"], [208, 208, 79, 79, "CID"], [208, 208, 91, 91, "CID"], [208, 208, 112, 112, "CID"], [208, 208, 119, 119, "CID"], [208, 208, 141, 141, "CID"], [208, 208, 177, 177, "CID"], [208, 208, 189, 189, "CID"], [208, 208, 203, 203, "CID"], [280, 280, 1, 1, "CID"], [280, 280, 32, 32, "CID"], [280, 280, 79, 79, "CID"], [280, 280, 91, 91, "CID"], [280, 280, 112, 112, "CID"], [280, 280, 119, 119, "CID"], [280, 280, 141, 141, "CID"], [280, 280, 177, 177, "CID"], [280, 280, 189, 189, "CID"], [280, 280, 203, 203, "CID"], [291, 291, 1, 1, "CID"], [291, 291, 32, 32, "CID"], [291, 291, 79, 79, "CID"], [291, 291, 91, 91, "CID"], [291, 291, 112, 112, "CID"], [291, 291, 119, 119, "CID"], [291, 291, 141, 141, "CID"], [291, 291, 177, 177, "CID"], [291, 291, 189, 189, "CID"], [291, 291, 203, 203, "CID"], [317, 317, 1, 1, "CID"], [317, 317, 32, 32, "CID"], [317, 317, 79, 79, "CID"], [317, 317, 91, 91, "CID"], [317, 317, 112, 112, "CID"], [317, 317, 119, 119, "CID"], [317, 317, 141, 141, "CID"], [317, 317, 177, 177, "CID"], [317, 317, 189, 189, "CID"], [317, 317, 203, 203, "CID"], [38, 38, 1, 1, "CID"], [38, 38, 32, 32, "CID"], [38, 38, 79, 79, "CID"], [38, 38, 91, 91, "CID"], [38, 38, 112, 112, "CID"], [38, 38, 119, 119, "CID"], [38, 38, 141, 141, "CID"], [38, 38, 177, 177, "CID"], [38, 38, 189, 189, "CID"], [38, 38, 203, 203, "CID"], [40, 40, 1, 1, "CID"], [40, 40, 32, 32, "CID"], [40, 40, 79, 79, "CID"], [40, 40, 91, 91, "CID"], [40, 40, 112, 112, "CID"], [40, 40, 119, 119, "CID"], [40, 40, 141, 141, "CID"], [40, 40, 177, 177, "CID"], [40, 40, 189, 189, "CID"], [40, 40, 203, 203, "CID"], [74, 74, 1, 1, "CID"], [74, 74, 32, 32, "CID"], [74, 74, 79, 79, "CID"], [74, 74, 91, 91, "CID"], [74, 74, 112, 112, "CID"], [74, 74, 119, 119, "CID"], [74, 74, 141, 141, "CID"], [74, 74, 177, 177, "CID"], [74, 74, 189, 189, "CID"], [74, 74, 203, 203, "CID"], [122, 122, 1, 1, "CID"], [122, 122, 32, 32, "CID"], [122, 122, 79, 79, "CID"], [122, 122, 91, 91, "CID"], [122, 122, 112, 112, "CID"], [122, 122, 119, 119, "CID"], [122, 122, 141, 141, "CID"], [122, 122, 177, 177, "CID"], [122, 122, 189, 189, "CID"], [122, 122, 203, 203, "CID"], [138, 138, 1, 1, "CID"], [138, 138, 32, 32, "CID"], [138, 138, 79, 79, "CID"], [138, 138, 91, 91, "CID"], [138, 138, 112, 112, "CID"], [138, 138, 119, 119, "CID"], [138, 138, 141, 141, "CID"], [138, 138, 177, 177, "CID"], [138, 138, 189, 189, "CID"], [138, 138, 203, 203, "CID"], [215, 215, 1, 1, "CID"], [215, 215, 32, 32, "CID"], [215, 215, 79, 79, "CID"], [215, 215, 91, 91, "CID"], [215, 215, 112, 112, "CID"], [215, 215, 119, 119, "CID"], [215, 215, 141, 141, "CID"], [215, 215, 177, 177, "CID"], [215, 215, 189, 189, "CID"], [215, 215, 203, 203, "CID"], [228, 228, 1, 1, "CID"], [228, 228, 32, 32, "CID"], [228, 228, 79, 79, "CID"], [228, 228, 91, 91, "CID"], [228, 228, 112, 112, "CID"], [228, 228, 119, 119, "CID"], [228, 228, 141, 141, "CID"], [228, 228, 177, 177, "CID"], [228, 228, 189, 189, "CID"], [228, 228, 203, 203, "CID"], [286, 286, 1, 1, "CID"], [286, 286, 32, 32, "CID"], [286, 286, 79, 79, "CID"], [286, 286, 91, 91, "CID"], [286, 286, 112, 112, "CID"], [286, 286, 119, 119, "CID"], [286, 286, 141, 141, "CID"], [286, 286, 177, 177, "CID"], [286, 286, 189, 189, "CID"], [286, 286, 203, 203, "CID"]]], "clusters": [], "translated": "<0>环孢素</0>肾、心脏和肝移植受者的早期<11>感染</11>。对81名肾脏移植患者、17名心脏移植患者和24名肝移植患者进行了<12>感染</12>随访。17名肾病患者接受了<21>硫唑嘌呤</21>（<22>Aza</22>）和<29>泼尼松</29>作为免疫抑制随机试验的一部分21<1>环孢菌素</1>-和-<30>泼尼松</30>-治疗肾移植患者。所有其他人都接受了<2>环孢菌素</2>和<31>泼尼松</31>。随机化的<23>Aza</23>患者总体<13>感染</13>（P小于0.05）和非病毒性<14>感染</14>（P小于0.02）多于随机<3>环孢菌素</3> 患者。心脏和肝脏患者的<15>感染</15>多于<4>环孢菌素</4>肾脏患者，但<16>感染</16>少于<24>Aza</24>肾脏患者。<5>环孢菌素</5>或<25>阿扎</25>肾移植患者无感染性死亡，但<17>感染</17>在6例心脏移植死亡中的3例中起主要作用，9例肝移植死亡中有8例死亡。服用<6>环孢素</6>的肾病患者<32>菌血症</32>最少。<18>感染</18>部位分析显示，肝病患者<33>腹部感染</33>、心脏病患者胸内<19>感染</19>和<34>泌尿道感染</34>在肾病患者中。肺部<20>感染</20>在接受<7>环孢菌素</7>治疗的肾病患者中比接受<26>Aza</26>治疗的患者少见（P小于0.05）。<27>Aza</27>患者的<35>葡萄球菌感染</35>显着高于所有其他移植组（P小于0.005），全身<36>真菌感染</36>仅发生在肝移植组。78%的<8>环孢菌素</8>患者和76%的<28>Aza</28>患者出现巨细胞病毒（CMV）脱落或抗体滴度血清学升高，或两者兼而有之。在<9>环孢菌素</9>患者中，15%有与<37>CMV感染</37>相关的症状。在所研究的65名<10>环孢菌素</10>患者中，有20%发现了<38>Epstein Barr病毒感染</38>的血清学证据。三个有相关症状，一个发展为<39>淋巴瘤</39>。", "revised": true}
{"doc_key": "6631522", "sentences": [["Effect", "of", "doxorubicin", "on", "[", "omega", "-", "I", "-", "131", "]", "heptadecanoic", "acid", "myocardial", "scintigraphy", "and", "echocardiography", "in", "dogs", ".", "The", "effects", "of", "serial", "treatment", "with", "doxorubicin", "on", "dynamic", "myocardial", "scintigraphy", "with", "[", "omega", "-", "I", "-", "131", "]", "heptadecanoic", "acid", "(", "I", "-", "131", "HA", ")", ",", "and", "on", "global", "left", "-", "ventricular", "function", "determined", "echocardiographically", ",", "were", "studied", "in", "a", "group", "of", "nine", "mongrel", "dogs", ".", "Total", "extractable", "myocardial", "lipid", "was", "compared", "postmortem", "between", "a", "group", "of", "control", "dogs", "and", "doxorubicin", "-", "treated", "dogs", ".", "A", "significant", "and", "then", "progressive", "fall", "in", "global", "LV", "function", "was", "observed", "at", "a", "cumulative", "doxorubicin", "dose", "of", "4", "mg", "/", "kg", ".", "A", "significant", "increase", "in", "the", "myocardial", "t1", "/", "2", "of", "the", "I", "-", "131", "HA", "was", "observed", "only", "at", "a", "higher", "cumulative", "dose", ",", "10", "mg", "/", "kg", ".", "No", "significant", "alteration", "in", "total", "extractable", "myocardial", "lipids", "was", "observed", "between", "control", "dogs", "and", "those", "treated", "with", "doxorubicin", ".", "Our", "findings", "suggest", "that", "the", "changes", "leading", "to", "an", "alteration", "of", "myocardial", "dynamic", "imaging", "with", "I", "-", "131", "HA", "are", "not", "the", "initiating", "factor", "in", "doxorubicin", "cardiotoxicity", "."]], "ner": [[[2, 2, "Chemical"], [26, 26, "Chemical"], [82, 82, "Chemical"], [102, 102, "Chemical"], [156, 156, "Chemical"], [183, 183, "Chemical"], [184, 184, "Disease"], [4, 12, "Chemical"], [32, 40, "Chemical"], [42, 45, "Chemical"], [121, 124, "Chemical"], [173, 176, "Chemical"]]], "relations": [[[2, 2, 184, 184, "CID"], [26, 26, 184, 184, "CID"], [82, 82, 184, 184, "CID"], [102, 102, 184, 184, "CID"], [156, 156, 184, 184, "CID"], [183, 183, 184, 184, "CID"]]], "clusters": [], "translated": "<0>多柔比星</0>对犬<7>[omega-I-131]十七烷酸</7>心肌显像和超声心动图的影响。 研究了<1>多柔比星</1>系列治疗对<8>[omega-I-131]十七烷酸</8>(<9>I-131HA</9>)动态心肌显像的影响，以及对通过超声心动图确定的整体左心室功能的影响，在一组九只杂种犬中进行。比较了对照犬和接受<2>多柔比星</2>治疗犬的尸检总可提取心肌脂质。在累积<3>阿霉素</3> 剂量为4mg/kg 时，观察到整体LV功能显着先下降然后逐渐下降。仅在累积剂量较高达到10mg/kg 时，才观察到<10>I-131HA</10>的心肌t1/2 显着增加。未观察到对照组和接受<4>多柔比星</4>治疗组的可提取心肌脂肪总量有显著变化。我们的研究结果表明，导致<11>I-131HA</11>心肌动态成像改变的变化不是<5>多柔比星</5><6>心脏毒性</6>的起始因素。", "revised": true}
{"doc_key": "7411769", "sentences": [["Indomethacin", "-", "induced", "hyperkalemia", "in", "three", "patients", "with", "gouty", "arthritis", ".", "We", "describe", "three", "patients", "in", "whom", "severe", ",", "life", "-", "threatening", "hyperkalemia", "and", "renal", "insufficiency", "developed", "after", "treatment", "of", "acute", "gouty", "arthritis", "with", "indomethacin", ".", "This", "complication", "may", "result", "from", "an", "inhibition", "of", "prostaglandin", "synthesis", "and", "consequent", "hyporeninemic", "hypoaidosteronism", ".", "Careful", "attention", "to", "renal", "function", "and", "potassium", "balance", "in", "patients", "receiving", "indomethacin", "or", "other", "nonsteroidal", "anti", "-", "inflammatory", "agents", ",", "particularly", "in", "those", "patients", "with", "diabetes", "mellitus", "or", "preexisting", "renal", "disease", ",", "will", "help", "prevent", "this", "potentially", "serious", "complication", "."]], "ner": [[[0, 0, "Chemical"], [34, 34, "Chemical"], [62, 62, "Chemical"], [3, 3, "Disease"], [22, 22, "Disease"], [24, 25, "Disease"], [8, 9, "Disease"], [31, 32, "Disease"], [48, 49, "Disease"], [76, 77, "Disease"], [80, 81, "Disease"], [44, 44, "Chemical"], [57, 57, "Chemical"]]], "relations": [[[0, 0, 3, 3, "CID"], [0, 0, 22, 22, "CID"], [34, 34, 3, 3, "CID"], [34, 34, 22, 22, "CID"], [62, 62, 3, 3, "CID"], [62, 62, 22, 22, "CID"], [0, 0, 24, 25, "CID"], [34, 34, 24, 25, "CID"], [62, 62, 24, 25, "CID"]]], "clusters": [], "translated": " <0>吲哚美辛</0> 引起的 <3>高血钾</3> 在三例 <6>痛风性关节炎</6> 患者中的表现。我们描述了三名患者，在使用 <1>吲哚美辛</1> 治疗急性 <7>痛风性关节炎</7> 后出现了严重、危及生命的 <4>高钾血症</4>和 <5>肾功能不全</5>。这种并发症可能是由于抑制 <11>前列腺素 </11>的合成和随之而来的<8>低肾素血症 hypoaidosteronism </8>引起的。在接受<2>吲哚美辛</2>或其他非甾体类抗炎药治疗的患者中，特别是那些患有 <9>糖尿病</9>或既往患有 <10>肾脏疾病</10> 的患者，特别注意肾功能和 <12>钾</12>平衡，有助于预防这种潜在的严重并发症。", "revised": true}
{"doc_key": "7457821", "sentences": [["Etomidate", ":", "a", "foreshortened", "clinical", "trial", ".", "A", "clinical", "evaluation", "of", "etomidate", "for", "outpatient", "cystoscopy", "was", "embarked", "upon", ".", "Unpremedicated", "patients", "were", "given", "fentanyl", "1", "microgram", "/", "kg", "followed", "by", "etomidate", "0", ".", "3", "mg", "/", "kg", ".", "Anaesthesia", "was", "maintained", "with", "intermittent", "etomidate", "in", "2", "-", "4", "mg", "doses", ".", "Patients", "were", "interviewed", "personally", "later", "the", "same", "day", ",", "and", "by", "questionnaire", "three", "to", "four", "weeks", "later", ".", "The", "trial", "was", "discontinued", "after", "20", "cases", "because", "of", "an", "unacceptable", "incidence", "of", "side", "effects", ".", "Venous", "pain", "occurred", "in", "68", "%", "of", "patients", "and", "50", "%", "had", "redness", ",", "pain", "or", "swelling", "related", "to", "the", "injection", "site", ",", "in", "some", "cases", "lasting", "up", "to", "three", "weeks", "after", "anaesthesia", ".", "Skeletal", "movements", "occurred", "in", "50", "%", "of", "patients", ";", "30", "%", "experienced", "respiratory", "upset", ",", "one", "sufficiently", "severe", "to", "necessitate", "abandoning", "the", "technique", ".", "Nausea", "and", "vomiting", "occurred", "in", "40", "%", "and", "25", "%", "had", "disturbing", "emergence", "psychoses", "."]], "ner": [[[0, 0, "Chemical"], [11, 11, "Chemical"], [30, 30, "Chemical"], [43, 43, "Chemical"], [86, 86, "Disease"], [99, 99, "Disease"], [131, 132, "Disease"], [143, 143, "Disease"], [145, 145, "Disease"], [156, 156, "Disease"], [101, 101, "Disease"], [23, 23, "Chemical"]]], "relations": [[[0, 0, 86, 86, "CID"], [0, 0, 99, 99, "CID"], [11, 11, 86, 86, "CID"], [11, 11, 99, 99, "CID"], [30, 30, 86, 86, "CID"], [30, 30, 99, 99, "CID"], [43, 43, 86, 86, "CID"], [43, 43, 99, 99, "CID"], [0, 0, 131, 132, "CID"], [11, 11, 131, 132, "CID"], [30, 30, 131, 132, "CID"], [43, 43, 131, 132, "CID"], [0, 0, 143, 143, "CID"], [11, 11, 143, 143, "CID"], [30, 30, 143, 143, "CID"], [43, 43, 143, 143, "CID"], [0, 0, 145, 145, "CID"], [11, 11, 145, 145, "CID"], [30, 30, 145, 145, "CID"], [43, 43, 145, 145, "CID"], [0, 0, 156, 156, "CID"], [11, 11, 156, 156, "CID"], [30, 30, 156, 156, "CID"], [43, 43, 156, 156, "CID"]]], "clusters": [], "translated": " <0>依托咪酯</0>：缩短的临床试验。 <1>依托咪酯</1>用于门诊膀胱镜检查的临床评价已着手进行。未预先用药的患者给予<11>芬太尼</11> 1 微克 / 千克，然后<2>依托咪酯</2> 0.3 毫克 / 千克。间歇性<3>依托咪酯</3>以 2-4 mg剂量维持麻醉。患者在同一天晚些时候接受面谈，并在三到四个星期后进行问卷调查。由于不可接受的副作用发生率，该试验在 20 例病例后终止。68%的患者出现静脉<4>疼痛</4>和50%有与注射部位相关的发红、 <5>疼痛</5>或<10>肿胀</10>，在某些情况下持续时间长达麻醉后三周。50%的患者出现骨骼运动；30%经历过<6>呼吸不适</6>，严重到需要放弃该技术。<7>恶心</7>和<8>呕吐</8>发生在40%，25%有令人不安的出现<9>精神病</9>。", "revised": true}
{"doc_key": "7477981", "sentences": [["Levodopa", "-", "induced", "dyskinesias", "are", "improved", "by", "fluoxetine", ".", "We", "evaluated", "the", "severity", "of", "motor", "disability", "and", "dyskinesias", "in", "seven", "levodopa", "-", "responsive", "patients", "with", "Parkinson", "'s", "disease", "after", "an", "acute", "challenge", "with", "the", "mixed", "dopamine", "agonist", ",", "apomorphine", ",", "before", "and", "after", "the", "administration", "of", "fluoxetine", "(", "20", "mg", "twice", "per", "day", ")", "for", "11", "+", "/", "-", "1", "days", ".", "After", "fluoxetine", "treatment", ",", "there", "was", "a", "significant", "47", "%", "improvement", "(", "p", "<", "0", ".", "05", ")", "of", "apomorphine", "-", "induced", "dyskinesias", "without", "modification", "of", "parkinsonian", "motor", "disability", ".", "The", "dyskinesias", "were", "reduced", "predominantly", "in", "the", "lower", "limbs", "during", "the", "onset", "and", "disappearance", "of", "dystonic", "dyskinesias", "(", "onset", "-", "and", "end", "-", "of", "-", "dose", "dyskinesias", ")", "and", "in", "the", "upper", "limbs", "during", "choreic", "mid", "-", "dose", "dyskinesias", ".", "The", "results", "suggest", "that", "increased", "brain", "serotoninergic", "transmission", "with", "fluoxetine", "may", "reduce", "levodopa", "-", "or", "dopamine", "agonist", "-", "induced", "dyskinesias", "without", "aggravating", "parkinsonian", "motor", "disability", "."]], "ner": [[[7, 7, "Chemical"], [46, 46, "Chemical"], [63, 63, "Chemical"], [141, 141, "Chemical"], [3, 3, "Disease"], [17, 17, "Disease"], [84, 84, "Disease"], [93, 93, "Disease"], [107, 108, "Disease"], [118, 118, "Disease"], [126, 130, "Disease"], [151, 151, "Disease"], [38, 38, "Chemical"], [81, 81, "Chemical"], [0, 0, "Chemical"], [20, 20, "Chemical"], [144, 144, "Chemical"], [14, 15, "Disease"], [89, 90, "Disease"], [155, 156, "Disease"], [25, 27, "Disease"], [88, 88, "Disease"], [154, 154, "Disease"], [35, 35, "Chemical"], [147, 147, "Chemical"]]], "relations": [[[7, 7, 3, 3, "CID"], [7, 7, 17, 17, "CID"], [7, 7, 84, 84, "CID"], [7, 7, 93, 93, "CID"], [7, 7, 107, 108, "CID"], [7, 7, 118, 118, "CID"], [7, 7, 126, 130, "CID"], [7, 7, 151, 151, "CID"], [46, 46, 3, 3, "CID"], [46, 46, 17, 17, "CID"], [46, 46, 84, 84, "CID"], [46, 46, 93, 93, "CID"], [46, 46, 107, 108, "CID"], [46, 46, 118, 118, "CID"], [46, 46, 126, 130, "CID"], [46, 46, 151, 151, "CID"], [63, 63, 3, 3, "CID"], [63, 63, 17, 17, "CID"], [63, 63, 84, 84, "CID"], [63, 63, 93, 93, "CID"], [63, 63, 107, 108, "CID"], [63, 63, 118, 118, "CID"], [63, 63, 126, 130, "CID"], [63, 63, 151, 151, "CID"], [141, 141, 3, 3, "CID"], [141, 141, 17, 17, "CID"], [141, 141, 84, 84, "CID"], [141, 141, 93, 93, "CID"], [141, 141, 107, 108, "CID"], [141, 141, 118, 118, "CID"], [141, 141, 126, 130, "CID"], [141, 141, 151, 151, "CID"], [38, 38, 3, 3, "CID"], [38, 38, 17, 17, "CID"], [38, 38, 84, 84, "CID"], [38, 38, 93, 93, "CID"], [38, 38, 107, 108, "CID"], [38, 38, 118, 118, "CID"], [38, 38, 126, 130, "CID"], [38, 38, 151, 151, "CID"], [81, 81, 3, 3, "CID"], [81, 81, 17, 17, "CID"], [81, 81, 84, 84, "CID"], [81, 81, 93, 93, "CID"], [81, 81, 107, 108, "CID"], [81, 81, 118, 118, "CID"], [81, 81, 126, 130, "CID"], [81, 81, 151, 151, "CID"]]], "clusters": [], "translated": "<14>左旋多巴</14>引起的<4>运动障碍</4>可通过<0>氟西汀</0>得到改善。我们评估了7名<15>左旋多巴</15>有反应的<20>帕金森病</20>患者<17>运动障碍</17>和<5>异动症</5>的严重程度，在服用(20毫克，每天两次)<1>氟西汀</1>之前和之后11 + / -1天，接受了混合<23>多巴胺</23>激动剂<12>阿扑吗啡</12>的急性挑战。在氟西汀<2>治疗后</2>，<13>阿扑吗啡</13>诱发的<6>异动症</6>显着改善了47%（p<0.05），而没有改变<21>帕金森</21>的<18>运动障碍</18>。运动障碍<7>在</7><8>肌张力障碍性运动障碍</8>（剂量开始和结束时的<9>运动障碍</9>）的发作和消失期主要在下肢减少，在<10>舞蹈病剂量期间</10>，上肢的运动障碍减少。结果表明，使用<3>氟西汀</3>增加大脑血清素能传输可能会减少<16>左旋多巴</16>-或<24>多巴胺</24>激动剂诱发的<11>运动障碍</11>，而不会加重<22>帕金森</22>的<19>运动障碍</19>。", "revised": true}
{"doc_key": "7671401", "sentences": [["Increased", "frequency", "and", "severity", "of", "angio", "-", "oedema", "related", "to", "long", "-", "term", "therapy", "with", "angiotensin", "-", "converting", "enzyme", "inhibitor", "in", "two", "patients", ".", "Adverse", "reactions", "to", "drugs", "are", "well", "recognized", "as", "a", "cause", "of", "acute", "or", "chronic", "urticaria", ",", "and", "angio", "-", "oedema", ".", "Angiotensin", "-", "converting", "enzyme", "(", "ACE", ")", "inhibitors", ",", "used", "to", "treat", "hypertension", "and", "congestive", "heart", "failure", ",", "were", "introduced", "in", "Europe", "in", "the", "middle", "of", "the", "eighties", ",", "and", "the", "use", "of", "these", "drugs", "has", "increased", "progressively", ".", "Soon", "after", "the", "introduction", "of", "ACE", "inhibitors", ",", "acute", "bouts", "of", "angio", "-", "oedema", "were", "reported", "in", "association", "with", "the", "use", "of", "these", "drugs", ".", "We", "wish", "to", "draw", "attention", "to", "the", "possibility", "of", "adverse", "reactions", "to", "ACE", "inhibitors", "after", "long", "-", "term", "use", "and", "in", "patients", "with", "pre", "-", "existing", "angio", "-", "oedema", "."]], "ner": [[[15, 19, "Chemical"], [45, 52, "Chemical"], [89, 90, "Chemical"], [121, 122, "Chemical"], [5, 7, "Disease"], [41, 43, "Disease"], [95, 97, "Disease"], [135, 137, "Disease"], [38, 38, "Disease"], [57, 57, "Disease"], [59, 61, "Disease"]]], "relations": [[[15, 19, 5, 7, "CID"], [15, 19, 41, 43, "CID"], [15, 19, 95, 97, "CID"], [15, 19, 135, 137, "CID"], [45, 52, 5, 7, "CID"], [45, 52, 41, 43, "CID"], [45, 52, 95, 97, "CID"], [45, 52, 135, 137, "CID"], [89, 90, 5, 7, "CID"], [89, 90, 41, 43, "CID"], [89, 90, 95, 97, "CID"], [89, 90, 135, 137, "CID"], [121, 122, 5, 7, "CID"], [121, 122, 41, 43, "CID"], [121, 122, 95, 97, "CID"], [121, 122, 135, 137, "CID"]]], "clusters": [], "translated": "两名患者 <4>血管性水肿</4> 的频率和严重程度增加与<0>血管紧张素转换酶抑制剂</0>的长期治疗有关。众所周知，药物不良反应是引起急性或慢性<8>荨麻疹</8>和<5>血管性水肿</5>的原因。<1>血管紧张素转换酶 (ACE) 抑制剂</1>，用于治疗<9>高血压</9>和<10>充血性心力衰竭</10>，于八十年代中期引入欧洲，并且这些药物的使用逐渐增加。<2>ACE抑制剂</2>推出后不久，据报道与使用这些药物有关的<6>血管性水肿</6>急性发作。我们希望提请注意<3>ACE抑制剂</3>在长期使用后和已有<7>血管性水肿</7>的患者中发生不良反应的可能性。", "revised": true}
{"doc_key": "7147232", "sentences": [["Cardiovascular", "effects", "of", "hypotension", "induced", "by", "adenosine", "triphosphate", "and", "sodium", "nitroprusside", "on", "dogs", "with", "denervated", "hearts", ".", "Adenosine", "triphosphate", "(", "ATP", ")", "and", "sodium", "nitroprusside", "(", "SNP", ")", "are", "administered", "to", "patients", "to", "induce", "and", "control", "hypotension", "during", "anesthesia", ".", "SNP", "is", "authorized", "for", "clinical", "use", "in", "USA", "and", "UK", ",", "and", "ATP", "is", "clinically", "used", "in", "other", "countries", "such", "as", "Japan", ".", "We", "investigated", "how", "these", "two", "drugs", "act", "on", "the", "cardiovascular", "systems", "of", "20", "dogs", "whose", "hearts", "had", "been", "denervated", "by", "a", "procedure", "we", "had", "devised", ".", "ATP", "(", "10", "dogs", ")", "or", "SNP", "(", "10", "dogs", ")", "was", "administered", "to", "reduce", "mean", "arterial", "pressure", "by", "30", "%", "to", "70", "%", "of", "control", ".", "Before", ",", "during", "and", "after", "induced", "hypotension", ",", "we", "measured", "major", "cardiovascular", "parameters", ".", "Hypotension", "induced", "by", "ATP", "was", "accompanied", "by", "significant", "decreases", "in", "mean", "pulmonary", "arterial", "pressure", "(", "p", "less", "than", "0", ".", "001", ")", ",", "central", "venous", "pressure", "(", "p", "less", "than", "0", ".", "001", ")", ",", "left", "ventricular", "end", "-", "diastolic", "pressure", "(", "p", "less", "than", "0", ".", "001", ")", ",", "total", "peripheral", "resistance", "(", "p", "less", "than", "0", ".", "001", ")", ",", "rate", "pressure", "product", "(", "p", "less", "than", "0", ".", "001", ")", ",", "total", "body", "oxygen", "consumption", "(", "p", "less", "than", "0", ".", "05", ")", ",", "and", "heart", "rate", "(", "p", "less", "than", "0", ".", "001", ")", ";", "all", "these", "variables", "returned", "normal", "within", "30", "min", "after", "ATP", "was", "stopped", ".", "Cardiac", "output", "did", "not", "change", ".", "During", "hypotension", "produced", "by", "SNP", "similar", "decreases", "were", "observed", "in", "mean", "pulmonary", "arterial", "pressure", "(", "p", "less", "than", "0", ".", "01", ")", ",", "central", "venous", "pressure", "(", "p", "less", "than", "0", ".", "001", ")", ",", "left", "ventricular", "end", "-", "diastolic", "pressure", "(", "p", "less", "than", "0", ".", "01", ")", ",", "total", "peripheral", "resistance", "(", "p", "less", "than", "0", ".", "001", ")", ",", "rate", "pressure", "product", "(", "p", "less", "than", "0", ".", "001", ")", ",", "and", "oxygen", "content", "difference", "between", "arterial", "and", "mixed", "venous", "blood", "(", "p", "less", "than", "0", ".", "05", ")", ",", "while", "heart", "rate", "(", "p", "less", "than", "0", ".", "001", ")", "and", "cardiac", "output", "(", "p", "less", "than", "0", ".", "05", ")", "were", "increased", ".", "Recoveries", "of", "heart", "rate", "and", "left", "ventricular", "end", "-", "diastolic", "pressure", "were", "not", "shown", "within", "60", "min", "after", "SNP", "had", "been", "stopped", ".", "Both", "ATP", "and", "SNP", "should", "act", "on", "the", "pacemaker", "tissue", "of", "the", "heart", "."]], "ner": [[[6, 7, "Chemical"], [17, 18, "Chemical"], [20, 20, "Chemical"], [52, 52, "Chemical"], [89, 89, "Chemical"], [133, 133, "Chemical"], [238, 238, "Chemical"], [390, 390, "Chemical"], [3, 3, "Disease"], [36, 36, "Disease"], [122, 122, "Disease"], [130, 130, "Disease"], [249, 249, "Disease"], [9, 10, "Chemical"], [23, 24, "Chemical"], [26, 26, "Chemical"], [40, 40, "Chemical"], [95, 95, "Chemical"], [252, 252, "Chemical"], [384, 384, "Chemical"], [392, 392, "Chemical"], [206, 206, "Chemical"], [323, 323, "Chemical"]]], "relations": [[[6, 7, 3, 3, "CID"], [6, 7, 36, 36, "CID"], [6, 7, 122, 122, "CID"], [6, 7, 130, 130, "CID"], [6, 7, 249, 249, "CID"], [17, 18, 3, 3, "CID"], [17, 18, 36, 36, "CID"], [17, 18, 122, 122, "CID"], [17, 18, 130, 130, "CID"], [17, 18, 249, 249, "CID"], [20, 20, 3, 3, "CID"], [20, 20, 36, 36, "CID"], [20, 20, 122, 122, "CID"], [20, 20, 130, 130, "CID"], [20, 20, 249, 249, "CID"], [52, 52, 3, 3, "CID"], [52, 52, 36, 36, "CID"], [52, 52, 122, 122, "CID"], [52, 52, 130, 130, "CID"], [52, 52, 249, 249, "CID"], [89, 89, 3, 3, "CID"], [89, 89, 36, 36, "CID"], [89, 89, 122, 122, "CID"], [89, 89, 130, 130, "CID"], [89, 89, 249, 249, "CID"], [133, 133, 3, 3, "CID"], [133, 133, 36, 36, "CID"], [133, 133, 122, 122, "CID"], [133, 133, 130, 130, "CID"], [133, 133, 249, 249, "CID"], [238, 238, 3, 3, "CID"], [238, 238, 36, 36, "CID"], [238, 238, 122, 122, "CID"], [238, 238, 130, 130, "CID"], [238, 238, 249, 249, "CID"], [390, 390, 3, 3, "CID"], [390, 390, 36, 36, "CID"], [390, 390, 122, 122, "CID"], [390, 390, 130, 130, "CID"], [390, 390, 249, 249, "CID"], [9, 10, 3, 3, "CID"], [9, 10, 36, 36, "CID"], [9, 10, 122, 122, "CID"], [9, 10, 130, 130, "CID"], [9, 10, 249, 249, "CID"], [23, 24, 3, 3, "CID"], [23, 24, 36, 36, "CID"], [23, 24, 122, 122, "CID"], [23, 24, 130, 130, "CID"], [23, 24, 249, 249, "CID"], [26, 26, 3, 3, "CID"], [26, 26, 36, 36, "CID"], [26, 26, 122, 122, "CID"], [26, 26, 130, 130, "CID"], [26, 26, 249, 249, "CID"], [40, 40, 3, 3, "CID"], [40, 40, 36, 36, "CID"], [40, 40, 122, 122, "CID"], [40, 40, 130, 130, "CID"], [40, 40, 249, 249, "CID"], [95, 95, 3, 3, "CID"], [95, 95, 36, 36, "CID"], [95, 95, 122, 122, "CID"], [95, 95, 130, 130, "CID"], [95, 95, 249, 249, "CID"], [252, 252, 3, 3, "CID"], [252, 252, 36, 36, "CID"], [252, 252, 122, 122, "CID"], [252, 252, 130, 130, "CID"], [252, 252, 249, 249, "CID"], [384, 384, 3, 3, "CID"], [384, 384, 36, 36, "CID"], [384, 384, 122, 122, "CID"], [384, 384, 130, 130, "CID"], [384, 384, 249, 249, "CID"], [392, 392, 3, 3, "CID"], [392, 392, 36, 36, "CID"], [392, 392, 122, 122, "CID"], [392, 392, 130, 130, "CID"], [392, 392, 249, 249, "CID"]]], "clusters": [], "translated": " <0>三磷酸腺苷</0>和<13>硝普钠</13>引起的<8>低血压</8>对去神经心脏犬的心血管影响。 <1>三磷酸腺苷</1>（<2>ATP</2>）和<14>硝普钠</14>（<15>SNP</15>）对患者给药以诱导和控制<9>麻醉期间的低血压</9>。 <16>SNP</16>在美国和英国获准临床使用，<3>ATP</3>在日本等其他国家获准临床使用。我们调查了这两种药物如何作用于20只狗的心血管系统，这些狗的心脏已通过我们设计的程序进行了去神经支配。 <4>ATP</4>（10只狗）或<17>SNP</17>（10只狗）被给药以将平均动脉压降低30%至70%的控制。在诱发<10>低血压</10>之前、期间和之后，我们测量了主要的心血管参数。 <11>ATP</11>引起的<5>低血压</5>伴有平均肺动脉压（p小于0.001）、中心静脉压（p小于0.001）、左心室舒张末期压（p小于0.001）、总外周阻力（p小于0.001）、率压乘积（p小于0.001）、全身<21>氧</21>消耗量(p小于0.05)和心率(p小于0.001)；在<6>ATP</6>停止后30分钟内，所有这些变量都恢复正常。心输出量没有变化。在<18>SNP</18>产生的<12>低血压</12>期间，观察到平均肺动脉压（p小于0.01）、中心静脉压（p小于0.001）、左侧心室舒张末期压（p小于0.01）、总外周阻力（p小于0.001）、心率压积（p小于0.001）和<22>氧</22>含量之间的差异动脉和混合静脉血(p小于0.05)，而心率(p小于0.001)和心输出量(p小于0.05)均增加。 <19>SNP</19>停止后60分钟内，心率和左心室舒张末期压未恢复。<7>ATP</7>和<20>SNP</20>都应该作用于心脏的起搏器组织。", "revised": true}
{"doc_key": "7378868", "sentences": [["Suxamethonium", "-", "induced", "jaw", "stiffness", "and", "myalgia", "associated", "with", "atypical", "cholinesterase", ":", "case", "report", ".", "An", "11", "-", "year", "-", "old", "boy", "was", "given", "halothane", ",", "nitrous", "oxide", "and", "oxygen", ",", "pancuronium", "0", ".", "4", "mg", "and", "suxamethonium", "100", "mg", "for", "induction", "of", "anaesthesia", ".", "In", "response", "to", "this", "a", "marked", "jaw", "stiffness", "occurred", "which", "lasted", "for", "two", "minutes", "and", "the", "anaesthesia", "were", "terminated", ".", "Four", "hours", "of", "apnoea", "ensued", "and", "he", "suffered", "generalized", "severe", "myalgia", "lasting", "for", "one", "week", ".", "He", "was", "found", "to", "have", "atypical", "plasma", "cholinesterase", "with", "a", "dibucaine", "number", "of", "12", ",", "indicating", "homozygocity", ".", "This", "was", "verified", "by", "study", "of", "the", "family", ".", "The", "case", "shows", "that", "prolonged", "jaw", "rigidity", "and", "myalgia", "may", "occur", "after", "suxamethonium", "in", "patients", "with", "atypical", "cholinesterase", "despite", "pretreatment", "with", "pancuronium", "."]], "ner": [[[0, 0, "Chemical"], [37, 37, "Chemical"], [120, 120, "Chemical"], [3, 4, "Disease"], [51, 52, "Disease"], [112, 114, "Disease"], [6, 6, "Disease"], [75, 75, "Disease"], [116, 116, "Disease"], [68, 68, "Disease"], [24, 24, "Chemical"], [26, 27, "Chemical"], [29, 29, "Chemical"], [31, 31, "Chemical"], [129, 129, "Chemical"], [91, 91, "Chemical"]]], "relations": [[[0, 0, 3, 4, "CID"], [0, 0, 51, 52, "CID"], [0, 0, 112, 114, "CID"], [37, 37, 3, 4, "CID"], [37, 37, 51, 52, "CID"], [37, 37, 112, 114, "CID"], [120, 120, 3, 4, "CID"], [120, 120, 51, 52, "CID"], [120, 120, 112, 114, "CID"], [0, 0, 6, 6, "CID"], [0, 0, 75, 75, "CID"], [0, 0, 116, 116, "CID"], [37, 37, 6, 6, "CID"], [37, 37, 75, 75, "CID"], [37, 37, 116, 116, "CID"], [120, 120, 6, 6, "CID"], [120, 120, 75, 75, "CID"], [120, 120, 116, 116, "CID"], [0, 0, 68, 68, "CID"], [37, 37, 68, 68, "CID"], [120, 120, 68, 68, "CID"]]], "clusters": [], "translated": " <0>琥珀胆碱</0>引起的<3>颌骨僵硬</3>和<6>肌痛</6>与非典型胆碱酯酶相关：病例报告。一名 11 岁男孩服用了<10>氟烷</10>、<11>氧化亚氮</11>和<12>氧气</12>、<13>泮库溴铵</13> 0.4 毫克和<1>琥珀胆碱</1> 100 毫克用于诱导麻醉。作为对此的反应，发生了明显的<4>下颌僵硬</4>，持续了两分钟，麻醉终止。随后发生了4小时的<9>呼吸暂停</9>和持续一周的全身性严重<7>肌痛</7>。他被发现具有非典型血浆胆碱酯酶，<15>二丁卡因</15>数为12，表明纯合子。家庭的研究证实了这一点。该病例表明，尽管预处理了<14>泮库溴铵</14>，非典型胆碱酯酶患者<2>琥珀胆碱</2>后仍可能出现持续的<5>下颌强直</5>和<8>肌痛</8>。", "revised": true}
{"doc_key": "8096565", "sentences": [["Transmural", "myocardial", "infarction", "with", "sumatriptan", ".", "For", "sumatriptan", ",", "tightness", "in", "the", "chest", "caused", "by", "an", "unknown", "mechanism", "has", "been", "reported", "in", "3", "-", "5", "%", "of", "users", ".", "We", "describe", "a", "47", "-", "year", "-", "old", "woman", "with", "an", "acute", "myocardial", "infarction", "after", "administration", "of", "sumatriptan", "6", "mg", "subcutaneously", "for", "cluster", "headache", ".", "The", "patient", "had", "no", "history", "of", "underlying", "ischaemic", "heart", "disease", "or", "Prinzmetal", "'s", "angina", ".", "She", "recovered", "without", "complications", "."]], "ner": [[[4, 4, "Chemical"], [7, 7, "Chemical"], [46, 46, "Chemical"], [1, 2, "Disease"], [41, 42, "Disease"], [51, 52, "Disease"], [61, 63, "Disease"], [65, 67, "Disease"]]], "relations": [[[4, 4, 1, 2, "CID"], [4, 4, 41, 42, "CID"], [7, 7, 1, 2, "CID"], [7, 7, 41, 42, "CID"], [46, 46, 1, 2, "CID"], [46, 46, 41, 42, "CID"]]], "clusters": [], "translated": "<0>舒马普坦</0>透壁<3>心肌梗塞</3>。对于<1>舒马普坦</1>，据报道有3-5%的使用者因未知机制导致胸闷。我们描述了一名47岁的女性，在因<5>丛集性头痛</5>皮下注射<2>舒马普坦</2>6mg后发生急性<4>心肌梗死</4>。患者没有潜在的<6>缺血性心脏病</6>或<7>Prinzmetal's angina</7>病史。她康复了，没有出现并发症。", "revised": true}
{"doc_key": "7967231", "sentences": [["Pharmacological", "studies", "on", "a", "new", "dihydrothienopyridine", "calcium", "antagonist", ",", "S", "-", "312", "-", "d", ".", "5th", "communication", ":", "anticonvulsant", "effects", "in", "mice", ".", "S", "-", "312", ",", "S", "-", "312", "-", "d", ",", "but", "not", "S", "-", "312", "-", "l", ",", "L", "-", "type", "calcium", "channel", "antagonists", ",", "showed", "anticonvulsant", "effects", "on", "the", "audiogenic", "tonic", "convulsions", "in", "DBA", "/", "2", "mice", ";", "and", "their", "ED50", "values", "were", "18", ".", "4", "(", "12", ".", "8", "-", "27", ".", "1", ")", "mg", "/", "kg", ",", "p", ".", "o", ".", "and", "15", ".", "0", "(", "10", ".", "2", "-", "23", ".", "7", ")", "mg", "/", "kg", ",", "p", ".", "o", ".", ",", "respectively", ",", "while", "that", "of", "flunarizine", "was", "34", ".", "0", "(", "26", ".", "0", "-", "44", ".", "8", ")", "mg", "/", "kg", ",", "p", ".", "o", ".", "Although", "moderate", "anticonvulsant", "effects", "of", "S", "-", "312", "-", "d", "in", "higher", "doses", "were", "observed", "against", "the", "clonic", "convulsions", "induced", "by", "pentylenetetrazole", "(", "85", "mg", "/", "kg", ",", "s", ".", "c", ".", ")", "or", "bemegride", "(", "40", "mg", "/", "kg", ",", "s", ".", "c", ".", ")", ",", "no", "effects", "were", "observed", "in", "convulsions", "induced", "by", "N", "-", "methyl", "-", "D", "-", "aspartate", ",", "picrotoxin", ",", "or", "electroshock", "in", "Slc", ":", "ddY", "mice", ".", "S", "-", "312", "-", "d", "may", "be", "useful", "in", "the", "therapy", "of", "certain", "types", "of", "human", "epilepsy", "."]], "ner": [[[157, 157, "Chemical"], [154, 154, "Disease"], [188, 188, "Disease"], [170, 170, "Chemical"], [199, 199, "Chemical"], [9, 13, "Chemical"], [23, 25, "Chemical"], [27, 31, "Chemical"], [141, 145, "Chemical"], [209, 213, "Chemical"], [53, 55, "Disease"], [225, 225, "Disease"], [44, 44, "Chemical"], [114, 114, "Chemical"], [191, 197, "Chemical"]]], "relations": [[[157, 157, 154, 154, "CID"], [157, 157, 188, 188, "CID"], [170, 170, 154, 154, "CID"], [170, 170, 188, 188, "CID"], [199, 199, 154, 154, "CID"], [199, 199, 188, 188, "CID"]]], "clusters": [], "translated": "一种新型二氢噻吩并吡啶类钙拮抗剂<5>S-312-d</5>的药理研究。第五次交流：对小鼠的抗惊厥作用。<6>S-312</6>，<7>S-312-d</7>，但不是S-312-l，L型<12>钙</12>通道拮抗剂，显示抗惊厥作用。DBA/2小鼠的<10>听源性强直性惊厥</10>，其中<6>S-312 </6>，<7>S-312-d</7> ，但不是S-312-l， L型<12>钙</12>通道拮抗剂，其ED50值分别为18.4（12.8-27.1）mg/kg，口服，和15.0（10.2-23.7）mg/kg，口服，而<13>氟桂利嗪</13>的ED50值为34.0（26.0-44.8）mg/kg，口服。虽然观察到<8>S-312-d</8>在较高剂量时对<0>戊四唑</0>（85mg/kg，皮下注射）或<3>贝美格列</3>（40mg/kg，皮下注射）引起的<1>弛缓性</1>惊厥有反应，但没有对由<14>N-甲基-D-天冬氨酸</14>、<4>印防己毒素</4>或Slc:ddY小鼠进行的电击诱导的<2>惊厥</2>有影响。<9>S-312-d</9>可用于治疗某些类型的人类<11>癫痫</11>。", "revised": true}
{"doc_key": "7949506", "sentences": [["Adverse", "interaction", "between", "clonidine", "and", "verapamil", ".", "OBJECTIVE", ":", "To", "report", "two", "cases", "of", "a", "possible", "adverse", "interaction", "between", "clonidine", "and", "verapamil", "resulting", "in", "atrioventricular", "(", "AV", ")", "block", "in", "both", "patients", "and", "severe", "hypotension", "in", "one", "patient", ".", "CASE", "SUMMARIES", ":", "A", "54", "-", "year", "-", "old", "woman", "with", "hyperaldosteronism", "was", "treated", "with", "verapamil", "480", "mg", "/", "d", "and", "spironolactone", "100", "mg", "/", "d", ".", "After", "the", "addition", "of", "a", "minimal", "dose", "of", "clonidine", "(", "0", ".", "15", "mg", "bid", ")", ",", "she", "developed", "complete", "AV", "block", "and", "severe", "hypotension", ",", "which", "resolved", "upon", "cessation", "of", "all", "medications", ".", "A", "65", "-", "year", "-", "old", "woman", "was", "treated", "with", "extended", "-", "release", "verapamil", "240", "mg", "/", "d", ".", "After", "the", "addition", "of", "clonidine", "0", ".", "15", "mg", "bid", "she", "developed", "complete", "AV", "block", ",", "which", "resolved", "after", "all", "therapy", "was", "stopped", ".", "DISCUSSION", ":", "An", "adverse", "interaction", "between", "clonidine", "and", "verapamil", "has", "not", "been", "reported", "previously", ".", "We", "describe", "two", "such", "cases", "and", "discuss", "the", "various", "mechanisms", "that", "might", "cause", "such", "an", "interaction", ".", "Clinicians", "should", "be", "acquainted", "with", "this", "possibly", "fatal", "interaction", "between", "two", "commonly", "used", "antihypertensive", "drugs", ".", "CONCLUSIONS", ":", "Caution", "is", "recommended", "in", "combining", "clonidine", "and", "verapamil", "therapy", ",", "even", "in", "patients", "who", "do", "not", "have", "sinus", "or", "AV", "node", "dysfunction", ".", "The", "two", "drugs", "may", "act", "synergistically", "on", "both", "the", "AV", "node", "and", "the", "peripheral", "circulation", "."]], "ner": [[[3, 3, "Chemical"], [19, 19, "Chemical"], [74, 74, "Chemical"], [123, 123, "Chemical"], [149, 149, "Chemical"], [198, 198, "Chemical"], [24, 28, "Disease"], [86, 87, "Disease"], [132, 133, "Disease"], [34, 34, "Disease"], [90, 90, "Disease"], [5, 5, "Chemical"], [21, 21, "Chemical"], [54, 54, "Chemical"], [113, 113, "Chemical"], [151, 151, "Chemical"], [200, 200, "Chemical"], [50, 50, "Disease"], [60, 60, "Chemical"]]], "relations": [[[3, 3, 24, 28, "CID"], [3, 3, 86, 87, "CID"], [3, 3, 132, 133, "CID"], [19, 19, 24, 28, "CID"], [19, 19, 86, 87, "CID"], [19, 19, 132, 133, "CID"], [74, 74, 24, 28, "CID"], [74, 74, 86, 87, "CID"], [74, 74, 132, 133, "CID"], [123, 123, 24, 28, "CID"], [123, 123, 86, 87, "CID"], [123, 123, 132, 133, "CID"], [149, 149, 24, 28, "CID"], [149, 149, 86, 87, "CID"], [149, 149, 132, 133, "CID"], [198, 198, 24, 28, "CID"], [198, 198, 86, 87, "CID"], [198, 198, 132, 133, "CID"], [3, 3, 34, 34, "CID"], [3, 3, 90, 90, "CID"], [19, 19, 34, 34, "CID"], [19, 19, 90, 90, "CID"], [74, 74, 34, 34, "CID"], [74, 74, 90, 90, "CID"], [123, 123, 34, 34, "CID"], [123, 123, 90, 90, "CID"], [149, 149, 34, 34, "CID"], [149, 149, 90, 90, "CID"], [198, 198, 34, 34, "CID"], [198, 198, 90, 90, "CID"], [5, 5, 24, 28, "CID"], [5, 5, 86, 87, "CID"], [5, 5, 132, 133, "CID"], [21, 21, 24, 28, "CID"], [21, 21, 86, 87, "CID"], [21, 21, 132, 133, "CID"], [54, 54, 24, 28, "CID"], [54, 54, 86, 87, "CID"], [54, 54, 132, 133, "CID"], [113, 113, 24, 28, "CID"], [113, 113, 86, 87, "CID"], [113, 113, 132, 133, "CID"], [151, 151, 24, 28, "CID"], [151, 151, 86, 87, "CID"], [151, 151, 132, 133, "CID"], [200, 200, 24, 28, "CID"], [200, 200, 86, 87, "CID"], [200, 200, 132, 133, "CID"], [5, 5, 34, 34, "CID"], [5, 5, 90, 90, "CID"], [21, 21, 34, 34, "CID"], [21, 21, 90, 90, "CID"], [54, 54, 34, 34, "CID"], [54, 54, 90, 90, "CID"], [113, 113, 34, 34, "CID"], [113, 113, 90, 90, "CID"], [151, 151, 34, 34, "CID"], [151, 151, 90, 90, "CID"], [200, 200, 34, 34, "CID"], [200, 200, 90, 90, "CID"]]], "clusters": [], "translated": "<0>可乐定</0>和<11>维拉帕米</11>之间的不良相互作用。目的：报告两例<1>可乐定</1>和<12>维拉帕米</12>之间可能的不良相互作用导致<6>房室（AV）传导阻滞</6>患者和严重<9>低血压</9>一名患者。病例总结：一名患有<17>醛固酮增多症</17>的54岁女性接受<13>维拉帕米</13>480 mg/d和<18>螺内酯</18>100 mg/d治疗。加入最小剂量的<2>可乐定</2>（0.15mg bid）后，她出现了完全性<7>房室传导阻滞</7>和严重的<10>低血压</10>，症状在停止所有药物治疗后缓解。一位65岁的女性接受缓释<14>维拉帕米</14>240 mg/d治疗。加入<3>可乐定</3> 0.15 毫克 bid 后，她出现了完全 <8>房室传导阻滞</8>，在所有治疗停止后消退。讨论：以前没有报道<4>可乐定</4>和<15>维拉帕米</15>之间的不良相互作用。我们描述了两个这样的案例，并讨论了可能导致此类交互的各种机制。临床医生应该熟悉两种常用抗高血压药物之间这种可能致命的相互作用。结论：建议谨慎联合使用<5>可乐定</5>和<16>维拉帕米</16>治疗，即使是在没有窦房结或房室结功能障碍的患者中也是如此。这两种药物可能协同作用于房室结和外周循环。", "revised": true}
{"doc_key": "8184922", "sentences": [["Assessment", "of", "cardiomyocyte", "DNA", "synthesis", "during", "hypertrophy", "in", "adult", "mice", ".", "The", "ability", "of", "cardiomyocytes", "to", "synthesize", "DNA", "in", "response", "to", "experimentally", "induced", "cardiac", "hypertrophy", "was", "assessed", "in", "adult", "mice", ".", "Isoproterenol", "delivered", "by", "osmotic", "minipump", "implantation", "in", "adult", "C3Heb", "/", "FeJ", "mice", "resulted", "in", "a", "46", "%", "increase", "in", "heart", "weight", "and", "a", "19", ".", "3", "%", "increase", "in", "cardiomyocyte", "area", ".", "No", "DNA", "synthesis", ",", "as", "assessed", "by", "autoradiographic", "analysis", "of", "isolated", "cardiomyocytes", ",", "was", "observed", "in", "control", "or", "hypertrophic", "hearts", ".", "A", "survey", "of", "15", "independent", "inbred", "strains", "of", "mice", "revealed", "that", "ventricular", "cardiomyocyte", "nuclear", "number", "ranged", "from", "3", "to", "13", "%", "mononucleate", ",", "suggesting", "that", "cardiomyocyte", "terminal", "differentiation", "is", "influenced", "directly", "or", "indirectly", "by", "genetic", "background", ".", "To", "determine", "whether", "the", "capacity", "for", "reactive", "DNA", "synthesis", "was", "also", "subject", "to", "genetic", "regulation", ",", "cardiac", "hypertrophy", "was", "induced", "in", "the", "strains", "of", "mice", "comprising", "the", "extremes", "of", "the", "nuclear", "number", "survey", ".", "These", "data", "indicate", "that", "adult", "mouse", "atrial", "and", "ventricular", "cardiomyocytes", "do", "not", "synthesize", "DNA", "in", "response", "to", "isoproterenol", "-", "induced", "cardiac", "hypertrophy", "."]], "ner": [[[31, 31, "Chemical"], [172, 172, "Chemical"], [23, 24, "Disease"], [81, 82, "Disease"], [137, 138, "Disease"], [175, 176, "Disease"], [6, 6, "Disease"]]], "relations": [[[31, 31, 23, 24, "CID"], [31, 31, 81, 82, "CID"], [31, 31, 137, 138, "CID"], [31, 31, 175, 176, "CID"], [172, 172, 23, 24, "CID"], [172, 172, 81, 82, "CID"], [172, 172, 137, 138, "CID"], [172, 172, 175, 176, "CID"]]], "clusters": [], "translated": "成年小鼠<6>肥大</6>期间心肌细胞 DNA 合成的评估。在成年小鼠中评估了心肌细胞合成 DNA 以响应实验诱导的<2>心脏肥大</2>的能力。<0>异丙肾上腺素</0>通过植入 C3Heb / FeJ 成年小鼠的渗透性微型泵输送导致心脏重量增加46%和19.3%的心肌细胞面积增加。通过分离的心肌细胞的放射自显影分析评估，在对照或<3>肥大的心脏</3>中没有观察到 DNA 合成。一项对15个独立近交系小鼠的调查显示，心室心肌细胞核数在3%到13%之间是单核的，表明心肌细胞终末分化直接或间接受到遗传背景的影响。为了确定反应性 DNA 合成的能力是否也受遗传调控，<4>心脏肥大</4>在包含核数调查极端值的小鼠品系中被诱导。这些数据表明，成年小鼠心房和心室心肌细胞不会合成 DNA 以响应<1>异丙肾上腺素</1>诱导的<5>心脏肥大</5>。", "revised": true}
{"doc_key": "8308951", "sentences": [["Cutaneous", "exposure", "to", "warfarin", "-", "like", "anticoagulant", "causing", "an", "intracerebral", "hemorrhage", ":", "a", "case", "report", ".", "A", "case", "of", "intercerebral", "hematoma", "due", "to", "warfarin", "-", "induced", "coagulopathy", "is", "presented", ".", "The", "39", "-", "year", "-", "old", "woman", "had", "spread", "a", "warfarin", "-", "type", "rat", "poison", "around", "her", "house", "weekly", "using", "her", "bare", "hands", ",", "with", "no", "washing", "post", "application", ".", "Percutaneous", "absorption", "of", "warfarin", "causing", "coagulopathy", ",", "reported", "three", "times", "in", "the", "past", ",", "is", "a", "significant", "risk", "if", "protective", "measures", ",", "such", "as", "gloves", ",", "are", "not", "used", ".", "An", "adverse", "drug", "interaction", "with", "piroxicam", ",", "which", "she", "took", "occasionally", ",", "may", "have", "exacerbated", "the", "coagulopathy", "."]], "ner": [[[3, 3, "Chemical"], [23, 23, "Chemical"], [40, 40, "Chemical"], [63, 63, "Chemical"], [9, 10, "Disease"], [20, 20, "Disease"], [26, 26, "Disease"], [65, 65, "Disease"], [106, 106, "Disease"], [95, 95, "Chemical"]]], "relations": [[[3, 3, 9, 10, "CID"], [23, 23, 9, 10, "CID"], [40, 40, 9, 10, "CID"], [63, 63, 9, 10, "CID"]]], "clusters": [], "translated": "皮肤暴露于 <0>华法林</0> 类抗凝剂导致 <4>脑出血</4>：病例报告。报道一例因<1>华法林</1>引起的<6>凝血功能障碍</6>引起的脑间<5>血肿</5>。这位39岁的妇女每周都会赤手在她的房子周围散布<2>华法林</2> 类老鼠药，施用后没有清洗。<3>华法林</3> 经皮吸收导致<7>凝血功能障碍</7>，过去曾有过三次报道，如果不使用保护措施，如手套，则风险很大。与她偶尔服用的<9>吡罗昔康</9>的不良药物相互作用可能加剧了<8>凝血功能障碍</8>。", "revised": true}
{"doc_key": "7727612", "sentences": [["Myoclonus", "associated", "with", "lorazepam", "therapy", "in", "very", "-", "low", "-", "birth", "-", "weight", "infants", ".", "Lorazepam", "is", "being", "used", "with", "increasing", "frequency", "as", "a", "sedative", "in", "the", "newborn", "and", "the", "young", "infant", ".", "Concern", "has", "been", "raised", "with", "regard", "to", "the", "safety", "of", "lorazepam", "in", "this", "age", "group", ",", "especially", "in", "very", "-", "low", "-", "birth", "-", "weight", "(", "VLBW", ";", "<", "1", ",", "500", "g", ")", "infants", ".", "Three", "young", "infants", ",", "all", "of", "birth", "weight", "<", "1", ",", "500", "g", ",", "experienced", "myoclonus", "following", "the", "intravenous", "administration", "of", "lorazepam", ".", "The", "potential", "neurotoxic", "effects", "of", "the", "drug", "(", "and", "its", "vehicle", ")", "in", "this", "population", "are", "discussed", ".", "Injectable", "lorazepam", "should", "be", "used", "with", "caution", "in", "VLBW", "infants", "."]], "ner": [[[3, 3, "Chemical"], [15, 15, "Chemical"], [43, 43, "Chemical"], [90, 90, "Chemical"], [111, 111, "Chemical"], [0, 0, "Disease"], [84, 84, "Disease"], [94, 94, "Disease"]]], "relations": [[[3, 3, 0, 0, "CID"], [3, 3, 84, 84, "CID"], [15, 15, 0, 0, "CID"], [15, 15, 84, 84, "CID"], [43, 43, 0, 0, "CID"], [43, 43, 84, 84, "CID"], [90, 90, 0, 0, "CID"], [90, 90, 84, 84, "CID"], [111, 111, 0, 0, "CID"], [111, 111, 84, 84, "CID"]]], "clusters": [], "translated": "<5>肌阵挛</5>与极低出生体重婴儿的<0>劳拉西泮</0>疗法有关。<1>劳拉西泮</1>作为新生儿和小婴儿的镇静剂使用频率越来越高。人们对<2>劳拉西泮</2>在该年龄组的安全性表示担忧，尤其是在极低出生体重 (VLBW; <1,500g) 婴儿中。3例出生体重<1,500g的小婴儿在静脉注射<3>劳拉西泮</3>后出现<6>肌阵挛</6>。讨论了该药物（及其载体）对该人群的潜在<7>神经毒性</7>作用。极低出生体重儿应谨慎使用可注射的<4>劳拉西泮</4>。", "revised": true}
{"doc_key": "8135424", "sentences": [["Flumazenil", "induces", "seizures", "and", "death", "in", "mixed", "cocaine", "-", "diazepam", "intoxications", ".", "STUDY", "HYPOTHESIS", ":", "Administration", "of", "the", "benzodiazepine", "antagonist", "flumazenil", "may", "unmask", "seizures", "in", "mixed", "cocaine", "-", "benzodiazepine", "intoxication", ".", "DESIGN", ":", "Male", "Sprague", "-", "Dawley", "rats", "received", "100", "mg", "/", "kg", "cocaine", "IP", "alone", ",", "5", "mg", "/", "kg", "diazepam", "alone", ",", "or", "a", "combination", "of", "diazepam", "and", "cocaine", ".", "Three", "minutes", "later", ",", "groups", "were", "challenged", "with", "vehicle", "or", "flumazenil", "5", "or", "10", "mg", "/", "kg", "IP", ".", "Animal", "behavior", ",", "seizures", "(", "time", "to", "and", "incidence", ")", ",", "death", "(", "time", "to", "and", "incidence", ")", ",", "and", "cortical", "EEG", "tracings", "were", "recorded", ".", "INTERVENTIONS", ":", "Administration", "of", "flumazenil", "to", "animals", "after", "they", "had", "received", "a", "combination", "dose", "of", "cocaine", "and", "diazepam", ".", "RESULTS", ":", "In", "group", "1", ",", "animals", "received", "cocaine", "followed", "by", "vehicle", ".", "This", "resulted", "in", "100", "%", "developing", "seizures", "and", "death", ".", "Group", "2", "received", "diazepam", "alone", "followed", "by", "vehicle", ".", "Animals", "became", "somnolent", "and", "none", "died", ".", "Group", "3", "received", "diazepam", "followed", "by", "5", "mg", "/", "kg", "flumazenil", ".", "Animals", "became", "somnolent", "after", "diazepam", "and", "then", "active", "after", "flumazenil", "administration", ".", "In", "group", "4", ",", "a", "combination", "of", "cocaine", "and", "diazepam", "was", "administered", "simultaneously", ".", "This", "resulted", "in", "no", "overt", "or", "EEG", "-", "detectable", "seizures", "and", "a", "50", "%", "incidence", "of", "death", ".", "Group", "5", "received", "a", "similar", "combination", "of", "cocaine", "and", "diazepam", ",", "followed", "later", "by", "5", "mg", "/", "kg", "flumazenil", ".", "This", "resulted", "in", "an", "increased", "incidence", "of", "seizures", ",", "90", "%", "(", "P", "<", ".", "01", ")", ",", "and", "death", ",", "100", "%", "(", "P", "<", "or", "=", ".", "01", ")", ",", "compared", "with", "group", "4", ".", "Group", "6", "received", "cocaine", "and", "diazepam", "followed", "by", "10", "mg", "/", "kg", "flumazenil", ".", "This", "also", "resulted", "in", "an", "increased", "incidence", "of", "seizures", ",", "90", "%", "(", "P", "<", "or", "=", ".", "01", ")", ",", "and", "death", ",", "90", "%", "(", "P", "<", "or", "=", ".", "05", ")", ",", "compared", "with", "group", "4", ".", "CONCLUSION", ":", "Flumazenil", "can", "unmask", "seizures", "and", "increase", "the", "incidence", "of", "death", "in", "a", "model", "of", "combined", "cocaine", "-", "diazepam", "intoxications", "."]], "ner": [[[0, 0, "Chemical"], [20, 20, "Chemical"], [72, 72, "Chemical"], [111, 111, "Chemical"], [175, 175, "Chemical"], [186, 186, "Chemical"], [239, 239, "Chemical"], [290, 290, "Chemical"], [334, 334, "Chemical"], [2, 2, "Disease"], [23, 23, "Disease"], [84, 84, "Disease"], [145, 145, "Disease"], [212, 212, "Disease"], [248, 248, "Disease"], [300, 300, "Disease"], [337, 337, "Disease"], [7, 7, "Chemical"], [26, 26, "Chemical"], [43, 43, "Chemical"], [60, 60, "Chemical"], [122, 122, "Chemical"], [134, 134, "Chemical"], [196, 196, "Chemical"], [228, 228, "Chemical"], [281, 281, "Chemical"], [349, 349, "Chemical"], [9, 9, "Chemical"], [51, 51, "Chemical"], [58, 58, "Chemical"], [124, 124, "Chemical"], [152, 152, "Chemical"], [168, 168, "Chemical"], [181, 181, "Chemical"], [198, 198, "Chemical"], [230, 230, "Chemical"], [283, 283, "Chemical"], [351, 351, "Chemical"], [18, 18, "Chemical"], [28, 28, "Chemical"]]], "relations": [[[0, 0, 2, 2, "CID"], [0, 0, 23, 23, "CID"], [0, 0, 84, 84, "CID"], [0, 0, 145, 145, "CID"], [0, 0, 212, 212, "CID"], [0, 0, 248, 248, "CID"], [0, 0, 300, 300, "CID"], [0, 0, 337, 337, "CID"], [20, 20, 2, 2, "CID"], [20, 20, 23, 23, "CID"], [20, 20, 84, 84, "CID"], [20, 20, 145, 145, "CID"], [20, 20, 212, 212, "CID"], [20, 20, 248, 248, "CID"], [20, 20, 300, 300, "CID"], [20, 20, 337, 337, "CID"], [72, 72, 2, 2, "CID"], [72, 72, 23, 23, "CID"], [72, 72, 84, 84, "CID"], [72, 72, 145, 145, "CID"], [72, 72, 212, 212, "CID"], [72, 72, 248, 248, "CID"], [72, 72, 300, 300, "CID"], [72, 72, 337, 337, "CID"], [111, 111, 2, 2, "CID"], [111, 111, 23, 23, "CID"], [111, 111, 84, 84, "CID"], [111, 111, 145, 145, "CID"], [111, 111, 212, 212, "CID"], [111, 111, 248, 248, "CID"], [111, 111, 300, 300, "CID"], [111, 111, 337, 337, "CID"], [175, 175, 2, 2, "CID"], [175, 175, 23, 23, "CID"], [175, 175, 84, 84, "CID"], [175, 175, 145, 145, "CID"], [175, 175, 212, 212, "CID"], [175, 175, 248, 248, "CID"], [175, 175, 300, 300, "CID"], [175, 175, 337, 337, "CID"], [186, 186, 2, 2, "CID"], [186, 186, 23, 23, "CID"], [186, 186, 84, 84, "CID"], [186, 186, 145, 145, "CID"], [186, 186, 212, 212, "CID"], [186, 186, 248, 248, "CID"], [186, 186, 300, 300, "CID"], [186, 186, 337, 337, "CID"], [239, 239, 2, 2, "CID"], [239, 239, 23, 23, "CID"], [239, 239, 84, 84, "CID"], [239, 239, 145, 145, "CID"], [239, 239, 212, 212, "CID"], [239, 239, 248, 248, "CID"], [239, 239, 300, 300, "CID"], [239, 239, 337, 337, "CID"], [290, 290, 2, 2, "CID"], [290, 290, 23, 23, "CID"], [290, 290, 84, 84, "CID"], [290, 290, 145, 145, "CID"], [290, 290, 212, 212, "CID"], [290, 290, 248, 248, "CID"], [290, 290, 300, 300, "CID"], [290, 290, 337, 337, "CID"], [334, 334, 2, 2, "CID"], [334, 334, 23, 23, "CID"], [334, 334, 84, 84, "CID"], [334, 334, 145, 145, "CID"], [334, 334, 212, 212, "CID"], [334, 334, 248, 248, "CID"], [334, 334, 300, 300, "CID"], [334, 334, 337, 337, "CID"], [7, 7, 2, 2, "CID"], [7, 7, 23, 23, "CID"], [7, 7, 84, 84, "CID"], [7, 7, 145, 145, "CID"], [7, 7, 212, 212, "CID"], [7, 7, 248, 248, "CID"], [7, 7, 300, 300, "CID"], [7, 7, 337, 337, "CID"], [26, 26, 2, 2, "CID"], [26, 26, 23, 23, "CID"], [26, 26, 84, 84, "CID"], [26, 26, 145, 145, "CID"], [26, 26, 212, 212, "CID"], [26, 26, 248, 248, "CID"], [26, 26, 300, 300, "CID"], [26, 26, 337, 337, "CID"], [43, 43, 2, 2, "CID"], [43, 43, 23, 23, "CID"], [43, 43, 84, 84, "CID"], [43, 43, 145, 145, "CID"], [43, 43, 212, 212, "CID"], [43, 43, 248, 248, "CID"], [43, 43, 300, 300, "CID"], [43, 43, 337, 337, "CID"], [60, 60, 2, 2, "CID"], [60, 60, 23, 23, "CID"], [60, 60, 84, 84, "CID"], [60, 60, 145, 145, "CID"], [60, 60, 212, 212, "CID"], [60, 60, 248, 248, "CID"], [60, 60, 300, 300, "CID"], [60, 60, 337, 337, "CID"], [122, 122, 2, 2, "CID"], [122, 122, 23, 23, "CID"], [122, 122, 84, 84, "CID"], [122, 122, 145, 145, "CID"], [122, 122, 212, 212, "CID"], [122, 122, 248, 248, "CID"], [122, 122, 300, 300, "CID"], [122, 122, 337, 337, "CID"], [134, 134, 2, 2, "CID"], [134, 134, 23, 23, "CID"], [134, 134, 84, 84, "CID"], [134, 134, 145, 145, "CID"], [134, 134, 212, 212, "CID"], [134, 134, 248, 248, "CID"], [134, 134, 300, 300, "CID"], [134, 134, 337, 337, "CID"], [196, 196, 2, 2, "CID"], [196, 196, 23, 23, "CID"], [196, 196, 84, 84, "CID"], [196, 196, 145, 145, "CID"], [196, 196, 212, 212, "CID"], [196, 196, 248, 248, "CID"], [196, 196, 300, 300, "CID"], [196, 196, 337, 337, "CID"], [228, 228, 2, 2, "CID"], [228, 228, 23, 23, "CID"], [228, 228, 84, 84, "CID"], [228, 228, 145, 145, "CID"], [228, 228, 212, 212, "CID"], [228, 228, 248, 248, "CID"], [228, 228, 300, 300, "CID"], [228, 228, 337, 337, "CID"], [281, 281, 2, 2, "CID"], [281, 281, 23, 23, "CID"], [281, 281, 84, 84, "CID"], [281, 281, 145, 145, "CID"], [281, 281, 212, 212, "CID"], [281, 281, 248, 248, "CID"], [281, 281, 300, 300, "CID"], [281, 281, 337, 337, "CID"], [349, 349, 2, 2, "CID"], [349, 349, 23, 23, "CID"], [349, 349, 84, 84, "CID"], [349, 349, 145, 145, "CID"], [349, 349, 212, 212, "CID"], [349, 349, 248, 248, "CID"], [349, 349, 300, 300, "CID"], [349, 349, 337, 337, "CID"], [9, 9, 2, 2, "CID"], [9, 9, 23, 23, "CID"], [9, 9, 84, 84, "CID"], [9, 9, 145, 145, "CID"], [9, 9, 212, 212, "CID"], [9, 9, 248, 248, "CID"], [9, 9, 300, 300, "CID"], [9, 9, 337, 337, "CID"], [51, 51, 2, 2, "CID"], [51, 51, 23, 23, "CID"], [51, 51, 84, 84, "CID"], [51, 51, 145, 145, "CID"], [51, 51, 212, 212, "CID"], [51, 51, 248, 248, "CID"], [51, 51, 300, 300, "CID"], [51, 51, 337, 337, "CID"], [58, 58, 2, 2, "CID"], [58, 58, 23, 23, "CID"], [58, 58, 84, 84, "CID"], [58, 58, 145, 145, "CID"], [58, 58, 212, 212, "CID"], [58, 58, 248, 248, "CID"], [58, 58, 300, 300, "CID"], [58, 58, 337, 337, "CID"], [124, 124, 2, 2, "CID"], [124, 124, 23, 23, "CID"], [124, 124, 84, 84, "CID"], [124, 124, 145, 145, "CID"], [124, 124, 212, 212, "CID"], [124, 124, 248, 248, "CID"], [124, 124, 300, 300, "CID"], [124, 124, 337, 337, "CID"], [152, 152, 2, 2, "CID"], [152, 152, 23, 23, "CID"], [152, 152, 84, 84, "CID"], [152, 152, 145, 145, "CID"], [152, 152, 212, 212, "CID"], [152, 152, 248, 248, "CID"], [152, 152, 300, 300, "CID"], [152, 152, 337, 337, "CID"], [168, 168, 2, 2, "CID"], [168, 168, 23, 23, "CID"], [168, 168, 84, 84, "CID"], [168, 168, 145, 145, "CID"], [168, 168, 212, 212, "CID"], [168, 168, 248, 248, "CID"], [168, 168, 300, 300, "CID"], [168, 168, 337, 337, "CID"], [181, 181, 2, 2, "CID"], [181, 181, 23, 23, "CID"], [181, 181, 84, 84, "CID"], [181, 181, 145, 145, "CID"], [181, 181, 212, 212, "CID"], [181, 181, 248, 248, "CID"], [181, 181, 300, 300, "CID"], [181, 181, 337, 337, "CID"], [198, 198, 2, 2, "CID"], [198, 198, 23, 23, "CID"], [198, 198, 84, 84, "CID"], [198, 198, 145, 145, "CID"], [198, 198, 212, 212, "CID"], [198, 198, 248, 248, "CID"], [198, 198, 300, 300, "CID"], [198, 198, 337, 337, "CID"], [230, 230, 2, 2, "CID"], [230, 230, 23, 23, "CID"], [230, 230, 84, 84, "CID"], [230, 230, 145, 145, "CID"], [230, 230, 212, 212, "CID"], [230, 230, 248, 248, "CID"], [230, 230, 300, 300, "CID"], [230, 230, 337, 337, "CID"], [283, 283, 2, 2, "CID"], [283, 283, 23, 23, "CID"], [283, 283, 84, 84, "CID"], [283, 283, 145, 145, "CID"], [283, 283, 212, 212, "CID"], [283, 283, 248, 248, "CID"], [283, 283, 300, 300, "CID"], [283, 283, 337, 337, "CID"], [351, 351, 2, 2, "CID"], [351, 351, 23, 23, "CID"], [351, 351, 84, 84, "CID"], [351, 351, 145, 145, "CID"], [351, 351, 212, 212, "CID"], [351, 351, 248, 248, "CID"], [351, 351, 300, 300, "CID"], [351, 351, 337, 337, "CID"]]], "clusters": [], "translated": "<0>氟马西尼</0> 在混合 <17>可卡因</17> - <27>地西泮</27> 中毒中诱导 <9>癫痫发作</9> 和死亡。研究假设：使用 <38>苯二氮卓</38> 拮抗剂 <1>氟马西尼</1> 可能会导致混合 <18>可卡因</18> - <39>苯二氮卓</39> 中毒的 <10>癫痫发作</10>。设计：Male Sprague-Dawley大鼠分别接受100 mg/kg <19>可卡因</19> IP，5 mg/kg <28>地西泮</28>单独接受，或同时接受 <20>可卡因</20> 和 <29>地西泮</29> 组合剂量。三分钟后，各组接受载体或 <2>氟马西尼</2> 5 或 10mg/kg IP 攻击。记录动物行为、<11>癫痫发作</11>（时间和发病率）、死亡（时间和发病率）和皮层 EEG 描记。干预：给予动物 <3>氟马西尼</3>，让它们在接受联合<21>可卡因</21>和<30>地西泮</30>剂量之后。结果：组1动物接受 <22>可卡因</22>，随后接受赋形剂。这导致100% 发生 <12>癫痫发作</12> 和死亡。组2接受<31>地西泮</31> 单独接受，随后接受赋形剂。动物变得昏昏欲睡，没有任何死亡。组3接受<32>地西泮</32>，随后接受 5 mg/kg <4>氟马西尼</4>。动物在接受<33>地西泮</33>后变得嗜睡，在接受 <5>氟马西尼</5>后变得活跃。在组4中，动物同时接受 <23>可卡因</23> 和 <34>地西泮</34>。这导致没有明显的或 EEG 可检测到的 <13>癫痫发作</13> 和50%的死亡发生率。组5接受了类似的 <24>可卡因</24> 和 <35>地西泮</35> 组合，并随后接受 5 mg/kg <6>氟马西尼</6>。这导致与组4相比，<14>癫痫发作</14> 的发生率增加了90%（P<.01），死亡发生率增加了100%（P< or =.01）。组6接受<25>可卡因</25>和<36>地西泮</36>，随后接受 10 mg/kg <7>氟马西尼</7>。这也导致与组4相比，<15>癫痫发作</15> 的发生率增加了90%（P< or =.01），死亡发生率增加了90%（P< or =.05）。结论： <8>氟马西尼</8>可以揭示<16>癫痫发作</16>，并增加了混合<26>可卡因</26>-<37>地西泮</37>中毒模型的死亡发生率。", "revised": true}
{"doc_key": "8188982", "sentences": [["Central", "cardiovascular", "effects", "of", "AVP", "and", "ANP", "in", "normotensive", "and", "spontaneously", "hypertensive", "rats", ".", "The", "purpose", "of", "the", "present", "study", "was", "to", "compare", "influence", "of", "central", "arginine", "vasopressin", "(", "AVP", ")", "and", "of", "atrial", "natriuretic", "peptide", "(", "ANP", ")", "on", "control", "of", "arterial", "blood", "pressure", "(", "MAP", ")", "and", "heart", "rate", "(", "HR", ")", "in", "normotensive", "(", "WKY", ")", "and", "spontaneously", "hypertensive", "(", "SHR", ")", "rats", ".", "Three", "series", "of", "experiments", "were", "performed", "on", "30", "WKY", "and", "30", "SHR", ",", "chronically", "instrumented", "with", "guide", "tubes", "in", "the", "lateral", "ventricle", "(", "LV", ")", "and", "arterial", "and", "venous", "catheters", ".", "MAP", "and", "HR", "were", "monitored", "before", "and", "after", "i", ".", "v", ".", "injections", "of", "either", "vehicle", "or", "1", ",", "10", "and", "50", "ng", "of", "AVP", "and", "25", ",", "125", "and", "500", "ng", "of", "ANP", ".", "Sensitivity", "of", "cardiac", "component", "of", "baroreflex", "(", "CCB", ")", ",", "expressed", "as", "a", "slope", "of", "the", "regression", "line", "was", "determined", "from", "relationships", "between", "systolic", "arterial", "pressure", "(", "SAP", ")", "and", "HR", "period", "(", "HRp", ")", "during", "phenylephrine", "(", "Phe", ")", "-", "induced", "hypertension", "and", "sodium", "nitroprusside", "(", "SN", ")", "-", "induced", "hypotension", ".", "CCB", "was", "measured", "before", "and", "after", "administration", "of", "either", "vehicle", ",", "AVP", ",", "ANP", ",", "or", "both", "peptides", "together", ".", "Increases", "of", "MAP", "occurred", "after", "LV", "administration", "of", "1", ",", "10", "and", "50", "ng", "of", "AVP", "in", "WKY", "and", "of", "10", "and", "50", "ng", "in", "SHR", ".", "ANP", "did", "not", "cause", "significant", "changes", "in", "MAP", "in", "both", "strains", "as", "compared", "to", "vehicle", ",", "but", "it", "abolished", "AVP", "-", "induced", "MAP", "increase", "in", "WKY", "and", "SHR", ".", "CCB", "was", "reduced", "in", "WKY", "and", "SHR", "after", "LV", "administration", "of", "AVP", "during", "SN", "-", "induced", "hypotension", ".", "In", "SHR", "but", "not", "in", "WKY", "administration", "of", "ANP", ",", "AVP", "and", "ANP", "+", "AVP", "decreased", "CCB", "during", "Phe", "-", "induced", "MAP", "elevation", ".", "The", "results", "indicate", "that", "centrally", "applied", "AVP", "and", "ANP", "exert", "differential", "effects", "on", "blood", "pressure", "and", "baroreflex", "control", "of", "heart", "rate", "in", "WKY", "and", "SHR", "and", "suggest", "interaction", "of", "these", "two", "peptides", "in", "blood", "pressure", "regulation", "at", "the", "level", "of", "central", "nervous", "system", "."]], "ner": [[[4, 4, "Chemical"], [26, 27, "Chemical"], [29, 29, "Chemical"], [122, 122, "Chemical"], [197, 197, "Chemical"], [221, 221, "Chemical"], [252, 252, "Chemical"], [273, 273, "Chemical"], [290, 290, "Chemical"], [294, 294, "Chemical"], [310, 310, "Chemical"], [11, 11, "Disease"], [61, 61, "Disease"], [175, 175, "Disease"], [169, 169, "Chemical"], [171, 171, "Chemical"], [298, 298, "Chemical"], [177, 178, "Chemical"], [180, 180, "Chemical"], [275, 275, "Chemical"], [184, 184, "Disease"], [278, 278, "Disease"]]], "relations": [[[4, 4, 11, 11, "CID"], [4, 4, 61, 61, "CID"], [4, 4, 175, 175, "CID"], [26, 27, 11, 11, "CID"], [26, 27, 61, 61, "CID"], [26, 27, 175, 175, "CID"], [29, 29, 11, 11, "CID"], [29, 29, 61, 61, "CID"], [29, 29, 175, 175, "CID"], [122, 122, 11, 11, "CID"], [122, 122, 61, 61, "CID"], [122, 122, 175, 175, "CID"], [197, 197, 11, 11, "CID"], [197, 197, 61, 61, "CID"], [197, 197, 175, 175, "CID"], [221, 221, 11, 11, "CID"], [221, 221, 61, 61, "CID"], [221, 221, 175, 175, "CID"], [252, 252, 11, 11, "CID"], [252, 252, 61, 61, "CID"], [252, 252, 175, 175, "CID"], [273, 273, 11, 11, "CID"], [273, 273, 61, 61, "CID"], [273, 273, 175, 175, "CID"], [290, 290, 11, 11, "CID"], [290, 290, 61, 61, "CID"], [290, 290, 175, 175, "CID"], [294, 294, 11, 11, "CID"], [294, 294, 61, 61, "CID"], [294, 294, 175, 175, "CID"], [310, 310, 11, 11, "CID"], [310, 310, 61, 61, "CID"], [310, 310, 175, 175, "CID"], [169, 169, 11, 11, "CID"], [169, 169, 61, 61, "CID"], [169, 169, 175, 175, "CID"], [171, 171, 11, 11, "CID"], [171, 171, 61, 61, "CID"], [171, 171, 175, 175, "CID"], [298, 298, 11, 11, "CID"], [298, 298, 61, 61, "CID"], [298, 298, 175, 175, "CID"], [177, 178, 184, 184, "CID"], [177, 178, 278, 278, "CID"], [180, 180, 184, 184, "CID"], [180, 180, 278, 278, "CID"], [275, 275, 184, 184, "CID"], [275, 275, 278, 278, "CID"]]], "clusters": [], "translated": "<0>AVP</0> 和 ANP 对正常血压和自发性<11>高血压</11>大鼠的中枢心血管作用。本研究的目的是比较中枢<1>精氨酸加压素</1> (<2>AVP</2>) 和心钠素 (ANP) 对控制动脉血压 (MAP) 和心率 (HR) 的影响在正常血压 (WKY) 和自发性<12>高血压</12> (SHR) 大鼠上。在30 WKY 和30 SHR 上进行了三个系列的实验，这些大鼠长期植入侧脑室 (LV) 导管以及动脉和静脉导管。注射前和注射后检测MAP和HR。注射载体或1、10 和50 ng 的<3>AVP</3>以及25、125 和500 ng的 ANP。通过在 <14>苯肾上腺素</14> (<15>Phe</15>) 诱导的<13>高血压</13>和在<17>亚硝酸普麦</17> (<18>SN</18>) 诱导的<20>低血压</20>时，计算心脏压力反射成分 (CCB) 的敏感性，其表示为收缩压 (SAP) 和心率周期 (HRp) 之间关系的斜率。在给予载体、<4>AVP</4>、ANP 或同时给予两种肽之前和之后测量 CCB。在 WKY 中，给予1、10 和50 ng的<5>AVP</5>以及在 SHR 中给予10 和50 ng后，MAP增加。ANP不会对两种菌株的MAP产生显着变化，与赋形剂相比，但它消除了<6>AVP</6>在WKY和SHR中诱导的MAP增加。在LV注射<7>AVP</7>后，在<19>SN</19>诱导的<21>低血压</21>期间，WKY 和 SHR的CCB减少。在 SHRs 而不是在 WKYs 中，给予ANP、<8>AVP</8>和 ANP +<9>AVP</9> 可以降低在<16>Phe</16>诱导的 MAP升高期间的 CCB。结果表明，中央应用<10>AVP</10>和ANP会对WKY和SHR中的血压和心率通过压力反射控制产生不同的效应，并表明这两种肽在中枢神经系统水平的血压调节中相互作用。", "revised": true}
{"doc_key": "7931490", "sentences": [["Efficacy", "and", "safety", "of", "granisetron", ",", "a", "selective", "5", "-", "hydroxytryptamine", "-", "3", "receptor", "antagonist", ",", "in", "the", "prevention", "of", "nausea", "and", "vomiting", "induced", "by", "high", "-", "dose", "cisplatin", ".", "PURPOSE", ":", "To", "assess", "the", "antiemetic", "effects", "and", "safety", "profile", "of", "four", "different", "doses", "of", "granisetron", "(", "Kytril", ";", "SmithKline", "Beecham", "Pharmaceuticals", ",", "Philadelphia", ",", "PA", ")", "when", "administered", "as", "a", "single", "intravenous", "(", "IV", ")", "dose", "for", "prophylaxis", "of", "cisplatin", "-", "induced", "nausea", "and", "vomiting", ".", "PATIENTS", "AND", "METHODS", ":", "One", "hundred", "eighty", "-", "four", "chemotherapy", "-", "naive", "patients", "receiving", "high", "-", "dose", "cisplatin", "(", "81", "to", "120", "mg", "/", "m2", ")", "were", "randomized", "to", "receive", "one", "of", "four", "granisetron", "doses", "(", "5", ",", "10", ",", "20", ",", "or", "40", "micrograms", "/", "kg", ")", "administered", "before", "chemotherapy", ".", "Patients", "were", "observed", "on", "an", "inpatient", "basis", "for", "18", "to", "24", "hours", ",", "and", "vital", "signs", ",", "nausea", ",", "vomiting", ",", "retching", ",", "and", "appetite", "were", "assessed", ".", "Safety", "analyses", "included", "incidence", "of", "adverse", "experiences", "and", "laboratory", "parameter", "changes", ".", "RESULTS", ":", "After", "granisetron", "doses", "of", "5", ",", "10", ",", "20", ",", "and", "40", "micrograms", "/", "kg", ",", "a", "major", "response", "(", "<", "or", "=", "two", "vomiting", "or", "retching", "episodes", ",", "and", "no", "antiemetic", "rescue", ")", "was", "recorded", "in", "23", "%", ",", "57", "%", ",", "58", "%", ",", "and", "60", "%", "of", "patients", ",", "respectively", ",", "and", "a", "complete", "response", "(", "no", "vomiting", "or", "retching", ",", "and", "no", "antiemetic", "rescue", ")", "in", "18", "%", ",", "41", "%", ",", "40", "%", ",", "and", "47", "%", "of", "patients", ",", "respectively", ".", "There", "was", "a", "statistically", "longer", "time", "to", "first", "episode", "of", "nausea", "(", "P", "=", ".", "0015", ")", "and", "vomiting", "(", "P", "=", ".", "0001", ")", ",", "and", "fewer", "patients", "were", "administered", "additional", "antiemetic", "medication", "in", "the", "10", "-", "micrograms", "/", "kg", "dosing", "groups", "than", "in", "the", "5", "-", "micrograms", "/", "kg", "dosing", "group", ".", "As", "granisetron", "dose", "increased", ",", "appetite", "return", "increased", "(", "P", "=", ".", "040", ")", ".", "Headache", "was", "the", "most", "frequently", "reported", "adverse", "event", "(", "20", "%", ")", ".", "CONCLUSION", ":", "A", "single", "10", "-", ",", "20", "-", ",", "or", "40", "-", "micrograms", "/", "kg", "dose", "of", "granisetron", "was", "effective", "in", "controlling", "vomiting", "in", "57", "%", "to", "60", "%", "of", "patients", "who", "received", "cisplatin", "at", "doses", "greater", "than", "81", "mg", "/", "m2", "and", "totally", "prevented", "vomiting", "in", "40", "%", "to", "47", "%", "of", "patients", ".", "There", "were", "no", "statistically", "significant", "differences", "in", "efficacy", "between", "the", "10", "-", "micrograms", "/", "kg", "dose", "and", "the", "20", "-", "and", "40", "-", "micrograms", "/", "kg", "doses", ".", "Granisetron", "was", "well", "tolerated", "at", "all", "doses", "."]], "ner": [[[4, 4, "Chemical"], [45, 45, "Chemical"], [47, 47, "Chemical"], [110, 110, "Chemical"], [172, 172, "Chemical"], [313, 313, "Chemical"], [358, 358, "Chemical"], [424, 424, "Chemical"], [327, 327, "Disease"], [28, 28, "Chemical"], [70, 70, "Chemical"], [94, 94, "Chemical"], [374, 374, "Chemical"], [20, 20, "Disease"], [73, 73, "Disease"], [146, 146, "Disease"], [268, 268, "Disease"], [22, 22, "Disease"], [75, 75, "Disease"], [148, 148, "Disease"], [195, 195, "Disease"], [231, 231, "Disease"], [276, 276, "Disease"], [363, 363, "Disease"], [386, 386, "Disease"], [8, 10, "Chemical"]]], "relations": [[[4, 4, 327, 327, "CID"], [45, 45, 327, 327, "CID"], [47, 47, 327, 327, "CID"], [110, 110, 327, 327, "CID"], [172, 172, 327, 327, "CID"], [313, 313, 327, 327, "CID"], [358, 358, 327, 327, "CID"], [424, 424, 327, 327, "CID"], [28, 28, 20, 20, "CID"], [28, 28, 73, 73, "CID"], [28, 28, 146, 146, "CID"], [28, 28, 268, 268, "CID"], [70, 70, 20, 20, "CID"], [70, 70, 73, 73, "CID"], [70, 70, 146, 146, "CID"], [70, 70, 268, 268, "CID"], [94, 94, 20, 20, "CID"], [94, 94, 73, 73, "CID"], [94, 94, 146, 146, "CID"], [94, 94, 268, 268, "CID"], [374, 374, 20, 20, "CID"], [374, 374, 73, 73, "CID"], [374, 374, 146, 146, "CID"], [374, 374, 268, 268, "CID"], [28, 28, 22, 22, "CID"], [28, 28, 75, 75, "CID"], [28, 28, 148, 148, "CID"], [28, 28, 195, 195, "CID"], [28, 28, 231, 231, "CID"], [28, 28, 276, 276, "CID"], [28, 28, 363, 363, "CID"], [28, 28, 386, 386, "CID"], [70, 70, 22, 22, "CID"], [70, 70, 75, 75, "CID"], [70, 70, 148, 148, "CID"], [70, 70, 195, 195, "CID"], [70, 70, 231, 231, "CID"], [70, 70, 276, 276, "CID"], [70, 70, 363, 363, "CID"], [70, 70, 386, 386, "CID"], [94, 94, 22, 22, "CID"], [94, 94, 75, 75, "CID"], [94, 94, 148, 148, "CID"], [94, 94, 195, 195, "CID"], [94, 94, 231, 231, "CID"], [94, 94, 276, 276, "CID"], [94, 94, 363, 363, "CID"], [94, 94, 386, 386, "CID"], [374, 374, 22, 22, "CID"], [374, 374, 75, 75, "CID"], [374, 374, 148, 148, "CID"], [374, 374, 195, 195, "CID"], [374, 374, 231, 231, "CID"], [374, 374, 276, 276, "CID"], [374, 374, 363, 363, "CID"], [374, 374, 386, 386, "CID"]]], "clusters": [], "translated": "<0>格拉司琼</0>的有效性和安全性，一种选择性<25> 5-羟色胺</25>-3受体拮抗剂，在预防<13>恶心</13>和<17>呕吐</17>由高剂量<9>顺铂</9>诱导。目的：评估四种不同剂量的<1>格拉司琼</1>（<2>Kytril</2>；SmithKline Beecham Pharmaceuticals，Philadelphia，PA）作为单次静脉注射（IV）时的止吐效果和安全性概况预防<10>顺铂</10>引起的<14>恶心</14>和<18>呕吐</18>的剂量。患者和方法：接受高剂量<11>顺铂</11>（81至120 mg/m2）的184名未接受化疗的患者随机接受四种<3>格拉司琼</3>剂量中的一种（5、10、20或40微克/公斤）化疗前给药。患者在住院期间观察18至24小时，评估生命体征、<15>恶心</15>、<19>呕吐</19>、干呕和食欲。安全性分析包括不良经历的发生率和实验室参数的变化。结果：在<4>格拉司琼</4>剂量为5、10、20和40微克/公斤后，主要反应（≤两次<20>呕吐</20>或干呕发作，并且没有止吐补救）分别在23%、57%、58%和60%的患者中记录到完全反应（无<21>呕吐</21>或干呕，并且无止吐措施）在18%、41%、40%和47%的患者。首次出现<16>恶心</16>（P=.0015）和<22>呕吐</22>（P=.0001）的时间在统计学上更长，并且在10微克/公斤给药组优于5微克/公斤给药组。随着<5>格拉司琼</5>剂量的增加，食欲恢复增加（P=.040）。<8>头痛</8>是最常报告的不良事件（20%）。结论：在剂量大于81 mg/m2的<12>顺铂</12>患者中，单次10、20或40微克/公斤剂量的<6>格拉司琼</6>可以控制57%到60%的<23>呕吐</23>，并且可以完全防止40%到47%的<24>呕吐</24>。10微克/千克剂量与20和40微克/千克剂量之间的疗效在统计学上没有显着差异。<7>格拉司琼</7>在所有剂量下均具有良好的耐受性。", "revised": true}
{"doc_key": "7492040", "sentences": [["Clinical", "safety", "of", "lidocaine", "in", "patients", "with", "cocaine", "-", "associated", "myocardial", "infarction", ".", "STUDY", "OBJECTIVE", ":", "To", "evaluate", "the", "safety", "of", "lidocaine", "in", "the", "setting", "of", "cocaine", "-", "induced", "myocardial", "infarction", "(", "MI", ")", ".", "DESIGN", ":", "A", "retrospective", ",", "multicenter", "study", ".", "SETTING", ":", "Twenty", "-", "nine", "university", ",", "university", "-", "affiliated", ",", "or", "community", "hospitals", "during", "a", "6", "-", "year", "period", "(", "total", "of", "117", "cumulative", "hospital", "-", "years", ")", ".", "PARTICIPANTS", ":", "Patients", "with", "cocaine", "-", "associated", "MI", "who", "received", "lidocaine", "in", "the", "emergency", "department", ".", "RESULTS", ":", "Of", "29", "patients", "who", "received", "lidocaine", "in", "the", "setting", "of", "cocaine", "-", "associated", "MI", ",", "no", "patient", "died", ";", "exhibited", "bradydysrhythmias", ",", "ventricular", "tachycardia", ",", "or", "ventricular", "fibrillation", ";", "or", "experienced", "seizures", "after", "administration", "of", "lidocaine", "(", "95", "%", "confidence", "interval", ",", "0", "%", "to", "11", "%", ")", ".", "CONCLUSION", ":", "Despite", "theoretical", "concerns", "that", "lidocaine", "may", "enhance", "cocaine", "toxicity", ",", "the", "use", "of", "lidocaine", "in", "patients", "with", "cocaine", "-", "associated", "MI", "was", "not", "associated", "with", "significant", "cardiovascular", "or", "central", "nervous", "system", "toxicity", "."]], "ner": [[[7, 7, "Chemical"], [26, 26, "Chemical"], [77, 77, "Chemical"], [101, 101, "Chemical"], [149, 149, "Chemical"], [159, 159, "Chemical"], [10, 11, "Disease"], [29, 30, "Disease"], [32, 32, "Disease"], [80, 80, "Disease"], [104, 104, "Disease"], [162, 162, "Disease"], [3, 3, "Chemical"], [21, 21, "Chemical"], [83, 83, "Chemical"], [96, 96, "Chemical"], [126, 126, "Chemical"], [146, 146, "Chemical"], [155, 155, "Chemical"], [111, 111, "Disease"], [113, 114, "Disease"], [117, 118, "Disease"], [122, 122, "Disease"], [150, 150, "Disease"], [168, 173, "Disease"]]], "relations": [[[7, 7, 10, 11, "CID"], [7, 7, 29, 30, "CID"], [7, 7, 32, 32, "CID"], [7, 7, 80, 80, "CID"], [7, 7, 104, 104, "CID"], [7, 7, 162, 162, "CID"], [26, 26, 10, 11, "CID"], [26, 26, 29, 30, "CID"], [26, 26, 32, 32, "CID"], [26, 26, 80, 80, "CID"], [26, 26, 104, 104, "CID"], [26, 26, 162, 162, "CID"], [77, 77, 10, 11, "CID"], [77, 77, 29, 30, "CID"], [77, 77, 32, 32, "CID"], [77, 77, 80, 80, "CID"], [77, 77, 104, 104, "CID"], [77, 77, 162, 162, "CID"], [101, 101, 10, 11, "CID"], [101, 101, 29, 30, "CID"], [101, 101, 32, 32, "CID"], [101, 101, 80, 80, "CID"], [101, 101, 104, 104, "CID"], [101, 101, 162, 162, "CID"], [149, 149, 10, 11, "CID"], [149, 149, 29, 30, "CID"], [149, 149, 32, 32, "CID"], [149, 149, 80, 80, "CID"], [149, 149, 104, 104, "CID"], [149, 149, 162, 162, "CID"], [159, 159, 10, 11, "CID"], [159, 159, 29, 30, "CID"], [159, 159, 32, 32, "CID"], [159, 159, 80, 80, "CID"], [159, 159, 104, 104, "CID"], [159, 159, 162, 162, "CID"]]], "clusters": [], "translated": "<12>利多卡因</12>在<0>可卡因</0>相关<6>心肌梗塞</6>患者中的临床安全性。研究目的：评估<13>利多卡因</13>在诱发的<1>可卡因</1><7>心肌梗死</7>（<8>MI</8>）中的安全性。设计：一项回顾性、多中心研究。地点：6年期间的29所大学、大学附属医院或社区医院（总共117个累计住院年）。参与者：在急诊科接受 <14>利多卡因</14> 治疗的<2>可卡因</2>相关<9>MI</9>患者。结果：在<3>可卡因</3>相关<10>MI</10>的情况下接受<15>利多卡因</15>治疗的29名患者中，没有患者死亡；没有表现出<19>心动过缓</19>、<20>室性心动过速</20>或<21>室性颤动</21>；或在服用<16>利多卡因</16>后经历过<22>癫痫发作</22>（95%置信区间，0%至11%）。结论：尽管理论上担心<17>利多卡因</17>可能会增强<4>可卡因</4><23>毒性</23>，但<18>利多卡因</18>在<5>可卡因</5>-相关的<11>MI</11>患者中的使用与显著的<24>心血管或中枢神经系统毒性</24>无关。", "revised": true}
{"doc_key": "8312983", "sentences": [["Delirium", "during", "fluoxetine", "treatment", ".", "A", "case", "report", ".", "The", "correlation", "between", "high", "serum", "tricyclic", "antidepressant", "concentrations", "and", "central", "nervous", "system", "side", "effects", "has", "been", "well", "established", ".", "Only", "a", "few", "reports", "exist", ",", "however", ",", "on", "the", "relationship", "between", "the", "serum", "concentrations", "of", "selective", "serotonin", "reuptake", "inhibitors", "(", "SSRIs", ")", "and", "their", "toxic", "effects", ".", "In", "some", "cases", ",", "a", "high", "serum", "concentration", "of", "citalopram", "(", ">", "600", "nmol", "/", "L", ")", "in", "elderly", "patients", "has", "been", "associated", "with", "increased", "somnolence", "and", "movement", "difficulties", ".", "Widespread", "cognitive", "disorders", ",", "such", "as", "delirium", ",", "have", "not", "been", "previously", "linked", "with", "high", "blood", "levels", "of", "SSRIs", ".", "In", "this", "report", ",", "we", "describe", "a", "patient", "with", "acute", "hyperkinetic", "delirium", "connected", "with", "a", "high", "serum", "total", "fluoxetine", "(", "fluoxetine", "plus", "desmethylfluoxetine", ")", "concentration", "."]], "ner": [[[2, 2, "Chemical"], [124, 124, "Chemical"], [126, 126, "Chemical"], [0, 0, "Disease"], [92, 92, "Disease"], [117, 117, "Disease"], [116, 116, "Disease"], [45, 45, "Chemical"], [65, 65, "Chemical"], [128, 128, "Chemical"], [81, 81, "Disease"], [83, 84, "Disease"], [87, 88, "Disease"]]], "relations": [[[2, 2, 0, 0, "CID"], [2, 2, 92, 92, "CID"], [2, 2, 117, 117, "CID"], [124, 124, 0, 0, "CID"], [124, 124, 92, 92, "CID"], [124, 124, 117, 117, "CID"], [126, 126, 0, 0, "CID"], [126, 126, 92, 92, "CID"], [126, 126, 117, 117, "CID"], [2, 2, 116, 116, "CID"], [124, 124, 116, 116, "CID"], [126, 126, 116, 116, "CID"]]], "clusters": [], "translated": " <3>谵妄</3> <0>氟西汀</0> 治疗期间。个案报告。已经充分证实了高血清三环类抗抑郁药浓度与中枢神经系统副作用之间的相关性。然而，对于选择性<7>5-羟色胺</7> 再摄取抑制剂(SSRIs) 血清浓度与它们的毒性作用之间的关系，只有少数报道。在某些情况下，高浓度<8>西酞普兰</8>(> 600 nmol/L)与增加的<10>嗜睡</10>和<11>运动障碍</11>有关。尚未将广泛的<12>认知障碍</12>，如<4>谵妄</4>，与血液中SSRIs的高水平联系起来。在这篇报道中，我们描述了一位患有急性<6>多动症</6><5>谵妄</5>的患者，该患者与高血清总量<1>氟西汀</1> (<2>氟西汀</2>+ <9>去甲基氟西汀</9>)有关。", "revised": true}
{"doc_key": "2974281", "sentences": [["Subacute", "effects", "of", "propranolol", "and", "B", "24", "/", "76", "on", "isoproterenol", "-", "induced", "rat", "heart", "hypertrophy", "in", "correlation", "with", "blood", "pressure", ".", "We", "compared", "the", "potential", "beta", "-", "receptor", "blocker", ",", "B", "24", "/", "76", "i", ".", "e", ".", "1", "-", "(", "2", ",", "4", "-", "dichlorophenoxy", ")", "-", "3", "[", "2", "-", "3", ",", "4", "-", "dimethoxyphenyl", ")", "ethanolamino", "]", "-", "prop", "an", "-", "2", "-", "ol", ",", "which", "is", "characterized", "by", "beta", "1", "-", "adrenoceptor", "blocking", "and", "beta", "2", "-", "adrenoceptor", "stimulating", "properties", "with", "propranolol", ".", "The", "studies", "were", "performed", "using", "an", "experimental", "model", "of", "isoproterenol", "-", "induced", "heart", "hypertrophy", "in", "rats", ".", "A", "correlation", "of", "the", "blood", "pressure", "was", "neither", "found", "in", "the", "development", "nor", "in", "the", "attempt", "to", "suppress", "the", "development", "of", "heart", "hypertrophy", "with", "the", "two", "beta", "-", "receptor", "blockers", ".", "Both", "beta", "-", "blockers", "influenced", "the", "development", "of", "hypertrophy", "to", "a", "different", ",", "but", "not", "reproducible", "extent", ".", "It", "was", "possible", "to", "suppress", "the", "increased", "ornithine", "decarboxylase", "activity", "with", "both", "beta", "-", "blockers", "in", "hypertrophied", "hearts", ",", "but", "there", "was", "no", "effect", "on", "the", "heart", "mass", ".", "Neither", "propranolol", "nor", "B", "24", "/", "76", "could", "stop", "the", "changes", "in", "the", "characteristic", "myosin", "isoenzyme", "pattern", "of", "the", "hypertrophied", "rat", "heart", ".", "Thus", ",", "the", "investigations", "did", "not", "provide", "any", "evidence", "that", "the", "beta", "-", "receptor", "blockers", "propranolol", "and", "B", "24", "/", "76", "have", "the", "potency", "to", "prevent", "isoproterenol", "from", "producing", "heart", "hypertrophy", "."]], "ner": [[[10, 10, "Chemical"], [97, 97, "Chemical"], [232, 232, "Chemical"], [14, 15, "Disease"], [100, 101, "Disease"], [126, 127, "Disease"], [170, 171, "Disease"], [235, 236, "Disease"], [3, 3, "Chemical"], [86, 86, "Chemical"], [184, 184, "Chemical"], [221, 221, "Chemical"], [144, 144, "Disease"], [202, 202, "Disease"], [161, 161, "Chemical"]]], "relations": [[[10, 10, 14, 15, "CID"], [10, 10, 100, 101, "CID"], [10, 10, 126, 127, "CID"], [10, 10, 170, 171, "CID"], [10, 10, 235, 236, "CID"], [97, 97, 14, 15, "CID"], [97, 97, 100, 101, "CID"], [97, 97, 126, 127, "CID"], [97, 97, 170, 171, "CID"], [97, 97, 235, 236, "CID"], [232, 232, 14, 15, "CID"], [232, 232, 100, 101, "CID"], [232, 232, 126, 127, "CID"], [232, 232, 170, 171, "CID"], [232, 232, 235, 236, "CID"]]], "clusters": [], "translated": "<8>普萘洛尔</8>和B 24 / 76对<0>异丙肾上腺素</0>诱导大鼠<3>心脏肥大</3>的亚急性作用与血压相关。我们比较了潜在的β受体阻滞剂B 24 / 76，即1-(2,4-二氯苯氧基)-3-[2-(3,4-二甲氧基苯基)乙醇]胺-丙醇，其特征在于β1-肾上腺素能受体阻断和β2-肾上腺素能受体刺激特性与<9>普萘洛尔</9>相比。这些研究是使用实验模型，即<1>异丙肾上腺素</1>诱导的大鼠<4>心脏肥大</4>。在用两种β受体阻滞剂抑制<5>心脏肥大</5>的发展过程中，也没有发现血压的相关性。两种β受体阻滞剂对<12>肥大</12>的发展有不同的影响，但程度不可重复。在<6>肥大的心脏</6>中，两种β受体阻滞剂都可以抑制增加的<14>鸟氨酸</14>脱羧酶活性，但对心脏质量没有影响。<10>普萘洛尔</10>和B 24 / 76都不能阻止产生<2>异丙肾上腺素</2>诱导的<7>心脏肥大</7>，同时也没有改变<13>肥大</13>大鼠心脏肌球蛋白同工酶特征模式。因此，调查没有提供任何证据表明β受体阻滞剂<11>普萘洛尔</11>和B 24 / 76具有防止<2>异丙肾上腺素</2>产生<7>心脏肥大</7>的能力。", "revised": true}
{"doc_key": "7644931", "sentences": [["Paclitaxel", "3", "-", "hour", "infusion", "given", "alone", "and", "combined", "with", "carboplatin", ":", "preliminary", "results", "of", "dose", "-", "escalation", "trials", ".", "Paclitaxel", "(", "Taxol", ";", "Bristol", "-", "Myers", "Squibb", "Company", ",", "Princeton", ",", "NJ", ")", "by", "3", "-", "hour", "infusion", "was", "combined", "with", "carboplatin", "in", "a", "phase", "I", "/", "II", "study", "directed", "to", "patients", "with", "non", "-", "small", "cell", "lung", "cancer", ".", "Carboplatin", "was", "given", "at", "a", "fixed", "target", "area", "under", "the", "concentration", "-", "time", "curve", "of", "6", ".", "0", "by", "the", "Calvert", "formula", ",", "whereas", "paclitaxel", "was", "escalated", "in", "patient", "cohorts", "from", "150", "mg", "/", "m2", "(", "dose", "level", "I", ")", "to", "175", ",", "200", ",", "225", ",", "and", "250", "mg", "/", "m2", ".", "The", "225", "mg", "/", "m2", "level", "was", "expanded", "for", "the", "phase", "II", "study", "since", "the", "highest", "level", "achieved", "(", "250", "mg", "/", "m2", ")", "required", "modification", "because", "of", "nonhematologic", "toxicities", "(", "arthralgia", "and", "sensory", "neuropathy", ")", ".", "Therapeutic", "effects", "were", "noted", "at", "all", "dose", "levels", ",", "with", "objective", "responses", "in", "17", "(", "two", "complete", "and", "15", "partial", "regressions", ")", "of", "41", "previously", "untreated", "patients", ".", "Toxicities", "were", "compared", "with", "a", "cohort", "of", "patients", "in", "a", "phase", "I", "trial", "of", "paclitaxel", "alone", "at", "identical", "dose", "levels", ".", "Carboplatin", "did", "not", "appear", "to", "add", "to", "the", "hematologic", "toxicities", "observed", ",", "and", "the", "paclitaxel", "/", "carboplatin", "combination", "could", "be", "dosed", "every", "3", "weeks", "."]], "ner": [[[0, 0, "Chemical"], [20, 20, "Chemical"], [22, 22, "Chemical"], [85, 85, "Chemical"], [193, 193, "Chemical"], [214, 214, "Chemical"], [145, 145, "Disease"], [147, 148, "Disease"], [208, 209, "Disease"], [54, 59, "Disease"], [143, 143, "Disease"], [179, 179, "Disease"], [10, 10, "Chemical"], [42, 42, "Chemical"], [61, 61, "Chemical"], [200, 200, "Chemical"], [216, 216, "Chemical"]]], "relations": [[[0, 0, 145, 145, "CID"], [20, 20, 145, 145, "CID"], [22, 22, 145, 145, "CID"], [85, 85, 145, 145, "CID"], [193, 193, 145, 145, "CID"], [214, 214, 145, 145, "CID"], [0, 0, 147, 148, "CID"], [20, 20, 147, 148, "CID"], [22, 22, 147, 148, "CID"], [85, 85, 147, 148, "CID"], [193, 193, 147, 148, "CID"], [214, 214, 147, 148, "CID"], [0, 0, 208, 209, "CID"], [20, 20, 208, 209, "CID"], [22, 22, 208, 209, "CID"], [85, 85, 208, 209, "CID"], [193, 193, 208, 209, "CID"], [214, 214, 208, 209, "CID"]]], "clusters": [], "translated": "<0>紫杉醇</0>3 小时输注单独给药和与<12>卡铂</12>联合给药：剂量递增试验的初步结果。<1>紫杉醇</1>（<2>Taxol</2>; Bristol-Myers Squibb Company，普林斯顿，新泽西州）通过 3 小时输注与<13>卡铂</13>在 I/II期联合研究针对<9>非小细胞肺癌</9>患者。 <14>卡铂</14>在Calvert公式下固定目标曲线下面积为6.0，而<3>紫杉醇</3>随着患者队列剂量递增，从150毫克/平方米（剂量水平 I）到175、200、225、250毫克/平方米。最高剂量达到了250毫克/平方米，但由于非血液毒性（<10>毒性</10>，<6>关节痛</6>和<7>感觉神经病</7>），因此需进行改动，因此扩大了225毫克/平方米剂量水平来进行II期研究。在所有剂量水平下都观察到治疗效果，在41例先前未治疗的患者中有17例（2例完全缓解和15例部分缓解）出现客观反应。 <11>毒性</11>与<4>仅紫杉醇</4>在相同剂量水平下进行的I期试验中的一组患者进行了比较。 <15>卡铂</15>似乎没有增加观察到的<8>血液学毒性</8>，<5>紫杉醇</5>/<16>卡铂</16>组合可以每3周进行一次给药。", "revised": true}
{"doc_key": "8511251", "sentences": [["Cocaine", "induced", "myocardial", "ischemia", ".", "We", "report", "a", "case", "of", "myocardial", "ischemia", "induced", "by", "cocaine", ".", "The", "ischemia", "probably", "induced", "by", "coronary", "artery", "spasm", "was", "reversed", "by", "nitroglycerin", "and", "calcium", "blocking", "agents", "."]], "ner": [[[0, 0, "Chemical"], [14, 14, "Chemical"], [2, 3, "Disease"], [10, 11, "Disease"], [21, 23, "Disease"], [17, 17, "Disease"], [27, 27, "Chemical"], [29, 29, "Chemical"]]], "relations": [[[0, 0, 2, 3, "CID"], [0, 0, 10, 11, "CID"], [14, 14, 2, 3, "CID"], [14, 14, 10, 11, "CID"], [0, 0, 21, 23, "CID"], [14, 14, 21, 23, "CID"]]], "clusters": [], "translated": "<0>可卡因</0>诱发<2>心肌缺血</2>。我们报告了一例由<1>可卡因</1>引起的<3>心肌缺血</3>。可能由<4>冠状动脉痉挛</4>引起的<5>缺血</5>被<6>硝酸甘油</6>和<7>钙</7>阻滞剂逆转。", "revised": true}
{"doc_key": "7739955", "sentences": [["Transvenous", "right", "ventricular", "pacing", "during", "cardiopulmonary", "resuscitation", "of", "pediatric", "patients", "with", "acute", "cardiomyopathy", ".", "We", "describe", "the", "cardiopulmonary", "resuscitation", "efforts", "on", "five", "patients", "who", "presented", "in", "acute", "circulatory", "failure", "from", "myocardial", "dysfunction", ".", "Three", "patients", "had", "acute", "viral", "myocarditis", ",", "one", "had", "a", "carbamazepine", "-", "induced", "acute", "eosinophilic", "myocarditis", ",", "and", "one", "had", "cardiac", "hemosiderosis", "resulting", "in", "acute", "cardiogenic", "shock", ".", "All", "patients", "were", "continuously", "monitored", "with", "central", "venous", "and", "arterial", "catheters", "in", "addition", "to", "routine", "noninvasive", "monitoring", ".", "An", "introducer", "sheath", ",", "a", "pacemaker", ",", "and", "sterile", "pacing", "wires", "were", "made", "readily", "available", "for", "the", "patients", ",", "should", "the", "need", "arise", "to", "terminate", "resistant", "cardiac", "dysrhythmias", ".", "All", "patients", "developed", "cardiocirculatory", "arrest", "associated", "with", "extreme", "hypotension", "and", "dysrhythmias", "within", "the", "first", "48", "hours", "of", "their", "admission", "to", "the", "pediatric", "intensive", "care", "unit", "(", "PICU", ")", ".", "Right", "ventricular", "pacemaker", "wires", "were", "inserted", "in", "all", "of", "them", "during", "cardiopulmonary", "resuscitation", "(", "CPR", ")", ".", "In", "four", "patients", ",", "cardiac", "pacing", "was", "used", ",", "resulting", "in", "a", "temporary", "captured", "rhythm", "and", "restoration", "of", "their", "cardiac", "output", ".", "These", "patients", "had", "a", "second", "event", "of", "cardiac", "arrest", ",", "resulting", "in", "death", ",", "within", "10", "to", "60", "minutes", ".", "In", "one", "patient", ",", "cardiac", "pacing", "was", "not", "used", ",", "because", "he", "converted", "to", "normal", "sinus", "rhythm", "by", "electrical", "defibrillation", "within", "three", "minutes", "of", "initiating", "CPR", ".", "We", "conclude", "that", "cardiac", "pacing", "during", "resuscitative", "efforts", "in", "pediatric", "patients", "suffering", "from", "acute", "myocardial", "dysfunction", "may", "not", "have", "long", "-", "term", "value", "in", "and", "of", "itself", ";", "however", ",", "if", "temporary", "hemodynamic", "stability", "is", "achieved", "by", "this", "procedure", ",", "it", "may", "provide", "additional", "time", "needed", "to", "institute", "other", "therapeutic", "modalities", "."]], "ner": [[[43, 43, "Chemical"], [38, 38, "Disease"], [47, 48, "Disease"], [12, 12, "Disease"], [30, 31, "Disease"], [237, 238, "Disease"], [27, 28, "Disease"], [58, 59, "Disease"], [106, 106, "Disease"], [118, 118, "Disease"], [116, 116, "Disease"], [183, 184, "Disease"]]], "relations": [[[43, 43, 38, 38, "CID"], [43, 43, 47, 48, "CID"]]], "clusters": [], "translated": "急性<3>心肌病</3>儿科患者心肺复苏时经静脉右心室起搏。我们描述了因<4>心肌功能障碍</4>而出现急性<6>循环衰竭</6>的五名患者的心肺复苏努力。三名患者患有急性病毒性<1>心肌炎</1>，一名患有<0>卡马西平</0>-诱发急性<2>嗜酸性粒细胞性心肌炎</2>，一名患有心脏含铁血黄素增多症导致急性<7>心源性震惊</7>。除常规无创监测外，所有患者均接受中央静脉和动脉导管的连续监测。如果需要终止顽固性<8>心律失常</8>，则可以随时为患者提供导管鞘、起搏器和无菌起搏线。所有患者在进入儿科重症监护病房(PICU)后的最初48小时内都出现了与极度<10>低血压</10>和<9>心律失常</9>相关的心脏循环骤停。在心肺复苏术(CPR)期间，所有患者都被植入了右心室起搏器导线。在四名患者中，使用了心脏起搏器，导致暂时捕获节律并恢复了他们的心输出量。这些患者在10到60分钟内发生了<11>心脏骤停</11>的第二次事件，导致死亡。一名患者未使用心脏起搏，因为他在开始心肺复苏后三分钟内通过电除颤转为正常窦性心律。我们得出结论，在患有急性<5>心肌功能障碍</5>的儿科患者的复苏过程中，心脏起搏本身可能没有长期价值；然而，如果通过该手术实现了暂时的血流动力学稳定，则可能需要额外的时间来进行其他治疗。", "revised": true}
{"doc_key": "3975902", "sentences": [["Cardiovascular", "dysfunction", "and", "hypersensitivity", "to", "sodium", "pentobarbital", "induced", "by", "chronic", "barium", "chloride", "ingestion", ".", "Barium", "-", "supplemented", "Long", "-", "Evans", "hooded", "rats", "were", "characterized", "by", "a", "persistent", "hypertension", "that", "was", "evident", "after", "1", "month", "of", "barium", "(", "100", "micrograms", "/", "ml", "mineral", "fortified", "water", ")", "treatment", ".", "Analysis", "of", "in", "vivo", "myocardial", "excitability", ",", "contractility", ",", "and", "metabolic", "characteristics", "at", "16", "months", "revealed", "other", "significant", "barium", "-", "induced", "disturbances", "within", "the", "cardiovascular", "system", ".", "The", "most", "distinctive", "aspect", "of", "the", "barium", "effect", "was", "a", "demonstrated", "hypersensitivity", "of", "the", "cardiovascular", "system", "to", "sodium", "pentobarbital", ".", "Under", "barbiturate", "anesthesia", ",", "virtually", "all", "of", "the", "myocardial", "contractile", "indices", "were", "depressed", "significantly", "in", "barium", "-", "exposed", "rats", "relative", "to", "the", "corresponding", "control", "-", "fed", "rats", ".", "The", "lack", "of", "a", "similar", "response", "to", "ketamine", "and", "xylazine", "anesthesia", "revealed", "that", "the", "cardiovascular", "actions", "of", "sodium", "pentobarbital", "in", "barium", "-", "treated", "rats", "were", "linked", "specifically", "to", "this", "anesthetic", ",", "and", "were", "not", "representative", "of", "a", "generalized", "anesthetic", "response", ".", "Other", "myocardial", "pathophysiologic", "and", "metabolic", "changes", "induced", "by", "barium", "were", "manifest", ",", "irrespective", "of", "the", "anesthetic", "employed", ".", "The", "contractile", "element", "shortening", "velocity", "of", "the", "cardiac", "muscle", "fibers", "was", "significantly", "slower", "in", "both", "groups", "of", "barium", "-", "treated", "rats", "relative", "to", "the", "control", "groups", ",", "irrespective", "of", "the", "anesthetic", "regimen", ".", "Similarly", ",", "significant", "disturbances", "in", "myocardial", "energy", "metabolism", "were", "detected", "in", "the", "barium", "-", "exposed", "rats", "which", "were", "consistent", "with", "the", "reduced", "contractile", "element", "shortening", "velocity", ".", "In", "addition", ",", "the", "excitability", "of", "the", "cardiac", "conduction", "system", "was", "depressed", "preferentially", "in", "the", "atrioventricular", "nodal", "region", "of", "hearts", "from", "barium", "-", "exposed", "rats", ".", "Overall", ",", "the", "altered", "cardiac", "contractility", "and", "excitability", "characteristics", ",", "the", "myocardial", "metabolic", "disturbances", ",", "and", "the", "hypersensitivity", "of", "the", "cardiovascular", "system", "to", "sodium", "pentobarbital", "suggest", "the", "existence", "of", "a", "heretofore", "undescribed", "cardiomyopathic", "disorder", "induced", "by", "chronic", "barium", "exposure", ".", "These", "experimental", "findings", "represent", "the", "first", "indication", "that", "life", "-", "long", "barium", "ingestion", "may", "have", "significant", "adverse", "effects", "on", "the", "mammalian", "cardiovascular", "system", "."]], "ner": [[[10, 11, "Chemical"], [27, 27, "Disease"], [299, 300, "Disease"], [5, 6, "Chemical"], [91, 92, "Chemical"], [139, 140, "Chemical"], [290, 291, "Chemical"], [0, 1, "Disease"], [68, 72, "Disease"], [14, 14, "Chemical"], [35, 35, "Chemical"], [65, 65, "Chemical"], [80, 80, "Chemical"], [109, 109, "Chemical"], [142, 142, "Chemical"], [171, 171, "Chemical"], [198, 198, "Chemical"], [226, 226, "Chemical"], [262, 262, "Chemical"], [304, 304, "Chemical"], [318, 318, "Chemical"], [95, 95, "Chemical"], [129, 129, "Chemical"], [131, 131, "Chemical"], [3, 3, "Disease"], [85, 85, "Disease"], [284, 284, "Disease"], [279, 280, "Disease"]]], "relations": [[[10, 11, 27, 27, "CID"], [10, 11, 299, 300, "CID"]]], "clusters": [], "translated": "<7>心血管功能障碍</7>和<24>超敏反应</24>对<3>戊巴比妥钠</3>的敏感反应由慢性<0>氯化钡</0>的摄入引起。 <9>钡</9>-补充的 Long-Evans hooded 大鼠被特征为持续的<1>高血压</1>，在 <10>钡</10>（100 微克/毫升矿物质强化水处理）的处理后一个月内变得明显。对在 16 个月时体内心肌兴奋性、收缩性和代谢特征的分析表明<11>钡</11>在心血管系统内引起了其他显着的<8>紊乱</8>。最突出的<12>钡</12>效应是心血管系统对<4>戊巴比妥钠</4>的<25>超敏反应</25>。在<21>巴比妥</21>的麻醉下，相对应的对照组的大鼠比<13>钡</13>暴露的大鼠显著降低了几乎所有的心肌收缩指数。 <5>戊巴比妥钠</5>在<14>钡</14>治疗的大鼠中的心血管作用是特异的，与全身麻醉反应无关，对<22>氯胺酮</22>和<23>甲苯噻嗪</23>麻醉无类似反应。<15>钡</15>引起的其他心肌病理生理和代谢变化是明显的，与使用的麻醉剂无关。相对于对照组，两组<16>钡</16>治疗的大鼠的心肌纤维收缩元件缩短速度均显著减慢，与麻醉方案无关。同样，在暴露于<17>钡</17>的大鼠中检测到心肌能量代谢的显着紊乱，这与收缩元件缩短速度降低一致。此外，<18>钡</18>暴露的大鼠的心脏传导系统中房室结区的兴奋性优先受到抑制。总体而言，心肌<2>病变</2>、改变的心肌收缩力和兴奋性特征、心肌<27>代谢紊乱</27>，以及心血管系统对<6>戊巴比妥钠</6>的<26>超敏反应</26>表明存在迄今未描述的由慢性<19>钡</19>暴露引起的心肌病。这些实验结果首次表明了终生摄入<20>钡</20>可能对哺乳动物的心血管系统产生重大不良影响。", "revised": true}
{"doc_key": "8748050", "sentences": [["Encephalopathy", "during", "amitriptyline", "therapy", ":", "are", "neuroleptic", "malignant", "syndrome", "and", "serotonin", "syndrome", "spectrum", "disorders", "?", "This", "report", "describes", "a", "case", "of", "encephalopathy", "developed", "in", "the", "course", "of", "amitriptyline", "therapy", ",", "during", "a", "remission", "of", "unipolar", "depression", ".", "This", "patient", "could", "have", "been", "diagnosed", "as", "having", "either", "neuroleptic", "malignant", "syndrome", "(", "NMS", ")", "or", "serotonin", "syndrome", "(", "SS", ")", ".", "The", "major", "determinant", "of", "the", "symptoms", "may", "have", "been", "dopamine", "/", "serotonin", "imbalance", "in", "the", "central", "nervous", "system", ".", "The", "NMS", "-", "like", "encephalopathy", "that", "develops", "in", "association", "with", "the", "use", "of", "antidepressants", "indicates", "that", "NMS", "and", "SS", "are", "spectrum", "disorders", "induced", "by", "drugs", "with", "both", "antidopaminergic", "and", "serotonergic", "effects", "."]], "ner": [[[2, 2, "Chemical"], [27, 27, "Chemical"], [0, 0, "Disease"], [21, 21, "Disease"], [82, 82, "Disease"], [68, 68, "Chemical"], [70, 70, "Chemical"], [6, 8, "Disease"], [46, 48, "Disease"], [50, 50, "Disease"], [79, 79, "Disease"], [94, 94, "Disease"], [10, 11, "Disease"], [53, 54, "Disease"], [56, 56, "Disease"], [96, 96, "Disease"], [34, 35, "Disease"]]], "relations": [[[2, 2, 0, 0, "CID"], [2, 2, 21, 21, "CID"], [2, 2, 82, 82, "CID"], [27, 27, 0, 0, "CID"], [27, 27, 21, 21, "CID"], [27, 27, 82, 82, "CID"]]], "clusters": [], "translated": "<0>阿米替林</0>治疗期间的<2>脑病</2>：<7>抗精神病药恶性综合征</7>和<12>5-羟色胺综合征</12>谱系障碍？本报告描述了<1>阿米替林</1>治疗过程中<16>单相抑郁症</16>缓解期间发生<3>脑病</3>的病例。该患者可能已被诊断为患有<8>抗精神病药物恶性综合征</8>（<9>NMS</9>）或<13>血清素综合征</13>（<14>SS</14>）。症状的主要决定因素可能是中枢神经系统的<5>多巴胺</5>/<6>血清素</6>失衡。<10>NMS</10>-与使用抗抑郁药相关的<4>脑病</4>表明<11>NMS</11>和<15>SS</15>是谱系障碍，由具有抗多巴胺能和血清素能作用的药物引起。", "revised": true}
{"doc_key": "8603459", "sentences": [["Doxorubicin", "-", "induced", "cardiotoxicity", "monitored", "by", "ECG", "in", "freely", "moving", "mice", ".", "A", "new", "model", "to", "test", "potential", "protectors", ".", "In", "laboratory", "animals", ",", "histology", "is", "most", "commonly", "used", "to", "study", "doxorubicin", "-", "induced", "cardiotoxicity", ".", "However", ",", "for", "monitoring", "during", "treatment", ",", "large", "numbers", "of", "animals", "are", "needed", ".", "Recently", "we", "developed", "a", "new", "method", "to", "measure", "ECG", "values", "in", "freely", "moving", "mice", "by", "telemetry", ".", "With", "this", "model", "we", "investigated", "the", "effect", "of", "chronic", "doxorubicin", "administration", "on", "the", "ECG", "of", "freely", "moving", "BALB", "/", "c", "mice", "and", "the", "efficacy", "of", "ICRF", "-", "187", "as", "a", "protective", "agent", ".", "The", "ST", "interval", "significantly", "widened", "from", "15", ".", "0", "+", "/", "-", "1", ".", "5", "to", "56", ".", "8", "+", "/", "-", "11", ".", "8", "ms", "in", "week", "10", "(", "7", "weekly", "doses", "of", "4", "mg", "/", "kg", "doxorubicin", "given", "i", ".", "v", ".", "plus", "3", "weeks", "of", "observation", ")", ".", "The", "ECG", "of", "the", "control", "animals", "did", "not", "change", "during", "the", "entire", "study", ".", "After", "sacrifice", "the", "hearts", "of", "doxorubicin", "-", "treated", "animals", "were", "enlarged", "and", "the", "atria", "were", "hypertrophic", ".", "As", "this", "schedule", "exerted", "more", "toxicity", "than", "needed", "to", "investigate", "protective", "agents", ",", "the", "protection", "of", "ICRF", "-", "187", "was", "determined", "using", "a", "dose", "schedule", "with", "lower", "general", "toxicity", "(", "6", "weekly", "doses", "of", "4", "mg", "/", "kg", "doxorubicin", "given", "i", ".", "v", ".", "plus", "2", "weeks", "of", "observation", ")", ".", "On", "this", "schedule", ",", "the", "animals", "'", "hearts", "appeared", "normal", "after", "sacrifice", "and", "ICRF", "-", "187", "(", "50", "mg", "/", "kg", "given", "i", ".", "p", ".", "1", "h", "before", "doxorubicin", ")", "provided", "almost", "full", "protection", ".", "These", "data", "were", "confirmed", "by", "histology", ".", "The", "results", "indicate", "that", "this", "new", "model", "is", "very", "sensitive", "and", "enables", "monitoring", "of", "the", "development", "of", "cardiotoxicity", "with", "time", ".", "These", "findings", "result", "in", "a", "model", "that", "allows", "the", "testing", "of", "protectors", "against", "doxorubicin", "-", "induced", "cardiotoxicity", "as", "demonstrated", "by", "the", "protection", "provided", "by", "ICRF", "-", "187", "."]], "ner": [[[0, 0, "Chemical"], [31, 31, "Chemical"], [76, 76, "Chemical"], [138, 138, "Chemical"], [170, 170, "Chemical"], [220, 220, "Chemical"], [262, 262, "Chemical"], [310, 310, "Chemical"], [3, 3, "Disease"], [34, 34, "Disease"], [293, 293, "Disease"], [313, 313, "Disease"], [180, 180, "Disease"], [187, 187, "Disease"], [210, 210, "Disease"], [92, 94, "Chemical"], [198, 200, "Chemical"], [246, 248, "Chemical"], [321, 323, "Chemical"]]], "relations": [[[0, 0, 3, 3, "CID"], [0, 0, 34, 34, "CID"], [0, 0, 293, 293, "CID"], [0, 0, 313, 313, "CID"], [31, 31, 3, 3, "CID"], [31, 31, 34, 34, "CID"], [31, 31, 293, 293, "CID"], [31, 31, 313, 313, "CID"], [76, 76, 3, 3, "CID"], [76, 76, 34, 34, "CID"], [76, 76, 293, 293, "CID"], [76, 76, 313, 313, "CID"], [138, 138, 3, 3, "CID"], [138, 138, 34, 34, "CID"], [138, 138, 293, 293, "CID"], [138, 138, 313, 313, "CID"], [170, 170, 3, 3, "CID"], [170, 170, 34, 34, "CID"], [170, 170, 293, 293, "CID"], [170, 170, 313, 313, "CID"], [220, 220, 3, 3, "CID"], [220, 220, 34, 34, "CID"], [220, 220, 293, 293, "CID"], [220, 220, 313, 313, "CID"], [262, 262, 3, 3, "CID"], [262, 262, 34, 34, "CID"], [262, 262, 293, 293, "CID"], [262, 262, 313, 313, "CID"], [310, 310, 3, 3, "CID"], [310, 310, 34, 34, "CID"], [310, 310, 293, 293, "CID"], [310, 310, 313, 313, "CID"]]], "clusters": [], "translated": "<0>多柔比星</0>诱导的<8>心脏毒性</8>在自由活动的小鼠中通过心电图监测。一种测试潜在保护剂的新模型。在实验室动物中，组织学最常用于研究<1>阿霉素</1>诱导的<9>心脏毒性</9>。然而，为了在治疗期间进行监测，需要大量的动物。最近，我们开发了一种通过遥测法测量自由活动 BALB/c小鼠心电图值的新方法。利用该模型，我们研究了慢性<2>多柔比星</2>给药对自由活动BALB/c小鼠心电图的影响以及<15>ICRF-187</15>作为保护剂的效力。ST间期从15.0+/-1.5ms到第10周56.8+/-11.8ms（每周静脉注射4 mg/kg <3> 阿霉素 </3>并观察3周）。对照动物的心电图在整个研究期间没有变化。处死后，<4>多柔比星</4>处理动物的心脏增大，心房<12>肥大</12>。由于此方案产生更多的<13>毒性</13>，而研究保护剂所需的毒性更低，因此我们使用表现出较低一般<14>毒性</14>的给药方案，测试了<16>ICRF-187</16>的保护作用（每周静脉注射4 mg/kg <5>阿霉素</5>并观察2周）。按照这个时间表，动物的心脏在处死后表现正常，<17>ICRF-187</17>（在<6>多柔比星</6>前1小时 i.p. 给予50mg/kg）提供了几乎完全的保护。这些数据得到了组织学的证实。结果表明，这种新模型非常灵敏，可以监测随时间发展的<10>心脏毒性</10> 。这些发现得到了一个模型的证实，该模型允许通过使用<18>ICRF-187</18>的保护剂测试针对<7>阿霉素</7>诱导的<11>心脏毒性</11>。", "revised": true}
{"doc_key": "8312343", "sentences": [["Pediatric", "heart", "transplantation", "without", "chronic", "maintenance", "steroids", ".", "From", "1986", "to", "February", "1993", ",", "40", "children", "aged", "2", "months", "to", "18", "years", "(", "average", "age", "10", ".", "4", "+", "/", "-", "5", ".", "8", "years", ")", "underwent", "heart", "transplantation", ".", "Indications", "for", "transplantation", "were", "idiopathic", "cardiomyopathy", "(", "52", "%", ")", ",", "congenital", "heart", "disease", "(", "35", "%", ")", "with", "and", "without", "prior", "repair", "(", "71", "%", "and", "29", "%", ",", "respectively", ")", ",", "hypertrophic", "cardiomyopathy", "(", "5", "%", ")", ",", "valvular", "heart", "disease", "(", "3", "%", ")", ",", "and", "doxorubicin", "cardiomyopathy", "(", "5", "%", ")", ".", "Patients", "were", "managed", "with", "cyclosporine", "and", "azathioprine", ".", "No", "prophylaxis", "with", "antilymphocyte", "globulin", "was", "used", ".", "Steroids", "were", "given", "to", "39", "%", "of", "patients", "for", "refractory", "rejection", ",", "but", "weaning", "was", "always", "attempted", "and", "generally", "successful", "(", "64", "%", ")", ".", "Five", "patients", "(", "14", "%", ")", "received", "maintenance", "steroids", ".", "Four", "patients", "died", "in", "the", "perioperative", "period", "and", "one", "died", "4", "months", "later", ".", "There", "have", "been", "no", "deaths", "related", "to", "rejection", "or", "infection", ".", "Average", "follow", "-", "up", "was", "36", "+", "/", "-", "19", "months", "(", "range", "1", "to", "65", "months", ")", ".", "Cumulative", "survival", "is", "88", "%", "at", "5", "years", ".", "In", "patients", "less", "than", "7", "years", "of", "age", ",", "rejection", "was", "monitored", "noninvasively", ".", "In", "the", "first", "postoperative", "month", ",", "89", "%", "of", "patients", "were", "treated", "for", "rejection", ".", "Freedom", "from", "serious", "infections", "was", "83", "%", "at", "1", "month", "and", "65", "%", "at", "1", "year", ".", "Cytomegalovirus", "infections", "were", "treated", "successfully", "with", "ganciclovir", "in", "11", "patients", ".", "No", "impairment", "of", "growth", "was", "observed", "in", "children", "who", "underwent", "transplantation", "compared", "with", "a", "control", "population", ".", "Twenty", "-", "one", "patients", "(", "60", "%", ")", "have", "undergone", "annual", "catheterizations", "and", "no", "sign", "of", "graft", "atherosclerosis", "has", "been", "observed", ".", "Seizures", "occurred", "in", "five", "patients", "(", "14", "%", ")", "and", "hypertension", "was", "treated", "in", "10", "patients", "(", "28", "%", ")", ".", "No", "patient", "was", "disabled", "and", "no", "lymphoproliferative", "disorder", "was", "observed", ".", "(", "ABSTRACT", "TRUNCATED", "AT", "250", "WORDS", ")"]], "ner": [[[89, 89, "Chemical"], [90, 90, "Disease"], [6, 6, "Chemical"], [112, 112, "Chemical"], [145, 145, "Chemical"], [44, 45, "Disease"], [51, 53, "Disease"], [73, 74, "Disease"], [80, 82, "Disease"], [170, 170, "Disease"], [232, 232, "Disease"], [246, 247, "Disease"], [291, 291, "Disease"], [296, 296, "Disease"], [306, 306, "Disease"], [323, 324, "Disease"], [100, 100, "Chemical"], [102, 102, "Chemical"], [252, 252, "Chemical"]]], "relations": [[[89, 89, 90, 90, "CID"]]], "clusters": [], "translated": "无需长期维持<2>类固醇</2>的小儿心脏移植。1986年至1993年2月，40名2个月至18岁（平均年龄10.4 +/- 5.8岁）的儿童接受了心脏移植手术。移植的指征是<5>特发性心肌病</5>（52%），<6>先天性心脏病</6>（35%）有和没有预先修复（分别为71%和29%），<7>肥厚型心肌病</7>（5%），<8>心脏瓣膜病</8>（3%），<0>多柔比星</0><1>心肌病</1>（5%）。患者接受<16>环孢菌素</16>和<17>硫唑嘌呤</17>治疗。未使用抗淋巴细胞球蛋白进行预防。<3>类固醇</3>被给予39%的难治性排斥反应患者，但总是尝试撤机并且通常成功(64%)。五名患者(14%)接受<4>维持类固醇</4>治疗。围手术期死亡4例，4个月后死亡1例。没有与排斥或<9>感染</9>相关的死亡。平均随访时间为36 +/- 19个月（范围为1至65个月）。5年累积生存率为88%。在小于7岁的患者中，排斥反应是通过无创方式监测的。在术后第一个月，89%的患者接受了排斥反应治疗。免受严重<10>感染</10>的情况在1个月时为83%，在1年时为65%。<11>巨细胞病毒感染</11>在11名患者中使用<18>更昔洛韦</18>成功治疗。与对照人群相比，接受移植的儿童未观察到生长障碍。21名患者(60%)每年进行一次导管插入术，未观察到移植物<12>动脉粥样硬化</12>的迹象。<13>癫痫发作</13>有5名患者(14%)发生，<14>高血压</14>有10名患者(28%)接受治疗。没有患者残疾，也没有观察到<15>淋巴增生性疾病</15>。（摘要被截断为250个单词）", "revised": true}
{"doc_key": "8392553", "sentences": [["Protective", "effect", "of", "clentiazem", "against", "epinephrine", "-", "induced", "cardiac", "injury", "in", "rats", ".", "We", "investigated", "the", "effects", "of", "clentiazem", ",", "a", "1", ",", "5", "-", "benzothiazepine", "calcium", "antagonist", ",", "on", "epinephrine", "-", "induced", "cardiomyopathy", "in", "rats", ".", "With", "2", "-", "week", "chronic", "epinephrine", "infusion", ",", "16", "of", "30", "rats", "died", "within", "4", "days", ",", "and", "severe", "ischemic", "lesions", "and", "fibrosis", "of", "the", "left", "ventricles", "were", "observed", ".", "In", "epinephrine", "-", "treated", "rats", ",", "left", "atrial", "and", "left", "ventricular", "papillary", "muscle", "contractile", "responses", "to", "isoproterenol", "were", "reduced", ",", "but", "responses", "to", "calcium", "were", "normal", "or", "enhanced", "compared", "to", "controls", ".", "Left", "ventricular", "alpha", "and", "beta", "adrenoceptor", "densities", "were", "also", "reduced", "compared", "to", "controls", ".", "Treatment", "with", "clentiazem", "prevented", "epinephrine", "-", "induced", "death", "(", "P", "<", ".", "05", ")", ",", "and", "attenuated", "the", "ventricular", "ischemic", "lesions", "and", "fibrosis", ",", "in", "a", "dose", "-", "dependent", "manner", ".", "Left", "atrial", "and", "left", "ventricular", "papillary", "muscle", "contractile", "responses", "to", "isoproterenol", "were", "reduced", "compared", "to", "controls", "in", "groups", "treated", "with", "clentiazem", "alone", ",", "but", "combined", "with", "epinephrine", ",", "clentiazem", "restored", "left", "atrial", "responses", "and", "enhanced", "left", "ventricular", "papillary", "responses", "to", "isoproterenol", ".", "On", "the", "other", "hand", "clentiazem", "did", "not", "prevent", "epinephrine", "-", "induced", "down", "-", "regulation", "of", "alpha", "and", "beta", "adrenoceptors", ".", "Interestingly", ",", "clentiazem", ",", "infused", "alone", ",", "resulted", "in", "decreased", "adrenergic", "receptor", "densities", "in", "the", "left", "ventricle", ".", "Clentiazem", "also", "did", "not", "prevent", "the", "enhanced", "responses", "to", "calcium", "seen", "in", "the", "epinephrine", "-", "treated", "animals", ",", "although", "the", "high", "dose", "of", "clentiazem", "partially", "attenuated", "the", "maximal", "response", "to", "calcium", "compared", "to", "epinephrine", "-", "treated", "animals", ".", "In", "conclusion", ",", "clentiazem", "attenuated", "epinephrine", "-", "induced", "cardiac", "injury", ",", "possibly", "through", "its", "effect", "on", "the", "adrenergic", "pathway", "."]], "ner": [[[5, 5, "Chemical"], [30, 30, "Chemical"], [42, 42, "Chemical"], [68, 68, "Chemical"], [117, 117, "Chemical"], [170, 170, "Chemical"], [194, 194, "Chemical"], [237, 237, "Chemical"], [257, 257, "Chemical"], [267, 267, "Chemical"], [33, 33, "Disease"], [3, 3, "Chemical"], [18, 18, "Chemical"], [115, 115, "Chemical"], [164, 164, "Chemical"], [172, 172, "Chemical"], [190, 190, "Chemical"], [208, 208, "Chemical"], [224, 224, "Chemical"], [247, 247, "Chemical"], [265, 265, "Chemical"], [8, 9, "Disease"], [270, 271, "Disease"], [56, 57, "Disease"], [132, 133, "Disease"], [59, 59, "Disease"], [135, 135, "Disease"], [21, 25, "Chemical"], [26, 26, "Chemical"], [90, 90, "Chemical"], [233, 233, "Chemical"], [254, 254, "Chemical"], [83, 83, "Chemical"], [154, 154, "Chemical"], [184, 184, "Chemical"]]], "relations": [[[5, 5, 33, 33, "CID"], [30, 30, 33, 33, "CID"], [42, 42, 33, 33, "CID"], [68, 68, 33, 33, "CID"], [117, 117, 33, 33, "CID"], [170, 170, 33, 33, "CID"], [194, 194, 33, 33, "CID"], [237, 237, 33, 33, "CID"], [257, 257, 33, 33, "CID"], [267, 267, 33, 33, "CID"]]], "clusters": [], "translated": "<11>克地亚卓</11>对<0>肾上腺素</0>所致大鼠<21>心脏损伤</21>的保护作用。我们研究了<12>克地亚卓</12>，一种<27>1,5-苯并硫氮卓</27><28>钙</28>拮抗剂对<1>肾上腺素</1>诱导的<10>大鼠心肌病</10>。慢性<2>肾上腺素</2>输注2周，30只大鼠中有16只在4天内死亡，并观察到左心室严重<23>缺血性病变</23>和<25>纤维化</25>。在<3>肾上腺素</3>治疗的大鼠中，左心房和左心室乳头肌对<32>异丙肾上腺素</32>的收缩反应减少，但对<29>钙</29>的反应正常或增强。左心室α和β肾上腺素能受体密度也降低与对照组相比。<13>克地亚卓</13>治疗可预防<4>肾上腺素</4>引起的死亡(P<.05)，并以剂量依赖的方式减轻心室<24>缺血性损伤</24>和<26>纤维化</26>。<14>克地亚卓</14>单独治疗会下降<33>异丙肾上腺素</33>的左心房和左心室乳头肌收缩反应与对照组相比，但与<5>肾上腺素</5>联合治疗，<15>克地亚卓</15>恢复了左心房反应并增强了左心室对<34>异丙肾上腺素</34>的乳头反应。另一方面，<16>克地亚卓</16>不能阻止<6>肾上腺素</6>诱导的α和β肾上腺素能受体下调。有趣的是，<17>克地亚卓</17>单独输注会导致左心室肾上腺素能受体密度降低。<18>克地亚卓</18>也没有阻止在<7>肾上腺素</7>治疗的动物中看到的对<30>钙</30>的增强反应，尽管高剂量的<19>克地亚卓</19>与<8>肾上腺素</8>治疗的动物相比，部分减弱了对<31>钙</31>的最大反应。总之，<20>克地亚卓</20>减轻了<9>肾上腺素</9>诱导的<22>心脏损伤</22>，可能是通过其对肾上腺素能途径的影响。", "revised": true}
{"doc_key": "8659767", "sentences": [["Epinephrine", "dysrhythmogenicity", "is", "not", "enhanced", "by", "subtoxic", "bupivacaine", "in", "dogs", ".", "Since", "bupivacaine", "and", "epinephrine", "may", "both", "precipitate", "dysrhythmias", ",", "circulating", "bupivacaine", "during", "regional", "anesthesia", "could", "potentiate", "dysrhythmogenic", "effects", "of", "epinephrine", ".", "We", "therefore", "examined", "whether", "bupivacaine", "alters", "the", "dysrhythmogenicity", "of", "subsequent", "administration", "of", "epinephrine", "in", "conscious", ",", "healthy", "dogs", "and", "in", "anesthetized", "dogs", "with", "myocardial", "infarction", ".", "Forty", "-", "one", "conscious", "dogs", "received", "10", "micrograms", ".", "kg", "-", "1", ".", "min", "-", "1", "epinephrine", ".", "Seventeen", "animals", "responded", "with", "ventricular", "tachycardia", "(", "VT", ")", "within", "3", "min", ".", "After", "3", "h", ",", "these", "responders", "randomly", "received", "1", "or", "2", "mg", "/", "kg", "bupivacaine", "or", "saline", "over", "5", "min", ",", "followed", "by", "10", "micrograms", ".", "kg", "-", "1", ".", "min", "-", "1", "epinephrine", ".", "In", "the", "bupivacaine", "groups", ",", "epinephrine", "caused", "fewer", "prodysrhythmic", "effects", "than", "without", "bupivacaine", ".", "VT", "appeared", "in", "fewer", "dogs", "and", "at", "a", "later", "time", ",", "and", "there", "were", "more", "sinoatrial", "beats", "and", "less", "ectopies", ".", "Epinephrine", "shortened", "QT", "less", "after", "bupivacaine", "than", "in", "control", "animals", ".", "One", "day", "after", "experimental", "myocardial", "infarction", ",", "six", "additional", "halothane", "-", "anesthetized", "dogs", "received", "4", "micrograms", ".", "kg", "-", "1", ".", "min", "-", "1", "epinephrine", "until", "VT", "appeared", ".", "After", "45", "min", ",", "1", "mg", "/", "kg", "bupivacaine", "was", "injected", "over", "5", "min", ",", "again", "followed", "by", "4", "micrograms", ".", "kg", "-", "1", ".", "min", "-", "1", "epinephrine", ".", "In", "these", "dogs", ",", "the", "prodysrhythmic", "response", "to", "epinephrine", "was", "also", "mitigated", "by", "preceding", "bupivacaine", ".", "Bupivacaine", "antagonizes", "epinephrine", "dysrhythmogenicity", "in", "conscious", "dogs", "susceptible", "to", "VT", "and", "in", "anesthetized", "dogs", "with", "spontaneous", "postinfarct", "dysrhythmias", ".", "There", "is", "no", "evidence", "that", "systemic", "subtoxic", "bupivacaine", "administration", "enhances", "the", "dysrhythmogenicity", "of", "subsequent", "epinephrine", "."]], "ner": [[[0, 0, "Chemical"], [14, 14, "Chemical"], [30, 30, "Chemical"], [44, 44, "Chemical"], [74, 74, "Chemical"], [122, 122, "Chemical"], [129, 129, "Chemical"], [159, 159, "Chemical"], [194, 194, "Chemical"], [227, 227, "Chemical"], [237, 237, "Chemical"], [247, 247, "Chemical"], [278, 278, "Chemical"], [80, 81, "Disease"], [83, 83, "Disease"], [138, 138, "Disease"], [196, 196, "Disease"], [254, 254, "Disease"], [18, 18, "Disease"], [262, 262, "Disease"], [55, 56, "Disease"], [174, 175, "Disease"], [7, 7, "Chemical"], [12, 12, "Chemical"], [21, 21, "Chemical"], [36, 36, "Chemical"], [103, 103, "Chemical"], [126, 126, "Chemical"], [136, 136, "Chemical"], [164, 164, "Chemical"], [207, 207, "Chemical"], [243, 243, "Chemical"], [245, 245, "Chemical"], [271, 271, "Chemical"], [179, 179, "Chemical"]]], "relations": [[[0, 0, 80, 81, "CID"], [0, 0, 83, 83, "CID"], [0, 0, 138, 138, "CID"], [0, 0, 196, 196, "CID"], [0, 0, 254, 254, "CID"], [14, 14, 80, 81, "CID"], [14, 14, 83, 83, "CID"], [14, 14, 138, 138, "CID"], [14, 14, 196, 196, "CID"], [14, 14, 254, 254, "CID"], [30, 30, 80, 81, "CID"], [30, 30, 83, 83, "CID"], [30, 30, 138, 138, "CID"], [30, 30, 196, 196, "CID"], [30, 30, 254, 254, "CID"], [44, 44, 80, 81, "CID"], [44, 44, 83, 83, "CID"], [44, 44, 138, 138, "CID"], [44, 44, 196, 196, "CID"], [44, 44, 254, 254, "CID"], [74, 74, 80, 81, "CID"], [74, 74, 83, 83, "CID"], [74, 74, 138, 138, "CID"], [74, 74, 196, 196, "CID"], [74, 74, 254, 254, "CID"], [122, 122, 80, 81, "CID"], [122, 122, 83, 83, "CID"], [122, 122, 138, 138, "CID"], [122, 122, 196, 196, "CID"], [122, 122, 254, 254, "CID"], [129, 129, 80, 81, "CID"], [129, 129, 83, 83, "CID"], [129, 129, 138, 138, "CID"], [129, 129, 196, 196, "CID"], [129, 129, 254, 254, "CID"], [159, 159, 80, 81, "CID"], [159, 159, 83, 83, "CID"], [159, 159, 138, 138, "CID"], [159, 159, 196, 196, "CID"], [159, 159, 254, 254, "CID"], [194, 194, 80, 81, "CID"], [194, 194, 83, 83, "CID"], [194, 194, 138, 138, "CID"], [194, 194, 196, 196, "CID"], [194, 194, 254, 254, "CID"], [227, 227, 80, 81, "CID"], [227, 227, 83, 83, "CID"], [227, 227, 138, 138, "CID"], [227, 227, 196, 196, "CID"], [227, 227, 254, 254, "CID"], [237, 237, 80, 81, "CID"], [237, 237, 83, 83, "CID"], [237, 237, 138, 138, "CID"], [237, 237, 196, 196, "CID"], [237, 237, 254, 254, "CID"], [247, 247, 80, 81, "CID"], [247, 247, 83, 83, "CID"], [247, 247, 138, 138, "CID"], [247, 247, 196, 196, "CID"], [247, 247, 254, 254, "CID"], [278, 278, 80, 81, "CID"], [278, 278, 83, 83, "CID"], [278, 278, 138, 138, "CID"], [278, 278, 196, 196, "CID"], [278, 278, 254, 254, "CID"]]], "clusters": [], "translated": "<0>肾上腺素</0> 亚毒性 <22>布比卡因</22> 不会增强犬的心律失常性。由于 <23>布比卡因</23> 和 <1>肾上腺素</1> 都可能导致 <18>心律失常</18>，因此在区域麻醉期间循环 <24>布比卡因</24> 可以增强 <2>肾上腺素</2> 的心律失常作用。因此，我们检查了 <25>布比卡因</25> 是否会改变清醒、健康的狗和患有 <20>心肌梗死</20> 的麻醉狗随后施用 <3>肾上腺素</3> 的心律失常性。四十一条清醒的狗接受了10微克·公斤-1·min-1的<4>肾上腺素</4>。17只动物在3分钟内出现<13>室性心动过速</13>（<14>VT</14>）。3小时后，这些反应者在5分钟内随机接受1或2mg/kg<26>布比卡因</26>或生理盐水，然后是10微克·公斤-1·min-1的<5>肾上腺素</5>。在<27>布比卡因</27>组中，<6>肾上腺素</6> 比没有<28>布比卡因</28> 引起更少的心律失常影响。<15>VT</15>犬出现较少且出现时间较晚，窦房性搏动较多，宫外搏动较少。<7>肾上腺素</7>与对照动物相比，在<29>布比卡因</29>后QT缩短更少。实验性<21>心肌梗塞</21>一天后，另外六只<34>氟烷</34>麻醉狗接受了4微克·公斤-1·min-1的<8>肾上腺素</8>直到出现<16>VT</16>。45分钟后，在5分钟内注射1mg/kg<30>布比卡因</30>，然后再次注射4微克·公斤-1·min-1的<9>肾上腺素</9>。在这些犬中，<31>布比卡因</31>也减轻了对<10>肾上腺素</10>的异常节律反应。<32>布比卡因</32>拮抗 <11>肾上腺素</11>对<17>VT</17>有意识的狗和具有自发性梗塞后<19>心律失常</19>的麻醉狗的心律失常性。没有证据表明全身亚毒性<33>布比卡因</33>给药会增强随后<12>肾上腺素</12>的心律失常性。", "revised": true}
{"doc_key": "8160791", "sentences": [["Mechanisms", "for", "protective", "effects", "of", "free", "radical", "scavengers", "on", "gentamicin", "-", "mediated", "nephropathy", "in", "rats", ".", "Studies", "were", "performed", "to", "examine", "the", "mechanisms", "for", "the", "protective", "effects", "of", "free", "radical", "scavengers", "on", "gentamicin", "(", "GM", ")", "-", "mediated", "nephropathy", ".", "Administration", "of", "GM", "at", "40", "mg", "/", "kg", "sc", "for", "13", "days", "to", "rats", "induced", "a", "significant", "reduction", "in", "renal", "blood", "flow", "(", "RBF", ")", "and", "inulin", "clearance", "(", "CIn", ")", "as", "well", "as", "marked", "tubular", "damage", ".", "A", "significant", "reduction", "in", "urinary", "guanosine", "3", "'", ",", "5", "'", "-", "cyclic", "monophosphate", "(", "cGMP", ")", "excretion", "and", "a", "significant", "increase", "in", "renal", "cortical", "renin", "and", "endothelin", "-", "1", "contents", "were", "also", "observed", "in", "GM", "-", "mediated", "nephropathy", ".", "Superoxide", "dismutase", "(", "SOD", ")", "or", "dimethylthiourea", "(", "DMTU", ")", "significantly", "lessened", "the", "GM", "-", "induced", "decrement", "in", "CIn", ".", "The", "SOD", "-", "induced", "increase", "in", "glomerular", "filtration", "rate", "was", "associated", "with", "a", "marked", "improvement", "in", "RBF", ",", "an", "increase", "in", "urinary", "cGMP", "excretion", ",", "and", "a", "decrease", "in", "renal", "renin", "and", "endothelin", "-", "1", "content", ".", "SOD", "did", "not", "attenuate", "the", "tubular", "damage", ".", "In", "contrast", ",", "DMTU", "significantly", "reduced", "the", "tubular", "damage", "and", "lipid", "peroxidation", ",", "but", "it", "did", "not", "affect", "renal", "hemodynamics", "and", "vasoactive", "substances", ".", "Neither", "SOD", "nor", "DMTU", "affected", "the", "renal", "cortical", "GM", "content", "in", "GM", "-", "treated", "rats", ".", "These", "results", "suggest", "that", "1", ")", "both", "SOD", "and", "DMTU", "have", "protective", "effects", "on", "GM", "-", "mediated", "nephropathy", ",", "2", ")", "the", "mechanisms", "for", "the", "protective", "effects", "differ", "for", "SOD", "and", "DMTU", ",", "and", "3", ")", "superoxide", "anions", "play", "a", "critical", "role", "in", "GM", "-", "induced", "renal", "vasoconstriction", "."]], "ner": [[[9, 9, "Chemical"], [32, 32, "Chemical"], [34, 34, "Chemical"], [42, 42, "Chemical"], [113, 113, "Chemical"], [131, 131, "Chemical"], [215, 215, "Chemical"], [218, 218, "Chemical"], [237, 237, "Chemical"], [266, 266, "Chemical"], [12, 12, "Disease"], [38, 38, "Disease"], [75, 76, "Disease"], [116, 116, "Disease"], [180, 181, "Disease"], [190, 191, "Disease"], [240, 240, "Disease"], [83, 91, "Chemical"], [93, 93, "Chemical"], [160, 160, "Chemical"], [118, 118, "Chemical"], [259, 259, "Chemical"], [124, 124, "Chemical"], [126, 126, "Chemical"], [186, 186, "Chemical"], [210, 210, "Chemical"], [232, 232, "Chemical"], [254, 254, "Chemical"]]], "relations": [[[9, 9, 12, 12, "CID"], [9, 9, 38, 38, "CID"], [9, 9, 75, 76, "CID"], [9, 9, 116, 116, "CID"], [9, 9, 180, 181, "CID"], [9, 9, 190, 191, "CID"], [9, 9, 240, 240, "CID"], [32, 32, 12, 12, "CID"], [32, 32, 38, 38, "CID"], [32, 32, 75, 76, "CID"], [32, 32, 116, 116, "CID"], [32, 32, 180, 181, "CID"], [32, 32, 190, 191, "CID"], [32, 32, 240, 240, "CID"], [34, 34, 12, 12, "CID"], [34, 34, 38, 38, "CID"], [34, 34, 75, 76, "CID"], [34, 34, 116, 116, "CID"], [34, 34, 180, 181, "CID"], [34, 34, 190, 191, "CID"], [34, 34, 240, 240, "CID"], [42, 42, 12, 12, "CID"], [42, 42, 38, 38, "CID"], [42, 42, 75, 76, "CID"], [42, 42, 116, 116, "CID"], [42, 42, 180, 181, "CID"], [42, 42, 190, 191, "CID"], [42, 42, 240, 240, "CID"], [113, 113, 12, 12, "CID"], [113, 113, 38, 38, "CID"], [113, 113, 75, 76, "CID"], [113, 113, 116, 116, "CID"], [113, 113, 180, 181, "CID"], [113, 113, 190, 191, "CID"], [113, 113, 240, 240, "CID"], [131, 131, 12, 12, "CID"], [131, 131, 38, 38, "CID"], [131, 131, 75, 76, "CID"], [131, 131, 116, 116, "CID"], [131, 131, 180, 181, "CID"], [131, 131, 190, 191, "CID"], [131, 131, 240, 240, "CID"], [215, 215, 12, 12, "CID"], [215, 215, 38, 38, "CID"], [215, 215, 75, 76, "CID"], [215, 215, 116, 116, "CID"], [215, 215, 180, 181, "CID"], [215, 215, 190, 191, "CID"], [215, 215, 240, 240, "CID"], [218, 218, 12, 12, "CID"], [218, 218, 38, 38, "CID"], [218, 218, 75, 76, "CID"], [218, 218, 116, 116, "CID"], [218, 218, 180, 181, "CID"], [218, 218, 190, 191, "CID"], [218, 218, 240, 240, "CID"], [237, 237, 12, 12, "CID"], [237, 237, 38, 38, "CID"], [237, 237, 75, 76, "CID"], [237, 237, 116, 116, "CID"], [237, 237, 180, 181, "CID"], [237, 237, 190, 191, "CID"], [237, 237, 240, 240, "CID"], [266, 266, 12, 12, "CID"], [266, 266, 38, 38, "CID"], [266, 266, 75, 76, "CID"], [266, 266, 116, 116, "CID"], [266, 266, 180, 181, "CID"], [266, 266, 190, 191, "CID"], [266, 266, 240, 240, "CID"]]], "clusters": [], "translated": "自由基清除剂对<0>庆大霉素</0><10>肾病</10>的保护作用机制。进行了研究以检查自由基清除剂对<1>庆大霉素</1>（<2>GM</2>）介导的<11>肾病</11>的保护作用的机制。在大鼠中，给药 <3> GM </3> 40 mg / kg 皮下注射 13 天后，显著降低了肾小球滤过速率（CIn）和肾血流量 (RBF)，并引起明显<12>肾小管损伤</12>。在<4> GM </4> - 介导的 <13>肾病</13>中，还观察到尿中<17>鸟嘌呤核苷酸 3'，5'-环磷酸盐</17>（<18>cGMP</18>）的显著降低，肾皮质中肾素和内皮素-1的含量的显著升高。<20>超氧化物</20>歧化酶（SOD）或<22>二甲基硫脲</22>（<23>DMTU</23>）均可显著减轻<5> GM </5> - 诱导的 CIn 下降。提高的肾小球滤过率与显着改善的 RBF、增加的尿<19>cGMP</19>排泄以及降低的肾素和内皮素-1含量相关。SOD 没有减轻<14>肾小管损伤</14>。相反，<24>DMTU</24> 显著减少 了 <15>肾小管损伤</15>和脂质过氧化，但不影响肾血流动力学和血管活性物质。SOD 和 <25>DMTU</25> 均不影响<7> GM </7>处理的大鼠肾皮质中的<6>GM</6>含量。这些结果表明：1) SOD 和 <26>DMTU</26> 都具有对 <8>GM</8> - 介导的 <16>肾病</16> 的保护作用；2) SOD 和 <27>DMTU</27> 的保护机制不同；3) <21>超氧化物</21>阴离子在<9>GM</9> - 诱导的肾血管收缩中起关键作用。", "revised": true}
{"doc_key": "8318674", "sentences": [["Pulmonary", "edema", "and", "shock", "after", "high", "-", "dose", "aracytine", "-", "C", "for", "lymphoma", ";", "possible", "role", "of", "TNF", "-", "alpha", "and", "PAF", ".", "Four", "out", "of", "23", "consecutive", "patients", "treated", "with", "high", "-", "dose", "Ara", "-", "C", "for", "lymphomas", "in", "our", "institution", "developed", "a", "strikingly", "similar", "syndrome", "during", "the", "perfusion", ".", "It", "was", "characterized", "by", "the", "onset", "of", "fever", ",", "diarrhea", ",", "shock", ",", "pulmonary", "edema", ",", "acute", "renal", "failure", ",", "metabolic", "acidosis", ",", "weight", "gain", "and", "leukocytosis", ".", "Thorough", "bacteriological", "screening", "failed", "to", "provide", "evidence", "of", "infection", ".", "Sequential", "biological", "assays", "of", "IL", "-", "1", ",", "IL", "-", "2", ",", "TNF", "and", "PAF", "were", "performed", "during", "Ara", "-", "C", "infusion", "to", "ten", "patients", ",", "including", "the", "four", "who", "developed", "the", "syndrome", ".", "TNF", "and", "PAF", "activity", "was", "found", "in", "the", "serum", "of", "respectively", "two", "and", "four", "of", "the", "cases", ",", "but", "not", "in", "the", "six", "controls", ".", "As", "TNF", "and", "PAF", "are", "thought", "to", "be", "involved", "in", "the", "development", "of", "septic", "shock", "and", "adult", "respiratory", "distress", "syndrome", ",", "we", "hypothesize", "that", "high", "-", "dose", "Ara", "-", "C", "may", "be", "associated", "with", "cytokine", "release", "."]], "ner": [[[8, 10, "Chemical"], [34, 36, "Chemical"], [107, 109, "Chemical"], [175, 177, "Chemical"], [0, 1, "Disease"], [64, 65, "Disease"], [3, 3, "Disease"], [62, 62, "Disease"], [162, 162, "Disease"], [58, 58, "Disease"], [60, 60, "Disease"], [67, 69, "Disease"], [71, 72, "Disease"], [74, 75, "Disease"], [77, 77, "Disease"], [12, 12, "Disease"], [38, 38, "Disease"], [87, 87, "Disease"], [164, 167, "Disease"]]], "relations": [[[8, 10, 0, 1, "CID"], [8, 10, 64, 65, "CID"], [34, 36, 0, 1, "CID"], [34, 36, 64, 65, "CID"], [107, 109, 0, 1, "CID"], [107, 109, 64, 65, "CID"], [175, 177, 0, 1, "CID"], [175, 177, 64, 65, "CID"], [8, 10, 3, 3, "CID"], [8, 10, 62, 62, "CID"], [8, 10, 162, 162, "CID"], [34, 36, 3, 3, "CID"], [34, 36, 62, 62, "CID"], [34, 36, 162, 162, "CID"], [107, 109, 3, 3, "CID"], [107, 109, 62, 62, "CID"], [107, 109, 162, 162, "CID"], [175, 177, 3, 3, "CID"], [175, 177, 62, 62, "CID"], [175, 177, 162, 162, "CID"], [8, 10, 58, 58, "CID"], [34, 36, 58, 58, "CID"], [107, 109, 58, 58, "CID"], [175, 177, 58, 58, "CID"], [8, 10, 60, 60, "CID"], [34, 36, 60, 60, "CID"], [107, 109, 60, 60, "CID"], [175, 177, 60, 60, "CID"], [8, 10, 67, 69, "CID"], [34, 36, 67, 69, "CID"], [107, 109, 67, 69, "CID"], [175, 177, 67, 69, "CID"], [8, 10, 71, 72, "CID"], [34, 36, 71, 72, "CID"], [107, 109, 71, 72, "CID"], [175, 177, 71, 72, "CID"], [8, 10, 74, 75, "CID"], [34, 36, 74, 75, "CID"], [107, 109, 74, 75, "CID"], [175, 177, 74, 75, "CID"], [8, 10, 77, 77, "CID"], [34, 36, 77, 77, "CID"], [107, 109, 77, 77, "CID"], [175, 177, 77, 77, "CID"]]], "clusters": [], "translated": "<4>肺水肿</4>和<6>休克</6><0>阿伐希汀-C</0>治疗<15>淋巴瘤</15>；TNF-α和PAF的可能作用。在我们机构接受高剂量<1>Ara-C</1>治疗<16>淋巴瘤</16>的连续23例患者中，有4例在灌注过程中出现了惊人相似的综合征。其特点是出现<9>发热</9>、<10>腹泻</10>、<7>休克</7>、<5>肺水肿</5>、<11>急性肾功能衰竭</11>、<12>代谢性酸中毒</12>、<13>体重增加</13>和<14>白细胞增多</14>。彻底的细菌学筛查未能提供<17>感染</17>的证据。在<2>Ara-C</2>输注过程中，对10名患者（包括4名出现该综合征的患者）进行了IL-1、IL-2、TNF和PAF的连续生物学测定。TNF和PAF活性分别在两个和四个病例的血清中发现，但在六个对照中没有。由于TNF和PAF被认为与感染性<8>休克</8>和<18>成人呼吸窘迫综合征</18>的发展有关，我们假设高剂量<3>Ara-C</3>可能与细胞因子释放有关。", "revised": true}
{"doc_key": "8755612", "sentences": [["Genetic", "separation", "of", "tumor", "growth", "and", "hemorrhagic", "phenotypes", "in", "an", "estrogen", "-", "induced", "tumor", ".", "Chronic", "administration", "of", "estrogen", "to", "the", "Fischer", "344", "(", "F344", ")", "rat", "induces", "growth", "of", "large", ",", "hemorrhagic", "pituitary", "tumors", ".", "Ten", "weeks", "of", "diethylstilbestrol", "(", "DES", ")", "treatment", "caused", "female", "F344", "rat", "pituitaries", "to", "grow", "to", "an", "average", "of", "109", ".", "2", "+", "/", "-", "6", ".", "3", "mg", "(", "mean", "+", "/", "-", "SE", ")", "versus", "11", ".", "3", "+", "/", "-", "1", ".", "4", "mg", "for", "untreated", "rats", ",", "and", "to", "become", "highly", "hemorrhagic", ".", "The", "same", "DES", "treatment", "produced", "no", "significant", "growth", "(", "8", ".", "9", "+", "/", "-", "0", ".", "5", "mg", "for", "treated", "females", "versus", "8", ".", "7", "+", "/", "-", "1", ".", "1", "for", "untreated", "females", ")", "or", "morphological", "changes", "in", "Brown", "Norway", "(", "BN", ")", "rat", "pituitaries", ".", "An", "F1", "hybrid", "of", "F344", "and", "BN", "exhibited", "significant", "pituitary", "growth", "after", "10", "weeks", "of", "DES", "treatment", "with", "an", "average", "mass", "of", "26", ".", "3", "+", "/", "-", "0", ".", "7", "mg", "compared", "with", "8", ".", "6", "+", "/", "-", "0", ".", "9", "mg", "for", "untreated", "rats", ".", "Surprisingly", ",", "the", "F1", "hybrid", "tumors", "were", "not", "hemorrhagic", "and", "had", "hemoglobin", "content", "and", "outward", "appearance", "identical", "to", "that", "of", "BN", ".", "Expression", "of", "both", "growth", "and", "morphological", "changes", "is", "due", "to", "multiple", "genes", ".", "However", ",", "while", "DES", "-", "induced", "pituitary", "growth", "exhibited", "quantitative", ",", "additive", "inheritance", ",", "the", "hemorrhagic", "phenotype", "exhibited", "recessive", ",", "epistatic", "inheritance", ".", "Only", "5", "of", "the", "160", "F2", "pituitaries", "exhibited", "the", "hemorrhagic", "phenotype", ";", "36", "of", "the", "160", "F2", "pituitaries", "were", "in", "the", "F344", "range", "of", "mass", ",", "but", "31", "of", "these", "were", "not", "hemorrhagic", ",", "indicating", "that", "the", "hemorrhagic", "phenotype", "is", "not", "merely", "a", "consequence", "of", "extensive", "growth", ".", "The", "hemorrhagic", "F2", "pituitaries", "were", "all", "among", "the", "most", "massive", ",", "indicating", "that", "some", "of", "the", "genes", "regulate", "both", "phenotypes", "."]], "ner": [[[39, 39, "Chemical"], [41, 41, "Chemical"], [95, 95, "Chemical"], [156, 156, "Chemical"], [227, 227, "Chemical"], [33, 34, "Disease"], [10, 10, "Chemical"], [18, 18, "Chemical"], [3, 3, "Disease"], [13, 13, "Disease"], [194, 194, "Disease"], [6, 6, "Disease"], [32, 32, "Disease"], [91, 91, "Disease"], [197, 197, "Disease"], [239, 239, "Disease"], [256, 256, "Disease"], [279, 279, "Disease"], [284, 284, "Disease"], [296, 296, "Disease"]]], "relations": [[[39, 39, 33, 34, "CID"], [41, 41, 33, 34, "CID"], [95, 95, 33, 34, "CID"], [156, 156, 33, 34, "CID"], [227, 227, 33, 34, "CID"]]], "clusters": [], "translated": "<8>肿瘤</8> 生长和 <11>出血</11> 表型在 <6>雌激素</6> 中的遗传分离 - 诱导的 <9>肿瘤</9>。对 Fischer 344 (F344) 大鼠长期给予 <7>雌激素</7> 可诱导大型 <12>出血性</12> <5>垂体瘤</5> 的生长。十周的 <0>己烯雌酚</0>（<1>DES</1>）处理导致雌性 F344 大鼠脑垂体平均增长到 109.2 +/- 6.3 毫克（平均值 +/- 标准误差）对比 11.3 +/- 1.4 毫克对于未治疗的大鼠，并变得高度 <13>出血</13>。相同的 <2>DES</2> 处理没有产生显着的生长（8.9 +/- 0.5 毫克处理的雌性对比 未处理的雌性 8.7 +/- 1.1 毫克）或 Brown Norway (BN) 大鼠垂体形态的变化。F344 和 BN 的 F1 杂种在 <3>DES</3> 治疗 10 周后表现出显著的垂体生长，平均质量为 26.3 +/- 0.7 毫克，对比未经治疗的大鼠 8.6 +/- 0.9 毫克。令人惊讶的是，F1 杂交 <10>肿瘤</10> 没有 <14>出血性</14>，血红蛋白含量和外观与 BN 相同。生长和形态变化的表达是由于多个基因。然而，虽然 <4>DES</4> 诱导的垂体生长表现出定量、加性遗传，但 <15>出血性</15> 表型表现出隐性、上位性遗传。160 个 F2 垂体中只有 5 个表现出 <16>出血</16> 表型；160 个 F2 垂体中有 36 个在 F344 质量范围内，但其中 31 个不是 <17>出血性</17>，这表明 <18>出血性</18> 表型不仅仅是广泛生长的结果。<19>出血性</19> F2 垂体体积最大，表明某些基因调节两种表型。", "revised": true}
{"doc_key": "8957205", "sentences": [["Human", "corticotropin", "-", "releasing", "hormone", "and", "thyrotropin", "-", "releasing", "hormone", "modulate", "the", "hypercapnic", "ventilatory", "response", "in", "humans", ".", "Human", "corticotropin", "-", "releasing", "hormone", "(", "hCRH", ")", "and", "thyrotropin", "-", "releasing", "hormone", "(", "TRH", ")", "are", "known", "to", "stimulate", "ventilation", "after", "i", ".", "v", ".", "administration", "in", "humans", ".", "In", "a", "placebo", "-", "controlled", ",", "single", "-", "blind", "study", "we", "aimed", "to", "clarify", "if", "both", "peptides", "act", "by", "altering", "central", "chemosensitivity", ".", "Two", "subsequent", "CO2", "-", "rebreathing", "tests", "were", "performed", "in", "healthy", "young", "volunteers", ".", "During", "the", "first", "test", "0", ".", "9", "%", "NaCl", "was", "given", "i", ".", "v", ".", ";", "during", "the", "second", "test", "200", "micrograms", "of", "hCRH", "(", "n", "=", "12", ")", "or", "400", "micrograms", "of", "TRH", "(", "n", "=", "6", ")", "was", "administered", "i", ".", "v", ".", "Nine", "subjects", "received", "0", ".", "9", "%", "NaCl", "i", ".", "v", ".", "during", "both", "rebreathing", "manoeuvres", ".", "The", "CO2", "-", "response", "curves", "for", "the", "two", "tests", "were", "compared", "within", "the", "same", "subject", ".", "In", "the", "hCRH", "group", "a", "marked", "parallel", "shift", "of", "the", "CO2", "-", "response", "curve", "to", "the", "left", "was", "observed", "after", "hCRH", "(", "P", "<", "0", ".", "01", ")", ".", "The", "same", "effect", "occurred", "following", "TRH", "but", "was", "less", "striking", "(", "P", "=", "0", ".", "05", ")", ".", "hCRH", "and", "TRH", "caused", "a", "reduction", "in", "the", "CO2", "threshold", ".", "The", "CO2", "-", "response", "curves", "in", "the", "control", "group", "were", "nearly", "identical", ".", "The", "results", "indicate", "an", "additive", "effect", "of", "both", "releasing", "hormones", "on", "the", "hypercapnic", "ventilatory", "response", "in", "humans", ",", "presumably", "independent", "of", "central", "chemosensitivity", "."]], "ner": [[[73, 73, "Chemical"], [147, 147, "Chemical"], [172, 172, "Chemical"], [217, 217, "Chemical"], [221, 221, "Chemical"], [12, 12, "Disease"], [245, 245, "Disease"], [1, 1, "Chemical"], [19, 19, "Chemical"], [6, 6, "Chemical"], [27, 27, "Chemical"], [92, 92, "Chemical"], [136, 136, "Chemical"]]], "relations": [[[73, 73, 12, 12, "CID"], [73, 73, 245, 245, "CID"], [147, 147, 12, 12, "CID"], [147, 147, 245, 245, "CID"], [172, 172, 12, 12, "CID"], [172, 172, 245, 245, "CID"], [217, 217, 12, 12, "CID"], [217, 217, 245, 245, "CID"], [221, 221, 12, 12, "CID"], [221, 221, 245, 245, "CID"]]], "clusters": [], "translated": "人类<7>促肾上腺皮质激素</7>-释放激素和<9>促甲状腺激素</9>-释放激素调节人类<5>高碳酸血症</5>通气反应。已知<8>人谷肽释放激素(hCRH)</8>和<10>促甲状腺激素(TRH)</10>可在i.v.给药后刺激通气。在一项安慰剂对照的单盲研究中，我们旨在阐明这两种肽是否通过改变中枢化学敏感性起作用。随后在健康的年轻志愿者中进行了两次<0>CO2</0> 再吸入测试。在第一次测试期间注射0.9% <11>NaCl</11>;在第二次测试中，注射200微克hCRH（n = 12）或400微克TRH（n = 6）。九名受试者在两个再吸入操作期间均注射0.9% <12>NaCl</12> i.v.。将两次测试的<1>CO2</1>反应曲线在同一受试者中进行比较。在hCRH组中，hCRH后观察到<2>CO2</2>-反应曲线明显向左平移(P<0.01)。 TRH后出现同样的效应，但不明显(P=0.05)。hCRH和TRH引起<3>CO2</3>阈值的降低。对照组的<4>CO2</4>-反应曲线几乎相同。结果表明，两种释放激素对人体<6>高碳酸血症</6>通气反应的累加效应可能与中枢化学敏感性无关。", "revised": true}
{"doc_key": "8829135", "sentences": [["Nefiracetam", "(", "DM", "-", "9384", ")", "reverses", "apomorphine", "-", "induced", "amnesia", "of", "a", "passive", "avoidance", "response", ":", "delayed", "emergence", "of", "the", "memory", "retention", "effects", ".", "Nefiracetam", "is", "a", "novel", "pyrrolidone", "derivative", "which", "attenuates", "scopolamine", "-", "induced", "learning", "and", "post", "-", "training", "consolidation", "deficits", ".", "Given", "that", "apomorphine", "inhibits", "passive", "avoidance", "retention", "when", "given", "during", "training", "or", "in", "a", "defined", "10", "-", "12h", "post", "-", "training", "period", ",", "we", "evaluated", "the", "ability", "of", "nefiracetam", "to", "attenuate", "amnesia", "induced", "by", "dopaminergic", "agonism", ".", "A", "step", "-", "down", "passive", "avoidance", "paradigm", "was", "employed", "and", "nefiracetam", "(", "3", "mg", "/", "kg", ")", "and", "apomorphine", "(", "0", ".", "5", "mg", "/", "kg", ")", "were", "given", "alone", "or", "in", "combination", "during", "training", "and", "at", "the", "10", "-", "12h", "post", "-", "training", "period", "of", "consolidation", ".", "Co", "-", "administration", "of", "nefiracetam", "and", "apomorphine", "during", "training", "or", "10h", "thereafter", "produced", "no", "significant", "anti", "-", "amnesic", "effect", ".", "However", ",", "administration", "of", "nefiracetam", "during", "training", "completely", "reversed", "the", "amnesia", "induced", "by", "apomorphine", "at", "the", "10h", "post", "-", "training", "time", "and", "the", "converse", "was", "also", "true", ".", "These", "effects", "were", "not", "mediated", "by", "a", "dopaminergic", "mechanism", "as", "nefiracetam", ",", "at", "millimolar", "concentrations", ",", "failed", "to", "displace", "either", "[", "3H", "]", "SCH", "23390", "or", "[", "3H", "]", "spiperone", "binding", "from", "D1", "or", "D2", "dopamine", "receptor", "subtypes", ",", "respectively", ".", "It", "is", "suggested", "that", "nefiracetam", "augments", "molecular", "processes", "in", "the", "early", "stages", "of", "events", "which", "ultimately", "lead", "to", "consolidation", "of", "memory", "."]], "ner": [[[7, 7, "Chemical"], [46, 46, "Chemical"], [99, 99, "Chemical"], [135, 135, "Chemical"], [162, 162, "Chemical"], [10, 10, "Disease"], [75, 75, "Disease"], [159, 159, "Disease"], [33, 33, "Chemical"], [36, 42, "Disease"], [0, 0, "Chemical"], [2, 4, "Chemical"], [25, 25, "Chemical"], [72, 72, "Chemical"], [91, 91, "Chemical"], [133, 133, "Chemical"], [153, 153, "Chemical"], [187, 187, "Chemical"], [222, 222, "Chemical"], [29, 29, "Chemical"], [200, 201, "Chemical"], [206, 206, "Chemical"], [212, 212, "Chemical"]]], "relations": [[[7, 7, 10, 10, "CID"], [7, 7, 75, 75, "CID"], [7, 7, 159, 159, "CID"], [46, 46, 10, 10, "CID"], [46, 46, 75, 75, "CID"], [46, 46, 159, 159, "CID"], [99, 99, 10, 10, "CID"], [99, 99, 75, 75, "CID"], [99, 99, 159, 159, "CID"], [135, 135, 10, 10, "CID"], [135, 135, 75, 75, "CID"], [135, 135, 159, 159, "CID"], [162, 162, 10, 10, "CID"], [162, 162, 75, 75, "CID"], [162, 162, 159, 159, "CID"], [33, 33, 36, 42, "CID"]]], "clusters": [], "translated": "<10>奈非西坦</10> ( <11>DM-9384</11> ) 逆转<0>阿朴吗啡</0> - 诱导的被动回避反应的<5>健忘症</5>：记忆的延迟出现保留效果。<12>奈非西坦</12>是一种新型<19>吡咯烷酮</19>衍生物，可减轻<8>东莨菪碱</8>诱导的<9>学习和训练后巩固缺陷</9>。鉴于<1>阿朴吗啡</1>在训练期间或训练后10-12小时内给予时会抑制被动回避保留，我们评估了<13>奈非西坦</13>减轻由多巴胺能激动剂诱导的<6>健忘症</6>。采用降压被动回避范式，在训练期间单独或联合给予<14>奈非西坦</14>（3 mg/kg）和<2>阿朴吗啡</2>（0.5 mg/kg）并在训练后的10-12小时巩固期。联合给药<15>奈非西坦</15>和<3>阿朴吗啡</3>在训练期间或训练后10小时后没有产生显着的抗遗忘作用。然而，在训练期间服用<16>奈非西坦</16>可完全逆转在训练后10小时时<4>阿朴吗啡</4>引起的<7>遗忘</7>，反之亦然。这些作用不是由多巴胺能机制介导的，因为<17>奈非西坦</17>在毫摩尔浓度下未能取代[3H]<20>SCH 23390</20>或[3H]<21>螺哌隆</21>分别与D1或D2<22>多巴胺</22>受体亚型结合。这表明<18>奈非西坦</18>在事件的早期阶段增强了分子过程，最终导致记忆的巩固。", "revised": true}
{"doc_key": "8808730", "sentences": [["Increased", "expression", "of", "neuronal", "nitric", "oxide", "synthase", "in", "bladder", "afferent", "pathways", "following", "chronic", "bladder", "irritation", ".", "Immunocytochemical", "techniques", "were", "used", "to", "examine", "alterations", "in", "the", "expression", "of", "neuronal", "nitric", "oxide", "synthase", "(", "NOS", ")", "in", "bladder", "pathways", "following", "acute", "and", "chronic", "irritation", "of", "the", "urinary", "tract", "of", "the", "rat", ".", "Chemical", "cystitis", "was", "induced", "by", "cyclophosphamide", "(", "CYP", ")", "which", "is", "metabolized", "to", "acrolein", ",", "an", "irritant", "eliminated", "in", "the", "urine", ".", "Injection", "of", "CYP", "(", "n", "=", "10", ",", "75", "mg", "/", "kg", ",", "i", ".", "p", ".", ")", "2", "hours", "prior", "to", "perfusion", "(", "acute", "treatment", ")", "of", "the", "animals", "increased", "Fos", "-", "immunoreactivity", "(", "IR", ")", "in", "neurons", "in", "the", "dorsal", "commissure", ",", "dorsal", "horn", ",", "and", "autonomic", "regions", "of", "spinal", "segments", "(", "L1", "-", "L2", "and", "L6", "-", "S1", ")", "which", "receive", "afferent", "inputs", "from", "the", "bladder", ",", "urethra", ",", "and", "ureter", ".", "Fos", "-", "IR", "in", "the", "spinal", "cord", "was", "not", "changed", "in", "rats", "receiving", "chronic", "CYP", "treatment", "(", "n", "=", "15", ",", "75", "mg", "/", "kg", ",", "i", ".", "p", ".", ",", "every", "3rd", "day", "for", "2", "weeks", ")", ".", "In", "control", "animals", "and", "in", "animals", "treated", "acutely", "with", "CYP", ",", "only", "small", "numbers", "of", "NOS", "-", "IR", "cells", "(", "0", ".", "5", "-", "0", ".", "7", "cell", "profiles", "/", "sections", ")", "were", "detected", "in", "the", "L6", "-", "S1", "dorsal", "root", "ganglia", "(", "DRG", ")", ".", "Chronic", "CYP", "administration", "significantly", "(", "P", "<", "or", "=", ".", "002", ")", "increased", "bladder", "weight", "by", "60", "%", "and", "increased", "(", "7", "-", "to", "11", "-", "fold", ")", "the", "numbers", "of", "NOS", "-", "immunoreactive", "(", "IR", ")", "afferent", "neurons", "in", "the", "L6", "-", "S1", "DRG", ".", "A", "small", "increase", "(", "1", ".", "5", "-", "fold", ")", "also", "occurred", "in", "the", "L1", "DRG", ",", "but", "no", "change", "was", "detected", "in", "the", "L2", "and", "L5", "DRG", ".", "Bladder", "afferent", "cells", "in", "the", "L6", "-", "S1", "DRG", "labeled", "by", "Fluorogold", "(", "40", "microliters", ")", "injected", "into", "the", "bladder", "wall", "did", "not", "exhibit", "NOS", "-", "IR", "in", "control", "animals", ";", "however", ",", "following", "chronic", "CYP", "administration", ",", "a", "significant", "percentage", "of", "bladder", "afferent", "neurons", "were", "NOS", "-", "IR", ":", "L6", "(", "19", ".", "8", "+", "/", "-", "4", ".", "6", "%", ")", "and", "S1", "(", "25", ".", "3", "+", "/", "-", "2", ".", "9", "%", ")", ".", "These", "results", "indicate", "that", "neuronal", "gene", "expression", "in", "visceral", "sensory", "pathways", "can", "be", "upregulated", "by", "chemical", "irritation", "of", "afferent", "receptors", "in", "the", "urinary", "tract", "and", "/", "or", "that", "pathological", "changes", "in", "the", "urinary", "tract", "can", "initiate", "chemical", "signals", "that", "alter", "the", "chemical", "properties", "of", "visceral", "afferent", "neurons", "."]], "ner": [[[55, 55, "Chemical"], [57, 57, "Chemical"], [74, 74, "Chemical"], [161, 161, "Chemical"], [195, 195, "Chemical"], [233, 233, "Chemical"], [342, 342, "Chemical"], [51, 51, "Disease"], [4, 5, "Chemical"], [28, 29, "Chemical"], [13, 14, "Disease"], [41, 45, "Disease"], [63, 63, "Chemical"]]], "relations": [[[55, 55, 51, 51, "CID"], [57, 57, 51, 51, "CID"], [74, 74, 51, 51, "CID"], [161, 161, 51, 51, "CID"], [195, 195, 51, 51, "CID"], [233, 233, 51, 51, "CID"], [342, 342, 51, 51, "CID"]]], "clusters": [], "translated": "慢性<10>膀胱刺激</10>后，神经元<8>一氧化氮</8>合酶在膀胱传入通路中的表达增加。免疫细胞化学技术用于检测大鼠尿道受到急性和慢性<11>刺激</11>后膀胱通路中神经元<9>一氧化氮</9>合酶(NOS)表达的变化。化学性<7>膀胱炎</7>是由<0>环磷酰胺</0> (<1>CYP</1>)引起的，它被代谢成<12>丙烯醛</12>，一种刺激物从尿液中排出。在动物灌注（急性处理）前2小时注射<2>CYP</2>（n = 10，75mg/kg，i.p.）增加了背连合神经元中的Fos-免疫反应性 (IR)、背角和脊柱节段（L1-L2和L6-S1）的自主区域，它们接收来自膀胱、尿道和输尿管的传入输入。在接受慢性<3>CYP</3>治疗的大鼠中，脊髓中的Fos-IR没有变化（n=15，75mg/kg，i.p.，每3天一次，持续2周）。在对照动物和用<4>CYP</4>急性处理的动物中，在L6-S1背根神经节中只检测到少量的NOS-IR细胞（0.5-0.7个细胞轮廓/切片）。慢性<5>CYP</5>给药显着（P<或=.002）增加膀胱重量60%并增加（7至11倍）L6-S1 DRG中NOS-免疫反应 (IR)传入神经元的数量。L1 DRG也有小幅增加（1.5倍），但L2和L5 DRG未检测到变化。注入膀胱壁的Fluorogold（40微升）标记的L6-S1 DRG中的膀胱传入细胞在对照动物中未表现出NOS-IR；然而，在慢性<6>CYP</6>给药后，显着百分率的膀胱传入神经元为NOS-IR：L6 (19.8+/-4.6%) 和 S1 (25.3+/-2.9%)。这些结果表明，内脏感觉通路中的神经元基因表达可以通过化学刺激泌尿道传入受体而上调和/或泌尿道的病理变化可以启动改变内脏传入神经元化学特性的化学信号。", "revised": true}
{"doc_key": "8985298", "sentences": [["Lamivudine", "is", "effective", "in", "suppressing", "hepatitis", "B", "virus", "DNA", "in", "Chinese", "hepatitis", "B", "surface", "antigen", "carriers", ":", "a", "placebo", "-", "controlled", "trial", ".", "Lamivudine", "is", "a", "novel", "2", "'", ",", "3", "'", "-", "dideoxy", "cytosine", "analogue", "that", "has", "potent", "inhibitory", "effects", "on", "hepatitis", "B", "virus", "replication", "in", "vitro", "and", "in", "vivo", ".", "We", "performed", "a", "single", "-", "blind", ",", "placebo", "-", "controlled", "study", "to", "assess", "its", "effectiveness", "and", "safety", "in", "Chinese", "hepatitis", "B", "surface", "antigen", "(", "HBsAg", ")", "carriers", ".", "Forty", "-", "two", "Chinese", "HBsAg", "carriers", "were", "randomized", "to", "receive", "placebo", "(", "6", "patients", ")", "or", "lamivudine", "orally", "in", "dosages", "of", "25", "mg", ",", "100", "mg", ",", "or", "300", "mg", "daily", "(", "12", "patients", "for", "each", "dosage", ")", ".", "The", "drug", "was", "given", "for", "4", "weeks", ".", "The", "patients", "were", "closely", "monitored", "clinically", ",", "biochemically", ",", "and", "serologically", "up", "to", "4", "weeks", "after", "drug", "treatment", ".", "All", "36", "patients", "receiving", "lamivudine", "had", "a", "decrease", "in", "hepatitis", "B", "virus", "(", "HBV", ")", "DNA", "values", "of", ">", "90", "%", "(", "P", "<", ".", "001", "compared", "with", "placebo", ")", ".", "Although", "25", "mg", "of", "lamivudine", "was", "slightly", "less", "effective", "than", "100", "mg", "(", "P", "=", ".", "011", ")", "and", "300", "mg", "(", "P", "=", ".", "005", ")", ",", "it", "still", "induced", "94", "%", "suppression", "of", "HBV", "DNA", "after", "the", "fourth", "week", "of", "therapy", ".", "HBV", "DNA", "values", "returned", "to", "pretreatment", "levels", "within", "4", "weeks", "of", "cessation", "of", "therapy", ".", "There", "was", "no", "change", "in", "the", "hepatitis", "B", "e", "antigen", "status", "or", "in", "aminotransferase", "levels", ".", "No", "serious", "adverse", "events", "were", "observed", ".", "In", "conclusion", ",", "a", "4", "-", "week", "course", "of", "lamivudine", "was", "safe", "and", "effective", "in", "suppression", "of", "HBV", "DNA", "in", "Chinese", "HBsAg", "carriers", ".", "The", "suppression", "was", ">", "90", "%", "but", "reversible", ".", "Studies", "with", "long", "-", "term", "lamivudine", "administration", "should", "be", "performed", "to", "determine", "if", "prolonged", "suppression", "of", "HBV", "DNA", "can", "be", "achieved", "."]], "ner": [[[11, 14, "Chemical"], [71, 74, "Chemical"], [76, 76, "Chemical"], [84, 84, "Chemical"], [280, 280, "Chemical"], [5, 6, "Disease"], [42, 43, "Disease"], [155, 156, "Disease"], [242, 243, "Disease"], [0, 0, "Chemical"], [23, 23, "Chemical"], [27, 34, "Chemical"], [96, 96, "Chemical"], [150, 150, "Chemical"], [181, 181, "Chemical"], [268, 268, "Chemical"], [297, 297, "Chemical"]]], "relations": [[[11, 14, 5, 6, "CID"], [11, 14, 42, 43, "CID"], [11, 14, 155, 156, "CID"], [11, 14, 242, 243, "CID"], [71, 74, 5, 6, "CID"], [71, 74, 42, 43, "CID"], [71, 74, 155, 156, "CID"], [71, 74, 242, 243, "CID"], [76, 76, 5, 6, "CID"], [76, 76, 42, 43, "CID"], [76, 76, 155, 156, "CID"], [76, 76, 242, 243, "CID"], [84, 84, 5, 6, "CID"], [84, 84, 42, 43, "CID"], [84, 84, 155, 156, "CID"], [84, 84, 242, 243, "CID"], [280, 280, 5, 6, "CID"], [280, 280, 42, 43, "CID"], [280, 280, 155, 156, "CID"], [280, 280, 242, 243, "CID"]]], "clusters": [], "translated": "<9>拉米夫定</9>可有效抑制中国<0>乙肝表面抗原</0>携带者的<5>乙肝</5><0>病毒DNA</0>：一项安慰剂对照试验。 <10>拉米夫定</10>是一种新型的<11>2' , 3'-双脱氧胞嘧啶</11>类似物，在体外和体内对<6>乙型肝炎</6><0>病毒复制</0>具有强效抑制作用。我们进行了一项单盲、安慰剂对照研究，以评估其在中国<1>乙型肝炎表面抗原</1>(<2>HBsAg</2>)携带者中的有效性和安全性。42 名中国<3>HBsAg</3>携带者随机接受安慰剂(6 名患者)或<12>拉米夫定</12>口服剂量为每天 25mg、100mg或300mg (每种 12 名患者) 剂量。服药 4 周。在药物治疗后的 4周 内，对患者进行临床、生化和血清学方面的密切监测。接受<13>拉米夫定</13>治疗的所有36名患者的<7>乙型肝炎病毒(HBV)DNA</7>值均降低了>90% (P<.001比较安慰剂)。尽管 25 毫克 <14>拉米夫定</14> 的疗效略低于100毫克 (P=.011)和300毫克 (P=.005)，但在治疗第4周后仍可抑制94%的 HBV DNA 。HBV DNA 值在停止治疗后4周内恢复到治疗前水平。<8>乙型肝炎</8>e抗原状态或转氨酶水平没有变化。没有观察到严重的不良事件。总之，4周疗程的<15>拉米夫定</15>对中国<4>HBsAg</4>携带者的HBV DNA 抑制是安全有效的。抑制>90%但可逆。应进行长期<16>拉米夫定</16>给药的研究，以确定是否可以实现对HBV DNA的长期抑制。", "revised": true}
{"doc_key": "8825380", "sentences": [["The", "effect", "of", "recombinant", "human", "insulin", "-", "like", "growth", "factor", "-", "I", "on", "chronic", "puromycin", "aminonucleoside", "nephropathy", "in", "rats", ".", "We", "recently", "demonstrated", "that", "recombinant", "hGH", "exacerbates", "renal", "functional", "and", "structural", "injury", "in", "chronic", "puromycin", "aminonucleoside", "(", "PAN", ")", "nephropathy", ",", "an", "experimental", "model", "of", "glomerular", "disease", ".", "Therefore", ",", "we", "examined", "whether", "recombinant", "human", "(", "rh", ")", "IGF", "-", "I", "is", "a", "safer", "alternative", "for", "the", "treatment", "of", "growth", "failure", "in", "rats", "with", "chronic", "PAN", "nephropathy", ".", "The", "glomerulopathy", "was", "induced", "by", "seven", "serial", "injections", "of", "PAN", "over", "12", "wk", ".", "Experimental", "animals", "(", "n", "=", "6", ")", "received", "rhIGF", "-", "I", ",", "400", "micrograms", "/", "d", ",", "whereas", "control", "rats", "(", "n", "=", "6", ")", "received", "the", "vehicle", ".", "rhIGF", "-", "I", "improved", "weight", "gain", "by", "14", "%", "(", "p", "<", "0", ".", "05", ")", ",", "without", "altering", "hematocrit", "or", "blood", "pressure", "in", "rats", "with", "renal", "disease", ".", "Urinary", "protein", "excretion", "was", "unaltered", "by", "rhIGF", "-", "I", "treatment", "in", "rats", "with", "chronic", "PAN", "nephropathy", ".", "After", "12", "wk", ",", "the", "inulin", "clearance", "was", "higher", "in", "rhIGF", "-", "I", "-", "treated", "rats", ",", "0", ".", "48", "+", "/", "-", "0", ".", "08", "versus", "0", ".", "24", "+", "/", "-", "0", ".", "06", "mL", "/", "min", "/", "100", "g", "of", "body", "weight", "in", "untreated", "PAN", "nephropathy", "animals", ",", "p", "<", "0", ".", "05", ".", "The", "improvement", "in", "GFR", "was", "not", "associated", "with", "enhanced", "glomerular", "hypertrophy", "or", "increased", "segmental", "glomerulosclerosis", ",", "tubulointerstitial", "injury", ",", "or", "renal", "cortical", "malondialdehyde", "content", ".", "In", "rats", "with", "PAN", "nephropathy", ",", "administration", "of", "rhIGF", "-", "I", "increased", "IGF", "-", "I", "and", "GH", "receptor", "gene", "expression", ",", "without", "altering", "the", "steady", "state", "level", "of", "IGF", "-", "I", "receptor", "mRNA", ".", "In", "normal", "rats", "with", "intact", "kidneys", ",", "rhIGF", "-", "I", "administration", "(", "n", "=", "4", ")", "did", "not", "alter", "weight", "gain", ",", "blood", "pressure", ",", "proteinuria", ",", "GFR", ",", "glomerular", "planar", "area", ",", "renal", "cortical", "malondialdehyde", "content", ",", "or", "glomerular", "or", "tubulointerstitial", "damage", ",", "compared", "with", "untreated", "animals", "(", "n", "=", "4", ")", ".", "rhIGF", "-", "I", "treatment", "reduced", "the", "steady", "state", "renal", "IGF", "-", "I", "mRNA", "level", "but", "did", "not", "modify", "gene", "expression", "of", "the", "IGF", "-", "I", "or", "GH", "receptors", ".", "We", "conclude", "that", ":", "1", ")", "administration", "of", "rhIGF", "-", "I", "improves", "growth", "and", "GFR", "in", "rats", "with", "chronic", "PAN", "nephropathy", "and", "2", ")", "unlike", "rhGH", ",", "long", "-", "term", "use", "of", "rhIGF", "-", "I", "does", "not", "worsen", "renal", "functional", "and", "structural", "injury", "in", "this", "disease", "model", "."]], "ner": [[[14, 15, "Chemical"], [34, 35, "Chemical"], [37, 37, "Chemical"], [75, 75, "Chemical"], [87, 87, "Chemical"], [164, 164, "Chemical"], [214, 214, "Chemical"], [252, 252, "Chemical"], [385, 385, "Chemical"], [16, 16, "Disease"], [39, 39, "Disease"], [45, 46, "Disease"], [76, 76, "Disease"], [79, 79, "Disease"], [147, 148, "Disease"], [165, 165, "Disease"], [215, 215, "Disease"], [233, 234, "Disease"], [253, 253, "Disease"], [324, 325, "Disease"], [386, 386, "Disease"], [69, 70, "Disease"], [238, 238, "Disease"], [308, 308, "Disease"], [246, 246, "Chemical"], [318, 318, "Chemical"]]], "relations": [[[14, 15, 16, 16, "CID"], [14, 15, 39, 39, "CID"], [14, 15, 45, 46, "CID"], [14, 15, 76, 76, "CID"], [14, 15, 79, 79, "CID"], [14, 15, 147, 148, "CID"], [14, 15, 165, 165, "CID"], [14, 15, 215, 215, "CID"], [14, 15, 233, 234, "CID"], [14, 15, 253, 253, "CID"], [14, 15, 324, 325, "CID"], [14, 15, 386, 386, "CID"], [34, 35, 16, 16, "CID"], [34, 35, 39, 39, "CID"], [34, 35, 45, 46, "CID"], [34, 35, 76, 76, "CID"], [34, 35, 79, 79, "CID"], [34, 35, 147, 148, "CID"], [34, 35, 165, 165, "CID"], [34, 35, 215, 215, "CID"], [34, 35, 233, 234, "CID"], [34, 35, 253, 253, "CID"], [34, 35, 324, 325, "CID"], [34, 35, 386, 386, "CID"], [37, 37, 16, 16, "CID"], [37, 37, 39, 39, "CID"], [37, 37, 45, 46, "CID"], [37, 37, 76, 76, "CID"], [37, 37, 79, 79, "CID"], [37, 37, 147, 148, "CID"], [37, 37, 165, 165, "CID"], [37, 37, 215, 215, "CID"], [37, 37, 233, 234, "CID"], [37, 37, 253, 253, "CID"], [37, 37, 324, 325, "CID"], [37, 37, 386, 386, "CID"], [75, 75, 16, 16, "CID"], [75, 75, 39, 39, "CID"], [75, 75, 45, 46, "CID"], [75, 75, 76, 76, "CID"], [75, 75, 79, 79, "CID"], [75, 75, 147, 148, "CID"], [75, 75, 165, 165, "CID"], [75, 75, 215, 215, "CID"], [75, 75, 233, 234, "CID"], [75, 75, 253, 253, "CID"], [75, 75, 324, 325, "CID"], [75, 75, 386, 386, "CID"], [87, 87, 16, 16, "CID"], [87, 87, 39, 39, "CID"], [87, 87, 45, 46, "CID"], [87, 87, 76, 76, "CID"], [87, 87, 79, 79, "CID"], [87, 87, 147, 148, "CID"], [87, 87, 165, 165, "CID"], [87, 87, 215, 215, "CID"], [87, 87, 233, 234, "CID"], [87, 87, 253, 253, "CID"], [87, 87, 324, 325, "CID"], [87, 87, 386, 386, "CID"], [164, 164, 16, 16, "CID"], [164, 164, 39, 39, "CID"], [164, 164, 45, 46, "CID"], [164, 164, 76, 76, "CID"], [164, 164, 79, 79, "CID"], [164, 164, 147, 148, "CID"], [164, 164, 165, 165, "CID"], [164, 164, 215, 215, "CID"], [164, 164, 233, 234, "CID"], [164, 164, 253, 253, "CID"], [164, 164, 324, 325, "CID"], [164, 164, 386, 386, "CID"], [214, 214, 16, 16, "CID"], [214, 214, 39, 39, "CID"], [214, 214, 45, 46, "CID"], [214, 214, 76, 76, "CID"], [214, 214, 79, 79, "CID"], [214, 214, 147, 148, "CID"], [214, 214, 165, 165, "CID"], [214, 214, 215, 215, "CID"], [214, 214, 233, 234, "CID"], [214, 214, 253, 253, "CID"], [214, 214, 324, 325, "CID"], [214, 214, 386, 386, "CID"], [252, 252, 16, 16, "CID"], [252, 252, 39, 39, "CID"], [252, 252, 45, 46, "CID"], [252, 252, 76, 76, "CID"], [252, 252, 79, 79, "CID"], [252, 252, 147, 148, "CID"], [252, 252, 165, 165, "CID"], [252, 252, 215, 215, "CID"], [252, 252, 233, 234, "CID"], [252, 252, 253, 253, "CID"], [252, 252, 324, 325, "CID"], [252, 252, 386, 386, "CID"], [385, 385, 16, 16, "CID"], [385, 385, 39, 39, "CID"], [385, 385, 45, 46, "CID"], [385, 385, 76, 76, "CID"], [385, 385, 79, 79, "CID"], [385, 385, 147, 148, "CID"], [385, 385, 165, 165, "CID"], [385, 385, 215, 215, "CID"], [385, 385, 233, 234, "CID"], [385, 385, 253, 253, "CID"], [385, 385, 324, 325, "CID"], [385, 385, 386, 386, "CID"]]], "clusters": [], "translated": "重组人胰岛素样生长因子-I对大鼠慢性<0>嘌呤霉素氨基核苷</0><9>肾病</9>的影响。我们最近证明，重组hGH会加剧慢性<1>嘌呤霉素氨基核苷</1> (<2>PAN</2>)<10>肾病</10>的肾功能和结构损伤，是一个<11>肾小球疾病的实验模型</11>。因此，我们检查了重组人(rh)IGF-I是否是治疗慢性<3>PAN</3><12>肾病</12>大鼠<21>生长障碍</21>的更安全替代方案。<13>肾小球病</13>是由12周内七次连续注射<4>PAN</4>引起的。实验动物 (n = 6) 接受rhIGF-I，400微克/天，而对照大鼠(n = 6) 接受载体。rhIGF-I使患有<14>肾病</14>大鼠的体重增加了14% (p < 0.05)，而没有改变血细胞比容或血压。在患有慢性<5>PAN</5><15>肾病</15>的大鼠中，rhIGF-I治疗未改变尿蛋白排泄。12wk后，rhIGF-I治疗大鼠的菊粉清除率较高，0.48+/-0.08对0.24+/-0.06mL/min/100g体重未经治疗的<6>PAN</6><16>肾病</16>动物，p < 0.05。GFR的改善与<17>肾小球肥大</17>或节段性<22>肾小球硬化</22>、肾小管间质损伤或肾皮质<24>丙二醛</24>含量增加无关。在患有<7>PAN</7><18>肾病</18>的大鼠中，rhIGF-I的给药增加了IGF-I和GH受体基因的表达，而不改变IGF-I受体mRNA的稳态水平。在具有完整肾脏的正常大鼠中，rhIGF-I给药(n = 4)没有改变体重增加、血压、<23>蛋白尿</23>、GFR、肾小球平面面积、肾皮质<25>丙二醛</25>含量，或肾小球或<19>肾小管间质损伤</19>，与未处理的动物(n = 4)相比。rhIGF-I治疗可降低稳态肾IGF-I mRNA水平，但不会改变IGF-I或GH受体的基因表达。我们得出结论：1)给予rhIGF-I改善慢性<8>PAN</8><20>肾病</20>大鼠的生长和GFR;2)与rhGH不同，长期使用rhIGF-I确实在这种疾病模型中不会加重肾功能和结构损伤。", "revised": true}
{"doc_key": "9132810", "sentences": [["Treatment", "-", "related", "disseminated", "necrotizing", "leukoencephalopathy", "with", "characteristic", "contrast", "enhancement", "of", "the", "white", "matter", ".", "This", "report", "describes", "unique", "contrast", "enhancement", "of", "the", "white", "matter", "on", "T1", "-", "weighted", "magnetic", "resonance", "images", "of", "two", "patients", "with", "disseminated", "necrotizing", "leukoencephalopathy", ",", "which", "developed", "from", "acute", "lymphoblastic", "leukemia", "treated", "with", "high", "-", "dose", "methotrexate", ".", "In", "both", "patients", ",", "the", "enhancement", "was", "more", "pronounced", "near", "the", "base", "of", "the", "brain", "than", "at", "the", "vertex", ".", "Necropsy", "of", "the", "first", "case", "revealed", "loss", "of", "myelination", "and", "necrosis", "of", "the", "white", "matter", ".", "Possible", "mechanisms", "causing", "such", "a", "leukoencephalopathy", "are", "discussed", "."]], "ner": [[[51, 51, "Chemical"], [5, 5, "Disease"], [38, 38, "Disease"], [94, 94, "Disease"], [79, 81, "Disease"], [83, 83, "Disease"], [43, 45, "Disease"]]], "relations": [[[51, 51, 5, 5, "CID"], [51, 51, 38, 38, "CID"], [51, 51, 94, 94, "CID"], [51, 51, 79, 81, "CID"], [51, 51, 83, 83, "CID"]]], "clusters": [], "translated": "治疗相关的播散性坏死性<1>白质脑病</1>伴有白质特征性对比增强。本报告描述了两名播散性坏死性<2>白质脑病</2>患者的T1加权磁共振图像上白质的独特对比增强，该患者由<6>急性淋巴细胞白血病</6>接受高剂量治疗<0>甲氨蝶呤</0>。在这两名患者中，大脑底部附近的增强比顶部更明显。第一个病例的尸检显示白质<4>髓鞘形成缺失</4>和<5>坏死</5>。讨论了导致这种<3>白质脑病</3>的可能机制。", "revised": true}
{"doc_key": "9197951", "sentences": [["Pupillary", "changes", "associated", "with", "the", "development", "of", "stimulant", "-", "induced", "mania", ":", "a", "case", "report", ".", "A", "30", "-", "year", "-", "old", "cocaine", "-", "dependent", "man", "who", "was", "a", "subject", "in", "a", "study", "evaluating", "the", "anticraving", "efficacy", "of", "the", "stimulant", "medication", "diethylpropion", "(", "DEP", ")", "became", "manic", "during", "his", "second", "week", "on", "the", "study", "drug", ".", "Pupillometric", "changes", "while", "on", "DEP", ",", "especially", "changes", "in", "the", "total", "power", "of", "pupillary", "oscillation", ",", "were", "dramatically", "different", "than", "those", "observed", "in", "the", "eight", "other", "study", "subjects", "who", "did", "not", "become", "manic", ".", "The", "large", "changes", "in", "total", "power", "of", "pupillary", "oscillation", "occurred", "a", "few", "days", "before", "the", "patient", "became", "fully", "manic", ".", "Such", "medication", "-", "associated", "changes", "in", "the", "total", "power", "of", "pupillary", "oscillation", "might", "be", "of", "utility", "in", "identifying", "persons", "at", "risk", "for", "manic", "-", "like", "adverse", "effects", "during", "the", "medical", "use", "of", "psychomotor", "stimulants", "or", "sympathomimetic", "agents", "."]], "ner": [[[41, 41, "Chemical"], [43, 43, "Chemical"], [60, 60, "Chemical"], [10, 10, "Disease"], [46, 46, "Disease"], [88, 88, "Disease"], [108, 108, "Disease"], [132, 132, "Disease"], [22, 22, "Chemical"], [69, 70, "Disease"], [97, 98, "Disease"], [120, 121, "Disease"]]], "relations": [[[41, 41, 10, 10, "CID"], [41, 41, 46, 46, "CID"], [41, 41, 88, 88, "CID"], [41, 41, 108, 108, "CID"], [41, 41, 132, 132, "CID"], [43, 43, 10, 10, "CID"], [43, 43, 46, 46, "CID"], [43, 43, 88, 88, "CID"], [43, 43, 108, 108, "CID"], [43, 43, 132, 132, "CID"], [60, 60, 10, 10, "CID"], [60, 60, 46, 46, "CID"], [60, 60, 88, 88, "CID"], [60, 60, 108, 108, "CID"], [60, 60, 132, 132, "CID"]]], "clusters": [], "translated": "与兴奋剂引起的 <3>躁狂症</3> 相关的瞳孔变化：病例报告。一名 30 岁的 <8>可卡因</8> 依赖男子，他是一项评估兴奋剂药物 <0>二乙基丙酸</0> (<1>DEP</1>) 抗瘾功效研究的受试者，在服用研究药物的第二周期间变得<4>狂躁</4>。 <2>DEP</2> 期间的瞳孔变化，尤其是总功率的<9>瞳孔振荡</9>变化，与其他八名未成为<5>躁狂症</5>的研究对象中观察到的变化显着不同。总功率的<10>瞳孔振荡</10>的巨大变化发生在患者完全<6>躁狂</6>前几天。这种药物 - 与 <11>瞳孔振荡</11> 的总功率相关的变化，可能有助于识别有<7>躁狂</7>风险的人 - 例如在精神运动兴奋剂或拟交感神经药物的医疗使用期间的不良反应。", "revised": true}
{"doc_key": "8667442", "sentences": [["Milk", "-", "alkali", "syndrome", "induced", "by", "1", ",", "25", "(", "OH", ")", "2D", "in", "a", "patient", "with", "hypoparathyroidism", ".", "Milk", "-", "alkali", "syndrome", "was", "first", "described", "70", "years", "ago", "in", "the", "context", "of", "the", "treatment", "of", "peptic", "ulcer", "disease", "with", "large", "amounts", "of", "calcium", "and", "alkali", ".", "Although", "with", "current", "ulcer", "therapy", "(", "H", "-", "2", "blockers", ",", "omeprazole", ",", "and", "sucralfate", ")", ",", "the", "frequency", "of", "milk", "-", "alkali", "syndrome", "has", "decreased", "significantly", ",", "the", "classic", "triad", "of", "hypercalcemia", ",", "alkalosis", ",", "and", "renal", "impairment", "remains", "the", "hallmark", "of", "the", "syndrome", ".", "Milk", "-", "alkali", "syndrome", "can", "present", "serious", "and", "occasionally", "life", "-", "threatening", "illness", "unless", "diagnosed", "and", "treated", "appropriately", ".", "This", "article", "presents", "a", "patient", "with", "hypoparathyroidism", "who", "was", "treated", "with", "calcium", "carbonate", "and", "calcitriol", "resulting", "in", "two", "admissions", "to", "the", "hospital", "for", "milk", "-", "alkali", "syndrome", ".", "The", "patient", "was", "successfully", "treated", "with", "intravenous", "pamidronate", "on", "his", "first", "admission", "and", "with", "hydrocortisone", "on", "the", "second", ".", "This", "illustrates", "intravenous", "pamidronate", "as", "a", "valuable", "therapeutic", "tool", "when", "milk", "-", "alkali", "syndrome", "presents", "as", "hypercalcemic", "emergency", "."]], "ner": [[[6, 12, "Chemical"], [126, 126, "Chemical"], [0, 3, "Disease"], [19, 22, "Disease"], [67, 70, "Disease"], [79, 79, "Disease"], [93, 96, "Disease"], [135, 138, "Disease"], [169, 172, "Disease"], [175, 176, "Disease"], [43, 43, "Chemical"], [45, 45, "Chemical"], [123, 124, "Chemical"], [81, 81, "Disease"], [84, 85, "Disease"], [58, 58, "Chemical"], [36, 38, "Disease"], [61, 61, "Chemical"], [147, 147, "Chemical"], [162, 162, "Chemical"], [154, 154, "Chemical"], [17, 17, "Disease"], [118, 118, "Disease"], [50, 50, "Disease"]]], "relations": [[[6, 12, 0, 3, "CID"], [6, 12, 19, 22, "CID"], [6, 12, 67, 70, "CID"], [6, 12, 79, 79, "CID"], [6, 12, 93, 96, "CID"], [6, 12, 135, 138, "CID"], [6, 12, 169, 172, "CID"], [6, 12, 175, 176, "CID"], [126, 126, 0, 3, "CID"], [126, 126, 19, 22, "CID"], [126, 126, 67, 70, "CID"], [126, 126, 79, 79, "CID"], [126, 126, 93, 96, "CID"], [126, 126, 135, 138, "CID"], [126, 126, 169, 172, "CID"], [126, 126, 175, 176, "CID"], [43, 43, 0, 3, "CID"], [43, 43, 19, 22, "CID"], [43, 43, 67, 70, "CID"], [43, 43, 79, 79, "CID"], [43, 43, 93, 96, "CID"], [43, 43, 135, 138, "CID"], [43, 43, 169, 172, "CID"], [43, 43, 175, 176, "CID"], [45, 45, 0, 3, "CID"], [45, 45, 19, 22, "CID"], [45, 45, 67, 70, "CID"], [45, 45, 79, 79, "CID"], [45, 45, 93, 96, "CID"], [45, 45, 135, 138, "CID"], [45, 45, 169, 172, "CID"], [45, 45, 175, 176, "CID"], [123, 124, 0, 3, "CID"], [123, 124, 19, 22, "CID"], [123, 124, 67, 70, "CID"], [123, 124, 79, 79, "CID"], [123, 124, 93, 96, "CID"], [123, 124, 135, 138, "CID"], [123, 124, 169, 172, "CID"], [123, 124, 175, 176, "CID"], [6, 12, 81, 81, "CID"], [126, 126, 81, 81, "CID"], [6, 12, 84, 85, "CID"], [126, 126, 84, 85, "CID"], [58, 58, 36, 38, "CID"], [61, 61, 36, 38, "CID"], [43, 43, 81, 81, "CID"], [43, 43, 84, 85, "CID"], [45, 45, 81, 81, "CID"], [45, 45, 84, 85, "CID"], [123, 124, 81, 81, "CID"], [123, 124, 84, 85, "CID"]]], "clusters": [], "translated": "这是中文翻译文本，请添加缺失的标记并且修正错位的标记。为了方便后续处理，你只能输出修正后的中文文本，以“”作为开始：<2>乳碱综合征</2>诱发于<21>甲状旁腺功能减退症</21>患者的<0>1,25(OH)2D</0>。 <3>乳碱综合征</3>首次在70年前在用大量<10>钙</10>和<11>碱</11>治疗<16>消化性溃疡病</16>的背景下被描述。尽管当前<23>溃疡</23>治疗（H-2受体拮抗剂、<15>奥美拉唑</15>和<17>硫糊铝</17>）已显著减少了<4>乳碱综合征</4>的发生率，但<5>高钙血症</5>、<13>碱中毒</13>和<14>肾功能损害</14>仍是该综合征的标志。除非得到适当的诊断和治疗，否则<6>乳碱综合症</6>可能导致严重甚至危及生命的疾病。本文介绍了一名接受<12>碳酸钙</12>和<1>骨化三醇</1>治疗的<22>甲状旁腺功能减退症</22>患者，因此两次住院治疗<7>乳碱综合征</7>。该患者在第一次入院时通过静脉注射<18>帕米膦酸</18>成功治疗;在第二次入院时使用<20>氢化可的松</20>，成功治疗。这说明，当<8>乳碱综合征</8>表现为<9>高钙血症</9>时，静脉注射<19>帕米膦酸</19>是一种有价值的治疗工具。", "revised": true}
{"doc_key": "9382023", "sentences": [["Hypertensive", "response", "during", "dobutamine", "stress", "echocardiography", ".", "Among", "3", ",", "129", "dobutamine", "stress", "echocardiographic", "studies", ",", "a", "hypertensive", "response", ",", "defined", "as", "systolic", "blood", "pressure", "(", "BP", ")", ">", "or", "=", "220", "mm", "Hg", "and", "/", "or", "diastolic", "BP", ">", "or", "=", "110", "mm", "Hg", ",", "occurred", "in", "30", "patients", "(", "1", "%", ")", ".", "Patients", "with", "this", "response", "more", "often", "had", "a", "history", "of", "hypertension", "and", "had", "higher", "resting", "systolic", "and", "diastolic", "BP", "before", "dobutamine", "infusion", "."]], "ner": [[[3, 3, "Chemical"], [11, 11, "Chemical"], [75, 75, "Chemical"], [0, 0, "Disease"], [17, 17, "Disease"], [65, 65, "Disease"]]], "relations": [[[3, 3, 0, 0, "CID"], [3, 3, 17, 17, "CID"], [3, 3, 65, 65, "CID"], [11, 11, 0, 0, "CID"], [11, 11, 17, 17, "CID"], [11, 11, 65, 65, "CID"], [75, 75, 0, 0, "CID"], [75, 75, 17, 17, "CID"], [75, 75, 65, 65, "CID"]]], "clusters": [], "translated": "<0> 多巴酚丁胺 </0> 负荷超声心动图期间的<3>高血压反应 </3>。在 129 项<1>多巴酚丁胺</1> 负荷超声心动图研究中，有 <4>高血压</4> 反应，定义为收缩压 (BP) ≥ 220 mmHg 和/或舒张压 ≥ 110 mmHg，发生在 30 名患者 (1%) 中。有这种反应的患者通常有 <5>高血压 </5> 病史，并且在<2>多巴酚丁胺</2>输注前有较高的静息收缩压和舒张压。", "revised": true}
{"doc_key": "7479194", "sentences": [["A", "large", "population", "-", "based", "follow", "-", "up", "study", "of", "trimethoprim", "-", "sulfamethoxazole", ",", "trimethoprim", ",", "and", "cephalexin", "for", "uncommon", "serious", "drug", "toxicity", ".", "We", "conducted", "a", "population", "-", "based", "45", "-", "day", "follow", "-", "up", "study", "of", "232", ",", "390", "people", "who", "were", "prescribed", "trimethoprim", "-", "sulfamethoxazole", "(", "TMP", "-", "SMZ", ")", ",", "266", ",", "951", "prescribed", "trimethoprim", "alone", ",", "and", "196", ",", "397", "prescribed", "cephalexin", ",", "to", "estimate", "the", "risk", "of", "serious", "liver", ",", "blood", ",", "skin", ",", "and", "renal", "disorders", "resulting", "in", "referral", "or", "hospitalization", "associated", "with", "these", "drugs", ".", "The", "results", "were", "based", "on", "information", "recorded", "on", "office", "computers", "by", "selected", "general", "practitioners", "in", "the", "United", "Kingdom", ",", "together", "with", "a", "review", "of", "clinical", "records", ".", "The", "risk", "of", "clinically", "important", "idiopathic", "liver", "disease", "was", "similar", "for", "persons", "prescribed", "TMP", "-", "SMZ", "(", "5", ".", "2", "/", "100", ",", "000", ")", "and", "those", "prescribed", "trimethoprim", "alone", "(", "3", ".", "8", "/", "100", ",", "000", ")", ".", "The", "risk", "for", "those", "prescribed", "cephalexin", "was", "somewhat", "lower", "(", "2", ".", "0", "/", "100", ",", "000", ")", ".", "Only", "five", "patients", "experienced", "blood", "disorders", ",", "one", "of", "whom", "was", "exposed", "to", "TMP", "-", "SMZ", ";", "of", "seven", "with", "erythema", "multiforme", "and", "Stevens", "-", "Johnson", "syndrome", ",", "four", "were", "exposed", "to", "TMP", "-", "SMZ", ".", "The", "one", "case", "of", "toxic", "epidermal", "necrolysis", "occurred", "in", "a", "patient", "who", "took", "cephalexin", ".", "Finally", ",", "only", "five", "cases", "of", "acute", "parenchymal", "renal", "disease", "occurred", ",", "none", "likely", "to", "be", "caused", "by", "a", "study", "drug", ".", "We", "conclude", "that", "the", "risk", "of", "the", "serious", "diseases", "studied", "is", "small", "for", "the", "three", "agents", ",", "and", "compares", "reasonably", "with", "the", "risk", "for", "many", "other", "antibiotics", "."]], "ner": [[[10, 12, "Chemical"], [45, 47, "Chemical"], [49, 51, "Chemical"], [133, 135, "Chemical"], [192, 194, "Chemical"], [211, 213, "Chemical"], [74, 82, "Disease"], [126, 127, "Disease"], [202, 205, "Disease"], [219, 221, "Disease"], [14, 14, "Chemical"], [58, 58, "Chemical"], [148, 148, "Chemical"], [17, 17, "Chemical"], [66, 66, "Chemical"], [165, 165, "Chemical"], [228, 228, "Chemical"], [21, 22, "Disease"], [238, 239, "Disease"], [199, 200, "Disease"]]], "relations": [[[10, 12, 74, 82, "CID"], [10, 12, 126, 127, "CID"], [45, 47, 74, 82, "CID"], [45, 47, 126, 127, "CID"], [49, 51, 74, 82, "CID"], [49, 51, 126, 127, "CID"], [133, 135, 74, 82, "CID"], [133, 135, 126, 127, "CID"], [192, 194, 74, 82, "CID"], [192, 194, 126, 127, "CID"], [211, 213, 74, 82, "CID"], [211, 213, 126, 127, "CID"], [10, 12, 202, 205, "CID"], [10, 12, 219, 221, "CID"], [45, 47, 202, 205, "CID"], [45, 47, 219, 221, "CID"], [49, 51, 202, 205, "CID"], [49, 51, 219, 221, "CID"], [133, 135, 202, 205, "CID"], [133, 135, 219, 221, "CID"], [192, 194, 202, 205, "CID"], [192, 194, 219, 221, "CID"], [211, 213, 202, 205, "CID"], [211, 213, 219, 221, "CID"], [14, 14, 74, 82, "CID"], [14, 14, 126, 127, "CID"], [58, 58, 74, 82, "CID"], [58, 58, 126, 127, "CID"], [148, 148, 74, 82, "CID"], [148, 148, 126, 127, "CID"], [17, 17, 74, 82, "CID"], [17, 17, 126, 127, "CID"], [66, 66, 74, 82, "CID"], [66, 66, 126, 127, "CID"], [165, 165, 74, 82, "CID"], [165, 165, 126, 127, "CID"], [228, 228, 74, 82, "CID"], [228, 228, 126, 127, "CID"], [17, 17, 202, 205, "CID"], [17, 17, 219, 221, "CID"], [66, 66, 202, 205, "CID"], [66, 66, 219, 221, "CID"], [165, 165, 202, 205, "CID"], [165, 165, 219, 221, "CID"], [228, 228, 202, 205, "CID"], [228, 228, 219, 221, "CID"]]], "clusters": [], "translated": "<0>甲氧苄氨嘧啶-磺胺甲恶唑</0>、<10>甲氧苄氨嘧啶</10>和<13>头孢氨苄</13>治疗罕见严重<17>药物毒性</17>的大型人群随访研究。我们对 232,390 名接受处方<1>甲氧苄氨嘧啶-磺胺甲恶唑</1> (<2>TMP-SMZ</2>)、266,951 名处方<11>甲氧苄氨嘧啶</11>和196,397 名处方<14>头孢氨苄</14>的患者进行了基于人群的45天随访研究，以估计使用这些药物导致严重<6>肝脏、血液、皮肤和肾脏疾病</6>，需要进行转诊或住院的风险。结果基于英国选定的全科医生在办公室电脑上记录的信息，以及对临床记录的审查得出。服用<3>TMP-SMZ</3> (5.2/100,000)和使用<12>甲氧苄氨嘧啶</12> (3.8/100,000)的人患有临床重要的特发性<7>肝病</7>的风险类似。使用<15>头孢氨苄</15>的人的风险略低 (2.0/100,000)。只有5名患者出现血液病，其中1名曾接触过<4>TMP-SMZ</4>; 从7名患有<19>多形性红斑</19>和<8>Stevens-Johnson综合征</8>的患者中，有4名接触过<5>TMP-SMZ</5>。 1例<9>中毒性表皮坏死松解症</9>发生在服用<16>头孢氨苄</16>的患者身上。最后，只发生了5例急性实质性<18>肾病</18>，没有一例肯定是研究药物引起的。我们得出结论，这三个药物所研究的严重疾病的风险很小，与许多其他抗生素的风险相比是合理的。", "revised": true}
{"doc_key": "9428298", "sentences": [["Continuously", "nebulized", "albuterol", "in", "severe", "exacerbations", "of", "asthma", "in", "adults", ":", "a", "case", "-", "controlled", "study", ".", "A", "retrospective", ",", "case", "-", "controlled", "analysis", "comparing", "patients", "admitted", "to", "a", "medical", "intensive", "care", "unit", "with", "severe", "exacerbations", "of", "asthma", "who", "received", "continuously", "nebulized", "albuterol", "(", "CNA", ")", "versus", "intermittent", "albuterol", "(", "INA", ")", "treatments", "is", "reported", ".", "Forty", "matched", "pairs", "of", "patients", "with", "asthma", "are", "compared", ".", "CNA", "was", "administered", "for", "a", "mean", "of", "11", "+", "/", "-", "10", "hr", ".", "The", "incidence", "of", "cardiac", "dysrhythmias", "was", "similar", "between", "groups", ".", "Symptomatic", "hypokalemia", "did", "not", "occur", ".", "CNA", "patients", "had", "higher", "heart", "rates", "during", "treatment", ",", "which", "may", "reflect", "severity", "of", "illness", ".", "The", "incidence", "of", "intubation", "was", "similar", ".", "We", "conclude", "that", "CNA", "and", "INA", "demonstrated", "similar", "profiles", "with", "regard", "to", "safety", ",", "morbidity", ",", "and", "mortality", "."]], "ner": [[[2, 2, "Chemical"], [42, 42, "Chemical"], [48, 48, "Chemical"], [83, 84, "Disease"], [7, 7, "Disease"], [37, 37, "Disease"], [62, 62, "Disease"], [91, 91, "Disease"]]], "relations": [[[2, 2, 83, 84, "CID"], [42, 42, 83, 84, "CID"], [48, 48, 83, 84, "CID"]]], "clusters": [], "translated": "持续雾化<0>沙丁胺醇</0>治疗成人<4>哮喘</4>严重恶化：一项病例对照研究。一项回顾性病例对照分析，比较了因<5>哮喘</5>严重恶化而入住内科重症监护病房的患者接受连续雾化<1>沙丁胺醇</1>（CNA）与间歇性<2>沙丁胺醇</2>（INA）治疗，匹配了40对<6>哮喘</6>患者。CNA的给药时间平均为11+/-10小时。<3>心律失常</3>的发生率相似，CNA与INA组之间无症状的<7>低钾血症</7>发生率相似。CNA患者在治疗期间心率较高，这可能反映了疾病的严重程度。插管的发生率相似。我们得出结论，CNA和INA在安全性、发病率和死亡率方面表现出相似的特征。", "revised": true}
{"doc_key": "8819482", "sentences": [["Effects", "of", "a", "new", "calcium", "antagonist", ",", "CD", "-", "832", ",", "on", "isoproterenol", "-", "induced", "myocardial", "ischemia", "in", "dogs", "with", "partial", "coronary", "stenosis", ".", "Effects", "of", "CD", "-", "832", "on", "isoproterenol", "(", "ISO", ")", "-", "induced", "myocardial", "ischemia", "were", "studied", "in", "dogs", "with", "partial", "coronary", "stenosis", "of", "the", "left", "circumflex", "coronary", "artery", "and", "findings", "were", "compared", "with", "those", "for", "nifedipine", "or", "diltiazem", ".", "In", "the", "presence", "of", "coronary", "artery", "stenosis", ",", "3", "-", "min", "periods", "of", "intracoronary", "ISO", "infusion", "(", "10", "ng", "/", "kg", "/", "min", ")", "increased", "heart", "rate", "and", "maximal", "rate", "of", "left", "ventricular", "pressure", "rise", ",", "which", "resulted", "in", "a", "decrease", "in", "percentage", "segmental", "shortening", "and", "ST", "-", "segment", "elevation", "of", "the", "epicardial", "electrocardiogram", ".", "After", "the", "control", "ISO", "infusion", "with", "stenosis", "was", "performed", ",", "equihypotensive", "doses", "of", "CD", "-", "832", "(", "3", "and", "10", "micrograms", "/", "kg", "/", "min", ",", "n", "=", "7", ")", ",", "nifedipine", "(", "1", "and", "3", "micrograms", "/", "kg", "/", "min", ",", "n", "=", "9", ")", "or", "diltiazem", "(", "10", "and", "30", "micrograms", "/", "kg", "/", "min", ",", "n", "=", "7", ")", "were", "infused", "5", "min", "before", "and", "during", "the", "second", "and", "third", "ISO", "infusion", ".", "Both", "CD", "-", "832", "and", "diltiazem", ",", "but", "not", "nifedipine", ",", "significantly", "reduced", "the", "increase", "in", "heart", "rate", "induced", "by", "ISO", "infusion", ".", "In", "contrast", "to", "nifedipine", ",", "CD", "-", "832", "(", "10", "micrograms", "/", "kg", "/", "min", ")", "prevented", "the", "decrease", "in", "percentage", "segmental", "shortening", "from", "32", "+", "/", "-", "12", "%", "to", "115", "+", "/", "-", "26", "%", "of", "the", "control", "value", "(", "P", "<", ".", "01", ")", "and", "ST", "-", "segment", "elevation", "from", "5", ".", "6", "+", "/", "-", "1", ".", "0", "mV", "to", "1", ".", "6", "+", "/", "-", "1", ".", "3", "mV", "(", "P", "<", ".", "01", ")", "at", "3", "min", "after", "ISO", "infusion", "with", "stenosis", ".", "Diltiazem", "(", "30", "micrograms", "/", "kg", "/", "min", ")", "also", "prevented", "the", "decrease", "in", "percentage", "segmental", "shortening", "from", "34", "+", "/", "-", "14", "%", "to", "63", "+", "/", "-", "18", "%", "of", "the", "control", "value", "(", "P", "<", ".", "05", ")", "and", "ST", "-", "segment", "elevation", "from", "4", ".", "7", "+", "/", "-", "0", ".", "7", "mV", "to", "2", ".", "1", "+", "/", "-", "0", ".", "7", "mV", "(", "P", "<", ".", "01", ")", "at", "3", "min", "after", "ISO", "infusion", "with", "stenosis", ".", "These", "data", "show", "that", "CD", "-", "832", "improves", "myocardial", "ischemia", "during", "ISO", "infusion", "with", "stenosis", "and", "suggest", "that", "the", "negative", "chronotropic", "property", "of", "CD", "-", "832", "plays", "a", "major", "role", "in", "the", "beneficial", "effects", "of", "CD", "-", "832", "."]], "ner": [[[12, 12, "Chemical"], [30, 30, "Chemical"], [32, 32, "Chemical"], [77, 77, "Chemical"], [121, 121, "Chemical"], [191, 191, "Chemical"], [214, 214, "Chemical"], [301, 301, "Chemical"], [384, 384, "Chemical"], [400, 400, "Chemical"], [15, 16, "Disease"], [36, 37, "Disease"], [397, 398, "Disease"], [4, 4, "Chemical"], [21, 22, "Disease"], [44, 45, "Disease"], [67, 69, "Disease"], [124, 124, "Disease"], [304, 304, "Disease"], [387, 387, "Disease"], [403, 403, "Disease"], [7, 9, "Chemical"], [26, 28, "Chemical"], [131, 133, "Chemical"], [195, 197, "Chemical"], [222, 224, "Chemical"], [393, 395, "Chemical"], [412, 414, "Chemical"], [424, 426, "Chemical"], [59, 59, "Chemical"], [149, 149, "Chemical"], [203, 203, "Chemical"], [220, 220, "Chemical"], [61, 61, "Chemical"], [165, 165, "Chemical"], [199, 199, "Chemical"], [306, 306, "Chemical"]]], "relations": [[[12, 12, 15, 16, "CID"], [12, 12, 36, 37, "CID"], [12, 12, 397, 398, "CID"], [30, 30, 15, 16, "CID"], [30, 30, 36, 37, "CID"], [30, 30, 397, 398, "CID"], [32, 32, 15, 16, "CID"], [32, 32, 36, 37, "CID"], [32, 32, 397, 398, "CID"], [77, 77, 15, 16, "CID"], [77, 77, 36, 37, "CID"], [77, 77, 397, 398, "CID"], [121, 121, 15, 16, "CID"], [121, 121, 36, 37, "CID"], [121, 121, 397, 398, "CID"], [191, 191, 15, 16, "CID"], [191, 191, 36, 37, "CID"], [191, 191, 397, 398, "CID"], [214, 214, 15, 16, "CID"], [214, 214, 36, 37, "CID"], [214, 214, 397, 398, "CID"], [301, 301, 15, 16, "CID"], [301, 301, 36, 37, "CID"], [301, 301, 397, 398, "CID"], [384, 384, 15, 16, "CID"], [384, 384, 36, 37, "CID"], [384, 384, 397, 398, "CID"], [400, 400, 15, 16, "CID"], [400, 400, 36, 37, "CID"], [400, 400, 397, 398, "CID"]]], "clusters": [], "translated": "新型<13>钙</13>拮抗剂<21>CD-832</21>对部分<0>异丙肾上腺素</0>诱导的<10>心肌缺血</10>的影响<14>冠状动脉狭窄</14>。在部分<15>左回旋支冠状动脉冠状动脉狭窄</15>的狗中，研究<22>CD-832</22>对<1>异丙肾上腺素</1>（<2>ISO</2>）诱导的<11>心肌缺血</11>的影响，并将其结果与用<29>硝苯地平</29>或<33>地尔硫卓</33>的结果进行比较。在<16>冠状动脉狭窄</16>存在的情况下，冠状动脉内输注<3>ISO</3>（10 ng / kg / min）3分钟，增加了心率和左室压力升高的最大率，导致心外膜心电图ST段升高和百分段收缩减少。在用<17>狭窄</17>进行控制<4>ISO</4>输注之后，在第二和第三次<5>ISO</5>输注之前和期间，注入同等血压剂量的<23>CD-832</23>（3和10μg / kg / min，n = 7），<30>硝苯地平</30>（1和3μg / kg / min，n = 9）或<34>地尔硫卓</34>（10和30μg / kg / min，n = 7）。既<24>CD-832</24>，又<35>地尔硫卓</35>均能显著降低<6>ISO</6>输注引起的心率增加，但<31>硝苯地平</31>则不能。与<32>硝苯地平</32>相比，<25>CD-832</25>（10μg/kg/min）防止了百分段收缩从32 + /- 12％下降到115 + /- 26％控制值（P <0.01）和在使用<18>狭窄</18>时，<7>ISO</7>输注后3分钟ST段升高从5.6 + /- 1.0mV降至1.6 + / - 1.3mV（P <0.01）。另一方面，<36>地尔硫卓</36>（30μg / kg / min）也能防止百分段收缩从对照值的34 + /- 14％下降到63 + /- 18％（P <0.05）和ST段抬高从4.7 + /- 0.7mV降至2.1 + /- 0.7mV（P <0.01），即在用<19>狭窄</19>时，<8>ISO</8>输注后3分钟。这些数据表明，<26>CD-832</26>改善了使用<9>ISO</9>输注时在<20>狭窄</20>情况下的<12>心肌缺血</12>，并表明<27>CD-832</27>的负性变时特性在<28>CD-832</28>的促进作用中起主导作用。", "revised": true}
{"doc_key": "9061777", "sentences": [["MK", "-", "801", "augments", "pilocarpine", "-", "induced", "electrographic", "seizure", "but", "protects", "against", "brain", "damage", "in", "rats", ".", "1", ".", "The", "authors", "examined", "the", "anticonvulsant", "effects", "of", "MK", "-", "801", "on", "the", "pilocarpine", "-", "induced", "seizure", "model", ".", "Intraperitoneal", "injection", "of", "pilocarpine", "(", "400", "mg", "/", "kg", ")", "induced", "tonic", "and", "clonic", "seizure", ".", "Scopolamine", "(", "10", "mg", "/", "kg", ")", "and", "pentobarbital", "(", "5", "mg", "/", "kg", ")", "prevented", "development", "of", "pilocarpine", "-", "induced", "behavioral", "seizure", "but", "MK", "-", "801", "(", "0", ".", "5", "mg", "/", "kg", ")", "did", "not", ".", "2", ".", "An", "electrical", "seizure", "measured", "with", "hippocampal", "EEG", "appeared", "in", "the", "pilocarpine", "-", "treated", "group", ".", "Scopolamine", "and", "pentobarbital", "blocked", "the", "pilocarpine", "-", "induced", "electrographic", "seizure", ",", "MK", "-", "801", "treatment", "augmented", "the", "electrographic", "seizure", "induced", "by", "pilocarpine", ".", "3", ".", "Brain", "damage", "was", "assessed", "by", "examining", "the", "hippocampus", "microscopically", ".", "Pilocarpine", "produced", "neuronal", "death", "in", "the", "hippocampus", ",", "which", "showed", "pyknotic", "changes", ".", "Pentobarbital", ",", "scopolamine", "and", "MK", "-", "801", "protected", "the", "brain", "damage", "by", "pilocarpine", ",", "though", "in", "the", "MK", "-", "801", "-", "treated", "group", ",", "the", "pyramidal", "cells", "of", "hippocampus", "appeared", "darker", "than", "normal", ".", "In", "all", "treatments", ",", "granule", "cells", "of", "the", "dentate", "gyrus", "were", "not", "affected", ".", "4", ".", "These", "results", "indicate", "that", "status", "epilepticus", "induced", "by", "pilocarpine", "is", "initiated", "by", "cholinergic", "overstimulation", "and", "propagated", "by", "glutamatergic", "transmission", ",", "the", "elevation", "of", "which", "may", "cause", "brain", "damage", "through", "an", "excitatory", "NMDA", "receptor", "-", "mediated", "mechanism", "."]], "ner": [[[0, 2, "Chemical"], [26, 28, "Chemical"], [77, 79, "Chemical"], [119, 121, "Chemical"], [160, 162, "Chemical"], [173, 175, "Chemical"], [8, 8, "Disease"], [34, 34, "Disease"], [48, 51, "Disease"], [75, 75, "Disease"], [95, 95, "Disease"], [117, 117, "Disease"], [126, 126, "Disease"], [4, 4, "Chemical"], [31, 31, "Chemical"], [40, 40, "Chemical"], [71, 71, "Chemical"], [103, 103, "Chemical"], [113, 113, "Chemical"], [129, 129, "Chemical"], [143, 143, "Chemical"], [168, 168, "Chemical"], [214, 214, "Chemical"], [145, 146, "Disease"], [210, 211, "Disease"], [12, 13, "Disease"], [133, 134, "Disease"], [165, 166, "Disease"], [232, 233, "Disease"], [53, 53, "Chemical"], [108, 108, "Chemical"], [158, 158, "Chemical"], [61, 61, "Chemical"], [110, 110, "Chemical"], [156, 156, "Chemical"], [237, 237, "Chemical"]]], "relations": [[[0, 2, 8, 8, "CID"], [0, 2, 34, 34, "CID"], [0, 2, 48, 51, "CID"], [0, 2, 75, 75, "CID"], [0, 2, 95, 95, "CID"], [0, 2, 117, 117, "CID"], [0, 2, 126, 126, "CID"], [26, 28, 8, 8, "CID"], [26, 28, 34, 34, "CID"], [26, 28, 48, 51, "CID"], [26, 28, 75, 75, "CID"], [26, 28, 95, 95, "CID"], [26, 28, 117, 117, "CID"], [26, 28, 126, 126, "CID"], [77, 79, 8, 8, "CID"], [77, 79, 34, 34, "CID"], [77, 79, 48, 51, "CID"], [77, 79, 75, 75, "CID"], [77, 79, 95, 95, "CID"], [77, 79, 117, 117, "CID"], [77, 79, 126, 126, "CID"], [119, 121, 8, 8, "CID"], [119, 121, 34, 34, "CID"], [119, 121, 48, 51, "CID"], [119, 121, 75, 75, "CID"], [119, 121, 95, 95, "CID"], [119, 121, 117, 117, "CID"], [119, 121, 126, 126, "CID"], [160, 162, 8, 8, "CID"], [160, 162, 34, 34, "CID"], [160, 162, 48, 51, "CID"], [160, 162, 75, 75, "CID"], [160, 162, 95, 95, "CID"], [160, 162, 117, 117, "CID"], [160, 162, 126, 126, "CID"], [173, 175, 8, 8, "CID"], [173, 175, 34, 34, "CID"], [173, 175, 48, 51, "CID"], [173, 175, 75, 75, "CID"], [173, 175, 95, 95, "CID"], [173, 175, 117, 117, "CID"], [173, 175, 126, 126, "CID"], [4, 4, 8, 8, "CID"], [4, 4, 34, 34, "CID"], [4, 4, 48, 51, "CID"], [4, 4, 75, 75, "CID"], [4, 4, 95, 95, "CID"], [4, 4, 117, 117, "CID"], [4, 4, 126, 126, "CID"], [31, 31, 8, 8, "CID"], [31, 31, 34, 34, "CID"], [31, 31, 48, 51, "CID"], [31, 31, 75, 75, "CID"], [31, 31, 95, 95, "CID"], [31, 31, 117, 117, "CID"], [31, 31, 126, 126, "CID"], [40, 40, 8, 8, "CID"], [40, 40, 34, 34, "CID"], [40, 40, 48, 51, "CID"], [40, 40, 75, 75, "CID"], [40, 40, 95, 95, "CID"], [40, 40, 117, 117, "CID"], [40, 40, 126, 126, "CID"], [71, 71, 8, 8, "CID"], [71, 71, 34, 34, "CID"], [71, 71, 48, 51, "CID"], [71, 71, 75, 75, "CID"], [71, 71, 95, 95, "CID"], [71, 71, 117, 117, "CID"], [71, 71, 126, 126, "CID"], [103, 103, 8, 8, "CID"], [103, 103, 34, 34, "CID"], [103, 103, 48, 51, "CID"], [103, 103, 75, 75, "CID"], [103, 103, 95, 95, "CID"], [103, 103, 117, 117, "CID"], [103, 103, 126, 126, "CID"], [113, 113, 8, 8, "CID"], [113, 113, 34, 34, "CID"], [113, 113, 48, 51, "CID"], [113, 113, 75, 75, "CID"], [113, 113, 95, 95, "CID"], [113, 113, 117, 117, "CID"], [113, 113, 126, 126, "CID"], [129, 129, 8, 8, "CID"], [129, 129, 34, 34, "CID"], [129, 129, 48, 51, "CID"], [129, 129, 75, 75, "CID"], [129, 129, 95, 95, "CID"], [129, 129, 117, 117, "CID"], [129, 129, 126, 126, "CID"], [143, 143, 8, 8, "CID"], [143, 143, 34, 34, "CID"], [143, 143, 48, 51, "CID"], [143, 143, 75, 75, "CID"], [143, 143, 95, 95, "CID"], [143, 143, 117, 117, "CID"], [143, 143, 126, 126, "CID"], [168, 168, 8, 8, "CID"], [168, 168, 34, 34, "CID"], [168, 168, 48, 51, "CID"], [168, 168, 75, 75, "CID"], [168, 168, 95, 95, "CID"], [168, 168, 117, 117, "CID"], [168, 168, 126, 126, "CID"], [214, 214, 8, 8, "CID"], [214, 214, 34, 34, "CID"], [214, 214, 48, 51, "CID"], [214, 214, 75, 75, "CID"], [214, 214, 95, 95, "CID"], [214, 214, 117, 117, "CID"], [214, 214, 126, 126, "CID"], [4, 4, 145, 146, "CID"], [31, 31, 145, 146, "CID"], [40, 40, 145, 146, "CID"], [71, 71, 145, 146, "CID"], [103, 103, 145, 146, "CID"], [113, 113, 145, 146, "CID"], [129, 129, 145, 146, "CID"], [143, 143, 145, 146, "CID"], [168, 168, 145, 146, "CID"], [214, 214, 145, 146, "CID"], [4, 4, 210, 211, "CID"], [31, 31, 210, 211, "CID"], [40, 40, 210, 211, "CID"], [71, 71, 210, 211, "CID"], [103, 103, 210, 211, "CID"], [113, 113, 210, 211, "CID"], [129, 129, 210, 211, "CID"], [143, 143, 210, 211, "CID"], [168, 168, 210, 211, "CID"], [214, 214, 210, 211, "CID"]]], "clusters": [], "translated": " <0>MK-801</0> 增强 <13>毛果芸香碱</13>诱导的脑电图<6>癫痫发作</6>，但防止大鼠<25>脑损伤</25>。1. 作者检查了<1>MK-801</1>对<14>毛果芸香碱</14>诱导的<7>癫痫发作</7>模型的抗惊厥作用。腹腔注射<15>毛果芸香碱</15>（400mg/kg）引起<8>强直和阵挛发作</8>。<29>东莨菪碱</29>（10mg/kg）和<32>戊巴比妥</32>（5mg/kg）阻止了<16>毛果芸香碱</16>诱导的行为<9>癫痫发作</9>的发展，但<2>MK-801</2>（0.5mg/kg）没有。 2. <17>毛果芸香碱</17>治疗组出现了用海马EEG测量的<10>癫痫发作</10>。 <30>东莨菪碱</30>和<33>戊巴比妥</33>阻断了<18>毛果芸香碱</18>诱导的<11>电图癫痫发作</11>，<3>MK-801</3>治疗增强了<19>毛果芸香碱</19>诱导的<12>电图癫痫发作</12>。 3. 通过显微镜检查海马体来评估<26>脑损伤</26>。<20>毛果芸香碱</20>在海马体中引起了<23>神经元死亡</23>，表现为核固缩。<34>戊巴比妥</34>、<31>东莨菪碱</31>和<4>MK-801</4>通过<21>毛果芸香碱</21>保护了<27>脑损伤</27>，虽然在<5>MK-801</5>处理组中海马体锥体细胞的颜色比正常变深。在所有处理中，颗粒细胞和齿状回均未受影响。4.这些结果表明，由于胆碱能过度刺激引起，<22>毛果芸香碱</22>诱导的<24>癫痫状态</24>是由谷氨酸能传递引起的，其升高可能通过<35>兴奋性</35> NMDA受体介导的机制导致<28>脑损伤</28>。", "revised": true}
{"doc_key": "9128918", "sentences": [["Chronic", "hyperprolactinemia", "and", "changes", "in", "dopamine", "neurons", ".", "The", "tuberoinfundibular", "dopaminergic", "(", "TIDA", ")", "system", "is", "known", "to", "inhibit", "prolactin", "(", "PRL", ")", "secretion", ".", "In", "young", "animals", "this", "system", "responds", "to", "acute", "elevations", "in", "serum", "PRL", "by", "increasing", "its", "activity", ".", "However", ",", "this", "responsiveness", "is", "lost", "in", "aging", "rats", "with", "chronically", "high", "serum", "PRL", "levels", ".", "The", "purpose", "of", "this", "study", "was", "to", "induce", "hyperprolactinemia", "in", "rats", "for", "extended", "periods", "of", "time", "and", "examine", "its", "effects", "on", "dopaminergic", "systems", "in", "the", "brain", ".", "Hyperprolactinemia", "was", "induced", "by", "treatment", "with", "haloperidol", ",", "a", "dopamine", "receptor", "antagonist", ",", "and", "Palkovits", "'", "microdissection", "technique", "in", "combination", "with", "high", "-", "performance", "liquid", "chromatography", "was", "used", "to", "measure", "neurotransmitter", "concentrations", "in", "several", "areas", "of", "the", "brain", ".", "After", "6", "months", "of", "hyperprolactinemia", ",", "dopamine", "(", "DA", ")", "concentrations", "in", "the", "median", "eminence", "(", "ME", ")", "increased", "by", "84", "%", "over", "the", "control", "group", ".", "Nine", "months", "of", "hyperprolactinemia", "produced", "a", "50", "%", "increase", "in", "DA", "concentrations", "in", "the", "ME", "over", "the", "control", "group", ".", "However", ",", "DA", "response", "was", "lost", "if", "a", "9", "-", "month", "long", "haloperidol", "-", "induced", "hyperprolactinemia", "was", "followed", "by", "a", "1", "1", "/", "2", "month", "-", "long", "extremely", "high", "increase", "in", "serum", "PRL", "levels", "produced", "by", "implantation", "of", "MMQ", "cells", "under", "the", "kidney", "capsule", ".", "There", "was", "no", "change", "in", "the", "levels", "of", "DA", ",", "norepinephrine", "(", "NE", ")", ",", "serotonin", "(", "5", "-", "HT", ")", ",", "or", "their", "metabolites", "in", "the", "arcuate", "nucleus", "(", "AN", ")", ",", "medial", "preoptic", "area", "(", "MPA", ")", ",", "caudate", "putamen", "(", "CP", ")", ",", "substantia", "nigra", "(", "SN", ")", ",", "and", "zona", "incerta", "(", "ZI", ")", ",", "except", "for", "a", "decrease", "in", "5", "-", "hydroxyindoleacetic", "acid", "(", "5", "-", "HIAA", ")", "in", "the", "AN", "after", "6", "-", "months", "of", "hyperprolactinemia", "and", "an", "increase", "in", "DA", "concentrations", "in", "the", "AN", "after", "9", "-", "months", "of", "hyperprolactinemia", ".", "These", "results", "demonstrate", "that", "hyperprolactinemia", "specifically", "affects", "TIDA", "neurons", "and", "these", "effects", "vary", ",", "depending", "on", "the", "duration", "and", "intensity", "of", "hyperprolactinemia", ".", "The", "age", "-", "related", "decrease", "in", "hypothalamic", "dopamine", "function", "may", "be", "associated", "with", "increases", "in", "PRL", "secretion", "."]], "ner": [[[91, 91, "Chemical"], [183, 183, "Chemical"], [1, 1, "Disease"], [66, 66, "Disease"], [85, 85, "Disease"], [128, 128, "Disease"], [154, 154, "Disease"], [186, 186, "Disease"], [297, 297, "Disease"], [312, 312, "Disease"], [318, 318, "Disease"], [335, 335, "Disease"], [5, 5, "Chemical"], [94, 94, "Chemical"], [130, 130, "Chemical"], [132, 132, "Chemical"], [161, 161, "Chemical"], [173, 173, "Chemical"], [224, 224, "Chemical"], [302, 302, "Chemical"], [344, 344, "Chemical"], [226, 226, "Chemical"], [228, 228, "Chemical"], [231, 231, "Chemical"], [233, 235, "Chemical"], [280, 283, "Chemical"], [285, 287, "Chemical"]]], "relations": [[[91, 91, 1, 1, "CID"], [91, 91, 66, 66, "CID"], [91, 91, 85, 85, "CID"], [91, 91, 128, 128, "CID"], [91, 91, 154, 154, "CID"], [91, 91, 186, 186, "CID"], [91, 91, 297, 297, "CID"], [91, 91, 312, 312, "CID"], [91, 91, 318, 318, "CID"], [91, 91, 335, 335, "CID"], [183, 183, 1, 1, "CID"], [183, 183, 66, 66, "CID"], [183, 183, 85, 85, "CID"], [183, 183, 128, 128, "CID"], [183, 183, 154, 154, "CID"], [183, 183, 186, 186, "CID"], [183, 183, 297, 297, "CID"], [183, 183, 312, 312, "CID"], [183, 183, 318, 318, "CID"], [183, 183, 335, 335, "CID"]]], "clusters": [], "translated": "慢性<2>高催乳素血症</2>和<12>多巴胺</12>神经元的变化。众所周知，结节漏斗多巴胺能 (TIDA) 系统会抑制催乳素 (PRL) 的分泌。在年轻动物中，该系统通过增加其活性来响应血清PRL的急剧升高。然而，这种反应性在具有长期高血清PRL水平的衰老大鼠中消失了。本研究的目的是在大鼠中长时间诱导<3>高催乳素血症</3>并检查其对大脑多巴胺能系统的影响。<4>高催乳素血症</4>是由<0>氟哌啶醇</0>（一种<13>多巴胺</13>受体拮抗剂）治疗引起的，并采用Palkovits的显微切割技术结合高效液相色谱法测量大脑几个区域的神经递质浓度。在<5>高催乳素血症</5>6个月后，中位隆起（ME）中的<14>多巴胺</14>（<15>DA</15>）浓度比对照组增加了84%。九个月的<6>高催乳素血症</6>导致ME中的<16>DA</16>浓度比对照组高50%。然而，如果持续9个月的<1>氟哌啶醇</1>诱导的<7>高催乳素血症</7>随后持续持续1 1/2个月的极高催乳素血症，<17>DA</17>反应就会消失，通过在肾囊下植入MMQ细胞产生的血清PRL水平升高。在弓状核(AN)、内侧视前区(MPA)、尾壳核(CP)、黑质(SN)和未定带(ZI)中的代谢物，除了<25>5-羟基吲哚乙酸</25> (<26>5-HIAA</26>) 在<8>高催乳素血症</8>后6个月和<19>DA</19>在<9>高催乳素血症</9>后9个月的AN中浓度有所增加，其他代谢物的含量均未改变，其中包括<18>DA</18>、<21>去甲肾上腺素</21>（<22>NE</22>）和<23>血清素</23>（<24>5-HT</24>）。这些结果表明，<10>高催乳素血症</10>对TIDA神经元有特异性影响，并且这些影响因<11>高催乳素血症</11>的持续时间和强度而异。与年龄相关的下丘脑<20>多巴胺</20>功能下降可能与PRL分泌增加有关。", "revised": true}
{"doc_key": "9272404", "sentences": [["The", "negative", "mucosal", "potential", ":", "separating", "central", "and", "peripheral", "effects", "of", "NSAIDs", "in", "man", ".", "OBJECTIVE", ":", "We", "wanted", "to", "test", "whether", "assessment", "of", "both", "a", "central", "pain", "-", "related", "signal", "(", "chemo", "-", "somatosensory", "evoked", "potential", ",", "CSSEP", ")", "and", "a", "concomitantly", "recorded", "peripheral", "signal", "(", "negative", "mucosal", "potential", ",", "NMP", ")", "allows", "for", "separation", "of", "central", "and", "peripheral", "effects", "of", "NSAIDs", ".", "For", "this", "purpose", ",", "experimental", "conditions", "were", "created", "in", "which", "NSAIDs", "had", "previously", "been", "observed", "to", "produce", "effects", "on", "phasic", "and", "tonic", "pain", "by", "either", "central", "or", "peripheral", "mechanisms", ".", "METHODS", ":", "According", "to", "a", "double", "-", "blind", ",", "randomised", ",", "controlled", ",", "threefold", "cross", "-", "over", "design", ",", "18", "healthy", "subjects", "(", "11", "males", ",", "7", "females", ";", "mean", "age", "26", "years", ")", "received", "either", "placebo", ",", "400", "mg", "ibuprofen", ",", "or", "800", "mg", "ibuprofen", ".", "Phasic", "pain", "was", "applied", "by", "means", "of", "short", "pulses", "of", "CO2", "to", "the", "nasal", "mucosa", "(", "stimulus", "duration", "500", "ms", ",", "interval", "approximately", "60", "s", ")", ",", "and", "tonic", "pain", "was", "induced", "in", "the", "nasal", "cavity", "by", "means", "of", "dry", "air", "of", "controlled", "temperature", ",", "humidity", "and", "flow", "rate", "(", "22", "degrees", "C", ",", "0", "%", "relative", "humidity", ",", "145", "ml", ".", "s", "-", "1", ")", ".", "Both", "CSSEPs", "as", "central", "and", "NMPs", "as", "peripheral", "correlates", "of", "pain", "were", "obtained", "in", "response", "to", "the", "CO2", "stimuli", ".", "Additionally", ",", "the", "subjects", "rated", "the", "intensity", "of", "both", "phasic", "and", "tonic", "pain", "by", "means", "of", "visual", "analogue", "scales", ".", "RESULTS", ":", "As", "described", "earlier", ",", "administration", "of", "ibuprofen", "was", "followed", "by", "a", "decrease", "in", "tonic", "pain", "but", "-", "relative", "to", "placebo", "-", "an", "increase", "in", "correlates", "of", "phasic", "pain", ",", "indicating", "a", "specific", "effect", "of", "ibuprofen", "on", "the", "interaction", "between", "the", "pain", "stimuli", "under", "these", "special", "experimental", "conditions", ".", "Based", "on", "the", "similar", "behaviour", "of", "CSSEP", "and", "NMP", ",", "it", "was", "concluded", "that", "the", "pharmacological", "process", "underlying", "this", "phenomenon", "was", "localised", "in", "the", "periphery", ".", "By", "means", "of", "the", "simultaneous", "recording", "of", "interrelated", "peripheral", "and", "central", "electrophysiologic", "correlates", "of", "nociception", ",", "it", "was", "possible", "to", "separate", "central", "and", "peripheral", "effects", "of", "an", "NSAID", ".", "The", "major", "advantage", "of", "this", "pain", "model", "is", "the", "possibility", "of", "obtaining", "peripheral", "pain", "-", "related", "activity", "directly", "using", "a", "non", "-", "invasive", "technique", "in", "humans", "."]], "ner": [[[134, 134, "Chemical"], [139, 139, "Chemical"], [256, 256, "Chemical"], [284, 284, "Chemical"], [27, 27, "Disease"], [86, 86, "Disease"], [142, 142, "Disease"], [170, 170, "Disease"], [218, 218, "Disease"], [240, 240, "Disease"], [264, 264, "Disease"], [277, 277, "Disease"], [290, 290, "Disease"], [358, 358, "Disease"], [366, 366, "Disease"], [151, 151, "Chemical"], [225, 225, "Chemical"]]], "relations": [[[134, 134, 27, 27, "CID"], [134, 134, 86, 86, "CID"], [134, 134, 142, 142, "CID"], [134, 134, 170, 170, "CID"], [134, 134, 218, 218, "CID"], [134, 134, 240, 240, "CID"], [134, 134, 264, 264, "CID"], [134, 134, 277, 277, "CID"], [134, 134, 290, 290, "CID"], [134, 134, 358, 358, "CID"], [134, 134, 366, 366, "CID"], [139, 139, 27, 27, "CID"], [139, 139, 86, 86, "CID"], [139, 139, 142, 142, "CID"], [139, 139, 170, 170, "CID"], [139, 139, 218, 218, "CID"], [139, 139, 240, 240, "CID"], [139, 139, 264, 264, "CID"], [139, 139, 277, 277, "CID"], [139, 139, 290, 290, "CID"], [139, 139, 358, 358, "CID"], [139, 139, 366, 366, "CID"], [256, 256, 27, 27, "CID"], [256, 256, 86, 86, "CID"], [256, 256, 142, 142, "CID"], [256, 256, 170, 170, "CID"], [256, 256, 218, 218, "CID"], [256, 256, 240, 240, "CID"], [256, 256, 264, 264, "CID"], [256, 256, 277, 277, "CID"], [256, 256, 290, 290, "CID"], [256, 256, 358, 358, "CID"], [256, 256, 366, 366, "CID"], [284, 284, 27, 27, "CID"], [284, 284, 86, 86, "CID"], [284, 284, 142, 142, "CID"], [284, 284, 170, 170, "CID"], [284, 284, 218, 218, "CID"], [284, 284, 240, 240, "CID"], [284, 284, 264, 264, "CID"], [284, 284, 277, 277, "CID"], [284, 284, 290, 290, "CID"], [284, 284, 358, 358, "CID"], [284, 284, 366, 366, "CID"]]], "clusters": [], "translated": "输出: 负粘膜电位：分离 NSAIDs 对人体的中枢和外周作用。目的：我们想测试评估中枢 <4>疼痛</4>相关信号（化学体感诱发电位 CSSEP）和伴随记录的外周信号（负粘膜电位 NMP）是否允许分离 NSAIDs 的中枢和外周作用。为此，我们创造了实验条件，在这些条件下，先前观察到 NSAIDs 通过中枢或外周机制对阶段性和强直性<5>疼痛</5> 产生影响。方法：根据双盲、随机、对照、三重交叉设计，18 名健康受试者（11 名男性，7 名女性；平均年龄 26 岁）接受安慰剂、400 mg <0>布洛芬</0>或800 毫克 <1>布洛芬</1>。阶段性<6>疼痛</6>通过<15>CO2</15>短脉冲作用于鼻粘膜（刺激持续时间 500 毫秒，间隔约 60 秒），而强直性<7>疼痛</7>是通过控制温度、湿度和流速（22 摄氏度、0% 相对湿度、145 毫升/s）的干燥空气诱导于鼻腔中。对于<8>疼痛</8>，中枢相关的 CSSEP 和外周相关的 NMP 都是在对<16>CO2</16>刺激的反应中获得的。此外，受试者通过视觉模拟量表评估阶段性和强直性<9>疼痛</9>的强度。结果：如前所述，服用<2>布洛芬</2>之后强直性<10>疼痛</10>减少，但相对于安慰剂 - 相关的<11>阶段性疼痛</11> ，表明在这些特殊实验条件下，<3>布洛芬</3>对<12>疼痛</12>刺激之间相互作用的特定影响。基于 CSSEP 和 NMP 的相似行为，可以得出结论，这种现象背后的药理过程局限于外周。通过同时记录与疼痛相关的外周和中枢电生理相关，可以分离 NSAIDs 的中枢和外周作用。这种<13>疼痛</13>模型的主要优点是可能在人类身上使用非侵入性技术直接获得外周<14>疼痛</14>相关活动。", "revised": true}
{"doc_key": "9158667", "sentences": [["Thrombotic", "complications", "in", "acute", "promyelocytic", "leukemia", "during", "all", "-", "trans", "-", "retinoic", "acid", "therapy", ".", "A", "case", "of", "acute", "renal", "failure", ",", "due", "to", "occlusion", "of", "renal", "vessels", "in", "a", "patient", "with", "acute", "promyelocytic", "leukemia", "(", "APL", ")", "treated", "with", "all", "-", "trans", "-", "retinoic", "acid", "(", "ATRA", ")", "and", "tranexamic", "acid", "has", "been", "described", "recently", ".", "We", "report", "a", "case", "of", "acute", "renal", "failure", "in", "an", "APL", "patient", "treated", "with", "ATRA", "alone", ".", "This", "case", "further", "supports", "the", "concern", "about", "thromboembolic", "complications", "associated", "with", "ATRA", "therapy", "in", "APL", "patients", ".", "The", "patients", ",", "a", "43", "-", "year", "-", "old", "man", ",", "presented", "all", "the", "signs", "and", "symptoms", "of", "APL", "and", "was", "included", "in", "a", "treatment", "protocol", "with", "ATRA", ".", "After", "10", "days", "of", "treatment", ",", "he", "developed", "acute", "renal", "failure", "that", "was", "completely", "reversible", "after", "complete", "remission", "of", "APL", "was", "achieved", "and", "therapy", "discontinued", ".", "We", "conclude", "that", "ATRA", "is", "a", "valid", "therapeutic", "choice", "for", "patients", "with", "APL", ",", "although", "the", "procoagulant", "tendency", "is", "not", "completely", "corrected", ".", "Thrombotic", "events", ",", "however", ",", "could", "be", "avoided", "by", "using", "low", "-", "dose", "heparin", "."]], "ner": [[[7, 12, "Chemical"], [40, 45, "Chemical"], [47, 47, "Chemical"], [71, 71, "Chemical"], [85, 85, "Chemical"], [118, 118, "Chemical"], [149, 149, "Chemical"], [0, 0, "Disease"], [169, 169, "Disease"], [18, 20, "Disease"], [62, 64, "Disease"], [128, 130, "Disease"], [50, 51, "Chemical"], [182, 182, "Chemical"], [3, 5, "Disease"], [32, 34, "Disease"], [36, 36, "Disease"], [67, 67, "Disease"], [88, 88, "Disease"], [109, 109, "Disease"], [139, 139, "Disease"], [158, 158, "Disease"], [81, 81, "Disease"]]], "relations": [[[7, 12, 0, 0, "CID"], [7, 12, 169, 169, "CID"], [40, 45, 0, 0, "CID"], [40, 45, 169, 169, "CID"], [47, 47, 0, 0, "CID"], [47, 47, 169, 169, "CID"], [71, 71, 0, 0, "CID"], [71, 71, 169, 169, "CID"], [85, 85, 0, 0, "CID"], [85, 85, 169, 169, "CID"], [118, 118, 0, 0, "CID"], [118, 118, 169, 169, "CID"], [149, 149, 0, 0, "CID"], [149, 149, 169, 169, "CID"], [7, 12, 18, 20, "CID"], [7, 12, 62, 64, "CID"], [7, 12, 128, 130, "CID"], [40, 45, 18, 20, "CID"], [40, 45, 62, 64, "CID"], [40, 45, 128, 130, "CID"], [47, 47, 18, 20, "CID"], [47, 47, 62, 64, "CID"], [47, 47, 128, 130, "CID"], [71, 71, 18, 20, "CID"], [71, 71, 62, 64, "CID"], [71, 71, 128, 130, "CID"], [85, 85, 18, 20, "CID"], [85, 85, 62, 64, "CID"], [85, 85, 128, 130, "CID"], [118, 118, 18, 20, "CID"], [118, 118, 62, 64, "CID"], [118, 118, 128, 130, "CID"], [149, 149, 18, 20, "CID"], [149, 149, 62, 64, "CID"], [149, 149, 128, 130, "CID"]]], "clusters": [], "translated": "<7><0>全反式维甲酸</0>治疗期间<14>急性早幼粒细胞白血病</14>的<0>血栓形成</0>并发症。<9>急性肾功能衰竭</9>一例，<15>急性早幼粒细胞白血病</15>（<16>APL</16>）因肾血管闭塞而接受<1>全反式维甲酸</1>（<2>ATRA</2>）和<12>氨甲环酸</12>最近已被描述。我们报告了一例<10>急性肾功能衰竭</10>的<17>APL</17>患者，仅接受<3>ATRA</3>治疗。该病例进一步支持了对<18>APL</18>患者与<4>ATRA</4>治疗相关的<22>血栓栓塞</22>并发症的担忧。患者是一名43岁的男性，表现出<19>APL</19>的所有症状和体征，并被纳入了<5>ATRA</5>治疗方案。治疗10天后，他出现了<11>急性肾功能衰竭</11>，在<20>APL</20>完全缓解并停止治疗后，这种情况是完全可逆的。我们得出结论，<6>ATRA</6>是<21>APL</21>患者的有效治疗选择，尽管促凝血倾向尚未完全纠正。<8>血栓</8>事件，然而，可以通过使用低剂量<13>肝素</13>来避免。", "revised": true}
{"doc_key": "9570197", "sentences": [["Effects", "of", "the", "intracoronary", "infusion", "of", "cocaine", "on", "left", "ventricular", "systolic", "and", "diastolic", "function", "in", "humans", ".", "BACKGROUND", ":", "In", "dogs", ",", "a", "large", "amount", "of", "intravenous", "cocaine", "causes", "a", "profound", "deterioration", "of", "left", "ventricular", "(", "LV", ")", "systolic", "function", "and", "an", "increase", "in", "LV", "end", "-", "diastolic", "pressure", ".", "This", "study", "was", "done", "to", "assess", "the", "influence", "of", "a", "high", "intracoronary", "cocaine", "concentration", "on", "LV", "systolic", "and", "diastolic", "function", "in", "humans", ".", "METHODS", "AND", "RESULTS", ":", "In", "20", "patients", "(", "14", "men", "and", "6", "women", "aged", "39", "to", "72", "years", ")", "referred", "for", "cardiac", "catheterization", "for", "the", "evaluation", "of", "chest", "pain", ",", "we", "measured", "heart", "rate", ",", "systemic", "arterial", "pressure", ",", "LV", "pressure", "and", "its", "first", "derivative", "(", "dP", "/", "dt", ")", ",", "and", "LV", "volumes", "and", "ejection", "fraction", "before", "and", "during", "the", "final", "2", "to", "3", "minutes", "of", "a", "15", "-", "minute", "intracoronary", "infusion", "of", "saline", "(", "n", "=", "10", ",", "control", "subjects", ")", "or", "cocaine", "hydrochloride", "1", "mg", "/", "min", "(", "n", "=", "10", ")", ".", "No", "variable", "changed", "with", "saline", ".", "With", "cocaine", ",", "the", "drug", "concentration", "in", "blood", "obtained", "from", "the", "coronary", "sinus", "was", "3", ".", "0", "+", "/", "-", "0", ".", "4", "(", "mean", "+", "/", "-", "SD", ")", "mg", "/", "L", ",", "similar", "in", "magnitude", "to", "the", "blood", "cocaine", "concentration", "reported", "in", "abusers", "dying", "of", "cocaine", "intoxication", ".", "Cocaine", "induced", "no", "significant", "change", "in", "heart", "rate", ",", "LV", "dP", "/", "dt", "(", "positive", "or", "negative", ")", ",", "or", "LV", "end", "-", "diastolic", "volume", ",", "but", "it", "caused", "an", "increase", "in", "systolic", "and", "mean", "arterial", "pressures", ",", "LV", "end", "-", "diastolic", "pressure", ",", "and", "LV", "end", "-", "systolic", "volume", ",", "as", "well", "as", "a", "decrease", "in", "LV", "ejection", "fraction", ".", "CONCLUSIONS", ":", "In", "humans", ",", "the", "intracoronary", "infusion", "of", "cocaine", "sufficient", "in", "amount", "to", "achieve", "a", "high", "drug", "concentration", "in", "coronary", "sinus", "blood", "causes", "a", "deterioration", "of", "LV", "systolic", "and", "diastolic", "performance", "."]], "ner": [[[6, 6, "Chemical"], [27, 27, "Chemical"], [62, 62, "Chemical"], [157, 158, "Chemical"], [176, 176, "Chemical"], [215, 215, "Chemical"], [222, 222, "Chemical"], [225, 225, "Chemical"], [295, 295, "Chemical"], [31, 39, "Disease"], [311, 317, "Disease"], [100, 101, "Disease"]]], "relations": [[[6, 6, 31, 39, "CID"], [6, 6, 311, 317, "CID"], [27, 27, 31, 39, "CID"], [27, 27, 311, 317, "CID"], [62, 62, 31, 39, "CID"], [62, 62, 311, 317, "CID"], [157, 158, 31, 39, "CID"], [157, 158, 311, 317, "CID"], [176, 176, 31, 39, "CID"], [176, 176, 311, 317, "CID"], [215, 215, 31, 39, "CID"], [215, 215, 311, 317, "CID"], [222, 222, 31, 39, "CID"], [222, 222, 311, 317, "CID"], [225, 225, 31, 39, "CID"], [225, 225, 311, 317, "CID"], [295, 295, 31, 39, "CID"], [295, 295, 311, 317, "CID"]]], "clusters": [], "translated": "<0>可卡因</0> 冠状动脉内输注对人类左心室收缩和舒张功能的影响。背景：在狗身上，大量静脉注射<1>可卡因</1>会导致<9>左心室（LV）收缩功能严重恶化</9>和LV舒张末期压力升高。这项研究旨在评估冠状动脉内高浓度<2>可卡因</2>对人类LV收缩和舒张功能的影响。方法和结果：在20名患者（14名男性和6名女性，年龄在39至72岁之间）因<11>胸痛</11>进行心导管检查，我们测量了心率、全身动脉压、LV压力及其一阶导数（dP / dt），以及LV体积和射血分数在15分钟冠状动脉内输注生理盐水（n = 10，对照受试者）或<3>可卡因盐酸</3>之前和期间的最后2至3分钟1毫克/分钟（n = 10）。生理盐水没有改变任何变量。对于<4>可卡因</4>，从冠状窦获得的血液中的药物浓度为3.0 +/- 0.4（平均值+/- SD）mg/L，与死于<6>可卡因</6>中毒的滥用者报告的血液<5>可卡因</5>浓度相似。<7>可卡因</7>不会引起心率、LV dP / dt（正或负）或LV舒张末期容积的显着变化，但会导致收缩压和平均动脉压、LV舒张末期压升高和LV收缩末期容积，以及LV射血分数的减少。结论：在人类中，冠状动脉内输注足量的<8>可卡因</8>以在冠状窦血液中达到高药物浓度会导致<10>左心室收缩和舒张功能的恶化</10>。", "revised": true}
{"doc_key": "8996419", "sentences": [["Population", "-", "based", "study", "of", "risk", "of", "venous", "thromboembolism", "associated", "with", "various", "oral", "contraceptives", ".", "BACKGROUND", ":", "Four", "studies", "published", "since", "December", ",", "1995", ",", "reported", "that", "the", "incidence", "of", "venous", "thromboembolism", "(", "VTE", ")", "was", "higher", "in", "women", "who", "used", "oral", "contraceptives", "(", "OCs", ")", "containing", "the", "third", "-", "generation", "progestagens", "gestodene", "or", "desogestrel", "than", "in", "users", "of", "OCs", "containing", "second", "-", "generation", "progestagens", ".", "However", ",", "confounding", "and", "bias", "in", "the", "design", "of", "these", "studies", "may", "have", "affected", "the", "findings", ".", "The", "aim", "of", "our", "study", "was", "to", "re", "-", "examine", "the", "association", "between", "risk", "of", "VTE", "and", "OC", "use", "with", "a", "different", "study", "design", "and", "analysis", "to", "avoid", "some", "of", "the", "bias", "and", "confounding", "of", "the", "earlier", "studies", ".", "METHODS", ":", "We", "used", "computer", "records", "of", "patients", "from", "143", "general", "practices", "in", "the", "UK", ".", "The", "study", "was", "based", "on", "the", "medical", "records", "of", "about", "540", ",", "000", "women", "born", "between", "1941", "and", "1981", ".", "All", "women", "who", "had", "a", "recorded", "diagnosis", "of", "deep", "-", "vein", "thrombosis", ",", "venous", "thrombosis", "not", "otherwise", "specified", ",", "or", "pulmonary", "embolus", "during", "the", "study", "period", ",", "and", "who", "had", "been", "treated", "with", "an", "anticoagulant", "were", "identified", "as", "potential", "cases", "of", "VTE", ".", "We", "did", "a", "cohort", "analysis", "to", "estimate", "and", "compare", "incidence", "of", "VTE", "in", "users", "of", "the", "main", "OC", "preparations", ",", "and", "a", "nested", "case", "-", "control", "study", "to", "calculate", "the", "odds", "ratios", "of", "VTE", "associated", "with", "use", "of", "different", "types", "of", "OC", ",", "after", "adjustment", "for", "potential", "confounding", "factors", ".", "In", "the", "case", "-", "control", "study", ",", "we", "matched", "cases", "to", "controls", "by", "exact", "year", "of", "birth", ",", "practice", ",", "and", "current", "use", "of", "OCs", ".", "We", "used", "a", "multiple", "logistic", "regression", "model", "that", "included", "body", "-", "mass", "index", ",", "number", "of", "cycles", ",", "change", "in", "type", "of", "OC", "prescribed", "within", "3", "months", "of", "the", "event", ",", "previous", "pregnancy", ",", "and", "concurrent", "disease", ".", "FINDINGS", ":", "85", "women", "met", "the", "inclusion", "criteria", "for", "VTE", ",", "two", "of", "whom", "were", "users", "of", "progestagen", "-", "only", "OCs", ".", "Of", "the", "83", "cases", "of", "VTE", "associated", "with", "use", "of", "combined", "OCs", ",", "43", "were", "recorded", "as", "deep", "-", "vein", "thrombosis", ",", "35", "as", "pulmonary", "thrombosis", ",", "and", "five", "as", "venous", "thrombosis", "not", "otherwise", "specified", ".", "The", "crude", "rate", "of", "VTE", "per", "10", ",", "000", "woman", "-", "years", "was", "4", ".", "10", "in", "current", "users", "of", "any", "OC", ",", "3", ".", "10", "in", "users", "of", "second", "-", "generation", "OCs", ",", "and", "4", ".", "96", "in", "users", "of", "third", "-", "generation", "preparations", ".", "After", "adjustment", "for", "age", ",", "the", "rate", "ratio", "of", "VTE", "in", "users", "of", "third", "-", "generation", "relative", "to", "second", "-", "generation", "OCs", "was", "1", ".", "68", "(", "95", "%", "CI", "1", ".", "04", "-", "2", ".", "75", ")", ".", "Logistic", "regression", "showed", "no", "significant", "difference", "in", "the", "risk", "of", "VTE", "between", "users", "of", "third", "-", "generation", "and", "second", "-", "generation", "OCs", ".", "Among", "users", "of", "third", "-", "generation", "progestagens", ",", "the", "risk", "of", "VTE", "was", "higher", "in", "users", "of", "desogestrel", "with", "20", "g", "ethinyloestradiol", "than", "in", "users", "of", "gestodene", "or", "desogestrel", "with", "30", "g", "ethinyloestradiol", ".", "With", "all", "second", "-", "generation", "OCs", "as", "the", "reference", ",", "the", "odds", "ratios", "for", "VTE", "were", "3", ".", "49", "(", "1", ".", "21", "-", "10", ".", "12", ")", "for", "desogestrel", "plus", "20", "g", "ethinyloestradiol", "and", "1", ".", "18", "(", "0", ".", "66", "-", "2", ".", "17", ")", "for", "the", "other", "third", "-", "generation", "progestagens", ".", "INTERPRETATION", ":", "The", "previously", "reported", "increase", "in", "odds", "ratio", "associated", "with", "third", "-", "generation", "OCs", "when", "compared", "with", "second", "-", "generation", "products", "is", "likely", "to", "have", "been", "the", "result", "of", "residual", "confounding", "by", "age", ".", "The", "increased", "odds", "ratio", "associated", "with", "products", "containing", "20", "micrograms", "ethinyloestradiol", "and", "desogestrel", "compared", "with", "the", "30", "micrograms", "product", "is", "biologically", "implausible", ",", "and", "is", "likely", "to", "be", "the", "result", "of", "preferential", "prescribing", "and", ",", "thus", ",", "confounding", "."]], "ner": [[[12, 13, "Chemical"], [41, 42, "Chemical"], [44, 44, "Chemical"], [59, 59, "Chemical"], [100, 100, "Chemical"], [218, 218, "Chemical"], [242, 242, "Chemical"], [275, 275, "Chemical"], [299, 299, "Chemical"], [335, 335, "Chemical"], [348, 348, "Chemical"], [394, 394, "Chemical"], [405, 405, "Chemical"], [440, 440, "Chemical"], [479, 479, "Chemical"], [520, 520, "Chemical"], [584, 584, "Chemical"], [7, 8, "Disease"], [30, 31, "Disease"], [33, 33, "Disease"], [98, 98, "Disease"], [199, 199, "Disease"], [212, 212, "Disease"], [234, 234, "Disease"], [324, 324, "Disease"], [342, 342, "Disease"], [377, 377, "Disease"], [428, 428, "Disease"], [468, 468, "Disease"], [492, 492, "Disease"], [529, 529, "Disease"], [51, 51, "Chemical"], [64, 64, "Chemical"], [487, 487, "Chemical"], [568, 568, "Chemical"], [52, 52, "Chemical"], [507, 507, "Chemical"], [54, 54, "Chemical"], [498, 498, "Chemical"], [509, 509, "Chemical"], [544, 544, "Chemical"], [617, 617, "Chemical"], [332, 332, "Chemical"], [502, 502, "Chemical"], [513, 513, "Chemical"], [548, 548, "Chemical"], [615, 615, "Chemical"], [166, 169, "Disease"], [171, 172, "Disease"], [354, 357, "Disease"], [367, 368, "Disease"], [362, 362, "Disease"]]], "relations": [[[12, 13, 7, 8, "CID"], [12, 13, 30, 31, "CID"], [12, 13, 33, 33, "CID"], [12, 13, 98, 98, "CID"], [12, 13, 199, 199, "CID"], [12, 13, 212, 212, "CID"], [12, 13, 234, 234, "CID"], [12, 13, 324, 324, "CID"], [12, 13, 342, 342, "CID"], [12, 13, 377, 377, "CID"], [12, 13, 428, 428, "CID"], [12, 13, 468, 468, "CID"], [12, 13, 492, 492, "CID"], [12, 13, 529, 529, "CID"], [41, 42, 7, 8, "CID"], [41, 42, 30, 31, "CID"], [41, 42, 33, 33, "CID"], [41, 42, 98, 98, "CID"], [41, 42, 199, 199, "CID"], [41, 42, 212, 212, "CID"], [41, 42, 234, 234, "CID"], [41, 42, 324, 324, "CID"], [41, 42, 342, 342, "CID"], [41, 42, 377, 377, "CID"], [41, 42, 428, 428, "CID"], [41, 42, 468, 468, "CID"], [41, 42, 492, 492, "CID"], [41, 42, 529, 529, "CID"], [44, 44, 7, 8, "CID"], [44, 44, 30, 31, "CID"], [44, 44, 33, 33, "CID"], [44, 44, 98, 98, "CID"], [44, 44, 199, 199, "CID"], [44, 44, 212, 212, "CID"], [44, 44, 234, 234, "CID"], [44, 44, 324, 324, "CID"], [44, 44, 342, 342, "CID"], [44, 44, 377, 377, "CID"], [44, 44, 428, 428, "CID"], [44, 44, 468, 468, "CID"], [44, 44, 492, 492, "CID"], [44, 44, 529, 529, "CID"], [59, 59, 7, 8, "CID"], [59, 59, 30, 31, "CID"], [59, 59, 33, 33, "CID"], [59, 59, 98, 98, "CID"], [59, 59, 199, 199, "CID"], [59, 59, 212, 212, "CID"], [59, 59, 234, 234, "CID"], [59, 59, 324, 324, "CID"], [59, 59, 342, 342, "CID"], [59, 59, 377, 377, "CID"], [59, 59, 428, 428, "CID"], [59, 59, 468, 468, "CID"], [59, 59, 492, 492, "CID"], [59, 59, 529, 529, "CID"], [100, 100, 7, 8, "CID"], [100, 100, 30, 31, "CID"], [100, 100, 33, 33, "CID"], [100, 100, 98, 98, "CID"], [100, 100, 199, 199, "CID"], [100, 100, 212, 212, "CID"], [100, 100, 234, 234, "CID"], [100, 100, 324, 324, "CID"], [100, 100, 342, 342, "CID"], [100, 100, 377, 377, "CID"], [100, 100, 428, 428, "CID"], [100, 100, 468, 468, "CID"], [100, 100, 492, 492, "CID"], [100, 100, 529, 529, "CID"], [218, 218, 7, 8, "CID"], [218, 218, 30, 31, "CID"], [218, 218, 33, 33, "CID"], [218, 218, 98, 98, "CID"], [218, 218, 199, 199, "CID"], [218, 218, 212, 212, "CID"], [218, 218, 234, 234, "CID"], [218, 218, 324, 324, "CID"], [218, 218, 342, 342, "CID"], [218, 218, 377, 377, "CID"], [218, 218, 428, 428, "CID"], [218, 218, 468, 468, "CID"], [218, 218, 492, 492, "CID"], [218, 218, 529, 529, "CID"], [242, 242, 7, 8, "CID"], [242, 242, 30, 31, "CID"], [242, 242, 33, 33, "CID"], [242, 242, 98, 98, "CID"], [242, 242, 199, 199, "CID"], [242, 242, 212, 212, "CID"], [242, 242, 234, 234, "CID"], [242, 242, 324, 324, "CID"], [242, 242, 342, 342, "CID"], [242, 242, 377, 377, "CID"], [242, 242, 428, 428, "CID"], [242, 242, 468, 468, "CID"], [242, 242, 492, 492, "CID"], [242, 242, 529, 529, "CID"], [275, 275, 7, 8, "CID"], [275, 275, 30, 31, "CID"], [275, 275, 33, 33, "CID"], [275, 275, 98, 98, "CID"], [275, 275, 199, 199, "CID"], [275, 275, 212, 212, "CID"], [275, 275, 234, 234, "CID"], [275, 275, 324, 324, "CID"], [275, 275, 342, 342, "CID"], [275, 275, 377, 377, "CID"], [275, 275, 428, 428, "CID"], [275, 275, 468, 468, "CID"], [275, 275, 492, 492, "CID"], [275, 275, 529, 529, "CID"], [299, 299, 7, 8, "CID"], [299, 299, 30, 31, "CID"], [299, 299, 33, 33, "CID"], [299, 299, 98, 98, "CID"], [299, 299, 199, 199, "CID"], [299, 299, 212, 212, "CID"], [299, 299, 234, 234, "CID"], [299, 299, 324, 324, "CID"], [299, 299, 342, 342, "CID"], [299, 299, 377, 377, "CID"], [299, 299, 428, 428, "CID"], [299, 299, 468, 468, "CID"], [299, 299, 492, 492, "CID"], [299, 299, 529, 529, "CID"], [335, 335, 7, 8, "CID"], [335, 335, 30, 31, "CID"], [335, 335, 33, 33, "CID"], [335, 335, 98, 98, "CID"], [335, 335, 199, 199, "CID"], [335, 335, 212, 212, "CID"], [335, 335, 234, 234, "CID"], [335, 335, 324, 324, "CID"], [335, 335, 342, 342, "CID"], [335, 335, 377, 377, "CID"], [335, 335, 428, 428, "CID"], [335, 335, 468, 468, "CID"], [335, 335, 492, 492, "CID"], [335, 335, 529, 529, "CID"], [348, 348, 7, 8, "CID"], [348, 348, 30, 31, "CID"], [348, 348, 33, 33, "CID"], [348, 348, 98, 98, "CID"], [348, 348, 199, 199, "CID"], [348, 348, 212, 212, "CID"], [348, 348, 234, 234, "CID"], [348, 348, 324, 324, "CID"], [348, 348, 342, 342, "CID"], [348, 348, 377, 377, "CID"], [348, 348, 428, 428, "CID"], [348, 348, 468, 468, "CID"], [348, 348, 492, 492, "CID"], [348, 348, 529, 529, "CID"], [394, 394, 7, 8, "CID"], [394, 394, 30, 31, "CID"], [394, 394, 33, 33, "CID"], [394, 394, 98, 98, "CID"], [394, 394, 199, 199, "CID"], [394, 394, 212, 212, "CID"], [394, 394, 234, 234, "CID"], [394, 394, 324, 324, "CID"], [394, 394, 342, 342, "CID"], [394, 394, 377, 377, "CID"], [394, 394, 428, 428, "CID"], [394, 394, 468, 468, "CID"], [394, 394, 492, 492, "CID"], [394, 394, 529, 529, "CID"], [405, 405, 7, 8, "CID"], [405, 405, 30, 31, "CID"], [405, 405, 33, 33, "CID"], [405, 405, 98, 98, "CID"], [405, 405, 199, 199, "CID"], [405, 405, 212, 212, "CID"], [405, 405, 234, 234, "CID"], [405, 405, 324, 324, "CID"], [405, 405, 342, 342, "CID"], [405, 405, 377, 377, "CID"], [405, 405, 428, 428, "CID"], [405, 405, 468, 468, "CID"], [405, 405, 492, 492, "CID"], [405, 405, 529, 529, "CID"], [440, 440, 7, 8, "CID"], [440, 440, 30, 31, "CID"], [440, 440, 33, 33, "CID"], [440, 440, 98, 98, "CID"], [440, 440, 199, 199, "CID"], [440, 440, 212, 212, "CID"], [440, 440, 234, 234, "CID"], [440, 440, 324, 324, "CID"], [440, 440, 342, 342, "CID"], [440, 440, 377, 377, "CID"], [440, 440, 428, 428, "CID"], [440, 440, 468, 468, "CID"], [440, 440, 492, 492, "CID"], [440, 440, 529, 529, "CID"], [479, 479, 7, 8, "CID"], [479, 479, 30, 31, "CID"], [479, 479, 33, 33, "CID"], [479, 479, 98, 98, "CID"], [479, 479, 199, 199, "CID"], [479, 479, 212, 212, "CID"], [479, 479, 234, 234, "CID"], [479, 479, 324, 324, "CID"], [479, 479, 342, 342, "CID"], [479, 479, 377, 377, "CID"], [479, 479, 428, 428, "CID"], [479, 479, 468, 468, "CID"], [479, 479, 492, 492, "CID"], [479, 479, 529, 529, "CID"], [520, 520, 7, 8, "CID"], [520, 520, 30, 31, "CID"], [520, 520, 33, 33, "CID"], [520, 520, 98, 98, "CID"], [520, 520, 199, 199, "CID"], [520, 520, 212, 212, "CID"], [520, 520, 234, 234, "CID"], [520, 520, 324, 324, "CID"], [520, 520, 342, 342, "CID"], [520, 520, 377, 377, "CID"], [520, 520, 428, 428, "CID"], [520, 520, 468, 468, "CID"], [520, 520, 492, 492, "CID"], [520, 520, 529, 529, "CID"], [584, 584, 7, 8, "CID"], [584, 584, 30, 31, "CID"], [584, 584, 33, 33, "CID"], [584, 584, 98, 98, "CID"], [584, 584, 199, 199, "CID"], [584, 584, 212, 212, "CID"], [584, 584, 234, 234, "CID"], [584, 584, 324, 324, "CID"], [584, 584, 342, 342, "CID"], [584, 584, 377, 377, "CID"], [584, 584, 428, 428, "CID"], [584, 584, 468, 468, "CID"], [584, 584, 492, 492, "CID"], [584, 584, 529, 529, "CID"]]], "clusters": [], "translated": "与各种<0>口服避孕药</0>相关的<17>静脉血栓栓塞</17>风险的基于人群的研究。背景：自1995年12月以来发表的四项研究报告说，使用<1>口服避孕药</1>的女性<18>静脉血栓栓塞症</18>（<19>VTE</19>）的发生率较高。其中含有第三代<31>孕激素</31>的<2>OCs</2>，如<35>孕二烯酮</35>或<37>去氧孕烯</37>，比包含<32>第二代孕激素</32>的OCs使用者<3>更高</3>。然而，这些研究设计中的混杂和偏倚可能影响了研究结果。我们研究的目的是重新检查<20> VTE </20>和<4> OC </4>使用之间的风险关联，在不同的研究设计和分析中避免一些偏差和混淆较早的研究。方法：我们使用了英国143家全科诊所患者的计算机记录。该研究基于1941年至1981年间出生的约540,000名女性的医疗记录。所有在研究期间被诊断为<47>深静脉血栓形成</47>，<48>静脉血栓形成</48>未另行说明或肺栓塞的女性，以及接受过抗凝血剂治疗的女性均被纳入确定为<21> VTE </21>的潜在病例。我们进行了队列分析以估计和比较主要<5> OC </5>制剂使用者中<22> VTE </22>的发生率，并进行了巢式病例对照研究以计算与使用不同类型的<6> OC </6>相关的<23>VTE</23>的比值比，在针对潜在的混杂因素进行调整后。在病例对照研究中，我们根据确切的出生年份、实践和目前使用<7>OCs</7>将病例与对照进行匹配。我们使用了多元逻辑回归模型，其中包括体重指数、周期数、事件发生后3个月内开出的<8>OC</8>类型变化、既往妊娠和并发疾病。调查结果：85名女性符合<24>VTE</24>的纳入标准，其中两名是<42>孕激素</42>的使用者-仅<9>口服避孕药</9>。在83例<25> VTE </25>与联合使用<10> OCs </10>相关的病例中，43例记录为<49>深静脉血栓形成</49>，35例记录为肺<51>血栓形成</51>和5个作为<50>静脉血栓形成</50>未另行说明。在当前<11> OC </11>的使用者中，<26>VTE</26>的粗发生率为每10,000名女性年龄为4.10，第二代<12>OCs</12>用户为3.10，第三代准备用户为4.96。年龄调整后，使用第三代相对于第二代<13> OCs </13>的<27>VTE </27>比率为1.68（95％置信区间1.04-2.75）。逻辑回归显示，第三代和第二代<14> OCs </14>使用者的<28>VTE </28>风险没有显着差异。在第三代<33>孕激素</33>的使用者中，使用20g<43>炔雌醇</43>的<38>去氧孕烯</38>的使用者发生<29>VTE</29>的风险与<36>孕二烯酮</36>或<39>去氧孕烯</39>和30g<44>炔雌醇</44>的使用者相比更高。以所有第二代<15>OCs</15>为基准，<30>VTE</30>的比值比分别为3.49（1.21-10.12）和1.18（0.66-2.17）的<40>去氧孕烯</40>加20g<45>炔雌醇</45>和其他第三代<34>孕激素</34>。解释：与第二代产品相比，先前报道的与第三代<16> OCs </16>相关的比值比增加可能是年龄残留混杂的结果。含有20μg<46>炔雌醇</46>和<41>去氧孕烯</41>的产品与30 μg产品相比的优势比增加在生物学上是不可信的，并且可能是优先处方的结果，从而导致混淆。", "revised": true}
{"doc_key": "9725303", "sentences": [["Nonopaque", "crystal", "deposition", "causing", "ureteric", "obstruction", "in", "patients", "with", "HIV", "undergoing", "indinavir", "therapy", ".", "OBJECTIVE", ":", "We", "describe", "the", "unique", "CT", "features", "of", "ureteric", "calculi", "in", "six", "HIV", "-", "infected", "patients", "receiving", "indinavir", ",", "the", "most", "commonly", "used", "HIV", "protease", "inhibitor", ",", "which", "is", "associated", "with", "an", "increased", "incidence", "of", "urolithiasis", ".", "CONCLUSION", ":", "Ureteric", "obstruction", "caused", "by", "precipitated", "indinavir", "crystals", "may", "be", "difficult", "to", "diagnose", "with", "unenhanced", "CT", ".", "The", "calculi", "are", "not", "opaque", ",", "and", "secondary", "signs", "of", "obstruction", "may", "be", "absent", "or", "minimal", "and", "should", "be", "sought", "carefully", ".", "Images", "may", "need", "to", "be", "obtained", "using", "i", ".", "v", ".", "contrast", "material", "to", "enable", "diagnosis", "of", "ureteric", "stones", "or", "obstruction", "in", "patients", "with", "HIV", "infection", "who", "receive", "indinavir", "therapy", "."]], "ner": [[[11, 11, "Chemical"], [32, 32, "Chemical"], [59, 59, "Chemical"], [120, 120, "Chemical"], [23, 24, "Disease"], [109, 112, "Disease"], [4, 5, "Disease"], [54, 55, "Disease"], [27, 29, "Disease"], [116, 117, "Disease"], [50, 50, "Disease"]]], "relations": [[[11, 11, 23, 24, "CID"], [11, 11, 109, 112, "CID"], [32, 32, 23, 24, "CID"], [32, 32, 109, 112, "CID"], [59, 59, 23, 24, "CID"], [59, 59, 109, 112, "CID"], [120, 120, 23, 24, "CID"], [120, 120, 109, 112, "CID"]]], "clusters": [], "translated": "不透明晶体沉积导致 <6>输尿管阻塞</6> 在接受 <0>茚地那韦</0> 治疗的 HIV 患者。目的：我们描述了6名 <8>HIV感染者</8> 接受 <1>茚地那韦</1> 治疗的患者中 <4>输尿管结石</4> 的独特 CT 特征，这是最常用的 HIV 蛋白酶抑制剂，它与 <10>尿石症</10> 的发病率增加有关。结论：<7>输尿管梗阻</7> 引起的<2>茚地那韦</2> 结晶析出，可能难以用非增强 CT 进行诊断。结石不是不透明的，阻塞的继发征象可能不存在或很少，应仔细寻找。可能需要使用造影剂获取图像以诊断接受 <3>茚地那韦</3> 治疗的 <9>HIV感染</9> 患者的 <5>输尿管结石或梗阻</5>。", "revised": true}
{"doc_key": "9323412", "sentences": [["Acute", "severe", "depression", "following", "peri", "-", "operative", "ondansetron", ".", "A", "41", "-", "year", "-", "old", "woman", "with", "a", "strong", "history", "of", "postoperative", "nausea", "and", "vomiting", "presented", "for", "abdominal", "hysterectomy", "3", "months", "after", "a", "previous", "anaesthetic", "where", "ondansetron", "prophylaxis", "had", "been", "used", ".", "She", "had", "developed", "a", "severe", "acute", "major", "depression", "disorder", "almost", "immediately", "thereafter", ",", "possibly", "related", "to", "the", "use", "of", "a", "serotonin", "antagonist", ".", "Nine", "years", "before", "she", "had", "experienced", "a", "self", "-", "limited", "puerperal", "depressive", "episode", ".", "Anaesthesia", "with", "a", "propofol", "infusion", "and", "avoidance", "of", "serotonin", "antagonists", "provided", "a", "nausea", "-", "free", "postoperative", "course", "without", "exacerbation", "of", "the", "depression", "disorder", "."]], "ner": [[[7, 7, "Chemical"], [36, 36, "Chemical"], [48, 50, "Disease"], [2, 2, "Disease"], [76, 77, "Disease"], [100, 101, "Disease"], [62, 62, "Chemical"], [87, 87, "Chemical"], [82, 82, "Chemical"], [21, 24, "Disease"], [91, 91, "Disease"]]], "relations": [[[7, 7, 48, 50, "CID"], [36, 36, 48, 50, "CID"]]], "clusters": [], "translated": "围手术期 <0>昂丹司琼</0> 后出现急性重度<3>抑郁症</3>。一名41岁的女性，有<9>术后恶心和呕吐</9>的严重病史，在之前使用<1>昂丹司琼</1>进行预防性麻醉后3个月接受了经腹子宫切除术。此后几乎立即，她患上了严重的急性<2>重度抑郁症</2>，可能与使用<6>血清素拮抗剂</6>有关。九年前，她经历了一次自限性<4>产褥期抑郁发作</4>。使用<8>丙泊酚</8>输注麻醉并避免使用<7>血清素拮抗剂</7>可提供<10>恶心</10>-无术后病程，且不会加重<5>抑郁症</5>。", "revised": true}
{"doc_key": "9759693", "sentences": [["Ischemic", "colitis", "and", "sumatriptan", "use", ".", "Sumatriptan", "succinate", ",", "a", "serotonin", "-", "1", "(", "5", "-", "hydroxytryptamine", "-", "1", ")", "receptor", "agonist", ",", "is", "an", "antimigraine", "drug", "that", "is", "reported", "to", "act", "by", "selectively", "constricting", "intracranial", "arteries", ".", "Recently", ",", "vasopressor", "responses", "that", "are", "distinct", "from", "the", "cranial", "circulation", "have", "been", "demonstrated", "to", "occur", "in", "the", "systemic", ",", "pulmonary", ",", "and", "coronary", "circulations", ".", "Cases", "have", "been", "published", "of", "coronary", "vasospasm", ",", "myocardial", "ischemia", ",", "and", "myocardial", "infarction", "occurring", "after", "sumatriptan", "use", ".", "We", "report", "on", "the", "development", "of", "8", "serious", "cases", "of", "ischemic", "colitis", "in", "patients", "with", "migraine", "treated", "with", "sumatriptan", "."]], "ner": [[[3, 3, "Chemical"], [6, 7, "Chemical"], [80, 80, "Chemical"], [101, 101, "Chemical"], [0, 1, "Disease"], [93, 94, "Disease"], [10, 10, "Chemical"], [14, 16, "Chemical"], [69, 70, "Disease"], [72, 73, "Disease"], [76, 77, "Disease"], [98, 98, "Disease"]]], "relations": [[[3, 3, 0, 1, "CID"], [3, 3, 93, 94, "CID"], [6, 7, 0, 1, "CID"], [6, 7, 93, 94, "CID"], [80, 80, 0, 1, "CID"], [80, 80, 93, 94, "CID"], [101, 101, 0, 1, "CID"], [101, 101, 93, 94, "CID"]]], "clusters": [], "translated": "<4>缺血性结肠炎</4>和<0>舒马普坦</0>使用。 <1>舒马普坦琥珀酸盐</1>，是一种<6>血清素</6>-1 (<7>5-羟色胺</7>-1) 受体激动剂，用于治疗偏头痛，其通过有选择性地收缩颅内动脉发挥作用。最近报道发现该药物除颅内动脉外，在全身、肺和冠状动脉循环中还有引起血管加压反应的效应。已有病例发表，使用<2>舒马普坦</2>后出现<8>冠状动脉痉挛</8>、<9>心肌缺血</9>和<10>心肌梗塞</10>。我们报告了 8 例<11>偏头痛</11>患者，在使用<3>舒马普坦</3>治疗期间出现 <5>缺血性结肠炎</5> 的情况。", "revised": true}
{"doc_key": "7661171", "sentences": [["The", "dose", "-", "dependent", "effect", "of", "misoprostol", "on", "indomethacin", "-", "induced", "renal", "dysfunction", "in", "well", "compensated", "cirrhosis", ".", "Misoprostol", "(", "200", "micrograms", ")", "has", "been", "shown", "to", "acutely", "counteract", "the", "indomethacin", "-", "induced", "renal", "dysfunction", "in", "well", "compensated", "cirrhotic", "patients", ".", "The", "aim", "of", "this", "study", "was", "to", "determine", "if", "the", "prophylactic", "value", "of", "misoprostol", "was", "dose", "-", "dependent", ".", "Parameters", "of", "renal", "hemodynamics", "and", "tubular", "sodium", "and", "water", "handling", "were", "assessed", "by", "clearance", "techniques", "in", "26", "well", "compensated", "cirrhotic", "patients", "before", "and", "after", "an", "oral", "combination", "of", "50", "mg", "of", "indomethacin", "and", "various", "doses", "of", "misoprostol", ".", "The", "200", "-", "micrograms", "dose", "was", "able", "to", "totally", "abolish", "the", "deleterious", "renal", "effects", "of", "indomethacin", ",", "whereas", "the", "800", "-", "micrograms", "dose", "resulted", "in", "significant", "worsening", "of", "renal", "hemodynamics", "and", "sodium", "retention", ".", "These", "changes", "were", "maximal", "in", "the", "hour", "immediately", "after", "medications", "and", "slowly", "returned", "toward", "base", "-", "line", "levels", "thereafter", ".", "These", "results", "suggest", "that", "the", "renal", "protective", "effects", "of", "misoprostol", "is", "dose", "-", "dependent", ".", "However", ",", "until", "this", "apparent", "ability", "of", "200", "micrograms", "of", "misoprostol", "to", "prevent", "the", "adverse", "effects", "of", "indomethacin", "on", "renal", "function", "is", "confirmed", "with", "chronic", "frequent", "dosing", ",", "it", "would", "be", "prudent", "to", "avoid", "nonsteroidal", "anti", "-", "inflammatory", "therapy", "in", "patients", "with", "cirrhosis", "."]], "ner": [[[8, 8, "Chemical"], [30, 30, "Chemical"], [91, 91, "Chemical"], [113, 113, "Chemical"], [184, 184, "Chemical"], [11, 12, "Disease"], [33, 34, "Disease"], [6, 6, "Chemical"], [18, 18, "Chemical"], [54, 54, "Chemical"], [96, 96, "Chemical"], [161, 161, "Chemical"], [177, 177, "Chemical"], [16, 16, "Disease"], [38, 38, "Disease"], [79, 79, "Disease"], [209, 209, "Disease"], [66, 66, "Chemical"], [129, 129, "Chemical"]]], "relations": [[[8, 8, 11, 12, "CID"], [8, 8, 33, 34, "CID"], [30, 30, 11, 12, "CID"], [30, 30, 33, 34, "CID"], [91, 91, 11, 12, "CID"], [91, 91, 33, 34, "CID"], [113, 113, 11, 12, "CID"], [113, 113, 33, 34, "CID"], [184, 184, 11, 12, "CID"], [184, 184, 33, 34, "CID"]]], "clusters": [], "translated": "<7>米索前列醇</7>对<0>吲哚美辛</0>诱导的<5>肾功能不全</5>在代偿良好的<13>肝硬化</13>中的剂量依赖性影响。 <8>米索前列醇</8>（200微克）已被证明可以在代偿良好的<14>肝硬化</14>患者中迅速抵消<1>吲哚美辛</1>诱导的<6>肾功能障碍</6>。本研究的目的是确定<9>米索前列醇</9>的预防价值是否具有剂量依赖性。参数的肾脏血液动力学和肾管<17>钠</17>和水的处理通过清除技术在 26 名代偿良好的<15>肝硬化</15>患者之前和之后评估口服组合 50 毫克<2>吲哚美辛</2>和各种剂量的<10>米索前列醇</10>。200微克的剂量能够完全消除<3>吲哚美辛</3>对肾脏的有害影响，而800微克的剂量导致肾脏血液动力学和<18>钠</18>潴留的显着恶化。这些变化在服药后的一小时内达到最大，然后慢慢恢复到基线水平。这些结果表明<11>米索前列醇</11>的肾脏保护作用具有剂量依赖性。然而，在长期频繁给药证实200微克的<12>米索前列醇</12>预防<4>吲哚美辛</4>对肾脏功能的不良影响之前，避免给<16>肝硬化</16>患者使用非甾体消炎药是谨慎的做法。", "revised": true}
{"doc_key": "9538487", "sentences": [["Hyperosmolar", "nonketotic", "coma", "precipitated", "by", "lithium", "-", "induced", "nephrogenic", "diabetes", "insipidus", ".", "A", "45", "-", "year", "-", "old", "man", ",", "with", "a", "10", "-", "year", "history", "of", "manic", "depression", "treated", "with", "lithium", ",", "was", "admitted", "with", "hyperosmolar", ",", "nonketotic", "coma", ".", "He", "gave", "a", "five", "-", "year", "history", "of", "polyuria", "and", "polydipsia", ",", "during", "which", "time", "urinalysis", "had", "been", "negative", "for", "glucose", ".", "After", "recovery", "from", "hyperglycaemia", ",", "he", "remained", "polyuric", "despite", "normal", "blood", "glucose", "concentrations", ";", "water", "deprivation", "testing", "indicated", "nephrogenic", "diabetes", "insipidus", ",", "likely", "to", "be", "lithium", "-", "induced", ".", "We", "hypothesize", "that", "when", "this", "man", "developed", "type", "2", "diabetes", ",", "chronic", "polyuria", "due", "to", "nephrogenic", "diabetes", "insipidus", "was", "sufficient", "to", "precipitate", "hyperosmolar", "dehydration", "."]], "ner": [[[5, 5, "Chemical"], [31, 31, "Chemical"], [88, 88, "Chemical"], [0, 2, "Disease"], [36, 39, "Disease"], [8, 10, "Disease"], [81, 83, "Disease"], [107, 109, "Disease"], [49, 49, "Disease"], [70, 70, "Disease"], [104, 104, "Disease"], [61, 61, "Chemical"], [74, 74, "Chemical"], [27, 28, "Disease"], [51, 51, "Disease"], [99, 101, "Disease"], [115, 115, "Disease"]]], "relations": [[[5, 5, 0, 2, "CID"], [5, 5, 36, 39, "CID"], [31, 31, 0, 2, "CID"], [31, 31, 36, 39, "CID"], [88, 88, 0, 2, "CID"], [88, 88, 36, 39, "CID"], [5, 5, 8, 10, "CID"], [5, 5, 81, 83, "CID"], [5, 5, 107, 109, "CID"], [31, 31, 8, 10, "CID"], [31, 31, 81, 83, "CID"], [31, 31, 107, 109, "CID"], [88, 88, 8, 10, "CID"], [88, 88, 81, 83, "CID"], [88, 88, 107, 109, "CID"], [5, 5, 49, 49, "CID"], [5, 5, 70, 70, "CID"], [5, 5, 104, 104, "CID"], [31, 31, 49, 49, "CID"], [31, 31, 70, 70, "CID"], [31, 31, 104, 104, "CID"], [88, 88, 49, 49, "CID"], [88, 88, 70, 70, "CID"], [88, 88, 104, 104, "CID"]]], "clusters": [], "translated": "<3>高渗性非酮症昏迷</3>由<0>锂</0>诱发<5>肾源性尿崩症</5>。一名45岁的男性，有10年的<13>躁狂抑郁症</13>病史，接受过<1>锂</1>治疗，因<4>高渗性非酮症昏迷</4>入院。他有5年的<8>多尿</8>和<14>多饮</14>病史，在此期间尿液分析呈阴性<11>葡萄糖</11>。从高血糖恢复后，尽管血液<12>葡萄糖</12>浓度正常，他仍然<9>多尿</9>；禁水试验表明<6>肾性尿崩症</6>，可能是<2>锂</2>诱发的。我们假设当这个人患上<15>2型糖尿病</15>时，由于<7>肾源性尿崩症</7>引起的慢性<10>多尿</10>足以导致高渗性<16>脱水</16>。", "revised": true}
{"doc_key": "9782254", "sentences": [["Pallidotomy", "with", "the", "gamma", "knife", ":", "a", "positive", "experience", ".", "51", "patients", "with", "medically", "refractory", "Parkinson", "'s", "disease", "underwent", "stereotactic", "posteromedial", "pallidotomy", "between", "August", "1993", "and", "February", "1997", "for", "treatment", "of", "bradykinesia", ",", "rigidity", ",", "and", "L", "-", "DOPA", "-", "induced", "dyskinesias", ".", "In", "29", "patients", ",", "the", "pallidotomies", "were", "performed", "with", "the", "Leksell", "Gamma", "Knife", "and", "in", "22", "they", "were", "performed", "with", "the", "standard", "radiofrequency", "(", "RF", ")", "method", ".", "Clinical", "assessment", "as", "well", "as", "blinded", "ratings", "of", "Unified", "Parkinson", "'s", "Disease", "Rating", "Scale", "(", "UPDRS", ")", "scores", "were", "carried", "out", "pre", "-", "and", "postoperatively", ".", "Mean", "follow", "-", "up", "time", "is", "20", ".", "6", "months", "(", "range", "6", "-", "48", ")", "and", "all", "except", "4", "patients", "have", "been", "followed", "more", "than", "one", "year", ".", "85", "percent", "of", "patients", "with", "dyskinesias", "were", "relieved", "of", "symptoms", ",", "regardless", "of", "whether", "the", "pallidotomies", "were", "performed", "with", "the", "Gamma", "Knife", "or", "radiofrequency", "methods", ".", "About", "2", "/", "3", "of", "the", "patients", "in", "both", "Gamma", "Knife", "and", "radiofrequency", "groups", "showed", "improvements", "in", "bradykinesia", "and", "rigidity", ",", "although", "when", "considered", "as", "a", "group", "neither", "the", "Gamma", "Knife", "nor", "the", "radiofrequency", "group", "showed", "statistically", "significant", "improvements", "in", "UPDRS", "scores", ".", "One", "patient", "in", "the", "Gamma", "Knife", "group", "(", "3", ".", "4", "%", ")", "developed", "a", "homonymous", "hemianopsia", "9", "months", "following", "treatment", "and", "5", "patients", "(", "27", ".", "7", "%", ")", "in", "the", "radiofrequency", "group", "became", "transiently", "confused", "postoperatively", ".", "No", "other", "complications", "were", "seen", ".", "Gamma", "Knife", "pallidotomy", "is", "as", "effective", "as", "radiofrequency", "pallidotomy", "in", "controlling", "certain", "of", "the", "symptoms", "of", "Parkinson", "'s", "disease", ".", "It", "may", "be", "the", "only", "practical", "technique", "available", "in", "certain", "patients", ",", "such", "as", "those", "who", "take", "anticoagulants", ",", "have", "bleeding", "diatheses", "or", "serious", "systemic", "medical", "illnesses", ".", "It", "is", "a", "viable", "option", "for", "other", "patients", "as", "well", "."]], "ner": [[[36, 38, "Chemical"], [41, 41, "Disease"], [131, 131, "Disease"], [15, 17, "Disease"], [80, 82, "Disease"], [256, 258, "Disease"], [31, 31, "Disease"], [169, 169, "Disease"], [33, 33, "Disease"], [171, 171, "Disease"], [210, 211, "Disease"], [280, 280, "Disease"]]], "relations": [[[36, 38, 41, 41, "CID"], [36, 38, 131, 131, "CID"]]], "clusters": [], "translated": "用伽玛刀进行苍白球切开术：一次积极的经历。1993年8月至1997年2月期间，51名难治性<3>帕金森病</3>患者接受立体定向后内侧苍白球切开术治疗<6>运动迟缓</6>、<8>强直</8>和<0>L-DOPA</0>-诱发<1>运动障碍</1>。29名患者使用Leksell伽玛刀进行苍白球切开术，22名患者使用标准射频(RF)方法进行。术前和术后进行临床评估和统一<4>帕金森病</4>评定量表(UPDRS)评分的盲法评分。平均随访时间为20.6个月(范围6-48)，除4名患者外，所有患者的随访均超过一年。85%的<2>运动障碍</2>患者症状得到缓解，无论苍白球切开术是用伽玛刀还是射频方法进行的。伽玛刀组和射频组中约有2/3的患者在<7>运动迟缓</7>和<9>强直</9>方面有所改善，尽管当作为一个组考虑时，伽玛刀组和射频组均未显示UPDRS分数在统计上有显着改善。伽玛刀组1例(3.4%)在治疗后9个月出现<10>同向偏盲</10>，射频组5例(27.7%)术后出现短暂意识模糊。未见其他并发症。伽玛刀苍白球切开术在控制<5>帕金森病</5>的某些症状方面与射频苍白球切开术一样有效。它可能是某些患者唯一可用的实用技术，例如服用抗凝血剂、有<11>出血</11>体质或有严重全身性疾病的患者。对于其他患者来说，这也是一个可行的选择。", "revised": true}
{"doc_key": "2767010", "sentences": [["Pharmacology", "of", "ACC", "-", "9653", "(", "phenytoin", "prodrug", ")", ".", "ACC", "-", "9653", ",", "the", "disodium", "phosphate", "ester", "of", "3", "-", "hydroxymethyl", "-", "5", ",", "5", "-", "diphenylhydantoin", ",", "is", "a", "prodrug", "of", "phenytoin", "with", "advantageous", "physicochemical", "properties", ".", "ACC", "-", "9653", "is", "rapidly", "converted", "enzymatically", "to", "phenytoin", "in", "vivo", ".", "ACC", "-", "9653", "and", "phenytoin", "sodium", "have", "equivalent", "anticonvulsant", "activity", "against", "seizures", "induced", "by", "maximal", "electroshock", "(", "MES", ")", "in", "mice", "following", "i", ".", "p", ".", ",", "oral", ",", "or", "i", ".", "v", ".", "administration", ".", "The", "ED50", "doses", "were", "16", "mg", "/", "kg", "for", "i", ".", "v", ".", "ACC", "-", "9653", "and", "8", "mg", "/", "kg", "for", "i", ".", "v", ".", "phenytoin", "sodium", ".", "ACC", "-", "9653", "and", "phenytoin", "sodium", "have", "similar", "antiarrhythmic", "activity", "against", "ouabain", "-", "induced", "ventricular", "tachycardia", "in", "anesthetized", "dogs", ".", "The", "total", "doses", "of", "ACC", "-", "9653", "or", "phenytoin", "sodium", "necessary", "to", "convert", "the", "arrhythmia", "to", "a", "normal", "sinus", "rhythm", "were", "24", "+", "/", "-", "6", "and", "14", "+", "/", "-", "3", "mg", "/", "kg", ",", "respectively", ".", "Only", "phenytoin", "sodium", "displayed", "in", "vitro", "antiarrhythmic", "activity", "against", "strophanthidin", "-", "induced", "arrhythmias", "in", "guinea", "pig", "right", "atria", ".", "In", "anesthetized", "dogs", ",", "a", "high", "dose", "of", "ACC", "-", "9653", "(", "31", "mg", "/", "kg", ")", "was", "infused", "over", "15", ",", "20", ",", "and", "30", "min", "and", "the", "responses", "were", "compared", "to", "an", "equimolar", "dose", "of", "phenytoin", "sodium", "(", "21", "mg", "/", "kg", ")", ".", "The", "ACC", "-", "9653", "and", "phenytoin", "sodium", "treatments", "produced", "similar", "marked", "reductions", "in", "diastolic", "blood", "pressure", "and", "contractile", "force", "(", "LVdP", "/", "dt", ")", ".", "The", "maximum", "effects", "of", "each", "treatment", "occurred", "at", "the", "time", "of", "maximum", "phenytoin", "sodium", "levels", ".", "Acute", "toxicity", "studies", "of", "ACC", "-", "9653", "and", "phenytoin", "sodium", "were", "carried", "out", "in", "mice", ",", "rats", ",", "rabbits", ",", "and", "dogs", "by", "i", ".", "v", ".", ",", "i", ".", "m", ".", ",", "and", "i", ".", "p", ".", "routes", "of", "administration", ".", "The", "systemic", "toxic", "signs", "of", "both", "agents", "were", "similar", "and", "occurred", "at", "approximately", "equivalent", "doses", ".", "Importantly", ",", "the", "local", "irritation", "of", "ACC", "-", "9653", "was", "markedly", "less", "than", "phenytoin", "sodium", "following", "i", ".", "m", ".", "administration", ".", "(", "ABSTRACT", "TRUNCATED", "AT", "250", "WORDS", ")"]], "ner": [[[127, 127, "Chemical"], [130, 131, "Disease"], [183, 183, "Chemical"], [150, 150, "Disease"], [186, 186, "Disease"], [2, 4, "Chemical"], [10, 12, "Chemical"], [39, 41, "Chemical"], [51, 53, "Chemical"], [55, 56, "Chemical"], [100, 102, "Chemical"], [113, 114, "Chemical"], [116, 118, "Chemical"], [120, 121, "Chemical"], [140, 142, "Chemical"], [144, 145, "Chemical"], [175, 176, "Chemical"], [201, 203, "Chemical"], [230, 231, "Chemical"], [240, 242, "Chemical"], [244, 245, "Chemical"], [276, 277, "Chemical"], [284, 286, "Chemical"], [288, 289, "Chemical"], [344, 346, "Chemical"], [351, 352, "Chemical"], [62, 62, "Disease"], [281, 281, "Disease"], [6, 6, "Chemical"], [33, 33, "Chemical"], [47, 47, "Chemical"], [19, 27, "Chemical"]]], "relations": [[[127, 127, 130, 131, "CID"], [183, 183, 150, 150, "CID"], [183, 183, 186, 186, "CID"]]], "clusters": [], "translated": "<5>ACC-9653</5>（<28>苯妥英</28>前药）的药理学。 <6>ACC-9653</6>，即<31>3-羟甲基-5,5-二苯基乙内酰脲</31>的磷酸二钠酯，是<29>苯妥英</29>的前药，具有良好的理化性质。<7>ACC-9653</7>在体内被酶促快速转化为<30>苯妥英</30>。<8>ACC-9653</8>和<9>苯妥英钠</9>对<26>最大电休克(MES)所致癫痫</26>在小鼠体内经i.p.、口服或i.v.给药后具有等效的抗癫痫活性。i.v.<10>ACC-9653</10>和i.v.<11>苯妥英钠</11>的ED50剂量分别为16 mg/kg和8 mg/kg。<12>ACC-9653</12>和<13>苯妥英钠</13>对麻醉犬<0>瓦巴因</0>-诱发的<1>室性心动过速</1>具有类似的抗心律失常活性。将<3>心律失常</3>转为正常窦性心律所需的<14>ACC-9653</14>或<15>苯妥英钠</15>的总剂量分别为24+/-6和14+/-3 mg/kg，分别。只有<16>苯妥英钠</16>对<2>马钱子酸</2>-诱导的<4>心律失常</4>在豚鼠右心房体外表现出抗心律失常活性。在麻醉犬中，将高剂量<17>ACC-9653</17>（31 mg/kg）在15、20和30分钟内输注，并将其回答与等摩尔剂量的<18>苯妥英钠</18>（21 mg/kg）比较。<19>ACC-9653</19>和<20>苯妥英钠</20>治疗在舒张压和收缩力（LVdP/dt）方面产生了类似的显着降低。每种治疗的最大作用发生在最大<21>苯妥英钠</21>水平时。<22>ACC-9653</22>和<23>苯妥英钠</23>的急性<27>毒性</27>研究在小鼠、大鼠、兔和狗中进行，由i.v.、i.m.和i.p.给药途径。两种药物的全身毒性症状相似，并且发生在大致相同的剂量下。重要的是，i.m.内<24>ACC-9653</24>的局部刺激明显低于<25>苯妥英钠</25>。（摘要被截断为250个单词）", "revised": true}
{"doc_key": "10219427", "sentences": [["Positive", "skin", "tests", "in", "late", "reactions", "to", "radiographic", "contrast", "media", ".", "In", "the", "last", "few", "years", "delayed", "reactions", "several", "hours", "after", "the", "injection", "of", "radiographic", "and", "contrast", "materials", "(", "PRC", ")", "have", "been", "described", "with", "increasing", "frequency", ".", "The", "authors", "report", "two", "observations", "on", "patients", "with", "delayed", "reactions", "in", "whom", "intradermoreactions", "(", "IDR", ")", "and", "patch", "tests", "to", "a", "series", "of", "ionic", "and", "non", "ionic", "PRC", "were", "studied", ".", "After", "angiography", "by", "the", "venous", "route", "in", "patient", "n", "degree", "1", "a", "biphasic", "reaction", "with", "an", "immediate", "reaction", "(", "dyspnea", ",", "loss", "of", "consciousness", ")", "and", "delayed", "macro", "-", "papular", "rash", "appeared", ",", "whilst", "patient", "n", "degree", "2", "developed", "a", "generalised", "sensation", "of", "heat", ",", "persistent", "pain", "at", "the", "site", "of", "injection", "immediately", "and", "a", "generalised", "macro", "-", "papular", "reaction", "after", "24", "hours", ".", "The", "skin", "tests", "revealed", "positive", "delayed", "reactions", "of", "24", "hours", "and", "48", "hours", "by", "IDR", "and", "patch", "tests", "to", "only", "some", "PRC", "with", "common", "chains", "in", "their", "structures", ".", "The", "positive", "skin", "tests", "are", "in", "favour", "of", "immunological", "reactions", "and", "may", "help", "in", "diagnosis", "of", "allergy", "in", "the", "patients", "."]], "ner": [[[8, 9, "Chemical"], [26, 27, "Chemical"], [29, 29, "Chemical"], [65, 65, "Chemical"], [154, 154, "Chemical"], [88, 88, "Disease"], [90, 92, "Disease"], [96, 99, "Disease"], [115, 115, "Disease"], [178, 178, "Disease"]]], "relations": [[[8, 9, 88, 88, "CID"], [26, 27, 88, 88, "CID"], [29, 29, 88, 88, "CID"], [65, 65, 88, 88, "CID"], [154, 154, 88, 88, "CID"], [8, 9, 90, 92, "CID"], [26, 27, 90, 92, "CID"], [29, 29, 90, 92, "CID"], [65, 65, 90, 92, "CID"], [154, 154, 90, 92, "CID"], [8, 9, 96, 99, "CID"], [26, 27, 96, 99, "CID"], [29, 29, 96, 99, "CID"], [65, 65, 96, 99, "CID"], [154, 154, 96, 99, "CID"], [8, 9, 115, 115, "CID"], [26, 27, 115, 115, "CID"], [29, 29, 115, 115, "CID"], [65, 65, 115, 115, "CID"], [154, 154, 115, 115, "CID"]]], "clusters": [], "translated": "对射线照相<0>造影剂</0>的后期反应呈阳性皮肤试验。在过去几年中，越来越频繁地描述了在注射放射照相材料和<1>造影剂</1> (<2>PRC</2>)后数小时出现延迟反应。作者报告了对延迟反应患者的两项观察结果，其中研究了皮内反应 (IDR) 和对一系列离子和非离子<3>PRC</3>的斑贴试验。1级患者通过静脉途径进行血管造影后出现双相反应，即刻反应（<5>呼吸困难</5>、<6>意识丧失</6>）和迟发性<7>大丘疹</7>出现，而n级2患者立即在注射部位出现全身热感、持续<8>疼痛</8>，24小时后出现全身大丘疹反应。通过IDR和斑贴试验，皮试显示24小时和48小时的阳性延迟反应仅针对结构中具有共同链的一些<4>PRC</4>。阳性皮肤试验有利于免疫反应，有助于诊断患者<9>过敏</9>。", "revised": true}
{"doc_key": "9881641", "sentences": [["Glibenclamide", "-", "sensitive", "hypotension", "produced", "by", "helodermin", "assessed", "in", "the", "rat", ".", "The", "effects", "of", "helodermin", ",", "a", "basic", "35", "-", "amino", "acid", "peptide", "isolated", "from", "the", "venom", "of", "a", "lizard", "salivary", "gland", ",", "on", "arterial", "blood", "pressure", "and", "heart", "rate", "were", "examined", "in", "the", "rat", ",", "focusing", "on", "the", "possibility", "that", "activation", "of", "ATP", "sensitive", "K", "+", "(", "K", "(", "ATP", ")", ")", "channels", "is", "involved", "in", "the", "responses", ".", "The", "results", "were", "also", "compared", "with", "those", "of", "vasoactive", "intestinal", "polypeptide", "(", "VIP", ")", ".", "Helodermin", "produced", "hypotension", "in", "a", "dose", "-", "dependent", "manner", "with", "approximately", "similar", "potency", "and", "duration", "to", "VIP", ".", "Hypotension", "induced", "by", "both", "peptides", "was", "significantly", "attenuated", "by", "glibenclamide", ",", "which", "abolished", "a", "levcromakalim", "-", "produced", "decrease", "in", "arterial", "blood", "pressure", ".", "Oxyhemoglobin", "did", "not", "affect", "helodermin", "-", "induced", "hypotension", ",", "whereas", "it", "shortened", "the", "duration", "of", "acetylcholine", "(", "ACh", ")", "-", "produced", "hypotension", ".", "These", "findings", "suggest", "that", "helodermin", "-", "produced", "hypotension", "is", "partly", "attributable", "to", "the", "activation", "of", "glibenclamide", "-", "sensitive", "K", "+", "channels", "(", "K", "(", "ATP", ")", "channels", ")", ",", "which", "presumably", "exist", "on", "arterial", "smooth", "muscle", "cells", ".", "EDRF", "(", "endothelium", "-", "derived", "relaxing", "factor", ")", "/", "nitric", "oxide", "does", "not", "seem", "to", "play", "an", "important", "role", "in", "the", "peptide", "-", "produced", "hypotension", "."]], "ner": [[[6, 6, "Chemical"], [15, 15, "Chemical"], [86, 86, "Chemical"], [131, 131, "Chemical"], [154, 154, "Chemical"], [3, 3, "Disease"], [88, 88, "Disease"], [104, 104, "Disease"], [134, 134, "Disease"], [148, 148, "Disease"], [157, 157, "Disease"], [212, 212, "Disease"], [118, 118, "Chemical"], [142, 142, "Chemical"], [144, 144, "Chemical"], [0, 0, "Chemical"], [113, 113, "Chemical"], [165, 165, "Chemical"], [21, 22, "Chemical"], [54, 54, "Chemical"], [61, 61, "Chemical"], [174, 174, "Chemical"], [56, 56, "Chemical"], [59, 59, "Chemical"], [168, 168, "Chemical"], [172, 172, "Chemical"], [197, 198, "Chemical"]]], "relations": [[[6, 6, 3, 3, "CID"], [6, 6, 88, 88, "CID"], [6, 6, 104, 104, "CID"], [6, 6, 134, 134, "CID"], [6, 6, 148, 148, "CID"], [6, 6, 157, 157, "CID"], [6, 6, 212, 212, "CID"], [15, 15, 3, 3, "CID"], [15, 15, 88, 88, "CID"], [15, 15, 104, 104, "CID"], [15, 15, 134, 134, "CID"], [15, 15, 148, 148, "CID"], [15, 15, 157, 157, "CID"], [15, 15, 212, 212, "CID"], [86, 86, 3, 3, "CID"], [86, 86, 88, 88, "CID"], [86, 86, 104, 104, "CID"], [86, 86, 134, 134, "CID"], [86, 86, 148, 148, "CID"], [86, 86, 157, 157, "CID"], [86, 86, 212, 212, "CID"], [131, 131, 3, 3, "CID"], [131, 131, 88, 88, "CID"], [131, 131, 104, 104, "CID"], [131, 131, 134, 134, "CID"], [131, 131, 148, 148, "CID"], [131, 131, 157, 157, "CID"], [131, 131, 212, 212, "CID"], [154, 154, 3, 3, "CID"], [154, 154, 88, 88, "CID"], [154, 154, 104, 104, "CID"], [154, 154, 134, 134, "CID"], [154, 154, 148, 148, "CID"], [154, 154, 157, 157, "CID"], [154, 154, 212, 212, "CID"], [118, 118, 3, 3, "CID"], [118, 118, 88, 88, "CID"], [118, 118, 104, 104, "CID"], [118, 118, 134, 134, "CID"], [118, 118, 148, 148, "CID"], [118, 118, 157, 157, "CID"], [118, 118, 212, 212, "CID"], [142, 142, 3, 3, "CID"], [142, 142, 88, 88, "CID"], [142, 142, 104, 104, "CID"], [142, 142, 134, 134, "CID"], [142, 142, 148, 148, "CID"], [142, 142, 157, 157, "CID"], [142, 142, 212, 212, "CID"], [144, 144, 3, 3, "CID"], [144, 144, 88, 88, "CID"], [144, 144, 104, 104, "CID"], [144, 144, 134, 134, "CID"], [144, 144, 148, 148, "CID"], [144, 144, 157, 157, "CID"], [144, 144, 212, 212, "CID"]]], "clusters": [], "translated": "<15>Glibenclamide</15> - 敏感的<5>低血压</5>由<0>Helodermin</0>在大鼠中评估。一种从蜥蜴唾液腺毒液中分离出来的碱性35-<18>氨基酸</18>肽<1>Helodermin</1>，在大鼠身上检测了动脉血压和心率的影响，重点是关于激活<19>ATP</19>敏感<22>K</22>+(<23>K</23>(<20>ATP</20>))通道参与反应的可能性。并将结果与血管活性肠多肽(VIP)的结果进行了比较。<2>Helodermin</2>以剂量依赖的方式产生<6>低血压</6>，其效力和持续时间与VIP大致相似。<7>两种肽引起的低血压</7>被<16>格列本脲</16>显着减弱，后者消除了<12>levcromakalim </12>产生的动脉血压下降。氧合血红蛋白不影响<3>Helodermin </3>-诱导的<8>低血压</8>，而它缩短了<13>乙酰胆碱</13>(<14>ACh</14>)-产生<9>低血压</9>。这些发现表明<4>Helodermin </4>-产生的<10>低血压</10>部分归因于<17>格列本脲</17>-敏感性<24>K</24> +通道的激活(<25>K</25>(<21>ATP</21>)通道)，推测存在于动脉平滑肌细胞上。EDRF(内皮衍生松弛因子)/<26>一氧化氮</26>在肽产生的<11>低血压</11>中似乎没有发挥重要作用。", "revised": true}
{"doc_key": "9071336", "sentences": [["Paclitaxel", ",", "5", "-", "fluorouracil", ",", "and", "folinic", "acid", "in", "metastatic", "breast", "cancer", ":", "BRE", "-", "26", ",", "a", "phase", "II", "trial", ".", "5", "-", "Fluorouracil", "plus", "folinic", "acid", "and", "paclitaxel", "(", "Taxol", ";", "Bristol", "-", "Myers", "Squibb", "Company", ",", "Princeton", ",", "NJ", ")", "are", "effective", "salvage", "therapies", "for", "metastatic", "breast", "cancer", "patients", ".", "Paclitaxel", "and", "5", "-", "fluorouracil", "have", "additive", "cytotoxicity", "in", "MCF", "-", "7", "cell", "lines", ".", "We", "performed", "a", "phase", "II", "trial", "of", "paclitaxel", "175", "mg", "/", "m2", "over", "3", "hours", "on", "day", "I", "followed", "by", "folinic", "acid", "300", "mg", "over", "1", "hour", "before", "5", "-", "fluorouracil", "350", "mg", "/", "m2", "on", "days", "1", "to", "3", "every", "28", "days", "(", "TFL", ")", "in", "women", "with", "metastatic", "breast", "cancer", ".", "Analysis", "is", "reported", "on", "37", "patients", "with", "a", "minimum", "of", "6", "months", "follow", "-", "up", "who", "received", "a", "total", "of", "192", "cycles", "of", "TFL", ":", "nine", "cycles", "(", "5", "%", ")", "were", "associated", "with", "grade", "3", "/", "4", "neutropenia", "requiring", "hospitalization", ";", "seven", "(", "4", "%", ")", "cycles", "in", "two", "patients", "required", "granulocyte", "colony", "-", "stimulating", "factor", "due", "to", "neutropenia", ";", "no", "patient", "required", "platelet", "transfusions", ".", "Grade", "3", "/", "4", "nonhematologic", "toxicities", "were", "uncommon", ".", "Among", "the", "34", "patients", "evaluable", "for", "response", ",", "there", "were", "three", "complete", "responses", "(", "9", "%", ")", "and", "18", "partial", "responses", "(", "53", "%", ")", "for", "an", "overall", "response", "rate", "of", "62", "%", ".", "Of", "the", "19", "evaluable", "patients", "with", "prior", "doxorubicin", "exposure", ",", "11", "(", "58", "%", ")", "responded", "compared", "with", "nine", "of", "15", "(", "60", "%", ")", "without", "prior", "doxorubicin", ".", "Plasma", "paclitaxel", "concentrations", "were", "measured", "at", "the", "completion", "of", "paclitaxel", "infusion", "and", "at", "24", "hours", "in", "19", "patients", ".", "TFL", "is", "an", "active", ",", "well", "-", "tolerated", "regimen", "in", "metastatic", "breast", "cancer", "."]], "ner": [[[0, 0, "Chemical"], [30, 30, "Chemical"], [32, 32, "Chemical"], [54, 54, "Chemical"], [76, 76, "Chemical"], [262, 262, "Chemical"], [270, 270, "Chemical"], [160, 160, "Disease"], [181, 181, "Disease"], [2, 4, "Chemical"], [23, 25, "Chemical"], [56, 58, "Chemical"], [97, 99, "Chemical"], [7, 8, "Chemical"], [27, 28, "Chemical"], [89, 90, "Chemical"], [11, 12, "Disease"], [50, 51, "Disease"], [119, 120, "Disease"], [291, 292, "Disease"], [61, 61, "Disease"], [194, 194, "Disease"], [174, 178, "Chemical"], [239, 239, "Chemical"], [259, 259, "Chemical"]]], "relations": [[[0, 0, 160, 160, "CID"], [0, 0, 181, 181, "CID"], [30, 30, 160, 160, "CID"], [30, 30, 181, 181, "CID"], [32, 32, 160, 160, "CID"], [32, 32, 181, 181, "CID"], [54, 54, 160, 160, "CID"], [54, 54, 181, 181, "CID"], [76, 76, 160, 160, "CID"], [76, 76, 181, 181, "CID"], [262, 262, 160, 160, "CID"], [262, 262, 181, 181, "CID"], [270, 270, 160, 160, "CID"], [270, 270, 181, 181, "CID"], [2, 4, 160, 160, "CID"], [2, 4, 181, 181, "CID"], [23, 25, 160, 160, "CID"], [23, 25, 181, 181, "CID"], [56, 58, 160, 160, "CID"], [56, 58, 181, 181, "CID"], [97, 99, 160, 160, "CID"], [97, 99, 181, 181, "CID"], [7, 8, 160, 160, "CID"], [7, 8, 181, 181, "CID"], [27, 28, 160, 160, "CID"], [27, 28, 181, 181, "CID"], [89, 90, 160, 160, "CID"], [89, 90, 181, 181, "CID"]]], "clusters": [], "translated": " <0>紫杉醇</0>、<9>5-氟尿嘧啶</9>和<13>亚叶酸</13>治疗转移性<16>乳腺癌</16>：BRE-26，II期试验。 <10>5-氟尿嘧啶</10>加<14>亚叶酸</14>和<1>紫杉醇</1>（<2>紫杉醇</2>；Bristol-Myers Squibb Company, Princeton, NJ）是转移性<17>乳腺癌</17>患者的有效挽救疗法。 <3>紫杉醇</3>和<11>5-氟尿嘧啶</11>在MCF-7细胞系中具有相加的<20>细胞毒性</20>。我们在第 1 天先注射<4>紫杉醇</4> 175 mg/m2（3小时内），随后给<15>亚叶酸</15> 300 mg注射1小时，最后在第1-3天，每28天服用 <12>5-氟尿嘧啶</12> 350 mg/m2 总共192个周期（TFL）治疗转移性<18>乳腺癌</18>女性。对至少6个月的随访下的37名患者进行了分析：9个周期(5 %)伴有3/4级<7>中性粒细胞减少</7>需住院治疗；7个周期（4 %）在两位患者中由于<8>中性粒细胞减少</8>需要<22>粒细胞集落刺激因子</22>；没有患者需要输血小板。3/4级非血液毒性<21>不常见</21>。在34名可评估反应的患者中，共有3个完全反应(9%)和18个部分反应(53%)，总体反应率为62%。在19名有<23>多柔比星</23>接触史的可评估患者中，有11人(58%)有反应，而15名之前没有接触过<24>多柔比星</24>的患者中，有9个人(60%)有反应。在输注<6>紫杉醇</6>后的24小时，测量了19名患者的血浆中<5>紫杉醇</5>的浓度。TFL是治疗转移性<19>乳腺癌</19>的一种有效且耐受性良好的方案。", "revised": true}
{"doc_key": "10427794", "sentences": [["Meloxicam", "-", "induced", "liver", "toxicity", ".", "We", "report", "the", "case", "of", "a", "female", "patient", "with", "rheumatoid", "arthritis", "who", "developed", "acute", "cytolytic", "hepatitis", "due", "to", "meloxicam", ".", "Recently", "introduced", "in", "Belgium", ",", "meloxicam", "is", "the", "first", "nonsteroidal", "antiinflammatory", "drug", "with", "selective", "action", "on", "the", "inducible", "form", "of", "cyclooxygenase", "2", ".", "The", "acute", "cytolytic", "hepatitis", "occurred", "rapidly", "after", "meloxicam", "administration", "and", "was", "associated", "with", "the", "development", "of", "antinuclear", "antibodies", "suggesting", "a", "hypersensitivity", "mechanism", ".", "This", "first", "case", "of", "meloxicam", "related", "liver", "toxicity", "demonstrates", "the", "potential", "of", "this", "drug", "to", "induce", "hepatic", "damage", "."]], "ner": [[[0, 0, "Chemical"], [24, 24, "Chemical"], [31, 31, "Chemical"], [56, 56, "Chemical"], [76, 76, "Chemical"], [3, 4, "Disease"], [21, 21, "Disease"], [52, 52, "Disease"], [78, 79, "Disease"], [88, 89, "Disease"], [69, 69, "Disease"], [15, 16, "Disease"]]], "relations": [[[0, 0, 3, 4, "CID"], [0, 0, 21, 21, "CID"], [0, 0, 52, 52, "CID"], [0, 0, 78, 79, "CID"], [0, 0, 88, 89, "CID"], [24, 24, 3, 4, "CID"], [24, 24, 21, 21, "CID"], [24, 24, 52, 52, "CID"], [24, 24, 78, 79, "CID"], [24, 24, 88, 89, "CID"], [31, 31, 3, 4, "CID"], [31, 31, 21, 21, "CID"], [31, 31, 52, 52, "CID"], [31, 31, 78, 79, "CID"], [31, 31, 88, 89, "CID"], [56, 56, 3, 4, "CID"], [56, 56, 21, 21, "CID"], [56, 56, 52, 52, "CID"], [56, 56, 78, 79, "CID"], [56, 56, 88, 89, "CID"], [76, 76, 3, 4, "CID"], [76, 76, 21, 21, "CID"], [76, 76, 52, 52, "CID"], [76, 76, 78, 79, "CID"], [76, 76, 88, 89, "CID"], [0, 0, 69, 69, "CID"], [24, 24, 69, 69, "CID"], [31, 31, 69, 69, "CID"], [56, 56, 69, 69, "CID"], [76, 76, 69, 69, "CID"]]], "clusters": [], "translated": "<0>美洛昔康</0> - 引起的<5>肝毒性</5>。我们报告了一名患有<11>类风湿性关节炎</11>的女性患者因<1>美洛昔康</1>而发展为急性溶细胞性<6>肝炎</6>的病例。最近在比利时推出的<2>美洛昔康</2>是第一种对诱导形式的环氧化酶2具有选择性作用的非甾体抗炎药。急性溶细胞性<7>肝炎</7>在<3>美洛昔康</3>给药后迅速发生，并与抗核抗体的产生相关，表明<10>超敏反应</10>机制。第一例<4>美洛昔康</4>相关<8>肝毒性</8>表明该药物有可能引起<9>肝损伤</9>。", "revised": true}
{"doc_key": "10327032", "sentences": [["Risk", "of", "transient", "hyperammonemic", "encephalopathy", "in", "cancer", "patients", "who", "received", "continuous", "infusion", "of", "5", "-", "fluorouracil", "with", "the", "complication", "of", "dehydration", "and", "infection", ".", "From", "1986", "to", "1998", ",", "29", "cancer", "patients", "who", "had", "32", "episodes", "of", "transient", "hyperammonemic", "encephalopathy", "related", "to", "continuous", "infusion", "of", "5", "-", "fluorouracil", "(", "5", "-", "FU", ")", "were", "identified", ".", "None", "of", "the", "patients", "had", "decompensated", "liver", "disease", ".", "Onset", "of", "hyperammonemic", "encephalopathy", "varied", "from", "0", ".", "5", "to", "5", "days", "(", "mean", ":", "2", ".", "6", "+", "/", "-", "1", ".", "3", "days", ")", "after", "the", "initiation", "of", "chemotherapy", ".", "Plasma", "ammonium", "level", "ranged", "from", "248", "to", "2387", "microg", "%", "(", "mean", ":", "626", "+", "/", "-", "431", "microg", "%", ")", ".", "Among", "the", "32", "episodes", ",", "26", "(", "81", "%", ")", "had", "various", "degrees", "of", "azotemia", ",", "18", "(", "56", "%", ")", "occurred", "during", "bacterial", "infections", "and", "14", "(", "44", "%", ")", "without", "infection", "occurred", "during", "periods", "of", "dehydration", ".", "Higher", "plasma", "ammonium", "levels", "and", "more", "rapid", "onset", "of", "hyperammonemia", "were", "seen", "in", "18", "patients", "with", "bacterial", "infections", "(", "p", "=", "0", ".", "003", "and", "0", ".", "0006", ",", "respectively", ")", "and", "in", "nine", "patients", "receiving", "high", "daily", "doses", "(", "2600", "or", "1800", "mg", "/", "m2", ")", "of", "5", "-", "FU", "(", "p", "=", "0", ".", "0001", "and", "<", "0", ".", "0001", ",", "respectively", ")", ".", "In", "25", "out", "of", "32", "episodes", "(", "78", "%", ")", ",", "plasma", "ammonium", "levels", "and", "mental", "status", "returned", "to", "normal", "within", "2", "days", "after", "adequate", "management", ".", "In", "conclusion", ",", "hyperammonemic", "encephalopathy", "can", "occur", "in", "patients", "receiving", "continuous", "infusion", "of", "5", "-", "FU", ".", "Azotemia", ",", "body", "fluid", "insufficiency", "and", "bacterial", "infections", "were", "frequently", "found", "in", "these", "patients", ".", "It", "is", "therefore", "important", "to", "recognize", "this", "condition", "in", "patients", "receiving", "continuous", "infusion", "of", "5", "-", "FU", "."]], "ner": [[[13, 15, "Chemical"], [45, 47, "Chemical"], [49, 51, "Chemical"], [206, 208, "Chemical"], [264, 266, "Chemical"], [297, 299, "Chemical"], [3, 4, "Disease"], [38, 39, "Disease"], [67, 68, "Disease"], [167, 167, "Disease"], [254, 255, "Disease"], [98, 98, "Chemical"], [160, 160, "Chemical"], [236, 236, "Chemical"], [6, 6, "Disease"], [30, 30, "Disease"], [20, 20, "Disease"], [156, 156, "Disease"], [22, 22, "Disease"], [151, 151, "Disease"], [62, 63, "Disease"], [133, 133, "Disease"], [268, 268, "Disease"], [142, 143, "Disease"], [174, 175, "Disease"], [274, 275, "Disease"]]], "relations": [[[13, 15, 3, 4, "CID"], [13, 15, 38, 39, "CID"], [13, 15, 67, 68, "CID"], [13, 15, 167, 167, "CID"], [13, 15, 254, 255, "CID"], [45, 47, 3, 4, "CID"], [45, 47, 38, 39, "CID"], [45, 47, 67, 68, "CID"], [45, 47, 167, 167, "CID"], [45, 47, 254, 255, "CID"], [49, 51, 3, 4, "CID"], [49, 51, 38, 39, "CID"], [49, 51, 67, 68, "CID"], [49, 51, 167, 167, "CID"], [49, 51, 254, 255, "CID"], [206, 208, 3, 4, "CID"], [206, 208, 38, 39, "CID"], [206, 208, 67, 68, "CID"], [206, 208, 167, 167, "CID"], [206, 208, 254, 255, "CID"], [264, 266, 3, 4, "CID"], [264, 266, 38, 39, "CID"], [264, 266, 67, 68, "CID"], [264, 266, 167, 167, "CID"], [264, 266, 254, 255, "CID"], [297, 299, 3, 4, "CID"], [297, 299, 38, 39, "CID"], [297, 299, 67, 68, "CID"], [297, 299, 167, 167, "CID"], [297, 299, 254, 255, "CID"]]], "clusters": [], "translated": "接受持续输注<0>5-氟尿嘧啶</0>的<14>癌症</14>患者发生短暂性<6>高氨血症性脑病</6>的风险并伴有<16>脱水</16>和并发症<18>感染</18>。从1986年到1998年，29名<15>癌症</15>患者发生了32次短暂性<7>高氨血症性脑病</7>与持续输注<1>5-氟尿嘧啶</1>（<2>5-FU</2>）被识别出来。所有患者均未发生失代偿性<20>肝病</20>。<8>高氨血症性脑病</8>的发病率从0.5到5天（平均:2.6+/-1.3天）化疗开始后。血浆<11>铵</11>水平范围为248至2387微克%（平均值:626+/-431微克%）。在32例中，26例（81%）有不同程度的<21>氮质血症</21>，18例（56%）发生于<23>细菌感染</23>，14例（44%）无<19>感染</19> 发生在<17>脱水</17>期间。在18名<24>细菌感染</24>患者中观察到更高的血浆<12>铵</12>水平和更快速的<9>高氨血症</9>（p=0.003和0.0006，分别）和九名接受高日剂量（2600或1800 mg/m2）<3>5-FU</3>的患者（分别为p=0.0001和<0.0001）。在32次发作中，有25次(78%)在适当处理后2天内血浆<13>铵</13>水平和精神状态恢复正常。总之，<10>高氨血症性脑病</10>可发生于接受<4>5-FU</4>持续输注的患者。<22>氮质血症</22>、体液不足和<25>细菌感染</25>在这些患者中常见。因此，在接受连续输注<5>5-FU</5>的患者中识别这种情况很重要。", "revised": true}
{"doc_key": "10087562", "sentences": [["Torsade", "de", "pointes", "ventricular", "tachycardia", "during", "low", "dose", "intermittent", "dobutamine", "treatment", "in", "a", "patient", "with", "dilated", "cardiomyopathy", "and", "congestive", "heart", "failure", ".", "The", "authors", "describe", "the", "case", "of", "a", "56", "-", "year", "-", "old", "woman", "with", "chronic", ",", "severe", "heart", "failure", "secondary", "to", "dilated", "cardiomyopathy", "and", "absence", "of", "significant", "ventricular", "arrhythmias", "who", "developed", "QT", "prolongation", "and", "torsade", "de", "pointes", "ventricular", "tachycardia", "during", "one", "cycle", "of", "intermittent", "low", "dose", "(", "2", ".", "5", "mcg", "/", "kg", "per", "min", ")", "dobutamine", ".", "This", "report", "of", "torsade", "de", "pointes", "ventricular", "tachycardia", "during", "intermittent", "dobutamine", "supports", "the", "hypothesis", "that", "unpredictable", "fatal", "arrhythmias", "may", "occur", "even", "with", "low", "doses", "and", "in", "patients", "with", "no", "history", "of", "significant", "rhythm", "disturbances", ".", "The", "mechanisms", "of", "proarrhythmic", "effects", "of", "Dubutamine", "are", "discussed", "."]], "ner": [[[9, 9, "Chemical"], [78, 78, "Chemical"], [90, 90, "Chemical"], [121, 121, "Chemical"], [0, 2, "Disease"], [56, 58, "Disease"], [83, 85, "Disease"], [3, 4, "Disease"], [59, 60, "Disease"], [86, 87, "Disease"], [15, 16, "Disease"], [43, 44, "Disease"], [18, 20, "Disease"], [39, 40, "Disease"], [49, 50, "Disease"], [97, 97, "Disease"], [53, 54, "Disease"]]], "relations": [[[9, 9, 0, 2, "CID"], [9, 9, 56, 58, "CID"], [9, 9, 83, 85, "CID"], [78, 78, 0, 2, "CID"], [78, 78, 56, 58, "CID"], [78, 78, 83, 85, "CID"], [90, 90, 0, 2, "CID"], [90, 90, 56, 58, "CID"], [90, 90, 83, 85, "CID"], [121, 121, 0, 2, "CID"], [121, 121, 56, 58, "CID"], [121, 121, 83, 85, "CID"]]], "clusters": [], "translated": " <4>尖端扭转型室性心动过速</4> <7>室性心动过速</7> 低剂量间歇性<0>多巴酚丁胺</0>治疗<10>扩张型心肌病</10>和<12>充血性心肌病</12>患者心力衰竭。作者描述了一名56岁女性的病例，她患有继发于<11>扩张型心肌病</11>的慢性、严重<13>心力衰竭</13>并且没有明显的<14>室性心律失常</14>在间歇性低剂量（每分钟2.5mcg/kg）的一个周期内出现<16>QT延长</16>和<5>尖端扭转型室性心动过速</5><8>室性心动过速</8><1>多巴酚丁胺</1>。这篇报道指出即使在低剂量和无明显节律失常病史的患者中也可能出现不可预测的致命性<15>心律失常</15>，从而支持了间歇性<2>多巴酚丁胺</2> <6>尖端扭转型室性心动过速</6> <9>室性心动过速</9>的致心律失常作用的假设。讨论了<3>多巴酚丁胺</3>的致心律失常作用机制。", "revised": true}
{"doc_key": "10510854", "sentences": [["Synthesis", "and", "preliminary", "pharmacological", "investigations", "of", "1", "-", "(", "1", ",", "2", "-", "dihydro", "-", "2", "-", "acenaphthylenyl", ")", "piperazine", "derivatives", "as", "potential", "atypical", "antipsychotic", "agents", "in", "mice", ".", "In", "research", "towards", "the", "development", "of", "new", "atypical", "antipsychotic", "agents", ",", "one", "strategy", "is", "that", "the", "dopaminergic", "system", "can", "be", "modulated", "through", "manipulation", "of", "the", "serotonergic", "system", ".", "The", "synthesis", "and", "preliminary", "pharmacological", "evaluation", "of", "a", "series", "of", "potential", "atypical", "antipsychotic", "agents", "based", "on", "the", "structure", "of", "1", "-", "(", "1", ",", "2", "-", "dihydro", "-", "2", "-", "acenaphthylenyl", ")", "piperazine", "(", "7", ")", "is", "described", ".", "Compound", "7e", ",", "5", "-", "{", "2", "-", "[", "4", "-", "(", "1", ",", "2", "-", "dihydro", "-", "2", "-", "acenaphthylenyl", ")", "piperazinyl", "]", "ethyl", "}", "-", "2", ",", "3", "-", "dihy", "dro", "-", "1H", "-", "indol", "-", "2", "-", "one", ",", "from", "this", "series", "showed", "significant", "affinities", "at", "the", "5", "-", "HT1A", "and", "5", "-", "HT2A", "receptors", "and", "moderate", "affinity", "at", "the", "D2", "receptor", ".", "7e", "exhibits", "a", "high", "reversal", "of", "catalepsy", "induced", "by", "haloperidol", "indicating", "its", "atypical", "antipsychotic", "nature", "."]], "ner": [[[171, 171, "Chemical"], [168, 168, "Disease"]]], "relations": [[[171, 171, 168, 168, "CID"]]], "clusters": [], "translated": "1-(1,2-二氢-2-苊基)哌嗪衍生物的合成和初步药理研究作为小鼠潜在的非典型抗精神病药物。在开发新的非典型抗精神病药的研究中，一种策略是可以通过操纵5-羟色胺能系统来调节多巴胺能系统。描述了基于1-(1,2-二氢-2-苯基)哌嗪（7）结构的一系列潜在的非典型抗精神病药物的合成和初步药理评价。化合物7e，5-{2-[4-(1,2-二氢-2-苊基)哌嗪基]乙基}-2,3-二氢吲哚-2-酮，从该系列中表现出在5-HT1A和5-HT2A受体上的显著亲和力，以及在D2受体上的中等亲和力。7e 表现出高度逆转由 <0>氟哌啶醇</0> 诱导的 <1>强直性昏厥</1>，表明其非典型抗精神病性质。", "revised": true}
{"doc_key": "9831002", "sentences": [["Neuroleptic", "malignant", "syndrome", "and", "methylphenidate", ".", "A", "1", "-", "year", "-", "old", "female", "presented", "with", "neuroleptic", "malignant", "syndrome", "probably", "caused", "by", "methylphenidate", ".", "She", "had", "defects", "in", "the", "supratentorial", "brain", "including", "the", "basal", "ganglia", "and", "the", "striatum", "(", "multicystic", "encephalomalacia", ")", "due", "to", "severe", "perinatal", "hypoxic", "-", "ischemic", "encephalopathy", ",", "which", "was", "considered", "to", "be", "a", "possible", "predisposing", "factor", "causing", "neuroleptic", "malignant", "syndrome", ".", "A", "dopaminergic", "blockade", "mechanism", "generally", "is", "accepted", "as", "the", "pathogenesis", "of", "this", "syndrome", ".", "However", ",", "methylphenidate", "is", "a", "dopamine", "agonist", "via", "the", "inhibition", "of", "uptake", "of", "dopamine", ",", "and", "therefore", "dopaminergic", "systems", "in", "the", "brainstem", "(", "mainly", "the", "midbrain", ")", "and", "the", "spinal", "cord", "were", "unlikely", "to", "participate", "in", "the", "onset", "of", "this", "syndrome", ".", "A", "relative", "gamma", "-", "aminobutyric", "acid", "-", "ergic", "deficiency", "might", "occur", "because", "diazepam", ",", "a", "gamma", "-", "aminobutyric", "acid", "-", "mimetic", "agent", ",", "was", "strikingly", "effective", ".", "This", "is", "the", "first", "reported", "patient", "with", "neuroleptic", "malignant", "syndrome", "probably", "caused", "by", "methylphenidate", "."]], "ner": [[[4, 4, "Chemical"], [21, 21, "Chemical"], [80, 80, "Chemical"], [160, 160, "Chemical"], [0, 2, "Disease"], [15, 17, "Disease"], [60, 62, "Disease"], [154, 156, "Disease"], [83, 83, "Chemical"], [91, 91, "Chemical"], [122, 125, "Chemical"], [135, 138, "Chemical"], [132, 132, "Chemical"], [38, 39, "Disease"], [45, 48, "Disease"]]], "relations": [[[4, 4, 0, 2, "CID"], [4, 4, 15, 17, "CID"], [4, 4, 60, 62, "CID"], [4, 4, 154, 156, "CID"], [21, 21, 0, 2, "CID"], [21, 21, 15, 17, "CID"], [21, 21, 60, 62, "CID"], [21, 21, 154, 156, "CID"], [80, 80, 0, 2, "CID"], [80, 80, 15, 17, "CID"], [80, 80, 60, 62, "CID"], [80, 80, 154, 156, "CID"], [160, 160, 0, 2, "CID"], [160, 160, 15, 17, "CID"], [160, 160, 60, 62, "CID"], [160, 160, 154, 156, "CID"]]], "clusters": [], "translated": "<4>抗精神病药物恶性综合征</4>和<0>哌醋甲酯</0>。一名1岁女性因<5>抗精神病药恶性综合征</5>就诊，可能由<1>哌醋甲酯</1>引起。由于严重的围产期<14>缺氧缺血性脑病</14>，她在幕上脑存在缺陷（<13>多囊性脑软化症</13>，包括基底神经节和纹状体）。这被认为是可能的诱发因素，引起了<6>抗精神病药物恶性综合征</6>。通常认为，这种综合征的发病机制是通过多巴胺能阻滞机制实现的。然而，<2>哌醋甲酯</2>通过抑制<9>多巴胺</9>的摄取作为一种<8>多巴胺</8>激动剂，因此不太可能抑制脑干（主要是中脑）和脊髓中的多巴胺能系统，参与本综合征的发作。相对来说，<10> γ-氨基丁酸</10>能受体可能存在缺陷，因为<12>地西泮</12>是一种<11>γ-氨基丁酸</11>（GABA）-模拟剂，可以产生明显的疗效。这是首例报道的可能由<3>哌醋甲酯</3>引起的<7>抗精神病药恶性综合征</7>患者。", "revised": true}
{"doc_key": "10401555", "sentences": [["Nociceptin", "/", "orphanin", "FQ", "and", "nocistatin", "on", "learning", "and", "memory", "impairment", "induced", "by", "scopolamine", "in", "mice", ".", "1", ".", "Nociceptin", ",", "also", "known", "as", "orphanin", "FQ", ",", "is", "an", "endogenous", "ligand", "for", "the", "orphan", "opioid", "receptor", "-", "like", "receptor", "1", "(", "ORL1", ")", "and", "involves", "in", "various", "functions", "in", "the", "central", "nervous", "system", "(", "CNS", ")", ".", "On", "the", "other", "hand", ",", "nocistatin", "is", "recently", "isolated", "from", "the", "same", "precursor", "as", "nociceptin", "and", "blocks", "nociceptin", "-", "induced", "allodynia", "and", "hyperalgesia", ".", "2", ".", "Although", "ORL1", "receptors", "which", "display", "a", "high", "degree", "of", "sequence", "homology", "with", "classical", "opioid", "receptors", "are", "abundant", "in", "the", "hippocampus", ",", "little", "is", "known", "regarding", "their", "role", "in", "learning", "and", "memory", ".", "3", ".", "The", "present", "study", "was", "designed", "to", "investigate", "whether", "nociceptin", "/", "orphanin", "FQ", "and", "nocistatin", "could", "modulate", "impairment", "of", "learning", "and", "memory", "induced", "by", "scopolamine", ",", "a", "muscarinic", "cholinergic", "receptor", "antagonist", ",", "using", "spontaneous", "alternation", "of", "Y", "-", "maze", "and", "step", "-", "down", "type", "passive", "avoidance", "tasks", "in", "mice", ".", "4", ".", "While", "nocistatin", "(", "0", ".", "5", "-", "5", ".", "0", "nmol", "mouse", "-", "1", ",", "i", ".", "c", ".", "v", ".", ")", "administered", "30", "min", "before", "spontaneous", "alternation", "performance", "or", "the", "training", "session", "of", "the", "passive", "avoidance", "task", ",", "had", "no", "effect", "on", "spontaneous", "alternation", "or", "passive", "avoidance", "behaviours", ",", "a", "lower", "per", "cent", "alternation", "and", "shorter", "median", "step", "-", "down", "latency", "in", "the", "retention", "test", "were", "obtained", "in", "nociceptin", "(", "1", ".", "5", "and", "/", "or", "5", ".", "0", "nmol", "mouse", "-", "1", ",", "i", ".", "c", ".", "v", ".", ")", "-", "treated", "normal", "mice", ".", "5", ".", "Administration", "of", "nocistatin", "(", "1", ".", "5", "and", "/", "or", "5", ".", "0", "nmol", "mouse", "-", "1", ",", "i", ".", "c", ".", "v", ".", ")", "30", "min", "before", "spontaneous", "alternation", "performance", "or", "the", "training", "session", "of", "the", "passive", "avoidance", "task", ",", "attenuated", "the", "scopolamine", "-", "induced", "impairment", "of", "spontaneous", "alternation", "and", "passive", "avoidance", "behaviours", ".", "6", ".", "These", "results", "indicated", "that", "nocistatin", ",", "a", "new", "biologically", "active", "peptide", ",", "ameliorates", "impairments", "of", "spontaneous", "alternation", "and", "passive", "avoidance", "induced", "by", "scopolamine", ",", "and", "suggested", "that", "these", "peptides", "play", "opposite", "roles", "in", "learning", "and", "memory", "."]], "ner": [[[13, 13, "Chemical"], [140, 140, "Chemical"], [310, 310, "Chemical"], [346, 346, "Chemical"], [7, 10, "Disease"], [133, 137, "Disease"], [0, 0, "Chemical"], [2, 3, "Chemical"], [19, 19, "Chemical"], [24, 25, "Chemical"], [71, 71, "Chemical"], [74, 74, "Chemical"], [125, 125, "Chemical"], [127, 128, "Chemical"], [237, 237, "Chemical"], [77, 77, "Disease"], [79, 79, "Disease"], [5, 5, "Chemical"], [62, 62, "Chemical"], [130, 130, "Chemical"], [169, 169, "Chemical"], [269, 269, "Chemical"], [328, 328, "Chemical"]]], "relations": [[[13, 13, 7, 10, "CID"], [13, 13, 133, 137, "CID"], [140, 140, 7, 10, "CID"], [140, 140, 133, 137, "CID"], [310, 310, 7, 10, "CID"], [310, 310, 133, 137, "CID"], [346, 346, 7, 10, "CID"], [346, 346, 133, 137, "CID"]]], "clusters": [], "translated": " <6> Nociceptin </6> / <7> orphanin FQ </7> 和 <17> nocistatin </17> 对由 <0> 东莨菪碱 </0> 所致的 <4> 学习记忆障碍 </4> 的影响在老鼠中。1. <8> Nociceptin </8>，又称为 <9> orphanin FQ </9>，是孤儿类阿片受体-1 (ORL1) 的内源性配体，参与中枢神经系统 (CNS) 的各种功能；另一方面，<18> nocistatin </18> 最近从与 <10> nociceptin </10> 相同的前体中分离出来，并阻断 <11> nociceptin </11> 诱导的 <15> 异感 </15> 和 <16> 痛觉过敏 </16>。2. 尽管 ORL1 受体与经典阿片受体具有较高的序列同源性，在海马区的作用还不十分清楚。3. 该研究旨在探讨 <12> nociceptin </12> / <13> orphanin FQ </13> 和 <19> nocistatin </19> 能否通过使用自发交替的 Y 迷宫和一种被动式避免任务——踏步下降型被动避免（step-down type passive avoidance）——来调节由 <1> 东莨菪碱 </1> 诱导的 <5> 学习和记忆障碍 </5>在小鼠中的表现。4. 而<20> nocistatin </20>（0.5~5.0 nmol mouse^-1, i.c.v.）在自发交替表现或被动回避任务训练前30分钟给药，对<14> 伤害感受肽 </14>（1.5 和/或 5.0 nmol mouse^-1, i.c.v.）治疗的正常小鼠没有效果。5. 而<21> nocistatin </21> （1.5 和/或 5.0 nmol mouse^-1, i.c.v.）给药30分钟后，使小鼠中使用的自发交替表现或被动回避任务训练的<2> 东莨菪碱 </2>诱导的障碍得到缓解。6. 这些结果表明，<22> nocistatin </22> 是一种新的生物活性肽，可以改善由 <3>东莨菪碱 </3> 诱导的自发交替和被动性避免的损伤，并表明这些肽在学习和记忆中发挥相反的作用。", "revised": true}
{"doc_key": "9646784", "sentences": [["Heparin", "-", "induced", "thrombocytopenia", ",", "paradoxical", "thromboembolism", ",", "and", "other", "side", "effects", "of", "heparin", "therapy", ".", "Although", "several", "new", "anticoagulant", "drugs", "are", "in", "development", ",", "heparin", "remains", "the", "drug", "of", "choice", "for", "most", "anticoagulation", "needs", ".", "The", "clinical", "effects", "of", "heparin", "are", "meritorious", ",", "but", "side", "effects", "do", "exist", ".", "Important", "untoward", "effects", "of", "heparin", "therapy", "including", "heparin", "-", "induced", "thrombocytopenia", ",", "heparin", "-", "associated", "osteoporosis", ",", "eosinophilia", ",", "skin", "reactions", ",", "allergic", "reactions", "other", "than", "thrombocytopenia", "and", "alopecia", "will", "be", "discussed", "in", "this", "article", "."]], "ner": [[[0, 0, "Chemical"], [13, 13, "Chemical"], [25, 25, "Chemical"], [40, 40, "Chemical"], [54, 54, "Chemical"], [57, 57, "Chemical"], [62, 62, "Chemical"], [3, 3, "Disease"], [60, 60, "Disease"], [76, 76, "Disease"], [6, 6, "Disease"], [65, 65, "Disease"], [67, 67, "Disease"], [69, 70, "Disease"], [72, 73, "Disease"], [78, 78, "Disease"]]], "relations": [[[0, 0, 3, 3, "CID"], [0, 0, 60, 60, "CID"], [0, 0, 76, 76, "CID"], [13, 13, 3, 3, "CID"], [13, 13, 60, 60, "CID"], [13, 13, 76, 76, "CID"], [25, 25, 3, 3, "CID"], [25, 25, 60, 60, "CID"], [25, 25, 76, 76, "CID"], [40, 40, 3, 3, "CID"], [40, 40, 60, 60, "CID"], [40, 40, 76, 76, "CID"], [54, 54, 3, 3, "CID"], [54, 54, 60, 60, "CID"], [54, 54, 76, 76, "CID"], [57, 57, 3, 3, "CID"], [57, 57, 60, 60, "CID"], [57, 57, 76, 76, "CID"], [62, 62, 3, 3, "CID"], [62, 62, 60, 60, "CID"], [62, 62, 76, 76, "CID"], [0, 0, 6, 6, "CID"], [13, 13, 6, 6, "CID"], [25, 25, 6, 6, "CID"], [40, 40, 6, 6, "CID"], [54, 54, 6, 6, "CID"], [57, 57, 6, 6, "CID"], [62, 62, 6, 6, "CID"], [0, 0, 65, 65, "CID"], [13, 13, 65, 65, "CID"], [25, 25, 65, 65, "CID"], [40, 40, 65, 65, "CID"], [54, 54, 65, 65, "CID"], [57, 57, 65, 65, "CID"], [62, 62, 65, 65, "CID"], [0, 0, 67, 67, "CID"], [13, 13, 67, 67, "CID"], [25, 25, 67, 67, "CID"], [40, 40, 67, 67, "CID"], [54, 54, 67, 67, "CID"], [57, 57, 67, 67, "CID"], [62, 62, 67, 67, "CID"], [0, 0, 69, 70, "CID"], [13, 13, 69, 70, "CID"], [25, 25, 69, 70, "CID"], [40, 40, 69, 70, "CID"], [54, 54, 69, 70, "CID"], [57, 57, 69, 70, "CID"], [62, 62, 69, 70, "CID"], [0, 0, 72, 73, "CID"], [13, 13, 72, 73, "CID"], [25, 25, 72, 73, "CID"], [40, 40, 72, 73, "CID"], [54, 54, 72, 73, "CID"], [57, 57, 72, 73, "CID"], [62, 62, 72, 73, "CID"], [0, 0, 78, 78, "CID"], [13, 13, 78, 78, "CID"], [25, 25, 78, 78, "CID"], [40, 40, 78, 78, "CID"], [54, 54, 78, 78, "CID"], [57, 57, 78, 78, "CID"], [62, 62, 78, 78, "CID"]]], "clusters": [], "translated": "<0>肝素</0>诱导的<7>血小板减少症</7>，矛盾的<10>血栓栓塞</10>，以及<1>肝素</1>治疗的其他副作用。尽管正在开发几种新的抗凝药物，<2>肝素</2>仍然是满足大多数抗凝需求的首选药物。 <3>肝素</3>的临床疗效肯定，但副作用确实存在。重要的<4>肝素</4>治疗副作用，包括<5>肝素</5>诱导的<8>血小板减少症</8>，<6>肝素</6>-相关的<11>骨质疏松症</11>，<12>嗜酸性粒细胞增多症</12>，<13>皮肤反应</13>，<14>过敏反应</14>（<9>血小板减少症</9>除外），以及<15>脱发</15>将在本文中进行讨论。", "revised": true}
{"doc_key": "10764869", "sentences": [["A", "case", "of", "bilateral", "optic", "neuropathy", "in", "a", "patient", "on", "tacrolimus", "(", "FK506", ")", "therapy", "after", "liver", "transplantation", ".", "PURPOSE", ":", "To", "report", "a", "case", "of", "bilateral", "optic", "neuropathy", "in", "a", "patient", "receiving", "tacrolimus", "(", "FK", "506", ",", "Prograf", ";", "Fujisawa", "USA", ",", "Inc", ",", "Deerfield", ",", "Illinois", ")", "for", "immunosuppression", "after", "orthotropic", "liver", "transplantation", ".", "METHOD", ":", "Case", "report", ".", "In", "a", "58", "-", "year", "-", "old", "man", "receiving", "tacrolimus", "after", "orthotropic", "liver", "transplantation", ",", "serial", "neuro", "-", "ophthalmologic", "examinations", "and", "laboratory", "studies", "were", "performed", ".", "RESULTS", ":", "The", "patient", "had", "episodic", "deterioration", "of", "vision", "in", "both", "eyes", ",", "with", "clinical", "features", "resembling", "ischemic", "optic", "neuropathies", ".", "Deterioration", "of", "vision", "occurred", "despite", "discontinuation", "of", "the", "tacrolimus", ".", "CONCLUSION", ":", "Tacrolimus", "and", "other", "immunosuppressive", "agents", "may", "be", "associated", "with", "optic", "nerve", "toxicity", "."]], "ner": [[[10, 10, "Chemical"], [12, 12, "Chemical"], [33, 33, "Chemical"], [35, 36, "Chemical"], [70, 70, "Chemical"], [116, 116, "Chemical"], [120, 120, "Chemical"], [4, 5, "Disease"], [27, 28, "Disease"], [129, 131, "Disease"], [104, 106, "Disease"], [108, 110, "Disease"]]], "relations": [[[10, 10, 4, 5, "CID"], [10, 10, 27, 28, "CID"], [10, 10, 129, 131, "CID"], [12, 12, 4, 5, "CID"], [12, 12, 27, 28, "CID"], [12, 12, 129, 131, "CID"], [33, 33, 4, 5, "CID"], [33, 33, 27, 28, "CID"], [33, 33, 129, 131, "CID"], [35, 36, 4, 5, "CID"], [35, 36, 27, 28, "CID"], [35, 36, 129, 131, "CID"], [70, 70, 4, 5, "CID"], [70, 70, 27, 28, "CID"], [70, 70, 129, 131, "CID"], [116, 116, 4, 5, "CID"], [116, 116, 27, 28, "CID"], [116, 116, 129, 131, "CID"], [120, 120, 4, 5, "CID"], [120, 120, 27, 28, "CID"], [120, 120, 129, 131, "CID"]]], "clusters": [], "translated": "肝移植术后<0>他克莫司</0>(<1>FK506</1>)治疗患者双侧<7>视神经病变</7>一例。目的：报告一名接受<2>他克莫司</2>治疗的患者出现双侧<8>视神经病变</8>的病例（<3>FK 506</3>，Prograf；Fujisawa USA，Inc，Deerfield，伊利诺伊州），用于正交异性肝移植后的免疫抑制。方法：病例报告。一名58岁的男性在接受正交异性肝移植后接受<4>他克莫司</4>治疗，进行了系列神经眼科检查和实验室研究。结果：患者双眼视力呈发作性下降，临床特征类似于<10>缺血性视神经病变</10>。<11>视力恶化</11>尽管停止了<5>他克莫司</5>。结论：<6>他克莫司</6>等免疫抑制剂可能与<9>视神经毒性</9>有关。", "revised": true}
{"doc_key": "10672628", "sentences": [["Sub", "-", "chronic", "inhibition", "of", "nitric", "-", "oxide", "synthesis", "modifies", "haloperidol", "-", "induced", "catalepsy", "and", "the", "number", "of", "NADPH", "-", "diaphorase", "neurons", "in", "mice", ".", "RATIONALE", ":", "NG", "-", "nitro", "-", "L", "-", "arginine", "(", "L", "-", "NOARG", ")", ",", "an", "inhibitor", "of", "nitric", "-", "oxide", "synthase", "(", "NOS", ")", ",", "induces", "catalepsy", "in", "mice", ".", "This", "effect", "undergoes", "rapid", "tolerance", ",", "showing", "a", "significant", "decrease", "after", "2", "days", "of", "sub", "-", "chronic", "L", "-", "NOARG", "treatment", ".", "Nitric", "oxide", "(", "NO", ")", "has", "been", "shown", "to", "influence", "dopaminergic", "neurotransmission", "in", "the", "striatum", ".", "Neuroleptic", "drugs", "such", "as", "haloperidol", ",", "which", "block", "dopamine", "receptors", ",", "also", "cause", "catalepsy", "in", "rodents", ".", "OBJECTIVES", ":", "To", "investigate", "the", "effects", "of", "subchronic", "L", "-", "NOARG", "treatment", "in", "haloperidol", "-", "induced", "catalepsy", "and", "the", "number", "of", "NOS", "neurons", "in", "areas", "related", "to", "motor", "control", ".", "METHODS", ":", "Male", "albino", "Swiss", "mice", "were", "treated", "sub", "-", "chronically", "(", "twice", "a", "day", "for", "4", "days", ")", "with", "L", "-", "NOARG", "(", "40", "mg", "/", "kg", "i", ".", "p", ".", ")", "or", "haloperidol", "(", "1", "mg", "/", "kg", "i", ".", "p", ".", ")", ".", "Catalepsy", "was", "evaluated", "at", "the", "beginning", "and", "the", "end", "of", "the", "treatments", ".", "Reduced", "nicotinamide", "adenine", "dinucleotide", "phosphate", "-", "diaphorase", "(", "NADPH", "-", "d", ")", "histochemistry", "was", "also", "employed", "to", "visualize", "NOS", "as", "an", "index", "of", "enzyme", "expression", "in", "mice", "brain", "regions", "related", "to", "motor", "control", ".", "RESULTS", ":", "L", "-", "NOARG", "sub", "-", "chronic", "administration", "produced", "tolerance", "of", "L", "-", "NOARG", "and", "of", "haloperidol", "-", "induced", "catalepsy", ".", "It", "also", "induced", "an", "increase", "in", "the", "number", "of", "NADPH", "-", "d", "-", "positive", "cells", "in", "the", "dorsal", "part", "of", "the", "caudate", "and", "accumbens", "nuclei", "compared", "with", "haloperidol", "and", "in", "the", "pedunculopontine", "tegmental", "nucleus", "compared", "with", "saline", ".", "In", "contrast", ",", "there", "was", "a", "decrease", "in", "NADPH", "-", "d", "neuron", "number", "in", "the", "substantia", "nigra", ",", "pars", "compacta", "in", "both", "haloperidol", "-", "treated", "and", "L", "-", "NOARG", "-", "treated", "animals", ".", "CONCLUSIONS", ":", "The", "results", "give", "further", "support", "to", "the", "hypothesis", "that", "NO", "plays", "a", "role", "in", "motor", "behavior", "control", "and", "suggest", "that", "it", "may", "take", "part", "in", "the", "synaptic", "changes", "produced", "by", "antipsychotic", "treatment", "."]], "ner": [[[10, 10, "Chemical"], [98, 98, "Chemical"], [124, 124, "Chemical"], [175, 175, "Chemical"], [251, 251, "Chemical"], [283, 283, "Chemical"], [316, 316, "Chemical"], [13, 13, "Disease"], [52, 52, "Disease"], [107, 107, "Disease"], [127, 127, "Disease"], [187, 187, "Disease"], [254, 254, "Disease"], [5, 7, "Chemical"], [43, 45, "Chemical"], [78, 79, "Chemical"], [81, 81, "Chemical"], [338, 338, "Chemical"], [18, 18, "Chemical"], [201, 204, "Chemical"], [208, 208, "Chemical"], [265, 265, "Chemical"], [302, 302, "Chemical"], [27, 33, "Chemical"], [35, 37, "Chemical"], [73, 75, "Chemical"], [119, 121, "Chemical"], [161, 163, "Chemical"], [236, 238, "Chemical"], [246, 248, "Chemical"], [320, 322, "Chemical"], [102, 102, "Chemical"]]], "relations": [[[10, 10, 13, 13, "CID"], [10, 10, 52, 52, "CID"], [10, 10, 107, 107, "CID"], [10, 10, 127, 127, "CID"], [10, 10, 187, 187, "CID"], [10, 10, 254, 254, "CID"], [98, 98, 13, 13, "CID"], [98, 98, 52, 52, "CID"], [98, 98, 107, 107, "CID"], [98, 98, 127, 127, "CID"], [98, 98, 187, 187, "CID"], [98, 98, 254, 254, "CID"], [124, 124, 13, 13, "CID"], [124, 124, 52, 52, "CID"], [124, 124, 107, 107, "CID"], [124, 124, 127, 127, "CID"], [124, 124, 187, 187, "CID"], [124, 124, 254, 254, "CID"], [175, 175, 13, 13, "CID"], [175, 175, 52, 52, "CID"], [175, 175, 107, 107, "CID"], [175, 175, 127, 127, "CID"], [175, 175, 187, 187, "CID"], [175, 175, 254, 254, "CID"], [251, 251, 13, 13, "CID"], [251, 251, 52, 52, "CID"], [251, 251, 107, 107, "CID"], [251, 251, 127, 127, "CID"], [251, 251, 187, 187, "CID"], [251, 251, 254, 254, "CID"], [283, 283, 13, 13, "CID"], [283, 283, 52, 52, "CID"], [283, 283, 107, 107, "CID"], [283, 283, 127, 127, "CID"], [283, 283, 187, 187, "CID"], [283, 283, 254, 254, "CID"], [316, 316, 13, 13, "CID"], [316, 316, 52, 52, "CID"], [316, 316, 107, 107, "CID"], [316, 316, 127, 127, "CID"], [316, 316, 187, 187, "CID"], [316, 316, 254, 254, "CID"]]], "clusters": [], "translated": "亚慢性抑制<13>一氧化氮</13>合成改变<0>氟哌啶醇</0>诱导的<7>僵直</7>和<18>NADPH</18>-心肌黄酶神经元的数量在小鼠中。基本原理：<23>NG-硝基-L-精氨酸</23>（<24>L-NOARG</24>），一种<14>一氧化氮</14>合酶（NOS）的抑制剂，诱导<8>小鼠强直性昏厥</8>。这种作用会迅速耐受，在亚慢性<25>L-NOARG</25>治疗2天后显着降低。<15>一氧化氮</15>（<16>NO</16>）已被证明会影响纹状体中的多巴胺能神经传递。神经安定药如<1>氟哌啶醇</1>，它阻断<31>多巴胺</31>受体，也会在啮齿类动物中引起<9>强直性昏厥</9>。目的：研究亚慢性<26>L-NOARG</26>治疗对<2>氟哌啶醇</2>-诱发的<10>僵住症</10>的影响以及运动控制相关区域的NOS神经元数量。方法：用<27>L-NOARG</27>（40mg/kg i.p.）或<3>氟哌啶醇</3>（1毫克/千克i.p.）治疗小白鼠。通过治疗开始和结束时的评估来确定<11>僵住症</11>。还原型<19>烟酰胺腺嘌呤二核苷酸磷酸</19>-心肌黄酶（<20>NADPH</20>-d）组织化学也被用来可视化NOS作为小鼠大脑区域与运动控制相关的酶表达指标。结果：<28>L-NOARG</28>亚慢性治疗诱导对<29>L-NOARG</29>和<4>氟哌啶醇</4>-诱导的<12>僵直</12>的耐受性。与<5>氟哌啶醇</5>相比，它还诱导了尾状核和伏隔核背侧<21>NADPH</21>-d阳性细胞数量的增加，与生理盐水相比。相比之下，黑质稠压部中的<22>NADPH</22>-d神经元数量在治疗后的动物中均有所下降，包括<6>氟哌啶醇</6>处理组和<30>L-NOARG</30>处理组。结论：结果进一步支持了<17>NO</17>在运动行为控制中发挥作用的假设，并暗示它可能参与抗精神病药物治疗产生的突触变化。", "revised": true}
{"doc_key": "10933650", "sentences": [["Attenuation", "of", "nephrotoxicity", "by", "a", "novel", "lipid", "nanosphere", "(", "NS", "-", "718", ")", "incorporating", "amphotericin", "B", ".", "NS", "-", "718", ",", "a", "lipid", "nanosphere", "incorporating", "amphotericin", "B", ",", "is", "effective", "against", "pathogenic", "fungi", "and", "has", "low", "toxicity", ".", "We", "compared", "the", "toxicity", "of", "NS", "-", "718", "with", "that", "of", "Fungizone", "(", "amphotericin", "B", "-", "sodium", "deoxycholate", ";", "D", "-", "AmB", ")", "in", "vitro", "using", "renal", "cell", "cultures", "and", "in", "vivo", "by", "biochemical", "analysis", ",", "histopathological", "study", "of", "the", "kidney", "and", "pharmacokinetic", "study", "of", "amphotericin", "B", "following", "intravenous", "infusion", "of", "the", "formulation", "in", "rats", ".", "Incubation", "with", "NS", "-", "718", "resulted", "in", "significantly", "less", "damage", "of", "cultured", "human", "renal", "proximal", "tubular", "epithelial", "cells", "compared", "with", "D", "-", "AmB", ".", "Serum", "blood", "urea", "and", "creatinine", "concentrations", "increased", "significantly", "in", "rats", "given", "an", "iv", "infusion", "of", "D", "-", "AmB", "3", "mg", "/", "kg", "but", "not", "in", "those", "given", "the", "same", "dose", "of", "NS", "-", "718", ".", "Histopathological", "examination", "of", "the", "kidney", "showed", "tubular", "necrosis", "in", "D", "-", "AmB", "-", "treated", "rats", "but", "no", "change", "in", "NS", "-", "718", "-", "treated", "rats", ".", "Amphotericin", "B", "concentrations", "in", "the", "kidney", "in", "NS", "-", "718", "-", "treated", "rats", "were", "higher", "than", "those", "in", "D", "-", "AmB", "-", "treated", "rats", ".", "Our", "in", "vitro", "and", "in", "vivo", "results", "suggest", "that", "incorporation", "of", "amphotericin", "B", "into", "lipid", "nanospheres", "of", "NS", "-", "718", "attenuates", "the", "nephrotoxicity", "of", "amphotericin", "B", "."]], "ner": [[[51, 55, "Chemical"], [57, 59, "Chemical"], [114, 116, "Chemical"], [133, 135, "Chemical"], [162, 164, "Chemical"], [197, 199, "Chemical"], [159, 160, "Disease"], [14, 15, "Chemical"], [25, 26, "Chemical"], [49, 49, "Chemical"], [83, 84, "Chemical"], [179, 180, "Chemical"], [215, 216, "Chemical"], [228, 229, "Chemical"], [2, 2, "Disease"], [226, 226, "Disease"], [120, 120, "Chemical"], [122, 122, "Chemical"], [36, 36, "Disease"], [41, 41, "Disease"]]], "relations": [[[51, 55, 159, 160, "CID"], [57, 59, 159, 160, "CID"], [114, 116, 159, 160, "CID"], [133, 135, 159, 160, "CID"], [162, 164, 159, 160, "CID"], [197, 199, 159, 160, "CID"]]], "clusters": [], "translated": "掺入 <7>两性霉素B</7>的新型脂质纳米球(NS-718)可减轻<14>肾毒性</14>。NS-718是一种含有<8>两性霉素B</8>的脂质纳米球，对致病真菌有效，<18>毒性较低</18>。我们比较了NS-718和<9>Fungizone</9>的<19>毒性</19>（<0>两性霉素B - 去氧胆酸钠</0>；<1>D-AmB</1>）在体外使用肾细胞培养物和体内生化分析、肾脏组织病理学研究和<10>两性霉素B</10>大鼠静脉输注后的药代动力学研究。与<2>D-AmB</2>相比，NS-718对培养的人肾近端小管上皮细胞的损伤明显更小。静脉输注<3>D-AmB</3>  3mg/kg的大鼠血清<16>尿素</16>和<17>肌酐</17>浓度显着增加，但给予相同剂量的大鼠NS-718则没有。肾脏的组织病理学检查显示<4>D-AmB</4>处理的大鼠<6>肾小管坏死</6>，但NS-718处理的大鼠无变化。<11>两性霉素B</11>在NS-718治疗大鼠肾脏中的浓度高于<5>D-AmB</5>治疗大鼠。我们的体外和体内结果表明，将<12>两性霉素B</12>掺入NS-718的脂质纳米球可减轻<15>肾毒性</15>的<13>两性霉素B</13>。", "revised": true}
{"doc_key": "10726030", "sentences": [["Clinical", "aspects", "of", "heparin", "-", "induced", "thrombocytopenia", "and", "thrombosis", "and", "other", "side", "effects", "of", "heparin", "therapy", ".", "Heparin", ",", "first", "used", "to", "prevent", "the", "clotting", "of", "blood", "in", "vitro", ",", "has", "been", "clinically", "used", "to", "treat", "thrombosis", "for", "more", "than", "50", "years", ".", "Although", "several", "new", "anticoagulant", "drugs", "are", "in", "development", ",", "heparin", "remains", "the", "anticoagulant", "of", "choice", "to", "treat", "acute", "thrombotic", "episodes", ".", "The", "clinical", "effects", "of", "heparin", "are", "meritorious", ",", "but", "side", "effects", "do", "exist", ".", "Bleeding", "is", "the", "primary", "untoward", "effect", "of", "heparin", ".", "Major", "bleeding", "is", "of", "primary", "concern", "in", "patients", "receiving", "heparin", "therapy", ".", "However", ",", "additional", "important", "untoward", "effects", "of", "heparin", "therapy", "include", "heparin", "-", "induced", "thrombocytopenia", ",", "heparin", "-", "associated", "osteoporosis", ",", "eosinophilia", ",", "skin", "reactions", ",", "allergic", "reactions", "other", "than", "thrombocytopenia", ",", "alopecia", ",", "transaminasemia", ",", "hyperkalemia", ",", "hypoaldosteronism", ",", "and", "priapism", ".", "These", "side", "effects", "are", "relatively", "rare", "in", "a", "given", "individual", ",", "but", "given", "the", "extremely", "widespread", "use", "of", "heparin", ",", "some", "are", "quite", "common", ",", "particularly", "HITT", "and", "osteoporosis", ".", "Although", "reasonable", "incidences", "of", "many", "of", "these", "side", "effects", "can", "be", "\"", "softly", "\"", "deduced", "from", "current", "reports", "dealing", "with", "unfractionated", "heparin", ",", "at", "present", "the", "incidences", "of", "these", "side", "effects", "with", "newer", "low", "molecular", "weight", "heparins", "appear", "to", "be", "much", "less", "common", ".", "However", ",", "only", "longer", "experience", "will", "more", "clearly", "define", "the", "incidence", "of", "each", "side", "effect", "with", "low", "molecular", "weight", "preparations", "."]], "ner": [[[3, 3, "Chemical"], [14, 14, "Chemical"], [17, 17, "Chemical"], [52, 52, "Chemical"], [68, 68, "Chemical"], [85, 85, "Chemical"], [96, 96, "Chemical"], [106, 106, "Chemical"], [109, 109, "Chemical"], [114, 114, "Chemical"], [159, 159, "Chemical"], [192, 192, "Chemical"], [207, 207, "Chemical"], [6, 6, "Disease"], [112, 112, "Disease"], [128, 128, "Disease"], [167, 167, "Disease"], [117, 117, "Disease"], [169, 169, "Disease"], [119, 119, "Disease"], [121, 122, "Disease"], [124, 125, "Disease"], [130, 130, "Disease"], [134, 134, "Disease"], [136, 136, "Disease"], [139, 139, "Disease"], [8, 8, "Disease"], [36, 36, "Disease"], [61, 61, "Disease"], [78, 78, "Disease"], [88, 88, "Disease"]]], "relations": [[[3, 3, 6, 6, "CID"], [3, 3, 112, 112, "CID"], [3, 3, 128, 128, "CID"], [3, 3, 167, 167, "CID"], [14, 14, 6, 6, "CID"], [14, 14, 112, 112, "CID"], [14, 14, 128, 128, "CID"], [14, 14, 167, 167, "CID"], [17, 17, 6, 6, "CID"], [17, 17, 112, 112, "CID"], [17, 17, 128, 128, "CID"], [17, 17, 167, 167, "CID"], [52, 52, 6, 6, "CID"], [52, 52, 112, 112, "CID"], [52, 52, 128, 128, "CID"], [52, 52, 167, 167, "CID"], [68, 68, 6, 6, "CID"], [68, 68, 112, 112, "CID"], [68, 68, 128, 128, "CID"], [68, 68, 167, 167, "CID"], [85, 85, 6, 6, "CID"], [85, 85, 112, 112, "CID"], [85, 85, 128, 128, "CID"], [85, 85, 167, 167, "CID"], [96, 96, 6, 6, "CID"], [96, 96, 112, 112, "CID"], [96, 96, 128, 128, "CID"], [96, 96, 167, 167, "CID"], [106, 106, 6, 6, "CID"], [106, 106, 112, 112, "CID"], [106, 106, 128, 128, "CID"], [106, 106, 167, 167, "CID"], [109, 109, 6, 6, "CID"], [109, 109, 112, 112, "CID"], [109, 109, 128, 128, "CID"], [109, 109, 167, 167, "CID"], [114, 114, 6, 6, "CID"], [114, 114, 112, 112, "CID"], [114, 114, 128, 128, "CID"], [114, 114, 167, 167, "CID"], [159, 159, 6, 6, "CID"], [159, 159, 112, 112, "CID"], [159, 159, 128, 128, "CID"], [159, 159, 167, 167, "CID"], [192, 192, 6, 6, "CID"], [192, 192, 112, 112, "CID"], [192, 192, 128, 128, "CID"], [192, 192, 167, 167, "CID"], [207, 207, 6, 6, "CID"], [207, 207, 112, 112, "CID"], [207, 207, 128, 128, "CID"], [207, 207, 167, 167, "CID"], [3, 3, 117, 117, "CID"], [3, 3, 169, 169, "CID"], [14, 14, 117, 117, "CID"], [14, 14, 169, 169, "CID"], [17, 17, 117, 117, "CID"], [17, 17, 169, 169, "CID"], [52, 52, 117, 117, "CID"], [52, 52, 169, 169, "CID"], [68, 68, 117, 117, "CID"], [68, 68, 169, 169, "CID"], [85, 85, 117, 117, "CID"], [85, 85, 169, 169, "CID"], [96, 96, 117, 117, "CID"], [96, 96, 169, 169, "CID"], [106, 106, 117, 117, "CID"], [106, 106, 169, 169, "CID"], [109, 109, 117, 117, "CID"], [109, 109, 169, 169, "CID"], [114, 114, 117, 117, "CID"], [114, 114, 169, 169, "CID"], [159, 159, 117, 117, "CID"], [159, 159, 169, 169, "CID"], [192, 192, 117, 117, "CID"], [192, 192, 169, 169, "CID"], [207, 207, 117, 117, "CID"], [207, 207, 169, 169, "CID"], [3, 3, 119, 119, "CID"], [14, 14, 119, 119, "CID"], [17, 17, 119, 119, "CID"], [52, 52, 119, 119, "CID"], [68, 68, 119, 119, "CID"], [85, 85, 119, 119, "CID"], [96, 96, 119, 119, "CID"], [106, 106, 119, 119, "CID"], [109, 109, 119, 119, "CID"], [114, 114, 119, 119, "CID"], [159, 159, 119, 119, "CID"], [192, 192, 119, 119, "CID"], [207, 207, 119, 119, "CID"], [3, 3, 121, 122, "CID"], [14, 14, 121, 122, "CID"], [17, 17, 121, 122, "CID"], [52, 52, 121, 122, "CID"], [68, 68, 121, 122, "CID"], [85, 85, 121, 122, "CID"], [96, 96, 121, 122, "CID"], [106, 106, 121, 122, "CID"], [109, 109, 121, 122, "CID"], [114, 114, 121, 122, "CID"], [159, 159, 121, 122, "CID"], [192, 192, 121, 122, "CID"], [207, 207, 121, 122, "CID"], [3, 3, 124, 125, "CID"], [14, 14, 124, 125, "CID"], [17, 17, 124, 125, "CID"], [52, 52, 124, 125, "CID"], [68, 68, 124, 125, "CID"], [85, 85, 124, 125, "CID"], [96, 96, 124, 125, "CID"], [106, 106, 124, 125, "CID"], [109, 109, 124, 125, "CID"], [114, 114, 124, 125, "CID"], [159, 159, 124, 125, "CID"], [192, 192, 124, 125, "CID"], [207, 207, 124, 125, "CID"], [3, 3, 130, 130, "CID"], [14, 14, 130, 130, "CID"], [17, 17, 130, 130, "CID"], [52, 52, 130, 130, "CID"], [68, 68, 130, 130, "CID"], [85, 85, 130, 130, "CID"], [96, 96, 130, 130, "CID"], [106, 106, 130, 130, "CID"], [109, 109, 130, 130, "CID"], [114, 114, 130, 130, "CID"], [159, 159, 130, 130, "CID"], [192, 192, 130, 130, "CID"], [207, 207, 130, 130, "CID"], [3, 3, 134, 134, "CID"], [14, 14, 134, 134, "CID"], [17, 17, 134, 134, "CID"], [52, 52, 134, 134, "CID"], [68, 68, 134, 134, "CID"], [85, 85, 134, 134, "CID"], [96, 96, 134, 134, "CID"], [106, 106, 134, 134, "CID"], [109, 109, 134, 134, "CID"], [114, 114, 134, 134, "CID"], [159, 159, 134, 134, "CID"], [192, 192, 134, 134, "CID"], [207, 207, 134, 134, "CID"], [3, 3, 136, 136, "CID"], [14, 14, 136, 136, "CID"], [17, 17, 136, 136, "CID"], [52, 52, 136, 136, "CID"], [68, 68, 136, 136, "CID"], [85, 85, 136, 136, "CID"], [96, 96, 136, 136, "CID"], [106, 106, 136, 136, "CID"], [109, 109, 136, 136, "CID"], [114, 114, 136, 136, "CID"], [159, 159, 136, 136, "CID"], [192, 192, 136, 136, "CID"], [207, 207, 136, 136, "CID"], [3, 3, 139, 139, "CID"], [14, 14, 139, 139, "CID"], [17, 17, 139, 139, "CID"], [52, 52, 139, 139, "CID"], [68, 68, 139, 139, "CID"], [85, 85, 139, 139, "CID"], [96, 96, 139, 139, "CID"], [106, 106, 139, 139, "CID"], [109, 109, 139, 139, "CID"], [114, 114, 139, 139, "CID"], [159, 159, 139, 139, "CID"], [192, 192, 139, 139, "CID"], [207, 207, 139, 139, "CID"]]], "clusters": [], "translated": "<0>肝素</0>引起的<13>血小板减少</13>和<26>血栓形成</26>以及<1>肝素</1>治疗的其他副作用的临床方面。<2>肝素</2>最早用于体外防止血液凝固，临床上用于治疗<27>血栓</27>已有50多年的历史。尽管正在开发几种新的抗凝药物，<3>肝素</3>仍然是治疗急性<28>血栓</28>发作的首选抗凝药物。 <4>肝素</4>的临床疗效肯定，但副作用确实存在。<29>出血</29>是<5>肝素</5>的主要不良反应。接受<6>肝素</6>治疗的患者主要关注<30>出血</30>。然而，<7>肝素</7>治疗的其他重要副作用包括<8>肝素</8>诱发的<14>血小板减少症</14>，<9>肝素</9>相关的<17>骨质疏松症</17>，<19>嗜酸性粒细胞增多</19>，<20>皮肤反应</20>，<21>过敏反应</21>，<15>血小板减少症</15>以外的过敏反应，<22>脱发</22>，转氨酶升高，<23>高钾血症</23>，<24>低醛固酮症</24>以及<25>阴茎异常勃起</25>。这些副作用在特定个体中相对罕见，但考虑到<10>肝素</10>的广泛使用，有些副作用很常见，特别是<16>HITT</16>和<18>骨质疏松症</18>。虽然许多这些副作用的合理发生率可以从当前处理非分离<11>肝素</11>的报告中“温和地”推断出来，但目前这些副作用在使用新型<12>低分子肝素</12>时的发生率似乎不太常见。然而，只有更长时间的经验才能更清楚地确定每种低分子肝素制剂的每种副作用的频率。", "revised": true}
{"doc_key": "10713017", "sentences": [["Anorexigens", "and", "pulmonary", "hypertension", "in", "the", "United", "States", ":", "results", "from", "the", "surveillance", "of", "North", "American", "pulmonary", "hypertension", ".", "BACKGROUND", ":", "The", "use", "of", "appetite", "suppressants", "in", "Europe", "has", "been", "associated", "with", "the", "development", "of", "primary", "pulmonary", "hypertension", "(", "PPH", ")", ".", "Recently", ",", "fenfluramine", "appetite", "suppressants", "became", "widely", "used", "in", "the", "United", "States", "but", "were", "withdrawn", "in", "September", "1997", "because", "of", "concerns", "over", "adverse", "effects", ".", "MATERIALS", "AND", "METHODS", ":", "We", "conducted", "a", "prospective", "surveillance", "study", "on", "patients", "diagnosed", "with", "pulmonary", "hypertension", "at", "12", "large", "referral", "centers", "in", "North", "America", ".", "Data", "collected", "on", "patients", "seen", "from", "September", "1", ",", "1996", ",", "to", "December", "31", ",", "1997", ",", "included", "the", "cause", "of", "the", "pulmonary", "hypertension", "and", "its", "severity", ".", "Patients", "with", "no", "identifiable", "cause", "of", "pulmonary", "hypertension", "were", "classed", "as", "PPH", ".", "A", "history", "of", "drug", "exposure", "also", "was", "taken", "with", "special", "attention", "on", "the", "use", "of", "antidepressants", ",", "anorexigens", ",", "and", "amphetamines", ".", "RESULTS", ":", "Five", "hundred", "seventy", "-", "nine", "patients", "were", "studied", ",", "205", "with", "PPH", "and", "374", "with", "pulmonary", "hypertension", "from", "other", "causes", "(", "secondary", "pulmonary", "hypertension", "[", "SPH", "]", ")", ".", "The", "use", "of", "anorexigens", "was", "common", "in", "both", "groups", ".", "However", ",", "of", "the", "medications", "surveyed", ",", "only", "the", "fenfluramines", "had", "a", "significant", "preferential", "association", "with", "PPH", "as", "compared", "with", "SPH", "(", "adjusted", "odds", "ratio", "for", "use", ">", "6", "months", ",", "7", ".", "5", ";", "95", "%", "confidence", "interval", ",", "1", ".", "7", "to", "32", ".", "4", ")", ".", "The", "association", "was", "stronger", "with", "longer", "duration", "of", "use", "when", "compared", "to", "shorter", "duration", "of", "use", "and", "was", "more", "pronounced", "in", "recent", "users", "than", "in", "remote", "users", ".", "An", "unexpectedly", "high", "(", "11", ".", "4", "%", ")", "number", "of", "patients", "with", "SPH", "had", "used", "anorexigens", ".", "CONCLUSION", ":", "The", "magnitude", "of", "the", "association", "with", "PPH", ",", "the", "increase", "of", "association", "with", "increasing", "duration", "of", "use", ",", "and", "the", "specificity", "for", "fenfluramines", "are", "consistent", "with", "previous", "studies", "indicating", "that", "fenfluramines", "are", "causally", "related", "to", "PPH", ".", "The", "high", "prevalence", "of", "anorexigen", "use", "in", "patients", "with", "SPH", "also", "raises", "the", "possibility", "that", "these", "drugs", "precipitate", "pulmonary", "hypertension", "in", "patients", "with", "underlying", "conditions", "associated", "with", "SPH", "."]], "ner": [[[44, 44, "Chemical"], [205, 205, "Chemical"], [315, 315, "Chemical"], [323, 323, "Chemical"], [2, 3, "Disease"], [16, 17, "Disease"], [35, 37, "Disease"], [39, 39, "Disease"], [81, 82, "Disease"], [114, 115, "Disease"], [126, 127, "Disease"], [131, 131, "Disease"], [168, 168, "Disease"], [172, 173, "Disease"], [179, 180, "Disease"], [212, 212, "Disease"], [299, 299, "Disease"], [328, 328, "Disease"], [348, 349, "Disease"], [153, 153, "Chemical"]]], "relations": [[[44, 44, 2, 3, "CID"], [44, 44, 16, 17, "CID"], [44, 44, 35, 37, "CID"], [44, 44, 39, 39, "CID"], [44, 44, 81, 82, "CID"], [44, 44, 114, 115, "CID"], [44, 44, 126, 127, "CID"], [44, 44, 131, 131, "CID"], [44, 44, 168, 168, "CID"], [44, 44, 172, 173, "CID"], [44, 44, 179, 180, "CID"], [44, 44, 212, 212, "CID"], [44, 44, 299, 299, "CID"], [44, 44, 328, 328, "CID"], [44, 44, 348, 349, "CID"], [205, 205, 2, 3, "CID"], [205, 205, 16, 17, "CID"], [205, 205, 35, 37, "CID"], [205, 205, 39, 39, "CID"], [205, 205, 81, 82, "CID"], [205, 205, 114, 115, "CID"], [205, 205, 126, 127, "CID"], [205, 205, 131, 131, "CID"], [205, 205, 168, 168, "CID"], [205, 205, 172, 173, "CID"], [205, 205, 179, 180, "CID"], [205, 205, 212, 212, "CID"], [205, 205, 299, 299, "CID"], [205, 205, 328, 328, "CID"], [205, 205, 348, 349, "CID"], [315, 315, 2, 3, "CID"], [315, 315, 16, 17, "CID"], [315, 315, 35, 37, "CID"], [315, 315, 39, 39, "CID"], [315, 315, 81, 82, "CID"], [315, 315, 114, 115, "CID"], [315, 315, 126, 127, "CID"], [315, 315, 131, 131, "CID"], [315, 315, 168, 168, "CID"], [315, 315, 172, 173, "CID"], [315, 315, 179, 180, "CID"], [315, 315, 212, 212, "CID"], [315, 315, 299, 299, "CID"], [315, 315, 328, 328, "CID"], [315, 315, 348, 349, "CID"], [323, 323, 2, 3, "CID"], [323, 323, 16, 17, "CID"], [323, 323, 35, 37, "CID"], [323, 323, 39, 39, "CID"], [323, 323, 81, 82, "CID"], [323, 323, 114, 115, "CID"], [323, 323, 126, 127, "CID"], [323, 323, 131, 131, "CID"], [323, 323, 168, 168, "CID"], [323, 323, 172, 173, "CID"], [323, 323, 179, 180, "CID"], [323, 323, 212, 212, "CID"], [323, 323, 299, 299, "CID"], [323, 323, 328, 328, "CID"], [323, 323, 348, 349, "CID"]]], "clusters": [], "translated": "美国的厌食剂和<4>肺动脉高压</4>：来自北美<5>肺动脉高压</5>监测的结果。背景：在欧洲，食欲抑制剂的使用与<6>原发性肺动脉高压</6> (<7>PPH</7>)的发展有关。最近，<0>芬氟拉明</0>食欲抑制剂在美国广泛使用，但由于担心不良反应于1997年9月被撤回。材料和方法：我们对北美12个大型转诊中心诊断为<8>肺动脉高压</8>的患者进行了前瞻性监测研究。从1996年9月1日到1997年12月31日期间收集的患者数据包括<9>肺动脉高压</9>的原因及其严重程度。没有可识别的<10>肺动脉高压</10>原因的患者被归类为<11>PPH</11>。还记录了药物接触史，特别注意使用抗抑郁药、食欲减退药和<19>苯丙胺</19>。结果：共研究了579名患者，其中205名患有<12>PPH</12>，374名患有因其他原因（继发性<14>肺动脉高压</14>[SPH]引起的<13>肺动脉高压</13>)。厌食剂的使用在两组中都很常见。然而，在接受调查的药物中，与SPH相比，只有<1>芬氟拉明</1>与<15>PPH</15>有显着的优先相关性（调整后的优势比>6个月，7.5; 95%置信区间，1.7至32.4）。与使用时间较短的用户相比，使用时间越长的关联越强烈，并且在最近的用户中比在远程用户中更明显。出乎意料地高(11.4%)的SPH患者使用过食欲减退剂。结论：与<16>PPH</16>关联的程度、关联随着使用时间的增加而增加，以及对<2>芬氟拉明</2>的特异性与之前的研究一致，表明<3>芬氟拉明</3>与<17>PPH</17>有因果关系。SPH患者使用厌食素的高流行率也增加了这些药物在具有与SPH相关的基础疾病的患者中诱发<18>肺动脉高压</18>的可能性。", "revised": true}
{"doc_key": "10960401", "sentences": [["Downbeat", "nystagmus", "associated", "with", "intravenous", "patient", "-", "controlled", "administration", "of", "morphine", ".", "IMPLICATIONS", ":", "This", "case", "documents", "a", "patient", "who", "developed", "dizziness", "with", "downbeating", "nystagmus", "while", "receiving", "a", "relatively", "large", "dose", "of", "IV", "patient", "-", "controlled", "analgesia", "morphine", ".", "Although", "there", "have", "been", "case", "reports", "of", "epidural", "morphine", "with", "these", "symptoms", "and", "signs", ",", "this", "has", "not", "been", "previously", "documented", "with", "IV", "or", "patient", "-", "controlled", "analgesia", "morphine", "."]], "ner": [[[10, 10, "Chemical"], [37, 37, "Chemical"], [47, 47, "Chemical"], [67, 67, "Chemical"], [0, 1, "Disease"], [23, 24, "Disease"], [21, 21, "Disease"]]], "relations": [[[10, 10, 0, 1, "CID"], [10, 10, 23, 24, "CID"], [37, 37, 0, 1, "CID"], [37, 37, 23, 24, "CID"], [47, 47, 0, 1, "CID"], [47, 47, 23, 24, "CID"], [67, 67, 0, 1, "CID"], [67, 67, 23, 24, "CID"], [10, 10, 21, 21, "CID"], [37, 37, 21, 21, "CID"], [47, 47, 21, 21, "CID"], [67, 67, 21, 21, "CID"]]], "clusters": [], "translated": "<4> 下压性眼球震颤 </4> 与患者自控静脉注射<0>吗啡</0>相关。意义：该病例记录了一名患者在接受相对大剂量的静脉自控镇痛剂<1>吗啡</1>时出现<5>下跳性眼球震颤</5>并伴有<6>头晕</6>。虽然有硬膜外<2>吗啡</2>出现这些症状和体征的病例报告，但以前没有关于静脉注射或患者自控镇痛<3>吗啡</3>的报道。", "revised": true}
{"doc_key": "10677406", "sentences": [["Prolonged", "left", "ventricular", "dysfunction", "occurs", "in", "patients", "with", "coronary", "artery", "disease", "after", "both", "dobutamine", "and", "exercise", "induced", "myocardial", "ischaemia", ".", "OBJECTIVE", ":", "To", "determine", "whether", "pharmacological", "stress", "leads", "to", "prolonged", "but", "reversible", "left", "ventricular", "dysfunction", "in", "patients", "with", "coronary", "artery", "disease", ",", "similar", "to", "that", "seen", "after", "exercise", ".", "DESIGN", ":", "A", "randomised", "crossover", "study", "of", "recovery", "time", "of", "systolic", "and", "diastolic", "left", "ventricular", "function", "after", "exercise", "and", "dobutamine", "induced", "ischaemia", ".", "SUBJECTS", ":", "10", "patients", "with", "stable", "angina", ",", "angiographically", "proven", "coronary", "artery", "disease", ",", "and", "normal", "left", "ventricular", "function", ".", "INTERVENTIONS", ":", "Treadmill", "exercise", "and", "dobutamine", "stress", "were", "performed", "on", "different", "days", ".", "Quantitative", "assessment", "of", "systolic", "and", "diastolic", "left", "ventricular", "function", "was", "performed", "using", "transthoracic", "echocardiography", "at", "baseline", "and", "at", "regular", "intervals", "after", "each", "test", ".", "RESULTS", ":", "Both", "forms", "of", "stress", "led", "to", "prolonged", "but", "reversible", "systolic", "and", "diastolic", "dysfunction", ".", "There", "was", "no", "difference", "in", "the", "maximum", "double", "product", "(", "p", "=", "0", ".", "53", ")", "or", "ST", "depression", "(", "p", "=", "0", ".", "63", ")", "with", "either", "form", "of", "stress", ".", "After", "exercise", ",", "ejection", "fraction", "was", "reduced", "at", "15", "and", "30", "minutes", "compared", "with", "baseline", "(", "mean", "(", "SEM", ")", ",", "-", "5", ".", "6", "(", "1", ".", "5", ")", "%", ",", "p", "<", "0", ".", "05", ";", "and", "-", "6", ".", "1", "(", "2", ".", "2", ")", "%", ",", "p", "<", "0", ".", "01", ")", ",", "and", "at", "30", "and", "45", "minutes", "after", "dobutamine", "(", "-", "10", ".", "8", "(", "1", ".", "8", ")", "%", "and", "-", "5", ".", "5", "(", "1", ".", "8", ")", "%", ",", "both", "p", "<", "0", ".", "01", ")", ".", "Regional", "analysis", "showed", "a", "reduction", "in", "the", "worst", "affected", "segment", "15", "and", "30", "minutes", "after", "exercise", "(", "-", "27", ".", "9", "(", "7", ".", "2", ")", "%", "and", "-", "28", ".", "6", "(", "5", ".", "7", ")", "%", ",", "both", "p", "<", "0", ".", "01", ")", ",", "and", "at", "30", "minutes", "after", "dobutamine", "(", "-", "32", "(", "5", ".", "3", ")", "%", ",", "p", "<", "0", ".", "01", ")", ".", "The", "isovolumic", "relaxation", "period", "was", "prolonged", "45", "minutes", "after", "each", "form", "of", "stress", "(", "p", "<", "0", ".", "05", ")", ".", "CONCLUSIONS", ":", "In", "patients", "with", "coronary", "artery", "disease", ",", "dobutamine", "induced", "ischaemia", "results", "in", "prolonged", "reversible", "left", "ventricular", "dysfunction", ",", "presumed", "to", "be", "myocardial", "stunning", ",", "similar", "to", "that", "seen", "after", "exercise", ".", "Dobutamine", "induced", "ischaemia", "could", "therefore", "be", "used", "to", "study", "the", "pathophysiology", "of", "this", "phenomenon", "further", "in", "patients", "with", "coronary", "artery", "disease", "."]], "ner": [[[13, 13, "Chemical"], [68, 68, "Chemical"], [97, 97, "Chemical"], [241, 241, "Chemical"], [325, 325, "Chemical"], [373, 373, "Chemical"], [397, 397, "Chemical"], [1, 3, "Disease"], [32, 34, "Disease"], [380, 382, "Disease"], [387, 388, "Disease"], [8, 10, "Disease"], [38, 40, "Disease"], [82, 84, "Disease"], [369, 371, "Disease"], [415, 417, "Disease"], [17, 18, "Disease"], [70, 70, "Disease"], [375, 375, "Disease"], [399, 399, "Disease"], [77, 78, "Disease"], [163, 163, "Disease"]]], "relations": [[[13, 13, 1, 3, "CID"], [13, 13, 32, 34, "CID"], [13, 13, 380, 382, "CID"], [68, 68, 1, 3, "CID"], [68, 68, 32, 34, "CID"], [68, 68, 380, 382, "CID"], [97, 97, 1, 3, "CID"], [97, 97, 32, 34, "CID"], [97, 97, 380, 382, "CID"], [241, 241, 1, 3, "CID"], [241, 241, 32, 34, "CID"], [241, 241, 380, 382, "CID"], [325, 325, 1, 3, "CID"], [325, 325, 32, 34, "CID"], [325, 325, 380, 382, "CID"], [373, 373, 1, 3, "CID"], [373, 373, 32, 34, "CID"], [373, 373, 380, 382, "CID"], [397, 397, 1, 3, "CID"], [397, 397, 32, 34, "CID"], [397, 397, 380, 382, "CID"], [13, 13, 387, 388, "CID"], [68, 68, 387, 388, "CID"], [97, 97, 387, 388, "CID"], [241, 241, 387, 388, "CID"], [325, 325, 387, 388, "CID"], [373, 373, 387, 388, "CID"], [397, 397, 387, 388, "CID"]]], "clusters": [], "translated": "<0>多巴酚丁胺</0>和运动引起的<16>心肌缺血</16>后，<11>冠状动脉疾病</11>患者会出现长期<7>左心室功能障碍</7>。目的：确定药物应激是否会导致<12>冠状动脉疾病</12>患者出现长期但可逆的<8>左心室功能障碍</8>，类似于运动后所见。设计：一项关于运动和<1>多巴酚丁胺</1>引起的<17>缺血</17>后左心室收缩和舒张功能恢复时间的随机交叉研究。受试者：10名<20>稳定型心绞痛</20>、血管造影证实<13>冠状动脉疾病</13>且左心室功能正常的患者。干预措施：跑步机锻炼和<2>多巴酚丁胺</2>压力在不同的日子进行。在基线和每次测试后定期使用经胸超声心动图对左心室收缩和舒张功能进行定量评估。结果：两种形式的压力都会导致长期但可逆的收缩和舒张功能障碍。最大双乘积（p=0.53）或ST<21>抑郁</21>（p=0.63）与任何一种压力形式都没有差异。运动后，与基线相比，15分钟和30分钟射血分数降低（平均值（SEM），-5.6（1.5）％，p<0.05；和-6.1（2.2）％，p<0.01），在<3>多巴酚丁胺</3>后30和45分钟（-10.8（1.8)%和-5.5（1.8）％，两者p<0.01）。区域分析显示在运动后15分钟和30分钟（-27.9（7.2）％和-28.6（5.7）％，均p<0.01），以及<4>多巴酚丁胺</4>后30分钟，受影响最严重的部分有所减少（-32（5.3）％，p<0.01）。等容舒张期在每种形式的应激后延长了45分钟（p<0.05）。结论：在<14>冠状动脉疾病</14>患者中，<5>多巴酚丁胺</5>引起的<18>缺血</18>导致长期可逆<9>左心室功能障碍</9>，推测是<10>心肌顿抑</10>，类似于运动后看到的。<6>多巴酚丁胺</6>诱导的<19>缺血</19>因此可用于进一步研究<15>冠状动脉疾病</15>患者这种现象的病理生理学。", "revised": true}
{"doc_key": "11105626", "sentences": [["A", "case", "of", "isotretinoin", "embryopathy", "with", "bilateral", "anotia", "and", "Taussig", "-", "Bing", "malformation", ".", "We", "report", "a", "newborn", "infant", "with", "multiple", "congenital", "anomalies", "(", "anotia", "and", "Taussig", "-", "Bing", "malformation", ")", "due", "to", "exposure", "to", "isotretinoin", "within", "the", "first", "trimester", ".", "In", "this", "paper", "we", "aim", "to", "draw", "to", "the", "fact", "that", "caution", "is", "needed", "when", "prescribing", "vitamin", "A", "-", "containing", "drugs", "to", "women", "of", "childbearing", "years", "."]], "ner": [[[35, 35, "Chemical"], [3, 4, "Disease"], [7, 7, "Disease"], [24, 24, "Disease"], [9, 12, "Disease"], [26, 29, "Disease"], [57, 58, "Chemical"]]], "relations": [[[35, 35, 3, 4, "CID"], [35, 35, 7, 7, "CID"], [35, 35, 24, 24, "CID"], [35, 35, 9, 12, "CID"], [35, 35, 26, 29, "CID"]]], "clusters": [], "translated": "<1>异维A酸胚胎病</1>伴双侧<2>无耳</2>和<4>Taussig-Bing畸形</4>一例。我们报告了一名新生儿由于在怀孕的最初三个月使用过<0>异维A酸</0>而患有多种先天性异常（<3>无耳</3>和<5>Taussig-Bing畸形</5>）。在本文中，我们的目的是提醒人们在给育龄妇女开具含有<6>维生素A</6>的药物处方时需要谨慎。", "revised": true}
{"doc_key": "9125676", "sentences": [["Efficacy", "and", "proarrhythmia", "with", "the", "use", "of", "d", ",", "l", "-", "sotalol", "for", "sustained", "ventricular", "tachyarrhythmias", ".", "This", "study", "prospectively", "evaluated", "the", "clinical", "efficacy", ",", "the", "incidence", "of", "torsades", "de", "pointes", ",", "and", "the", "presumable", "risk", "factors", "for", "torsades", "de", "pointes", "in", "patients", "treated", "with", "d", ",", "l", "-", "sotalol", "for", "sustained", "ventricular", "tachyarrhythmias", ".", "Eighty", "-", "one", "consecutive", "patients", "(", "54", "with", "coronary", "artery", "disease", ",", "and", "20", "with", "dilated", "cardiomyopathy", ")", "with", "inducible", "sustained", "ventricular", "tachycardia", "or", "ventricular", "fibrillation", "received", "oral", "d", ",", "l", "-", "sotalol", "to", "prevent", "induction", "of", "the", "ventricular", "tachyarrhythmia", ".", "During", "oral", "loading", "with", "d", ",", "l", "-", "sotalol", ",", "continuous", "electrocardiographic", "(", "ECG", ")", "monitoring", "was", "performed", ".", "Those", "patients", "in", "whom", "d", ",", "l", "-", "sotalol", "prevented", "induction", "of", "ventricular", "tachycardia", "or", "ventricular", "fibrillation", "were", "discharged", "with", "the", "drug", "and", "followed", "up", "on", "an", "outpatient", "basis", "for", "21", "+", "/", "-", "18", "months", ".", "Induction", "of", "the", "ventricular", "tachyarrhythmia", "was", "prevented", "by", "oral", "d", ",", "l", "-", "sotalol", "in", "35", "(", "43", "%", ")", "patients", ";", "the", "ventricular", "tachyarrhythmia", "remained", "inducible", "in", "40", "(", "49", "%", ")", "patients", ";", "and", "two", "(", "2", ".", "5", "%", ")", "patients", "did", "not", "tolerate", "even", "40", "mg", "of", "d", ",", "l", "-", "sotalol", "once", "daily", ".", "Four", "(", "5", "%", ")", "patients", "had", "from", "torsades", "de", "pointes", "during", "the", "initial", "oral", "treatment", "with", "d", ",", "l", "-", "sotalol", ".", "Neither", "ECG", "[", "sinus", "-", "cycle", "length", "(", "SCL", ")", ",", "QT", "or", "QTc", "interval", ",", "or", "U", "wave", "]", "nor", "clinical", "parameters", "identified", "patients", "at", "risk", "for", "torsades", "de", "pointes", ".", "However", ",", "the", "oral", "dose", "of", "d", ",", "l", "-", "sotalol", "was", "significantly", "lower", "in", "patients", "with", "torsades", "de", "pointes", "(", "200", "+", "/", "-", "46", "vs", ".", "328", "+", "/", "-", "53", "mg", "/", "day", ";", "p", "=", "0", ".", "0017", ")", ".", "Risk", "factors", "associated", "with", "the", "development", "of", "torsades", "de", "pointes", "were", "the", "appearance", "of", "an", "U", "wave", "(", "p", "=", "0", ".", "049", ")", ",", "female", "gender", "(", "p", "=", "0", ".", "015", ")", ",", "and", "significant", "dose", "-", "corrected", "changes", "of", "SCL", ",", "QT", "interval", ",", "and", "QTc", "interval", "(", "p", "<", "0", ".", "05", ")", ".", "During", "follow", "-", "up", ",", "seven", "(", "20", "%", ")", "patients", "had", "a", "nonfatal", "ventricular", "tachycardia", "recurrence", ",", "and", "two", "(", "6", "%", ")", "patients", "died", "suddenly", ".", "One", "female", "patient", "with", "stable", "cardiac", "disease", "had", "recurrent", "torsades", "de", "pointes", "after", "2", "years", "of", "successful", "treatment", "with", "d", ",", "l", "-", "sotalol", ".", "Torsades", "de", "pointes", "occurred", "early", "during", "treatment", "even", "with", "low", "doses", "of", "oral", "d", ",", "l", "-", "sotalol", ".", "Pronounced", "changes", "in", "the", "surface", "ECG", "(", "cycle", "length", ",", "QT", ",", "and", "QTc", ")", "in", "relation", "to", "the", "dose", "of", "oral", "d", ",", "l", "-", "sotalol", "might", "identify", "a", "subgroup", "of", "patients", "with", "an", "increased", "risk", "for", "torsades", "de", "pointes", ".", "Other", "ECG", "parameters", "before", "the", "application", "of", "d", ",", "l", "-", "sotalol", "did", "not", "identify", "patients", "at", "increased", "risk", "for", "torsades", "de", "pointes", ".", "Recurrence", "rates", "of", "ventricular", "tachyarrhythmias", "are", "high", "despite", "complete", "suppression", "of", "the", "arrhythmia", "during", "programmed", "stimulation", ".", "Therefore", "programmed", "electrical", "stimulation", "in", "the", "case", "of", "d", ",", "l", "-", "sotalol", "seems", "to", "be", "of", "limited", "prognostic", "value", "."]], "ner": [[[7, 11, "Chemical"], [45, 49, "Chemical"], [83, 87, "Chemical"], [100, 104, "Chemical"], [119, 123, "Chemical"], [161, 165, "Chemical"], [203, 207, "Chemical"], [228, 232, "Chemical"], [272, 276, "Chemical"], [415, 419, "Chemical"], [434, 438, "Chemical"], [462, 466, "Chemical"], [489, 493, "Chemical"], [531, 535, "Chemical"], [28, 30, "Disease"], [38, 40, "Disease"], [219, 221, "Disease"], [262, 264, "Disease"], [283, 285, "Disease"], [317, 319, "Disease"], [405, 407, "Disease"], [421, 423, "Disease"], [478, 480, "Disease"], [502, 504, "Disease"], [14, 15, "Disease"], [52, 53, "Disease"], [76, 77, "Disease"], [93, 94, "Disease"], [127, 128, "Disease"], [155, 156, "Disease"], [175, 176, "Disease"], [382, 383, "Disease"], [509, 510, "Disease"], [63, 65, "Disease"], [70, 71, "Disease"], [79, 80, "Disease"], [130, 131, "Disease"], [401, 402, "Disease"], [518, 518, "Disease"]]], "relations": [[[7, 11, 28, 30, "CID"], [7, 11, 38, 40, "CID"], [7, 11, 219, 221, "CID"], [7, 11, 262, 264, "CID"], [7, 11, 283, 285, "CID"], [7, 11, 317, 319, "CID"], [7, 11, 405, 407, "CID"], [7, 11, 421, 423, "CID"], [7, 11, 478, 480, "CID"], [7, 11, 502, 504, "CID"], [45, 49, 28, 30, "CID"], [45, 49, 38, 40, "CID"], [45, 49, 219, 221, "CID"], [45, 49, 262, 264, "CID"], [45, 49, 283, 285, "CID"], [45, 49, 317, 319, "CID"], [45, 49, 405, 407, "CID"], [45, 49, 421, 423, "CID"], [45, 49, 478, 480, "CID"], [45, 49, 502, 504, "CID"], [83, 87, 28, 30, "CID"], [83, 87, 38, 40, "CID"], [83, 87, 219, 221, "CID"], [83, 87, 262, 264, "CID"], [83, 87, 283, 285, "CID"], [83, 87, 317, 319, "CID"], [83, 87, 405, 407, "CID"], [83, 87, 421, 423, "CID"], [83, 87, 478, 480, "CID"], [83, 87, 502, 504, "CID"], [100, 104, 28, 30, "CID"], [100, 104, 38, 40, "CID"], [100, 104, 219, 221, "CID"], [100, 104, 262, 264, "CID"], [100, 104, 283, 285, "CID"], [100, 104, 317, 319, "CID"], [100, 104, 405, 407, "CID"], [100, 104, 421, 423, "CID"], [100, 104, 478, 480, "CID"], [100, 104, 502, 504, "CID"], [119, 123, 28, 30, "CID"], [119, 123, 38, 40, "CID"], [119, 123, 219, 221, "CID"], [119, 123, 262, 264, "CID"], [119, 123, 283, 285, "CID"], [119, 123, 317, 319, "CID"], [119, 123, 405, 407, "CID"], [119, 123, 421, 423, "CID"], [119, 123, 478, 480, "CID"], [119, 123, 502, 504, "CID"], [161, 165, 28, 30, "CID"], [161, 165, 38, 40, "CID"], [161, 165, 219, 221, "CID"], [161, 165, 262, 264, "CID"], [161, 165, 283, 285, "CID"], [161, 165, 317, 319, "CID"], [161, 165, 405, 407, "CID"], [161, 165, 421, 423, "CID"], [161, 165, 478, 480, "CID"], [161, 165, 502, 504, "CID"], [203, 207, 28, 30, "CID"], [203, 207, 38, 40, "CID"], [203, 207, 219, 221, "CID"], [203, 207, 262, 264, "CID"], [203, 207, 283, 285, "CID"], [203, 207, 317, 319, "CID"], [203, 207, 405, 407, "CID"], [203, 207, 421, 423, "CID"], [203, 207, 478, 480, "CID"], [203, 207, 502, 504, "CID"], [228, 232, 28, 30, "CID"], [228, 232, 38, 40, "CID"], [228, 232, 219, 221, "CID"], [228, 232, 262, 264, "CID"], [228, 232, 283, 285, "CID"], [228, 232, 317, 319, "CID"], [228, 232, 405, 407, "CID"], [228, 232, 421, 423, "CID"], [228, 232, 478, 480, "CID"], [228, 232, 502, 504, "CID"], [272, 276, 28, 30, "CID"], [272, 276, 38, 40, "CID"], [272, 276, 219, 221, "CID"], [272, 276, 262, 264, "CID"], [272, 276, 283, 285, "CID"], [272, 276, 317, 319, "CID"], [272, 276, 405, 407, "CID"], [272, 276, 421, 423, "CID"], [272, 276, 478, 480, "CID"], [272, 276, 502, 504, "CID"], [415, 419, 28, 30, "CID"], [415, 419, 38, 40, "CID"], [415, 419, 219, 221, "CID"], [415, 419, 262, 264, "CID"], [415, 419, 283, 285, "CID"], [415, 419, 317, 319, "CID"], [415, 419, 405, 407, "CID"], [415, 419, 421, 423, "CID"], [415, 419, 478, 480, "CID"], [415, 419, 502, 504, "CID"], [434, 438, 28, 30, "CID"], [434, 438, 38, 40, "CID"], [434, 438, 219, 221, "CID"], [434, 438, 262, 264, "CID"], [434, 438, 283, 285, "CID"], [434, 438, 317, 319, "CID"], [434, 438, 405, 407, "CID"], [434, 438, 421, 423, "CID"], [434, 438, 478, 480, "CID"], [434, 438, 502, 504, "CID"], [462, 466, 28, 30, "CID"], [462, 466, 38, 40, "CID"], [462, 466, 219, 221, "CID"], [462, 466, 262, 264, "CID"], [462, 466, 283, 285, "CID"], [462, 466, 317, 319, "CID"], [462, 466, 405, 407, "CID"], [462, 466, 421, 423, "CID"], [462, 466, 478, 480, "CID"], [462, 466, 502, 504, "CID"], [489, 493, 28, 30, "CID"], [489, 493, 38, 40, "CID"], [489, 493, 219, 221, "CID"], [489, 493, 262, 264, "CID"], [489, 493, 283, 285, "CID"], [489, 493, 317, 319, "CID"], [489, 493, 405, 407, "CID"], [489, 493, 421, 423, "CID"], [489, 493, 478, 480, "CID"], [489, 493, 502, 504, "CID"], [531, 535, 28, 30, "CID"], [531, 535, 38, 40, "CID"], [531, 535, 219, 221, "CID"], [531, 535, 262, 264, "CID"], [531, 535, 283, 285, "CID"], [531, 535, 317, 319, "CID"], [531, 535, 405, 407, "CID"], [531, 535, 421, 423, "CID"], [531, 535, 478, 480, "CID"], [531, 535, 502, 504, "CID"]]], "clusters": [], "translated": "使用 <0>d,l-索他洛尔</0>治疗持续性<24>室性快速性心律失常</24>的疗效和促心律失常。本研究前瞻性地评估了接受<1>d,l-索他洛尔</1>治疗的患者的临床疗效、<14>尖端扭转型室速</14>的发生率以及<15>尖端扭转型室速</15>的可能危险因素，持续性<25>室性心动过速</25>。连续81名患者（54名<33>冠状动脉疾病</33>，20名<34>扩张型心肌病</34>）伴有可诱发的持续性<26>室性心动过速</26>或<35>心室颤动</35>，口服<2>d,l-索他洛尔</2>预防<27>室性心动过速</27>的诱发。在<3>d,l-索他洛尔</3>口服负荷期间，进行连续心电图（ECG）监测。<4>d,l-索他洛尔</4>可预防<28>室性心动过速</28>或<36>心室颤动</36>的患者出院时服用该药物并在门诊进行随访21 +/- 18个月。35例（43%）患者通过口服<5>天左旋索他洛尔</5>预防了<29>室性快速性心律失常</29>的诱发；<30>室性心动过速</30>在40（49%）名患者中仍可诱发；两名（2.5%）患者甚至不能耐受每天一次40毫克<6>天左旋索他洛尔</6>。四名（5%）患者在使用<7>d,l‑索他洛尔</7>进行初始口服治疗期间出现了<16>尖端扭转型室速</16>。心电图[窦性周期长度（SCL）、QT或QTc间期或U波]和临床参数均未确定患者存在<17>尖端扭转型室速</17>的风险。然而，<8>d,l-索他洛尔</8>的口服剂量在<18>尖端扭转型室性心动过速</18>患者中明显较低（200+/-46vs.328+/-53mg/天；p = 0.0017）。与<19>尖端扭转型室速</19>发展相关的危险因素是U波的出现（p = 0.049）、女性（p = 0.015）和SCL的显着剂量校正变化、QT间期和QTc间期（p < 0.05）。随访期间，7例（20%）患者出现非致死性<31>室性心动过速</31>复发，2例（6%）患者猝死。一名患有稳定<37>心脏病</37>的女性患者在使用<9>d,l-索他洛尔</9>成功治疗2年后再次出现<20>尖端扭转型室性心动过速</20>。<21>尖端扭转型室性心动过速</21>发生在治疗早期，即使口服低剂量<10>d,l-索他洛尔</10>也是如此。体表心电图（周期长度、QT和QTc）与口服<11>d,l-索他洛尔</11>剂量相关的明显变化可能会识别出<22>型扭转型室性心动过速风险增加的患者亚组。</22>应用<12>天前的其他心电图参数，左旋索他洛尔</12>并未识别出<23>尖端扭转型室性心动过速</23>风险增加的患者。尽管在程序刺激期间完全抑制了<38>心律失常</38>，但<32>室性心动过速</32>的复发率仍然很高。因此，在<13>d,l-索他洛尔</13>的情况下程序化电刺激的预后价值似乎有限。", "revised": true}
{"doc_key": "10770468", "sentences": [["Hypercalcemia", ",", "arrhythmia", ",", "and", "mood", "stabilizers", ".", "Recent", "findings", "in", "a", "bipolar", "patient", "receiving", "maintenance", "lithium", "therapy", "who", "developed", "hypercalcemia", "and", "severe", "bradyarrhythmia", "prompted", "the", "authors", "to", "conduct", "a", "retrospective", "study", "of", "bipolar", "patients", "with", "lithium", "-", "associated", "hypercalcemia", ".", "A", "printout", "of", "all", "cases", "of", "hypercalcemia", "that", "presented", "during", "a", "1", "-", "year", "period", "was", "generated", ".", "After", "eliminating", "spurious", "hypercalcemias", "or", "those", "associated", "with", "intravenous", "fluids", ",", "the", "authors", "identified", "18", "non", "-", "lithium", "-", "treated", "patients", "with", "hypercalcemias", "related", "to", "malignancies", "and", "other", "medical", "conditions", "(", "group", "A", ")", "and", "12", "patients", "with", "lithium", "-", "associated", "hypercalcemia", "(", "group", "B", ")", ".", "Patients", "in", "group", "B", "were", "not", "comparable", "to", "those", "in", "group", "A", ",", "as", "the", "latter", "were", "medically", "compromised", "and", "were", "receiving", "multiple", "pharmacotherapies", ".", "Thus", ",", "two", "control", "groups", "were", "generated", ":", "group", "C1", ",", "which", "included", "age", "-", "and", "sex", "-", "comparable", "lithium", "-", "treated", "bipolar", "normocalcemic", "patients", ",", "and", "group", "C2", ",", "which", "included", "bipolar", "normocalcemic", "patients", "treated", "with", "anticonvulsant", "mood", "stabilizers", ".", "The", "electrocardiographic", "(", "ECG", ")", "findings", "for", "patients", "in", "group", "B", "were", "compared", "with", "those", "of", "patients", "in", "groups", "C1", "and", "C2", ".", "It", "was", "found", "that", "these", "groups", "did", "not", "differ", "in", "their", "overall", "frequency", "of", "ECG", "abnormalities", ";", "however", ",", "there", "were", "significant", "differences", "in", "the", "frequency", "of", "conduction", "defects", ".", "Patients", "with", "hypercalcemia", "resulting", "from", "medical", "diseases", "and", "bipolar", "patients", "with", "lithium", "-", "associated", "hypercalcemia", "had", "significantly", "higher", "frequencies", "of", "conduction", "defects", ".", "Patients", "in", "group", "A", "had", "significant", "mortality", "at", "2", "-", "year", "follow", "-", "up", "(", "28", "%", ")", ",", "in", "contrast", "to", "zero", "mortality", "in", "the", "other", "three", "groups", ".", "The", "clinical", "implications", "of", "these", "findings", "are", "discussed", "."]], "ner": [[[16, 16, "Chemical"], [36, 36, "Chemical"], [76, 76, "Chemical"], [97, 97, "Chemical"], [150, 150, "Chemical"], [236, 236, "Chemical"], [0, 0, "Disease"], [20, 20, "Disease"], [39, 39, "Disease"], [47, 47, "Disease"], [62, 62, "Disease"], [81, 81, "Disease"], [100, 100, "Disease"], [227, 227, "Disease"], [239, 239, "Disease"], [2, 2, "Disease"], [12, 12, "Disease"], [33, 33, "Disease"], [153, 153, "Disease"], [163, 163, "Disease"], [233, 233, "Disease"], [23, 23, "Disease"], [84, 84, "Disease"]]], "relations": [[[16, 16, 0, 0, "CID"], [16, 16, 20, 20, "CID"], [16, 16, 39, 39, "CID"], [16, 16, 47, 47, "CID"], [16, 16, 62, 62, "CID"], [16, 16, 81, 81, "CID"], [16, 16, 100, 100, "CID"], [16, 16, 227, 227, "CID"], [16, 16, 239, 239, "CID"], [36, 36, 0, 0, "CID"], [36, 36, 20, 20, "CID"], [36, 36, 39, 39, "CID"], [36, 36, 47, 47, "CID"], [36, 36, 62, 62, "CID"], [36, 36, 81, 81, "CID"], [36, 36, 100, 100, "CID"], [36, 36, 227, 227, "CID"], [36, 36, 239, 239, "CID"], [76, 76, 0, 0, "CID"], [76, 76, 20, 20, "CID"], [76, 76, 39, 39, "CID"], [76, 76, 47, 47, "CID"], [76, 76, 62, 62, "CID"], [76, 76, 81, 81, "CID"], [76, 76, 100, 100, "CID"], [76, 76, 227, 227, "CID"], [76, 76, 239, 239, "CID"], [97, 97, 0, 0, "CID"], [97, 97, 20, 20, "CID"], [97, 97, 39, 39, "CID"], [97, 97, 47, 47, "CID"], [97, 97, 62, 62, "CID"], [97, 97, 81, 81, "CID"], [97, 97, 100, 100, "CID"], [97, 97, 227, 227, "CID"], [97, 97, 239, 239, "CID"], [150, 150, 0, 0, "CID"], [150, 150, 20, 20, "CID"], [150, 150, 39, 39, "CID"], [150, 150, 47, 47, "CID"], [150, 150, 62, 62, "CID"], [150, 150, 81, 81, "CID"], [150, 150, 100, 100, "CID"], [150, 150, 227, 227, "CID"], [150, 150, 239, 239, "CID"], [236, 236, 0, 0, "CID"], [236, 236, 20, 20, "CID"], [236, 236, 39, 39, "CID"], [236, 236, 47, 47, "CID"], [236, 236, 62, 62, "CID"], [236, 236, 81, 81, "CID"], [236, 236, 100, 100, "CID"], [236, 236, 227, 227, "CID"], [236, 236, 239, 239, "CID"]]], "clusters": [], "translated": "<6>高钙血症</6>、<15>心律失常</15>和情绪稳定剂。一名接受<0>锂</0>维持治疗的<16>双相</16>患者出现<7>高钙血症</7>和严重<21>缓慢性心律失常</21>的近期发现促使作者进行了一项<17>双相</17>患者<1>锂</1>相关<8>高钙血症</8>的回顾性研究。生成了在 1 年期间出现的所有<9>高钙血症</9>病例的打印输出。在排除假性<10>高钙血症</10>或与静脉输液相关的那些之后，作者确定了 18 名未接受<2>锂</2>治疗的患者，他们患有与<22>恶性肿瘤</22>相关的<11>高钙血症</11>和其他医疗条件（A 组）和 12 名<3>锂</3>相关的<12>高钙血症</12>患者（B 组）。B 组的患者与 A 组的患者没有可比性，因为后者身体状况不佳，正在接受多种药物治疗。因此，产生了两个对照组：C1 组，其中包括年龄和性别相当的<4>锂</4>治疗的<18>双相</18>正常血钙患者，以及 C2 组，其中包括<19>双相</19>用抗惊厥情绪稳定剂治疗的正常血钙患者。将 B 组患者的心电图 (ECG) 结果与 C1 和 C2 组患者的结果进行比较。结果发现，这些组的 ECG 异常总体频率没有差异；然而，传导缺陷的频率存在显着差异。内科疾病引起的<13>高钙血症</13>患者和<20>双相</20><5>锂</5>相关的<14>高钙血症</14>患者的传导缺陷发生率明显较高。A 组患者在 2 年随访时死亡率显着 (28%)，而其他三组患者的死亡率为零。讨论了这些发现的临床意义。", "revised": true}
{"doc_key": "11299446", "sentences": [["Worsening", "of", "Parkinsonism", "after", "the", "use", "of", "veralipride", "for", "treatment", "of", "menopause", ":", "case", "report", ".", "We", "describe", "a", "female", "patient", "with", "stable", "Parkinson", "'s", "disease", "who", "has", "shown", "a", "marked", "worsening", "of", "her", "motor", "functions", "following", "therapy", "of", "menopause", "related", "symptoms", "with", "veralipride", ",", "as", "well", "as", "the", "improvement", "of", "her", "symptoms", "back", "to", "baseline", "after", "discontinuation", "of", "the", "drug", ".", "We", "emphasize", "the", "anti", "-", "dopaminergic", "effect", "of", "veralipride", "."]], "ner": [[[7, 7, "Chemical"], [43, 43, "Chemical"], [70, 70, "Chemical"], [2, 2, "Disease"], [23, 25, "Disease"]]], "relations": [[[7, 7, 2, 2, "CID"], [7, 7, 23, 25, "CID"], [43, 43, 2, 2, "CID"], [43, 43, 23, 25, "CID"], [70, 70, 2, 2, "CID"], [70, 70, 23, 25, "CID"]]], "clusters": [], "translated": "使用<0>维拉必利</0>治疗绝经后<3>帕金森症</3>恶化：病例报告。我们描述了一名患有稳定型<4>帕金森病</4>的女性患者，在使用<1>维拉必利</1>治疗更年期相关症状后，她的运动功能明显恶化，并且停药后她的症状恢复到基线。我们强调<2>维拉必利</2>的抗多巴胺能作用。", "revised": true}
{"doc_key": "11026989", "sentences": [["The", "effect", "of", "pupil", "dilation", "with", "tropicamide", "on", "vision", "and", "driving", "simulator", "performance", ".", "PURPOSE", ":", "To", "assess", "the", "effect", "of", "pupil", "dilation", "on", "vision", "and", "driving", "ability", ".", "METHODS", ":", "A", "series", "of", "tests", "on", "various", "parameters", "of", "visual", "function", "and", "driving", "simulator", "performance", "were", "performed", "on", "12", "healthy", "drivers", ",", "before", "and", "after", "pupil", "dilation", "using", "guttae", "tropicamide", "1", "%", ".", "A", "driving", "simulator", "(", "Transport", "Research", "Laboratory", ")", "was", "used", "to", "measure", "reaction", "time", "(", "RT", ")", ",", "speed", "maintenance", "and", "steering", "accuracy", ".", "Tests", "of", "basic", "visual", "function", "included", "high", "-", "and", "low", "-", "contrast", "visual", "acuity", "(", "HCVA", "and", "LCVA", ")", ",", "Pelli", "-", "Robson", "contrast", "threshold", "(", "CT", ")", "and", "Goldmann", "perimetry", "(", "FIELDS", ")", ".", "Useful", "Field", "of", "View", "(", "UFOV", "-", "-", "a", "test", "of", "visual", "attention", ")", "was", "also", "undertaken", ".", "The", "mean", "differences", "in", "the", "pre", "-", "and", "post", "-", "dilatation", "measurements", "were", "tested", "for", "statistical", "significance", "at", "the", "95", "%", "level", "using", "one", "-", "tail", "paired", "t", "-", "tests", ".", "RESULTS", ":", "Pupillary", "dilation", "resulted", "in", "a", "statistically", "significant", "deterioration", "in", "CT", "and", "HCVA", "only", ".", "Five", "of", "12", "drivers", "also", "exhibited", "deterioration", "in", "LCVA", ",", "CT", "and", "RT", ".", "Little", "evidence", "emerged", "for", "deterioration", "in", "FIELDS", "and", "UFOV", ".", "Also", ",", "7", "of", "12", "drivers", "appeared", "to", "adjust", "their", "driving", "behaviour", "by", "reducing", "their", "speed", "on", "the", "driving", "simulator", ",", "leading", "to", "improved", "steering", "accuracy", ".", "CONCLUSIONS", ":", "Pupillary", "dilation", "may", "lead", "to", "a", "decrease", "in", "vision", "and", "daylight", "driving", "performance", "in", "young", "people", ".", "A", "larger", "study", ",", "including", "a", "broader", "spectrum", "of", "subjects", ",", "is", "warranted", "before", "guidelines", "can", "be", "recommended", "."]], "ner": [[[6, 6, "Chemical"], [59, 59, "Chemical"], [3, 4, "Disease"], [21, 22, "Disease"], [55, 56, "Disease"], [173, 174, "Disease"], [240, 241, "Disease"]]], "relations": [[[6, 6, 3, 4, "CID"], [6, 6, 21, 22, "CID"], [6, 6, 55, 56, "CID"], [6, 6, 173, 174, "CID"], [6, 6, 240, 241, "CID"], [59, 59, 3, 4, "CID"], [59, 59, 21, 22, "CID"], [59, 59, 55, 56, "CID"], [59, 59, 173, 174, "CID"], [59, 59, 240, 241, "CID"]]], "clusters": [], "translated": "<2>瞳孔散大</2>与<0>托吡卡胺</0>对视力和驾驶模拟器性能的影响。目的：评估<3>瞳孔散大</3>对视力和驾驶能力的影响。方法：对 12 名健康驾驶员在使用 1%<1>托吡卡胺</1>前后进行一系列视功能参数和驾驶模拟器性能测试。使用驾驶模拟器（运输研究实验室）来测量反应时间（RT）、速度维持和转向精度。基本视功能测试包括高对比度和低对比度视力（HCVA 和 LCVA）、Pelli-Robson 对比度阈值（CT）和 Goldmann 视野计（FIELDS）。还进行了有用视野（UFOV - 视觉注意力测试）。使用单尾配对 t 检验在 95% 的水平上测试<4>瞳孔散大</4>前和<4>瞳孔散大</4>后测量值的平均差异的统计显着性。结果：<5>瞳孔散大</5>仅导致 CT 和 HCVA 在统计学上显着恶化。12 名司机中有 5 名的 LCVA、CT 和 RT 也出现恶化。几乎没有证据表明 FIELDS 和 UFOV 恶化。此外，12 名司机中有 7 名似乎通过在驾驶模拟器上降低车速来调整他们的驾驶行为，从而提高了转向精度。结论：<6>瞳孔散大</6>可能导致年轻人视力和日间驾驶表现下降。在推荐指南之前，需要进行更大规模的研究，包括更广泛的主题。", "revised": true}
{"doc_key": "11135381", "sentences": [["Effect", "of", "methoxamine", "on", "maximum", "urethral", "pressure", "in", "women", "with", "genuine", "stress", "incontinence", ":", "a", "placebo", "-", "controlled", ",", "double", "-", "blind", "crossover", "study", ".", "The", "aim", "of", "the", "study", "was", "to", "evaluate", "the", "potential", "role", "for", "a", "selective", "alpha1", "-", "adrenoceptor", "agonist", "in", "the", "treatment", "of", "urinary", "stress", "incontinence", ".", "A", "randomised", ",", "double", "-", "blind", ",", "placebo", "-", "controlled", ",", "crossover", "study", "design", "was", "employed", ".", "Half", "log", "incremental", "doses", "of", "intravenous", "methoxamine", "or", "placebo", "(", "saline", ")", "were", "administered", "to", "a", "group", "of", "women", "with", "genuine", "stress", "incontinence", "while", "measuring", "maximum", "urethral", "pressure", "(", "MUP", ")", ",", "blood", "pressure", ",", "heart", "rate", ",", "and", "symptomatic", "side", "effects", ".", "Methoxamine", "evoked", "non", "-", "significant", "increases", "in", "MUP", "and", "diastolic", "blood", "pressure", "but", "caused", "a", "significant", "rise", "in", "systolic", "blood", "pressure", "and", "significant", "fall", "in", "heart", "rate", "at", "maximum", "dosage", ".", "Systemic", "side", "effects", "including", "piloerection", ",", "headache", ",", "and", "cold", "extremities", "were", "experienced", "in", "all", "subjects", ".", "The", "results", "indicate", "that", "the", "clinical", "usefulness", "of", "direct", ",", "peripherally", "acting", "sub", "-", "type", "-", "selective", "alpha1", "-", "adrenoceptor", "agonists", "in", "the", "medical", "treatment", "of", "stress", "incontinence", "may", "be", "limited", "by", "associated", "piloerection", "and", "cardiovascular", "side", "effects", "."]], "ner": [[[2, 2, "Chemical"], [74, 74, "Chemical"], [111, 111, "Chemical"], [125, 131, "Disease"], [148, 148, "Disease"], [11, 12, "Disease"], [47, 49, "Disease"], [89, 90, "Disease"], [185, 186, "Disease"]]], "relations": [[[2, 2, 125, 131, "CID"], [74, 74, 125, 131, "CID"], [111, 111, 125, 131, "CID"], [2, 2, 148, 148, "CID"], [74, 74, 148, 148, "CID"], [111, 111, 148, 148, "CID"]]], "clusters": [], "translated": "<0>甲氧胺</0> 对真正<5>压力性尿失禁</5>妇女最大尿道压力的影响：安慰剂对照、双盲交叉研究。该研究的目的是评估选择性α1-肾上腺素能受体激动剂在治疗<6>压力性尿失禁</6>中的潜在作用。采用随机、双盲、安慰剂对照、交叉研究设计。对一组真正<7>压力性尿失禁</7>的女性进行半数对数增量静脉注射<1>甲氧明</1>或安慰剂（生理盐水），同时测量最大尿道压（MUP）、血压、心率和症状性副作用。<2>甲氧胺</2>引起MUP和舒张压的非显著升高，但在最大剂量下引起<3>收缩压显著升高</3>和心率显著下降。所有受试者均出现全身性副作用，包括立毛、<4>头痛</4>和四肢发冷。结果表明，直接的、外周作用的亚型选择性α1-肾上腺素能受体激动剂在<8>压力性尿失禁</8>的医学治疗中的临床应用可能受到相关的立毛和心血管副作用的限制。", "revised": true}
{"doc_key": "10986547", "sentences": [["Efficacy", "of", "olanzapine", "in", "acute", "bipolar", "mania", ":", "a", "double", "-", "blind", ",", "placebo", "-", "controlled", "study", ".", "The", "Olanzipine", "HGGW", "Study", "Group", ".", "BACKGROUND", ":", "We", "compared", "the", "efficacy", "and", "safety", "of", "olanzapine", "vs", "placebo", "for", "the", "treatment", "of", "acute", "bipolar", "mania", ".", "METHODS", ":", "Four", "-", "week", ",", "randomized", ",", "double", "-", "blind", ",", "parallel", "study", ".", "A", "total", "of", "115", "patients", "with", "a", "DSM", "-", "IV", "diagnosis", "of", "bipolar", "disorder", ",", "manic", "or", "mixed", ",", "were", "randomized", "to", "olanzapine", ",", "5", "to", "20", "mg", "/", "d", "(", "n", "=", "55", ")", ",", "or", "placebo", "(", "n", "=", "60", ")", ".", "The", "primary", "efficacy", "measure", "was", "the", "Young", "-", "Mania", "Rating", "Scale", "(", "Y", "-", "MRS", ")", "total", "score", ".", "Response", "and", "euthymia", "were", "defined", ",", "a", "priori", ",", "as", "at", "least", "a", "50", "%", "improvement", "from", "baseline", "to", "end", "point", "and", "as", "a", "score", "of", "no", "less", "than", "12", "at", "end", "point", "in", "the", "Y", "-", "MRS", "total", "score", ",", "respectively", ".", "Safety", "was", "assessed", "using", "adverse", "events", ",", "Extrapyramidal", "Symptom", "(", "EPS", ")", "rating", "scales", ",", "laboratory", "values", ",", "electrocardiograms", ",", "vital", "signs", ",", "and", "weight", "change", ".", "RESULTS", ":", "Olanzapine", "-", "treated", "patients", "demonstrated", "a", "statistically", "significant", "greater", "mean", "(", "+", "/", "-", "SD", ")", "improvement", "in", "Y", "-", "MRS", "total", "score", "than", "placebo", "-", "treated", "patients", "(", "-", "14", ".", "8", "+", "/", "-", "12", ".", "5", "and", "-", "8", ".", "1", "+", "/", "-", "12", ".", "7", ",", "respectively", ";", "P", "<", ".", "001", ")", ",", "which", "was", "evident", "at", "the", "first", "postbaseline", "observation", "1", "week", "after", "randomization", "and", "was", "maintained", "throughout", "the", "study", "(", "last", "observation", "carried", "forward", ")", ".", "Olanzapine", "-", "treated", "patients", "demonstrated", "a", "higher", "rate", "of", "response", "(", "65", "%", "vs", "43", "%", ",", "respectively", ";", "P", "=", ".", "02", ")", "and", "euthymia", "(", "61", "%", "vs", "36", "%", ",", "respectively", ";", "P", "=", ".", "01", ")", "than", "placebo", "-", "treated", "patients", ".", "There", "were", "no", "statistically", "significant", "differences", "in", "EPSs", "between", "groups", ".", "However", ",", "olanzapine", "-", "treated", "patients", "had", "a", "statistically", "significant", "greater", "mean", "(", "+", "/", "-", "SD", ")", "weight", "gain", "than", "placebo", "-", "treated", "patients", "(", "2", ".", "1", "+", "/", "-", "2", ".", "8", "vs", "0", ".", "45", "+", "/", "-", "2", ".", "3", "kg", ",", "respectively", ")", "and", "also", "experienced", "more", "treatment", "-", "emergent", "somnolence", "(", "21", "patients", "[", "38", ".", "2", "%", "]", "vs", "5", "[", "8", ".", "3", "%", "]", ",", "respectively", ")", ".", "CONCLUSION", ":", "Olanzapine", "demonstrated", "greater", "efficacy", "than", "placebo", "in", "the", "treatment", "of", "acute", "bipolar", "mania", "and", "was", "generally", "well", "tolerated", "."]], "ner": [[[2, 2, "Chemical"], [19, 19, "Chemical"], [33, 33, "Chemical"], [81, 81, "Chemical"], [194, 194, "Chemical"], [278, 278, "Chemical"], [337, 337, "Chemical"], [415, 415, "Chemical"], [353, 354, "Disease"], [391, 391, "Disease"], [5, 6, "Disease"], [41, 42, "Disease"], [71, 72, "Disease"], [74, 74, "Disease"], [111, 111, "Disease"], [426, 427, "Disease"], [172, 173, "Disease"], [175, 175, "Disease"], [331, 331, "Disease"]]], "relations": [[[2, 2, 353, 354, "CID"], [19, 19, 353, 354, "CID"], [33, 33, 353, 354, "CID"], [81, 81, 353, 354, "CID"], [194, 194, 353, 354, "CID"], [278, 278, 353, 354, "CID"], [337, 337, 353, 354, "CID"], [415, 415, 353, 354, "CID"], [2, 2, 391, 391, "CID"], [19, 19, 391, 391, "CID"], [33, 33, 391, 391, "CID"], [81, 81, 391, 391, "CID"], [194, 194, 391, 391, "CID"], [278, 278, 391, 391, "CID"], [337, 337, 391, 391, "CID"], [415, 415, 391, 391, "CID"]]], "clusters": [], "translated": "<0>奥氮平</0>在急性<10>双相躁狂症</10>中的功效：一项双盲、安慰剂对照研究。<1>奥氮平</1> HGGW 研究组。背景：我们比较了<2>奥氮平</2>与安慰剂治疗急性<11>双相躁狂症</11>的疗效和安全性。方法：为期4周的随机、双盲、平行研究。共有115名DSM-IV诊断为<12>双相情感障碍</12>、<13>躁狂</13>或混合型患者，随机分配至<3>奥氮平</3>，5至20毫克/d （n=55），或安慰剂（n=60）。主要疗效指标是Young-<14>躁狂</14>评定量表(Y-MRS)总分。反应和情绪愉悦被先验地定义为从基线到终点至少有50%的改善，以及Y-MRS总分在终点时的分数不少于12。使用不良事件、<16>锥体外系症状</16> (<17>EPS</17>) 评定量表、实验室值、心电图、生命体征和体重变化来评估安全性。结果：<4>奥氮平</4>治疗的患者在Y-MRS总分上比安慰剂治疗的患者（-14.8+/-12.5和-8.1+/-12.7，分别为；P<.001）明显改善，这在随机化后1周的第一次基线后观察中很明显，并在整个研究过程中保持不变（最后一次观察结转）。 <5>奥氮平</5>治疗的患者表现出更高的反应率（65% vs 43%，分别为P=.02）和情绪愉悦（61% vs 36%，分别为P=.01）与接受安慰剂治疗的患者相比。组间<18>EPS</18>差异无统计学意义。然而，<6>奥氮平</6>治疗的患者的平均（+/- SD）<8>体重增加</8>高于接受安慰剂治疗的患者（2.1+/-2.8 vs 0.45+/-2.3公斤，分别为），也出现了更多的治疗紧急<9>嗜睡</9>（分别为21名患者[38.2%]和5名[8.3%]）。结论：<7>奥氮平</7>治疗急性<15>双相躁狂</15>的疗效优于安慰剂，且总体耐受性良好。", "revised": true}
{"doc_key": "10985896", "sentences": [["Phase", "2", "trial", "of", "liposomal", "doxorubicin", "(", "40", "mg", "/", "m", "(", "2", ")", ")", "in", "platinum", "/", "paclitaxel", "-", "refractory", "ovarian", "and", "fallopian", "tube", "cancers", "and", "primary", "carcinoma", "of", "the", "peritoneum", ".", "BACKGROUND", ":", "Several", "studies", "have", "demonstrated", "liposomal", "doxorubicin", "(", "Doxil", ")", "to", "be", "an", "active", "antineoplastic", "agent", "in", "platinum", "-", "resistant", "ovarian", "cancer", ",", "with", "dose", "limiting", "toxicity", "of", "the", "standard", "dosing", "regimen", "(", "50", "mg", "/", "m", "(", "2", ")", "q", "4", "weeks", ")", "being", "severe", "erythrodysesthesia", "(", "\"", "hand", "-", "foot", "syndrome", "\"", ")", "and", "stomatitis", ".", "We", "wished", "to", "develop", "a", "more", "tolerable", "liposomal", "doxorubicin", "treatment", "regimen", "and", "document", "its", "level", "of", "activity", "in", "a", "well", "-", "defined", "patient", "population", "with", "platinum", "/", "paclitaxel", "-", "refractory", "disease", ".", "METHODS", "AND", "MATERIALS", ":", "Patients", "with", "ovarian", "or", "fallopian", "tube", "cancers", "or", "primary", "peritoneal", "carcinoma", "with", "platinum", "/", "paclitaxel", "-", "refractory", "disease", "(", "stable", "or", "progressive", "disease", "following", "treatment", "with", "these", "agents", "or", "previous", "objective", "response", "<", "3", "months", "in", "duration", ")", "were", "treated", "with", "liposomal", "doxorubicin", "at", "a", "dose", "of", "40", "mg", "/", "m", "(", "2", ")", "q", "4", "weeks", ".", "RESULTS", ":", "A", "total", "of", "49", "patients", "(", "median", "age", ":", "60", ";", "range", "41", "-", "81", ")", "entered", "this", "phase", "2", "trial", ".", "The", "median", "number", "of", "prior", "regimens", "was", "2", "(", "range", ":", "1", "-", "6", ")", ".", "Six", "(", "12", "%", ")", "and", "4", "(", "8", "%", ")", "patients", "experienced", "grade", "2", "hand", "-", "foot", "syndrome", "and", "stomatitis", ",", "respectively", "(", "no", "episodes", "of", "grade", "3", ")", ".", "One", "patient", "developed", "grade", "3", "diarrhea", "requiring", "hospitalization", "for", "hydration", ".", "Six", "(", "12", "%", ")", "individuals", "required", "dose", "reductions", ".", "The", "median", "number", "of", "courses", "of", "liposomal", "doxorubicin", "administered", "on", "this", "protocol", "was", "2", "(", "range", ":", "1", "-", "12", ")", ".", "Four", "of", "44", "patients", "(", "9", "%", ")", "evaluable", "for", "response", "exhibited", "objective", "and", "subjective", "evidence", "of", "an", "antineoplastic", "effect", "of", "therapy", ".", "CONCLUSION", ":", "This", "modified", "liposomal", "doxorubicin", "regimen", "results", "in", "less", "toxicity", "(", "stomatitis", ",", "hand", "-", "foot", "syndrome", ")", "than", "the", "standard", "FDA", "-", "approved", "dose", "schedule", ".", "Definite", ",", "although", "limited", ",", "antineoplastic", "activity", "is", "observed", "in", "patients", "with", "well", "-", "defined", "platinum", "-", "and", "paclitaxel", "-", "refractory", "ovarian", "cancer", "."]], "ner": [[[5, 5, "Chemical"], [40, 40, "Chemical"], [42, 42, "Chemical"], [100, 100, "Chemical"], [170, 170, "Chemical"], [285, 285, "Chemical"], [328, 328, "Chemical"], [80, 80, "Disease"], [83, 86, "Disease"], [241, 244, "Disease"], [337, 340, "Disease"], [90, 90, "Disease"], [246, 246, "Disease"], [335, 335, "Disease"], [262, 262, "Disease"], [21, 25, "Disease"], [54, 55, "Disease"], [130, 134, "Disease"], [372, 373, "Disease"], [28, 31, "Disease"], [137, 138, "Disease"], [60, 60, "Disease"], [333, 333, "Disease"], [16, 16, "Chemical"], [51, 51, "Chemical"], [117, 117, "Chemical"], [140, 140, "Chemical"], [366, 366, "Chemical"], [18, 18, "Chemical"], [119, 119, "Chemical"], [142, 142, "Chemical"], [369, 369, "Chemical"]]], "relations": [[[5, 5, 80, 80, "CID"], [5, 5, 83, 86, "CID"], [5, 5, 241, 244, "CID"], [5, 5, 337, 340, "CID"], [40, 40, 80, 80, "CID"], [40, 40, 83, 86, "CID"], [40, 40, 241, 244, "CID"], [40, 40, 337, 340, "CID"], [42, 42, 80, 80, "CID"], [42, 42, 83, 86, "CID"], [42, 42, 241, 244, "CID"], [42, 42, 337, 340, "CID"], [100, 100, 80, 80, "CID"], [100, 100, 83, 86, "CID"], [100, 100, 241, 244, "CID"], [100, 100, 337, 340, "CID"], [170, 170, 80, 80, "CID"], [170, 170, 83, 86, "CID"], [170, 170, 241, 244, "CID"], [170, 170, 337, 340, "CID"], [285, 285, 80, 80, "CID"], [285, 285, 83, 86, "CID"], [285, 285, 241, 244, "CID"], [285, 285, 337, 340, "CID"], [328, 328, 80, 80, "CID"], [328, 328, 83, 86, "CID"], [328, 328, 241, 244, "CID"], [328, 328, 337, 340, "CID"], [5, 5, 90, 90, "CID"], [5, 5, 246, 246, "CID"], [5, 5, 335, 335, "CID"], [40, 40, 90, 90, "CID"], [40, 40, 246, 246, "CID"], [40, 40, 335, 335, "CID"], [42, 42, 90, 90, "CID"], [42, 42, 246, 246, "CID"], [42, 42, 335, 335, "CID"], [100, 100, 90, 90, "CID"], [100, 100, 246, 246, "CID"], [100, 100, 335, 335, "CID"], [170, 170, 90, 90, "CID"], [170, 170, 246, 246, "CID"], [170, 170, 335, 335, "CID"], [285, 285, 90, 90, "CID"], [285, 285, 246, 246, "CID"], [285, 285, 335, 335, "CID"], [328, 328, 90, 90, "CID"], [328, 328, 246, 246, "CID"], [328, 328, 335, 335, "CID"], [5, 5, 262, 262, "CID"], [40, 40, 262, 262, "CID"], [42, 42, 262, 262, "CID"], [100, 100, 262, 262, "CID"], [170, 170, 262, 262, "CID"], [285, 285, 262, 262, "CID"], [328, 328, 262, 262, "CID"]]], "clusters": [], "translated": "<23>铂</23>/<28>紫杉醇</28>脂质体<0>多柔比星</0>（40 mg/m(2)）的2期试验- 难治性<15>卵巢癌和输卵管癌</15>和原发性<19>腹膜癌</19>。背景：几项研究表明，脂质体<1>阿霉素</1>（<2>Doxil</2>）是治疗<24>铂</24>耐药<16>卵巢癌</16>的活性抗肿瘤剂，标准给药方案（50 mg/m(2)每4周一次）的剂量限制性<21>毒性</21>是严重的<7>红斑感觉</7>（“<8>手足综合征</8>”）和<11> 口腔炎 </11>。我们希望开发一种更耐受的脂质体<3>阿霉素</3>治疗方案，并记录其在使用<25>铂类</25>/<29>紫杉醇</29>的明确患者群体中的活性水平-顽固性疾病。方法和材料：患有<17>卵巢癌或输卵管癌</17>或原发性<20>腹膜癌</20>且使用<26>铂类</26>/<30>紫杉醇</30>的患者-难治性疾病（用这些药物治疗后疾病稳定或进展，或之前的客观反应持续时间<3个月）用脂质体<4>多柔比星</4>治疗，剂量为40 mg/m(2)每4周一次。结果：共有49名患者（中位年龄：60岁；范围41-81岁）进入了该2期试验。既往治疗方案的中位数为2（范围：1-6）。6名（12%）和4名（8%）患者分别经历了2级<9>手足综合征</9>和<12>口腔炎</12>（无3级发作）。一名患者出现3级<14>腹泻</14>，需要住院补液。6个（12%）人需要减少剂量。本方案中脂质体<5>多柔比星</5>疗程的中位数为2（范围：1-12）。可评估反应的44名患者中有4名（9%）表现出治疗抗肿瘤效果的客观和主观证据。结论：这种改良脂质体<6>多柔比星</6>方案导致<22>毒性</22>（<13>口腔炎</13>，<10>手足综合征</10>）低于标准方案FDA批准的剂量表。在定义明确的<27>铂</27>和<31>紫杉醇</31>难治性<18>卵巢癌</18>患者中观察到明确但有限的抗肿瘤活性。", "revised": true}
{"doc_key": "11395263", "sentences": [["Cardioprotective", "effects", "of", "Picrorrhiza", "kurroa", "against", "isoproterenol", "-", "induced", "myocardial", "stress", "in", "rats", ".", "The", "cardioprotective", "effect", "of", "the", "ethanol", "extract", "of", "Picrorrhiza", "kurroa", "rhizomes", "and", "roots", "(", "PK", ")", "on", "isoproterenol", "-", "induced", "myocardial", "infarction", "in", "rats", "with", "respect", "to", "lipid", "metabolism", "in", "serum", "and", "heart", "tissue", "has", "been", "investigated", ".", "Oral", "pre", "-", "treatment", "with", "PK", "(", "80", "mg", "kg", "(", "-", "1", ")", "day", "(", "-", "1", ")", "for", "15", "days", ")", "significantly", "prevented", "the", "isoproterenol", "-", "induced", "myocardial", "infarction", "and", "maintained", "the", "rats", "at", "near", "normal", "status", "."]], "ner": [[[6, 6, "Chemical"], [31, 31, "Chemical"], [78, 78, "Chemical"], [34, 35, "Disease"], [81, 82, "Disease"], [19, 19, "Chemical"]]], "relations": [[[6, 6, 34, 35, "CID"], [6, 6, 81, 82, "CID"], [31, 31, 34, 35, "CID"], [31, 31, 81, 82, "CID"], [78, 78, 34, 35, "CID"], [78, 78, 81, 82, "CID"]]], "clusters": [], "translated": "黑胡桃对<0>异丙肾上腺素</0>诱发的大鼠心肌应激的心脏保护作用。对黑胡桃（PK）根茎的<5>乙醇</5>提取物研究表明，对于<1>异丙肾上腺素</1>诱发的<3>心肌梗死</3>，其心脏保护作用在血清和心脏组织的脂质代谢方面得到了探究。经口服预先处理PK（80 mg kg (-1) day (-1) for 15 days），能够显著预防<2>异丙肾上腺素</2>诱发的<4>心肌梗死</4>，并使大鼠保持接近正常状态。", "revised": true}
{"doc_key": "11366874", "sentences": [["Viracept", "and", "irregular", "heartbeat", "warning", ".", "A", "group", "of", "doctors", "in", "Boston", "warn", "that", "the", "protease", "inhibitor", "Viracept", "may", "cause", "an", "irregular", "heart", "beat", ",", "known", "as", "bradycardia", ",", "in", "people", "with", "HIV", ".", "Bradycardia", "occurred", "in", "a", "45", "-", "year", "-", "old", "male", "patient", "who", "was", "Viracept", "in", "combination", "with", "other", "anti", "-", "HIV", "drugs", ".", "The", "symptoms", "ceased", "after", "switching", "to", "another", "drug", "combination", "."]], "ner": [[[0, 0, "Chemical"], [17, 17, "Chemical"], [47, 47, "Chemical"], [27, 27, "Disease"], [34, 34, "Disease"], [2, 3, "Disease"], [21, 23, "Disease"]]], "relations": [[[0, 0, 27, 27, "CID"], [0, 0, 34, 34, "CID"], [17, 17, 27, 27, "CID"], [17, 17, 34, 34, "CID"], [47, 47, 27, 27, "CID"], [47, 47, 34, 34, "CID"]]], "clusters": [], "translated": " <0> Viracept </0> 和<5>不规则心跳</5> 警告。波士顿的一组医生警告说，蛋白酶抑制剂<1> Viracept </1>可能会导致HIV 感染者<6>心律不齐</6>，即<3>心动过缓</3>。 <4>心动过缓</4> 发生在一名45岁的男性患者身上，他正在与其他抗 HIV药物联合使用<2> Viracept </2>。改用另一种药物组合后症状消失。", "revised": true}
{"doc_key": "11439380", "sentences": [["Thalidomide", "neuropathy", "in", "patients", "treated", "for", "metastatic", "prostate", "cancer", ".", "We", "prospectively", "evaluated", "thalidomide", "-", "induced", "neuropathy", "using", "electrodiagnostic", "studies", ".", "Sixty", "-", "seven", "men", "with", "metastatic", "androgen", "-", "independent", "prostate", "cancer", "in", "an", "open", "-", "label", "trial", "of", "oral", "thalidomide", "underwent", "neurologic", "examinations", "and", "nerve", "conduction", "studies", "(", "NCS", ")", "prior", "to", "and", "at", "3", "-", "month", "intervals", "during", "treatment", ".", "NCS", "included", "recording", "of", "sensory", "nerve", "action", "potentials", "(", "SNAPs", ")", "from", "median", ",", "radial", ",", "ulnar", ",", "and", "sural", "nerves", ".", "SNAP", "amplitudes", "for", "each", "nerve", "were", "expressed", "as", "the", "percentage", "of", "its", "baseline", ",", "and", "the", "mean", "of", "the", "four", "was", "termed", "the", "SNAP", "index", ".", "A", "40", "%", "decline", "in", "the", "SNAP", "index", "was", "considered", "clinically", "significant", ".", "Thalidomide", "was", "discontinued", "in", "55", "patients", "for", "lack", "of", "therapeutic", "response", ".", "Of", "67", "patients", "initially", "enrolled", ",", "24", "remained", "on", "thalidomide", "for", "3", "months", ",", "8", "remained", "at", "6", "months", ",", "and", "3", "remained", "at", "9", "months", ".", "Six", "patients", "developed", "neuropathy", ".", "Clinical", "symptoms", "and", "a", "decline", "in", "the", "SNAP", "index", "occurred", "concurrently", ".", "Older", "age", "and", "cumulative", "dose", "were", "possible", "contributing", "factors", ".", "Neuropathy", "may", "thus", "be", "a", "common", "complication", "of", "thalidomide", "in", "older", "patients", ".", "The", "SNAP", "index", "can", "be", "used", "to", "monitor", "peripheral", "neuropathy", ",", "but", "not", "for", "early", "detection", "."]], "ner": [[[0, 0, "Chemical"], [13, 13, "Chemical"], [40, 40, "Chemical"], [123, 123, "Chemical"], [144, 144, "Chemical"], [197, 197, "Chemical"], [210, 211, "Disease"], [1, 1, "Disease"], [16, 16, "Disease"], [165, 165, "Disease"], [189, 189, "Disease"], [7, 8, "Disease"], [30, 31, "Disease"], [27, 27, "Chemical"]]], "relations": [[[0, 0, 210, 211, "CID"], [13, 13, 210, 211, "CID"], [40, 40, 210, 211, "CID"], [123, 123, 210, 211, "CID"], [144, 144, 210, 211, "CID"], [197, 197, 210, 211, "CID"]]], "clusters": [], "translated": "<0>沙利度胺</0> <7>神经病变</7> ：转移性<11>前列腺癌</11>患者治疗。我们使用电诊断研究前瞻性地评估了<1>沙利度胺</1>诱发的<8>神经病变</8>。在口服<2>沙利度胺</2>的开放标签试验中，67名患有<13>雄激素</13>-独立<12>转移性前列腺癌</12>的男性接受了神经系统检查和神经传导研究(NCS)，在治疗前和治疗期间每隔3个月进行一次。NCS包括记录正中神经、桡神经、尺神经和腓肠神经的感觉神经动作电位(SNAP)。每条神经的SNAP振幅表示为其基线的百分比，四个神经元的平均值称为SNAP指数。SNAP指数下降40%被认为具有临床意义。<3>沙利度胺</3>因缺乏治疗反应停用于55例患者。在最初入组的67名患者中，24名患者继续使用<4>沙利度胺</4>3个月，8名患者保持在6个月，3名患者保持在9个月。6名患者出现<9>神经病变</9>。临床症状和SNAP指数下降同时发生。年龄较大和累积剂量是可能的影响因素。<10>神经病变</10>因此可能是老年患者<5>沙利度胺</5>的常见并发症。SNAP指数可用于监测<6>周围神经病变</6>，但不能用于早期检测。", "revised": true}
{"doc_key": "10939760", "sentences": [["Patterns", "of", "sulfadiazine", "acute", "nephrotoxicity", ".", "Sulfadiazine", "acute", "nephrotoxicity", "is", "reviving", "specially", "because", "of", "its", "use", "in", "toxoplasmosis", "in", "HIV", "-", "positive", "patients", ".", "We", "report", "4", "cases", ",", "one", "of", "them", "in", "a", "previously", "healthy", "person", ".", "Under", "treatment", "with", "sulfadiazine", "they", "developed", "oliguria", ",", "abdominal", "pain", ",", "renal", "failure", "and", "showed", "multiple", "radiolucent", "renal", "calculi", "in", "echography", ".", "All", "patients", "recovered", "their", "previous", "normal", "renal", "function", "after", "adequate", "hydration", "and", "alcalinization", ".", "A", "nephrostomy", "tube", "had", "to", "be", "placed", "in", "one", "of", "the", "patients", "for", "ureteral", "lithiasis", "in", "a", "single", "functional", "kidney", ".", "None", "of", "them", "needed", "dialysis", "or", "a", "renal", "biopsy", "because", "of", "a", "typical", "benign", "course", ".", "Treatment", "with", "sulfadiazine", "requires", "exquisite", "control", "of", "renal", "function", ",", "an", "increase", "in", "water", "ingestion", "and", "possibly", "the", "alcalinization", "of", "the", "urine", ".", "We", "communicate", "a", "case", "in", "a", "previously", "healthy", "person", ",", "a", "fact", "not", "found", "in", "the", "recent", "literature", ".", "Probably", "many", "more", "cases", "are", "not", "detected", ".", "We", "think", "that", "a", "prospective", "study", "would", "be", "useful", "."]], "ner": [[[2, 2, "Chemical"], [6, 6, "Chemical"], [41, 41, "Chemical"], [113, 113, "Chemical"], [3, 4, "Disease"], [7, 8, "Disease"], [55, 56, "Disease"], [17, 17, "Disease"], [44, 44, "Disease"], [46, 47, "Disease"], [49, 50, "Disease"], [87, 88, "Disease"]]], "relations": [[[2, 2, 3, 4, "CID"], [2, 2, 7, 8, "CID"], [6, 6, 3, 4, "CID"], [6, 6, 7, 8, "CID"], [41, 41, 3, 4, "CID"], [41, 41, 7, 8, "CID"], [113, 113, 3, 4, "CID"], [113, 113, 7, 8, "CID"], [2, 2, 55, 56, "CID"], [6, 6, 55, 56, "CID"], [41, 41, 55, 56, "CID"], [113, 113, 55, 56, "CID"]]], "clusters": [], "translated": "<0>磺胺嘧啶</0> <4>急性肾毒性</4>的模式。<1>磺胺嘧啶</1><5>急性肾毒性</5>特别是因为它用于治疗<7>HIV阳性</7>患者的<7>弓形虫病</7>而重新流行起来。我们报告了4例，其中一例发生在以前健康的人身上。在<2>磺胺嘧啶</2>治疗下，他们出现了<8>少尿</8>、<9>腹痛</9>、<10>肾功能衰竭</10>并表现出多发透亮性<6>肾结石</6>在回声描记术中。所有患者在充分水化和碱化后均恢复了原先的正常肾功能。因单个功能性肾脏<11>输尿管结石</11>，必须在其中一名患者中放置<11>肾造口管</11>。由于典型的良性病程，他们都不需要<3>透析</3>或<3>肾活检</3>。用<3>磺胺嘧啶</3>治疗需要精确控制肾功能、增加饮水量并可能碱化尿液。我们交流了一个以前健康的人的案例，这是最近文献中没有发现的事实。可能还有更多病例未被发现。我们认为前瞻性研究会有用。", "revised": true}
{"doc_key": "11385188", "sentences": [["Prevalence", "of", "heart", "disease", "in", "asymptomatic", "chronic", "cocaine", "users", ".", "To", "determine", "the", "prevalence", "of", "heart", "disease", "in", "outpatient", "young", "asymptomatic", "chronic", "cocaine", "users", ",", "35", "cocaine", "users", "and", "32", "age", "-", "matched", "controls", "underwent", "resting", "and", "exercise", "electrocardiography", "(", "ECG", ")", "and", "Doppler", "echocardiography", ".", "Findings", "consistent", "with", "coronary", "artery", "disease", "were", "detected", "in", "12", "(", "34", "%", ")", "patients", "and", "3", "(", "9", "%", ")", "controls", "(", "p", "=", "0", ".", "01", ")", ".", "Decreased", "left", "ventricular", "systolic", "function", "was", "demonstrated", "in", "5", "(", "14", "%", ")", "patients", ",", "but", "in", "none", "of", "the", "controls", "(", "p", "=", "0", ".", "055", ")", ".", "Finally", ",", "resting", "and", "peak", "exercise", "abnormal", "left", "ventricular", "filling", "was", "detected", "in", "38", "and", "35", "%", "of", "patients", "as", "compared", "to", "19", "and", "9", "%", "of", "controls", ",", "respectively", "(", "p", "=", "0", ".", "11", "and", "0", ".", "02", ",", "respectively", ")", ".", "We", "conclude", "that", "coronary", "artery", "or", "myocardial", "disease", "is", "common", "(", "38", "%", ")", "in", "young", "asymptomatic", "chronic", "cocaine", "users", ".", "Therefore", ",", "screening", "ECG", "and", "echocardiography", "may", "be", "warranted", "in", "these", "patients", "."]], "ner": [[[7, 7, "Chemical"], [22, 22, "Chemical"], [26, 26, "Chemical"], [167, 167, "Chemical"], [49, 51, "Disease"], [152, 156, "Disease"], [2, 3, "Disease"], [15, 16, "Disease"], [111, 114, "Disease"]]], "relations": [[[7, 7, 49, 51, "CID"], [7, 7, 152, 156, "CID"], [22, 22, 49, 51, "CID"], [22, 22, 152, 156, "CID"], [26, 26, 49, 51, "CID"], [26, 26, 152, 156, "CID"], [167, 167, 49, 51, "CID"], [167, 167, 152, 156, "CID"]]], "clusters": [], "translated": " <6>心脏病</6>在无症状慢性<0>可卡因</0>使用者中的患病率。为了确定门诊年轻无症状慢性<1>可卡因</1>使用者的<7>心脏病</7>患病率，对35名<2>可卡因</2>使用者和32名年龄匹配的对照组进行了静息和运动心电图检查（心电图）和多普勒超声心动图。在12（34%）名患者和3（9%）名对照者（p = 0.01）中检测到与<4>冠状动脉疾病</4>一致的发现。5（14%）名患者的左心室收缩功能下降，但对照组均未出现 (p = 0.055) 。最后，在38%和35%的患者中检测到静息和运动高峰期<8>左心室充盈异常</8>，而对照组分别为19%和9%（分别为p = 0.11和0.02）。我们得出结论，<5>冠状动脉或心肌疾病</5>在年轻的无症状慢性<3>可卡因</3>使用者中很常见（38%）。因此，可能需要对这些患者进行心电图和超声心动图筛查。", "revised": true}
{"doc_key": "9889429", "sentences": [["Long", "-", "term", "efficacy", "and", "adverse", "event", "of", "nifedipine", "sustained", "-", "release", "tablets", "for", "cyclosporin", "A", "-", "induced", "hypertension", "in", "patients", "with", "psoriasis", ".", "Thirteen", "psoriatic", "patients", "with", "hypertension", "during", "the", "course", "of", "cyclosporin", "A", "therapy", "were", "treated", "for", "25", "months", "with", "a", "calcium", "channel", "blocker", ",", "sustained", "-", "release", "nifedipine", ",", "to", "study", "the", "clinical", "antihypertensive", "effects", "and", "adverse", "events", "during", "treatment", "with", "both", "drugs", ".", "Seven", "of", "the", "13", "patients", "had", "exhibited", "a", "subclinical", "hypertensive", "state", "before", "cyclosporin", "A", "therapy", ".", "Both", "systolic", "and", "diastolic", "blood", "pressures", "of", "these", "13", "patients", "were", "decreased", "significantly", "after", "4", "weeks", "of", "nifedipine", "therapy", ",", "and", "blood", "pressure", "was", "maintained", "within", "the", "normal", "range", "thereafter", "for", "25", "months", ".", "The", "adverse", "events", "during", "combined", "therapy", "with", "cyclosporin", "A", "and", "nifedipine", "included", "an", "increase", "in", "blood", "urea", "nitrogen", "levels", "in", "9", "of", "the", "13", "patients", "and", "development", "of", "gingival", "hyperplasia", "in", "2", "of", "the", "13", "patients", ".", "Our", "findings", "indicate", "that", "sustained", "-", "release", "nifedipine", "is", "useful", "for", "hypertensive", "psoriatic", "patients", "under", "long", "-", "term", "treatment", "with", "cyclosporin", "A", ",", "but", "that", "these", "patients", "should", "be", "monitored", "for", "gingival", "hyperplasia", "."]], "ner": [[[8, 8, "Chemical"], [50, 50, "Chemical"], [100, 100, "Chemical"], [127, 127, "Chemical"], [161, 161, "Chemical"], [145, 146, "Disease"], [185, 186, "Disease"], [14, 15, "Chemical"], [33, 34, "Chemical"], [79, 80, "Chemical"], [124, 125, "Chemical"], [174, 175, "Chemical"], [18, 18, "Disease"], [28, 28, "Disease"], [76, 76, "Disease"], [165, 165, "Disease"], [22, 22, "Disease"], [25, 25, "Disease"], [166, 166, "Disease"], [43, 43, "Chemical"], [132, 134, "Chemical"]]], "relations": [[[8, 8, 145, 146, "CID"], [8, 8, 185, 186, "CID"], [50, 50, 145, 146, "CID"], [50, 50, 185, 186, "CID"], [100, 100, 145, 146, "CID"], [100, 100, 185, 186, "CID"], [127, 127, 145, 146, "CID"], [127, 127, 185, 186, "CID"], [161, 161, 145, 146, "CID"], [161, 161, 185, 186, "CID"], [14, 15, 18, 18, "CID"], [14, 15, 28, 28, "CID"], [14, 15, 76, 76, "CID"], [14, 15, 165, 165, "CID"], [33, 34, 18, 18, "CID"], [33, 34, 28, 28, "CID"], [33, 34, 76, 76, "CID"], [33, 34, 165, 165, "CID"], [79, 80, 18, 18, "CID"], [79, 80, 28, 28, "CID"], [79, 80, 76, 76, "CID"], [79, 80, 165, 165, "CID"], [124, 125, 18, 18, "CID"], [124, 125, 28, 28, "CID"], [124, 125, 76, 76, "CID"], [124, 125, 165, 165, "CID"], [174, 175, 18, 18, "CID"], [174, 175, 28, 28, "CID"], [174, 175, 76, 76, "CID"], [174, 175, 165, 165, "CID"], [14, 15, 145, 146, "CID"], [14, 15, 185, 186, "CID"], [33, 34, 145, 146, "CID"], [33, 34, 185, 186, "CID"], [79, 80, 145, 146, "CID"], [79, 80, 185, 186, "CID"], [124, 125, 145, 146, "CID"], [124, 125, 185, 186, "CID"], [174, 175, 145, 146, "CID"], [174, 175, 185, 186, "CID"]]], "clusters": [], "translated": "<0>硝苯地平</0><7>缓释片</7>治疗<7>环孢素A</7>所致<12>高血压</12>在<16>银屑病</16>患者中的远期疗效及不良反应。13例<17>银屑病</17>患者在接受<8>环孢菌素A</8>治疗过程中伴随<13>高血压</13>，25个月间接受缓释<1>硝苯地平</1><19>钙</19>通道阻滞剂治疗，以研究两种药物治疗期间的临床降压作用和不良反应。这13名患者中有7名在接受<9>环孢菌素 A </9>治疗前表现出亚临床<14>高血压</14>状态。在接受<2>硝苯地平</2>治疗4周后，这13名患者的收缩压和舒张压均明显下降，此后血压维持在正常范围内25个月。在<10>环孢菌素A</10>和<3>硝苯地平</3>联合治疗期间，不良反应包括13名患者中的9名患者的<20>血尿素氮</20>水平升高以及2名患者的<5>牙龈增生</5>。我们的研究结果表明，缓释<4>硝苯地平</4>对<18>银屑病</18>合并<15>高血压</15>长期接受<11>环孢素A</11>治疗的患者是有效的，但应监测这些患者的<6>牙龈增生</6>。", "revised": true}
{"doc_key": "11474137", "sentences": [["Overexpression", "of", "copper", "/", "zinc", "-", "superoxide", "dismutase", "protects", "from", "kanamycin", "-", "induced", "hearing", "loss", ".", "The", "participation", "of", "reactive", "oxygen", "species", "in", "aminoglycoside", "-", "induced", "ototoxicity", "has", "been", "deduced", "from", "observations", "that", "aminoglycoside", "-", "iron", "complexes", "catalyze", "the", "formation", "of", "superoxide", "radicals", "in", "vitro", "and", "that", "antioxidants", "attenuate", "ototoxicity", "in", "vivo", ".", "We", "therefore", "hypothesized", "that", "overexpression", "of", "Cu", "/", "Zn", "-", "superoxide", "dismutase", "(", "h", "-", "SOD1", ")", "should", "protect", "transgenic", "mice", "from", "ototoxicity", ".", "Immunocytochemistry", "confirmed", "expression", "of", "h", "-", "SOD1", "in", "inner", "ear", "tissues", "of", "transgenic", "C57BL", "/", "6", "-", "TgN", "[", "SOD1", "]", "3Cje", "mice", ".", "Transgenic", "and", "nontransgenic", "littermates", "received", "kanamycin", "(", "400", "mg", "/", "kg", "body", "weight", "/", "day", ")", "for", "10", "days", "beginning", "on", "day", "10", "after", "birth", ".", "Auditory", "thresholds", "were", "tested", "by", "evoked", "auditory", "brain", "stem", "responses", "at", "1", "month", "after", "birth", ".", "In", "nontransgenic", "animals", ",", "the", "threshold", "in", "the", "kanamycin", "-", "treated", "group", "was", "45", "-", "50", "dB", "higher", "than", "in", "saline", "-", "injected", "controls", ".", "In", "the", "transgenic", "group", ",", "kanamycin", "increased", "the", "threshold", "by", "only", "15", "dB", "over", "the", "respective", "controls", ".", "The", "effects", "were", "similar", "at", "12", "and", "24", "kHz", ".", "The", "protection", "by", "overexpression", "of", "superoxide", "dismutase", "supports", "the", "hypothesis", "that", "oxidant", "stress", "plays", "a", "significant", "role", "in", "aminoglycoside", "-", "induced", "ototoxicity", ".", "The", "results", "also", "suggest", "transgenic", "animals", "as", "suitable", "models", "to", "investigate", "the", "underlying", "mechanisms", "and", "possible", "strategies", "for", "prevention", "."]], "ner": [[[10, 10, "Chemical"], [106, 106, "Chemical"], [151, 151, "Chemical"], [173, 173, "Chemical"], [13, 14, "Disease"], [2, 2, "Chemical"], [59, 59, "Chemical"], [26, 26, "Disease"], [49, 49, "Disease"], [75, 75, "Disease"], [217, 217, "Disease"], [4, 4, "Chemical"], [61, 61, "Chemical"], [6, 6, "Chemical"], [41, 41, "Chemical"], [63, 63, "Chemical"], [201, 201, "Chemical"], [20, 20, "Chemical"], [23, 23, "Chemical"], [33, 33, "Chemical"], [214, 214, "Chemical"], [35, 35, "Chemical"]]], "relations": [[[10, 10, 13, 14, "CID"], [106, 106, 13, 14, "CID"], [151, 151, 13, 14, "CID"], [173, 173, 13, 14, "CID"]]], "clusters": [], "translated": "<5>铜</5> / <11>锌</11> - <13>超氧化物</13> 歧化酶的过表达可防止<0>卡那霉素</0> - 诱导的<4>听力损失</4> 。活性<17>氧</17>物种参与<18>氨基糖苷类</18> - 诱导的<7>耳毒性</7>已根据观察结果推断含有<21>铁</21>的<19>氨基糖苷类络合物</19>在体外催化<14>超氧化物</14>自由基的形成，并且抗氧化剂在体内减弱<8>耳毒性</8>。因此，我们假设<6>Cu</6> / <12>Zn</12> - <15>超氧化物</15>歧化酶（h-SOD1）的过度表达应该保护转基因小鼠免受<9>耳毒性</9>。免疫细胞化学证实h-SOD1在转基因C57BL/6-TgN[SOD1]3Cje小鼠的内耳组织中表达。从出生后第10天开始，转基因和非转基因同窝仔鼠接受<1>卡那霉素</1>（400毫克/千克体重/天）10天。出生后1个月通过诱发听觉脑干反应测试听觉阈值。在非转基因动物中，<2>卡那霉素</2>处理组的阈值比注射盐水的对照组高45-50 dB。在转基因组中，<3>卡那霉素</3>使阈值仅比各自的对照增加了15 dB。在12和24 kHz时效果相似。<16>超氧化物</16>歧化酶过表达的保护作用支持氧化应激在<20>氨基糖苷类</20>诱导的<10>耳毒性</10>中起重要作用的假设。结果还表明转基因动物是研究潜在机制和可能的预防策略的合适模型。", "revised": true}
{"doc_key": "11401944", "sentences": [["Phase", "2", "early", "afterdepolarization", "as", "a", "trigger", "of", "polymorphic", "ventricular", "tachycardia", "in", "acquired", "long", "-", "QT", "syndrome", ":", "direct", "evidence", "from", "intracellular", "recordings", "in", "the", "intact", "left", "ventricular", "wall", ".", "BACKGROUND", ":", "This", "study", "examined", "the", "role", "of", "phase", "2", "early", "afterdepolarization", "(", "EAD", ")", "in", "producing", "a", "trigger", "to", "initiate", "torsade", "de", "pointes", "(", "TdP", ")", "with", "QT", "prolongation", "induced", "by", "dl", "-", "sotalol", "and", "azimilide", ".", "The", "contribution", "of", "transmural", "dispersion", "of", "repolarization", "(", "TDR", ")", "to", "transmural", "propagation", "of", "EAD", "and", "the", "maintenance", "of", "TdP", "was", "also", "evaluated", ".", "METHODS", "AND", "RESULTS", ":", "Transmembrane", "action", "potentials", "from", "epicardium", ",", "midmyocardium", ",", "and", "endocardium", "were", "recorded", "simultaneously", ",", "together", "with", "a", "transmural", "ECG", ",", "in", "arterially", "perfused", "canine", "and", "rabbit", "left", "ventricular", "preparations", ".", "dl", "-", "Sotalol", "preferentially", "prolonged", "action", "potential", "duration", "(", "APD", ")", "in", "M", "cells", "dose", "-", "dependently", "(", "1", "to", "100", "micromol", "/", "L", ")", ",", "leading", "to", "QT", "prolongation", "and", "an", "increase", "in", "TDR", ".", "Azimilide", ",", "however", ",", "significantly", "prolonged", "APD", "and", "QT", "interval", "at", "concentrations", "from", "0", ".", "1", "to", "10", "micromol", "/", "L", "but", "shortened", "them", "at", "30", "micromol", "/", "L", ".", "Unlike", "dl", "-", "sotalol", ",", "azimilide", "(", ">", "3", "micromol", "/", "L", ")", "increased", "epicardial", "APD", "markedly", ",", "causing", "a", "diminished", "TDR", ".", "Although", "both", "dl", "-", "sotalol", "and", "azimilide", "rarely", "induced", "EADs", "in", "canine", "left", "ventricles", ",", "they", "produced", "frequent", "EADs", "in", "rabbits", ",", "in", "which", "more", "pronounced", "QT", "prolongation", "was", "seen", ".", "An", "increase", "in", "TDR", "by", "dl", "-", "sotalol", "facilitated", "transmural", "propagation", "of", "EADs", "that", "initiated", "multiple", "episodes", "of", "spontaneous", "TdP", "in", "3", "of", "6", "rabbit", "left", "ventricles", ".", "Of", "note", ",", "although", "azimilide", "(", "3", "to", "10", "micromol", "/", "L", ")", "increased", "APD", "more", "than", "dl", "-", "sotalol", ",", "its", "EADs", "often", "failed", "to", "propagate", "transmurally", ",", "probably", "because", "of", "a", "diminished", "TDR", ".", "CONCLUSIONS", ":", "This", "study", "provides", "the", "first", "direct", "evidence", "from", "intracellular", "action", "potential", "recordings", "that", "phase", "2", "EAD", "can", "be", "generated", "from", "intact", "ventricular", "wall", "and", "produce", "a", "trigger", "to", "initiate", "the", "onset", "of", "TdP", "under", "QT", "prolongation", "."]], "ner": [[[64, 64, "Chemical"], [128, 128, "Chemical"], [195, 195, "Chemical"], [219, 219, "Chemical"], [253, 253, "Chemical"], [293, 293, "Chemical"], [13, 16, "Disease"], [58, 59, "Disease"], [154, 155, "Disease"], [241, 242, "Disease"], [346, 347, "Disease"], [51, 53, "Disease"], [55, 55, "Disease"], [87, 87, "Disease"], [265, 265, "Disease"], [344, 344, "Disease"], [9, 10, "Disease"], [66, 66, "Chemical"], [162, 162, "Chemical"], [197, 197, "Chemical"], [221, 221, "Chemical"], [278, 278, "Chemical"]]], "relations": [[[64, 64, 13, 16, "CID"], [64, 64, 58, 59, "CID"], [64, 64, 154, 155, "CID"], [64, 64, 241, 242, "CID"], [64, 64, 346, 347, "CID"], [128, 128, 13, 16, "CID"], [128, 128, 58, 59, "CID"], [128, 128, 154, 155, "CID"], [128, 128, 241, 242, "CID"], [128, 128, 346, 347, "CID"], [195, 195, 13, 16, "CID"], [195, 195, 58, 59, "CID"], [195, 195, 154, 155, "CID"], [195, 195, 241, 242, "CID"], [195, 195, 346, 347, "CID"], [219, 219, 13, 16, "CID"], [219, 219, 58, 59, "CID"], [219, 219, 154, 155, "CID"], [219, 219, 241, 242, "CID"], [219, 219, 346, 347, "CID"], [253, 253, 13, 16, "CID"], [253, 253, 58, 59, "CID"], [253, 253, 154, 155, "CID"], [253, 253, 241, 242, "CID"], [253, 253, 346, 347, "CID"], [293, 293, 13, 16, "CID"], [293, 293, 58, 59, "CID"], [293, 293, 154, 155, "CID"], [293, 293, 241, 242, "CID"], [293, 293, 346, 347, "CID"], [64, 64, 51, 53, "CID"], [64, 64, 55, 55, "CID"], [64, 64, 87, 87, "CID"], [64, 64, 265, 265, "CID"], [64, 64, 344, 344, "CID"], [128, 128, 51, 53, "CID"], [128, 128, 55, 55, "CID"], [128, 128, 87, 87, "CID"], [128, 128, 265, 265, "CID"], [128, 128, 344, 344, "CID"], [195, 195, 51, 53, "CID"], [195, 195, 55, 55, "CID"], [195, 195, 87, 87, "CID"], [195, 195, 265, 265, "CID"], [195, 195, 344, 344, "CID"], [219, 219, 51, 53, "CID"], [219, 219, 55, 55, "CID"], [219, 219, 87, 87, "CID"], [219, 219, 265, 265, "CID"], [219, 219, 344, 344, "CID"], [253, 253, 51, 53, "CID"], [253, 253, 55, 55, "CID"], [253, 253, 87, 87, "CID"], [253, 253, 265, 265, "CID"], [253, 253, 344, 344, "CID"], [293, 293, 51, 53, "CID"], [293, 293, 55, 55, "CID"], [293, 293, 87, 87, "CID"], [293, 293, 265, 265, "CID"], [293, 293, 344, 344, "CID"]]], "clusters": [], "translated": "2期早期后除极化作为获得性<6>长QT综合症</6>中多形性<16>室性心动过速</16>的触发因素：来自完整左心室壁细胞内记录的直接证据。背景：本研究检查了2期早期后除极化（EAD）在触发引发<11>尖端扭转型室性心动过速</11>（<12>TdP</12>）和<7>QT延长</7>中的作用由dl-<0>索他洛尔</0>和<17>阿齐利特</17>诱导。还评估了跨壁复极色散（TDR）对EAD跨壁传播和<13>TdP</13>维持的贡献。方法和结果：在动脉灌注的犬和兔左心室准备中，同时记录心外膜、心肌中部和心内膜的跨膜动作电位，以及透壁心电图。dl-<1>索他洛尔</1>优先延长M细胞的动作电位持续时间（APD），剂量依赖性（1至100微摩尔/升），导致<8>QT延长</8>和TDR增加。<18>阿齐利特</18>然而，从0.1至10微摩尔/升缩短30微摩尔/升。与dl-<2>索他洛尔</2>不同，<19>阿齐利特</19>（>3微摩尔/升）显着增加心外膜APD，导致TDR降低。尽管dl-<3>索他洛尔</3>和<20>阿齐利特</20>很少在犬类左心室中诱发EAD，但它们在家兔中产生频繁的EAD，其中更明显的<9>QT延长</9>见过。dl-<4>索他洛尔</4>增加TDR促进了EAD的跨壁传播，在6只兔子的左心室中的3只中引发了多次自发性<14>TdP</14>发作。值得注意的是，尽管<21>阿齐利特</21>（3至10微摩尔/升）比dl-<5>索他洛尔</5>更能增加APD，但它的EAD通常不能透壁传播，这可能是因为TDR减弱。结论：这项研究提供了第一个来自细胞内动作电位记录的直接证据，表明2期EAD可以从完整的心室壁产生，并产生触发以启动<15>TdP</15>在<10>QT延长</10>。", "revised": true}
{"doc_key": "11835460", "sentences": [["Levodopa", "-", "induced", "ocular", "dyskinesias", "in", "Parkinson", "'s", "disease", ".", "Levodopa", "-", "induced", "ocular", "dyskinesias", "are", "very", "uncommon", ".", "Usually", "they", "occur", "simultaneously", "with", "limb", "peak", "-", "dose", "choreatic", "dyskinesias", ".", "We", "report", "on", "a", "patient", "with", "leftward", "and", "upward", "deviations", "of", "gaze", "during", "the", "peak", "effect", "of", "levodopa", ",", "and", "hypothesize", "that", "a", "severe", "dopaminergic", "denervation", "in", "the", "caudate", "nucleus", "is", "needed", "for", "the", "appearance", "of", "these", "levodopa", "-", "induce", "ocular", "dyskinesias", "."]], "ner": [[[0, 0, "Chemical"], [10, 10, "Chemical"], [48, 48, "Chemical"], [68, 68, "Chemical"], [3, 4, "Disease"], [13, 14, "Disease"], [71, 72, "Disease"], [6, 8, "Disease"], [28, 29, "Disease"]]], "relations": [[[0, 0, 3, 4, "CID"], [0, 0, 13, 14, "CID"], [0, 0, 71, 72, "CID"], [10, 10, 3, 4, "CID"], [10, 10, 13, 14, "CID"], [10, 10, 71, 72, "CID"], [48, 48, 3, 4, "CID"], [48, 48, 13, 14, "CID"], [48, 48, 71, 72, "CID"], [68, 68, 3, 4, "CID"], [68, 68, 13, 14, "CID"], [68, 68, 71, 72, "CID"]]], "clusters": [], "translated": "<0>左旋多巴</0>诱发<4>眼球运动障碍</4>在<7>帕金森病</7>中。<1>左旋多巴</1>引起的<5>眼球运动障碍</5>非常罕见。通常它们与肢体峰值剂量<8>舞蹈病性运动障碍</8>同时发生。我们报告了一名患者，在 <2>左旋多巴</2> 的峰值效应期间出现凝视向左和向上的偏差，并假设这些<3>左旋多巴</3>诱发<6>眼球运动障碍</6>的出现需要尾状核中严重的多巴胺能去神经支配。", "revised": true}
{"doc_key": "11229942", "sentences": [["Cocaine", ",", "ethanol", ",", "and", "cocaethylene", "cardiotoxity", "in", "an", "animal", "model", "of", "cocaine", "and", "ethanol", "abuse", ".", "OBJECTIVES", ":", "Simultaneous", "abuse", "of", "cocaine", "and", "ethanol", "affects", "12", "million", "Americans", "annually", ".", "In", "combination", ",", "these", "substances", "are", "substantially", "more", "toxic", "than", "either", "drug", "alone", ".", "Their", "combined", "cardiac", "toxicity", "may", "be", "due", "to", "independent", "effects", "of", "each", "drug", ";", "however", ",", "they", "may", "also", "be", "due", "to", "cocaethylene", "(", "CE", ")", ",", "a", "cocaine", "metabolite", "formed", "only", "in", "the", "presence", "of", "ethanol", ".", "The", "purpose", "of", "this", "study", "was", "to", "delineate", "the", "role", "of", "CE", "in", "the", "combined", "cardiotoxicity", "of", "cocaine", "and", "ethanol", "in", "a", "model", "simulating", "their", "abuse", ".", "METHODS", ":", "Twenty", "-", "three", "dogs", "were", "randomized", "to", "receive", "either", "1", ")", "three", "intravenous", "(", "IV", ")", "boluses", "of", "cocaine", "7", ".", "5", "mg", "/", "kg", "with", "ethanol", "(", "1", "g", "/", "kg", ")", "as", "an", "IV", "infusion", "(", "C", "+", "E", ",", "n", "=", "8", ")", ",", "2", ")", "three", "cocaine", "boluses", "only", "(", "C", ",", "n", "=", "6", ")", ",", "3", ")", "ethanol", "infusion", "only", "(", "E", ",", "n", "=", "5", ")", ",", "or", "4", ")", "placebo", "boluses", "and", "infusion", "(", "n", "=", "4", ")", ".", "Hemodynamic", "measurements", ",", "electrocardiograms", ",", "and", "serum", "drug", "concentrations", "were", "obtained", "at", "baseline", ",", "and", "then", "at", "fixed", "time", "intervals", "after", "each", "drug", "was", "administered", ".", "RESULTS", ":", "Two", "of", "eight", "dogs", "in", "the", "C", "+", "E", "group", "experienced", "cardiovascular", "collapse", ".", "The", "most", "dramatic", "hemodynamic", "changes", "occurred", "after", "each", "cocaine", "bolus", "in", "the", "C", "+", "E", "and", "C", "only", "groups", ";", "however", ",", "persistent", "hemodynamic", "changes", "occurred", "in", "the", "C", "+", "E", "group", ".", "Peak", "CE", "levels", "were", "associated", "with", "a", "45", "%", "(", "SD", "+", "/", "-", "22", "%", ",", "95", "%", "CI", "=", "22", "%", "to", "69", "%", ")", "decrease", "in", "cardiac", "output", "(", "p", "<", "0", ".", "05", ")", ",", "a", "56", "%", "(", "SD", "+", "/", "-", "23", "%", ",", "95", "%", "CI", "=", "32", "%", "to", "80", "%", ")", "decrease", "in", "dP", "/", "dt", "(", "max", ")", "(", "p", "<", ".", "006", ")", ",", "and", "a", "23", "%", "(", "SD", "+", "/", "-", "15", "%", ",", "95", "%", "CI", "=", "7", "%", "to", "49", "%", ")", "decrease", "in", "SVO", "(", "2", ")", "(", "p", "<", "0", ".", "025", ")", ".", "Ventricular", "arrhythmias", "were", "primarily", "observed", "in", "the", "C", "+", "E", "group", ",", "in", "which", "four", "of", "eight", "dogs", "experienced", "ventricular", "tachycardia", ".", "CONCLUSIONS", ":", "Cocaine", "and", "ethanol", "in", "combination", "were", "more", "toxic", "than", "either", "substance", "alone", ".", "Co", "-", "administration", "resulted", "in", "prolonged", "cardiac", "toxicity", "and", "was", "dysrhythmogenic", ".", "Peak", "serum", "cocaethylene", "concentrations", "were", "associated", "with", "prolonged", "myocardial", "depression", "."]], "ner": [[[0, 0, "Chemical"], [73, 73, "Chemical"], [100, 100, "Chemical"], [130, 130, "Chemical"], [162, 162, "Chemical"], [249, 249, "Chemical"], [409, 409, "Chemical"], [404, 405, "Disease"], [2, 2, "Chemical"], [81, 81, "Chemical"], [102, 102, "Chemical"], [138, 138, "Chemical"], [175, 175, "Chemical"], [411, 411, "Chemical"], [5, 5, "Chemical"], [67, 67, "Chemical"], [69, 69, "Chemical"], [94, 94, "Chemical"], [275, 275, "Chemical"], [436, 436, "Chemical"], [301, 304, "Disease"], [6, 6, "Disease"], [47, 48, "Disease"], [98, 98, "Disease"], [428, 429, "Disease"], [12, 15, "Disease"], [20, 24, "Disease"], [385, 386, "Disease"], [442, 443, "Disease"]]], "relations": [[[0, 0, 404, 405, "CID"], [73, 73, 404, 405, "CID"], [100, 100, 404, 405, "CID"], [130, 130, 404, 405, "CID"], [162, 162, 404, 405, "CID"], [249, 249, 404, 405, "CID"], [409, 409, 404, 405, "CID"], [2, 2, 404, 405, "CID"], [81, 81, 404, 405, "CID"], [102, 102, 404, 405, "CID"], [138, 138, 404, 405, "CID"], [175, 175, 404, 405, "CID"], [411, 411, 404, 405, "CID"], [5, 5, 301, 304, "CID"], [67, 67, 301, 304, "CID"], [69, 69, 301, 304, "CID"], [94, 94, 301, 304, "CID"], [275, 275, 301, 304, "CID"], [436, 436, 301, 304, "CID"]]], "clusters": [], "translated": "<0>可卡因</0>、<8>乙醇</8>和<14>可卡乙烯</14><21>心脏毒性</21>在<25>可卡因和乙醇滥用动物模型</25>中。目标: 同时<26>滥用可卡因和乙醇</26>每年影响1200万美国人。结合起来, 这些物质比单独使用任何一种药物的毒性都大得多。它们的联合<22>心脏毒性</22>可能是由于每种药物的独立作用所致；然而, 它们也可能是由于<15>可卡乙烯</15> (<16>CE</16>), 一种仅在<9>乙醇</9>存在下形成的<1>可卡因</1>代谢物。本研究的目的是描述<17>CE</17>在联合使用<2>可卡因</2>和<10>乙醇</10>中的<23>心脏毒性</23>，模拟他们虐待的模型。方法: 23只狗被随机分配接受1) 三个<3>可卡因</3> 7.5 mg/kg，在<11>乙醇</11>（1g/kg）作为静脉输注（C+E，n=8）, 2) 三个<4>可卡因 </4> 仅推注 (C, n = 6), 3) 仅<12>乙醇</12>输注 (E, n = 5), 或 4) 安慰剂推注和输注(n=4)。在基线时获得血流动力学测量值、心电图和血清药物浓度，然后在每种药物给药后以固定的时间间隔获得。结果：C+E组八只狗中有两只经历了心血管衰竭。最显着的血流动力学变化发生在每次<5>可卡因</5>推注后，C+E和C only组；然而，C+E组出现了持续的血流动力学变化。峰值<18>CE</18>水平与45% (SD +/- 22%, 95% CI = 22% to 69%)<20>心输出量下降</20> (p < 0. 05) , 56% (SD +/- 23%, 95% CI = 32% to 80%) dP/dt (max) (p <.006) 和23% (SD +/- 15 %, 95% CI = 7% to 49%) SVO 减少 (2) (p < 0.025)。<27>室性心律失常</27>主要在C+E组中观察到，其中8只犬中有4只出现<7>室性心动过速</7>。结论：<6>可卡因</6>和<13>乙醇</13>的组合比单独使用任何一种物质的毒性更大。共同给药导致延长的<24>心脏毒性</24>并且是致心律失常的。血清峰值<19>可卡乙烯</19>浓度与延长的<28>心肌抑制</28>有关。", "revised": true}
{"doc_key": "11380496", "sentences": [["Frequency", "of", "appearance", "of", "myeloperoxidase", "-", "antineutrophil", "cytoplasmic", "antibody", "(", "MPO", "-", "ANCA", ")", "in", "Graves", "'", "disease", "patients", "treated", "with", "propylthiouracil", "and", "the", "relationship", "between", "MPO", "-", "ANCA", "and", "clinical", "manifestations", ".", "OBJECTIVE", ":", "Myeloperoxidase", "antineutrophil", "cytoplasmic", "antibody", "(", "MPO", "-", "ANCA", ")", "-", "positive", "vasculitis", "has", "been", "reported", "in", "patients", "with", "Graves", "'", "disease", "who", "were", "treated", "with", "propylthiouracil", "(", "PTU", ")", ".", "The", "appearance", "of", "MPO", "-", "ANCA", "in", "these", "cases", "was", "suspected", "of", "being", "related", "to", "PTU", "because", "the", "titres", "of", "MPO", "-", "ANCA", "decreased", "when", "PTU", "was", "stopped", ".", "Nevertheless", ",", "there", "have", "been", "no", "studies", "on", "the", "temporal", "relationship", "between", "the", "appearance", "of", "MPO", "-", "ANCA", "and", "vasculitis", "during", "PTU", "therapy", ",", "or", "on", "the", "incidence", "of", "MPO", "-", "ANCA", "in", "untreated", "Graves", "'", "disease", "patients", ".", "Therefore", ",", "we", "sought", "to", "address", "these", "parameters", "in", "patients", "with", "Graves", "'", "disease", ".", "PATIENTS", ":", "We", "investigated", "102", "untreated", "patients", "with", "hyperthyroidism", "due", "to", "Graves", "'", "disease", "for", "the", "presence", "of", "MPO", "-", "ANCA", ",", "and", "for", "the", "development", "vasculitis", "after", "starting", "PTU", "therapy", ".", "Twenty", "-", "nine", "of", "them", "were", "later", "excluded", "because", "of", "adverse", "effects", "of", "PTU", "or", "because", "the", "observation", "period", "was", "less", "than", "3", "months", ".", "The", "remaining", "73", "patients", "(", "55", "women", "and", "18", "men", ")", ",", "all", "of", "whom", "were", "examined", "for", "more", "than", "3", "months", ",", "were", "adopted", "as", "the", "subjects", "of", "the", "investigation", ".", "The", "median", "observation", "period", "was", "23", ".", "6", "months", "(", "range", ":", "3", "-", "37", "months", ")", ".", "MEASUREMENTS", ":", "MPO", "-", "ANCA", "was", "measured", "at", "intervals", "of", "2", "-", "6", "months", ".", "RESULTS", ":", "Before", "treatment", ",", "the", "MPO", "-", "ANCA", "titres", "of", "all", "102", "untreated", "Graves", "'", "disease", "patients", "were", "within", "the", "reference", "range", "(", "below", "10", "U", "/", "ml", ")", ".", "Three", "(", "4", ".", "1", "%", ")", "of", "the", "73", "patients", "were", "positive", "for", "MPO", "-", "ANCA", "at", "13", ",", "16", "and", "17", "months", ",", "respectively", ",", "after", "the", "start", "of", "PTU", "therapy", ".", "In", "two", "of", "them", ",", "the", "MPO", "-", "ANCA", "titres", "transiently", "increased", "to", "12", ".", "8", "and", "15", ".", "0", "U", "/", "ml", ",", "respectively", ",", "despite", "continued", "PTU", "therapy", ",", "but", "no", "vasculitic", "disorders", "developed", ".", "In", "the", "third", "patient", ",", "the", "MPO", "-", "ANCA", "titre", "increased", "to", "204", "U", "/", "ml", "and", "she", "developed", "a", "higher", "fever", ",", "oral", "ulcers", "and", "polyarthralgia", ",", "but", "the", "symptoms", "resolved", "2", "weeks", "after", "stopping", "PTU", "therapy", ",", "and", "the", "MPO", "-", "ANCA", "titre", "decreased", "to", "20", ".", "7", "U", "/", "ml", "by", "4", "months", "after", "discontinuing", "PTU", ".", "CONCLUSIONS", ":", "PTU", "therapy", "may", "be", "related", "to", "the", "appearance", "of", "MPO", "-", "ANCA", ",", "but", "MPO", "-", "ANCA", "does", "not", "appear", "to", "be", "closely", "related", "to", "vasculitis", "."]], "ner": [[[21, 21, "Chemical"], [60, 60, "Chemical"], [62, 62, "Chemical"], [80, 80, "Chemical"], [90, 90, "Chemical"], [115, 115, "Chemical"], [177, 177, "Chemical"], [193, 193, "Chemical"], [332, 332, "Chemical"], [363, 363, "Chemical"], [408, 408, "Chemical"], [430, 430, "Chemical"], [434, 434, "Chemical"], [393, 393, "Disease"], [395, 396, "Disease"], [398, 398, "Disease"], [15, 17, "Disease"], [53, 55, "Disease"], [128, 130, "Disease"], [144, 146, "Disease"], [159, 161, "Disease"], [284, 286, "Disease"], [46, 46, "Disease"], [113, 113, "Disease"], [174, 174, "Disease"], [459, 459, "Disease"], [156, 156, "Disease"], [368, 369, "Disease"]]], "relations": [[[21, 21, 393, 393, "CID"], [60, 60, 393, 393, "CID"], [62, 62, 393, 393, "CID"], [80, 80, 393, 393, "CID"], [90, 90, 393, 393, "CID"], [115, 115, 393, 393, "CID"], [177, 177, 393, 393, "CID"], [193, 193, 393, 393, "CID"], [332, 332, 393, 393, "CID"], [363, 363, 393, 393, "CID"], [408, 408, 393, 393, "CID"], [430, 430, 393, 393, "CID"], [434, 434, 393, 393, "CID"], [21, 21, 395, 396, "CID"], [60, 60, 395, 396, "CID"], [62, 62, 395, 396, "CID"], [80, 80, 395, 396, "CID"], [90, 90, 395, 396, "CID"], [115, 115, 395, 396, "CID"], [177, 177, 395, 396, "CID"], [193, 193, 395, 396, "CID"], [332, 332, 395, 396, "CID"], [363, 363, 395, 396, "CID"], [408, 408, 395, 396, "CID"], [430, 430, 395, 396, "CID"], [434, 434, 395, 396, "CID"], [21, 21, 398, 398, "CID"], [60, 60, 398, 398, "CID"], [62, 62, 398, 398, "CID"], [80, 80, 398, 398, "CID"], [90, 90, 398, 398, "CID"], [115, 115, 398, 398, "CID"], [177, 177, 398, 398, "CID"], [193, 193, 398, 398, "CID"], [332, 332, 398, 398, "CID"], [363, 363, 398, 398, "CID"], [408, 408, 398, 398, "CID"], [430, 430, 398, 398, "CID"], [434, 434, 398, 398, "CID"]]], "clusters": [], "translated": "<0>丙基硫氧嘧啶</0>治疗<16>Graves病</16>患者髓过氧化物酶-抗中性粒细胞胞浆抗体(MPO-ANCA)的出现频率及MPO-ANCA与临床表现的关系。目的：髓过氧化物酶抗中性粒细胞胞质抗体 (MPO-ANCA) - 阳性<22>血管炎</22>曾在接受 <1>丙基硫氧嘧啶</1> 治疗的<17>Graves病</17>患者中报告(<2>PTU</2>)。这些病例中MPO-ANCA的出现被怀疑与<3>PTU</3>有关，因为停用<4>PTU</4>时MPO-ANCA滴度降低。然而，尚无关于<5>PTU</5>治疗期间MPO-ANCA的出现与<23>血管炎</23>之间的时间关系的研究，或未治疗的<18>Graves病</18>患者中MPO-ANCA发生率的研究。因此，我们试图解决患有<19>Graves病</19>的患者的这些参数。患者：我们调查了102名因<20>Graves病</20>而未接受治疗的<26>甲状腺功能亢进症</26>患者是否存在MPO-ANCA，以及开始治疗后是否发生了<24>血管炎</24><6>PTU</6>治疗。其中29例后来因<7>PTU</7>的不良反应或观察期不足3个月而被排除。其余73例（女性55例，男性18例）均接受检查3个月以上，作为调查对象。中位观察期为23.6个月（范围：3-37个月）。测量：每隔2-6个月测量一次MPO-ANCA。结果：治疗前，102例未治疗的<21>Graves病</21>患者的MPO-ANCA滴度均在参考范围内（低于10U/ml）。在<8>PTU</8>治疗开始后的第13、16和17个月，73例患者中有3例(4.1%)MPO-ANCA呈阳性。在其中两个中，MPO-ANCA滴度短暂地增加到12.8和15.0 U/ml，尽管继续<9>PTU</9>治疗，但未发生<27>血管炎</27>。第三位患者的MPO-ANCA滴度增加到204 U/ml，她出现了更高的<13>发烧</13>、<14>口腔溃疡</14>和<15>多关节痛</15>，但是停止<10>PTU</10>治疗2周后症状消失，MPO-ANCA滴度降至20.7 U/ml停止<11>PTU</11>后4个月。结论：<12>PTU</12>治疗可能与MPO-ANCA的出现有关，但MPO-ANCA与<25>血管炎</25>似乎无密切关系。", "revised": true}
{"doc_key": "11176729", "sentences": [["Toleration", "of", "high", "doses", "of", "angiotensin", "-", "converting", "enzyme", "inhibitors", "in", "patients", "with", "chronic", "heart", "failure", ":", "results", "from", "the", "ATLAS", "trial", ".", "The", "Assessment", "of", "Treatment", "with", "Lisinopril", "and", "Survival", ".", "BACKGROUND", ":", "Treatment", "with", "angiotensin", "-", "converting", "enzyme", "(", "ACE", ")", "inhibitors", "reduces", "mortality", "and", "morbidity", "in", "patients", "with", "chronic", "heart", "failure", "(", "CHF", ")", ",", "but", "most", "affected", "patients", "are", "not", "receiving", "these", "agents", "or", "are", "being", "treated", "with", "doses", "lower", "than", "those", "found", "to", "be", "efficacious", "in", "trials", ",", "primarily", "because", "of", "concerns", "about", "the", "safety", "and", "tolerability", "of", "these", "agents", ",", "especially", "at", "the", "recommended", "doses", ".", "The", "present", "study", "examines", "the", "safety", "and", "tolerability", "of", "high", "-", "compared", "with", "low", "-", "dose", "lisinopril", "in", "CHF", ".", "METHODS", ":", "The", "Assessment", "of", "Lisinopril", "and", "Survival", "study", "was", "a", "multicenter", ",", "randomized", ",", "double", "-", "blind", "trial", "in", "which", "patients", "with", "or", "without", "previous", "ACE", "inhibitor", "treatment", "were", "stabilized", "receiving", "medium", "-", "dose", "lisinopril", "(", "12", ".", "5", "or", "15", ".", "0", "mg", "once", "daily", "[", "OD", "]", ")", "for", "2", "to", "4", "weeks", "and", "then", "randomized", "to", "high", "-", "(", "35", ".", "0", "or", "32", ".", "5", "mg", "OD", ")", "or", "low", "-", "dose", "(", "5", ".", "0", "or", "2", ".", "5", "mg", "OD", ")", "groups", ".", "Patients", "with", "New", "York", "Heart", "Association", "classes", "II", "to", "IV", "CHF", "and", "left", "ventricular", "ejection", "fractions", "of", "no", "greater", "than", "0", ".", "30", "(", "n", "=", "3164", ")", "were", "randomized", "and", "followed", "up", "for", "a", "median", "of", "46", "months", ".", "We", "examined", "the", "occurrence", "of", "adverse", "events", "and", "the", "need", "for", "discontinuation", "and", "dose", "reduction", "during", "treatment", ",", "with", "a", "focus", "on", "hypotension", "and", "renal", "dysfunction", ".", "RESULTS", ":", "Of", "405", "patients", "not", "previously", "receiving", "an", "ACE", "inhibitor", ",", "doses", "in", "only", "4", ".", "2", "%", "could", "not", "be", "titrated", "to", "the", "medium", "doses", "required", "for", "randomization", "because", "of", "symptoms", "possibly", "related", "to", "hypotension", "(", "2", ".", "0", "%", ")", "or", "because", "of", "renal", "dysfunction", "or", "hyperkalemia", "(", "2", ".", "3", "%", ")", ".", "Doses", "in", "more", "than", "90", "%", "of", "randomized", "patients", "in", "the", "high", "-", "and", "low", "-", "dose", "groups", "were", "titrated", "to", "their", "assigned", "target", ",", "and", "the", "mean", "doses", "of", "blinded", "medication", "in", "both", "groups", "remained", "similar", "throughout", "the", "study", ".", "Withdrawals", "occurred", "in", "27", ".", "1", "%", "of", "the", "high", "-", "and", "30", ".", "7", "%", "of", "the", "low", "-", "dose", "groups", ".", "Subgroups", "presumed", "to", "be", "at", "higher", "risk", "for", "ACE", "inhibitor", "intolerance", "(", "blood", "pressure", ",", "<", "120", "mm", "Hg", ";", "creatinine", ",", ">", "or", "=", "132", ".", "6", "micromol", "/", "L", "[", ">", "or", "=", "1", ".", "5", "mg", "/", "dL", "]", ";", "age", ",", ">", "or", "=", "70", "years", ";", "and", "patients", "with", "diabetes", ")", "generally", "tolerated", "the", "high", "-", "dose", "strategy", ".", "CONCLUSIONS", ":", "These", "findings", "demonstrate", "that", "ACE", "inhibitor", "therapy", "in", "most", "patients", "with", "CHF", "can", "be", "successfully", "titrated", "to", "and", "maintained", "at", "high", "doses", ",", "and", "that", "more", "aggressive", "use", "of", "these", "agents", "is", "warranted", "."]], "ner": [[[28, 28, "Chemical"], [118, 118, "Chemical"], [127, 127, "Chemical"], [157, 157, "Chemical"], [274, 274, "Disease"], [315, 315, "Disease"], [276, 277, "Disease"], [325, 326, "Disease"], [328, 328, "Disease"], [5, 9, "Chemical"], [36, 43, "Chemical"], [148, 149, "Chemical"], [288, 289, "Chemical"], [408, 409, "Chemical"], [470, 471, "Chemical"], [14, 15, "Disease"], [52, 53, "Disease"], [55, 55, "Disease"], [120, 120, "Disease"], [222, 222, "Disease"], [477, 477, "Disease"], [454, 454, "Disease"], [420, 420, "Chemical"]]], "relations": [[[28, 28, 274, 274, "CID"], [28, 28, 315, 315, "CID"], [118, 118, 274, 274, "CID"], [118, 118, 315, 315, "CID"], [127, 127, 274, 274, "CID"], [127, 127, 315, 315, "CID"], [157, 157, 274, 274, "CID"], [157, 157, 315, 315, "CID"], [28, 28, 276, 277, "CID"], [28, 28, 325, 326, "CID"], [118, 118, 276, 277, "CID"], [118, 118, 325, 326, "CID"], [127, 127, 276, 277, "CID"], [127, 127, 325, 326, "CID"], [157, 157, 276, 277, "CID"], [157, 157, 325, 326, "CID"], [28, 28, 328, 328, "CID"], [118, 118, 328, 328, "CID"], [127, 127, 328, 328, "CID"], [157, 157, 328, 328, "CID"]]], "clusters": [], "translated": "慢性<15>心力衰竭</15>患者对高剂量<9>血管紧张素转换酶抑制剂</9>的耐受性：ATLAS试验的结果。 <0>赖诺普利</0>治疗和生存的评估。 背景：使用<10>血管紧张素转换酶（ACE）抑制剂</10>治疗可降低慢性<16>心力衰竭</16> (<17>CHF</17>)患者的死亡率和发病率，但受影响最大患者没有接受这些药物治疗，或者接受的治疗剂量低于试验中发现的有效剂量，这主要是因为担心这些药物的安全性和耐受性，尤其是在推荐剂量下。本研究考察了高剂量和低剂量<1>赖诺普利</1>在<18>CHF</18>中的安全性和耐受性。方法：<2>赖诺普利</2>的评估和生存研究是一项多中心、随机、双盲试验，其中接受或未接受过<11>ACE抑制剂</11>治疗的患者稳定接受中等剂量<3>赖诺普利</3>（12.5或15.0 mg每天一次[OD]）持续2至4周，然后随机分为高剂量（35.0或32.5 mg OD）或低剂量（5.0或2.5 mg OD）组。纽约心脏协会II至IV级<19>CHF</19>且左心室射血分数不大于0的患者30名(n=3164)被随机分配并随访中位数为46个月。我们检查了不良事件的发生以及治疗期间是否需要停药和减少剂量，重点是<4>低血压</4>和<6>肾功能障碍</6>。结果：在405名先前未接受过<12>ACE抑制剂</12>治疗的患者中，只有4名接受过剂量。由于可能与<5>低血压</5>(2.0%)相关的症状或由于<7>肾功能不全</7>或<8>高钾血症</8>，2%无法滴定至随机化所需的中等剂量（2.3%）。在高剂量组和低剂量组中，超过90%的随机患者的剂量被滴定到他们指定的目标，并且在整个研究过程中，两组的盲法用药平均剂量保持相似。提款发生在27.1%的高30.7%的低剂量组。被推定为<13>ACE抑制剂</13>不耐受风险较高的亚组（血压<120 mm Hg；<22>肌酐</22>，>或=132.6微摩尔/升[>或=1.5 mg/dL]；年龄>或=70岁；以及患有<21>糖尿病</21>）的患者通常可以耐受高剂量策略。结论：这些研究结果表明，对于大多数<20>CHF</20>患者，<14>ACE抑制剂</14>治疗可以成功地调整至高剂量并维持在高剂量，并且需要更积极地使用这些药物。", "revised": true}
{"doc_key": "11915580", "sentences": [["A", "comparison", "of", "glyceryl", "trinitrate", "with", "diclofenac", "for", "the", "treatment", "of", "primary", "dysmenorrhea", ":", "an", "open", ",", "randomized", ",", "cross", "-", "over", "trial", ".", "Primary", "dysmenorrhea", "is", "a", "syndrome", "characterized", "by", "painful", "uterine", "contractility", "caused", "by", "a", "hypersecretion", "of", "endometrial", "prostaglandins", ";", "non", "-", "steroidal", "anti", "-", "inflammatory", "drugs", "are", "the", "first", "choice", "for", "its", "treatment", ".", "However", ",", "in", "vivo", "and", "in", "vitro", "studies", "have", "demonstrated", "that", "myometrial", "cells", "are", "also", "targets", "of", "the", "relaxant", "effects", "of", "nitric", "oxide", "(", "NO", ")", ".", "The", "aim", "of", "the", "present", "study", "was", "to", "determine", "the", "efficacy", "of", "glyceryl", "trinitrate", "(", "GTN", ")", ",", "an", "NO", "donor", ",", "in", "the", "resolution", "of", "primary", "dysmenorrhea", "in", "comparison", "with", "diclofenac", "(", "DCF", ")", ".", "A", "total", "of", "24", "patients", "with", "the", "diagnosis", "of", "severe", "primary", "dysmenorrhea", "were", "studied", "during", "two", "consecutive", "menstrual", "cycles", ".", "In", "an", "open", ",", "cross", "-", "over", ",", "controlled", "design", ",", "patients", "were", "randomized", "to", "receive", "either", "DCF", "per", "os", "or", "GTN", "patches", "the", "first", "days", "of", "menses", ",", "when", "menstrual", "cramps", "became", "unendurable", ".", "In", "the", "subsequent", "cycle", "the", "other", "treatment", "was", "used", ".", "Patients", "received", "up", "to", "3", "doses", "/", "day", "of", "50", "mg", "DCF", "or", "2", ".", "5", "mg", "/", "24", "h", "transdermal", "GTN", "for", "the", "first", "3", "days", "of", "the", "cycle", ",", "according", "to", "their", "needs", ".", "The", "participants", "recorded", "menstrual", "symptoms", "and", "possible", "side", "-", "effects", "at", "different", "times", "(", "0", ",", "30", ",", "60", ",", "120", "minutes", ")", "after", "the", "first", "dose", "of", "medication", "on", "the", "first", "day", "of", "the", "cycle", ",", "with", "both", "drugs", ".", "The", "difference", "in", "pain", "intensity", "score", "(", "DPI", ")", "was", "the", "main", "outcome", "variable", ".", "Both", "treatments", "significantly", "reduced", "DPI", "by", "the", "30th", "minute", "(", "GTN", ",", "-", "12", ".", "8", "+", "/", "-", "17", ".", "9", ";", "DCF", ",", "-", "18", ".", "9", "+", "/", "-", "16", ".", "6", ")", ".", "However", ",", "DCF", "continued", "to", "be", "effective", "in", "reducing", "pelvic", "pain", "for", "two", "hours", ",", "whereas", "GTN", "scores", "remained", "more", "or", "less", "stable", "after", "30", "min", "and", "significantly", "higher", "than", "those", "for", "DFC", "(", "after", "one", "hour", ":", "GTN", ",", "-", "12", ".", "8", "+", "/", "-", "17", ".", "9", ";", "DFC", ",", "-", "18", ".", "9", "+", "/", "-", "16", ".", "6", "and", "after", "two", "hours", ":", "GTN", ",", "-", "23", ".", "7", "+", "/", "-", "20", ".", "5", ";", "DFC", ",", "-", "59", ".", "7", "+", "/", "-", "17", ".", "9", ",", "p", "=", "0", ".", "0001", ")", ".", "Low", "back", "pain", "was", "also", "relieved", "by", "both", "drugs", ".", "Headache", "was", "significantly", "increased", "by", "GTN", "but", "not", "by", "DCF", ".", "Eight", "patients", "stopped", "using", "GTN", "because", "headache", "-", "-", "attributed", "to", "its", "use", "-", "-", "became", "intolerable", ".", "These", "findings", "indicate", "that", "GTN", "has", "a", "reduced", "efficacy", "and", "tolerability", "by", "comparison", "with", "DCF", "in", "the", "treatment", "of", "primary", "dysmenorrhea", "."]], "ner": [[[3, 4, "Chemical"], [96, 97, "Chemical"], [99, 99, "Chemical"], [161, 161, "Chemical"], [206, 206, "Chemical"], [287, 287, "Chemical"], [330, 330, "Chemical"], [352, 352, "Chemical"], [382, 382, "Chemical"], [430, 430, "Chemical"], [440, 440, "Chemical"], [458, 458, "Chemical"], [425, 425, "Disease"], [442, 442, "Disease"], [12, 12, "Disease"], [25, 25, "Disease"], [111, 111, "Disease"], [131, 131, "Disease"], [474, 474, "Disease"], [265, 265, "Disease"], [323, 324, "Disease"], [415, 417, "Disease"], [6, 6, "Chemical"], [115, 115, "Chemical"], [117, 117, "Chemical"], [157, 157, "Chemical"], [196, 196, "Chemical"], [300, 300, "Chemical"], [316, 316, "Chemical"], [434, 434, "Chemical"], [468, 468, "Chemical"], [40, 40, "Chemical"], [78, 79, "Chemical"], [81, 81, "Chemical"], [103, 103, "Chemical"]]], "relations": [[[3, 4, 425, 425, "CID"], [3, 4, 442, 442, "CID"], [96, 97, 425, 425, "CID"], [96, 97, 442, 442, "CID"], [99, 99, 425, 425, "CID"], [99, 99, 442, 442, "CID"], [161, 161, 425, 425, "CID"], [161, 161, 442, 442, "CID"], [206, 206, 425, 425, "CID"], [206, 206, 442, 442, "CID"], [287, 287, 425, 425, "CID"], [287, 287, 442, 442, "CID"], [330, 330, 425, 425, "CID"], [330, 330, 442, 442, "CID"], [352, 352, 425, 425, "CID"], [352, 352, 442, 442, "CID"], [382, 382, 425, 425, "CID"], [382, 382, 442, 442, "CID"], [430, 430, 425, 425, "CID"], [430, 430, 442, 442, "CID"], [440, 440, 425, 425, "CID"], [440, 440, 442, 442, "CID"], [458, 458, 425, 425, "CID"], [458, 458, 442, 442, "CID"]]], "clusters": [], "translated": "<0>甘油三硝酸酯</0>与<22>双氯芬酸</22>治疗原发性<14>痛经</14>的比较：一项开放、随机、交叉试验。原发性<15>痛经</15>是一种以子宫内膜<31>前列腺素</31>分泌过多引起的子宫收缩痛为特征的综合征；非甾体抗炎药是其治疗的首选药物。然而，体内和体外研究表明，肌层细胞也是<32>一氧化氮</32> (<33>NO</33>) 松弛作用的靶点。本研究的目的是确定<1>甘油三硝酸酯</1> (<2>GTN</2>)，一种<34>NO</34>供体，在解决原发性<16>痛经</16>与<23>双氯芬酸</23> (<24>DCF</24>)比较。在连续两个月经周期期间对总共24名诊断为严重原发性<17>痛经</17>的患者进行了研究。在开放、交叉、对照设计中，患者被随机分配接受<25>DCF</25>口服或<3>甘油三硝酸酯</3>贴剂，在月经来潮的第一天，当痛经变得难以忍受时。在随后的周期中，使用了另一种治疗方法。患者每天最多接受3剂50 mg<26>DCF</26>或2.5毫克/24小时透皮<4>GTN</4>用于周期的前3天，根据他们的需要。参与者在周期的第一天第一次服药后的不同时间（0、30、60、120分钟）记录了两种药物的月经症状和可能的副作用。<19>疼痛</19>强度评分 (DPI) 的差异是主要的结果变量。到第30分钟，两种治疗均显着降低DPI（<5>甘油三硝酸酯</5>，-12.8+/-17.9；<27>双氯芬酸</27>，-18.9+/-16.6）。然而，<28>双氯芬酸</28>继续有效减轻<20>骨盆疼痛</20>两个小时，而<6>甘油三硝酸酯</6>评分在30分钟后或多或少保持稳定，并且明显更高比DCF的那些（一小时后：<7>甘油三硝酸酯</7>，-12.8+/-17.9；DCF，-18.9+/-16.6和两小时后：<8>甘油三硝酸酯</8>，-23.7+/-20.5；DCF，-59.7+/-17.9，p=0.0001）。<21>腰痛</21>也被这两种药物缓解了。<12>头痛</12>显着增加<9>甘油三硝酸酯</9>而不是<29>双氯芬酸</29>。八名患者停止使用<10>甘油三硝酸酯</10>因为<13>头痛</13> - 归因于它的使用 - 变得无法忍受。这些发现表明，与<30>双氯芬酸</30>相比，<11>甘油三硝酸酯</11>治疗原发性<18>痛经</18>的疗效和耐受性均有所降低。", "revised": true}
{"doc_key": "12051122", "sentences": [["Hyponatremia", "and", "syndrome", "of", "inappropriate", "anti", "-", "diuretic", "hormone", "reported", "with", "the", "use", "of", "Vincristine", ":", "an", "over", "-", "representation", "of", "Asians", "?", "PURPOSE", ":", "This", "retrospective", "study", "used", "a", "pharmaceutical", "company", "'s", "global", "safety", "database", "to", "determine", "the", "reporting", "rate", "of", "hyponatremia", "and", "/", "or", "syndrome", "of", "inappropriate", "secretion", "of", "anti", "-", "diuretic", "hormone", "(", "SIADH", ")", "among", "vincristine", "-", "treated", "patients", "and", "to", "explore", "the", "possibility", "of", "at", "-", "risk", "population", "subgroups", ".", "METHOD", ":", "We", "searched", "the", "Eli", "Lilly", "and", "Company", "'s", "computerized", "adverse", "event", "database", "for", "all", "reported", "cases", "of", "hyponatremia", "and", "/", "or", "SIADH", "as", "of", "1", "November", "1999", "that", "had", "been", "reported", "during", "the", "use", "of", "vincristine", ".", "RESULTS", ":", "A", "total", "of", "76", "cases", "of", "hyponatremia", "and", "/", "or", "SIADH", "associated", "with", "vincristine", "use", "were", "identified", ".", "The", "overall", "reporting", "rate", "was", "estimated", "to", "be", "1", ".", "3", "/", "100", ",", "000", "treated", "patients", ".", "The", "average", "age", "of", "patients", "was", "35", ".", "6", "+", "/", "-", "28", ".", "3", "years", ",", "and", "62", "%", "were", "males", ".", "Approximately", "75", "%", "of", "the", "patients", "were", "receiving", "treatment", "for", "leukemia", "or", "lymphoma", ".", "Among", "the", "39", "reports", "that", "included", "information", "on", "race", ",", "the", "racial", "distribution", "was", ":", "1", "Black", ",", "3", "Caucasian", ",", "and", "35", "Asian", ".", "CONCLUSION", ":", "Our", "data", "suggest", "that", "Asian", "patients", "may", "be", "at", "increased", "risk", "of", "hyponatremia", "and", "/", "or", "SIADH", "associated", "with", "vincristine", "use", ".", "Although", "the", "overall", "reported", "rate", "of", "SIADH", "associated", "with", "vincristine", "is", "very", "low", ",", "physicians", "caring", "for", "Asian", "oncology", "patients", "should", "be", "aware", "of", "this", "potential", "serious", "but", "reversible", "adverse", "event", "."]], "ner": [[[14, 14, "Chemical"], [59, 59, "Chemical"], [112, 112, "Chemical"], [129, 129, "Chemical"], [235, 235, "Chemical"], [247, 247, "Chemical"], [0, 0, "Disease"], [42, 42, "Disease"], [94, 94, "Disease"], [122, 122, "Disease"], [228, 228, "Disease"], [2, 8, "Disease"], [46, 54, "Disease"], [56, 56, "Disease"], [98, 98, "Disease"], [126, 126, "Disease"], [232, 232, "Disease"], [244, 244, "Disease"], [185, 185, "Disease"], [187, 187, "Disease"]]], "relations": [[[14, 14, 0, 0, "CID"], [14, 14, 42, 42, "CID"], [14, 14, 94, 94, "CID"], [14, 14, 122, 122, "CID"], [14, 14, 228, 228, "CID"], [59, 59, 0, 0, "CID"], [59, 59, 42, 42, "CID"], [59, 59, 94, 94, "CID"], [59, 59, 122, 122, "CID"], [59, 59, 228, 228, "CID"], [112, 112, 0, 0, "CID"], [112, 112, 42, 42, "CID"], [112, 112, 94, 94, "CID"], [112, 112, 122, 122, "CID"], [112, 112, 228, 228, "CID"], [129, 129, 0, 0, "CID"], [129, 129, 42, 42, "CID"], [129, 129, 94, 94, "CID"], [129, 129, 122, 122, "CID"], [129, 129, 228, 228, "CID"], [235, 235, 0, 0, "CID"], [235, 235, 42, 42, "CID"], [235, 235, 94, 94, "CID"], [235, 235, 122, 122, "CID"], [235, 235, 228, 228, "CID"], [247, 247, 0, 0, "CID"], [247, 247, 42, 42, "CID"], [247, 247, 94, 94, "CID"], [247, 247, 122, 122, "CID"], [247, 247, 228, 228, "CID"], [14, 14, 2, 8, "CID"], [14, 14, 46, 54, "CID"], [14, 14, 56, 56, "CID"], [14, 14, 98, 98, "CID"], [14, 14, 126, 126, "CID"], [14, 14, 232, 232, "CID"], [14, 14, 244, 244, "CID"], [59, 59, 2, 8, "CID"], [59, 59, 46, 54, "CID"], [59, 59, 56, 56, "CID"], [59, 59, 98, 98, "CID"], [59, 59, 126, 126, "CID"], [59, 59, 232, 232, "CID"], [59, 59, 244, 244, "CID"], [112, 112, 2, 8, "CID"], [112, 112, 46, 54, "CID"], [112, 112, 56, 56, "CID"], [112, 112, 98, 98, "CID"], [112, 112, 126, 126, "CID"], [112, 112, 232, 232, "CID"], [112, 112, 244, 244, "CID"], [129, 129, 2, 8, "CID"], [129, 129, 46, 54, "CID"], [129, 129, 56, 56, "CID"], [129, 129, 98, 98, "CID"], [129, 129, 126, 126, "CID"], [129, 129, 232, 232, "CID"], [129, 129, 244, 244, "CID"], [235, 235, 2, 8, "CID"], [235, 235, 46, 54, "CID"], [235, 235, 56, 56, "CID"], [235, 235, 98, 98, "CID"], [235, 235, 126, 126, "CID"], [235, 235, 232, 232, "CID"], [235, 235, 244, 244, "CID"], [247, 247, 2, 8, "CID"], [247, 247, 46, 54, "CID"], [247, 247, 56, 56, "CID"], [247, 247, 98, 98, "CID"], [247, 247, 126, 126, "CID"], [247, 247, 232, 232, "CID"], [247, 247, 244, 244, "CID"]]], "clusters": [], "translated": " <6>低钠血症</6>和<11>抗利尿激素不当分泌综合征</11>报告使用<0>长春新碱</0>：亚洲人的比例过高？目的：这项回顾性研究使用一家制药公司的全球安全数据库来确定<7>低钠血症</7>和/或<12>抗利尿激素分泌不当综合征</12>的报告率（<13>SIADH</13>）在<1>长春新碱</1>治疗的患者中，并探索高危人群亚群的可能性。方法：我们在Eli Lilly and Company的计算机化不良事件数据库中搜索了截至1999年11月1日为止报告的所有<8>低钠血症</8>和/或<14>SIADH</14>病例，这些病例与<2>长春新碱</2>的使用相关。结果：共有76例<9>低钠血症</9>和/或<15>SIADH</15>与<3>长春新碱</3>使用相关。总体报告率估计为1.3/100,000接受治疗的患者。患者的平均年龄为35.6 +/- 28.3年，62%为男性。大约75%的患者正在接受<18>白血病</18>或<19>淋巴瘤</19>的治疗。在包含种族信息的39份报告中，种族分布为：1份黑人、3份高加索人和35份亚洲人。结论：我们的数据表明，亚洲患者发生<10>低钠血症</10>和/或<16>SIADH</16>的风险可能与<4>长春新碱</4>的使用有关。尽管与<5>长春新碱</5>相关的<17>SIADH</17>的总体报告率非常低，但照顾亚洲肿瘤患者的医生应该意识到这种潜在的严重但可逆的不良事件。", "revised": true}
{"doc_key": "11936424", "sentences": [["Temocapril", ",", "a", "long", "-", "acting", "non", "-", "SH", "group", "angiotensin", "converting", "enzyme", "inhibitor", ",", "modulates", "glomerular", "injury", "in", "chronic", "puromycin", "aminonucleoside", "nephrosis", ".", "The", "purpose", "of", "the", "present", "study", "was", "to", "determine", "whether", "chronic", "administration", "of", "temocapril", ",", "a", "long", "-", "acting", "non", "-", "SH", "group", "angiotensin", "converting", "enzyme", "(", "ACE", ")", "inhibitor", ",", "reduced", "proteinuria", ",", "inhibited", "glomerular", "hypertrophy", "and", "prevented", "glomerulosclerosis", "in", "chronic", "puromycin", "aminonucleoside", "(", "PAN", ")", "-", "induced", "nephrotic", "rats", ".", "Nephrosis", "was", "induced", "by", "injection", "of", "PAN", "(", "15mg", "/", "100g", "body", "weight", ")", "in", "male", "Sprague", "-", "Dawley", "(", "SD", ")", "rats", ".", "Four", "groups", "were", "used", ",", "i", ")", "the", "PAN", "group", "(", "14", ")", ",", "ii", ")", "PAN", "/", "temocapril", "(", "13", ")", ",", "iii", ")", "temocapril", "(", "14", ")", "and", "iv", ")", "untreated", "controls", "(", "15", ")", ".", "Temocapril", "(", "8", "mg", "/", "kg", "/", "day", ")", "was", "administered", "to", "the", "rats", "which", "were", "killed", "at", "weeks", "4", ",", "14", "or", "20", ".", "At", "each", "time", "point", ",", "systolic", "blood", "pressure", "(", "BP", ")", ",", "urinary", "protein", "excretion", "and", "renal", "histopathological", "findings", "were", "evaluated", ",", "and", "morphometric", "image", "analysis", "was", "done", ".", "Systolic", "BP", "in", "the", "PAN", "group", "was", "significantly", "high", "at", "4", ",", "14", "and", "20", "weeks", ",", "but", "was", "normal", "in", "the", "PAN", "/", "temocapril", "group", ".", "Urinary", "protein", "excretion", "in", "the", "PAN", "group", "increased", "significantly", ",", "peaking", "at", "8", "days", ",", "then", "decreased", "at", "4", "weeks", ",", "but", "rose", "again", "significantly", "at", "14", "and", "20", "weeks", ".", "Temocapril", "did", "not", "attenuate", "proteinuria", "at", "8", "days", ",", "but", "it", "did", "markedly", "lower", "it", "from", "weeks", "4", "to", "20", ".", "The", "glomerulosclerosis", "index", "(", "GSI", ")", "was", "6", ".", "21", "%", "at", "4", "weeks", "and", "respectively", "25", ".", "35", "%", "and", "30", ".", "49", "%", "at", "14", "and", "20", "weeks", "in", "the", "PAN", "group", ".", "There", "was", "a", "significant", "correlation", "between", "urinary", "protein", "excretion", "and", "GSI", "(", "r", "=", "0", ".", "808", ",", "p", "<", "0", ".", "0001", ")", ".", "The", "ratio", "of", "glomerular", "tuft", "area", "to", "the", "area", "of", "Bowman", "'s", "capsules", "(", "GT", "/", "BC", ")", "in", "the", "PAN", "group", "was", "significantly", "increased", ",", "but", "it", "was", "significantly", "lower", "in", "the", "PAN", "/", "temocapril", "group", ".", "It", "appears", "that", "temocapril", "was", "effective", "in", "retarding", "renal", "progression", "and", "protected", "renal", "function", "in", "PAN", "neprotic", "rats", "."]], "ner": [[[20, 21, "Chemical"], [66, 67, "Chemical"], [69, 69, "Chemical"], [82, 82, "Chemical"], [108, 108, "Chemical"], [116, 116, "Chemical"], [196, 196, "Chemical"], [214, 214, "Chemical"], [224, 224, "Chemical"], [303, 303, "Chemical"], [351, 351, "Chemical"], [364, 364, "Chemical"], [384, 384, "Chemical"], [22, 22, "Disease"], [76, 76, "Disease"], [385, 385, "Disease"], [56, 56, "Disease"], [254, 254, "Disease"], [0, 0, "Chemical"], [37, 37, "Chemical"], [118, 118, "Chemical"], [125, 125, "Chemical"], [138, 138, "Chemical"], [216, 216, "Chemical"], [250, 250, "Chemical"], [366, 366, "Chemical"], [372, 372, "Chemical"], [16, 17, "Disease"], [60, 60, "Disease"], [63, 63, "Disease"], [272, 272, "Disease"], [73, 73, "Disease"], [10, 10, "Chemical"], [47, 47, "Chemical"]]], "relations": [[[20, 21, 22, 22, "CID"], [20, 21, 76, 76, "CID"], [20, 21, 385, 385, "CID"], [66, 67, 22, 22, "CID"], [66, 67, 76, 76, "CID"], [66, 67, 385, 385, "CID"], [69, 69, 22, 22, "CID"], [69, 69, 76, 76, "CID"], [69, 69, 385, 385, "CID"], [82, 82, 22, 22, "CID"], [82, 82, 76, 76, "CID"], [82, 82, 385, 385, "CID"], [108, 108, 22, 22, "CID"], [108, 108, 76, 76, "CID"], [108, 108, 385, 385, "CID"], [116, 116, 22, 22, "CID"], [116, 116, 76, 76, "CID"], [116, 116, 385, 385, "CID"], [196, 196, 22, 22, "CID"], [196, 196, 76, 76, "CID"], [196, 196, 385, 385, "CID"], [214, 214, 22, 22, "CID"], [214, 214, 76, 76, "CID"], [214, 214, 385, 385, "CID"], [224, 224, 22, 22, "CID"], [224, 224, 76, 76, "CID"], [224, 224, 385, 385, "CID"], [303, 303, 22, 22, "CID"], [303, 303, 76, 76, "CID"], [303, 303, 385, 385, "CID"], [351, 351, 22, 22, "CID"], [351, 351, 76, 76, "CID"], [351, 351, 385, 385, "CID"], [364, 364, 22, 22, "CID"], [364, 364, 76, 76, "CID"], [364, 364, 385, 385, "CID"], [384, 384, 22, 22, "CID"], [384, 384, 76, 76, "CID"], [384, 384, 385, 385, "CID"], [20, 21, 56, 56, "CID"], [20, 21, 254, 254, "CID"], [66, 67, 56, 56, "CID"], [66, 67, 254, 254, "CID"], [69, 69, 56, 56, "CID"], [69, 69, 254, 254, "CID"], [82, 82, 56, 56, "CID"], [82, 82, 254, 254, "CID"], [108, 108, 56, 56, "CID"], [108, 108, 254, 254, "CID"], [116, 116, 56, 56, "CID"], [116, 116, 254, 254, "CID"], [196, 196, 56, 56, "CID"], [196, 196, 254, 254, "CID"], [214, 214, 56, 56, "CID"], [214, 214, 254, 254, "CID"], [224, 224, 56, 56, "CID"], [224, 224, 254, 254, "CID"], [303, 303, 56, 56, "CID"], [303, 303, 254, 254, "CID"], [351, 351, 56, 56, "CID"], [351, 351, 254, 254, "CID"], [364, 364, 56, 56, "CID"], [364, 364, 254, 254, "CID"], [384, 384, 56, 56, "CID"], [384, 384, 254, 254, "CID"]]], "clusters": [], "translated": "<18>Temocapril</18>是一种长效非SH组<32>血管紧张素</32>转化酶抑制剂，可调节慢性<0>嘌呤霉素氨基核苷</0>诱导的<13>肾病</13>中的<27>肾小球损伤</27>。本研究的目的是确定长期服用<19>替莫卡普利</19>，一种长效非SH组<33>血管紧张素</33>转换酶（ACE）抑制剂，是否能减少<16>蛋白尿</16>，抑制肾小球<28>肥大</28>并预防慢性<1>嘌呤霉素氨基核苷</1>（<2>PAN</2>）诱导的<29>肾小球硬化</29><31>肾病</31>大鼠。 <14>肾病</14> 是通过给雄性Sprague-Dawley（SD）大鼠注射<3>PAN</3>（15mg/100g体重）引起的。使用了四个组，i) <4>PAN</4>组（14），ii)<5>PAN</5>/<20>temocapril</20>(13)，iii)<21>temocapril</21>（14）和iv)未处理的对照（15）。<22>替莫卡普利</22>（8mg/kg/天）给药于第4、14或20周处死的大鼠。在每个时间点，评估收缩压（BP）、尿蛋白排泄和肾组织病理学结果，并进行形态学图像分析。 <6>PAN</6>组收缩压在4、14、20周显着升高，而<7>PAN</7>/<23>替莫卡普利</23>组收缩压正常。<8>PAN</8>组尿蛋白排泄显着增加，在第8天达到峰值，然后在第4周下降，但在第14和20周再次显着上升。<24>Temocapril</24>在第8天时未减轻<17>蛋白尿</17>，但从第4周到第20周显着降低。<30>肾小球硬化</30>指数（GSI）为6.21%，分别为25.35％和30.49％在14周和20周的<9>PAN</9>组，存在显着相关性(r=0.808，p<0.0001)。<10>PAN</10>组肾小球簇面积与鲍曼囊面积比值（GT/BC）显着增加，<11>PAN</11>/<25>替莫普利</25>组显着降低。<26>替莫卡普利</26>似乎能有效延缓<12>PAN</12><15>坏死性</15>大鼠的肾脏进展并保护肾功能。", "revised": true}
{"doc_key": "11745287", "sentences": [["Phase", "II", "study", "of", "carboplatin", "and", "liposomal", "doxorubicin", "in", "patients", "with", "recurrent", "squamous", "cell", "carcinoma", "of", "the", "cervix", ".", "BACKGROUND", ":", "The", "activity", "of", "the", "combination", "of", "carboplatin", "and", "liposomal", "doxorubicin", "was", "tested", "in", "a", "Phase", "II", "study", "of", "patients", "with", "recurrent", "cervical", "carcinoma", ".", "METHODS", ":", "The", "combination", "of", "carboplatin", "(", "area", "under", "the", "concentration", "curve", "[", "AUC", "]", ",", "5", ")", "and", "liposomal", "doxorubicin", "(", "Doxil", ";", "starting", "dose", ",", "40", "mg", "/", "m", "(", "2", ")", ")", "was", "administered", "intravenously", "every", "28", "days", "to", "37", "patients", "with", "recurrent", "squamous", "cell", "cervical", "carcinoma", "to", "determine", "antitumor", "activity", "and", "toxicity", "profile", ".", "RESULTS", ":", "Twenty", "-", "nine", "patients", "were", "assessable", "for", "response", ",", "and", "35", "patients", "were", "assessable", "for", "toxicity", ".", "The", "overall", "response", "rate", "was", "38", "%", ",", "the", "median", "time", "to", "response", "was", "10", "weeks", ",", "the", "median", "duration", "of", "response", "was", "26", "weeks", ",", "and", "the", "median", "survival", "was", "37", "weeks", ".", "The", "main", "toxic", "effect", "was", "myelosuppression", ",", "with", "Grade", "3", "and", "4", "neutropenia", "in", "16", "patients", ",", "anemia", "in", "12", "patients", ",", "thrombocytopenia", "in", "11", "patients", ",", "and", "neutropenic", "fever", "in", "3", "patients", ".", "Four", "patients", "had", "five", "infusion", "-", "related", "reactions", "during", "the", "infusion", "of", "liposomal", "doxorubicin", ",", "leading", "to", "treatment", "discontinuation", "in", "three", "patients", ".", "Grade", ">", "or", "=", "2", "nonhematologic", "toxicity", "included", "nausea", "in", "17", "patients", ",", "emesis", "in", "14", "patients", ",", "fatigue", "in", "9", "patients", ",", "mucositis", "and", "/", "or", "stomatitis", "in", "8", "patients", ",", "constipation", "in", "6", "patients", ",", "weight", "loss", "in", "5", "patients", ",", "hand", "-", "foot", "syndrome", "in", "2", "patients", ",", "and", "skin", "reactions", "in", "3", "patients", ".", "CONCLUSIONS", ":", "The", "combination", "of", "carboplatin", "and", "liposomal", "doxorubicin", "has", "modest", "activity", "in", "patients", "with", "recurrent", "cervical", "carcinoma", "."]], "ner": [[[4, 4, "Chemical"], [27, 27, "Chemical"], [50, 50, "Chemical"], [276, 276, "Chemical"], [168, 168, "Disease"], [184, 185, "Disease"], [173, 173, "Disease"], [178, 178, "Disease"], [221, 221, "Disease"], [226, 226, "Disease"], [231, 231, "Disease"], [236, 236, "Disease"], [245, 245, "Disease"], [250, 251, "Disease"], [265, 266, "Disease"], [7, 7, "Chemical"], [30, 30, "Chemical"], [65, 65, "Chemical"], [67, 67, "Chemical"], [203, 203, "Chemical"], [279, 279, "Chemical"], [12, 17, "Disease"], [91, 94, "Disease"], [42, 43, "Disease"], [287, 288, "Disease"], [100, 100, "Disease"], [120, 120, "Disease"], [219, 219, "Disease"], [161, 161, "Disease"], [240, 240, "Disease"], [256, 259, "Disease"]]], "relations": [[[4, 4, 168, 168, "CID"], [4, 4, 184, 185, "CID"], [27, 27, 168, 168, "CID"], [27, 27, 184, 185, "CID"], [50, 50, 168, 168, "CID"], [50, 50, 184, 185, "CID"], [276, 276, 168, 168, "CID"], [276, 276, 184, 185, "CID"], [4, 4, 173, 173, "CID"], [27, 27, 173, 173, "CID"], [50, 50, 173, 173, "CID"], [276, 276, 173, 173, "CID"], [4, 4, 178, 178, "CID"], [27, 27, 178, 178, "CID"], [50, 50, 178, 178, "CID"], [276, 276, 178, 178, "CID"], [4, 4, 221, 221, "CID"], [27, 27, 221, 221, "CID"], [50, 50, 221, 221, "CID"], [276, 276, 221, 221, "CID"], [4, 4, 226, 226, "CID"], [27, 27, 226, 226, "CID"], [50, 50, 226, 226, "CID"], [276, 276, 226, 226, "CID"], [4, 4, 231, 231, "CID"], [27, 27, 231, 231, "CID"], [50, 50, 231, 231, "CID"], [276, 276, 231, 231, "CID"], [4, 4, 236, 236, "CID"], [27, 27, 236, 236, "CID"], [50, 50, 236, 236, "CID"], [276, 276, 236, 236, "CID"], [4, 4, 245, 245, "CID"], [27, 27, 245, 245, "CID"], [50, 50, 245, 245, "CID"], [276, 276, 245, 245, "CID"], [4, 4, 250, 251, "CID"], [27, 27, 250, 251, "CID"], [50, 50, 250, 251, "CID"], [276, 276, 250, 251, "CID"], [4, 4, 265, 266, "CID"], [27, 27, 265, 266, "CID"], [50, 50, 265, 266, "CID"], [276, 276, 265, 266, "CID"], [7, 7, 168, 168, "CID"], [7, 7, 184, 185, "CID"], [30, 30, 168, 168, "CID"], [30, 30, 184, 185, "CID"], [65, 65, 168, 168, "CID"], [65, 65, 184, 185, "CID"], [67, 67, 168, 168, "CID"], [67, 67, 184, 185, "CID"], [203, 203, 168, 168, "CID"], [203, 203, 184, 185, "CID"], [279, 279, 168, 168, "CID"], [279, 279, 184, 185, "CID"], [7, 7, 173, 173, "CID"], [30, 30, 173, 173, "CID"], [65, 65, 173, 173, "CID"], [67, 67, 173, 173, "CID"], [203, 203, 173, 173, "CID"], [279, 279, 173, 173, "CID"], [7, 7, 178, 178, "CID"], [30, 30, 178, 178, "CID"], [65, 65, 178, 178, "CID"], [67, 67, 178, 178, "CID"], [203, 203, 178, 178, "CID"], [279, 279, 178, 178, "CID"], [7, 7, 221, 221, "CID"], [30, 30, 221, 221, "CID"], [65, 65, 221, 221, "CID"], [67, 67, 221, 221, "CID"], [203, 203, 221, 221, "CID"], [279, 279, 221, 221, "CID"], [7, 7, 226, 226, "CID"], [30, 30, 226, 226, "CID"], [65, 65, 226, 226, "CID"], [67, 67, 226, 226, "CID"], [203, 203, 226, 226, "CID"], [279, 279, 226, 226, "CID"], [7, 7, 231, 231, "CID"], [30, 30, 231, 231, "CID"], [65, 65, 231, 231, "CID"], [67, 67, 231, 231, "CID"], [203, 203, 231, 231, "CID"], [279, 279, 231, 231, "CID"], [7, 7, 236, 236, "CID"], [30, 30, 236, 236, "CID"], [65, 65, 236, 236, "CID"], [67, 67, 236, 236, "CID"], [203, 203, 236, 236, "CID"], [279, 279, 236, 236, "CID"], [7, 7, 245, 245, "CID"], [30, 30, 245, 245, "CID"], [65, 65, 245, 245, "CID"], [67, 67, 245, 245, "CID"], [203, 203, 245, 245, "CID"], [279, 279, 245, 245, "CID"], [7, 7, 250, 251, "CID"], [30, 30, 250, 251, "CID"], [65, 65, 250, 251, "CID"], [67, 67, 250, 251, "CID"], [203, 203, 250, 251, "CID"], [279, 279, 250, 251, "CID"], [7, 7, 265, 266, "CID"], [30, 30, 265, 266, "CID"], [65, 65, 265, 266, "CID"], [67, 67, 265, 266, "CID"], [203, 203, 265, 266, "CID"], [279, 279, 265, 266, "CID"]]], "clusters": [], "translated": "<0>卡铂</0>和脂质体<15>多柔比星</15>治疗复发性<21>宫颈鳞状细胞癌</21>的II期研究。背景：<1>卡铂</1>和脂质体<16>阿霉素</16>的组合的活性在复发性<23>宫颈癌</23>患者的II期研究中进行了测试。方法：<2>卡铂</2>（浓度曲线下面积[AUC]，5）和脂质体<17>多柔比星</17>（<18>多西尔</18>；起始剂量，40 mg/m(2)）每28天静脉注射一次给37名复发性<22>鳞状细胞宫颈癌</22>患者，以确定抗肿瘤活性和<25>毒性</25>特征。结果：29名患者可评估反应，35名患者可评估<26>毒性</26>。总体反应率为38%，中位反应时间为10周，中位反应持续时间为26周，中位生存期为37周。主要毒性作用是<28>骨髓抑制</28>，16例患者出现3级和4级<4>中性粒细胞减少</4>，12例<6>贫血</6>，11例<7>血小板减少</7>，3例<5>中性粒细胞减少性发热</5>。4名患者在输注脂质体<19>多柔比星</19>期间发生了5次输液相关反应，导致3名患者停止治疗。>或=2级非血液学<27>毒性</27>包括17名患者的<8>恶心</8>，14名患者的<9>呕吐</9>，9名患者的<10>疲劳</10>，8例<11>粘膜炎</11>和/或<29>口腔炎</29>，6例<12>便秘</12>，5例<13>体重减轻</13>，2例<30>手足综合征</30>，3例<14>皮肤反应</14>。结论：<3>卡铂</3>和脂质体<20>多柔比星</20>的组合对复发性<24>宫颈癌</24>患者具有适度的活性。", "revised": true}
{"doc_key": "10462057", "sentences": [["Induction", "of", "apoptosis", "by", "remoxipride", "metabolites", "in", "HL60", "and", "CD34", "+", "/", "CD19", "-", "human", "bone", "marrow", "progenitor", "cells", ":", "potential", "relevance", "to", "remoxipride", "-", "induced", "aplastic", "anemia", ".", "The", "antipsychotic", "agent", ",", "remoxipride", "[", "(", "S", ")", "-", "(", "-", ")", "-", "3", "-", "bromo", "-", "N", "-", "[", "(", "1", "-", "ethyl", "-", "2", "-", "pyrrolidinyl", ")", "methyl", "]", "-", "2", ",", "6", "-", "dimethoxybenz", "amide", "]", "has", "been", "associated", "with", "acquired", "aplastic", "anemia", ".", "We", "have", "examined", "the", "ability", "of", "remoxipride", ",", "three", "pyrrolidine", "ring", "metabolites", "and", "five", "aromatic", "ring", "metabolites", "of", "the", "parent", "compound", "to", "induce", "apoptosis", "in", "HL60", "cells", "and", "human", "bone", "marrow", "progenitor", "(", "HBMP", ")", "cells", ".", "Cells", "were", "treated", "for", "0", "-", "24", "h", "with", "each", "compound", "(", "0", "-", "200", "microM", ")", ".", "Apoptosis", "was", "assessed", "by", "fluorescence", "microscopy", "in", "Hoechst", "33342", "-", "and", "propidium", "iodide", "stained", "cell", "samples", ".", "Results", "were", "confirmed", "by", "determination", "of", "internucleosomal", "DNA", "fragmentation", "using", "gel", "electrophoresis", "for", "HL60", "cell", "samples", "and", "terminal", "deoxynucleotidyl", "transferase", "assay", "in", "HBMP", "cells", ".", "The", "catechol", "and", "hydroquinone", "metabolites", ",", "NCQ436", "and", "NCQ344", ",", "induced", "apoptosis", "in", "HL60", "and", "HBMP", "cells", "in", "a", "time", "-", "and", "concentration", "dependent", "manner", ",", "while", "the", "phenols", ",", "NCR181", ",", "FLA873", ",", "and", "FLA797", ",", "and", "the", "derivatives", "formed", "by", "oxidation", "of", "the", "pyrrolidine", "ring", ",", "FLA838", ",", "NCM001", ",", "and", "NCL118", ",", "had", "no", "effect", ".", "No", "necrosis", "was", "observed", "in", "cells", "treated", "with", "NCQ436", "but", "NCQ344", "had", "a", "biphasic", "effect", "in", "both", "cell", "types", ",", "inducing", "apoptosis", "at", "lower", "concentrations", "and", "necrosis", "at", "higher", "concentrations", ".", "These", "data", "show", "that", "the", "catechol", "and", "hydroquinone", "metabolites", "of", "remoxipride", "have", "direct", "toxic", "effects", "in", "HL60", "and", "HBMP", "cells", ",", "leading", "to", "apoptosis", ",", "while", "the", "phenol", "metabolites", "were", "inactive", ".", "Similarly", ",", "benzene", "-", "derived", "catechol", "and", "hydroquinone", ",", "but", "not", "phenol", ",", "induce", "apoptosis", "in", "HBMP", "cells", "[", "Moran", "et", "al", ".", ",", "Mol", ".", "Pharmacol", ".", ",", "50", "(", "1996", ")", "610", "-", "615", "]", ".", "We", "propose", "that", "remoxipride", "and", "benzene", "may", "induce", "aplastic", "anemia", "via", "production", "of", "similar", "reactive", "metabolites", "and", "that", "the", "ability", "of", "NCQ436", "and", "NCQ344", "to", "induce", "apoptosis", "in", "HBMP", "cells", "may", "contribute", "to", "the", "mechanism", "underlying", "acquired", "aplastic", "anemia", "that", "has", "been", "associated", "with", "remoxipride", "."]], "ner": [[[4, 4, "Chemical"], [23, 23, "Chemical"], [33, 33, "Chemical"], [35, 67, "Chemical"], [83, 83, "Chemical"], [274, 274, "Chemical"], [337, 337, "Chemical"], [378, 378, "Chemical"], [26, 27, "Disease"], [74, 75, "Disease"], [342, 343, "Disease"], [371, 372, "Disease"], [298, 298, "Chemical"], [339, 339, "Chemical"], [234, 234, "Disease"], [259, 259, "Disease"], [86, 86, "Chemical"], [219, 219, "Chemical"], [139, 140, "Chemical"], [143, 144, "Chemical"], [175, 175, "Chemical"], [269, 269, "Chemical"], [301, 301, "Chemical"], [177, 177, "Chemical"], [271, 271, "Chemical"], [303, 303, "Chemical"], [180, 180, "Chemical"], [241, 241, "Chemical"], [355, 355, "Chemical"], [182, 182, "Chemical"], [243, 243, "Chemical"], [357, 357, "Chemical"], [202, 202, "Chemical"], [209, 209, "Chemical"], [291, 291, "Chemical"], [307, 307, "Chemical"]]], "relations": [[[4, 4, 26, 27, "CID"], [4, 4, 74, 75, "CID"], [4, 4, 342, 343, "CID"], [4, 4, 371, 372, "CID"], [23, 23, 26, 27, "CID"], [23, 23, 74, 75, "CID"], [23, 23, 342, 343, "CID"], [23, 23, 371, 372, "CID"], [33, 33, 26, 27, "CID"], [33, 33, 74, 75, "CID"], [33, 33, 342, 343, "CID"], [33, 33, 371, 372, "CID"], [35, 67, 26, 27, "CID"], [35, 67, 74, 75, "CID"], [35, 67, 342, 343, "CID"], [35, 67, 371, 372, "CID"], [83, 83, 26, 27, "CID"], [83, 83, 74, 75, "CID"], [83, 83, 342, 343, "CID"], [83, 83, 371, 372, "CID"], [274, 274, 26, 27, "CID"], [274, 274, 74, 75, "CID"], [274, 274, 342, 343, "CID"], [274, 274, 371, 372, "CID"], [337, 337, 26, 27, "CID"], [337, 337, 74, 75, "CID"], [337, 337, 342, 343, "CID"], [337, 337, 371, 372, "CID"], [378, 378, 26, 27, "CID"], [378, 378, 74, 75, "CID"], [378, 378, 342, 343, "CID"], [378, 378, 371, 372, "CID"], [298, 298, 26, 27, "CID"], [298, 298, 74, 75, "CID"], [298, 298, 342, 343, "CID"], [298, 298, 371, 372, "CID"], [339, 339, 26, 27, "CID"], [339, 339, 74, 75, "CID"], [339, 339, 342, 343, "CID"], [339, 339, 371, 372, "CID"]]], "clusters": [], "translated": "HL60和CD34 + / CD19 - 人骨髓祖细胞中<0>瑞莫必利</0>代谢物诱导细胞凋亡：与<1>瑞莫必利</1>诱导的<8>再生障碍性贫血</8>的潜在相关性。抗精神病药<2>瑞莫必利</2>[<3>(S)-(-)-3-溴-N-[(1-乙基-2-吡咯烷基)甲基]-2,6-二甲氧基苯甲酰胺</3>]与获得性<9>再生障碍性贫血</9>相关。我们检测了<4>瑞莫必利</4>、母体化合物的三种<16>吡咯烷</16>环代谢物和五种芳环代谢物诱导HL60细胞和人骨髓祖细胞(HBMP)细胞凋亡的能力。用每种化合物(0-200 microM)处理细胞0-24小时。在<18>Hoechst 33342</18>和<19>碘化丙锭</19>染色的细胞样本中，通过荧光显微镜评估细胞凋亡。通过使用HL60细胞样品的凝胶电泳和HBMP细胞中的末端脱氧核苷酸转移酶测定法确定核小体间DNA片段化，证实了结果。<20>儿茶酚</20>和<23>对苯二酚</23>代谢物<26>NCQ436</26>和<29>NCQ344</29>浓度依赖性和时间依赖性地诱导HL60和HBMP细胞凋亡，而<32>酚类</32>、NCR181、FLA873和<33>FLA797</33>，以及<17>吡咯烷</17>环氧化形成的衍生物、FLA838、NCM001和NCL118，没有效果。在用<27>NCQ436</27>处理的细胞中未观察到<14>坏死</14>，但<30>NCQ344</30>在较低浓度下诱导细胞凋亡，在较高浓度下诱导<15>坏死</15>。这些数据表明，<5>瑞莫必利</5>的<21>儿茶酚</21>和<24>对苯二酚</24>代谢物对HL60和HBMP细胞有直接的毒性作用，导致细胞凋亡，而<34>苯酚</34>代谢物无活性。同样，<12>苯</12>衍生的<22>儿茶酚</22>和<25>对苯二酚</25>而不是<35>苯酚</35>诱导HBMP细胞凋亡[Moran等人。,分子药效学。,50(1996)610-615]。我们提出<6>瑞莫必利</6>和<13>苯</13>可能通过产生类似的反应性代谢物诱导<10>再生障碍性贫血</10>，而<28>NCQ436</28>的能力和<31>NCQ344</31>诱导HBMP细胞凋亡可能有助于获得性<11>再生障碍性贫血</11>的潜在机制，该机制与<7>瑞莫必利</7>相关。", "revised": true}
{"doc_key": "10390729", "sentences": [["The", "effects", "of", "quinine", "and", "4", "-", "aminopyridine", "on", "conditioned", "place", "preference", "and", "changes", "in", "motor", "activity", "induced", "by", "morphine", "in", "rats", ".", "1", ".", "The", "effects", "of", "two", "unselective", "potassium", "(", "K", "(", "+", ")", "-", ")", "channel", "blockers", ",", "quinine", "(", "12", ".", "5", ",", "25", "and", "50", "mg", "/", "kg", ")", "and", "4", "-", "aminopyridine", "(", "1", "and", "2", "mg", "/", "kg", ")", ",", "on", "conditioned", "place", "preference", "and", "biphasic", "changes", "in", "motor", "activity", "induced", "by", "morphine", "(", "10", "mg", "/", "kg", ")", "were", "tested", "in", "Wistar", "rats", ".", "Quinine", "is", "known", "to", "block", "voltage", "-", ",", "calcium", "-", "and", "ATP", "-", "sensitive", "K", "(", "+", ")", "-", "channels", "while", "4", "-", "aminopyridine", "is", "known", "to", "block", "voltage", "-", "sensitive", "K", "(", "+", ")", "-", "channels", ".", "2", ".", "In", "the", "counterbalanced", "method", ",", "quinine", "attenuated", "morphine", "-", "induced", "place", "preference", ",", "whereas", "4", "-", "aminopyridine", "was", "ineffective", ".", "In", "the", "motor", "activity", "test", "measured", "with", "an", "Animex", "-", "activity", "meter", "neither", "of", "the", "K", "(", "+", ")", "-", "channel", "blockers", "affected", "morphine", "-", "induced", "hypoactivity", ",", "but", "both", "K", "(", "+", ")", "-", "channel", "blockers", "prevented", "morphine", "-", "induced", "secondary", "hyperactivity", ".", "3", ".", "These", "results", "suggest", "the", "involvement", "of", "quinine", "-", "sensitive", "but", "not", "4", "-", "aminopyridine", "-", "sensitive", "K", "(", "+", ")", "-", "channels", "in", "morphine", "reward", ".", "It", "is", "also", "suggested", "that", "the", "blockade", "of", "K", "(", "+", ")", "-", "channels", "sensitive", "to", "these", "blockers", "is", "not", "sufficient", "to", "prevent", "morphine", "-", "induced", "hypoactivity", "whereas", "morphine", "-", "induced", "hyperactivity", "seems", "to", "be", "connected", "to", "both", "quinine", "-", "and", "4", "-", "aminopyridine", "-", "sensitive", "K", "(", "+", ")", "-", "channels", "."]], "ner": [[[19, 19, "Chemical"], [79, 79, "Chemical"], [139, 139, "Chemical"], [175, 175, "Chemical"], [190, 190, "Chemical"], [221, 221, "Chemical"], [247, 247, "Chemical"], [252, 252, "Chemical"], [194, 194, "Disease"], [255, 255, "Disease"], [3, 3, "Chemical"], [41, 41, "Chemical"], [92, 92, "Chemical"], [137, 137, "Chemical"], [204, 204, "Chemical"], [262, 262, "Chemical"], [178, 178, "Disease"], [250, 250, "Disease"], [5, 7, "Chemical"], [55, 57, "Chemical"], [113, 115, "Chemical"], [146, 148, "Chemical"], [209, 211, "Chemical"], [265, 267, "Chemical"], [30, 30, "Chemical"], [32, 32, "Chemical"], [106, 106, "Chemical"], [123, 123, "Chemical"], [167, 167, "Chemical"], [182, 182, "Chemical"], [214, 214, "Chemical"], [232, 232, "Chemical"], [270, 270, "Chemical"], [100, 100, "Chemical"], [103, 103, "Chemical"]]], "relations": [[[19, 19, 194, 194, "CID"], [19, 19, 255, 255, "CID"], [79, 79, 194, 194, "CID"], [79, 79, 255, 255, "CID"], [139, 139, 194, 194, "CID"], [139, 139, 255, 255, "CID"], [175, 175, 194, 194, "CID"], [175, 175, 255, 255, "CID"], [190, 190, 194, 194, "CID"], [190, 190, 255, 255, "CID"], [221, 221, 194, 194, "CID"], [221, 221, 255, 255, "CID"], [247, 247, 194, 194, "CID"], [247, 247, 255, 255, "CID"], [252, 252, 194, 194, "CID"], [252, 252, 255, 255, "CID"]]], "clusters": [], "translated": " <10>奎宁</10>和<18>4-氨基吡啶</18>对<0>吗啡</0>大鼠条件性位置偏爱和运动活动改变的影响。1.两种非选择性<24>钾</24>(<25>K</25>(+)-)通道阻滞剂<11>奎宁</11>（12.5、25和50mg/kg）的作用和<19>4-氨基吡啶</19>（1和2mg/kg），在Wistar老鼠中测试了<1>吗啡</1>（10mg/kg）诱导的条件性位置偏爱和双相变化的运动活动。 <12>奎宁</12>已知可阻断电压敏感、<33>钙</33>敏感和<34>ATP</34>敏感的<26>K</26>(+)-通道，而<20>4-氨基吡啶</20>已知可阻断电压敏感的<27>K</27>(+)-通道。2.在平衡法中，<13>奎宁</13>减弱了<2>吗啡</2>诱导的位置偏好，而<21>4-氨基吡啶</21>无效。在通过Animex活动仪测量的运动活动测试中，<28> K </28>(+)-通道阻滞剂均未影响<3>吗啡 </3>-诱发的<16>活动减退</16>，但两种<29>K</29>(+)-通道阻滞剂均可预防<4>吗啡 </4>-诱发的继发性<8>多动症</8>。3.这些结果表明<14>奎宁</14>-敏感，但不是<22>4-氨基吡啶</22>-敏感的<30>K</30>(+)-频道参与了<5>吗啡</5>的奖赏。同时也表明，阻断对这些阻滞剂敏感的<31>K</31>(+)-频道不足以预防<6>吗啡</6>-诱导的<17>活动减退</17>，而<7>吗啡</7>-诱导的<9>多动性</9>似乎与敏感于<15>奎宁</15>和<23>4-氨基吡啶</23>的<32>K</32>(+)-频道有关。", "revised": true}
{"doc_key": "12372954", "sentences": [["Acute", "interstitial", "nephritis", "due", "to", "nicergoline", "(", "Sermion", ")", ".", "We", "report", "a", "case", "of", "acute", "interstitial", "nephritis", "(", "AIN", ")", "due", "to", "nicergoline", "(", "Sermion", ")", ".", "A", "50", "-", "year", "-", "old", "patient", "admitted", "to", "our", "hospital", "for", "fever", "and", "acute", "renal", "failure", ".", "Before", "admission", ",", "he", "had", "been", "taking", "nicergoline", "and", "bendazac", "lysine", "due", "to", "retinal", "vein", "occlusion", "at", "ophthalmologic", "department", ".", "Thereafter", ",", "he", "experienced", "intermittent", "fever", "and", "skin", "rash", ".", "On", "admission", ",", "clinical", "symptoms", "(", "i", ".", "e", ".", "arthralgia", "and", "fever", ")", "and", "laboratory", "findings", "(", "i", ".", "e", ".", "eosinophilia", "and", "renal", "failure", ")", "suggested", "AIN", ",", "and", "which", "was", "confirmed", "by", "pathologic", "findings", "on", "renal", "biopsy", ".", "A", "lymphocyte", "transformation", "test", "demonstrated", "a", "positive", "result", "against", "nicergoline", ".", "Treatment", "was", "consisted", "of", "withdrawal", "of", "nicergoline", "and", "intravenous", "methylprednisolone", ",", "and", "his", "renal", "function", "was", "completely", "recovered", ".", "To", "our", "knowledge", ",", "this", "is", "the", "first", "report", "of", "nicergoline", "-", "associated", "AIN", "."]], "ner": [[[5, 5, "Chemical"], [7, 7, "Chemical"], [23, 23, "Chemical"], [25, 25, "Chemical"], [53, 53, "Chemical"], [126, 126, "Chemical"], [134, 134, "Chemical"], [157, 157, "Chemical"], [1, 2, "Disease"], [16, 17, "Disease"], [19, 19, "Disease"], [104, 104, "Disease"], [160, 160, "Disease"], [40, 40, "Disease"], [71, 71, "Disease"], [88, 88, "Disease"], [86, 86, "Disease"], [98, 98, "Disease"], [100, 101, "Disease"], [55, 56, "Chemical"], [137, 137, "Chemical"], [42, 44, "Disease"], [59, 61, "Disease"], [73, 74, "Disease"]]], "relations": [[[5, 5, 1, 2, "CID"], [5, 5, 16, 17, "CID"], [5, 5, 19, 19, "CID"], [5, 5, 104, 104, "CID"], [5, 5, 160, 160, "CID"], [7, 7, 1, 2, "CID"], [7, 7, 16, 17, "CID"], [7, 7, 19, 19, "CID"], [7, 7, 104, 104, "CID"], [7, 7, 160, 160, "CID"], [23, 23, 1, 2, "CID"], [23, 23, 16, 17, "CID"], [23, 23, 19, 19, "CID"], [23, 23, 104, 104, "CID"], [23, 23, 160, 160, "CID"], [25, 25, 1, 2, "CID"], [25, 25, 16, 17, "CID"], [25, 25, 19, 19, "CID"], [25, 25, 104, 104, "CID"], [25, 25, 160, 160, "CID"], [53, 53, 1, 2, "CID"], [53, 53, 16, 17, "CID"], [53, 53, 19, 19, "CID"], [53, 53, 104, 104, "CID"], [53, 53, 160, 160, "CID"], [126, 126, 1, 2, "CID"], [126, 126, 16, 17, "CID"], [126, 126, 19, 19, "CID"], [126, 126, 104, 104, "CID"], [126, 126, 160, 160, "CID"], [134, 134, 1, 2, "CID"], [134, 134, 16, 17, "CID"], [134, 134, 19, 19, "CID"], [134, 134, 104, 104, "CID"], [134, 134, 160, 160, "CID"], [157, 157, 1, 2, "CID"], [157, 157, 16, 17, "CID"], [157, 157, 19, 19, "CID"], [157, 157, 104, 104, "CID"], [157, 157, 160, 160, "CID"], [5, 5, 40, 40, "CID"], [5, 5, 71, 71, "CID"], [5, 5, 88, 88, "CID"], [7, 7, 40, 40, "CID"], [7, 7, 71, 71, "CID"], [7, 7, 88, 88, "CID"], [23, 23, 40, 40, "CID"], [23, 23, 71, 71, "CID"], [23, 23, 88, 88, "CID"], [25, 25, 40, 40, "CID"], [25, 25, 71, 71, "CID"], [25, 25, 88, 88, "CID"], [53, 53, 40, 40, "CID"], [53, 53, 71, 71, "CID"], [53, 53, 88, 88, "CID"], [126, 126, 40, 40, "CID"], [126, 126, 71, 71, "CID"], [126, 126, 88, 88, "CID"], [134, 134, 40, 40, "CID"], [134, 134, 71, 71, "CID"], [134, 134, 88, 88, "CID"], [157, 157, 40, 40, "CID"], [157, 157, 71, 71, "CID"], [157, 157, 88, 88, "CID"], [5, 5, 86, 86, "CID"], [7, 7, 86, 86, "CID"], [23, 23, 86, 86, "CID"], [25, 25, 86, 86, "CID"], [53, 53, 86, 86, "CID"], [126, 126, 86, 86, "CID"], [134, 134, 86, 86, "CID"], [157, 157, 86, 86, "CID"], [5, 5, 98, 98, "CID"], [7, 7, 98, 98, "CID"], [23, 23, 98, 98, "CID"], [25, 25, 98, 98, "CID"], [53, 53, 98, 98, "CID"], [126, 126, 98, 98, "CID"], [134, 134, 98, 98, "CID"], [157, 157, 98, 98, "CID"], [5, 5, 100, 101, "CID"], [7, 7, 100, 101, "CID"], [23, 23, 100, 101, "CID"], [25, 25, 100, 101, "CID"], [53, 53, 100, 101, "CID"], [126, 126, 100, 101, "CID"], [134, 134, 100, 101, "CID"], [157, 157, 100, 101, "CID"]]], "clusters": [], "translated": "急性<8>间质性肾炎</8>由于<0>尼麦角林</0>（<1>Sermion</1>）。我们报告了一例由<2>尼麦角林</2>（<3>Sermion</3>）引起的急性<9>间质性肾炎</9>（<10>AIN</10>）。患者女，50岁，因<13>发热</13>和<21>急性肾功能衰竭</21>入院。入院前因眼科<22>视网膜静脉阻塞</22>服用<4>尼麦角林</4>和<19>苯达扎赖氨酸</19>。此后，他经历了间歇性<14>发烧</14>和<23>皮疹</23>。入院时，临床症状（即<15>发热</15>和<16>关节痛</16>）和实验室检查结果（即<17>嗜酸性粒细胞增多</17>和<18>肾功能衰竭</18>）提示<11>AIN</11>，并经肾活检病理结果证实。淋巴细胞转化试验显示出针对<5>尼麦角林</5>的阳性结果。经停用<6>尼麦角林</6>和静注<20>甲泼尼龙</20>治疗，肾功能完全恢复。据我们所知，这是<7>尼麦角林</7>相关<12>AIN</12>的首次报道。", "revised": true}
{"doc_key": "11799346", "sentences": [["Antimicrobial", "-", "induced", "mania", "(", "antibiomania", ")", ":", "a", "review", "of", "spontaneous", "reports", ".", "The", "authors", "reviewed", "reported", "cases", "of", "antibiotic", "-", "induced", "manic", "episodes", "by", "means", "of", "a", "MEDLINE", "and", "PsychLit", "search", "for", "reports", "of", "antibiotic", "-", "induced", "mania", ".", "Unpublished", "reports", "were", "requested", "from", "the", "World", "Health", "Organization", "(", "WHO", ")", "and", "the", "Food", "and", "Drug", "Administration", "(", "FDA", ")", ".", "Twenty", "-", "one", "reports", "of", "antimicrobial", "-", "induced", "mania", "were", "found", "in", "the", "literature", ".", "There", "were", "6", "cases", "implicating", "clarithromycin", ",", "13", "implicating", "isoniazid", ",", "and", "1", "case", "each", "implicating", "erythromycin", "and", "amoxicillin", ".", "The", "WHO", "reported", "82", "cases", ".", "Of", "these", ",", "clarithromycin", "was", "implicated", "in", "23", "(", "27", ".", "6", "%", ")", "cases", ",", "ciprofloxacin", "in", "12", "(", "14", ".", "4", "%", ")", "cases", ",", "and", "ofloxacin", "in", "10", "(", "12", "%", ")", "cases", ".", "Cotrimoxazole", ",", "metronidazole", ",", "and", "erythromycin", "were", "involved", "in", "15", "reported", "manic", "episodes", ".", "Cases", "reported", "by", "the", "FDA", "showed", "clarithromycin", "and", "ciprofloxacin", "to", "be", "the", "most", "frequently", "associated", "with", "the", "development", "of", "mania", ".", "Statistical", "analysis", "of", "the", "data", "would", "not", "have", "demonstrated", "a", "significant", "statistical", "correlative", "risk", "and", "was", "therefore", "not", "undertaken", ".", "Patients", "have", "an", "increased", "risk", "of", "developing", "mania", "while", "being", "treated", "with", "antimicrobials", ".", "Although", "this", "is", "not", "a", "statistically", "significant", "risk", ",", "physicians", "must", "be", "aware", "of", "the", "effect", "and", "reversibility", ".", "Further", "research", "clearly", "is", "required", "to", "determine", "the", "incidence", "of", "antimicrobial", "-", "induced", "mania", ",", "the", "relative", "risk", "factors", "of", "developing", "an", "antimicrobial", "-", "induced", "manic", "episode", "among", "various", "demographic", "populations", ",", "and", "the", "incidence", "of", "patients", "who", "continue", "to", "have", "persistent", "affective", "disorders", "once", "the", "initial", "episode", ",", "which", "occurs", "while", "the", "patient", "is", "taking", "antibiotics", ",", "subsides", ".", "The", "authors", "elected", "to", "name", "this", "syndrome", "\"", "antibiomania", ".", "\""]], "ner": [[[83, 83, "Chemical"], [107, 107, "Chemical"], [161, 161, "Chemical"], [3, 3, "Disease"], [5, 5, "Disease"], [23, 23, "Disease"], [39, 39, "Disease"], [71, 71, "Disease"], [152, 152, "Disease"], [174, 174, "Disease"], [203, 203, "Disease"], [242, 242, "Disease"], [254, 254, "Disease"], [297, 297, "Disease"], [87, 87, "Chemical"], [94, 94, "Chemical"], [146, 146, "Chemical"], [96, 96, "Chemical"], [120, 120, "Chemical"], [163, 163, "Chemical"], [132, 132, "Chemical"], [141, 141, "Chemical"], [143, 143, "Chemical"]]], "relations": [[[83, 83, 3, 3, "CID"], [83, 83, 5, 5, "CID"], [83, 83, 23, 23, "CID"], [83, 83, 39, 39, "CID"], [83, 83, 71, 71, "CID"], [83, 83, 152, 152, "CID"], [83, 83, 174, 174, "CID"], [83, 83, 203, 203, "CID"], [83, 83, 242, 242, "CID"], [83, 83, 254, 254, "CID"], [83, 83, 297, 297, "CID"], [107, 107, 3, 3, "CID"], [107, 107, 5, 5, "CID"], [107, 107, 23, 23, "CID"], [107, 107, 39, 39, "CID"], [107, 107, 71, 71, "CID"], [107, 107, 152, 152, "CID"], [107, 107, 174, 174, "CID"], [107, 107, 203, 203, "CID"], [107, 107, 242, 242, "CID"], [107, 107, 254, 254, "CID"], [107, 107, 297, 297, "CID"], [161, 161, 3, 3, "CID"], [161, 161, 5, 5, "CID"], [161, 161, 23, 23, "CID"], [161, 161, 39, 39, "CID"], [161, 161, 71, 71, "CID"], [161, 161, 152, 152, "CID"], [161, 161, 174, 174, "CID"], [161, 161, 203, 203, "CID"], [161, 161, 242, 242, "CID"], [161, 161, 254, 254, "CID"], [161, 161, 297, 297, "CID"], [87, 87, 3, 3, "CID"], [87, 87, 5, 5, "CID"], [87, 87, 23, 23, "CID"], [87, 87, 39, 39, "CID"], [87, 87, 71, 71, "CID"], [87, 87, 152, 152, "CID"], [87, 87, 174, 174, "CID"], [87, 87, 203, 203, "CID"], [87, 87, 242, 242, "CID"], [87, 87, 254, 254, "CID"], [87, 87, 297, 297, "CID"], [94, 94, 3, 3, "CID"], [94, 94, 5, 5, "CID"], [94, 94, 23, 23, "CID"], [94, 94, 39, 39, "CID"], [94, 94, 71, 71, "CID"], [94, 94, 152, 152, "CID"], [94, 94, 174, 174, "CID"], [94, 94, 203, 203, "CID"], [94, 94, 242, 242, "CID"], [94, 94, 254, 254, "CID"], [94, 94, 297, 297, "CID"], [146, 146, 3, 3, "CID"], [146, 146, 5, 5, "CID"], [146, 146, 23, 23, "CID"], [146, 146, 39, 39, "CID"], [146, 146, 71, 71, "CID"], [146, 146, 152, 152, "CID"], [146, 146, 174, 174, "CID"], [146, 146, 203, 203, "CID"], [146, 146, 242, 242, "CID"], [146, 146, 254, 254, "CID"], [146, 146, 297, 297, "CID"], [96, 96, 3, 3, "CID"], [96, 96, 5, 5, "CID"], [96, 96, 23, 23, "CID"], [96, 96, 39, 39, "CID"], [96, 96, 71, 71, "CID"], [96, 96, 152, 152, "CID"], [96, 96, 174, 174, "CID"], [96, 96, 203, 203, "CID"], [96, 96, 242, 242, "CID"], [96, 96, 254, 254, "CID"], [96, 96, 297, 297, "CID"], [120, 120, 3, 3, "CID"], [120, 120, 5, 5, "CID"], [120, 120, 23, 23, "CID"], [120, 120, 39, 39, "CID"], [120, 120, 71, 71, "CID"], [120, 120, 152, 152, "CID"], [120, 120, 174, 174, "CID"], [120, 120, 203, 203, "CID"], [120, 120, 242, 242, "CID"], [120, 120, 254, 254, "CID"], [120, 120, 297, 297, "CID"], [163, 163, 3, 3, "CID"], [163, 163, 5, 5, "CID"], [163, 163, 23, 23, "CID"], [163, 163, 39, 39, "CID"], [163, 163, 71, 71, "CID"], [163, 163, 152, 152, "CID"], [163, 163, 174, 174, "CID"], [163, 163, 203, 203, "CID"], [163, 163, 242, 242, "CID"], [163, 163, 254, 254, "CID"], [163, 163, 297, 297, "CID"], [132, 132, 3, 3, "CID"], [132, 132, 5, 5, "CID"], [132, 132, 23, 23, "CID"], [132, 132, 39, 39, "CID"], [132, 132, 71, 71, "CID"], [132, 132, 152, 152, "CID"], [132, 132, 174, 174, "CID"], [132, 132, 203, 203, "CID"], [132, 132, 242, 242, "CID"], [132, 132, 254, 254, "CID"], [132, 132, 297, 297, "CID"], [141, 141, 3, 3, "CID"], [141, 141, 5, 5, "CID"], [141, 141, 23, 23, "CID"], [141, 141, 39, 39, "CID"], [141, 141, 71, 71, "CID"], [141, 141, 152, 152, "CID"], [141, 141, 174, 174, "CID"], [141, 141, 203, 203, "CID"], [141, 141, 242, 242, "CID"], [141, 141, 254, 254, "CID"], [141, 141, 297, 297, "CID"], [143, 143, 3, 3, "CID"], [143, 143, 5, 5, "CID"], [143, 143, 23, 23, "CID"], [143, 143, 39, 39, "CID"], [143, 143, 71, 71, "CID"], [143, 143, 152, 152, "CID"], [143, 143, 174, 174, "CID"], [143, 143, 203, 203, "CID"], [143, 143, 242, 242, "CID"], [143, 143, 254, 254, "CID"], [143, 143, 297, 297, "CID"]]], "clusters": [], "translated": "抗生素引起的<3>躁狂症</3>(<4>反生物狂热</4>)：对自发报告的回顾。作者通过MEDLINE和PsychLit搜索抗生素诱发<6>躁狂</6>的报告，回顾了抗生素诱发<5>躁狂</5>发作的报告病例。要求世界卫生组织(WHO)和食品药品监督管理局(FDA)提供未发表的报告。文献中发现了21篇关于抗生素引起的<7>狂热</7>的报道。<0>克拉霉素</0>6例，<14>异烟肼</14>13例，<15>红霉素</15>、<17>阿莫西林</17>各1例。世界卫生组织报告了82例。其中，<1>克拉霉素</1>涉及23例（27.6%），<18>环丙沙星</18>涉及12例（14.4%），<20>氧氟沙星</20>在10 (12%) 个案例中。<21>复方新诺明</21>、<22>甲硝唑</22>和<16>红霉素</16>参与了15例报道的<8>躁狂</8>发作。FDA报告的病例显示，<2>克拉霉素</2>和<19>环丙沙星</19>最常与<9>躁狂症</9>的发展相关。数据的统计分析不会显示显着的统计相关风险，因此未进行。接受抗菌药物治疗的患者发生<10>躁狂症</10>的风险会增加。虽然这不是统计上显着的风险，但医生必须了解其影响和可逆性。显然需要进一步的研究来确定抗菌素诱发的<11>躁狂</11>的发生率，不同人群中抗菌素诱发的<12>躁狂</12>发作的相对危险因素，以及持续性情感障碍患者在服用抗生素期间发生的初始发作消退后仍持续存在。作者选择将这种综合症命名为“<13>反生物狂</13>”。", "revised": true}
{"doc_key": "11708428", "sentences": [["Prednisone", "induces", "anxiety", "and", "glial", "cerebral", "changes", "in", "rats", ".", "OBJECTIVE", ":", "To", "assess", "whether", "prednisone", "(", "PDN", ")", "produces", "anxiety", "and", "/", "or", "cerebral", "glial", "changes", "in", "rats", ".", "METHODS", ":", "Male", "Wistar", "rats", "were", "studied", "and", "3", "groups", "were", "formed", "(", "8", "rats", "per", "group", ")", ".", "The", "moderate", "-", "dose", "group", "received", "5", "mg", "/", "kg", "/", "day", "PDN", "released", "from", "a", "subcutaneous", "implant", ".", "In", "the", "high", "-", "dose", "group", ",", "implants", "containing", "PDN", "equivalent", "to", "60", "mg", "/", "kg", "/", "day", "were", "applied", ".", "In", "the", "control", "group", "implants", "contained", "no", "PDN", ".", "Anxiety", "was", "assessed", "using", "an", "open", "field", "and", "elevated", "plus", "-", "maze", "devices", ".", "The", "number", "of", "cells", "and", "cytoplasmic", "transformation", "of", "astrocytes", "and", "microglia", "cells", "were", "assessed", "by", "immunohistochemical", "analyses", ".", "RESULTS", ":", "Anxiety", "was", "documented", "in", "both", "groups", "of", "PDN", "treated", "rats", "compared", "with", "controls", ".", "The", "magnitude", "of", "transformation", "of", "the", "microglia", "assessed", "by", "the", "number", "of", "intersections", "was", "significantly", "higher", "in", "the", "PDN", "groups", "than", "in", "controls", "in", "the", "prefrontal", "cortex", "(", "moderate", "-", "dose", ",", "24", ".", "1", ";", "high", "-", "dose", ",", "23", ".", "6", ";", "controls", "18", ".", "7", ";", "p", "<", "0", ".", "01", ")", "and", "striatum", "(", "moderate", "-", "dose", "25", ".", "6", ";", "high", "-", "dose", "26", ".", "3", ";", "controls", "18", ".", "9", ";", "p", "<", "0", ".", "01", ")", ",", "but", "not", "in", "hippocampus", ".", "The", "number", "of", "stained", "microglia", "cells", "was", "significantly", "higher", "in", "the", "PDN", "treated", "groups", "in", "the", "prefrontal", "cortex", "than", "in", "controls", "(", "moderate", "-", "dose", ",", "29", ".", "1", ";", "high", "-", "dose", ",", "28", ".", "4", ";", "control", ",", "17", ".", "7", "cells", "per", "field", ";", "p", "<", "0", ".", "01", ")", ".", "Stained", "microglia", "cells", "were", "significantly", "more", "numerous", "striatum", "and", "hippocampus", "in", "the", "high", "-", "dose", "group", "compared", "to", "controls", ".", "CONCLUSION", ":", "Subacute", "exposure", "to", "PDN", "induced", "anxiety", "and", "reactivity", "of", "microglia", ".", "The", "relevance", "of", "these", "features", "for", "patients", "using", "PDN", "remains", "to", "be", "elucidated", "."]], "ner": [[[0, 0, "Chemical"], [15, 15, "Chemical"], [17, 17, "Chemical"], [61, 61, "Chemical"], [77, 77, "Chemical"], [96, 96, "Chemical"], [139, 139, "Chemical"], [164, 164, "Chemical"], [246, 246, "Chemical"], [314, 314, "Chemical"], [330, 330, "Chemical"], [2, 2, "Disease"], [20, 20, "Disease"], [98, 98, "Disease"], [132, 132, "Disease"], [316, 316, "Disease"]]], "relations": [[[0, 0, 2, 2, "CID"], [0, 0, 20, 20, "CID"], [0, 0, 98, 98, "CID"], [0, 0, 132, 132, "CID"], [0, 0, 316, 316, "CID"], [15, 15, 2, 2, "CID"], [15, 15, 20, 20, "CID"], [15, 15, 98, 98, "CID"], [15, 15, 132, 132, "CID"], [15, 15, 316, 316, "CID"], [17, 17, 2, 2, "CID"], [17, 17, 20, 20, "CID"], [17, 17, 98, 98, "CID"], [17, 17, 132, 132, "CID"], [17, 17, 316, 316, "CID"], [61, 61, 2, 2, "CID"], [61, 61, 20, 20, "CID"], [61, 61, 98, 98, "CID"], [61, 61, 132, 132, "CID"], [61, 61, 316, 316, "CID"], [77, 77, 2, 2, "CID"], [77, 77, 20, 20, "CID"], [77, 77, 98, 98, "CID"], [77, 77, 132, 132, "CID"], [77, 77, 316, 316, "CID"], [96, 96, 2, 2, "CID"], [96, 96, 20, 20, "CID"], [96, 96, 98, 98, "CID"], [96, 96, 132, 132, "CID"], [96, 96, 316, 316, "CID"], [139, 139, 2, 2, "CID"], [139, 139, 20, 20, "CID"], [139, 139, 98, 98, "CID"], [139, 139, 132, 132, "CID"], [139, 139, 316, 316, "CID"], [164, 164, 2, 2, "CID"], [164, 164, 20, 20, "CID"], [164, 164, 98, 98, "CID"], [164, 164, 132, 132, "CID"], [164, 164, 316, 316, "CID"], [246, 246, 2, 2, "CID"], [246, 246, 20, 20, "CID"], [246, 246, 98, 98, "CID"], [246, 246, 132, 132, "CID"], [246, 246, 316, 316, "CID"], [314, 314, 2, 2, "CID"], [314, 314, 20, 20, "CID"], [314, 314, 98, 98, "CID"], [314, 314, 132, 132, "CID"], [314, 314, 316, 316, "CID"], [330, 330, 2, 2, "CID"], [330, 330, 20, 20, "CID"], [330, 330, 98, 98, "CID"], [330, 330, 132, 132, "CID"], [330, 330, 316, 316, "CID"]]], "clusters": [], "translated": " <0>泼尼松</0>诱导大鼠<11>焦虑</11>和神经胶质脑变化。目的：评估<1>强的松</1>（<2>PDN</2>）是否在大鼠中产生<12>焦虑</12>和/或脑胶质细胞变化。方法：研究雄性Wistar大鼠，分为3组（每组8只）。中等剂量组接受从皮下植入物释放的 <3>5 mg kg天 PDN</3>。在高剂量组中，应用了含有相当于<4>60 mg kg天 PDN</4>的植入物。在对照组中，植入物不含<5>PDN</5>。<13>焦虑</13>使用开放区域和高架十字迷宫装置进行评估。通过免疫组织化学分析评估星形胶质细胞和小胶质细胞的细胞数量和细胞质转化。结果：<14>焦虑</14>在<6>PDN</6>治疗的两组大鼠中均有记录，与对照组相比。在<7>PDN</7>组中，前额叶皮层中，通过交叉点数量评估的小胶质细胞转化程度明显高于对照组（中等剂量24.1，高剂量23.6，对照组18.7，P < 0.01），以及纹状体（中等剂量25.6，高剂量26.3，对照组18.9，P < 0.01），但未见明显差异的海马。在<8>PDN</8>治疗组的前额叶皮层中，染色的小胶质细胞数量显着高于对照组 （中剂量29.1，高剂量28.4，对照组17.7，每个视野的细胞数，P < 0.01）。高剂量组纹状体和海马中染色的小胶质细胞数量明显增多，与对照组相比有显著性差异。结论：亚急性暴露于<9>PDN</9>引起小胶质细胞<15>焦虑</15>和反应性。对于使用<10>PDN</10>的患者的这些特征的相关性有待进一步阐明。", "revised": true}
{"doc_key": "12452552", "sentences": [["Neuroleptic", "malignant", "syndrome", "complicated", "by", "massive", "intestinal", "bleeding", "in", "a", "patient", "with", "chronic", "renal", "failure", ".", "A", "patient", "with", "chronic", "renal", "failure", "(", "CRF", ")", "developed", "neuroleptic", "malignant", "syndrome", "(", "NMS", ")", "after", "administration", "of", "risperidone", "and", "levomepromazine", ".", "In", "addition", "to", "the", "typical", "symptoms", "of", "NMS", ",", "massive", "intestinal", "bleeding", "was", "observed", "during", "the", "episode", ".", "This", "report", "suggests", "that", "NMS", "in", "a", "patient", "with", "CRF", "may", "be", "complicated", "by", "intestinal", "bleeding", "and", "needs", "special", "caution", "for", "this", "complication", "."]], "ner": [[[35, 35, "Chemical"], [0, 2, "Disease"], [26, 28, "Disease"], [30, 30, "Disease"], [46, 46, "Disease"], [61, 61, "Disease"], [37, 37, "Chemical"], [7, 7, "Disease"], [50, 50, "Disease"], [72, 72, "Disease"], [12, 14, "Disease"], [19, 21, "Disease"], [23, 23, "Disease"], [66, 66, "Disease"]]], "relations": [[[35, 35, 0, 2, "CID"], [35, 35, 26, 28, "CID"], [35, 35, 30, 30, "CID"], [35, 35, 46, 46, "CID"], [35, 35, 61, 61, "CID"], [37, 37, 0, 2, "CID"], [37, 37, 26, 28, "CID"], [37, 37, 30, 30, "CID"], [37, 37, 46, 46, "CID"], [37, 37, 61, 61, "CID"]]], "clusters": [], "translated": " <1>抗精神病药恶性综合征</1>并发大量肠<7>出血</7>在<10>慢性肾功能衰竭</10>患者。<11>慢性肾功能衰竭</11>(<12>CRF</12>)患者在服用利培酮<0>和</0><6>左美丙嗪</6>后发生<2>抗精神病药物恶性综合征</2>(<3>NMS</3>)。除了典型的<4>NMS</4>症状外，发作期间还观察到大量肠道<8>出血</8>。本报告提示，<5>NMS</5>在<13>CRF</13>患者可能并发肠道<9>出血</9>，需要特别注意该并发症。", "revised": true}
{"doc_key": "12059909", "sentences": [["Delayed", "toxicity", "of", "cyclophosphamide", "on", "the", "bladder", "of", "DBA", "/", "2", "and", "C57BL", "/", "6", "female", "mouse", ".", "The", "present", "study", "describes", "the", "delayed", "development", "of", "a", "severe", "bladder", "pathology", "in", "a", "susceptible", "strain", "of", "mice", "(", "DBA", "/", "2", ")", "but", "not", "in", "a", "resistant", "strain", "(", "C57BL", "/", "6", ")", "when", "both", "were", "treated", "with", "a", "single", "300", "mg", "/", "kg", "dose", "of", "cyclophosphamide", "(", "CY", ")", ".", "Inbred", "DBA", "/", "2", "and", "C57BL", "/", "6", "female", "mice", "were", "injected", "with", "CY", ",", "and", "the", "effect", "of", "the", "drug", "on", "the", "bladder", "was", "assessed", "during", "100", "days", "by", "light", "microscopy", "using", "different", "staining", "procedures", ",", "and", "after", "30", "days", "by", "conventional", "electron", "microscopy", ".", "Early", "CY", "toxicity", "caused", "a", "typical", "haemorrhagic", "cystitis", "in", "both", "strains", "that", "was", "completely", "repaired", "in", "about", "7", "-", "10", "days", ".", "After", "30", "days", "of", "CY", "injection", "ulcerous", "and", "non", "-", "ulcerous", "forms", "of", "chronic", "cystitis", "appeared", "in", "86", "%", "of", "DBA", "/", "2", "mice", "but", "only", "in", "4", "%", "of", "C57BL", "/", "6", "mice", ".", "Delayed", "cystitis", "was", "characterized", "by", "infiltration", "and", "transepithelial", "passage", "into", "the", "lumen", "of", "inflammatory", "cells", "and", "by", "frequent", "exfoliation", "of", "the", "urothelium", ".", "Mast", "cells", "appeared", "in", "the", "connective", "and", "muscular", "layers", "of", "the", "bladder", "at", "a", "much", "higher", "number", "in", "DBA", "/", "2", "mice", "than", "in", "C57BL", "/", "6", "mice", "or", "untreated", "controls", ".", "Electron", "microscopy", "disclosed", "the", "absence", "of", "the", "typical", "discoidal", "vesicles", "normally", "present", "in", "the", "cytoplasm", "of", "surface", "cells", ".", "Instead", ",", "numerous", "abnormal", "vesicles", "containing", "one", "or", "several", "dark", "granules", "were", "observed", "in", "the", "cytoplasm", "of", "cells", "from", "all", "the", "epithelial", "layers", ".", "Delayed", "cystitis", "still", "persisted", "in", "DBA", "/", "2", "mice", "100", "days", "after", "treatment", ".", "These", "results", "indicate", "that", "delayed", "toxicity", "of", "CY", "in", "female", "DBA", "/", "2", "mice", "causes", "a", "bladder", "pathology", "that", "is", "not", "observed", "in", "C57BL", "/", "6", "mice", ".", "This", "pathology", "resembles", "interstitial", "cystitis", "in", "humans", "and", "could", "perhaps", "be", "used", "as", "an", "animal", "model", "for", "studies", "on", "the", "disease", "."]], "ner": [[[3, 3, "Chemical"], [65, 65, "Chemical"], [67, 67, "Chemical"], [83, 83, "Chemical"], [117, 117, "Chemical"], [142, 142, "Chemical"], [292, 292, "Chemical"], [122, 122, "Disease"], [123, 123, "Disease"], [152, 152, "Disease"], [174, 174, "Disease"], [272, 272, "Disease"], [1, 1, "Disease"], [118, 118, "Disease"], [290, 290, "Disease"], [316, 317, "Disease"]]], "relations": [[[3, 3, 122, 122, "CID"], [65, 65, 122, 122, "CID"], [67, 67, 122, 122, "CID"], [83, 83, 122, 122, "CID"], [117, 117, 122, 122, "CID"], [142, 142, 122, 122, "CID"], [292, 292, 122, 122, "CID"], [3, 3, 123, 123, "CID"], [3, 3, 152, 152, "CID"], [3, 3, 174, 174, "CID"], [3, 3, 272, 272, "CID"], [65, 65, 123, 123, "CID"], [65, 65, 152, 152, "CID"], [65, 65, 174, 174, "CID"], [65, 65, 272, 272, "CID"], [67, 67, 123, 123, "CID"], [67, 67, 152, 152, "CID"], [67, 67, 174, 174, "CID"], [67, 67, 272, 272, "CID"], [83, 83, 123, 123, "CID"], [83, 83, 152, 152, "CID"], [83, 83, 174, 174, "CID"], [83, 83, 272, 272, "CID"], [117, 117, 123, 123, "CID"], [117, 117, 152, 152, "CID"], [117, 117, 174, 174, "CID"], [117, 117, 272, 272, "CID"], [142, 142, 123, 123, "CID"], [142, 142, 152, 152, "CID"], [142, 142, 174, 174, "CID"], [142, 142, 272, 272, "CID"], [292, 292, 123, 123, "CID"], [292, 292, 152, 152, "CID"], [292, 292, 174, 174, "CID"], [292, 292, 272, 272, "CID"]]], "clusters": [], "translated": "<0>环磷酰胺</0>对DBA/2和C57BL/6雌性小鼠膀胱的迟发性<12>毒性</12>。本研究描述了延迟发展的严重膀胱病理在易感品系(DBA/2)，使之产生类似于人类间质性膀胱炎的病理，而抗性品系(C57BL/6)则不具有相应的毒性表现，两者均接受单次 300 mg / kg 剂量<1>环磷酰胺</1><2>CY</2>。近交系DBA/2和C57BL/6雌性小鼠注射<3>CY</3>，在100天期间通过光学显微镜使用不同的染色程序评估药物对膀胱的影响，并在30天后通过常规和电子显微镜评估药物对膀胱的影响。早期的<4>CY</4><13>毒性</13>引起两个品系典型的<7>出血性</7><8>膀胱炎</8>，大约在7-10天内完全修复。<5>CY</5>注射30天后，在86%的DBA/2小鼠中出现溃疡和非溃疡形式的慢性<9>膀胱炎</9>，而只有4%的C57BL/6小鼠出现。迟发性<10>膀胱炎</10> 的特征是炎症细胞浸润和跨上皮细胞进入管腔，以及尿路上皮频繁脱落。在DBA/2小鼠中，肥大细胞出现在膀胱的结缔组织层和肌肉层中，其数量比在C57BL/6小鼠或未治疗的对照小鼠中多得多。电子显微镜显示不存在通常存在于表面细胞的细胞质中的典型盘状囊泡。取而代之的是在所有上皮层细胞的细胞质中观察到大量含有一个或数个深色颗粒的异常囊泡。在治疗100天后，DBA/2小鼠仍持续存在迟发性<11>膀胱炎</11>。这些结果表明，在雌性DBA/2小鼠中，<6>CY</6>的延迟<14>毒性</14>会导致膀胱病变，而此毒性在C57BL/6小鼠中未观察到。这种病理类似于人类的<15>间质性膀胱炎</15>，或许可以用作研究该疾病的动物模型。", "revised": true}
{"doc_key": "12559315", "sentences": [["Indomethacin", "-", "induced", "morphologic", "changes", "in", "the", "rat", "urinary", "bladder", "epithelium", ".", "OBJECTIVES", ":", "To", "evaluate", "the", "morphologic", "changes", "in", "rat", "urothelium", "induced", "by", "indomethacin", ".", "Nonsteroidal", "anti", "-", "inflammatory", "drug", "-", "induced", "cystitis", "is", "a", "poorly", "recognized", "and", "under", "-", "reported", "condition", ".", "In", "addition", "to", "tiaprofenic", "acid", ",", "indomethacin", "has", "been", "reported", "to", "be", "associated", "with", "this", "condition", ".", "METHODS", ":", "Three", "groups", "were", "established", ":", "a", "control", "group", "(", "n", "=", "10", ")", ",", "a", "high", "-", "dose", "group", "(", "n", "=", "10", ")", ",", "treated", "with", "one", "intraperitoneal", "injection", "of", "indomethacin", "20", "mg", "/", "kg", ",", "and", "a", "therapeutic", "dose", "group", "(", "n", "=", "10", ")", "in", "which", "oral", "indomethacin", "was", "administered", "3", ".", "25", "mg", "/", "kg", "body", "weight", "daily", "for", "3", "weeks", ".", "The", "animals", "were", "then", "killed", "and", "the", "bladders", "removed", "for", "light", "and", "electron", "microscopic", "studies", ".", "RESULTS", ":", "The", "light", "microscopic", "findings", "showed", "some", "focal", "epithelial", "degeneration", "that", "was", "more", "prominent", "in", "the", "high", "-", "dose", "group", ".", "When", "compared", "with", "the", "control", "group", ",", "both", "indomethacin", "groups", "revealed", "statistically", "increased", "numbers", "of", "mast", "cells", "in", "the", "mucosa", "(", "P", "<", "0", ".", "0001", ")", "and", "penetration", "of", "lanthanum", "nitrate", "through", "intercellular", "areas", "of", "the", "epithelium", ".", "Furthermore", ",", "the", "difference", "in", "mast", "cell", "counts", "between", "the", "high", "and", "therapeutic", "dose", "groups", "was", "also", "statistically", "significant", "(", "P", "<", "0", ".", "0001", ")", ".", "CONCLUSIONS", ":", "Indomethacin", "resulted", "in", "histopathologic", "findings", "typical", "of", "interstitial", "cystitis", ",", "such", "as", "leaky", "bladder", "epithelium", "and", "mucosal", "mastocytosis", ".", "The", "true", "incidence", "of", "nonsteroidal", "anti", "-", "inflammatory", "drug", "-", "induced", "cystitis", "in", "humans", "must", "be", "clarified", "by", "prospective", "clinical", "trials", "."]], "ner": [[[0, 0, "Chemical"], [24, 24, "Chemical"], [50, 50, "Chemical"], [94, 94, "Chemical"], [113, 113, "Chemical"], [175, 175, "Chemical"], [235, 235, "Chemical"], [242, 243, "Disease"], [252, 252, "Disease"], [33, 33, "Disease"], [265, 265, "Disease"], [47, 48, "Chemical"], [197, 198, "Chemical"]]], "relations": [[[0, 0, 242, 243, "CID"], [24, 24, 242, 243, "CID"], [50, 50, 242, 243, "CID"], [94, 94, 242, 243, "CID"], [113, 113, 242, 243, "CID"], [175, 175, 242, 243, "CID"], [235, 235, 242, 243, "CID"], [0, 0, 252, 252, "CID"], [24, 24, 252, 252, "CID"], [50, 50, 252, 252, "CID"], [94, 94, 252, 252, "CID"], [113, 113, 252, 252, "CID"], [175, 175, 252, 252, "CID"], [235, 235, 252, 252, "CID"]]], "clusters": [], "translated": " <0>吲哚美辛</0> - 诱导大鼠膀胱上皮细胞的形态学变化。目的：评价<1>吲哚美辛</1>诱导大鼠尿路上皮的形态学变化。非甾体类抗炎药引起的<9>膀胱炎</9>是一种鲜为人知且报道不足的疾病。除<11>噻洛芬酸</11>外，据报道<2>吲哚美辛</2>与这种情况有关。方法：设三组：对照组（n=10）、高剂量组（n=10），腹腔注射<3>吲哚美辛</3> 20 mg/kg，治疗剂量组（n=10）口服<4>吲哚美辛</4>每天3.25毫克/千克体重，持续3周。然后杀死动物并取出膀胱进行光学和电子显微镜研究。结果：光镜下可见局灶性上皮变性，高剂量组更明显。与对照组相比，<5>吲哚美辛</5>组均显示粘膜中肥大细胞数量显着增加 (P < 0.0001) 并且<12>硝酸镧</12>通过细胞间区域渗透上皮细胞。此外，高剂量组和治疗剂量组之间的肥大细胞计数差异也具有统计学意义 (P < 0.0001) 。结论：<6>吲哚美辛</6>导致<7>间质性膀胱炎</7>的典型组织病理学表现，如膀胱上皮渗漏和粘膜<8>肥大细胞增多症</8>。人类非甾体类抗炎药引起的<10>膀胱炎</10>的真实发生率必须通过前瞻性临床试验来阐明。", "revised": true}
{"doc_key": "12699527", "sentences": [["Anaesthetic", "complications", "associated", "with", "myotonia", "congenita", ":", "case", "study", "and", "comparison", "with", "other", "myotonic", "disorders", ".", "Myotonia", "congenita", "(", "MC", ")", "is", "caused", "by", "a", "defect", "in", "the", "skeletal", "muscle", "chloride", "channel", "function", ",", "which", "may", "cause", "sustained", "membrane", "depolarisation", ".", "We", "describe", "a", "previously", "healthy", "32", "-", "year", "-", "old", "woman", "who", "developed", "a", "life", "-", "threatening", "muscle", "spasm", "and", "secondary", "ventilation", "difficulties", "following", "a", "preoperative", "injection", "of", "suxamethonium", ".", "The", "muscle", "spasms", "disappeared", "spontaneously", "and", "the", "surgery", "proceeded", "without", "further", "problems", ".", "When", "subsequently", "questioned", ",", "she", "reported", "minor", "symptoms", "suggesting", "a", "myotonic", "condition", ".", "Myotonia", "was", "found", "on", "clinical", "examination", "and", "EMG", ".", "The", "diagnosis", "MC", "was", "confirmed", "genetically", ".", "Neither", "the", "patient", "nor", "the", "anaesthetist", "were", "aware", "of", "the", "diagnosis", "before", "this", "potentially", "lethal", "complication", "occurred", ".", "We", "give", "a", "brief", "overview", "of", "ion", "channel", "disorders", "including", "malignant", "hyperthermia", "and", "their", "anaesthetic", "considerations", "."]], "ner": [[[69, 69, "Chemical"], [58, 59, "Disease"], [72, 73, "Disease"], [30, 30, "Chemical"], [4, 5, "Disease"], [16, 17, "Disease"], [19, 19, "Disease"], [108, 108, "Disease"], [13, 14, "Disease"], [94, 95, "Disease"], [97, 97, "Disease"], [141, 142, "Disease"]]], "relations": [[[69, 69, 58, 59, "CID"], [69, 69, 72, 73, "CID"]]], "clusters": [], "translated": "与<4>先天性肌强直</4>相关的麻醉并发症：个案研究和与其他<8>强直疾病</8>的比较。<5>先天性肌强直</5>（<6>MC</6>）是由骨骼肌<3>氯</3>通道功能缺陷引起的，可引起持续的膜去极化。我们描述了一名既往健康的32岁女性，她在术前注射<0>琥珀胆碱</0>后出现危及生命的<1>肌肉痉挛</1>和二次通气困难。<2>肌肉痉挛</2>自然消失，手术顺利进行。当随后接受询问时，她报告了轻微的症状，提示<9>肌强直状态</9>。<10>肌强直</10>在临床检查和肌电图中被发现。<7>MC</7>的诊断已通过基因证实。在这种可能致命的并发症发生之前，患者和麻醉师都不知道诊断结果。我们简要概述离子通道疾病，包括<11>恶性高热</11>及其麻醉注意事项。", "revised": true}
{"doc_key": "12487093", "sentences": [["Blood", "brain", "barrier", "in", "right", "-", "and", "left", "-", "pawed", "female", "rats", "assessed", "by", "a", "new", "staining", "method", ".", "The", "asymmetrical", "breakdown", "of", "the", "blood", "-", "brain", "barrier", "(", "BBB", ")", "was", "studied", "in", "female", "rats", ".", "Paw", "preference", "was", "assessed", "by", "a", "food", "reaching", "test", ".", "Adrenaline", "-", "induced", "hypertension", "was", "used", "to", "destroy", "the", "BBB", ",", "which", "was", "evaluated", "using", "triphenyltetrazolium", "(", "TTC", ")", "staining", "of", "the", "brain", "slices", "just", "after", "giving", "adrenaline", "for", "30", "s", ".", "In", "normal", "rats", ",", "the", "whole", "brain", "sections", "exhibited", "complete", "staining", "with", "TTC", ".", "After", "adrenaline", "infusion", "for", "30", "s", ",", "there", "were", "large", "unstained", "areas", "in", "the", "left", "brain", "in", "right", "-", "pawed", "animals", ",", "and", "vice", "versa", "in", "left", "-", "pawed", "animals", ".", "Similar", "results", "were", "obtained", "in", "seizure", "-", "induced", "breakdown", "of", "BBB", ".", "These", "results", "were", "explained", "by", "an", "asymmetric", "cerebral", "blood", "flow", "depending", "upon", "the", "paw", "preference", "in", "rats", ".", "It", "was", "suggested", "that", "this", "new", "method", "and", "the", "results", "are", "consistent", "with", "contralateral", "motor", "control", "that", "may", "be", "important", "in", "determining", "the", "dominant", "cerebral", "hemisphere", "in", "animals", "."]], "ner": [[[47, 47, "Chemical"], [74, 74, "Chemical"], [94, 94, "Chemical"], [50, 50, "Disease"], [129, 129, "Disease"], [62, 62, "Chemical"], [64, 64, "Chemical"], [91, 91, "Chemical"]]], "relations": [[[47, 47, 50, 50, "CID"], [74, 74, 50, 50, "CID"], [94, 94, 50, 50, "CID"]]], "clusters": [], "translated": "用一种新的染色方法评估<0>右爪</0>和<1>左爪</1>雌性大鼠的血脑屏障。在雌性大鼠中研究了血脑屏障 (<3>BBB</3>)的不对称破坏。爪子偏好通过食物到达测试来评估。<3>肾上腺素</3> - 诱导的<5>高血压</5>用于破坏血脑屏障，使用<5>三苯基四氮唑</5> (<6>TTC</6>)染色评估血脑屏障给予<3>肾上腺素</3>30秒后的脑切片。正常大鼠全脑切片<7>TTC</7>完全染色。<2>肾上腺素</2>输注30s后，<0>右爪动物</0>左脑有大片未染色区域，<1>左爪动物</1>则相反。在<4>癫痫发作</4>诱导的<3>BBB</3>分解中获得了类似的结果。这些结果可以用取决于大鼠爪子偏好的不对称脑血流来解释。有人提出，这种新方法和结果与对侧运动控制一致，对侧运动控制可能对确定动物的优势大脑半球很重要。", "revised": true}
{"doc_key": "12165618", "sentences": [["Persistent", "sterile", "leukocyturia", "is", "associated", "with", "impaired", "renal", "function", "in", "human", "immunodeficiency", "virus", "type", "1", "-", "infected", "children", "treated", "with", "indinavir", ".", "BACKGROUND", ":", "Prolonged", "administration", "of", "indinavir", "is", "associated", "with", "the", "occurrence", "of", "a", "variety", "of", "renal", "complications", "in", "adults", ".", "These", "well", "-", "documented", "side", "effects", "have", "restricted", "the", "use", "of", "this", "potent", "protease", "inhibitor", "in", "children", ".", "DESIGN", ":", "A", "prospective", "study", "to", "monitor", "indinavir", "-", "related", "nephrotoxicity", "in", "a", "cohort", "of", "30", "human", "immunodeficiency", "virus", "type", "1", "-", "infected", "children", "treated", "with", "indinavir", ".", "METHODS", ":", "Urinary", "pH", ",", "albumin", ",", "creatinine", ",", "the", "presence", "of", "erythrocytes", ",", "leukocytes", ",", "bacteria", "and", "crystals", ",", "and", "culture", "were", "analyzed", "every", "3", "months", "for", "96", "weeks", ".", "Serum", "creatinine", "levels", "were", "routinely", "determined", "at", "the", "same", "time", "points", ".", "Steady", "-", "state", "pharmacokinetics", "of", "indinavir", "were", "done", "at", "week", "4", "after", "the", "initiation", "of", "indinavir", ".", "RESULTS", ":", "The", "cumulative", "incidence", "of", "persistent", "sterile", "leukocyturia", "(", ">", "or", "=", "75", "cells", "/", "micro", "L", "in", "at", "least", "2", "consecutive", "visits", ")", "after", "96", "weeks", "was", "53", "%", ".", "Persistent", "sterile", "leukocyturia", "was", "frequently", "associated", "with", "a", "mild", "increase", "in", "the", "urine", "albumin", "/", "creatinine", "ratio", "and", "by", "microscopic", "hematuria", ".", "The", "cumulative", "incidence", "of", "serum", "creatinine", "levels", ">", "50", "%", "above", "normal", "was", "33", "%", "after", "96", "weeks", ".", "Children", "with", "persistent", "sterile", "leukocyturia", "more", "frequently", "had", "serum", "creatinine", "levels", "of", "50", "%", "above", "normal", "than", "those", "children", "without", "persistent", "sterile", "leukocyturia", ".", "In", "children", "younger", "than", "5", ".", "6", "years", ",", "persistent", "sterile", "leukocyturia", "was", "significantly", "more", "frequent", "than", "in", "older", "children", ".", "A", "higher", "cumulative", "incidence", "of", "persistent", "leukocyturia", "was", "found", "in", "children", "with", "an", "area", "under", "the", "curve", ">", "19", "mg", "/", "L", "x", "h", "or", "a", "peak", "serum", "level", "of", "indinavir", ">", "12", "mg", "/", "L", ".", "In", "4", "children", ",", "indinavir", "was", "discontinued", "because", "of", "nephrotoxicity", ".", "Subsequently", ",", "the", "serum", "creatinine", "levels", "decreased", ",", "the", "urine", "albumin", "/", "creatinine", "ratios", "returned", "to", "zero", ",", "and", "the", "leukocyturia", "disappeared", "within", "3", "months", ".", "CONCLUSIONS", ":", "Children", "treated", "with", "indinavir", "have", "a", "high", "cumulative", "incidence", "of", "persistent", "sterile", "leukocyturia", ".", "Children", "with", "persistent", "sterile", "leukocyturia", "more", "frequently", "had", "an", "increase", "in", "serum", "creatinine", "levels", "of", ">", "50", "%", "above", "normal", ".", "Younger", "children", "have", "an", "additional", "risk", "for", "renal", "complications", ".", "The", "impairment", "of", "the", "renal", "function", "in", "these", "children", "occurred", "in", "the", "absence", "of", "clinical", "symptoms", "of", "nephrolithiasis", ".", "Indinavir", "-", "associated", "nephrotoxicity", "must", "be", "monitored", "closely", ",", "especially", "in", "children", "with", "risk", "factors", "such", "as", "persistent", "sterile", "leukocyturia", ",", "age", "<", "5", ".", "6", "years", ",", "an", "area", "under", "the", "curve", "of", "indinavir", ">", "19", "mg", "/", "L", "x", "h", ",", "and", "a", "C", "(", "max", ")", ">", "12", "mg", "/", "L", "."]], "ner": [[[20, 20, "Chemical"], [27, 27, "Chemical"], [67, 67, "Chemical"], [86, 86, "Chemical"], [136, 136, "Chemical"], [146, 146, "Chemical"], [296, 296, "Chemical"], [307, 307, "Chemical"], [345, 345, "Chemical"], [406, 406, "Chemical"], [440, 440, "Chemical"], [6, 8, "Disease"], [70, 70, "Disease"], [312, 312, "Disease"], [388, 392, "Disease"], [409, 409, "Disease"], [200, 200, "Disease"], [95, 95, "Chemical"], [120, 120, "Chemical"], [195, 195, "Chemical"], [207, 207, "Chemical"], [230, 230, "Chemical"], [318, 318, "Chemical"], [326, 326, "Chemical"], [368, 368, "Chemical"], [10, 16, "Disease"], [76, 82, "Disease"], [404, 404, "Disease"]]], "relations": [[[20, 20, 6, 8, "CID"], [20, 20, 70, 70, "CID"], [20, 20, 312, 312, "CID"], [20, 20, 388, 392, "CID"], [20, 20, 409, 409, "CID"], [27, 27, 6, 8, "CID"], [27, 27, 70, 70, "CID"], [27, 27, 312, 312, "CID"], [27, 27, 388, 392, "CID"], [27, 27, 409, 409, "CID"], [67, 67, 6, 8, "CID"], [67, 67, 70, 70, "CID"], [67, 67, 312, 312, "CID"], [67, 67, 388, 392, "CID"], [67, 67, 409, 409, "CID"], [86, 86, 6, 8, "CID"], [86, 86, 70, 70, "CID"], [86, 86, 312, 312, "CID"], [86, 86, 388, 392, "CID"], [86, 86, 409, 409, "CID"], [136, 136, 6, 8, "CID"], [136, 136, 70, 70, "CID"], [136, 136, 312, 312, "CID"], [136, 136, 388, 392, "CID"], [136, 136, 409, 409, "CID"], [146, 146, 6, 8, "CID"], [146, 146, 70, 70, "CID"], [146, 146, 312, 312, "CID"], [146, 146, 388, 392, "CID"], [146, 146, 409, 409, "CID"], [296, 296, 6, 8, "CID"], [296, 296, 70, 70, "CID"], [296, 296, 312, 312, "CID"], [296, 296, 388, 392, "CID"], [296, 296, 409, 409, "CID"], [307, 307, 6, 8, "CID"], [307, 307, 70, 70, "CID"], [307, 307, 312, 312, "CID"], [307, 307, 388, 392, "CID"], [307, 307, 409, 409, "CID"], [345, 345, 6, 8, "CID"], [345, 345, 70, 70, "CID"], [345, 345, 312, 312, "CID"], [345, 345, 388, 392, "CID"], [345, 345, 409, 409, "CID"], [406, 406, 6, 8, "CID"], [406, 406, 70, 70, "CID"], [406, 406, 312, 312, "CID"], [406, 406, 388, 392, "CID"], [406, 406, 409, 409, "CID"], [440, 440, 6, 8, "CID"], [440, 440, 70, 70, "CID"], [440, 440, 312, 312, "CID"], [440, 440, 388, 392, "CID"], [440, 440, 409, 409, "CID"], [20, 20, 200, 200, "CID"], [27, 27, 200, 200, "CID"], [67, 67, 200, 200, "CID"], [86, 86, 200, 200, "CID"], [136, 136, 200, 200, "CID"], [146, 146, 200, 200, "CID"], [296, 296, 200, 200, "CID"], [307, 307, 200, 200, "CID"], [345, 345, 200, 200, "CID"], [406, 406, 200, 200, "CID"], [440, 440, 200, 200, "CID"]]], "clusters": [], "translated": "在 <25> 1 型人类免疫缺陷病毒感染 </25>接受 <0> 茚地那韦 </0> 治疗的儿童中，持续性无菌性白细胞尿与 <11> 肾功能受损 </11> 相关。背景：长期服用 <1> 茚地那韦 </1> 与成人多种肾脏并发症的发生有关。这些有据可查的副作用限制了这种强效蛋白酶抑制剂在儿童中的使用。设计：一项前瞻性研究，以监测 <2> 茚地那韦 </2> -相关的 <12> 肾毒性 </12> 在 30 名 <26> 人类免疫缺陷病毒 1 型感染 </26> 儿童中接受 <3> 茚地那韦 </3> 治疗。方法：每 3 个月分析一次尿液 pH 值、白蛋白、<17> 肌酐 </17>、红细胞、白细胞、细菌和晶体以及培养物，持续 96 周。在同一时间点常规测定血清 <18> 肌酐 </18>水平。 <4> 茚地那韦 </4> 的稳态药代动力学是在 <5> 茚地那韦 </5> 开始后第 4 周进行的。结果：96 周后，持续性无菌性白细胞尿症（≥ 75 个细胞/微升至少连续 2 次就诊）的累积发生率为 53%。持续性无菌性白细胞尿通常与尿白蛋白/<19> 肌酐 </19>比值轻度升高和镜下 <16> 血尿 </16> 相关。96 周后，血清 <20> 肌酐 </20>水平超过正常水平 > 50% 的累积发生率为 33%。与没有持续性无菌性白细胞尿症的儿童相比，有持续性无菌性白细胞尿症的儿童血清 <21> 肌酐 </21> 水平更常高于正常水平50%。在 5 岁以下的儿童中，持续性无菌性白细胞尿明显多于年龄较大的儿童。在曲线下面积 > 19 mg/L x h 或 <6> 茚地那韦 </6> > 12 mg/L 血清峰值水平的儿童中，持续性白细胞尿的累积发生率较高。在 4 名儿童中，停药因 <7> 茚地那韦 </7> 的 <13> 肾毒性 </13>。随后，血清 <22> 肌酐 </22> 水平下降，尿白蛋白/<23> 肌酐 </23>比值恢复为零，白细胞尿在 3 个月内消失。结论：接受 <8> 茚地那韦 </8> 治疗的儿童持续性无菌性白细胞尿的累积发生率较高。患有持续性无菌性白细胞尿症的儿童血清 <24> 肌酐 </24> 水平比正常值高出50%以上的频率更高。年幼的儿童患肾脏并发症的风险更高。这些儿童的 <14> 肾功能损害 </14> 是在没有 <27> 肾结石 </27> 临床症状的情况下发生的。 <9> 茚地那韦 </9> -相关的 <15> 肾毒性 </15> 必须密切监测，尤其是在有危险因素如持续性无菌性白细胞尿、年龄 <5 的儿童中。6年，<10> 茚地那韦 </10> 曲线下面积 > 19 mg/L x h，C (max) > 12 mg/L。", "revised": true}
{"doc_key": "12828076", "sentences": [["Increased", "serum", "soluble", "Fas", "in", "patients", "with", "acute", "liver", "failure", "due", "to", "paracetamol", "overdose", ".", "BACKGROUND", "/", "AIMS", ":", "Experimental", "studies", "have", "suggested", "that", "apoptosis", "via", "the", "Fas", "/", "Fas", "Ligand", "signaling", "system", "may", "play", "an", "important", "role", "in", "the", "development", "of", "acute", "liver", "failure", ".", "The", "aim", "of", "the", "study", "was", "to", "investigate", "the", "soluble", "form", "of", "Fas", "in", "patients", "with", "acute", "liver", "failure", ".", "METHODOLOGY", ":", "Serum", "levels", "of", "sFas", "(", "soluble", "Fas", ")", "were", "measured", "by", "ELISA", "in", "24", "patients", "with", "acute", "liver", "failure", "and", "10", "normal", "control", "subjects", ".", "Serum", "levels", "of", "tumor", "necrosis", "factor", "-", "alpha", "and", "interferon", "-", "gamma", "were", "also", "determined", "by", "ELISA", ".", "RESULTS", ":", "Serum", "sFas", "was", "significantly", "increased", "in", "patients", "with", "acute", "liver", "failure", "(", "median", ",", "26", ".", "8", "U", "/", "mL", ";", "range", ",", "6", ".", "9", "-", "52", ".", "7", "U", "/", "mL", ")", "compared", "to", "the", "normal", "controls", "(", "median", ",", "8", ".", "6", "U", "/", "mL", ";", "range", ",", "6", ".", "5", "-", "12", ".", "0", "U", "/", "mL", ",", "P", "<", "0", ".", "0001", ")", ".", "Levels", "were", "significantly", "greater", "in", "patients", "with", "acute", "liver", "failure", "due", "to", "paracetamol", "overdose", "(", "median", ",", "28", ".", "7", "U", "/", "mL", ";", "range", ",", "12", ".", "8", "-", "52", ".", "7", "U", "/", "mL", ",", "n", "=", "17", ")", "than", "those", "due", "to", "non", "-", "A", "to", "E", "hepatitis", "(", "median", ",", "12", ".", "5", "U", "/", "mL", ";", "range", ",", "6", ".", "9", "-", "46", ".", "0", "U", "/", "mL", ",", "n", "=", "7", ",", "P", "<", "0", ".", "01", ")", ".", "There", "was", "no", "relationship", "of", "sFas", "to", "eventual", "outcome", "in", "the", "patients", ".", "A", "significant", "correlation", "was", "observed", "between", "serum", "sFas", "levels", "and", "aspartate", "aminotransferase", "(", "r", "=", "0", ".", "613", ",", "P", "<", "0", ".", "01", ")", ".", "CONCLUSIONS", ":", "The", "increased", "concentration", "of", "sFas", "in", "serum", "of", "patients", "with", "acute", "liver", "failure", "may", "reflect", "activation", "of", "Fas", "-", "mediated", "apoptosis", "in", "the", "liver", "and", "this", "together", "with", "increased", "tumor", "necrosis", "factor", "-", "alpha", "may", "be", "an", "important", "factor", "in", "liver", "cell", "loss", "."]], "ner": [[[12, 12, "Chemical"], [194, 194, "Chemical"], [7, 9, "Disease"], [42, 44, "Disease"], [62, 64, "Disease"], [84, 86, "Disease"], [121, 123, "Disease"], [189, 191, "Disease"], [318, 320, "Disease"], [290, 290, "Chemical"], [13, 13, "Disease"], [195, 195, "Disease"], [96, 96, "Disease"], [337, 337, "Disease"], [97, 97, "Disease"], [338, 338, "Disease"], [232, 232, "Disease"]]], "relations": [[[12, 12, 7, 9, "CID"], [12, 12, 42, 44, "CID"], [12, 12, 62, 64, "CID"], [12, 12, 84, 86, "CID"], [12, 12, 121, 123, "CID"], [12, 12, 189, 191, "CID"], [12, 12, 318, 320, "CID"], [194, 194, 7, 9, "CID"], [194, 194, 42, 44, "CID"], [194, 194, 62, 64, "CID"], [194, 194, 84, 86, "CID"], [194, 194, 121, 123, "CID"], [194, 194, 189, 191, "CID"], [194, 194, 318, 320, "CID"]]], "clusters": [], "translated": "由于<0>对乙酰氨基酚</0><10>过量服用</10>而<2>急性肝功能衰竭</2>患者的血清可溶性Fas升高。背景/目的：实验研究表明，通过Fas/Fas配体信号系统发生的细胞凋亡可能在<3>急性肝衰竭</3>的发生发展中发挥重要作用。该研究的目的是调查<4>急性肝功能衰竭</4>患者体内Fas的可溶性形式。方法学：通过ELISA法测量24名<5>急性肝功能衰竭</5>患者和10名正常对照受试者的血清sFas（可溶性Fas）水平。<12>肿瘤</12><14>坏死</14>因子-α和干扰素-γ的血清水平也通过ELISA测定。结果：<6>急性肝功能衰竭</6>患者的血清sFas显着升高（中位数，26.8 U/mL；范围，6.9-52.7 U/mL）与正常对照组（中位数，8.6 U/mL；范围，6.5-12.0 U/mL，P < 0.0001）相比。由于<1>对乙酰氨基酚</1><11>过量服用</11>而导致<7>急性肝功能衰竭</7>的患者的水平明显更高（中位数，28.7 U/mL；范围，12.8-52.7 U/mL，n=17）比非甲型至戊型<16>肝炎</16>（中位数，12.5 U/mL；范围，6.9-46.0 U/mL，n=7，P<0.01）。sFas与患者的最终结果无关。血清sFas水平与<9>天门冬氨酸</9>转氨酶显着相关（r=0.613，P<0.01）。结论：<8>急性肝功能衰竭</8>患者血清中sFas浓度的升高可能反映了肝脏中Fas介导的细胞凋亡的激活，同时伴随着<13>肿瘤</13><15>坏死的增加</15>因子-α可能是肝细胞丢失的重要因素。", "revised": true}
{"doc_key": "12644816", "sentences": [["An", "open", "-", "label", "phase", "II", "study", "of", "low", "-", "dose", "thalidomide", "in", "androgen", "-", "independent", "prostate", "cancer", ".", "The", "antiangiogenic", "effects", "of", "thalidomide", "have", "been", "assessed", "in", "clinical", "trials", "in", "patients", "with", "various", "solid", "and", "haematological", "malignancies", ".", "Thalidomide", "blocks", "the", "activity", "of", "angiogenic", "agents", "including", "bFGF", ",", "VEGF", "and", "IL", "-", "6", ".", "We", "undertook", "an", "open", "-", "label", "study", "using", "thalidomide", "100", "mg", "once", "daily", "for", "up", "to", "6", "months", "in", "20", "men", "with", "androgen", "-", "independent", "prostate", "cancer", ".", "The", "mean", "time", "of", "study", "was", "109", "days", "(", "median", "107", ",", "range", "4", "-", "184", "days", ")", ".", "Patients", "underwent", "regular", "measurement", "of", "prostate", "-", "specific", "antigen", "(", "PSA", ")", ",", "urea", "and", "electrolytes", ",", "serum", "bFGF", "and", "VEGF", ".", "Three", "men", "(", "15", "%", ")", "showed", "a", "decline", "in", "serum", "PSA", "of", "at", "least", "50", "%", ",", "sustained", "throughout", "treatment", ".", "Of", "16", "men", "treated", "for", "at", "least", "2", "months", ",", "six", "(", "37", ".", "5", "%", ")", "showed", "a", "fall", "in", "absolute", "PSA", "by", "a", "median", "of", "48", "%", ".", "Increasing", "levels", "of", "serum", "bFGF", "and", "VEGF", "were", "associated", "with", "progressive", "disease", ";", "five", "of", "six", "men", "who", "demonstrated", "a", "fall", "in", "PSA", "also", "showed", "a", "decline", "in", "bFGF", "and", "VEGF", "levels", ",", "and", "three", "of", "four", "men", "with", "a", "rising", "PSA", "showed", "an", "increase", "in", "both", "growth", "factors", ".", "Adverse", "effects", "included", "constipation", ",", "morning", "drowsiness", ",", "dizziness", "and", "rash", ",", "and", "resulted", "in", "withdrawal", "from", "the", "study", "by", "three", "men", ".", "Evidence", "of", "peripheral", "sensory", "neuropathy", "was", "found", "in", "nine", "of", "13", "men", "before", "treatment", ".", "In", "the", "seven", "men", "who", "completed", "six", "months", "on", "thalidomide", ",", "subclinical", "evidence", "of", "peripheral", "neuropathy", "was", "found", "in", "four", "before", "treatment", ",", "but", "in", "all", "seven", "at", "repeat", "testing", ".", "The", "findings", "indicate", "that", "thalidomide", "may", "be", "an", "option", "for", "patients", "who", "have", "failed", "other", "forms", "of", "therapy", ",", "provided", "close", "follow", "-", "up", "is", "maintained", "for", "development", "of", "peripheral", "neuropathy", "."]], "ner": [[[11, 11, "Chemical"], [23, 23, "Chemical"], [39, 39, "Chemical"], [63, 63, "Chemical"], [273, 273, "Chemical"], [299, 299, "Chemical"], [229, 229, "Disease"], [232, 232, "Disease"], [234, 234, "Disease"], [236, 236, "Disease"], [251, 253, "Disease"], [278, 279, "Disease"], [324, 325, "Disease"], [16, 17, "Disease"], [80, 81, "Disease"], [36, 37, "Disease"], [13, 13, "Chemical"], [77, 77, "Chemical"], [115, 115, "Chemical"]]], "relations": [[[11, 11, 229, 229, "CID"], [23, 23, 229, 229, "CID"], [39, 39, 229, 229, "CID"], [63, 63, 229, 229, "CID"], [273, 273, 229, 229, "CID"], [299, 299, 229, 229, "CID"], [11, 11, 232, 232, "CID"], [23, 23, 232, 232, "CID"], [39, 39, 232, 232, "CID"], [63, 63, 232, 232, "CID"], [273, 273, 232, 232, "CID"], [299, 299, 232, 232, "CID"], [11, 11, 234, 234, "CID"], [23, 23, 234, 234, "CID"], [39, 39, 234, 234, "CID"], [63, 63, 234, 234, "CID"], [273, 273, 234, 234, "CID"], [299, 299, 234, 234, "CID"], [11, 11, 236, 236, "CID"], [23, 23, 236, 236, "CID"], [39, 39, 236, 236, "CID"], [63, 63, 236, 236, "CID"], [273, 273, 236, 236, "CID"], [299, 299, 236, 236, "CID"], [11, 11, 251, 253, "CID"], [11, 11, 278, 279, "CID"], [11, 11, 324, 325, "CID"], [23, 23, 251, 253, "CID"], [23, 23, 278, 279, "CID"], [23, 23, 324, 325, "CID"], [39, 39, 251, 253, "CID"], [39, 39, 278, 279, "CID"], [39, 39, 324, 325, "CID"], [63, 63, 251, 253, "CID"], [63, 63, 278, 279, "CID"], [63, 63, 324, 325, "CID"], [273, 273, 251, 253, "CID"], [273, 273, 278, 279, "CID"], [273, 273, 324, 325, "CID"], [299, 299, 251, 253, "CID"], [299, 299, 278, 279, "CID"], [299, 299, 324, 325, "CID"]]], "clusters": [], "translated": "低剂量 <0>沙利度胺</0> 在<16>雄激素</16>-非依赖性<13>前列腺癌</13>中的开放标签II期研究。 <1>沙利度胺</1>的抗血管生成作用已在各种实体和<15>血液系统恶性肿瘤</15>患者的临床试验中得到评估。<2>沙利度胺</2> 阻断血管生成剂的活性，包括bFGF、VEGF和IL-6。我们对20名患有<17>雄激素</17>-非依赖性<14>前列腺癌</14>的男性进行了一项开放标签研究，使用<3>沙利度胺</3> 100 mg 每天一次，持续长达6个月。平均研究时间为109天（中位数107，范围4-184天）。对患者进行前列腺特异性抗原（PSA）、<18>尿素</18>和电解质、血清bFGF和VEGF的定期测量。三名男性（15%）的血清PSA下降至少50%，并在整个治疗过程中持续下降。在接受至少2个月治疗的16名男性中，有6名（37.5%）的绝对PSA下降了48%的中位数。血清bFGF和VEGF水平升高与疾病进展相关；表现出PSA下降的六分之五的bFGF和VEGF水平也下降，而PSA升高的四分之三的两种生长因子均有所增加。不良反应包括<6>便秘</6>、早晨<7>嗜睡</7>、<8>头晕</8>和<9>皮疹</9>，并导致三名男性退出研究。13名男性中有9名在治疗前发现有<10>周围感觉神经病变</10>的证据。在完成<4>沙利度胺</4>六个月治疗的7名男性中，有4名在治疗前发现了<11>周围神经病变</11>的亚临床证据，但在重复测试时发现了所有7名男性。研究结果表明，<5>沙利度胺</5>可能是其他治疗形式失败的患者的一种选择，前提是要密切随访以防止<12>周围神经病变</12>的发生。", "revised": true}
{"doc_key": "11425091", "sentences": [["Prenatal", "cocaine", "exposure", "and", "cranial", "sonographic", "findings", "in", "preterm", "infants", ".", "PURPOSE", ":", "Prenatal", "cocaine", "exposure", "has", "been", "linked", "with", "subependymal", "hemorrhage", "and", "the", "formation", "of", "cysts", "that", "are", "detectable", "on", "cranial", "sonography", "in", "neonates", "born", "at", "term", ".", "We", "sought", "to", "determine", "if", "prenatal", "cocaine", "exposure", "increases", "the", "incidence", "of", "subependymal", "cysts", "in", "preterm", "infants", ".", "METHODS", ":", "We", "retrospectively", "reviewed", "the", "medical", "records", "and", "cranial", "sonograms", "obtained", "during", "a", "1", "-", "year", "period", "on", "122", "premature", "(", "<", "36", "weeks", "of", "gestation", ")", "infants", ".", "Infants", "were", "categorized", "into", "1", "of", "2", "groups", ":", "those", "exposed", "to", "cocaine", "and", "those", "not", "exposed", "to", "cocaine", ".", "Infants", "were", "assigned", "to", "the", "cocaine", "-", "exposed", "group", "if", "there", "was", "a", "maternal", "history", "of", "cocaine", "abuse", "during", "pregnancy", "or", "if", "maternal", "or", "neonatal", "urine", "toxicology", "results", "were", "positive", "at", "the", "time", "of", "delivery", ".", "RESULTS", ":", "Five", "of", "the", "122", "infants", "were", "excluded", "from", "the", "study", "because", "of", "insufficient", "medical", "and", "drug", "histories", ".", "The", "incidence", "of", "subependymal", "cysts", "in", "the", "117", "remaining", "infants", "was", "14", "%", "(", "16", "of", "117", ")", ".", "The", "incidence", "of", "subependymal", "cysts", "in", "infants", "exposed", "to", "cocaine", "prenatally", "was", "44", "%", "(", "8", "of", "18", ")", "compared", "with", "8", "%", "(", "8", "of", "99", ")", "in", "the", "unexposed", "group", "(", "p", "<", "0", ".", "01", ")", ".", "CONCLUSIONS", ":", "We", "found", "an", "increased", "incidence", "of", "subependymal", "cyst", "formation", "in", "preterm", "infants", "who", "were", "exposed", "to", "cocaine", "prenatally", ".", "This", "result", "is", "consistent", "with", "results", "of", "similar", "studies", "in", "term", "infants", "."]], "ner": [[[1, 1, "Chemical"], [14, 14, "Chemical"], [45, 45, "Chemical"], [99, 99, "Chemical"], [105, 105, "Chemical"], [112, 112, "Chemical"], [191, 191, "Chemical"], [240, 240, "Chemical"], [8, 9, "Disease"], [54, 55, "Disease"], [77, 85, "Disease"], [234, 235, "Disease"], [26, 26, "Disease"], [51, 52, "Disease"], [166, 167, "Disease"], [185, 186, "Disease"], [230, 231, "Disease"], [21, 21, "Disease"], [123, 124, "Disease"]]], "relations": [[[1, 1, 8, 9, "CID"], [1, 1, 54, 55, "CID"], [1, 1, 77, 85, "CID"], [1, 1, 234, 235, "CID"], [14, 14, 8, 9, "CID"], [14, 14, 54, 55, "CID"], [14, 14, 77, 85, "CID"], [14, 14, 234, 235, "CID"], [45, 45, 8, 9, "CID"], [45, 45, 54, 55, "CID"], [45, 45, 77, 85, "CID"], [45, 45, 234, 235, "CID"], [99, 99, 8, 9, "CID"], [99, 99, 54, 55, "CID"], [99, 99, 77, 85, "CID"], [99, 99, 234, 235, "CID"], [105, 105, 8, 9, "CID"], [105, 105, 54, 55, "CID"], [105, 105, 77, 85, "CID"], [105, 105, 234, 235, "CID"], [112, 112, 8, 9, "CID"], [112, 112, 54, 55, "CID"], [112, 112, 77, 85, "CID"], [112, 112, 234, 235, "CID"], [191, 191, 8, 9, "CID"], [191, 191, 54, 55, "CID"], [191, 191, 77, 85, "CID"], [191, 191, 234, 235, "CID"], [240, 240, 8, 9, "CID"], [240, 240, 54, 55, "CID"], [240, 240, 77, 85, "CID"], [240, 240, 234, 235, "CID"], [1, 1, 26, 26, "CID"], [1, 1, 51, 52, "CID"], [1, 1, 166, 167, "CID"], [1, 1, 185, 186, "CID"], [1, 1, 230, 231, "CID"], [14, 14, 26, 26, "CID"], [14, 14, 51, 52, "CID"], [14, 14, 166, 167, "CID"], [14, 14, 185, 186, "CID"], [14, 14, 230, 231, "CID"], [45, 45, 26, 26, "CID"], [45, 45, 51, 52, "CID"], [45, 45, 166, 167, "CID"], [45, 45, 185, 186, "CID"], [45, 45, 230, 231, "CID"], [99, 99, 26, 26, "CID"], [99, 99, 51, 52, "CID"], [99, 99, 166, 167, "CID"], [99, 99, 185, 186, "CID"], [99, 99, 230, 231, "CID"], [105, 105, 26, 26, "CID"], [105, 105, 51, 52, "CID"], [105, 105, 166, 167, "CID"], [105, 105, 185, 186, "CID"], [105, 105, 230, 231, "CID"], [112, 112, 26, 26, "CID"], [112, 112, 51, 52, "CID"], [112, 112, 166, 167, "CID"], [112, 112, 185, 186, "CID"], [112, 112, 230, 231, "CID"], [191, 191, 26, 26, "CID"], [191, 191, 51, 52, "CID"], [191, 191, 166, 167, "CID"], [191, 191, 185, 186, "CID"], [191, 191, 230, 231, "CID"], [240, 240, 26, 26, "CID"], [240, 240, 51, 52, "CID"], [240, 240, 166, 167, "CID"], [240, 240, 185, 186, "CID"], [240, 240, 230, 231, "CID"]]], "clusters": [], "translated": "产前<0>可卡因</0>暴露和<8>早产儿</8>的头颅超声检查结果。目的：产前<1>可卡因</1>暴露与室管膜下<17>出血</17>和<12>囊肿</12>的形成有关，这些在足月出生的新生儿的颅骨超声检查中可检测到。我们试图确定产前<2>可卡因</2>暴露是否会增加<9>早产儿</9>的<13>室管膜下囊肿</13>的发生率。方法：我们回顾性地回顾了122名<10>早产儿（<36周妊娠）</10>在1年期间获得的医疗记录和颅骨声像图。婴儿被分为2组中的1组：接触<3>可卡因</3>的婴儿和未接触<4>可卡因</4>的婴儿。如果母亲在怀孕期间有<18>可卡因滥用</18>史，或者分娩时母亲或新生儿尿液毒理学结果呈阳性，则将婴儿分配到<5>可卡因</5>暴露组。结果：122名婴儿中有5名因病史和药物史不足而被排除在研究之外。其余117名婴儿中<14>室管膜下囊肿</14>的发生率为14%（117名中的16名）。产前接触<6>可卡因</6>的婴儿<15>室管膜下囊肿</15>的发生率为44%（18人中有8人），而未接触组为8%（99人中有8人）（p<0.01）。结论：我们发现在产前接触<7>可卡因</7>的<11>早产儿</11>中<16>室管膜下囊肿</16>形成的发生率增加。这一结果与类似研究在足月儿中的结果一致。", "revised": true}
{"doc_key": "12498738", "sentences": [["Carvedilol", "protects", "against", "doxorubicin", "-", "induced", "mitochondrial", "cardiomyopathy", ".", "Several", "cytopathic", "mechanisms", "have", "been", "suggested", "to", "mediate", "the", "dose", "-", "limiting", "cumulative", "and", "irreversible", "cardiomyopathy", "caused", "by", "doxorubicin", ".", "Recent", "evidence", "indicates", "that", "oxidative", "stress", "and", "mitochondrial", "dysfunction", "are", "key", "factors", "in", "the", "pathogenic", "process", ".", "The", "objective", "of", "this", "investigation", "was", "to", "test", "the", "hypothesis", "that", "carvedilol", ",", "a", "nonselective", "beta", "-", "adrenergic", "receptor", "antagonist", "with", "potent", "antioxidant", "properties", ",", "protects", "against", "the", "cardiac", "and", "hepatic", "mitochondrial", "bioenergetic", "dysfunction", "associated", "with", "subchronic", "doxorubicin", "toxicity", ".", "Heart", "and", "liver", "mitochondria", "were", "isolated", "from", "rats", "treated", "for", "7", "weeks", "with", "doxorubicin", "(", "2", "mg", "/", "kg", "sc", "/", "week", ")", ",", "carvedilol", "(", "1", "mg", "/", "kg", "ip", "/", "week", ")", ",", "or", "the", "combination", "of", "the", "two", "drugs", ".", "Heart", "mitochondria", "isolated", "from", "doxorubicin", "-", "treated", "rats", "exhibited", "depressed", "rates", "for", "state", "3", "respiration", "(", "336", "+", "/", "-", "26", "versus", "425", "+", "/", "-", "53", "natom", "O", "/", "min", "/", "mg", "protein", ")", "and", "a", "lower", "respiratory", "control", "ratio", "(", "RCR", ")", "(", "4", ".", "3", "+", "/", "-", "0", ".", "6", "versus", "5", ".", "8", "+", "/", "-", "0", ".", "4", ")", "compared", "with", "cardiac", "mitochondria", "isolated", "from", "saline", "-", "treated", "rats", ".", "Mitochondrial", "calcium", "-", "loading", "capacity", "and", "the", "activity", "of", "NADH", "-", "dehydrogenase", "were", "also", "suppressed", "in", "cardiac", "mitochondria", "from", "doxorubicin", "-", "treated", "rats", ".", "Doxorubicin", "treatment", "also", "caused", "a", "decrease", "in", "RCR", "for", "liver", "mitochondria", "(", "3", ".", "9", "+", "/", "-", "0", ".", "9", "versus", "5", ".", "6", "+", "/", "-", "0", ".", "7", "for", "control", "rats", ")", "and", "inhibition", "of", "hepatic", "cytochrome", "oxidase", "activity", ".", "Coadministration", "of", "carvedilol", "decreased", "the", "extent", "of", "cellular", "vacuolization", "in", "cardiac", "myocytes", "and", "prevented", "the", "inhibitory", "effect", "of", "doxorubicin", "on", "mitochondrial", "respiration", "in", "both", "heart", "and", "liver", ".", "Carvedilol", "also", "prevented", "the", "decrease", "in", "mitochondrial", "Ca", "(", "2", "+", ")", "loading", "capacity", "and", "the", "inhibition", "of", "the", "respiratory", "complexes", "of", "heart", "mitochondria", "caused", "by", "doxorubicin", ".", "Carvedilol", "by", "itself", "did", "not", "affect", "any", "of", "the", "parameters", "measured", "for", "heart", "or", "liver", "mitochondria", ".", "It", "is", "concluded", "that", "this", "protection", "by", "carvedilol", "against", "both", "the", "structural", "and", "functional", "cardiac", "tissue", "damage", "may", "afford", "significant", "clinical", "advantage", "in", "minimizing", "the", "dose", "-", "limiting", "mitochondrial", "dysfunction", "and", "cardiomyopathy", "that", "accompanies", "long", "-", "term", "doxorubicin", "therapy", "in", "cancer", "patients", "."]], "ner": [[[3, 3, "Chemical"], [27, 27, "Chemical"], [83, 83, "Chemical"], [99, 99, "Chemical"], [133, 133, "Chemical"], [224, 224, "Chemical"], [229, 229, "Chemical"], [290, 290, "Chemical"], [326, 326, "Chemical"], [382, 382, "Chemical"], [7, 7, "Disease"], [24, 24, "Disease"], [376, 376, "Disease"], [0, 0, "Chemical"], [57, 57, "Chemical"], [110, 110, "Chemical"], [274, 274, "Chemical"], [300, 300, "Chemical"], [328, 328, "Chemical"], [352, 352, "Chemical"], [36, 37, "Disease"], [373, 374, "Disease"], [84, 84, "Disease"], [385, 385, "Disease"], [206, 206, "Chemical"], [307, 307, "Chemical"]]], "relations": [[[3, 3, 7, 7, "CID"], [3, 3, 24, 24, "CID"], [3, 3, 376, 376, "CID"], [27, 27, 7, 7, "CID"], [27, 27, 24, 24, "CID"], [27, 27, 376, 376, "CID"], [83, 83, 7, 7, "CID"], [83, 83, 24, 24, "CID"], [83, 83, 376, 376, "CID"], [99, 99, 7, 7, "CID"], [99, 99, 24, 24, "CID"], [99, 99, 376, 376, "CID"], [133, 133, 7, 7, "CID"], [133, 133, 24, 24, "CID"], [133, 133, 376, 376, "CID"], [224, 224, 7, 7, "CID"], [224, 224, 24, 24, "CID"], [224, 224, 376, 376, "CID"], [229, 229, 7, 7, "CID"], [229, 229, 24, 24, "CID"], [229, 229, 376, 376, "CID"], [290, 290, 7, 7, "CID"], [290, 290, 24, 24, "CID"], [290, 290, 376, 376, "CID"], [326, 326, 7, 7, "CID"], [326, 326, 24, 24, "CID"], [326, 326, 376, 376, "CID"], [382, 382, 7, 7, "CID"], [382, 382, 24, 24, "CID"], [382, 382, 376, 376, "CID"]]], "clusters": [], "translated": " \n<13>卡维地洛</13>可预防<0>阿霉素</0>诱导的线粒体<10>心肌病</10>。已经提出了几种细胞病变机制来介导由<1>阿霉素</1>引起的剂量限制性累积和不可逆的<11>心肌病</11>。最近的证据表明，氧化应激和<20>线粒体功能障碍</20>是致病过程中的关键因素。本研究的目的是验证以下假设：<14>卡维地洛</14>是一种具有强抗氧化特性的非选择性β-肾上腺素能受体拮抗剂，可预防与亚慢性<2>阿霉素</2>相关的心脏和肝脏线粒体生物能功能障碍<22>毒性</22>。心脏和肝脏线粒体从治疗了7周<3>多柔比星</3>（2 mg/kg sc/周）、<15>卡维地洛</15>（1 mg/kg ip/周）或两种药物的组合的大鼠体内分离。从<4>阿霉素</4>分离的心脏线粒体，与盐水处理的大鼠心脏线粒体相比，状态下的呼吸速率降低（336 +/- 26比425 +/- 53 natom O/min/mg蛋白质）且呼吸控制比（RCR）降低（4.3 +/- 0.6比5.8 +/- 0.4）。心脏线粒体中纳吉谷脱氢酶的活性和<24>钙</24>负载能力也在<5>多柔比星</5>处理的大鼠心脏线粒体中受到抑制。<6>多柔比星</6>治疗还导致肝线粒体的呼吸控制比降低（3.9 +/- 0.9比对照组大鼠的5.6 +/- 0.7）和肝细胞色素氧化酶活性的抑制。共同给药<16>卡维地洛</16>减少了心肌细胞中细胞空泡化的程度，并阻止了<7>多柔比星</7>对心脏和肝脏线粒体呼吸的抑制作用。<17>卡维地洛</17>还可抑制<8>多柔比星</8>引起的线粒体<25>Ca</25>(2+)负载能力下降和心脏线粒体呼吸复合物抑制。<18>卡维地洛</18>本身不影响心脏或肝脏线粒体的任何测量参数。结论是，<19>卡维地洛</19>对结构和功能性心肌组织损伤的这种保护作用可能在最大限度地减少剂量限制性<21>线粒体功能障碍</21>和<12>心肌病</12>方面提供显着的临床优势，伴随长期<9>阿霉素</9>治疗<23>癌症</23>患者。", "revised": true}
{"doc_key": "12677626", "sentences": [["Central", "nervous", "system", "toxicity", "following", "the", "administration", "of", "levobupivacaine", "for", "lumbar", "plexus", "block", ":", "A", "report", "of", "two", "cases", ".", "BACKGROUND", "AND", "OBJECTIVES", ":", "Central", "nervous", "system", "and", "cardiac", "toxicity", "following", "the", "administration", "of", "local", "anesthetics", "is", "a", "recognized", "complication", "of", "regional", "anesthesia", ".", "Levobupivacaine", ",", "the", "pure", "S", "(", "-", ")", "enantiomer", "of", "bupivacaine", ",", "was", "developed", "to", "improve", "the", "cardiac", "safety", "profile", "of", "bupivacaine", ".", "We", "describe", "2", "cases", "of", "grand", "mal", "seizures", "following", "accidental", "intravascular", "injection", "of", "levobupivacaine", ".", "CASE", "REPORT", ":", "Two", "patients", "presenting", "for", "elective", "orthopedic", "surgery", "of", "the", "lower", "limb", "underwent", "blockade", "of", "the", "lumbar", "plexus", "via", "the", "posterior", "approach", ".", "Immediately", "after", "the", "administration", "of", "levobupivacaine", "0", ".", "5", "%", "with", "epinephrine", "2", ".", "5", "microgram", "/", "mL", ",", "the", "patients", "developed", "grand", "mal", "seizures", ",", "despite", "negative", "aspiration", "for", "blood", "and", "no", "clinical", "signs", "of", "intravenous", "epinephrine", "administration", ".", "The", "seizures", "were", "successfully", "treated", "with", "sodium", "thiopental", "in", "addition", "to", "succinylcholine", "in", "1", "patient", ".", "Neither", "patient", "developed", "signs", "of", "cardiovascular", "toxicity", ".", "Both", "patients", "were", "treated", "preoperatively", "with", "beta", "-", "adrenergic", "antagonist", "medications", ",", "which", "may", "have", "masked", "the", "cardiovascular", "signs", "of", "the", "unintentional", "intravascular", "administration", "of", "levobupivacaine", "with", "epinephrine", ".", "CONCLUSIONS", ":", "Although", "levobupivacaine", "may", "have", "a", "safer", "cardiac", "toxicity", "profile", "than", "racemic", "bupivacaine", ",", "if", "adequate", "amounts", "of", "levobupivacaine", "reach", "the", "circulation", ",", "it", "will", "result", "in", "convulsions", ".", "Plasma", "concentrations", "sufficient", "to", "result", "in", "central", "nervous", "system", "toxicity", "did", "not", "produce", "manifestations", "of", "cardiac", "toxicity", "in", "these", "2", "patients", "."]], "ner": [[[8, 8, "Chemical"], [44, 44, "Chemical"], [80, 80, "Chemical"], [112, 112, "Chemical"], [196, 196, "Chemical"], [203, 203, "Chemical"], [219, 219, "Chemical"], [72, 74, "Disease"], [129, 131, "Disease"], [0, 3, "Disease"], [24, 29, "Disease"], [236, 239, "Disease"], [54, 54, "Chemical"], [65, 65, "Chemical"], [213, 213, "Chemical"], [118, 118, "Chemical"], [144, 144, "Chemical"], [198, 198, "Chemical"], [153, 154, "Chemical"], [158, 158, "Chemical"], [208, 209, "Disease"], [245, 246, "Disease"], [148, 148, "Disease"], [228, 228, "Disease"], [168, 169, "Disease"]]], "relations": [[[8, 8, 72, 74, "CID"], [8, 8, 129, 131, "CID"], [44, 44, 72, 74, "CID"], [44, 44, 129, 131, "CID"], [80, 80, 72, 74, "CID"], [80, 80, 129, 131, "CID"], [112, 112, 72, 74, "CID"], [112, 112, 129, 131, "CID"], [196, 196, 72, 74, "CID"], [196, 196, 129, 131, "CID"], [203, 203, 72, 74, "CID"], [203, 203, 129, 131, "CID"], [219, 219, 72, 74, "CID"], [219, 219, 129, 131, "CID"]]], "clusters": [], "translated": " <0>左旋布比卡因</0>腰丛神经阻滞后的<9>中枢神经系统毒性</9>二例报告。背景和目的：<10>局部麻醉药给药后是区域麻醉公认的并发症中枢神经系统和心脏毒性</10>。 <1> 左旋布比卡因 </1>是<12>布比卡因</12>的纯S(-)对映体，旨在改善<13>布比卡因</13>的心脏安全性。我们描述了2例在意外血管内注射<2>左旋布比卡因</2>后发生<7>癫痫大发作</7>的病例。病例报告：两名接受择期下肢骨科手术的患者经后路阻滞腰丛神经。在<3>左旋布比卡因</3> 0.5%与<15>肾上腺素</15>2.5微克/毫升给药后，患者出现<8>癫痫大发作</8>，尽管抽吸血液为阴性且静脉注射<16>肾上腺素</16>没有临床症状。<22>癫痫发作</22>除了1名患者使用<18>硫喷妥钠</18>，另外1名患者使用<19>琥珀胆碱</19>成功治疗。两名患者均未出现<24>心血管毒性</24>的体征。两名患者术前均接受了β-肾上腺素能拮抗剂药物治疗，这可能掩盖了无意中血管内给予<4>左旋布比卡因</4>和<17>肾上腺素</17>的心血管症状。结论：尽管<5>左布比卡因</5>可能比外消旋<14>布比卡因</14>具有更安全的<20>心脏毒性</20>，但如果足量的<6>左布比卡因</6>达到循环，会导致<23>抽搐</23>。在这2名患者中，足以导致<11>中枢神经系统毒性</11>的血浆浓度并未产生<21>心脏毒性</21>的表现。", "revised": true}
{"doc_key": "12865514", "sentences": [["Bilateral", "subthalamic", "nucleus", "stimulation", "for", "Parkinson", "'s", "disease", ".", "High", "frequency", "stimulation", "of", "the", "subthalamic", "nucleus", "(", "STN", ")", "is", "known", "to", "ameliorate", "the", "signs", "and", "symptoms", "of", "advanced", "Parkinson", "'s", "disease", ".", "AIM", ":", "We", "studied", "the", "effect", "of", "high", "frequency", "STN", "stimulation", "in", "23", "patients", ".", "METHOD", ":", "Twenty", "-", "three", "patients", "suffering", "from", "severe", "Parkinson", "'s", "disease", "(", "Stages", "III", "-", "V", "on", "Hoehn", "and", "Yahr", "scale", ")", "and", ",", "particularly", "bradykinesia", ",", "rigidity", ",", "and", "levodopa", "-", "induced", "dyskinesias", "underwent", "bilateral", "implantation", "of", "electrodes", "in", "the", "STN", ".", "Preoperative", "and", "postoperative", "assessments", "of", "these", "patients", "at", "1", ",", "3", ",", "6", "and", "12", "months", "follow", "-", "up", ",", "in", "\"", "on", "\"", "and", "\"", "off", "\"", "drug", "conditions", ",", "was", "carried", "out", "using", "Unified", "Parkinson", "'s", "Disease", "Rating", "Scale", ",", "Hoehn", "and", "Yahr", "staging", ",", "England", "activities", "of", "daily", "living", "score", "and", "video", "recordings", ".", "RESULTS", ":", "After", "one", "year", "of", "electrical", "stimulation", "of", "the", "STN", ",", "the", "patients", "'", "scores", "for", "activities", "of", "daily", "living", "and", "motor", "examination", "scores", "(", "Unified", "Parkinson", "'s", "Disease", "Rating", "Scale", "parts", "II", "and", "III", ")", "off", "medication", "improved", "by", "62", "%", "and", "61", "%", "respectively", "(", "p", "<", "0", ".", "0005", ")", ".", "The", "subscores", "for", "the", "akinesia", ",", "rigidity", ",", "tremor", "and", "gait", "also", "improved", ".", "(", "p", "<", "0", ".", "0005", ")", ".", "The", "average", "levodopa", "dose", "decreased", "from", "813", "mg", "to", "359", "mg", ".", "The", "cognitive", "functions", "remained", "unchanged", ".", "Two", "patients", "developed", "device", "-", "related", "complications", "and", "two", "patients", "experienced", "abnormal", "weight", "gain", ".", "CONCLUSION", ":", "Bilateral", "subthalamic", "nucleus", "stimulation", "is", "an", "effective", "treatment", "for", "advanced", "Parkinson", "'s", "disease", ".", "It", "reduces", "the", "severity", "of", "\"", "off", "\"", "phase", "symptoms", ",", "improves", "the", "axial", "symptoms", "and", "reduces", "levodopa", "requirements", ".", "The", "reduction", "in", "the", "levodopa", "dose", "is", "useful", "in", "controlling", "drug", "-", "induced", "dyskinesias", "."]], "ner": [[[79, 79, "Chemical"], [228, 228, "Chemical"], [292, 292, "Chemical"], [299, 299, "Chemical"], [82, 82, "Disease"], [208, 208, "Disease"], [305, 308, "Disease"], [5, 7, "Disease"], [29, 31, "Disease"], [57, 59, "Disease"], [128, 130, "Disease"], [176, 178, "Disease"], [271, 273, "Disease"], [74, 74, "Disease"], [76, 76, "Disease"], [210, 210, "Disease"], [212, 212, "Disease"]]], "relations": [[[79, 79, 82, 82, "CID"], [79, 79, 208, 208, "CID"], [79, 79, 305, 308, "CID"], [228, 228, 82, 82, "CID"], [228, 228, 208, 208, "CID"], [228, 228, 305, 308, "CID"], [292, 292, 82, 82, "CID"], [292, 292, 208, 208, "CID"], [292, 292, 305, 308, "CID"], [299, 299, 82, 82, "CID"], [299, 299, 208, 208, "CID"], [299, 299, 305, 308, "CID"]]], "clusters": [], "translated": "双侧丘脑底核刺激治疗<7>帕金森病</7>。众所周知，高频刺激丘脑底核 (STN) 可以改善晚期<8>帕金森病</8>的体征和症状。目的：研究高频STN刺激对23例患者的影响。方法：23 名患有严重<9>帕金森氏病</9>（Hoehn 和 Yahr 量表的 III - V 期），尤其是<13>运动迟缓</13>、<14>强直</14>和<0>左旋多巴</0>诱发的<4>运动障碍</4>在STN中进行双侧电极植入。使用统一<10>帕金森氏病</10>评定量表，在“开”和“关”药物条件下，对这些患者进行1、3、6和12个月随访的术前和术后评估，Hoehn和Yahr分期，英国日常生活评分和录像活动。结果：经过一年的STN电刺激后，患者的日常生活活动评分和运动检查评分（统一<11>帕金森氏病</11>评定量表第II部分和第III部分）在药物治疗后提高了62%和61%（p < 0.0005）。<5>运动不能</5>，<15>僵硬</15>，<16>震颤</16>和步态的分项得分也有所改善。 (p < 0.0005)。平均<1>左旋多巴</1>剂量从813毫克减少到359毫克。认知功能保持不变。两名患者出现了与设备相关的并发症，两名患者体重异常增加。结论：双侧丘脑底核电刺激术是治疗晚期<12>帕金森氏病</12>的有效方法。它减轻了“关”期症状的严重程度，改善了中轴症状并减少了<2>左旋多巴</2>的需要量。<3>左旋多巴</3>剂量的减少有助于控制<6>药物引起的运动障碍</6>。", "revised": true}
{"doc_key": "12752472", "sentences": [["Respiratory", "pattern", "in", "a", "rat", "model", "of", "epilepsy", ".", "PURPOSE", ":", "Apnea", "is", "known", "to", "occur", "during", "seizures", ",", "but", "systematic", "studies", "of", "ictal", "respiratory", "changes", "in", "adults", "are", "few", ".", "Data", "regarding", "respiratory", "pattern", "defects", "during", "interictal", "periods", "also", "are", "scarce", ".", "Here", "we", "sought", "to", "generate", "information", "with", "regard", "to", "the", "interictal", "period", "in", "animals", "with", "pilocarpine", "-", "induced", "epilepsy", ".", "METHODS", ":", "Twelve", "rats", "(", "six", "chronically", "epileptic", "animals", "and", "six", "controls", ")", "were", "anesthetized", ",", "given", "tracheotomies", ",", "and", "subjected", "to", "hyperventilation", "or", "hypoventilation", "conditions", ".", "Breathing", "movements", "caused", "changes", "in", "thoracic", "volume", "and", "forced", "air", "to", "flow", "tidally", "through", "a", "pneumotachograph", ".", "This", "flow", "was", "measured", "by", "using", "a", "differential", "pressure", "transducer", ",", "passed", "through", "a", "polygraph", ",", "and", "from", "this", "to", "a", "computer", "with", "custom", "software", "that", "derived", "ventilation", "(", "VE", ")", ",", "tidal", "volume", "(", "VT", ")", ",", "inspiratory", "time", "(", "TI", ")", ",", "expiratory", "time", "(", "TE", ")", ",", "breathing", "frequency", "(", "f", ")", ",", "and", "mean", "inspiratory", "flow", "(", "VT", "/", "TI", ")", "on", "a", "breath", "-", "by", "-", "breath", "basis", ".", "RESULTS", ":", "The", "hyperventilation", "maneuver", "caused", "a", "decrease", "in", "spontaneous", "ventilation", "in", "pilocarpine", "-", "treated", "and", "control", "rats", ".", "Although", "VE", "had", "a", "similar", "decrease", "in", "both", "groups", ",", "in", "the", "epileptic", "group", ",", "the", "decrease", "in", "VE", "was", "due", "to", "a", "significant", "(", "p", "<", "0", ".", "05", ")", "increase", "in", "TE", "peak", "in", "relation", "to", "that", "of", "the", "control", "animals", ".", "The", "hypoventilation", "maneuver", "led", "to", "an", "increase", "in", "the", "arterial", "Paco2", ",", "followed", "by", "an", "increase", "in", "VE", ".", "In", "the", "epileptic", "group", ",", "the", "increase", "in", "VE", "was", "mediated", "by", "a", "significant", "(", "p", "<", "0", ".", "05", ")", "decrease", "in", "TE", "peak", "compared", "with", "the", "control", "group", ".", "Systemic", "application", "of", "KCN", ",", "to", "evaluate", "the", "effects", "of", "peripheral", "chemoreception", "activation", "on", "ventilation", ",", "led", "to", "a", "similar", "increase", "in", "VE", "for", "both", "groups", ".", "CONCLUSIONS", ":", "The", "data", "indicate", "that", "pilocarpine", "-", "treated", "animals", "have", "an", "altered", "ability", "to", "react", "to", "(", "or", "compensate", "for", ")", "blood", "gas", "changes", "with", "changes", "in", "ventilation", "and", "suggest", "that", "it", "is", "centrally", "determined", ".", "We", "speculate", "on", "the", "possible", "relation", "of", "the", "current", "findings", "on", "treating", "different", "epilepsy", "-", "associated", "conditions", "."]], "ner": [[[58, 58, "Chemical"], [193, 193, "Chemical"], [327, 327, "Chemical"], [7, 7, "Disease"], [61, 61, "Disease"], [70, 70, "Disease"], [212, 212, "Disease"], [265, 265, "Disease"], [371, 371, "Disease"], [11, 11, "Disease"], [17, 17, "Disease"], [85, 85, "Disease"], [184, 184, "Disease"]]], "relations": [[[58, 58, 7, 7, "CID"], [58, 58, 61, 61, "CID"], [58, 58, 70, 70, "CID"], [58, 58, 212, 212, "CID"], [58, 58, 265, 265, "CID"], [58, 58, 371, 371, "CID"], [193, 193, 7, 7, "CID"], [193, 193, 61, 61, "CID"], [193, 193, 70, 70, "CID"], [193, 193, 212, 212, "CID"], [193, 193, 265, 265, "CID"], [193, 193, 371, 371, "CID"], [327, 327, 7, 7, "CID"], [327, 327, 61, 61, "CID"], [327, 327, 70, 70, "CID"], [327, 327, 212, 212, "CID"], [327, 327, 265, 265, "CID"], [327, 327, 371, 371, "CID"]]], "clusters": [], "translated": "<3>癫痫</3>大鼠模型的呼吸模式。目的：<9>呼吸暂停</9>已知发生在<10>癫痫发作</10>期间，但对成人发作期呼吸变化的系统研究很少。关于发作间期呼吸模式缺陷的数据也很少。在这里，我们试图生成关于<0>毛果芸香碱</0>诱发的<4>癫痫</4>动物的发作间期的信息。方法：对12只大鼠（6只慢性<5>癫痫</5>动物和6只对照组）进行麻醉，进行气管切开术，并使其处于<11>过度通气</11>或通气不足的状态。呼吸运动引起胸腔容积的变化，并迫使空气潮汐地流过呼吸速度描记器。该流量通过使用压差传感器测量，通过测谎仪，并从该传感器传输到装有定制软件的计算机，计算得出通气量（VE）、潮气量（VT）、吸气时间（TI）、呼气时间（TE）、呼吸频率(f)和每次呼吸的平均吸气流量(VT/TI)。结果：<12>过度通气</12>操作导致<1>毛果芸香碱</1>治疗组和对照组大鼠的自主通气减少。尽管VE在两组中都有相似的降低，但在<6>癫痫</6>组中，VE的降低是由于与对照组动物相比，TE峰值显着增加(p < 0.05)。通气不足操作导致动脉Paco2增加，随后VE增加。在<7>癫痫</7>组中，与对照组相比，VE的增加是由TE峰值显着（p < 0.05）降低介导的。全身应用KCN来评估外周化学感受激活对通气的影响，导致两组的VE增加相似。结论：数据表明，<2>毛果芸香碱</2>处理的动物对血气变化的反应（或补偿）能力随着通气的变化而改变，表明这是集中决定的。我们推测当前研究结果与治疗不同<8>癫痫</8>相关病症的可能关系。", "revised": true}
{"doc_key": "12950111", "sentences": [["Treatment", "of", "compensatory", "gustatory", "hyperhidrosis", "with", "topical", "glycopyrrolate", ".", "Gustatory", "hyperhidrosis", "is", "facial", "sweating", "usually", "associated", "with", "the", "eating", "of", "hot", "spicy", "food", "or", "even", "smelling", "this", "food", ".", "Current", "options", "of", "treatment", "include", "oral", "anticholinergic", "drugs", ",", "the", "topical", "application", "of", "anticholinergics", "or", "aluminum", "chloride", ",", "and", "the", "injection", "of", "botulinum", "toxin", ".", "Thirteen", "patients", "have", "been", "treated", "to", "date", "with", "1", ".", "5", "%", "or", "2", "%", "topical", "glycopyrrolate", ".", "All", "patients", "had", "gustatory", "hyperhidrosis", ",", "which", "interfered", "with", "their", "social", "activities", ",", "after", "transthroacic", "endoscopic", "sympathectomy", ",", "and", "which", "was", "associated", "with", "compensatory", "focal", "hyperhidrosis", ".", "After", "applying", "topical", "glycopyrrolate", ",", "the", "subjective", "effect", "was", "excellent", "(", "no", "sweating", "after", "eating", "hot", "spicy", "food", ")", "in", "10", "patients", "(", "77", "%", ")", ",", "and", "fair", "(", "clearly", "reduced", "sweating", ")", "in", "3", "patients", "(", "23", "%", ")", ".", "All", "had", "reported", "incidents", "of", "being", "very", "embarrassed", "whilst", "eating", "hot", "spicy", "foods", ".", "Adverse", "effects", "included", "a", "mildly", "dry", "mouth", "and", "a", "sore", "throat", "in", "2", "patients", "(", "2", "%", "glycopyrrolate", ")", ",", "a", "light", "headache", "in", "1", "patient", "(", "1", ".", "5", "%", "glycopyrrolate", ")", ".", "The", "topical", "application", "of", "a", "glycopyrrolate", "pad", "appeared", "to", "be", "safe", ",", "efficacious", ",", "well", "tolerated", ",", "and", "a", "convenient", "method", "of", "treatment", "for", "moderate", "to", "severe", "symptoms", "of", "gustatory", "hyperhidrosis", "in", "post", "transthoracic", "endoscopic", "sympathectomy", "or", "sympathicotomy", "patients", ",", "with", "few", "side", "effects", "."]], "ner": [[[7, 7, "Chemical"], [70, 70, "Chemical"], [102, 102, "Chemical"], [172, 172, "Chemical"], [186, 186, "Chemical"], [194, 194, "Chemical"], [164, 165, "Disease"], [177, 177, "Disease"], [3, 4, "Disease"], [9, 10, "Disease"], [13, 13, "Disease"], [75, 76, "Disease"], [111, 111, "Disease"], [131, 131, "Disease"], [218, 219, "Disease"], [44, 45, "Chemical"], [97, 97, "Disease"], [160, 161, "Disease"]]], "relations": [[[7, 7, 164, 165, "CID"], [70, 70, 164, 165, "CID"], [102, 102, 164, 165, "CID"], [172, 172, 164, 165, "CID"], [186, 186, 164, 165, "CID"], [194, 194, 164, 165, "CID"], [7, 7, 177, 177, "CID"], [70, 70, 177, 177, "CID"], [102, 102, 177, 177, "CID"], [172, 172, 177, 177, "CID"], [186, 186, 177, 177, "CID"], [194, 194, 177, 177, "CID"]]], "clusters": [], "translated": "用局部<0>格隆溴铵</0>治疗代偿性<8>味觉多汗症</8>。 <9>味觉多汗症</9>是面部<10>出汗</10>，通常与吃辛辣食物甚至闻到这种食物有关。目前的治疗选择包括口服抗胆碱能药物、局部应用抗胆碱能药物或<15>氯化铝</15>，以及注射肉毒杆菌毒素。迄今为止，已有13名患者接受了1.5%或2%外用<1>格隆溴铵</1>。所有患者经喉内镜下交感神经切除术后均出现<11>味觉多汗症</11>，影响社交活动，并伴有代偿性局灶性<16>多汗</16>。外用<2>格隆溴铵</2>后，10例患者(77%)主观效果极佳(进食辛辣食物后无<12>出汗</12>)，中等(<13>出汗明显减少</13>)3例(23%)。所有人都报告说在吃辛辣食物时感到非常尴尬。不良反应包括2名患者（2%<3>格隆溴铵</3>）出现轻度<17>口干</17>和<6>喉咙痛</6>，轻度<7>头痛</7>在1名患者中（1.5%<4>格隆溴铵</4>）。局部应用<5>格隆溴铵</5>垫似乎安全、有效、耐受性良好，是治疗经胸内窥镜交感神经切除术后中度至重度<14>味觉多汗症</14>症状的便捷方法，或者对交感神经切开术患者有效，副作用很少。", "revised": true}
{"doc_key": "12535818", "sentences": [["Amiodarone", "and", "the", "risk", "of", "bradyarrhythmia", "requiring", "permanent", "pacemaker", "in", "elderly", "patients", "with", "atrial", "fibrillation", "and", "prior", "myocardial", "infarction", ".", "OBJECTIVES", ":", "The", "aim", "of", "this", "study", "was", "to", "determine", "whether", "the", "use", "of", "amiodarone", "in", "patients", "with", "atrial", "fibrillation", "(", "AF", ")", "increases", "the", "risk", "of", "bradyarrhythmia", "requiring", "a", "permanent", "pacemaker", ".", "BACKGROUND", ":", "Reports", "of", "severe", "bradyarrhythmia", "during", "amiodarone", "therapy", "are", "infrequent", "and", "limited", "to", "studies", "assessing", "the", "therapy", "'s", "use", "in", "the", "management", "of", "patients", "with", "ventricular", "arrhythmias", ".", "METHODS", ":", "A", "study", "cohort", "of", "8", ",", "770", "patients", "age", ">", "or", "=", "65", "years", "with", "a", "new", "diagnosis", "of", "AF", "was", "identified", "from", "a", "provincewide", "database", "of", "Quebec", "residents", "with", "a", "myocardial", "infarction", "(", "MI", ")", "between", "1991", "and", "1999", ".", "Using", "a", "nested", "case", "-", "control", "design", ",", "477", "cases", "of", "bradyarrhythmia", "requiring", "a", "permanent", "pacemaker", "were", "matched", "(", "1", ":", "4", ")", "to", "1", ",", "908", "controls", ".", "Multivariable", "logistic", "regression", "was", "used", "to", "estimate", "the", "odds", "ratio", "(", "OR", ")", "of", "pacemaker", "insertion", "associated", "with", "amiodarone", "use", ",", "controlling", "for", "baseline", "risk", "factors", "and", "exposure", "to", "sotalol", ",", "Class", "I", "antiarrhythmic", "agents", ",", "beta", "-", "blockers", ",", "calcium", "channel", "blockers", ",", "and", "digoxin", ".", "RESULTS", ":", "amiodarone", "use", "was", "associated", "with", "an", "increased", "risk", "of", "pacemaker", "insertion", "(", "OR", ":", "2", ".", "14", ",", "95", "%", "confidence", "interval", "[", "CI", "]", ":", "1", ".", "30", "to", "3", ".", "54", ")", ".", "This", "effect", "was", "modified", "by", "gender", ",", "with", "a", "greater", "risk", "in", "women", "versus", "men", "(", "OR", ":", "3", ".", "86", ",", "95", "%", "CI", ":", "1", ".", "70", "to", "8", ".", "75", "vs", ".", "OR", ":", "1", ".", "52", ",", "95", "%", "CI", ":", "0", ".", "80", "to", "2", ".", "89", ")", ".", "Digoxin", "was", "the", "only", "other", "medication", "associated", "with", "an", "increased", "risk", "of", "pacemaker", "insertion", "(", "OR", ":", "1", ".", "78", ",", "95", "%", "CI", ":", "1", ".", "37", "to", "2", ".", "31", ")", ".", "CONCLUSIONS", ":", "This", "study", "suggests", "that", "the", "use", "of", "amiodarone", "in", "elderly", "patients", "with", "AF", "and", "a", "previous", "MI", "increases", "the", "risk", "of", "bradyarrhythmia", "requiring", "a", "permanent", "pacemaker", ".", "The", "finding", "of", "an", "augmented", "risk", "of", "pacemaker", "insertion", "in", "elderly", "women", "receiving", "amiodarone", "requires", "further", "investigation", "."]], "ner": [[[0, 0, "Chemical"], [34, 34, "Chemical"], [60, 60, "Chemical"], [172, 172, "Chemical"], [203, 203, "Chemical"], [335, 335, "Chemical"], [368, 368, "Chemical"], [5, 5, "Disease"], [47, 47, "Disease"], [58, 58, "Disease"], [136, 136, "Disease"], [349, 349, "Disease"], [13, 14, "Disease"], [38, 39, "Disease"], [41, 41, "Disease"], [103, 103, "Disease"], [340, 340, "Disease"], [17, 18, "Disease"], [115, 116, "Disease"], [118, 118, "Disease"], [344, 344, "Disease"], [79, 80, "Disease"], [183, 183, "Chemical"], [194, 194, "Chemical"], [199, 199, "Chemical"], [292, 292, "Chemical"]]], "relations": [[[0, 0, 5, 5, "CID"], [0, 0, 47, 47, "CID"], [0, 0, 58, 58, "CID"], [0, 0, 136, 136, "CID"], [0, 0, 349, 349, "CID"], [34, 34, 5, 5, "CID"], [34, 34, 47, 47, "CID"], [34, 34, 58, 58, "CID"], [34, 34, 136, 136, "CID"], [34, 34, 349, 349, "CID"], [60, 60, 5, 5, "CID"], [60, 60, 47, 47, "CID"], [60, 60, 58, 58, "CID"], [60, 60, 136, 136, "CID"], [60, 60, 349, 349, "CID"], [172, 172, 5, 5, "CID"], [172, 172, 47, 47, "CID"], [172, 172, 58, 58, "CID"], [172, 172, 136, 136, "CID"], [172, 172, 349, 349, "CID"], [203, 203, 5, 5, "CID"], [203, 203, 47, 47, "CID"], [203, 203, 58, 58, "CID"], [203, 203, 136, 136, "CID"], [203, 203, 349, 349, "CID"], [335, 335, 5, 5, "CID"], [335, 335, 47, 47, "CID"], [335, 335, 58, 58, "CID"], [335, 335, 136, 136, "CID"], [335, 335, 349, 349, "CID"], [368, 368, 5, 5, "CID"], [368, 368, 47, 47, "CID"], [368, 368, 58, 58, "CID"], [368, 368, 136, 136, "CID"], [368, 368, 349, 349, "CID"]]], "clusters": [], "translated": " <0>胺碘酮</0>和<7>心动过缓</7>的风险：<12>心房颤动</12>和既往<17>心肌梗死</17>的老年患者需要永久性起搏器。目的：本研究的目的是确定<1>胺碘酮</1>在<13>心房颤动</13>（<14>AF</14>）患者中的使用是否会增加<8>缓慢性心律失常</8>需要永久起搏器。背景：在<2>胺碘酮</2>治疗期间出现严重<9>缓慢性心律失常</9>的报告并不常见，而且仅限于评估该疗法在治疗<21>室性心律失常</21>患者中的应用的研究。方法：从患有<18>心肌梗死</18>的魁北克全省居民数据库中确定了一个由8,770名年龄≥65岁且新诊断为<15>AF</15>的患者组成的研究队列（<19>MI</19>）1991年至1999年。使用嵌套病例对照设计，将477例需要永久性起搏器的<10>心动过缓</10>与1,908例对照进行匹配（1:4）。多变量logistic回归用于估计与<3>胺碘酮</3>使用相关的起搏器插入的比值比（OR），控制基线危险因素和接触<22>索他洛尔</22>，I类抗心律失常药物，β受体阻滞剂，<23>钙</23>通道阻滞剂和<24>地高辛</24>。结果：<4>胺碘酮</4>的使用与植入起搏器的风险增加相关（OR:2.14，95%置信区间[CI]:1.30至3.54）。这种影响因性别而异，女性比男性风险更大（OR:3.86，95%CI:1.70至8.75对比OR:1.52，95%CI:0.80至2.89）。<25>地高辛</25>是唯一与起搏器插入风险增加相关的其他药物（OR:1.78，95%CI:1.37至2.31）。结论：这项研究表明，在患有<16>AF</16>和既往<20>MI</20>的老年患者中使用<5>胺碘酮</5>会增加<11>心动过缓</11>需要永久起搏器。接受<6>胺碘酮</6>治疗的老年妇女植入起搏器的风险增加，这一发现需要进一步调查。", "revised": true}
{"doc_key": "14616590", "sentences": [["Pharmacological", "characteristics", "and", "side", "effects", "of", "a", "new", "galenic", "formulation", "of", "propofol", "without", "soyabean", "oil", ".", "We", "compared", "the", "pharmacokinetics", ",", "pharmacodynamics", "and", "safety", "profile", "of", "a", "new", "galenic", "formulation", "of", "propofol", "(", "AM149", "1", "%", ")", ",", "which", "does", "not", "contain", "soyabean", "oil", ",", "with", "a", "standard", "formulation", "of", "propofol", "(", "Disoprivan", "1", "%", ")", ".", "In", "a", "randomised", ",", "double", "-", "blind", ",", "cross", "-", "over", "study", ",", "30", "healthy", "volunteers", "received", "a", "single", "intravenous", "bolus", "injection", "of", "2", ".", "5", "mg", ".", "kg", "-", "1", "propofol", ".", "Plasma", "propofol", "levels", "were", "measured", "for", "48", "h", "following", "drug", "administration", "and", "evaluated", "according", "to", "a", "three", "-", "compartment", "model", ".", "The", "pharmacodynamic", "parameters", "assessed", "included", "induction", "and", "emergence", "times", ",", "respiratory", "and", "cardiovascular", "effects", ",", "and", "pain", "on", "injection", ".", "Patients", "were", "monitored", "for", "side", "effects", "over", "48", "h", ".", "Owing", "to", "a", "high", "incidence", "of", "thrombophlebitis", ",", "the", "study", "was", "terminated", "prematurely", "and", "only", "the", "data", "of", "the", "two", "parallel", "treatment", "groups", "(", "15", "patients", "in", "each", "group", ")", "were", "analysed", ".", "Plasma", "concentrations", "did", "not", "differ", "significantly", "between", "the", "two", "formulations", ".", "Anaesthesia", "induction", "and", "emergence", "times", ",", "respiratory", "and", "cardiovascular", "variables", "showed", "no", "significant", "differences", "between", "the", "two", "treatment", "groups", ".", "Pain", "on", "injection", "(", "80", "vs", ".", "20", "%", ",", "p", "<", "0", ".", "01", ")", "and", "thrombophlebitis", "(", "93", ".", "3", "vs", ".", "6", ".", "6", "%", ",", "p", "<", "0", ".", "001", ")", "occurred", "more", "frequently", "with", "AM149", "than", "with", "Disoprivan", ".", "Although", "both", "formulations", "had", "similar", "pharmacokinetic", "and", "pharmacodynamic", "profiles", "the", "new", "formulation", "is", "not", "suitable", "for", "clinical", "use", "due", "to", "the", "high", "incidence", "of", "thrombophlebitis", "produced", "."]], "ner": [[[11, 11, "Chemical"], [31, 31, "Chemical"], [50, 50, "Chemical"], [52, 52, "Chemical"], [88, 88, "Chemical"], [91, 91, "Chemical"], [247, 247, "Chemical"], [127, 127, "Disease"], [205, 205, "Disease"], [147, 147, "Disease"], [222, 222, "Disease"], [273, 273, "Disease"]]], "relations": [[[11, 11, 127, 127, "CID"], [11, 11, 205, 205, "CID"], [31, 31, 127, 127, "CID"], [31, 31, 205, 205, "CID"], [50, 50, 127, 127, "CID"], [50, 50, 205, 205, "CID"], [52, 52, 127, 127, "CID"], [52, 52, 205, 205, "CID"], [88, 88, 127, 127, "CID"], [88, 88, 205, 205, "CID"], [91, 91, 127, 127, "CID"], [91, 91, 205, 205, "CID"], [247, 247, 127, 127, "CID"], [247, 247, 205, 205, "CID"], [11, 11, 147, 147, "CID"], [11, 11, 222, 222, "CID"], [11, 11, 273, 273, "CID"], [31, 31, 147, 147, "CID"], [31, 31, 222, 222, "CID"], [31, 31, 273, 273, "CID"], [50, 50, 147, 147, "CID"], [50, 50, 222, 222, "CID"], [50, 50, 273, 273, "CID"], [52, 52, 147, 147, "CID"], [52, 52, 222, 222, "CID"], [52, 52, 273, 273, "CID"], [88, 88, 147, 147, "CID"], [88, 88, 222, 222, "CID"], [88, 88, 273, 273, "CID"], [91, 91, 147, 147, "CID"], [91, 91, 222, 222, "CID"], [91, 91, 273, 273, "CID"], [247, 247, 147, 147, "CID"], [247, 247, 222, 222, "CID"], [247, 247, 273, 273, "CID"]]], "clusters": [], "translated": "不含大豆油的<0>丙泊酚</0>新盖伦制剂的药理特性和副作用。我们比较了不含大豆油的<1>丙泊酚</1>（AM149 1%），与标准制剂的<2>丙泊酚</2>（<3>地索普利凡</3>1%）药代动力学、药效学和安全性概况。在一项随机、双盲、交叉研究中，30名健康志愿者接受了2.5毫克/kg-1<4>异丙酚</4>。给药后48小时内测量血浆<5>异丙酚</5>水平，并根据三室模型进行评估。评估的药效学参数包括诱导和出现时间、呼吸和心血管影响，以及注射时的<7>疼痛</7>。在48小时内监测患者的副作用。由于<9>血栓性静脉炎</9>发生率高，该研究提前终止，仅分析两个平行治疗组(每组15例患者)的数据。两种制剂的血浆浓度没有显着差异。麻醉诱导和苏醒时间、呼吸和心血管变量在两个治疗组之间没有显着差异。<8>注射时疼痛</8>(80% vs. 20%，p<0.01)和<10>血栓性静脉炎</10>(93.3% vs. 6.6%，p<0.001) AM149比<6> Disoprivan </6>更频繁。尽管这两种制剂具有相似的药代动力学和药效学特征，但由于<11>血栓性静脉炎</11>的高发生率，新制剂不适合临床使用。", "revised": true}
{"doc_key": "12359538", "sentences": [["Utility", "of", "troponin", "I", "in", "patients", "with", "cocaine", "-", "associated", "chest", "pain", ".", "Baseline", "electrocardiogram", "abnormalities", "and", "market", "elevations", "not", "associated", "with", "myocardial", "necrosis", "make", "accurate", "diagnosis", "of", "myocardial", "infarction", "(", "MI", ")", "difficult", "in", "patients", "with", "cocaine", "-", "associated", "chest", "pain", ".", "Troponin", "sampling", "may", "offer", "greater", "diagnostic", "utility", "in", "these", "patients", ".", "OBJECTIVE", ":", "To", "assess", "outcomes", "based", "on", "troponin", "positivity", "in", "patients", "with", "cocaine", "chest", "pain", "admitted", "for", "exclusion", "of", "MI", ".", "METHODS", ":", "Outcomes", "were", "examined", "in", "patients", "admitted", "for", "possible", "MI", "after", "cocaine", "use", ".", "All", "patients", "underwent", "a", "rapid", "rule", "-", "in", "protocol", "that", "included", "serial", "sampling", "of", "creatine", "kinase", "(", "CK", ")", ",", "CK", "-", "MB", ",", "and", "cardiac", "troponin", "I", "(", "cTnI", ")", "over", "eight", "hours", ".", "Outcomes", "included", "CK", "-", "MB", "MI", "(", "CK", "-", "MB", ">", "or", "=", "8", "ng", "/", "mL", "with", "a", "relative", "index", "[", "(", "CK", "-", "MB", "x", "100", ")", "/", "total", "CK", "]", ">", "or", "=", "4", ",", "cardiac", "death", ",", "and", "significant", "coronary", "disease", "(", ">", "or", "=", "50", "%", ")", ".", "RESULTS", ":", "Of", "the", "246", "admitted", "patients", ",", "34", "(", "14", "%", ")", "met", "CK", "-", "MB", "criteria", "for", "MI", "and", "38", "(", "16", "%", ")", "had", "cTnI", "elevations", ".", "Angiography", "was", "performed", "in", "29", "of", "38", "patients", "who", "were", "cTnI", "-", "positive", ",", "with", "significant", "disease", "present", "in", "25", "(", "86", "%", ")", ".", "Three", "of", "the", "four", "patients", "without", "significant", "disease", "who", "had", "cTnI", "elevations", "met", "CK", "-", "MB", "criteria", "for", "MI", ",", "and", "the", "other", "had", "a", "peak", "CK", "-", "MB", "level", "of", "13", "ng", "/", "mL", ".", "Sensitivities", ",", "specificities", ",", "and", "positive", "and", "negative", "likelihood", "ratios", "for", "predicting", "cardiac", "death", "or", "significant", "disease", "were", "high", "for", "both", "CK", "-", "MB", "MI", "and", "cTnI", "and", "were", "not", "significantly", "different", ".", "CONCLUSIONS", ":", "Most", "patients", "with", "cTnI", "elevations", "meet", "CK", "-", "MB", "criteria", "for", "MI", ",", "as", "well", "as", "have", "a", "high", "incidence", "of", "underlying", "significant", "disease", ".", "Troponin", "appears", "to", "have", "an", "equivalent", "diagnostic", "accuracy", "compared", "with", "CK", "-", "MB", "for", "diagnosing", "necrosis", "in", "patients", "with", "cocaine", "-", "associated", "chest", "pain", "and", "suspected", "MI", "."]], "ner": [[[7, 7, "Chemical"], [37, 37, "Chemical"], [66, 66, "Chemical"], [87, 87, "Chemical"], [348, 348, "Chemical"], [28, 29, "Disease"], [31, 31, "Disease"], [73, 73, "Disease"], [85, 85, "Disease"], [130, 130, "Disease"], [197, 197, "Disease"], [251, 251, "Disease"], [293, 293, "Disease"], [315, 315, "Disease"], [355, 355, "Disease"], [10, 11, "Disease"], [40, 41, "Disease"], [67, 68, "Disease"], [351, 352, "Disease"], [22, 23, "Disease"], [163, 164, "Disease"], [281, 282, "Disease"], [168, 169, "Disease"], [344, 344, "Disease"], [104, 104, "Chemical"]]], "relations": [[[7, 7, 28, 29, "CID"], [7, 7, 31, 31, "CID"], [7, 7, 73, 73, "CID"], [7, 7, 85, 85, "CID"], [7, 7, 130, 130, "CID"], [7, 7, 197, 197, "CID"], [7, 7, 251, 251, "CID"], [7, 7, 293, 293, "CID"], [7, 7, 315, 315, "CID"], [7, 7, 355, 355, "CID"], [37, 37, 28, 29, "CID"], [37, 37, 31, 31, "CID"], [37, 37, 73, 73, "CID"], [37, 37, 85, 85, "CID"], [37, 37, 130, 130, "CID"], [37, 37, 197, 197, "CID"], [37, 37, 251, 251, "CID"], [37, 37, 293, 293, "CID"], [37, 37, 315, 315, "CID"], [37, 37, 355, 355, "CID"], [66, 66, 28, 29, "CID"], [66, 66, 31, 31, "CID"], [66, 66, 73, 73, "CID"], [66, 66, 85, 85, "CID"], [66, 66, 130, 130, "CID"], [66, 66, 197, 197, "CID"], [66, 66, 251, 251, "CID"], [66, 66, 293, 293, "CID"], [66, 66, 315, 315, "CID"], [66, 66, 355, 355, "CID"], [87, 87, 28, 29, "CID"], [87, 87, 31, 31, "CID"], [87, 87, 73, 73, "CID"], [87, 87, 85, 85, "CID"], [87, 87, 130, 130, "CID"], [87, 87, 197, 197, "CID"], [87, 87, 251, 251, "CID"], [87, 87, 293, 293, "CID"], [87, 87, 315, 315, "CID"], [87, 87, 355, 355, "CID"], [348, 348, 28, 29, "CID"], [348, 348, 31, 31, "CID"], [348, 348, 73, 73, "CID"], [348, 348, 85, 85, "CID"], [348, 348, 130, 130, "CID"], [348, 348, 197, 197, "CID"], [348, 348, 251, 251, "CID"], [348, 348, 293, 293, "CID"], [348, 348, 315, 315, "CID"], [348, 348, 355, 355, "CID"]]], "clusters": [], "translated": "肌钙蛋白 I 在<0>可卡因</0>相关<15>胸痛</15>患者中的效用。与<1>可卡因</1>-相关的<16>胸痛</16>，使得与<5>心肌梗塞</5>（<6>MI</6>）患者的诊断变得困难，基线心电图异常和市场升高都不会与<19>心肌坏死</19>有关。肌钙蛋白取样可为这些患者提供更大的诊断效用。目的：评估因为<2>可卡因</2>相关<17>胸痛</17>而入院检查<7> MI </7>的患者的肌钙蛋白阳性结果。方法：对<3>可卡因</3>使用后可能出现<8>MI</8>的入院患者进行检查。所有患者都接受了一项快速调整方案，其中包括在8小时内对<24>肌酸</24>激酶（CK）、CK-MB和心肌肌钙蛋白I（cTnI）进行连续采样。结果包括CK-MB<9>MI</9>（CK-MB≥8ng/mL，相对指数[(CK-MBx100)/总CK]≥4，<20>心源性死亡</20>，和>50%的显著<22>冠状动脉疾病</22>）。结果：在246名入院患者中，34名（14％）符合CK-MB标准<10>MI</10>并且38（16％）的cTnI升高。在38名cTnI阳性患者中有29名进行了血管造影，25名（86％）有明显疾病。四名没有明显疾病但是cTnI升高的患者中有三名符合CK-<11>MI</11>的MB标准，另一个的CK-MB峰值水平为13ng/mL。预测<21>心源性死亡</21>的敏感性、特异性以及阳性和阴性似然比或显著疾病对于CK-MB<12>MI</12>和cTnI均较高，并且没有显着差异。结论：大多数cTnI升高的患者符合CK-MB<13>MI</13>标准，同时发病率很高由于潜在的重大疾病。与CK-MB相比，在诊断与<4>可卡因</4>相关<18>的胸痛</18>并疑似<14>心肌梗塞</14>患者的<23>坏死</23>方面，肌钙蛋白似乎具有相同的诊断准确性。", "revised": true}
{"doc_key": "15094729", "sentences": [["The", "natural", "history", "of", "Vigabatrin", "associated", "visual", "field", "defects", "in", "patients", "electing", "to", "continue", "their", "medication", ".", "PURPOSE", ":", "To", "determine", "the", "natural", "history", "of", "visual", "field", "defects", "in", "a", "group", "of", "patients", "known", "to", "have", "Vigabatrin", "-", "associated", "changes", "who", "elected", "to", "continue", "the", "medication", "because", "of", "good", "seizure", "control", ".", "METHODS", ":", "All", "patients", "taking", "Vigabatrin", "alone", "or", "in", "combination", "with", "other", "antiepileptic", "drugs", "for", "at", "least", "5", "years", "(", "range", "5", "-", "12", "years", ")", "were", "entered", "into", "a", "visual", "surveillance", "programme", ".", "Patients", "were", "followed", "up", "at", "6", "-", "monthly", "intervals", "for", "not", "less", "than", "18", "months", "(", "range", "18", "-", "43", "months", ")", ".", "In", "all", ",", "16", "patients", "with", "unequivocal", "defects", "continued", "the", "medication", ".", "Following", "already", "published", "methodology", "(", "Eye", "2002", ";", "16", ";", "567", "-", "571", ")", "monocular", "mean", "radial", "degrees", "(", "MRDs", ")", "to", "the", "I", "/", "4e", "isopter", "on", "Goldmann", "perimetry", "was", "calculated", "for", "the", "right", "eye", "at", "the", "time", "of", "discovery", "of", "a", "visual", "field", "defect", "and", "again", "after", "not", "less", "than", "18", "months", "follow", "-", "up", ".", "RESULTS", ":", "Mean", "right", "eye", "MRD", "at", "presentation", "was", "36", ".", "98", "degrees", "(", "range", "22", ".", "25", "-", "51", ".", "0", ")", ",", "compared", "to", "38", ".", "40", "degrees", "(", "range", "22", ".", "5", "-", "49", ".", "75", ")", "after", "follow", "-", "up", ";", "P", "=", "0", ".", "338", "unpaired", "t", "-", "test", ".", "Only", "one", "patient", "demonstrated", "a", "deterioration", "in", "visual", "field", "during", "the", "study", "period", "and", "discontinued", "treatment", ".", "CONCLUSION", ":", "Established", "visual", "field", "defects", "presumed", "to", "be", "due", "to", "Vigabatrin", "therapy", "did", "not", "usually", "progress", "in", "spite", "of", "continuing", "use", "of", "the", "medication", ".", "These", "data", "give", "support", "to", "the", "hypothesis", "that", "the", "pathogenesis", "of", "Vigabatrin", "-", "associated", "visual", "field", "defects", "may", "be", "an", "idiosyncratic", "adverse", "drug", "reaction", "rather", "than", "dose", "-", "dependent", "toxicity", "."]], "ner": [[[4, 4, "Chemical"], [36, 36, "Chemical"], [57, 57, "Chemical"], [262, 262, "Chemical"], [288, 288, "Chemical"], [6, 8, "Disease"], [25, 27, "Disease"], [164, 166, "Disease"], [239, 242, "Disease"], [254, 256, "Disease"], [291, 293, "Disease"], [49, 49, "Disease"], [306, 306, "Disease"]]], "relations": [[[4, 4, 6, 8, "CID"], [4, 4, 25, 27, "CID"], [4, 4, 164, 166, "CID"], [4, 4, 239, 242, "CID"], [4, 4, 254, 256, "CID"], [4, 4, 291, 293, "CID"], [36, 36, 6, 8, "CID"], [36, 36, 25, 27, "CID"], [36, 36, 164, 166, "CID"], [36, 36, 239, 242, "CID"], [36, 36, 254, 256, "CID"], [36, 36, 291, 293, "CID"], [57, 57, 6, 8, "CID"], [57, 57, 25, 27, "CID"], [57, 57, 164, 166, "CID"], [57, 57, 239, 242, "CID"], [57, 57, 254, 256, "CID"], [57, 57, 291, 293, "CID"], [262, 262, 6, 8, "CID"], [262, 262, 25, 27, "CID"], [262, 262, 164, 166, "CID"], [262, 262, 239, 242, "CID"], [262, 262, 254, 256, "CID"], [262, 262, 291, 293, "CID"], [288, 288, 6, 8, "CID"], [288, 288, 25, 27, "CID"], [288, 288, 164, 166, "CID"], [288, 288, 239, 242, "CID"], [288, 288, 254, 256, "CID"], [288, 288, 291, 293, "CID"]]], "clusters": [], "translated": "<0>氨己烯酸</0>的自然史与选择继续服药的患者<5>视野缺损</5>有关。目的：确定已知有<1>氨己烯酸</1>相关变化的一组患者中<6>视野缺损</6>的自然史，这些患者因良好的<11>癫痫发作而选择继续服药控制</11>。方法：所有服用<2>Vigabatrin</2>单独或与其他抗癫痫药物联合服用至少5年（范围5-12岁）的患者都被纳入视觉监测计划。患者每6个月随访一次，时间不少于18个月（范围18-43个月）。总共有16名有明确缺陷的患者继续服药。按照已经发表的方法（Eye 2002；16；567-571），在发现<7>视野缺损</7>时，测量右眼到I/4e等光周纹度（MRD），并在不少于18个月的随访后再次进行测量。结果：就诊时平均右眼MRD为36.98度（范围22.25-51.0），与后续随访的MRD 38.40度（范围22.5-49.75）相比，P=0.338（未配对t检验）。只有一名患者在研究期间视野<8>恶化</8>并停止了治疗。结论：已确立的<9>视野缺损</9>被推测是由于<3>氨己烯酸</3>治疗引起的，尽管继续使用药物，但通常不会进展。这些数据支持以下假设：<4>氨己烯酸</4>-相关<10>视野缺损</10>的发病机制可能是一种特殊的药物不良反应，而不是剂量依赖性<12>毒性</12>。", "revised": true}
{"doc_key": "15321332", "sentences": [["A", "case", "of", "postoperative", "anxiety", "due", "to", "low", "dose", "droperidol", "used", "with", "patient", "-", "controlled", "analgesia", ".", "A", "multiparous", "woman", "in", "good", "psychological", "health", "underwent", "urgent", "caesarean", "section", "in", "labour", ".", "Postoperatively", ",", "she", "was", "given", "a", "patient", "-", "controlled", "analgesia", "device", "delivering", "boluses", "of", "diamorphine", "0", ".", "5", "mg", "and", "droperidol", "0", ".", "025", "mg", ".", "Whilst", "using", "the", "device", "she", "gradually", "became", "anxious", ",", "the", "feeling", "worsening", "after", "each", "bolus", ".", "The", "diagnosis", "of", "droperidol", "-", "induced", "psychological", "disturbance", "was", "not", "made", "straight", "away", "although", "on", "subsequent", "close", "questioning", "the", "patient", "gave", "a", "very", "clear", "history", ".", "After", "she", "had", "received", "a", "total", "of", "only", "0", ".", "9", "mg", "droperidol", ",", "a", "syringe", "containing", "diamorphine", "only", "was", "substituted", "and", "her", "unease", "resolved", "completely", ".", "We", "feel", "that", ",", "although", "the", "dramatic", "extrapyramidal", "side", "effects", "of", "dopaminergic", "antiemetics", "are", "well", "known", ",", "more", "subtle", "manifestations", "may", "easily", "be", "overlooked", "."]], "ner": [[[9, 9, "Chemical"], [51, 51, "Chemical"], [76, 76, "Chemical"], [111, 111, "Chemical"], [4, 4, "Disease"], [79, 80, "Disease"], [45, 45, "Chemical"], [116, 116, "Chemical"]]], "relations": [[[9, 9, 4, 4, "CID"], [9, 9, 79, 80, "CID"], [51, 51, 4, 4, "CID"], [51, 51, 79, 80, "CID"], [76, 76, 4, 4, "CID"], [76, 76, 79, 80, "CID"], [111, 111, 4, 4, "CID"], [111, 111, 79, 80, "CID"]]], "clusters": [], "translated": "小剂量<0>氟哌利多</0>患者自控镇痛术后<4>焦虑</4>1例。一名心理健康的经产妇在分娩时接受了紧急剖腹产手术。术后，她接受了患者自控镇痛装置的注射<6>二吗啡</6> 0.5 mg和<1>氟哌利多</1> 0.025毫克。在使用该装置的过程中，她逐渐变得焦虑，每次推注后感觉都会恶化。诊断<2>氟哌利多</2>引起的<5>心理障碍</5>并没有立即做出，尽管在随后的密切询问中，患者给出了非常清楚的病史。在她收到之后一共只有0.9毫克<3>氟哌利多</3>，取代了仅含<7>二氢吗啡</7>的注射器，她的不安得到了彻底解决。我们认为，虽然多巴胺能止吐药显着的锥体外系副作用是众所周知的，但更微妙的表现很容易被忽视。", "revised": true}
{"doc_key": "14748761", "sentences": [["Vinorelbine", "-", "related", "cardiac", "events", ":", "a", "meta", "-", "analysis", "of", "randomized", "clinical", "trials", ".", "Several", "cases", "of", "cardiac", "adverse", "reactions", "related", "to", "vinorelbine", "(", "VNR", ")", "have", "been", "reported", "in", "the", "literature", ".", "In", "order", "to", "quantify", "the", "incidence", "of", "these", "cardiac", "events", ",", "we", "performed", "a", "meta", "-", "analysis", "of", "clinical", "trials", "comparing", "VNR", "with", "other", "chemotherapeutic", "agents", "in", "the", "treatment", "of", "various", "malignancies", ".", "Randomized", "clinical", "trials", "comparing", "VNR", "with", "other", "drugs", "in", "the", "treatment", "of", "cancer", "were", "searched", "in", "Medline", ",", "Embase", ",", "Evidence", "-", "based", "Medicine", "Reviews", "databases", "and", "the", "Cochrane", "library", "from", "1987", "to", "2002", ".", "Outcomes", "of", "interest", "were", "severe", "cardiac", "events", ",", "toxic", "deaths", "and", "cardiac", "event", "-", "related", "deaths", "reported", "in", "each", "publication", ".", "We", "found", "19", "trials", ",", "involving", "2441", "patients", "treated", "by", "VNR", "and", "2050", "control", "patients", ".", "The", "incidence", "of", "cardiac", "events", "with", "VNR", "was", "1", ".", "19", "%", "[", "95", "%", "confidence", "interval", "(", "CI", ")", "(", "0", ".", "75", ";", "1", ".", "67", ")", "]", ".", "There", "was", "no", "difference", "in", "the", "risk", "of", "cardiac", "events", "between", "VNR", "and", "other", "drugs", "[", "odds", "ratio", ":", "0", ".", "92", ",", "95", "%", "CI", "(", "0", ".", "54", ";", "1", ".", "55", ")", "]", ".", "The", "risk", "of", "VNR", "cardiac", "events", "was", "similar", "to", "vindesine", "(", "VDS", ")", "and", "other", "cardiotoxic", "drugs", "[", "fluorouracil", ",", "anthracyclines", ",", "gemcitabine", "(", "GEM", ")", "em", "leader", "]", ".", "Even", "if", "it", "did", "not", "reach", "statistical", "significance", "because", "of", "a", "few", "number", "of", "cases", ",", "the", "risk", "was", "lower", "in", "trials", "excluding", "patients", "with", "cardiac", "history", ",", "and", "seemed", "to", "be", "higher", "in", "trials", "including", "patients", "with", "pre", "-", "existing", "cardiac", "diseases", ".", "Vinorelbine", "-", "related", "cardiac", "events", "concern", "about", "1", "%", "of", "treated", "patients", "in", "clinical", "trials", ".", "However", ",", "the", "risk", "associated", "with", "VNR", "seems", "to", "be", "similar", "to", "that", "of", "other", "chemotherapeutic", "agents", "in", "the", "same", "indications", "."]], "ner": [[[0, 0, "Chemical"], [23, 23, "Chemical"], [25, 25, "Chemical"], [55, 55, "Chemical"], [71, 71, "Chemical"], [133, 133, "Chemical"], [145, 145, "Chemical"], [181, 181, "Chemical"], [210, 210, "Chemical"], [281, 281, "Chemical"], [303, 303, "Chemical"], [222, 222, "Disease"], [65, 65, "Disease"], [79, 79, "Disease"], [278, 279, "Disease"], [216, 216, "Chemical"], [218, 218, "Chemical"], [225, 225, "Chemical"], [227, 227, "Chemical"], [229, 229, "Chemical"], [231, 231, "Chemical"]]], "relations": [[[0, 0, 222, 222, "CID"], [23, 23, 222, 222, "CID"], [25, 25, 222, 222, "CID"], [55, 55, 222, 222, "CID"], [71, 71, 222, 222, "CID"], [133, 133, 222, 222, "CID"], [145, 145, 222, 222, "CID"], [181, 181, 222, 222, "CID"], [210, 210, 222, 222, "CID"], [281, 281, 222, 222, "CID"], [303, 303, 222, 222, "CID"]]], "clusters": [], "translated": "<0>长春瑞滨</0> 相关的心脏事件：随机临床试验的荟萃分析。文献中报道了几例与<1>长春瑞滨</1>（<2>VNR</2>）相关的心脏不良反应。为了量化这些心脏事件的发生率，我们对比较<3>VNR</3>与其他化疗药物治疗各种<12>恶性肿瘤</12>的临床试验进行了荟萃分析。从1987年到2002年，在Medline、Embase、循证医学评论数据库和Cochrane图书馆中搜索了比较<4>VNR</4>和其他药物治疗<13>癌症</13>的随机临床试验。感兴趣的结果是每份出版物中报告的严重心脏事件、毒性死亡和与心脏事件相关的死亡。我们找到了19项试验，涉及2441名接受<5>VNR</5>治疗的患者和2050名对照患者。<6>VNR</6>的心脏事件发生率为1.19% [95%置信区间（CI）（0.75;1.67）]。<7>VNR</7>与其他药物之间的心脏事件风险没有差异[比值比：0.92，95% CI（0.54;1.55）]。<8>VNR</8>心脏事件的风险与<15>长春地辛</15>（<16>VDS</16>）和其他<11>心脏毒性</11>药物相似[<17>氟尿嘧啶</17>，<18>蒽环类药物</18>，<19>吉西他滨</19>（<20>GEM</20>）em leader]。即使由于病例数少而没有达到统计学显着性，但在排除有心脏病史患者的试验中风险较低，而在包括既往有<14>心脏病</14>的患者的试验中风险似乎更高。<9>长春瑞滨</9>相关的心脏事件涉及临床试验中大约1%的接受治疗的患者。然而，与<10>VNR</10>相关的风险似乎与相同适应症的其他化疗药物相似。", "revised": true}
{"doc_key": "12523489", "sentences": [["Cocaine", "-", "induced", "hyperactivity", "is", "more", "influenced", "by", "adenosine", "receptor", "agonists", "than", "amphetamine", "-", "induced", "hyperactivity", ".", "The", "influence", "of", "adenosine", "receptor", "agonists", "and", "antagonists", "on", "cocaine", "-", "and", "amphetamine", "-", "induced", "hyperactivity", "was", "examined", "in", "mice", ".", "All", "adenosine", "receptor", "agonists", "significantly", "decreased", "the", "locomotor", "activity", "in", "mice", ",", "and", "the", "effects", "were", "dose", "-", "dependent", ".", "It", "seems", "that", "adenosine", "A1", "and", "A2", "receptors", "might", "be", "involved", "in", "this", "reaction", ".", "Moreover", ",", "all", "adenosine", "receptor", "agonists", ":", "2", "-", "p", "-", "(", "2", "-", "carboxyethyl", ")", "phenethylamino", "-", "5", "'", "-", "N", "-", "ethylcarboxamidoadenosine", "(", "CGS", "21680", ")", ",", "A2A", "receptor", "agonist", ",", "N6", "-", "cyclopentyladenosine", "(", "CPA", ")", ",", "A1", "receptor", "agonist", ",", "and", "5", "'", "-", "N", "-", "ethylcarboxamidoadenosine", "(", "NECA", ")", ",", "A2", "/", "A1", "receptor", "agonist", "significantly", "and", "dose", "-", "dependently", "decreased", "cocaine", "-", "induced", "locomotor", "activity", ".", "CPA", "reduced", "cocaine", "action", "at", "the", "doses", "which", ",", "given", "alone", ",", "did", "not", "influence", "motility", ",", "while", "CGS", "21680", "and", "NECA", "decreased", "the", "action", "of", "cocaine", "at", "the", "doses", "which", ",", "given", "alone", ",", "decreased", "locomotor", "activity", "in", "animals", ".", "These", "results", "suggest", "the", "involvement", "of", "both", "adenosine", "receptors", "in", "the", "action", "of", "cocaine", "although", "agonists", "of", "A1", "receptors", "seem", "to", "have", "stronger", "influence", "on", "it", ".", "The", "selective", "blockade", "of", "A2", "adenosine", "receptor", "by", "DMPX", "(", "3", ",", "7", "-", "dimethyl", "-", "1", "-", "propargylxanthine", ")", "significantly", "enhanced", "cocaine", "-", "induced", "locomotor", "activity", "of", "animals", ".", "Caffeine", "had", "similar", "action", "but", "the", "effect", "was", "not", "significant", ".", "CPT", "(", "8", "-", "cyclopentyltheophylline", ")", "-", "-", "A1", "receptor", "antagonist", ",", "did", "not", "show", "any", "influence", "in", "this", "test", ".", "Similarly", ",", "all", "adenosine", "receptor", "agonists", "decreased", "amphetamine", "-", "induced", "hyperactivity", ",", "but", "at", "the", "higher", "doses", "than", "those", "which", "were", "active", "in", "cocaine", "-", "induced", "hyperactivity", ".", "The", "selective", "blockade", "of", "A2", "adenosine", "receptors", "(", "DMPX", ")", "and", "non", "-", "selective", "blockade", "of", "adenosine", "receptors", "(", "caffeine", ")", "significantly", "increased", "the", "action", "of", "amphetamine", "in", "the", "locomotor", "activity", "test", ".", "Our", "results", "have", "shown", "that", "all", "adenosine", "receptor", "agonists", "(", "A1", "and", "A2", ")", "reduce", "cocaine", "-", "and", "amphetamine", "-", "induced", "locomotor", "activity", "and", "indicate", "that", "cocaine", "-", "induced", "hyperactivity", "is", "more", "influenced", "by", "adenosine", "receptor", "agonists", "(", "particularly", "A1", "receptors", ")", "than", "amphetamine", "-", "induced", "hyperactivity", "."]], "ner": [[[0, 0, "Chemical"], [26, 26, "Chemical"], [139, 139, "Chemical"], [147, 147, "Chemical"], [171, 171, "Chemical"], [199, 199, "Chemical"], [235, 235, "Chemical"], [298, 298, "Chemical"], [351, 351, "Chemical"], [362, 362, "Chemical"], [43, 46, "Disease"], [12, 12, "Chemical"], [29, 29, "Chemical"], [282, 282, "Chemical"], [329, 329, "Chemical"], [354, 354, "Chemical"], [379, 379, "Chemical"], [221, 221, "Chemical"], [223, 231, "Chemical"], [311, 311, "Chemical"], [3, 3, "Disease"], [15, 15, "Disease"], [32, 32, "Disease"], [285, 285, "Disease"], [301, 301, "Disease"], [365, 365, "Disease"], [382, 382, "Disease"], [8, 8, "Chemical"], [20, 20, "Chemical"], [39, 39, "Chemical"], [61, 61, "Chemical"], [76, 76, "Chemical"], [193, 193, "Chemical"], [218, 218, "Chemical"], [278, 278, "Chemical"], [308, 308, "Chemical"], [319, 319, "Chemical"], [342, 342, "Chemical"], [370, 370, "Chemical"], [80, 96, "Chemical"], [98, 99, "Chemical"], [163, 164, "Chemical"], [106, 108, "Chemical"], [110, 110, "Chemical"], [145, 145, "Chemical"], [118, 123, "Chemical"], [125, 125, "Chemical"], [166, 166, "Chemical"], [243, 243, "Chemical"], [322, 322, "Chemical"], [254, 254, "Chemical"], [256, 258, "Chemical"]]], "relations": [[[0, 0, 43, 46, "CID"], [26, 26, 43, 46, "CID"], [139, 139, 43, 46, "CID"], [147, 147, 43, 46, "CID"], [171, 171, 43, 46, "CID"], [199, 199, 43, 46, "CID"], [235, 235, 43, 46, "CID"], [298, 298, 43, 46, "CID"], [351, 351, 43, 46, "CID"], [362, 362, 43, 46, "CID"], [12, 12, 43, 46, "CID"], [29, 29, 43, 46, "CID"], [282, 282, 43, 46, "CID"], [329, 329, 43, 46, "CID"], [354, 354, 43, 46, "CID"], [379, 379, 43, 46, "CID"], [221, 221, 43, 46, "CID"], [223, 231, 43, 46, "CID"], [311, 311, 43, 46, "CID"]]], "clusters": [], "translated": " <0>可卡因</0>-诱发的<20>多动</20>比<11>苯丙胺</11>-诱发的<21>多动</21>更受<27>腺苷</27>受体激动剂的影响。 <28>腺苷</28>受体激动剂和拮抗剂对<1>可卡因</1>和<12>苯丙胺</12>诱导的<22>多动症</22>小鼠的影响。所有<29>腺苷</29>受体激动剂均能显着<10>降低小鼠的自发活动</10>，且作用呈剂量依赖性。看来<30>腺苷</30>A1和A2受体可能参与了这个反应。此外，所有<31>腺苷</31>受体激动剂：<39>2-p-(2-羧乙基)苯乙氨基-5'-N-乙基甲酰氨基腺苷</39>（<40>CGS 21680</40>），A2A受体激动剂、<42>N6-环戊基腺苷</42>（<43>CPA</43>），A1受体激动剂、<45>5'-N-乙基甲酰氨基腺苷</45>（<46>NECA</46>），A2/A1受体激动剂可显着且剂量依赖性地降低<2>可卡因</2>诱导的运动活性。 <44>CPA</44>降低了<3>可卡因</3>的作用，单独给予的剂量不影响动力，而<41>CGS 21680</41>和<47>NECA</47>降低<4>可卡因</4>的作用，其剂量单独给予会降低动物的运动活动。这些结果表明<32>腺苷</32>受体参与了<5>可卡因</5>的作用，尽管A1受体的激动剂似乎对其有更强的影响。<17>DMPX</17>（<18>3,7-二甲基-1-炔丙基黄嘌呤</18>）选择性阻断A2<33>腺苷</33>受体显著增强<6>可卡因</6>-诱导动物的运动活动。<48>咖啡因</48>有类似作用，但效果不显着。<50>CPT</50>（<51>8-环戊基茶碱</51>）--A1受体拮抗剂，在本试验中无影响。同样，所有<34>腺苷</34>受体激动剂均能降低<13>苯丙胺</13>引起的<23>多动症</23>，但剂量高于那些在<7>可卡因</7>-诱发<24>多动</24>有活性的剂量。选择性阻断A2<35>腺苷</35>受体（<19>DMPX</19>）和非选择性阻断<36>腺苷</36>受体（<49>咖啡因</49>）显着在运动活动测试中增加了<14>苯丙胺</14>的作用。我们的结果表明，所有<37>腺苷</37>受体激动剂（A1和A2）都会减少<8>可卡因</8>-和<15>苯丙胺</15>-诱导的运动活性，并表明<9>可卡因</9>-诱发的<25>多动症</25>比<16>苯丙胺</16>-诱发的<26>多动症</26>更受<38>腺苷</38>受体激动剂（特别是A1受体）的影响更大。", "revised": true}
{"doc_key": "15265979", "sentences": [["Disruption", "of", "hepatic", "lipid", "homeostasis", "in", "mice", "after", "amiodarone", "treatment", "is", "associated", "with", "peroxisome", "proliferator", "-", "activated", "receptor", "-", "alpha", "target", "gene", "activation", ".", "Amiodarone", ",", "an", "efficacious", "and", "widely", "used", "antiarrhythmic", "agent", ",", "has", "been", "reported", "to", "cause", "hepatotoxicity", "in", "some", "patients", ".", "To", "gain", "insight", "into", "the", "mechanism", "of", "this", "unwanted", "effect", ",", "mice", "were", "administered", "various", "doses", "of", "amiodarone", "and", "examined", "for", "changes", "in", "hepatic", "histology", "and", "gene", "regulation", ".", "Amiodarone", "induced", "hepatomegaly", ",", "hepatocyte", "microvesicular", "lipid", "accumulation", ",", "and", "a", "significant", "decrease", "in", "serum", "triglycerides", "and", "glucose", ".", "Northern", "blot", "analysis", "of", "hepatic", "RNA", "revealed", "a", "dose", "-", "dependent", "increase", "in", "the", "expression", "of", "a", "number", "of", "genes", "critical", "for", "fatty", "acid", "oxidation", ",", "lipoprotein", "assembly", ",", "and", "lipid", "transport", ".", "Many", "of", "these", "genes", "are", "regulated", "by", "the", "peroxisome", "proliferator", "-", "activated", "receptor", "-", "alpha", "(", "PPARalpha", ")", ",", "a", "ligand", "-", "activated", "nuclear", "hormone", "receptor", "transcription", "factor", ".", "The", "absence", "of", "induction", "of", "these", "genes", "as", "well", "as", "hepatomegaly", "in", "PPARalpha", "knockout", "[", "PPARalpha", "-", "/", "-", "]", "mice", "indicated", "that", "the", "effects", "of", "amiodarone", "were", "dependent", "upon", "the", "presence", "of", "a", "functional", "PPARalpha", "gene", ".", "Compared", "to", "wild", "-", "type", "mice", ",", "treatment", "of", "PPARalpha", "-", "/", "-", "mice", "with", "amiodarone", "resulted", "in", "an", "increased", "rate", "and", "extent", "of", "total", "body", "weight", "loss", ".", "The", "inability", "of", "amiodarone", "to", "directly", "activate", "either", "human", "or", "mouse", "PPARalpha", "transiently", "expressed", "in", "human", "HepG2", "hepatoma", "cells", "indicates", "that", "the", "effects", "of", "amiodarone", "on", "the", "function", "of", "this", "receptor", "were", "indirect", ".", "Based", "upon", "these", "results", ",", "we", "conclude", "that", "amiodarone", "disrupts", "hepatic", "lipid", "homeostasis", "and", "that", "the", "increased", "expression", "of", "PPARalpha", "target", "genes", "is", "secondary", "to", "this", "toxic", "effect", ".", "These", "results", "provide", "important", "new", "mechanistic", "information", "regarding", "the", "hepatotoxic", "effects", "of", "amiodarone", "and", "indicate", "that", "PPARalpha", "protects", "against", "amiodarone", "-", "induced", "hepatotoxicity", "."]], "ner": [[[8, 8, "Chemical"], [24, 24, "Chemical"], [61, 61, "Chemical"], [73, 73, "Chemical"], [180, 180, "Chemical"], [207, 207, "Chemical"], [224, 224, "Chemical"], [245, 245, "Chemical"], [263, 263, "Chemical"], [296, 296, "Chemical"], [303, 303, "Chemical"], [39, 39, "Disease"], [293, 293, "Disease"], [306, 306, "Disease"], [75, 75, "Disease"], [164, 164, "Disease"], [218, 219, "Disease"], [238, 238, "Disease"], [88, 88, "Chemical"], [90, 90, "Chemical"], [114, 115, "Chemical"]]], "relations": [[[8, 8, 39, 39, "CID"], [8, 8, 293, 293, "CID"], [8, 8, 306, 306, "CID"], [24, 24, 39, 39, "CID"], [24, 24, 293, 293, "CID"], [24, 24, 306, 306, "CID"], [61, 61, 39, 39, "CID"], [61, 61, 293, 293, "CID"], [61, 61, 306, 306, "CID"], [73, 73, 39, 39, "CID"], [73, 73, 293, 293, "CID"], [73, 73, 306, 306, "CID"], [180, 180, 39, 39, "CID"], [180, 180, 293, 293, "CID"], [180, 180, 306, 306, "CID"], [207, 207, 39, 39, "CID"], [207, 207, 293, 293, "CID"], [207, 207, 306, 306, "CID"], [224, 224, 39, 39, "CID"], [224, 224, 293, 293, "CID"], [224, 224, 306, 306, "CID"], [245, 245, 39, 39, "CID"], [245, 245, 293, 293, "CID"], [245, 245, 306, 306, "CID"], [263, 263, 39, 39, "CID"], [263, 263, 293, 293, "CID"], [263, 263, 306, 306, "CID"], [296, 296, 39, 39, "CID"], [296, 296, 293, 293, "CID"], [296, 296, 306, 306, "CID"], [303, 303, 39, 39, "CID"], [303, 303, 293, 293, "CID"], [303, 303, 306, 306, "CID"], [8, 8, 75, 75, "CID"], [8, 8, 164, 164, "CID"], [24, 24, 75, 75, "CID"], [24, 24, 164, 164, "CID"], [61, 61, 75, 75, "CID"], [61, 61, 164, 164, "CID"], [73, 73, 75, 75, "CID"], [73, 73, 164, 164, "CID"], [180, 180, 75, 75, "CID"], [180, 180, 164, 164, "CID"], [207, 207, 75, 75, "CID"], [207, 207, 164, 164, "CID"], [224, 224, 75, 75, "CID"], [224, 224, 164, 164, "CID"], [245, 245, 75, 75, "CID"], [245, 245, 164, 164, "CID"], [263, 263, 75, 75, "CID"], [263, 263, 164, 164, "CID"], [296, 296, 75, 75, "CID"], [296, 296, 164, 164, "CID"], [303, 303, 75, 75, "CID"], [303, 303, 164, 164, "CID"]]], "clusters": [], "translated": "<0>胺碘酮</0>治疗后小鼠肝脏脂质稳态的破坏与过氧化物酶体增殖物激活受体-α靶基因激活有关。<1>胺碘酮</1>是一种有效且广泛使用的抗心律失常药，据报道它会在一些患者中引起<11>肝毒性</11>。为了深入了解这种不利影响的机制，给小鼠注射了不同剂量的<2>胺碘酮</2>，并检查了肝脏组织学和基因调控的变化。<3>胺碘酮</3>引起<14>肝肿大</14>，肝细胞微泡脂质堆积，血清<18>甘油三酯</18>和<19>葡萄糖</19>显着降低。肝RNA的Northern印迹分析显示，许多对<20>脂肪酸</20>氧化，脂蛋白组装和脂质转运至关重要的基因表达呈剂量依赖性增加。其中许多基因受过氧化物酶体增殖物激活受体-α (PPARalpha)的调节，PPARalpha是一种配体激活的核激素受体转录因子。在 PPARalpha 敲除 [PPARalpha-/-] 小鼠中没有诱导这些基因以及<15>肝肿大</15>表明<4>胺碘酮</4>的作用取决于功能性 PPARalpha的存在基因。与野生型小鼠相比，用<5>胺碘酮</5>治疗 PPARalpha -/- 小鼠导致全身<16>体重减轻</16>的速度和程度增加。<6>胺碘酮</6>不能直接激活在人 HepG2 <17>肝癌</17>细胞中瞬时表达的人或小鼠 PPARalpha，这表明<7>胺碘酮</7>对这种受体是间接的。基于这些结果，我们得出结论，<8>胺碘酮</8>会破坏肝脏脂质体内平衡，并且 PPARalpha 靶基因的表达增加是这种毒性作用的次要因素。这些结果提供了有关<9>胺碘酮</9>的<12>肝毒性</12>作用的重要新机制信息，并表明 PPARalpha 可防止<10>胺碘酮</10>诱导的<13>肝毒性</13>。", "revised": true}
{"doc_key": "15366550", "sentences": [["Accurate", "patient", "history", "contributes", "to", "differentiating", "diabetes", "insipidus", ":", "a", "case", "study", ".", "This", "case", "study", "highlights", "the", "important", "contribution", "of", "nursing", "in", "obtaining", "an", "accurate", "health", "history", ".", "The", "case", "discussed", "herein", "initially", "appeared", "to", "be", "neurogenic", "diabetes", "insipidus", "(", "DI", ")", "secondary", "to", "a", "traumatic", "brain", "injury", ".", "The", "nursing", "staff", ",", "by", "reviewing", "the", "patient", "'s", "health", "history", "with", "his", "family", ",", "discovered", "a", "history", "of", "polydipsia", "and", "long", "-", "standing", "lithium", "use", ".", "Lithium", "is", "implicated", "in", "drug", "-", "induced", "nephrogenic", "DI", ",", "and", "because", "the", "patient", "had", "not", "received", "lithium", "since", "being", "admitted", "to", "the", "hospital", ",", "his", "treatment", "changed", "to", "focus", "on", "nephrogenic", "DI", ".", "By", "combining", "information", "from", "the", "patient", "history", ",", "the", "physical", "examination", ",", "and", "radiologic", "and", "laboratory", "studies", ",", "the", "critical", "care", "team", "demonstrated", "that", "the", "patient", "had", "been", "self", "-", "treating", "his", "lithium", "-", "induced", "nephrogenic", "DI", "and", "developed", "neurogenic", "DI", "secondary", "to", "brain", "trauma", ".", "Thus", "successful", "treatment", "required", "that", "nephrogenic", "and", "neurogenic", "DI", "be", "treated", "concomitantly", "."]], "ner": [[[74, 74, "Chemical"], [77, 77, "Chemical"], [94, 94, "Chemical"], [143, 143, "Chemical"], [37, 39, "Disease"], [84, 85, "Disease"], [108, 109, "Disease"], [146, 147, "Disease"], [150, 151, "Disease"], [164, 165, "Disease"], [6, 7, "Disease"], [41, 41, "Disease"], [46, 48, "Disease"], [154, 155, "Disease"], [69, 69, "Disease"]]], "relations": [[[74, 74, 37, 39, "CID"], [74, 74, 84, 85, "CID"], [74, 74, 108, 109, "CID"], [74, 74, 146, 147, "CID"], [74, 74, 150, 151, "CID"], [74, 74, 164, 165, "CID"], [77, 77, 37, 39, "CID"], [77, 77, 84, 85, "CID"], [77, 77, 108, 109, "CID"], [77, 77, 146, 147, "CID"], [77, 77, 150, 151, "CID"], [77, 77, 164, 165, "CID"], [94, 94, 37, 39, "CID"], [94, 94, 84, 85, "CID"], [94, 94, 108, 109, "CID"], [94, 94, 146, 147, "CID"], [94, 94, 150, 151, "CID"], [94, 94, 164, 165, "CID"], [143, 143, 37, 39, "CID"], [143, 143, 84, 85, "CID"], [143, 143, 108, 109, "CID"], [143, 143, 146, 147, "CID"], [143, 143, 150, 151, "CID"], [143, 143, 164, 165, "CID"]]], "clusters": [], "translated": "准确的病史有助于鉴别<10>尿崩症</10>：一个案例研究。这个案例研究强调了护理在获得准确健康史方面的重要贡献。此处讨论的病例最初似乎是继发于<12>创伤性脑损伤</12>的<4>神经源性尿崩症</4>（<11>DI</11>）。护理人员通过与家人一起回顾患者的健康史，发现有<14>烦渴</14>和长期<0>锂</0>使用史。<1>锂</1>与药物性<5>肾源性尿崩症</5>有关，因患者入院后未服用<2>锂</2>，治疗改为关注<6>肾源性尿崩症</6>。通过结合来自患者病史、体格检查、放射学和实验室研究的信息，重症监护小组证明患者一直在自我治疗他的<3>锂</3>-诱发的<7>肾源性尿崩症</7>继发于<13>脑外伤</13>并发展为<8>神经源性尿崩症</8>。因此，成功的治疗需要同时治疗肾源性和<9>神经源性尿崩症</9>。", "revised": true}
{"doc_key": "10975596", "sentences": [["Hemodynamic", "and", "antiadrenergic", "effects", "of", "dronedarone", "and", "amiodarone", "in", "animals", "with", "a", "healed", "myocardial", "infarction", ".", "The", "hemodynamic", "and", "antiadrenergic", "effects", "of", "dronedarone", ",", "a", "noniodinated", "compound", "structurally", "related", "to", "amiodarone", ",", "were", "compared", "with", "those", "of", "amiodarone", "after", "prolonged", "oral", "administration", ",", "both", "at", "rest", "and", "during", "sympathetic", "stimulation", "in", "conscious", "dogs", "with", "a", "healed", "myocardial", "infarction", ".", "All", "dogs", "(", "n", "=", "6", ")", "randomly", "received", "orally", "dronedarone", "(", "10", "and", "30", "mg", "/", "kg", ")", ",", "amiodarone", "(", "10", "and", "30", "mg", "/", "kg", ")", ",", "and", "placebo", "twice", "daily", "for", "7", "days", ",", "with", "a", "3", "-", "week", "washout", "between", "consecutive", "treatments", ".", "Heart", "rate", "(", "HR", ")", ",", "mean", "arterial", "pressure", "(", "MBP", ")", ",", "positive", "rate", "of", "increase", "of", "left", "ventricular", "pressure", "(", "+", "LVdP", "/", "dt", ")", ",", "echocardiographically", "assessed", "left", "ventricular", "ejection", "fraction", "(", "LVEF", ")", ",", "and", "fractional", "shortening", "(", "FS", ")", ",", "as", "well", "as", "chronotropic", "response", "to", "isoproterenol", "and", "exercise", "-", "induced", "sympathetic", "stimulation", "were", "evaluated", "under", "baseline", "and", "posttreatment", "conditions", ".", "Resting", "values", "of", "LVEF", ",", "FS", ",", "+", "LVdP", "/", "dt", ",", "and", "MBP", "remained", "unchanged", "whatever", "the", "drug", "and", "the", "dosing", "regimen", ",", "whereas", "resting", "HR", "was", "significantly", "and", "dose", "-", "dependently", "lowered", "after", "dronedarone", "and", "to", "a", "lesser", "extent", "after", "amiodarone", ".", "Both", "dronedarone", "and", "amiodarone", "significantly", "reduced", "the", "exercise", "-", "induced", "tachycardia", "and", ",", "at", "the", "highest", "dose", ",", "decreased", "the", "isoproterenol", "-", "induced", "tachycardia", ".", "Thus", ",", "dronedarone", "and", "amiodarone", "displayed", "a", "similar", "level", "of", "antiadrenergic", "effect", "and", "did", "not", "impair", "the", "resting", "left", "ventricular", "function", ".", "Consequently", ",", "dronedarone", "might", "be", "particularly", "suitable", "for", "the", "treatment", "and", "prevention", "of", "various", "clinical", "arrhythmias", ",", "without", "compromising", "the", "left", "ventricular", "function", "."]], "ner": [[[158, 158, "Chemical"], [237, 237, "Chemical"], [227, 227, "Disease"], [240, 240, "Disease"], [5, 5, "Chemical"], [22, 22, "Chemical"], [69, 69, "Chemical"], [208, 208, "Chemical"], [218, 218, "Chemical"], [244, 244, "Chemical"], [266, 266, "Chemical"], [13, 14, "Disease"], [56, 57, "Disease"], [279, 279, "Disease"], [7, 7, "Chemical"], [30, 30, "Chemical"], [37, 37, "Chemical"], [79, 79, "Chemical"], [215, 215, "Chemical"], [220, 220, "Chemical"], [246, 246, "Chemical"]]], "relations": [[[158, 158, 227, 227, "CID"], [158, 158, 240, 240, "CID"], [237, 237, 227, 227, "CID"], [237, 237, 240, 240, "CID"]]], "clusters": [], "translated": "<4>决奈达隆</4>和<14>胺碘酮</14>对已治愈的<11>心肌梗塞</11>动物的血液动力学和抗肾上腺素能作用。与<15>胺碘酮</15>结构相关的非碘化化合物<5>决奈达隆</5>与<16>胺碘酮</16>长期口服给药后的血流动力学和抗肾上腺素能作用进行了比较，均在<12>心肌梗死已痊愈</12>的有意识的狗在休息和交感神经刺激期间。所有狗（<n>6</n>）随机接受口服<6>决奈达隆</6>（10和30毫克/公斤），<17>胺碘酮</17>（10和30毫克/公斤）和安慰剂，每天两次，持续7天，连续治疗之间有3周的清除期。心率（HR）、平均动脉压（MBP）、左心室压力正增加率（+LVdP/dt）、超声心动图评估的左心室射血分数（LVEF）和缩短分数（FS），以及变时反应对<0>异丙肾上腺素</0>和运动引起的交感神经刺激在基线和治疗后条件下进行了评估。无论药物和给药方案如何，静息LVEF、FS、+LVdP/dt和MBP的值都保持不变，而静息HR在<7>决奈达隆</7>后显着且剂量依赖性降低，并且在<18>胺碘酮</18>后程度较小。同时，<8>决奈达隆</8>和<19>胺碘酮</19>均显着降低了运动引起的<2>心动过速</2>并且在最高剂量下，降低了<1>异丙肾上腺素诱发的</1><3>心动过速</3>。因此，<9>决奈达隆</9>和<20>胺碘酮</20>表现出相似水平的抗肾上腺素能作用，并且不损害静息左心室功能。因此，<10>决奈达隆</10>可能特别适用于临床上各种<13>心律失常</13>的治疗和预防，且不会损害左心室功能。", "revised": true}
{"doc_key": "15609701", "sentences": [["Sotalol", "-", "induced", "coronary", "spasm", "in", "a", "patient", "with", "dilated", "cardiomyopathy", "associated", "with", "sustained", "ventricular", "tachycardia", ".", "A", "54", "-", "year", "-", "old", "man", "with", "severe", "left", "ventricular", "dysfunction", "due", "to", "dilated", "cardiomyopathy", "was", "referred", "to", "our", "hospital", "for", "symptomatic", "incessant", "sustained", "ventricular", "tachycardia", "(", "VT", ")", ".", "After", "the", "administration", "of", "nifekalant", "hydrochloride", ",", "sustained", "VT", "was", "terminated", ".", "An", "alternate", "class", "III", "agent", ",", "sotalol", ",", "was", "also", "effective", "for", "the", "prevention", "of", "VT", ".", "However", ",", "one", "month", "after", "switching", "over", "nifekalant", "to", "sotalol", ",", "a", "short", "duration", "of", "ST", "elevation", "was", "documented", "in", "ECG", "monitoring", "at", "almost", "the", "same", "time", "for", "three", "consecutive", "days", ".", "ST", "elevation", "with", "chest", "discomfort", "disappeared", "since", "he", "began", "taking", "long", "-", "acting", "diltiazem", ".", "Coronary", "vasospasm", "may", "be", "induced", "by", "the", "non", "-", "selective", "beta", "-", "blocking", "properties", "of", "sotalol", "."]], "ner": [[[0, 0, "Chemical"], [66, 66, "Chemical"], [86, 86, "Chemical"], [139, 139, "Chemical"], [3, 4, "Disease"], [124, 125, "Disease"], [9, 10, "Disease"], [31, 32, "Disease"], [14, 15, "Disease"], [42, 43, "Disease"], [45, 45, "Disease"], [56, 56, "Disease"], [75, 75, "Disease"], [27, 28, "Disease"], [52, 53, "Chemical"], [84, 84, "Chemical"], [122, 122, "Chemical"]]], "relations": [[[0, 0, 3, 4, "CID"], [0, 0, 124, 125, "CID"], [66, 66, 3, 4, "CID"], [66, 66, 124, 125, "CID"], [86, 86, 3, 4, "CID"], [86, 86, 124, 125, "CID"], [139, 139, 3, 4, "CID"], [139, 139, 124, 125, "CID"]]], "clusters": [], "translated": " <0>索他洛尔</0> - 在<6>扩张型心肌病</6>伴有持续性<8>室性心动过速</8>的患者中引起<4>冠状动脉痉挛</4>。一名因<7>扩张型心肌病</7>导致严重左<13>心室功能不全</13>的54岁男性因症状性持续性<9>室性心动过速</9>转诊至我院（<10>VT</10>）。<14>盐酸尼非卡兰</14>给药后，持续性<11>VT</11>终止。另一种III类药物<1>索他洛尔</1>也可有效预防<12>VT</12>。然而，在将<15>尼非卡兰</15>换成<2>索他洛尔</2>一个月后，连续三天的心电图监测几乎同时记录到短暂的ST段抬高。自开始服用长效<16>地尔硫卓</16>后，ST段抬高伴胸部不适消失。<5>冠状血管痉挛</5>可能由<3>索他洛尔</3>的非选择性β受体阻滞特性引起。", "revised": true}
{"doc_key": "15482540", "sentences": [["Factors", "contributing", "to", "ribavirin", "-", "induced", "anemia", ".", "BACKGROUND", "AND", "AIM", ":", "Interferon", "and", "ribavirin", "combination", "therapy", "for", "chronic", "hepatitis", "C", "produces", "hemolytic", "anemia", ".", "This", "study", "was", "conducted", "to", "identify", "the", "factors", "contributing", "to", "ribavirin", "-", "induced", "anemia", ".", "METHODS", ":", "Eighty", "-", "eight", "patients", "with", "chronic", "hepatitis", "C", "who", "received", "interferon", "-", "alpha", "-", "2b", "at", "a", "dose", "of", "6", "MU", "administered", "intramuscularly", "for", "24", "weeks", "in", "combination", "with", "ribavirin", "administered", "orally", "at", "a", "dose", "of", "600", "mg", "or", "800", "mg", "participated", "in", "the", "study", ".", "A", "hemoglobin", "concentration", "of", "<", "10", "g", "/", "dL", "was", "defined", "as", "ribavirin", "-", "induced", "anemia", ".", "RESULTS", ":", "Ribavirin", "-", "induced", "anemia", "occurred", "in", "18", "(", "20", ".", "5", "%", ")", "patients", "during", "treatment", ".", "A", "2", "g", "/", "dL", "decrease", "in", "hemoglobin", "concentrations", "in", "patients", "with", "anemia", "was", "observed", "at", "week", "2", "after", "the", "start", "of", "treatment", ".", "The", "hemoglobin", "concentration", "in", "patients", "with", ">", "or", "=", "2", "g", "/", "dL", "decrease", "at", "week", "2", "was", "observed", "to", "be", "significantly", "lower", "even", "after", "week", "2", "than", "in", "patients", "with", "<", "2", "g", "/", "dL", "decrease", "(", "P", "<", "0", ".", "01", ")", ".", "A", "significant", "relationship", "was", "observed", "between", "the", "rate", "of", "reduction", "of", "hemoglobin", "concentrations", "at", "week", "2", "and", "the", "severity", "of", "anemia", "(", "P", "<", "0", ".", "01", ")", ".", "Such", "factors", "as", "sex", "(", "female", ")", ",", "age", "(", ">", "or", "=", "60", "years", "old", ")", ",", "and", "the", "ribavirin", "dose", "by", "body", "weight", "(", "12", "mg", "/", "kg", "or", "more", ")", "were", "significant", "by", "univariate", "analysis", ".", "CONCLUSIONS", ":", "Careful", "administration", "is", "necessary", "in", "patients", ">", "or", "=", "60", "years", "old", ",", "in", "female", "patients", ",", "and", "in", "patients", "receiving", "a", "ribavirin", "dose", "of", "12", "mg", "/", "kg", "or", "more", ".", "Patients", "who", "experience", "a", "fall", "in", "hemoglobin", "concentrations", "of", "2", "g", "/", "dL", "or", "more", "at", "week", "2", "after", "the", "start", "of", "treatment", "should", "be", "monitored", "with", "particular", "care", "."]], "ner": [[[3, 3, "Chemical"], [14, 14, "Chemical"], [35, 35, "Chemical"], [71, 71, "Chemical"], [100, 100, "Chemical"], [107, 107, "Chemical"], [242, 242, "Chemical"], [285, 285, "Chemical"], [22, 23, "Disease"], [12, 12, "Chemical"], [52, 56, "Chemical"], [6, 6, "Disease"], [38, 38, "Disease"], [103, 103, "Disease"], [110, 110, "Disease"], [136, 136, "Disease"], [213, 213, "Disease"], [18, 20, "Disease"], [47, 49, "Disease"]]], "relations": [[[3, 3, 22, 23, "CID"], [14, 14, 22, 23, "CID"], [35, 35, 22, 23, "CID"], [71, 71, 22, 23, "CID"], [100, 100, 22, 23, "CID"], [107, 107, 22, 23, "CID"], [242, 242, 22, 23, "CID"], [285, 285, 22, 23, "CID"], [12, 12, 22, 23, "CID"], [52, 56, 22, 23, "CID"]]], "clusters": [], "translated": "<0>利巴韦林</0>诱发<11>贫血</11>的因素。背景与目的：<9>干扰素</9>和<1>利巴韦林</1>联合治疗<17>慢性丙型肝炎</17>产生<8>溶血性贫血</8>。本研究旨在确定导致<2>利巴韦林</2>诱发<12>贫血</12>的因素。方法：88例<18>慢性丙型肝炎</18>患者接受<10>干扰素-α-2b</10>以6MU的剂量肌肉注射24周并联合<3>利巴韦林</3>以600毫克或800毫克的剂量口服给药参与了该研究。血红蛋白浓度<10 g/dL被定义为<4>利巴韦林</4>诱导的<13>贫血</13>。结果：18例（20.5%）患者在治疗期间发生<5>利巴韦林</5>所致<14>贫血</14>。在开始治疗后第2周观察到<15>贫血</15>患者的血红蛋白浓度降低2 g/dL。观察到第2周时下降>或=2 g/dL的患者的血红蛋白浓度甚至在第2周后仍显着低于下降<2 g/dL的患者(P<0.01)。第2周血红蛋白浓度下降率与<16>贫血</16>严重程度之间存在显着相关性(P<0.01)。单变量分析显示，性别（女性）、年龄（≥60岁）、<6>利巴韦林</6>剂量（12mg/kg或以上）等因素均具有显着性。结论：年龄≥60岁的患者、女性患者以及接受<7>利巴韦林</7>剂量为12mg/kg或以上的患者需要谨慎给药。治疗开始后第2周血红蛋白浓度下降2g/dL或更多的患者应特别注意监测。", "revised": true}
{"doc_key": "12912689", "sentences": [["Ocular", "motility", "changes", "after", "subtenon", "carboplatin", "chemotherapy", "for", "retinoblastoma", ".", "BACKGROUND", ":", "Focal", "subtenon", "carboplatin", "injections", "have", "recently", "been", "used", "as", "a", "presumably", "toxicity", "-", "free", "adjunct", "to", "systemic", "chemotherapy", "for", "intraocular", "retinoblastoma", ".", "OBJECTIVE", ":", "To", "report", "our", "clinical", "experience", "with", "abnormal", "ocular", "motility", "in", "patients", "treated", "with", "subtenon", "carboplatin", "chemotherapy", ".", "METHODS", ":", "We", "noted", "abnormal", "ocular", "motility", "in", "10", "consecutive", "patients", "with", "retinoblastoma", "who", "had", "received", "subtenon", "carboplatin", ".", "During", "ocular", "manipulation", "under", "general", "anesthesia", ",", "we", "assessed", "their", "eyes", "by", "forced", "duction", "testing", ",", "comparing", "ocular", "motility", "after", "tumor", "control", "with", "ocular", "motility", "at", "diagnosis", ".", "Eyes", "subsequently", "enucleated", "because", "of", "treatment", "failure", "(", "n", "=", "4", ")", "were", "examined", "histologically", ".", "RESULTS", ":", "Limitation", "of", "ocular", "motility", "was", "detected", "in", "all", "12", "eyes", "of", "10", "patients", "treated", "for", "intraocular", "retinoblastoma", "with", "1", "to", "6", "injections", "of", "subtenon", "carboplatin", "as", "part", "of", "multimodality", "therapy", ".", "Histopathological", "examination", "revealed", "many", "lipophages", "in", "the", "periorbital", "fat", "surrounding", "the", "optic", "nerve", "in", "1", "eye", ",", "indicative", "of", "phagocytosis", "of", "previously", "existing", "fat", "cells", "and", "suggesting", "prior", "fat", "necrosis", ".", "The", "enucleations", "were", "technically", "difficult", "and", "hazardous", "for", "globe", "rupture", "because", "of", "extensive", "orbital", "soft", "tissue", "adhesions", ".", "CONCLUSIONS", ":", "Subtenon", "carboplatin", "chemotherapy", "is", "associated", "with", "significant", "fibrosis", "of", "orbital", "soft", "tissues", ",", "leading", "to", "mechanical", "restriction", "of", "eye", "movements", "and", "making", "subsequent", "enucleation", "difficult", ".", "Subtenon", "carboplatin", "is", "not", "free", "of", "toxicity", ",", "and", "its", "use", "is", "best", "restricted", "to", "specific", "indications", "."]], "ner": [[[5, 5, "Chemical"], [14, 14, "Chemical"], [50, 50, "Chemical"], [70, 70, "Chemical"], [142, 142, "Chemical"], [201, 201, "Chemical"], [227, 227, "Chemical"], [42, 44, "Disease"], [57, 59, "Disease"], [207, 207, "Disease"], [8, 8, "Disease"], [32, 32, "Disease"], [65, 65, "Disease"], [134, 134, "Disease"], [23, 23, "Disease"], [232, 232, "Disease"], [92, 92, "Disease"], [178, 178, "Disease"], [189, 189, "Disease"]]], "relations": [[[5, 5, 42, 44, "CID"], [5, 5, 57, 59, "CID"], [14, 14, 42, 44, "CID"], [14, 14, 57, 59, "CID"], [50, 50, 42, 44, "CID"], [50, 50, 57, 59, "CID"], [70, 70, 42, 44, "CID"], [70, 70, 57, 59, "CID"], [142, 142, 42, 44, "CID"], [142, 142, 57, 59, "CID"], [201, 201, 42, 44, "CID"], [201, 201, 57, 59, "CID"], [227, 227, 42, 44, "CID"], [227, 227, 57, 59, "CID"], [5, 5, 207, 207, "CID"], [14, 14, 207, 207, "CID"], [50, 50, 207, 207, "CID"], [70, 70, 207, 207, "CID"], [142, 142, 207, 207, "CID"], [201, 201, 207, 207, "CID"], [227, 227, 207, 207, "CID"]]], "clusters": [], "translated": "视网膜母细胞瘤<10></10>眼球腱下<0>卡铂</0>化疗后眼球运动的变化。背景：局部<1>球囊下卡铂</1>注射最近被用作眼内<11>视网膜母细胞瘤</11>的一种可能<14>毒性</14>-无全身化疗的辅助手段。目的：报告我们在接受眼球腱下<2>卡铂</2>化疗的患者中发生<7>异常眼球运动</7>的临床经验。方法：我们注意到10名连续<12>视网膜母细胞瘤</12>患者的<8>异常眼球运动</8>，这些患者接受了眼球腱下<3>卡铂</3>治疗。在全身麻醉下进行眼部操作期间，我们通过强制牵拉试验评估了他们的眼睛，比较了肿瘤<16>控制</16>后的眼球运动与诊断时的眼球运动。随后对因治疗失败而摘除眼球的眼睛 (n = 4) 进行了组织学检查。结果：10名眼内<13>视网膜母细胞瘤</13>患者的所有12只眼均检测到眼球运动受限，其中1至6次注射眼球腱下<4>卡铂</4>作为多模式治疗的一部分。组织病理学检查显示1只眼睛的视神经周围的眶周脂肪中有许多噬脂体，表明先前存在的脂肪细胞被吞噬并提示先前的<17>脂肪坏死</17>。由于广泛的眼眶软组织粘连，眼球摘除术在技术上很困难且有<18>破裂</18>的危险。结论：球囊下<5>卡铂</5>化疗与眼眶软组织显着<9>纤维化</9>有关，导致眼球运动机械性受限，使随后的眼球摘除困难。亚替农<6>卡铂</6>并非没有<15>毒性</15>，其使用最好限于特定适应症。", "revised": true}
{"doc_key": "15627798", "sentences": [["Inhibition", "of", "nuclear", "factor", "-", "kappaB", "activation", "attenuates", "tubulointerstitial", "nephritis", "induced", "by", "gentamicin", ".", "BACKGROUND", ":", "Animals", "treated", "with", "gentamicin", "can", "show", "residual", "areas", "of", "interstitial", "fibrosis", "in", "the", "renal", "cortex", ".", "This", "study", "investigated", "the", "expression", "of", "nuclear", "factor", "-", "kappaB", "(", "NF", "-", "kappaB", ")", ",", "mitogen", "-", "activated", "protein", "(", "MAP", ")", "kinases", "and", "macrophages", "in", "the", "renal", "cortex", "and", "structural", "and", "functional", "renal", "changes", "of", "rats", "treated", "with", "gentamicin", "or", "gentamicin", "+", "pyrrolidine", "dithiocarbamate", "(", "PDTC", ")", ",", "an", "NF", "-", "kappaB", "inhibitor", ".", "METHODS", ":", "38", "female", "Wistar", "rats", "were", "injected", "with", "gentamicin", ",", "40", "mg", "/", "kg", ",", "twice", "a", "day", "for", "9", "days", ",", "38", "with", "gentamicin", "+", "PDTC", ",", "and", "28", "with", "0", ".", "15", "M", "NaCl", "solution", ".", "The", "animals", "were", "killed", "5", "and", "30", "days", "after", "these", "injections", "and", "the", "kidneys", "were", "removed", "for", "histological", "and", "immunohistochemical", "studies", ".", "The", "results", "of", "the", "immunohistochemical", "studies", "were", "scored", "according", "to", "the", "extent", "of", "staining", ".", "The", "fractional", "interstitial", "area", "was", "determined", "by", "morphometry", ".", "RESULTS", ":", "Gentamicin", "-", "treated", "rats", "presented", "a", "transitory", "increase", "in", "plasma", "creatinine", "levels", ".", "Increased", "ED", "-", "1", ",", "MAP", "kinases", "and", "NF", "-", "kappaB", "staining", "were", "also", "observed", "in", "the", "renal", "cortex", "from", "all", "gentamicin", "-", "treated", "rats", "compared", "to", "control", "(", "p", "<", "0", ".", "05", ")", ".", "The", "animals", "killed", "on", "day", "30", "also", "presented", "fibrosis", "in", "the", "renal", "cortex", "despite", "the", "recovery", "of", "renal", "function", ".", "Treatment", "with", "PDTC", "reduced", "the", "functional", "and", "structural", "changes", "induced", "by", "gentamicin", ".", "CONCLUSIONS", ":", "These", "data", "show", "that", "inhibition", "of", "NF", "-", "kappaB", "activation", "attenuates", "tubulointerstitial", "nephritis", "induced", "by", "gentamicin", "."]], "ner": [[[12, 12, "Chemical"], [19, 19, "Chemical"], [72, 72, "Chemical"], [74, 74, "Chemical"], [97, 97, "Chemical"], [113, 113, "Chemical"], [175, 175, "Chemical"], [209, 209, "Chemical"], [255, 255, "Chemical"], [274, 274, "Chemical"], [8, 9, "Disease"], [270, 271, "Disease"], [76, 77, "Chemical"], [79, 79, "Chemical"], [115, 115, "Chemical"], [246, 246, "Chemical"], [124, 124, "Chemical"], [185, 185, "Chemical"], [26, 26, "Disease"], [232, 232, "Disease"]]], "relations": [[[12, 12, 8, 9, "CID"], [12, 12, 270, 271, "CID"], [19, 19, 8, 9, "CID"], [19, 19, 270, 271, "CID"], [72, 72, 8, 9, "CID"], [72, 72, 270, 271, "CID"], [74, 74, 8, 9, "CID"], [74, 74, 270, 271, "CID"], [97, 97, 8, 9, "CID"], [97, 97, 270, 271, "CID"], [113, 113, 8, 9, "CID"], [113, 113, 270, 271, "CID"], [175, 175, 8, 9, "CID"], [175, 175, 270, 271, "CID"], [209, 209, 8, 9, "CID"], [209, 209, 270, 271, "CID"], [255, 255, 8, 9, "CID"], [255, 255, 270, 271, "CID"], [274, 274, 8, 9, "CID"], [274, 274, 270, 271, "CID"]]], "clusters": [], "translated": "抑制核因子-kappaB活化可减轻<0>庆大霉素</0>诱导的<10>肾小管间质性肾炎</10>。背景：用 <1>庆大霉素</1>治疗的动物可以在肾皮质中显示间质<18>纤维化</18>的残余区域。本研究调查了用<2>庆大霉素</2>或<3>庆大霉素</3>+<12>吡咯烷二硫代氨基甲酸酯</12> (<13>PDTC</13>)，一种NF-kappaB抑制剂。方法：38只雌性Wistar大鼠注射<4>庆大霉素</4>，40 mg/kg，每天2次，连续9天，38只注射<5>庆大霉素</5>+<14>PDTC</14>，和28只使用0.15M<16>NaCl</16>溶液。这些动物在这些注射后5天和30天被处死，并取出肾脏用于组织学和免疫组织化学研究。根据染色程度对免疫组织化学研究的结果进行评分。部分间质面积由形态测定法确定。结果：<6>庆大霉素</6>处理的大鼠血浆<17>肌酐</17>水平暂时升高。与对照组相比，在所有<7>庆大霉素</7>处理的大鼠的肾皮质中也观察到ED-1、MAP激酶和NF-kappaB染色增加(p<0.05)。尽管肾功能恢复，但在第30天处死的动物的肾皮质也出现了<19>纤维化</19>。<15>PDTC</15>治疗减少了<8>庆大霉素</8>诱导的功能和结构变化。结论：这些数据表明，抑制NF-kappaB活化可减轻<9>庆大霉素</9>诱导的<11>肾小管间质性肾炎</11>。", "revised": true}
{"doc_key": "12119460", "sentences": [["High", "-", "dose", "5", "-", "fluorouracil", "/", "folinic", "acid", "in", "combination", "with", "three", "-", "weekly", "mitomycin", "C", "in", "the", "treatment", "of", "advanced", "gastric", "cancer", ".", "A", "phase", "II", "study", ".", "BACKGROUND", ":", "The", "24", "-", "hour", "continuous", "infusion", "of", "5", "-", "fluorouracil", "(", "5", "-", "FU", ")", "and", "folinic", "acid", "(", "FA", ")", "as", "part", "of", "several", "new", "multidrug", "chemotherapy", "regimens", "in", "advanced", "gastric", "cancer", "(", "AGC", ")", "has", "shown", "to", "be", "effective", ",", "with", "low", "toxicity", ".", "In", "a", "previous", "phase", "II", "study", "with", "3", "-", "weekly", "bolus", "5", "-", "FU", ",", "FA", "and", "mitomycin", "C", "(", "MMC", ")", "we", "found", "a", "low", "toxicity", "rate", "and", "response", "rates", "comparable", "to", "those", "of", "regimens", "such", "as", "ELF", ",", "FAM", "or", "FAMTX", ",", "and", "a", "promising", "median", "overall", "survival", ".", "In", "order", "to", "improve", "this", "MMC", "-", "dependent", "schedule", "we", "initiated", "a", "phase", "II", "study", "with", "high", "-", "dose", "5", "-", "FU", "/", "FA", "and", "3", "-", "weekly", "bolus", "MMC", ".", "PATIENTS", "AND", "METHODS", ":", "From", "February", ",", "1998", "to", "September", ",", "2000", "we", "recruited", "33", "patients", "with", "AGC", "to", "receive", "weekly", "24", "-", "hour", "5", "-", "FU", "2", ",", "600", "mg", "/", "m", "(", "2", ")", "preceded", "by", "2", "-", "hour", "FA", "500", "mg", "/", "m", "(", "2", ")", "for", "6", "weeks", ",", "followed", "by", "a", "2", "-", "week", "rest", "period", ".", "Bolus", "MMC", "10", "mg", "/", "m", "(", "2", ")", "was", "added", "in", "3", "-", "weekly", "intervals", ".", "Treatment", "given", "on", "an", "outpatient", "basis", ",", "using", "portable", "pump", "systems", ",", "was", "repeated", "on", "day", "57", ".", "Patients", "'", "characteristics", "were", ":", "male", "/", "female", "ratio", "20", "/", "13", ";", "median", "age", "57", "(", "27", "-", "75", ")", "years", ";", "median", "WHO", "status", "1", "(", "0", "-", "2", ")", ".", "18", "patients", "had", "a", "primary", "AGC", ",", "and", "15", "showed", "a", "relapsed", "AGC", ".", "Median", "follow", "-", "up", "was", "11", ".", "8", "months", "(", "range", "of", "those", "surviving", ":", "2", ".", "7", "-", "11", ".", "8", "months", ")", ".", "RESULTS", ":", "32", "patients", "were", "evaluable", "for", "response", "-", "complete", "remission", "9", ".", "1", "%", "(", "n", "=", "3", ")", ",", "partial", "remission", "45", ".", "5", "%", "(", "n", "=", "15", ")", ",", "no", "change", "27", ".", "3", "%", "(", "n", "=", "9", ")", ",", "progressive", "disease", "15", ".", "1", "%", "(", "n", "=", "5", ")", ".", "Median", "overall", "survival", "time", "was", "10", ".", "2", "months", "[", "95", "%", "confidence", "interval", "(", "CI", ")", ":", "8", ".", "7", "-", "11", ".", "6", "]", ",", "and", "median", "progression", "-", "free", "survival", "time", "was", "7", ".", "6", "months", "(", "95", "%", "CI", ":", "4", ".", "4", "-", "10", ".", "9", ")", ".", "The", "worst", "toxicities", "(", "%", ")", "observed", "were", "(", "CTC", "-", "NCI", "1", "/", "2", "/", "3", ")", ":", "leukopenia", "45", ".", "5", "/", "18", ".", "2", "/", "6", ".", "1", ",", "thrombocytopenia", "33", ".", "3", "/", "9", ".", "1", "/", "6", ".", "1", ",", "vomitus", "24", ".", "2", "/", "9", ".", "1", "/", "0", ",", "diarrhea", "36", ".", "4", "/", "6", ".", "1", "/", "3", ".", "0", ",", "stomatitis", "18", ".", "2", "/", "9", ".", "1", "/", "0", ",", "hand", "-", "foot", "syndrome", "12", ".", "1", "/", "0", "/", "0", ".", "Two", "patients", "developed", "hemolytic", "-", "uremic", "syndrome", "(", "HUS", ")", ".", "CONCLUSIONS", ":", "High", "-", "dose", "5", "-", "FU", "/", "FA", "/", "MMC", "is", "an", "effective", "and", "well", "-", "tolerated", "outpatient", "regimen", "for", "AGC", "(", "objective", "response", "rate", "54", ".", "6", "%", ")", ".", "It", "may", "serve", "as", "an", "alternative", "to", "cisplatin", "-", "containing", "regimens", ";", "however", ",", "it", "has", "to", "be", "considered", "that", "possibly", "HUS", "may", "occur", "."]], "ner": [[[3, 5, "Chemical"], [39, 41, "Chemical"], [43, 45, "Chemical"], [89, 91, "Chemical"], [148, 150, "Chemical"], [184, 186, "Chemical"], [547, 549, "Chemical"], [458, 458, "Disease"], [471, 471, "Disease"], [484, 484, "Disease"], [495, 495, "Disease"], [508, 508, "Disease"], [519, 522, "Disease"], [534, 537, "Disease"], [539, 539, "Disease"], [596, 596, "Disease"], [7, 8, "Chemical"], [48, 49, "Chemical"], [51, 51, "Chemical"], [93, 93, "Chemical"], [152, 152, "Chemical"], [201, 201, "Chemical"], [551, 551, "Chemical"], [15, 16, "Chemical"], [95, 96, "Chemical"], [98, 98, "Chemical"], [134, 134, "Chemical"], [158, 158, "Chemical"], [223, 223, "Chemical"], [553, 553, "Chemical"], [22, 23, "Disease"], [63, 64, "Disease"], [66, 66, "Disease"], [177, 177, "Disease"], [295, 295, "Disease"], [302, 302, "Disease"], [564, 564, "Disease"], [76, 76, "Disease"], [104, 104, "Disease"], [441, 441, "Disease"], [582, 582, "Chemical"]]], "relations": [[[3, 5, 458, 458, "CID"], [39, 41, 458, 458, "CID"], [43, 45, 458, 458, "CID"], [89, 91, 458, 458, "CID"], [148, 150, 458, 458, "CID"], [184, 186, 458, 458, "CID"], [547, 549, 458, 458, "CID"], [3, 5, 471, 471, "CID"], [39, 41, 471, 471, "CID"], [43, 45, 471, 471, "CID"], [89, 91, 471, 471, "CID"], [148, 150, 471, 471, "CID"], [184, 186, 471, 471, "CID"], [547, 549, 471, 471, "CID"], [3, 5, 484, 484, "CID"], [39, 41, 484, 484, "CID"], [43, 45, 484, 484, "CID"], [89, 91, 484, 484, "CID"], [148, 150, 484, 484, "CID"], [184, 186, 484, 484, "CID"], [547, 549, 484, 484, "CID"], [3, 5, 495, 495, "CID"], [39, 41, 495, 495, "CID"], [43, 45, 495, 495, "CID"], [89, 91, 495, 495, "CID"], [148, 150, 495, 495, "CID"], [184, 186, 495, 495, "CID"], [547, 549, 495, 495, "CID"], [3, 5, 508, 508, "CID"], [39, 41, 508, 508, "CID"], [43, 45, 508, 508, "CID"], [89, 91, 508, 508, "CID"], [148, 150, 508, 508, "CID"], [184, 186, 508, 508, "CID"], [547, 549, 508, 508, "CID"], [3, 5, 519, 522, "CID"], [39, 41, 519, 522, "CID"], [43, 45, 519, 522, "CID"], [89, 91, 519, 522, "CID"], [148, 150, 519, 522, "CID"], [184, 186, 519, 522, "CID"], [547, 549, 519, 522, "CID"], [3, 5, 534, 537, "CID"], [3, 5, 539, 539, "CID"], [3, 5, 596, 596, "CID"], [39, 41, 534, 537, "CID"], [39, 41, 539, 539, "CID"], [39, 41, 596, 596, "CID"], [43, 45, 534, 537, "CID"], [43, 45, 539, 539, "CID"], [43, 45, 596, 596, "CID"], [89, 91, 534, 537, "CID"], [89, 91, 539, 539, "CID"], [89, 91, 596, 596, "CID"], [148, 150, 534, 537, "CID"], [148, 150, 539, 539, "CID"], [148, 150, 596, 596, "CID"], [184, 186, 534, 537, "CID"], [184, 186, 539, 539, "CID"], [184, 186, 596, 596, "CID"], [547, 549, 534, 537, "CID"], [547, 549, 539, 539, "CID"], [547, 549, 596, 596, "CID"], [7, 8, 458, 458, "CID"], [48, 49, 458, 458, "CID"], [51, 51, 458, 458, "CID"], [93, 93, 458, 458, "CID"], [152, 152, 458, 458, "CID"], [201, 201, 458, 458, "CID"], [551, 551, 458, 458, "CID"], [7, 8, 471, 471, "CID"], [48, 49, 471, 471, "CID"], [51, 51, 471, 471, "CID"], [93, 93, 471, 471, "CID"], [152, 152, 471, 471, "CID"], [201, 201, 471, 471, "CID"], [551, 551, 471, 471, "CID"], [7, 8, 484, 484, "CID"], [48, 49, 484, 484, "CID"], [51, 51, 484, 484, "CID"], [93, 93, 484, 484, "CID"], [152, 152, 484, 484, "CID"], [201, 201, 484, 484, "CID"], [551, 551, 484, 484, "CID"], [7, 8, 495, 495, "CID"], [48, 49, 495, 495, "CID"], [51, 51, 495, 495, "CID"], [93, 93, 495, 495, "CID"], [152, 152, 495, 495, "CID"], [201, 201, 495, 495, "CID"], [551, 551, 495, 495, "CID"], [7, 8, 508, 508, "CID"], [48, 49, 508, 508, "CID"], [51, 51, 508, 508, "CID"], [93, 93, 508, 508, "CID"], [152, 152, 508, 508, "CID"], [201, 201, 508, 508, "CID"], [551, 551, 508, 508, "CID"], [7, 8, 519, 522, "CID"], [48, 49, 519, 522, "CID"], [51, 51, 519, 522, "CID"], [93, 93, 519, 522, "CID"], [152, 152, 519, 522, "CID"], [201, 201, 519, 522, "CID"], [551, 551, 519, 522, "CID"], [7, 8, 534, 537, "CID"], [7, 8, 539, 539, "CID"], [7, 8, 596, 596, "CID"], [48, 49, 534, 537, "CID"], [48, 49, 539, 539, "CID"], [48, 49, 596, 596, "CID"], [51, 51, 534, 537, "CID"], [51, 51, 539, 539, "CID"], [51, 51, 596, 596, "CID"], [93, 93, 534, 537, "CID"], [93, 93, 539, 539, "CID"], [93, 93, 596, 596, "CID"], [152, 152, 534, 537, "CID"], [152, 152, 539, 539, "CID"], [152, 152, 596, 596, "CID"], [201, 201, 534, 537, "CID"], [201, 201, 539, 539, "CID"], [201, 201, 596, 596, "CID"], [551, 551, 534, 537, "CID"], [551, 551, 539, 539, "CID"], [551, 551, 596, 596, "CID"], [15, 16, 458, 458, "CID"], [95, 96, 458, 458, "CID"], [98, 98, 458, 458, "CID"], [134, 134, 458, 458, "CID"], [158, 158, 458, 458, "CID"], [223, 223, 458, 458, "CID"], [553, 553, 458, 458, "CID"], [15, 16, 471, 471, "CID"], [95, 96, 471, 471, "CID"], [98, 98, 471, 471, "CID"], [134, 134, 471, 471, "CID"], [158, 158, 471, 471, "CID"], [223, 223, 471, 471, "CID"], [553, 553, 471, 471, "CID"], [15, 16, 484, 484, "CID"], [95, 96, 484, 484, "CID"], [98, 98, 484, 484, "CID"], [134, 134, 484, 484, "CID"], [158, 158, 484, 484, "CID"], [223, 223, 484, 484, "CID"], [553, 553, 484, 484, "CID"], [15, 16, 495, 495, "CID"], [95, 96, 495, 495, "CID"], [98, 98, 495, 495, "CID"], [134, 134, 495, 495, "CID"], [158, 158, 495, 495, "CID"], [223, 223, 495, 495, "CID"], [553, 553, 495, 495, "CID"], [15, 16, 508, 508, "CID"], [95, 96, 508, 508, "CID"], [98, 98, 508, 508, "CID"], [134, 134, 508, 508, "CID"], [158, 158, 508, 508, "CID"], [223, 223, 508, 508, "CID"], [553, 553, 508, 508, "CID"], [15, 16, 519, 522, "CID"], [95, 96, 519, 522, "CID"], [98, 98, 519, 522, "CID"], [134, 134, 519, 522, "CID"], [158, 158, 519, 522, "CID"], [223, 223, 519, 522, "CID"], [553, 553, 519, 522, "CID"], [15, 16, 534, 537, "CID"], [15, 16, 539, 539, "CID"], [15, 16, 596, 596, "CID"], [95, 96, 534, 537, "CID"], [95, 96, 539, 539, "CID"], [95, 96, 596, 596, "CID"], [98, 98, 534, 537, "CID"], [98, 98, 539, 539, "CID"], [98, 98, 596, 596, "CID"], [134, 134, 534, 537, "CID"], [134, 134, 539, 539, "CID"], [134, 134, 596, 596, "CID"], [158, 158, 534, 537, "CID"], [158, 158, 539, 539, "CID"], [158, 158, 596, 596, "CID"], [223, 223, 534, 537, "CID"], [223, 223, 539, 539, "CID"], [223, 223, 596, 596, "CID"], [553, 553, 534, 537, "CID"], [553, 553, 539, 539, "CID"], [553, 553, 596, 596, "CID"]]], "clusters": [], "translated": "大剂量<0>5-氟尿嘧啶</0>/<16>亚叶酸</16>联合三周<23>丝裂霉素C</23>治疗晚期<30>胃癌</30>。II期研究。背景：24小时连续输注<1>5-氟尿嘧啶</1>（<2>5-FU</2>）和<17>亚叶酸</17>（<18>FA</18>）作为晚期<31>胃癌</31>（<32>AGC</32>）几种新的多药化疗方案的一部分，已被证明是有效的，且<37>毒性较低</37>。在先前的II期研究中，每周一次推注<3>5-FU</3>、<19>FA</19>和<24>丝裂霉素C</24>（<25>MMC</25>），我们发现低<38>毒性</38>率和反应率与ELF、FAM或FAMTX等方案相当，并且有一个有希望的中位总生存期。为了改善这种<26>MMC</26>依赖性时间表，我们启动了一项II期研究，采用高剂量<4>5-FU</4>/<20>FA</20>和3周推注<27>丝裂霉素C</27>。患者和方法：从1998年2月到2000年9月，我们招募了33名<33>AGC</33>患者，每周24小时接受<5>5-FU</5> 2,600 mg/m(2)之前2小时<21>FA</21> 500 mg/m(2)持续6周，然后是2周的休息期。团注<28>MMC</28>10 mg/m(2)，每3周一次。第57天重复门诊治疗，使用便携式泵系统。患者的特征是：男性/女性比例为20/13；中位年龄57(27-75)岁；世卫组织地位中位数1(0-2)。18名患者出现原发性<34>AGC</34>，15名患者出现复发性<35>AGC</35>。中位随访时间为11.8个月（幸存者范围：2.7-11.8个月）。结果：32名患者可评估反应-完全缓解9.1%（n=3），部分缓解45.5%（n=15），没有变化27.3%（n=9），进行性疾病15.1%（n=5）。中位总生存时间为10.2个月[95%置信区间（CI）：8.7-11.6]，中位无进展生存时间为7.6个月（95%CI：4.4-10.9）。观察到的最严重的<39>毒性</39>（%）是(CTC-NCI 1/2/3)：<7>白细胞减少</7>45.5/18.2/6.1，<8>血小板减少</8>33.3/9.1/6.1，<9>呕吐物</9>24.2/9.1/0，<10>腹泻</10>36.4/6.1/3.0，<11>口腔炎</11>18.2/9.1/0，<12>手足综合症</12>12.1/0/0。两例患者出现<13>溶血尿毒综合征</13>（<14>HUS</14>）。结论：高剂量<6>5-FU</6>/<22>FA</22>/<29>MMC</29>是一种有效且耐受性良好的<36>AGC</36>门诊治疗方案（客观反应率54.6%）。它可以替代含<40>顺铂</40>的方案；但是，必须考虑可能发生<15>HUS</15>。", "revised": true}
{"doc_key": "15953230", "sentences": [["Two", "cases", "of", "amisulpride", "overdose", ":", "a", "cause", "for", "prolonged", "QT", "syndrome", ".", "Two", "cases", "of", "deliberate", "self", "-", "poisoning", "with", "5", "g", "and", "3", ".", "6", "g", "of", "amisulpride", ",", "respectively", ",", "are", "reported", ".", "In", "both", "cases", ",", "QT", "prolongation", "and", "hypocalcaemia", "were", "noted", ".", "The", "QT", "prolongation", "appeared", "to", "respond", "to", "administration", "of", "i", ".", "v", ".", "calcium", "gluconate", "."]], "ner": [[[3, 3, "Chemical"], [29, 29, "Chemical"], [9, 11, "Disease"], [40, 41, "Disease"], [48, 49, "Disease"], [43, 43, "Disease"], [4, 4, "Disease"], [19, 19, "Disease"], [60, 61, "Chemical"]]], "relations": [[[3, 3, 9, 11, "CID"], [3, 3, 40, 41, "CID"], [3, 3, 48, 49, "CID"], [29, 29, 9, 11, "CID"], [29, 29, 40, 41, "CID"], [29, 29, 48, 49, "CID"], [3, 3, 43, 43, "CID"], [29, 29, 43, 43, "CID"]]], "clusters": [], "translated": "<0>氨磺必利</0> <6>过量</6>两例：成为<2>QT间期延长综合征</2>原因。据报道，分别用了 5 g 和 3 g 6的<1>氨磺必利</1>实施故意自体<7>中毒</7>。在这两例中，都有<3> QT间期延长</3>和 <5>低钙血症</5>。似乎用i.v. <8>葡萄糖酸钙</8>治疗能缓解<4> QT间期延长</4>。", "revised": true}
{"doc_key": "15815446", "sentences": [["Focal", "cerebral", "ischemia", "in", "rats", ":", "effect", "of", "phenylephrine", "-", "induced", "hypertension", "during", "reperfusion", ".", "After", "180", "min", "of", "temporary", "middle", "cerebral", "artery", "occlusion", "in", "spontaneously", "hypertensive", "rats", ",", "the", "effect", "of", "phenylephrine", "-", "induced", "hypertension", "on", "ischemic", "brain", "injury", "and", "blood", "-", "brain", "barrier", "permeability", "was", "determined", ".", "Blood", "pressure", "was", "manipulated", "by", "one", "of", "the", "following", "schedules", "during", "120", "min", "of", "reperfusion", ":", "Control", ",", "normotensive", "reperfusion", ";", "90", "/", "hypertension", "(", "90", "/", "HTN", ")", ",", "blood", "pressure", "was", "increased", "by", "35", "mm", "Hg", "during", "the", "initial", "90", "min", "of", "reperfusion", "only", ";", "15", "/", "hypertension", "(", "15", "/", "HTN", ")", ",", "normotensive", "reperfusion", "for", "30", "min", "followed", "by", "15", "min", "of", "hypertension", "and", "75", "min", "of", "normotension", ".", "Part", "A", ",", "for", "eight", "rats", "in", "each", "group", "brain", "injury", "was", "evaluated", "by", "staining", "tissue", "using", "2", ",", "3", ",", "5", "-", "triphenyltetrazolium", "chloride", "and", "edema", "was", "evaluated", "by", "microgravimetry", ".", "Part", "B", ",", "for", "eight", "different", "rats", "in", "each", "group", "blood", "-", "brain", "barrier", "permeability", "was", "evaluated", "by", "measuring", "the", "amount", "and", "extent", "of", "extravasation", "of", "Evans", "Blue", "dye", ".", "Brain", "injury", "(", "percentage", "of", "the", "ischemic", "hemisphere", ")", "was", "less", "in", "the", "15", "/", "HTN", "group", "(", "16", "+", "/", "-", "6", ",", "mean", "+", "/", "-", "SD", ")", "versus", "the", "90", "/", "HTN", "group", "(", "30", "+", "/", "-", "6", ")", ",", "which", "was", "in", "turn", "less", "than", "the", "control", "group", "(", "42", "+", "/", "-", "5", ")", ".", "Specific", "gravity", "was", "greater", "in", "the", "15", "/", "HTN", "group", "(", "1", ".", "043", "+", "/", "-", "0", ".", "002", ")", "versus", "the", "90", "/", "HTN", "(", "1", ".", "036", "+", "/", "-", "0", ".", "003", ")", "and", "control", "(", "1", ".", "037", "+", "/", "-", "0", ".", "003", ")", "groups", ".", "Evans", "Blue", "(", "mug", "g", "-", "1", "of", "brain", "tissue", ")", "was", "greater", "in", "the", "90", "/", "HTN", "group", "(", "24", ".", "4", "+", "/", "-", "6", ".", "0", ")", "versus", "the", "control", "group", "(", "12", ".", "3", "+", "/", "-", "4", ".", "1", ")", ",", "which", "was", "in", "turn", "greater", "than", "the", "15", "/", "HTN", "group", "(", "7", ".", "3", "+", "/", "-", "3", ".", "2", ")", ".", "This", "study", "supports", "a", "hypothesis", "that", "during", "reperfusion", ",", "a", "short", "interval", "of", "hypertension", "decreases", "brain", "injury", "and", "edema", ";", "and", "that", "sustained", "hypertension", "increases", "the", "risk", "of", "vasogenic", "edema", "."]], "ner": [[[8, 8, "Chemical"], [32, 32, "Chemical"], [11, 11, "Disease"], [26, 26, "Disease"], [35, 35, "Disease"], [72, 72, "Disease"], [76, 76, "Disease"], [98, 98, "Disease"], [102, 102, "Disease"], [115, 115, "Disease"], [199, 199, "Disease"], [218, 218, "Disease"], [253, 253, "Disease"], [270, 270, "Disease"], [314, 314, "Disease"], [352, 352, "Disease"], [379, 379, "Disease"], [389, 389, "Disease"], [1, 2, "Disease"], [190, 191, "Disease"], [139, 146, "Chemical"], [297, 298, "Chemical"], [20, 23, "Disease"], [37, 39, "Disease"], [131, 132, "Disease"], [184, 185, "Disease"], [381, 382, "Disease"], [148, 148, "Disease"], [384, 384, "Disease"], [394, 395, "Disease"]]], "relations": [[[8, 8, 11, 11, "CID"], [8, 8, 26, 26, "CID"], [8, 8, 35, 35, "CID"], [8, 8, 72, 72, "CID"], [8, 8, 76, 76, "CID"], [8, 8, 98, 98, "CID"], [8, 8, 102, 102, "CID"], [8, 8, 115, 115, "CID"], [8, 8, 199, 199, "CID"], [8, 8, 218, 218, "CID"], [8, 8, 253, 253, "CID"], [8, 8, 270, 270, "CID"], [8, 8, 314, 314, "CID"], [8, 8, 352, 352, "CID"], [8, 8, 379, 379, "CID"], [8, 8, 389, 389, "CID"], [32, 32, 11, 11, "CID"], [32, 32, 26, 26, "CID"], [32, 32, 35, 35, "CID"], [32, 32, 72, 72, "CID"], [32, 32, 76, 76, "CID"], [32, 32, 98, 98, "CID"], [32, 32, 102, 102, "CID"], [32, 32, 115, 115, "CID"], [32, 32, 199, 199, "CID"], [32, 32, 218, 218, "CID"], [32, 32, 253, 253, "CID"], [32, 32, 270, 270, "CID"], [32, 32, 314, 314, "CID"], [32, 32, 352, 352, "CID"], [32, 32, 379, 379, "CID"], [32, 32, 389, 389, "CID"]]], "clusters": [], "translated": "大鼠局灶性<18>脑缺血</18>：再灌注过程中<0>去氧肾上腺素</0>诱导的<2>高血压</2>的作用。自发性<3>高血压</3>大鼠<22>大脑中动脉暂时闭塞</22> 180 分钟后，<1>苯肾上腺素</1> - 诱导的<4>高血压</4>对<23>缺血性脑损伤</23>和血脑屏障通透性进行了测定。在 120 分钟的再灌注期间，通过以下时间表之一控制血压：控制，正常血压再灌注；90/<5>高血压</5>（90/<6>HTN</6>），仅在再灌注的最初 90 分钟内血压升高 35 mm Hg；15/<7>高血压</7>（15/<8>HTN</8>），正常血压再灌注 30 分钟，然后<9>高血压</9> 15 分钟，正常血压 75 分钟。A 部分，每组 8 只大鼠<24>脑损伤</24>通过使用<20>2, 3, 5 - 三苯基氯化四氮唑</20>和<27>水肿</27>的组织染色进行评估；B 部分，每组八只不同的大鼠，通过测量伊文思蓝染料的外渗量和程度来评估血脑屏障通透性。 <25>脑损伤</25>（<19>缺血性半球</19>的百分比）在 15/<10>HTN</10> 组中较少（16 + / - 6，平均值 + / - SD），与90/<11>HTN</11> 组（30 + /- 6）相比，后者又低于对照组（42 + /- 5）。15/<12>HTN</12> 组（1.043 + / - 0.002）的比重高于90/<13>HTN</13> （1.036 + / - 0.003）和对照（1.037 +/ - 0.003）组。 <21>伊文思蓝</21>（脑组织的 mugg - 1）在90/<14>HTN</14>组（24.4 + /- 6.0）与对照组（12.3 + /- 4.1），这又大于15/<15>HTN</15>组（7.3 + /- 3.2）。该研究支持一个假设，即在再灌注期间，<16>高血压</16>的短时间间隔减少了<26>脑损伤</26>和<28>水肿</28>；并且持续<17>高血压</17>会增加<29>血管源性水肿</29>的风险。", "revised": true}
{"doc_key": "9869655", "sentences": [["Differential", "effects", "of", "17alpha", "-", "ethinylestradiol", "on", "the", "neutral", "and", "acidic", "pathways", "of", "bile", "salt", "synthesis", "in", "the", "rat", ".", "Effects", "of", "17alpha", "-", "ethinylestradiol", "(", "EE", ")", "on", "the", "neutral", "and", "acidic", "biosynthetic", "pathways", "of", "bile", "salt", "(", "BS", ")", "synthesis", "were", "evaluated", "in", "rats", "with", "an", "intact", "enterohepatic", "circulation", "and", "in", "rats", "with", "long", "-", "term", "bile", "diversion", "to", "induce", "BS", "synthesis", ".", "For", "this", "purpose", ",", "bile", "salt", "pool", "composition", ",", "synthesis", "of", "individual", "BS", "in", "vivo", ",", "hepatic", "activities", ",", "and", "expression", "levels", "of", "cholesterol", "7alpha", "-", "hydroxylase", "(", "CYP7A", ")", ",", "and", "sterol", "27", "-", "hydroxylase", "(", "CYP27", ")", ",", "as", "well", "as", "of", "other", "enzymes", "involved", "in", "BS", "synthesis", ",", "were", "analyzed", "in", "rats", "treated", "with", "EE", "(", "5", "mg", "/", "kg", ",", "3", "days", ")", "or", "its", "vehicle", ".", "BS", "pool", "size", "was", "decreased", "by", "27", "%", "but", "total", "BS", "synthesis", "was", "not", "affected", "by", "EE", "in", "intact", "rats", ".", "Synthesis", "of", "cholate", "was", "reduced", "by", "68", "%", "in", "EE", "-", "treated", "rats", ",", "while", "that", "of", "chenodeoxycholate", "was", "increased", "by", "60", "%", ".", "The", "recently", "identified", "Delta22", "-", "isomer", "of", "beta", "-", "muricholate", "contributed", "for", "5", ".", "4", "%", "and", "18", ".", "3", "%", "(", "P", "<", "0", ".", "01", ")", "to", "the", "pool", "in", "control", "and", "EE", "-", "treated", "rats", ",", "respectively", ",", "but", "could", "not", "be", "detected", "in", "bile", "after", "exhaustion", "of", "the", "pool", ".", "A", "clear", "reduction", "of", "BS", "synthesis", "was", "found", "in", "bile", "-", "diverted", "rats", "treated", "with", "EE", ",", "yet", "biliary", "BS", "composition", "was", "only", "minimally", "affected", ".", "Activity", "of", "CYP7A", "was", "decreased", "by", "EE", "in", "both", "intact", "and", "bile", "-", "diverted", "rats", ",", "whereas", "the", "activity", "of", "the", "CYP27", "was", "not", "affected", ".", "Hepatic", "mRNA", "levels", "of", "CYP7A", "were", "significantly", "reduced", "by", "EE", "in", "bile", "-", "diverted", "rats", "only", ";", "CYP27", "mRNA", "levels", "were", "not", "affected", "by", "EE", ".", "In", "addition", ",", "mRNA", "levels", "of", "sterol", "12alpha", "-", "hydroxylase", "and", "lithocholate", "6beta", "-", "hydroxylase", "were", "increased", "by", "bile", "diversion", "and", "suppressed", "by", "EE", ".", "This", "study", "shows", "that", "17alpha", "-", "ethinylestradiol", "(", "EE", ")", "-", "induced", "intrahepatic", "cholestasis", "in", "rats", "is", "associated", "with", "selective", "inhibition", "of", "the", "neutral", "pathway", "of", "bile", "salt", "(", "BS", ")", "synthesis", ".", "Simultaneous", "impairment", "of", "other", "enzymes", "in", "the", "BS", "biosynthetic", "pathways", "may", "contribute", "to", "overall", "effects", "of", "EE", "on", "BS", "synthesis", "."]], "ner": [[[3, 5, "Chemical"], [22, 24, "Chemical"], [26, 26, "Chemical"], [122, 122, "Chemical"], [152, 152, "Chemical"], [166, 166, "Chemical"], [215, 215, "Chemical"], [250, 250, "Chemical"], [267, 267, "Chemical"], [296, 296, "Chemical"], [311, 311, "Chemical"], [336, 336, "Chemical"], [342, 344, "Chemical"], [346, 346, "Chemical"], [387, 387, "Chemical"], [350, 351, "Disease"], [13, 14, "Chemical"], [36, 37, "Chemical"], [39, 39, "Chemical"], [62, 62, "Chemical"], [69, 70, "Chemical"], [77, 77, "Chemical"], [113, 113, "Chemical"], [136, 136, "Chemical"], [146, 146, "Chemical"], [239, 239, "Chemical"], [254, 254, "Chemical"], [364, 365, "Chemical"], [367, 367, "Chemical"], [378, 378, "Chemical"], [389, 389, "Chemical"], [88, 88, "Chemical"], [97, 97, "Chemical"], [319, 319, "Chemical"], [159, 159, "Chemical"], [174, 174, "Chemical"]]], "relations": [[[3, 5, 350, 351, "CID"], [22, 24, 350, 351, "CID"], [26, 26, 350, 351, "CID"], [122, 122, 350, 351, "CID"], [152, 152, 350, 351, "CID"], [166, 166, 350, 351, "CID"], [215, 215, 350, 351, "CID"], [250, 250, 350, 351, "CID"], [267, 267, 350, 351, "CID"], [296, 296, 350, 351, "CID"], [311, 311, 350, 351, "CID"], [336, 336, 350, 351, "CID"], [342, 344, 350, 351, "CID"], [346, 346, 350, 351, "CID"], [387, 387, 350, 351, "CID"]]], "clusters": [], "translated": "缺失标记已添加并且错位的标记已修正：<0>17α-炔雌醇</0>对大鼠<16>胆汁盐</16>合成的中性和酸性途径的不同影响。 <1>17α-炔雌醇</1>（<2>EE</2>）对<17>胆汁盐</17>（<18>BS</18>）中性和酸性生物合成途径的影响在具有完整肠肝循环的大鼠和长期胆汁改道诱导<19>BS</19>合成的大鼠中进行了评估。为此，<20>胆汁盐</20>池组成、体内个体<21>BS</21>的合成、肝活性和<31>胆固醇</31><27>7alpha-羟化酶（CYP7A）</27>的表达水平，以及参与<22>BS</22>合成的其他酶，在用<3>EE</3>治疗的大鼠中进行了分析（5毫克/公斤，3天）或其载体。 <23>BS</23>池大小减少了27%，但总<24>BS</24>合成不受完整大鼠<4>EE</4>的影响。 <34>胆酸盐</34>的合成在<5>EE</5>处理的大鼠中减少了68%，而<35>鹅脱氧胆酸盐</35>的合成增加了60%。最近发现的Delta22-beta-muricholate异构体贡献了5.4%和18.3%（P<0.01）到对照和用<6>EE</6>处理的大鼠的池中，分别，但在池耗尽后不能在胆汁中检测到。在用<7>EE</7>治疗的胆汁转移大鼠中发现<25>BS</25>合成明显减少，但胆汁<26>BS</26>成分仅受到最小影响。<8>EE</8>在完整和胆汁转移的大鼠中CYP7A的活性均降低，而<32>甾醇</32><27>27-羟化酶（CYP27）</27>的活性未受影响。<9>EE</9>仅在胆汁改道大鼠中CYP7A的肝脏mRNA水平显着降低；CYP27 mRNA水平不受<10>EE</10>的影响。此外，<33>甾醇</33><22>12α-羟化酶和石胆酸盐6β-羟化酶</22>的mRNA水平被胆汁改道增加而被<11>EE</11>抑制。本研究表明，<12>17alpha-炔雌醇</12>（<13>EE</13>）在大鼠中诱导的<15>肝内胆汁淤积</15>与选择性抑制<27>胆盐</27>（<28>BS</28>）的中性途径有关。<29>BS</29>生物合成途径中其他酶的同时受损可能有助于<14>EE</14>对<30>BS</30>合成的总体影响。", "revised": true}
{"doc_key": "15625689", "sentences": [["Swallowing", "abnormalities", "and", "dyskinesia", "in", "Parkinson", "'s", "disease", ".", "Gastrointestinal", "abnormalities", "in", "Parkinson", "'s", "disease", "(", "PD", ")", "have", "been", "known", "for", "almost", "two", "centuries", ",", "but", "many", "aspects", "concerning", "their", "pathophysiology", "have", "not", "been", "completely", "clarified", ".", "The", "aim", "of", "this", "study", "was", "to", "characterize", "the", "oropharyngeal", "dynamics", "in", "PD", "patients", "with", "and", "without", "levodopa", "-", "induced", "dyskinesia", ".", "Fifteen", "dyskinetic", ",", "12", "nondyskinetic", "patients", ",", "and", "a", "control", "group", "were", "included", ".", "Patients", "were", "asked", "about", "dysphagia", "and", "evaluated", "with", "the", "Unified", "Parkinson", "'s", "Disease", "Rating", "Scale", "Parts", "II", "and", "III", "and", "the", "Hoehn", "and", "Yahr", "scale", ".", "Deglutition", "was", "assessed", "using", "modified", "barium", "swallow", "with", "videofluoroscopy", ".", "Nondyskinetic", "patients", ",", "but", "not", "the", "dyskinetic", "ones", ",", "showed", "less", "oropharyngeal", "swallowing", "efficiency", "(", "OPSE", ")", "for", "liquid", "food", "than", "controls", "(", "Dunnett", ",", "P", "=", "0", ".", "02", ")", ".", "Dyskinetic", "patients", "tended", "to", "have", "a", "greater", "OPSE", "than", "nondyskinetic", "(", "Dunnett", ",", "P", "=", "0", ".", "06", ")", ".", "Patients", "who", "were", "using", "a", "higher", "dose", "of", "levodopa", "had", "a", "greater", "OPSE", "and", "a", "trend", "toward", "a", "smaller", "oral", "transit", "time", "(", "Pearson", "'s", "correlation", ",", "P", "=", "0", ".", "01", "and", "0", ".", "08", ",", "respectively", ")", ".", "Neither", "the", "report", "of", "dysphagia", "nor", "any", "of", "the", "PD", "severity", "parameters", "correlated", "to", "the", "videofluoroscopic", "variables", ".", "In", "the", "current", "study", ",", "dyskinetic", "patients", "performed", "better", "in", "swallowing", "function", ",", "which", "could", "be", "explained", "on", "the", "basis", "of", "a", "greater", "levodopa", "dose", ".", "Our", "results", "suggest", "a", "role", "for", "levodopa", "in", "the", "oral", "phase", "of", "deglutition", "and", "confirm", "that", "dysphagia", "is", "not", "a", "good", "predictor", "of", "deglutition", "alterations", "in", "PD", "."]], "ner": [[[55, 55, "Chemical"], [170, 170, "Chemical"], [243, 243, "Chemical"], [252, 252, "Chemical"], [3, 3, "Disease"], [58, 58, "Disease"], [61, 61, "Disease"], [116, 116, "Disease"], [142, 142, "Disease"], [225, 225, "Disease"], [0, 1, "Disease"], [105, 105, "Chemical"], [5, 7, "Disease"], [12, 14, "Disease"], [16, 16, "Disease"], [50, 50, "Disease"], [84, 86, "Disease"], [211, 211, "Disease"], [272, 272, "Disease"], [9, 10, "Disease"], [78, 78, "Disease"], [206, 206, "Disease"], [262, 262, "Disease"]]], "relations": [[[55, 55, 3, 3, "CID"], [55, 55, 58, 58, "CID"], [55, 55, 61, 61, "CID"], [55, 55, 116, 116, "CID"], [55, 55, 142, 142, "CID"], [55, 55, 225, 225, "CID"], [170, 170, 3, 3, "CID"], [170, 170, 58, 58, "CID"], [170, 170, 61, 61, "CID"], [170, 170, 116, 116, "CID"], [170, 170, 142, 142, "CID"], [170, 170, 225, 225, "CID"], [243, 243, 3, 3, "CID"], [243, 243, 58, 58, "CID"], [243, 243, 61, 61, "CID"], [243, 243, 116, 116, "CID"], [243, 243, 142, 142, "CID"], [243, 243, 225, 225, "CID"], [252, 252, 3, 3, "CID"], [252, 252, 58, 58, "CID"], [252, 252, 61, 61, "CID"], [252, 252, 116, 116, "CID"], [252, 252, 142, 142, "CID"], [252, 252, 225, 225, "CID"]]], "clusters": [], "translated": "<10>吞咽异常</10>和<4>运动障碍</4>在<12>帕金森病</12>中出现。近两个世纪来已为人们所知<13>帕金森氏病</13> (<14>PD</14>)的<19>胃肠道异常</19>，但其病理生理学的许多方面尚未完全阐明。本研究的目的是描述患有<0>左旋多巴</0>-诱发<5>运动障碍</5>和不伴有运动障碍的<15>PD</15>患者的口咽动力学特征。包括15名<6>运动障碍</6>患者，12名非运动障碍患者和一个对照组。患者被问及<20>吞咽困难</20>，并使用统一<16>帕金森氏病</16>评定量表第II部分和第III部分以及Hoehn和Yahr量表进行评估。使用改良的<11>钡剂</11>吞咽法和荧光透视法评估吞咽情况。非运动障碍患者，而不是<7>运动障碍</7>患者，对液体食物的口咽吞咽效率(OPSE)低于对照组(Dunnett，P=0.02)。<8>运动障碍</8>患者的OPSE往往高于非运动障碍患者(Dunnett，P=0.06)。使用较高剂量的<1>左旋多巴</1>的患者具有更高的OPSE和更短的口腔传输时间(Trend, Pearson's correlation, P=0.01 and 0.08, respectively)。<17>PD</17>的报告<21>吞咽困难</21>和任何严重性参数均与电视透视变量无关。在目前的研究中，<9>运动障碍</9>患者表现出更好的吞咽功能，这可以用更大的<2>左旋多巴</2>剂量来解释。我们的结果表明<3>左旋多巴</3>在吞咽的口腔阶段起作用，并证实<22>吞咽困难</22>不是<18>PD</18>吞咽改变的良好预测因子。", "revised": true}
{"doc_key": "15282950", "sentences": [["Protective", "effect", "of", "Terminalia", "chebula", "against", "experimental", "myocardial", "injury", "induced", "by", "isoproterenol", ".", "Cardioprotective", "effect", "of", "ethanolic", "extract", "of", "Terminalia", "chebula", "fruits", "(", "500", "mg", "/", "kg", "body", "wt", ")", "was", "examined", "in", "isoproterenol", "(", "200", "mg", "/", "kg", "body", "wt", ")", "induced", "myocardial", "damage", "in", "rats", ".", "In", "isoproterenol", "administered", "rats", ",", "the", "level", "of", "lipid", "peroxides", "increased", "significantly", "in", "the", "serum", "and", "heart", ".", "A", "significant", "decrease", "was", "observed", "in", "the", "activity", "of", "the", "myocardial", "marker", "enzymes", "with", "a", "concomitant", "increase", "in", "their", "activity", "in", "serum", ".", "Histopathological", "examination", "was", "carried", "out", "to", "confirm", "the", "myocardial", "necrosis", ".", "T", ".", "chebula", "extract", "pretreatment", "was", "found", "to", "ameliorate", "the", "effect", "of", "isoproterenol", "on", "lipid", "peroxide", "formation", "and", "retained", "the", "activities", "of", "the", "diagnostic", "marker", "enzymes", "."]], "ner": [[[11, 11, "Chemical"], [33, 33, "Chemical"], [49, 49, "Chemical"], [112, 112, "Chemical"], [7, 8, "Disease"], [43, 44, "Disease"], [98, 98, "Disease"], [3, 4, "Chemical"], [16, 21, "Chemical"], [100, 103, "Chemical"], [57, 57, "Chemical"], [115, 115, "Chemical"]]], "relations": [[[11, 11, 7, 8, "CID"], [11, 11, 43, 44, "CID"], [33, 33, 7, 8, "CID"], [33, 33, 43, 44, "CID"], [49, 49, 7, 8, "CID"], [49, 49, 43, 44, "CID"], [112, 112, 7, 8, "CID"], [112, 112, 43, 44, "CID"], [11, 11, 98, 98, "CID"], [33, 33, 98, 98, "CID"], [49, 49, 98, 98, "CID"], [112, 112, 98, 98, "CID"]]], "clusters": [], "translated": "<7>榄仁</7>对<0>异丙肾上腺素</0>所致实验性<4>心肌损伤</4>的保护作用。在<1>异丙肾上腺素</1>（200 mg/kg体重）诱导的<5>心肌损伤</5>中，应用了<8>榄仁乙醇提取物</8>（500 mg/kg体重）进行心肌保护。在<2>异丙肾上腺素</2>注入的大鼠中，血浆和心脏中的脂质<10>过氧化物</10>水平显著升高，而心肌标志酶的活性显著降低，并同时在血清中上升。通过组织病理学检查证实了 <6>心肌坏死</6>。发现预先使用<9>榄仁提取物</9>可改善<3>异丙肾上腺素</3>对脂质<11>过氧化物</11>形成的影响，保留了诊断标志酶的活性。", "revised": true}
{"doc_key": "15882284", "sentences": [["Case", "-", "control", "study", "of", "regular", "analgesic", "and", "nonsteroidal", "anti", "-", "inflammatory", "use", "and", "end", "-", "stage", "renal", "disease", ".", "BACKGROUND", ":", "Studies", "on", "the", "association", "between", "the", "long", "-", "term", "use", "of", "aspirin", "and", "other", "analgesic", "and", "nonsteroidal", "anti", "-", "inflammatory", "drugs", "(", "NSAIDs", ")", "and", "end", "-", "stage", "renal", "disease", "(", "ESRD", ")", "have", "given", "conflicting", "results", ".", "In", "order", "to", "examine", "this", "association", ",", "a", "case", "-", "control", "study", "with", "incident", "cases", "of", "ESRD", "was", "carried", "out", ".", "METHODS", ":", "The", "cases", "were", "all", "patients", "entering", "the", "local", "dialysis", "program", "because", "of", "ESRD", "in", "the", "study", "area", "between", "June", "1", ",", "1995", "and", "November", "30", ",", "1997", ".", "They", "were", "classified", "according", "to", "the", "underlying", "disease", ",", "which", "had", "presumably", "led", "them", "to", "ESRD", ".", "Controls", "were", "patients", "admitted", "to", "the", "same", "hospitals", "from", "where", "the", "cases", "arose", ",", "also", "matched", "by", "age", "and", "sex", ".", "Odds", "ratios", "were", "calculated", "using", "a", "conditional", "logistic", "model", ",", "including", "potential", "confounding", "factors", ",", "both", "for", "the", "whole", "study", "population", "and", "for", "the", "various", "underlying", "diseases", ".", "RESULTS", ":", "Five", "hundred", "and", "eighty", "-", "three", "cases", "and", "1190", "controls", "were", "included", "in", "the", "analysis", ".", "Long", "-", "term", "use", "of", "any", "analgesic", "was", "associated", "with", "an", "overall", "odds", "ratio", "of", "1", ".", "22", "(", "95", "%", "CI", ",", "0", ".", "89", "-", "1", ".", "66", ")", ".", "For", "specific", "groups", "of", "drugs", ",", "the", "risks", "were", "1", ".", "56", "(", "1", ".", "05", "-", "2", ".", "30", ")", "for", "aspirin", ",", "1", ".", "03", "(", "0", ".", "60", "-", "1", ".", "76", ")", "for", "pyrazolones", ",", "0", ".", "80", "(", "0", ".", "39", "-", "1", ".", "63", ")", "for", "paracetamol", ",", "and", "0", ".", "94", "(", "0", ".", "57", "-", "1", ".", "56", ")", "for", "nonaspirin", "NSAIDs", ".", "The", "risk", "of", "ESRD", "associated", "with", "aspirin", "was", "related", "to", "the", "cumulated", "dose", "and", "duration", "of", "use", ",", "and", "it", "was", "particularly", "high", "among", "the", "subset", "of", "patients", "with", "vascular", "nephropathy", "as", "underlying", "disease", "[", "2", ".", "35", "(", "1", ".", "17", "-", "4", ".", "72", ")", "]", ".", "CONCLUSION", ":", "Our", "data", "indicate", "that", "long", "-", "term", "use", "of", "nonaspirin", "analgesic", "drugs", "and", "NSAIDs", "is", "not", "associated", "with", "an", "increased", "risk", "of", "ESRD", ".", "However", ",", "the", "chronic", "use", "of", "aspirin", "may", "increase", "the", "risk", "of", "ESRD", "."]], "ner": [[[33, 33, "Chemical"], [249, 249, "Chemical"], [304, 304, "Chemical"], [379, 379, "Chemical"], [14, 18, "Disease"], [47, 51, "Disease"], [53, 53, "Disease"], [76, 76, "Disease"], [95, 95, "Disease"], [126, 126, "Disease"], [301, 301, "Disease"], [371, 371, "Disease"], [385, 385, "Disease"], [264, 264, "Chemical"], [279, 279, "Chemical"], [328, 328, "Disease"]]], "relations": [[[33, 33, 14, 18, "CID"], [33, 33, 47, 51, "CID"], [33, 33, 53, 53, "CID"], [33, 33, 76, 76, "CID"], [33, 33, 95, 95, "CID"], [33, 33, 126, 126, "CID"], [33, 33, 301, 301, "CID"], [33, 33, 371, 371, "CID"], [33, 33, 385, 385, "CID"], [249, 249, 14, 18, "CID"], [249, 249, 47, 51, "CID"], [249, 249, 53, 53, "CID"], [249, 249, 76, 76, "CID"], [249, 249, 95, 95, "CID"], [249, 249, 126, 126, "CID"], [249, 249, 301, 301, "CID"], [249, 249, 371, 371, "CID"], [249, 249, 385, 385, "CID"], [304, 304, 14, 18, "CID"], [304, 304, 47, 51, "CID"], [304, 304, 53, 53, "CID"], [304, 304, 76, 76, "CID"], [304, 304, 95, 95, "CID"], [304, 304, 126, 126, "CID"], [304, 304, 301, 301, "CID"], [304, 304, 371, 371, "CID"], [304, 304, 385, 385, "CID"], [379, 379, 14, 18, "CID"], [379, 379, 47, 51, "CID"], [379, 379, 53, 53, "CID"], [379, 379, 76, 76, "CID"], [379, 379, 95, 95, "CID"], [379, 379, 126, 126, "CID"], [379, 379, 301, 301, "CID"], [379, 379, 371, 371, "CID"], [379, 379, 385, 385, "CID"]]], "clusters": [], "translated": "常规镇痛药和非甾体类抗炎药的使用与<4>终末期肾病</4>的病例对照研究。背景：长期服用<0>阿司匹林</0>等镇痛药和非甾体抗炎药(NSAIDs)与<5>终末期肾病</5>的相关性研究(<6>ESRD</6>)给出了相互矛盾的结果。为了检查这种关联，对<7>ESRD</7>事件进行了病例对照研究。方法：病例均为研究区1995年6月1日至1997年11月30日因<8>ESRD</8>进入当地透析项目的患者。他们根据可能导致他们进入<9>ESRD</9>的基础疾病进行分类。对照组是出现病例的同一家医院收治的患者，年龄和性别也相匹配。比值比是使用条件逻辑模型计算的，包括潜在的混杂因素，既适用于整个研究人群，也适用于各种潜在疾病。结果：583个病例和1190个对照被纳入分析。长期使用任何镇痛药的总体比值比为1.22 (95% CI, 0.89-1.66)。对于特定的药物组，风险为1.56 (1.05-2.30)对于<1>阿司匹林</1>，1.03 (0.60-1.76)对于<13>吡唑啉酮</13>，0.80(0.39-1.63)对于<14>对乙酰氨基酚</14>，而0.94(0.57-1.56)对于非阿司匹林NSAID。<10>终末期肾病</10>与<2>阿司匹林</2>相关的风险与累积剂量和使用时间有关，在血管性<15>肾病</15>作为基础疾病[2.35(1.17-4.72)]。结论：我们的数据表明，长期使用非阿司匹林镇痛药和NSAIDs与<11>ESRD</11>风险增加无关。然而，长期服用<3>阿司匹林</3>可能会增加<12>终末期肾病</12>的风险。", "revised": true}
{"doc_key": "15614572", "sentences": [["Effects", "of", "the", "antidepressant", "trazodone", ",", "a", "5", "-", "HT", "2A", "/", "2C", "receptor", "antagonist", ",", "on", "dopamine", "-", "dependent", "behaviors", "in", "rats", ".", "RATIONALE", ":", "5", "-", "Hydroxytryptamine", ",", "via", "stimulation", "of", "5", "-", "HT", "2C", "receptors", ",", "exerts", "a", "tonic", "inhibitory", "influence", "on", "dopaminergic", "neurotransmission", ",", "whereas", "activation", "of", "5", "-", "HT", "2A", "receptors", "enhances", "stimulated", "DAergic", "neurotransmission", ".", "The", "antidepressant", "trazodone", "is", "a", "5", "-", "HT", "2A", "/", "2C", "receptor", "antagonist", ".", "OBJECTIVES", ":", "To", "evaluate", "the", "effect", "of", "trazodone", "treatment", "on", "behaviors", "dependent", "on", "the", "functional", "status", "of", "the", "nigrostriatal", "DAergic", "system", ".", "METHODS", ":", "The", "effect", "of", "pretreatment", "with", "trazodone", "on", "dexamphetamine", "-", "and", "apomorphine", "-", "induced", "oral", "stereotypies", ",", "on", "catalepsy", "induced", "by", "haloperidol", "and", "apomorphine", "(", "0", ".", "05", "mg", "/", "kg", ",", "i", ".", "p", ".", ")", ",", "on", "ergometrine", "-", "induced", "wet", "dog", "shake", "(", "WDS", ")", "behavior", "and", "fluoxetine", "-", "induced", "penile", "erections", "was", "studied", "in", "rats", ".", "We", "also", "investigated", "whether", "trazodone", "induces", "catalepsy", "in", "rats", ".", "RESULTS", ":", "Trazodone", "at", "2", ".", "5", "-", "20", "mg", "/", "kg", "i", ".", "p", ".", "did", "not", "induce", "catalepsy", ",", "and", "did", "not", "antagonize", "apomorphine", "(", "1", ".", "5", "and", "3", "mg", "/", "kg", ")", "stereotypy", "and", "apomorphine", "(", "0", ".", "05", "mg", "/", "kg", ")", "-", "induced", "catalepsy", ".", "However", ",", "pretreatment", "with", "5", ",", "10", "and", "20", "mg", "/", "kg", "i", ".", "p", ".", "trazodone", "enhanced", "dexamphetamine", "stereotypy", ",", "and", "antagonized", "haloperidol", "catalepsy", ",", "ergometrine", "-", "induced", "WDS", "behavior", "and", "fluoxetine", "-", "induced", "penile", "erections", ".", "Trazodone", "at", "30", ",", "40", "and", "50", "mg", "/", "kg", "i", ".", "p", ".", "induced", "catalepsy", "and", "antagonized", "apomorphine", "and", "dexamphetamine", "stereotypies", ".", "CONCLUSIONS", ":", "Our", "results", "indicate", "that", "trazodone", "at", "2", ".", "5", "-", "20", "mg", "/", "kg", "does", "not", "block", "pre", "-", "and", "postsynaptic", "striatal", "D2", "DA", "receptors", ",", "while", "at", "30", ",", "40", "and", "50", "mg", "/", "kg", "it", "blocks", "postsynaptic", "striatal", "D2", "DA", "receptors", ".", "Furthermore", ",", "at", "5", ",", "10", "and", "20", "mg", "/", "kg", ",", "trazodone", "blocks", "5", "-", "HT", "2A", "and", "5", "-", "HT", "2C", "receptors", ".", "We", "suggest", "that", "trazodone", "(", "5", ",", "10", "and", "20", "mg", "/", "kg", ")", ",", "by", "blocking", "the", "5", "-", "HT", "2C", "receptors", ",", "releases", "the", "nigrostriatal", "DAergic", "neurons", "from", "tonic", "inhibition", "caused", "by", "5", "-", "HT", ",", "and", "thereby", "potentiates", "dexamphetamine", "stereotypy", "and", "antagonizes", "haloperidol", "catalepsy", "."]], "ner": [[[109, 109, "Chemical"], [121, 121, "Chemical"], [193, 193, "Chemical"], [206, 206, "Chemical"], [275, 275, "Chemical"], [116, 116, "Disease"], [164, 164, "Disease"], [187, 187, "Disease"], [217, 217, "Disease"], [243, 243, "Disease"], [272, 272, "Disease"], [397, 397, "Disease"], [119, 119, "Chemical"], [242, 242, "Chemical"], [396, 396, "Chemical"], [4, 4, "Chemical"], [63, 63, "Chemical"], [82, 82, "Chemical"], [104, 104, "Chemical"], [162, 162, "Chemical"], [170, 170, "Chemical"], [235, 235, "Chemical"], [257, 257, "Chemical"], [286, 286, "Chemical"], [338, 338, "Chemical"], [354, 354, "Chemical"], [112, 113, "Disease"], [7, 9, "Chemical"], [26, 28, "Chemical"], [33, 35, "Chemical"], [51, 53, "Chemical"], [66, 68, "Chemical"], [340, 342, "Chemical"], [345, 347, "Chemical"], [369, 371, "Chemical"], [385, 387, "Chemical"], [17, 17, "Chemical"], [106, 106, "Chemical"], [237, 237, "Chemical"], [277, 277, "Chemical"], [392, 392, "Chemical"], [137, 137, "Chemical"], [245, 245, "Chemical"], [148, 148, "Chemical"], [251, 251, "Chemical"]]], "relations": [[[109, 109, 116, 116, "CID"], [109, 109, 164, 164, "CID"], [109, 109, 187, 187, "CID"], [109, 109, 217, 217, "CID"], [109, 109, 243, 243, "CID"], [109, 109, 272, 272, "CID"], [109, 109, 397, 397, "CID"], [121, 121, 116, 116, "CID"], [121, 121, 164, 164, "CID"], [121, 121, 187, 187, "CID"], [121, 121, 217, 217, "CID"], [121, 121, 243, 243, "CID"], [121, 121, 272, 272, "CID"], [121, 121, 397, 397, "CID"], [193, 193, 116, 116, "CID"], [193, 193, 164, 164, "CID"], [193, 193, 187, 187, "CID"], [193, 193, 217, 217, "CID"], [193, 193, 243, 243, "CID"], [193, 193, 272, 272, "CID"], [193, 193, 397, 397, "CID"], [206, 206, 116, 116, "CID"], [206, 206, 164, 164, "CID"], [206, 206, 187, 187, "CID"], [206, 206, 217, 217, "CID"], [206, 206, 243, 243, "CID"], [206, 206, 272, 272, "CID"], [206, 206, 397, 397, "CID"], [275, 275, 116, 116, "CID"], [275, 275, 164, 164, "CID"], [275, 275, 187, 187, "CID"], [275, 275, 217, 217, "CID"], [275, 275, 243, 243, "CID"], [275, 275, 272, 272, "CID"], [275, 275, 397, 397, "CID"], [119, 119, 116, 116, "CID"], [119, 119, 164, 164, "CID"], [119, 119, 187, 187, "CID"], [119, 119, 217, 217, "CID"], [119, 119, 243, 243, "CID"], [119, 119, 272, 272, "CID"], [119, 119, 397, 397, "CID"], [242, 242, 116, 116, "CID"], [242, 242, 164, 164, "CID"], [242, 242, 187, 187, "CID"], [242, 242, 217, 217, "CID"], [242, 242, 243, 243, "CID"], [242, 242, 272, 272, "CID"], [242, 242, 397, 397, "CID"], [396, 396, 116, 116, "CID"], [396, 396, 164, 164, "CID"], [396, 396, 187, 187, "CID"], [396, 396, 217, 217, "CID"], [396, 396, 243, 243, "CID"], [396, 396, 272, 272, "CID"], [396, 396, 397, 397, "CID"]]], "clusters": [], "translated": "抗抑郁药<15>曲唑酮</15>，一种<27>5-HT</27> 2A/2C 受体拮抗剂，对大鼠<36>多巴胺</36>依赖行为的影响。基本原理：<28>5-羟色胺</28>通过刺激<29>5-HT</29> 2C 受体，对多巴胺能神经传递产生强直抑制作用，而激活<30>5-HT</30>2A 受体增强了受刺激的 DAergic 神经传递。抗抑郁药<16>曲唑酮</16>是一种<31>5-HT</31>2A/2C受体拮抗剂。目的：评估<17>曲唑酮</17>治疗对依赖于黑质纹状体 DAergic 系统功能状态的行为的影响。方法：用<18>曲唑酮</18>预处理对<37>右苯丙胺</37>和<0>阿朴吗啡</0>诱导的<26>口腔刻板印象</26>，对<12>氟哌啶醇</12>和<1>阿扑莫芬</1>诱导的<5>催化</5>的影响 （0.05 mg/kg，i.p.）对<41>麦角新碱</41>诱导的强直性昏厥和<43>氟西汀</43>诱导的阴茎勃起。我们还研究了<19>曲唑酮</19>是否会在大鼠中诱发<6>强直性昏厥</6>。结果：<20>曲唑酮</20>，2.5-20毫克/千克i.p.不诱发<7>强直性昏厥</7>，不拮抗<2>阿扑吗啡</2>（1.5和3 mg/kg）刻板和<3>阿朴吗啡</3>（0.05 mg/kg）-诱发<8>强直性昏厥</8>。然而，预处理用5、10和20 mg/kg i.p.的<21>曲唑酮</21>增强<38>右苯丙胺</38>刻板印象，并拮抗<13>氟哌啶醇</13><9>僵直</9>、<42>麦角新碱</42>诱导的WDS行为和<44>氟西汀</44>-诱导阴茎勃起。<22>曲唑酮</22>，30、40和50 mg/kg i.p.诱发<10>强直性昏厥</10>并拮抗<4>阿朴吗啡 </4>和<39>右苯丙胺</39>刻板印象。结论：我们的结果表明<23>曲唑酮</23>在2.5-20 mg/kg不阻断突触前和突触后纹状体D2 DA受体，而在30、40和50 mg/kg 时它阻断突触后纹状体D2 DA受体。此外，在5、10和20 mg/kg时，<24>曲唑酮</24>阻断<32>5-HT</32>2A和<33>5-HT</33>2C 受体。我们建议<25> 曲唑酮</25> （5、10和20 mg/kg），通过阻断<34>5-HT</34>2C受体，从 <35> 5-HT </35>引起的强直抑制中释放黑质纹状体 DAergic 神经元，从而增强<40>右苯丙胺</40>刻板作用，拮抗<14>氟哌啶醇</14><11> 强直性昏厥</11>。", "revised": true}
{"doc_key": "16083708", "sentences": [["Drug", "-", "induced", "liver", "injury", ":", "an", "analysis", "of", "461", "incidences", "submitted", "to", "the", "Spanish", "registry", "over", "a", "10", "-", "year", "period", ".", "BACKGROUND", "&", "AIMS", ":", "Progress", "in", "the", "understanding", "of", "susceptibility", "factors", "to", "drug", "-", "induced", "liver", "injury", "(", "DILI", ")", "and", "outcome", "predictability", "are", "hampered", "by", "the", "lack", "of", "systematic", "programs", "to", "detect", "bona", "fide", "cases", ".", "METHODS", ":", "A", "cooperative", "network", "was", "created", "in", "1994", "in", "Spain", "to", "identify", "all", "suspicions", "of", "DILI", "following", "a", "prospective", "structured", "report", "form", ".", "The", "liver", "damage", "was", "characterized", "according", "to", "hepatocellular", ",", "cholestatic", ",", "and", "mixed", "laboratory", "criteria", "and", "to", "histologic", "criteria", "when", "available", ".", "Further", "evaluation", "of", "causality", "assessment", "was", "centrally", "performed", ".", "RESULTS", ":", "Since", "April", "1994", "to", "August", "2004", ",", "461", "out", "of", "570", "submitted", "cases", ",", "involving", "505", "drugs", ",", "were", "deemed", "to", "be", "related", "to", "DILI", ".", "The", "antiinfective", "group", "of", "drugs", "was", "the", "more", "frequently", "incriminated", ",", "amoxicillin", "-", "clavulanate", "accounting", "for", "the", "12", ".", "8", "%", "of", "the", "whole", "series", ".", "The", "hepatocellular", "pattern", "of", "damage", "was", "the", "most", "common", "(", "58", "%", ")", ",", "was", "inversely", "correlated", "with", "age", "(", "P", "<", ".", "0001", ")", ",", "and", "had", "the", "worst", "outcome", "(", "Cox", "regression", ",", "P", "<", ".", "034", ")", ".", "Indeed", ",", "the", "incidence", "of", "liver", "transplantation", "and", "death", "in", "this", "group", "was", "11", ".", "7", "%", "if", "patients", "had", "jaundice", "at", "presentation", ",", "whereas", "the", "corresponding", "figure", "was", "3", ".", "8", "%", "in", "nonjaundiced", "patients", "(", "P", "<", ".", "04", ")", ".", "Factors", "associated", "with", "the", "development", "of", "fulminant", "hepatic", "failure", "were", "female", "sex", "(", "OR", "=", "25", ";", "95", "%", "CI", ":", "4", ".", "1", "-", "151", ";", "P", "<", ".", "0001", ")", ",", "hepatocellular", "damage", "(", "OR", "=", "7", ".", "9", ";", "95", "%", "CI", ":", "1", ".", "6", "-", "37", ";", "P", "<", ".", "009", ")", ",", "and", "higher", "baseline", "plasma", "bilirubin", "value", "(", "OR", "=", "1", ".", "15", ";", "95", "%", "CI", ":", "1", ".", "09", "-", "1", ".", "22", ";", "P", "<", ".", "0001", ")", ".", "CONCLUSIONS", ":", "Patients", "with", "drug", "-", "induced", "hepatocellular", "jaundice", "have", "11", ".", "7", "%", "chance", "of", "progressing", "to", "death", "or", "transplantation", ".", "Amoxicillin", "-", "clavulanate", "stands", "out", "as", "the", "most", "common", "drug", "related", "to", "DILI", "."]], "ner": [[[154, 156, "Chemical"], [364, 366, "Chemical"], [0, 4, "Disease"], [35, 39, "Disease"], [41, 41, "Disease"], [76, 76, "Disease"], [85, 86, "Disease"], [141, 141, "Disease"], [376, 376, "Disease"], [230, 230, "Disease"], [350, 350, "Disease"], [315, 315, "Chemical"], [93, 93, "Disease"], [259, 261, "Disease"]]], "relations": [[[154, 156, 0, 4, "CID"], [154, 156, 35, 39, "CID"], [154, 156, 41, 41, "CID"], [154, 156, 76, 76, "CID"], [154, 156, 85, 86, "CID"], [154, 156, 141, 141, "CID"], [154, 156, 376, 376, "CID"], [364, 366, 0, 4, "CID"], [364, 366, 35, 39, "CID"], [364, 366, 41, 41, "CID"], [364, 366, 76, 76, "CID"], [364, 366, 85, 86, "CID"], [364, 366, 141, 141, "CID"], [364, 366, 376, 376, "CID"], [154, 156, 230, 230, "CID"], [154, 156, 350, 350, "CID"], [364, 366, 230, 230, "CID"], [364, 366, 350, 350, "CID"]]], "clusters": [], "translated": " <2>药物性肝损伤</2>：对10年期间提交给西班牙登记处的461起事件的分析。背景和目的：<3>药物性肝损伤</3> (<4>DILI</4>)易感因素的理解进展和结果的可预测性因缺乏检测真实病例的系统程序而受到阻碍。方法：1994年在西班牙创建了一个合作网络，以根据前瞻性结构化报告表确定所有对<5>DILI</5>的怀疑。<6>肝损伤</6>的特征是根据肝细胞、<12>胆汁淤积</12>和混合实验室标准以及可用的组织学标准。因果关系评估的进一步评估集中进行。结果：自1994年4月至2004年8月，提交的570例中有461例涉及505种药物，被认为与<7>DILI</7>有关。抗感染类药物出现频率最高，<0>阿莫西林-克拉维酸盐</0>占12.8%的整个系列。肝细胞损伤模式最常见(58%)，与年龄呈负相关(P<.0001)，结果最差(Cox回归，P<.034)。事实上，该组肝移植和死亡的发生率为11.7%，如果患者在就诊时有<9>黄疸</9>，而相应的数字是3.8%的非黄疸患者(P<.04)。与<13>暴发性肝衰竭</13>发生相关的因素是女性(OR=25; 95%CI: 4.1-151; P<.0001)，肝细胞损伤(OR=7.9; 95%CI: 1.6-37; P<.009)，以及更高的基线血浆<11>胆红素</11>值(OR=1.15; 95%CI: 1.09-1.22; P<.0001)。结论：药物性肝细胞性<10>黄疸</10>患者有11.7%的机会发展到死亡或移植。<1>阿莫西林-克拉维酸盐</1>是最常见的<8>DILI</8>相关药物。", "revised": true}
{"doc_key": "16092435", "sentences": [["Morphological", "evaluation", "of", "the", "effect", "of", "d", "-", "ribose", "on", "adriamycin", "-", "evoked", "cardiotoxicity", "in", "rats", ".", "The", "influence", "of", "d", "-", "ribose", "on", "adriamycin", "-", "induced", "myocardiopathy", "in", "rats", "was", "studied", ".", "Adriamycin", "in", "the", "cumulative", "dose", "of", "25", "mg", "/", "kg", "evoked", "fully", "developed", "cardiac", "toxicity", ".", "D", "-", "ribose", "in", "the", "multiple", "doses", "of", "200", "mg", "/", "kg", "did", "not", "influence", "ADR", "cardiotoxicity", "."]], "ner": [[[10, 10, "Chemical"], [24, 24, "Chemical"], [33, 33, "Chemical"], [64, 64, "Chemical"], [27, 27, "Disease"], [6, 8, "Chemical"], [20, 22, "Chemical"], [49, 51, "Chemical"], [13, 13, "Disease"], [46, 47, "Disease"], [65, 65, "Disease"]]], "relations": [[[10, 10, 27, 27, "CID"], [24, 24, 27, 27, "CID"], [33, 33, 27, 27, "CID"], [64, 64, 27, 27, "CID"]]], "clusters": [], "translated": "<5>d-核糖</5>对<0>阿霉素</0>引起的<8>心脏毒性</8>的影响进行了大鼠形态学评价。研究发现<6>d-核糖</6>对<1>阿霉素</1>致大鼠<4>心肌病</4>的影响。累积剂量为25 mg/kg的<2>阿霉素</2>可引发全身<9>心脏毒性</9>。多次给予200 mg/kg的<7>D-核糖</7>未对<3>ADR</3>引起的<10>心脏毒性</10>产生影响。", "revised": true}
{"doc_key": "15096374", "sentences": [["Induction", "of", "rosaceiform", "dermatitis", "during", "treatment", "of", "facial", "inflammatory", "dermatoses", "with", "tacrolimus", "ointment", ".", "BACKGROUND", ":", "Tacrolimus", "ointment", "is", "increasingly", "used", "for", "anti", "-", "inflammatory", "treatment", "of", "sensitive", "areas", "such", "as", "the", "face", ",", "and", "recent", "observations", "indicate", "that", "the", "treatment", "is", "effective", "in", "steroid", "-", "aggravated", "rosacea", "and", "perioral", "dermatitis", ".", "We", "report", "on", "rosaceiform", "dermatitis", "as", "a", "complication", "of", "treatment", "with", "tacrolimus", "ointment", ".", "OBSERVATIONS", ":", "Six", "adult", "patients", "with", "inflammatory", "facial", "dermatoses", "were", "treated", "with", "tacrolimus", "ointment", "because", "of", "the", "ineffectiveness", "of", "standard", "treatments", ".", "Within", "2", "to", "3", "weeks", "of", "initially", "effective", "and", "well", "-", "tolerated", "treatment", ",", "3", "patients", "with", "a", "history", "of", "rosacea", "and", "1", "with", "a", "history", "of", "acne", "experienced", "sudden", "worsening", "with", "pustular", "rosaceiform", "lesions", ".", "Biopsy", "revealed", "an", "abundance", "of", "Demodex", "mites", "in", "2", "of", "these", "patients", ".", "In", "1", "patient", "with", "eyelid", "eczema", ",", "rosaceiform", "periocular", "dermatitis", "gradually", "appeared", "after", "3", "weeks", "of", "treatment", ".", "In", "1", "patient", "with", "atopic", "dermatitis", ",", "telangiectatic", "and", "papular", "rosacea", "insidiously", "appeared", "after", "5", "months", "of", "treatment", ".", "CONCLUSIONS", ":", "Our", "observations", "suggest", "that", "the", "spectrum", "of", "rosaceiform", "dermatitis", "as", "a", "complication", "of", "treatment", "with", "tacrolimus", "ointment", "is", "heterogeneous", ".", "A", "variety", "of", "factors", ",", "such", "as", "vasoactive", "properties", "of", "tacrolimus", ",", "proliferation", "of", "Demodex", "due", "to", "local", "immunosuppression", ",", "and", "the", "occlusive", "properties", "of", "the", "ointment", ",", "may", "be", "involved", "in", "the", "observed", "phenomena", ".", "Future", "studies", "are", "needed", "to", "identify", "individual", "risk", "factors", "."]], "ner": [[[11, 11, "Chemical"], [16, 16, "Chemical"], [63, 63, "Chemical"], [78, 78, "Chemical"], [191, 191, "Chemical"], [206, 206, "Chemical"], [47, 47, "Disease"], [108, 108, "Disease"], [164, 165, "Disease"], [3, 3, "Disease"], [56, 56, "Disease"], [184, 184, "Disease"], [44, 44, "Chemical"], [7, 9, "Disease"], [72, 74, "Disease"], [49, 50, "Disease"], [145, 146, "Disease"], [115, 115, "Disease"], [142, 142, "Disease"], [159, 160, "Disease"]]], "relations": [[[11, 11, 47, 47, "CID"], [11, 11, 108, 108, "CID"], [11, 11, 164, 165, "CID"], [16, 16, 47, 47, "CID"], [16, 16, 108, 108, "CID"], [16, 16, 164, 165, "CID"], [63, 63, 47, 47, "CID"], [63, 63, 108, 108, "CID"], [63, 63, 164, 165, "CID"], [78, 78, 47, 47, "CID"], [78, 78, 108, 108, "CID"], [78, 78, 164, 165, "CID"], [191, 191, 47, 47, "CID"], [191, 191, 108, 108, "CID"], [191, 191, 164, 165, "CID"], [206, 206, 47, 47, "CID"], [206, 206, 108, 108, "CID"], [206, 206, 164, 165, "CID"]]], "clusters": [], "translated": "<0>他克莫司</0>软膏治疗<13>面部炎症性皮肤病</13>过程中酒渣鼻样<9>皮炎</9>的诱发。背景：<1>他克莫司</1>软膏越来越多地用于面部等敏感部位的抗炎治疗，最近的观察表明该治疗对<12>类固醇</12>-加重的<6>酒渣鼻</6>和<15>口周皮炎</15>是有效的。我们报告了酒渣鼻样<10>皮炎</10>作为<2>他克莫司</2>软膏治疗的并发症。观察结果：由于标准治疗无效，6名患有<14>炎症性面部皮肤病</14>的成年患者接受了<3>他克莫司</3>软膏治疗。在最初有效且耐受性良好的治疗后的2至3周内，3名有<7>酒渣鼻</7>病史的患者和1名有<17>痤疮</17>病史的患者突然恶化，出现酒渣鼻样脓疱样皮损。活检显示其中2名患者体内有大量蠕形螨。1例眼睑<18>湿疹</18>，治疗3周后逐渐出现酒渣鼻样<16>眼周皮炎</16>。1例<19>特应性皮炎</19>患者治疗5个月后隐匿性出现毛细血管扩张和<8>丘疹性红斑痤疮</8>。结论：我们的观察表明，酒渣鼻样<11>皮炎</11>作为<4>他克莫司</4>软膏治疗并发症的范围是异质的。多种因素，如<5>他克莫司</5>的血管活性、局部免疫抑制引起的蠕形螨增殖，以及软膏的封闭特性，都可能与观察到的现象有关。未来的研究需要确定个体风险因素。", "revised": true}
{"doc_key": "15605432", "sentences": [["Oxidative", "damage", "precedes", "nitrative", "damage", "in", "adriamycin", "-", "induced", "cardiac", "mitochondrial", "injury", ".", "The", "purpose", "of", "the", "present", "study", "was", "to", "determine", "if", "elevated", "reactive", "oxygen", "(", "ROS", ")", "/", "nitrogen", "species", "(", "RNS", ")", "reported", "to", "be", "present", "in", "adriamycin", "(", "ADR", ")", "-", "induced", "cardiotoxicity", "actually", "resulted", "in", "cardiomyocyte", "oxidative", "/", "nitrative", "damage", ",", "and", "to", "quantitatively", "determine", "the", "time", "course", "and", "subcellular", "localization", "of", "these", "postulated", "damage", "products", "using", "an", "in", "vivo", "approach", ".", "B6C3", "mice", "were", "treated", "with", "a", "single", "dose", "of", "20", "mg", "/", "kg", "ADR", ".", "Ultrastructural", "damage", "and", "levels", "of", "4", "-", "hydroxy", "-", "2", "-", "nonenal", "(", "4HNE", ")", "-", "protein", "adducts", "and", "3", "-", "nitrotyrosine", "(", "3NT", ")", "were", "analyzed", ".", "Quantitative", "ultrastructural", "damage", "using", "computerized", "image", "techniques", "showed", "cardiomyocyte", "injury", "as", "early", "as", "3", "hours", ",", "with", "mitochondria", "being", "the", "most", "extensively", "and", "progressively", "injured", "subcellular", "organelle", ".", "Analysis", "of", "4HNE", "protein", "adducts", "by", "immunogold", "electron", "microscopy", "showed", "appearance", "of", "4HNE", "protein", "adducts", "in", "mitochondria", "as", "early", "as", "3", "hours", ",", "with", "a", "peak", "at", "6", "hours", "and", "subsequent", "decline", "at", "24", "hours", ".", "3NT", "levels", "were", "significantly", "increased", "in", "all", "subcellular", "compartments", "at", "6", "hours", "and", "subsequently", "declined", "at", "24", "hours", ".", "Our", "data", "showed", "ADR", "induced", "4HNE", "-", "protein", "adducts", "in", "mitochondria", "at", "the", "same", "time", "point", "as", "when", "mitochondrial", "injury", "initially", "appeared", ".", "These", "results", "document", "for", "the", "first", "time", "in", "vivo", "that", "mitochondrial", "oxidative", "damage", "precedes", "nitrative", "damage", ".", "The", "progressive", "nature", "of", "mitochondrial", "injury", "suggests", "that", "mitochondria", ",", "not", "other", "subcellular", "organelles", ",", "are", "the", "major", "site", "of", "intracellular", "injury", "."]], "ner": [[[6, 6, "Chemical"], [40, 40, "Chemical"], [42, 42, "Chemical"], [90, 90, "Chemical"], [206, 206, "Chemical"], [10, 11, "Disease"], [221, 222, "Disease"], [236, 238, "Disease"], [247, 248, "Disease"], [46, 46, "Disease"], [25, 25, "Chemical"], [30, 30, "Chemical"], [97, 103, "Chemical"], [105, 105, "Chemical"], [150, 150, "Chemical"], [160, 160, "Chemical"], [208, 208, "Chemical"], [111, 113, "Chemical"], [115, 115, "Chemical"], [184, 184, "Chemical"]]], "relations": [[[6, 6, 10, 11, "CID"], [6, 6, 221, 222, "CID"], [6, 6, 236, 238, "CID"], [6, 6, 247, 248, "CID"], [40, 40, 10, 11, "CID"], [40, 40, 221, 222, "CID"], [40, 40, 236, 238, "CID"], [40, 40, 247, 248, "CID"], [42, 42, 10, 11, "CID"], [42, 42, 221, 222, "CID"], [42, 42, 236, 238, "CID"], [42, 42, 247, 248, "CID"], [90, 90, 10, 11, "CID"], [90, 90, 221, 222, "CID"], [90, 90, 236, 238, "CID"], [90, 90, 247, 248, "CID"], [206, 206, 10, 11, "CID"], [206, 206, 221, 222, "CID"], [206, 206, 236, 238, "CID"], [206, 206, 247, 248, "CID"]]], "clusters": [], "translated": "在<0>阿霉素</0>诱导的心脏<5>线粒体损伤</5>中，氧化损伤先于硝化损伤。本研究的目的是确定升高的活性<10>氧</10>（ROS）/<11>氮</11>物种（RNS）是否报告存在于<1>阿霉素</1>（<2>ADR</2>）诱导的<9>心脏毒性</9>实际上导致心肌细胞氧化/硝化损伤，并使用体内方法定量确定这些假定损伤产物的时程和亚细胞定位。B6C3小鼠单次给药20 mg/kg<3>ADR</3>。超微结构损伤和<12>4-羟基-2-壬烯醛</12>（<13>4HNE</13>）-蛋白加合物和<17>3-硝基酪氨酸</17>（<18>3NT</18>）进行了分析。使用计算机化图像技术的定量超微结构损伤显示心肌细胞损伤早在3小时，线粒体是最广泛和进行性损伤的亚细胞器。免疫金电镜分析<14>4HNE</14>蛋白加合物显示，<15>4HNE</15>蛋白加合物最早3小时在线粒体中出现，6小时达到峰值，24小时下降。<19>3NT</19>水平在所有亚细胞区室中在6小时时显着增加，随后在24小时时下降。我们的数据显示，<4>ADR</4>诱导线粒体中的<16>4HNE</16>-蛋白加合物与<6>线粒体损伤</6>最初出现的时间点相同。这些结果首次在体内证明<7>线粒体氧化损伤</7>先于硝化损伤。<8>线粒体损伤的进行性</8>表明，线粒体而非其他亚细胞器是细胞内损伤的主要部位。", "revised": true}
{"doc_key": "15987266", "sentences": [["Growth", "-", "associated", "protein", "43", "expression", "in", "hippocampal", "molecular", "layer", "of", "chronic", "epileptic", "rats", "treated", "with", "cycloheximide", ".", "PURPOSE", ":", "GAP43", "has", "been", "thought", "to", "be", "linked", "with", "mossy", "fiber", "sprouting", "(", "MFS", ")", "in", "various", "experimental", "models", "of", "epilepsy", ".", "To", "investigate", "how", "GAP43", "expression", "(", "GAP43", "-", "ir", ")", "correlates", "with", "MFS", ",", "we", "assessed", "the", "intensity", "(", "densitometry", ")", "and", "extension", "(", "width", ")", "of", "GAP43", "-", "ir", "in", "the", "inner", "molecular", "layer", "of", "the", "dentate", "gyrus", "(", "IML", ")", "of", "rats", "subject", "to", "status", "epilepticus", "induced", "by", "pilocarpine", "(", "Pilo", ")", ",", "previously", "injected", "or", "not", "with", "cycloheximide", "(", "CHX", ")", ",", "which", "has", "been", "shown", "to", "inhibit", "MFS", ".", "METHODS", ":", "CHX", "was", "injected", "before", "the", "Pilo", "injection", "in", "adult", "Wistar", "rats", ".", "The", "Pilo", "group", "was", "injected", "with", "the", "same", "drugs", ",", "except", "for", "CHX", ".", "Animals", "were", "killed", "between", "30", "and", "60", "days", "later", ",", "and", "brain", "sections", "were", "processed", "for", "GAP43", "immunohistochemistry", ".", "RESULTS", ":", "Densitometry", "showed", "no", "significant", "difference", "regarding", "GAP43", "-", "ir", "in", "the", "IML", "between", "Pilo", ",", "CHX", "+", "Pilo", ",", "and", "control", "groups", ".", "However", ",", "the", "results", "of", "the", "width", "of", "the", "GAP43", "-", "ir", "band", "in", "the", "IML", "showed", "that", "CHX", "+", "Pilo", "and", "control", "animals", "had", "a", "significantly", "larger", "band", "(", "p", "=", "0", ".", "03", ")", "as", "compared", "with", "that", "in", "the", "Pilo", "group", ".", "CONCLUSIONS", ":", "Our", "current", "finding", "that", "animals", "in", "the", "CHX", "+", "Pilo", "group", "have", "a", "GAP43", "-", "ir", "band", "in", "the", "IML", ",", "similar", "to", "that", "of", "controls", ",", "reinforces", "prior", "data", "on", "the", "blockade", "of", "MFS", "in", "these", "animals", ".", "The", "change", "in", "GAP43", "-", "ir", "present", "in", "Pilo", "-", "treated", "animals", "was", "a", "thinning", "of", "the", "band", "to", "a", "very", "narrow", "layer", "just", "above", "the", "granule", "cell", "layer", "that", "is", "likely", "to", "be", "associated", "with", "the", "loss", "of", "hilar", "cell", "projections", "that", "express", "GAP", "-", "43", "."]], "ner": [[[91, 91, "Chemical"], [93, 93, "Chemical"], [121, 121, "Chemical"], [129, 129, "Chemical"], [176, 176, "Chemical"], [180, 180, "Chemical"], [206, 206, "Chemical"], [228, 228, "Chemical"], [242, 242, "Chemical"], [280, 280, "Chemical"], [87, 88, "Disease"], [16, 16, "Chemical"], [101, 101, "Chemical"], [103, 103, "Chemical"], [116, 116, "Chemical"], [140, 140, "Chemical"], [178, 178, "Chemical"], [204, 204, "Chemical"], [240, 240, "Chemical"], [12, 12, "Disease"], [39, 39, "Disease"]]], "relations": [[[91, 91, 87, 88, "CID"], [93, 93, 87, 88, "CID"], [121, 121, 87, 88, "CID"], [129, 129, 87, 88, "CID"], [176, 176, 87, 88, "CID"], [180, 180, 87, 88, "CID"], [206, 206, 87, 88, "CID"], [228, 228, 87, 88, "CID"], [242, 242, 87, 88, "CID"], [280, 280, 87, 88, "CID"]]], "clusters": [], "translated": "<11>放线菌酮</11>慢性<19>癫痫</19>大鼠海马分子层生长相关蛋白43的表达。目的：在各种<20>癫痫</20>实验模型中，GAP43被认为与苔藓纤维发芽(MFS)相关。为了研究GAP43表达(GAP43-ir)如何与MFS相关联，我们评估了由<0>毛果芸香碱</0> (<1>Pilo</1>)诱导的<10>状态癫痫</10>，之前注射过或未注射过<12>放线菌酮</12> (<13>CHX</13>)，这已被证明可以抑制MFS。方法：<14>CHX</14>在成年Wistar大鼠<2>Pilo</2>注射前注射。<3>Pilo</3>组除<15>CHX</15>外注射相同药物。动物在30到60天后被处死，脑切片进行GAP43免疫组织化学处理。结果：密度测定显示<4>Pilo</4>、<16>CHX</16>+<5>Pilo</5>和对照组间IML中GAP43-ir无显着差异。然而，IML中GAP43-ir谱带宽度的结果显示，<17>CHX</17>+<6>Pilo</6>和对照动物具有明显更大的谱带(p=0.03)与<7>Pilo</7>组相比。结论：我们目前的发现是，<18>CHX</18>+<8>Pilo</8>组的动物在IML中有一个GAP43-ir带，与对照组相似，强化了先前关于阻断这些动物的MFS。GAP43的变化-在<9>Pilo</9>处理过的动物中存在-是一个非常窄的层，带变薄到颗粒细胞层正上方，这可能与表达GAP-43的肺门细胞投射有关。", "revised": true}
{"doc_key": "16034922", "sentences": [["Long", "term", "hormone", "therapy", "for", "perimenopausal", "and", "postmenopausal", "women", ".", "BACKGROUND", ":", "Hormone", "therapy", "(", "HT", ")", "is", "widely", "used", "for", "controlling", "menopausal", "symptoms", ".", "It", "has", "also", "been", "used", "for", "the", "management", "and", "prevention", "of", "cardiovascular", "disease", ",", "osteoporosis", "and", "dementia", "in", "older", "women", "but", "the", "evidence", "supporting", "its", "use", "for", "these", "indications", "is", "largely", "observational", ".", "OBJECTIVES", ":", "To", "assess", "the", "effect", "of", "long", "-", "term", "HT", "on", "mortality", ",", "heart", "disease", ",", "venous", "thromboembolism", ",", "stroke", ",", "transient", "ischaemic", "attacks", ",", "breast", "cancer", ",", "colorectal", "cancer", ",", "ovarian", "cancer", ",", "endometrial", "cancer", ",", "gallbladder", "disease", ",", "cognitive", "function", ",", "dementia", ",", "fractures", "and", "quality", "of", "life", ".", "SEARCH", "STRATEGY", ":", "We", "searched", "the", "following", "databases", "up", "to", "November", "2004", ":", "the", "Cochrane", "Menstrual", "Disorders", "and", "Subfertility", "Group", "Trials", "Register", ",", "Cochrane", "Central", "Register", "of", "Controlled", "Trials", "(", "CENTRAL", ")", ",", "MEDLINE", ",", "EMBASE", ",", "Biological", "Abstracts", ".", "Relevant", "non", "-", "indexed", "journals", "and", "conference", "abstracts", "were", "also", "searched", ".", "SELECTION", "CRITERIA", ":", "Randomised", "double", "-", "blind", "trials", "of", "HT", "(", "oestrogens", "with", "or", "without", "progestogens", ")", "versus", "placebo", ",", "taken", "for", "at", "least", "one", "year", "by", "perimenopausal", "or", "postmenopausal", "women", ".", "DATA", "COLLECTION", "AND", "ANALYSIS", ":", "Fifteen", "RCTs", "were", "included", ".", "Trials", "were", "assessed", "for", "quality", "and", "two", "review", "authors", "extracted", "data", "independently", ".", "They", "calculated", "risk", "ratios", "for", "dichotomous", "outcomes", "and", "weighted", "mean", "differences", "for", "continuous", "outcomes", ".", "Clinical", "heterogeneity", "precluded", "meta", "-", "analysis", "for", "most", "outcomes", ".", "MAIN", "RESULTS", ":", "All", "the", "statistically", "significant", "results", "were", "derived", "from", "the", "two", "biggest", "trials", ".", "In", "relatively", "healthy", "women", ",", "combined", "continuous", "HT", "significantly", "increased", "the", "risk", "of", "venous", "thromboembolism", "or", "coronary", "event", "(", "after", "one", "year", "'s", "use", ")", ",", "stroke", "(", "after", "3", "years", ")", ",", "breast", "cancer", "(", "after", "5", "years", ")", "and", "gallbladder", "disease", ".", "Long", "-", "term", "oestrogen", "-", "only", "HT", "also", "significantly", "increased", "the", "risk", "of", "stroke", "and", "gallbladder", "disease", ".", "Overall", ",", "the", "only", "statistically", "significant", "benefits", "of", "HT", "were", "a", "decreased", "incidence", "of", "fractures", "and", "colon", "cancer", "with", "long", "-", "term", "use", ".", "Among", "relatively", "healthy", "women", "over", "65", "years", "taking", "continuous", "combined", "HT", ",", "there", "was", "a", "statistically", "significant", "increase", "in", "the", "incidence", "of", "dementia", ".", "Among", "women", "with", "cardiovascular", "disease", ",", "long", "-", "term", "use", "of", "combined", "continuous", "HT", "significantly", "increased", "the", "risk", "of", "venous", "thromboembolism", ".", "No", "trials", "focussed", "specifically", "on", "younger", "women", ".", "However", ",", "one", "trial", "analysed", "subgroups", "of", "2839", "relatively", "healthy", "50", "to", "59", "year", "-", "old", "women", "taking", "combined", "continuous", "HT", "and", "1637", "taking", "oestrogen", "-", "only", "HT", ",", "versus", "similar", "-", "sized", "placebo", "groups", ".", "The", "only", "significantly", "increased", "risk", "reported", "was", "for", "venous", "thromboembolism", "in", "women", "taking", "combined", "continuous", "HT", ";", "their", "absolute", "risk", "remained", "very", "low", ".", "AUTHORS", "'", "CONCLUSIONS", ":", "HT", "is", "not", "indicated", "for", "the", "routine", "management", "of", "chronic", "disease", ".", "We", "need", "more", "evidence", "on", "the", "safety", "of", "HT", "for", "menopausal", "symptom", "control", ",", "though", "short", "-", "term", "use", "appears", "to", "be", "relatively", "safe", "for", "healthy", "younger", "women", "."]], "ner": [[[173, 173, "Chemical"], [305, 305, "Chemical"], [422, 422, "Chemical"], [36, 37, "Disease"], [371, 372, "Disease"], [177, 177, "Chemical"], [41, 41, "Disease"], [102, 102, "Disease"], [366, 366, "Disease"], [75, 76, "Disease"], [271, 272, "Disease"], [387, 388, "Disease"], [442, 443, "Disease"], [78, 78, "Disease"], [284, 284, "Disease"], [315, 315, "Disease"], [84, 85, "Disease"], [291, 292, "Disease"], [96, 97, "Disease"], [299, 300, "Disease"], [317, 318, "Disease"], [22, 23, "Disease"], [39, 39, "Disease"], [72, 73, "Disease"], [80, 82, "Disease"], [87, 88, "Disease"], [90, 91, "Disease"], [93, 94, "Disease"], [104, 104, "Disease"], [334, 334, "Disease"], [336, 337, "Disease"], [471, 472, "Disease"]]], "relations": [[[173, 173, 36, 37, "CID"], [173, 173, 371, 372, "CID"], [305, 305, 36, 37, "CID"], [305, 305, 371, 372, "CID"], [422, 422, 36, 37, "CID"], [422, 422, 371, 372, "CID"], [177, 177, 36, 37, "CID"], [177, 177, 371, 372, "CID"], [173, 173, 41, 41, "CID"], [173, 173, 102, 102, "CID"], [173, 173, 366, 366, "CID"], [305, 305, 41, 41, "CID"], [305, 305, 102, 102, "CID"], [305, 305, 366, 366, "CID"], [422, 422, 41, 41, "CID"], [422, 422, 102, 102, "CID"], [422, 422, 366, 366, "CID"], [177, 177, 41, 41, "CID"], [177, 177, 102, 102, "CID"], [177, 177, 366, 366, "CID"], [173, 173, 75, 76, "CID"], [173, 173, 271, 272, "CID"], [173, 173, 387, 388, "CID"], [173, 173, 442, 443, "CID"], [305, 305, 75, 76, "CID"], [305, 305, 271, 272, "CID"], [305, 305, 387, 388, "CID"], [305, 305, 442, 443, "CID"], [422, 422, 75, 76, "CID"], [422, 422, 271, 272, "CID"], [422, 422, 387, 388, "CID"], [422, 422, 442, 443, "CID"], [177, 177, 75, 76, "CID"], [177, 177, 271, 272, "CID"], [177, 177, 387, 388, "CID"], [177, 177, 442, 443, "CID"], [173, 173, 78, 78, "CID"], [173, 173, 284, 284, "CID"], [173, 173, 315, 315, "CID"], [305, 305, 78, 78, "CID"], [305, 305, 284, 284, "CID"], [305, 305, 315, 315, "CID"], [422, 422, 78, 78, "CID"], [422, 422, 284, 284, "CID"], [422, 422, 315, 315, "CID"], [177, 177, 78, 78, "CID"], [177, 177, 284, 284, "CID"], [177, 177, 315, 315, "CID"], [173, 173, 84, 85, "CID"], [173, 173, 291, 292, "CID"], [305, 305, 84, 85, "CID"], [305, 305, 291, 292, "CID"], [422, 422, 84, 85, "CID"], [422, 422, 291, 292, "CID"], [177, 177, 84, 85, "CID"], [177, 177, 291, 292, "CID"], [173, 173, 96, 97, "CID"], [173, 173, 299, 300, "CID"], [173, 173, 317, 318, "CID"], [305, 305, 96, 97, "CID"], [305, 305, 299, 300, "CID"], [305, 305, 317, 318, "CID"], [422, 422, 96, 97, "CID"], [422, 422, 299, 300, "CID"], [422, 422, 317, 318, "CID"], [177, 177, 96, 97, "CID"], [177, 177, 299, 300, "CID"], [177, 177, 317, 318, "CID"]]], "clusters": [], "translated": "围绝经期和绝经后妇女的长期激素治疗。背景：激素疗法 (HT) 广泛用于控制 <21> 绝经期症状 </21>。它还被用于管理和预防老年妇女的 <3> 心血管疾病 </3>、<22> 骨质疏松症 </22> 和 <6> 痴呆症 </6>，但支持其用于这些适应症的证据主要是观察性的。目的：评估长期 HT 对死亡率、<23> 心脏病 </23>、<9> 静脉血栓栓塞 </9>、<13> 中风 </13>、<24> 短暂性脑缺血发作 </24>、<16> 乳腺癌 </16>、<25> 结直肠癌 </25>、<26> 卵巢癌 </26>、<27> 子宫内膜癌 </27>、<18> 胆囊疾病 </18>、认知功能、<7> 痴呆 </7>、<28> 骨折 </28> 和生活质量。搜索策略：我们搜索了截至 2004 年 11 月的以下数据库：Cochrane 月经失调和生育力低下组试验注册库、Cochrane 对照试验中心注册库 (CENTRAL)、MEDLINE、EMBASE、Biological Abstracts。还搜索了相关的非索引期刊和会议摘要。选择标准：HT（<0> 雌激素 </0> 有或没有<5> 孕激素 </5>）与安慰剂的随机双盲试验，由围绝经期或绝经后妇女服用至少一年。数据收集和分析：包括 15 个随机对照试验。对试验进行质量评估，两位评价作者独立提取数据。他们计算了二分类结果的风险比和连续结果的加权平均差。临床异质性排除了对大多数结果的荟萃分析。主要结果：所有具有统计学意义的结果均来自两个最大的试验。在相对健康的女性中，联合连续 HT 显着增加了 <10> 静脉血栓栓塞 </10> 或冠状动脉事件 (使用一年后)、<14> 中风 </14> ( 3 年后)、<17> 乳腺癌 </17> ( 5 年后) 和 <19> 胆囊疾病 </19> 的风险。长期 <1> 雌激素 </1> -仅 HT 也显着增加了 <15> 中风 </15> 和 <20> 胆囊疾病 </20> 的风险。总的来说，HT 唯一具有统计学意义的好处是长期使用可降低 <29> 骨折 </29> 和 <30> 结肠癌 </30> 的发生率。在连续服用联合 HT 的 65 岁以上相对健康的女性中，<8> 痴呆症 </8> 的发病率显着增加。在患有<4> 心血管疾病 </4>的女性中，长期联合连续 HT 显着增加了<11> 静脉血栓栓塞 </11> 的风险。没有专门针对年轻女性的试验。然而，一项试验分析了 2839 名相对健康的 50 至 59 岁女性联合连续 HT 和 1637 名服用 <2> 雌激素 </2> 单独 HT 的亚组，与人数相似的安慰剂组。报告的唯一显着增加的风险是<12> 静脉血栓栓塞 </12> 在服用联合连续 HT 的女性中；他们的绝对风险仍然很低。作者的结论：HT 不适用于 <31> 慢性疾病 </31> 的常规管理。我们需要更多关于 HT 用于绝经期症状控制的安全性的证据，尽管短期使用对于健康的年轻女性来说似乎是相对安全的。", "revised": true}
{"doc_key": "15018178", "sentences": [["MRI", "findings", "of", "hypoxic", "cortical", "laminar", "necrosis", "in", "a", "child", "with", "hemolytic", "anemia", "crisis", ".", "We", "present", "magnetic", "resonance", "imaging", "findings", "of", "a", "5", "-", "year", "-", "old", "girl", "who", "had", "a", "rapidly", "installing", "hemolytic", "anemia", "crisis", "induced", "by", "trimethoprim", "-", "sulfomethoxazole", ",", "resulting", "in", "cerebral", "anoxia", "leading", "to", "permanent", "damage", ".", "Magnetic", "Resonance", "imaging", "revealed", "cortical", "laminar", "necrosis", "in", "arterial", "border", "zones", "in", "both", "cerebral", "hemispheres", ",", "ischemic", "changes", "in", "subcortical", "white", "matter", "of", "left", "cerebral", "hemisphere", ",", "and", "in", "the", "left", "putamen", ".", "Although", "cortical", "laminar", "necrosis", "is", "a", "classic", "entity", "in", "adulthood", "related", "to", "conditions", "of", "energy", "depletions", ",", "there", "are", "few", "reports", "available", "in", "children", ".", "A", "wide", "review", "of", "the", "literature", "is", "also", "presented", "."]], "ner": [[[39, 41, "Chemical"], [11, 12, "Disease"], [34, 35, "Disease"], [6, 6, "Disease"], [58, 58, "Disease"], [88, 88, "Disease"], [45, 46, "Disease"]]], "relations": [[[39, 41, 11, 12, "CID"], [39, 41, 34, 35, "CID"]]], "clusters": [], "translated": "<1>溶血性贫血</1>危象患儿缺氧皮质层状<3>坏死</3>的MRI表现。我们展示了一名5岁女孩的磁共振成像结果，她因<0>甲氧苄氨嘧啶-磺胺甲恶唑</0>诱发了快速发展的<2>溶血性贫血</2>危象，导致<6>脑缺氧</6>导致永久性损坏。磁共振成像显示双侧大脑半球动脉边界区皮质层状<4>坏死</4>，左侧大脑半球皮质下白质和左侧壳核缺血性改变。尽管皮质层状<5>坏死</5>是成年期与能量耗竭状况相关的典型实体，但在儿童中的报道很少。还介绍了对文献的广泛审查。", "revised": true}
{"doc_key": "16731636", "sentences": [["Enhanced", "isoproterenol", "-", "induced", "cardiac", "hypertrophy", "in", "transgenic", "rats", "with", "low", "brain", "angiotensinogen", ".", "We", "have", "previously", "shown", "that", "a", "permanent", "deficiency", "in", "the", "brain", "renin", "-", "angiotensin", "system", "(", "RAS", ")", "may", "increase", "the", "sensitivity", "of", "the", "baroreflex", "control", "of", "heart", "rate", ".", "In", "this", "study", "we", "aimed", "at", "studying", "the", "involvement", "of", "the", "brain", "RAS", "in", "the", "cardiac", "reactivity", "to", "the", "beta", "-", "adrenoceptor", "(", "beta", "-", "AR", ")", "agonist", "isoproterenol", "(", "Iso", ")", ".", "Transgenic", "rats", "with", "low", "brain", "angiotensinogen", "(", "TGR", ")", "were", "used", ".", "In", "isolated", "hearts", ",", "Iso", "induced", "a", "significantly", "greater", "increase", "in", "left", "ventricular", "(", "LV", ")", "pressure", "and", "maximal", "contraction", "(", "+", "dP", "/", "dt", "(", "max", ")", ")", "in", "the", "TGR", "than", "in", "the", "Sprague", "-", "Dawley", "(", "SD", ")", "rats", ".", "LV", "hypertrophy", "induced", "by", "Iso", "treatment", "was", "significantly", "higher", "in", "TGR", "than", "in", "SD", "rats", "(", "in", "g", "LV", "wt", "/", "100", "g", "body", "wt", ",", "0", ".", "28", "+", "/", "-", "0", ".", "004", "vs", ".", "0", ".", "24", "+", "/", "-", "0", ".", "004", ",", "respectively", ")", ".", "The", "greater", "LV", "hypertrophy", "in", "TGR", "rats", "was", "associated", "with", "more", "pronounced", "downregulation", "of", "beta", "-", "AR", "and", "upregulation", "of", "LV", "beta", "-", "AR", "kinase", "-", "1", "mRNA", "levels", "compared", "with", "those", "in", "SD", "rats", ".", "The", "decrease", "in", "the", "heart", "rate", "(", "HR", ")", "induced", "by", "the", "beta", "-", "AR", "antagonist", "metoprolol", "in", "conscious", "rats", "was", "significantly", "attenuated", "in", "TGR", "compared", "with", "SD", "rats", "(", "-", "9", ".", "9", "+", "/", "-", "1", ".", "7", "%", "vs", ".", "-", "18", ".", "1", "+", "/", "-", "1", ".", "5", "%", ")", ",", "whereas", "the", "effect", "of", "parasympathetic", "blockade", "by", "atropine", "on", "HR", "was", "similar", "in", "both", "strains", ".", "These", "results", "indicate", "that", "TGR", "are", "more", "sensitive", "to", "beta", "-", "AR", "agonist", "-", "induced", "cardiac", "inotropic", "response", "and", "hypertrophy", ",", "possibly", "due", "to", "chronically", "low", "sympathetic", "outflow", "directed", "to", "the", "heart", "."]], "ner": [[[1, 1, "Chemical"], [72, 72, "Chemical"], [74, 74, "Chemical"], [93, 93, "Chemical"], [136, 136, "Chemical"], [4, 5, "Disease"], [132, 133, "Disease"], [184, 185, "Disease"], [305, 306, "Disease"], [309, 309, "Disease"], [27, 27, "Chemical"], [234, 234, "Chemical"], [281, 281, "Chemical"]]], "relations": [[[1, 1, 4, 5, "CID"], [1, 1, 132, 133, "CID"], [1, 1, 184, 185, "CID"], [72, 72, 4, 5, "CID"], [72, 72, 132, 133, "CID"], [72, 72, 184, 185, "CID"], [74, 74, 4, 5, "CID"], [74, 74, 132, 133, "CID"], [74, 74, 184, 185, "CID"], [93, 93, 4, 5, "CID"], [93, 93, 132, 133, "CID"], [93, 93, 184, 185, "CID"], [136, 136, 4, 5, "CID"], [136, 136, 132, 133, "CID"], [136, 136, 184, 185, "CID"]]], "clusters": [], "translated": "增强<0>异丙肾上腺素</0>诱导的<5>心脏肥大</5>在脑血管紧张素原低的转基因大鼠中。我们之前已经表明，脑肾素-<10>血管紧张素</10>系统 (RAS) 的永久性缺陷可能会增加压力反射控制心率的敏感性。在这项研究中，我们旨在研究大脑 RAS 在心脏对 β-肾上腺素能受体 (β-AR) 激动剂<1>异丙肾上腺素</1>（<2>Iso</2>）的反应中的作用。使用低脑血管紧张素原(TGR)的转基因大鼠。在离体心脏中，<3>Iso</3>导致TGR大鼠的左心室(LV)压力和最大收缩（+dP/dt(max)）显着高于Sprague-Dawley(SD)大鼠。<6>左心室肥大</6>由<4>Iso</4>处理引起的TGR显着高于SD大鼠（单位为g LV wt / 100 g body wt，0.28 +/- 0.004 vs. 0.24 +/-0.004，分别）。与SD大鼠相比，TGR大鼠的<7>LV肥大</7>与更明显的β-AR下调和LV beta-AR激酶-1 mRNA水平的上调相关。与SD大鼠相比，在TGR中由β-AR拮抗剂<11>美托洛尔</11>诱导的清醒大鼠心率(HR)显着减弱（-9.9+/-1.7% vs. -18.1+/-1.5%），而<12>阿托品</12>对副交感神经阻滞的影响在两种菌株中的HR上是相似的。这些结果表明，TGR对β-AR激动剂诱导的<8>心肌收缩力</8>反应和<9>肥大</9>更敏感，这可能是由于指向心脏的交感神经流出量长期较低。", "revised": true}
{"doc_key": "15859361", "sentences": [["Safety", "of", "celecoxib", "in", "patients", "with", "adverse", "skin", "reactions", "to", "acetaminophen", "(", "paracetamol", ")", "and", "nimesulide", "associated", "or", "not", "with", "common", "non", "-", "steroidal", "anti", "-", "inflammatory", "drugs", ".", "BACKGROUND", ":", "Acetaminophen", "(", "paracetamol", "-", "-", "P", ")", "and", "Nimesulide", "(", "N", ")", "are", "widely", "used", "analgesic", "-", "antipyretic", "/", "anti", "-", "inflammatory", "drugs", ".", "The", "rate", "of", "adverse", "hypersensitivity", "reactions", "to", "these", "agents", "is", "generally", "low", ".", "On", "the", "contrary", "non", "-", "steroidal", "anti", "-", "inflammatory", "drugs", "(", "NSAIDs", ")", "are", "commonly", "involved", "in", "such", "reactions", ".", "Celecoxib", "(", "CE", ")", "is", "a", "novel", "drug", ",", "with", "high", "selectivity", "and", "affinity", "for", "COX", "-", "2", "enzyme", ".", "OBJECTIVE", ":", "We", "evaluated", "the", "tolerability", "of", "CE", "in", "a", "group", "of", "patients", "with", "documented", "history", "of", "adverse", "cutaneous", "reactions", "to", "P", "and", "N", "associated", "or", "not", "to", "classic", "NSAIDs", ".", "METHODS", ":", "We", "studied", "9", "patients", "with", "hypersensitivity", "to", "P", "and", "N", "with", "or", "without", "associated", "reactions", "to", "classic", "NSAIDs", ".", "The", "diagnosis", "of", "P", "and", "N", "-", "induced", "skin", "reactions", "was", "based", "in", "vivo", "challenge", ".", "The", "placebo", "was", "blindly", "administered", "at", "the", "beginning", "of", "each", "challenge", ".", "After", "three", "days", ",", "a", "cumulative", "dosage", "of", "200", "mg", "of", "CE", "in", "refracted", "doses", "were", "given", ".", "After", "2", "-", "3", "days", ",", "a", "single", "dose", "of", "200", "mg", "was", "administered", ".", "All", "patients", "were", "observed", "for", "6", "hours", "after", "each", "challenge", ",", "and", "controlled", "again", "after", "24", "hours", "to", "exclude", "delayed", "reactions", ".", "The", "challenge", "was", "considered", "positive", "if", "one", "or", "more", "of", "the", "following", "appeared", ":", "erythema", ",", "rush", "or", "urticaria", "-", "angioedema", ".", "RESULTS", ":", "No", "reaction", "was", "observed", "with", "placebo", "and", "eight", "patients", "(", "88", ".", "8", "%", ")", "tolerated", "CE", ".", "Only", "one", "patient", "developed", "a", "moderate", "angioedema", "of", "the", "lips", ".", "CONCLUSION", ":", "Only", "one", "hypersensitivity", "reaction", "to", "CE", "was", "documented", "among", "9", "P", "and", "N", "-", "highly", "NSAIDs", "intolerant", "patients", ".", "Thus", ",", "we", "conclude", "that", "CE", "is", "a", "reasonably", "safe", "alternative", "to", "be", "used", "in", "subjects", "who", "do", "not", "tolerate", "P", "and", "N", "."]], "ner": [[[2, 2, "Chemical"], [88, 88, "Chemical"], [90, 90, "Chemical"], [115, 115, "Chemical"], [199, 199, "Chemical"], [283, 283, "Chemical"], [303, 303, "Chemical"], [322, 322, "Chemical"], [263, 263, "Disease"], [291, 291, "Disease"], [10, 10, "Chemical"], [12, 12, "Chemical"], [31, 31, "Chemical"], [33, 33, "Chemical"], [36, 36, "Chemical"], [129, 129, "Chemical"], [148, 148, "Chemical"], [163, 163, "Chemical"], [308, 308, "Chemical"], [337, 337, "Chemical"], [7, 8, "Disease"], [126, 127, "Disease"], [168, 169, "Disease"], [15, 15, "Chemical"], [39, 39, "Chemical"], [41, 41, "Chemical"], [131, 131, "Chemical"], [150, 150, "Chemical"], [165, 165, "Chemical"], [310, 310, "Chemical"], [339, 339, "Chemical"], [59, 59, "Disease"], [146, 146, "Disease"], [300, 300, "Disease"], [257, 257, "Disease"], [261, 261, "Disease"]]], "relations": [[[2, 2, 263, 263, "CID"], [2, 2, 291, 291, "CID"], [88, 88, 263, 263, "CID"], [88, 88, 291, 291, "CID"], [90, 90, 263, 263, "CID"], [90, 90, 291, 291, "CID"], [115, 115, 263, 263, "CID"], [115, 115, 291, 291, "CID"], [199, 199, 263, 263, "CID"], [199, 199, 291, 291, "CID"], [283, 283, 263, 263, "CID"], [283, 283, 291, 291, "CID"], [303, 303, 263, 263, "CID"], [303, 303, 291, 291, "CID"], [322, 322, 263, 263, "CID"], [322, 322, 291, 291, "CID"], [10, 10, 7, 8, "CID"], [10, 10, 126, 127, "CID"], [10, 10, 168, 169, "CID"], [12, 12, 7, 8, "CID"], [12, 12, 126, 127, "CID"], [12, 12, 168, 169, "CID"], [31, 31, 7, 8, "CID"], [31, 31, 126, 127, "CID"], [31, 31, 168, 169, "CID"], [33, 33, 7, 8, "CID"], [33, 33, 126, 127, "CID"], [33, 33, 168, 169, "CID"], [36, 36, 7, 8, "CID"], [36, 36, 126, 127, "CID"], [36, 36, 168, 169, "CID"], [129, 129, 7, 8, "CID"], [129, 129, 126, 127, "CID"], [129, 129, 168, 169, "CID"], [148, 148, 7, 8, "CID"], [148, 148, 126, 127, "CID"], [148, 148, 168, 169, "CID"], [163, 163, 7, 8, "CID"], [163, 163, 126, 127, "CID"], [163, 163, 168, 169, "CID"], [308, 308, 7, 8, "CID"], [308, 308, 126, 127, "CID"], [308, 308, 168, 169, "CID"], [337, 337, 7, 8, "CID"], [337, 337, 126, 127, "CID"], [337, 337, 168, 169, "CID"], [15, 15, 7, 8, "CID"], [15, 15, 126, 127, "CID"], [15, 15, 168, 169, "CID"], [39, 39, 7, 8, "CID"], [39, 39, 126, 127, "CID"], [39, 39, 168, 169, "CID"], [41, 41, 7, 8, "CID"], [41, 41, 126, 127, "CID"], [41, 41, 168, 169, "CID"], [131, 131, 7, 8, "CID"], [131, 131, 126, 127, "CID"], [131, 131, 168, 169, "CID"], [150, 150, 7, 8, "CID"], [150, 150, 126, 127, "CID"], [150, 150, 168, 169, "CID"], [165, 165, 7, 8, "CID"], [165, 165, 126, 127, "CID"], [165, 165, 168, 169, "CID"], [310, 310, 7, 8, "CID"], [310, 310, 126, 127, "CID"], [310, 310, 168, 169, "CID"], [339, 339, 7, 8, "CID"], [339, 339, 126, 127, "CID"], [339, 339, 168, 169, "CID"]]], "clusters": [], "translated": "<0>塞来昔布</0>在对<10>对乙酰氨基酚</10>（<11>扑热息痛</11>）和<23>尼美舒利</23>有不良<20>皮肤反应</20>的患者中的安全性与普通非甾体类抗炎药相关或无关。背景：<12>对乙酰氨基酚</12>（<13>扑热息痛</13> - - <14>P</14>）和<24>尼美舒利</24>（<25>N</25>）是广泛使用的镇痛解热/抗炎药。对这些药物的不良<31>超敏反应</31>反应率通常较低。相反，非甾体抗炎药(NSAIDs)通常参与此类反应。<1>塞来昔布</1>(<2>CE</2>)是一种新型药物，对COX-2酶具有高选择性和亲和力。目的：我们评估了一组患者对<3>CE</3>的耐受性，这些患者有不良<21>皮肤反应</21>对<15>P</15>和<26>N</26>与经典NSAIDs相关或无关。方法：我们研究了9名对<16>P</16>和<27>N</27>有或没有对经典NSAIDs相关反应的<32>超敏反应</32>患者。<17>P</17>和<28>N</28>诱发的<22>皮肤反应</22>的诊断是基于体内刺激。安慰剂是在每次挑战开始时盲目服用的。三天后，给予累积剂量为200 mg的<4>CE</4>折射剂量。2-3天后，给予单剂量200毫克。每次挑战后观察所有患者6小时，并在24小时后再次控制以排除延迟反应。如果出现以下一项或多项，则认为挑战是积极的：<34>红斑</34>、皮疹或<35>荨麻疹</35>-<8>血管性水肿</8>。结果：安慰剂组未观察到反应，8名患者(88.8%)耐受<5>CE</5>。只有一名患者出现中度的嘴唇<9>血管性水肿</9>。结论：9例<18>P</18>和<29>N</29>对NSAIDs高度不耐受的患者中只有1例<6>CE</6>发生<33>超敏反应</33>。因此，我们得出结论，<7>CE</7>是一种相当安全的替代方案，可用于不能耐受<19>P</19>和<30>N</30>的受试者。", "revised": true}
{"doc_key": "16112787", "sentences": [["In", "vivo", "evidences", "suggesting", "the", "role", "of", "oxidative", "stress", "in", "pathogenesis", "of", "vancomycin", "-", "induced", "nephrotoxicity", ":", "protection", "by", "erdosteine", ".", "The", "aims", "of", "this", "study", "were", "to", "examine", "vancomycin", "(", "VCM", ")", "-", "induced", "oxidative", "stress", "that", "promotes", "production", "of", "reactive", "oxygen", "species", "(", "ROS", ")", "and", "to", "investigate", "the", "role", "of", "erdosteine", ",", "an", "expectorant", "agent", ",", "which", "has", "also", "antioxidant", "properties", ",", "on", "kidney", "tissue", "against", "the", "possible", "VCM", "-", "induced", "renal", "impairment", "in", "rats", ".", "Rats", "were", "divided", "into", "three", "groups", ":", "sham", ",", "VCM", "and", "VCM", "plus", "erdosteine", ".", "VCM", "was", "administrated", "intraperitoneally", "(", "i", ".", "p", ".", ")", "with", "200mgkg", "(", "-", "1", ")", "twice", "daily", "for", "7", "days", ".", "Erdosteine", "was", "administered", "orally", ".", "VCM", "administration", "to", "control", "rats", "significantly", "increased", "renal", "malondialdehyde", "(", "MDA", ")", "and", "urinary", "N", "-", "acetyl", "-", "beta", "-", "d", "-", "glucosaminidase", "(", "NAG", ",", "a", "marker", "of", "renal", "tubular", "injury", ")", "excretion", "but", "decreased", "superoxide", "dismutase", "(", "SOD", ")", "and", "catalase", "(", "CAT", ")", "activities", ".", "Erdosteine", "administration", "with", "VCM", "injections", "caused", "significantly", "decreased", "renal", "MDA", "and", "urinary", "NAG", "excretion", ",", "and", "increased", "SOD", "activity", ",", "but", "not", "CAT", "activity", "in", "renal", "tissue", "when", "compared", "with", "VCM", "alone", ".", "Erdosteine", "showed", "histopathological", "protection", "against", "VCM", "-", "induced", "nephrotoxicity", ".", "There", "were", "a", "significant", "dilatation", "of", "tubular", "lumens", ",", "extensive", "epithelial", "cell", "vacuolization", ",", "atrophy", ",", "desquamation", ",", "and", "necrosis", "in", "VCM", "-", "treated", "rats", "more", "than", "those", "of", "the", "control", "and", "the", "erdosteine", "groups", ".", "Erdosteine", "caused", "a", "marked", "reduction", "in", "the", "extent", "of", "tubular", "damage", ".", "It", "is", "concluded", "that", "oxidative", "tubular", "damage", "plays", "an", "important", "role", "in", "the", "VCM", "-", "induced", "nephrotoxicity", "and", "the", "modulation", "of", "oxidative", "stress", "with", "erdosteine", "reduces", "the", "VCM", "-", "induced", "kidney", "damage", "both", "at", "the", "biochemical", "and", "histological", "levels", "."]], "ner": [[[12, 12, "Chemical"], [29, 29, "Chemical"], [31, 31, "Chemical"], [71, 71, "Chemical"], [88, 88, "Chemical"], [90, 90, "Chemical"], [94, 94, "Chemical"], [121, 121, "Chemical"], [172, 172, "Chemical"], [199, 199, "Chemical"], [207, 207, "Chemical"], [233, 233, "Chemical"], [273, 273, "Chemical"], [287, 287, "Chemical"], [15, 15, "Disease"], [74, 75, "Disease"], [150, 152, "Disease"], [210, 210, "Disease"], [276, 276, "Disease"], [290, 291, "Disease"], [226, 226, "Disease"], [231, 231, "Disease"], [19, 19, "Chemical"], [53, 53, "Chemical"], [92, 92, "Chemical"], [116, 116, "Chemical"], [169, 169, "Chemical"], [202, 202, "Chemical"], [245, 245, "Chemical"], [248, 248, "Chemical"], [284, 284, "Chemical"], [42, 42, "Chemical"], [129, 129, "Chemical"], [131, 131, "Chemical"], [178, 178, "Chemical"], [157, 157, "Chemical"]]], "relations": [[[12, 12, 15, 15, "CID"], [12, 12, 74, 75, "CID"], [12, 12, 150, 152, "CID"], [12, 12, 210, 210, "CID"], [12, 12, 276, 276, "CID"], [12, 12, 290, 291, "CID"], [29, 29, 15, 15, "CID"], [29, 29, 74, 75, "CID"], [29, 29, 150, 152, "CID"], [29, 29, 210, 210, "CID"], [29, 29, 276, 276, "CID"], [29, 29, 290, 291, "CID"], [31, 31, 15, 15, "CID"], [31, 31, 74, 75, "CID"], [31, 31, 150, 152, "CID"], [31, 31, 210, 210, "CID"], [31, 31, 276, 276, "CID"], [31, 31, 290, 291, "CID"], [71, 71, 15, 15, "CID"], [71, 71, 74, 75, "CID"], [71, 71, 150, 152, "CID"], [71, 71, 210, 210, "CID"], [71, 71, 276, 276, "CID"], [71, 71, 290, 291, "CID"], [88, 88, 15, 15, "CID"], [88, 88, 74, 75, "CID"], [88, 88, 150, 152, "CID"], [88, 88, 210, 210, "CID"], [88, 88, 276, 276, "CID"], [88, 88, 290, 291, "CID"], [90, 90, 15, 15, "CID"], [90, 90, 74, 75, "CID"], [90, 90, 150, 152, "CID"], [90, 90, 210, 210, "CID"], [90, 90, 276, 276, "CID"], [90, 90, 290, 291, "CID"], [94, 94, 15, 15, "CID"], [94, 94, 74, 75, "CID"], [94, 94, 150, 152, "CID"], [94, 94, 210, 210, "CID"], [94, 94, 276, 276, "CID"], [94, 94, 290, 291, "CID"], [121, 121, 15, 15, "CID"], [121, 121, 74, 75, "CID"], [121, 121, 150, 152, "CID"], [121, 121, 210, 210, "CID"], [121, 121, 276, 276, "CID"], [121, 121, 290, 291, "CID"], [172, 172, 15, 15, "CID"], [172, 172, 74, 75, "CID"], [172, 172, 150, 152, "CID"], [172, 172, 210, 210, "CID"], [172, 172, 276, 276, "CID"], [172, 172, 290, 291, "CID"], [199, 199, 15, 15, "CID"], [199, 199, 74, 75, "CID"], [199, 199, 150, 152, "CID"], [199, 199, 210, 210, "CID"], [199, 199, 276, 276, "CID"], [199, 199, 290, 291, "CID"], [207, 207, 15, 15, "CID"], [207, 207, 74, 75, "CID"], [207, 207, 150, 152, "CID"], [207, 207, 210, 210, "CID"], [207, 207, 276, 276, "CID"], [207, 207, 290, 291, "CID"], [233, 233, 15, 15, "CID"], [233, 233, 74, 75, "CID"], [233, 233, 150, 152, "CID"], [233, 233, 210, 210, "CID"], [233, 233, 276, 276, "CID"], [233, 233, 290, 291, "CID"], [273, 273, 15, 15, "CID"], [273, 273, 74, 75, "CID"], [273, 273, 150, 152, "CID"], [273, 273, 210, 210, "CID"], [273, 273, 276, 276, "CID"], [273, 273, 290, 291, "CID"], [287, 287, 15, 15, "CID"], [287, 287, 74, 75, "CID"], [287, 287, 150, 152, "CID"], [287, 287, 210, 210, "CID"], [287, 287, 276, 276, "CID"], [287, 287, 290, 291, "CID"]]], "clusters": [], "translated": "体内证据表明氧化应激在<0>万古霉素</0>诱导的<14>肾毒性</14>发病机制中的作用：<22>厄多司坦</22>的保护作用。本研究的目的是检测<1>万古霉素</1>（<2>VCM</2>）诱导的促进活性<31>氧</31>物质（ROS）产生的氧化应激，并研究<23>厄多司坦</23>是一种祛痰剂，也具有抗氧化作用，它对肾组织的作用可能是<3>VCM</3>诱导的大鼠<15>肾功能损害</15>。大鼠分为三组：假手术组、<4>VCM</4>组和<5>VCM</5>加<24>厄多司坦</24>组。<6>VCM</6>以200mgkg (-1)的剂量腹腔注射(i.p.)，每天2次，连续7天。<25>厄多司坦</25>口服给药。<7>VCM</7>给予对照大鼠显着增加肾<32>丙二醛</32>（<33>MDA</33>）和尿N-乙酰-β-D-葡糖胺酶(NAG，标志物<16>肾小管损伤</16>)排泄减少，但<35>超氧化物</35>歧化酶(SOD)和过氧化氢酶(CAT)活性下降。<26>厄多司坦</26>与<8>VCM</8>注射剂给药导致显着降低肾脏<34>丙二醛</34>和尿NAG排泄，并增加SOD活性，但不增加肾组织中的CAT活性，单独使用<9>VCM</9>。<27>厄多司坦</27>显示出针对<10>VCM</10>诱导的<17>肾毒性</17>的组织病理学保护作用。<11>VCM</11>组大鼠肾小管管腔明显扩张，上皮细胞广泛空泡化，<20>萎缩</20>，脱屑，<21>坏死</21>，较对照组和<28>厄多司坦</28>组明显。 <29>厄多司坦</29>导致肾小管损伤程度显着降低。结论是，氧化性肾小管损伤在<12>VCM</12>诱导的<18>肾毒性</18>中起重要作用，<30>厄多司坦</30>调节氧化应激可降低<13>VCM</13>在生化和组织学水平上引起的<19>肾损伤</19>。", "revised": true}
{"doc_key": "16906379", "sentences": [["Minocycline", "-", "induced", "vasculitis", "fulfilling", "the", "criteria", "of", "polyarteritis", "nodosa", ".", "A", "47", "-", "year", "-", "old", "man", "who", "had", "been", "taking", "minocycline", "for", "palmoplantar", "pustulosis", "developed", "fever", ",", "myalgias", ",", "polyneuropathy", ",", "and", "testicular", "pain", ",", "with", "elevated", "C", "-", "reactive", "protein", "(", "CRP", ")", ".", "Neither", "myeloperoxidase", "-", "nor", "proteinase", "-", "3", "-", "antineutrophil", "cytoplasmic", "antibody", "was", "positive", ".", "These", "manifestations", "met", "the", "American", "College", "of", "Rheumatology", "1990", "criteria", "for", "the", "classification", "of", "polyarteritis", "nodosa", ".", "Stopping", "minocycline", "led", "to", "amelioration", "of", "symptoms", "and", "normalization", "of", "CRP", "level", ".", "To", "our", "knowledge", ",", "this", "is", "the", "second", "case", "of", "minocycline", "-", "induced", "vasculitis", "satisfying", "the", "criteria", ".", "Differential", "diagnosis", "for", "drug", "-", "induced", "disease", "is", "invaluable", "even", "for", "patients", "with", "classical", "polyarteritis", "nodosa", "."]], "ner": [[[0, 0, "Chemical"], [22, 22, "Chemical"], [79, 79, "Chemical"], [101, 101, "Chemical"], [8, 9, "Disease"], [75, 76, "Disease"], [123, 124, "Disease"], [3, 3, "Disease"], [104, 104, "Disease"], [24, 25, "Disease"], [27, 27, "Disease"], [29, 29, "Disease"], [31, 31, "Disease"], [34, 35, "Disease"]]], "relations": [[[0, 0, 8, 9, "CID"], [0, 0, 75, 76, "CID"], [0, 0, 123, 124, "CID"], [22, 22, 8, 9, "CID"], [22, 22, 75, 76, "CID"], [22, 22, 123, 124, "CID"], [79, 79, 8, 9, "CID"], [79, 79, 75, 76, "CID"], [79, 79, 123, 124, "CID"], [101, 101, 8, 9, "CID"], [101, 101, 75, 76, "CID"], [101, 101, 123, 124, "CID"]]], "clusters": [], "translated": " \n\n<0>米诺环素</0>诱发的<7>血管炎</7>符合<4>结节性多动脉炎</4>的标准。一位47岁的男性一直服用<1>米诺环素</1>治疗<9>掌跖脓疱病</9>，出现了<10>发烧</10>、<11>肌痛</11>、<12>多发性神经病</12>和<13>睾丸疼痛</13>，伴有升高的C-反应蛋白(CRP)。髓过氧化物酶-和蛋白酶-3-抗中性粒细胞胞浆抗体均未阳性。这些表现符合美国风湿病学会1990年对<5>结节性多动脉炎</5>的分类标准。停止<2>米诺环素</2>导致症状改善和CRP水平正常化。据了解，这是第2例<3>米诺环素</3>致<8>血管炎</8>符合标准的病例。即使对于典型的<6>结节性多动脉炎</6>患者，药物引起的疾病的鉴别诊断也是非常宝贵的。", "revised": true}
{"doc_key": "12948256", "sentences": [["Ethambutol", "and", "optic", "neuropathy", ".", "PURPOSE", ":", "To", "demonstrate", "the", "association", "between", "ethambutol", "and", "optic", "neuropathy", ".", "METHOD", ":", "Thirteen", "patients", "who", "developed", "optic", "neuropathy", "after", "being", "treated", "with", "ethambutol", "for", "tuberculosis", "of", "the", "lung", "or", "lymph", "node", "at", "Siriraj", "Hospital", "between", "1997", "and", "2001", "were", "retrospectively", "reviewed", ".", "The", "clinical", "characteristics", "and", "initial", "and", "final", "visual", "acuity", "were", "analyzed", "to", "determine", "visual", "outcome", ".", "RESULTS", ":", "All", "patients", "had", "optic", "neuropathy", "between", "1", "to", "6", "months", "(", "mean", "=", "2", ".", "9", "months", ")", "after", "starting", "ethambutol", "therapy", "at", "a", "dosage", "ranging", "from", "13", "to", "20", "mg", "/", "kg", "/", "day", "(", "mean", "=", "17", "mg", "/", "kg", "/", "day", ")", ".", "Seven", "(", "54", "%", ")", "of", "the", "13", "patients", "experienced", "visual", "recovery", "after", "stopping", "the", "drug", ".", "Of", "6", "patients", "with", "irreversible", "visual", "impairment", ",", "4", "patients", "had", "diabetes", "mellitus", ",", "glaucoma", "and", "a", "history", "of", "heavy", "smoking", ".", "CONCLUSION", ":", "Early", "recognition", "of", "optic", "neuropathy", "should", "be", "considered", "in", "patients", "with", "ethambutol", "therapy", ".", "A", "low", "dose", "and", "prompt", "discontinuation", "of", "the", "drug", "is", "recommended", "particularly", "in", "individuals", "with", "diabetes", "mellitus", ",", "glaucoma", "or", "who", "are", "heavy", "smokers", "."]], "ner": [[[0, 0, "Chemical"], [12, 12, "Chemical"], [29, 29, "Chemical"], [87, 87, "Chemical"], [165, 165, "Chemical"], [2, 3, "Disease"], [14, 15, "Disease"], [23, 24, "Disease"], [70, 71, "Disease"], [157, 158, "Disease"], [31, 37, "Disease"], [135, 136, "Disease"], [141, 142, "Disease"], [183, 184, "Disease"], [144, 144, "Disease"], [186, 186, "Disease"]]], "relations": [[[0, 0, 2, 3, "CID"], [0, 0, 14, 15, "CID"], [0, 0, 23, 24, "CID"], [0, 0, 70, 71, "CID"], [0, 0, 157, 158, "CID"], [12, 12, 2, 3, "CID"], [12, 12, 14, 15, "CID"], [12, 12, 23, 24, "CID"], [12, 12, 70, 71, "CID"], [12, 12, 157, 158, "CID"], [29, 29, 2, 3, "CID"], [29, 29, 14, 15, "CID"], [29, 29, 23, 24, "CID"], [29, 29, 70, 71, "CID"], [29, 29, 157, 158, "CID"], [87, 87, 2, 3, "CID"], [87, 87, 14, 15, "CID"], [87, 87, 23, 24, "CID"], [87, 87, 70, 71, "CID"], [87, 87, 157, 158, "CID"], [165, 165, 2, 3, "CID"], [165, 165, 14, 15, "CID"], [165, 165, 23, 24, "CID"], [165, 165, 70, 71, "CID"], [165, 165, 157, 158, "CID"]]], "clusters": [], "translated": " <0>乙胺丁醇</0>和<5>视神经病变</5>。目的：证明<1>乙胺丁醇</1>和<6>视神经病变</6>之间的关联。方法：在 Siriraj 医院接受 <2>乙胺丁醇</2>治疗<10>肺结核或淋巴结结核</10>的 13 名患者是回顾性地审查，这些患者在治疗后出现<7>视神经病变</7>。分析临床特征以及初始和最终视力以确定视力结果。结果：所有患者在开始<3>乙胺丁醇</3>治疗后 1 至 6 个月（平均 = 2.9 个月）均出现<8>视神经病变</8>，治疗剂量范围为 13 至 20 毫克/千克/天（平均 = 17 毫克/千克/天）。13 名患者中有 7 名（54%）在停药后视力恢复。6例不可逆<11>视力障碍</11>患者中，4例人有<12>糖尿病</12>、<14>青光眼</14>和重度吸烟史。结论：接受<4>乙胺丁醇</4>治疗的患者应考虑及早发现<9>视神经病变</9>。建议特别是病人群中的<13>糖尿病</13>、<15>青光眼</15>或重度吸烟者低剂量并立即停药。", "revised": true}
{"doc_key": "16723784", "sentences": [["Clinical", "evaluation", "of", "adverse", "effects", "during", "bepridil", "administration", "for", "atrial", "fibrillation", "and", "flutter", ".", "BACKGROUND", ":", "Bepridil", "hydrochloride", "(", "Bpd", ")", "has", "attracted", "attention", "as", "an", "effective", "drug", "for", "atrial", "fibrillation", "(", "AF", ")", "and", "atrial", "flutter", "(", "AFL", ")", ".", "However", ",", "serious", "adverse", "effects", ",", "including", "torsade", "de", "pointes", "(", "Tdp", ")", ",", "have", "been", "reported", ".", "METHODS", "AND", "RESULTS", ":", "Adverse", "effects", "of", "Bpd", "requiring", "discontinuation", "of", "treatment", "were", "evaluated", ".", "Bpd", "was", "administered", "to", "459", "patients", "(", "361", "males", ",", "63", "+", "/", "-", "12", "years", "old", ")", "comprising", "378", "AF", "and", "81", "AFL", "cases", ".", "Mean", "left", "ventricular", "ejection", "fraction", "and", "atrial", "dimension", "(", "LAD", ")", "were", "66", "+", "/", "-", "11", "%", "and", "40", "+", "/", "-", "6", "mm", ",", "respectively", ".", "Adverse", "effects", "were", "observed", "in", "19", "patients", "(", "4", "%", ")", "during", "an", "average", "follow", "-", "up", "of", "20", "months", ".", "There", "was", "marked", "QT", "prolongation", "greater", "than", "0", ".", "55", "s", "in", "13", "patients", ",", "bradycardia", "less", "than", "40", "beats", "/", "min", "in", "6", "patients", ",", "dizziness", "and", "general", "fatigue", "in", "1", "patient", "each", ".", "In", "4", "of", "13", "patients", "with", "QT", "prolongation", ",", "Tdp", "occurred", ".", "The", "major", "triggering", "factors", "of", "Tdp", "were", "hypokalemia", "and", "sudden", "decrease", "in", "heart", "rate", ".", "There", "were", "no", "differences", "in", "the", "clinical", "backgrounds", "of", "the", "patients", "with", "and", "without", "Tdp", "other", "than", "LAD", "and", "age", ",", "which", "were", "larger", "and", "older", "in", "the", "patients", "with", "Tdp", ".", "CONCLUSION", ":", "Careful", "observation", "of", "serum", "potassium", "concentration", "and", "the", "ECG", "should", "always", "be", "done", "during", "Bpd", "administration", ",", "particularly", "in", "elderly", "patients", "."]], "ner": [[[6, 6, "Chemical"], [16, 17, "Chemical"], [19, 19, "Chemical"], [66, 66, "Chemical"], [74, 74, "Chemical"], [259, 259, "Chemical"], [48, 50, "Disease"], [52, 52, "Disease"], [193, 193, "Disease"], [201, 201, "Disease"], [225, 225, "Disease"], [241, 241, "Disease"], [152, 153, "Disease"], [190, 191, "Disease"], [164, 164, "Disease"], [175, 175, "Disease"], [178, 178, "Disease"], [249, 249, "Chemical"], [9, 12, "Disease"], [29, 30, "Disease"], [32, 32, "Disease"], [94, 94, "Disease"], [35, 36, "Disease"], [38, 38, "Disease"], [97, 97, "Disease"], [203, 203, "Disease"]]], "relations": [[[6, 6, 48, 50, "CID"], [6, 6, 52, 52, "CID"], [6, 6, 193, 193, "CID"], [6, 6, 201, 201, "CID"], [6, 6, 225, 225, "CID"], [6, 6, 241, 241, "CID"], [16, 17, 48, 50, "CID"], [16, 17, 52, 52, "CID"], [16, 17, 193, 193, "CID"], [16, 17, 201, 201, "CID"], [16, 17, 225, 225, "CID"], [16, 17, 241, 241, "CID"], [19, 19, 48, 50, "CID"], [19, 19, 52, 52, "CID"], [19, 19, 193, 193, "CID"], [19, 19, 201, 201, "CID"], [19, 19, 225, 225, "CID"], [19, 19, 241, 241, "CID"], [66, 66, 48, 50, "CID"], [66, 66, 52, 52, "CID"], [66, 66, 193, 193, "CID"], [66, 66, 201, 201, "CID"], [66, 66, 225, 225, "CID"], [66, 66, 241, 241, "CID"], [74, 74, 48, 50, "CID"], [74, 74, 52, 52, "CID"], [74, 74, 193, 193, "CID"], [74, 74, 201, 201, "CID"], [74, 74, 225, 225, "CID"], [74, 74, 241, 241, "CID"], [259, 259, 48, 50, "CID"], [259, 259, 52, 52, "CID"], [259, 259, 193, 193, "CID"], [259, 259, 201, 201, "CID"], [259, 259, 225, 225, "CID"], [259, 259, 241, 241, "CID"], [6, 6, 152, 153, "CID"], [6, 6, 190, 191, "CID"], [16, 17, 152, 153, "CID"], [16, 17, 190, 191, "CID"], [19, 19, 152, 153, "CID"], [19, 19, 190, 191, "CID"], [66, 66, 152, 153, "CID"], [66, 66, 190, 191, "CID"], [74, 74, 152, 153, "CID"], [74, 74, 190, 191, "CID"], [259, 259, 152, 153, "CID"], [259, 259, 190, 191, "CID"], [6, 6, 164, 164, "CID"], [16, 17, 164, 164, "CID"], [19, 19, 164, 164, "CID"], [66, 66, 164, 164, "CID"], [74, 74, 164, 164, "CID"], [259, 259, 164, 164, "CID"], [6, 6, 175, 175, "CID"], [16, 17, 175, 175, "CID"], [19, 19, 175, 175, "CID"], [66, 66, 175, 175, "CID"], [74, 74, 175, 175, "CID"], [259, 259, 175, 175, "CID"], [6, 6, 178, 178, "CID"], [16, 17, 178, 178, "CID"], [19, 19, 178, 178, "CID"], [66, 66, 178, 178, "CID"], [74, 74, 178, 178, "CID"], [259, 259, 178, 178, "CID"], [249, 249, 48, 50, "CID"], [249, 249, 52, 52, "CID"], [249, 249, 193, 193, "CID"], [249, 249, 201, 201, "CID"], [249, 249, 225, 225, "CID"], [249, 249, 241, 241, "CID"]]], "clusters": [], "translated": "<0>苄普地尔</0>治疗<18>房颤和扑动</18>不良反应的临床评价。背景：<1>盐酸苄普地尔</1>（<2>Bpd</2>）作为治疗<19>心房颤动</19>（<20>AF</20>）和<22>心房扑动</22>（<23>AFL</23>）的有效药物受到了注意。然而，已报告了严重的副作用，包括<6>尖端扭转型室速</6>（<7>Tdp</7>）。方法和结果：评估了需要停止治疗的<3>Bpd</3>的不良反应。对包括 378 名<21>AF</21>和 81 名<24>AFL</24>患者在内的 459 名患者（361 名男性，年龄为 63 + /- 12 岁）进行了<4>Bpd</4>的给药。平均左室射血分数和心房尺寸 (LAD) 分别为 66 +/-11%和40 +/-6 mm。在平均 20 个月的随访期间，有 19 名患者 (4%) 出现不良反应。有 13 例患者出现明显的<12>QT 延长</12>大于0.55 s，6例患者出现<14>心动过缓</14>少于40 次/分，1例患者分别出现了<15>头晕</15>和全身<16>乏力</16>。13 例患者出现<13>QT 间期延长</13>，其中 4 例发生了<8>Tdp</8>。<9>Tdp</9>的主要诱发因素是<25>低钾血症</25>和心率突然减慢。与未出现<10>Tdp</10>的患者相比，出现<11>Tdp</11>的患者除了LAD和年龄较大外，其临床背景没有差异。结论：在给予<5>Bpd</5>治疗期间，尤其是对于老年患者，应始终仔细观察血清<17>钾</17>浓度和心电图。", "revised": true}
{"doc_key": "17028363", "sentences": [["Acute", "renal", "failure", "associated", "with", "prolonged", "intake", "of", "slimming", "pills", "containing", "anthraquinones", ".", "Chinese", "herbal", "medicine", "preparations", "are", "widely", "available", "and", "often", "regarded", "by", "the", "public", "as", "natural", "and", "safe", "remedies", "for", "a", "variety", "of", "medical", "conditions", ".", "Nephropathy", "caused", "by", "Chinese", "herbs", "has", "previously", "been", "reported", ",", "usually", "involving", "the", "use", "of", "aristolochic", "acids", ".", "We", "report", "a", "23", "-", "year", "-", "old", "woman", "who", "developed", "acute", "renal", "failure", "following", "prolonged", "use", "of", "a", "proprietary", "Chinese", "herbal", "slimming", "pill", "that", "contained", "anthraquinone", "derivatives", ",", "extracted", "from", "Rhizoma", "Rhei", "(", "rhubarb", ")", ".", "The", "renal", "injury", "was", "probably", "aggravated", "by", "the", "concomitant", "intake", "of", "a", "non", "-", "steroidal", "anti", "-", "inflammatory", "drug", ",", "diclofenac", ".", "Renal", "pathology", "was", "that", "of", "hypocellular", "interstitial", "fibrosis", ".", "Spontaneous", "renal", "recovery", "occurred", "upon", "cessation", "of", "the", "slimming", "pills", ",", "but", "mild", "interstitial", "fibrosis", "and", "tubular", "atrophy", "was", "still", "evident", "histologically", "4", "months", "later", ".", "Although", "a", "causal", "relationship", "between", "the", "use", "of", "an", "anthraquinone", "-", "containing", "herbal", "agent", "and", "renal", "injury", "remains", "to", "be", "proven", ",", "phytotherapy", "-", "associated", "interstitial", "nephropathy", "should", "be", "considered", "in", "patients", "who", "present", "with", "unexplained", "renal", "failure", "."]], "ner": [[[13, 14, "Chemical"], [41, 42, "Chemical"], [76, 77, "Chemical"], [0, 2, "Disease"], [67, 69, "Disease"], [94, 95, "Disease"], [165, 166, "Disease"], [113, 113, "Chemical"], [11, 11, "Chemical"], [82, 82, "Chemical"], [159, 159, "Chemical"], [53, 54, "Chemical"], [38, 38, "Disease"], [176, 176, "Disease"], [122, 122, "Disease"], [138, 138, "Disease"], [141, 141, "Disease"], [186, 187, "Disease"]]], "relations": [[[13, 14, 0, 2, "CID"], [13, 14, 67, 69, "CID"], [13, 14, 94, 95, "CID"], [13, 14, 165, 166, "CID"], [41, 42, 0, 2, "CID"], [41, 42, 67, 69, "CID"], [41, 42, 94, 95, "CID"], [41, 42, 165, 166, "CID"], [76, 77, 0, 2, "CID"], [76, 77, 67, 69, "CID"], [76, 77, 94, 95, "CID"], [76, 77, 165, 166, "CID"], [113, 113, 0, 2, "CID"], [113, 113, 67, 69, "CID"], [113, 113, 94, 95, "CID"], [113, 113, 165, 166, "CID"]]], "clusters": [], "translated": "<3>急性肾功能衰竭</3>与长期服用含有<8>蒽醌类</8>的减肥药有关。<0>中草药</0>药物制剂应用广泛，通常被公众视为治疗各种疾病的天然且安全的药物。<12>肾病</12>由<1>中草药</1>引起，此前已有报道，通常涉及使用<11>马兜铃酸</11>。我们报告了一名23岁的女性，未能使用含有<9>蒽醌</9>衍生物的专有<2>中草药</2>减胖药后，她患了<4>急性肾功能衰竭</4>，从Rhizoma Rhei（大黄）提取。<5>肾损伤</5>可能因同时服用非甾体抗炎药<7>双氯芬酸</7>而加重。肾脏病理为细胞间质<14>纤维化</14>。停用减肥药后肾脏自然恢复，但4个月后，仍可在组织学上看到轻度<15>间质纤维化</15>和肾小管<16>萎缩</16>。虽然使用含<10>蒽醌</10>的草药与<6>肾损伤</6>之间的因果关系仍有待证实，但应考虑在患有不明原因的<17>肾功能衰竭</17>的患者中出现与植物疗法相关的间质性<13>肾病</13>。", "revised": true}
{"doc_key": "15991002", "sentences": [["Nicotine", "antagonizes", "caffeine", "-", "but", "not", "pentylenetetrazole", "-", "induced", "anxiogenic", "effect", "in", "mice", ".", "RATIONALE", ":", "Nicotine", "and", "caffeine", "are", "widely", "consumed", "licit", "psychoactive", "drugs", "worldwide", ".", "Epidemiological", "studies", "showed", "that", "they", "were", "generally", "used", "concurrently", ".", "Although", "some", "studies", "in", "experimental", "animals", "indicate", "clear", "pharmacological", "interactions", "between", "them", ",", "no", "studies", "have", "shown", "a", "specific", "interaction", "on", "anxiety", "responses", ".", "OBJECTIVES", ":", "The", "present", "study", "investigates", "the", "effects", "of", "nicotine", "on", "anxiety", "induced", "by", "caffeine", "and", "another", "anxiogenic", "drug", ",", "pentylenetetrazole", ",", "in", "mice", ".", "The", "elevated", "plus", "-", "maze", "(", "EPM", ")", "test", "was", "used", "to", "evaluate", "the", "effects", "of", "drugs", "on", "anxiety", ".", "METHODS", ":", "Adult", "male", "Swiss", "Webster", "mice", "(", "25", "-", "32", "g", ")", "were", "given", "nicotine", "(", "0", ".", "05", "-", "0", ".", "25", "mg", "/", "kg", "s", ".", "c", ".", ")", "or", "saline", "10", "min", "before", "caffeine", "(", "70", "mg", "/", "kg", "i", ".", "p", ".", ")", "or", "pentylenetetrazole", "(", "15", "and", "30", "mg", "/", "kg", "i", ".", "p", ".", ")", "injections", ".", "After", "15", "min", ",", "mice", "were", "evaluated", "for", "their", "open", "-", "and", "closed", "-", "arm", "time", "and", "entries", "on", "the", "EPM", "for", "a", "10", "-", "min", "session", ".", "Locomotor", "activity", "was", "recorded", "for", "individual", "groups", "by", "using", "the", "same", "treatment", "protocol", "with", "the", "EPM", "test", ".", "RESULTS", ":", "Nicotine", "(", "0", ".", "05", "-", "0", ".", "25", "mg", "/", "kg", ")", "itself", "did", "not", "produce", "any", "significant", "effect", "in", "the", "EPM", "test", ",", "whereas", "caffeine", "(", "70", "mg", "/", "kg", ")", "and", "pentylenetetrazole", "(", "30", "mg", "/", "kg", ")", "produced", "an", "anxiogenic", "effect", ",", "apparent", "with", "decreases", "in", "open", "-", "arm", "time", "and", "entry", ".", "Nicotine", "(", "0", ".", "25", "mg", "/", "kg", ")", "pretreatment", "blocked", "the", "caffeine", "-", "but", "not", "pentylenetetrazole", "-", "induced", "anxiety", ".", "Administration", "of", "each", "drug", "and", "their", "combinations", "did", "not", "produce", "any", "effect", "on", "locomotor", "activity", ".", "CONCLUSIONS", ":", "Our", "results", "suggest", "that", "the", "antagonistic", "effect", "of", "nicotine", "on", "caffeine", "-", "induced", "anxiety", "is", "specific", "to", "caffeine", ",", "instead", "of", "a", "non", "-", "specific", "anxiolytic", "effect", ".", "Thus", ",", "it", "may", "extend", "the", "current", "findings", "on", "the", "interaction", "between", "nicotine", "and", "caffeine", "."]], "ner": [[[2, 2, "Chemical"], [18, 18, "Chemical"], [75, 75, "Chemical"], [143, 143, "Chemical"], [244, 244, "Chemical"], [287, 287, "Chemical"], [324, 324, "Chemical"], [331, 331, "Chemical"], [356, 356, "Chemical"], [58, 58, "Disease"], [72, 72, "Disease"], [104, 104, "Disease"], [294, 294, "Disease"], [327, 327, "Disease"], [6, 6, "Chemical"], [81, 81, "Chemical"], [155, 155, "Chemical"], [252, 252, "Chemical"], [291, 291, "Chemical"], [0, 0, "Chemical"], [16, 16, "Chemical"], [70, 70, "Chemical"], [121, 121, "Chemical"], [218, 218, "Chemical"], [275, 275, "Chemical"], [322, 322, "Chemical"], [354, 354, "Chemical"]]], "relations": [[[2, 2, 58, 58, "CID"], [2, 2, 72, 72, "CID"], [2, 2, 104, 104, "CID"], [2, 2, 294, 294, "CID"], [2, 2, 327, 327, "CID"], [18, 18, 58, 58, "CID"], [18, 18, 72, 72, "CID"], [18, 18, 104, 104, "CID"], [18, 18, 294, 294, "CID"], [18, 18, 327, 327, "CID"], [75, 75, 58, 58, "CID"], [75, 75, 72, 72, "CID"], [75, 75, 104, 104, "CID"], [75, 75, 294, 294, "CID"], [75, 75, 327, 327, "CID"], [143, 143, 58, 58, "CID"], [143, 143, 72, 72, "CID"], [143, 143, 104, 104, "CID"], [143, 143, 294, 294, "CID"], [143, 143, 327, 327, "CID"], [244, 244, 58, 58, "CID"], [244, 244, 72, 72, "CID"], [244, 244, 104, 104, "CID"], [244, 244, 294, 294, "CID"], [244, 244, 327, 327, "CID"], [287, 287, 58, 58, "CID"], [287, 287, 72, 72, "CID"], [287, 287, 104, 104, "CID"], [287, 287, 294, 294, "CID"], [287, 287, 327, 327, "CID"], [324, 324, 58, 58, "CID"], [324, 324, 72, 72, "CID"], [324, 324, 104, 104, "CID"], [324, 324, 294, 294, "CID"], [324, 324, 327, 327, "CID"], [331, 331, 58, 58, "CID"], [331, 331, 72, 72, "CID"], [331, 331, 104, 104, "CID"], [331, 331, 294, 294, "CID"], [331, 331, 327, 327, "CID"], [356, 356, 58, 58, "CID"], [356, 356, 72, 72, "CID"], [356, 356, 104, 104, "CID"], [356, 356, 294, 294, "CID"], [356, 356, 327, 327, "CID"], [6, 6, 58, 58, "CID"], [6, 6, 72, 72, "CID"], [6, 6, 104, 104, "CID"], [6, 6, 294, 294, "CID"], [6, 6, 327, 327, "CID"], [81, 81, 58, 58, "CID"], [81, 81, 72, 72, "CID"], [81, 81, 104, 104, "CID"], [81, 81, 294, 294, "CID"], [81, 81, 327, 327, "CID"], [155, 155, 58, 58, "CID"], [155, 155, 72, 72, "CID"], [155, 155, 104, 104, "CID"], [155, 155, 294, 294, "CID"], [155, 155, 327, 327, "CID"], [252, 252, 58, 58, "CID"], [252, 252, 72, 72, "CID"], [252, 252, 104, 104, "CID"], [252, 252, 294, 294, "CID"], [252, 252, 327, 327, "CID"], [291, 291, 58, 58, "CID"], [291, 291, 72, 72, "CID"], [291, 291, 104, 104, "CID"], [291, 291, 294, 294, "CID"], [291, 291, 327, 327, "CID"]]], "clusters": [], "translated": "<19>尼古丁</19>拮抗<0>咖啡因</0> - 但不是<14>戊四唑</14> - 诱导的小鼠焦虑作用。理由：<20>尼古丁</20>和<1>咖啡因</1>是全世界广泛消费的合法精神药物。流行病学研究表明，它们通常同时使用。虽然一些实验动物研究表明它们之间存在明显的药理学相互作用，但没有研究表明对<9>焦虑</9>反应有特定的相互作用。目的：本研究调查了<21>尼古丁</21>对<2>咖啡因</2>和另一种致焦虑药物<15>戊四唑</15>引起的<10>焦虑</10>的影响，在小鼠中。高架十字迷宫（EPM）试验用于评估药物对<11>焦虑</11>的影响。方法：成年雄性 Swiss Webster 小鼠 (25 - 32 g ) 在<22>尼古丁</22>（0 . 05 - 0 . 25 mg/kg s.c.）或生理盐水注射后 10 分钟内注射<3>咖啡因</3>（70 mg/kg i.p.）或<16>戊四唑</16>（15和30 mg/kg i.p.）。 15 分钟后，记录小鼠在 EPM 测试中的开臂时间和闭臂时间，以及进入时间，每个小组使用同样的治疗方案记录其运动活动。结果：<23>尼古丁</23>（0.05-0.25mg/kg）本身在EPM试验中没有产生任何显着影响，而<4>咖啡因</4>（70mg/kg）和<17>戊四唑</17>（30 mg/kg）则呈现明显的焦虑作用，表现为张开臂时间和进入次数的减少。<24>尼古丁</24>（0.25mg/kg）的预处理可以阻止<5>咖啡因</5> - 但不能阻止<18>戊四唑</18> - 引起的<12>焦虑</12> 。每种药物及其组合的给药均不影响运动活动。结论：本研究表明，<25>尼古丁</25>对<6>咖啡因</6> - 诱导的<13>焦虑</13>的拮抗作用特异于<7>咖啡因</7>，而非一种非特异性抗焦虑作用。该研究拓展了现有关于<26>尼古丁</26>和<8>咖啡因</8>相互作用的研究结果。", "revised": true}
{"doc_key": "16309808", "sentences": [["Does", "domperidone", "potentiate", "mirtazapine", "-", "associated", "restless", "legs", "syndrome", "?", "There", "is", "now", "evidence", "to", "suggest", "a", "central", "role", "for", "the", "dopaminergic", "system", "in", "restless", "legs", "syndrome", "(", "RLS", ")", ".", "For", "example", ",", "the", "symptoms", "of", "RLS", "can", "be", "dramatically", "improved", "by", "levodopa", "and", "dopamine", "agonists", ",", "whereas", "central", "dopamine", "D2", "receptor", "antagonists", "can", "induce", "or", "aggravate", "RLS", "symptoms", ".", "To", "our", "knowledge", ",", "there", "is", "no", "previous", "report", "regarding", "whether", "domperidone", ",", "a", "peripheral", "dopamine", "D2", "receptor", "antagonist", ",", "can", "also", "induce", "or", "aggravate", "symptoms", "of", "RLS", ".", "Mirtazapine", ",", "the", "first", "noradrenergic", "and", "specific", "serotonergic", "antidepressant", "(", "NaSSA", ")", ",", "has", "been", "associated", "with", "RLS", "in", "several", "recent", "publications", ".", "The", "authors", "report", "here", "a", "depressed", "patient", "comorbid", "with", "postprandial", "dyspepsia", "who", "developed", "RLS", "after", "mirtazapine", "had", "been", "added", "to", "his", "domperidone", "therapy", ".", "Our", "patient", "started", "to", "have", "symptoms", "of", "RLS", "only", "after", "he", "had", "been", "treated", "with", "mirtazapine", ",", "and", "his", "RLS", "symptoms", "resolved", "completely", "upon", "discontinuation", "of", "his", "mirtazapine", ".", "Such", "a", "temporal", "relationship", "between", "the", "use", "of", "mirtazapine", "and", "the", "symptoms", "of", "RLS", "in", "our", "patient", "did", "not", "support", "a", "potentiating", "effect", "of", "domperione", "on", "mirtazapine", "-", "associated", "RLS", ".", "However", ",", "physicians", "should", "be", "aware", "of", "the", "possibility", "that", "mirtazapine", "can", "be", "associated", "with", "RLS", "in", "some", "individuals", ",", "especially", "those", "receiving", "concomitant", "dopamine", "D2", "receptor", "antagonists", "."]], "ner": [[[3, 3, "Chemical"], [90, 90, "Chemical"], [128, 128, "Chemical"], [152, 152, "Chemical"], [164, 164, "Chemical"], [174, 174, "Chemical"], [192, 192, "Chemical"], [207, 207, "Chemical"], [6, 8, "Disease"], [24, 26, "Disease"], [28, 28, "Disease"], [37, 37, "Disease"], [58, 58, "Disease"], [88, 88, "Disease"], [107, 107, "Disease"], [126, 126, "Disease"], [144, 144, "Disease"], [156, 156, "Disease"], [179, 179, "Disease"], [195, 195, "Disease"], [212, 212, "Disease"], [1, 1, "Chemical"], [72, 72, "Chemical"], [134, 134, "Chemical"], [190, 190, "Chemical"], [122, 123, "Disease"], [43, 43, "Chemical"], [45, 45, "Chemical"], [50, 50, "Chemical"], [76, 76, "Chemical"], [221, 221, "Chemical"]]], "relations": [[[3, 3, 6, 8, "CID"], [3, 3, 24, 26, "CID"], [3, 3, 28, 28, "CID"], [3, 3, 37, 37, "CID"], [3, 3, 58, 58, "CID"], [3, 3, 88, 88, "CID"], [3, 3, 107, 107, "CID"], [3, 3, 126, 126, "CID"], [3, 3, 144, 144, "CID"], [3, 3, 156, 156, "CID"], [3, 3, 179, 179, "CID"], [3, 3, 195, 195, "CID"], [3, 3, 212, 212, "CID"], [90, 90, 6, 8, "CID"], [90, 90, 24, 26, "CID"], [90, 90, 28, 28, "CID"], [90, 90, 37, 37, "CID"], [90, 90, 58, 58, "CID"], [90, 90, 88, 88, "CID"], [90, 90, 107, 107, "CID"], [90, 90, 126, 126, "CID"], [90, 90, 144, 144, "CID"], [90, 90, 156, 156, "CID"], [90, 90, 179, 179, "CID"], [90, 90, 195, 195, "CID"], [90, 90, 212, 212, "CID"], [128, 128, 6, 8, "CID"], [128, 128, 24, 26, "CID"], [128, 128, 28, 28, "CID"], [128, 128, 37, 37, "CID"], [128, 128, 58, 58, "CID"], [128, 128, 88, 88, "CID"], [128, 128, 107, 107, "CID"], [128, 128, 126, 126, "CID"], [128, 128, 144, 144, "CID"], [128, 128, 156, 156, "CID"], [128, 128, 179, 179, "CID"], [128, 128, 195, 195, "CID"], [128, 128, 212, 212, "CID"], [152, 152, 6, 8, "CID"], [152, 152, 24, 26, "CID"], [152, 152, 28, 28, "CID"], [152, 152, 37, 37, "CID"], [152, 152, 58, 58, "CID"], [152, 152, 88, 88, "CID"], [152, 152, 107, 107, "CID"], [152, 152, 126, 126, "CID"], [152, 152, 144, 144, "CID"], [152, 152, 156, 156, "CID"], [152, 152, 179, 179, "CID"], [152, 152, 195, 195, "CID"], [152, 152, 212, 212, "CID"], [164, 164, 6, 8, "CID"], [164, 164, 24, 26, "CID"], [164, 164, 28, 28, "CID"], [164, 164, 37, 37, "CID"], [164, 164, 58, 58, "CID"], [164, 164, 88, 88, "CID"], [164, 164, 107, 107, "CID"], [164, 164, 126, 126, "CID"], [164, 164, 144, 144, "CID"], [164, 164, 156, 156, "CID"], [164, 164, 179, 179, "CID"], [164, 164, 195, 195, "CID"], [164, 164, 212, 212, "CID"], [174, 174, 6, 8, "CID"], [174, 174, 24, 26, "CID"], [174, 174, 28, 28, "CID"], [174, 174, 37, 37, "CID"], [174, 174, 58, 58, "CID"], [174, 174, 88, 88, "CID"], [174, 174, 107, 107, "CID"], [174, 174, 126, 126, "CID"], [174, 174, 144, 144, "CID"], [174, 174, 156, 156, "CID"], [174, 174, 179, 179, "CID"], [174, 174, 195, 195, "CID"], [174, 174, 212, 212, "CID"], [192, 192, 6, 8, "CID"], [192, 192, 24, 26, "CID"], [192, 192, 28, 28, "CID"], [192, 192, 37, 37, "CID"], [192, 192, 58, 58, "CID"], [192, 192, 88, 88, "CID"], [192, 192, 107, 107, "CID"], [192, 192, 126, 126, "CID"], [192, 192, 144, 144, "CID"], [192, 192, 156, 156, "CID"], [192, 192, 179, 179, "CID"], [192, 192, 195, 195, "CID"], [192, 192, 212, 212, "CID"], [207, 207, 6, 8, "CID"], [207, 207, 24, 26, "CID"], [207, 207, 28, 28, "CID"], [207, 207, 37, 37, "CID"], [207, 207, 58, 58, "CID"], [207, 207, 88, 88, "CID"], [207, 207, 107, 107, "CID"], [207, 207, 126, 126, "CID"], [207, 207, 144, 144, "CID"], [207, 207, 156, 156, "CID"], [207, 207, 179, 179, "CID"], [207, 207, 195, 195, "CID"], [207, 207, 212, 212, "CID"]]], "clusters": [], "translated": "<21>多潘立酮</21> 是否会增强 <0>米氮平</0> 相关的<8> 不宁腿综合征 </8>？现在有证据表明多巴胺能系统在<9>不宁腿综合征</9> (<10>RLS</10>) 中起着重要作用。例如，<26>左旋多巴</26>和<27>多巴胺</27>激动剂可显着改善<11>RLS</11>的症状，而中枢<28>多巴胺</28>D2受体拮抗剂可诱发或加重<12>RLS</12>症状。据我们所知，外周<29>多巴胺</29>D2受体拮抗剂<22>多潘立酮</22>是否也可诱发或加重<13>RLS</13>的症状，目前尚无报道。<1>米氮平</1>是第一种去甲肾上腺素能和特异性血清素能抗抑郁药(NaSSA)，在最近的几篇出版物中已将其与<14>RLS</14>相关联。作者在此报告了一名患有<25>餐后消化不良</25>的抑郁症患者，他在<23>多潘立酮</23>治疗中加入了<2>米氮平</2>后发展为<15>RLS</15>。我们的患者仅在接受<3>米氮平</3>治疗后才开始出现<16>RLS</16>症状，并且他的<17>RLS</17>症状在停止服用<4>米氮平</4>后完全消失。我们患者使用<5>米氮平</5>与<18>RLS</18>症状之间的这种时间关系不支持<24>多潘立酮</24>对<6>米氮平</6>相关的<19>RLS</19>的增强作用。然而，医生应该意识到<7>米氮平</7>可能与某些个体的<20>RLS</20>相关，尤其是那些同时接受<30>多巴胺</30>D2受体拮抗剂的个体。", "revised": true}
{"doc_key": "16876986", "sentences": [["Physical", "training", "decreases", "susceptibility", "to", "subsequent", "pilocarpine", "-", "induced", "seizures", "in", "the", "rat", ".", "Regular", "motor", "activity", "has", "many", "benefits", "for", "mental", "and", "physical", "condition", "but", "its", "implications", "for", "epilepsy", "are", "still", "controversial", ".", "In", "order", "to", "elucidate", "this", "problem", ",", "we", "have", "studied", "the", "effect", "of", "long", "-", "term", "physical", "activity", "on", "susceptibility", "to", "subsequent", "seizures", ".", "Male", "Wistar", "rats", "were", "subjected", "to", "repeated", "training", "sessions", "in", "a", "treadmill", "and", "swimming", "pool", ".", "Thereafter", ",", "seizures", "were", "induced", "by", "pilocarpine", "injections", "in", "trained", "and", "non", "-", "trained", "control", "groups", ".", "During", "the", "acute", "period", "of", "status", "epilepticus", ",", "we", "measured", ":", "(", "1", ")", "the", "latency", "of", "the", "first", "motor", "sign", ",", "(", "2", ")", "the", "intensity", "of", "seizures", ",", "(", "3", ")", "the", "time", "when", "it", "occurred", "within", "the", "6", "-", "h", "observation", "period", ",", "and", "(", "4", ")", "the", "time", "when", "the", "acute", "period", "ended", ".", "All", "these", "behavioral", "parameters", "showed", "statistically", "significant", "changes", "suggesting", "that", "regular", "physical", "exercises", "decrease", "susceptibility", "to", "subsequently", "induced", "seizures", "and", "ameliorate", "the", "course", "of", "experimentally", "induced", "status", "epilepticus", "."]], "ner": [[[6, 6, "Chemical"], [80, 80, "Chemical"], [9, 9, "Disease"], [56, 56, "Disease"], [76, 76, "Disease"], [119, 119, "Disease"], [167, 167, "Disease"], [96, 97, "Disease"], [175, 176, "Disease"], [29, 29, "Disease"]]], "relations": [[[6, 6, 9, 9, "CID"], [6, 6, 56, 56, "CID"], [6, 6, 76, 76, "CID"], [6, 6, 119, 119, "CID"], [6, 6, 167, 167, "CID"], [80, 80, 9, 9, "CID"], [80, 80, 56, 56, "CID"], [80, 80, 76, 76, "CID"], [80, 80, 119, 119, "CID"], [80, 80, 167, 167, "CID"], [6, 6, 96, 97, "CID"], [6, 6, 175, 176, "CID"], [80, 80, 96, 97, "CID"], [80, 80, 175, 176, "CID"]]], "clusters": [], "translated": "体育锻炼降低了大鼠随后对<0>毛果芸香碱</0>诱导的<2>癫痫发作</2>的易感性。有规律的运动对精神和身体状况有很多好处，但它对<9>癫痫</9>的影响仍然存在争议。为了阐明这个问题，我们研究了长期体力活动对后续<3>癫痫发作</3>易感性的影响。雄性Wistar大鼠在跑步机和游泳池中接受反复训练。此后，在受过训练和未受过训练的对照组中，通过<1>毛果芸香碱</1>注射诱导<4>癫痫发作</4>。在<7>癫痫持续状态</7>的急性期，我们测量了：(1)第一运动征的潜伏期，(2)<5>癫痫发作</5>的强度，(3)发生时间及(4)急性期结束时间。所有这些行为参数均显示出统计学上的显着变化，表明定期体育锻炼可降低对随后诱发的<6>癫痫发作</6>的易感性，并改善实验诱发的<8>癫痫持续状态</8>的过程。", "revised": true}
{"doc_key": "15630069", "sentences": [["Glucose", "metabolism", "in", "patients", "with", "schizophrenia", "treated", "with", "atypical", "antipsychotic", "agents", ":", "a", "frequently", "sampled", "intravenous", "glucose", "tolerance", "test", "and", "minimal", "model", "analysis", ".", "BACKGROUND", ":", "While", "the", "incidence", "of", "new", "-", "onset", "diabetes", "mellitus", "may", "be", "increasing", "in", "patients", "with", "schizophrenia", "treated", "with", "certain", "atypical", "antipsychotic", "agents", ",", "it", "remains", "unclear", "whether", "atypical", "agents", "are", "directly", "affecting", "glucose", "metabolism", "or", "simply", "increasing", "known", "risk", "factors", "for", "diabetes", ".", "OBJECTIVE", ":", "To", "study", "the", "2", "drugs", "most", "clearly", "implicated", "(", "clozapine", "and", "olanzapine", ")", "and", "risperidone", "using", "a", "frequently", "sampled", "intravenous", "glucose", "tolerance", "test", ".", "DESIGN", ":", "A", "cross", "-", "sectional", "design", "in", "stable", ",", "treated", "patients", "with", "schizophrenia", "evaluated", "using", "a", "frequently", "sampled", "intravenous", "glucose", "tolerance", "test", "and", "the", "Bergman", "minimal", "model", "analysis", ".", "SETTING", ":", "Subjects", "were", "recruited", "from", "an", "urban", "community", "mental", "health", "clinic", "and", "were", "studied", "at", "a", "general", "clinical", "research", "center", ".", "Patients", "Fifty", "subjects", "signed", "informed", "consent", "and", "41", "underwent", "the", "frequently", "sampled", "intravenous", "glucose", "tolerance", "test", ".", "Thirty", "-", "six", "nonobese", "subjects", "with", "schizophrenia", "or", "schizoaffective", "disorder", ",", "matched", "by", "body", "mass", "index", "and", "treated", "with", "either", "clozapine", ",", "olanzapine", ",", "or", "risperidone", ",", "were", "included", "in", "the", "analysis", ".", "MAIN", "OUTCOME", "MEASURES", ":", "Fasting", "plasma", "glucose", "and", "fasting", "serum", "insulin", "levels", ",", "insulin", "sensitivity", "index", ",", "homeostasis", "model", "assessment", "of", "insulin", "resistance", ",", "and", "glucose", "effectiveness", ".", "RESULTS", ":", "The", "mean", "+", "/", "-", "SD", "duration", "of", "treatment", "with", "the", "identified", "atypical", "antipsychotic", "agent", "was", "68", ".", "3", "+", "/", "-", "28", ".", "9", "months", "(", "clozapine", ")", ",", "29", ".", "5", "+", "/", "-", "17", ".", "5", "months", "(", "olanzapine", ")", ",", "and", "40", ".", "9", "+", "/", "-", "33", ".", "7", "(", "risperidone", ")", ".", "Fasting", "serum", "insulin", "concentrations", "differed", "among", "groups", "(", "F", "(", "33", ")", "=", "3", ".", "35", ";", "P", "=", ".", "047", ")", "(", "clozapine", ">", "olanzapine", ">", "risperidone", ")", "with", "significant", "differences", "between", "clozapine", "and", "risperidone", "(", "t", "(", "33", ")", "=", "2", ".", "32", ";", "P", "=", ".", "03", ")", "and", "olanzapine", "and", "risperidone", "(", "t", "(", "33", ")", "=", "2", ".", "15", ";", "P", "=", ".", "04", ")", ".", "There", "was", "a", "significant", "difference", "in", "insulin", "sensitivity", "index", "among", "groups", "(", "F", "(", "33", ")", "=", "10", ".", "66", ";", "P", "<", ".", "001", ")", "(", "clozapine", "<", "olanzapine", "<", "risperidone", ")", ",", "with", "subjects", "who", "received", "clozapine", "and", "olanzapine", "exhibiting", "significant", "insulin", "resistance", "compared", "with", "subjects", "who", "were", "treated", "with", "risperidone", "(", "clozapine", "vs", "risperidone", ",", "t", "(", "33", ")", "=", "-", "4", ".", "29", ";", "P", "<", ".", "001", ";", "olanzapine", "vs", "risperidone", ",", "t", "(", "33", ")", "=", "-", "3", ".", "62", ";", "P", "=", ".", "001", "[", "P", "<", ".", "001", "]", ")", ".", "The", "homeostasis", "model", "assessment", "of", "insulin", "resistance", "also", "differed", "significantly", "among", "groups", "(", "F", "(", "33", ")", "=", "4", ".", "92", ";", "P", "=", ".", "01", ")", "(", "clozapine", ">", "olanzapine", ">", "risperidone", ")", "(", "clozapine", "vs", "risperidone", ",", "t", "(", "33", ")", "=", "2", ".", "94", ";", "P", "=", ".", "006", ";", "olanzapine", "vs", "risperidone", ",", "t", "(", "33", ")", "=", "2", ".", "42", ";", "P", "=", ".", "02", ")", ".", "There", "was", "a", "significant", "difference", "among", "groups", "in", "glucose", "effectiveness", "(", "F", "(", "30", ")", "=", "4", ".", "18", ";", "P", "=", ".", "02", ")", "(", "clozapine", "<", "olanzapine", "<", "risperidone", ")", "with", "significant", "differences", "between", "clozapine", "and", "risperidone", "(", "t", "(", "30", ")", "=", "-", "2", ".", "59", ";", "P", "=", ".", "02", ")", "and", "olanzapine", "and", "risperidone", "(", "t", "(", "30", ")", "=", "-", "2", ".", "34", ",", "P", "=", ".", "03", ")", ".", "CONCLUSIONS", ":", "Both", "nonobese", "clozapine", "-", "and", "olanzapine", "-", "treated", "groups", "displayed", "significant", "insulin", "resistance", "and", "impairment", "of", "glucose", "effectiveness", "compared", "with", "risperidone", "-", "treated", "subjects", ".", "Patients", "taking", "clozapine", "and", "olanzapine", "must", "be", "examined", "for", "insulin", "resistance", "and", "its", "consequences", "."]], "ner": [[[80, 80, "Chemical"], [184, 184, "Chemical"], [254, 254, "Chemical"], [308, 308, "Chemical"], [318, 318, "Chemical"], [383, 383, "Chemical"], [394, 394, "Chemical"], [410, 410, "Chemical"], [483, 483, "Chemical"], [490, 490, "Chemical"], [553, 553, "Chemical"], [563, 563, "Chemical"], [607, 607, "Chemical"], [632, 632, "Chemical"], [210, 211, "Disease"], [218, 219, "Disease"], [362, 363, "Disease"], [399, 400, "Disease"], [460, 461, "Disease"], [616, 617, "Disease"], [639, 640, "Disease"], [82, 82, "Chemical"], [186, 186, "Chemical"], [268, 268, "Chemical"], [310, 310, "Chemical"], [337, 337, "Chemical"], [385, 385, "Chemical"], [396, 396, "Chemical"], [429, 429, "Chemical"], [485, 485, "Chemical"], [508, 508, "Chemical"], [555, 555, "Chemical"], [583, 583, "Chemical"], [610, 610, "Chemical"], [634, 634, "Chemical"], [0, 0, "Chemical"], [16, 16, "Chemical"], [58, 58, "Chemical"], [91, 91, "Chemical"], [115, 115, "Chemical"], [160, 160, "Chemical"], [203, 203, "Chemical"], [222, 222, "Chemical"], [535, 535, "Chemical"], [621, 621, "Chemical"], [5, 5, "Disease"], [41, 41, "Disease"], [108, 108, "Disease"], [170, 170, "Disease"], [33, 34, "Disease"], [67, 67, "Disease"], [172, 173, "Disease"], [85, 85, "Chemical"], [189, 189, "Chemical"], [282, 282, "Chemical"], [312, 312, "Chemical"], [320, 320, "Chemical"], [339, 339, "Chemical"], [387, 387, "Chemical"], [408, 408, "Chemical"], [412, 412, "Chemical"], [431, 431, "Chemical"], [487, 487, "Chemical"], [492, 492, "Chemical"], [510, 510, "Chemical"], [557, 557, "Chemical"], [565, 565, "Chemical"], [585, 585, "Chemical"], [625, 625, "Chemical"]]], "relations": [[[80, 80, 210, 211, "CID"], [80, 80, 218, 219, "CID"], [80, 80, 362, 363, "CID"], [80, 80, 399, 400, "CID"], [80, 80, 460, 461, "CID"], [80, 80, 616, 617, "CID"], [80, 80, 639, 640, "CID"], [184, 184, 210, 211, "CID"], [184, 184, 218, 219, "CID"], [184, 184, 362, 363, "CID"], [184, 184, 399, 400, "CID"], [184, 184, 460, 461, "CID"], [184, 184, 616, 617, "CID"], [184, 184, 639, 640, "CID"], [254, 254, 210, 211, "CID"], [254, 254, 218, 219, "CID"], [254, 254, 362, 363, "CID"], [254, 254, 399, 400, "CID"], [254, 254, 460, 461, "CID"], [254, 254, 616, 617, "CID"], [254, 254, 639, 640, "CID"], [308, 308, 210, 211, "CID"], [308, 308, 218, 219, "CID"], [308, 308, 362, 363, "CID"], [308, 308, 399, 400, "CID"], [308, 308, 460, 461, "CID"], [308, 308, 616, 617, "CID"], [308, 308, 639, 640, "CID"], [318, 318, 210, 211, "CID"], [318, 318, 218, 219, "CID"], [318, 318, 362, 363, "CID"], [318, 318, 399, 400, "CID"], [318, 318, 460, 461, "CID"], [318, 318, 616, 617, "CID"], [318, 318, 639, 640, "CID"], [383, 383, 210, 211, "CID"], [383, 383, 218, 219, "CID"], [383, 383, 362, 363, "CID"], [383, 383, 399, 400, "CID"], [383, 383, 460, 461, "CID"], [383, 383, 616, 617, "CID"], [383, 383, 639, 640, "CID"], [394, 394, 210, 211, "CID"], [394, 394, 218, 219, "CID"], [394, 394, 362, 363, "CID"], [394, 394, 399, 400, "CID"], [394, 394, 460, 461, "CID"], [394, 394, 616, 617, "CID"], [394, 394, 639, 640, "CID"], [410, 410, 210, 211, "CID"], [410, 410, 218, 219, "CID"], [410, 410, 362, 363, "CID"], [410, 410, 399, 400, "CID"], [410, 410, 460, 461, "CID"], [410, 410, 616, 617, "CID"], [410, 410, 639, 640, "CID"], [483, 483, 210, 211, "CID"], [483, 483, 218, 219, "CID"], [483, 483, 362, 363, "CID"], [483, 483, 399, 400, "CID"], [483, 483, 460, 461, "CID"], [483, 483, 616, 617, "CID"], [483, 483, 639, 640, "CID"], [490, 490, 210, 211, "CID"], [490, 490, 218, 219, "CID"], [490, 490, 362, 363, "CID"], [490, 490, 399, 400, "CID"], [490, 490, 460, 461, "CID"], [490, 490, 616, 617, "CID"], [490, 490, 639, 640, "CID"], [553, 553, 210, 211, "CID"], [553, 553, 218, 219, "CID"], [553, 553, 362, 363, "CID"], [553, 553, 399, 400, "CID"], [553, 553, 460, 461, "CID"], [553, 553, 616, 617, "CID"], [553, 553, 639, 640, "CID"], [563, 563, 210, 211, "CID"], [563, 563, 218, 219, "CID"], [563, 563, 362, 363, "CID"], [563, 563, 399, 400, "CID"], [563, 563, 460, 461, "CID"], [563, 563, 616, 617, "CID"], [563, 563, 639, 640, "CID"], [607, 607, 210, 211, "CID"], [607, 607, 218, 219, "CID"], [607, 607, 362, 363, "CID"], [607, 607, 399, 400, "CID"], [607, 607, 460, 461, "CID"], [607, 607, 616, 617, "CID"], [607, 607, 639, 640, "CID"], [632, 632, 210, 211, "CID"], [632, 632, 218, 219, "CID"], [632, 632, 362, 363, "CID"], [632, 632, 399, 400, "CID"], [632, 632, 460, 461, "CID"], [632, 632, 616, 617, "CID"], [632, 632, 639, 640, "CID"], [82, 82, 210, 211, "CID"], [82, 82, 218, 219, "CID"], [82, 82, 362, 363, "CID"], [82, 82, 399, 400, "CID"], [82, 82, 460, 461, "CID"], [82, 82, 616, 617, "CID"], [82, 82, 639, 640, "CID"], [186, 186, 210, 211, "CID"], [186, 186, 218, 219, "CID"], [186, 186, 362, 363, "CID"], [186, 186, 399, 400, "CID"], [186, 186, 460, 461, "CID"], [186, 186, 616, 617, "CID"], [186, 186, 639, 640, "CID"], [268, 268, 210, 211, "CID"], [268, 268, 218, 219, "CID"], [268, 268, 362, 363, "CID"], [268, 268, 399, 400, "CID"], [268, 268, 460, 461, "CID"], [268, 268, 616, 617, "CID"], [268, 268, 639, 640, "CID"], [310, 310, 210, 211, "CID"], [310, 310, 218, 219, "CID"], [310, 310, 362, 363, "CID"], [310, 310, 399, 400, "CID"], [310, 310, 460, 461, "CID"], [310, 310, 616, 617, "CID"], [310, 310, 639, 640, "CID"], [337, 337, 210, 211, "CID"], [337, 337, 218, 219, "CID"], [337, 337, 362, 363, "CID"], [337, 337, 399, 400, "CID"], [337, 337, 460, 461, "CID"], [337, 337, 616, 617, "CID"], [337, 337, 639, 640, "CID"], [385, 385, 210, 211, "CID"], [385, 385, 218, 219, "CID"], [385, 385, 362, 363, "CID"], [385, 385, 399, 400, "CID"], [385, 385, 460, 461, "CID"], [385, 385, 616, 617, "CID"], [385, 385, 639, 640, "CID"], [396, 396, 210, 211, "CID"], [396, 396, 218, 219, "CID"], [396, 396, 362, 363, "CID"], [396, 396, 399, 400, "CID"], [396, 396, 460, 461, "CID"], [396, 396, 616, 617, "CID"], [396, 396, 639, 640, "CID"], [429, 429, 210, 211, "CID"], [429, 429, 218, 219, "CID"], [429, 429, 362, 363, "CID"], [429, 429, 399, 400, "CID"], [429, 429, 460, 461, "CID"], [429, 429, 616, 617, "CID"], [429, 429, 639, 640, "CID"], [485, 485, 210, 211, "CID"], [485, 485, 218, 219, "CID"], [485, 485, 362, 363, "CID"], [485, 485, 399, 400, "CID"], [485, 485, 460, 461, "CID"], [485, 485, 616, 617, "CID"], [485, 485, 639, 640, "CID"], [508, 508, 210, 211, "CID"], [508, 508, 218, 219, "CID"], [508, 508, 362, 363, "CID"], [508, 508, 399, 400, "CID"], [508, 508, 460, 461, "CID"], [508, 508, 616, 617, "CID"], [508, 508, 639, 640, "CID"], [555, 555, 210, 211, "CID"], [555, 555, 218, 219, "CID"], [555, 555, 362, 363, "CID"], [555, 555, 399, 400, "CID"], [555, 555, 460, 461, "CID"], [555, 555, 616, 617, "CID"], [555, 555, 639, 640, "CID"], [583, 583, 210, 211, "CID"], [583, 583, 218, 219, "CID"], [583, 583, 362, 363, "CID"], [583, 583, 399, 400, "CID"], [583, 583, 460, 461, "CID"], [583, 583, 616, 617, "CID"], [583, 583, 639, 640, "CID"], [610, 610, 210, 211, "CID"], [610, 610, 218, 219, "CID"], [610, 610, 362, 363, "CID"], [610, 610, 399, 400, "CID"], [610, 610, 460, 461, "CID"], [610, 610, 616, 617, "CID"], [610, 610, 639, 640, "CID"], [634, 634, 210, 211, "CID"], [634, 634, 218, 219, "CID"], [634, 634, 362, 363, "CID"], [634, 634, 399, 400, "CID"], [634, 634, 460, 461, "CID"], [634, 634, 616, 617, "CID"], [634, 634, 639, 640, "CID"]]], "clusters": [], "translated": " <35>葡萄糖</35>代谢<45>精神分裂症</45>治疗与非典型抗精神病药：频繁抽样静脉内<36>葡萄糖</36>耐量试验和最小模型分析。背景：虽然接受某些非典型抗精神病药治疗的<46>精神分裂症</46>患者新发<49>糖尿病</49>的发病率可能增加，但仍不清楚非典型药物是否直接影响<37>葡萄糖</37>代谢或简单地增加<50>糖尿病</50>的已知危险因素。目的：研究最明确涉及的2种药物（<0>氯氮平</0>和<21>奥氮平</21>）和<52>利培酮</52>使用频繁采样的静脉内<38>葡萄糖</38>耐受性测试。设计：一项横断面设计，在稳定的接受治疗的<47>精神分裂症</47>患者中进行评估，使用频繁采样的静脉内<39>葡萄糖</39>耐量试验和Bergman最小模型分析。地点：受试者是从城市社区心理健康诊所招募的，并在综合临床研究中心进行研究。患者50名受试者签署了知情同意书，41名受试者接受了频繁取样的静脉内<40>葡萄糖</40>耐量试验。36名非肥胖受试者患有<48>精神分裂症</48>或<51>分裂情感障碍</51>，按体重指数匹配并接受<1>氯氮平</1>或<22>奥氮平</22>治疗或<53>利培酮</53>被纳入分析。主要观察指标：空腹血浆<41>葡萄糖</41>和空腹血清胰岛素水平、<14>胰岛素敏感性</14>指数、<15>胰岛素抵抗</15>的稳态模型评估和<42>葡萄糖</42>有效性。结果：使用已鉴定的非典型抗精神病药物治疗的平均 +/- SD 持续时间为68.3 +/- 28.9个月（<2>氯氮平</2>），29.5 +/- 17.5个月（<23>奥氮平</23>），和40.9 +/- 33.7（<54>利培酮</54>）。空腹血清胰岛素浓度组间差异(F(33)=3.35；P=.047)(<3>氯氮平</3>><24>奥氮平</24>><55>利培酮</55>)，<4>氯氮平</4>和<56>利培酮</56>有显着差异(t(33)=2.32；P=.03)和<25>奥氮平</25>和<57>利培酮</57>(t(33)=2.15;P=.04)。各组<16>胰岛素敏感性</16>指数差异有统计学意义(F(33)=10.66;P<.001)(<5>氯氮平</5><<26>奥氮平</26><<58>利培酮</58>)，与接受治疗的受试者相比，接受<6>氯氮平</6>和<27>奥氮平</27>的受试者表现出显着的<17>胰岛素抵抗</17>与<59>利培酮</59>(<7>氯氮平</7>对比<60>利培酮</60>，t(33)=-4.29；P<.001；<28>奥氮平</28>对比<61>利培酮</61>，t(33)=-3.62;P=.001 [P<.001])。<18>胰岛素抵抗</18>的稳态模型评估在各组之间也存在显着差异(F(33)=4.92;P=.01)(<8>氯氮平</8>> <29>奥氮平</29> > <62>利培酮</62>) (<9>氯氮平</9>对比<63>利培酮</63>，t(33)=2.94; P=.006；<30>奥氮平</30> 对比<64>利培酮</64>，t(33)=2.42;P=.02)。 <43>葡萄糖</43>有效性组间差异显着(F(30)=4.18;P=.02)(<10>氯氮平</10><<31>奥氮平</31><<65>利培酮</65>)，<11>氯氮平</11>和<66>利培酮</66>(t(30)=-2.59;P=.02)以及<32>奥氮平</32>和<67>利培酮</67>(t(30)=-2.34,P=.03)有显着差异。结论：非肥胖型<12>氯氮平</12>和<33>奥 氮平</33>治疗组均表现出显着的<19>胰岛素抵抗</19>和<44>葡萄糖</44>有效性受损，<68>利培酮</68>-治疗的受试者。服用<13>氯氮平</13>和<34>奥氮平</34>的患者必须检查<20>胰岛素抵抗</20>及其后果。", "revised": true}
{"doc_key": "16369751", "sentences": [["5", "-", "Fluorouracil", "cardiotoxicity", "induced", "by", "alpha", "-", "fluoro", "-", "beta", "-", "alanine", ".", "Cardiotoxicity", "is", "a", "rare", "complication", "occurring", "during", "5", "-", "fluorouracil", "(", "5", "-", "FU", ")", "treatment", "for", "malignancies", ".", "We", "herein", "report", "the", "case", "of", "a", "70", "-", "year", "-", "old", "man", "with", "5", "-", "FU", "-", "induced", "cardiotoxicity", ",", "in", "whom", "a", "high", "serum", "level", "of", "alpha", "-", "fluoro", "-", "beta", "-", "alanine", "(", "FBAL", ")", "was", "observed", ".", "The", "patient", ",", "who", "had", "unresectable", "colon", "cancer", "metastases", "to", "the", "liver", "and", "lung", ",", "was", "referred", "to", "us", "for", "chemotherapy", "from", "an", "affiliated", "hospital", ";", "he", "had", "no", "cardiac", "history", ".", "After", "admission", ",", "the", "patient", "received", "a", "continuous", "intravenous", "infusion", "of", "5", "-", "FU", "(", "1000", "mg", "/", "day", ")", ",", "during", "which", "precordial", "pain", "with", "right", "bundle", "branch", "block", "occurred", "concomitantly", "with", "a", "high", "serum", "FBAL", "concentration", "of", "1955", "ng", "/", "ml", ".", "Both", "the", "precordial", "pain", "and", "the", "electrocardiographic", "changes", "disappeared", "spontaneously", "after", "the", "discontinuation", "of", "5", "-", "FU", ".", "As", "the", "precordial", "pain", "in", "this", "patient", "was", "considered", "to", "have", "been", "due", "to", "5", "-", "FU", "-", "induced", "cardiotoxicity", ",", "the", "administration", "of", "5", "-", "FU", "was", "abandoned", ".", "Instead", ",", "oral", "administration", "of", "S", "-", "1", "(", "a", "derivative", "of", "5", "-", "FU", ")", ",", "at", "200", "mg", "/", "day", "twice", "a", "week", ",", "was", "instituted", ",", "because", "S", "-", "1", "has", "a", "strong", "inhibitory", "effect", "on", "dihydropyrimidine", "dehydrogenase", ",", "which", "catalyzes", "the", "degradative", "of", "5", "-", "FU", "into", "FBAL", ".", "The", "serum", "FBAL", "concentration", "subsequently", "decreased", "to", "352", "ng", "/", "ml", ",", "the", "same", "as", "the", "value", "measured", "on", "the", "first", "day", "of", "S", "-", "1", "administration", ".", "Thereafter", ",", "no", "cardiac", "symptoms", "were", "observed", ".", "The", "patient", "achieved", "a", "partial", "response", "6", "months", "after", "the", "initiation", "of", "the", "S", "-", "1", "treatment", ".", "The", "experience", "of", "this", "case", ",", "together", "with", "a", "review", "of", "the", "literature", ",", "suggests", "that", "FBAL", "is", "related", "to", "5", "-", "FU", "-", "induced", "cardiotoxicity", ".", "S", "-", "1", "may", "be", "administered", "safely", "to", "patients", "with", "5", "-", "FU", "-", "induced", "cardiotoxicity", "."]], "ner": [[[0, 2, "Chemical"], [21, 23, "Chemical"], [25, 27, "Chemical"], [47, 49, "Chemical"], [117, 119, "Chemical"], [164, 166, "Chemical"], [182, 184, "Chemical"], [192, 194, "Chemical"], [210, 212, "Chemical"], [245, 247, "Chemical"], [325, 327, "Chemical"], [342, 344, "Chemical"], [129, 130, "Disease"], [152, 153, "Disease"], [170, 171, "Disease"], [132, 135, "Disease"], [3, 3, "Disease"], [14, 14, "Disease"], [52, 52, "Disease"], [187, 187, "Disease"], [330, 330, "Disease"], [347, 347, "Disease"], [31, 31, "Disease"], [80, 81, "Disease"], [282, 283, "Disease"], [6, 12, "Chemical"], [61, 67, "Chemical"], [69, 69, "Chemical"], [142, 142, "Chemical"], [249, 249, "Chemical"], [253, 253, "Chemical"], [321, 321, "Chemical"], [237, 237, "Chemical"]]], "relations": [[[0, 2, 129, 130, "CID"], [0, 2, 152, 153, "CID"], [0, 2, 170, 171, "CID"], [21, 23, 129, 130, "CID"], [21, 23, 152, 153, "CID"], [21, 23, 170, 171, "CID"], [25, 27, 129, 130, "CID"], [25, 27, 152, 153, "CID"], [25, 27, 170, 171, "CID"], [47, 49, 129, 130, "CID"], [47, 49, 152, 153, "CID"], [47, 49, 170, 171, "CID"], [117, 119, 129, 130, "CID"], [117, 119, 152, 153, "CID"], [117, 119, 170, 171, "CID"], [164, 166, 129, 130, "CID"], [164, 166, 152, 153, "CID"], [164, 166, 170, 171, "CID"], [182, 184, 129, 130, "CID"], [182, 184, 152, 153, "CID"], [182, 184, 170, 171, "CID"], [192, 194, 129, 130, "CID"], [192, 194, 152, 153, "CID"], [192, 194, 170, 171, "CID"], [210, 212, 129, 130, "CID"], [210, 212, 152, 153, "CID"], [210, 212, 170, 171, "CID"], [245, 247, 129, 130, "CID"], [245, 247, 152, 153, "CID"], [245, 247, 170, 171, "CID"], [325, 327, 129, 130, "CID"], [325, 327, 152, 153, "CID"], [325, 327, 170, 171, "CID"], [342, 344, 129, 130, "CID"], [342, 344, 152, 153, "CID"], [342, 344, 170, 171, "CID"], [0, 2, 132, 135, "CID"], [21, 23, 132, 135, "CID"], [25, 27, 132, 135, "CID"], [47, 49, 132, 135, "CID"], [117, 119, 132, 135, "CID"], [164, 166, 132, 135, "CID"], [182, 184, 132, 135, "CID"], [192, 194, 132, 135, "CID"], [210, 212, 132, 135, "CID"], [245, 247, 132, 135, "CID"], [325, 327, 132, 135, "CID"], [342, 344, 132, 135, "CID"]]], "clusters": [], "translated": "<0>5-氟尿嘧啶</0><16>心脏毒性</16>由<25>α-氟-β-丙氨酸</25>引起。 <17>心脏毒性</17>是<1>5-氟尿嘧啶</1>（<2>5-FU</2>）治疗<22>恶性肿瘤</22>期间发生的罕见并发症。我们在此报告了一名患有<3>5-FU</3>-诱导的<18>心脏毒性</18>的70岁男性的病例，其中观察到血清中<26>α-氟-β丙氨酸</26> (<27>FBAL</27>) 的高浓度。患者因<23>结肠癌</23>肝肺转移无法切除，从附属医院转诊至我们进行化疗；他没有心脏病史。入院后，患者持续静脉滴注<4>5-FU</4>（1000mg/天），期间<12>心前区疼痛</12>伴随<15>右束支传导阻滞</15>与1955 ng/ml 的高血清<28>FBAL</28>浓度同时出现。停用<5>5-FU</5>后，<13>心前区疼痛</13>及心电图改变均自行消失。由于该患者的<14>心前区疼痛</14>被认为是由于<6>5-FU</6>-引起的<19>心脏毒性</19>，因此给予<7>5-FU</7>被废弃了。相反，开始每周两次口服S-1（<8>5-FU</8>的衍生物），每次200毫克/天，因为S-1对<32>二氢嘧啶脱氢酶</32>有很强的抑制作用，催化<9>5-FU</9>降解为<29>FBAL</29>。随后，血清<30>FBAL</30>浓度降至352 ng/ml，与S-1给药第一天测得的值相同。此后，未观察到<24>心脏症状</24>。患者在S-1治疗开始后6个月达到部分缓解。本病例的经验以及对文献的回顾表明，<31>FBAL</31>与<10>5-FU</10>诱导的<20>心脏毒性</20>有关。S-1可以安全地用于<11>5-FU</11>-诱导的<21>心脏毒性</21>的患者。", "revised": true}
{"doc_key": "15276093", "sentences": [["Safety", "and", "compliance", "with", "once", "-", "daily", "niacin", "extended", "-", "release", "/", "lovastatin", "as", "initial", "therapy", "in", "the", "Impact", "of", "Medical", "Subspecialty", "on", "Patient", "Compliance", "to", "Treatment", "(", "IMPACT", ")", "study", ".", "Niacin", "extended", "-", "release", "/", "lovastatin", "is", "a", "new", "combination", "product", "approved", "for", "treatment", "of", "primary", "hypercholesterolemia", "and", "mixed", "dyslipidemia", ".", "This", "open", "-", "labeled", ",", "multicenter", "study", "evaluated", "the", "safety", "of", "bedtime", "niacin", "extended", "-", "release", "/", "lovastatin", "when", "dosed", "as", "initial", "therapy", "and", "patient", "compliance", "to", "treatment", "in", "various", "clinical", "practice", "settings", ".", "A", "total", "of", "4", ",", "499", "patients", "with", "dyslipidemia", "requiring", "drug", "intervention", "was", "enrolled", "at", "1", ",", "081", "sites", ".", "Patients", "were", "treated", "with", "1", "tablet", "(", "500", "mg", "of", "niacin", "extended", "-", "release", "/", "20", "mg", "of", "lovastatin", ")", "once", "nightly", "for", "4", "weeks", "and", "then", "2", "tablets", "for", "8", "weeks", ".", "Patients", "also", "received", "dietary", "counseling", ",", "educational", "materials", ",", "and", "reminders", "to", "call", "a", "toll", "-", "free", "number", "that", "provided", "further", "education", "about", "dyslipidemia", "and", "niacin", "extended", "-", "release", "/", "lovastatin", ".", "Primary", "end", "points", "were", "study", "compliance", ",", "increases", "in", "liver", "transaminases", "to", ">", "3", "times", "the", "upper", "limit", "of", "normal", ",", "and", "clinical", "myopathy", ".", "Final", "study", "status", "was", "available", "for", "4", ",", "217", "patients", "(", "94", "%", ")", ".", "Compliance", "to", "niacin", "extended", "-", "release", "/", "lovastatin", "was", "77", "%", ",", "with", "3", ",", "245", "patients", "completing", "the", "study", ".", "Patients", "in", "the", "southeast", "and", "those", "enrolled", "by", "endocrinologists", "had", "the", "lowest", "compliance", "and", "highest", "adverse", "event", "rates", ".", "Flushing", "was", "the", "most", "common", "adverse", "event", ",", "reported", "by", "18", "%", "of", "patients", "and", "leading", "to", "discontinuation", "by", "6", "%", ".", "Incidence", "of", "increased", "aspartate", "aminotransferase", "and", "/", "or", "alanine", "aminotransferase", ">", "3", "times", "the", "upper", "limit", "of", "normal", "was", "<", "0", ".", "3", "%", ".", "An", "increase", "of", "creatine", "phosphokinase", "to", ">", "5", "times", "the", "upper", "limit", "of", "normal", "occurred", "in", "0", ".", "24", "%", "of", "patients", ",", "and", "no", "cases", "of", "drug", "-", "induced", "myopathy", "were", "observed", ".", "Niacin", "extended", "-", "release", "/", "lovastatin", "1", ",", "000", "/", "40", "mg", ",", "dosed", "as", "initial", "therapy", ",", "was", "associated", "with", "good", "compliance", "and", "safety", "and", "had", "very", "low", "incidences", "of", "increased", "liver", "and", "muscle", "enzymes", "."]], "ner": [[[7, 12, "Chemical"], [32, 37, "Chemical"], [65, 70, "Chemical"], [165, 170, "Chemical"], [214, 219, "Chemical"], [333, 338, "Chemical"], [252, 252, "Disease"], [48, 48, "Disease"], [51, 51, "Disease"], [95, 95, "Disease"], [163, 163, "Disease"], [195, 195, "Disease"], [329, 329, "Disease"], [117, 117, "Chemical"], [125, 125, "Chemical"], [277, 277, "Chemical"], [282, 282, "Chemical"], [302, 302, "Chemical"]]], "relations": [[[7, 12, 252, 252, "CID"], [32, 37, 252, 252, "CID"], [65, 70, 252, 252, "CID"], [165, 170, 252, 252, "CID"], [214, 219, 252, 252, "CID"], [333, 338, 252, 252, "CID"]]], "clusters": [], "translated": "每日一次<0>烟酸缓释剂/洛伐他汀</0>作为医学亚专业对患者治疗依从性影响 (IMPACT) 研究的初始治疗的安全性和依从性。<1>烟酸缓释剂/洛伐他汀</1>是批准用于治疗原发性<7>高胆固醇血症</7>和混合性<8>血脂异常</8>的新组合产品。这项开放标签的多中心研究评估了睡前服用<2>烟酸缓释剂/洛伐他汀</2>作为初始治疗的安全性以及患者在各种临床实践环境中对治疗的依从性。共有 4,499 例需要药物干预的<9>血脂异常</9>患者在1,081个研究中心纳入研究。患者接受1片 (500毫克<13>烟酸</13>缓释剂/20毫克<14>洛伐他汀</14>) 每晚一次治疗 4周，然后2片，每晚一次，治疗 8周。患者还接受了饮食咨询、教育材料和拨打免费电话的提醒，该电话提供有关 <10>血脂异常</10> 和 <3>烟酸缓释剂/洛伐他汀</3> 的进一步教育。主要终点为研究依从性、肝转氨酶升高到正常上限的3倍以上，以及临床<11>肌病</11> 。\n\n最终研究状态可用于 4,217名患者(94%)。<4>烟酸缓释剂/洛伐他汀</4> 的依从性为 77% ，3,245名患者完成了研究。东南部地区和内分泌学家招募的患者依从性最低，不良事件发生率最高。 <6>脸红</6>是最常见的不良事件，报告占18%的患者，6%的患者因此停药。升高的<15>天冬氨酸</15>转氨酶和<16>丙氨酸</16>转氨酶大于正常值的3倍的发生率为<0.3%。0.24%的患者出现<17>肌酸激酶</17>升高至超过正常上限的5倍，未观察到药物引起的 <12>肌病</12>。\n\n以1,000/40 mg的剂量作为初始治疗的<5>烟酸缓释剂/洛伐他汀</5>具有良好的依从性和安全性，并且肝酶和肌酶的升高率极低。", "revised": true}
{"doc_key": "16911931", "sentences": [["Intramuscular", "hepatitis", "B", "immune", "globulin", "combined", "with", "lamivudine", "in", "prevention", "of", "hepatitis", "B", "recurrence", "after", "liver", "transplantation", ".", "BACKGROUND", ":", "Combined", "hepatitis", "B", "immune", "globulin", "(", "HBIg", ")", "and", "lamivudine", "in", "prophylaxis", "of", "the", "recurrence", "of", "hepatitis", "B", "after", "liver", "transplantation", "has", "significantly", "improved", "the", "survival", "of", "HBsAg", "positive", "patients", ".", "This", "study", "was", "undertaken", "to", "evaluate", "the", "outcomes", "of", "liver", "transplantation", "for", "patients", "with", "hepatitis", "B", "virus", "(", "HBV", ")", ".", "METHODS", ":", "A", "retrospective", "chart", "analysis", "and", "a", "review", "of", "the", "organ", "transplant", "database", "identified", "51", "patients", "(", "43", "men", "and", "8", "women", ")", "transplanted", "for", "benign", "HBV", "-", "related", "cirrhotic", "diseases", "between", "June", "2002", "and", "December", "2004", "who", "had", "survived", "more", "than", "3", "months", ".", "HBIg", "was", "administered", "intravenously", "during", "the", "first", "week", "and", "intramuscularly", "thereafter", ".", "RESULTS", ":", "At", "a", "median", "follow", "-", "up", "of", "14", ".", "1", "months", ",", "the", "overall", "recurrence", "rate", "in", "the", "51", "patients", "was", "3", ".", "9", "%", "(", "2", "/", "51", ")", ".", "The", "overall", "patient", "survival", "was", "88", ".", "3", "%", ",", "and", "82", ".", "4", "%", "after", "1", "and", "2", "years", ",", "respectively", ".", "A", "daily", "oral", "dose", "of", "100", "mg", "lamivudine", "for", "2", "weeks", "before", "transplantation", "for", "10", "patients", "enabled", "57", ".", "1", "%", "(", "4", "/", "7", ")", "and", "62", ".", "5", "%", "(", "5", "/", "8", ")", "of", "HBV", "-", "DNA", "and", "HBeAg", "positive", "patients", "respectively", "to", "convert", "to", "be", "negative", ".", "Intramuscular", "HBIg", "was", "well", "tolerated", "in", "all", "patients", ".", "CONCLUSION", ":", "Lamivudine", "combined", "with", "intramuscular", "HBIg", "can", "effectively", "prevent", "allograft", "from", "the", "recurrence", "of", "HBV", "after", "liver", "transplantation", "."]], "ner": [[[227, 227, "Chemical"], [1, 2, "Disease"], [11, 12, "Disease"], [21, 22, "Disease"], [36, 37, "Disease"], [65, 66, "Disease"], [7, 7, "Chemical"], [29, 29, "Chemical"], [193, 193, "Chemical"], [248, 248, "Chemical"], [47, 47, "Chemical"], [102, 103, "Disease"]]], "relations": [[[227, 227, 1, 2, "CID"], [227, 227, 11, 12, "CID"], [227, 227, 21, 22, "CID"], [227, 227, 36, 37, "CID"], [227, 227, 65, 66, "CID"]]], "clusters": [], "translated": "肌注<1>乙肝</1>免疫球蛋白联合<6>拉米夫定</6>预防肝移植术后<2>乙肝</2>复发。背景：<3>乙型肝炎</3>免疫球蛋白（HBIg）联合<7>拉米夫定</7>预防肝移植术后<4>乙型肝炎</4>复发，显着提高了<10>HBsAg</10>阳性患者的生存率。本研究旨在评估<5>乙型肝炎</5>病毒（HBV）患者肝移植的结果。方法：回顾性分析文件和移植数据库，确定了在 2002 年 6 月至 2004 年 12 月间移植的 51 名良性 HBV 相关<11>肝硬化疾病</11>患者（43名男性和 8 名女性），存活时间超过 3 个月。HBIg 在第一周内静脉注射，随后改为肌肉注射。结果：随访时间的中位数为 14.1 个月，51 例患者总复发率为 3.9%（2/51）。患者总生存率分别为 88.3 %，在 1 年和 2 年后分别为 82.4 % 和 74%。把 100 毫克<8>拉米夫定</8>每天口服 2 周后，10 名患者的 57.1 %（4/7）和 62.5 %（5/8）的 HBV-DNA 和<0> HBeAg </0> 阳性患者转为阴性。所有患者均耐受肌肉注射的 HBIg。结论：肌注 HBIg 和<9>拉米夫定</9>联合使用可有效预防肝移植术后 HBV 复发。", "revised": true}
{"doc_key": "15817013", "sentences": [["People", "aged", "over", "75", "in", "atrial", "fibrillation", "on", "warfarin", ":", "the", "rate", "of", "major", "hemorrhage", "and", "stroke", "in", "more", "than", "500", "patient", "-", "years", "of", "follow", "-", "up", ".", "OBJECTIVES", ":", "To", "determine", "the", "incidence", "of", "major", "hemorrhage", "and", "stroke", "in", "people", "aged", "76", "and", "older", "with", "atrial", "fibrillation", "on", "adjusted", "-", "dose", "warfarin", "who", "had", "been", "recently", "been", "admitted", "to", "hospital", ".", "DESIGN", ":", "A", "retrospective", "observational", "cohort", "study", ".", "SETTING", ":", "A", "major", "healthcare", "network", "involving", "four", "tertiary", "hospitals", ".", "PARTICIPANTS", ":", "Two", "hundred", "thirty", "-", "five", "patients", "aged", "76", "and", "older", "admitted", "to", "a", "major", "healthcare", "network", "between", "July", "1", ",", "2001", ",", "and", "June", "30", ",", "2002", ",", "with", "atrial", "fibrillation", "on", "warfarin", "were", "enrolled", ".", "MEASUREMENTS", ":", "Information", "regarding", "major", "bleeding", "episodes", ",", "strokes", ",", "and", "warfarin", "use", "was", "obtained", "from", "patients", ",", "relatives", ",", "primary", "physicians", ",", "and", "medical", "records", ".", "RESULTS", ":", "Two", "hundred", "twenty", "-", "eight", "patients", "(", "42", "%", "men", ")", "with", "a", "mean", "age", "of", "81", ".", "1", "(", "range", "76", "-", "94", ")", "were", "included", "in", "the", "analysis", ".", "Total", "follow", "-", "up", "on", "warfarin", "was", "530", "years", "(", "mean", "28", "months", ")", ".", "There", "were", "53", "major", "hemorrhages", ",", "for", "an", "annual", "rate", "of", "10", ".", "0", "%", ",", "including", "24", "(", "45", ".", "3", "%", ")", "life", "-", "threatening", "and", "five", "(", "9", ".", "4", "%", ")", "fatal", "bleeds", ".", "The", "annual", "stroke", "rate", "after", "initiation", "of", "warfarin", "was", "2", ".", "6", "%", ".", "CONCLUSION", ":", "The", "rate", "of", "major", "hemorrhage", "was", "high", "in", "this", "old", ",", "frail", "group", ",", "but", "excluding", "fatalities", ",", "resulted", "in", "no", "long", "-", "term", "sequelae", ",", "and", "the", "stroke", "rate", "on", "warfarin", "was", "low", ",", "demonstrating", "how", "effective", "warfarin", "treatment", "is", "."]], "ner": [[[8, 8, "Chemical"], [53, 53, "Chemical"], [116, 116, "Chemical"], [131, 131, "Chemical"], [185, 185, "Chemical"], [240, 240, "Chemical"], [280, 280, "Chemical"], [287, 287, "Chemical"], [14, 14, "Disease"], [37, 37, "Disease"], [125, 125, "Disease"], [199, 199, "Disease"], [253, 253, "Disease"], [5, 6, "Disease"], [47, 48, "Disease"], [113, 114, "Disease"], [16, 16, "Disease"], [39, 39, "Disease"], [128, 128, "Disease"], [235, 235, "Disease"], [277, 277, "Disease"]]], "relations": [[[8, 8, 14, 14, "CID"], [8, 8, 37, 37, "CID"], [8, 8, 125, 125, "CID"], [8, 8, 199, 199, "CID"], [8, 8, 253, 253, "CID"], [53, 53, 14, 14, "CID"], [53, 53, 37, 37, "CID"], [53, 53, 125, 125, "CID"], [53, 53, 199, 199, "CID"], [53, 53, 253, 253, "CID"], [116, 116, 14, 14, "CID"], [116, 116, 37, 37, "CID"], [116, 116, 125, 125, "CID"], [116, 116, 199, 199, "CID"], [116, 116, 253, 253, "CID"], [131, 131, 14, 14, "CID"], [131, 131, 37, 37, "CID"], [131, 131, 125, 125, "CID"], [131, 131, 199, 199, "CID"], [131, 131, 253, 253, "CID"], [185, 185, 14, 14, "CID"], [185, 185, 37, 37, "CID"], [185, 185, 125, 125, "CID"], [185, 185, 199, 199, "CID"], [185, 185, 253, 253, "CID"], [240, 240, 14, 14, "CID"], [240, 240, 37, 37, "CID"], [240, 240, 125, 125, "CID"], [240, 240, 199, 199, "CID"], [240, 240, 253, 253, "CID"], [280, 280, 14, 14, "CID"], [280, 280, 37, 37, "CID"], [280, 280, 125, 125, "CID"], [280, 280, 199, 199, "CID"], [280, 280, 253, 253, "CID"], [287, 287, 14, 14, "CID"], [287, 287, 37, 37, "CID"], [287, 287, 125, 125, "CID"], [287, 287, 199, 199, "CID"], [287, 287, 253, 253, "CID"]]], "clusters": [], "translated": "75 岁以上因<13>心房颤动</13>在接受<0>华法林</0>治疗的患者中：超过 500 例患者 - 年随访中的主要<8>出血</8>和<16>中风</16>发生率。目的：确定最近入院的年龄在76岁及以上，患有<14>心房颤动</14>且接受调整剂量<1>华法林</1>的人的主要<9>出血</9>和<17>中风</17>的发生率。设计：一项回顾性观察性队列研究。背景：一个涉及四家三级医院的大型医疗保健网络。参与者：235名76岁及以上、于2001年7月1日至2002年6月30日期间，在<2>使用华法林</2>治疗的<15>心房颤动</15>患者注册。测量：从患者、亲属、初级医生和病历中获取有关主要<10>出血</10>、<18>中风</18>和<3>华法林</3>使用的信息。结果：分析中包括 228 名患者（42%男性），平均年龄为81.1（范围76-94）。在<4>使用华法林</4>的总随访时间为530年（平均28个月）。共有53例严重<11>出血</11>，年发病率为10.0%，其中包括24例（45.3%）威胁生命和五例（9.4%）致死性出血。<5>使用华法林</5>后的年<19>中风</19>率为2.6%。结论：在这个老年、虚弱的人群中，主要<12>出血</12>的发生率很高，但排除死亡后，没有长期的后遗症，而<6>使用华法林</6>的年<20>中风</20>率很低，证明了<7>华法林</7>的有效治疗。", "revised": true}
{"doc_key": "17042797", "sentences": [["Stereological", "methods", "reveal", "the", "robust", "size", "and", "stability", "of", "ectopic", "hilar", "granule", "cells", "after", "pilocarpine", "-", "induced", "status", "epilepticus", "in", "the", "adult", "rat", ".", "Following", "status", "epilepticus", "in", "the", "rat", ",", "dentate", "granule", "cell", "neurogenesis", "increases", "greatly", ",", "and", "many", "of", "the", "new", "neurons", "appear", "to", "develop", "ectopically", ",", "in", "the", "hilar", "region", "of", "the", "hippocampal", "formation", ".", "It", "has", "been", "suggested", "that", "the", "ectopic", "hilar", "granule", "cells", "could", "contribute", "to", "the", "spontaneous", "seizures", "that", "ultimately", "develop", "after", "status", "epilepticus", ".", "However", ",", "the", "population", "has", "never", "been", "quantified", ",", "so", "it", "is", "unclear", "whether", "it", "is", "substantial", "enough", "to", "have", "a", "strong", "influence", "on", "epileptogenesis", ".", "To", "quantify", "this", "population", ",", "the", "total", "number", "of", "ectopic", "hilar", "granule", "cells", "was", "estimated", "using", "unbiased", "stereology", "at", "different", "times", "after", "pilocarpine", "-", "induced", "status", "epilepticus", ".", "The", "number", "of", "hilar", "neurons", "immunoreactive", "for", "Prox", "-", "1", ",", "a", "granule", "-", "cell", "-", "specific", "marker", ",", "was", "estimated", "using", "the", "optical", "fractionator", "method", ".", "The", "results", "indicate", "that", "the", "size", "of", "the", "hilar", "ectopic", "granule", "cell", "population", "after", "status", "epilepticus", "is", "substantial", ",", "and", "stable", "over", "time", ".", "Interestingly", ",", "the", "size", "of", "the", "population", "appears", "to", "be", "correlated", "with", "the", "frequency", "of", "behavioral", "seizures", ",", "because", "animals", "with", "more", "ectopic", "granule", "cells", "in", "the", "hilus", "have", "more", "frequent", "behavioral", "seizures", ".", "The", "hilar", "ectopic", "granule", "cell", "population", "does", "not", "appear", "to", "vary", "systematically", "across", "the", "septotemporal", "axis", ",", "although", "it", "is", "associated", "with", "an", "increase", "in", "volume", "of", "the", "hilus", ".", "The", "results", "provide", "new", "insight", "into", "the", "potential", "role", "of", "ectopic", "hilar", "granule", "cells", "in", "the", "pilocarpine", "model", "of", "temporal", "lobe", "epilepsy", "."]], "ner": [[[14, 14, "Chemical"], [129, 129, "Chemical"], [266, 266, "Chemical"], [17, 18, "Disease"], [25, 26, "Disease"], [78, 79, "Disease"], [132, 133, "Disease"], [176, 177, "Disease"], [269, 271, "Disease"], [73, 73, "Disease"], [202, 202, "Disease"], [218, 218, "Disease"]]], "relations": [[[14, 14, 17, 18, "CID"], [14, 14, 25, 26, "CID"], [14, 14, 78, 79, "CID"], [14, 14, 132, 133, "CID"], [14, 14, 176, 177, "CID"], [129, 129, 17, 18, "CID"], [129, 129, 25, 26, "CID"], [129, 129, 78, 79, "CID"], [129, 129, 132, 133, "CID"], [129, 129, 176, 177, "CID"], [266, 266, 17, 18, "CID"], [266, 266, 25, 26, "CID"], [266, 266, 78, 79, "CID"], [266, 266, 132, 133, "CID"], [266, 266, 176, 177, "CID"], [14, 14, 269, 271, "CID"], [129, 129, 269, 271, "CID"], [266, 266, 269, 271, "CID"]]], "clusters": [], "translated": "体视学方法揭示了<0>毛果芸香碱</0>诱导成年大鼠<3>癫痫持续状态</3>后异位<4>肺门颗粒细胞</4>的稳健大小和稳定性。在大鼠<4>癫痫持续状态</4>后，齿状颗粒细胞的神经发生大大增加，许多新的神经元似乎在海马结构的门区异位发育。有人提出，异位<4>肺门颗粒细胞</4>可能导致自发性<9>癫痫发作</9>，最终在<5>癫痫持续状态</5>后发展。然而，人口从未被量化过，因此尚不清楚它是否足够大以对癫痫发生产生强烈影响。为了量化这个群体，在<1>毛果芸香碱</1>诱导的<6>癫痫持续状态</6>后的不同时间，使用无偏体视学估计<4>异位肺门颗粒细胞</4>的总数。对 Prox-1（一种颗粒细胞特异性标记物）具有免疫反应性的<4>肺门神经元</4>数量是使用光学分馏器方法估算的。结果表明，<7>癫痫持续状态</7>后<4>肺门异位颗粒细胞</4>群的大小是相当大的，并且随着时间的推移是稳定的。有趣的是，种群大小似乎与行为<10>癫痫发作</10>的频率相关，因为在<4>门</4>中具有更多异位颗粒细胞的动物具有更频繁的行为<11>癫痫发作</11>。<4>肺门异位颗粒细胞</4>群在隔颞轴上似乎没有系统性变化，尽管它与<4>肺门体积</4>的增加有关。该结果为异位<4>肺门颗粒细胞</4>在<2>毛果芸香碱</2>模型的<8>颞叶癫痫</8>中的潜在作用提供了新的见解。", "revised": true}
{"doc_key": "16323982", "sentences": [["Antiandrogenic", "therapy", "can", "cause", "coronary", "arterial", "disease", ".", "AIM", ":", "To", "study", "the", "change", "of", "lipid", "metabolism", "by", "antiandrogen", "therapy", "in", "patients", "with", "prostate", "cancer", ".", "MATERIALS", "AND", "METHODS", ":", "We", "studied", "with", "a", "2", ".", "5", "years", "follow", "-", "up", "the", "changes", "in", "plasma", "cholesterols", "(", "C", ")", ",", "triglycerides", "(", "TG", ")", ",", "lipoproteins", "(", "LP", ")", ",", "and", "apolipoproteins", "(", "Apo", ")", "B", "-", "100", ",", "A", "-", "I", ",", "and", "A", "-", "II", "pro", "fi", "les", "in", "24", "patients", "of", "mean", "age", "60", "years", "with", "low", "risk", "prostate", "cancer", "(", "stage", ":", "T1cN0M0", ",", "Gleason", "score", ":", "2", "-", "5", ")", "during", "treatment", "with", "cyproterone", "acetate", "(", "CPA", ")", "without", "surgical", "management", "or", "radiation", "therapy", ".", "RESULTS", ":", "Significant", "decreases", "of", "HDL", "-", "C", ",", "Apo", "A", "-", "I", "and", "Apo", "A", "-", "II", "and", "an", "increase", "of", "triglyceride", "levels", "in", "VLDL", "were", "induced", "by", "CPA", ".", "After", "a", "period", "of", "2", ".", "5", "years", "on", "CPA", "treatment", ",", "four", "patients", "out", "of", "twenty", "-", "four", "were", "found", "to", "be", "affected", "by", "coronary", "heart", "disease", ".", "CONCLUSIONS", ":", "Ischaemic", "coronary", "arteriosclerosis", "with", "an", "incidence", "rate", "of", "16", ".", "6", "%", "as", "caused", "by", "prolonged", "CPA", "therapy", "is", "mediated", "through", "changes", "in", "HDL", "cholesterol", ",", "Apo", "A", "-", "I", "and", "Apo", "A", "-", "II", "pro", "fi", "les", ",", "other", "than", "the", "well", "-", "known", "hyperglyceridemic", "effect", "caused", "by", "estrogen", "."]], "ner": [[[108, 109, "Chemical"], [111, 111, "Chemical"], [149, 149, "Chemical"], [160, 160, "Chemical"], [198, 198, "Chemical"], [4, 6, "Disease"], [183, 184, "Disease"], [227, 228, "Disease"], [45, 45, "Chemical"], [47, 47, "Chemical"], [206, 206, "Chemical"], [50, 50, "Chemical"], [52, 52, "Chemical"], [142, 142, "Chemical"], [231, 231, "Chemical"], [23, 24, "Disease"], [91, 92, "Disease"], [176, 178, "Disease"]]], "relations": [[[108, 109, 4, 6, "CID"], [108, 109, 183, 184, "CID"], [111, 111, 4, 6, "CID"], [111, 111, 183, 184, "CID"], [149, 149, 4, 6, "CID"], [149, 149, 183, 184, "CID"], [160, 160, 4, 6, "CID"], [160, 160, 183, 184, "CID"], [198, 198, 4, 6, "CID"], [198, 198, 183, 184, "CID"], [108, 109, 227, 228, "CID"], [111, 111, 227, 228, "CID"], [149, 149, 227, 228, "CID"], [160, 160, 227, 228, "CID"], [198, 198, 227, 228, "CID"]]], "clusters": [], "translated": "抗雄激素治疗可引起<5>冠状动脉疾病</5>。目的：研究<15>前列腺癌</15>患者抗雄激素治疗后脂质代谢的变化。材料和方法：我们研究了一个2.5年随访血浆<8>胆固醇</8>（<9>C</9>）、<11>甘油三酯</11>（<12>TG</12>）、脂蛋白（LP）和载脂蛋白（Apo）B-100、A-I和A-II谱在24名平均年龄60岁的低危<16>前列腺癌</16>患者中（分期：T1cN0M0，格里森评分：2-5）在用<0>醋酸环丙孕酮</0>（<1>CPA</1>）治疗期间，没有手术治疗或放射治疗。结果：<2>CPA</2>可显着降低VLDL中HDL-C、Apo A-I和Apo A-II水平，增加<13>甘油三酯</13>水平。经过一段2.5年的<3>CPA</3>治疗后，24名患者中有4名被发现患有<17>冠心病</17>。结论：缺血性<6>冠状动脉硬化</6>发病率为16.6%，由长期<4>CPA</4>治疗引起的是通过HDL<10>胆固醇</10>、Apo A-I和Apo A-II谱的变化介导的，除了众所周知的由<14>雌激素</14>引起的<7>高血甘油三酯效应</7>。", "revised": true}
{"doc_key": "17159032", "sentences": [["Early", "paracentral", "visual", "field", "loss", "in", "patients", "taking", "hydroxychloroquine", ".", "OBJECTIVE", ":", "To", "review", "the", "natural", "history", "and", "ocular", "and", "systemic", "adverse", "effects", "of", "patients", "taking", "hydroxychloroquine", "sulfate", "who", "attended", "an", "ophthalmic", "screening", "program", ".", "DESIGN", ":", "Retrospective", "study", ".", "RESULTS", ":", "Records", "of", "262", "patients", "who", "were", "taking", "hydroxychloroquine", "and", "screened", "in", "the", "Department", "of", "Ophthalmology", "were", "reviewed", ".", "Of", "the", "262", "patients", ",", "14", "(", "18", "%", ")", "of", "76", "who", "had", "stopped", "treatment", "at", "the", "time", "of", "the", "study", "experienced", "documented", "adverse", "effects", ".", "Systemic", "adverse", "effects", "occurred", "in", "8", "patients", "(", "10", ".", "5", "%", ")", "and", "ocular", "adverse", "effects", ",", "in", "5", "(", "6", ".", "5", "%", ")", ".", "Thirty", "-", "five", "patients", "(", "13", ".", "4", "%", ")", "had", "visual", "field", "abnormalities", ",", "which", "were", "attributed", "to", "hydroxychloroquine", "treatment", "in", "4", "patients", "(", "1", ".", "5", "%", ")", ".", "Three", "of", "the", "4", "patients", "were", "taking", "less", "than", "6", ".", "5", "mg", "/", "kg", "per", "day", "and", "all", "patients", "had", "normal", "renal", "and", "liver", "function", "test", "results", ".", "CONCLUSIONS", ":", "The", "current", "study", "used", "a", "protocol", "of", "visual", "acuity", "and", "color", "vision", "assessment", ",", "funduscopy", ",", "and", "Humphrey", "10", "-", "2", "visual", "field", "testing", "and", "shows", "that", "visual", "field", "defects", "appeared", "before", "any", "corresponding", "changes", "in", "any", "other", "tested", "clinical", "parameters", ";", "the", "defects", "were", "reproducible", "and", "the", "test", "parameters", "were", "reliable", ".", "Patients", "taking", "hydroxychloroquine", "can", "demonstrate", "a", "toxic", "reaction", "in", "the", "retina", "despite", "the", "absence", "of", "known", "risk", "factors", ".", "Screening", ",", "including", "Humphrey", "10", "-", "2", "visual", "field", "assessment", ",", "is", "recommended", "2", "years", "after", "the", "initial", "baseline", "and", "yearly", "thereafter", "."]], "ner": [[[8, 8, "Chemical"], [26, 27, "Chemical"], [49, 49, "Chemical"], [133, 133, "Chemical"], [231, 231, "Chemical"], [2, 4, "Disease"], [125, 127, "Disease"], [203, 205, "Disease"]]], "relations": [[[8, 8, 2, 4, "CID"], [8, 8, 125, 127, "CID"], [8, 8, 203, 205, "CID"], [26, 27, 2, 4, "CID"], [26, 27, 125, 127, "CID"], [26, 27, 203, 205, "CID"], [49, 49, 2, 4, "CID"], [49, 49, 125, 127, "CID"], [49, 49, 203, 205, "CID"], [133, 133, 2, 4, "CID"], [133, 133, 125, 127, "CID"], [133, 133, 203, 205, "CID"], [231, 231, 2, 4, "CID"], [231, 231, 125, 127, "CID"], [231, 231, 203, 205, "CID"]]], "clusters": [], "translated": "服用<0>羟氯喹</0>的患者早期旁中心<5>视野丧失</5>。目的：回顾参加眼科筛查计划并服用<1>硫酸羟氯喹</1>的患者的自然史以及眼部和全身不良反应。设计：回顾性研究。结果：回顾了眼科筛查的262名服用<2>羟氯喹</2>患者的病历。在262名患者中，76名在研究期间停止治疗的患者中有14名（18%）经历了有记录的不良反应。8名患者（10.5%）出现全身不良反应，5名患者（6.5%）出现眼部不良反应。35例（13.4%）患者有<6>视野异常</6>，其中4例（1.5%）因<3>羟氯喹</3>治疗所致。4名患者中有3名服用的剂量少于6.5 mg/kg每天，所有患者的肾功能和肝功能检查结果均正常。结论：目前的研究使用了视力和色觉评估、眼底检查和Humphrey 10-2视野测试的方案，表明<7>视野缺损</7>出现在任何其他测试的临床参数的任何相应变化之前；缺陷重现性好，测试参数可靠。服用<4>羟氯喹</4>的患者可能会出现视网膜毒性反应，建议在初始基线后2年进行筛查，包括Humphrey 10-2视野评估，此后每年进行一次。", "revised": true}
{"doc_key": "15229250", "sentences": [["Structural", "abnormalities", "in", "the", "brains", "of", "human", "subjects", "who", "use", "methamphetamine", ".", "We", "visualize", ",", "for", "the", "first", "time", ",", "the", "profile", "of", "structural", "deficits", "in", "the", "human", "brain", "associated", "with", "chronic", "methamphetamine", "(", "MA", ")", "abuse", ".", "Studies", "of", "human", "subjects", "who", "have", "used", "MA", "chronically", "have", "revealed", "deficits", "in", "dopaminergic", "and", "serotonergic", "systems", "and", "cerebral", "metabolic", "abnormalities", ".", "Using", "magnetic", "resonance", "imaging", "(", "MRI", ")", "and", "new", "computational", "brain", "-", "mapping", "techniques", ",", "we", "determined", "the", "pattern", "of", "structural", "brain", "alterations", "associated", "with", "chronic", "MA", "abuse", "in", "human", "subjects", "and", "related", "these", "deficits", "to", "cognitive", "impairment", ".", "We", "used", "high", "-", "resolution", "MRI", "and", "surface", "-", "based", "computational", "image", "analyses", "to", "map", "regional", "abnormalities", "in", "the", "cortex", ",", "hippocampus", ",", "white", "matter", ",", "and", "ventricles", "in", "22", "human", "subjects", "who", "used", "MA", "and", "21", "age", "-", "matched", ",", "healthy", "controls", ".", "Cortical", "maps", "revealed", "severe", "gray", "-", "matter", "deficits", "in", "the", "cingulate", ",", "limbic", ",", "and", "paralimbic", "cortices", "of", "MA", "abusers", "(", "averaging", "11", ".", "3", "%", "below", "control", ";", "p", "<", "0", ".", "05", ")", ".", "On", "average", ",", "MA", "abusers", "had", "7", ".", "8", "%", "smaller", "hippocampal", "volumes", "than", "control", "subjects", "(", "p", "<", "0", ".", "01", ";", "left", ",", "p", "=", "0", ".", "01", ";", "right", ",", "p", "<", "0", ".", "05", ")", "and", "significant", "white", "-", "matter", "hypertrophy", "(", "7", ".", "0", "%", ";", "p", "<", "0", ".", "01", ")", ".", "Hippocampal", "deficits", "were", "mapped", "and", "correlated", "with", "memory", "performance", "on", "a", "word", "-", "recall", "test", "(", "p", "<", "0", ".", "05", ")", ".", "MRI", "-", "based", "maps", "suggest", "that", "chronic", "methamphetamine", "abuse", "causes", "a", "selective", "pattern", "of", "cerebral", "deterioration", "that", "contributes", "to", "impaired", "memory", "performance", ".", "MA", "may", "selectively", "damage", "the", "medial", "temporal", "lobe", "and", ",", "consistent", "with", "metabolic", "studies", ",", "the", "cingulate", "-", "limbic", "cortex", ",", "inducing", "neuroadaptation", ",", "neuropil", "reduction", ",", "or", "cell", "death", ".", "Prominent", "white", "-", "matter", "hypertrophy", "may", "result", "from", "altered", "myelination", "and", "adaptive", "glial", "changes", ",", "including", "gliosis", "secondary", "to", "neuronal", "damage", ".", "These", "brain", "substrates", "may", "help", "account", "for", "the", "symptoms", "of", "MA", "abuse", ",", "providing", "therapeutic", "targets", "for", "drug", "-", "induced", "brain", "injury", "."]], "ner": [[[10, 10, "Chemical"], [32, 32, "Chemical"], [34, 34, "Chemical"], [45, 45, "Chemical"], [86, 86, "Chemical"], [133, 133, "Chemical"], [161, 161, "Chemical"], [182, 182, "Chemical"], [267, 267, "Chemical"], [283, 283, "Chemical"], [346, 346, "Chemical"], [23, 28, "Disease"], [115, 126, "Disease"], [356, 357, "Disease"], [279, 281, "Disease"], [57, 58, "Disease"], [96, 97, "Disease"], [223, 223, "Disease"], [318, 318, "Disease"], [330, 330, "Disease"], [333, 334, "Disease"]]], "relations": [[[10, 10, 23, 28, "CID"], [10, 10, 115, 126, "CID"], [10, 10, 356, 357, "CID"], [32, 32, 23, 28, "CID"], [32, 32, 115, 126, "CID"], [32, 32, 356, 357, "CID"], [34, 34, 23, 28, "CID"], [34, 34, 115, 126, "CID"], [34, 34, 356, 357, "CID"], [45, 45, 23, 28, "CID"], [45, 45, 115, 126, "CID"], [45, 45, 356, 357, "CID"], [86, 86, 23, 28, "CID"], [86, 86, 115, 126, "CID"], [86, 86, 356, 357, "CID"], [133, 133, 23, 28, "CID"], [133, 133, 115, 126, "CID"], [133, 133, 356, 357, "CID"], [161, 161, 23, 28, "CID"], [161, 161, 115, 126, "CID"], [161, 161, 356, 357, "CID"], [182, 182, 23, 28, "CID"], [182, 182, 115, 126, "CID"], [182, 182, 356, 357, "CID"], [267, 267, 23, 28, "CID"], [267, 267, 115, 126, "CID"], [267, 267, 356, 357, "CID"], [283, 283, 23, 28, "CID"], [283, 283, 115, 126, "CID"], [283, 283, 356, 357, "CID"], [346, 346, 23, 28, "CID"], [346, 346, 115, 126, "CID"], [346, 346, 356, 357, "CID"], [10, 10, 279, 281, "CID"], [32, 32, 279, 281, "CID"], [34, 34, 279, 281, "CID"], [45, 45, 279, 281, "CID"], [86, 86, 279, 281, "CID"], [133, 133, 279, 281, "CID"], [161, 161, 279, 281, "CID"], [182, 182, 279, 281, "CID"], [267, 267, 279, 281, "CID"], [283, 283, 279, 281, "CID"], [346, 346, 279, 281, "CID"]]], "clusters": [], "translated": "使用<0>甲基苯丙胺</0>的人类受试者的大脑结构异常。我们首次形象化了与慢性<1>甲基苯丙胺</1>（<2>MA</2>）滥用相关的<11>人脑结构缺陷</11>的概况。对长期使用<3>MA</3>的人类受试者的研究表明，多巴胺能和血清素能系统存在缺陷，并且大脑<15>代谢异常</15>。我们使用磁共振成像（MRI）和新的计算大脑绘图技术，确定了与人类受试者慢性<4>MA</4>滥用相关的大脑结构改变模式，并将这些缺陷与<16>认知障碍</16>相关。我们使用高分辨率MRI和基于表面的计算图像分析来绘制 22 名使用<5>MA</5>和 21 名年龄匹配的健康对照者的皮层、海马体、白质和脑室的区域<12>异常</12>。皮层图显示<6>MA</6>滥用者的扣带回、边缘和旁边缘皮层存在严重的灰质缺陷（平均比对照组低11.3%；p<0.05）。平均而言，<7>MA</7>滥用者的海马体体积比对照组小7.8%（p<0.01；左侧p=0.01；右侧p<0.05），以及存在显著白质<17>肥大</17>（7.0%；p<0.01）。海马缺陷被映射并与单词记忆测试中的记忆表现相关联（p<0.05）。基于MRI的地图表明，慢性<8>甲基苯丙胺</8>滥用会导致大脑退化的选择性模式，从而导致<14>记忆力受损</14>。<9>MA</9>可能会选择性地损害内侧颞叶，并且与代谢研究一致，还会损害扣带回边缘皮层，从而诱导神经适应、神经细胞减少或细胞死亡。显著的白质<18>肥大</18>可能由于髓鞘形成改变和适应性胶质细胞变化引起，包括继发于<20>神经元损伤</20>的<19>神经胶质增生</19>。这些脑底物可能有助于解释<10>MA</10>滥用的症状，为药物引起的<13>脑损伤</13>提供治疗靶点。", "revised": true}
{"doc_key": "16810074", "sentences": [["Mechanisms", "of", "hypertension", "induced", "by", "nitric", "oxide", "(", "NO", ")", "deficiency", ":", "focus", "on", "venous", "function", ".", "Loss", "of", "endothelial", "cell", "-", "derived", "nitric", "oxide", "(", "NO", ")", "in", "hypertension", "is", "a", "hallmark", "of", "arterial", "dysfunction", ".", "Experimental", "hypertension", "created", "by", "the", "removal", "of", "NO", ",", "however", ",", "involves", "mechanisms", "in", "addition", "to", "decreased", "arterial", "vasodilator", "activity", ".", "These", "include", "augmented", "endothelin", "-", "1", "(", "ET", "-", "1", ")", "release", ",", "increased", "sympathetic", "nervous", "system", "activity", ",", "and", "elevated", "tissue", "oxidative", "stress", ".", "We", "hypothesized", "that", "increased", "venous", "smooth", "muscle", "(", "venomotor", ")", "tone", "plays", "a", "role", "in", "Nomega", "-", "nitro", "-", "L", "-", "arginine", "(", "LNNA", ")", "hypertension", "through", "these", "mechanisms", ".", "Rats", "were", "treated", "with", "the", "NO", "synthase", "inhibitor", "LNNA", "(", "0", ".", "5", "g", "/", "L", "in", "drinking", "water", ")", "for", "2", "weeks", ".", "Mean", "arterial", "pressure", "of", "conscious", "rats", "was", "119", "+", "/", "-", "2", "mm", "Hg", "in", "control", "and", "194", "+", "/", "-", "5", "mm", "Hg", "in", "LNNA", "rats", "(", "P", "<", "0", ".", "05", ")", ".", "Carotid", "arteries", "and", "vena", "cava", "were", "removed", "for", "measurement", "of", "isometric", "contraction", ".", "Maximal", "contraction", "to", "norepinephrine", "was", "modestly", "reduced", "in", "arteries", "from", "LNNA", "compared", "with", "control", "rats", "whereas", "the", "maximum", "contraction", "to", "ET", "-", "1", "was", "significantly", "reduced", "(", "54", "%", "control", ")", ".", "Maximum", "contraction", "of", "vena", "cava", "to", "norepinephrine", "(", "37", "%", "control", ")", "also", "was", "reduced", "but", "no", "change", "in", "response", "to", "ET", "-", "1", "was", "observed", ".", "Mean", "circulatory", "filling", "pressure", ",", "an", "in", "vivo", "measure", "of", "venomotor", "tone", ",", "was", "not", "elevated", "in", "LNNA", "hypertension", "at", "1", "or", "2", "weeks", "after", "LNNA", ".", "The", "superoxide", "scavenger", "tempol", "(", "30", ",", "100", ",", "and", "300", "micromol", "kg", "(", "-", "1", ")", ",", "IV", ")", "did", "not", "change", "arterial", "pressure", "in", "control", "rats", "but", "caused", "a", "dose", "-", "dependent", "decrease", "in", "LNNA", "rats", "(", "-", "18", "+", "/", "-", "8", ",", "-", "26", "+", "/", "-", "15", ",", "and", "-", "54", "+", "/", "-", "11", "mm", "Hg", ")", ".", "Similarly", ",", "ganglionic", "blockade", "with", "hexamethonium", "caused", "a", "significantly", "greater", "fall", "in", "LNNA", "hypertensive", "rats", "(", "76", "+", "/", "-", "9", "mm", "Hg", ")", "compared", "with", "control", "rats", "(", "35", "+", "/", "-", "10", "mm", "Hg", ")", ".", "Carotid", "arteries", ",", "vena", "cava", ",", "and", "sympathetic", "ganglia", "from", "LNNA", "rats", "had", "higher", "basal", "levels", "of", "superoxide", "compared", "with", "those", "from", "control", "rats", ".", "These", "data", "suggest", "that", "while", "NO", "deficiency", "increases", "oxidative", "stress", "and", "sympathetic", "activity", "in", "both", "arterial", "and", "venous", "vessels", ",", "the", "impact", "on", "veins", "does", "not", "make", "a", "major", "contribution", "to", "this", "form", "of", "hypertension", "."]], "ner": [[[5, 6, "Chemical"], [8, 8, "Chemical"], [23, 24, "Chemical"], [26, 26, "Chemical"], [44, 44, "Chemical"], [118, 118, "Chemical"], [403, 403, "Chemical"], [2, 2, "Disease"], [29, 29, "Disease"], [38, 38, "Disease"], [108, 108, "Disease"], [262, 262, "Disease"], [348, 348, "Disease"], [432, 432, "Disease"], [98, 104, "Chemical"], [106, 106, "Chemical"], [121, 121, "Chemical"], [162, 162, "Chemical"], [195, 195, "Chemical"], [261, 261, "Chemical"], [269, 269, "Chemical"], [307, 307, "Chemical"], [347, 347, "Chemical"], [383, 383, "Chemical"], [188, 188, "Chemical"], [223, 223, "Chemical"], [272, 272, "Chemical"], [390, 390, "Chemical"], [274, 274, "Chemical"], [340, 340, "Chemical"], [34, 35, "Disease"]]], "relations": [[[5, 6, 2, 2, "CID"], [5, 6, 29, 29, "CID"], [5, 6, 38, 38, "CID"], [5, 6, 108, 108, "CID"], [5, 6, 262, 262, "CID"], [5, 6, 348, 348, "CID"], [5, 6, 432, 432, "CID"], [8, 8, 2, 2, "CID"], [8, 8, 29, 29, "CID"], [8, 8, 38, 38, "CID"], [8, 8, 108, 108, "CID"], [8, 8, 262, 262, "CID"], [8, 8, 348, 348, "CID"], [8, 8, 432, 432, "CID"], [23, 24, 2, 2, "CID"], [23, 24, 29, 29, "CID"], [23, 24, 38, 38, "CID"], [23, 24, 108, 108, "CID"], [23, 24, 262, 262, "CID"], [23, 24, 348, 348, "CID"], [23, 24, 432, 432, "CID"], [26, 26, 2, 2, "CID"], [26, 26, 29, 29, "CID"], [26, 26, 38, 38, "CID"], [26, 26, 108, 108, "CID"], [26, 26, 262, 262, "CID"], [26, 26, 348, 348, "CID"], [26, 26, 432, 432, "CID"], [44, 44, 2, 2, "CID"], [44, 44, 29, 29, "CID"], [44, 44, 38, 38, "CID"], [44, 44, 108, 108, "CID"], [44, 44, 262, 262, "CID"], [44, 44, 348, 348, "CID"], [44, 44, 432, 432, "CID"], [118, 118, 2, 2, "CID"], [118, 118, 29, 29, "CID"], [118, 118, 38, 38, "CID"], [118, 118, 108, 108, "CID"], [118, 118, 262, 262, "CID"], [118, 118, 348, 348, "CID"], [118, 118, 432, 432, "CID"], [403, 403, 2, 2, "CID"], [403, 403, 29, 29, "CID"], [403, 403, 38, 38, "CID"], [403, 403, 108, 108, "CID"], [403, 403, 262, 262, "CID"], [403, 403, 348, 348, "CID"], [403, 403, 432, 432, "CID"]]], "clusters": [], "translated": "<0>一氧化氮</0>（<1>NO</1>）缺乏引起的<7>高血压</7>机制：重点在于静脉功能。<8>高血压</8>中内皮细胞衍生的<2>一氧化氮</2> (<3>NO</3>)的丢失是<30>动脉功能障碍</30>的标志。然而，通过去除<4>NO</4>产生的实验性<9>高血压</9>，除了降低动脉血管扩张活性外，还涉及其他机制。这些包括增加内皮素-1 (ET-1)释放、增加交感神经系统活动和增加组织氧化应激。我们假设增加的静脉平滑肌（静脉运动）张力通过这些机制在<14>Nomega-硝基-L-精氨酸</14>(<15>LNNA</15>)<10>高血压</10>中起作用。大鼠用<5>NO</5>合酶抑制剂<16>LNNA</16>（饮用水中0.5 g/L）处理2周。清醒大鼠的平均动脉压在对照组为119±2 mmHg，在<17>LNNA</17>大鼠为194±5 mmHg(P < 0.05)。移除颈动脉和腔静脉以测量等长收缩。与对照大鼠相比，<18>LNNA</18>的动脉对<24>去甲肾上腺素</24>的最大收缩适度降低，而对ET-1的最大收缩显着降低（54%对照）。腔静脉对<25>去甲肾上腺素</25>的最大收缩（37%对照）也有所降低，但未观察到对ET-1的反应发生变化。在<20>LNNA</20>后1或2周，<19>LNNA</19><11>高血压</11>的平均循环充盈压（静脉运动张力的体内测量值）没有升高。<26>超氧化物</26>清除剂<28>tempol</28>（30、100和300 μmol kg(-1)，IV）不改变对照大鼠的动脉压，但引起剂量依赖性降低<21>LNNA</21>大鼠（-18±8、-26±15和-54±11 mmHg）。同样，与对照大鼠相比，<29>六甲铵</29>神经节阻滞导致<22>LNNA</22><12>高血压</12>大鼠（76±9 mmHg）显着下降（35±10 mmHg）。<23>LNNA</23>大鼠的颈动脉、腔静脉和交感神经节的<27>超氧化物</27>基础水平高于对照大鼠。这些数据表明，虽然<6>NO</6>缺乏会增加动脉和静脉血管中的氧化应激和交感神经活动，但对静脉的影响不会对这种形式的<13>高血压</13>产生重大影响。", "revised": true}
{"doc_key": "16801510", "sentences": [["Drug", "-", "induced", "long", "QT", "syndrome", "in", "injection", "drug", "users", "receiving", "methadone", ":", "high", "frequency", "in", "hospitalized", "patients", "and", "risk", "factors", ".", "BACKGROUND", ":", "Drug", "-", "induced", "long", "QT", "syndrome", "is", "a", "serious", "adverse", "drug", "reaction", ".", "Methadone", "prolongs", "the", "QT", "interval", "in", "vitro", "in", "a", "dose", "-", "dependent", "manner", ".", "In", "the", "inpatient", "setting", ",", "the", "frequency", "of", "QT", "interval", "prolongation", "with", "methadone", "treatment", ",", "its", "dose", "dependence", ",", "and", "the", "importance", "of", "cofactors", "such", "as", "drug", "-", "drug", "interactions", "remain", "unknown", ".", "METHODS", ":", "We", "performed", "a", "systematic", ",", "retrospective", "study", "comparing", "active", "or", "former", "intravenous", "drug", "users", "receiving", "methadone", "and", "those", "not", "receiving", "methadone", "among", "all", "patients", "hospitalized", "over", "a", "5", "-", "year", "period", "in", "a", "tertiary", "care", "hospital", ".", "A", "total", "of", "167", "patients", "receiving", "methadone", "fulfilled", "the", "inclusion", "criteria", "and", "were", "compared", "with", "a", "control", "group", "of", "80", "injection", "drug", "users", "not", "receiving", "methadone", ".", "In", "addition", "to", "methadone", "dose", ",", "15", "demographic", ",", "biological", ",", "and", "pharmacological", "variables", "were", "considered", "as", "potential", "risk", "factors", "for", "QT", "prolongation", ".", "RESULTS", ":", "Among", "167", "methadone", "maintenance", "patients", ",", "the", "prevalence", "of", "QTc", "prolongation", "to", "0", ".", "50", "second", "(", "(", "1", "/", "2", ")", ")", "or", "longer", "was", "16", ".", "2", "%", "compared", "with", "0", "%", "in", "80", "control", "subjects", ".", "Six", "patients", "(", "3", ".", "6", "%", ")", "in", "the", "methadone", "group", "presented", "torsades", "de", "pointes", ".", "QTc", "length", "was", "weakly", "but", "significantly", "associated", "with", "methadone", "daily", "dose", "(", "Spearman", "rank", "correlation", "coefficient", ",", "0", ".", "20", ";", "P", "<", ".", "01", ")", ".", "Multivariate", "regression", "analysis", "allowed", "attribution", "of", "31", ".", "8", "%", "of", "QTc", "variability", "to", "methadone", "dose", ",", "cytochrome", "P", "-", "450", "3A4", "drug", "-", "drug", "interactions", ",", "hypokalemia", ",", "and", "altered", "liver", "function", ".", "CONCLUSIONS", ":", "QT", "interval", "prolongation", "in", "methadone", "maintenance", "patients", "hospitalized", "in", "a", "tertiary", "care", "center", "is", "a", "frequent", "finding", ".", "Methadone", "dose", ",", "presence", "of", "cytochrome", "P", "-", "450", "3A4", "inhibitors", ",", "potassium", "level", ",", "and", "liver", "function", "contribute", "to", "QT", "prolongation", ".", "Long", "QT", "syndrome", "can", "occur", "with", "low", "doses", "of", "methadone", "."]], "ner": [[[11, 11, "Chemical"], [37, 37, "Chemical"], [63, 63, "Chemical"], [101, 101, "Chemical"], [106, 106, "Chemical"], [129, 129, "Chemical"], [148, 148, "Chemical"], [153, 153, "Chemical"], [178, 178, "Chemical"], [225, 225, "Chemical"], [240, 240, "Chemical"], [273, 273, "Chemical"], [299, 299, "Chemical"], [313, 313, "Chemical"], [345, 345, "Chemical"], [3, 5, "Disease"], [27, 29, "Disease"], [59, 61, "Disease"], [171, 172, "Disease"], [295, 297, "Disease"], [333, 334, "Disease"], [336, 338, "Disease"], [325, 325, "Chemical"], [228, 230, "Disease"], [286, 286, "Disease"]]], "relations": [[[11, 11, 3, 5, "CID"], [11, 11, 27, 29, "CID"], [11, 11, 59, 61, "CID"], [11, 11, 171, 172, "CID"], [11, 11, 295, 297, "CID"], [11, 11, 333, 334, "CID"], [11, 11, 336, 338, "CID"], [37, 37, 3, 5, "CID"], [37, 37, 27, 29, "CID"], [37, 37, 59, 61, "CID"], [37, 37, 171, 172, "CID"], [37, 37, 295, 297, "CID"], [37, 37, 333, 334, "CID"], [37, 37, 336, 338, "CID"], [63, 63, 3, 5, "CID"], [63, 63, 27, 29, "CID"], [63, 63, 59, 61, "CID"], [63, 63, 171, 172, "CID"], [63, 63, 295, 297, "CID"], [63, 63, 333, 334, "CID"], [63, 63, 336, 338, "CID"], [101, 101, 3, 5, "CID"], [101, 101, 27, 29, "CID"], [101, 101, 59, 61, "CID"], [101, 101, 171, 172, "CID"], [101, 101, 295, 297, "CID"], [101, 101, 333, 334, "CID"], [101, 101, 336, 338, "CID"], [106, 106, 3, 5, "CID"], [106, 106, 27, 29, "CID"], [106, 106, 59, 61, "CID"], [106, 106, 171, 172, "CID"], [106, 106, 295, 297, "CID"], [106, 106, 333, 334, "CID"], [106, 106, 336, 338, "CID"], [129, 129, 3, 5, "CID"], [129, 129, 27, 29, "CID"], [129, 129, 59, 61, "CID"], [129, 129, 171, 172, "CID"], [129, 129, 295, 297, "CID"], [129, 129, 333, 334, "CID"], [129, 129, 336, 338, "CID"], [148, 148, 3, 5, "CID"], [148, 148, 27, 29, "CID"], [148, 148, 59, 61, "CID"], [148, 148, 171, 172, "CID"], [148, 148, 295, 297, "CID"], [148, 148, 333, 334, "CID"], [148, 148, 336, 338, "CID"], [153, 153, 3, 5, "CID"], [153, 153, 27, 29, "CID"], [153, 153, 59, 61, "CID"], [153, 153, 171, 172, "CID"], [153, 153, 295, 297, "CID"], [153, 153, 333, 334, "CID"], [153, 153, 336, 338, "CID"], [178, 178, 3, 5, "CID"], [178, 178, 27, 29, "CID"], [178, 178, 59, 61, "CID"], [178, 178, 171, 172, "CID"], [178, 178, 295, 297, "CID"], [178, 178, 333, 334, "CID"], [178, 178, 336, 338, "CID"], [225, 225, 3, 5, "CID"], [225, 225, 27, 29, "CID"], [225, 225, 59, 61, "CID"], [225, 225, 171, 172, "CID"], [225, 225, 295, 297, "CID"], [225, 225, 333, 334, "CID"], [225, 225, 336, 338, "CID"], [240, 240, 3, 5, "CID"], [240, 240, 27, 29, "CID"], [240, 240, 59, 61, "CID"], [240, 240, 171, 172, "CID"], [240, 240, 295, 297, "CID"], [240, 240, 333, 334, "CID"], [240, 240, 336, 338, "CID"], [273, 273, 3, 5, "CID"], [273, 273, 27, 29, "CID"], [273, 273, 59, 61, "CID"], [273, 273, 171, 172, "CID"], [273, 273, 295, 297, "CID"], [273, 273, 333, 334, "CID"], [273, 273, 336, 338, "CID"], [299, 299, 3, 5, "CID"], [299, 299, 27, 29, "CID"], [299, 299, 59, 61, "CID"], [299, 299, 171, 172, "CID"], [299, 299, 295, 297, "CID"], [299, 299, 333, 334, "CID"], [299, 299, 336, 338, "CID"], [313, 313, 3, 5, "CID"], [313, 313, 27, 29, "CID"], [313, 313, 59, 61, "CID"], [313, 313, 171, 172, "CID"], [313, 313, 295, 297, "CID"], [313, 313, 333, 334, "CID"], [313, 313, 336, 338, "CID"], [345, 345, 3, 5, "CID"], [345, 345, 27, 29, "CID"], [345, 345, 59, 61, "CID"], [345, 345, 171, 172, "CID"], [345, 345, 295, 297, "CID"], [345, 345, 333, 334, "CID"], [345, 345, 336, 338, "CID"]]], "clusters": [], "translated": "药物引起的<15>长QT综合征</15>在注射吸毒者接受<0>美沙酮</0>时：住院患者中高频率和危险因素。背景：药物引起的<16>长QT综合征</16>是一种严重的药物不良反应。<1>美沙酮</1>在体外以剂量依赖的方式延长QT间期。在住院环境中，<2>美沙酮</2>治疗导致<17>QT间期延长</17>的频率、其剂量依赖性以及药物相互作用等辅助因素的重要性仍然未知。方法：我们进行了一项系统的回顾性研究，比较在五年期间住院的所有患者中接受或曾接受静脉注射毒品的患者，其中一组接受<3>美沙酮</3>，另一组未接受<4>美沙酮</4>。 167名接受<5>美沙酮</5>的患者符合纳入标准，并与未接受<6>美沙酮</6>的80名注射吸毒者作为对照组进行比较。除了<7>美沙酮</7>剂量外，考虑了15个人口统计学、生物学和药理学变量作为<18>QT延长</18>的潜在危险因素。结果：在167例<8>美沙酮</8>维持治疗患者中，QTc延长率为0.50秒((1/2))或更长时间为16.2%，与80名对照组的0%相比。 6名<9>美沙酮</9>组患者（3.6%）出现<23>尖端扭转型室速</23>。QTc长度与<10>美沙酮</10>日剂量有微弱但显着的相关性（斯皮尔曼等级相关系数为0.20，P<0.01）。多元回归分析允许31.8%的QTc变异性与<11>美沙酮</11>剂量、细胞色素P-450 3A4药物相互作用、<24>低血钾</24>和肝功能变异有关。结论：在三级医疗中心住院的<12>美沙酮</12>维持治疗患者中，<19>QT间期延长</19>是普遍现象。<13>美沙酮</13>剂量、细胞色素P-450 3A4抑制剂的存在、<22>血钾</22>水平和肝功能是<20>QT延长</20>的因素。即使在低剂量下，<14>美沙酮</14>也可能导致<21>长QT综合征</21>。", "revised": true}
{"doc_key": "17069550", "sentences": [["A", "prospective", ",", "open", "-", "label", "trial", "of", "galantamine", "in", "autistic", "disorder", ".", "OBJECTIVE", ":", "Post", "-", "mortem", "studies", "have", "reported", "abnormalities", "of", "the", "cholinergic", "system", "in", "autism", ".", "The", "purpose", "of", "this", "study", "was", "to", "assess", "the", "use", "of", "galantamine", ",", "an", "acetylcholinesterase", "inhibitor", "and", "nicotinic", "receptor", "modulator", ",", "in", "the", "treatment", "of", "interfering", "behaviors", "in", "children", "with", "autism", ".", "METHODS", ":", "Thirteen", "medication", "-", "free", "children", "with", "autism", "(", "mean", "age", ",", "8", ".", "8", "+", "/", "-", "3", ".", "5", "years", ")", "participated", "in", "a", "12", "-", "week", ",", "open", "-", "label", "trial", "of", "galantamine", ".", "Patients", "were", "rated", "monthly", "by", "parents", "on", "the", "Aberrant", "Behavior", "Checklist", "(", "ABC", ")", "and", "the", "Conners", "'", "Parent", "Rating", "Scale", "-", "Revised", ",", "and", "by", "a", "physician", "using", "the", "Children", "'s", "Psychiatric", "Rating", "Scale", "and", "the", "Clinical", "Global", "Impressions", "scale", ".", "RESULTS", ":", "Patients", "showed", "a", "significant", "reduction", "in", "parent", "-", "rated", "irritability", "and", "social", "withdrawal", "on", "the", "ABC", "as", "well", "as", "significant", "improvements", "in", "emotional", "lability", "and", "inattention", "on", "the", "Conners", "'", "Parent", "Rating", "Scale", "-", "-", "Revised", ".", "Similarly", ",", "clinician", "ratings", "showed", "reductions", "in", "the", "anger", "subscale", "of", "the", "Children", "'s", "Psychiatric", "Rating", "Scale", ".", "Eight", "of", "13", "participants", "were", "rated", "as", "responders", "on", "the", "basis", "of", "their", "improvement", "scores", "on", "the", "Clinical", "Global", "Impressions", "scale", ".", "Overall", ",", "galantamine", "was", "well", "-", "tolerated", ",", "with", "no", "significant", "adverse", "effects", "apart", "from", "headaches", "in", "one", "patient", ".", "CONCLUSION", ":", "In", "this", "open", "trial", ",", "galantamine", "was", "well", "-", "tolerated", "and", "appeared", "to", "be", "beneficial", "for", "the", "treatment", "of", "interfering", "behaviors", "in", "children", "with", "autism", ",", "particularly", "aggression", ",", "behavioral", "dyscontrol", ",", "and", "inattention", ".", "Further", "controlled", "trials", "are", "warranted", "."]], "ner": [[[8, 8, "Chemical"], [40, 40, "Chemical"], [97, 97, "Chemical"], [222, 222, "Chemical"], [247, 247, "Chemical"], [235, 235, "Disease"], [10, 11, "Disease"], [27, 27, "Disease"], [59, 59, "Disease"], [69, 69, "Disease"], [266, 266, "Disease"], [152, 152, "Disease"], [269, 269, "Disease"], [271, 272, "Disease"], [275, 275, "Disease"]]], "relations": [[[8, 8, 235, 235, "CID"], [40, 40, 235, 235, "CID"], [97, 97, 235, 235, "CID"], [222, 222, 235, 235, "CID"], [247, 247, 235, 235, "CID"]]], "clusters": [], "translated": "<0>加兰他敏</0>在<6>自闭症</6>中的前瞻性、开放标签试验。目的：验尸研究报告了<7>自闭症</7>胆碱能系统的异常。本研究的目的是评估<1>加兰他敏</1>（一种乙酰胆碱酯酶抑制剂和烟碱受体调节剂）在治疗<8>自闭症</8>儿童的干扰行为中的应用。方法：13 名患有<9>自闭症</9>且未接受药物治疗的儿童（平均年龄 8 . 8 + /- 3 . 5 岁）参加了为期 12 周的<2>加兰他敏</2>开放标签试验。父母每月根据异常行为检查表(ABC)和Conners父母评定量表-修订版，以及医生使用儿童精神病学评定量表和临床整体印象量表对患者进行评分。结果：患者在 ABC 上表现出父母评定的<11>易怒</11>和社交退缩显着减少，以及在 Conners父母评定量表-修订版中情绪不稳定和注意力不集中的显着改善。同样，临床医生的评分显示儿童精神病学评定量表的愤怒分量表有所减少。8 名参与者中有 13 名被评为反应者，根据他们在临床整体印象量表上的改善分数。总的来说，<3>加兰他敏</3>耐受性良好，除了一名患者出现<5>头痛</5>外没有明显的不良反应。结论：在这项开放标签试验中，<4>加兰他敏</4>耐受性良好，似乎有益于治疗<10>自闭症</10>儿童的干扰行为，尤其是<12>攻击性</12>、<13>行为失控</13>和<14>注意力不集中</14>。需要进一步的对照试验。", "revised": true}
{"doc_key": "17035713", "sentences": [["Chloroacetaldehyde", "as", "a", "sulfhydryl", "reagent", ":", "the", "role", "of", "critical", "thiol", "groups", "in", "ifosfamide", "nephropathy", ".", "Chloroacetaldehyde", "(", "CAA", ")", "is", "a", "metabolite", "of", "the", "alkylating", "agent", "ifosfamide", "(", "IFO", ")", "and", "putatively", "responsible", "for", "renal", "damage", "following", "anti", "-", "tumor", "therapy", "with", "IFO", ".", "Depletion", "of", "sulfhydryl", "(", "SH", ")", "groups", "has", "been", "reported", "from", "cell", "culture", ",", "animal", "and", "clinical", "studies", ".", "In", "this", "work", "the", "effect", "of", "CAA", "on", "human", "proximal", "tubule", "cells", "in", "primary", "culture", "(", "hRPTEC", ")", "was", "investigated", ".", "Toxicity", "of", "CAA", "was", "determined", "by", "protein", "content", ",", "cell", "number", ",", "LDH", "release", ",", "trypan", "blue", "exclusion", "assay", "and", "caspase", "-", "3", "activity", ".", "Free", "thiols", "were", "measured", "by", "the", "method", "of", "Ellman", ".", "CAA", "reduced", "hRPTEC", "cell", "number", "and", "protein", ",", "induced", "a", "loss", "in", "free", "intracellular", "thiols", "and", "an", "increase", "in", "necrosis", "markers", ".", "CAA", "but", "not", "acrolein", "inhibited", "the", "cysteine", "proteases", "caspase", "-", "3", ",", "caspase", "-", "8", "and", "cathepsin", "B", ".", "Caspase", "activation", "by", "cisplatin", "was", "inhibited", "by", "CAA", ".", "In", "cells", "stained", "with", "fluorescent", "dyes", "targeting", "lysosomes", ",", "CAA", "induced", "an", "increase", "in", "lysosomal", "size", "and", "lysosomal", "leakage", ".", "The", "effects", "of", "CAA", "on", "cysteine", "protease", "activities", "and", "thiols", "could", "be", "reproduced", "in", "cell", "lysate", ".", "Acidification", ",", "which", "slowed", "the", "reaction", "of", "CAA", "with", "thiol", "donors", ",", "could", "also", "attenuate", "effects", "of", "CAA", "on", "necrosis", "markers", ",", "thiol", "depletion", "and", "cysteine", "protease", "inhibition", "in", "living", "cells", ".", "Thus", ",", "CAA", "directly", "reacts", "with", "cellular", "protein", "and", "non", "-", "protein", "thiols", ",", "mediating", "its", "toxicity", "on", "hRPTEC", ".", "This", "effect", "can", "be", "reduced", "by", "acidification", ".", "Therefore", ",", "urinary", "acidification", "could", "be", "an", "option", "to", "prevent", "IFO", "nephropathy", "in", "patients", "."]], "ner": [[[13, 13, "Chemical"], [27, 27, "Chemical"], [29, 29, "Chemical"], [43, 43, "Chemical"], [277, 277, "Chemical"], [14, 14, "Disease"], [35, 36, "Disease"], [278, 278, "Disease"], [0, 0, "Chemical"], [16, 16, "Chemical"], [18, 18, "Chemical"], [70, 70, "Chemical"], [87, 87, "Chemical"], [120, 120, "Chemical"], [142, 142, "Chemical"], [168, 168, "Chemical"], [179, 179, "Chemical"], [193, 193, "Chemical"], [214, 214, "Chemical"], [224, 224, "Chemical"], [241, 241, "Chemical"], [40, 40, "Disease"], [85, 85, "Disease"], [255, 255, "Disease"], [139, 139, "Disease"], [226, 226, "Disease"], [10, 10, "Chemical"], [111, 111, "Chemical"], [134, 134, "Chemical"], [199, 199, "Chemical"], [216, 216, "Chemical"], [229, 229, "Chemical"], [251, 251, "Chemical"], [100, 101, "Chemical"], [145, 145, "Chemical"], [148, 148, "Chemical"], [195, 195, "Chemical"], [232, 232, "Chemical"], [164, 164, "Chemical"]]], "relations": [[[13, 13, 14, 14, "CID"], [13, 13, 35, 36, "CID"], [13, 13, 278, 278, "CID"], [27, 27, 14, 14, "CID"], [27, 27, 35, 36, "CID"], [27, 27, 278, 278, "CID"], [29, 29, 14, 14, "CID"], [29, 29, 35, 36, "CID"], [29, 29, 278, 278, "CID"], [43, 43, 14, 14, "CID"], [43, 43, 35, 36, "CID"], [43, 43, 278, 278, "CID"], [277, 277, 14, 14, "CID"], [277, 277, 35, 36, "CID"], [277, 277, 278, 278, "CID"]]], "clusters": [], "translated": " <8>氯乙醛</8>作为巯基试剂：<26>硫醇</26>基团在<0>异环磷酰胺</0><5>肾病</5>中的作用。 <9><8>氯乙醛</8></9>（<10><8>CAA</8></10>）是烷化剂<1>异环磷酰胺</1>（<2>IFO</2>）的代谢产物，据推定负责<3>IFO</3>抗<21>肿瘤</21>治疗后的<6>肾损伤</6>。细胞培养、动物和临床研究报告了巯基（SH）基团的耗尽。在这项工作中，研究了<11><8>CAA</8></11>对原代培养的人近端小管细胞（hRPTEC）的影响。<12><22>CAA</22></12>的<22>毒性</22>通过蛋白质含量、细胞数、LDH释放、<33>台盼蓝</33>排斥试验和caspase-3活性测定。游离<27>硫醇</27>的测定采用Ellman的方法。<13><8>CAA</8></13>减少hRPTEC细胞数量和蛋白质，诱导细胞内游离<28>硫醇</28>的损失和<24>坏死</24>标记物的增加。<14><8>CAA</8></14>而非<34>丙烯醛</34>抑制<35>半胱氨酸</35>蛋白酶caspase-3、caspase-8和组织蛋白酶B。<15><8>CAA</8></15>抑制了<38>顺铂</38>引起的caspase激活。在用靶向溶酶体的荧光染料染色的细胞中，<16><8>CAA</8></16>诱导溶酶体体积增加和溶酶体渗漏。<17><8>CAA</8></17>对<36>半胱氨酸</36>蛋白酶活性和<29>硫醇</29>的影响可以在细胞裂解物中重现。酸化减缓了<18><8>CAA</8></18>与<30>硫醇</30>供体的反应，也可以减弱<19><8>CAA</8></19>对<25>坏死</25>标记物的影响，活细胞中的<31>硫醇</31>消耗和<37>半胱氨酸</37>蛋白酶抑制。因此，<20><8>CAA</8></20>直接与细胞蛋白和非蛋白<32>硫醇</32>反应，介导其对hRPTEC的<23>毒性</23>。这种影响可以通过酸化来降低。因此，尿液酸化可能是预防<4><1>IFO</1></4><7>肾病</7>患者的一种选择。", "revised": true}
{"doc_key": "17297207", "sentences": [["Quinine", "-", "induced", "arrhythmia", "in", "a", "patient", "with", "severe", "malaria", ".", "It", "was", "reported", "that", "there", "was", "a", "case", "of", "severe", "malaria", "patient", "with", "jaundice", "who", "presented", "with", "arrhythmia", "(", "premature", "ventricular", "contraction", ")", "while", "getting", "quinine", "infusion", "was", "reported", ".", "A", "man", ",", "25", "years", "old", ",", "was", "admitted", "to", "hospital", "with", "high", "fever", ",", "chill", ",", "vomiting", ",", "jaundice", ".", "The", "patient", "was", "fully", "conscious", ",", "blood", "pressure", "120", "/", "80", "mmHg", ",", "pulse", "rate", "100", "x", "/", "minute", ",", "regular", ".", "On", "admission", ",", "laboratory", "examination", "showed", "Plasmodium", "falciparum", "(", "+", "+", "+", "+", ")", ",", "total", "bilirubin", "8", ".", "25", "mg", "/", "dL", ",", "conjugated", "bilirubin", "4", ".", "36", "mg", "/", "dL", ",", "unconjugated", "bilirubin", "3", ".", "89", "mg", "/", "dL", ",", "potassium", "3", ".", "52", "meq", "/", "L", "Patient", "was", "diagnosed", "as", "severe", "malaria", "with", "jaundice", "and", "got", "quinine", "infusion", "in", "dextrose", "5", "%", "500", "mg", "/", "8", "hour", ".", "On", "the", "second", "day", "the", "patient", "had", "vomitus", ",", "diarrhea", ",", "tinnitus", ",", "loss", "of", "hearing", ".", "After", "30", "hours", "of", "quinine", "infusion", "the", "patient", "felt", "palpitation", "and", "electrocardiography", "(", "ECG", ")", "recording", "showed", "premature", "ventricular", "contraction", "(", "PVC", ")", ">", "5", "x", "/", "minute", ",", "trigemini", ",", "constant", "type", "-", "-", "sinoatrial", "block", ",", "positive", "U", "wave", ".", "He", "was", "treated", "with", "lidocaine", "50", "mg", "intravenously", "followed", "by", "infusion", "1500", "mg", "in", "dextrose", "5", "%", "/", "24", "hour", "and", "potassium", "aspartate", "tablet", ".", "Quinine", "infusion", "was", "discontinued", "and", "changed", "with", "sulfate", "quinine", "tablets", ".", "Three", "hours", "later", "the", "patient", "felt", "better", ",", "the", "frequency", "of", "PVC", "reduced", "to", "4", "-", "5", "x", "/", "minute", "and", "on", "the", "third", "day", "ECG", "was", "normal", ",", "potassium", "level", "was", "3", ".", "34", "meq", "/", "L", ".", "He", "was", "discharged", "on", "7th", "day", "in", "good", "condition", ".", "Quinine", ",", "like", "quinidine", ",", "is", "a", "chincona", "alkaloid", "that", "has", "anti", "-", "arrhythmic", "property", ",", "although", "it", "also", "pro", "-", "arrhythmic", "that", "can", "cause", "various", "arrhythmias", ",", "including", "severe", "arrhythmia", "such", "as", "multiple", "PVC", ".", "Administration", "of", "parenteral", "quinine", "must", "be", "done", "carefully", "and", "with", "good", "observation", "because", "of", "its", "pro", "-", "arrhythmic", "effect", ",", "especially", "in", "older", "patients", "who", "have", "heart", "diseases", "or", "patients", "with", "electrolyte", "disorder", "(", "hypokalemia", ")", "which", "frequently", "occurs", "due", "to", "vomiting", "and", "or", "diarrhea", "in", "malaria", "cases", "."]], "ner": [[[0, 0, "Chemical"], [36, 36, "Chemical"], [143, 143, "Chemical"], [176, 176, "Chemical"], [239, 239, "Chemical"], [247, 247, "Chemical"], [299, 299, "Chemical"], [338, 338, "Chemical"], [30, 32, "Disease"], [189, 191, "Disease"], [193, 193, "Disease"], [261, 261, "Disease"], [333, 333, "Disease"], [3, 3, "Disease"], [28, 28, "Disease"], [312, 312, "Disease"], [320, 320, "Disease"], [325, 325, "Disease"], [329, 329, "Disease"], [352, 352, "Disease"], [8, 9, "Disease"], [20, 21, "Disease"], [137, 138, "Disease"], [24, 24, "Disease"], [60, 60, "Disease"], [140, 140, "Disease"], [54, 54, "Disease"], [56, 56, "Disease"], [58, 58, "Disease"], [162, 162, "Disease"], [376, 376, "Disease"], [164, 164, "Disease"], [379, 379, "Disease"], [166, 166, "Disease"], [168, 170, "Disease"], [207, 208, "Disease"], [361, 362, "Disease"], [366, 367, "Disease"], [369, 369, "Disease"], [381, 381, "Disease"], [100, 100, "Chemical"], [109, 109, "Chemical"], [118, 118, "Chemical"], [126, 126, "Chemical"], [279, 279, "Chemical"], [146, 146, "Chemical"], [228, 228, "Chemical"], [218, 218, "Chemical"], [235, 236, "Chemical"], [302, 302, "Chemical"]]], "relations": [[[0, 0, 30, 32, "CID"], [0, 0, 189, 191, "CID"], [0, 0, 193, 193, "CID"], [0, 0, 261, 261, "CID"], [0, 0, 333, 333, "CID"], [36, 36, 30, 32, "CID"], [36, 36, 189, 191, "CID"], [36, 36, 193, 193, "CID"], [36, 36, 261, 261, "CID"], [36, 36, 333, 333, "CID"], [143, 143, 30, 32, "CID"], [143, 143, 189, 191, "CID"], [143, 143, 193, 193, "CID"], [143, 143, 261, 261, "CID"], [143, 143, 333, 333, "CID"], [176, 176, 30, 32, "CID"], [176, 176, 189, 191, "CID"], [176, 176, 193, 193, "CID"], [176, 176, 261, 261, "CID"], [176, 176, 333, 333, "CID"], [239, 239, 30, 32, "CID"], [239, 239, 189, 191, "CID"], [239, 239, 193, 193, "CID"], [239, 239, 261, 261, "CID"], [239, 239, 333, 333, "CID"], [247, 247, 30, 32, "CID"], [247, 247, 189, 191, "CID"], [247, 247, 193, 193, "CID"], [247, 247, 261, 261, "CID"], [247, 247, 333, 333, "CID"], [299, 299, 30, 32, "CID"], [299, 299, 189, 191, "CID"], [299, 299, 193, 193, "CID"], [299, 299, 261, 261, "CID"], [299, 299, 333, 333, "CID"], [338, 338, 30, 32, "CID"], [338, 338, 189, 191, "CID"], [338, 338, 193, 193, "CID"], [338, 338, 261, 261, "CID"], [338, 338, 333, 333, "CID"]]], "clusters": [], "translated": "<0>奎宁</0> - 诱发<13>心律失常</13> <20>严重疟疾</20> 患者。据报道有一例<21>严重疟疾</21>伴有<23>黄疸</23>的患者出现<14>心律失常</14>（<8>室性早搏</8>)同时得到<1>奎宁</1>输液的报道。男性，25岁，因高烧<26></26>、<27>寒战</27>、<28>呕吐</28>、<24>黄疸</24>入院。患者完全清醒，血压 120 / 80 mmHg，脉率 100 x / 分钟，规则。入院时实验室检查示恶性疟原虫(+++)，总<40>胆红素</40>8．25 mg/dL，共轭<41>胆红素</41> 4．36毫克/分升，未结合的<42>胆红素</42> 3．89毫克/分升，<43>钾</43> 3．52 meq/L患者被诊断为<22>严重疟疾</22>伴有<25>黄疸</25>并在<45>葡萄糖</45>5% 500 mg中输注<2>奎宁</2>/ 8小时。第二天，患者出现<29>呕吐</29>、<31>腹泻</31>、<33>耳鸣</33>、<34>听力下降</34>。<3>奎宁</3>输注30小时后，患者感到心悸，心电图（ECG）记录显示<9>室性早搏</9>（<10>PVC</10>）>5次/分钟，三联，恒定型--<35>窦房传导阻滞</35>，U波正向。他接受了<47>利多卡因</47>50mg静脉注射，随后输注1500 mg的<46>葡萄糖</46>5%/24小时和<48>天冬氨酸钾</48>片剂。停用<4>奎宁</4>输液，改用硫酸盐<5>奎宁</5>片。 3 小时后患者感觉好些，<11>PVC</11> 频率减少到 4-5 次/分钟，第三天心电图正常，<44>钾</44>水平为3.34毫克当量/升。他于第7天出院，情况良好。<6>奎宁</6>，像<49>奎尼丁</49>一样，是一种具有抗<15>心律失常</15>特性的金鸡纳生物碱，尽管它也促成-<16>心律失常</16>可引起各种<17>心律失常</17>，包括严重的<18>心律失常</18>如多发性<12>PVC</12>。肠外给药<7>奎宁</7>必须仔细观察，因为它会导致<19>心律失常</19>，尤其是对于患有<36>心脏病</36>或患有<37>电解质紊乱</37>（<38>低钾血症</38>）的患者在<39>疟疾</39>例中经常发生<30>呕吐</30>和/或<32>腹泻</32>。", "revised": true}
{"doc_key": "17484470", "sentences": [["Mitral", "annuloplasty", "as", "a", "ventricular", "restoration", "method", "for", "the", "failing", "left", "ventricle", ":", "a", "pilot", "study", ".", "BACKGROUND", "AND", "AIM", "OF", "THE", "STUDY", ":", "Undersized", "mitral", "annuloplasty", "(", "MAP", ")", "is", "effective", "in", "patients", "with", "dilated", "cardiomyopathy", "and", "functional", "mitral", "regurgitation", "(", "MR", ")", "since", ",", "as", "well", "as", "addressing", "the", "MR", ",", "the", "MAP", "may", "also", "reshape", "the", "dilated", "left", "ventricular", "(", "LV", ")", "base", ".", "However", ",", "the", "direct", "benefits", "of", "this", "possible", "reshaping", "on", "LV", "function", "in", "the", "absence", "of", "underlying", "MR", "remain", "incompletely", "understood", ".", "The", "study", "aim", "was", "to", "identify", "these", "benefits", "in", "a", "canine", "model", "of", "acute", "heart", "failure", ".", "METHODS", ":", "Six", "dogs", "underwent", "MAP", "with", "a", "prosthetic", "band", "on", "the", "posterior", "mitral", "annulus", ",", "using", "four", "mattress", "sutures", ".", "The", "sutures", "were", "passed", "individually", "through", "four", "tourniquets", "and", "exteriorized", "untied", "via", "the", "left", "atriotomy", ".", "Sonomicrometry", "crystals", "were", "implanted", "around", "the", "mitral", "annulus", "and", "left", "ventricle", "to", "measure", "geometry", "and", "regional", "function", ".", "Acute", "heart", "failure", "was", "induced", "by", "propranolol", "and", "volume", "loading", "after", "weaning", "from", "cardiopulmonary", "bypass", ";", "an", "absence", "of", "MR", "was", "confirmed", "by", "echocardiography", ".", "MAP", "was", "accomplished", "by", "cinching", "the", "tourniquets", ".", "Data", "were", "acquired", "at", "baseline", ",", "after", "induction", "of", "acute", "heart", "failure", ",", "and", "after", "MAP", ".", "RESULTS", ":", "MAP", "decreased", "mitral", "annular", "dimensions", "in", "both", "commissure", "-", "commissure", "and", "septal", "-", "lateral", "directions", ".", "Concomitantly", ",", "the", "diastolic", "diameter", "of", "the", "LV", "base", "and", "LV", "sphericity", "decreased", "(", "i", ".", "e", ".", ",", "improved", ")", "from", "37", ".", "4", "+", "/", "-", "9", ".", "3", "to", "35", ".", "9", "+", "/", "-", "10", "mm", "(", "p", "=", "0", ".", "063", ")", ",", "and", "from", "67", ".", "9", "+", "/", "-", "18", ".", "6", "%", "to", "65", ".", "3", "+", "/", "-", "18", ".", "9", "%", "(", "p", "=", "0", ".", "016", ")", ",", "respectively", ".", "Decreases", "were", "evident", "in", "both", "LV", "end", "-", "diastolic", "pressure", "(", "from", "17", "+", "/", "-", "7", "to", "15", "+", "/", "-", "6", "mmHg", ",", "p", "=", "0", ".", "0480", "and", "Tau", "(", "from", "48", "+", "/", "-", "8", "to", "45", "+", "/", "-", "8", "ms", ",", "p", "<", "0", ".", "01", ")", ",", "while", "fractional", "shortening", "at", "the", "LV", "base", "increased", "from", "7", ".", "7", "+", "/", "-", "4", ".", "5", "%", "to", "9", ".", "4", "+", "/", "-", "4", ".", "5", "%", "(", "p", "=", "0", ".", "045", ")", ".", "After", "MAP", ",", "increases", "were", "identified", "in", "both", "cardiac", "output", "(", "from", "1", ".", "54", "+", "/", "-", "0", ".", "57", "to", "1", ".", "65", "+", "/", "-", "0", ".", "57", "1", "/", "min", ")", "and", "Emax", "(", "from", "1", ".", "86", "+", "/", "-", "0", ".", "9", "to", "2", ".", "41", "+", "/", "-", "1", ".", "31", "mmHg", "/", "ml", ")", ".", "CONCLUSION", ":", "The", "data", "acquired", "suggest", "that", "isolated", "MAP", "may", "have", "certain", "benefits", "on", "LV", "dimension", "/", "function", "in", "acute", "heart", "failure", ",", "even", "in", "the", "absence", "of", "MR", ".", "However", ",", "further", "investigations", "are", "warranted", "in", "a", "model", "of", "chronic", "heart", "failure", "."]], "ner": [[[167, 167, "Chemical"], [9, 11, "Disease"], [103, 104, "Disease"], [162, 163, "Disease"], [204, 205, "Disease"], [485, 486, "Disease"], [506, 507, "Disease"], [35, 36, "Disease"], [39, 40, "Disease"], [42, 42, "Disease"], [51, 51, "Disease"], [84, 84, "Disease"], [180, 180, "Disease"], [493, 493, "Disease"]]], "relations": [[[167, 167, 9, 11, "CID"], [167, 167, 103, 104, "CID"], [167, 167, 162, 163, "CID"], [167, 167, 204, 205, "CID"], [167, 167, 485, 486, "CID"], [167, 167, 506, 507, "CID"]]], "clusters": [], "translated": "二尖瓣成形术作为<1>左心室衰竭</1>的心室修复方法：初步研究。研究背景和目的：小尺寸二尖瓣成形术（MAP）对<7>扩张型心肌病</7>和功能性<8>二尖瓣反流</8>（<9>MR</9>）患者有效，因为，除了解决<10>MR</10>问题，MAP还可以重塑扩张的左心室（LV）底部。然而，在没有潜在的<11>MR</11>的情况下，这种可能重塑LV功能的直接好处仍未完全了解。该研究的目的是在急性<2>心力衰竭</2>犬模型中确定这些益处。方法：六只狗在后二尖瓣环上使用假体带进行MAP，使用四根褥式缝合线。缝合线分别穿过四个止血带，并通过左心房切开术解开。在二尖瓣环和左心室周围植入超声测微晶体，以测量几何形状和区域功能。体外循环撤机后<0>心得安</0>，并容量负荷诱发急性<3>心力衰竭</3>；超声心动图证实没有<12>MR</12>。MAP是通过收紧止血带完成的。数据是在基线、急性<4>心力衰竭</4>诱导后和MAP后采集的。结果：MAP减少了二尖瓣环在连合-连合和间隔外侧方向的尺寸。同时，左室底部的舒张期直径和左室球形度从37.4+/-9.3下降（即改善）到35.9+/-10毫米（p=0.063），并且从67.9+/-18.6%至65.3+/-18.9%（p=0.016），分别。 LV舒张末期压（从17+/-7到15+/-6毫米汞柱，p=0.0480）和Tau（从48+/-8到45+/-8毫秒，p<0.01），而LV碱基的缩短分数从7.7+/-4.5%增加到9.4+/-4.5%（p=0.045）。在MAP之后，两者均有增加心输出量（从1.54+/-0.57到1.65+/-0.57 1/分钟）和Emax（从1.86+/-0.9到2.41+/-1.31mmHg/ml）。结论：获得的数据表明，即使在没有<13>MR</13>的情况下，单独的MAP可能对急性<5>心力衰竭</5>的LV尺寸/功能有一定的好处，需要在慢性<6>心力衰竭</6>模型中进一步研究。", "revised": true}
{"doc_key": "17351238", "sentences": [["A", "dramatic", "drop", "in", "blood", "pressure", "following", "prehospital", "GTN", "administration", ".", "A", "male", "in", "his", "sixties", "with", "no", "history", "of", "cardiac", "chest", "pain", "awoke", "with", "chest", "pain", "following", "an", "afternoon", "sleep", ".", "The", "patient", "did", "not", "self", "medicate", ".", "The", "patient", "'s", "observations", "were", "within", "normal", "limits", ",", "he", "was", "administered", "oxygen", "via", "a", "face", "mask", "and", "glyceryl", "trinitrate", "(", "GTN", ")", ".", "Several", "minutes", "after", "the", "GTN", "the", "patient", "experienced", "a", "sudden", "drop", "in", "blood", "pressure", "and", "heart", "rate", ",", "this", "was", "rectified", "by", "atropine", "sulphate", "and", "a", "fluid", "challenge", ".", "There", "was", "no", "further", "deterioration", "in", "the", "patient", "'s", "condition", "during", "transport", "to", "hospital", ".", "There", "are", "very", "few", "documented", "case", "like", "this", "in", "the", "prehospital", "scientific", "literature", ".", "The", "cause", "appears", "to", "be", "the", "Bezold", "-", "Jarish", "reflex", ",", "stimulation", "of", "the", "ventricular", "walls", "which", "in", "turn", "decreases", "sympathetic", "outflow", "from", "the", "vasomotor", "centre", ".", "Prehospital", "care", "providers", "who", "are", "managing", "any", "patient", "with", "a", "syncopal", "episode", "that", "fails", "to", "recover", "within", "a", "reasonable", "time", "frame", "should", "consider", "the", "Bezold", "-", "Jarisch", "reflex", "as", "the", "cause", "and", "manage", "the", "patient", "accordingly", "."]], "ner": [[[8, 8, "Chemical"], [57, 58, "Chemical"], [60, 60, "Chemical"], [67, 67, "Chemical"], [2, 5, "Disease"], [73, 76, "Disease"], [51, 51, "Chemical"], [85, 86, "Chemical"], [21, 22, "Disease"], [25, 26, "Disease"], [158, 159, "Disease"]]], "relations": [[[8, 8, 2, 5, "CID"], [8, 8, 73, 76, "CID"], [57, 58, 2, 5, "CID"], [57, 58, 73, 76, "CID"], [60, 60, 2, 5, "CID"], [60, 60, 73, 76, "CID"], [67, 67, 2, 5, "CID"], [67, 67, 73, 76, "CID"], [51, 51, 2, 5, "CID"], [51, 51, 73, 76, "CID"]]], "clusters": [], "translated": "院前<0>GTN</0>给药后，<4>血压显着下降</4>。一位没有心脏病史的60多岁男性<8>胸痛</8>在午睡后因<9>胸痛</9>醒来。患者没有自行用药。患者的观察结果在正常范围内，他通过面罩和<1>三硝酸甘油酯</1>（<2>GTN</2>）给予<6>氧气</6>。几分钟后的<3>GTN</3>，患者经历了突然的<5>血压下降</5>和心率，这通过<7>硫酸阿托品</7>和液体挑战得到纠正。在送往医院的过程中，病人的病情没有进一步恶化。院前科学文献中很少有这样的案例记载。原因似乎是Bezold-Jarish反射，刺激心室壁，进而减少血管运动中枢的交感神经流出。院前护理人员在处理任何未能在合理时间范围内恢复的<10>晕厥发作</10>患者时，应将Bezold-Jarisch反射视为病因，并对患者进行相应处理。", "revised": true}
{"doc_key": "16880771", "sentences": [["Tonic", "dopaminergic", "stimulation", "impairs", "associative", "learning", "in", "healthy", "subjects", ".", "Endogenous", "dopamine", "plays", "a", "central", "role", "in", "salience", "coding", "during", "associative", "learning", ".", "Administration", "of", "the", "dopamine", "precursor", "levodopa", "enhances", "learning", "in", "healthy", "subjects", "and", "stroke", "patients", ".", "Because", "levodopa", "increases", "both", "phasic", "and", "tonic", "dopaminergic", "neurotransmission", ",", "the", "critical", "mechanism", "mediating", "the", "enhancement", "of", "learning", "is", "unresolved", ".", "We", "here", "probed", "how", "selective", "tonic", "dopaminergic", "stimulation", "affects", "associative", "learning", ".", "Forty", "healthy", "subjects", "were", "trained", "in", "a", "novel", "vocabulary", "of", "45", "concrete", "nouns", "over", "the", "course", "of", "5", "consecutive", "training", "days", "in", "a", "prospective", ",", "randomized", ",", "double", "-", "blind", ",", "placebo", "-", "controlled", "design", ".", "Subjects", "received", "the", "tonically", "stimulating", "dopamine", "-", "receptor", "agonist", "pergolide", "(", "0", ".", "1", "mg", ")", "vs", "placebo", "120", "min", "before", "training", "on", "each", "training", "day", ".", "The", "dopamine", "agonist", "significantly", "impaired", "novel", "word", "learning", "compared", "to", "placebo", ".", "This", "learning", "decrement", "persisted", "up", "to", "the", "last", "follow", "-", "up", "4", "weeks", "post", "-", "training", ".", "Subjects", "treated", "with", "pergolide", "also", "showed", "restricted", "emotional", "responses", "compared", "to", "the", "PLACEBO", "group", ".", "The", "extent", "of", "'", "flattened", "'", "affect", "with", "pergolide", "was", "related", "to", "the", "degree", "of", "learning", "inhibition", ".", "These", "findings", "suggest", "that", "tonic", "occupation", "of", "dopamine", "receptors", "impairs", "learning", "by", "competition", "with", "phasic", "dopamine", "signals", ".", "Thus", ",", "phasic", "signaling", "seems", "to", "be", "the", "critical", "mechanism", "by", "which", "dopamine", "enhances", "associative", "learning", "in", "healthy", "subjects", "and", "stroke", "patients", "."]], "ner": [[[116, 116, "Chemical"], [166, 166, "Chemical"], [186, 186, "Chemical"], [3, 5, "Disease"], [138, 141, "Disease"], [11, 11, "Chemical"], [26, 26, "Chemical"], [112, 112, "Chemical"], [135, 135, "Chemical"], [203, 203, "Chemical"], [211, 211, "Chemical"], [226, 226, "Chemical"], [28, 28, "Chemical"], [39, 39, "Chemical"], [35, 35, "Disease"], [234, 234, "Disease"]]], "relations": [[[116, 116, 3, 5, "CID"], [116, 116, 138, 141, "CID"], [166, 166, 3, 5, "CID"], [166, 166, 138, 141, "CID"], [186, 186, 3, 5, "CID"], [186, 186, 138, 141, "CID"]]], "clusters": [], "translated": "强直多巴胺能刺激<3>损害健康受试者的联想学习</3>。内源性<5>多巴胺</5>在联想学习过程中的显着性编码中起着核心作用。<6>多巴胺</6>前体<12>左旋多巴</12>的给药可增强健康受试者和<14>中风</14>患者的学习能力。因为<13>左旋多巴</13>增加阶段性和强直性多巴胺能神经传递，调节学习增强的关键机制尚未解决。我们在这里探讨了选择性强直多巴胺能刺激如何影响联想学习。在前瞻性、随机、双盲、安慰剂对照设计中，40名健康受试者在连续5天的训练过程中接受了45个具体名词的新词汇训练。受试者在每个训练日训练前120分钟接受强直刺激<7>多巴胺</7>受体激动剂<0>培高利特</0>（0.1毫克）与安慰剂。与安慰剂相比，<8>多巴胺</8>激动剂显着<4>损害新词学习</4>。这种学习减量一直持续到培训后4周的最后一次跟进。与安慰剂组相比，接受<1>培高利特</1>治疗的受试者也表现出情绪反应受限。<2>培高利特</2>的'扁平化'影响程度与学习抑制的程度有关。这些发现表明，<9>多巴胺</9>受体的紧张性占据会通过与阶段性<10>多巴胺</10>信号的竞争而损害学习。因此，相位信号似乎是<11>多巴胺</11>增强健康受试者和<15>中风</15>患者联想学习的关键机制。", "revised": true}
{"doc_key": "17356399", "sentences": [["Acute", "encephalopathy", "and", "cerebral", "vasospasm", "after", "multiagent", "chemotherapy", "including", "PEG", "-", "asparaginase", "and", "intrathecal", "cytarabine", "for", "the", "treatment", "of", "acute", "lymphoblastic", "leukemia", ".", "A", "7", "-", "year", "-", "old", "girl", "with", "an", "unusual", "reaction", "to", "induction", "chemotherapy", "for", "precursor", "B", "-", "cell", "acute", "lymphoblastic", "leukemia", "(", "ALL", ")", "is", "described", ".", "The", "patient", "developed", "acute", "encephalopathy", "evidenced", "by", "behavioral", "changes", ",", "aphasia", ",", "incontinence", ",", "visual", "hallucinations", ",", "and", "right", "-", "sided", "weakness", "with", "diffuse", "cerebral", "vasospasm", "on", "magnetic", "resonance", "angiography", "after", "the", "administration", "of", "intrathecal", "cytarabine", ".", "Vincristine", ",", "dexamethasone", ",", "and", "polyethylene", "glycol", "-", "asparaginase", "were", "also", "administered", "before", "the", "episode", "as", "part", "of", "induction", "therapy", ".", "Neurologic", "status", "returned", "to", "baseline", "within", "10", "days", "of", "the", "acute", "event", ",", "and", "magnetic", "resonance", "angiography", "findings", "returned", "to", "normal", "4", "months", "later", "."]], "ner": [[[9, 11, "Chemical"], [93, 96, "Chemical"], [3, 4, "Disease"], [75, 76, "Disease"], [14, 14, "Chemical"], [86, 86, "Chemical"], [88, 88, "Chemical"], [90, 90, "Chemical"], [61, 61, "Disease"], [63, 63, "Disease"], [65, 66, "Disease"], [72, 72, "Disease"], [0, 1, "Disease"], [54, 55, "Disease"], [19, 21, "Disease"], [42, 44, "Disease"], [46, 46, "Disease"]]], "relations": [[[9, 11, 3, 4, "CID"], [9, 11, 75, 76, "CID"], [93, 96, 3, 4, "CID"], [93, 96, 75, 76, "CID"], [14, 14, 3, 4, "CID"], [14, 14, 75, 76, "CID"], [86, 86, 3, 4, "CID"], [86, 86, 75, 76, "CID"], [88, 88, 3, 4, "CID"], [88, 88, 75, 76, "CID"], [90, 90, 3, 4, "CID"], [90, 90, 75, 76, "CID"], [9, 11, 61, 61, "CID"], [93, 96, 61, 61, "CID"], [9, 11, 63, 63, "CID"], [93, 96, 63, 63, "CID"], [9, 11, 65, 66, "CID"], [93, 96, 65, 66, "CID"], [9, 11, 72, 72, "CID"], [93, 96, 72, 72, "CID"], [14, 14, 61, 61, "CID"], [86, 86, 61, 61, "CID"], [14, 14, 63, 63, "CID"], [86, 86, 63, 63, "CID"], [14, 14, 65, 66, "CID"], [86, 86, 65, 66, "CID"], [14, 14, 72, 72, "CID"], [86, 86, 72, 72, "CID"], [88, 88, 61, 61, "CID"], [90, 90, 61, 61, "CID"], [88, 88, 63, 63, "CID"], [90, 90, 63, 63, "CID"], [88, 88, 65, 66, "CID"], [90, 90, 65, 66, "CID"], [88, 88, 72, 72, "CID"], [90, 90, 72, 72, "CID"]]], "clusters": [], "translated": " <12>急性脑病</12>和<2>脑血管痉挛</2>多药化疗后<0> 聚乙二醇-门冬酰胺酶</0>和鞘内注射<4> 阿糖胞苷</4>治疗<14> 急性淋巴细胞白血病</14>. 一名7岁女孩对前体B细胞<15>急性淋巴细胞白血病</15>（<16> ALL </16>）的诱导化疗反应异常。患者出现<13>急性脑病</13>，表现为行为改变、<8>失语</8>、<9>失禁</9>、<10>幻视</10>和右侧<11>无力</11>伴弥漫性<3> 脑血管痉挛</3>鞘内注射<5> 阿糖胞苷</5>后磁共振血管造影。<6> 长春新碱</6>、<1>聚乙二醇-天冬酰胺酶</1>和<7> 地塞米松</7>也作为诱导治疗的一部分在发作前给药。神经系统状态在急性事件发生后10天内恢复到基线，磁共振血管造影结果在4个月后恢复正常。", "revised": true}
{"doc_key": "16565833", "sentences": [["The", "influence", "of", "the", "time", "interval", "between", "monoHER", "and", "doxorubicin", "administration", "on", "the", "protection", "against", "doxorubicin", "-", "induced", "cardiotoxicity", "in", "mice", ".", "PURPOSE", ":", "Despite", "its", "well", "-", "known", "cardiotoxicity", ",", "the", "anthracyclin", "doxorubicin", "(", "DOX", ")", "continues", "to", "be", "an", "effective", "and", "widely", "used", "chemotherapeutic", "agent", ".", "DOX", "-", "induced", "cardiac", "damage", "presumably", "results", "from", "the", "formation", "of", "free", "radicals", "by", "DOX", ".", "Reactive", "oxygen", "species", "particularly", "affect", "the", "cardiac", "myocytes", "because", "these", "cells", "seem", "to", "have", "a", "relatively", "poor", "antioxidant", "defense", "system", ".", "The", "semisynthetic", "flavonoid", "monohydroxyethylrutoside", "(", "monoHER", ")", "showed", "cardioprotection", "against", "DOX", "-", "induced", "cardiotoxicity", "through", "its", "radical", "scavenging", "and", "iron", "chelating", "properties", ".", "Because", "of", "the", "relatively", "short", "final", "half", "-", "life", "of", "monoHER", "(", "about", "30", "min", ")", ",", "it", "is", "expected", "that", "the", "time", "interval", "between", "monoHER", "and", "DOX", "might", "be", "of", "influence", "on", "the", "cardioprotective", "effect", "of", "monoHER", ".", "Therefore", ",", "the", "aim", "of", "the", "present", "study", "was", "to", "investigate", "this", "possible", "effect", ".", "METHODS", ":", "Six", "groups", "of", "6", "BALB", "/", "c", "mice", "were", "treated", "with", "saline", ",", "DOX", "alone", "or", "DOX", "(", "4", "mg", "/", "kg", "i", ".", "v", ".", ")", "preceded", "by", "monoHER", "(", "500", "mg", "/", "kg", "i", ".", "p", ".", ")", "with", "an", "interval", "of", "10", ",", "30", ",", "60", "or", "120", "min", ".", "After", "a", "6", "-", "week", "treatment", "period", "and", "additional", "observation", "for", "2", "weeks", ",", "the", "mice", "were", "sacrificed", ".", "Their", "cardiac", "tissues", "were", "processed", "for", "light", "microscopy", ",", "after", "which", "cardiomyocyte", "damage", "was", "evaluated", "according", "to", "Billingham", "(", "in", "Cancer", "Treat", "Rep", "62", "(", "6", ")", ":", "865", "-", "872", ",", "1978", ")", ".", "Microscopic", "evaluation", "revealed", "that", "treatment", "with", "DOX", "alone", "induced", "significant", "cardiac", "damage", "in", "comparison", "to", "the", "saline", "control", "group", "(", "P", "<", "0", ".", "001", ")", ".", "RESULTS", ":", "The", "number", "of", "damaged", "cardiomyocytes", "was", "9", ".", "6", "-", "fold", "(", "95", "%", "CI", "4", ".", "4", "-", "21", ".", "0", ")", "higher", "in", "mice", "treated", "with", "DOX", "alone", "than", "that", "in", "animals", "of", "the", "control", "group", ".", "The", "ratio", "of", "aberrant", "cardiomyocytes", "in", "mice", "treated", "with", "DOX", "preceded", "by", "monoHER", "and", "those", "in", "mice", "treated", "with", "saline", "ranged", "from", "1", ".", "6", "to", "2", ".", "8", "(", "mean", "2", ".", "2", ",", "95", "%", "CI", "1", ".", "2", "-", "4", ".", "1", ",", "P", "=", "0", ".", "019", ")", ".", "The", "mean", "protective", "effect", "by", "adding", "monoHER", "before", "DOX", "led", "to", "a", "significant", "4", ".", "4", "-", "fold", "reduction", "(", "P", "<", "0", ".", "001", ",", "95", "%", "CI", "2", ".", "3", "-", "8", ".", "2", ")", "of", "abnormal", "cardiomyocytes", ".", "This", "protective", "effect", "did", "not", "depend", "on", "the", "time", "interval", "between", "monoHER", "and", "DOX", "administration", "(", "P", "=", "0", ".", "345", ")", ".", "CONCLUSION", ":", "The", "results", "indicate", "that", "in", "an", "outpatient", "clinical", "setting", "monoHER", "may", "be", "administered", "shortly", "before", "DOX", "."]], "ner": [[[9, 9, "Chemical"], [15, 15, "Chemical"], [33, 33, "Chemical"], [35, 35, "Chemical"], [48, 48, "Chemical"], [62, 62, "Chemical"], [95, 95, "Chemical"], [135, 135, "Chemical"], [177, 177, "Chemical"], [180, 180, "Chemical"], [277, 277, "Chemical"], [328, 328, "Chemical"], [348, 348, "Chemical"], [400, 400, "Chemical"], [446, 446, "Chemical"], [473, 473, "Chemical"], [247, 248, "Disease"], [7, 7, "Chemical"], [88, 88, "Chemical"], [90, 90, "Chemical"], [118, 118, "Chemical"], [133, 133, "Chemical"], [145, 145, "Chemical"], [193, 193, "Chemical"], [351, 351, "Chemical"], [398, 398, "Chemical"], [444, 444, "Chemical"], [467, 467, "Chemical"], [18, 18, "Disease"], [29, 29, "Disease"], [98, 98, "Disease"], [51, 52, "Disease"], [281, 282, "Disease"], [256, 256, "Disease"], [65, 65, "Chemical"], [87, 87, "Chemical"], [104, 104, "Chemical"]]], "relations": [[[9, 9, 247, 248, "CID"], [15, 15, 247, 248, "CID"], [33, 33, 247, 248, "CID"], [35, 35, 247, 248, "CID"], [48, 48, 247, 248, "CID"], [62, 62, 247, 248, "CID"], [95, 95, 247, 248, "CID"], [135, 135, 247, 248, "CID"], [177, 177, 247, 248, "CID"], [180, 180, 247, 248, "CID"], [277, 277, 247, 248, "CID"], [328, 328, 247, 248, "CID"], [348, 348, 247, 248, "CID"], [400, 400, 247, 248, "CID"], [446, 446, 247, 248, "CID"], [473, 473, 247, 248, "CID"]]], "clusters": [], "translated": "<17>monoHER</17>和<0>多柔比星</0>给药时间间隔对小鼠<1>多柔比星</1>诱导的<28>心脏毒性</28>保护作用的影响。目的：尽管其众所周知的<29>心脏毒性</29>，蒽环类药物<2>阿霉素</2> (<3>DOX</3>)仍然是一种有效且广泛使用的化疗药物。<4>DOX</4>-诱导的<31>心脏损伤</31>可能是<5>DOX</5>形成自由基的结果。活性<34>氧</34>物种特别影响心肌细胞，因为这些细胞似乎具有相对较差的抗氧化防御系统。半合成<35>类黄酮</35><18>单羟基乙基芸香糖苷</18> (<19>monoHER</19>)显示出针对<6>DOX</6>的心脏保护作用-诱导的<30>心脏毒性</30>通过它的自由基清除和<36>铁</36>螯合性能。由于<20>monoHER</20>的最终半衰期相对较短（约30分钟），预计<21>monoHER</21>和<7>DOX</7>之间的时间间隔可能影响<22>monoHER</22>的心脏保护作用。因此，本研究的目的是调查这种可能的影响。用盐水、<8>DOX</8>单独或<9>DOX</9> (4mg/kg i.v.) 先于<23>monoHER</23> (500mg/kg i.p.) 10、30、60或120分钟间隔给予六组BALB/c小鼠治疗。治疗6周后再额外观察2周，然后处死小鼠。对他们的心脏组织进行光学显微镜处理，然后根据Billingham评估<16>心肌细胞损伤</16>（in<33>Cancer</33>Treat Rep 62(6):865-872,1978）。显微评估显示，并以盐水对照组( P <0.001 )为比较，<10>DOX</10>单独治疗可以启动显着的<32>心脏 损伤</32>。结果：使用<11>DOX</11>单独治疗小鼠的受损心肌细胞数比对照组动物高6倍( 95% CI 4.4-21.0 )。在用<12>DOX</12>处理的小鼠中, 先用<24>monoHER</24>处理的小鼠和用盐水处理的小鼠中异常心肌细胞的比率范围为1.6-2.8 (平均值2.2, 95% CI 1.2-4.1, P = 0.019)。在<13>DOX</13>之前添加<25>monoHER</25>的平均保护效果显着地减少异常心肌细胞4倍(P<0.001, 95% CI 2.3-8.2)。这种保护作用不依赖于<26>monoHER</26>和<14>DOX</14>给药之间的时间间隔 (P = 0.345)。结论：结果表明，在门诊临床环境中，<27>monoHER</27>可以在<15>DOX</15>之前不久进行给药。", "revised": true}
{"doc_key": "16920333", "sentences": [["Anticonvulsant", "effect", "of", "eslicarbazepine", "acetate", "(", "BIA", "2", "-", "093", ")", "on", "seizures", "induced", "by", "microperfusion", "of", "picrotoxin", "in", "the", "hippocampus", "of", "freely", "moving", "rats", ".", "Eslicarbazepine", "acetate", "(", "BIA", "2", "-", "093", ",", "S", "-", "(", "-", ")", "-", "10", "-", "acetoxy", "-", "10", ",", "11", "-", "dihydro", "-", "5H", "-", "dibenzo", "/", "b", ",", "f", "/", "azepine", "-", "5", "-", "carboxamide", ")", "is", "a", "novel", "antiepileptic", "drug", ",", "now", "in", "Phase", "III", "clinical", "trials", ",", "designed", "with", "the", "aim", "of", "improving", "efficacy", "and", "safety", "in", "comparison", "with", "the", "structurally", "related", "drugs", "carbamazepine", "(", "CBZ", ")", "and", "oxcarbazepine", "(", "OXC", ")", ".", "We", "have", "studied", "the", "effects", "of", "oral", "treatment", "with", "eslicarbazepine", "acetate", "on", "a", "whole", "-", "animal", "model", "in", "which", "partial", "seizures", "can", "be", "elicited", "repeatedly", "on", "different", "days", "without", "changes", "in", "threshold", "or", "seizure", "patterns", ".", "In", "the", "animals", "treated", "with", "threshold", "doses", "of", "picrotoxin", ",", "the", "average", "number", "of", "seizures", "was", "2", ".", "3", "+", "/", "-", "1", ".", "2", ",", "and", "average", "seizure", "duration", "was", "39", ".", "5", "+", "/", "-", "8", ".", "4s", ".", "Pre", "-", "treatment", "with", "a", "dose", "of", "30", "mg", "/", "kg", "2h", "before", "picrotoxin", "microperfusion", "prevented", "seizures", "in", "the", "75", "%", "of", "the", "rats", ".", "Lower", "doses", "(", "3", "and", "10mg", "/", "kg", ")", "did", "not", "suppress", "seizures", ",", "however", ",", "after", "administration", "of", "10mg", "/", "kg", ",", "significant", "reductions", "in", "seizures", "duration", "(", "24", ".", "3", "+", "/", "-", "6", ".", "8s", ")", "and", "seizure", "number", "(", "1", ".", "6", "+", "/", "-", "0", ".", "34", ")", "were", "found", ".", "No", "adverse", "effects", "of", "eslicarbazepine", "acetate", "were", "observed", "in", "the", "behavioral", "/", "EEG", "patterns", "studied", ",", "including", "sleep", "/", "wakefulness", "cycle", ",", "at", "the", "doses", "studied", "."]], "ner": [[[17, 17, "Chemical"], [147, 147, "Chemical"], [193, 193, "Chemical"], [12, 12, "Disease"], [123, 123, "Disease"], [136, 136, "Disease"], [153, 153, "Disease"], [167, 167, "Disease"], [196, 196, "Disease"], [217, 217, "Disease"], [231, 231, "Disease"], [245, 245, "Disease"], [3, 4, "Chemical"], [6, 9, "Chemical"], [26, 27, "Chemical"], [29, 32, "Chemical"], [34, 62, "Chemical"], [112, 113, "Chemical"], [265, 266, "Chemical"], [93, 93, "Chemical"], [95, 95, "Chemical"], [98, 98, "Chemical"], [100, 100, "Chemical"]]], "relations": [[[17, 17, 12, 12, "CID"], [17, 17, 123, 123, "CID"], [17, 17, 136, 136, "CID"], [17, 17, 153, 153, "CID"], [17, 17, 167, 167, "CID"], [17, 17, 196, 196, "CID"], [17, 17, 217, 217, "CID"], [17, 17, 231, 231, "CID"], [17, 17, 245, 245, "CID"], [147, 147, 12, 12, "CID"], [147, 147, 123, 123, "CID"], [147, 147, 136, 136, "CID"], [147, 147, 153, 153, "CID"], [147, 147, 167, 167, "CID"], [147, 147, 196, 196, "CID"], [147, 147, 217, 217, "CID"], [147, 147, 231, 231, "CID"], [147, 147, 245, 245, "CID"], [193, 193, 12, 12, "CID"], [193, 193, 123, 123, "CID"], [193, 193, 136, 136, "CID"], [193, 193, 153, 153, "CID"], [193, 193, 167, 167, "CID"], [193, 193, 196, 196, "CID"], [193, 193, 217, 217, "CID"], [193, 193, 231, 231, "CID"], [193, 193, 245, 245, "CID"]]], "clusters": [], "translated": "<12>醋酸艾司利卡西平</12>（<13>BIA 2-093</13>）对自由移动的老鼠在<0>海马</0>微灌注<3>印防己毒素</3>引发的<4>癫痫发作</4>具有抗惊厥作用。 <14>醋酸艾司利卡西平</14>（<15>BIA 2-093</15>，<16>S-(-)-10-乙酰氧基-10,11-二氢-5H-二苯并b,f/氮杂-5-甲酰胺</16>）是一种新型抗癫痫药物，目前处于III期临床试验阶段，旨在改善与其结构相关的药物<19>卡马西平</19>（<20>CBZ</20>）和<21>奥卡西平</21>（<22>OXC</22>）相比的疗效和安全性。我们研究了口服<17>醋酸艾司利卡西平</17>对整个动物模型的影响，在该模型中，可以在不同的日子重复引发部分<4>癫痫发作</4>，而<5>阈值或发作模式不会发生变化</5>。在用<1>印防己毒素</1>处理的动物中，<6>癫痫发作</6>的平均次数为2.3+/-1.2，平均<7>发作</7>持续时间为39.5+/-8.4秒。在<2>印防己毒素</2>微灌注前2小时以30 mg/kg的剂量进行预处理可预防75%的大鼠的<8>癫痫发作</8>。较低剂量（3和10毫克/千克）没有抑制<9>癫痫发作</9>，但是，在给予10毫克/千克后，<10>癫痫发作</10>持续时间显着减少（24.3+/-6.8秒）和<11>缉获</11>数量（1.6+/-0.34）被发现。在所研究的行为/EEG模式（包括睡眠/觉醒周期）中，在所研究的剂量下，未观察到<18>醋酸艾司利卡西平</18>的不良反应。", "revised": true}
{"doc_key": "17543491", "sentences": [["Frequency", "of", "transient", "ipsilateral", "vocal", "cord", "paralysis", "in", "patients", "undergoing", "carotid", "endarterectomy", "under", "local", "anesthesia", ".", "BACKGROUND", ":", "Especially", "because", "of", "improvements", "in", "clinical", "neurologic", "monitoring", ",", "carotid", "endarterectomy", "done", "under", "local", "anesthesia", "has", "become", "the", "technique", "of", "choice", "in", "several", "centers", ".", "Temporary", "ipsilateral", "vocal", "nerve", "palsies", "due", "to", "local", "anesthetics", "have", "been", "described", ",", "however", ".", "Such", "complications", "are", "most", "important", "in", "situations", "where", "there", "is", "a", "pre", "-", "existing", "contralateral", "paralysis", ".", "We", "therefore", "examined", "the", "effect", "of", "local", "anesthesia", "on", "vocal", "cord", "function", "to", "better", "understand", "its", "possible", "consequences", ".", "METHODS", ":", "This", "prospective", "study", "included", "28", "patients", "undergoing", "carotid", "endarterectomy", "under", "local", "anesthesia", ".", "Vocal", "cord", "function", "was", "evaluated", "before", ",", "during", ",", "and", "after", "surgery", "(", "postoperative", "day", "1", ")", "using", "flexible", "laryngoscopy", ".", "Anesthesia", "was", "performed", "by", "injecting", "20", "to", "40", "mL", "of", "a", "mixture", "of", "long", "-", "acting", "(", "ropivacaine", ")", "and", "short", "-", "acting", "(", "prilocaine", ")", "anesthetic", ".", "RESULTS", ":", "All", "patients", "had", "normal", "vocal", "cord", "function", "preoperatively", ".", "Twelve", "patients", "(", "43", "%", ")", "were", "found", "to", "have", "intraoperative", "ipsilateral", "vocal", "cord", "paralysis", ".", "It", "resolved", "in", "all", "cases", "<", "or", "=", "24", "hours", ".", "There", "were", "no", "significant", "differences", "in", "operating", "time", "or", "volume", "or", "frequency", "of", "anesthetic", "administration", "in", "patients", "with", "temporary", "vocal", "cord", "paralysis", "compared", "with", "those", "without", ".", "CONCLUSION", ":", "Local", "anesthesia", "led", "to", "temporary", "ipsilateral", "vocal", "cord", "paralysis", "in", "almost", "half", "of", "these", "patients", ".", "Because", "pre", "-", "existing", "paralysis", "is", "of", "a", "relevant", "frequency", "(", "up", "to", "3", "%", ")", ",", "a", "preoperative", "evaluation", "of", "vocal", "cord", "function", "before", "carotid", "endarterectomy", "under", "local", "anesthesia", "is", "recommended", "to", "avoid", "intraoperative", "bilateral", "paralysis", ".", "In", "patients", "with", "preoperative", "contralateral", "vocal", "cord", "paralysis", ",", "surgery", "under", "general", "anesthesia", "should", "be", "considered", "."]], "ner": [[[154, 154, "Chemical"], [4, 6, "Disease"], [45, 47, "Disease"], [181, 183, "Disease"], [215, 217, "Disease"], [231, 233, "Disease"], [284, 286, "Disease"], [147, 147, "Chemical"], [73, 73, "Disease"], [245, 245, "Disease"], [277, 277, "Disease"]]], "relations": [[[154, 154, 4, 6, "CID"], [154, 154, 45, 47, "CID"], [154, 154, 181, 183, "CID"], [154, 154, 215, 217, "CID"], [154, 154, 231, 233, "CID"], [154, 154, 284, 286, "CID"]]], "clusters": [], "translated": "在局部麻醉下接受颈动脉内膜切除术的患者发生短暂性同侧<1>声带麻痹</1>的频率。背景：特别是由于临床神经监测的改进，在局部麻醉下进行的颈动脉内膜切除术已成为几个中心的首选技术。然而，由于局部麻醉剂导致的暂时性同侧<2>声带神经麻痹</2>已有描述。这种并发症在已经存在对侧<8>麻痹</8>的情况下最为严重。因此，我们检查了局部麻醉对声带功能的影响，以更好地了解其可能产生的后果。方法：这项前瞻性研究包括28名在局部麻醉下接受颈动脉内膜切除术的患者。在手术前、手术中和手术后（术后第1天）使用可弯曲喉镜评估声带功能。通过注射20至40 mL的长效（<7>罗哌卡因</7>）和短效（<0>丙胺卡因</0>）麻醉剂混合物进行麻醉。结果：所有患者术前声带功能均正常。12例（43%）被发现有术中同侧<3>声带麻痹</3>。它在所有情况下都解决了<=24小时。与没有暂时性<4>声带麻痹</4>的患者相比，手术时间或麻醉药给药量或频率没有显着差异。结论：局部麻醉导致近半数患者出现暂时性同侧<5>声带麻痹</5>。由于预先存在的<9>麻痹</9>具有相关频率（高达3%），建议在局部麻醉下进行颈动脉内膜切除术之前对声带功能进行术前评估，以避免术中双侧<10>麻痹</10>。对于术前有对侧<6>声带麻痹</6>的患者，应考虑全麻手术。", "revised": true}
{"doc_key": "17346443", "sentences": [["Penicillamine", "-", "related", "lichenoid", "dermatitis", "and", "utility", "of", "zinc", "acetate", "in", "a", "Wilson", "disease", "patient", "with", "hepatic", "presentation", ",", "anxiety", "and", "SPECT", "abnormalities", ".", "Wilson", "'s", "disease", "is", "an", "autosomal", "recessive", "disorder", "of", "hepatic", "copper", "metabolism", "with", "consequent", "copper", "accumulation", "and", "toxicity", "in", "many", "tissues", "and", "consequent", "hepatic", ",", "neurologic", "and", "psychiatric", "disorders", ".", "We", "report", "a", "case", "of", "Wilson", "'s", "disease", "with", "chronic", "liver", "disease", ";", "moreover", ",", "in", "our", "patient", ",", "presenting", "also", "with", "high", "levels", "of", "state", "anxiety", "without", "depression", ",", "99mTc", "-", "ECD", "-", "SPECT", "showed", "cortical", "hypoperfusion", "in", "frontal", "lobes", ",", "more", "marked", "on", "the", "left", "frontal", "lobe", ".", "During", "the", "follow", "-", "up", "of", "our", "patient", ",", "penicillamine", "was", "interrupted", "after", "the", "appearance", "of", "a", "lichenoid", "dermatitis", ",", "and", "zinc", "acetate", "permitted", "to", "continue", "the", "successful", "treatment", "of", "the", "patient", "without", "side", "-", "effects", ".", "In", "our", "case", "the", "therapy", "with", "zinc", "acetate", "represented", "an", "effective", "treatment", "for", "a", "Wilson", "'s", "disease", "patient", "in", "which", "penicillamine", "-", "related", "side", "effects", "appeared", ".", "The", "safety", "of", "the", "zinc", "acetate", "allowed", "us", "to", "avoid", "other", "potentially", "toxic", "chelating", "drugs", ";", "this", "observation", "is", "in", "line", "with", "the", "growing", "evidence", "on", "the", "efficacy", "of", "the", "drug", "in", "the", "treatment", "of", "Wilson", "'s", "disease", ".", "Since", "most", "of", "Wilson", "'s", "disease", "penicillamine", "-", "treated", "patients", "do", "not", "seem", "to", "develop", "this", "skin", "lesion", ",", "it", "could", "be", "conceivable", "that", "a", "specific", "genetic", "factor", "is", "involved", "in", "drug", "response", ".", "Further", "studies", "are", "needed", "for", "a", "better", "clarification", "of", "Wilson", "'s", "disease", "therapy", ",", "and", "in", "particular", "to", "differentiate", "specific", "therapies", "for", "different", "Wilson", "'s", "disease", "phenotypes", "."]], "ner": [[[0, 0, "Chemical"], [113, 113, "Chemical"], [161, 161, "Chemical"], [213, 213, "Chemical"], [3, 4, "Disease"], [121, 122, "Disease"], [12, 13, "Disease"], [24, 26, "Disease"], [59, 61, "Disease"], [155, 157, "Disease"], [203, 205, "Disease"], [210, 212, "Disease"], [250, 252, "Disease"], [264, 266, "Disease"], [19, 19, "Disease"], [80, 80, "Disease"], [41, 41, "Disease"], [47, 52, "Disease"], [63, 65, "Disease"], [82, 82, "Disease"], [223, 224, "Disease"], [8, 9, "Chemical"], [125, 126, "Chemical"], [147, 148, "Chemical"], [172, 173, "Chemical"], [34, 34, "Chemical"], [38, 38, "Chemical"]]], "relations": [[[0, 0, 3, 4, "CID"], [0, 0, 121, 122, "CID"], [113, 113, 3, 4, "CID"], [113, 113, 121, 122, "CID"], [161, 161, 3, 4, "CID"], [161, 161, 121, 122, "CID"], [213, 213, 3, 4, "CID"], [213, 213, 121, 122, "CID"]]], "clusters": [], "translated": "<0>青霉胺</0> - 相关的<4>苔藓样皮炎</4>和<21>醋酸锌</21>在<6>威尔逊病</6>患者伴有肝脏表现，<14>焦虑</14>和SPECT异常的应用。 <7>威尔逊氏病</7> 是一种常染色体隐性遗传病，肝部<25>铜</25>代谢异常，导致<26>铜</26>在许多组织中大量积聚，引起<16>毒性</16>，并导致<17>肝脏、神经和精神障碍</17>。我们报告了一例<8>威尔逊氏病</8>合并<18>慢性肝病</18>的患者；此外，在我们的患者中，还表现出高水平的情感<15>焦虑</15>，但没有<19>抑郁</19>，99mTc-ECD-SPECT显示额叶皮质低灌注，左额叶更明显。在我们的患者的后续随访期间，<1>青霉胺</1>因出现<5>苔藓样皮炎</5>而被停止使用，<22>醋酸锌</22>使得患者的成功治疗得以继续且没有副作用。在我们的病例中，<23>醋酸锌</23>疗法代表了对出现<2>青霉胺</2>相关副作用的<9>威尔逊氏病</9>患者的有效治疗。使用<24>醋酸锌</24>的安全性使我们避免使用其他可能具有毒性的螯合药物。这一观察结果符合越来越多关于该药物在<10>威尔逊氏病</10>治疗中疗效的证据。由于大多数<11>威尔逊氏病</11> <3>青霉胺</3>治疗的患者似乎没有出现这种<20>皮肤损伤</20>，可以想象特定的遗传因素参与了药物的反应。需要进一步研究特异的<13>威尔逊氏病</13>表型的特定疗法，以更好地阐明<12>威尔逊氏病</12>的治疗。", "revised": true}
{"doc_key": "17223814", "sentences": [["Peri", "-", "operative", "atrioventricular", "block", "as", "a", "result", "of", "chemotherapy", "with", "epirubicin", "and", "paclitaxel", ".", "A", "47", "-", "year", "-", "old", "woman", "presented", "for", "mastectomy", "and", "immediate", "latissimus", "dorsi", "flap", "reconstruction", "having", "been", "diagnosed", "with", "carcinoma", "of", "the", "breast", "6", "months", "previously", ".", "In", "the", "preceding", "months", "she", "had", "received", "neo", "-", "adjuvant", "chemotherapy", "with", "epirubicin", ",", "paclitaxel", "(", "Taxol", ")", "and", "cyclophosphamide", ".", "This", "had", "been", "apparently", "uncomplicated", "and", "she", "had", "maintained", "a", "remarkably", "high", "level", "of", "physical", "activity", ".", "She", "was", "found", "to", "be", "bradycardic", "at", "pre", "-", "operative", "assessment", "but", "had", "no", "cardiac", "symptoms", ".", "Second", "degree", "Mobitz", "type", "II", "atrioventricular", "block", "was", "diagnosed", "on", "electrocardiogram", ",", "and", "temporary", "transvenous", "ventricular", "pacing", "instituted", "in", "the", "peri", "-", "operative", "period", ".", "We", "discuss", "how", "evidence", "-", "based", "guidelines", "would", "not", "have", "been", "helpful", "in", "this", "case", ",", "and", "how", "chemotherapy", "can", "exhibit", "substantial", "cardiotoxicity", "that", "may", "develop", "over", "many", "years", ".", "We", "suggest", "that", "patients", "who", "have", "received", "chemotherapy", "at", "any", "time", "should", "have", "a", "pre", "-", "operative", "electrocardiogram", "even", "if", "they", "are", "asymptomatic", "."]], "ner": [[[11, 11, "Chemical"], [55, 55, "Chemical"], [3, 4, "Disease"], [103, 104, "Disease"], [13, 13, "Chemical"], [57, 57, "Chemical"], [59, 59, "Chemical"], [62, 62, "Chemical"], [35, 38, "Disease"], [86, 86, "Disease"], [145, 145, "Disease"]]], "relations": [[[11, 11, 3, 4, "CID"], [11, 11, 103, 104, "CID"], [55, 55, 3, 4, "CID"], [55, 55, 103, 104, "CID"], [13, 13, 3, 4, "CID"], [13, 13, 103, 104, "CID"], [57, 57, 3, 4, "CID"], [57, 57, 103, 104, "CID"], [59, 59, 3, 4, "CID"], [59, 59, 103, 104, "CID"], [62, 62, 3, 4, "CID"], [62, 62, 103, 104, "CID"]]], "clusters": [], "translated": "围手术期<2>房室传导阻滞</2>是由于化疗药 <0>表柔比星</0> 和<4>紫杉醇</4> 导致的。一名 47 岁的女性在 6 个月前被诊断出患有<8>乳腺癌</8>并接受了乳房切除术和即刻背阔肌皮瓣重建术。在之前的几个月里，她接受了新辅助化疗，包括<1>表柔比星</1>、<5>紫杉醇</5>（<6>Taxol</6>）和<7>环磷酰胺</7>。这显然并不复杂，而且她一直保持着非常高水平的身体活动。术前评估发现她<9>心动过缓</9>，但没有心脏症状。心电图确诊二度MobitzⅡ型<3>房室传导阻滞</3>，围手术期行临时经静脉心室起搏。我们讨论了基于证据的指南如何在这种情况下没有帮助，以及化学疗法如何表现出可能会在多年内发展的显着<10>心脏毒性</10>。我们建议无论何时接受过化疗的患者，即使无症状，也应进行术前心电图检查。", "revised": true}
{"doc_key": "17151160", "sentences": [["Randomized", "comparison", "of", "olanzapine", "versus", "risperidone", "for", "the", "treatment", "of", "first", "-", "episode", "schizophrenia", ":", "4", "-", "month", "outcomes", ".", "OBJECTIVE", ":", "The", "authors", "compared", "4", "-", "month", "treatment", "outcomes", "for", "olanzapine", "versus", "risperidone", "in", "patients", "with", "first", "-", "episode", "schizophrenia", "spectrum", "disorders", ".", "METHOD", ":", "One", "hundred", "twelve", "subjects", "(", "70", "%", "male", ";", "mean", "age", "=", "23", ".", "3", "years", "[", "SD", "=", "5", ".", "1", "]", ")", "with", "first", "-", "episode", "schizophrenia", "(", "75", "%", ")", ",", "schizophreniform", "disorder", "(", "17", "%", ")", ",", "or", "schizoaffective", "disorder", "(", "8", "%", ")", "were", "randomly", "assigned", "to", "treatment", "with", "olanzapine", "(", "2", ".", "5", "-", "20", "mg", "/", "day", ")", "or", "risperidone", "(", "1", "-", "6", "mg", "/", "day", ")", ".", "RESULTS", ":", "Response", "rates", "did", "not", "significantly", "differ", "between", "olanzapine", "(", "43", ".", "7", "%", ",", "95", "%", "CI", "=", "28", ".", "8", "%", "-", "58", ".", "6", "%", ")", "and", "risperidone", "(", "54", ".", "3", "%", ",", "95", "%", "CI", "=", "39", ".", "9", "%", "-", "68", ".", "7", "%", ")", ".", "Among", "those", "responding", "to", "treatment", ",", "more", "subjects", "in", "the", "olanzapine", "group", "(", "40", ".", "9", "%", ",", "95", "%", "CI", "=", "16", ".", "8", "%", "-", "65", ".", "0", "%", ")", "than", "in", "the", "risperidone", "group", "(", "18", ".", "9", "%", ",", "95", "%", "CI", "=", "0", "%", "-", "39", ".", "2", "%", ")", "had", "subsequent", "ratings", "not", "meeting", "response", "criteria", ".", "Negative", "symptom", "outcomes", "and", "measures", "of", "parkinsonism", "and", "akathisia", "did", "not", "differ", "between", "medications", ".", "Extrapyramidal", "symptom", "severity", "scores", "were", "1", ".", "4", "(", "95", "%", "CI", "=", "1", ".", "2", "-", "1", ".", "6", ")", "with", "risperidone", "and", "1", ".", "2", "(", "95", "%", "CI", "=", "1", ".", "0", "-", "1", ".", "4", ")", "with", "olanzapine", ".", "Significantly", "more", "weight", "gain", "occurred", "with", "olanzapine", "than", "with", "risperidone", ":", "the", "increase", "in", "weight", "at", "4", "months", "relative", "to", "baseline", "weight", "was", "17", ".", "3", "%", "(", "95", "%", "CI", "=", "14", ".", "2", "%", "-", "20", ".", "5", "%", ")", "with", "olanzapine", "and", "11", ".", "3", "%", "(", "95", "%", "CI", "=", "8", ".", "4", "%", "-", "14", ".", "3", "%", ")", "with", "risperidone", ".", "Body", "mass", "index", "at", "baseline", "and", "at", "4", "months", "was", "24", ".", "3", "(", "95", "%", "CI", "=", "22", ".", "8", "-", "25", ".", "7", ")", "versus", "28", ".", "2", "(", "95", "%", "CI", "=", "26", ".", "7", "-", "29", ".", "7", ")", "with", "olanzapine", "and", "23", ".", "9", "(", "95", "%", "CI", "=", "22", ".", "5", "-", "25", ".", "3", ")", "versus", "26", ".", "7", "(", "95", "%", "CI", "=", "25", ".", "2", "-", "28", ".", "2", ")", "with", "risperidone", ".", "CONCLUSIONS", ":", "Clinical", "outcomes", "with", "risperidone", "were", "equal", "to", "those", "with", "olanzapine", ",", "and", "response", "may", "be", "more", "stable", ".", "Olanzapine", "may", "have", "an", "advantage", "for", "motor", "side", "effects", ".", "Both", "medications", "caused", "substantial", "rapid", "weight", "gain", ",", "but", "weight", "gain", "was", "greater", "with", "olanzapine", "."]], "ner": [[[3, 3, "Chemical"], [31, 31, "Chemical"], [100, 100, "Chemical"], [131, 131, "Chemical"], [185, 185, "Chemical"], [294, 294, "Chemical"], [302, 302, "Chemical"], [339, 339, "Chemical"], [407, 407, "Chemical"], [456, 456, "Chemical"], [465, 465, "Chemical"], [489, 489, "Chemical"], [253, 254, "Disease"], [298, 299, "Disease"], [480, 481, "Disease"], [484, 485, "Disease"], [5, 5, "Chemical"], [33, 33, "Chemical"], [112, 112, "Chemical"], [153, 153, "Chemical"], [210, 210, "Chemical"], [275, 275, "Chemical"], [305, 305, "Chemical"], [361, 361, "Chemical"], [443, 443, "Chemical"], [450, 450, "Chemical"], [13, 13, "Disease"], [40, 40, "Disease"], [74, 74, "Disease"], [80, 81, "Disease"], [88, 89, "Disease"], [244, 244, "Disease"], [246, 246, "Disease"]]], "relations": [[[3, 3, 253, 254, "CID"], [31, 31, 253, 254, "CID"], [100, 100, 253, 254, "CID"], [131, 131, 253, 254, "CID"], [185, 185, 253, 254, "CID"], [294, 294, 253, 254, "CID"], [302, 302, 253, 254, "CID"], [339, 339, 253, 254, "CID"], [407, 407, 253, 254, "CID"], [456, 456, 253, 254, "CID"], [465, 465, 253, 254, "CID"], [489, 489, 253, 254, "CID"], [3, 3, 298, 299, "CID"], [3, 3, 480, 481, "CID"], [3, 3, 484, 485, "CID"], [31, 31, 298, 299, "CID"], [31, 31, 480, 481, "CID"], [31, 31, 484, 485, "CID"], [100, 100, 298, 299, "CID"], [100, 100, 480, 481, "CID"], [100, 100, 484, 485, "CID"], [131, 131, 298, 299, "CID"], [131, 131, 480, 481, "CID"], [131, 131, 484, 485, "CID"], [185, 185, 298, 299, "CID"], [185, 185, 480, 481, "CID"], [185, 185, 484, 485, "CID"], [294, 294, 298, 299, "CID"], [294, 294, 480, 481, "CID"], [294, 294, 484, 485, "CID"], [302, 302, 298, 299, "CID"], [302, 302, 480, 481, "CID"], [302, 302, 484, 485, "CID"], [339, 339, 298, 299, "CID"], [339, 339, 480, 481, "CID"], [339, 339, 484, 485, "CID"], [407, 407, 298, 299, "CID"], [407, 407, 480, 481, "CID"], [407, 407, 484, 485, "CID"], [456, 456, 298, 299, "CID"], [456, 456, 480, 481, "CID"], [456, 456, 484, 485, "CID"], [465, 465, 298, 299, "CID"], [465, 465, 480, 481, "CID"], [465, 465, 484, 485, "CID"], [489, 489, 298, 299, "CID"], [489, 489, 480, 481, "CID"], [489, 489, 484, 485, "CID"], [5, 5, 253, 254, "CID"], [33, 33, 253, 254, "CID"], [112, 112, 253, 254, "CID"], [153, 153, 253, 254, "CID"], [210, 210, 253, 254, "CID"], [275, 275, 253, 254, "CID"], [305, 305, 253, 254, "CID"], [361, 361, 253, 254, "CID"], [443, 443, 253, 254, "CID"], [450, 450, 253, 254, "CID"], [5, 5, 298, 299, "CID"], [5, 5, 480, 481, "CID"], [5, 5, 484, 485, "CID"], [33, 33, 298, 299, "CID"], [33, 33, 480, 481, "CID"], [33, 33, 484, 485, "CID"], [112, 112, 298, 299, "CID"], [112, 112, 480, 481, "CID"], [112, 112, 484, 485, "CID"], [153, 153, 298, 299, "CID"], [153, 153, 480, 481, "CID"], [153, 153, 484, 485, "CID"], [210, 210, 298, 299, "CID"], [210, 210, 480, 481, "CID"], [210, 210, 484, 485, "CID"], [275, 275, 298, 299, "CID"], [275, 275, 480, 481, "CID"], [275, 275, 484, 485, "CID"], [305, 305, 298, 299, "CID"], [305, 305, 480, 481, "CID"], [305, 305, 484, 485, "CID"], [361, 361, 298, 299, "CID"], [361, 361, 480, 481, "CID"], [361, 361, 484, 485, "CID"], [443, 443, 298, 299, "CID"], [443, 443, 480, 481, "CID"], [443, 443, 484, 485, "CID"], [450, 450, 298, 299, "CID"], [450, 450, 480, 481, "CID"], [450, 450, 484, 485, "CID"]]], "clusters": [], "translated": "<0>奥氮平</0>与<16>利培酮</16>治疗首发<26>精神分裂症</26>的随机比较：4个月的结果。目的：作者比较了<1>奥氮平</1>与<17>利培酮</17>在首发<27>精神分裂症</27>谱系障碍患者中的4个月治疗结果。方法：112名受试者（70%为男性；平均年龄=23.3岁[SD=5.1]）患有首发<28>精神分裂症</28>（75%），<29>精神分裂症样障碍</29>（17%）或<30>分裂情感障碍</30>（8%）被随机分配接受<2>奥氮平</2>（2.5-20毫克/天）或<18>利培酮</18>（1-6毫克/天）治疗。结果：<3>奥氮平</3>（43.7%，95% CI=28.8%-58.6%）和<19>利培酮</19>（54.3%，95% CI=39.9%-68.7%）。在那些对治疗有反应的人中，<4>奥氮平</4>组（40.9%，95% CI=16.8%-65.0%）比<20>利培酮</20>组有更多的受试者组（18.9%，95% CI=0%-39.2%）的后续评级不符合响应标准。<31>帕金森症</31>和<32>静坐不能</32>的阴性症状结果和测量值在不同药物之间没有差异。<12>锥体外系症状</12>严重程度评分为1.4（95% CI=1.2-1.6）与<21>利培酮</21>和1.2（95% CI=1.0-1.4）与<5>奥氮平</5>。<6>奥氮平</6>组<13>体重增加</13>明显多于<22>利培酮</22>组：4个月时体重相对于基线体重增加17.3%（95% CI=14.2%-20.5%）与<7>奥氮平</7>和11.3%（95% CI=8.4%-14.3%）与<23>利培酮</23>。基线和4个月时的体重指数为24.3（95% CI=22.8-25.7）对比28.2（95% CI=26.7-29.7）与<8>奥氮平</8>和23.9（95% CI=22.5-25.3）对比26.7（95% CI=25.2-28.2）与<24>利培酮</24>。结论：<25>利培酮</25>的临床结果与<9>奥氮平</9>的临床结果相同，反应可能更稳定。<10>奥氮平</10>可能对运动副作用有优势。两种药物均导致<14>体重快速增加</14>，但<15>体重增加</15>在<11>奥氮平</11>时更显着。", "revised": true}
{"doc_key": "17879100", "sentences": [["Non", "-", "steroidal", "anti", "-", "inflammatory", "drugs", "-", "associated", "acute", "interstitial", "nephritis", "with", "granular", "tubular", "basement", "membrane", "deposits", ".", "Acute", "tubulo", "-", "interstitial", "nephritis", "(", "ATIN", ")", "is", "an", "important", "cause", "of", "acute", "renal", "failure", "resulting", "from", "a", "variety", "of", "insults", ",", "including", "immune", "complex", "-", "mediated", "tubulo", "-", "interstitial", "injury", ",", "but", "drugs", "such", "as", "non", "-", "steroidal", "anti", "-", "inflammatory", "drugs", "(", "NSAIDs", ")", "are", "a", "far", "more", "frequent", "cause", ".", "Overall", ",", "as", "an", "entity", ",", "ATIN", "remains", "under", "-", "diagnosed", ",", "as", "symptoms", "resolve", "spontaneously", "if", "the", "medication", "is", "stopped", ".", "We", "report", "on", "a", "14", "-", "year", "-", "old", "boy", "who", "developed", "acute", "renal", "failure", "2", "weeks", "after", "aortic", "valve", "surgery", ".", "He", "was", "put", "on", "aspirin", "following", "surgery", "and", "took", "ibuprofen", "for", "fever", "for", "nearly", "a", "week", "prior", "to", "presentation", ".", "He", "then", "presented", "to", "the", "emergency", "department", "feeling", "quite", "ill", "and", "was", "found", "to", "have", "a", "blood", "urea", "nitrogen", "(", "BUN", ")", "concentration", "of", "of", "147", "mg", "/", "dl", ",", "creatinine", "of", "15", ".", "3", "mg", "/", "dl", "and", "serum", "potassium", "of", "8", ".", "7", "mEq", "/", "l", ".", "Dialysis", "was", "immediately", "initiated", ".", "A", "kidney", "biopsy", "showed", "inflammatory", "infiltrate", "consistent", "with", "ATIN", ".", "However", ",", "in", "the", "tubular", "basement", "membrane", "(", "TBM", ")", ",", "very", "intense", "granular", "deposits", "of", "polyclonal", "IgG", "and", "C3", "were", "noted", ".", "He", "needed", "dialysis", "for", "2", "weeks", "and", "was", "treated", "successfully", "with", "steroids", "for", "6", "months", ".", "His", "renal", "recovery", "and", "disappearance", "of", "proteinuria", "took", "a", "year", ".", "In", "conclusion", ",", "this", "is", "a", "first", "report", "of", "NSAIDs", "-", "associated", "ATIN", ",", "showing", "deposits", "of", "granular", "immune", "complex", "present", "only", "in", "the", "TBM", "and", "not", "in", "the", "glomeruli", "."]], "ner": [[[126, 126, "Chemical"], [10, 11, "Disease"], [47, 50, "Disease"], [32, 34, "Disease"], [107, 109, "Disease"], [121, 121, "Chemical"], [153, 155, "Chemical"], [157, 157, "Chemical"], [167, 167, "Chemical"], [177, 177, "Chemical"], [235, 235, "Chemical"], [19, 23, "Disease"], [25, 25, "Disease"], [79, 79, "Disease"], [199, 199, "Disease"], [263, 263, "Disease"], [128, 128, "Disease"], [246, 246, "Disease"]]], "relations": [[[126, 126, 10, 11, "CID"], [126, 126, 47, 50, "CID"], [126, 126, 32, 34, "CID"], [126, 126, 107, 109, "CID"]]], "clusters": [], "translated": "非甾体抗炎药相关的急性<1>间质性肾炎</1>伴颗粒状肾小管基底膜沉积。<11>急性肾小管-间质性肾炎</11> (<12>ATIN</12>) 是<3>急性肾功能衰竭</3>的重要原因，由多种损伤引起，包括免疫复合物介导的<2>肾小管间质损伤</2>，但非甾体抗炎药(NSAIDs)等药物是更常见的原因。总体而言，<13>ATIN</13>仍未得到充分诊断，因为如果停药，症状会自发消退。我们报告了一名14岁男孩在主动脉瓣手术后2周<4>急性肾功能衰竭</4>。他在手术后接受了<5>阿司匹林</5>治疗，并在就诊前服用<0>布洛芬</0>治疗<16>发烧</16>近一周。然后他到急诊科就诊，感觉很不舒服，被发现有<6>血尿素氮</6> (<7>BUN</7>)浓度为147 mg/dl，<8>肌酐</8>共15.3 mg/dl和血清<9>钾</9>的8.7毫当量/升。立即开始透析。肾活检显示炎症浸润符合<14>ATIN</14>。然而，在管状基底膜(TBM)中，注意到多克隆IgG和C3的非常强烈的颗粒沉积。他需要透析2周，并用<10>类固醇</10>成功治疗了6个月。他的肾脏恢复和<17>蛋白尿</17>的消失用了一年时间。总之，这是NSAIDs相关的<15>ATIN</15>的第一份报告，显示颗粒免疫复合物沉积物仅存在于TBM中，而不存在于肾小球中。", "revised": true}
{"doc_key": "18025637", "sentences": [["Branch", "retinal", "vein", "occlusion", "and", "fluoxetine", ".", "A", "case", "of", "branch", "retinal", "vein", "occlusion", "associated", "with", "fluoxetine", "-", "induced", "secondary", "hypertension", "is", "described", ".", "Although", "an", "infrequent", "complication", "of", "selective", "serotonin", "reuptake", "inhibitor", "therapy", ",", "it", "is", "important", "that", "ophthalmologists", "are", "aware", "that", "these", "agents", "can", "cause", "hypertension", "because", "this", "class", "of", "drugs", "is", "widely", "prescribed", "."]], "ner": [[[5, 5, "Chemical"], [16, 16, "Chemical"], [1, 3, "Disease"], [11, 13, "Disease"], [20, 20, "Disease"], [47, 47, "Disease"], [30, 30, "Chemical"]]], "relations": [[[5, 5, 1, 3, "CID"], [5, 5, 11, 13, "CID"], [16, 16, 1, 3, "CID"], [16, 16, 11, 13, "CID"], [5, 5, 20, 20, "CID"], [5, 5, 47, 47, "CID"], [16, 16, 20, 20, "CID"], [16, 16, 47, 47, "CID"]]], "clusters": [], "translated": "分支<2>视网膜静脉阻塞</2>和<0>氟西汀</0>。描述了<3>视网膜分支静脉阻塞</3>病例，伴随<1>氟西汀</1>诱发的二<4>级高血压</4>。虽然选择性再<6>摄取</6>抑制剂治疗的并发症很少见，但重要的是眼科医生要意识到这些药物可引起<5>高血压</5>，因为这类药物被广泛使用。", "revised": true}
{"doc_key": "17572393", "sentences": [["Neuroprotective", "effects", "of", "melatonin", "upon", "the", "offspring", "cerebellar", "cortex", "in", "the", "rat", "model", "of", "BCNU", "-", "induced", "cortical", "dysplasia", ".", "Cortical", "dysplasia", "is", "a", "malformation", "characterized", "by", "defects", "in", "proliferation", ",", "migration", "and", "maturation", ".", "This", "study", "was", "designed", "to", "evaluate", "the", "alterations", "in", "offspring", "rat", "cerebellum", "induced", "by", "maternal", "exposure", "to", "carmustine", "-", "[", "1", ",", "3", "-", "bis", "(", "2", "-", "chloroethyl", ")", "-", "1", "-", "nitrosoure", "]", "(", "BCNU", ")", "and", "to", "investigate", "the", "effects", "of", "exogenous", "melatonin", "upon", "cerebellar", "BCNU", "-", "induced", "cortical", "dysplasia", ",", "using", "histological", "and", "biochemical", "analyses", ".", "Pregnant", "Wistar", "rats", "were", "assigned", "to", "five", "groups", ":", "intact", "-", "control", ",", "saline", "-", "control", ",", "melatonin", "-", "treated", ",", "BCNU", "-", "exposed", "and", "BCNU", "-", "exposed", "plus", "melatonin", ".", "Rats", "were", "exposed", "to", "BCNU", "on", "embryonic", "day", "15", "and", "melatonin", "was", "given", "until", "delivery", ".", "Immuno", "/", "histochemistry", "and", "electron", "microscopy", "were", "carried", "out", "on", "the", "offspring", "cerebellum", ",", "and", "levels", "of", "malondialdehyde", "and", "superoxide", "dismutase", "were", "determined", ".", "Histopathologically", ",", "typical", "findings", "were", "observed", "in", "the", "cerebella", "from", "the", "control", "groups", ",", "but", "the", "findings", "consistent", "with", "early", "embryonic", "development", "were", "noted", "in", "BCNU", "-", "exposed", "cortical", "dysplasia", "group", ".", "There", "was", "a", "marked", "increase", "in", "the", "number", "of", "TUNEL", "positive", "cells", "and", "nestin", "positive", "cells", "in", "BCNU", "-", "exposed", "group", ",", "but", "a", "decreased", "immunoreactivity", "to", "glial", "fibrillary", "acidic", "protein", ",", "synaptophysin", "and", "transforming", "growth", "factor", "beta1", "was", "observed", ",", "indicating", "a", "delayed", "maturation", ",", "and", "melatonin", "significantly", "reversed", "these", "changes", ".", "Malondialdehyde", "level", "in", "BCNU", "-", "exposed", "group", "was", "higher", "than", "those", "in", "control", "groups", "and", "melatonin", "decreased", "malondialdehyde", "levels", "in", "BCNU", "group", "(", "P", "<", "0", ".", "01", ")", ",", "while", "there", "were", "no", "significant", "differences", "in", "the", "superoxide", "dismutase", "levels", "between", "these", "groups", ".", "These", "data", "suggest", "that", "exposure", "of", "animals", "to", "BCNU", "during", "pregnancy", "leads", "to", "delayed", "maturation", "of", "offspring", "cerebellum", "and", "melatonin", "protects", "the", "cerebellum", "against", "the", "effects", "of", "BCNU", "."]], "ner": [[[14, 14, "Chemical"], [52, 52, "Chemical"], [55, 68, "Chemical"], [71, 71, "Chemical"], [83, 83, "Chemical"], [116, 116, "Chemical"], [120, 120, "Chemical"], [130, 130, "Chemical"], [191, 191, "Chemical"], [215, 215, "Chemical"], [254, 254, "Chemical"], [271, 271, "Chemical"], [304, 304, "Chemical"], [323, 323, "Chemical"], [17, 18, "Disease"], [20, 21, "Disease"], [86, 87, "Disease"], [194, 195, "Disease"], [3, 3, "Chemical"], [80, 80, "Chemical"], [112, 112, "Chemical"], [124, 124, "Chemical"], [136, 136, "Chemical"], [245, 245, "Chemical"], [266, 266, "Chemical"], [315, 315, "Chemical"], [159, 159, "Chemical"], [251, 251, "Chemical"], [268, 268, "Chemical"], [161, 161, "Chemical"], [289, 289, "Chemical"]]], "relations": [[[14, 14, 17, 18, "CID"], [14, 14, 20, 21, "CID"], [14, 14, 86, 87, "CID"], [14, 14, 194, 195, "CID"], [52, 52, 17, 18, "CID"], [52, 52, 20, 21, "CID"], [52, 52, 86, 87, "CID"], [52, 52, 194, 195, "CID"], [55, 68, 17, 18, "CID"], [55, 68, 20, 21, "CID"], [55, 68, 86, 87, "CID"], [55, 68, 194, 195, "CID"], [71, 71, 17, 18, "CID"], [71, 71, 20, 21, "CID"], [71, 71, 86, 87, "CID"], [71, 71, 194, 195, "CID"], [83, 83, 17, 18, "CID"], [83, 83, 20, 21, "CID"], [83, 83, 86, 87, "CID"], [83, 83, 194, 195, "CID"], [116, 116, 17, 18, "CID"], [116, 116, 20, 21, "CID"], [116, 116, 86, 87, "CID"], [116, 116, 194, 195, "CID"], [120, 120, 17, 18, "CID"], [120, 120, 20, 21, "CID"], [120, 120, 86, 87, "CID"], [120, 120, 194, 195, "CID"], [130, 130, 17, 18, "CID"], [130, 130, 20, 21, "CID"], [130, 130, 86, 87, "CID"], [130, 130, 194, 195, "CID"], [191, 191, 17, 18, "CID"], [191, 191, 20, 21, "CID"], [191, 191, 86, 87, "CID"], [191, 191, 194, 195, "CID"], [215, 215, 17, 18, "CID"], [215, 215, 20, 21, "CID"], [215, 215, 86, 87, "CID"], [215, 215, 194, 195, "CID"], [254, 254, 17, 18, "CID"], [254, 254, 20, 21, "CID"], [254, 254, 86, 87, "CID"], [254, 254, 194, 195, "CID"], [271, 271, 17, 18, "CID"], [271, 271, 20, 21, "CID"], [271, 271, 86, 87, "CID"], [271, 271, 194, 195, "CID"], [304, 304, 17, 18, "CID"], [304, 304, 20, 21, "CID"], [304, 304, 86, 87, "CID"], [304, 304, 194, 195, "CID"], [323, 323, 17, 18, "CID"], [323, 323, 20, 21, "CID"], [323, 323, 86, 87, "CID"], [323, 323, 194, 195, "CID"]]], "clusters": [], "translated": "<18>褪黑激素</18>对<0>BCNU</0>诱导的<14>皮质发育不良</14>大鼠后代小脑皮质的神经保护作用。 <15>皮质发育不良</15>是一种以增殖、迁移和成熟缺陷为特征的畸形。本研究旨在评估母体暴露于<1>卡莫司汀</1>- [<2>1,3-双(2-氯乙基)-1-亚硝基脲</2>] (<3>BCNU</3>) 并通过组织学和生化研究外源性<19>褪黑激素</19>对小脑<4>BCNU</4>诱导的<16>皮质发育不良</16>的影响分析。怀孕的Wistar大鼠被分为五组：完整对照、盐水对照、<20>褪黑激素</20>-处理、<5>BCNU</5>-暴露和<6>BCNU</6>-暴露加<21>褪黑激素</21>。大鼠在胚胎第15天接触<7>BCNU</7>，并给予<22>褪黑激素</22>直至分娩。对子代小脑进行免疫/组织化学和电子显微镜检查，测定<26>丙二醛</26>和<29>超氧化物</29>歧化酶水平。组织病理学上，对照组小脑有典型表现，<8>BCNU</8>暴露<17>皮质发育不良</17>组表现出与早期胚胎发育一致的表现。<9>BCNU</9>暴露组TUNEL阳性细胞和巢蛋白阳性细胞明显增多，但对胶质纤维酸性蛋白、突触蛋白和转化生长因子beta1的免疫反应性降低，表明延迟成熟和<23>褪黑激素</23>显着逆转了这些变化。<10>BCNU</10>暴露组<27>丙二醛</27>水平高于对照组，<24>褪黑激素</24>降低<28>丙二醛</28>水平的作用仅在<11>BCNU</11>组显著(P < 0.01)，而各组<30>超氧化物</30>歧化酶水平无显著差异。这些数据表明，动物在怀孕期间接触<12>BCNU</12>会导致后代小脑成熟延迟，而<25>褪黑激素</25>会保护小脑免受<13>BCNU</13>的影响。", "revised": true}
{"doc_key": "17496739", "sentences": [["Piperacillin", "/", "tazobactam", "-", "induced", "seizure", "rapidly", "reversed", "by", "high", "flux", "hemodialysis", "in", "a", "patient", "on", "peritoneal", "dialysis", ".", "Despite", "popular", "use", "of", "piperacillin", ",", "the", "dire", "neurotoxicity", "associated", "with", "piperacillin", "still", "goes", "unrecognized", ",", "leading", "to", "a", "delay", "in", "appropriate", "management", ".", "We", "report", "a", "57", "-", "year", "-", "old", "woman", "with", "end", "-", "stage", "renal", "disease", "receiving", "continuous", "ambulatory", "peritoneal", "dialysis", "(", "CAPD", ")", ",", "who", "developed", "slurred", "speech", ",", "tremor", ",", "bizarre", "behavior", ",", "progressive", "mental", "confusion", ",", "and", "2", "episodes", "of", "generalized", "tonic", "-", "clonic", "seizure", "(", "GTCS", ")", "after", "5", "doses", "of", "piperacillin", "/", "tazobactam", "(", "2", "g", "/", "250", "mg", ")", "were", "given", "for", "bronchiectasis", "with", "secondary", "infection", ".", "The", "laboratory", "data", "revealed", "normal", "plasma", "electrolyte", "and", "ammonia", "levels", "but", "leukocytosis", ".", "Neurologic", "examinations", "showed", "dysarthria", "and", "bilateral", "Babinski", "sign", ".", "Computed", "tomography", "of", "brain", "and", "electroencephalogram", "were", "unremarkable", ".", "Despite", "the", "use", "of", "antiepileptic", "agents", ",", "another", "GTCS", "episode", "recurred", "after", "the", "sixth", "dose", "of", "piperacillin", "/", "tazobactam", ".", "Brain", "magnetic", "resonance", "imaging", "did", "not", "demonstrate", "acute", "infarction", "and", "organic", "brain", "lesions", ".", "Initiation", "of", "high", "-", "flux", "hemodialysis", "rapidly", "reversed", "the", "neurologic", "symptoms", "within", "4", "hours", ".", "Piperacillin", "-", "induced", "encephalopathy", "should", "be", "considered", "in", "any", "uremic", "patients", "with", "unexplained", "neurological", "manifestations", ".", "CAPD", "is", "inefficient", "in", "removing", "piperacillin", ",", "whereas", "hemodialysis", "can", "rapidly", "terminate", "the", "piperacillin", "-", "induced", "encephalopathy", "."]], "ner": [[[0, 2, "Chemical"], [97, 99, "Chemical"], [162, 164, "Chemical"], [72, 72, "Disease"], [79, 79, "Disease"], [86, 89, "Disease"], [91, 91, "Disease"], [154, 154, "Disease"], [5, 5, "Disease"], [27, 27, "Disease"], [53, 57, "Disease"], [110, 110, "Disease"], [112, 113, "Disease"], [126, 126, "Disease"], [131, 131, "Disease"], [174, 174, "Disease"], [198, 198, "Disease"], [227, 227, "Disease"], [204, 204, "Disease"], [23, 23, "Chemical"], [30, 30, "Chemical"], [195, 195, "Chemical"], [216, 216, "Chemical"], [224, 224, "Chemical"], [123, 123, "Chemical"]]], "relations": [[[0, 2, 72, 72, "CID"], [97, 99, 72, 72, "CID"], [162, 164, 72, 72, "CID"], [0, 2, 79, 79, "CID"], [97, 99, 79, 79, "CID"], [162, 164, 79, 79, "CID"], [0, 2, 86, 89, "CID"], [0, 2, 91, 91, "CID"], [0, 2, 154, 154, "CID"], [97, 99, 86, 89, "CID"], [97, 99, 91, 91, "CID"], [97, 99, 154, 154, "CID"], [162, 164, 86, 89, "CID"], [162, 164, 91, 91, "CID"], [162, 164, 154, 154, "CID"]]], "clusters": [], "translated": "<0>哌拉西林/他唑巴坦</0>诱导的<8>癫痫发作</8>在腹膜透析患者中被高通量血液透析迅速逆转。尽管<19>哌拉西林</19>的广泛使用，与<20>哌拉西林</20>相关的可怕的<9>神经毒性</9>仍然未被认识，导致适当管理的延误。我们报告了一位患有<10>终末期肾病</10>的57岁女性，她接受持续性非卧床腹膜透析(CAPD)，出现言语不清，<3>震颤</3>，行为怪异，进行性智力障碍<4>意识模糊</4>和2次全身性<5>强直阵挛发作</5>(<6>GTCS</6>)在5剂<1>哌拉西林/他唑巴坦</1>后(2 g/250 mg)用于<11>支气管扩张</11>伴<12>继发感染</12>。实验室数据显示血浆电解质和<24>氨</24>水平正常，但<13>白细胞增多</13>。神经系统检查显示<14>构音障碍</14>和双侧Babinski征。脑部计算机断层扫描和脑电图无异常。尽管使用了抗癫痫药，但在第6剂<2>哌拉西林/他唑巴坦</2>后，又一次<7>GTCS</7>发作复发。脑磁共振成像未显示急性<15>梗塞</15>和器质性脑病变。高通量血液透析的启动在4小时内迅速逆转了神经系统症状。<21>哌拉西林</21>诱导的<16>脑病</16>应考虑到任何<18>尿毒症</18>患者出现不明原因的神经系统表现。CAPD不能有效清除<22>哌拉西林</22>，而血液透析可以迅速终止<23>哌拉西林</23>引起的<17>脑病</17>。", "revised": true}
{"doc_key": "17828434", "sentences": [["Myo", "-", "inositol", "-", "1", "-", "phosphate", "(", "MIP", ")", "synthase", "inhibition", ":", "in", "-", "vivo", "study", "in", "rats", ".", "Lithium", "and", "valproate", "are", "the", "prototypic", "mood", "stabilizers", "and", "have", "diverse", "structures", "and", "targets", ".", "Both", "drugs", "influence", "inositol", "metabolism", ".", "Lithium", "inhibits", "IMPase", "and", "valproate", "inhibits", "MIP", "synthase", ".", "This", "study", "shows", "that", "MIP", "synthase", "inhibition", "does", "not", "replicate", "or", "augment", "the", "effects", "of", "lithium", "in", "the", "inositol", "sensitive", "pilocarpine", "-", "induced", "seizures", "model", ".", "This", "lack", "of", "effects", "may", "stem", "from", "the", "low", "contribution", "of", "de", "-", "novo", "synthesis", "to", "cellular", "inositol", "supply", "or", "to", "the", "inhibition", "of", "the", "de", "-", "novo", "synthesis", "by", "lithium", "itself", "."]], "ner": [[[70, 70, "Chemical"], [73, 73, "Disease"], [0, 6, "Chemical"], [8, 8, "Chemical"], [47, 47, "Chemical"], [54, 54, "Chemical"], [20, 20, "Chemical"], [41, 41, "Chemical"], [65, 65, "Chemical"], [106, 106, "Chemical"], [22, 22, "Chemical"], [45, 45, "Chemical"], [38, 38, "Chemical"], [68, 68, "Chemical"], [93, 93, "Chemical"]]], "relations": [[[70, 70, 73, 73, "CID"]]], "clusters": [], "translated": " <2>Myo-inositol-1-phosphate</2>（<3>MIP</3>）合酶抑制：大鼠体内研究。 <6>锂</6>和<10>丙戊酸盐</10>是原型情绪稳定剂，具有多种结构和靶点。这两种药物都会影响<12>肌醇</12>代谢。<7>锂</7>抑制IMPase，<11>丙戊酸盐</11>抑制<4>MIP</4>合酶。该研究表明，<5>MIP</5>合酶抑制不会复制或增强<8>锂</8>在<0>毛果芸香碱</0>诱发的<1>癫痫发作</1>模型中<13>肌醇</13>敏感性的作用。这种影响的缺乏可能源于从头合成对细胞<14>肌醇</14>供应的低贡献或<9>锂</9>本身对从头合成的抑制。", "revised": true}
{"doc_key": "17379047", "sentences": [["Comparison", "of", "valsartan", "/", "hydrochlorothiazide", "combination", "therapy", "at", "doses", "up", "to", "320", "/", "25", "mg", "versus", "monotherapy", ":", "a", "double", "-", "blind", ",", "placebo", "-", "controlled", "study", "followed", "by", "long", "-", "term", "combination", "therapy", "in", "hypertensive", "adults", ".", "BACKGROUND", ":", "One", "third", "of", "patients", "treated", "for", "hypertension", "attain", "adequate", "blood", "pressure", "(", "BP", ")", "control", ",", "and", "multidrug", "regimens", "are", "often", "required", ".", "Given", "the", "lifelong", "nature", "of", "hypertension", ",", "there", "is", "a", "need", "to", "evaluate", "the", "long", "-", "term", "efficacy", "and", "tolerability", "of", "higher", "doses", "of", "combination", "anti", "-", "hypertensive", "therapies", ".", "OBJECTIVE", ":", "This", "study", "investigated", "the", "efficacy", "and", "tolerability", "of", "valsartan", "(", "VAL", ")", "or", "hydrochlorothiazide", "(", "HCTZ", ")", "-", "monotherapy", "and", "higher", "-", "dose", "combinations", "in", "patients", "with", "essential", "hypertension", ".", "METHODS", ":", "The", "first", "part", "of", "this", "study", "was", "an", "8", "-", "week", ",", "multicenter", ",", "randomized", ",", "double", "-", "blind", ",", "placebo", "controlled", ",", "parallel", "-", "group", "trial", ".", "Patients", "with", "essential", "hypertension", "(", "mean", "sitting", "diastolic", "BP", "[", "MSDBP", "]", ",", ">", "or", "=", "95", "mm", "Hg", "and", "<", "110", "mm", "Hg", ")", "were", "randomized", "to", "1", "of", "8", "treatment", "groups", ":", "VAL", "160", "or", "320", "mg", ";", "HCTZ", "12", ".", "5", "or", "25", "mg", ";", "VAL", "/", "HCTZ", "160", "/", "12", ".", "5", ",", "320", "/", "12", ".", "5", ",", "or", "320", "/", "25", "mg", ";", "or", "placebo", ".", "Mean", "changes", "in", "MSDBP", "and", "mean", "sitting", "systolic", "BP", "(", "MSSBP", ")", "were", "analyzed", "at", "the", "8", "-", "week", "core", "study", "end", "point", ".", "VAL", "/", "HCTZ", "320", "/", "12", ".", "5", "and", "320", "/", "25", "mg", "were", "further", "investigated", "in", "a", "54", "-", "week", ",", "open", "-", "label", "extension", ".", "Response", "was", "defined", "as", "MSDBP", "<", "90", "mm", "Hg", "or", "a", ">", "or", "=", "10", "mm", "Hg", "decrease", "compared", "to", "baseline", ".", "Control", "was", "defined", "as", "MSDBP", "<", "90", "mm", "Hg", "compared", "with", "baseline", ".", "Tolerability", "was", "assessed", "by", "monitoring", "adverse", "events", "at", "randomization", "and", "all", "subsequent", "study", "visits", "and", "regular", "evaluation", "of", "hematology", "and", "blood", "chemistry", ".", "RESULTS", ":", "A", "total", "of", "1346", "patients", "were", "randomized", "into", "the", "8", "-", "week", "core", "study", "(", "734", "men", ",", "612", "women", ";", "924", "white", ",", "291", "black", ",", "23", "Asian", ",", "108", "other", ";", "mean", "age", ",", "52", ".", "7", "years", ";", "mean", "weight", ",", "92", ".", "6", "kg", ")", ".", "All", "active", "treatments", "were", "associated", "with", "significantly", "reduced", "MSSBP", "and", "MSDBP", "during", "the", "core", "8", "-", "week", "study", ",", "with", "each", "monotherapy", "significantly", "contributing", "to", "the", "overall", "effect", "of", "combination", "therapy", "(", "VAL", "and", "HCTZ", ",", "P", "<", "0", ".", "001", ")", ".", "Each", "combination", "was", "associated", "with", "significantly", "greater", "reductions", "in", "MSSBP", "and", "MSDBP", "compared", "with", "the", "monotherapies", "and", "placebo", "(", "all", ",", "P", "<", "0", ".", "001", ")", ".", "The", "mean", "reduction", "in", "MSSBP", "/", "MSDBP", "with", "VAL", "/", "HCTZ", "320", "/", "25", "mg", "was", "24", ".", "7", "/", "16", ".", "6", "mm", "Hg", ",", "compared", "with", "5", ".", "9", "/", "7", ".", "0", "mm", "Hg", "with", "placebo", ".", "The", "reduction", "in", "MSSBP", "was", "significantly", "greater", "with", "VAL", "/", "HCTZ", "320", "/", "25", "mg", "compared", "with", "VAL", "/", "HCTZ", "160", "/", "12", ".", "5", "mg", "(", "P", "<", "0", ".", "002", ")", ".", "Rates", "of", "response", "and", "BP", "control", "were", "significantly", "higher", "in", "the", "groups", "that", "received", "combination", "treatment", "compared", "with", "those", "that", "received", "monotherapy", ".", "The", "incidence", "of", "hypokalemia", "was", "lower", "with", "VAL", "/", "HCTZ", "combinations", "(", "1", ".", "8", "%", "-", "6", ".", "1", "%", ")", "than", "with", "HCTZ", "monotherapies", "(", "7", ".", "1", "%", "-", "13", ".", "3", "%", ")", ".", "The", "majority", "of", "adverse", "events", "in", "the", "core", "study", "were", "of", "mild", "to", "moderate", "severity", ".", "The", "efficacy", "and", "tolerability", "of", "VAL", "/", "HCTZ", "combinations", "were", "maintained", "during", "the", "extension", "(", "797", "patients", ")", ".", "CONCLUSIONS", ":", "In", "this", "study", "population", ",", "combination", "therapies", "with", "VAL", "/", "HCTZ", "were", "associated", "with", "significantly", "greater", "BP", "reductions", "compared", "with", "either", "monotherapy", ",", "were", "well", "tolerated", ",", "and", "were", "associated", "with", "less", "hypokalemia", "than", "HCTZ", "alone", "."]], "ner": [[[4, 4, "Chemical"], [108, 108, "Chemical"], [110, 110, "Chemical"], [195, 195, "Chemical"], [205, 205, "Chemical"], [253, 253, "Chemical"], [422, 422, "Chemical"], [469, 469, "Chemical"], [509, 509, "Chemical"], [518, 518, "Chemical"], [565, 565, "Chemical"], [580, 580, "Chemical"], [617, 617, "Chemical"], [641, 641, "Chemical"], [665, 665, "Chemical"], [559, 559, "Disease"], [663, 663, "Disease"], [2, 2, "Chemical"], [103, 103, "Chemical"], [105, 105, "Chemical"], [189, 189, "Chemical"], [203, 203, "Chemical"], [251, 251, "Chemical"], [420, 420, "Chemical"], [467, 467, "Chemical"], [507, 507, "Chemical"], [516, 516, "Chemical"], [563, 563, "Chemical"], [615, 615, "Chemical"], [639, 639, "Chemical"], [35, 35, "Disease"], [46, 46, "Disease"], [68, 68, "Disease"], [90, 90, "Disease"], [122, 123, "Disease"], [157, 158, "Disease"]]], "relations": [[[4, 4, 559, 559, "CID"], [4, 4, 663, 663, "CID"], [108, 108, 559, 559, "CID"], [108, 108, 663, 663, "CID"], [110, 110, 559, 559, "CID"], [110, 110, 663, 663, "CID"], [195, 195, 559, 559, "CID"], [195, 195, 663, 663, "CID"], [205, 205, 559, 559, "CID"], [205, 205, 663, 663, "CID"], [253, 253, 559, 559, "CID"], [253, 253, 663, 663, "CID"], [422, 422, 559, 559, "CID"], [422, 422, 663, 663, "CID"], [469, 469, 559, 559, "CID"], [469, 469, 663, 663, "CID"], [509, 509, 559, 559, "CID"], [509, 509, 663, 663, "CID"], [518, 518, 559, 559, "CID"], [518, 518, 663, 663, "CID"], [565, 565, 559, 559, "CID"], [565, 565, 663, 663, "CID"], [580, 580, 559, 559, "CID"], [580, 580, 663, 663, "CID"], [617, 617, 559, 559, "CID"], [617, 617, 663, 663, "CID"], [641, 641, 559, 559, "CID"], [641, 641, 663, 663, "CID"], [665, 665, 559, 559, "CID"], [665, 665, 663, 663, "CID"]]], "clusters": [], "translated": "<17>缬沙坦</17> / <0>氢氯噻嗪</0> 剂量高达 320 / 25 mg 的联合疗法与单一疗法的比较：一项双盲、安慰剂对照研究，随后在<30>高血压</30>成年人。背景：接受<31>高血压</31>治疗的患者中有三分之一的血压（BP）得到了充分控制，并且通常需要多药治疗。鉴于<32>高血压</32>的终生性，有必要评估更高剂量联合抗<33>高血压</33>疗法的长期疗效和耐受性。目的：本研究调查了<18>缬沙坦</18>（<19>VAL</19>）或<1>氢氯噻嗪</1>（<2>HCTZ</2>）的疗效和耐受性 - 单一疗法和<34>原发性高血压</34>患者的高剂量组合。方法：本研究的第一部分是一项为期8周、多中心、随机、双盲、安慰剂对照的平行组试验。<35>原发性高血压</35>（平均坐位舒张压[MSDBP]，≥95 mm Hg且<110 mm Hg）患者被随机分配到8个治疗组中的1个：<20>VAL</20>160或320毫克；<3>氢氯噻嗪</3>12.5或25毫克；<21>VAL</21> / <4>HCTZ</4>160 / 12.5、320 / 12.5或320 / 25毫克；或安慰剂。在8周的核心研究终点分析了MSDBP和平均坐位收缩压（MSSBP）的平均变化。<22>VAL</22> / <5>HCTZ</5>320 / 12.5和320 / 25毫克在54周的开放标签扩展中得到进一步研究。响应定义为与基线相比，MSDBP < 90 mm Hg或≥10 mm Hg降低。对照定义为与基线相比MSDBP < 90 mm Hg。耐受性是通过监测随机化时的不良事件和所有随后的研究访问以及血液学和血液化学的定期评估来评估的。结果：共有1346名患者被随机分配到为期8周的核心研究中（734名男性，612名女性；924名白人，291名黑人，23名亚洲人，108名其他人；平均年龄52.7岁；平均体重92.6 kg）。在为期8周的核心研究中，所有积极治疗均与显着降低MSSBP和MSDBP相关，每种单一疗法均显着促进联合治疗的总体效果（<23>VAL</23>和<6>HCTZ</6>，P < 0.001）。与单一疗法和安慰剂相比，每种组合都与MSSBP和MSDBP显着更大的降低有关（所有，P < 0.001）。<24>VAL</24> / <7>HCTZ</7>320 / 25 mg的MSSBP / MSDBP平均降低为24.7/16.6毫米汞柱，与5.9/7.0毫米汞柱与安慰剂相比。 <25>VAL</25> / <8>HCTZ</8>320 / 25 mg与<26>VAL</26> /<9>HCTZ</9>160 / 12.5毫克相比，MSSBP的降低显着更大（P < 0.002）。相比于接受单一治疗的组，接受联合治疗的组的响应率和血压控制率显着更高。 <27>VAL</27> / <10>HCTZ</10>组合（1.8% - 6.1%）的<15>低钾血症</15>发生率低于<11>HCTZ</11>单一疗法（7.1% - 13.3%）。核心研究中的大多数不良事件为轻度至中度严重程度。 <28>VAL</28> / <12>HCTZ</12>组合的疗效和耐受性在延长期间得以维持（797名患者）。结论：在该研究人群中，<29>VAL</29> / <13>HCTZ</13>的联合治疗与任一单一治疗相比显着更大的降压效果，耐受性良好，并且<16>低血钾</16>优于单独使用<14>HCTZ</14>。", "revised": true}
{"doc_key": "17879217", "sentences": [["Rifampicin", "-", "associated", "segmental", "necrotizing", "glomerulonephritis", "in", "staphylococcal", "endocarditis", ".", "Segmental", "necrotising", "glomerulonephritis", "has", "been", "reported", "as", "complication", "of", "rifampicin", "therapy", "in", "patients", "receiving", "treatment", "for", "tuberculosis", ".", "Changing", "epidemiology", "of", "infections", "such", "as", "infective", "endocarditis", "(", "IE", ")", "has", "led", "to", "an", "increase", "in", "the", "use", "of", "rifampicin", "for", "Staphylococcal", "infections", ".", "We", "describe", "a", "case", "of", "a", "patient", "with", "Staphylococcal", "IE", "who", "developed", "acute", "renal", "failure", "secondary", "to", "a", "segmental", "necrotising", "glomerulonephritis", "while", "being", "treated", "with", "rifampicin", ",", "and", "review", "the", "literature", "regarding", "this", "complication", "of", "rifampicin", "therapy", "."]], "ner": [[[0, 0, "Chemical"], [19, 19, "Chemical"], [48, 48, "Chemical"], [78, 78, "Chemical"], [88, 88, "Chemical"], [5, 5, "Disease"], [12, 12, "Disease"], [73, 73, "Disease"], [65, 67, "Disease"], [7, 8, "Disease"], [50, 51, "Disease"], [61, 62, "Disease"], [34, 35, "Disease"], [37, 37, "Disease"], [26, 26, "Disease"], [31, 31, "Disease"]]], "relations": [[[0, 0, 5, 5, "CID"], [0, 0, 12, 12, "CID"], [0, 0, 73, 73, "CID"], [19, 19, 5, 5, "CID"], [19, 19, 12, 12, "CID"], [19, 19, 73, 73, "CID"], [48, 48, 5, 5, "CID"], [48, 48, 12, 12, "CID"], [48, 48, 73, 73, "CID"], [78, 78, 5, 5, "CID"], [78, 78, 12, 12, "CID"], [78, 78, 73, 73, "CID"], [88, 88, 5, 5, "CID"], [88, 88, 12, 12, "CID"], [88, 88, 73, 73, "CID"], [0, 0, 65, 67, "CID"], [19, 19, 65, 67, "CID"], [48, 48, 65, 67, "CID"], [78, 78, 65, 67, "CID"], [88, 88, 65, 67, "CID"]]], "clusters": [], "translated": " <0>利福平</0> - 在<9>葡萄球菌性心内膜炎</9>中与节段性坏死性<5>肾小球肾炎</5>相关。节段性坏死性<6>肾小球肾炎</6>已被报告为<1>利福平</1>疗法在接受<14>结核病</14>治疗的患者中的并发症。改变的流行病学<15>感染</15>（例如<12> 感染性心内膜炎 </12> ( <13> IE </13> )）导致<2>利福平</2>的使用增加，可以在<10>葡萄球菌感染</10> 中使用。我们描述了一名患有<11>葡萄球菌IE</11>的患者的病例，该患者在接受<3>利福平</3>治疗期间继发于节段性坏死性<7>肾小球肾炎</7>并继发<8>急性肾功能衰竭</8>，并复习有关<4>利福平</4>治疗这一并发症的文献。", "revised": true}
{"doc_key": "17255138", "sentences": [["Risks", "and", "benefits", "of", "COX", "-", "2", "inhibitors", "vs", "non", "-", "selective", "NSAIDs", ":", "does", "their", "cardiovascular", "risk", "exceed", "their", "gastrointestinal", "benefit", "?", "A", "retrospective", "cohort", "study", ".", "OBJECTIVES", ":", "The", "risk", "of", "acute", "myocardial", "infarction", "(", "AMI", ")", "with", "COX", "-", "2", "inhibitors", "may", "offset", "their", "gastrointestinal", "(", "GI", ")", "benefit", "compared", "with", "non", "-", "selective", "(", "NS", ")", "non", "-", "steroidal", "anti", "-", "inflammatory", "drugs", "(", "NSAIDs", ")", ".", "We", "aimed", "to", "compare", "the", "risks", "of", "hospitalization", "for", "AMI", "and", "GI", "bleeding", "among", "elderly", "patients", "using", "COX", "-", "2", "inhibitors", ",", "NS", "-", "NSAIDs", "and", "acetaminophen", ".", "METHODS", ":", "We", "conducted", "a", "retrospective", "cohort", "study", "using", "administrative", "data", "of", "patients", ">", "or", "=", "65", "years", "of", "age", "who", "filled", "a", "prescription", "for", "NSAID", "or", "acetaminophen", "during", "1999", "-", "2002", ".", "Outcomes", "were", "compared", "using", "Cox", "regression", "models", "with", "time", "-", "dependent", "exposures", ".", "RESULTS", ":", "Person", "-", "years", "of", "exposure", "among", "non", "-", "users", "of", "aspirin", "were", ":", "75", ",", "761", "to", "acetaminophen", ",", "42", ",", "671", "to", "rofecoxib", "65", ",", "860", "to", "celecoxib", ",", "and", "37", ",", "495", "to", "NS", "-", "NSAIDs", ".", "Among", "users", "of", "aspirin", ",", "they", "were", ":", "14", ",", "671", "to", "rofecoxib", ",", "22", ",", "875", "to", "celecoxib", ",", "9", ",", "832", "to", "NS", "-", "NSAIDs", "and", "38", ",", "048", "to", "acetaminophen", ".", "Among", "non", "-", "users", "of", "aspirin", ",", "the", "adjusted", "hazard", "ratios", "(", "95", "%", "confidence", "interval", ")", "of", "hospitalization", "for", "AMI", "/", "GI", "vs", "the", "acetaminophen", "(", "with", "no", "aspirin", ")", "group", "were", ":", "rofecoxib", "1", ".", "27", "(", "1", ".", "13", ",", "1", ".", "42", ")", ",", "celecoxib", "0", ".", "93", "(", "0", ".", "83", ",", "1", ".", "03", ")", ",", "naproxen", "1", ".", "59", "(", "1", ".", "31", ",", "1", ".", "93", ")", ",", "diclofenac", "1", ".", "17", "(", "0", ".", "99", ",", "1", ".", "38", ")", "and", "ibuprofen", "1", ".", "05", "(", "0", ".", "74", ",", "1", ".", "51", ")", ".", "Among", "users", "of", "aspirin", ",", "they", "were", ":", "rofecoxib", "1", ".", "73", "(", "1", ".", "52", ",", "1", ".", "98", ")", ",", "celecoxib", "1", ".", "34", "(", "1", ".", "19", ",", "1", ".", "52", ")", ",", "ibuprofen", "1", ".", "51", "(", "0", ".", "95", ",", "2", ".", "41", ")", ",", "diclofenac", "1", ".", "69", "(", "1", ".", "35", ",", "2", ".", "10", ")", ",", "naproxen", "1", ".", "35", "(", "0", ".", "97", ",", "1", ".", "88", ")", "and", "acetaminophen", "1", ".", "29", "(", "1", ".", "17", ",", "1", ".", "42", ")", ".", "CONCLUSION", ":", "Among", "non", "-", "users", "of", "aspirin", ",", "naproxen", "seemed", "to", "carry", "the", "highest", "risk", "for", "AMI", "/", "GI", "bleeding", ".", "The", "AMI", "/", "GI", "toxicity", "of", "celecoxib", "was", "similar", "to", "that", "of", "acetaminophen", "and", "seemed", "to", "be", "better", "than", "those", "of", "rofecoxib", "and", "NS", "-", "NSAIDs", ".", "Among", "users", "of", "aspirin", ",", "both", "celecoxib", "and", "naproxen", "seemed", "to", "be", "the", "least", "toxic", "."]], "ner": [[[4, 7, "Chemical"], [40, 43, "Chemical"], [88, 91, "Chemical"], [33, 35, "Disease"], [37, 37, "Disease"], [80, 80, "Disease"], [240, 240, "Disease"], [433, 433, "Disease"], [439, 439, "Disease"], [60, 66, "Chemical"], [170, 170, "Chemical"], [198, 198, "Chemical"], [254, 254, "Chemical"], [332, 332, "Chemical"], [459, 459, "Chemical"], [282, 282, "Chemical"], [388, 388, "Chemical"], [425, 425, "Chemical"], [473, 473, "Chemical"], [82, 83, "Disease"], [435, 436, "Disease"], [442, 442, "Disease"], [97, 97, "Chemical"], [126, 126, "Chemical"], [164, 164, "Chemical"], [218, 218, "Chemical"], [245, 245, "Chemical"], [402, 402, "Chemical"], [450, 450, "Chemical"], [157, 157, "Chemical"], [189, 189, "Chemical"], [225, 225, "Chemical"], [249, 249, "Chemical"], [327, 327, "Chemical"], [423, 423, "Chemical"], [468, 468, "Chemical"], [175, 175, "Chemical"], [204, 204, "Chemical"], [268, 268, "Chemical"], [346, 346, "Chemical"], [444, 444, "Chemical"], [471, 471, "Chemical"], [296, 296, "Chemical"], [374, 374, "Chemical"], [310, 310, "Chemical"], [360, 360, "Chemical"]]], "relations": [[[4, 7, 33, 35, "CID"], [4, 7, 37, 37, "CID"], [4, 7, 80, 80, "CID"], [4, 7, 240, 240, "CID"], [4, 7, 433, 433, "CID"], [4, 7, 439, 439, "CID"], [40, 43, 33, 35, "CID"], [40, 43, 37, 37, "CID"], [40, 43, 80, 80, "CID"], [40, 43, 240, 240, "CID"], [40, 43, 433, 433, "CID"], [40, 43, 439, 439, "CID"], [88, 91, 33, 35, "CID"], [88, 91, 37, 37, "CID"], [88, 91, 80, 80, "CID"], [88, 91, 240, 240, "CID"], [88, 91, 433, 433, "CID"], [88, 91, 439, 439, "CID"], [60, 66, 33, 35, "CID"], [60, 66, 37, 37, "CID"], [60, 66, 80, 80, "CID"], [60, 66, 240, 240, "CID"], [60, 66, 433, 433, "CID"], [60, 66, 439, 439, "CID"], [170, 170, 33, 35, "CID"], [170, 170, 37, 37, "CID"], [170, 170, 80, 80, "CID"], [170, 170, 240, 240, "CID"], [170, 170, 433, 433, "CID"], [170, 170, 439, 439, "CID"], [198, 198, 33, 35, "CID"], [198, 198, 37, 37, "CID"], [198, 198, 80, 80, "CID"], [198, 198, 240, 240, "CID"], [198, 198, 433, 433, "CID"], [198, 198, 439, 439, "CID"], [254, 254, 33, 35, "CID"], [254, 254, 37, 37, "CID"], [254, 254, 80, 80, "CID"], [254, 254, 240, 240, "CID"], [254, 254, 433, 433, "CID"], [254, 254, 439, 439, "CID"], [332, 332, 33, 35, "CID"], [332, 332, 37, 37, "CID"], [332, 332, 80, 80, "CID"], [332, 332, 240, 240, "CID"], [332, 332, 433, 433, "CID"], [332, 332, 439, 439, "CID"], [459, 459, 33, 35, "CID"], [459, 459, 37, 37, "CID"], [459, 459, 80, 80, "CID"], [459, 459, 240, 240, "CID"], [459, 459, 433, 433, "CID"], [459, 459, 439, 439, "CID"], [282, 282, 33, 35, "CID"], [282, 282, 37, 37, "CID"], [282, 282, 80, 80, "CID"], [282, 282, 240, 240, "CID"], [282, 282, 433, 433, "CID"], [282, 282, 439, 439, "CID"], [388, 388, 33, 35, "CID"], [388, 388, 37, 37, "CID"], [388, 388, 80, 80, "CID"], [388, 388, 240, 240, "CID"], [388, 388, 433, 433, "CID"], [388, 388, 439, 439, "CID"], [425, 425, 33, 35, "CID"], [425, 425, 37, 37, "CID"], [425, 425, 80, 80, "CID"], [425, 425, 240, 240, "CID"], [425, 425, 433, 433, "CID"], [425, 425, 439, 439, "CID"], [473, 473, 33, 35, "CID"], [473, 473, 37, 37, "CID"], [473, 473, 80, 80, "CID"], [473, 473, 240, 240, "CID"], [473, 473, 433, 433, "CID"], [473, 473, 439, 439, "CID"], [60, 66, 82, 83, "CID"], [60, 66, 435, 436, "CID"], [170, 170, 82, 83, "CID"], [170, 170, 435, 436, "CID"], [198, 198, 82, 83, "CID"], [198, 198, 435, 436, "CID"], [254, 254, 82, 83, "CID"], [254, 254, 435, 436, "CID"], [332, 332, 82, 83, "CID"], [332, 332, 435, 436, "CID"], [459, 459, 82, 83, "CID"], [459, 459, 435, 436, "CID"], [282, 282, 82, 83, "CID"], [282, 282, 435, 436, "CID"], [388, 388, 82, 83, "CID"], [388, 388, 435, 436, "CID"], [425, 425, 82, 83, "CID"], [425, 425, 435, 436, "CID"], [473, 473, 82, 83, "CID"], [473, 473, 435, 436, "CID"]]], "clusters": [], "translated": "<0>COX-2 抑制剂</0>与非选择性 NSAID的风险和益处：它们的心血管风险是否超过胃肠道益处？一项回顾性队列研究。目的：<3>急性心肌梗死</3> (<4>AMI</4>)与非选择性<9>非甾体抗炎药</9>(NSAIDs)相比，<1>COX-2抑制剂</1>的风险可能会抵消其胃肠道 (GI) 获益(NS)。我们旨在比较使用<2>COX-2抑制剂</2>、NS-NSAIDs和<22>对乙酰氨基酚</22>的老年患者因<5>AMI</5>和<19>GI出血</19>住院的风险。方法：我们使用 1999 年至 2002 年期间≥65岁并开具NSAID或<23>对乙酰氨基酚</23>处方的患者的管理数据进行了一项回顾性队列研究。使用具有时间依赖性暴露的Cox回归模型比较结果。结果：未服用<29>阿司匹林</29>的人年暴露量分别为：75,761至<24>对乙酰氨基酚</24>，42,671至<10>罗非考昔</10>,65,860至<36>塞来昔布</36>，以及37,495和NS-NSAIDs。在<30>阿司匹林</30>的使用者中，他们分别是：14,671到<11>罗非昔布</11>，22,875到<37>塞来昔布</37>，9,832到NS-NSAIDs和38,048到<25>对乙酰氨基酚</25>。在<31>阿司匹林</31>的非使用者中，因<6>AMI</6>/GI与<26>对乙酰氨基酚</26>住院的调整后风险比（95%置信区间）（无<32>阿司匹林</32>）组分别为：<12>罗非昔布</12>1.27(1.13,1.42)，<38>塞来昔布</38>0.93(0.83,1.03)，<15>萘普生</15>1.59(1.31,1.93)，<42>双氯芬酸</42>1.17(0.99,1.38)和<44>布洛芬</44>1.05(0.74,1.51)。在<33>阿司匹林</33>的使用者中，他们分别是：<13>罗非考昔</13>1.73(1.52,1.98)，<39>塞来昔布</39>1.34(1.19,1.52)，<45>布洛芬</45>1.51(0.95,2.41)，<43>双氯芬酸</43>1.69(1.35,2.10)，<16>萘普生</16>1.35(0.97,1.88)和<27>对乙酰氨基酚</27>1.29(1.17,1.42)。结论：在未服用<34>阿司匹林</34>的人群中，<17>萘普生</17>似乎具有最高的<7>AMI</7>/<20>胃肠道出血</20>风险。<40>塞来昔布</40>的<8>AMI</8>/GI<21>毒性</21>与<28>对乙酰氨基酚</28>相似，似乎优于<14>罗非考昔</14>和NS-NSAIDs。在<35>阿司匹林</35>的使用者中，<41>塞来昔布</41>和<18>萘普生</18>似乎毒性最小。", "revised": true}
{"doc_key": "18165598", "sentences": [["The", "differential", "effects", "of", "bupivacaine", "and", "lidocaine", "on", "prostaglandin", "E2", "release", ",", "cyclooxygenase", "gene", "expression", "and", "pain", "in", "a", "clinical", "pain", "model", ".", "BACKGROUND", ":", "In", "addition", "to", "blocking", "nociceptive", "input", "from", "surgical", "sites", ",", "long", "-", "acting", "local", "anesthetics", "might", "directly", "modulate", "inflammation", ".", "In", "the", "present", "study", ",", "we", "describe", "the", "proinflammatory", "effects", "of", "bupivacaine", "on", "local", "prostaglandin", "E2", "(", "PGE2", ")", "production", "and", "cyclooxygenase", "(", "COX", ")", "gene", "expression", "that", "increases", "postoperative", "pain", "in", "human", "subjects", ".", "METHODS", ":", "Subjects", "(", "n", "=", "114", ")", "undergoing", "extraction", "of", "impacted", "third", "molars", "received", "either", "2", "%", "lidocaine", "or", "0", ".", "5", "%", "bupivacaine", "before", "surgery", "and", "either", "rofecoxib", "50", "mg", "or", "placebo", "orally", "90", "min", "before", "surgery", "and", "for", "the", "following", "48", "h", ".", "Oral", "mucosal", "biopsies", "were", "taken", "before", "surgery", "and", "48", "h", "after", "surgery", ".", "After", "extraction", ",", "a", "microdialysis", "probe", "was", "placed", "at", "the", "surgical", "site", "for", "PGE2", "and", "thromboxane", "B2", "(", "TXB2", ")", "measurements", ".", "RESULTS", ":", "The", "bupivacaine", "/", "rofecoxib", "group", "reported", "significantly", "less", "pain", ",", "as", "assessed", "by", "a", "visual", "analog", "scale", ",", "compared", "with", "the", "other", "three", "treatment", "groups", "over", "the", "first", "4", "h", ".", "However", ",", "the", "bupivacaine", "/", "placebo", "group", "reported", "significantly", "more", "pain", "at", "24", "h", "and", "PGE2", "levels", "during", "the", "first", "4", "h", "were", "significantly", "higher", "than", "the", "other", "three", "treatment", "groups", ".", "Moreover", ",", "bupivacaine", "significantly", "increased", "COX", "-", "2", "gene", "expression", "at", "48", "h", "as", "compared", "with", "the", "lidocaine", "/", "placebo", "group", ".", "Thromboxane", "levels", "were", "not", "significantly", "affected", "by", "any", "of", "the", "treatments", ",", "indicating", "that", "the", "effects", "seen", "were", "attributable", "to", "inhibition", "of", "COX", "-", "2", ",", "but", "not", "COX", "-", "1", ".", "CONCLUSIONS", ":", "These", "results", "suggest", "that", "bupivacaine", "stimulates", "COX", "-", "2", "gene", "expression", "after", "tissue", "injury", ",", "which", "is", "associated", "with", "higher", "PGE2", "production", "and", "pain", "after", "the", "local", "anesthetic", "effect", "dissipates", "."]], "ner": [[[4, 4, "Chemical"], [56, 56, "Chemical"], [104, 104, "Chemical"], [164, 164, "Chemical"], [197, 197, "Chemical"], [228, 228, "Chemical"], [286, 286, "Chemical"], [43, 43, "Disease"], [74, 75, "Disease"], [16, 16, "Disease"], [20, 20, "Disease"], [171, 171, "Disease"], [204, 204, "Disease"], [305, 305, "Disease"], [294, 295, "Disease"], [6, 6, "Chemical"], [98, 98, "Chemical"], [243, 243, "Chemical"], [8, 9, "Chemical"], [59, 60, "Chemical"], [62, 62, "Chemical"], [152, 152, "Chemical"], [209, 209, "Chemical"], [302, 302, "Chemical"], [109, 109, "Chemical"], [166, 166, "Chemical"], [154, 155, "Chemical"], [157, 157, "Chemical"], [248, 248, "Chemical"]]], "relations": [[[4, 4, 43, 43, "CID"], [56, 56, 43, 43, "CID"], [104, 104, 43, 43, "CID"], [164, 164, 43, 43, "CID"], [197, 197, 43, 43, "CID"], [228, 228, 43, 43, "CID"], [286, 286, 43, 43, "CID"], [4, 4, 74, 75, "CID"], [56, 56, 74, 75, "CID"], [104, 104, 74, 75, "CID"], [164, 164, 74, 75, "CID"], [197, 197, 74, 75, "CID"], [228, 228, 74, 75, "CID"], [286, 286, 74, 75, "CID"]]], "clusters": [], "translated": "<0>布比卡因</0>和<15>利多卡因</15>对<18>前列腺素E2</18>释放、环氧合酶基因表达和<9>疼痛</9>的不同影响<10>疼痛</10>模型。背景：除了阻断来自手术部位的伤害感受输入外，长效局部麻醉药还可能直接调节<7>炎症</7>。在本研究中，我们描述了<1>布比卡因</1>对局部<19>前列腺素E2</19>（<20>PGE2</20>）产生和增加环氧合酶（COX）基因表达的促炎作用，这增加了<8>术后疼痛</8>的人类受试者。 方法：接受阻生第三磨牙拔除的受试者（n = 114）接受2%<16>利多卡因</16>或0.5%<2>布比卡因</2>，并在手术前90分钟和接下来的48小时内口服50mg <24>罗非考昔</24>或安慰剂。手术前和手术后48小时进行口腔粘膜活检。拔牙后，在手术部位放置微透析探针进行<21>PGE2</21>和<26>血栓素B2</26>（<27>TXB2</27>）的测定。 结果：<3>布比卡因</3>/<25>罗非考昔</25>组报告的<11>疼痛</11>显着减少，评估方法为视觉模拟量表，与其他三个治疗组相比，在前4小时内表现出较好的效果。 然而，<4>布比卡因</4>/<12>安慰剂</12>组报告24小时内疼痛显着增加，前4小时内<22>PGE2</22>水平显着高于其他三个治疗组。此外，与<17>利多卡因</17>/<12>安慰剂</12>组相比，<5>布比卡因</5>在48小时时显着增加了COX-2基因的表达。<28>血栓素</28>水平不受任何处理的显着影响，表明所观察到的影响归因于对COX-2的抑制而不是COX-1。 结论：这些结果表明，<6>布比卡因</6>在<14>组织损伤</14>后刺激COX-2基因表达，这与更高的<23>PGE2</23>产生和局部麻醉作用消退后的<13>疼痛</13>水平有关。", "revised": true}
{"doc_key": "18340638", "sentences": [["Azathioprine", "-", "induced", "suicidal", "erythrocyte", "death", ".", "BACKGROUND", ":", "Azathioprine", "is", "widely", "used", "as", "an", "immunosuppressive", "drug", ".", "The", "side", "effects", "of", "azathioprine", "include", "anemia", ",", "which", "has", "been", "attributed", "to", "bone", "marrow", "suppression", ".", "Alternatively", ",", "anemia", "could", "result", "from", "accelerated", "suicidal", "erythrocyte", "death", "or", "eryptosis", ",", "which", "is", "characterized", "by", "exposure", "of", "phosphatidylserine", "(", "PS", ")", "at", "the", "erythrocyte", "surface", "and", "by", "cell", "shrinkage", ".", "METHODS", ":", "The", "present", "experiments", "explored", "whether", "azathioprine", "influences", "eryptosis", ".", "According", "to", "annexin", "V", "binding", ",", "erythrocytes", "from", "patients", "indeed", "showed", "a", "significant", "increase", "of", "PS", "exposure", "within", "1", "week", "of", "treatment", "with", "azathioprine", ".", "In", "a", "second", "series", ",", "cytosolic", "Ca2", "+", "activity", "(", "Fluo3", "fluorescence", ")", ",", "cell", "volume", "(", "forward", "scatter", ")", ",", "and", "PS", "-", "exposure", "(", "annexin", "V", "binding", ")", "were", "determined", "by", "FACS", "analysis", "in", "erythrocytes", "from", "healthy", "volunteers", ".", "RESULTS", ":", "Exposure", "to", "azathioprine", "(", ">", "or", "=", "2", "microg", "/", "mL", ")", "for", "48", "hours", "increased", "cytosolic", "Ca2", "+", "activity", "and", "annexin", "V", "binding", "and", "decreased", "forward", "scatter", ".", "The", "effect", "of", "azathioprine", "on", "both", "annexin", "V", "binding", "and", "forward", "scatter", "was", "significantly", "blunted", "in", "the", "nominal", "absence", "of", "extracellular", "Ca2", "+", ".", "CONCLUSIONS", ":", "Azathioprine", "triggers", "suicidal", "erythrocyte", "death", ",", "an", "effect", "presumably", "contributing", "to", "azathioprine", "-", "induced", "anemia", "."]], "ner": [[[0, 0, "Chemical"], [9, 9, "Chemical"], [22, 22, "Chemical"], [74, 74, "Chemical"], [101, 101, "Chemical"], [148, 148, "Chemical"], [178, 178, "Chemical"], [201, 201, "Chemical"], [212, 212, "Chemical"], [24, 24, "Disease"], [37, 37, "Disease"], [215, 215, "Disease"], [54, 54, "Chemical"], [56, 56, "Chemical"], [93, 93, "Chemical"], [125, 125, "Chemical"], [109, 109, "Chemical"], [163, 163, "Chemical"], [196, 196, "Chemical"], [113, 113, "Chemical"]]], "relations": [[[0, 0, 24, 24, "CID"], [0, 0, 37, 37, "CID"], [0, 0, 215, 215, "CID"], [9, 9, 24, 24, "CID"], [9, 9, 37, 37, "CID"], [9, 9, 215, 215, "CID"], [22, 22, 24, 24, "CID"], [22, 22, 37, 37, "CID"], [22, 22, 215, 215, "CID"], [74, 74, 24, 24, "CID"], [74, 74, 37, 37, "CID"], [74, 74, 215, 215, "CID"], [101, 101, 24, 24, "CID"], [101, 101, 37, 37, "CID"], [101, 101, 215, 215, "CID"], [148, 148, 24, 24, "CID"], [148, 148, 37, 37, "CID"], [148, 148, 215, 215, "CID"], [178, 178, 24, 24, "CID"], [178, 178, 37, 37, "CID"], [178, 178, 215, 215, "CID"], [201, 201, 24, 24, "CID"], [201, 201, 37, 37, "CID"], [201, 201, 215, 215, "CID"], [212, 212, 24, 24, "CID"], [212, 212, 37, 37, "CID"], [212, 212, 215, 215, "CID"]]], "clusters": [], "translated": " <0>硫唑嘌呤</0>-诱导自杀性红细胞死亡。背景：<1>硫唑嘌呤</1>是一种广泛应用的免疫抑制药物。<2>硫唑嘌呤</2>的副作用包括<9>贫血</9>，这归因于骨髓抑制。或者，<10>贫血</10>可能由红细胞加速自杀死亡或红细胞增多症引起，其特征是红细胞表面的<12>磷脂酰丝氨酸</12>(<13>PS</13>)和细胞收缩。方法：本实验探讨了<3>硫唑嘌呤</3>是否影响红细胞的自杀性死亡。根据膜联蛋白 V 结合，患者的红细胞在<4>硫唑嘌呤</4>治疗后1周内确实显示<14> PS </14>暴露显着增加。在第二个系列中，通过 FACS 分析对健康志愿者的红细胞进行测定，包括细胞溶质<16>Ca2</16>+活性（<19>Fluo3</19>荧光）、细胞体积（前向散射）和<15>PS</15>-暴露（膜联蛋白 V 结合）。结果：暴露于<5>硫唑嘌呤</5>(>或=2微克/毫升)的48小时内，红细胞细胞溶质<17>Ca2</17>+活性和膜联蛋白 V 结合均增加，前向散射则下降。在名义上细胞外<18>Ca2</18>+不存在的情况下，<6>硫唑嘌呤</6>对膜联蛋白 V 结合和前向散射的影响显著减弱。结论：<7>硫唑嘌呤</7>引发自杀性红细胞死亡，这种作用可能导致<8>硫唑嘌呤</8>诱导的<11>贫血</11>。", "revised": true}
{"doc_key": "18189308", "sentences": [["p75NTR", "expression", "in", "rat", "urinary", "bladder", "sensory", "neurons", "and", "spinal", "cord", "with", "cyclophosphamide", "-", "induced", "cystitis", ".", "A", "role", "for", "nerve", "growth", "factor", "(", "NGF", ")", "in", "contributing", "to", "increased", "voiding", "frequency", "and", "altered", "sensation", "from", "the", "urinary", "bladder", "has", "been", "suggested", ".", "Previous", "studies", "have", "examined", "the", "expression", "and", "regulation", "of", "tyrosine", "kinase", "receptors", "(", "Trks", ")", "in", "micturition", "reflexes", "with", "urinary", "bladder", "inflammation", ".", "The", "present", "studies", "examine", "the", "expression", "and", "regulation", "of", "another", "receptor", "known", "to", "bind", "NGF", ",", "p75", "(", "NTR", ")", ",", "after", "various", "durations", "of", "bladder", "inflammation", "induced", "by", "cyclophosphamide", "(", "CYP", ")", ".", "CYP", "-", "induced", "cystitis", "increased", "(", "P", "<", "or", "=", "0", ".", "001", ")", "p75", "(", "NTR", ")", "expression", "in", "the", "superficial", "lateral", "and", "medial", "dorsal", "horn", "in", "L1", "-", "L2", "and", "L6", "-", "S1", "spinal", "segments", ".", "The", "number", "of", "p75", "(", "NTR", ")", "-", "immunoreactive", "(", "-", "IR", ")", "cells", "in", "the", "lumbosacral", "dorsal", "root", "ganglia", "(", "DRG", ")", "also", "increased", "(", "P", "<", "or", "=", "0", ".", "05", ")", "with", "CYP", "-", "induced", "cystitis", "(", "acute", ",", "intermediate", ",", "and", "chronic", ")", ".", "Quantitative", ",", "real", "-", "time", "polymerase", "chain", "reaction", "also", "demonstrated", "significant", "increases", "(", "P", "<", "or", "=", "0", ".", "01", ")", "in", "p75", "(", "NTR", ")", "mRNA", "in", "DRG", "with", "intermediate", "and", "chronic", "CYP", "-", "induced", "cystitis", ".", "Retrograde", "dye", "-", "tracing", "techniques", "with", "Fastblue", "were", "used", "to", "identify", "presumptive", "bladder", "afferent", "cells", "in", "the", "lumbosacral", "DRG", ".", "In", "bladder", "afferent", "cells", "in", "DRG", ",", "p75", "(", "NTR", ")", "-", "IR", "was", "also", "increased", "(", "P", "<", "or", "=", "0", ".", "01", ")", "with", "cystitis", ".", "In", "addition", "to", "increases", "in", "p75", "(", "NTR", ")", "-", "IR", "in", "DRG", "cell", "bodies", ",", "increases", "(", "P", "<", "or", "=", "0", ".", "001", ")", "in", "pericellular", "(", "encircling", "DRG", "cells", ")", "p75", "(", "NTR", ")", "-", "IR", "in", "DRG", "also", "increased", ".", "Confocal", "analyses", "demonstrated", "that", "pericellular", "p75", "(", "NTR", ")", "-", "IR", "was", "not", "colocalized", "with", "the", "glial", "marker", ",", "glial", "fibrillary", "acidic", "protein", "(", "GFAP", ")", ".", "These", "studies", "demonstrate", "that", "p75", "(", "NTR", ")", "expression", "in", "micturition", "reflexes", "is", "present", "constitutively", "and", "modified", "by", "bladder", "inflammation", ".", "The", "functional", "significance", "of", "p75", "(", "NTR", ")", "expression", "in", "micturition", "reflexes", "remains", "to", "be", "determined", "."]], "ner": [[[12, 12, "Chemical"], [95, 95, "Chemical"], [97, 97, "Chemical"], [100, 100, "Chemical"], [173, 173, "Chemical"], [219, 219, "Chemical"], [15, 15, "Disease"], [62, 64, "Disease"], [91, 92, "Disease"], [103, 103, "Disease"], [176, 176, "Disease"], [222, 222, "Disease"], [270, 270, "Disease"], [361, 362, "Disease"], [52, 52, "Chemical"]]], "relations": [[[12, 12, 15, 15, "CID"], [12, 12, 62, 64, "CID"], [12, 12, 91, 92, "CID"], [12, 12, 103, 103, "CID"], [12, 12, 176, 176, "CID"], [12, 12, 222, 222, "CID"], [12, 12, 270, 270, "CID"], [12, 12, 361, 362, "CID"], [95, 95, 15, 15, "CID"], [95, 95, 62, 64, "CID"], [95, 95, 91, 92, "CID"], [95, 95, 103, 103, "CID"], [95, 95, 176, 176, "CID"], [95, 95, 222, 222, "CID"], [95, 95, 270, 270, "CID"], [95, 95, 361, 362, "CID"], [97, 97, 15, 15, "CID"], [97, 97, 62, 64, "CID"], [97, 97, 91, 92, "CID"], [97, 97, 103, 103, "CID"], [97, 97, 176, 176, "CID"], [97, 97, 222, 222, "CID"], [97, 97, 270, 270, "CID"], [97, 97, 361, 362, "CID"], [100, 100, 15, 15, "CID"], [100, 100, 62, 64, "CID"], [100, 100, 91, 92, "CID"], [100, 100, 103, 103, "CID"], [100, 100, 176, 176, "CID"], [100, 100, 222, 222, "CID"], [100, 100, 270, 270, "CID"], [100, 100, 361, 362, "CID"], [173, 173, 15, 15, "CID"], [173, 173, 62, 64, "CID"], [173, 173, 91, 92, "CID"], [173, 173, 103, 103, "CID"], [173, 173, 176, 176, "CID"], [173, 173, 222, 222, "CID"], [173, 173, 270, 270, "CID"], [173, 173, 361, 362, "CID"], [219, 219, 15, 15, "CID"], [219, 219, 62, 64, "CID"], [219, 219, 91, 92, "CID"], [219, 219, 103, 103, "CID"], [219, 219, 176, 176, "CID"], [219, 219, 222, 222, "CID"], [219, 219, 270, 270, "CID"], [219, 219, 361, 362, "CID"]]], "clusters": [], "translated": "<0>环磷酰胺</0>致<6>膀胱炎</6>大鼠膀胱感觉神经元和脊髓p75NTR的表达。有人提出神经生长因子 (NGF) 在促进排尿频率增加和膀胱感觉改变方面的作用。先前的研究已经检测了<14>酪氨酸</14>激酶受体(Trks)在排尿反射中与<7>膀胱炎症</7>的表达和调节。目前的研究检查了另一种已知结合NGF的受体p75(NTR)的表达和调节，在<8>膀胱炎症</8>由<1>环磷酰胺</1>(<2>CYP</2>)。<3>CYP</3>-诱导的<9>膀胱炎</9>增加(P < or = 0 . 001) p75(NTR)在L1-L2和L6-S1脊髓浅外侧和内侧背角的表达段。腰骶背根神经节(DRG)中p75(NTR)-免疫反应(-IR)细胞的数量也随着<4>CYP</4>诱导的<10>膀胱炎</10>增加(P < or = 0 . 05)（急性、中期和慢性）。定量、实时聚合酶链反应也显示显着增加(P < 或 = 0 . 01) DRG中的p75(NTR)mRNA与中期和慢性<5>CYP</5>-诱导的<11>膀胱炎</11>。使用Fastblue逆行染料示踪技术来识别腰骶DRG中假定的膀胱传入细胞。在膀胱传入细胞中，p75(NTR)-IR也随着<12>膀胱炎</12>增加(P < or = 0. 01)。除了DRG细胞体中p75(NTR)-IR增加外，DRG细胞周围(环绕DRG细胞)p75(NTR)-IR也增加(P < or = 0. 001)。共聚焦分析表明细胞周围p75(NTR)-IR没有与神经胶质标记、神经胶质原纤维酸性蛋白(GFAP)共定位。这些研究表明，排尿反射中的p75(NTR)表达是组成型的，并受<13>膀胱炎症</13>的影响。p75(NTR)表达在排尿反射中的功能意义仍有待确定。", "revised": true}
{"doc_key": "18399341", "sentences": [["Clinical", "comparison", "of", "cardiorespiratory", "effects", "during", "unilateral", "and", "conventional", "spinal", "anaesthesia", ".", "BACKGROUND", ":", "Spinal", "anaesthesia", "is", "widely", "employed", "in", "clinical", "practice", "but", "has", "the", "main", "drawback", "of", "post", "-", "spinal", "block", "hypotension", ".", "Efforts", "must", "therefore", "continue", "to", "be", "made", "to", "obviate", "this", "setback", "OBJECTIVE", ":", "To", "evaluate", "the", "cardiovascular", "and", "respiratory", "changes", "during", "unilateral", "and", "conventional", "spinal", "anaesthesia", ".", "METHODS", ":", "With", "ethical", "approval", ",", "we", "studied", "74", "American", "Society", "of", "Anesthesiologists", "(", "ASA", ")", ",", "physical", "status", "class", "1", "and", "2", "patients", "scheduled", "for", "elective", "unilateral", "lower", "limb", "surgery", ".", "Patients", "were", "randomly", "allocated", "into", "one", "of", "two", "groups", ":", "lateral", "and", "conventional", "spinal", "anaesthesia", "groups", ".", "In", "the", "lateral", "position", "with", "operative", "side", "down", ",", "patients", "recived", "10", "mg", "(", "2mls", ")", "of", "0", ".", "5", "%", "hyperbaric", "bupivacaine", "through", "a", "25", "-", "gauge", "spinal", "needle", ".", "Patients", "in", "the", "unilateral", "group", "were", "maintained", "in", "the", "lateral", "position", "for", "15", "minutes", "following", "spinal", "injection", "while", "those", "in", "the", "conventional", "group", "were", "turned", "supine", "immediately", "after", "injection", ".", "Blood", "pressure", ",", "heart", "rate", ",", "respiratory", "rate", "and", "oxygen", "saturation", "were", "monitored", "over", "1", "hour", ".", "RESULTS", ":", "Three", "patients", "(", "8", ".", "1", "%", ")", "in", "the", "unilateral", "group", "and", "5", "(", "13", ".", "5", "%", ")", "in", "the", "conventional", "group", "developed", "hypotension", ",", "P", "=", "0", ".", "71", ".", "Four", "(", "10", ".", "8", "%", ")", "patients", "in", "the", "conventional", "group", "and", "1", "(", "2", ".", "7", "%", ")", "in", "the", "unilateral", "group", ",", "P", "=", "0", ".", "17", "required", "epinephrine", "infusion", "to", "treat", "hypotension", ".", "Patients", "in", "the", "conventional", "group", "had", "statistically", "significant", "greater", "fall", "in", "the", "systolic", "blood", "pressures", "at", "15", ",", "30", "and", "45", "minutes", "when", "compared", "to", "the", "baseline", "(", "P", "=", "0", ".", "003", ",", "0", ".", "001", "and", "0", ".", "004", ")", ".", "The", "mean", "respiratory", "rate", "and", "oxygen", "saturations", "in", "the", "two", "groups", "were", "similar", ".", "CONCLUSION", ":", "Compared", "to", "conventional", "spinal", "anaesthesia", ",", "unilateral", "spinal", "anaesthesia", "was", "associated", "with", "fewer", "cardiovascular", "perturbations", ".", "Also", ",", "the", "type", "of", "spinal", "block", "instituted", "affected", "neither", "the", "respiratory", "rate", "nor", "the", "arterial", "oxygen", "saturation", "."]], "ner": [[[132, 132, "Chemical"], [32, 32, "Disease"], [215, 215, "Disease"], [258, 258, "Disease"], [180, 180, "Chemical"], [308, 308, "Chemical"], [351, 351, "Chemical"], [254, 254, "Chemical"]]], "relations": [[[132, 132, 32, 32, "CID"], [132, 132, 215, 215, "CID"], [132, 132, 258, 258, "CID"]]], "clusters": [], "translated": "单侧和常规脊髓麻醉期间心肺效应的临床比较。背景：脊髓麻醉广泛应用于临床，但其主要缺点是脊髓阻滞后<1>低血压</1>。因此，必须继续努力避免这种挫折。目的：评估单侧和常规脊髓麻醉期间心血管和呼吸系统的变化。方法：经伦理批准，我们研究了 74 名美国麻醉医师协会 (ASA) 身体状况 1 级和 2 名计划择期单侧下肢手术的患者。患者被随机分配到两组中的一组：侧麻和常规脊髓麻醉组。在手术侧朝下的侧卧位，患者接受了 10 mg (2mls) 的 0.5%高压<0>布比卡因</0>通过 25 号脊椎穿刺针。单侧组患者在脊柱注射后保持侧卧位 15 分钟，而常规组患者在注射后立即转为仰卧位。在 1 小时内监测血压、心率、呼吸频率和<4>氧饱和度</4>。结果：单侧组 3 例 ( 8.1% ) 和常规组 5 例 ( 13.5% ) 出现<2>低血压</2>，P = 0.71 。常规组 4 例 ( 10.8% ) ，单侧组 1 例 ( 2.7% )，P = 0.17 需要<7>肾上腺素</7>输液治疗<3>低血压</3>。与基线相比，常规组患者在 15、30 和 45 分钟时的收缩压下降具有统计学意义（P = 0.003、0.001 和 0.004）。两组的平均呼吸频率和<5>氧饱和度</5>相似。结论：与传统的脊髓麻醉相比，单侧脊髓麻醉与较少的心血管扰动有关。此外，脊柱阻滞的类型既不影响呼吸频率也不影响动脉<6>氧饱和度</6>。", "revised": true}
{"doc_key": "18422462", "sentences": [["Spectrum", "of", "adverse", "events", "after", "generic", "HAART", "in", "southern", "Indian", "HIV", "-", "infected", "patients", ".", "To", "determine", "the", "incidence", "of", "clinically", "significant", "adverse", "events", "after", "long", "-", "term", ",", "fixed", "-", "dose", ",", "generic", "highly", "active", "antiretroviral", "therapy", "(", "HAART", ")", "use", "among", "HIV", "-", "infected", "individuals", "in", "South", "India", ",", "we", "examined", "the", "experiences", "of", "3154", "HIV", "-", "infected", "individuals", "who", "received", "a", "minimum", "of", "3", "months", "of", "generic", "HAART", "between", "February", "1996", "and", "December", "2006", "at", "a", "tertiary", "HIV", "care", "referral", "center", "in", "South", "India", ".", "The", "most", "common", "regimens", "were", "3TC", "+", "d4T", "+", "nevirapine", "(", "NVP", ")", "(", "54", ".", "8", "%", ")", ",", "zidovudine", "(", "AZT", ")", "+", "3TC", "+", "NVP", "(", "14", ".", "5", "%", ")", ",", "3TC", "+", "d4T", "+", "efavirenz", "(", "EFV", ")", "(", "20", ".", "1", "%", ")", ",", "and", "AZT", "+", "3TC", "+", "EFV", "(", "5", ".", "4", "%", ")", ".", "The", "most", "common", "adverse", "events", "and", "median", "CD4", "at", "time", "of", "event", "were", "rash", "(", "15", ".", "2", "%", ";", "CD4", ",", "285", "cells", "/", "microL", ")", "and", "peripheral", "neuropathy", "(", "9", ".", "0", "%", "and", "348", "cells", "/", "microL", ")", ".", "Clinically", "significant", "anemia", "(", "hemoglobin", "<", "7", "g", "/", "dL", ")", "was", "observed", "in", "5", ".", "4", "%", "of", "patients", "(", "CD4", ",", "165", "cells", "/", "microL", ")", "and", "hepatitis", "(", "clinical", "jaundice", "with", "alanine", "aminotransferase", ">", "5", "times", "upper", "limits", "of", "normal", ")", "in", "3", ".", "5", "%", "of", "patients", "(", "CD4", ",", "260", "cells", "/", "microL", ")", ".", "Women", "were", "significantly", "more", "likely", "to", "experience", "lactic", "acidosis", ",", "while", "men", "were", "significantly", "more", "likely", "to", "experience", "immune", "reconstitution", "syndrome", "(", "p", "<", "0", ".", "05", ")", ".", "Among", "the", "patients", "with", "1", "year", "of", "follow", "-", "up", ",", "NVP", "therapy", "was", "significantly", "associated", "with", "developing", "rash", "and", "d4T", "therapy", "with", "developing", "peripheral", "neuropathy", "(", "p", "<", "0", ".", "05", ")", ".", "Anemia", "and", "hepatitis", "often", "occur", "within", "12", "weeks", "of", "initiating", "generic", "HAART", ".", "Frequent", "and", "early", "monitoring", "for", "these", "toxicities", "is", "warranted", "in", "developing", "countries", "where", "generic", "HAART", "is", "increasingly", "available", "."]], "ner": [[[95, 95, "Chemical"], [125, 125, "Chemical"], [302, 302, "Chemical"], [179, 180, "Disease"], [306, 307, "Disease"], [97, 97, "Chemical"], [99, 99, "Chemical"], [115, 115, "Chemical"], [293, 293, "Chemical"], [164, 164, "Disease"], [300, 300, "Disease"], [93, 93, "Chemical"], [113, 113, "Chemical"], [123, 123, "Chemical"], [141, 141, "Chemical"], [10, 12, "Disease"], [43, 45, "Disease"], [57, 59, "Disease"], [108, 108, "Chemical"], [110, 110, "Chemical"], [139, 139, "Chemical"], [127, 127, "Chemical"], [129, 129, "Chemical"], [143, 143, "Chemical"], [227, 227, "Chemical"], [195, 195, "Disease"], [316, 316, "Disease"], [222, 222, "Disease"], [318, 318, "Disease"], [225, 225, "Disease"], [260, 261, "Disease"], [271, 273, "Disease"], [335, 335, "Disease"]]], "relations": [[[95, 95, 179, 180, "CID"], [95, 95, 306, 307, "CID"], [125, 125, 179, 180, "CID"], [125, 125, 306, 307, "CID"], [302, 302, 179, 180, "CID"], [302, 302, 306, 307, "CID"], [97, 97, 164, 164, "CID"], [97, 97, 300, 300, "CID"], [99, 99, 164, 164, "CID"], [99, 99, 300, 300, "CID"], [115, 115, 164, 164, "CID"], [115, 115, 300, 300, "CID"], [293, 293, 164, 164, "CID"], [293, 293, 300, 300, "CID"]]], "clusters": [], "translated": "印度南部<15>HIV感染者</15>患者接受普通HAART后的不良事件谱。为了确定在印度南部<16>HIV感染者</16>中长期、固定剂量、通用高效抗逆转录病毒疗法（HAART）使用后临床显着不良事件的发生率，我们检查了3154<17>HIV感染者</17>在1996年2月至2006年12月期间在南印度的三级HIV护理转诊中心接受了至少3个月的普通HAART治疗的个体。最常见的方案是<11>3TC</11>+<0>d4T</0>+<5>奈韦拉平</5>（<6>NVP</6>）（54.8%），<18>齐多夫定</18>（<19>AZT</19>）+<12>3TC</12>+<7>NVP</7>（14.5%），<13>3TC</13>+<1>d4T</1>+<21>依非韦伦</21>（<22>EFV</22>）（20.1%）和<20>AZT</20>+<14>3TC</14>+<23>EFV</23>（5.4%）。最常见的不良事件和事件发生时的中位CD4是<9>皮疹</9>（15.2%; CD4，285个细胞/微升）和<3>周围神经病变</3>（9.0%和348个细胞/微升）。临床显著<25>贫血</25>（血红蛋白<7 g/dL）在5.4%的患者中观察到（CD4，165个细胞/microL），而<27>肝炎</27>（临床<29>黄疸</29>和<24>丙氨酸</24>氨基转移酶> 5倍正常上限）在3.5%的患者中观察到（CD4，260个细胞/微升）。女性明显更容易出现<30>乳酸性酸中毒</30>，而男性明显更容易出现<31>免疫重建综合征</31> (p < 0.05)。在随访1年的患者中，<8>NVP </8>治疗与发生<10>皮疹</10>显着相关，<2>d4T</2>治疗与发生<4>周围神经病变</4>显着相关（ p < 0.05）。<26>贫血</26>和<28>肝炎</28>通常在开始普通HAART治疗后12周内发生。在通用HAART越来越多的发展中国家，有必要对这些<32>毒性</32>进行频繁和早期监测。", "revised": true}
{"doc_key": "19154241", "sentences": [["Long", "-", "term", "lithium", "therapy", "leading", "to", "hyperparathyroidism", ":", "a", "case", "report", ".", "PURPOSE", ":", "This", "paper", "reviews", "the", "effect", "of", "chronic", "lithium", "therapy", "on", "serum", "calcium", "level", "and", "parathyroid", "glands", ",", "its", "pathogenesis", ",", "and", "treatment", "options", ".", "We", "examined", "the", "case", "of", "a", "lithium", "-", "treated", "patient", "who", "had", "recurrent", "hypercalcemia", "to", "better", "understand", "the", "disease", "process", ".", "CONCLUSION", ":", "Primary", "hyperparathyroidism", "is", "a", "rare", "but", "potentially", "life", "-", "threatening", "side", "effect", "of", "long", "-", "term", "lithium", "therapy", ".", "Careful", "patient", "selection", "and", "long", "-", "term", "follow", "-", "up", "can", "reduce", "morbidity", ".", "PRACTICAL", "IMPLICATIONS", ":", "As", "much", "as", "15", "%", "of", "lithium", "-", "treated", "patients", "become", "hypercalcemic", ".", "By", "routinely", "monitoring", "serum", "calcium", "levels", ",", "healthcare", "providers", "can", "improve", "the", "quality", "of", "life", "of", "this", "patient", "group", "."]], "ner": [[[3, 3, "Chemical"], [22, 22, "Chemical"], [45, 45, "Chemical"], [78, 78, "Chemical"], [104, 104, "Chemical"], [7, 7, "Disease"], [52, 52, "Disease"], [109, 109, "Disease"], [62, 63, "Disease"], [26, 26, "Chemical"], [115, 115, "Chemical"]]], "relations": [[[3, 3, 7, 7, "CID"], [22, 22, 7, 7, "CID"], [45, 45, 7, 7, "CID"], [78, 78, 7, 7, "CID"], [104, 104, 7, 7, "CID"], [3, 3, 52, 52, "CID"], [3, 3, 109, 109, "CID"], [22, 22, 52, 52, "CID"], [22, 22, 109, 109, "CID"], [45, 45, 52, 52, "CID"], [45, 45, 109, 109, "CID"], [78, 78, 52, 52, "CID"], [78, 78, 109, 109, "CID"], [104, 104, 52, 52, "CID"], [104, 104, 109, 109, "CID"]]], "clusters": [], "translated": "长期<0>锂</0>治疗导致<5>甲状旁腺功能亢进</5>：病例报告。目的：本文综述了慢性<1>锂</1>疗法对血清<9>钙</9>水平和甲状旁腺的影响、其发病机制和治疗方案。我们检查了一名 <2>锂</2>治疗患者的病例，该患者患有复发性<6>高钙血症</6>以更好地了解疾病过程。结论：<8>原发性甲状旁腺功能亢进</8>是一种罕见但可能危及生命的长期<3>锂</3>治疗副作用。仔细选择患者和长期随访可以降低发病率。实际意义：多达 15% 的 <4>锂</4>治疗患者会出现<7>高钙血症</7>。通过定期监测血清<10>钙</10>水平，医疗保健提供者可以改善该患者群体的生活质量。", "revised": true}
{"doc_key": "18801087", "sentences": [["Amiodarone", "-", "related", "pulmonary", "mass", "and", "unique", "membranous", "glomerulonephritis", "in", "a", "patient", "with", "valvular", "heart", "disease", ":", "Diagnostic", "pitfall", "and", "new", "findings", ".", "Amiodarone", "is", "an", "anti", "-", "arrhythmic", "drug", "for", "life", "-", "threatening", "tachycardia", ",", "but", "various", "adverse", "effects", "have", "been", "reported", ".", "Reported", "herein", "is", "an", "autopsy", "case", "of", "valvular", "heart", "disease", ",", "in", "a", "patient", "who", "developed", "a", "lung", "mass", "(", "1", ".", "5", "cm", "in", "diameter", ")", "and", "proteinuria", "(", "2", ".", "76", "g", "/", "day", ")", "after", "treatment", "with", "amiodarone", "for", "a", "long", "time", ".", "The", "lung", "mass", "was", "highly", "suspected", "to", "be", "lung", "cancer", "on", "CT", "and", "positron", "emission", "tomography", ",", "but", "histologically", "the", "lesion", "was", "composed", "of", "lymphoplasmacytic", "infiltrates", "in", "alveolar", "walls", "and", "intra", "-", "alveolar", "accumulation", "of", "foamy", "macrophages", "containing", "characteristic", "myelinoid", "bodies", ",", "indicating", "that", "it", "was", "an", "amiodarone", "-", "related", "lesion", ".", "In", "addition", ",", "the", "lung", "tissue", "had", "unevenly", "distributed", "hemosiderin", "deposition", ",", "and", "abnormally", "tortuous", "capillaries", "were", "seen", "in", "the", "mass", "and", "in", "heavily", "hemosiderotic", "lung", "portions", "outside", "the", "mass", ".", "In", "the", "kidneys", ",", "glomeruli", "had", "membrane", "spikes", ",", "prominent", "swelling", "of", "podocytes", "and", "subepithelial", "deposits", ",", "which", "were", "sometimes", "large", "and", "hump", "-", "like", ".", "Autoimmune", "diseases", ",", "viral", "hepatitis", ",", "malignant", "neoplasms", "or", "other", "diseases", "with", "a", "known", "relationship", "to", "membranous", "glomerulonephritis", "were", "not", "found", ".", "The", "present", "case", "highlights", "the", "possibility", "that", "differential", "diagnosis", "between", "an", "amiodarone", "-", "related", "pulmonary", "lesion", "and", "a", "neoplasm", "can", "be", "very", "difficult", "radiologically", ",", "and", "suggests", "that", "membranous", "glomerulonephritis", "might", "be", "another", "possible", "complication", "of", "amiodarone", "treatment", "."]], "ner": [[[0, 0, "Chemical"], [23, 23, "Chemical"], [84, 84, "Chemical"], [137, 137, "Chemical"], [232, 232, "Chemical"], [257, 257, "Chemical"], [3, 4, "Disease"], [61, 62, "Disease"], [91, 92, "Disease"], [235, 236, "Disease"], [7, 8, "Disease"], [215, 216, "Disease"], [249, 250, "Disease"], [151, 151, "Disease"], [166, 166, "Disease"], [13, 15, "Disease"], [51, 53, "Disease"], [28, 28, "Disease"], [34, 34, "Disease"], [72, 72, "Disease"], [98, 99, "Disease"], [199, 200, "Disease"], [202, 203, "Disease"], [206, 206, "Disease"], [239, 239, "Disease"]]], "relations": [[[0, 0, 3, 4, "CID"], [0, 0, 61, 62, "CID"], [0, 0, 91, 92, "CID"], [0, 0, 235, 236, "CID"], [23, 23, 3, 4, "CID"], [23, 23, 61, 62, "CID"], [23, 23, 91, 92, "CID"], [23, 23, 235, 236, "CID"], [84, 84, 3, 4, "CID"], [84, 84, 61, 62, "CID"], [84, 84, 91, 92, "CID"], [84, 84, 235, 236, "CID"], [137, 137, 3, 4, "CID"], [137, 137, 61, 62, "CID"], [137, 137, 91, 92, "CID"], [137, 137, 235, 236, "CID"], [232, 232, 3, 4, "CID"], [232, 232, 61, 62, "CID"], [232, 232, 91, 92, "CID"], [232, 232, 235, 236, "CID"], [257, 257, 3, 4, "CID"], [257, 257, 61, 62, "CID"], [257, 257, 91, 92, "CID"], [257, 257, 235, 236, "CID"], [0, 0, 7, 8, "CID"], [0, 0, 215, 216, "CID"], [0, 0, 249, 250, "CID"], [23, 23, 7, 8, "CID"], [23, 23, 215, 216, "CID"], [23, 23, 249, 250, "CID"], [84, 84, 7, 8, "CID"], [84, 84, 215, 216, "CID"], [84, 84, 249, 250, "CID"], [137, 137, 7, 8, "CID"], [137, 137, 215, 216, "CID"], [137, 137, 249, 250, "CID"], [232, 232, 7, 8, "CID"], [232, 232, 215, 216, "CID"], [232, 232, 249, 250, "CID"], [257, 257, 7, 8, "CID"], [257, 257, 215, 216, "CID"], [257, 257, 249, 250, "CID"], [0, 0, 151, 151, "CID"], [0, 0, 166, 166, "CID"], [23, 23, 151, 151, "CID"], [23, 23, 166, 166, "CID"], [84, 84, 151, 151, "CID"], [84, 84, 166, 166, "CID"], [137, 137, 151, 151, "CID"], [137, 137, 166, 166, "CID"], [232, 232, 151, 151, "CID"], [232, 232, 166, 166, "CID"], [257, 257, 151, 151, "CID"], [257, 257, 166, 166, "CID"]]], "clusters": [], "translated": " \n\n<0>胺碘酮</0>-与<6>肺肿块</6>和独特的<10>膜性肾小球肾炎</10>相关的<15>瓣膜性心脏病</15>患者：诊断误区和新发现。 <1>胺碘酮</1>是一种抗<17>心律失常</17>药，可治疗危及生命的<18>心动过速</18>，但也有各种不良反应的报道。本文报道的是一例<16>瓣膜性心脏病</16>的尸检病例，该患者出现了<7>肺部肿块</7>（直径1.5厘米）和<19>蛋白尿</19>（2.76g/day）长期用<2>胺碘酮</2>治疗后。 <8>肺肿块</8>在CT和正电子发射断层扫描上高度怀疑<20>肺癌</20>，但组织学上病变由肺泡壁淋巴浆细胞浸润和肺泡内泡沫状积聚组成，含有特征性髓鞘小体的巨噬细胞，提示为<3>胺碘酮</3>相关病变。此外，肺组织中<13>含铁血黄素</13>沉积不均匀，肿块内及肿块外<14>含铁血黄素</14>重度肺部可见异常迂曲的毛细血管。在肾脏中，肾小球有膜刺，足细胞明显肿胀和上皮下沉积物，有时呈巨大的驼峰状。未发现<21>自身免疫性疾病</21>、<22>病毒性肝炎</22>、<23>恶性肿瘤</23>或与<11>膜性肾小球肾炎</11>已知相关的其他疾病。本病例强调了以下可能性：<4>胺碘酮</4>相关的<9>肺部病变</9>和<24>肿瘤</24>在放射学上可能非常困难，并表明<12>膜性肾小球肾炎</12>可能是<5>胺碘酮</5>治疗的另一种可能并发症。", "revised": true}
{"doc_key": "19139825", "sentences": [["Topotecan", "in", "combination", "with", "radiotherapy", "in", "unresectable", "glioblastoma", ":", "a", "phase", "2", "study", ".", "Improving", "glioblastoma", "multiforme", "(", "GBM", ")", "treatment", "with", "radio", "-", "chemotherapy", "remains", "a", "challenge", ".", "Topotecan", "is", "an", "attractive", "option", "as", "it", "exhibits", "growth", "inhibition", "of", "human", "glioma", "as", "well", "as", "brain", "penetration", ".", "The", "present", "study", "assessed", "the", "combination", "of", "radiotherapy", "(", "60", "Gy", "/", "30", "fractions", "/", "40", "days", ")", "and", "topotecan", "(", "0", ".", "9", "mg", "/", "m", "(", "2", ")", "/", "day", "on", "days", "1", "-", "5", "on", "weeks", "1", ",", "3", "and", "5", ")", "in", "50", "adults", "with", "histologically", "proven", "and", "untreated", "GBM", ".", "The", "incidence", "of", "non", "-", "hematological", "toxicities", "was", "low", "and", "grade", "3", "-", "4", "hematological", "toxicities", "were", "reported", "in", "20", "patients", "(", "mainly", "lymphopenia", "and", "neutropenia", ")", ".", "Partial", "response", "and", "stabilization", "rates", "were", "2", "%", "and", "32", "%", ",", "respectively", ",", "with", "an", "overall", "time", "to", "progression", "of", "12", "weeks", ".", "One", "-", "year", "overall", "survival", "(", "OS", ")", "rate", "was", "42", "%", ",", "with", "a", "median", "OS", "of", "40", "weeks", ".", "Topotecan", "in", "combination", "with", "radiotherapy", "was", "well", "tolerated", ".", "However", ",", "while", "response", "and", "stabilization", "concerned", "one", "-", "third", "of", "the", "patients", ",", "the", "study", "did", "not", "show", "increased", "benefits", "in", "terms", "of", "survival", "in", "patients", "with", "unresectable", "GBM", "."]], "ner": [[[0, 0, "Chemical"], [29, 29, "Chemical"], [67, 67, "Chemical"], [176, 176, "Chemical"], [126, 126, "Disease"], [128, 128, "Disease"], [7, 7, "Disease"], [15, 16, "Disease"], [18, 18, "Disease"], [101, 101, "Disease"], [214, 214, "Disease"], [41, 41, "Disease"], [109, 109, "Disease"], [118, 118, "Disease"]]], "relations": [[[0, 0, 126, 126, "CID"], [29, 29, 126, 126, "CID"], [67, 67, 126, 126, "CID"], [176, 176, 126, 126, "CID"], [0, 0, 128, 128, "CID"], [29, 29, 128, 128, "CID"], [67, 67, 128, 128, "CID"], [176, 176, 128, 128, "CID"]]], "clusters": [], "translated": "<0>拓扑替康</0>联合放疗治疗不可切除的<6>胶质母细胞瘤</6>：2期研究。改善<7>多形性胶质母细胞瘤</7>（<8>GBM</8>）的放化疗治疗仍然是一个挑战。<1>拓扑替康</1>是一个有吸引力的选择，因为它表现出对人类<11>神经胶质瘤</11>的生长抑制以及脑渗透。本研究评估了放疗（60 Gy/30次/40天）和<2>拓扑替康</2>（0.9 mg/m(2)/天，第1-5天，第1、3周和5）在50名经组织学证实且未经治疗的<9>GBM</9>成人中。非血液学<12>毒性</12>的发生率很低，20名患者报告了3-4级血液学<13>毒性</13>（主要是<4>淋巴细胞减少</4>和<5>中性粒细胞减少</5>）。部分缓解率和稳定率分别为2%和32%，总体进展时间为12周。一年总生存(OS)率为42%，中位OS为40周。<3>拓扑替康</3>联合放疗耐受性良好。然而，虽然反应和稳定涉及三分之一的患者，但该研究并未显示<10>不可切除的GBM</10>患者的生存获益增加。", "revised": true}
{"doc_key": "18945509", "sentences": [["Risk", "of", "coronary", "artery", "disease", "associated", "with", "initial", "sulphonylurea", "treatment", "of", "patients", "with", "type", "2", "diabetes", ":", "a", "matched", "case", "-", "control", "study", ".", "AIMS", ":", "This", "study", "sought", "to", "assess", "the", "risk", "of", "developing", "coronary", "artery", "disease", "(", "CAD", ")", "associated", "with", "initial", "treatment", "of", "type", "2", "diabetes", "with", "different", "sulphonylureas", ".", "METHODS", ":", "In", "type", "2", "diabetic", "patients", ",", "cases", "who", "developed", "CAD", "were", "compared", "retrospectively", "with", "controls", "that", "did", "not", ".", "The", "20", "-", "year", "risk", "of", "CAD", "at", "diagnosis", "of", "diabetes", ",", "using", "the", "UKPDS", "risk", "engine", ",", "was", "used", "to", "match", "cases", "with", "controls", ".", "RESULTS", ":", "The", "76", "cases", "of", "CAD", "were", "compared", "with", "152", "controls", ".", "The", "hazard", "of", "developing", "CAD", "(", "95", "%", "CI", ")", "associated", "with", "initial", "treatment", "increased", "by", "2", ".", "4", "-", "fold", "(", "1", ".", "3", "-", "4", ".", "3", ",", "P", "=", "0", ".", "004", ")", "with", "glibenclamide", ";", "2", "-", "fold", "(", "0", ".", "9", "-", "4", ".", "6", ",", "P", "=", "0", ".", "099", ")", "with", "glipizide", ";", "2", ".", "9", "-", "fold", "(", "1", ".", "6", "-", "5", ".", "1", ",", "P", "=", "0", ".", "000", ")", "with", "either", ",", "and", "was", "unchanged", "with", "metformin", ".", "The", "hazard", "decreased", "0", ".", "3", "-", "fold", "(", "0", ".", "7", "-", "1", ".", "7", ",", "P", "=", "0", ".", "385", ")", "with", "glimepiride", ",", "0", ".", "4", "-", "fold", "(", "0", ".", "7", "-", "1", ".", "3", ",", "P", "=", "0", ".", "192", ")", "with", "gliclazide", ",", "and", "0", ".", "4", "-", "fold", "(", "0", ".", "7", "-", "1", ".", "1", ",", "P", "=", "0", ".", "09", ")", "with", "either", ".", "CONCLUSIONS", ":", "Initiating", "treatment", "of", "type", "2", "diabetes", "with", "glibenclamide", "or", "glipizide", "is", "associated", "with", "increased", "risk", "of", "CAD", "in", "comparison", "to", "gliclazide", "or", "glimepiride", ".", "If", "confirmed", ",", "this", "may", "be", "important", "because", "most", "Indian", "patients", "receive", "the", "cheaper", "older", "sulphonylureas", ",", "and", "present", "guidelines", "do", "not", "distinguish", "between", "individual", "agents", "."]], "ner": [[[150, 150, "Chemical"], [284, 284, "Chemical"], [2, 4, "Disease"], [35, 37, "Disease"], [39, 39, "Disease"], [64, 64, "Disease"], [80, 80, "Disease"], [106, 106, "Disease"], [117, 117, "Disease"], [293, 293, "Disease"], [171, 171, "Chemical"], [286, 286, "Chemical"], [200, 200, "Chemical"], [226, 226, "Chemical"], [299, 299, "Chemical"], [249, 249, "Chemical"], [297, 297, "Chemical"], [13, 15, "Disease"], [46, 48, "Disease"], [56, 58, "Disease"], [280, 282, "Disease"], [84, 84, "Disease"]]], "relations": [[[150, 150, 2, 4, "CID"], [150, 150, 35, 37, "CID"], [150, 150, 39, 39, "CID"], [150, 150, 64, 64, "CID"], [150, 150, 80, 80, "CID"], [150, 150, 106, 106, "CID"], [150, 150, 117, 117, "CID"], [150, 150, 293, 293, "CID"], [284, 284, 2, 4, "CID"], [284, 284, 35, 37, "CID"], [284, 284, 39, 39, "CID"], [284, 284, 64, 64, "CID"], [284, 284, 80, 80, "CID"], [284, 284, 106, 106, "CID"], [284, 284, 117, 117, "CID"], [284, 284, 293, 293, "CID"]]], "clusters": [], "translated": " <2>冠状动脉疾病</2>的风险与<17>2型糖尿病</17>患者的初始磺脲类药物治疗相关：匹配病例对照研究。目的：本研究旨在评估发生<3>冠状动脉疾病</3> (<4>CAD</4>)的风险与使用不同磺脲类药物初始治疗<18>2型糖尿病</18>相关。方法：在<19>2型糖尿病</19>患者中，将发生<5>CAD</5>的病例与未发生的对照组进行回顾性比较。使用UKPDS风险引擎，将诊断为<21>糖尿病</21>时<6>CAD</6>的20年风险用于匹配病例与对照。结果：将76例<7>CAD</7>与152例对照进行比较。与初始治疗相关的发生<8>CAD</8> (95%CI)的风险增加了2.4倍 (1.3-4.3，P=0.004) 与<0>格列本脲</0>；2倍(0.9-4.6，P=0.099)与<10>格列吡嗪</10>；2.9倍(1.6-5.1，P=0.000)与任意一种，与<12>二甲双胍</12>没有变化。危险降低0.3倍(0.7-1.7，P=0.385)与<13>格列美脲</13>，0.4倍(0.7-1.3，P=0.192)与<15>格列齐特</15>，和0.4倍(0.7-1.1，P=0.09)与任意一种。结论：<1>格列本脲</1>或<11>格列吡嗪</11>开始治疗<20>2型糖尿病</20>与<9>CAD</9>风险增加相关，<16>格列齐特</16>或<14>格列美脲</14>作为初始治疗药物危险性较低。如果得到证实，这可能很重要，因为大多数印度患者接受的是更便宜的老磺脲类药物，而目前的指南并不区分不同的药物。", "revised": true}
{"doc_key": "19020118", "sentences": [["The", "risks", "of", "aprotinin", "and", "tranexamic", "acid", "in", "cardiac", "surgery", ":", "a", "one", "-", "year", "follow", "-", "up", "of", "1188", "consecutive", "patients", ".", "BACKGROUND", ":", "Our", "aim", "was", "to", "investigate", "postoperative", "complications", "and", "mortality", "after", "administration", "of", "aprotinin", "compared", "to", "tranexamic", "acid", "in", "an", "unselected", ",", "consecutive", "cohort", ".", "METHODS", ":", "Perioperative", "data", "from", "consecutive", "cardiac", "surgery", "patients", "were", "prospectively", "collected", "between", "September", "2005", "and", "June", "2006", "in", "a", "university", "-", "affiliated", "clinic", "(", "n", "=", "1188", ")", ".", "During", "the", "first", "5", "mo", ",", "596", "patients", "received", "aprotinin", "(", "Group", "A", ")", ";", "in", "the", "next", "5", "mo", ",", "592", "patients", "were", "treated", "with", "tranexamic", "acid", "(", "Group", "T", ")", ".", "Except", "for", "antifibrinolytic", "therapy", ",", "the", "anesthetic", "and", "surgical", "protocols", "remained", "unchanged", ".", "RESULTS", ":", "The", "pre", "-", "and", "intraoperative", "variables", "were", "comparable", "between", "the", "treatment", "groups", ".", "Postoperatively", ",", "a", "significantly", "higher", "incidence", "of", "seizures", "was", "found", "in", "Group", "T", "(", "4", ".", "6", "%", "vs", "1", ".", "2", "%", ",", "P", "<", "0", ".", "001", ")", ".", "This", "difference", "was", "also", "significant", "in", "the", "primary", "valve", "surgery", "and", "the", "high", "risk", "surgery", "subgroups", "(", "7", ".", "9", "%", "vs", "1", ".", "2", "%", ",", "P", "=", "0", ".", "003", ";", "7", ".", "3", "%", "vs", "2", ".", "4", "%", ",", "P", "=", "0", ".", "035", ",", "respectively", ")", ".", "Persistent", "atrial", "fibrillation", "(", "7", ".", "9", "%", "vs", "2", ".", "3", "%", ",", "P", "=", "0", ".", "020", ")", "and", "renal", "failure", "(", "9", ".", "7", "%", "vs", "1", ".", "7", "%", ",", "P", "=", "0", ".", "002", ")", "were", "also", "more", "common", "in", "Group", "T", ",", "in", "the", "primary", "valve", "surgery", "subgroup", ".", "On", "the", "contrary", ",", "among", "primary", "coronary", "artery", "bypass", "surgery", "patients", ",", "there", "were", "more", "acute", "myocardial", "infarctions", "and", "renal", "dysfunction", "in", "Group", "A", "(", "5", ".", "8", "%", "vs", "2", ".", "0", "%", ",", "P", "=", "0", ".", "027", ";", "22", ".", "5", "%", "vs", "15", ".", "2", "%", ",", "P", "=", "0", ".", "036", ",", "respectively", ")", ".", "The", "1", "-", "yr", "mortality", "was", "significantly", "higher", "after", "aprotinin", "treatment", "in", "the", "high", "risk", "surgery", "group", "(", "17", ".", "7", "%", "vs", "9", ".", "8", "%", ",", "P", "=", "0", ".", "034", ")", ".", "CONCLUSION", ":", "Both", "antifibrinolytic", "drugs", "bear", "the", "risk", "of", "adverse", "outcome", "depending", "on", "the", "type", "of", "cardiac", "surgery", ".", "Administration", "of", "aprotinin", "should", "be", "avoided", "in", "coronary", "artery", "bypass", "graft", "and", "high", "risk", "patients", ",", "whereas", "administration", "of", "tranexamic", "acid", "is", "not", "recommended", "in", "valve", "surgery", "."]], "ner": [[[5, 6, "Chemical"], [40, 41, "Chemical"], [105, 106, "Chemical"], [411, 412, "Chemical"], [147, 147, "Disease"], [244, 245, "Disease"], [294, 295, "Disease"], [297, 298, "Disease"]]], "relations": [[[5, 6, 147, 147, "CID"], [40, 41, 147, 147, "CID"], [105, 106, 147, 147, "CID"], [411, 412, 147, 147, "CID"], [5, 6, 244, 245, "CID"], [40, 41, 244, 245, "CID"], [105, 106, 244, 245, "CID"], [411, 412, 244, 245, "CID"]]], "clusters": [], "translated": "抑肽酶和<0>氨甲环酸</0>在心脏手术中的风险：对 1188 名连续患者的一年随访。背景：我们的目的是在一个未选择的连续队列中调查抑肽酶与<1>氨甲环酸</1>给药后的术后并发症和死亡率。方法：前瞻性收集 2005 年 9 月至 2006 年 6 月期间在大学附属诊所 (n = 1188) 的连续心脏手术患者的围手术期数据。在前 5 个月期间，596 名患者接受了抑肽酶治疗（A 组）；在接下来的5个月内，592名患者接受了<2>氨甲环酸</2>治疗（T 组）。除了抗纤维蛋白溶解疗法外，麻醉和手术方案保持不变。结果：术前和术中变量在治疗组之间具有可比性。术后，T 组<4>癫痫发作</4>发生率显着升高（4.6% vs 1.2%，P < 0.001）。这种差异在主要瓣膜手术和高风险手术亚组中也很显着（分别为7.9% vs 1.2%，P = 0.003；7.3% vs 2.4%，P = 0.035，分别） 。持续性心房颤动（7.9% vs 2.3%，P = 0.020）和<5>肾功能衰竭</5>（9.7% vs 1.7%，P = 0.002）也更常见于T 组，在原发性瓣膜手术亚组中。相反，在原发性冠状动脉旁路手术患者中，A 组急性<6>心肌梗死</6>和<7>肾功能不全</7>发生率更高（5.8% vs 2.0%，P = 0.027；22.5% vs 15.2%，P = 0.036，分别）。高危手术组接受抑肽酶治疗后的1年死亡率显着升高（17.7% vs 9.8%，P = 0.034）。结论：根据心脏手术的类型，两种抗纤维蛋白溶解药物都有不良后果的风险。冠状动脉旁路移植术和高危患者应避免使用抑肽酶，而瓣膜手术中不推荐使用<3>氨甲环酸</3>。", "revised": true}
{"doc_key": "17384765", "sentences": [["Succimer", "chelation", "improves", "learning", ",", "attention", ",", "and", "arousal", "regulation", "in", "lead", "-", "exposed", "rats", "but", "produces", "lasting", "cognitive", "impairment", "in", "the", "absence", "of", "lead", "exposure", ".", "BACKGROUND", ":", "There", "is", "growing", "pressure", "for", "clinicians", "to", "prescribe", "chelation", "therapy", "at", "only", "slightly", "elevated", "blood", "lead", "levels", ".", "However", ",", "very", "few", "studies", "have", "evaluated", "whether", "chelation", "improves", "cognitive", "outcomes", "in", "Pb", "-", "exposed", "children", ",", "or", "whether", "these", "agents", "have", "adverse", "effects", "that", "may", "affect", "brain", "development", "in", "the", "absence", "of", "Pb", "exposure", ".", "OBJECTIVES", ":", "The", "present", "study", "was", "designed", "to", "answer", "these", "questions", ",", "using", "a", "rodent", "model", "of", "early", "childhood", "Pb", "exposure", "and", "treatment", "with", "succimer", ",", "a", "widely", "used", "chelating", "agent", "for", "the", "treatment", "of", "Pb", "poisoning", ".", "RESULTS", ":", "Pb", "exposure", "produced", "lasting", "impairments", "in", "learning", ",", "attention", ",", "inhibitory", "control", ",", "and", "arousal", "regulation", ",", "paralleling", "the", "areas", "of", "dysfunction", "seen", "in", "Pb", "-", "exposed", "children", ".", "Succimer", "treatment", "of", "the", "Pb", "-", "exposed", "rats", "significantly", "improved", "learning", ",", "attention", ",", "and", "arousal", "regulation", ",", "although", "the", "efficacy", "of", "the", "treatment", "varied", "as", "a", "function", "of", "the", "Pb", "exposure", "level", "and", "the", "specific", "functional", "deficit", ".", "In", "contrast", ",", "succimer", "treatment", "of", "rats", "not", "previously", "exposed", "to", "Pb", "produced", "lasting", "and", "pervasive", "cognitive", "and", "affective", "dysfunction", "comparable", "in", "magnitude", "to", "that", "produced", "by", "the", "higher", "Pb", "exposure", "regimen", ".", "CONCLUSIONS", ":", "These", "are", "the", "first", "data", ",", "to", "our", "knowledge", ",", "to", "show", "that", "treatment", "with", "any", "chelating", "agent", "can", "alleviate", "cognitive", "deficits", "due", "to", "Pb", "exposure", ".", "These", "findings", "suggest", "that", "it", "may", "be", "possible", "to", "identify", "a", "succimer", "treatment", "protocol", "that", "improves", "cognitive", "outcomes", "in", "Pb", "-", "exposed", "children", ".", "However", ",", "they", "also", "suggest", "that", "succimer", "treatment", "should", "be", "strongly", "discouraged", "for", "children", "who", "do", "not", "have", "elevated", "tissue", "levels", "of", "Pb", "or", "other", "heavy", "metals", "."]], "ner": [[[0, 0, "Chemical"], [108, 108, "Chemical"], [153, 153, "Chemical"], [195, 195, "Chemical"], [265, 265, "Chemical"], [284, 284, "Chemical"], [18, 19, "Disease"], [208, 211, "Disease"], [247, 248, "Disease"], [11, 11, "Chemical"], [24, 24, "Chemical"], [44, 44, "Chemical"], [60, 60, "Chemical"], [81, 81, "Chemical"], [103, 103, "Chemical"], [124, 124, "Chemical"], [148, 148, "Chemical"], [157, 157, "Chemical"], [183, 183, "Chemical"], [203, 203, "Chemical"], [221, 221, "Chemical"], [251, 251, "Chemical"], [273, 273, "Chemical"], [300, 300, "Chemical"], [128, 139, "Disease"], [119, 120, "Disease"]]], "relations": [[[0, 0, 18, 19, "CID"], [0, 0, 208, 211, "CID"], [0, 0, 247, 248, "CID"], [108, 108, 18, 19, "CID"], [108, 108, 208, 211, "CID"], [108, 108, 247, 248, "CID"], [153, 153, 18, 19, "CID"], [153, 153, 208, 211, "CID"], [153, 153, 247, 248, "CID"], [195, 195, 18, 19, "CID"], [195, 195, 208, 211, "CID"], [195, 195, 247, 248, "CID"], [265, 265, 18, 19, "CID"], [265, 265, 208, 211, "CID"], [265, 265, 247, 248, "CID"], [284, 284, 18, 19, "CID"], [284, 284, 208, 211, "CID"], [284, 284, 247, 248, "CID"], [11, 11, 128, 139, "CID"], [24, 24, 128, 139, "CID"], [44, 44, 128, 139, "CID"], [60, 60, 128, 139, "CID"], [81, 81, 128, 139, "CID"], [103, 103, 128, 139, "CID"], [124, 124, 128, 139, "CID"], [148, 148, 128, 139, "CID"], [157, 157, 128, 139, "CID"], [183, 183, 128, 139, "CID"], [203, 203, 128, 139, "CID"], [221, 221, 128, 139, "CID"], [251, 251, 128, 139, "CID"], [273, 273, 128, 139, "CID"], [300, 300, 128, 139, "CID"]]], "clusters": [], "translated": "<0>琥珀酸</0>螯合可改善<9>铅</9>暴露大鼠的学习、注意力和觉醒调节，但在没有<10>铅</10>曝光的情况下会导致持久的<6>认知障碍</6>。背景：临床医生在血液<11>铅</11>水平轻微升高时开具螯合疗法的压力越来越大。然而，很少有研究评估螯合剂对<12>Pb</12>暴露儿童的认知结果是否有所改善，或这些药物是否会在没有<13>Pb</13>暴露的情况下产生可能影响大脑发育的副作用。目标：本研究旨在回答这些问题，使用啮齿动物模型在早期儿童<14>Pb</14>暴露和治疗<25>铅中毒</25>的广泛螯合剂<1>琥珀酸</1>方面进行研究。结果：<15>Pb</15>暴露在学习、注意力、抑制控制和觉醒调节方面产生持久的<24>损伤</24>，与<16>Pb</16>暴露儿童中观察到的功能障碍区域平行。而<2>琥珀酸</2>处理<17>Pb</17>暴露的大鼠显着改善了学习、注意力和觉醒调节，尽管治疗效果随<18>Pb</18>暴露水平和特定的功能缺陷而异。相反，对于以前未暴露于<19>Pb</19>的大鼠，<3>琥珀酸</3>的处理产生了持久和普遍的<7>认知和情感功能障碍</7>，这种损伤程度与高水平的<20>Pb</20>暴露方案相当。结论：据我们所知，这是第一个显示任何螯合剂治疗可以减轻因<21>铅</21>暴露引起的<8>认知缺陷</8>的数据。这些发现表明，可以确定适当的<4>琥珀酸</4>治疗方案，改善<22> Pb </22> 暴露儿童的认知结果。但是，他们还认为，针对未升高的<23>Pb</23>或其他重金属组织水平的儿童，强烈建议不使用<5>琥珀酸</5>进行治疗。", "revised": true}
{"doc_key": "19108278", "sentences": [["The", "biological", "properties", "of", "the", "optical", "isomers", "of", "propranolol", "and", "their", "effects", "on", "cardiac", "arrhythmias", ".", "1", ".", "The", "optical", "isomers", "of", "propranolol", "have", "been", "compared", "for", "their", "beta", "-", "blocking", "and", "antiarrhythmic", "activities", ".", "2", ".", "In", "blocking", "the", "positive", "inotropic", "and", "chronotropic", "responses", "to", "isoprenaline", ",", "(", "+", ")", "-", "propranolol", "had", "less", "than", "one", "hundredth", "the", "potency", "of", "(", "-", ")", "-", "propranolol", ".", "At", "dose", "levels", "of", "(", "+", ")", "-", "propranolol", "which", "attenuated", "the", "responses", "to", "isoprenaline", ",", "there", "was", "a", "significant", "prolongation", "of", "the", "PR", "interval", "of", "the", "electrocardiogram", ".", "3", ".", "The", "metabolic", "responses", "to", "isoprenaline", "in", "dogs", "(", "an", "increase", "in", "circulating", "glucose", ",", "lactate", "and", "free", "fatty", "acids", ")", "were", "all", "blocked", "by", "(", "-", ")", "-", "propranolol", ".", "(", "+", ")", "-", "Propranolol", "had", "no", "effect", "on", "fatty", "acid", "mobilization", "but", "significantly", "reduced", "the", "increments", "in", "both", "lactate", "and", "glucose", ".", "4", ".", "Both", "isomers", "of", "propranolol", "possessed", "similar", "depressant", "potency", "on", "isolated", "atrial", "muscle", "taken", "from", "guinea", "-", "pigs", ".", "5", ".", "The", "isomers", "of", "propranolol", "exhibited", "similar", "local", "anaesthetic", "potencies", "on", "an", "isolated", "frog", "nerve", "preparation", "at", "a", "level", "approximately", "three", "times", "that", "of", "procaine", ".", "The", "racemic", "compound", "was", "significantly", "less", "potent", "than", "either", "isomer", ".", "6", ".", "Both", "isomers", "of", "propranolol", "were", "capable", "of", "preventing", "adrenaline", "-", "induced", "cardiac", "arrhythmias", "in", "cats", "anaesthetized", "with", "halothane", ",", "but", "the", "mean", "dose", "of", "(", "-", ")", "-", "propranolol", "was", "0", ".", "09", "+", "/", "-", "0", ".", "02", "mg", "/", "kg", "whereas", "that", "of", "(", "+", ")", "-", "propranolol", "was", "4", ".", "2", "+", "/", "-", "1", ".", "2", "mg", "/", "kg", ".", "At", "the", "effective", "dose", "level", "of", "(", "+", ")", "-", "propranolol", "there", "was", "a", "significant", "prolongation", "of", "the", "PR", "interval", "of", "the", "electrocardiogram", ".", "Blockade", "of", "arrhythmias", "with", "both", "isomers", "was", "surmountable", "by", "increasing", "the", "dose", "of", "adrenaline", ".", "7", ".", "Both", "isomers", "of", "propranolol", "were", "also", "capable", "of", "reversing", "ventricular", "tachycardia", "caused", "by", "ouabain", "in", "anaesthetized", "cats", "and", "dogs", ".", "The", "dose", "of", "(", "-", ")", "-", "propranolol", "was", "significantly", "smaller", "than", "that", "of", "(", "+", ")", "-", "propranolol", "in", "both", "species", "but", "much", "higher", "than", "that", "required", "to", "produce", "evidence", "of", "beta", "-", "blockade", ".", "8", ".", "The", "implications", "of", "these", "results", "are", "discussed", "."]], "ner": [[[219, 219, "Chemical"], [312, 312, "Chemical"], [13, 14, "Disease"], [222, 223, "Disease"], [301, 301, "Disease"], [228, 228, "Chemical"], [329, 329, "Chemical"], [325, 326, "Disease"], [8, 8, "Chemical"], [22, 22, "Chemical"], [52, 52, "Chemical"], [65, 65, "Chemical"], [75, 75, "Chemical"], [126, 126, "Chemical"], [132, 132, "Chemical"], [156, 156, "Chemical"], [176, 176, "Chemical"], [214, 214, "Chemical"], [239, 239, "Chemical"], [260, 260, "Chemical"], [285, 285, "Chemical"], [319, 319, "Chemical"], [343, 343, "Chemical"], [354, 354, "Chemical"], [46, 46, "Chemical"], [81, 81, "Chemical"], [102, 102, "Chemical"], [110, 110, "Chemical"], [149, 149, "Chemical"], [112, 112, "Chemical"], [147, 147, "Chemical"], [115, 116, "Chemical"], [137, 138, "Chemical"], [196, 196, "Chemical"]]], "relations": [[[219, 219, 13, 14, "CID"], [219, 219, 222, 223, "CID"], [219, 219, 301, 301, "CID"], [312, 312, 13, 14, "CID"], [312, 312, 222, 223, "CID"], [312, 312, 301, 301, "CID"], [228, 228, 13, 14, "CID"], [228, 228, 222, 223, "CID"], [228, 228, 301, 301, "CID"], [329, 329, 325, 326, "CID"]]], "clusters": [], "translated": "<8>普萘洛尔</8>光学异构体的生物学特性及其对<2>心律失常</2>的影响。1. <9>普萘洛尔</9>的旋光异构体的β阻断和抗心律失常活性已经过比较。2.在阻断对<24>异丙肾上腺素</24>的正性肌力和变时性反应时，(+)-<10>普萘洛尔</10>的效力不到(-)-<11>普萘洛尔</11>的百分之一。在减弱对<25>异丙肾上腺素</25>反应的(+)-<12>普萘洛尔</12>剂量水平下，心电图PR间期显着延长。3.狗对<26>异丙肾上腺素</26>的代谢反应（循环<27>葡萄糖</27>、<29>乳酸</29>和游离<31>脂肪酸</31>的增加）都是被(-)-<13>普萘洛尔</13>阻断。(+)-<14>普萘洛尔</14>对<32>脂肪酸</32>动员没有影响，但显着降低了<30>乳酸</30>和<28>葡萄糖</28>的增量。4.<15>普萘洛尔</15>的两种异构体对取自豚鼠的离体心房肌具有相似的抑制效力。5.<16>普萘洛尔</16>的异构体对分离的青蛙神经制剂表现出相似的局部麻醉效力，其水平约为<33>普鲁卡因</33>的三倍。外消旋化合物的效力明显低于任一异构体。6.<17>普萘洛尔</17>的两种异构体都能够预防<0>肾上腺素</0>-诱导的<3>心律失常</3>在用<5>氟烷</5>麻醉的猫中，但平均(-)-<18>普萘洛尔</18>剂量为0.09+/-0.02毫克/千克而(+)-<19>普萘洛尔</19>为4.2+/-1.2毫克/千克。在(+)-<20>普萘洛尔</20>的有效剂量水平下，心电图PR间期明显延长。通过增加<1>肾上腺素</1>的剂量，可以克服两种异构体对<4>心律失常</4>的阻断作用。7.<21>普萘洛尔</21>的两种异构体还能够逆转麻醉猫和狗因<6>哇巴因</6>引起的<7>室性心动过速</7>。在两个物种中，(-)-<22>普萘洛尔</22>的剂量明显小于(+)-<23>普萘洛尔</23>的剂量，但远高于产生β-阻断证据所需的剂量。8.讨论了这些结果的含义。", "revised": true}
{"doc_key": "19184102", "sentences": [["Nonalcoholic", "fatty", "liver", "disease", "during", "valproate", "therapy", ".", "Valproic", "acid", "(", "VPA", ")", "is", "effective", "for", "the", "treatment", "of", "many", "types", "of", "epilepsy", ",", "but", "its", "use", "can", "be", "associated", "with", "an", "increase", "in", "body", "weight", ".", "We", "report", "a", "case", "of", "nonalcoholic", "fatty", "liver", "disease", "(", "NAFLD", ")", "arising", "in", "a", "child", "who", "developed", "obesity", "during", "VPA", "treatment", ".", "Laboratory", "data", "revealed", "hyperinsulinemia", "with", "insulin", "resistance", ".", "After", "the", "withdrawal", "of", "VPA", "therapy", ",", "our", "patient", "showed", "a", "significant", "weight", "loss", ",", "a", "decrease", "of", "body", "mass", "index", ",", "and", "normalization", "of", "metabolic", "and", "endocrine", "parameters", ";", "moreover", ",", "ultrasound", "measurements", "showed", "a", "complete", "normalization", ".", "The", "present", "case", "suggests", "that", "obesity", ",", "hyperinsulinemia", ",", "insulin", "resistance", ",", "and", "long", "-", "term", "treatment", "with", "VPA", "may", "be", "all", "associated", "with", "the", "development", "of", "NAFLD", ";", "this", "side", "effect", "is", "reversible", "after", "VPA", "withdrawal", "."]], "ner": [[[5, 5, "Chemical"], [8, 9, "Chemical"], [11, 11, "Chemical"], [57, 57, "Chemical"], [72, 72, "Chemical"], [125, 125, "Chemical"], [142, 142, "Chemical"], [0, 3, "Disease"], [42, 45, "Disease"], [47, 47, "Disease"], [134, 134, "Disease"], [55, 55, "Disease"], [112, 112, "Disease"], [63, 63, "Disease"], [114, 114, "Disease"], [65, 66, "Disease"], [116, 117, "Disease"], [22, 22, "Disease"], [80, 81, "Disease"]]], "relations": [[[5, 5, 0, 3, "CID"], [5, 5, 42, 45, "CID"], [5, 5, 47, 47, "CID"], [5, 5, 134, 134, "CID"], [8, 9, 0, 3, "CID"], [8, 9, 42, 45, "CID"], [8, 9, 47, 47, "CID"], [8, 9, 134, 134, "CID"], [11, 11, 0, 3, "CID"], [11, 11, 42, 45, "CID"], [11, 11, 47, 47, "CID"], [11, 11, 134, 134, "CID"], [57, 57, 0, 3, "CID"], [57, 57, 42, 45, "CID"], [57, 57, 47, 47, "CID"], [57, 57, 134, 134, "CID"], [72, 72, 0, 3, "CID"], [72, 72, 42, 45, "CID"], [72, 72, 47, 47, "CID"], [72, 72, 134, 134, "CID"], [125, 125, 0, 3, "CID"], [125, 125, 42, 45, "CID"], [125, 125, 47, 47, "CID"], [125, 125, 134, 134, "CID"], [142, 142, 0, 3, "CID"], [142, 142, 42, 45, "CID"], [142, 142, 47, 47, "CID"], [142, 142, 134, 134, "CID"], [5, 5, 55, 55, "CID"], [5, 5, 112, 112, "CID"], [8, 9, 55, 55, "CID"], [8, 9, 112, 112, "CID"], [11, 11, 55, 55, "CID"], [11, 11, 112, 112, "CID"], [57, 57, 55, 55, "CID"], [57, 57, 112, 112, "CID"], [72, 72, 55, 55, "CID"], [72, 72, 112, 112, "CID"], [125, 125, 55, 55, "CID"], [125, 125, 112, 112, "CID"], [142, 142, 55, 55, "CID"], [142, 142, 112, 112, "CID"], [5, 5, 63, 63, "CID"], [5, 5, 114, 114, "CID"], [8, 9, 63, 63, "CID"], [8, 9, 114, 114, "CID"], [11, 11, 63, 63, "CID"], [11, 11, 114, 114, "CID"], [57, 57, 63, 63, "CID"], [57, 57, 114, 114, "CID"], [72, 72, 63, 63, "CID"], [72, 72, 114, 114, "CID"], [125, 125, 63, 63, "CID"], [125, 125, 114, 114, "CID"], [142, 142, 63, 63, "CID"], [142, 142, 114, 114, "CID"], [5, 5, 65, 66, "CID"], [5, 5, 116, 117, "CID"], [8, 9, 65, 66, "CID"], [8, 9, 116, 117, "CID"], [11, 11, 65, 66, "CID"], [11, 11, 116, 117, "CID"], [57, 57, 65, 66, "CID"], [57, 57, 116, 117, "CID"], [72, 72, 65, 66, "CID"], [72, 72, 116, 117, "CID"], [125, 125, 65, 66, "CID"], [125, 125, 116, 117, "CID"], [142, 142, 65, 66, "CID"], [142, 142, 116, 117, "CID"]]], "clusters": [], "translated": "<7>非酒精性脂肪肝</7>在<0>丙戊酸盐</0>治疗期间。 <1>丙戊酸</1>（<2>VPA</2>）可有效治疗多种类型的<17>癫痫</17>，但使用它可能会导致体重增加。我们报告了一例<8>非酒精性脂肪性肝病</8>（<9>NAFLD</9>），该病例发生于一名儿童，该儿童在<3>VPA</3>治疗期间出现了<11>肥胖</11>。实验室数据显示<13>高胰岛素血症</13>伴有<15>胰岛素抵抗</15>。在停止<4>VPA</4>治疗后，我们的患者表现出明显的<18>体重减轻</18>、体重指数下降以及代谢和内分泌参数正常化；此外，超声测量显示完全正常化。本病例表明<12>肥胖</12>、<14>高胰岛素血症</14>、<16>胰岛素抵抗</16>和长期使用<5>VPA</5>可能与<10>NAFLD</10>的发展有关；这种副作用在<6>VPA</6>停药后是可逆的。", "revised": true}
{"doc_key": "18450790", "sentences": [["Thalidomide", "and", "sensory", "neurotoxicity", ":", "a", "neurophysiological", "study", ".", "BACKGROUND", ":", "Recent", "studies", "confirmed", "a", "high", "incidence", "of", "sensory", "axonal", "neuropathy", "in", "patients", "treated", "with", "different", "doses", "of", "thalidomide", ".", "The", "study", "'s", "aims", "were", "to", "measure", "variations", "in", "sural", "nerve", "sensory", "action", "potential", "(", "SAP", ")", "amplitude", "in", "patients", "with", "refractory", "cutaneous", "lupus", "erythematosus", "(", "CLE", ")", "treated", "with", "thalidomide", "and", "use", "these", "findings", "to", "identify", "the", "neurotoxic", "potential", "of", "thalidomide", "and", "the", "recovery", "capacity", "of", "sensory", "fibres", "after", "discontinuation", "of", "treatment", ".", "PATIENTS", "AND", "METHODS", ":", "Clinical", "and", "electrophysiological", "data", "in", "12", "female", "patients", "with", "CLE", "during", "treatment", "with", "thalidomide", "and", "up", "to", "47", "months", "after", "discontinuation", "of", "treatment", "were", "analysed", ".", "Sural", "nerve", "SAP", "amplitude", "reduction", ">", "or", "=", "40", "%", "was", "the", "criteria", "for", "discontinuing", "therapy", ".", "RESULTS", ":", "During", "treatment", ",", "11", "patients", "showed", "a", "reduction", "in", "sural", "nerve", "SAP", "amplitude", "compared", "to", "baseline", "values", "(", "9", "with", "a", "reduction", ">", "or", "=", "50", "%", "and", "2", "<", "50", "%", ")", ".", "One", "patient", "showed", "no", "changes", "in", "SAP", "amplitude", ".", "Five", "patients", "complained", "of", "paresthesias", "and", "leg", "cramps", ".", "After", "thalidomide", "treatment", ",", "sural", "SAP", "amplitude", "recovered", "in", "3", "patients", ".", "At", "detection", "of", "reduction", "in", "sural", "nerve", "SAP", "amplitude", ",", "the", "median", "thalidomide", "cumulative", "dose", "was", "21", ".", "4", "g", ".", "The", "threshold", "neurotoxic", "dosage", "is", "lower", "than", "previously", "reported", ".", "CONCLUSIONS", ":", "Sural", "nerve", "SAP", "amplitude", "reduction", "is", "a", "reliable", "and", "sensitive", "marker", "of", "degeneration", "and", "recovery", "of", "sensory", "fibres", ".", "This", "electrophysiological", "parameter", "provides", "information", "about", "subclinical", "neurotoxic", "potential", "of", "thalidomide", "but", "is", "not", "helpful", "in", "predicting", "the", "appearance", "of", "sensory", "symptoms", "."]], "ner": [[[0, 0, "Chemical"], [28, 28, "Chemical"], [60, 60, "Chemical"], [71, 71, "Chemical"], [101, 101, "Chemical"], [186, 186, "Chemical"], [209, 209, "Chemical"], [259, 259, "Chemical"], [2, 3, "Disease"], [18, 20, "Disease"], [180, 180, "Disease"], [183, 183, "Disease"], [52, 54, "Disease"], [56, 56, "Disease"], [97, 97, "Disease"], [68, 68, "Disease"], [220, 220, "Disease"], [256, 256, "Disease"]]], "relations": [[[0, 0, 2, 3, "CID"], [0, 0, 18, 20, "CID"], [28, 28, 2, 3, "CID"], [28, 28, 18, 20, "CID"], [60, 60, 2, 3, "CID"], [60, 60, 18, 20, "CID"], [71, 71, 2, 3, "CID"], [71, 71, 18, 20, "CID"], [101, 101, 2, 3, "CID"], [101, 101, 18, 20, "CID"], [186, 186, 2, 3, "CID"], [186, 186, 18, 20, "CID"], [209, 209, 2, 3, "CID"], [209, 209, 18, 20, "CID"], [259, 259, 2, 3, "CID"], [259, 259, 18, 20, "CID"], [0, 0, 180, 180, "CID"], [28, 28, 180, 180, "CID"], [60, 60, 180, 180, "CID"], [71, 71, 180, 180, "CID"], [101, 101, 180, 180, "CID"], [186, 186, 180, 180, "CID"], [209, 209, 180, 180, "CID"], [259, 259, 180, 180, "CID"], [0, 0, 183, 183, "CID"], [28, 28, 183, 183, "CID"], [60, 60, 183, 183, "CID"], [71, 71, 183, 183, "CID"], [101, 101, 183, 183, "CID"], [186, 186, 183, 183, "CID"], [209, 209, 183, 183, "CID"], [259, 259, 183, 183, "CID"]]], "clusters": [], "translated": "<0>沙利度胺</0>和<8>感觉神经毒性</8>：一项神经生理学研究。背景：最近的研究证实，在接受不同剂量的<1>沙利度胺</1>治疗的患者中，<9>感觉轴索性神经病变</9>的发生率很高。该研究的目的是测量变异，用 <2>沙利度胺</2> 治疗的难治性<12>皮肤红斑狼疮</12>（<13>CLE</13>）患者的腓肠神经感觉动作电位（ SAP ）幅度，并利用这些研究结果来确定<3>沙利度胺</3>的<15>神经毒性</15>潜力和治疗停止后感觉纤维的恢复能力。患者和方法：分析了12名女性<14>CLE</14>患者在治疗<4>沙利度胺</4>和停药后长达47个月的临床和电生理数据。腓肠神经 SAP 振幅降低 > 或 = 40% 是停止治疗的标准。结果：治疗期间，11名患者的腓肠神经 SAP 振幅与基线值相比有所降低（9例降低 > 或 = 50%，2例降低<50%）。一名患者的 SAP 振幅没有变化。五名患者抱怨<10>感觉异常</10>和腿部<11>抽筋</11>。 3例患者在<5>沙利度胺</5>治疗后腓肠神经 SAP 波幅度恢复。在检测到腓肠神经 SAP 振幅降低时，中位<6>沙利度胺</6>累积剂量为21.4克。阈值<16>神经毒性</16>剂量低于先前报道的剂量。结论：腓肠神经 SAP 振幅降低是感觉纤维退化和恢复的可靠且敏感的指标。该电生理参数提供了有关<7>沙利度胺</7>亚临床<17>神经毒性</17>潜力的信息，但无法预测出现感觉症状。", "revised": true}
{"doc_key": "19178808", "sentences": [["Comparison", "of", "laryngeal", "mask", "with", "endotracheal", "tube", "for", "anesthesia", "in", "endoscopic", "sinus", "surgery", ".", "BACKGROUND", ":", "The", "purpose", "of", "this", "study", "was", "to", "compare", "surgical", "conditions", ",", "including", "the", "amount", "of", "intraoperative", "bleeding", "as", "well", "as", "intraoperative", "blood", "pressure", ",", "during", "functional", "endoscopic", "sinus", "surgery", "(", "FESS", ")", "using", "flexible", "reinforced", "laryngeal", "mask", "airway", "(", "FRLMA", ")", "versus", "endotracheal", "tube", "(", "ETT", ")", "in", "maintaining", "controlled", "hypotension", "anesthesia", "induced", "by", "propofol", "-", "remifentanil", "total", "i", ".", "v", ".", "anesthesia", "(", "TIVA", ")", ".", "METHODS", ":", "Sixty", "normotensive", "American", "Society", "of", "Anesthesiologists", "I", "-", "II", "adult", "patients", "undergoing", "FESS", "under", "controlled", "hypotension", "anesthesia", "caused", "by", "propofol", "-", "remifentanil", "-", "TIVA", "were", "randomly", "assigned", "into", "two", "groups", ":", "group", "I", ",", "FRLMA", ";", "group", "II", ",", "ETT", ".", "Hemorrhage", "was", "measured", "and", "the", "visibility", "of", "the", "operative", "field", "was", "evaluated", "according", "to", "a", "six", "-", "point", "scale", ".", "RESULTS", ":", "Controlled", "hypotension", "was", "achieved", "within", "a", "shorter", "period", "using", "laryngeal", "mask", "using", "lower", "rates", "of", "remifentanil", "infusion", "and", "lower", "total", "dose", "of", "remifentanil", ".", "CONCLUSION", ":", "In", "summary", ",", "our", "results", "indicate", "that", "airway", "management", "using", "FRLMA", "during", "controlled", "hypotension", "anesthesia", "provided", "better", "surgical", "conditions", "in", "terms", "of", "quality", "of", "operative", "field", "and", "blood", "loss", "and", "allowed", "for", "convenient", "induced", "hypotension", "with", "low", "doses", "of", "remifentanil", "during", "TIVA", "in", "patients", "undergoing", "FESS", "."]], "ner": [[[70, 70, "Chemical"], [104, 104, "Chemical"], [66, 66, "Disease"], [100, 100, "Disease"], [149, 149, "Disease"], [187, 187, "Disease"], [208, 208, "Disease"], [72, 72, "Chemical"], [106, 106, "Chemical"], [163, 163, "Chemical"], [170, 170, "Chemical"], [213, 213, "Chemical"], [32, 32, "Disease"], [126, 126, "Disease"]]], "relations": [[[70, 70, 66, 66, "CID"], [70, 70, 100, 100, "CID"], [70, 70, 149, 149, "CID"], [70, 70, 187, 187, "CID"], [70, 70, 208, 208, "CID"], [104, 104, 66, 66, "CID"], [104, 104, 100, 100, "CID"], [104, 104, 149, 149, "CID"], [104, 104, 187, 187, "CID"], [104, 104, 208, 208, "CID"], [72, 72, 66, 66, "CID"], [72, 72, 100, 100, "CID"], [72, 72, 149, 149, "CID"], [72, 72, 187, 187, "CID"], [72, 72, 208, 208, "CID"], [106, 106, 66, 66, "CID"], [106, 106, 100, 100, "CID"], [106, 106, 149, 149, "CID"], [106, 106, 187, 187, "CID"], [106, 106, 208, 208, "CID"], [163, 163, 66, 66, "CID"], [163, 163, 100, 100, "CID"], [163, 163, 149, 149, "CID"], [163, 163, 187, 187, "CID"], [163, 163, 208, 208, "CID"], [170, 170, 66, 66, "CID"], [170, 170, 100, 100, "CID"], [170, 170, 149, 149, "CID"], [170, 170, 187, 187, "CID"], [170, 170, 208, 208, "CID"], [213, 213, 66, 66, "CID"], [213, 213, 100, 100, "CID"], [213, 213, 149, 149, "CID"], [213, 213, 187, 187, "CID"], [213, 213, 208, 208, "CID"]]], "clusters": [], "translated": "鼻内窥镜手术中喉罩与气管插管麻醉的比较。背景：本研究的目的是比较手术条件，包括术中<12>出血量</12>以及术中血压，在功能性内窥镜鼻窦手术(FESS)中使用柔性强化喉罩气道(FRLMA)与气管插管(ETT)相比，<0>丙泊酚</0>-<7>瑞芬太尼</7>诱导的控制性<2>低血压</2>麻醉总i.诉。麻醉(TIVA)。方法：60例血压正常的美国麻醉医师协会I-II级成年患者在<1>异丙酚</1>-<8>瑞芬太尼</8>-TIVA引起的控制性<3>低血压</3>麻醉下接受FESS，分为两组：第一组，FRLMA；第二组，ETT。<13>出血</13>进行了测量，手术视野的可见度根据六点量表进行了评估。结果：使用喉罩、较低的<9>瑞芬太尼</9>输注率和较低的<10>瑞芬太尼</10>总剂量，可在较短时间内实现控制性<4>低血压</4>。结论：总之，我们的结果表明，在控制性<5>低血压</5>麻醉期间使用FRLMA气道管理在手术野质量和失血方面提供了更好的手术条件，并允许方便地诱导<6>低血压</6> 在接受FESS的患者中，在TIVA期间使用低剂量的<11>瑞芬太尼</11>。", "revised": true}
{"doc_key": "19419794", "sentences": [["Increased", "vulnerability", "to", "6", "-", "hydroxydopamine", "lesion", "and", "reduced", "development", "of", "dyskinesias", "in", "mice", "lacking", "CB1", "cannabinoid", "receptors", ".", "Motor", "impairment", ",", "dopamine", "(", "DA", ")", "neuronal", "activity", "and", "proenkephalin", "(", "PENK", ")", "gene", "expression", "in", "the", "caudate", "-", "putamen", "(", "CPu", ")", "were", "measured", "in", "6", "-", "OHDA", "-", "lesioned", "and", "treated", "(", "L", "-", "DOPA", "+", "benserazide", ")", "CB1", "KO", "and", "WT", "mice", ".", "A", "lesion", "induced", "by", "6", "-", "OHDA", "produced", "more", "severe", "motor", "deterioration", "in", "CB1", "KO", "mice", "accompanied", "by", "more", "loss", "of", "DA", "neurons", "and", "increased", "PENK", "gene", "expression", "in", "the", "CPu", ".", "Oxidative", "/", "nitrosative", "and", "neuroinflammatory", "parameters", "were", "estimated", "in", "the", "CPu", "and", "cingulate", "cortex", "(", "Cg", ")", ".", "CB1", "KO", "mice", "exhibited", "higher", "MDA", "levels", "and", "iNOS", "protein", "expression", "in", "the", "CPu", "and", "Cg", "compared", "to", "WT", "mice", ".", "Treatment", "with", "L", "-", "DOPA", "+", "benserazide", "(", "12", "weeks", ")", "resulted", "in", "less", "severe", "dyskinesias", "in", "CB1", "KO", "than", "in", "WT", "mice", ".", "The", "results", "revealed", "that", "the", "lack", "of", "cannabinoid", "CB1", "receptors", "increased", "the", "severity", "of", "motor", "impairment", "and", "DA", "lesion", ",", "and", "reduced", "L", "-", "DOPA", "-", "induced", "dyskinesias", ".", "These", "results", "suggest", "that", "activation", "of", "CB1", "receptors", "offers", "neuroprotection", "against", "dopaminergic", "lesion", "and", "the", "development", "of", "L", "-", "DOPA", "-", "induced", "dyskinesias", "."]], "ner": [[[183, 185, "Chemical"], [207, 209, "Chemical"], [11, 11, "Disease"], [152, 152, "Disease"], [188, 188, "Disease"], [212, 212, "Disease"], [3, 5, "Chemical"], [46, 48, "Chemical"], [70, 72, "Chemical"], [22, 22, "Chemical"], [24, 24, "Chemical"], [87, 87, "Chemical"], [178, 178, "Chemical"], [29, 29, "Chemical"], [31, 31, "Chemical"], [91, 91, "Chemical"], [54, 58, "Chemical"], [139, 143, "Chemical"], [121, 121, "Chemical"]]], "relations": [[[183, 185, 11, 11, "CID"], [183, 185, 152, 152, "CID"], [183, 185, 188, 188, "CID"], [183, 185, 212, 212, "CID"], [207, 209, 11, 11, "CID"], [207, 209, 152, 152, "CID"], [207, 209, 188, 188, "CID"], [207, 209, 212, 212, "CID"]]], "clusters": [], "translated": "在缺乏 CB1 大麻素受体的小鼠中，<6>6-羟基多巴胺</6>损伤的易感性增加，<2>运动障碍</2>的发展减少。运动障碍、<9>多巴胺</9>（<10>DA</10>）神经元活动和 <13>脑啡肽原</13>（<14>PENK</14>）基因表达（CPu）在 <7>6-OHDA</7> 损伤和治疗 (<16>L-DOPA+苄丝肼</16>) CB1 KO 和 WT 小鼠中测量。 <8>6-OHDA</8> 诱导的损伤在 CB1 KO 小鼠中产生更严重的运动退化，伴随着更多的 <11>DA</11> 神经元损失和增加的 <15> PENK </15> 基因表达中央处理器。在 CPu 和扣带皮层 (Cg) 中估计了氧化/亚硝化和神经炎症参数。CB1 KO 小鼠在 CPu 和 Cg 中表现出更高的 <18> MDA </18> 水平和 iNOS 蛋白表达，与 WT 小鼠相比。治疗 (<17> L-DOPA+苄丝肼 </17>) (12 周) 导致 CB1 KO 小鼠的<3>运动障碍</3>比 WT 小鼠更轻。结果表明，缺乏大麻素 CB1 受体会增加运动障碍和 <12> DA </12> 损伤的严重程度，并减少 <0>L-DOPA</0> 引起的 <4>运动障碍</4>。这些结果表明，CB1 受体的激活提供了针对多巴胺能损伤和<1> L-DOPA </1> 诱导的<5> 运动障碍 </5> 发展的神经保护作用。", "revised": true}
{"doc_key": "19447152", "sentences": [["Animal", "model", "of", "mania", "induced", "by", "ouabain", ":", "Evidence", "of", "oxidative", "stress", "in", "submitochondrial", "particles", "of", "the", "rat", "brain", ".", "The", "intracerebroventricular", "(", "ICV", ")", "administration", "of", "ouabain", "(", "a", "Na", "(", "+", ")", "/", "K", "(", "+", ")", "-", "ATPase", "inhibitor", ")", "in", "rats", "has", "been", "suggested", "to", "mimic", "some", "symptoms", "of", "human", "bipolar", "mania", ".", "Clinical", "studies", "have", "shown", "that", "bipolar", "disorder", "may", "be", "related", "to", "mitochondrial", "dysfunction", ".", "Herein", ",", "we", "investigated", "the", "behavioral", "and", "biochemical", "effects", "induced", "by", "the", "ICV", "administration", "of", "ouabain", "in", "rats", ".", "To", "achieve", "this", "aim", ",", "the", "effects", "of", "ouabain", "injection", "immediately", "after", "and", "7", "days", "following", "a", "single", "ICV", "administration", "(", "at", "concentrations", "of", "10", "(", "-", "2", ")", "and", "10", "(", "-", "3", ")", "M", ")", "on", "locomotion", "was", "measured", "using", "the", "open", "-", "field", "test", ".", "Additionally", ",", "thiobarbituric", "acid", "reactive", "substances", "(", "TBARSs", ")", "and", "superoxide", "production", "were", "measured", "in", "submitochondrial", "particles", "of", "the", "prefrontal", "cortex", ",", "hippocampus", ",", "striatum", "and", "amygdala", ".", "Our", "findings", "demonstrated", "that", "ouabain", "at", "10", "(", "-", "2", ")", "and", "10", "(", "-", "3", ")", "M", "induced", "hyperlocomotion", "in", "rats", ",", "and", "this", "response", "remained", "up", "to", "7", "days", "following", "a", "single", "ICV", "injection", ".", "In", "addition", ",", "we", "observed", "that", "the", "persistent", "increase", "in", "the", "rat", "spontaneous", "locomotion", "is", "associated", "with", "increased", "TBARS", "levels", "and", "superoxide", "generation", "in", "submitochondrial", "particles", "in", "the", "prefrontal", "cortex", ",", "striatum", "and", "amygdala", ".", "In", "conclusion", ",", "ouabain", "-", "induced", "mania", "-", "like", "behavior", "may", "provide", "a", "useful", "animal", "model", "to", "test", "the", "hypothesis", "of", "the", "involvement", "of", "oxidative", "stress", "in", "bipolar", "disorder", "."]], "ner": [[[6, 6, "Chemical"], [27, 27, "Chemical"], [86, 86, "Chemical"], [98, 98, "Chemical"], [170, 170, "Chemical"], [241, 241, "Chemical"], [3, 3, "Disease"], [54, 55, "Disease"], [62, 63, "Disease"], [244, 244, "Disease"], [265, 266, "Disease"], [30, 30, "Chemical"], [35, 35, "Chemical"], [140, 141, "Chemical"], [148, 148, "Chemical"], [224, 224, "Chemical"], [68, 69, "Disease"], [185, 185, "Disease"]]], "relations": [[[6, 6, 3, 3, "CID"], [6, 6, 54, 55, "CID"], [6, 6, 62, 63, "CID"], [6, 6, 244, 244, "CID"], [6, 6, 265, 266, "CID"], [27, 27, 3, 3, "CID"], [27, 27, 54, 55, "CID"], [27, 27, 62, 63, "CID"], [27, 27, 244, 244, "CID"], [27, 27, 265, 266, "CID"], [86, 86, 3, 3, "CID"], [86, 86, 54, 55, "CID"], [86, 86, 62, 63, "CID"], [86, 86, 244, 244, "CID"], [86, 86, 265, 266, "CID"], [98, 98, 3, 3, "CID"], [98, 98, 54, 55, "CID"], [98, 98, 62, 63, "CID"], [98, 98, 244, 244, "CID"], [98, 98, 265, 266, "CID"], [170, 170, 3, 3, "CID"], [170, 170, 54, 55, "CID"], [170, 170, 62, 63, "CID"], [170, 170, 244, 244, "CID"], [170, 170, 265, 266, "CID"], [241, 241, 3, 3, "CID"], [241, 241, 54, 55, "CID"], [241, 241, 62, 63, "CID"], [241, 241, 244, 244, "CID"], [241, 241, 265, 266, "CID"]]], "clusters": [], "translated": "<0>哇巴因</0>诱发的<6>躁狂</6>动物模型：大鼠大脑亚线粒体颗粒氧化应激的证据。已建议在大鼠脑室内 (ICV) 施用<1>哇巴因</1>（一种<11> Na</11> (+)/<12> K</12> (+) - ATP 酶抑制剂）模仿人类<7>躁郁症</7>的一些症状。临床研究表明，<8>双相情感障碍</8>可能与<16>线粒体功能障碍</16>有关。在此，我们研究了通过 ICV 给药<2>哇巴因</2>诱导大鼠的行为和生化效应。为实现这一目标，使用单次 ICV 给药后立即和 7 天后注射<3>哇巴因</3>对运动的影响（浓度分别为 10(-2)和10(-3) M）开展试验。此外，在前额叶皮层、海马、纹状体和杏仁核的线粒体颗粒中测量了<13>硫代巴比妥酸</13>活性物质（TBARSs）和<14>超氧化物</14>的产生。我们的研究结果表明，<4>哇巴因</4>在10(-2)和10(-3) M诱导大鼠<17>过度运动</17>，并且这种反应在单次 ICV 注射后保持长达 7 天。此外，我们观察到大鼠自发运动的持续增加与前额皮质、纹状体和杏仁核中线粒体颗粒中 TBARS 水平和<15>超氧化物</15>生成的增加有关。总之，<5>哇巴因</5>诱导的<9>躁狂</9>样行为可能提供有用的动物模型来检验氧化应激参与<10>双相情感障碍</10>的假设。", "revised": true}
{"doc_key": "19515070", "sentences": [["Intraoperative", "dialysis", "during", "liver", "transplantation", "with", "citrate", "dialysate", ".", "Liver", "transplantation", "for", "acutely", "ill", "patients", "with", "fulminant", "liver", "failure", "carries", "high", "intraoperative", "and", "immediate", "postoperative", "risks", ".", "These", "are", "increased", "with", "the", "presence", "of", "concomitant", "acute", "kidney", "injury", "(", "AKI", ")", "and", "intraoperative", "dialysis", "is", "sometimes", "required", "to", "allow", "the", "transplant", "to", "proceed", ".", "The", "derangements", "in", "the", "procoagulant", "and", "anticoagulant", "pathways", "during", "fulminant", "liver", "failure", "can", "lead", "to", "difficulties", "with", "anticoagulation", "during", "dialysis", ",", "especially", "when", "continued", "in", "the", "operating", "room", ".", "Systemic", "anticoagulation", "is", "unsafe", "and", "regional", "citrate", "anticoagulation", "in", "the", "absence", "of", "a", "functional", "liver", "carries", "the", "risk", "of", "citrate", "toxicity", ".", "Citrate", "dialysate", ",", "a", "new", "dialysate", "with", "citric", "acid", "can", "be", "used", "for", "anticoagulation", "in", "patients", "who", "can", "not", "tolerate", "heparin", "or", "regional", "citrate", ".", "We", "report", "a", "case", "of", "a", "40", "-", "year", "-", "old", "female", "with", "acetaminophen", "-", "induced", "fulminant", "liver", "failure", "with", "associated", "AKI", "who", "underwent", "intraoperative", "dialytic", "support", "during", "liver", "transplantation", "anticoagulated", "with", "citrate", "dialysate", "during", "the", "entire", "procedure", ".", "The", "patient", "tolerated", "the", "procedure", "well", "without", "any", "signs", "of", "citrate", "toxicity", "and", "maintained", "adequate", "anticoagulation", "for", "patency", "of", "the", "dialysis", "circuit", ".", "Citrate", "dialysate", "is", "a", "safe", "alternative", "for", "intradialytic", "support", "of", "liver", "transplantation", "in", "fulminant", "liver", "failure", "."]], "ner": [[[143, 143, "Chemical"], [16, 18, "Disease"], [63, 65, "Disease"], [146, 148, "Disease"], [205, 207, "Disease"], [35, 37, "Disease"], [39, 39, "Disease"], [151, 151, "Disease"], [6, 6, "Chemical"], [89, 89, "Chemical"], [102, 102, "Chemical"], [105, 105, "Chemical"], [112, 113, "Chemical"], [128, 128, "Chemical"], [162, 162, "Chemical"], [179, 179, "Chemical"], [192, 192, "Chemical"], [103, 103, "Disease"], [180, 180, "Disease"], [125, 125, "Chemical"]]], "relations": [[[143, 143, 16, 18, "CID"], [143, 143, 63, 65, "CID"], [143, 143, 146, 148, "CID"], [143, 143, 205, 207, "CID"], [143, 143, 35, 37, "CID"], [143, 143, 39, 39, "CID"], [143, 143, 151, 151, "CID"]]], "clusters": [], "translated": "<8>柠檬酸盐</8>透析液肝移植术中透析。对<1>暴发性肝功能衰竭</1>的急性病患者进行肝移植具有很高的术中和术后即刻风险。这些随着伴随的<5>急性肾损伤</5> (<6>AKI</6>)的存在而增加，并且有时需要术中透析以允许移植继续进行。 <2>暴发性肝功能衰竭</2>期间促凝和抗凝途径的紊乱可导致透析期间抗凝困难，尤其是在手术室继续进行时。全身抗凝是不安全的，在没有功能性肝脏的情况下，局部<9>柠檬酸盐</9>抗凝具有<10>柠檬酸盐</10><17>毒性</17>的风险。<11>柠檬酸盐</11>透析液，一种含有<12>柠檬酸</12>的新型透析液，可用于不能耐受<19>肝素</19>或局部<13>柠檬酸盐</13>的患者抗凝治疗。我们报告了一例40岁女性因<0>对乙酰氨基酚</0>引起的<3>暴发性肝衰竭</3>并伴有<7>AKI</7>，她在肝脏手术期间接受了术中透析支持移植全程用<14>柠檬酸盐</14>透析液抗凝。患者对该过程的耐受性良好，没有任何<15>柠檬酸盐</15><18>毒性</18>的体征，并保持足够的抗凝以保持透析回路的通畅。<16>柠檬酸盐</16>透析液是<4>暴发性肝衰竭</4>肝移植透析期间支持的安全替代品。", "revised": true}
{"doc_key": "4082192", "sentences": [["The", "role", "of", "p", "-", "aminophenol", "in", "acetaminophen", "-", "induced", "nephrotoxicity", ":", "effect", "of", "bis", "(", "p", "-", "nitrophenyl", ")", "phosphate", "on", "acetaminophen", "and", "p", "-", "aminophenol", "nephrotoxicity", "and", "metabolism", "in", "Fischer", "344", "rats", ".", "Acetaminophen", "(", "APAP", ")", "produces", "proximal", "tubular", "necrosis", "in", "Fischer", "344", "(", "F344", ")", "rats", ".", "Recently", ",", "p", "-", "aminophenol", "(", "PAP", ")", ",", "a", "known", "potent", "nephrotoxicant", ",", "was", "identified", "as", "a", "metabolite", "of", "APAP", "in", "F344", "rats", ".", "The", "purpose", "of", "this", "study", "was", "to", "determine", "if", "PAP", "formation", "is", "a", "requisite", "step", "in", "APAP", "-", "induced", "nephrotoxicity", ".", "Therefore", ",", "the", "effect", "of", "bis", "(", "p", "-", "nitrophenyl", ")", "phosphate", "(", "BNPP", ")", ",", "an", "acylamidase", "inhibitor", ",", "on", "APAP", "and", "PAP", "nephrotoxicity", "and", "metabolism", "was", "determined", ".", "BNPP", "(", "1", "to", "8", "mM", ")", "reduced", "APAP", "deacetylation", "and", "covalent", "binding", "in", "F344", "renal", "cortical", "homogenates", "in", "a", "concentration", "-", "dependent", "manner", ".", "Pretreatment", "of", "animals", "with", "BNPP", "prior", "to", "APAP", "or", "PAP", "administration", "resulted", "in", "marked", "reduction", "of", "APAP", "(", "900", "mg", "/", "kg", ")", "nephrotoxicity", "but", "not", "PAP", "nephrotoxicity", ".", "This", "result", "was", "not", "due", "to", "altered", "disposition", "of", "either", "APAP", "or", "acetylated", "metabolites", "in", "plasma", "or", "renal", "cortical", "and", "hepatic", "tissue", ".", "Rather", ",", "BNPP", "pretreatment", "reduced", "the", "fraction", "of", "APAP", "excreted", "as", "PAP", "by", "64", "and", "75", "%", "after", "APAP", "doses", "of", "750", "and", "900", "mg", "/", "kg", ".", "BNPP", "did", "not", "alter", "the", "excretion", "of", "APAP", "or", "any", "of", "its", "non", "-", "deacetylated", "metabolites", "nor", "did", "BNPP", "alter", "excretion", "of", "PAP", "or", "its", "metabolites", "after", "PAP", "doses", "of", "150", "and", "300", "mg", "/", "kg", ".", "Therefore", ",", "the", "BNPP", "-", "induced", "reduction", "in", "APAP", "-", "induced", "nephrotoxicity", "appears", "to", "be", "due", "to", "inhibition", "of", "APAP", "deacetylation", ".", "It", "is", "concluded", "that", "PAP", "formation", ",", "in", "vivo", ",", "accounts", ",", "at", "least", "in", "part", ",", "for", "APAP", "-", "induced", "renal", "tubular", "necrosis", "."]], "ner": [[[3, 5, "Chemical"], [24, 26, "Chemical"], [53, 55, "Chemical"], [57, 57, "Chemical"], [85, 85, "Chemical"], [120, 120, "Chemical"], [161, 161, "Chemical"], [178, 178, "Chemical"], [215, 215, "Chemical"], [254, 254, "Chemical"], [259, 259, "Chemical"], [295, 295, "Chemical"], [41, 42, "Disease"], [312, 314, "Disease"], [7, 7, "Chemical"], [22, 22, "Chemical"], [35, 35, "Chemical"], [37, 37, "Chemical"], [71, 71, "Chemical"], [92, 92, "Chemical"], [118, 118, "Chemical"], [135, 135, "Chemical"], [159, 159, "Chemical"], [168, 168, "Chemical"], [191, 191, "Chemical"], [212, 212, "Chemical"], [222, 222, "Chemical"], [239, 239, "Chemical"], [277, 277, "Chemical"], [288, 288, "Chemical"], [309, 309, "Chemical"], [10, 10, "Disease"], [27, 27, "Disease"], [95, 95, "Disease"], [121, 121, "Disease"], [175, 175, "Disease"], [179, 179, "Disease"], [280, 280, "Disease"], [14, 20, "Chemical"], [102, 108, "Chemical"], [110, 110, "Chemical"], [127, 127, "Chemical"], [156, 156, "Chemical"], [206, 206, "Chemical"], [232, 232, "Chemical"], [250, 250, "Chemical"], [272, 272, "Chemical"]]], "relations": [[[3, 5, 41, 42, "CID"], [3, 5, 312, 314, "CID"], [24, 26, 41, 42, "CID"], [24, 26, 312, 314, "CID"], [53, 55, 41, 42, "CID"], [53, 55, 312, 314, "CID"], [57, 57, 41, 42, "CID"], [57, 57, 312, 314, "CID"], [85, 85, 41, 42, "CID"], [85, 85, 312, 314, "CID"], [120, 120, 41, 42, "CID"], [120, 120, 312, 314, "CID"], [161, 161, 41, 42, "CID"], [161, 161, 312, 314, "CID"], [178, 178, 41, 42, "CID"], [178, 178, 312, 314, "CID"], [215, 215, 41, 42, "CID"], [215, 215, 312, 314, "CID"], [254, 254, 41, 42, "CID"], [254, 254, 312, 314, "CID"], [259, 259, 41, 42, "CID"], [259, 259, 312, 314, "CID"], [295, 295, 41, 42, "CID"], [295, 295, 312, 314, "CID"], [7, 7, 41, 42, "CID"], [7, 7, 312, 314, "CID"], [22, 22, 41, 42, "CID"], [22, 22, 312, 314, "CID"], [35, 35, 41, 42, "CID"], [35, 35, 312, 314, "CID"], [37, 37, 41, 42, "CID"], [37, 37, 312, 314, "CID"], [71, 71, 41, 42, "CID"], [71, 71, 312, 314, "CID"], [92, 92, 41, 42, "CID"], [92, 92, 312, 314, "CID"], [118, 118, 41, 42, "CID"], [118, 118, 312, 314, "CID"], [135, 135, 41, 42, "CID"], [135, 135, 312, 314, "CID"], [159, 159, 41, 42, "CID"], [159, 159, 312, 314, "CID"], [168, 168, 41, 42, "CID"], [168, 168, 312, 314, "CID"], [191, 191, 41, 42, "CID"], [191, 191, 312, 314, "CID"], [212, 212, 41, 42, "CID"], [212, 212, 312, 314, "CID"], [222, 222, 41, 42, "CID"], [222, 222, 312, 314, "CID"], [239, 239, 41, 42, "CID"], [239, 239, 312, 314, "CID"], [277, 277, 41, 42, "CID"], [277, 277, 312, 314, "CID"], [288, 288, 41, 42, "CID"], [288, 288, 312, 314, "CID"], [309, 309, 41, 42, "CID"], [309, 309, 312, 314, "CID"]]], "clusters": [], "translated": "<0>对氨基苯酚</0>在<14>对乙酰氨基酚</14>诱导的<31>肾毒性</31>中的作用：共价结合抑制剂<38>双（对硝基苯基）磷酸酯</38>对<15>对乙酰氨基酚</15>和<1>对氨基苯酚</1><32>肾毒性</32>和Fischer 344大鼠的代谢。在Fischer 344 (F344)大鼠中，<16>对乙酰氨基酚</16> (<17>APAP</17>)会导致近端<12>肾小管坏死</12>。最近，在F344大鼠中鉴定出<2>对氨基苯酚</2> (<3>PAP</3>) 作为<18>APAP</18>的代谢物，其是一种已知的强效肾毒剂。本研究的目的是确定<4>PAP</4>的形成是否是<19>APAP</19>诱导的<33>肾毒性</33>的必要步骤。因此，确定了酰基酰胺酶抑制剂<39>双（对硝基苯基）磷酸酯</39> (<40>BNPP</40>)对<20>对乙酰氨基酚</20>和<5>对氨基苯酚</5><34>肾毒性</34>和代谢的影响。在一定浓度下(1-8 mM)，<41>BNPP</41>能以浓度依赖的方式减少F344肾皮质匀浆中<21>APAP</21>的去乙酰化和共价结合。用<42>BNPP</42>预处理动物(在<22>APAP</22>或<6>PAP</6>给药前)，会显著减少<23>APAP</23>（900毫克/公斤）诱导的<35>肾毒性</35>，而不会减少<7>PAP</7>诱导的<36>肾毒性</36>。这个结果不是由于在血浆或肾皮质和肝组织中<24>APAP</24>或乙酰化代谢物的处置变化。相反，<43>BNPP</43>预处理减少了以<8>PAP</8>的形式排出的<25>APAP</25>的比例，比例分别为在<26>APAP</26>剂量为750和900毫克/千克时，分别降低了64％和75％。在<26>APAP</26>剂量为750和900毫克/千克时，<44>BNPP</44>不会改变<27>APAP</27>或其所有非脱乙酰代谢物的排出量，而<45>BNPP</45>也不会改变在<10>PAP</10>剂量为150和300毫克/公斤后<9>PAP</9>或其代谢物的排出量。因此，<46>BNPP</46>诱导的减少<28>APAP</28>诱导<37>肾毒性</37>似乎是由于抑制了<29>APAP</29>的去乙酰化作用。结论是，<11>PAP</11>在体内的形成至少部分解释了<30>APAP</30>诱导的<13>肾小管坏死</13>。", "revised": true}
{"doc_key": "19553912", "sentences": [["Posttransplant", "anemia", ":", "the", "role", "of", "sirolimus", ".", "Posttransplant", "anemia", "is", "a", "common", "problem", "that", "may", "hinder", "patients", "'", "quality", "of", "life", ".", "It", "occurs", "in", "12", "to", "76", "%", "of", "patients", ",", "and", "is", "most", "common", "in", "the", "immediate", "posttransplant", "period", ".", "A", "variety", "of", "factors", "have", "been", "identified", "that", "increase", "the", "risk", "of", "posttransplant", "anemia", ",", "of", "which", "the", "level", "of", "renal", "function", "is", "most", "important", ".", "Sirolimus", ",", "a", "mammalian", "target", "of", "rapamycin", "inhibitor", ",", "has", "been", "implicated", "as", "playing", "a", "special", "role", "in", "posttransplant", "anemia", ".", "This", "review", "considers", "anemia", "associated", "with", "sirolimus", ",", "including", "its", "presentation", ",", "mechanisms", ",", "and", "management", "."]], "ner": [[[6, 6, "Chemical"], [69, 69, "Chemical"], [75, 75, "Chemical"], [96, 96, "Chemical"], [1, 1, "Disease"], [9, 9, "Disease"], [56, 56, "Disease"], [88, 88, "Disease"], [93, 93, "Disease"]]], "relations": [[[6, 6, 1, 1, "CID"], [6, 6, 9, 9, "CID"], [6, 6, 56, 56, "CID"], [6, 6, 88, 88, "CID"], [6, 6, 93, 93, "CID"], [69, 69, 1, 1, "CID"], [69, 69, 9, 9, "CID"], [69, 69, 56, 56, "CID"], [69, 69, 88, 88, "CID"], [69, 69, 93, 93, "CID"], [75, 75, 1, 1, "CID"], [75, 75, 9, 9, "CID"], [75, 75, 56, 56, "CID"], [75, 75, 88, 88, "CID"], [75, 75, 93, 93, "CID"], [96, 96, 1, 1, "CID"], [96, 96, 9, 9, "CID"], [96, 96, 56, 56, "CID"], [96, 96, 88, 88, "CID"], [96, 96, 93, 93, "CID"]]], "clusters": [], "translated": "移植后<4>贫血</4>：<0>西罗莫司</0>的作用。移植后<5>贫血</5>是一个常见问题，可能会影响患者的生活质量。它发生在12%到76%的患者中，最常见于移植后即刻。已确定多种因素会增加移植后<6>贫血</6>的风险，其中肾功能水平最为重要。<1>西罗莫司</1>是哺乳动物<2>雷帕霉素</2>抑制剂的靶标，已被认为在移植后<7>贫血</7>中发挥特殊作用。本综述考虑了与<3>西罗莫司</3>相关的<8>贫血</8>，包括其表现、机制和管理。", "revised": true}
{"doc_key": "19263707", "sentences": [["Carbimazole", "induced", "ANCA", "positive", "vasculitis", ".", "Anti", "-", "thyroid", "drugs", ",", "like", "carbimazole", "and", "propylthiouracil", "(", "PTU", ")", "are", "commonly", "prescribed", "for", "the", "treatment", "of", "hyperthyroidism", ".", "One", "should", "be", "aware", "of", "the", "side", "effects", "of", "antithyroid", "medications", ".", "Antineutrophil", "cytoplasmic", "antibody", "(", "ANCA", ")", "-", "-", "associated", "vasculitis", "is", "a", "potentially", "life", "-", "threatening", "adverse", "effect", "of", "antithyroidmedications", ".", "We", "report", "a", "patient", "with", "Graves", "'", "disease", "who", "developed", "ANCA", "positive", "carbimazole", "induced", "vasculitis", ".", "The", "episode", "was", "characterized", "by", "a", "vasculitic", "skin", "rash", "associated", "with", "large", "joint", "arthritis", ",", "pyrexia", "and", "parotiditis", "but", "no", "renal", "or", "pulmonary", "involvement", ".", "He", "was", "referred", "to", "us", "for", "neurological", "evaluation", "because", "he", "had", "difficulty", "in", "getting", "up", "from", "squatting", "position", "and", "was", "suspected", "to", "have", "myositis", ".", "Carbimazole", "and", "methimazole", "have", "a", "lower", "incidence", "of", "reported", "ANCA", "positive", "side", "effects", "than", "PUT", ".", "To", "the", "best", "of", "our", "knowledge", "this", "is", "the", "first", "ANCA", "positive", "carbimazole", "induced", "vasculitis", "case", "reported", "from", "India", "."]], "ner": [[[0, 0, "Chemical"], [12, 12, "Chemical"], [72, 72, "Chemical"], [126, 126, "Chemical"], [154, 154, "Chemical"], [2, 4, "Disease"], [39, 48, "Disease"], [89, 89, "Disease"], [91, 91, "Disease"], [93, 93, "Disease"], [6, 9, "Chemical"], [36, 37, "Chemical"], [58, 58, "Chemical"], [25, 25, "Disease"], [65, 67, "Disease"], [74, 74, "Disease"], [82, 82, "Disease"], [156, 156, "Disease"], [83, 84, "Disease"], [124, 124, "Disease"], [14, 14, "Chemical"], [16, 16, "Chemical"], [128, 128, "Chemical"]]], "relations": [[[0, 0, 2, 4, "CID"], [0, 0, 39, 48, "CID"], [12, 12, 2, 4, "CID"], [12, 12, 39, 48, "CID"], [72, 72, 2, 4, "CID"], [72, 72, 39, 48, "CID"], [126, 126, 2, 4, "CID"], [126, 126, 39, 48, "CID"], [154, 154, 2, 4, "CID"], [154, 154, 39, 48, "CID"], [0, 0, 89, 89, "CID"], [12, 12, 89, 89, "CID"], [72, 72, 89, 89, "CID"], [126, 126, 89, 89, "CID"], [154, 154, 89, 89, "CID"], [0, 0, 91, 91, "CID"], [12, 12, 91, 91, "CID"], [72, 72, 91, 91, "CID"], [126, 126, 91, 91, "CID"], [154, 154, 91, 91, "CID"], [0, 0, 93, 93, "CID"], [12, 12, 93, 93, "CID"], [72, 72, 93, 93, "CID"], [126, 126, 93, 93, "CID"], [154, 154, 93, 93, "CID"], [6, 9, 2, 4, "CID"], [6, 9, 39, 48, "CID"], [36, 37, 2, 4, "CID"], [36, 37, 39, 48, "CID"], [58, 58, 2, 4, "CID"], [58, 58, 39, 48, "CID"], [6, 9, 89, 89, "CID"], [36, 37, 89, 89, "CID"], [58, 58, 89, 89, "CID"], [6, 9, 91, 91, "CID"], [36, 37, 91, 91, "CID"], [58, 58, 91, 91, "CID"], [6, 9, 93, 93, "CID"], [36, 37, 93, 93, "CID"], [58, 58, 93, 93, "CID"]]], "clusters": [], "translated": " <0>卡比马唑</0> 诱发 <5>ANCA阳性血管炎</5>。 <10>抗甲状腺药物</10>，如 <1>卡比马唑</1> 和 <20>丙基硫氧嘧啶</20>（<21>PTU</21>）通常用于治疗 <13>甲亢</13>。人们应该意识到 <11>抗甲状腺药物</11> 的副作用。 <6>抗中性粒细胞胞浆抗体（ANCA）相关血管炎</6> 是 <12>抗甲状腺药物</12> 的潜在危及生命的不良反应。我们报告了一名患有<14> Graves病</14>的患者，该患者发生了 ANCA 阳性 <2>卡比马唑</2> 诱发的 <15>血管炎</15>。该事件的特点是 <16>血管炎</16> <18>皮疹</18>，伴有大关节 <7>关节炎</7>、<8>发热</8> 和 <9>腮腺炎</9> 但没有肾脏或肺部受累。他被转诊至我们进行神经系统评估，因为他难以从蹲位起身，并被怀疑患有 <19>肌炎</19>。 <3>卡比马唑</3> 和 <22>甲巯咪唑</22>报告的 ANCA 阳性副作用发生率低于 PTU。据我们所知，这是印度报告的第一例 ANCA 阳性 <4>卡比马唑</4> 诱发的 <17>血管炎</17> 病例。", "revised": true}
{"doc_key": "19728177", "sentences": [["Prolonged", "hypothermia", "as", "a", "bridge", "to", "recovery", "for", "cerebral", "edema", "and", "intracranial", "hypertension", "associated", "with", "fulminant", "hepatic", "failure", ".", "BACKGROUND", ":", "To", "review", "evidence", "-", "based", "treatment", "options", "in", "patients", "with", "cerebral", "edema", "complicating", "fulminant", "hepatic", "failure", "(", "FHF", ")", "and", "discuss", "the", "potential", "applications", "of", "hypothermia", ".", "METHOD", ":", "Case", "-", "based", "observations", "from", "a", "medical", "intensive", "care", "unit", "(", "MICU", ")", "in", "a", "tertiary", "care", "facility", "in", "a", "27", "-", "year", "-", "old", "female", "with", "FHF", "from", "acetaminophen", "and", "resultant", "cerebral", "edema", ".", "RESULTS", ":", "Our", "patient", "was", "admitted", "to", "the", "MICU", "after", "being", "found", "unresponsive", "with", "presumed", "toxicity", "from", "acetaminophen", "which", "was", "ingested", "over", "a", "2", "-", "day", "period", ".", "The", "patient", "had", "depressed", "of", "mental", "status", "lasting", "at", "least", "24", "h", "prior", "to", "admission", ".", "Initial", "evaluation", "confirmed", "FHF", "from", "acetaminophen", "and", "cerebral", "edema", ".", "The", "patient", "was", "treated", "with", "hyperosmolar", "therapy", ",", "hyperventilation", ",", "sedation", ",", "and", "chemical", "paralysis", ".", "Her", "intracranial", "pressure", "remained", "elevated", "despite", "maximal", "medical", "therapy", ".", "We", "then", "initiated", "therapeutic", "hypothermia", "which", "was", "continued", "for", "5", "days", ".", "At", "re", "-", "warming", ",", "patient", "had", "resolution", "of", "her", "cerebral", "edema", "and", "intracranial", "hypertension", ".", "At", "discharge", ",", "she", "had", "complete", "recovery", "of", "neurological", "and", "hepatic", "functions", ".", "CONCLUSION", ":", "In", "patients", "with", "FHF", "and", "cerebral", "edema", "from", "acetaminophen", "overdose", ",", "prolonged", "therapeutic", "hypothermia", "could", "potentially", "be", "used", "as", "a", "life", "saving", "therapy", "and", "a", "bridge", "to", "hepatic", "and", "neurological", "recovery", ".", "A", "clinical", "trial", "of", "hypothermia", "in", "patients", "with", "this", "condition", "is", "warranted", "."]], "ner": [[[79, 79, "Chemical"], [102, 102, "Chemical"], [134, 134, "Chemical"], [216, 216, "Chemical"], [8, 9, "Disease"], [31, 32, "Disease"], [82, 83, "Disease"], [136, 137, "Disease"], [187, 188, "Disease"], [213, 214, "Disease"], [11, 12, "Disease"], [190, 191, "Disease"], [15, 17, "Disease"], [34, 36, "Disease"], [38, 38, "Disease"], [77, 77, "Disease"], [132, 132, "Disease"], [211, 211, "Disease"], [1, 1, "Disease"], [46, 46, "Disease"], [169, 169, "Disease"], [221, 221, "Disease"], [244, 244, "Disease"], [100, 100, "Disease"], [147, 147, "Disease"], [153, 153, "Disease"], [217, 217, "Disease"]]], "relations": [[[79, 79, 8, 9, "CID"], [79, 79, 31, 32, "CID"], [79, 79, 82, 83, "CID"], [79, 79, 136, 137, "CID"], [79, 79, 187, 188, "CID"], [79, 79, 213, 214, "CID"], [102, 102, 8, 9, "CID"], [102, 102, 31, 32, "CID"], [102, 102, 82, 83, "CID"], [102, 102, 136, 137, "CID"], [102, 102, 187, 188, "CID"], [102, 102, 213, 214, "CID"], [134, 134, 8, 9, "CID"], [134, 134, 31, 32, "CID"], [134, 134, 82, 83, "CID"], [134, 134, 136, 137, "CID"], [134, 134, 187, 188, "CID"], [134, 134, 213, 214, "CID"], [216, 216, 8, 9, "CID"], [216, 216, 31, 32, "CID"], [216, 216, 82, 83, "CID"], [216, 216, 136, 137, "CID"], [216, 216, 187, 188, "CID"], [216, 216, 213, 214, "CID"], [79, 79, 11, 12, "CID"], [79, 79, 190, 191, "CID"], [102, 102, 11, 12, "CID"], [102, 102, 190, 191, "CID"], [134, 134, 11, 12, "CID"], [134, 134, 190, 191, "CID"], [216, 216, 11, 12, "CID"], [216, 216, 190, 191, "CID"], [79, 79, 15, 17, "CID"], [79, 79, 34, 36, "CID"], [79, 79, 38, 38, "CID"], [79, 79, 77, 77, "CID"], [79, 79, 132, 132, "CID"], [79, 79, 211, 211, "CID"], [102, 102, 15, 17, "CID"], [102, 102, 34, 36, "CID"], [102, 102, 38, 38, "CID"], [102, 102, 77, 77, "CID"], [102, 102, 132, 132, "CID"], [102, 102, 211, 211, "CID"], [134, 134, 15, 17, "CID"], [134, 134, 34, 36, "CID"], [134, 134, 38, 38, "CID"], [134, 134, 77, 77, "CID"], [134, 134, 132, 132, "CID"], [134, 134, 211, 211, "CID"], [216, 216, 15, 17, "CID"], [216, 216, 34, 36, "CID"], [216, 216, 38, 38, "CID"], [216, 216, 77, 77, "CID"], [216, 216, 132, 132, "CID"], [216, 216, 211, 211, "CID"]]], "clusters": [], "translated": "延长<18>低温</18>作为<4>脑水肿</4>和<10>颅内高压</10>与<12>暴发性肝功能衰竭</12>恢复的桥梁。背景：回顾<5>脑水肿</5>并发<13>暴发性肝功能衰竭</13>(<14>FHF</14>)患者的循证治疗选择，并讨论<19>体温过低</19>的潜在应用。方法：来自三级医疗机构医疗重症监护病房(MICU)的基于病例的观察，患者是一名因<0>对乙酰氨基酚</0>导致<15>FHF</15>的27岁女性，结果<6>脑水肿</6>。结果：我们的患者被发现对<1>对乙酰氨基酚</1>的假定<23>毒性</23>无反应后被收入MICU，该药物在2天内被摄入。患者入院前精神状态抑郁持续至少24小时。初步评估证实<2>对乙酰氨基酚</2>引起<16>FHF</16>和<7>脑水肿</7>。患者接受了高渗疗法、<24>过度通气</24>、镇静和化学<25>麻痹</25>治疗。尽管进行了最大程度的药物治疗，她的颅内压仍然升高。然后我们开始治疗<20>低温</20>，持续了5天。重新加温时，患者的<8>脑水肿</8>和<11>颅内高压</11>均已消退。出院时，她的神经和肝功能完全恢复。结论：<17>FHF</17>和<9>脑水肿</9>患者<3>对乙酰氨基酚</3><26>过量服用</26>，延长治疗性<21>低温治疗</21>可能被用作挽救生命的疗法以及肝脏和神经恢复的桥梁。有必要对这种情况的患者进行<22>体温过低</22>的临床试验。", "revised": true}
{"doc_key": "18987260", "sentences": [["Reduced", "progression", "of", "adriamycin", "nephropathy", "in", "spontaneously", "hypertensive", "rats", "treated", "by", "losartan", ".", "BACKGROUND", ":", "The", "aim", "of", "the", "study", "was", "to", "investigate", "the", "antihypertensive", "effects", "of", "angiotensin", "II", "type", "-", "1", "receptor", "blocker", ",", "losartan", ",", "and", "its", "potential", "in", "slowing", "down", "renal", "disease", "progression", "in", "spontaneously", "hypertensive", "rats", "(", "SHR", ")", "with", "adriamycin", "(", "ADR", ")", "nephropathy", ".", "METHODS", ":", "Six", "-", "month", "-", "old", "female", "SHR", "were", "randomly", "selected", "in", "six", "groups", ".", "Two", "control", "groups", "(", "SH", "(", "6", ")", ",", "SH", "(", "12", ")", ")", "received", "vehicle", ".", "Groups", "ADR", "(", "6", ")", ",", "ADR", "+", "LOS", "(", "6", ")", "and", "ADR", "(", "12", ")", ",", "and", "ADR", "+", "LOS", "(", "12", ")", "received", "ADR", "(", "2", "mg", "/", "kg", "/", "b", ".", "w", ".", "i", ".", "v", ".", ")", "twice", "in", "a", "3", "-", "week", "interval", ".", "Group", "ADR", "+", "LOS", "(", "6", ")", "received", "losartan", "(", "10", "mg", "/", "kg", "/", "b", ".", "w", ".", "/", "day", "by", "gavages", ")", "for", "6", "weeks", "and", "group", "ADR", "+", "LOS", "(", "12", ")", "for", "12", "weeks", "after", "second", "injection", "of", "ADR", ".", "Animals", "were", "killed", "after", "6", "or", "12", "weeks", ",", "respectively", ".", "Haemodynamic", "measurements", "were", "performed", "on", "anaesthetized", "animals", ",", "blood", "and", "urine", "samples", "were", "taken", "for", "biochemical", "analysis", "and", "the", "left", "kidney", "was", "processed", "for", "morphological", "studies", ".", "RESULTS", ":", "Short", "-", "term", "losartan", "treatment", ",", "besides", "antihypertensive", "effect", ",", "improved", "glomerular", "filtration", "rate", "and", "ameliorated", "glomerulosclerosis", "resulting", "in", "decreased", "proteinuria", ".", "Prolonged", "treatment", "with", "losartan", "showed", "further", "reduction", "of", "glomerulosclerosis", "associated", "with", "reduced", "progression", "of", "tubular", "atrophy", "and", "interstitial", "fibrosis", ",", "thus", "preventing", "heavy", "proteinuria", "and", "chronic", "renal", "failure", ".", "Losartan", "reduced", "uraemia", "and", "increased", "urea", "clearance", "in", "advanced", "ADR", "nephropathy", "in", "SHR", ".", "Histological", "examination", "showed", "that", "losartan", "could", "prevent", "tubular", "atrophy", ",", "interstitial", "infiltration", "and", "fibrosis", "in", "ADR", "nephropathy", ".", "CONCLUSION", ":", "Losartan", "reduces", "the", "rate", "of", "progression", "of", "ADR", "-", "induced", "focal", "segmental", "glomerulosclerosis", "to", "end", "-", "stage", "renal", "disease", "in", "SHR", "."]], "ner": [[[3, 3, "Chemical"], [54, 54, "Chemical"], [56, 56, "Chemical"], [94, 94, "Chemical"], [99, 99, "Chemical"], [106, 106, "Chemical"], [112, 112, "Chemical"], [119, 119, "Chemical"], [144, 144, "Chemical"], [172, 172, "Chemical"], [185, 185, "Chemical"], [287, 287, "Chemical"], [307, 307, "Chemical"], [319, 319, "Chemical"], [247, 247, "Disease"], [272, 272, "Disease"], [280, 280, "Disease"], [322, 324, "Disease"], [4, 4, "Disease"], [43, 44, "Disease"], [58, 58, "Disease"], [288, 288, "Disease"], [308, 308, "Disease"], [7, 7, "Disease"], [48, 48, "Disease"], [243, 243, "Disease"], [257, 257, "Disease"], [264, 264, "Disease"], [300, 300, "Disease"], [266, 267, "Disease"], [305, 305, "Disease"], [274, 276, "Disease"], [326, 330, "Disease"], [11, 11, "Chemical"], [35, 35, "Chemical"], [101, 101, "Chemical"], [114, 114, "Chemical"], [146, 146, "Chemical"], [151, 151, "Chemical"], [174, 174, "Chemical"], [230, 230, "Chemical"], [252, 252, "Chemical"], [278, 278, "Chemical"], [296, 296, "Chemical"], [312, 312, "Chemical"], [27, 28, "Chemical"], [283, 283, "Chemical"]]], "relations": [[[3, 3, 247, 247, "CID"], [3, 3, 272, 272, "CID"], [54, 54, 247, 247, "CID"], [54, 54, 272, 272, "CID"], [56, 56, 247, 247, "CID"], [56, 56, 272, 272, "CID"], [94, 94, 247, 247, "CID"], [94, 94, 272, 272, "CID"], [99, 99, 247, 247, "CID"], [99, 99, 272, 272, "CID"], [106, 106, 247, 247, "CID"], [106, 106, 272, 272, "CID"], [112, 112, 247, 247, "CID"], [112, 112, 272, 272, "CID"], [119, 119, 247, 247, "CID"], [119, 119, 272, 272, "CID"], [144, 144, 247, 247, "CID"], [144, 144, 272, 272, "CID"], [172, 172, 247, 247, "CID"], [172, 172, 272, 272, "CID"], [185, 185, 247, 247, "CID"], [185, 185, 272, 272, "CID"], [287, 287, 247, 247, "CID"], [287, 287, 272, 272, "CID"], [307, 307, 247, 247, "CID"], [307, 307, 272, 272, "CID"], [319, 319, 247, 247, "CID"], [319, 319, 272, 272, "CID"], [3, 3, 280, 280, "CID"], [54, 54, 280, 280, "CID"], [56, 56, 280, 280, "CID"], [94, 94, 280, 280, "CID"], [99, 99, 280, 280, "CID"], [106, 106, 280, 280, "CID"], [112, 112, 280, 280, "CID"], [119, 119, 280, 280, "CID"], [144, 144, 280, 280, "CID"], [172, 172, 280, 280, "CID"], [185, 185, 280, 280, "CID"], [287, 287, 280, 280, "CID"], [307, 307, 280, 280, "CID"], [319, 319, 280, 280, "CID"], [3, 3, 322, 324, "CID"], [54, 54, 322, 324, "CID"], [56, 56, 322, 324, "CID"], [94, 94, 322, 324, "CID"], [99, 99, 322, 324, "CID"], [106, 106, 322, 324, "CID"], [112, 112, 322, 324, "CID"], [119, 119, 322, 324, "CID"], [144, 144, 322, 324, "CID"], [172, 172, 322, 324, "CID"], [185, 185, 322, 324, "CID"], [287, 287, 322, 324, "CID"], [307, 307, 322, 324, "CID"], [319, 319, 322, 324, "CID"]]], "clusters": [], "translated": " <0>阿霉素</0> <18>肾病</18> 在自发性<23>高血压</23>大鼠中经<33>氯沙坦</33>治疗其进展减缓。背景：本研究的目的是研究1型<45>血管紧张素II</45>受体阻滞剂<34>氯沙坦</34>的抗高血压作用，及其在减缓<19>肾病</19>在自发性<24>高血压</24>大鼠（SHR）中经<1>阿霉素</1>（<2>ADR</2>）<20>肾病</20>的进展。方法: 将6个月大的雌性SHR随机分为6组。两个对照组（SH（6），SH（12））接受了载体。组<3>ADR</3>（6）、组<5>ADR</5>（12）、组<4>ADR</4>+<35>LOS</35>（6）和组<6>ADR</6>+<36>LOS</36>（12）在3周内两次注射<7>ADR</7>（2 mg/kg/b.w.i.v.）罗。组<8>ADR</8>+<37>LOS</37>（6）接受<38>氯沙坦</38>（10 mg/kg/b.w./day by gavages）治疗6周，组<9>ADR</9>+<39>LOS</39>（12）在第二次注射<10>ADR</10>后治疗12周。分别在6周或12周后处死动物。对麻醉动物进行血液动力学测量，获取血液和尿液样本进行生化分析，处理左肾进行形态学研究。结果：短期<40>氯沙坦</40>治疗不仅具有降压作用，还提高了肾小球滤过率，并改善了<25>肾小球硬化</25>，从而导致<14>蛋白尿</14>减轻。长期治疗<41>氯沙坦</41>进一步减轻了<26>肾小球硬化</26>，减缓了肾小管<27>萎缩</27>和<29>间质纤维化</29>的进展，从而预防了严重<15>蛋白尿</15>和<31>慢性肾功能衰竭</31>。在SHR的晚期<11>ADR</11><21>肾病</21>中，<42>氯沙坦</42>降低了<16>尿毒症</16>并增加了<46>尿素</46>的清除率。组织学检查显示<43>氯沙坦</43>可预防<12>ADR</12><22>肾病</22>中的肾小管<28>萎缩</28>、间质浸润和<30>纤维化</30>。结论：<44>氯沙坦</44>降低了<13>ADR</13>-诱导的<17>局灶节段性肾小球硬化</17>至<32>终末期肾病</32>的进展速度。", "revised": true}
{"doc_key": "19914299", "sentences": [["Fluoxetine", "improves", "the", "memory", "deficits", "caused", "by", "the", "chemotherapy", "agent", "5", "-", "fluorouracil", ".", "Cancer", "patients", "who", "have", "been", "treated", "with", "systemic", "adjuvant", "chemotherapy", "have", "described", "experiencing", "deteriorations", "in", "cognition", ".", "A", "widely", "used", "chemotherapeutic", "agent", ",", "5", "-", "fluorouracil", "(", "5", "-", "FU", ")", ",", "readily", "crosses", "the", "blood", "-", "brain", "barrier", "and", "so", "could", "have", "a", "direct", "effect", "on", "brain", "function", ".", "In", "particular", "this", "anti", "mitotic", "drug", "could", "reduce", "cell", "proliferation", "in", "the", "neurogenic", "regions", "of", "the", "adult", "brain", ".", "In", "contrast", "reports", "indicate", "that", "hippocampal", "dependent", "neurogenesis", "and", "cognition", "are", "enhanced", "by", "the", "SSRI", "antidepressant", "Fluoxetine", ".", "In", "this", "investigation", "the", "behavioural", "effects", "of", "chronic", "(", "two", "week", ")", "treatment", "with", "5", "-", "FU", "and", "(", "three", "weeks", ")", "with", "Fluoxetine", "either", "separately", "or", "in", "combination", "with", "5", "-", "FU", "were", "tested", "on", "adult", "Lister", "hooded", "rats", ".", "Behavioural", "effects", "were", "tested", "using", "a", "context", "dependent", "conditioned", "emotional", "response", "test", "(", "CER", ")", "which", "showed", "that", "animals", "treated", "with", "5", "-", "FU", "had", "a", "significant", "reduction", "in", "freezing", "time", "compared", "to", "controls", ".", "A", "separate", "group", "of", "animals", "was", "tested", "using", "a", "hippocampal", "dependent", "spatial", "working", "memory", "test", ",", "the", "object", "location", "recognition", "test", "(", "OLR", ")", ".", "Animals", "treated", "only", "with", "5", "-", "FU", "showed", "significant", "deficits", "in", "their", "ability", "to", "carry", "out", "the", "OLR", "task", "but", "co", "administration", "of", "Fluoxetine", "improved", "their", "performance", ".", "5", "-", "FU", "chemotherapy", "caused", "a", "significant", "reduction", "in", "the", "number", "of", "proliferating", "cells", "in", "the", "sub", "granular", "zone", "of", "the", "dentate", "gyrus", "compared", "to", "controls", ".", "This", "reduction", "was", "eliminated", "when", "Fluoxetine", "was", "co", "administered", "with", "5", "-", "FU", ".", "Fluoxetine", "on", "its", "own", "had", "no", "effect", "on", "proliferating", "cell", "number", "or", "behaviour", ".", "These", "findings", "suggest", "that", "5", "-", "FU", "can", "negatively", "affect", "both", "cell", "proliferation", "and", "hippocampal", "dependent", "working", "memory", "and", "that", "these", "deficits", "can", "be", "reversed", "by", "the", "simultaneous", "administration", "of", "the", "antidepressant", "Fluoxetine", "."]], "ner": [[[10, 12, "Chemical"], [37, 39, "Chemical"], [41, 43, "Chemical"], [115, 117, "Chemical"], [131, 133, "Chemical"], [163, 165, "Chemical"], [206, 208, "Chemical"], [230, 232, "Chemical"], [267, 269, "Chemical"], [289, 291, "Chemical"], [3, 4, "Disease"], [0, 0, "Chemical"], [99, 99, "Chemical"], [124, 124, "Chemical"], [225, 225, "Chemical"], [262, 262, "Chemical"], [271, 271, "Chemical"], [317, 317, "Chemical"], [14, 14, "Disease"], [97, 97, "Chemical"]]], "relations": [[[10, 12, 3, 4, "CID"], [37, 39, 3, 4, "CID"], [41, 43, 3, 4, "CID"], [115, 117, 3, 4, "CID"], [131, 133, 3, 4, "CID"], [163, 165, 3, 4, "CID"], [206, 208, 3, 4, "CID"], [230, 232, 3, 4, "CID"], [267, 269, 3, 4, "CID"], [289, 291, 3, 4, "CID"]]], "clusters": [], "translated": " <11>氟西汀</11>改善由化疗药物<0>5-氟尿嘧啶</0>引起的<10>记忆障碍</10>。 <18>癌症</18>接受过全身辅助化疗的患者描述了认知能力的下降。一种广泛使用的化疗药物<1>5-氟尿嘧啶</1>（<2>5-FU</2>）很容易穿过血脑屏障，因此可以对大脑功能产生直接影响。特别是这种抗有丝分裂药物可以减少成人大脑神经源性区域的细胞增殖。相比之下，报告表明<19>SSRI</19>抗抑郁药<12>氟西汀</12>可增强海马依赖性神经发生和认知。在这项调查中，慢性（两周）<3>5-FU</3>治疗和（三周）<13> 氟西汀 </13> 单独治疗或与<4>5-FU</4>联合治疗的行为影响在成年Lister 蒙面鼠身上进行了测试。使用情境依赖性条件情绪反应测试(CER)测试行为效果，结果表明接受 <5>5-FU</5>处理的动物的冻结时间显着减少。另一组动物使用依赖于海马体的空间工作记忆测试，即物体位置识别测试(OLR)，进行了测试。仅用<6>5-FU</6>治疗的动物在执行OLR任务的能力方面表现出显着缺陷，但同时服用<14>氟西汀</14>可改善它们的表现。<7>5-FU</7>化疗导致齿状回亚颗粒区增殖细胞数量显着减少。这种减少被消除，当 <15> 氟西汀 </15> 与<8>5-FU</8>共同给药时。<16>氟西汀</16>本身对增殖细胞数量或行为没有影响。这些发现表明 <9>5-FU</9>会对细胞增殖和海马依赖性工作记忆产生负面影响，并且这些缺陷可以通过同时服用抗抑郁药<17>氟西汀</17>来逆转。", "revised": true}
{"doc_key": "19392810", "sentences": [["Rhabdomyolysis", "and", "brain", "ischemic", "stroke", "in", "a", "heroin", "-", "dependent", "male", "under", "methadone", "maintenance", "therapy", ".", "OBJECTIVE", ":", "There", "are", "several", "complications", "associated", "with", "heroin", "abuse", ",", "some", "of", "which", "are", "life", "-", "threatening", ".", "Methadone", "may", "aggravate", "this", "problem", ".", "METHOD", ":", "A", "clinical", "case", "description", ".", "RESULTS", ":", "A", "33", "-", "year", "-", "old", "man", "presented", "with", "rhabdomyolysis", "and", "cerebral", "ischemic", "stroke", "after", "intravenous", "heroin", ".", "He", "had", "used", "heroin", "since", "age", "20", ",", "and", "had", "used", "150", "mg", "methadone", "daily", "for", "6", "months", ".", "He", "was", "found", "unconsciousness", "at", "home", "and", "was", "sent", "to", "our", "hospital", ".", "In", "the", "ER", ",", "his", "opiate", "level", "was", "4497", "ng", "/", "ml", ".", "In", "the", "ICU", ",", "we", "found", "rhabdomyolysis", ",", "acute", "renal", "failure", "and", "acute", "respiratory", "failure", ".", "After", "transfer", "to", "an", "internal", "ward", ",", "we", "noted", "aphasia", "and", "weakness", "of", "his", "left", "limbs", ".", "After", "MRI", ",", "we", "found", "cerebral", "ischemic", "infarction", ".", "CONCLUSION", ":", "Those", "using", "methadone", "and", "heroin", "simultaneously", "may", "increase", "risk", "of", "rhabdomyolysis", "and", "ischemic", "stroke", ".", "Patients", "under", "methadone", "maintenance", "therapy", "should", "be", "warned", "regarding", "these", "serious", "adverse", "events", ".", "Hypotheses", "of", "heroin", "-", "related", "rhabdomyolysis", "and", "stroke", "in", "heroin", "abusers", "are", "discussed", "."]], "ner": [[[7, 7, "Chemical"], [66, 66, "Chemical"], [71, 71, "Chemical"], [161, 161, "Chemical"], [188, 188, "Chemical"], [195, 195, "Chemical"], [0, 0, "Disease"], [59, 59, "Disease"], [119, 119, "Disease"], [167, 167, "Disease"], [191, 191, "Disease"], [12, 12, "Chemical"], [35, 35, "Chemical"], [81, 81, "Chemical"], [159, 159, "Chemical"], [174, 174, "Chemical"], [193, 193, "Disease"], [3, 4, "Disease"], [62, 63, "Disease"], [151, 153, "Disease"], [169, 170, "Disease"], [24, 25, "Disease"], [90, 90, "Disease"], [121, 123, "Disease"], [126, 127, "Disease"], [138, 138, "Disease"], [140, 140, "Disease"]]], "relations": [[[7, 7, 0, 0, "CID"], [7, 7, 59, 59, "CID"], [7, 7, 119, 119, "CID"], [7, 7, 167, 167, "CID"], [7, 7, 191, 191, "CID"], [66, 66, 0, 0, "CID"], [66, 66, 59, 59, "CID"], [66, 66, 119, 119, "CID"], [66, 66, 167, 167, "CID"], [66, 66, 191, 191, "CID"], [71, 71, 0, 0, "CID"], [71, 71, 59, 59, "CID"], [71, 71, 119, 119, "CID"], [71, 71, 167, 167, "CID"], [71, 71, 191, 191, "CID"], [161, 161, 0, 0, "CID"], [161, 161, 59, 59, "CID"], [161, 161, 119, 119, "CID"], [161, 161, 167, 167, "CID"], [161, 161, 191, 191, "CID"], [188, 188, 0, 0, "CID"], [188, 188, 59, 59, "CID"], [188, 188, 119, 119, "CID"], [188, 188, 167, 167, "CID"], [188, 188, 191, 191, "CID"], [195, 195, 0, 0, "CID"], [195, 195, 59, 59, "CID"], [195, 195, 119, 119, "CID"], [195, 195, 167, 167, "CID"], [195, 195, 191, 191, "CID"], [12, 12, 0, 0, "CID"], [12, 12, 59, 59, "CID"], [12, 12, 119, 119, "CID"], [12, 12, 167, 167, "CID"], [12, 12, 191, 191, "CID"], [35, 35, 0, 0, "CID"], [35, 35, 59, 59, "CID"], [35, 35, 119, 119, "CID"], [35, 35, 167, 167, "CID"], [35, 35, 191, 191, "CID"], [81, 81, 0, 0, "CID"], [81, 81, 59, 59, "CID"], [81, 81, 119, 119, "CID"], [81, 81, 167, 167, "CID"], [81, 81, 191, 191, "CID"], [159, 159, 0, 0, "CID"], [159, 159, 59, 59, "CID"], [159, 159, 119, 119, "CID"], [159, 159, 167, 167, "CID"], [159, 159, 191, 191, "CID"], [174, 174, 0, 0, "CID"], [174, 174, 59, 59, "CID"], [174, 174, 119, 119, "CID"], [174, 174, 167, 167, "CID"], [174, 174, 191, 191, "CID"], [7, 7, 193, 193, "CID"], [66, 66, 193, 193, "CID"], [71, 71, 193, 193, "CID"], [161, 161, 193, 193, "CID"], [188, 188, 193, 193, "CID"], [195, 195, 193, 193, "CID"], [12, 12, 193, 193, "CID"], [35, 35, 193, 193, "CID"], [81, 81, 193, 193, "CID"], [159, 159, 193, 193, "CID"], [174, 174, 193, 193, "CID"]]], "clusters": [], "translated": " <6>横纹肌溶解症</6>和脑部<17>缺血性中风</17><0>海洛因</0>依赖男性<11>美沙酮</11>维持治疗。目的：<21>海洛因滥用</21>会导致多种并发症，其中一些会危及生命。<12>美沙酮</12>可能会加重这个问题。方法：临床病例描述。结果：一名33岁男性在静脉注射<1>海洛因</1>后出现<7>横纹肌溶解症</7>和脑部<18>缺血性卒中</18>。他从20岁开始吸食<2>海洛因</2>，并且每天使用150毫克<13>美沙酮</13>6个月。他在家中被发现<22>昏迷</22>，被送往我们医院。在急诊室，他的鸦片浓度为4497 ng/ml。在ICU，我们发现了<8>横纹肌溶解症</8>、<23>急性肾衰竭</23>和急性<24>呼吸衰竭</24>。转到内科病房后，我们注意到他的左肢<26>无力</26>和<25>失语</25>。MRI检查后发现<19>脑缺血梗塞</19>。结论：同时使用<3>海洛因</3>和<14>美沙酮</14>可能增加<9>横纹肌溶解症</9>和<20>缺血性脑卒中</20>的风险。接受<15>美沙酮</15>维持治疗的患者应注意这些严重的不良事件。讨论了<5>海洛因</5>滥用者中<4>海洛因</4>相关<10>横纹肌溶解</10>和<16>中风</16>的假设。", "revised": true}
{"doc_key": "19549709", "sentences": [["Efficacy", "of", "everolimus", "(", "RAD001", ")", "in", "patients", "with", "advanced", "NSCLC", "previously", "treated", "with", "chemotherapy", "alone", "or", "with", "chemotherapy", "and", "EGFR", "inhibitors", ".", "BACKGROUND", ":", "Treatment", "options", "are", "scarce", "in", "pretreated", "advanced", "non", "-", "small", "-", "cell", "lung", "cancer", "(", "NSCLC", ")", "patients", ".", "RAD001", ",", "an", "oral", "inhibitor", "of", "the", "mammalian", "target", "of", "rapamycin", "(", "mTOR", ")", ",", "has", "shown", "phase", "I", "efficacy", "in", "NSCLC", ".", "METHODS", ":", "Stage", "IIIb", "or", "IV", "NSCLC", "patients", ",", "with", "two", "or", "fewer", "prior", "chemotherapy", "regimens", ",", "one", "platinum", "based", "(", "stratum", "1", ")", "or", "both", "chemotherapy", "and", "epidermal", "growth", "factor", "receptor", "tyrosine", "kinase", "inhibitors", "(", "stratum", "2", ")", ",", "received", "RAD001", "10", "mg", "/", "day", "until", "progression", "or", "unacceptable", "toxicity", ".", "Primary", "objective", "was", "overall", "response", "rate", "(", "ORR", ")", ".", "Analyses", "of", "markers", "associated", "with", "the", "mTOR", "pathway", "were", "carried", "out", "on", "archival", "tumor", "from", "a", "subgroup", "using", "immunohistochemistry", "(", "IHC", ")", "and", "direct", "mutation", "sequencing", ".", "RESULTS", ":", "Eighty", "-", "five", "patients", "were", "enrolled", ",", "42", "in", "stratum", "1", "and", "43", "in", "stratum", ".", "ORR", "was", "4", ".", "7", "%", "(", "7", ".", "1", "%", "stratum", "1", ";", "2", ".", "3", "%", "stratum", "2", ")", ".", "Overall", "disease", "control", "rate", "was", "47", ".", "1", "%", ".", "Median", "progression", "-", "free", "survivals", "(", "PFSs", ")", "were", "2", ".", "6", "(", "stratum", "1", ")", "and", "2", ".", "7", "months", "(", "stratum", "2", ")", ".", "Common", ">", "or", "=", "grade", "3", "events", "were", "fatigue", ",", "dyspnea", ",", "stomatitis", ",", "anemia", ",", "and", "thrombocytopenia", ".", "Pneumonitis", ",", "probably", "or", "possibly", "related", ",", "mainly", "grade", "1", "/", "2", ",", "occurred", "in", "25", "%", ".", "Cox", "regression", "analysis", "of", "IHC", "scores", "found", "that", "only", "phospho", "AKT", "(", "pAKT", ")", "was", "a", "significant", "independent", "predictor", "of", "worse", "PFS", ".", "CONCLUSIONS", ":", "RAD001", "10", "mg", "/", "day", "was", "well", "tolerated", ",", "showing", "modest", "clinical", "activity", "in", "pretreated", "NSCLC", ".", "Evaluation", "of", "RAD001", "plus", "standard", "therapy", "for", "metastatic", "NSCLC", "continues", "."]], "ner": [[[2, 2, "Chemical"], [4, 4, "Chemical"], [44, 44, "Chemical"], [108, 108, "Chemical"], [294, 294, "Chemical"], [313, 313, "Chemical"], [240, 240, "Disease"], [242, 242, "Disease"], [244, 244, "Disease"], [246, 246, "Disease"], [249, 249, "Disease"], [10, 10, "Disease"], [32, 38, "Disease"], [40, 40, "Disease"], [65, 65, "Disease"], [73, 73, "Disease"], [309, 309, "Disease"], [319, 319, "Disease"], [117, 117, "Disease"], [142, 142, "Disease"], [251, 251, "Disease"], [54, 54, "Chemical"], [85, 85, "Chemical"], [99, 99, "Chemical"]]], "relations": [[[2, 2, 240, 240, "CID"], [4, 4, 240, 240, "CID"], [44, 44, 240, 240, "CID"], [108, 108, 240, 240, "CID"], [294, 294, 240, 240, "CID"], [313, 313, 240, 240, "CID"], [2, 2, 242, 242, "CID"], [4, 4, 242, 242, "CID"], [44, 44, 242, 242, "CID"], [108, 108, 242, 242, "CID"], [294, 294, 242, 242, "CID"], [313, 313, 242, 242, "CID"], [2, 2, 244, 244, "CID"], [4, 4, 244, 244, "CID"], [44, 44, 244, 244, "CID"], [108, 108, 244, 244, "CID"], [294, 294, 244, 244, "CID"], [313, 313, 244, 244, "CID"], [2, 2, 246, 246, "CID"], [4, 4, 246, 246, "CID"], [44, 44, 246, 246, "CID"], [108, 108, 246, 246, "CID"], [294, 294, 246, 246, "CID"], [313, 313, 246, 246, "CID"], [2, 2, 249, 249, "CID"], [4, 4, 249, 249, "CID"], [44, 44, 249, 249, "CID"], [108, 108, 249, 249, "CID"], [294, 294, 249, 249, "CID"], [313, 313, 249, 249, "CID"]]], "clusters": [], "translated": "<0>依维莫司</0>（<1>RAD001</1>）对先前接受过单独化疗或化疗和EGFR抑制剂治疗的晚期<11>NSCLC</11>患者的疗效。 背景：既往接受过治疗的晚期<12>非小细胞肺癌</12>（<13>NSCLC</13>）患者的治疗选择很少。<2>RAD001</2>是哺乳动物<21>雷帕霉素</21>（mTOR）靶标的口服抑制剂，在<14>NSCLC</14>中显示出I期疗效。 方法：IIIb或IV期<15>NSCLC</15>患者，有两种或更少的既往化疗方案，一种基于<22>铂</22>（第1层）或两种化疗和表皮生长因子受体<23>酪氨酸</23>激酶抑制剂（第2层），接受<3>RAD001</3> 10毫克/天直至进展或不可接受的<18>毒性</18>。主要目标是总体缓解率(ORR)。使用免疫组织化学(IHC)和直接突变测序对来自亚组的存档<19>肿瘤</19>进行了与mTOR通路相关的标志物分析。 结果：共纳入85例患者，第1层42例，第2层43例。ORR为4.7%（7.1%第1层；2.3%第2层）。总体疾病控制率为47.1%。中位无进展生存期（PFSs）为2.6（第1层）和2.7个月（第2层）。常见>或=3级事件为<6>疲劳</6>、<7>呼吸困难</7>、<8>口腔炎</8>、<9>贫血</9>和<10>血小板减少症</10>。<20>肺炎</20>，可能或可能相关，主要是1/2级，发生率为25%。IHC评分的Cox回归分析发现，只有磷酸化AKT(pAKT)是较差PFS的重要独立预测因子。 结论：<4>RAD001</4> 10 mg/天耐受性良好，在既往治疗过的<16>NSCLC</16>中表现出适度的临床活性。<5>RAD001</5>联合标准疗法治疗转移性<17>NSCLC</17>的评估仍在继续。", "revised": true}
{"doc_key": "19293073", "sentences": [["Aspirin", "for", "the", "primary", "prevention", "of", "cardiovascular", "events", ":", "an", "update", "of", "the", "evidence", "for", "the", "U", ".", "S", ".", "Preventive", "Services", "Task", "Force", ".", "BACKGROUND", ":", "Coronary", "heart", "disease", "and", "cerebrovascular", "disease", "are", "leading", "causes", "of", "death", "in", "the", "United", "States", ".", "In", "2002", ",", "the", "U", ".", "S", ".", "Preventive", "Services", "Task", "Force", "(", "USPSTF", ")", "strongly", "recommended", "that", "clinicians", "discuss", "aspirin", "with", "adults", "who", "are", "at", "increased", "risk", "for", "coronary", "heart", "disease", ".", "PURPOSE", ":", "To", "determine", "the", "benefits", "and", "harms", "of", "taking", "aspirin", "for", "the", "primary", "prevention", "of", "myocardial", "infarctions", ",", "strokes", ",", "and", "death", ".", "DATA", "SOURCES", ":", "MEDLINE", "and", "Cochrane", "Library", "(", "search", "dates", ",", "1", "January", "2001", "to", "28", "August", "2008", ")", ",", "recent", "systematic", "reviews", ",", "reference", "lists", "of", "retrieved", "articles", ",", "and", "suggestions", "from", "experts", ".", "STUDY", "SELECTION", ":", "English", "-", "language", "randomized", ",", "controlled", "trials", "(", "RCTs", ")", ";", "case", "-", "control", "studies", ";", "meta", "-", "analyses", ";", "and", "systematic", "reviews", "of", "aspirin", "versus", "control", "for", "the", "primary", "prevention", "of", "cardiovascular", "disease", "(", "CVD", ")", "were", "selected", "to", "answer", "the", "following", "questions", ":", "Does", "aspirin", "decrease", "coronary", "heart", "events", ",", "strokes", ",", "death", "from", "coronary", "heart", "events", "or", "stroke", ",", "or", "all", "-", "cause", "mortality", "in", "adults", "without", "known", "CVD", "?", "Does", "aspirin", "increase", "gastrointestinal", "bleeding", "or", "hemorrhagic", "strokes", "?", "DATA", "EXTRACTION", ":", "All", "studies", "were", "reviewed", ",", "abstracted", ",", "and", "rated", "for", "quality", "by", "using", "predefined", "USPSTF", "criteria", ".", "DATA", "SYNTHESIS", ":", "New", "evidence", "from", "1", "good", "-", "quality", "RCT", ",", "1", "good", "-", "quality", "meta", "-", "analysis", ",", "and", "2", "fair", "-", "quality", "subanalyses", "of", "RCTs", "demonstrates", "that", "aspirin", "use", "reduces", "the", "number", "of", "CVD", "events", "in", "patients", "without", "known", "CVD", ".", "Men", "in", "these", "studies", "experienced", "fewer", "myocardial", "infarctions", "and", "women", "experienced", "fewer", "ischemic", "strokes", ".", "Aspirin", "does", "not", "seem", "to", "affect", "CVD", "mortality", "or", "all", "-", "cause", "mortality", "in", "either", "men", "or", "women", ".", "The", "use", "of", "aspirin", "for", "primary", "prevention", "increases", "the", "risk", "for", "major", "bleeding", "events", ",", "primarily", "gastrointestinal", "bleeding", "events", ",", "in", "both", "men", "and", "women", ".", "Men", "have", "an", "increased", "risk", "for", "hemorrhagic", "strokes", "with", "aspirin", "use", ".", "A", "new", "RCT", "and", "meta", "-", "analysis", "suggest", "that", "the", "risk", "for", "hemorrhagic", "strokes", "in", "women", "is", "not", "statistically", "significantly", "increased", ".", "LIMITATIONS", ":", "New", "evidence", "on", "aspirin", "for", "the", "primary", "prevention", "of", "CVD", "is", "limited", ".", "The", "dose", "of", "aspirin", "used", "in", "the", "RCTs", "varied", ",", "which", "prevented", "the", "estimation", "of", "the", "most", "appropriate", "dose", "for", "primary", "prevention", ".", "Several", "of", "the", "RCTs", "were", "conducted", "within", "populations", "of", "health", "professionals", ",", "which", "potentially", "limits", "generalizability", ".", "CONCLUSION", ":", "Aspirin", "reduces", "the", "risk", "for", "myocardial", "infarction", "in", "men", "and", "strokes", "in", "women", ".", "Aspirin", "use", "increases", "the", "risk", "for", "serious", "bleeding", "events", "."]], "ner": [[[0, 0, "Chemical"], [63, 63, "Chemical"], [86, 86, "Chemical"], [162, 162, "Chemical"], [184, 184, "Chemical"], [212, 212, "Chemical"], [270, 270, "Chemical"], [299, 299, "Chemical"], [321, 321, "Chemical"], [353, 353, "Chemical"], [383, 383, "Chemical"], [396, 396, "Chemical"], [435, 435, "Chemical"], [449, 449, "Chemical"], [95, 95, "Disease"], [190, 190, "Disease"], [198, 198, "Disease"], [217, 218, "Disease"], [297, 297, "Disease"], [350, 351, "Disease"], [368, 369, "Disease"], [445, 445, "Disease"], [214, 215, "Disease"], [334, 335, "Disease"], [27, 29, "Disease"], [72, 74, "Disease"], [31, 32, "Disease"], [92, 93, "Disease"], [290, 291, "Disease"], [440, 441, "Disease"], [170, 171, "Disease"], [173, 173, "Disease"], [209, 209, "Disease"], [276, 276, "Disease"], [282, 282, "Disease"], [305, 305, "Disease"], [389, 389, "Disease"], [330, 330, "Disease"], [456, 456, "Disease"]]], "relations": [[[0, 0, 95, 95, "CID"], [0, 0, 190, 190, "CID"], [0, 0, 198, 198, "CID"], [0, 0, 217, 218, "CID"], [0, 0, 297, 297, "CID"], [0, 0, 350, 351, "CID"], [0, 0, 368, 369, "CID"], [0, 0, 445, 445, "CID"], [63, 63, 95, 95, "CID"], [63, 63, 190, 190, "CID"], [63, 63, 198, 198, "CID"], [63, 63, 217, 218, "CID"], [63, 63, 297, 297, "CID"], [63, 63, 350, 351, "CID"], [63, 63, 368, 369, "CID"], [63, 63, 445, 445, "CID"], [86, 86, 95, 95, "CID"], [86, 86, 190, 190, "CID"], [86, 86, 198, 198, "CID"], [86, 86, 217, 218, "CID"], [86, 86, 297, 297, "CID"], [86, 86, 350, 351, "CID"], [86, 86, 368, 369, "CID"], [86, 86, 445, 445, "CID"], [162, 162, 95, 95, "CID"], [162, 162, 190, 190, "CID"], [162, 162, 198, 198, "CID"], [162, 162, 217, 218, "CID"], [162, 162, 297, 297, "CID"], [162, 162, 350, 351, "CID"], [162, 162, 368, 369, "CID"], [162, 162, 445, 445, "CID"], [184, 184, 95, 95, "CID"], [184, 184, 190, 190, "CID"], [184, 184, 198, 198, "CID"], [184, 184, 217, 218, "CID"], [184, 184, 297, 297, "CID"], [184, 184, 350, 351, "CID"], [184, 184, 368, 369, "CID"], [184, 184, 445, 445, "CID"], [212, 212, 95, 95, "CID"], [212, 212, 190, 190, "CID"], [212, 212, 198, 198, "CID"], [212, 212, 217, 218, "CID"], [212, 212, 297, 297, "CID"], [212, 212, 350, 351, "CID"], [212, 212, 368, 369, "CID"], [212, 212, 445, 445, "CID"], [270, 270, 95, 95, "CID"], [270, 270, 190, 190, "CID"], [270, 270, 198, 198, "CID"], [270, 270, 217, 218, "CID"], [270, 270, 297, 297, "CID"], [270, 270, 350, 351, "CID"], [270, 270, 368, 369, "CID"], [270, 270, 445, 445, "CID"], [299, 299, 95, 95, "CID"], [299, 299, 190, 190, "CID"], [299, 299, 198, 198, "CID"], [299, 299, 217, 218, "CID"], [299, 299, 297, 297, "CID"], [299, 299, 350, 351, "CID"], [299, 299, 368, 369, "CID"], [299, 299, 445, 445, "CID"], [321, 321, 95, 95, "CID"], [321, 321, 190, 190, "CID"], [321, 321, 198, 198, "CID"], [321, 321, 217, 218, "CID"], [321, 321, 297, 297, "CID"], [321, 321, 350, 351, "CID"], [321, 321, 368, 369, "CID"], [321, 321, 445, 445, "CID"], [353, 353, 95, 95, "CID"], [353, 353, 190, 190, "CID"], [353, 353, 198, 198, "CID"], [353, 353, 217, 218, "CID"], [353, 353, 297, 297, "CID"], [353, 353, 350, 351, "CID"], [353, 353, 368, 369, "CID"], [353, 353, 445, 445, "CID"], [383, 383, 95, 95, "CID"], [383, 383, 190, 190, "CID"], [383, 383, 198, 198, "CID"], [383, 383, 217, 218, "CID"], [383, 383, 297, 297, "CID"], [383, 383, 350, 351, "CID"], [383, 383, 368, 369, "CID"], [383, 383, 445, 445, "CID"], [396, 396, 95, 95, "CID"], [396, 396, 190, 190, "CID"], [396, 396, 198, 198, "CID"], [396, 396, 217, 218, "CID"], [396, 396, 297, 297, "CID"], [396, 396, 350, 351, "CID"], [396, 396, 368, 369, "CID"], [396, 396, 445, 445, "CID"], [435, 435, 95, 95, "CID"], [435, 435, 190, 190, "CID"], [435, 435, 198, 198, "CID"], [435, 435, 217, 218, "CID"], [435, 435, 297, 297, "CID"], [435, 435, 350, 351, "CID"], [435, 435, 368, 369, "CID"], [435, 435, 445, 445, "CID"], [449, 449, 95, 95, "CID"], [449, 449, 190, 190, "CID"], [449, 449, 198, 198, "CID"], [449, 449, 217, 218, "CID"], [449, 449, 297, 297, "CID"], [449, 449, 350, 351, "CID"], [449, 449, 368, 369, "CID"], [449, 449, 445, 445, "CID"], [0, 0, 214, 215, "CID"], [0, 0, 334, 335, "CID"], [63, 63, 214, 215, "CID"], [63, 63, 334, 335, "CID"], [86, 86, 214, 215, "CID"], [86, 86, 334, 335, "CID"], [162, 162, 214, 215, "CID"], [162, 162, 334, 335, "CID"], [184, 184, 214, 215, "CID"], [184, 184, 334, 335, "CID"], [212, 212, 214, 215, "CID"], [212, 212, 334, 335, "CID"], [270, 270, 214, 215, "CID"], [270, 270, 334, 335, "CID"], [299, 299, 214, 215, "CID"], [299, 299, 334, 335, "CID"], [321, 321, 214, 215, "CID"], [321, 321, 334, 335, "CID"], [353, 353, 214, 215, "CID"], [353, 353, 334, 335, "CID"], [383, 383, 214, 215, "CID"], [383, 383, 334, 335, "CID"], [396, 396, 214, 215, "CID"], [396, 396, 334, 335, "CID"], [435, 435, 214, 215, "CID"], [435, 435, 334, 335, "CID"], [449, 449, 214, 215, "CID"], [449, 449, 334, 335, "CID"]]], "clusters": [], "translated": " <0>阿司匹林</0>用于心血管事件的一级预防：U 的证据更新。年代。预防服务工作组。<24>背景：</24><24>冠心病</24>和<26>脑血管疾病</26>是美国的主要死因。2002年，美国预防服务工作组（USPSTF）强烈建议临床医生与风险增加的成年人讨论<1>阿司匹林</1>以预防<25>冠心病</25>。 <24>目的：</24>确定使用<2>阿司匹林</2>进行一级预防对<27>心肌梗塞</27>、<14>中风</14>和死亡所产生的益处和危害。 <24>数据来源：</24>MEDLINE和Cochrane图书馆（搜索日期为2001年1月1日至2008年8月28日）；近期系统评价；检索后的参考文献；以及专家建议。 <24>研究选择：</24>选择英语语言的随机对照试验（RCT）；病例对照研究；荟萃分析； <3>阿司匹林</3>与<30>心血管疾病</30> （<31> CVD </31>）一级预防对照的系统评价和系统评价，回答以下问题：使用 <4>阿司匹林</4> 减少冠心病事件、<15>中风</15>、冠心病事件或<16>中风</16> 的死亡率，或减少无已知 <32> CVD </32> 的成年人的全因死亡率吗？使用 <5>阿司匹林</5> 会增加<22>胃肠道出血</22>或<17>出血性中风</17> 的风险吗？ <24>数据提取：</24>使用预定义的 USPSTF 标准对所有研究进行审查、提取和质量评级。 <24>数据综合：</24>来自1项高质量的RCT、1项高质量的荟萃分析和2项质量一般的RCT子分析的新证据表明，使用<6>阿司匹林</6>可减少无已知 <34> CVD </34>的患者的<33> CVD </33>发生率。在这些研究中，男性发生<28>心肌梗塞</28>的可能性更低，女性发生<18>缺血性中风</18>的可能性更低。 <7>阿司匹林</7>似乎不会影响男性或女性的<35> CVD </35>死亡率或全因死亡率。使用<8>阿司匹林</8>进行一级预防将增加男性和女性出现主要<37>出血</37>事件的风险，主要是由于<23>胃肠道出血</23>。使用<9>阿司匹林</9>会增加男性<19>出血性中风</19>的风险。一项新的随机对照试验和荟萃分析建议女性<20>出血性中风</20>的风险未显着增加。 <24>局限性： </24>有限的新证据表明，用于<36>CVD</36>一级预防的<10>阿司匹林</10>。RCT中使用的<11>阿司匹林</11> 剂量不同，这妨碍了评估适用于一级预防的最佳剂量。几个RCT是在卫生专业人群内进行的，可能限制了普遍性。 <24>结论：</24> <12>阿司匹林</12>减少男性<29>心肌梗塞</29>和女性<21>中风</21> 的风险，但使用<13>阿司匹林</13>将增加严重<38>出血</38>事件的风险。", "revised": true}
{"doc_key": "19715529", "sentences": [["Late", "fulminant", "posterior", "reversible", "encephalopathy", "syndrome", "after", "liver", "transplant", ".", "OBJECTIVES", ":", "Posterior", "leukoencephalopathy", "due", "to", "calcineurin", "-", "inhibitor", "-", "related", "neurotoxicity", "is", "a", "rare", "but", "severe", "complication", "that", "results", "from", "treatment", "with", "immunosuppressive", "agents", "(", "primarily", "those", "administered", "after", "a", "liver", "or", "kidney", "transplant", ")", ".", "The", "pathophysiologic", "mechanisms", "of", "that", "disorder", "remain", "unknown", ".", "CASE", ":", "We", "report", "the", "case", "of", "a", "46", "-", "year", "-", "old", "woman", "who", "received", "a", "liver", "transplant", "in", "our", "center", "as", "treatment", "for", "alcoholic", "cirrhosis", "and", "in", "whom", "either", "a", "fulminant", "course", "of", "posterior", "leukoencephalopathy", "or", "posterior", "reversible", "encephalopathy", "syndrome", "developed", "110", "days", "after", "transplant", ".", "After", "an", "initially", "uneventful", "course", "after", "the", "transplant", ",", "the", "patient", "rapidly", "fell", "into", "deep", "coma", ".", "RESULTS", ":", "Cerebral", "MRI", "scan", "showed", "typical", "signs", "of", "enhancement", "in", "the", "pontine", "and", "posterior", "regions", ".", "Switching", "the", "immunosuppressive", "regimen", "from", "tacrolimus", "to", "cyclosporine", "did", "not", "improve", "the", "clinical", "situation", ".", "The", "termination", "of", "treatment", "with", "any", "calcineurin", "inhibitor", "resulted", "in", "a", "complete", "resolution", "of", "that", "complication", ".", "CONCLUSIONS", ":", "Posterior", "reversible", "encephalopathy", "syndrome", "after", "liver", "transplant", "is", "rare", ".", "We", "recommend", "a", "complete", "cessation", "of", "any", "calcineurin", "inhibitor", "rather", "than", "a", "dose", "reduction", "."]], "ner": [[[143, 143, "Chemical"], [2, 5, "Disease"], [12, 13, "Disease"], [91, 92, "Disease"], [94, 97, "Disease"], [172, 175, "Disease"], [145, 145, "Chemical"], [21, 21, "Disease"], [81, 82, "Disease"]]], "relations": [[[143, 143, 2, 5, "CID"], [143, 143, 12, 13, "CID"], [143, 143, 91, 92, "CID"], [143, 143, 94, 97, "CID"], [143, 143, 172, 175, "CID"]]], "clusters": [], "translated": "肝移植后晚期暴发性<1>后部可逆性脑病综合征</1>。目的：<2>后部白质脑病</2>由于钙调神经磷酸酶抑制剂相关<7>神经毒性</7>是一种罕见但严重的并发症，由免疫抑制剂（主要是在肝或肾移植后给药）治疗引起。该疾病的病理生理机制仍然未知。案例：我们报告了一名 46 岁女性的病例，她在我们中心接受了肝移植治疗<8>酒精性肝硬化</8>，并且发生了<3>后部白质脑病</3>的暴发性病程或<4>后部可逆性脑病综合征</4>在移植后 110 天出现。移植后经过最初平静的过程后，患者迅速陷入深度昏迷。结果：脑MRI扫描显示脑桥和后部区域有典型的强化征象。将免疫抑制方案从<0>他克莫司</0>换成<6>环孢菌素</6>并没有改善临床情况。终止任何钙调神经磷酸酶抑制剂治疗可完全解决该并发症。结论：<5>肝移植术后后部可逆性脑病综合征</5>少见。我们建议完全停用任何钙调神经磷酸酶抑制剂，而不是减少剂量。", "revised": true}
{"doc_key": "19967075", "sentences": [["Decreased", "Expression", "of", "Na", "/", "K", "-", "ATPase", ",", "NHE3", ",", "NBC1", ",", "AQP1", "and", "OAT", "in", "Gentamicin", "-", "induced", "Nephropathy", ".", "The", "present", "study", "was", "aimed", "to", "determine", "whether", "there", "is", "an", "altered", "regulation", "of", "tubular", "transporters", "in", "gentamicin", "-", "induced", "nephropathy", ".", "Sprague", "-", "Dawley", "male", "rats", "(", "200~250", "g", ")", "were", "subcutaneously", "injected", "with", "gentamicin", "(", "100", "mg", "/", "kg", "per", "day", ")", "for", "7", "days", ",", "and", "the", "expression", "of", "tubular", "transporters", "was", "determined", "by", "immunoblotting", "and", "immunohistochemistry", ".", "The", "mRNA", "and", "protein", "expression", "of", "OAT", "was", "also", "determined", ".", "Gentamicin", "-", "treated", "rats", "exhibited", "significantly", "decreased", "creatinine", "clearance", "along", "with", "increased", "plasma", "creatinine", "levels", ".", "Accordingly", ",", "the", "fractional", "excretion", "of", "sodium", "increased", ".", "Urine", "volume", "was", "increased", ",", "while", "urine", "osmolality", "and", "free", "water", "reabsorption", "were", "decreased", ".", "Immunoblotting", "and", "immunohistochemistry", "revealed", "decreased", "expression", "of", "Na", "(", "+", ")", "/", "K", "(", "+", ")", "-", "ATPase", ",", "NHE3", ",", "NBC1", ",", "and", "AQP1", "in", "the", "kidney", "of", "gentamicin", "-", "treated", "rats", ".", "The", "expression", "of", "OAT1", "and", "OAT3", "was", "also", "decreased", ".", "Gentamicin", "-", "induced", "nephropathy", "may", "at", "least", "in", "part", "be", "causally", "related", "with", "a", "decreased", "expression", "of", "Na", "(", "+", ")", "/", "K", "(", "+", ")", "-", "ATPase", ",", "NHE3", ",", "NBC1", ",", "AQP1", "and", "OAT", "."]], "ner": [[[17, 17, "Chemical"], [39, 39, "Chemical"], [57, 57, "Chemical"], [94, 94, "Chemical"], [163, 163, "Chemical"], [178, 178, "Chemical"], [20, 20, "Disease"], [42, 42, "Disease"], [181, 181, "Disease"], [3, 3, "Chemical"], [116, 116, "Chemical"], [141, 141, "Chemical"], [195, 195, "Chemical"], [5, 5, "Chemical"], [146, 146, "Chemical"], [200, 200, "Chemical"], [101, 101, "Chemical"], [107, 107, "Chemical"]]], "relations": [[[17, 17, 20, 20, "CID"], [17, 17, 42, 42, "CID"], [17, 17, 181, 181, "CID"], [39, 39, 20, 20, "CID"], [39, 39, 42, 42, "CID"], [39, 39, 181, 181, "CID"], [57, 57, 20, 20, "CID"], [57, 57, 42, 42, "CID"], [57, 57, 181, 181, "CID"], [94, 94, 20, 20, "CID"], [94, 94, 42, 42, "CID"], [94, 94, 181, 181, "CID"], [163, 163, 20, 20, "CID"], [163, 163, 42, 42, "CID"], [163, 163, 181, 181, "CID"], [178, 178, 20, 20, "CID"], [178, 178, 42, 42, "CID"], [178, 178, 181, 181, "CID"]]], "clusters": [], "translated": "在<0>庆大霉素</0>诱导的<6>肾病</6>中，<9>Na</9>/<13>K</13>-ATP酶、NHE3、NBC1、AQP1和OAT的表达降低。本研究旨在确定<1>庆大霉素</1>诱导的<7>肾病</7>中肾小管转运蛋白的调节是否发生改变。Sprague-Dawley雄性大鼠 (200~250 g) 皮下注射<2>庆大霉素</2> (100 mg/kg per day) 连续 7 天，免疫印迹和免疫组化检测肾小管转运蛋白的表达。还测定了OAT的 mRNA 和蛋白质表达。<3>庆大霉素</3> -处理的大鼠表现出显着降低的<16>肌酐</16>清除率 along with increased plasma<17>肌酐</17>水平。因此，<10>钠</10>的排泄分数增加。尿量增加，而尿渗透压和游离水重吸收降低。免疫印迹和免疫组织化学显示<11>Na</11>(+)/<14>K</14>(+)-ATP酶、NHE3、NBC1和AQP1在<4>庆大霉素</4>-处理过的老鼠肾脏中的表达降低。OAT1 和OAT3 的表达也降低。<5> 庆大霉素</5> -诱导的<8>肾病</8> 可能至少部分与<12>Na</12>(+)/<15>K</15>(+)-ATP酶、NHE3、NBC1、AQP1和OAT的表达降低有因果关系。", "revised": true}
{"doc_key": "20024739", "sentences": [["Longitudinal", "association", "of", "alcohol", "use", "with", "HIV", "disease", "progression", "and", "psychological", "health", "of", "women", "with", "HIV", ".", "We", "evaluated", "the", "association", "of", "alcohol", "consumption", "and", "depression", ",", "and", "their", "effects", "on", "HIV", "disease", "progression", "among", "women", "with", "HIV", ".", "The", "study", "included", "871", "women", "with", "HIV", "who", "were", "recruited", "from", "1993", "-", "1995", "in", "four", "US", "cities", ".", "The", "participants", "had", "physical", "examination", ",", "medical", "record", "extraction", ",", "and", "venipuncture", ",", "CD4", "+", "T", "-", "cell", "counts", "determination", ",", "measurement", "of", "depression", "symptoms", "(", "using", "the", "self", "-", "report", "Center", "for", "Epidemiological", "Studies", "-", "Depression", "Scale", ")", ",", "and", "alcohol", "use", "assessment", "at", "enrollment", ",", "and", "semiannually", "until", "March", "2000", ".", "Multilevel", "random", "coefficient", "ordinal", "models", "as", "well", "as", "multilevel", "models", "with", "joint", "responses", "were", "used", "in", "the", "analysis", ".", "There", "was", "no", "significant", "association", "between", "level", "of", "alcohol", "use", "and", "CD4", "+", "T", "-", "cell", "counts", ".", "When", "participants", "were", "stratified", "by", "antiretroviral", "therapy", "(", "ART", ")", "use", ",", "the", "association", "between", "alcohol", "and", "CD4", "+", "T", "-", "cell", "did", "not", "reach", "statistical", "significance", ".", "The", "association", "between", "alcohol", "consumption", "and", "depression", "was", "significant", "(", "p", "<", "0", ".", "001", ")", ".", "Depression", "had", "a", "significant", "negative", "effect", "on", "CD4", "+", "T", "-", "cell", "counts", "over", "time", "regardless", "of", "ART", "use", ".", "Our", "findings", "suggest", "that", "alcohol", "consumption", "has", "a", "direct", "association", "with", "depression", ".", "Moreover", ",", "depression", "is", "associated", "with", "HIV", "disease", "progression", ".", "Our", "findings", "have", "implications", "for", "the", "provision", "of", "alcohol", "use", "interventions", "and", "psychological", "resources", "to", "improve", "the", "health", "of", "women", "with", "HIV", "."]], "ner": [[[3, 3, "Chemical"], [22, 22, "Chemical"], [99, 99, "Chemical"], [138, 138, "Chemical"], [163, 163, "Chemical"], [179, 179, "Chemical"], [217, 217, "Chemical"], [244, 244, "Chemical"], [25, 25, "Disease"], [81, 81, "Disease"], [94, 94, "Disease"], [182, 182, "Disease"], [193, 193, "Disease"], [224, 224, "Disease"], [228, 228, "Disease"], [6, 7, "Disease"], [31, 32, "Disease"], [232, 233, "Disease"]]], "relations": [[[3, 3, 25, 25, "CID"], [3, 3, 81, 81, "CID"], [3, 3, 94, 94, "CID"], [3, 3, 182, 182, "CID"], [3, 3, 193, 193, "CID"], [3, 3, 224, 224, "CID"], [3, 3, 228, 228, "CID"], [22, 22, 25, 25, "CID"], [22, 22, 81, 81, "CID"], [22, 22, 94, 94, "CID"], [22, 22, 182, 182, "CID"], [22, 22, 193, 193, "CID"], [22, 22, 224, 224, "CID"], [22, 22, 228, 228, "CID"], [99, 99, 25, 25, "CID"], [99, 99, 81, 81, "CID"], [99, 99, 94, 94, "CID"], [99, 99, 182, 182, "CID"], [99, 99, 193, 193, "CID"], [99, 99, 224, 224, "CID"], [99, 99, 228, 228, "CID"], [138, 138, 25, 25, "CID"], [138, 138, 81, 81, "CID"], [138, 138, 94, 94, "CID"], [138, 138, 182, 182, "CID"], [138, 138, 193, 193, "CID"], [138, 138, 224, 224, "CID"], [138, 138, 228, 228, "CID"], [163, 163, 25, 25, "CID"], [163, 163, 81, 81, "CID"], [163, 163, 94, 94, "CID"], [163, 163, 182, 182, "CID"], [163, 163, 193, 193, "CID"], [163, 163, 224, 224, "CID"], [163, 163, 228, 228, "CID"], [179, 179, 25, 25, "CID"], [179, 179, 81, 81, "CID"], [179, 179, 94, 94, "CID"], [179, 179, 182, 182, "CID"], [179, 179, 193, 193, "CID"], [179, 179, 224, 224, "CID"], [179, 179, 228, 228, "CID"], [217, 217, 25, 25, "CID"], [217, 217, 81, 81, "CID"], [217, 217, 94, 94, "CID"], [217, 217, 182, 182, "CID"], [217, 217, 193, 193, "CID"], [217, 217, 224, 224, "CID"], [217, 217, 228, 228, "CID"], [244, 244, 25, 25, "CID"], [244, 244, 81, 81, "CID"], [244, 244, 94, 94, "CID"], [244, 244, 182, 182, "CID"], [244, 244, 193, 193, "CID"], [244, 244, 224, 224, "CID"], [244, 244, 228, 228, "CID"]]], "clusters": [], "translated": "<0>酒精</0>使用与<15>HIV疾病</15>进展和感染 HIV 女性的心理健康的纵向关联。我们评估了<1>饮酒</1>与<8>抑郁</8>之间的关联，以及它们对感染 HIV 的女性<16>HIV疾病</16>进展的影响。该研究包括871名感染 HIV 的女性，她们在 1993 年至 1995 年间在美国四个城市招募。参与者进行了体格检查、病历提取和静脉穿刺、CD4+ T 细胞计数测定、<9>抑郁症</9>症状测量（使用自我报告流行病学研究中心-<10>抑郁</10>量表）和<2>饮酒</2>使用评估，在入学时和每六个月进行，直到 2000 年 3 月。分析中使用了多级随机系数序数模型以及具有联合响应的多级模型。与<3>饮酒</3>使用水平和 CD4+ T 细胞计数之间没有显着关联。当参与者按抗逆转录病毒疗法 (ART) 的使用情况进行分层时，<4>饮酒</4>与 CD4+ T 细胞的关联未达到统计学意义。<5>饮酒</5>与<11>抑郁症</11>之间的关联显著（p < 0.001）。<12>抑郁</12>症会显著负面影响 CD4+ T 细胞计数随时间的变化，无论是否使用 ART。我们的研究结果表明，<6>饮酒</6>使用与<13>抑郁症</13>直接相关。此外，<14>抑郁症</14>与<17>HIV疾病</17>的进展存在关联。我们的研究结果对提供<7>饮酒</7>使用干预措施和心理资源以改善感染 HIV 的女性的健康具有重要意义。", "revised": true}
{"doc_key": "19841052", "sentences": [["Smoking", "of", "crack", "cocaine", "as", "a", "risk", "factor", "for", "HIV", "infection", "among", "people", "who", "use", "injection", "drugs", ".", "BACKGROUND", ":", "Little", "is", "known", "about", "the", "possible", "role", "that", "smoking", "crack", "cocaine", "has", "on", "the", "incidence", "of", "HIV", "infection", ".", "Given", "the", "increasing", "use", "of", "crack", "cocaine", ",", "we", "sought", "to", "examine", "whether", "use", "of", "this", "illicit", "drug", "has", "become", "a", "risk", "factor", "for", "HIV", "infection", ".", "METHODS", ":", "We", "included", "data", "from", "people", "participating", "in", "the", "Vancouver", "Injection", "Drug", "Users", "Study", "who", "reported", "injecting", "illicit", "drugs", "at", "least", "once", "in", "the", "month", "before", "enrolment", ",", "lived", "in", "the", "greater", "Vancouver", "area", ",", "were", "HIV", "-", "negative", "at", "enrolment", "and", "completed", "at", "least", "1", "follow", "-", "up", "study", "visit", ".", "To", "determine", "whether", "the", "risk", "of", "HIV", "seroconversion", "among", "daily", "smokers", "of", "crack", "cocaine", "changed", "over", "time", ",", "we", "used", "Cox", "proportional", "hazards", "regression", "and", "divided", "the", "study", "into", "3", "periods", ":", "May", "1", ",", "1996", "-", "Nov", ".", "30", ",", "1999", "(", "period", "1", ")", ",", "Dec", ".", "1", ",", "1999", "-", "Nov", ".", "30", ",", "2002", "(", "period", "2", ")", ",", "and", "Dec", ".", "1", ",", "2002", "-", "Dec", ".", "30", ",", "2005", "(", "period", "3", ")", ".", "RESULTS", ":", "Overall", ",", "1048", "eligible", "injection", "drug", "users", "were", "included", "in", "our", "study", ".", "Of", "these", ",", "137", "acquired", "HIV", "infection", "during", "follow", "-", "up", ".", "The", "mean", "proportion", "of", "participants", "who", "reported", "daily", "smoking", "of", "crack", "cocaine", "increased", "from", "11", ".", "6", "%", "in", "period", "1", "to", "39", ".", "7", "%", "in", "period", "3", ".", "After", "adjusting", "for", "potential", "confounders", ",", "we", "found", "that", "the", "risk", "of", "HIV", "seroconversion", "among", "participants", "who", "were", "daily", "smokers", "of", "crack", "cocaine", "increased", "over", "time", "(", "period", "1", ":", "hazard", "ratio", "[", "HR", "]", "1", ".", "03", ",", "95", "%", "confidence", "interval", "[", "CI", "]", "0", ".", "57", "-", "1", ".", "85", ";", "period", "2", ":", "HR", "1", ".", "68", ",", "95", "%", "CI", "1", ".", "01", "-", "2", ".", "80", ";", "and", "period", "3", ":", "HR", "2", ".", "74", ",", "95", "%", "CI", "1", ".", "06", "-", "7", ".", "11", ")", ".", "INTERPRETATION", ":", "Smoking", "of", "crack", "cocaine", "was", "found", "to", "be", "an", "independent", "risk", "factor", "for", "HIV", "seroconversion", "among", "people", "who", "were", "injection", "drug", "users", ".", "This", "finding", "points", "to", "the", "urgent", "need", "for", "evidence", "-", "based", "public", "health", "initiatives", "targeted", "at", "people", "who", "smoke", "crack", "cocaine", "."]], "ner": [[[2, 3, "Chemical"], [29, 30, "Chemical"], [44, 45, "Chemical"], [131, 132, "Chemical"], [236, 237, "Chemical"], [277, 278, "Chemical"], [354, 355, "Chemical"], [394, 395, "Chemical"], [125, 126, "Disease"], [268, 269, "Disease"], [365, 366, "Disease"], [9, 10, "Disease"], [36, 37, "Disease"], [63, 64, "Disease"], [219, 220, "Disease"]]], "relations": [[[2, 3, 125, 126, "CID"], [2, 3, 268, 269, "CID"], [2, 3, 365, 366, "CID"], [29, 30, 125, 126, "CID"], [29, 30, 268, 269, "CID"], [29, 30, 365, 366, "CID"], [44, 45, 125, 126, "CID"], [44, 45, 268, 269, "CID"], [44, 45, 365, 366, "CID"], [131, 132, 125, 126, "CID"], [131, 132, 268, 269, "CID"], [131, 132, 365, 366, "CID"], [236, 237, 125, 126, "CID"], [236, 237, 268, 269, "CID"], [236, 237, 365, 366, "CID"], [277, 278, 125, 126, "CID"], [277, 278, 268, 269, "CID"], [277, 278, 365, 366, "CID"], [354, 355, 125, 126, "CID"], [354, 355, 268, 269, "CID"], [354, 355, 365, 366, "CID"], [394, 395, 125, 126, "CID"], [394, 395, 268, 269, "CID"], [394, 395, 365, 366, "CID"]]], "clusters": [], "translated": "吸食<0>快克可卡因</0>是注射吸毒者<11>感染艾滋病毒</11>的危险因素。背景：关于吸烟<1>快克可卡因</1>对<12>HIV感染</12>的可能影响知之甚少。鉴于<2>快克可卡因</2>的使用越来越多，我们试图检查使用这种非法药物是否已成为<13>HIV感染</13>的危险因素。方法：我们纳入了参与温哥华注射吸毒者研究的人的数据，这些人报告在入组前一个月至少注射过一次非法药物，居住在大温哥华地区，在入组时为HIV阴性并完成了至少1次随访考察访问。为了确定每天吸食<3>快克可卡因</3>的人中<8>HIV血清转化</8>的风险是否随时间变化，我们使用Cox比例风险回归并将研究分为3个时期：1996年5月1日-11月30日（第1期），1999年12月1日-2002年11月30日（第2期）和2002年12月1日30-2005年12月30日（第3期）。结果：总的来说，我们的研究包括1048名符合条件的注射吸毒者。其中，137例在随访期间获得<14>HIV感染</14>。报告每天吸食<4>快克可卡因</4>的参与者的平均比例从11.6%（第1期）增加到39.7%（第3期）。调整潜在混杂因素后，我们发现每天吸食<5>快克可卡因</5>的参与者中<9>HIV血清转化</9>的风险随时间增加（第1期：<0>HR 1.03，95%</0>置信区间<1>[CI]0.57-1.85</1>；第2期：<2>HR 1.68，95%</2>CI 1.01-2.80；第3期：<3>HR 2.74，95%</3>CI 1.06-7.11）。解读：研究发现，<6>吸食快克可卡因</6>是注射吸毒者<10>HIV血清转化</10>的独立危险因素。这一发现表明，迫切需要采取循证公共卫生举措，针对<7>吸食快克可卡因</7>的人群进行干预。", "revised": true}
{"doc_key": "19920070", "sentences": [["Liver", "-", "specific", "ablation", "of", "integrin", "-", "linked", "kinase", "in", "mice", "results", "in", "enhanced", "and", "prolonged", "cell", "proliferation", "and", "hepatomegaly", "after", "phenobarbital", "administration", ".", "We", "have", "recently", "demonstrated", "that", "disruption", "of", "extracellular", "matrix", "(", "ECM", ")", "/", "integrin", "signaling", "via", "elimination", "of", "integrin", "-", "linked", "kinase", "(", "ILK", ")", "in", "hepatocytes", "interferes", "with", "signals", "leading", "to", "termination", "of", "liver", "regeneration", ".", "This", "study", "investigates", "the", "role", "of", "ILK", "in", "liver", "enlargement", "induced", "by", "phenobarbital", "(", "PB", ")", ".", "Wild", "-", "type", "(", "WT", ")", "and", "ILK", ":", "liver", "-", "/", "-", "mice", "were", "given", "PB", "(", "0", ".", "1", "%", "in", "drinking", "water", ")", "for", "10", "days", ".", "Livers", "were", "harvested", "on", "2", ",", "5", ",", "and", "10", "days", "during", "PB", "administration", ".", "In", "the", "hepatocyte", "-", "specific", "ILK", "/", "liver", "-", "/", "-", "mice", ",", "the", "liver", ":", "body", "weight", "ratio", "was", "more", "than", "double", "as", "compared", "to", "0", "h", "at", "day", "2", "(", "2", ".", "5", "times", ")", ",", "while", "at", "days", "5", "and", "10", ",", "it", "was", "enlarged", "three", "times", ".", "In", "the", "WT", "mice", ",", "the", "increase", "was", "as", "expected", "from", "previous", "literature", "(", "1", ".", "8", "times", ")", "and", "seems", "to", "have", "leveled", "off", "after", "day", "2", ".", "There", "were", "slightly", "increased", "proliferating", "cell", "nuclear", "antigen", "-", "positive", "cells", "in", "the", "ILK", "/", "liver", "-", "/", "-", "animals", "at", "day", "2", "as", "compared", "to", "WT", "after", "PB", "administration", ".", "In", "the", "WT", "animals", ",", "the", "proliferative", "response", "had", "come", "back", "to", "normal", "by", "days", "5", "and", "10", ".", "Hepatocytes", "of", "the", "ILK", "/", "liver", "-", "/", "-", "mice", "continued", "to", "proliferate", "up", "until", "day", "10", ".", "ILK", "/", "liver", "-", "/", "-", "mice", "also", "showed", "increased", "expression", "of", "key", "genes", "involved", "in", "hepatocyte", "proliferation", "at", "different", "time", "points", "during", "PB", "administration", ".", "In", "summary", ",", "ECM", "proteins", "communicate", "with", "the", "signaling", "machinery", "of", "dividing", "cells", "via", "ILK", "to", "regulate", "hepatocyte", "proliferation", "and", "termination", "of", "the", "proliferative", "response", ".", "Lack", "of", "ILK", "in", "the", "hepatocytes", "imparts", "prolonged", "proliferative", "response", "not", "only", "to", "stimuli", "related", "to", "liver", "regeneration", "but", "also", "to", "xenobiotic", "chemical", "mitogens", ",", "such", "as", "PB", "."]], "ner": [[[21, 21, "Chemical"], [73, 73, "Chemical"], [75, 75, "Chemical"], [94, 94, "Chemical"], [120, 120, "Chemical"], [231, 231, "Chemical"], [294, 294, "Chemical"], [350, 350, "Chemical"], [19, 19, "Disease"]]], "relations": [[[21, 21, 19, 19, "CID"], [73, 73, 19, 19, "CID"], [75, 75, 19, 19, "CID"], [94, 94, 19, 19, "CID"], [120, 120, 19, 19, "CID"], [231, 231, 19, 19, "CID"], [294, 294, 19, 19, "CID"], [350, 350, 19, 19, "CID"]]], "clusters": [], "translated": "在<0>苯巴比妥</0>给药后，小鼠体内整合素连接激酶(ILK)的肝脏特异性消融导致细胞增殖增强和延长以及<8>肝肿大</8>。我们最近证明，通过消除肝细胞中的整合素连接激酶（ILK）来破坏细胞外基质(ECM) /整合素信号，会干扰导致肝再生终止的信号。本研究探讨了 ILK 在<1>苯巴比妥</1>(<2>PB</2>)诱导的肝肿大中的作用。野生型(WT)和 ILK：肝-/-小鼠被给予<3>PB</3>（0.1% 饮用水中）10 天。在<4>PB</4>给药期间的第 2、5和10天收获肝脏。在ILK / liver - / -特异性肝细胞小鼠中，肝脏：体重比增加了一倍以上（2.5倍），而在第五天和第十天，它扩大了三倍。在野生型小鼠中，增加与之前的文献预期一致（1.8倍），并且似乎在第二天后趋于平稳。与野生动物相比，<5> PB </5> 给药后，ILK / 肝脏- / - 动物体内的增殖细胞核抗原阳性细胞略有增加。在野生动物中，增殖反应在第五天和第十天恢复正常。ILK / liver - / -小鼠的肝细胞持续增殖直至第十天。ILK / liver - / -小鼠在<6>PB</6>给药期间的不同时间点也表现出参与肝细胞增殖的关键基因表达增加。总之，ECM 蛋白通过 ILK 与分裂细胞的信号机制进行通讯，从而调节肝细胞增殖和增殖反应的终止。肝细胞缺乏 ILK 不仅会延长对与肝再生相关的刺激的增殖反应，还会延长对异生化学有丝分裂剂（如<7> PB </7>）的增殖反应。", "revised": true}
{"doc_key": "16867246", "sentences": [["Association", "of", "DRD2", "polymorphisms", "and", "chlorpromazine", "-", "induced", "extrapyramidal", "syndrome", "in", "Chinese", "schizophrenic", "patients", ".", "AIM", ":", "Extrapyramidal", "syndrome", "(", "EPS", ")", "is", "most", "commonly", "affected", "by", "typical", "antipsychotic", "drugs", "that", "have", "a", "high", "affinity", "with", "the", "D2", "receptor", ".", "Recently", ",", "many", "research", "groups", "have", "reported", "on", "the", "positive", "relationship", "between", "the", "genetic", "variations", "in", "the", "DRD2", "gene", "and", "the", "therapeutic", "response", "in", "schizophrenia", "patients", "as", "a", "result", "of", "the", "role", "of", "variations", "in", "the", "receptor", "in", "modulating", "receptor", "expression", ".", "In", "this", "study", ",", "we", "evaluate", "the", "role", "DRD2", "plays", "in", "chlorpromazine", "-", "induced", "EPS", "in", "schizophrenic", "patients", ".", "METHODS", ":", "We", "identified", "seven", "SNP", "(", "single", "nucleotide", "polymorphism", ")", "(", "-", "141Cins", ">", "del", ",", "TaqIB", ",", "TaqID", ",", "Ser311Cys", ",", "rs6275", ",", "rs6277", "and", "TaqIA", ")", "in", "the", "DRD2", "gene", "in", "146", "schizophrenic", "inpatients", "(", "59", "with", "EPS", "and", "87", "without", "EPS", "according", "to", "the", "Simpson", "-", "Angus", "Scale", ")", "treated", "with", "chlorpromazine", "after", "8", "weeks", ".", "The", "alleles", "of", "all", "loci", "were", "determined", "by", "PCR", "(", "polymerase", "chain", "reaction", ")", ".", "RESULTS", ":", "Polymorphisms", "TaqID", ",", "Ser311Cys", "and", "rs6277", "were", "not", "polymorphic", "in", "the", "population", "recruited", "in", "the", "present", "study", ".", "No", "statistical", "significance", "was", "found", "in", "the", "allele", "distribution", "of", "-", "141Cins", ">", "del", ",", "TaqIB", ",", "rs6275", "and", "TaqIA", "or", "in", "the", "estimated", "haplotypes", "(", "constituted", "by", "TaqIB", ",", "rs6275", "and", "TaqIA", ")", "in", "linkage", "disequilibrium", "between", "the", "two", "groups", ".", "CONCLUSION", ":", "Our", "results", "did", "not", "lend", "strong", "support", "to", "the", "view", "that", "the", "genetic", "variation", "of", "the", "DRD2", "gene", "plays", "a", "major", "role", "in", "the", "individually", "variable", "adverse", "effect", "induced", "by", "chlorpromazine", ",", "at", "least", "in", "Chinese", "patients", "with", "schizophrenia", ".", "Our", "results", "confirmed", "a", "previous", "study", "on", "the", "relationship", "between", "DRD2", "and", "EPS", "in", "Caucasians", "."]], "ner": [[[5, 5, "Chemical"], [93, 93, "Chemical"], [156, 156, "Chemical"], [270, 270, "Chemical"], [8, 9, "Disease"], [17, 18, "Disease"], [20, 20, "Disease"], [96, 96, "Disease"], [141, 141, "Disease"], [145, 145, "Disease"], [292, 292, "Disease"], [12, 12, "Disease"], [64, 64, "Disease"], [98, 98, "Disease"], [136, 136, "Disease"], [278, 278, "Disease"]]], "relations": [[[5, 5, 8, 9, "CID"], [5, 5, 17, 18, "CID"], [5, 5, 20, 20, "CID"], [5, 5, 96, 96, "CID"], [5, 5, 141, 141, "CID"], [5, 5, 145, 145, "CID"], [5, 5, 292, 292, "CID"], [93, 93, 8, 9, "CID"], [93, 93, 17, 18, "CID"], [93, 93, 20, 20, "CID"], [93, 93, 96, 96, "CID"], [93, 93, 141, 141, "CID"], [93, 93, 145, 145, "CID"], [93, 93, 292, 292, "CID"], [156, 156, 8, 9, "CID"], [156, 156, 17, 18, "CID"], [156, 156, 20, 20, "CID"], [156, 156, 96, 96, "CID"], [156, 156, 141, 141, "CID"], [156, 156, 145, 145, "CID"], [156, 156, 292, 292, "CID"], [270, 270, 8, 9, "CID"], [270, 270, 17, 18, "CID"], [270, 270, 20, 20, "CID"], [270, 270, 96, 96, "CID"], [270, 270, 141, 141, "CID"], [270, 270, 145, 145, "CID"], [270, 270, 292, 292, "CID"]]], "clusters": [], "translated": "中国<11>精神分裂症</11>患者DRD2基因多态性与<0>氯丙嗪</0>诱发的<4>锥体外系综合征</4>的相关性。目的：<5>锥体外系综合征</5>（<6>EPS</6>）最常见于与D2受体具有高亲和力的典型抗精神病药物。最近，许多研究小组报道了DRD2基因的遗传变异与<12>精神分裂症</12>患者的治疗反应之间的正相关关系，这是由于受体变异在调节受体表达中的作用。在这项研究中，我们评估了 DRD2 在<13>精神分裂症</13>患者的<1>氯丙嗪</1>诱导的<7>EPS</7>中的作用。方法：我们在146名<14>精神分裂症</14>住院患者（59名有<8>EPS</8>和87名无<9>EPS</9>，以Simpson-Angus评分为标准）接受<2>氯丙嗪</2>治疗8周后，鉴定DRD2基因中的7个SNP（单核苷酸多态性）（-141Cins>del、TaqIB、TaqID、Ser311Cys、rs6275、rs6277和TaqIA）。所有位点的等位基因均通过PCR（聚合酶链反应）确定。结果：多态性TaqID、Ser311Cys和rs6277在本研究招募的人群中没有多态性。两组间连锁不平衡的-141Cins>del、TaqIB、rs6275和TaqIA的等位基因分布或估计的单倍型（由TaqIB、rs6275和TaqIA构成）均无统计学意义。结论：我们的结果并未有力支持DRD2基因的遗传变异在<3>氯丙嗪</3>诱导的个体可变不良反应中起主要作用的观点，至少在中国<15>精神分裂症</15>患者中如此。我们的结果证实了先前关于白种人中DRD2和<10>EPS</10>之间关系的研究。", "revised": true}
{"doc_key": "20192893", "sentences": [["Contrast", "medium", "nephrotoxicity", "after", "renal", "artery", "and", "coronary", "angioplasty", ".", "BACKGROUND", ":", "Renal", "dysfunction", "induced", "by", "iodinated", "contrast", "medium", "(", "CM", ")", "administration", "can", "minimize", "the", "benefit", "of", "the", "interventional", "procedure", "in", "patients", "undergoing", "renal", "angioplasty", "(", "PTRA", ")", ".", "PURPOSE", ":", "To", "compare", "the", "susceptibility", "to", "nephrotoxic", "effect", "of", "CM", "in", "patients", "undergoing", "PTRA", "with", "that", "of", "patients", "submitted", "to", "percutaneous", "coronary", "intervention", "(", "PCI", ")", ".", "MATERIAL", "AND", "METHODS", ":", "A", "total", "of", "33", "patients", "successfully", "treated", "with", "PTRA", "(", "PTRA", "group", ",", "mean", "age", "70", "+", "/", "-", "12", "years", ",", "23", "female", ",", "basal", "creatinine", "1", ".", "46", "+", "/", "-", "0", ".", "79", ",", "range", "0", ".", "7", "-", "4", ".", "9", "mg", "/", "dl", ")", "were", "compared", "with", "33", "patients", "undergoing", "successful", "PCI", "(", "PCI", "group", ")", ",", "matched", "for", "basal", "creatinine", "(", "1", ".", "44", "+", "/", "-", "0", ".", "6", ",", "range", "0", ".", "7", "-", "3", ".", "4", "mg", "/", "dl", ")", ",", "gender", ",", "and", "age", ".", "In", "both", "groups", "postprocedural", "(", "48", "h", ")", "serum", "creatinine", "was", "measured", ".", "RESULTS", ":", "Postprocedural", "creatinine", "level", "decreased", "nonsignificantly", "in", "the", "PTRA", "group", "(", "1", ".", "46", "+", "/", "-", "0", ".", "8", "vs", ".", "1", ".", "34", "+", "/", "-", "0", ".", "5", "mg", "/", "dl", ",", "P", "=", "NS", ")", "and", "increased", "significantly", "in", "the", "PCI", "group", "(", "1", ".", "44", "+", "/", "-", "0", ".", "6", "vs", ".", "1", ".", "57", "+", "/", "-", "0", ".", "7", "mg", "/", "dl", ",", "P", "<", "0", ".", "02", ")", ".", "Changes", "in", "serum", "creatinine", "after", "intervention", "(", "after", "-", "before", ")", "were", "significantly", "different", "between", "the", "PTRA", "and", "PCI", "groups", "(", "-", "0", ".", "12", "+", "/", "-", "0", ".", "5", "vs", ".", "0", ".", "13", "+", "/", "-", "0", ".", "3", ",", "P", "=", "0", ".", "014", ")", ".", "This", "difference", "was", "not", "related", "to", "either", "a", "different", "clinical", "risk", "profile", "or", "to", "the", "volume", "of", "CM", "administered", ".", "CONCLUSION", ":", "In", "this", "preliminary", "study", "patients", "submitted", "to", "PTRA", "showed", "a", "lower", "susceptibility", "to", "renal", "damage", "induced", "by", "CM", "administration", "than", "PCI", "patients", ".", "The", "effectiveness", "of", "PTRA", "on", "renal", "function", "seems", "to", "be", "barely", "influenced", "by", "CM", "toxicity", "."]], "ner": [[[0, 1, "Chemical"], [17, 18, "Chemical"], [20, 20, "Chemical"], [50, 50, "Chemical"], [326, 326, "Chemical"], [348, 348, "Chemical"], [367, 367, "Chemical"], [2, 2, "Disease"], [12, 13, "Disease"], [47, 47, "Disease"], [344, 345, "Disease"], [368, 368, "Disease"], [98, 98, "Chemical"], [137, 137, "Chemical"], [176, 176, "Chemical"], [183, 183, "Chemical"], [262, 262, "Chemical"]]], "relations": [[[0, 1, 2, 2, "CID"], [0, 1, 12, 13, "CID"], [0, 1, 47, 47, "CID"], [0, 1, 344, 345, "CID"], [17, 18, 2, 2, "CID"], [17, 18, 12, 13, "CID"], [17, 18, 47, 47, "CID"], [17, 18, 344, 345, "CID"], [20, 20, 2, 2, "CID"], [20, 20, 12, 13, "CID"], [20, 20, 47, 47, "CID"], [20, 20, 344, 345, "CID"], [50, 50, 2, 2, "CID"], [50, 50, 12, 13, "CID"], [50, 50, 47, 47, "CID"], [50, 50, 344, 345, "CID"], [326, 326, 2, 2, "CID"], [326, 326, 12, 13, "CID"], [326, 326, 47, 47, "CID"], [326, 326, 344, 345, "CID"], [348, 348, 2, 2, "CID"], [348, 348, 12, 13, "CID"], [348, 348, 47, 47, "CID"], [348, 348, 344, 345, "CID"], [367, 367, 2, 2, "CID"], [367, 367, 12, 13, "CID"], [367, 367, 47, 47, "CID"], [367, 367, 344, 345, "CID"]]], "clusters": [], "translated": "<0>对比剂</0> <7>肾毒性</7>：肾动脉和冠状动脉血管成形术后。背景：由碘酸 <1>造影剂</1>（<2>CM</2>）引起的<8>肾功能失常</8>可以最大限度地减少接受肾血管成形术（PTRA）患者介入手术的益处。目的：比较接受 PTRA 的患者和接受经皮冠状动脉介入治疗（PCI）的患者对<3>CM</3>的<9>肾毒性</9>作用的易感性。材料和方法：共33例成功接受PTRA治疗的患者（PTRA组，平均年龄70+/-12岁，23名女性，基础<12>肌酐</12>1.46+/-0.79，范围0.7-4.9 mg/dl）与33名接受成功PCI的患者（PCI组）进行了比较，匹配基础<13>肌酐</13>（1.44+/-0.6，范围0.7-3.4 mg/dl），性别和年龄。在两组中，均测量了术后（48小时）血清<14>肌酐</14>。结果：PTRA组的术后<15>肌酐</15>水平无显着下降（1.46+/-0.8 对比1.34+/-0.5 mg/dl，P=NS），但PCI组中术后<15>肌酐</15>水平显着升高（1.44+/-0.6对比1.57+/-0.7 mg/dl，P<0.02）。干预后（术后-术前）血清<16>肌酐</16>的变化在PTRA和PCI组之间有显着差异（-0.12+/-0.5对比0.13+/-0.3，P=0.014）。这种差异与不同的临床风险概况或<4>CM</4>给药量无关。结论：在这项初步研究中，接受PTRA治疗的患者对<5>CM</5>给药引起的<10>肾损伤</10>的易感性低于PCI患者。PTRA对肾功能的有效性似乎几乎不受<6>CM</6>的<11>毒性</11>的影响。", "revised": true}
{"doc_key": "19655282", "sentences": [["Coronary", "computerized", "tomography", "angiography", "for", "rapid", "discharge", "of", "low", "-", "risk", "patients", "with", "cocaine", "-", "associated", "chest", "pain", ".", "BACKGROUND", ":", "Most", "patients", "presenting", "to", "emergency", "departments", "(", "EDs", ")", "with", "cocaine", "-", "associated", "chest", "pain", "are", "admitted", "for", "at", "least", "12", "hours", "and", "receive", "a", "\"", "rule", "out", "acute", "coronary", "syndrome", "\"", "protocol", ",", "often", "with", "noninvasive", "testing", "prior", "to", "discharge", ".", "In", "patients", "without", "cocaine", "use", ",", "coronary", "computerized", "tomography", "angiography", "(", "CTA", ")", "has", "been", "shown", "to", "be", "useful", "for", "identifying", "a", "group", "of", "patients", "at", "low", "risk", "for", "cardiac", "events", "who", "can", "be", "safely", "discharged", ".", "It", "is", "unclear", "whether", "a", "coronary", "CTA", "strategy", "would", "be", "efficacious", "in", "cocaine", "-", "associated", "chest", "pain", ",", "as", "coronary", "vasospasm", "may", "account", "for", "some", "of", "the", "ischemia", ".", "We", "studied", "whether", "a", "negative", "coronary", "CTA", "in", "patients", "with", "cocaine", "-", "associated", "chest", "pain", "could", "identify", "a", "subset", "safe", "for", "discharge", ".", "METHODS", ":", "We", "prospectively", "evaluated", "the", "safety", "of", "coronary", "CTA", "for", "low", "-", "risk", "patients", "who", "presented", "to", "the", "ED", "with", "cocaineassociated", "chest", "pain", "(", "self", "-", "reported", "or", "positive", "urine", "test", ")", ".", "Consecutive", "patients", "received", "either", "immediate", "coronary", "CTA", "in", "the", "ED", "(", "without", "serial", "markers", ")", "or", "underwent", "coronary", "CTA", "after", "a", "brief", "observation", "period", "with", "serial", "cardiac", "marker", "measurements", ".", "Patients", "with", "negative", "coronary", "CTA", "(", "maximal", "stenosis", "less", "than", "50", "%", ")", "were", "discharged", ".", "The", "main", "outcome", "was", "30", "-", "day", "cardiovascular", "death", "or", "myocardial", "infarction", ".", "RESULTS", ":", "A", "total", "of", "59", "patients", "with", "cocaine", "-", "associated", "chest", "pain", "were", "evaluated", ".", "Patients", "had", "a", "mean", "age", "of", "45", ".", "6", "+", "/", "-", "6", ".", "6", "yrs", "and", "were", "86", "%", "black", ",", "66", "%", "male", ".", "Seventy", "-", "nine", "percent", "had", "a", "normal", "or", "nonspecific", "ECG", "and", "85", "%", "had", "a", "TIMI", "score", "<", "2", ".", "Twenty", "patients", "received", "coronary", "CTA", "immediately", "in", "the", "ED", ",", "18", "of", "whom", "were", "discharged", "following", "CTA", "(", "90", "%", ")", ".", "Thirty", "-", "nine", "received", "coronary", "CTA", "after", "a", "brief", "observation", "period", ",", "with", "37", "discharged", "home", "following", "CTA", "(", "95", "%", ")", ".", "Six", "patients", "had", "coronary", "stenosis", ">", "or", "=", "50", "%", ".", "During", "the", "30", "-", "day", "follow", "-", "up", "period", ",", "no", "patients", "died", "of", "a", "cardiovascular", "event", "(", "0", "%", ";", "95", "%", "CI", ",", "0", "-", "6", ".", "1", "%", ")", "and", "no", "patient", "sustained", "a", "nonfatal", "myocardial", "infarction", "(", "0", "%", ";", "95", "%", "CI", ",", "0", "-", "6", ".", "1", "%", ")", ".", "CONCLUSIONS", ":", "Although", "cocaine", "-", "associated", "myocardial", "ischemia", "can", "result", "from", "coronary", "vasoconstriction", ",", "patients", "with", "cocaine", "associated", "chest", "pain", ",", "a", "non", "-", "ischemic", "ECG", ",", "and", "a", "TIMI", "risk", "score", "<", "2", "may", "be", "safely", "discharged", "from", "the", "ED", "after", "a", "negative", "coronary", "CTA", "with", "a", "low", "risk", "of", "30", "-", "day", "adverse", "events", "."]], "ner": [[[13, 13, "Chemical"], [31, 31, "Chemical"], [66, 66, "Chemical"], [112, 112, "Chemical"], [139, 139, "Chemical"], [253, 253, "Chemical"], [422, 422, "Chemical"], [435, 435, "Chemical"], [16, 17, "Disease"], [34, 35, "Disease"], [115, 116, "Disease"], [142, 143, "Disease"], [174, 175, "Disease"], [256, 257, "Disease"], [437, 438, "Disease"], [425, 426, "Disease"], [49, 51, "Disease"], [119, 120, "Disease"], [127, 127, "Disease"], [443, 443, "Disease"], [223, 223, "Disease"], [242, 243, "Disease"], [401, 402, "Disease"], [355, 356, "Disease"]]], "relations": [[[13, 13, 16, 17, "CID"], [13, 13, 34, 35, "CID"], [13, 13, 115, 116, "CID"], [13, 13, 142, 143, "CID"], [13, 13, 174, 175, "CID"], [13, 13, 256, 257, "CID"], [13, 13, 437, 438, "CID"], [31, 31, 16, 17, "CID"], [31, 31, 34, 35, "CID"], [31, 31, 115, 116, "CID"], [31, 31, 142, 143, "CID"], [31, 31, 174, 175, "CID"], [31, 31, 256, 257, "CID"], [31, 31, 437, 438, "CID"], [66, 66, 16, 17, "CID"], [66, 66, 34, 35, "CID"], [66, 66, 115, 116, "CID"], [66, 66, 142, 143, "CID"], [66, 66, 174, 175, "CID"], [66, 66, 256, 257, "CID"], [66, 66, 437, 438, "CID"], [112, 112, 16, 17, "CID"], [112, 112, 34, 35, "CID"], [112, 112, 115, 116, "CID"], [112, 112, 142, 143, "CID"], [112, 112, 174, 175, "CID"], [112, 112, 256, 257, "CID"], [112, 112, 437, 438, "CID"], [139, 139, 16, 17, "CID"], [139, 139, 34, 35, "CID"], [139, 139, 115, 116, "CID"], [139, 139, 142, 143, "CID"], [139, 139, 174, 175, "CID"], [139, 139, 256, 257, "CID"], [139, 139, 437, 438, "CID"], [253, 253, 16, 17, "CID"], [253, 253, 34, 35, "CID"], [253, 253, 115, 116, "CID"], [253, 253, 142, 143, "CID"], [253, 253, 174, 175, "CID"], [253, 253, 256, 257, "CID"], [253, 253, 437, 438, "CID"], [422, 422, 16, 17, "CID"], [422, 422, 34, 35, "CID"], [422, 422, 115, 116, "CID"], [422, 422, 142, 143, "CID"], [422, 422, 174, 175, "CID"], [422, 422, 256, 257, "CID"], [422, 422, 437, 438, "CID"], [435, 435, 16, 17, "CID"], [435, 435, 34, 35, "CID"], [435, 435, 115, 116, "CID"], [435, 435, 142, 143, "CID"], [435, 435, 174, 175, "CID"], [435, 435, 256, 257, "CID"], [435, 435, 437, 438, "CID"], [13, 13, 425, 426, "CID"], [31, 31, 425, 426, "CID"], [66, 66, 425, 426, "CID"], [112, 112, 425, 426, "CID"], [139, 139, 425, 426, "CID"], [253, 253, 425, 426, "CID"], [422, 422, 425, 426, "CID"], [435, 435, 425, 426, "CID"]]], "clusters": [], "translated": "冠状动脉计算机断层扫描血管造影术可使患有<0>可卡因</0>的低危患者快速出院-相关<8>胸痛</8>。背景：大多数因<1>可卡因</1>相关<9>胸痛</9>到急诊科(EDs)就诊的患者入院至少 12 小时，并接受“排除 <16>急性冠脉综合征</16>”协议，通常在出院前进行无创测试。对于未使用<2>可卡因</2>的患者，冠状动脉计算机断层扫描血管造影(CTA)已被证明有助于确定一组心脏事件风险较低且可以安全出院的患者。目前尚不清楚冠状动脉CTA策略是否对<3>可卡因</3>相关的<10>胸痛</10>有效，因为<17>冠状动脉血管痉挛</17>可能是<18>缺血</18>。我们研究了<4>可卡因</4>相关的<11>胸痛</11>患者的冠状动脉CTA阴性是否可以确定出院的安全子集。方法：我们前瞻性地评估了冠状动脉CTA对因可卡因相关<12>胸痛</12>（自我报告或尿检阳性）到急诊室就诊的低危患者的安全性。连续的患者在急诊室接受即刻冠状动脉CTA（无连续标记物）或在短暂观察期后接受连续心脏标记物测量的冠状动脉CTA。冠状动脉CTA阴性（最大<20>狭窄</20>小于50%）的患者出院。主要结局为30天心血管死亡或<21>心肌梗死</21>。结果：共有59名<5>可卡因</5>相关<13>胸痛</13>患者接受了评估。患者的平均年龄为45岁。6+/-6.6岁，86%是黑人，66%是男性。79%的心电图正常或非特异性，85%的TIMI评分<2。20名患者在急诊室立即接受了冠状动脉CTA，其中18名在CTA后出院(90%)。39人在短暂的观察期后接受了冠状动脉CTA，其中37人在接受CTA后出院回家(95%)。6名患者<23>冠状动脉狭窄</23> ≥50%。在30天的随访期间，没有患者死于心血管事件(0%;95% CI，0-6.1%)，并且没有患者发生非致命性<22>心肌梗死</22>(0%;95% CI，0-6.1%)。结论：虽然<6>可卡因</6>相关<15>心肌缺血</15>可由于冠状动脉收缩引起，但是，搭配非<19>缺血性</19>心电图和TIMI风险评分的<7>可卡因</7>相关<14>胸痛</14>患者，在冠状动脉CTA阴性后可以安全地出院，且30天不良事件的风险较低。", "revised": true}
{"doc_key": "19531695", "sentences": [["Delirium", "in", "a", "patient", "with", "toxic", "flecainide", "plasma", "concentrations", ":", "the", "role", "of", "a", "pharmacokinetic", "drug", "interaction", "with", "paroxetine", ".", "OBJECTIVE", ":", "To", "describe", "a", "case", "of", "flecainide", "-", "induced", "delirium", "associated", "with", "a", "pharmacokinetic", "drug", "interaction", "with", "paroxetine", ".", "CASE", "SUMMARY", ":", "A", "69", "-", "year", "-", "old", "white", "female", "presented", "to", "the", "emergency", "department", "with", "a", "history", "of", "confusion", "and", "paranoia", "over", "the", "past", "several", "days", ".", "On", "admission", "the", "patient", "was", "taking", "carvedilol", "12", "mg", "twice", "daily", ",", "warfarin", "2", "mg", "/", "day", ",", "folic", "acid", "1", "mg", "/", "day", ",", "levothyroxine", "100", "microg", "/", "day", ",", "pantoprazole", "40", "mg", "/", "day", ",", "paroxetine", "40", "mg", "/", "day", ",", "and", "flecainide", "100", "mg", "twice", "daily", ".", "Flecainide", "had", "been", "started", "2", "weeks", "prior", "for", "atrial", "fibrillation", ".", "Laboratory", "test", "findings", "on", "admission", "were", "notable", "only", "for", "a", "flecainide", "plasma", "concentration", "of", "1360", "microg", "/", "L", "(", "reference", "range", "200", "-", "1000", ")", ".", "A", "metabolic", "drug", "interaction", "between", "flecainide", "and", "paroxetine", ",", "which", "the", "patient", "had", "been", "taking", "for", "more", "than", "5", "years", ",", "was", "considered", ".", "Paroxetine", "was", "discontinued", "and", "the", "dose", "of", "flecainide", "was", "reduced", "to", "50", "mg", "twice", "daily", ".", "Her", "delirium", "resolved", "3", "days", "later", ".", "DISCUSSION", ":", "Flecainide", "and", "pharmacologically", "similar", "agents", "that", "interact", "with", "sodium", "channels", "may", "cause", "delirium", "in", "susceptible", "patients", ".", "A", "MEDLINE", "search", "(", "1966", "-", "January", "2009", ")", "revealed", "one", "in", "vivo", "pharmacokinetic", "study", "on", "the", "interaction", "between", "flecainide", ",", "a", "CYP2D6", "substrate", ",", "and", "paroxetine", ",", "a", "CYP2D6", "inhibitor", ",", "as", "well", "as", "3", "case", "reports", "of", "flecainide", "-", "induced", "delirium", ".", "According", "to", "the", "Naranjo", "probability", "scale", ",", "flecainide", "was", "the", "probable", "cause", "of", "the", "patient", "'s", "delirium", ";", "the", "Horn", "Drug", "Interaction", "Probability", "Scale", "indicates", "a", "possible", "pharmacokinetic", "drug", "interaction", "between", "flecainide", "and", "paroxetine", ".", "CONCLUSIONS", ":", "Supratherapeutic", "flecainide", "plasma", "concentrations", "may", "cause", "delirium", ".", "Because", "toxicity", "may", "occur", "when", "flecainide", "is", "prescribed", "with", "paroxetine", "and", "other", "potent", "CYP2D6", "inhibitors", ",", "flecainide", "plasma", "concentrations", "should", "be", "monitored", "closely", "with", "commencement", "of", "CYP2D6", "inhibitors", "."]], "ner": [[[6, 6, "Chemical"], [27, 27, "Chemical"], [113, 113, "Chemical"], [119, 119, "Chemical"], [140, 140, "Chemical"], [161, 161, "Chemical"], [187, 187, "Chemical"], [205, 205, "Chemical"], [241, 241, "Chemical"], [261, 261, "Chemical"], [273, 273, "Chemical"], [297, 297, "Chemical"], [304, 304, "Chemical"], [316, 316, "Chemical"], [327, 327, "Chemical"], [0, 0, "Disease"], [30, 30, "Disease"], [197, 197, "Disease"], [217, 217, "Disease"], [264, 264, "Disease"], [282, 282, "Disease"], [309, 309, "Disease"], [18, 18, "Chemical"], [38, 38, "Chemical"], [106, 106, "Chemical"], [163, 163, "Chemical"], [180, 180, "Chemical"], [248, 248, "Chemical"], [299, 299, "Chemical"], [320, 320, "Chemical"], [75, 75, "Chemical"], [81, 81, "Chemical"], [87, 88, "Chemical"], [94, 94, "Chemical"], [100, 100, "Chemical"], [213, 213, "Chemical"], [60, 60, "Disease"], [62, 62, "Disease"], [127, 128, "Disease"], [312, 312, "Disease"]]], "relations": [[[6, 6, 0, 0, "CID"], [6, 6, 30, 30, "CID"], [6, 6, 197, 197, "CID"], [6, 6, 217, 217, "CID"], [6, 6, 264, 264, "CID"], [6, 6, 282, 282, "CID"], [6, 6, 309, 309, "CID"], [27, 27, 0, 0, "CID"], [27, 27, 30, 30, "CID"], [27, 27, 197, 197, "CID"], [27, 27, 217, 217, "CID"], [27, 27, 264, 264, "CID"], [27, 27, 282, 282, "CID"], [27, 27, 309, 309, "CID"], [113, 113, 0, 0, "CID"], [113, 113, 30, 30, "CID"], [113, 113, 197, 197, "CID"], [113, 113, 217, 217, "CID"], [113, 113, 264, 264, "CID"], [113, 113, 282, 282, "CID"], [113, 113, 309, 309, "CID"], [119, 119, 0, 0, "CID"], [119, 119, 30, 30, "CID"], [119, 119, 197, 197, "CID"], [119, 119, 217, 217, "CID"], [119, 119, 264, 264, "CID"], [119, 119, 282, 282, "CID"], [119, 119, 309, 309, "CID"], [140, 140, 0, 0, "CID"], [140, 140, 30, 30, "CID"], [140, 140, 197, 197, "CID"], [140, 140, 217, 217, "CID"], [140, 140, 264, 264, "CID"], [140, 140, 282, 282, "CID"], [140, 140, 309, 309, "CID"], [161, 161, 0, 0, "CID"], [161, 161, 30, 30, "CID"], [161, 161, 197, 197, "CID"], [161, 161, 217, 217, "CID"], [161, 161, 264, 264, "CID"], [161, 161, 282, 282, "CID"], [161, 161, 309, 309, "CID"], [187, 187, 0, 0, "CID"], [187, 187, 30, 30, "CID"], [187, 187, 197, 197, "CID"], [187, 187, 217, 217, "CID"], [187, 187, 264, 264, "CID"], [187, 187, 282, 282, "CID"], [187, 187, 309, 309, "CID"], [205, 205, 0, 0, "CID"], [205, 205, 30, 30, "CID"], [205, 205, 197, 197, "CID"], [205, 205, 217, 217, "CID"], [205, 205, 264, 264, "CID"], [205, 205, 282, 282, "CID"], [205, 205, 309, 309, "CID"], [241, 241, 0, 0, "CID"], [241, 241, 30, 30, "CID"], [241, 241, 197, 197, "CID"], [241, 241, 217, 217, "CID"], [241, 241, 264, 264, "CID"], [241, 241, 282, 282, "CID"], [241, 241, 309, 309, "CID"], [261, 261, 0, 0, "CID"], [261, 261, 30, 30, "CID"], [261, 261, 197, 197, "CID"], [261, 261, 217, 217, "CID"], [261, 261, 264, 264, "CID"], [261, 261, 282, 282, "CID"], [261, 261, 309, 309, "CID"], [273, 273, 0, 0, "CID"], [273, 273, 30, 30, "CID"], [273, 273, 197, 197, "CID"], [273, 273, 217, 217, "CID"], [273, 273, 264, 264, "CID"], [273, 273, 282, 282, "CID"], [273, 273, 309, 309, "CID"], [297, 297, 0, 0, "CID"], [297, 297, 30, 30, "CID"], [297, 297, 197, 197, "CID"], [297, 297, 217, 217, "CID"], [297, 297, 264, 264, "CID"], [297, 297, 282, 282, "CID"], [297, 297, 309, 309, "CID"], [304, 304, 0, 0, "CID"], [304, 304, 30, 30, "CID"], [304, 304, 197, 197, "CID"], [304, 304, 217, 217, "CID"], [304, 304, 264, 264, "CID"], [304, 304, 282, 282, "CID"], [304, 304, 309, 309, "CID"], [316, 316, 0, 0, "CID"], [316, 316, 30, 30, "CID"], [316, 316, 197, 197, "CID"], [316, 316, 217, 217, "CID"], [316, 316, 264, 264, "CID"], [316, 316, 282, 282, "CID"], [316, 316, 309, 309, "CID"], [327, 327, 0, 0, "CID"], [327, 327, 30, 30, "CID"], [327, 327, 197, 197, "CID"], [327, 327, 217, 217, "CID"], [327, 327, 264, 264, "CID"], [327, 327, 282, 282, "CID"], [327, 327, 309, 309, "CID"], [18, 18, 0, 0, "CID"], [18, 18, 30, 30, "CID"], [18, 18, 197, 197, "CID"], [18, 18, 217, 217, "CID"], [18, 18, 264, 264, "CID"], [18, 18, 282, 282, "CID"], [18, 18, 309, 309, "CID"], [38, 38, 0, 0, "CID"], [38, 38, 30, 30, "CID"], [38, 38, 197, 197, "CID"], [38, 38, 217, 217, "CID"], [38, 38, 264, 264, "CID"], [38, 38, 282, 282, "CID"], [38, 38, 309, 309, "CID"], [106, 106, 0, 0, "CID"], [106, 106, 30, 30, "CID"], [106, 106, 197, 197, "CID"], [106, 106, 217, 217, "CID"], [106, 106, 264, 264, "CID"], [106, 106, 282, 282, "CID"], [106, 106, 309, 309, "CID"], [163, 163, 0, 0, "CID"], [163, 163, 30, 30, "CID"], [163, 163, 197, 197, "CID"], [163, 163, 217, 217, "CID"], [163, 163, 264, 264, "CID"], [163, 163, 282, 282, "CID"], [163, 163, 309, 309, "CID"], [180, 180, 0, 0, "CID"], [180, 180, 30, 30, "CID"], [180, 180, 197, 197, "CID"], [180, 180, 217, 217, "CID"], [180, 180, 264, 264, "CID"], [180, 180, 282, 282, "CID"], [180, 180, 309, 309, "CID"], [248, 248, 0, 0, "CID"], [248, 248, 30, 30, "CID"], [248, 248, 197, 197, "CID"], [248, 248, 217, 217, "CID"], [248, 248, 264, 264, "CID"], [248, 248, 282, 282, "CID"], [248, 248, 309, 309, "CID"], [299, 299, 0, 0, "CID"], [299, 299, 30, 30, "CID"], [299, 299, 197, 197, "CID"], [299, 299, 217, 217, "CID"], [299, 299, 264, 264, "CID"], [299, 299, 282, 282, "CID"], [299, 299, 309, 309, "CID"], [320, 320, 0, 0, "CID"], [320, 320, 30, 30, "CID"], [320, 320, 197, 197, "CID"], [320, 320, 217, 217, "CID"], [320, 320, 264, 264, "CID"], [320, 320, 282, 282, "CID"], [320, 320, 309, 309, "CID"]]], "clusters": [], "translated": "<15>谵妄</15>在具有毒性<0>氟卡尼</0>血浆浓度的患者中：药代动力学药物与<22>帕罗西汀</22>相互作用的作用。目的：描述一例<1>氟卡尼</1>诱发的<16>谵妄</16>与<23>帕罗西汀</23>的药代动力学药物相互作用。病例概要：一名69岁的白人女性因过去几天的<36>意识模糊</36>和<37>偏执</37>病史到急诊室就诊。入院时，患者正在服用<30>卡维地洛</30> 12 mg，每天两次，<31>华法林</31> 2 mg/天，<32>叶酸</32> 1 mg/天，<33>左旋甲状腺素</33> 100 微克/天，<34>泮托拉唑</34> 40 毫克/天，<24>帕罗西汀</24> 40 毫克/天，<2>氟卡尼</2> 100 毫克，每天两次。<3>氟卡尼</3>在<38>心房颤动</38>前2周开始使用。入院时的实验室检查结果值得注意的是<4>氟卡尼</4>血浆浓度为1360微克/升（参考范围200-1000）。考虑患者服用5年以上的<5>氟卡尼</5>与<25>帕罗西汀</25>之间存在代谢性药物相互作用。<26>帕罗西汀</26>停用，<6>氟卡尼</6>的剂量减至50mg，每日两次。3天后，她的<17>谵妄</17>消失了。讨论：<7>氟卡尼</7>和与<35>钠</35>通道相互作用的药理学类似药物可能导致易感患者<18>谵妄</18>。MEDLINE搜索（1966年-2009年1月）揭示了一项关于<8>氟卡尼</8>（一种CYP2D6底物）和<27>帕罗西汀</27>（一种CYP2D6抑制剂）之间相互作用的体内药代动力学研究，以及 3 <9>氟卡尼</9>诱发<19>谵妄</19>的病例报告。根据Naranjo概率量表，<10>氟卡尼</10>是患者<20>谵妄</20>的可能原因；Horn药物相互作用概率量表表明<11>氟卡尼</11>和<28>帕罗西汀</28>之间可能存在药代动力学药物相互作用。结论：超治疗<12>氟卡尼</12>血浆浓度可能引起<21>谵妄</21>。因为<13>氟卡尼</13>与<29>帕罗西汀</29>和其他强效CYP2D6抑制剂一起开具处方时可能会发生<39>毒性</39>，因此应监测<14>氟卡尼</14>血浆浓度与CYP2D6抑制剂的启动密切相关。", "revised": true}
{"doc_key": "20129423", "sentences": [["Fatal", "carbamazepine", "induced", "fulminant", "eosinophilic", "(", "hypersensitivity", ")", "myocarditis", ":", "emphasis", "on", "anatomical", "and", "histological", "characteristics", ",", "mechanisms", "and", "genetics", "of", "drug", "hypersensitivity", "and", "differential", "diagnosis", ".", "The", "most", "severe", "adverse", "reactions", "to", "carbamazepine", "have", "been", "observed", "in", "the", "haemopoietic", "system", ",", "the", "liver", "and", "the", "cardiovascular", "system", ".", "A", "frequently", "fatal", ",", "although", "exceptionally", "rare", "side", "effect", "of", "carbamazepine", "is", "necrotizing", "eosinophilic", "(", "hypersensitivity", ")", "myocarditis", ".", "We", "report", "a", "case", "of", "hypersensitivity", "myocarditis", "secondary", "to", "administration", "of", "carbamazepine", ".", "Acute", "hypersensitivity", "myocarditis", "was", "not", "suspected", "clinically", ",", "and", "the", "diagnosis", "was", "made", "post", "-", "mortem", ".", "Histology", "revealed", "diffuse", "infiltration", "of", "the", "myocardium", "by", "eosinophils", "and", "lymphocytes", "with", "myocyte", "damage", ".", "Clinically", ",", "death", "was", "due", "to", "cardiogenic", "shock", ".", "To", "best", "of", "our", "knowledge", "this", "is", "the", "second", "case", "of", "fatal", "carbamazepine", "induced", "myocarditis", "reported", "in", "English", "literature", "."]], "ner": [[[1, 1, "Chemical"], [33, 33, "Chemical"], [59, 59, "Chemical"], [79, 79, "Chemical"], [134, 134, "Chemical"], [3, 4, "Disease"], [6, 6, "Disease"], [21, 22, "Disease"], [64, 64, "Disease"], [73, 73, "Disease"], [82, 82, "Disease"], [8, 8, "Disease"], [66, 66, "Disease"], [74, 74, "Disease"], [83, 83, "Disease"], [136, 136, "Disease"], [119, 120, "Disease"]]], "relations": [[[1, 1, 3, 4, "CID"], [33, 33, 3, 4, "CID"], [59, 59, 3, 4, "CID"], [79, 79, 3, 4, "CID"], [134, 134, 3, 4, "CID"], [1, 1, 6, 6, "CID"], [1, 1, 21, 22, "CID"], [1, 1, 64, 64, "CID"], [1, 1, 73, 73, "CID"], [1, 1, 82, 82, "CID"], [33, 33, 6, 6, "CID"], [33, 33, 21, 22, "CID"], [33, 33, 64, 64, "CID"], [33, 33, 73, 73, "CID"], [33, 33, 82, 82, "CID"], [59, 59, 6, 6, "CID"], [59, 59, 21, 22, "CID"], [59, 59, 64, 64, "CID"], [59, 59, 73, 73, "CID"], [59, 59, 82, 82, "CID"], [79, 79, 6, 6, "CID"], [79, 79, 21, 22, "CID"], [79, 79, 64, 64, "CID"], [79, 79, 73, 73, "CID"], [79, 79, 82, 82, "CID"], [134, 134, 6, 6, "CID"], [134, 134, 21, 22, "CID"], [134, 134, 64, 64, "CID"], [134, 134, 73, 73, "CID"], [134, 134, 82, 82, "CID"], [1, 1, 8, 8, "CID"], [1, 1, 66, 66, "CID"], [1, 1, 74, 74, "CID"], [1, 1, 83, 83, "CID"], [1, 1, 136, 136, "CID"], [33, 33, 8, 8, "CID"], [33, 33, 66, 66, "CID"], [33, 33, 74, 74, "CID"], [33, 33, 83, 83, "CID"], [33, 33, 136, 136, "CID"], [59, 59, 8, 8, "CID"], [59, 59, 66, 66, "CID"], [59, 59, 74, 74, "CID"], [59, 59, 83, 83, "CID"], [59, 59, 136, 136, "CID"], [79, 79, 8, 8, "CID"], [79, 79, 66, 66, "CID"], [79, 79, 74, 74, "CID"], [79, 79, 83, 83, "CID"], [79, 79, 136, 136, "CID"], [134, 134, 8, 8, "CID"], [134, 134, 66, 66, "CID"], [134, 134, 74, 74, "CID"], [134, 134, 83, 83, "CID"], [134, 134, 136, 136, "CID"], [1, 1, 119, 120, "CID"], [33, 33, 119, 120, "CID"], [59, 59, 119, 120, "CID"], [79, 79, 119, 120, "CID"], [134, 134, 119, 120, "CID"]]], "clusters": [], "translated": "致死性<0>卡马西平</0>诱发<5>暴发性嗜酸性粒细胞增多</5>（<6>超敏反应</6>）<11>心肌炎</11>：强调<7>药物过敏</7>与鉴别诊断，心肌炎的解剖学和组织学特征、机制和遗传学。在造血系统、肝脏和心血管系统中观察到<1>卡马西平</1>最严重的不良反应。<2>卡马西平</2>的一个经常致命但极为罕见的副作用是坏死性嗜酸性粒细胞增多（<8>超敏反应</8>）<12>心肌炎</12>。我们报告了继发于<3>卡马西平</3>的<9>超敏反应</9><13>心肌炎</13>病例。临床上未怀疑到急性<10>超敏反应</10><14>心肌炎</14>，经尸检确诊。组织学显示心肌被嗜酸性粒细胞和淋巴细胞弥漫性浸润，伴有心肌细胞损伤。临床上，死于<16>心源性休克</16>。据我们所知，这是英文文献中报道的第二例因<4>卡马西平</4>引起的<15>心肌炎</15>致死性病例。", "revised": true}
{"doc_key": "17954033", "sentences": [["Rate", "of", "YMDD", "motif", "mutants", "in", "lamivudine", "-", "untreated", "Iranian", "patients", "with", "chronic", "hepatitis", "B", "virus", "infection", ".", "BACKGROUND", ":", "Lamivudine", "is", "used", "for", "the", "treatment", "of", "chronic", "hepatitis", "B", "patients", ".", "Recent", "studies", "show", "that", "the", "YMDD", "motif", "mutants", "(", "resistant", "hepatitis", "B", "virus", ")", "occur", "as", "natural", "genome", "variability", "in", "lamivudine", "-", "untreated", "chronic", "hepatitis", "B", "patients", ".", "In", "this", "study", "we", "aimed", "to", "determine", "the", "rate", "of", "YMDD", "motif", "mutants", "in", "lamivudine", "-", "untreated", "chronic", "hepatitis", "B", "patients", "in", "Iran", ".", "PATIENTS", "AND", "METHODS", ":", "A", "total", "of", "77", "chronic", "hepatitis", "B", "patients", "who", "had", "not", "been", "treated", "with", "lamivudine", "were", "included", "in", "the", "study", ".", "Serum", "samples", "from", "patients", "were", "tested", "by", "polymerase", "chain", "reaction", "-", "restriction", "fragment", "length", "polymorphism", "(", "PCR", "-", "RFLP", ")", "for", "detection", "of", "YMDD", "motif", "mutants", ".", "All", "patients", "were", "also", "tested", "for", "liver", "enzymes", ",", "anti", "-", "HCV", ",", "HBeAg", ",", "and", "anti", "-", "HBe", ".", "RESULTS", ":", "Of", "the", "77", "patients", "enrolled", "in", "the", "study", ",", "73", "%", "were", "male", "and", "27", "%", "were", "female", ".", "Mean", "ALT", "and", "AST", "levels", "were", "124", ".", "4", "+", "/", "-", "73", ".", "4", "and", "103", ".", "1", "+", "/", "-", "81", "IU", "/", "l", ",", "respectively", ".", "HBeAg", "was", "positive", "in", "40", "%", "and", "anti", "-", "HBe", "in", "60", "%", "of", "the", "patients", ".", "Anti", "-", "HCV", "was", "negative", "in", "all", "of", "them", ".", "YMDD", "motif", "mutants", "were", "not", "detected", "in", "any", "of", "the", "patients", "despite", "the", "liver", "enzyme", "levels", "and", "the", "presence", "of", "HBeAg", "or", "anti", "-", "HBe", ".", "CONCLUSION", ":", "Although", "the", "natural", "occurrence", "of", "YMDD", "motif", "mutants", "in", "lamivudine", "-", "untreated", "patients", "with", "chronic", "hepatitis", "B", "has", "been", "reported", ",", "these", "mutants", "were", "not", "detected", "in", "Iranian", "lamivudine", "-", "untreated", "chronic", "hepatitis", "B", "patients", "."]], "ner": [[[149, 149, "Chemical"], [206, 206, "Chemical"], [253, 253, "Chemical"], [12, 16, "Disease"], [27, 29, "Disease"], [55, 57, "Disease"], [77, 79, "Disease"], [92, 94, "Disease"], [275, 277, "Disease"], [292, 294, "Disease"], [6, 6, "Chemical"], [20, 20, "Chemical"], [52, 52, "Chemical"], [74, 74, "Chemical"], [102, 102, "Chemical"], [270, 270, "Chemical"], [289, 289, "Chemical"], [42, 43, "Disease"]]], "relations": [[[149, 149, 12, 16, "CID"], [149, 149, 27, 29, "CID"], [149, 149, 55, 57, "CID"], [149, 149, 77, 79, "CID"], [149, 149, 92, 94, "CID"], [149, 149, 275, 277, "CID"], [149, 149, 292, 294, "CID"], [206, 206, 12, 16, "CID"], [206, 206, 27, 29, "CID"], [206, 206, 55, 57, "CID"], [206, 206, 77, 79, "CID"], [206, 206, 92, 94, "CID"], [206, 206, 275, 277, "CID"], [206, 206, 292, 294, "CID"], [253, 253, 12, 16, "CID"], [253, 253, 27, 29, "CID"], [253, 253, 55, 57, "CID"], [253, 253, 77, 79, "CID"], [253, 253, 92, 94, "CID"], [253, 253, 275, 277, "CID"], [253, 253, 292, 294, "CID"]]], "clusters": [], "translated": "在伊朗，未经过<10>拉米夫定</10>治疗<3>慢性乙型肝炎病毒感染</3>患者中的YMDD基序突变率。背景：用于治疗<4>慢性乙型肝炎</4>患者的是<11>拉米夫定</11>。最近的研究表明YMDD基序突变体（抗性<17>乙型肝炎</17>病毒）在未经<12>拉米夫定</12>治疗的<5>慢性乙型肝炎</5>患者中以基因的自然可变形式出现了。在这项研究中，我们的目的是确定伊朗未经<13>拉米夫定</13>治疗的<6>慢性乙型肝炎</6>患者中YMDD基序突变体的比率。患者和方法：本研究纳入77名未接受<14>拉米夫定</14>治疗的<7>慢性乙型肝炎</7>患者。通过聚合酶链反应-限制性片段长度多态性(PCR-RFLP)检测患者的血清样本以检测YMDD基序突变体。所有患者还进行了肝酶、抗-HCV、<0> HBeAg </0>和抗-HBe的检测。结果：在参加研究的77名患者中，男性占73％，女性占27％。平均ALT和AST水平分别为124.4+/-73.4和103.1+/-81 IU/l，<1> HBeAg </1>阳性占40％，抗-HBe阳性占60％。所有患者的抗-HCV抗体都为阴性。尽管肝酶水平和存在<2> HBeAg </2>或抗HBe，但在任何患者中均未检测到YMDD基序突变体。结论:尽管自然发生的YMDD基序突变体在未经<15>拉米夫定</15>治疗的<8>慢性乙型肝炎</8>患者中已被报道，但在伊朗未经过<16>拉米夫定</16>治疗的<9>慢性乙型肝炎</9>患者中未检测到YMDD基序突变体。", "revised": true}
{"doc_key": "20589632", "sentences": [["Trimethoprim", "-", "induced", "immune", "hemolytic", "anemia", "in", "a", "pediatric", "oncology", "patient", "presenting", "as", "an", "acute", "hemolytic", "transfusion", "reaction", ".", "A", "10", "-", "year", "-", "old", "male", "with", "acute", "leukemia", "presented", "with", "post", "-", "chemotherapy", "anemia", ".", "During", "red", "cell", "transfusion", ",", "he", "developed", "hemoglobinuria", ".", "Transfusion", "reaction", "workup", "was", "negative", ".", "Drug", "-", "induced", "immune", "hemolytic", "anemia", "was", "suspected", "because", "of", "positive", "direct", "antiglobulin", "test", ",", "negative", "eluate", ",", "and", "microspherocytes", "on", "smear", "pre", "-", "and", "post", "-", "transfusion", ".", "Drug", "studies", "using", "the", "indirect", "antiglobulin", "test", "were", "strongly", "positive", "with", "trimethoprim", "and", "trimethoprim", "-", "sulfamethoxazole", "but", "negative", "with", "sulfamethoxazole", ".", "The", "patient", "recovered", "after", "discontinuing", "the", "drug", ",", "with", "no", "recurrence", "in", "2", "years", ".", "Other", "causes", "of", "anemia", "should", "be", "considered", "in", "patients", "with", "worse", "-", "than", "-", "expected", "anemia", "after", "chemotherapy", ".", "Furthermore", ",", "hemolysis", "during", "transfusion", "is", "not", "always", "a", "transfusion", "reaction", "."]], "ner": [[[0, 0, "Chemical"], [91, 91, "Chemical"], [4, 5, "Disease"], [55, 56, "Disease"], [27, 28, "Disease"], [34, 34, "Disease"], [119, 119, "Disease"], [131, 131, "Disease"], [43, 43, "Disease"], [137, 137, "Disease"], [93, 95, "Chemical"], [99, 99, "Chemical"]]], "relations": [[[0, 0, 4, 5, "CID"], [0, 0, 55, 56, "CID"], [91, 91, 4, 5, "CID"], [91, 91, 55, 56, "CID"]]], "clusters": [], "translated": " <0>甲氧苄啶</0> 诱导的免疫<2>溶血性贫血</2>，在一个表现为急性溶血性输血反应的儿童肿瘤患者中被诊断出。一名患有<4>急性白血病</4>的10岁男性因为化疗后<5>贫血</5>而就诊。在输红细胞的过程中，他出现了<8>血红蛋白尿</8>。输血反应检查结果为阴性。因为直接抗球蛋白试验阳性，洗脱液阴性，输血前后涂片可见小球红细胞，疑为药物诱导的免疫性<3>溶血性贫血</3>。使用间接抗球蛋白试验进行的药物研究对<1>甲氧苄氨嘧啶</1>和<10>甲氧苄氨嘧啶- 磺胺甲恶唑</10>呈现强阳性，但对<11>磺胺甲恶唑</11>呈阴性。病人停药后痊愈，之后2年无复发。对于化疗后<7>贫血</7>比预期更严重的患者，应考虑<6>贫血</6>的其他原因。此外，输血过程中<9>溶血</9>并不总是输血反应。", "revised": true}
{"doc_key": "20034406", "sentences": [["Chemokine", "CCL2", "and", "its", "receptor", "CCR2", "are", "increased", "in", "the", "hippocampus", "following", "pilocarpine", "-", "induced", "status", "epilepticus", ".", "BACKGROUND", ":", "Neuroinflammation", "occurs", "after", "seizures", "and", "is", "implicated", "in", "epileptogenesis", ".", "CCR2", "is", "a", "chemokine", "receptor", "for", "CCL2", "and", "their", "interaction", "mediates", "monocyte", "infiltration", "in", "the", "neuroinflammatory", "cascade", "triggered", "in", "different", "brain", "pathologies", ".", "In", "this", "work", "CCR2", "and", "CCL2", "expression", "were", "examined", "following", "status", "epilepticus", "(", "SE", ")", "induced", "by", "pilocarpine", "injection", ".", "METHODS", ":", "SE", "was", "induced", "by", "pilocarpine", "injection", ".", "Control", "rats", "were", "injected", "with", "saline", "instead", "of", "pilocarpine", ".", "Five", "days", "after", "SE", ",", "CCR2", "staining", "in", "neurons", "and", "glial", "cells", "was", "examined", "using", "imunohistochemical", "analyses", ".", "The", "number", "of", "CCR2", "positive", "cells", "was", "determined", "using", "stereology", "probes", "in", "the", "hippocampus", ".", "CCL2", "expression", "in", "the", "hippocampus", "was", "examined", "by", "molecular", "assay", ".", "RESULTS", ":", "Increased", "CCR2", "was", "observed", "in", "the", "hippocampus", "after", "SE", ".", "Seizures", "also", "resulted", "in", "alterations", "to", "the", "cell", "types", "expressing", "CCR2", ".", "Increased", "numbers", "of", "neurons", "that", "expressed", "CCR2", "was", "observed", "following", "SE", ".", "Microglial", "cells", "were", "more", "closely", "apposed", "to", "the", "CCR2", "-", "labeled", "cells", "in", "SE", "rats", ".", "In", "addition", ",", "rats", "that", "experienced", "SE", "exhibited", "CCR2", "-", "labeling", "in", "populations", "of", "hypertrophied", "astrocytes", ",", "especially", "in", "CA1", "and", "dentate", "gyrus", ".", "These", "CCR2", "+", "astroctytes", "were", "not", "observed", "in", "control", "rats", ".", "Examination", "of", "CCL2", "expression", "showed", "that", "it", "was", "elevated", "in", "the", "hippocampus", "following", "SE", ".", "CONCLUSION", ":", "The", "data", "show", "that", "CCR2", "and", "CCL2", "are", "up", "-", "regulated", "in", "the", "hippocampus", "after", "pilocarpine", "-", "induced", "SE", ".", "Seizures", "also", "result", "in", "changes", "to", "CCR2", "receptor", "expression", "in", "neurons", "and", "astrocytes", ".", "These", "changes", "might", "be", "involved", "in", "detrimental", "neuroplasticity", "and", "neuroinflammatory", "changes", "that", "occur", "following", "seizures", "."]], "ner": [[[12, 12, "Chemical"], [70, 70, "Chemical"], [79, 79, "Chemical"], [90, 90, "Chemical"], [255, 255, "Chemical"], [15, 16, "Disease"], [63, 64, "Disease"], [66, 66, "Disease"], [75, 75, "Disease"], [95, 95, "Disease"], [146, 146, "Disease"], [170, 170, "Disease"], [185, 185, "Disease"], [194, 194, "Disease"], [236, 236, "Disease"], [258, 258, "Disease"], [20, 20, "Disease"], [45, 45, "Disease"], [283, 283, "Disease"], [23, 23, "Disease"], [148, 148, "Disease"], [260, 260, "Disease"], [288, 288, "Disease"], [202, 202, "Disease"]]], "relations": [[[12, 12, 15, 16, "CID"], [12, 12, 63, 64, "CID"], [12, 12, 66, 66, "CID"], [12, 12, 75, 75, "CID"], [12, 12, 95, 95, "CID"], [12, 12, 146, 146, "CID"], [12, 12, 170, 170, "CID"], [12, 12, 185, 185, "CID"], [12, 12, 194, 194, "CID"], [12, 12, 236, 236, "CID"], [12, 12, 258, 258, "CID"], [70, 70, 15, 16, "CID"], [70, 70, 63, 64, "CID"], [70, 70, 66, 66, "CID"], [70, 70, 75, 75, "CID"], [70, 70, 95, 95, "CID"], [70, 70, 146, 146, "CID"], [70, 70, 170, 170, "CID"], [70, 70, 185, 185, "CID"], [70, 70, 194, 194, "CID"], [70, 70, 236, 236, "CID"], [70, 70, 258, 258, "CID"], [79, 79, 15, 16, "CID"], [79, 79, 63, 64, "CID"], [79, 79, 66, 66, "CID"], [79, 79, 75, 75, "CID"], [79, 79, 95, 95, "CID"], [79, 79, 146, 146, "CID"], [79, 79, 170, 170, "CID"], [79, 79, 185, 185, "CID"], [79, 79, 194, 194, "CID"], [79, 79, 236, 236, "CID"], [79, 79, 258, 258, "CID"], [90, 90, 15, 16, "CID"], [90, 90, 63, 64, "CID"], [90, 90, 66, 66, "CID"], [90, 90, 75, 75, "CID"], [90, 90, 95, 95, "CID"], [90, 90, 146, 146, "CID"], [90, 90, 170, 170, "CID"], [90, 90, 185, 185, "CID"], [90, 90, 194, 194, "CID"], [90, 90, 236, 236, "CID"], [90, 90, 258, 258, "CID"], [255, 255, 15, 16, "CID"], [255, 255, 63, 64, "CID"], [255, 255, 66, 66, "CID"], [255, 255, 75, 75, "CID"], [255, 255, 95, 95, "CID"], [255, 255, 146, 146, "CID"], [255, 255, 170, 170, "CID"], [255, 255, 185, 185, "CID"], [255, 255, 194, 194, "CID"], [255, 255, 236, 236, "CID"], [255, 255, 258, 258, "CID"]]], "clusters": [], "translated": "在 <0>毛果芸香碱</0> 诱导的 <5>癫痫持续状态</5> 后，趋化因子 CCL2 及其受体 CCR2 在海马体中增加。背景： <16>神经炎症</16> 发生在 <19>癫痫发作</19> 之后，并且与癫痫发生有关。CCR2 是 CCL2 的趋化因子受体，它们的相互作用介导在不同脑部病变中触发的 <17>神经炎症</17> 级联中的单核细胞浸润。本研究检测了 <1>毛果芸香碱</1> 注射引起的 <6>癫痫持续状态</6> (<7>SE</7>) 后 CCR2 和 CCL2 的表达。方法： <2>毛果芸香碱</2> 注射液诱导 <8>SE</8>。对照大鼠注射生理盐水代替 <3>毛果芸香碱</3>。 <9>SE</9> 后五天，使用免疫组织化学分析检查神经元和神经胶质细胞中的 CCR2 染色。使用海马体视学探针确定 CCR2 阳性细胞的数量。分子检测方法检测海马 CCL2 的表达。结果： <10>SE</10> 后海马 CCR2 升高。同时， <20>癫痫发作</20> 也导致表达 CCR2 的细胞类型发生改变。在 <11>SE</11> 后观察到表达 CCR2 的神经元数量增加。在 <12>SE</12> 大鼠中，小胶质细胞与 CCR2 标记的细胞更接近。此外，经历过 <13>SE</13> 的大鼠在 <23>肥大</23> 星形胶质细胞群中表现出 CCR2 标记，尤其是在 CA1 和齿状回中。在对照大鼠中未观察到这些 CCR2+ 星形胶质细胞。对 CCL2 表达的检查表明，它在 <14>SE</14> 后在海马体中升高。结论：数据表明， <4>毛果芸香碱</4> 诱导 <15>SE</15> 后，CCR2 和 CCL2 在海马中上调。同时， <21>癫痫发作</21> 还会导致神经元和星形胶质细胞中 CCR2 受体表达的变化。这些变化可能与 <22>癫痫发作</22> 后发生的有害神经可塑性和 <18>神经炎症</18> 变化有关。", "revised": true}
{"doc_key": "20046642", "sentences": [["Metallothionein", "induction", "reduces", "caspase", "-", "3", "activity", "and", "TNFalpha", "levels", "with", "preservation", "of", "cognitive", "function", "and", "intact", "hippocampal", "neurons", "in", "carmustine", "-", "treated", "rats", ".", "Hippocampal", "integrity", "is", "essential", "for", "cognitive", "functions", ".", "On", "the", "other", "hand", ",", "induction", "of", "metallothionein", "(", "MT", ")", "by", "ZnSO", "(", "4", ")", "and", "its", "role", "in", "neuroprotection", "has", "been", "documented", ".", "The", "present", "study", "aimed", "to", "explore", "the", "effect", "of", "MT", "induction", "on", "carmustine", "(", "BCNU", ")", "-", "induced", "hippocampal", "cognitive", "dysfunction", "in", "rats", ".", "A", "total", "of", "60", "male", "Wistar", "albino", "rats", "were", "randomly", "divided", "into", "four", "groups", "(", "15", "/", "group", ")", ":", "The", "control", "group", "injected", "with", "single", "doses", "of", "normal", "saline", "(", "i", ".", "c", ".", "v", ")", "followed", "24", "h", "later", "by", "BCNU", "solvent", "(", "i", ".", "v", ")", ".", "The", "second", "group", "administered", "ZnSO", "(", "4", ")", "(", "0", ".", "1", "micromol", "/", "10", "microl", "normal", "saline", ",", "i", ".", "c", ".", "v", ",", "once", ")", "then", "BCNU", "solvent", "(", "i", ".", "v", ")", "after", "24", "h", ".", "Third", "group", "received", "BCNU", "(", "20", "mg", "/", "kg", ",", "i", ".", "v", ",", "once", ")", "24", "h", "after", "injection", "with", "normal", "saline", "(", "i", ".", "c", ".", "v", ")", ".", "Fourth", "group", "received", "a", "single", "dose", "of", "ZnSO", "(", "4", ")", "(", "0", ".", "1", "micromol", "/", "10", "microl", "normal", "saline", ",", "i", ".", "c", ".", "v", ")", "then", "BCNU", "(", "20", "mg", "/", "kg", ",", "i", ".", "v", ",", "once", ")", "after", "24", "h", ".", "The", "obtained", "data", "revealed", "that", "BCNU", "administration", "resulted", "in", "deterioration", "of", "learning", "and", "short", "-", "term", "memory", "(", "STM", ")", ",", "as", "measured", "by", "using", "radial", "arm", "water", "maze", ",", "accompanied", "with", "decreased", "hippocampal", "glutathione", "reductase", "(", "GR", ")", "activity", "and", "reduced", "glutathione", "(", "GSH", ")", "content", ".", "Also", ",", "BCNU", "administration", "increased", "serum", "tumor", "necrosis", "factor", "-", "alpha", "(", "TNFalpha", ")", ",", "hippocampal", "MT", "and", "malondialdehyde", "(", "MDA", ")", "contents", "as", "well", "as", "caspase", "-", "3", "activity", "in", "addition", "to", "histological", "alterations", ".", "ZnSO", "(", "4", ")", "pretreatment", "counteracted", "BCNU", "-", "induced", "inhibition", "of", "GR", "and", "depletion", "of", "GSH", "and", "resulted", "in", "significant", "reduction", "in", "the", "levels", "of", "MDA", "and", "TNFalpha", "as", "well", "as", "the", "activity", "of", "caspase", "-", "3", ".", "The", "histological", "features", "were", "improved", "in", "hippocampus", "of", "rats", "treated", "with", "ZnSO", "(", "4", ")", "+", "BCNU", "compared", "to", "only", "BCNU", "-", "treated", "animals", ".", "In", "conclusion", ",", "MT", "induction", "halts", "BCNU", "-", "induced", "hippocampal", "toxicity", "as", "it", "prevented", "GR", "inhibition", "and", "GSH", "depletion", "and", "counteracted", "the", "increased", "levels", "of", "TNFalpha", ",", "MDA", "and", "caspase", "-", "3", "activity", "with", "subsequent", "preservation", "of", "cognition", "."]], "ner": [[[20, 20, "Chemical"], [70, 70, "Chemical"], [72, 72, "Chemical"], [124, 124, "Chemical"], [160, 160, "Chemical"], [174, 174, "Chemical"], [231, 231, "Chemical"], [253, 253, "Chemical"], [298, 298, "Chemical"], [338, 338, "Chemical"], [386, 386, "Chemical"], [390, 390, "Chemical"], [401, 401, "Chemical"], [77, 78, "Disease"], [257, 264, "Disease"], [0, 0, "Chemical"], [40, 40, "Chemical"], [42, 42, "Chemical"], [67, 67, "Chemical"], [312, 312, "Chemical"], [398, 398, "Chemical"], [302, 302, "Disease"], [303, 303, "Disease"], [405, 405, "Disease"], [45, 48, "Chemical"], [136, 139, "Chemical"], [209, 212, "Chemical"], [332, 335, "Chemical"], [381, 384, "Chemical"], [282, 282, "Chemical"], [290, 290, "Chemical"], [292, 292, "Chemical"], [347, 347, "Chemical"], [412, 412, "Chemical"], [314, 314, "Chemical"], [316, 316, "Chemical"], [357, 357, "Chemical"], [422, 422, "Chemical"]]], "relations": [[[20, 20, 77, 78, "CID"], [70, 70, 77, 78, "CID"], [72, 72, 77, 78, "CID"], [124, 124, 77, 78, "CID"], [160, 160, 77, 78, "CID"], [174, 174, 77, 78, "CID"], [231, 231, 77, 78, "CID"], [253, 253, 77, 78, "CID"], [298, 298, 77, 78, "CID"], [338, 338, 77, 78, "CID"], [386, 386, 77, 78, "CID"], [390, 390, 77, 78, "CID"], [401, 401, 77, 78, "CID"], [20, 20, 257, 264, "CID"], [70, 70, 257, 264, "CID"], [72, 72, 257, 264, "CID"], [124, 124, 257, 264, "CID"], [160, 160, 257, 264, "CID"], [174, 174, 257, 264, "CID"], [231, 231, 257, 264, "CID"], [253, 253, 257, 264, "CID"], [298, 298, 257, 264, "CID"], [338, 338, 257, 264, "CID"], [386, 386, 257, 264, "CID"], [390, 390, 257, 264, "CID"], [401, 401, 257, 264, "CID"]]], "clusters": [], "translated": " <15>金属硫蛋白</15>诱导可降低半胱天冬酶-3活性和TNFalpha水平，同时在<0>卡莫司汀</0>治疗的大鼠中保持认知功能和完整的海马神经元。海马完整性对于认知功能至关重要。另一方面，<24>ZnSO(4)</24>诱导<16>金属硫蛋白</16>（<17>MT</17>）及其在神经保护中的作用已被证实。本研究旨在探讨<18>MT</18>诱导对<1>卡莫司汀</1>（<2>BCNU</2>）诱导的海马<13>认知功能障碍</13>的影响。老鼠。60只雄性Wistar白化大鼠随机分为4组（15只/组）：对照组单次注射生理盐水（i.c.v）24h后注射<3>BCNU</3>溶剂（i.v）。第二组给予<25>ZnSO(4)</25>（0.1μmol/10μl生理盐水，i.c.v，一次）然后24h后给予<4>BCNU</4>溶剂（i.v）。第三组<5>BCNU</5>（20mg/kg，i.v，一次）注射生理盐水(i.c.v) 24h 后。第四组接受单剂量的<26>ZnSO(4)</26>（0.1 μmol/10 μl 生理盐水，i.c.v）然后24h后给予<6> BCNU </6>（20 mg/kg，i.v，一次）。获得的数据显示，<7>BCNU</7>给药导致<14>学习和短期记忆恶化</14>（STM），通过使用桡臂水迷宫测量，伴随着海马体减少<29>谷胱甘肽</29>还原酶（GR）活性和还原的<30>谷胱甘肽</30>（<31>GSH</31>）含量。此外，<8>BCNU</8>给药增加了血清<21>肿瘤</21><22>坏死</22>因子-α(TNFalpha)、海马<19>金属硫蛋白</19>和<34>丙二醛</34>(<35>MDA</35>)含量以及caspase-3活性以及组织学改变。<27>ZnSO(4)</27>预处理抵消了<9>BCNU</9> - 诱导的GR抑制和<32>GSH</32>的消耗，并导致<36>MDA水平显着降低</36>和TNFalpha以及caspase-3的活性。与仅用<11>BCNU</11>处理的动物相比，用<28>ZnSO(4)</28>+<10>BCNU</10>处理的大鼠海马组织学特征得到改善。总之，<20>金属硫蛋白</20>诱导停止了<12>BCNU</12>诱导的海马体<23>毒性</23>，因为它阻止了GR抑制和<33>GSH</33>耗竭并抵消了增加TNFalpha、<37>MDA</37>和caspase-3活性水平，随后保持认知。", "revised": true}
{"doc_key": "19815465", "sentences": [["Binasal", "visual", "field", "defects", "are", "not", "specific", "to", "vigabatrin", ".", "This", "study", "investigated", "the", "visual", "defects", "associated", "with", "the", "antiepileptic", "drug", "vigabatrin", "(", "VGB", ")", ".", "Two", "hundred", "four", "people", "with", "epilepsy", "were", "grouped", "on", "the", "basis", "of", "antiepileptic", "drug", "therapy", "(", "current", ",", "previous", ",", "or", "no", "exposure", "to", "VGB", ")", ".", "Groups", "were", "matched", "with", "respect", "to", "age", ",", "gender", ",", "and", "seizure", "frequency", ".", "All", "patients", "underwent", "objective", "assessment", "of", "electrophysiological", "function", "(", "wide", "-", "field", "multifocal", "electroretinography", ")", "and", "conventional", "visual", "field", "testing", "(", "static", "perimetry", ")", ".", "Bilateral", "visual", "field", "constriction", "was", "observed", "in", "59", "%", "of", "patients", "currently", "taking", "VGB", ",", "43", "%", "of", "patients", "who", "previously", "took", "VGB", ",", "and", "24", "%", "of", "patients", "with", "no", "exposure", "to", "VGB", ".", "Assessment", "of", "retinal", "function", "revealed", "abnormal", "responses", "in", "48", "%", "of", "current", "VGB", "users", "and", "22", "%", "of", "prior", "VGB", "users", ",", "but", "in", "none", "of", "the", "patients", "without", "previous", "exposure", "to", "VGB", ".", "Bilateral", "visual", "field", "abnormalities", "are", "common", "in", "the", "treated", "epilepsy", "population", ",", "irrespective", "of", "drug", "history", ".", "Assessment", "by", "conventional", "static", "perimetry", "may", "neither", "be", "sufficiently", "sensitive", "nor", "specific", "to", "reliably", "identify", "retinal", "toxicity", "associated", "with", "VGB", "."]], "ner": [[[8, 8, "Chemical"], [21, 21, "Chemical"], [23, 23, "Chemical"], [50, 50, "Chemical"], [105, 105, "Chemical"], [114, 114, "Chemical"], [125, 125, "Chemical"], [139, 139, "Chemical"], [146, 146, "Chemical"], [159, 159, "Chemical"], [197, 197, "Chemical"], [0, 3, "Disease"], [14, 15, "Disease"], [161, 164, "Disease"], [193, 194, "Disease"], [31, 31, "Disease"], [170, 170, "Disease"], [64, 64, "Disease"]]], "relations": [[[8, 8, 0, 3, "CID"], [8, 8, 14, 15, "CID"], [8, 8, 161, 164, "CID"], [21, 21, 0, 3, "CID"], [21, 21, 14, 15, "CID"], [21, 21, 161, 164, "CID"], [23, 23, 0, 3, "CID"], [23, 23, 14, 15, "CID"], [23, 23, 161, 164, "CID"], [50, 50, 0, 3, "CID"], [50, 50, 14, 15, "CID"], [50, 50, 161, 164, "CID"], [105, 105, 0, 3, "CID"], [105, 105, 14, 15, "CID"], [105, 105, 161, 164, "CID"], [114, 114, 0, 3, "CID"], [114, 114, 14, 15, "CID"], [114, 114, 161, 164, "CID"], [125, 125, 0, 3, "CID"], [125, 125, 14, 15, "CID"], [125, 125, 161, 164, "CID"], [139, 139, 0, 3, "CID"], [139, 139, 14, 15, "CID"], [139, 139, 161, 164, "CID"], [146, 146, 0, 3, "CID"], [146, 146, 14, 15, "CID"], [146, 146, 161, 164, "CID"], [159, 159, 0, 3, "CID"], [159, 159, 14, 15, "CID"], [159, 159, 161, 164, "CID"], [197, 197, 0, 3, "CID"], [197, 197, 14, 15, "CID"], [197, 197, 161, 164, "CID"], [8, 8, 193, 194, "CID"], [21, 21, 193, 194, "CID"], [23, 23, 193, 194, "CID"], [50, 50, 193, 194, "CID"], [105, 105, 193, 194, "CID"], [114, 114, 193, 194, "CID"], [125, 125, 193, 194, "CID"], [139, 139, 193, 194, "CID"], [146, 146, 193, 194, "CID"], [159, 159, 193, 194, "CID"], [197, 197, 193, 194, "CID"]]], "clusters": [], "translated": "<11>双鼻视野缺损</11>不是<0>氨己烯酸</0>特有的。本研究调查了与抗癫痫药物<1>氨己烯酸</1> (<2>VGB</2>) 相关的<12>视觉缺陷</12>。 204 名患有<15>癫痫症</15>的人根据抗癫痫药物治疗（目前、既往或未接触过<3>VGB</3>）进行分组。各组在年龄、性别和<17>发作</17>频率方面匹配。所有患者都接受了电生理功能的客观评估（广域多焦视网膜电图）和常规视野测试（静态视野计）。目前服用<4>VGB</4>的患者中有59%观察到双侧视野收缩，之前服用过<5>VGB</5>的患者有43%，没有接触过<6>VGB</6>的患者有24%。视网膜功能评估显示48%的当前<7>VGB</7>用户和22%的先前<8>VGB</8>用户有异常反应，但没有先前未暴露于<9>VGB</9>的患者。常规静态计算机视野测试可能既不够灵敏也不够特异，无法可靠地识别与<10>VGB</10>相关的<14>视网膜毒性</14>。<13>双侧视野异常</13>在接受治疗的 <16>癫痫</16> 人群中很常见，与用药史无关。", "revised": true}
{"doc_key": "20447294", "sentences": [["Studies", "of", "synergy", "between", "morphine", "and", "a", "novel", "sodium", "channel", "blocker", ",", "CNSB002", ",", "in", "rat", "models", "of", "inflammatory", "and", "neuropathic", "pain", ".", "OBJECTIVE", ":", "This", "study", "determined", "the", "antihyperalgesic", "effect", "of", "CNSB002", ",", "a", "sodium", "channel", "blocker", "with", "antioxidant", "properties", "given", "alone", "and", "in", "combinations", "with", "morphine", "in", "rat", "models", "of", "inflammatory", "and", "neuropathic", "pain", ".", "DESIGN", ":", "Dose", "response", "curves", "for", "nonsedating", "doses", "of", "morphine", "and", "CNSB002", "given", "intraperitoneally", "alone", "and", "together", "in", "combinations", "were", "constructed", "for", "antihyperalgesic", "effect", "using", "paw", "withdrawal", "from", "noxious", "heat", "in", "two", "rat", "pain", "models", ":", "carrageenan", "-", "induced", "paw", "inflammation", "and", "streptozotocin", "(", "STZ", ")", "-", "induced", "diabetic", "neuropathy", ".", "RESULTS", ":", "The", "maximum", "nonsedating", "doses", "were", ":", "morphine", ",", "3", ".", "2", "mg", "/", "kg", ";", "CNSB002", "10", ".", "0", "mg", "/", "kg", ";", "5", ".", "0", "mg", "/", "kg", "CNSB002", "with", "morphine", "3", ".", "2", "mg", "/", "kg", "in", "combination", ".", "The", "doses", "calculated", "to", "cause", "50", "%", "reversal", "of", "hyperalgesia", "(", "ED50", ")", "were", "7", ".", "54", "(", "1", ".", "81", ")", "and", "4", ".", "83", "(", "1", ".", "54", ")", "in", "the", "carrageenan", "model", "and", "44", ".", "18", "(", "1", ".", "37", ")", "and", "9", ".", "14", "(", "1", ".", "24", ")", "in", "the", "STZ", "-", "induced", "neuropathy", "model", "for", "CNSB002", "and", "morphine", ",", "respectively", "(", "mg", "/", "kg", ";", "mean", ",", "SEM", ")", ".", "These", "values", "were", "greater", "than", "the", "maximum", "nonsedating", "doses", ".", "The", "ED50", "values", "for", "morphine", "when", "given", "in", "combination", "with", "CNSB002", "(", "5", "mg", "/", "kg", ")", "were", "less", "than", "the", "maximum", "nonsedating", "dose", ":", "0", ".", "56", "(", "1", ".", "55", ")", "in", "the", "carrageenan", "model", "and", "1", ".", "37", "(", "1", ".", "23", ")", "in", "the", "neuropathy", "model", "(", "mg", "/", "kg", ";", "mean", ",", "SEM", ")", ".", "The", "antinociception", "after", "morphine", "(", "3", ".", "2", "mg", "/", "kg", ")", "was", "increased", "by", "co", "-", "administration", "with", "CNSB002", "from", "28", ".", "0", "and", "31", ".", "7", "%", "to", "114", ".", "6", "and", "56", ".", "9", "%", "reversal", "of", "hyperalgesia", "in", "the", "inflammatory", "and", "neuropathic", "models", ",", "respectively", "(", "P", "<", "0", ".", "01", ";", "one", "-", "way", "analysis", "of", "variance", "-", "significantly", "greater", "than", "either", "drug", "given", "alone", ")", ".", "CONCLUSIONS", ":", "The", "maximum", "antihyperalgesic", "effect", "achievable", "with", "nonsedating", "doses", "of", "morphine", "may", "be", "increased", "significantly", "when", "the", "drug", "is", "used", "in", "combination", "with", "CNSB002", "."]], "ner": [[[93, 93, "Chemical"], [184, 184, "Chemical"], [272, 272, "Chemical"], [97, 97, "Disease"], [160, 160, "Disease"], [337, 337, "Disease"], [99, 99, "Chemical"], [101, 101, "Chemical"], [206, 206, "Chemical"], [105, 106, "Disease"], [4, 4, "Chemical"], [47, 47, "Chemical"], [66, 66, "Chemical"], [116, 116, "Chemical"], [141, 141, "Chemical"], [214, 214, "Chemical"], [241, 241, "Chemical"], [300, 300, "Chemical"], [380, 380, "Chemical"], [20, 21, "Disease"], [54, 55, "Disease"], [90, 90, "Disease"], [209, 209, "Disease"], [285, 285, "Disease"], [342, 342, "Disease"], [8, 8, "Chemical"], [35, 35, "Chemical"], [12, 12, "Chemical"], [32, 32, "Chemical"], [68, 68, "Chemical"], [125, 125, "Chemical"], [139, 139, "Chemical"], [212, 212, "Chemical"], [247, 247, "Chemical"], [316, 316, "Chemical"], [393, 393, "Chemical"]]], "relations": [[[93, 93, 97, 97, "CID"], [184, 184, 97, 97, "CID"], [272, 272, 97, 97, "CID"], [93, 93, 160, 160, "CID"], [93, 93, 337, 337, "CID"], [184, 184, 160, 160, "CID"], [184, 184, 337, 337, "CID"], [272, 272, 160, 160, "CID"], [272, 272, 337, 337, "CID"], [99, 99, 105, 106, "CID"], [101, 101, 105, 106, "CID"], [206, 206, 105, 106, "CID"], [99, 99, 160, 160, "CID"], [99, 99, 337, 337, "CID"], [101, 101, 160, 160, "CID"], [101, 101, 337, 337, "CID"], [206, 206, 160, 160, "CID"], [206, 206, 337, 337, "CID"]]], "clusters": [], "translated": "<10>吗啡</10>与新型<25>钠</25>通道阻滞剂<27>CNSB002</27>在炎症和<19>神经性疼痛</19>大鼠模型中的协同作用研究。目的：本研究确定了<28>CNSB002</28>的抗痛觉过敏作用，这是一种具有抗氧化特性的<26>钠</26>通道阻滞剂，单独给予以及与<11>吗啡</11>联合给予大鼠模型炎症和<20>神经性疼痛</20>。设计：<12>吗啡</12>和<29>CNSB002</29>的非镇静剂量的剂量反应曲线，在两只大鼠<21>疼痛</21>模型中构建了腹膜内单独给药和联合给药的抗痛觉过敏作用，使用爪子从有害热中缩回：<0>角叉菜胶</0>-诱导爪<3>炎症</3>和<6>链脲佐菌素</6> (<7>STZ</7>)-诱导<9>糖尿病性神经病变</9>。结果：最大非镇静剂量为：<13>吗啡</13>，3.2毫克/千克；<30>CNSB002</30>，10.0毫克/千克；5.0毫克/千克<31>CNSB002</31>与<14>吗啡</14>，3.2毫克/千克合用。计算出引起50%逆转<4>痛觉过敏</4>(ED50)的剂量为7.54(1.81)和4.83(1.54)在<1>角叉菜胶</1>模型和44.18(1.37)和9.14(1.24)在<8>STZ</8>诱导的<22>神经病变</22>模型中分别用于<32>CNSB002</32>和<15>吗啡</15>(mg/公斤;平均值，SEM)。这些值大于最大非镇静剂量。当与<33>CNSB002</33>(5毫克/千克)联合使用时，<16>吗啡</16>的ED50值低于最大非镇静剂量:0.56(1.55)在<2>角叉菜胶</2>模型和1.37(1.23)在<23>神经病变</23>模型中(mg/千克;平均值，SEM)。在炎症和<24>神经性</24>模型中，<17>吗啡</17>(3.2毫克/千克)的镇痛作用通过与<34>CNSB002</34>的联合给药从28.0和31.7%增加到了114.6和56.9%的<5>痛觉过敏</5>逆转(P<0.01;单向方差分析 —— 显着大于单独给予任何一种药物)。结论：当药物与<35>CNSB002</35>联合使用时，非镇静剂量的<18>吗啡</18>可达到的最大抗痛觉过敏作用可能会显着增加。", "revised": true}
{"doc_key": "20513036", "sentences": [["Abductor", "paralysis", "after", "botox", "injection", "for", "adductor", "spasmodic", "dysphonia", ".", "OBJECTIVES", "/", "HYPOTHESIS", ":", "Botulinum", "toxin", "(", "Botox", ")", "injections", "into", "the", "thyroarytenoid", "muscles", "are", "the", "current", "standard", "of", "care", "for", "adductor", "spasmodic", "dysphonia", "(", "ADSD", ")", ".", "Reported", "adverse", "effects", "include", "a", "period", "of", "breathiness", ",", "throat", "pain", ",", "and", "difficulty", "with", "swallowing", "liquids", ".", "Here", "we", "report", "multiple", "cases", "of", "bilateral", "abductor", "paralysis", "following", "Botox", "injections", "for", "ADSD", ",", "a", "complication", "previously", "unreported", ".", "STUDY", "DESIGN", ":", "Retrospective", "case", "series", ".", "METHODS", ":", "Patients", "that", "received", "Botox", "injections", "for", "spasmodic", "dysphonia", "between", "January", "2000", "and", "October", "2009", "were", "evaluated", ".", "Patients", "with", "ADSD", "were", "identified", ".", "The", "number", "of", "treatments", "received", "and", "adverse", "effects", "were", "noted", ".", "For", "patients", "with", "bilateral", "abductor", "paralysis", ",", "age", ",", "sex", ",", "paralytic", "Botox", "dose", ",", "prior", "Botox", "dose", ",", "and", "course", "following", "paralysis", "were", "noted", ".", "RESULTS", ":", "From", "a", "database", "of", "452", "patients", "receiving", "Botox", ",", "352", "patients", "had", "been", "diagnosed", "with", "ADSD", ".", "Of", "these", "352", "patients", ",", "eight", "patients", "suffered", "bilateral", "abductor", "paralysis", ",", "and", "two", "suffered", "this", "complication", "twice", ".", "All", "affected", "patients", "were", "females", "over", "the", "age", "of", "50", "years", ".", "Most", "patients", "had", "received", "treatments", "prior", "to", "abductor", "paralysis", "and", "continued", "receiving", "after", "paralysis", ".", "Seven", "patients", "recovered", "after", "a", "brief", "period", "of", "activity", "restrictions", ",", "and", "one", "underwent", "a", "tracheotomy", ".", "The", "incidence", "of", "abductor", "paralysis", "after", "Botox", "injection", "for", "ADSD", "was", "0", ".", "34", "%", ".", "CONCLUSIONS", ":", "Bilateral", "abductor", "paralysis", "is", "a", "rare", "complication", "of", "Botox", "injections", "for", "ADSD", ",", "causing", "difficulty", "with", "breathing", "upon", "exertion", ".", "The", "likely", "mechanism", "of", "paralysis", "is", "diffusion", "of", "Botox", "around", "the", "muscular", "process", "of", "the", "arytenoid", "to", "the", "posterior", "cricoarytenoid", "muscles", ".", "The", "paralysis", "is", "temporary", ",", "and", "watchful", "waiting", "with", "restriction", "of", "activity", "is", "the", "recommended", "management", "."]], "ner": [[[3, 3, "Chemical"], [17, 17, "Chemical"], [66, 66, "Chemical"], [88, 88, "Chemical"], [131, 131, "Chemical"], [135, 135, "Chemical"], [154, 154, "Chemical"], [233, 233, "Chemical"], [253, 253, "Chemical"], [273, 273, "Chemical"], [6, 8, "Disease"], [31, 33, "Disease"], [35, 35, "Disease"], [69, 69, "Disease"], [104, 104, "Disease"], [162, 162, "Disease"], [236, 236, "Disease"], [256, 256, "Disease"], [1, 1, "Disease"], [64, 64, "Disease"], [124, 124, "Disease"], [141, 141, "Disease"], [174, 174, "Disease"], [203, 203, "Disease"], [208, 208, "Disease"], [231, 231, "Disease"], [247, 247, "Disease"], [269, 269, "Disease"], [288, 288, "Disease"], [47, 48, "Disease"], [91, 92, "Disease"]]], "relations": [[[3, 3, 6, 8, "CID"], [3, 3, 31, 33, "CID"], [3, 3, 35, 35, "CID"], [3, 3, 69, 69, "CID"], [3, 3, 104, 104, "CID"], [3, 3, 162, 162, "CID"], [3, 3, 236, 236, "CID"], [3, 3, 256, 256, "CID"], [17, 17, 6, 8, "CID"], [17, 17, 31, 33, "CID"], [17, 17, 35, 35, "CID"], [17, 17, 69, 69, "CID"], [17, 17, 104, 104, "CID"], [17, 17, 162, 162, "CID"], [17, 17, 236, 236, "CID"], [17, 17, 256, 256, "CID"], [66, 66, 6, 8, "CID"], [66, 66, 31, 33, "CID"], [66, 66, 35, 35, "CID"], [66, 66, 69, 69, "CID"], [66, 66, 104, 104, "CID"], [66, 66, 162, 162, "CID"], [66, 66, 236, 236, "CID"], [66, 66, 256, 256, "CID"], [88, 88, 6, 8, "CID"], [88, 88, 31, 33, "CID"], [88, 88, 35, 35, "CID"], [88, 88, 69, 69, "CID"], [88, 88, 104, 104, "CID"], [88, 88, 162, 162, "CID"], [88, 88, 236, 236, "CID"], [88, 88, 256, 256, "CID"], [131, 131, 6, 8, "CID"], [131, 131, 31, 33, "CID"], [131, 131, 35, 35, "CID"], [131, 131, 69, 69, "CID"], [131, 131, 104, 104, "CID"], [131, 131, 162, 162, "CID"], [131, 131, 236, 236, "CID"], [131, 131, 256, 256, "CID"], [135, 135, 6, 8, "CID"], [135, 135, 31, 33, "CID"], [135, 135, 35, 35, "CID"], [135, 135, 69, 69, "CID"], [135, 135, 104, 104, "CID"], [135, 135, 162, 162, "CID"], [135, 135, 236, 236, "CID"], [135, 135, 256, 256, "CID"], [154, 154, 6, 8, "CID"], [154, 154, 31, 33, "CID"], [154, 154, 35, 35, "CID"], [154, 154, 69, 69, "CID"], [154, 154, 104, 104, "CID"], [154, 154, 162, 162, "CID"], [154, 154, 236, 236, "CID"], [154, 154, 256, 256, "CID"], [233, 233, 6, 8, "CID"], [233, 233, 31, 33, "CID"], [233, 233, 35, 35, "CID"], [233, 233, 69, 69, "CID"], [233, 233, 104, 104, "CID"], [233, 233, 162, 162, "CID"], [233, 233, 236, 236, "CID"], [233, 233, 256, 256, "CID"], [253, 253, 6, 8, "CID"], [253, 253, 31, 33, "CID"], [253, 253, 35, 35, "CID"], [253, 253, 69, 69, "CID"], [253, 253, 104, 104, "CID"], [253, 253, 162, 162, "CID"], [253, 253, 236, 236, "CID"], [253, 253, 256, 256, "CID"], [273, 273, 6, 8, "CID"], [273, 273, 31, 33, "CID"], [273, 273, 35, 35, "CID"], [273, 273, 69, 69, "CID"], [273, 273, 104, 104, "CID"], [273, 273, 162, 162, "CID"], [273, 273, 236, 236, "CID"], [273, 273, 256, 256, "CID"]]], "clusters": [], "translated": "<10>内收肌痉挛性发声困难</10><0>肉毒杆菌素</0>注射后双侧外展肌<18>麻痹</18>。目标/假设：肉毒杆菌毒素(<1>肉毒杆菌素</1>)注射到甲状软骨肌是目前治疗<11>内收肌痉挛性发声障碍</11>(<12>ADSD</12>)的标准治疗方法。报告的不良反应包括一段时间的呼吸困难、<29>喉咙痛</29>和吞咽液体困难。在这里，我们报告了多例因<13>ADSD</13>注射<2>肉毒杆菌素</2>而导致双侧外展肌<19>麻痹</19>的并发症，这是一种以前未报告的并发症。研究设计：回顾性病例系列。方法：对在2000年1月至2009年10月期间因<30>痉挛性发音障碍</30>接受<3>肉毒杆菌素</3>注射的患者进行评估。确定了患有<14>ADSD</14>的患者。记录接受治疗的次数和不良反应。对于双侧外展肌<20>麻痹</20>的患者，年龄、性别、麻痹性<4>肉毒杆菌素</4>剂量、既往<5>肉毒杆菌素</5>剂量以及<21>麻痹</21>后的病程被注意到。结果：在一个包含452名接受<6>肉毒杆菌素</6>治疗的患者的数据库中，有352名患者被诊断为<15>ADSD</15>。这352例患者中，8例出现双侧外展肌<22>麻痹</22>，2例出现2次。所有受影响的患者都是50岁以上的女性。大多数患者在外展肌<23>麻痹</23>之前接受过治疗，并在<24>麻痹</24>之后继续接受治疗。7名患者在短暂的活动限制后康复，一名患者接受了气管切开术。<16>肉毒杆菌素</16>注射<7>治疗痉挛性发音障碍</7>后双侧外展肌<25>麻痹</25>的发生率为0.34%。结论：双侧外展肌<26>麻痹</26>是<8>肉毒杆菌素</8>注射治疗<17>痉挛性发音障碍</17>的罕见并发症，导致用力时呼吸困难。<27>麻痹</27>的可能机制是<9>肉毒杆菌素</9>在杓状软骨肌突周围扩散到环杓后肌。<28>麻痹</28>是暂时的，建议在限制活动的情况下观察等待。", "revised": true}
{"doc_key": "20828385", "sentences": [["Cytostatic", "and", "anti", "-", "angiogenic", "effects", "of", "temsirolimus", "in", "refractory", "mantle", "cell", "lymphoma", ".", "Mantle", "cell", "lymphoma", "(", "MCL", ")", "is", "a", "rare", "and", "aggressive", "type", "of", "B", "-", "cell", "non", "-", "Hodgkin", "'s", "lymphoma", ".", "Patients", "become", "progressively", "refractory", "to", "conventional", "chemotherapy", ",", "and", "their", "prognosis", "is", "poor", ".", "However", ",", "a", "38", "%", "remission", "rate", "has", "been", "recently", "reported", "in", "refractory", "MCL", "treated", "with", "temsirolimus", ",", "a", "mTOR", "inhibitor", ".", "Here", "we", "had", "the", "opportunity", "to", "study", "a", "case", "of", "refractory", "MCL", "who", "had", "tumor", "regression", "two", "months", "after", "temsirolimus", "treatment", ",", "and", "a", "progression", "-", "free", "survival", "of", "10", "months", ".", "In", "this", "case", ",", "lymph", "node", "biopsies", "were", "performed", "before", "and", "six", "months", "after", "temsirolimus", "therapy", ".", "Comparison", "of", "the", "two", "biopsies", "showed", "that", "temsirolimus", "inhibited", "tumor", "cell", "proliferation", "through", "cell", "cycle", "arrest", ",", "but", "did", "not", "induce", "any", "change", "in", "the", "number", "of", "apoptotic", "tumor", "cells", ".", "Apart", "from", "this", "cytostatic", "effect", ",", "temsirolimus", "had", "an", "antiangiogenic", "effect", "with", "decrease", "of", "tumor", "microvessel", "density", "and", "of", "VEGF", "expression", ".", "Moreover", ",", "numerous", "patchy", ",", "well", "-", "limited", "fibrotic", "areas", ",", "compatible", "with", "post", "-", "necrotic", "tissue", "repair", ",", "were", "found", "after", "6", "-", "month", "temsirolimus", "therapy", ".", "Thus", ",", "temsirolimus", "reduced", "tumor", "burden", "through", "associated", "cytostatic", "and", "anti", "-", "angiogenic", "effects", ".", "This", "dual", "effect", "of", "temsirolimus", "on", "tumor", "tissue", "could", "contribute", "to", "its", "recently", "reported", "efficiency", "in", "refractory", "MCL", "resistant", "to", "conventional", "chemotherapy", "."]], "ner": [[[7, 7, "Chemical"], [66, 66, "Chemical"], [91, 91, "Chemical"], [118, 118, "Chemical"], [128, 128, "Chemical"], [158, 158, "Chemical"], [199, 199, "Chemical"], [204, 204, "Chemical"], [221, 221, "Chemical"], [189, 189, "Disease"], [10, 12, "Disease"], [14, 16, "Disease"], [18, 18, "Disease"], [63, 63, "Disease"], [83, 83, "Disease"], [234, 234, "Disease"], [27, 34, "Disease"], [86, 86, "Disease"], [130, 130, "Disease"], [149, 149, "Disease"], [166, 166, "Disease"], [206, 206, "Disease"], [223, 223, "Disease"]]], "relations": [[[7, 7, 189, 189, "CID"], [66, 66, 189, 189, "CID"], [91, 91, 189, 189, "CID"], [118, 118, 189, 189, "CID"], [128, 128, 189, 189, "CID"], [158, 158, 189, 189, "CID"], [199, 199, 189, 189, "CID"], [204, 204, 189, 189, "CID"], [221, 221, 189, 189, "CID"]]], "clusters": [], "translated": " <0>替西罗莫司</0> 在难治性<10>套细胞淋巴瘤</10>中的细胞抑制和抗血管生成作用。<11>套细胞淋巴瘤</11>（<12>MCL</12>）是一种罕见的侵袭性<16>B细胞非霍奇金淋巴瘤</16>。患者逐渐对常规化疗产生耐药性，预后很差。然而，最近有报道称，在接受mTOR抑制剂<1>替西罗莫司</1>治疗后，难治性<13>MCL</13>的缓解率为38%。在这里，我们有机会研究了一个难治性<14>MCL</14>病例，该病例在<2>替西罗莫司</2>治疗两个月后出现了<17>肿瘤</17>消退，并且无进展生存期为10个月。在该病例中，在<3>替西罗莫司</3>治疗前和治疗后6个月进行了淋巴结活检。两种活检的比较表明，<4>替西罗莫司</4>通过细胞周期阻滞抑制<18>肿瘤</18>细胞增殖，但未引起任何凋亡<19>肿瘤</19>细胞数量的变化。除了这种细胞抑制作用外，<5>替西罗莫司</5>还具有抗血管生成作用，可降低<20>肿瘤</20>微血管密度和VEGF表达。此外，在6个月的<6>替西罗莫司</6>治疗后，发现许多斑片状、局限性纤维化区域，与<9>坏死</9>后的组织修复相符。因此，<7>替西罗莫司</7>通过相关的细胞生长抑制和抗血管生成作用减轻<21>肿瘤</21>负荷。<8>替西罗莫司</8>对<22>肿瘤</22>组织的双重作用可能有助于其最近报道的对常规化疗耐药的难治性<15>MCL</15>的有效性。", "revised": true}
{"doc_key": "20927253", "sentences": [["Diffuse", "skeletal", "pain", "after", "administration", "of", "alendronate", ".", "BACKGROUND", ":", "Osteoporosis", "is", "caused", "by", "bone", "resorption", "in", "excess", "of", "bone", "formation", ",", "and", "bisphosphonates", ",", "are", "used", "to", "inhibit", "bone", "resorption", ".", "Alendronate", ",", "a", "biphosphonate", ",", "is", "effective", "for", "both", "the", "treatment", "and", "prevention", "of", "osteoporosis", "in", "postmenopausal", "women", ".", "Side", "effects", "are", "relatively", "few", "and", "prominently", "gastrointestinal", ".", "Musculoskeletal", "pain", "may", "be", "an", "important", "side", "effect", "in", "these", "patients", ".", "We", "presented", "a", "patient", "admitted", "to", "our", "out", "-", "patient", "clinic", "with", "diffuse", "skeletal", "pain", "after", "three", "consecutive", "administration", "of", "alendronate", ".", "CONCLUSION", ":", "We", "conclude", "that", "patients", "with", "osteoporosis", "can", "report", "pain", ",", "and", "bisphosphonate", "-", "related", "pain", "should", "also", "be", "considered", "before", "ascribing", "this", "complaint", "to", "osteoporosis", "."]], "ner": [[[6, 6, "Chemical"], [32, 32, "Chemical"], [92, 92, "Chemical"], [2, 2, "Disease"], [86, 86, "Disease"], [104, 104, "Disease"], [110, 110, "Disease"], [23, 23, "Chemical"], [107, 107, "Chemical"], [10, 10, "Disease"], [46, 46, "Disease"], [101, 101, "Disease"], [120, 120, "Disease"], [60, 61, "Disease"]]], "relations": [[[6, 6, 2, 2, "CID"], [6, 6, 86, 86, "CID"], [6, 6, 104, 104, "CID"], [6, 6, 110, 110, "CID"], [32, 32, 2, 2, "CID"], [32, 32, 86, 86, "CID"], [32, 32, 104, 104, "CID"], [32, 32, 110, 110, "CID"], [92, 92, 2, 2, "CID"], [92, 92, 86, 86, "CID"], [92, 92, 104, 104, "CID"], [92, 92, 110, 110, "CID"]]], "clusters": [], "translated": "服用<0>阿仑膦酸盐</0>后出现弥漫性骨骼<3>疼痛</3>。背景：<9>骨质疏松症</9>是由骨吸收超过骨形成引起的，<7>双膦酸盐</7>用于抑制骨吸收。<1>阿仑膦酸盐</1>是一种双膦酸盐，可有效治疗和预防绝经后妇女的<10>骨质疏松症</10>。副作用相对较少，主要是胃肠道反应。<13>肌肉骨骼疼痛</13>可能是这些患者的重要副作用。我们介绍了一位在连续三次服用<2>阿仑膦酸盐</2>后因弥漫性骨骼<4>疼痛</4>入院的患者。结论：我们得出结论，<11>骨质疏松症</11>患者可以报告<5>疼痛</5>，并且在治疗前还应考虑<8>双膦酸盐</8>相关的<6>疼痛</6>，将此投诉归因于<12>骨质疏松症</12>。", "revised": true}
{"doc_key": "20859899", "sentences": [["Syncope", "caused", "by", "hyperkalemia", "during", "use", "of", "a", "combined", "therapy", "with", "the", "angiotensin", "-", "converting", "enzyme", "inhibitor", "and", "spironolactone", ".", "A", "76", "year", "-", "old", "woman", "with", "a", "history", "of", "coronary", "artery", "bypass", "grafting", "and", "prior", "myocardial", "infarction", "was", "transferred", "to", "the", "emergency", "room", "with", "loss", "of", "consciousness", "due", "to", "marked", "bradycardia", "caused", "by", "hyperkalemia", ".", "The", "concentration", "of", "serum", "potassium", "was", "high", ",", "and", "normal", "sinus", "rhythm", "was", "restored", "after", "correction", "of", "the", "serum", "potassium", "level", ".", "The", "cause", "of", "hyperkalemia", "was", "considered", "to", "be", "several", "doses", "of", "spiranolactone", ",", "an", "aldosterone", "antagonist", ",", "in", "addition", "to", "the", "long", "-", "term", "intake", "of", "ramipril", ",", "an", "ACE", "inhibitor", ".", "This", "case", "is", "a", "good", "example", "of", "electrolyte", "imbalance", "causing", "acute", "life", "-", "threatening", "cardiac", "events", ".", "Clinicians", "should", "be", "alert", "to", "the", "possibility", "of", "hyperkalemia", ",", "especially", "in", "elderly", "patients", "using", "ACE", "/", "ARB", "in", "combination", "with", "potassium", "sparing", "agents", "and", "who", "have", "mild", "renal", "disturbance", "."]], "ner": [[[18, 18, "Chemical"], [89, 89, "Chemical"], [3, 3, "Disease"], [54, 54, "Disease"], [81, 81, "Disease"], [135, 135, "Disease"], [104, 104, "Chemical"], [60, 60, "Chemical"], [75, 75, "Chemical"], [148, 148, "Chemical"], [51, 51, "Disease"], [12, 12, "Chemical"], [0, 0, "Disease"], [92, 92, "Chemical"], [36, 37, "Disease"], [45, 47, "Disease"], [155, 156, "Disease"]]], "relations": [[[18, 18, 3, 3, "CID"], [18, 18, 54, 54, "CID"], [18, 18, 81, 81, "CID"], [18, 18, 135, 135, "CID"], [89, 89, 3, 3, "CID"], [89, 89, 54, 54, "CID"], [89, 89, 81, 81, "CID"], [89, 89, 135, 135, "CID"], [104, 104, 3, 3, "CID"], [104, 104, 54, 54, "CID"], [104, 104, 81, 81, "CID"], [104, 104, 135, 135, "CID"], [60, 60, 51, 51, "CID"], [75, 75, 51, 51, "CID"], [148, 148, 51, 51, "CID"]]], "clusters": [], "translated": "在使用<11>血管紧张素</11>-转化酶抑制剂和<0>螺内酯</0>联合治疗期间<2>高钾血症</2>引起的<12>晕厥</12>。一名 76 岁的女性有冠状动脉旁路移植术史和既往<14>心肌梗死</14>，被转移到急诊室，由于明显的<10>心动过缓</10>，<15>意识丧失</15>，由<3>高钾血症</3>引起。血清<7>钾</7>浓度高，纠正血清<8>钾</8>水平后恢复正常窦性心律。 <4>高钾血症</4>的原因被认为是多次服用<1>螺内酯</1>，一种<13>醛固酮</13>拮抗剂，此外还有长期摄入<6>雷米普利</6>，一种ACE抑制剂。这个病例是电解质失衡导致急性危及生命的心脏事件的一个很好的例子。临床医生应警惕<5>高钾血症</5>的可能性，尤其是在使用ACE/ARB联合<9>保钾</9>药物和有轻度<16>肾功能障碍</16>的老年患者中。", "revised": true}
{"doc_key": "20408947", "sentences": [["Medical", "and", "psychiatric", "outcomes", "for", "patients", "transplanted", "for", "acetaminophen", "-", "induced", "acute", "liver", "failure", ":", "a", "case", "-", "control", "study", ".", "BACKGROUND", ":", "Acetaminophen", "-", "induced", "hepatotoxicity", "is", "the", "most", "common", "cause", "of", "acute", "liver", "failure", "(", "ALF", ")", "in", "the", "UK", ".", "Patients", "often", "consume", "the", "drug", "with", "suicidal", "intent", "or", "with", "a", "background", "of", "substance", "dependence", ".", "AIMS", "AND", "METHODS", ":", "We", "compared", "the", "severity", "of", "pretransplant", "illness", ",", "psychiatric", "co", "-", "morbidity", ",", "medical", "and", "psychosocial", "outcomes", "of", "all", "patients", "who", "had", "undergone", "liver", "transplantation", "(", "LT", ")", "emergently", "between", "1999", "-", "2004", "for", "acetaminophen", "-", "induced", "ALF", "(", "n", "=", "36", ")", "with", "age", "-", "and", "sex", "-", "matched", "patients", "undergoing", "emergent", "LT", "for", "non", "-", "acetaminophen", "-", "induced", "ALF", "(", "n", "=", "35", ")", "and", "elective", "LT", "for", "chronic", "liver", "disease", "(", "CLD", ",", "n", "=", "34", ")", ".", "RESULTS", ":", "Acetaminophen", "-", "induced", "ALF", "patients", "undergoing", "LT", "had", "a", "greater", "severity", "of", "pre", "-", "LT", "illness", "reflected", "by", "higher", "Acute", "Physiology", "and", "Chronic", "Health", "Evaluation", "II", "scores", "and", "requirement", "for", "organ", "support", "compared", "with", "the", "other", "two", "groups", ".", "Twenty", "(", "56", "%", ")", "acetaminophen", "-", "induced", "ALF", "patients", "had", "a", "formal", "psychiatric", "diagnosis", "before", "LT", "(", "non", "-", "acetaminophen", "-", "induced", "ALF", "=", "0", "/", "35", ",", "CLD", "=", "2", "/", "34", ";", "P", "<", "0", ".", "01", "for", "all", ")", "and", "nine", "(", "25", "%", ")", "had", "a", "previous", "suicide", "attempt", ".", "During", "follow", "-", "up", "(", "median", "5", "years", ")", ",", "there", "were", "no", "significant", "differences", "in", "rejection", "(", "acute", "and", "chronic", ")", ",", "graft", "failure", "or", "survival", "between", "the", "groups", "(", "acetaminophen", "-", "induced", "ALF", "1", "year", "87", "%", ",", "5", "years", "75", "%", ";", "non", "-", "acetaminophen", "-", "induced", "ALF", "88", "%", ",", "78", "%", ";", "CLD", "93", "%", ",", "82", "%", ":", "P", ">", "0", ".", "6", "log", "rank", ")", ".", "Two", "acetaminophen", "-", "induced", "ALF", "patients", "reattempted", "suicide", "post", "-", "LT", "(", "one", "died", "8", "years", "post", "-", "LT", ")", ".", "CONCLUSIONS", ":", "Despite", "a", "high", "prevalence", "of", "psychiatric", "disturbance", ",", "outcomes", "for", "patients", "transplanted", "emergently", "for", "acetaminophen", "-", "induced", "ALF", "were", "comparable", "to", "those", "transplanted", "for", "non", "-", "acetaminophen", "-", "induced", "ALF", "and", "electively", "for", "CLD", ".", "Multidisciplinary", "approaches", "with", "long", "-", "term", "psychiatric", "follow", "-", "up", "may", "contribute", "to", "low", "post", "-", "transplant", "suicide", "rates", "seen", "and", "low", "rates", "of", "graft", "loss", "because", "of", "non", "-", "compliance", "."]], "ner": [[[8, 8, "Chemical"], [23, 23, "Chemical"], [97, 97, "Chemical"], [120, 120, "Chemical"], [146, 146, "Chemical"], [190, 190, "Chemical"], [205, 205, "Chemical"], [271, 271, "Chemical"], [287, 287, "Chemical"], [314, 314, "Chemical"], [350, 350, "Chemical"], [362, 362, "Chemical"], [11, 13, "Disease"], [33, 35, "Disease"], [37, 37, "Disease"], [100, 100, "Disease"], [123, 123, "Disease"], [149, 149, "Disease"], [193, 193, "Disease"], [208, 208, "Disease"], [274, 274, "Disease"], [290, 290, "Disease"], [317, 317, "Disease"], [353, 353, "Disease"], [365, 365, "Disease"], [26, 26, "Disease"], [133, 135, "Disease"], [137, 137, "Disease"], [214, 214, "Disease"], [297, 297, "Disease"], [369, 369, "Disease"]]], "relations": [[[8, 8, 11, 13, "CID"], [8, 8, 33, 35, "CID"], [8, 8, 37, 37, "CID"], [8, 8, 100, 100, "CID"], [8, 8, 123, 123, "CID"], [8, 8, 149, 149, "CID"], [8, 8, 193, 193, "CID"], [8, 8, 208, 208, "CID"], [8, 8, 274, 274, "CID"], [8, 8, 290, 290, "CID"], [8, 8, 317, 317, "CID"], [8, 8, 353, 353, "CID"], [8, 8, 365, 365, "CID"], [23, 23, 11, 13, "CID"], [23, 23, 33, 35, "CID"], [23, 23, 37, 37, "CID"], [23, 23, 100, 100, "CID"], [23, 23, 123, 123, "CID"], [23, 23, 149, 149, "CID"], [23, 23, 193, 193, "CID"], [23, 23, 208, 208, "CID"], [23, 23, 274, 274, "CID"], [23, 23, 290, 290, "CID"], [23, 23, 317, 317, "CID"], [23, 23, 353, 353, "CID"], [23, 23, 365, 365, "CID"], [97, 97, 11, 13, "CID"], [97, 97, 33, 35, "CID"], [97, 97, 37, 37, "CID"], [97, 97, 100, 100, "CID"], [97, 97, 123, 123, "CID"], [97, 97, 149, 149, "CID"], [97, 97, 193, 193, "CID"], [97, 97, 208, 208, "CID"], [97, 97, 274, 274, "CID"], [97, 97, 290, 290, "CID"], [97, 97, 317, 317, "CID"], [97, 97, 353, 353, "CID"], [97, 97, 365, 365, "CID"], [120, 120, 11, 13, "CID"], [120, 120, 33, 35, "CID"], [120, 120, 37, 37, "CID"], [120, 120, 100, 100, "CID"], [120, 120, 123, 123, "CID"], [120, 120, 149, 149, "CID"], [120, 120, 193, 193, "CID"], [120, 120, 208, 208, "CID"], [120, 120, 274, 274, "CID"], [120, 120, 290, 290, "CID"], [120, 120, 317, 317, "CID"], [120, 120, 353, 353, "CID"], [120, 120, 365, 365, "CID"], [146, 146, 11, 13, "CID"], [146, 146, 33, 35, "CID"], [146, 146, 37, 37, "CID"], [146, 146, 100, 100, "CID"], [146, 146, 123, 123, "CID"], [146, 146, 149, 149, "CID"], [146, 146, 193, 193, "CID"], [146, 146, 208, 208, "CID"], [146, 146, 274, 274, "CID"], [146, 146, 290, 290, "CID"], [146, 146, 317, 317, "CID"], [146, 146, 353, 353, "CID"], [146, 146, 365, 365, "CID"], [190, 190, 11, 13, "CID"], [190, 190, 33, 35, "CID"], [190, 190, 37, 37, "CID"], [190, 190, 100, 100, "CID"], [190, 190, 123, 123, "CID"], [190, 190, 149, 149, "CID"], [190, 190, 193, 193, "CID"], [190, 190, 208, 208, "CID"], [190, 190, 274, 274, "CID"], [190, 190, 290, 290, "CID"], [190, 190, 317, 317, "CID"], [190, 190, 353, 353, "CID"], [190, 190, 365, 365, "CID"], [205, 205, 11, 13, "CID"], [205, 205, 33, 35, "CID"], [205, 205, 37, 37, "CID"], [205, 205, 100, 100, "CID"], [205, 205, 123, 123, "CID"], [205, 205, 149, 149, "CID"], [205, 205, 193, 193, "CID"], [205, 205, 208, 208, "CID"], [205, 205, 274, 274, "CID"], [205, 205, 290, 290, "CID"], [205, 205, 317, 317, "CID"], [205, 205, 353, 353, "CID"], [205, 205, 365, 365, "CID"], [271, 271, 11, 13, "CID"], [271, 271, 33, 35, "CID"], [271, 271, 37, 37, "CID"], [271, 271, 100, 100, "CID"], [271, 271, 123, 123, "CID"], [271, 271, 149, 149, "CID"], [271, 271, 193, 193, "CID"], [271, 271, 208, 208, "CID"], [271, 271, 274, 274, "CID"], [271, 271, 290, 290, "CID"], [271, 271, 317, 317, "CID"], [271, 271, 353, 353, "CID"], [271, 271, 365, 365, "CID"], [287, 287, 11, 13, "CID"], [287, 287, 33, 35, "CID"], [287, 287, 37, 37, "CID"], [287, 287, 100, 100, "CID"], [287, 287, 123, 123, "CID"], [287, 287, 149, 149, "CID"], [287, 287, 193, 193, "CID"], [287, 287, 208, 208, "CID"], [287, 287, 274, 274, "CID"], [287, 287, 290, 290, "CID"], [287, 287, 317, 317, "CID"], [287, 287, 353, 353, "CID"], [287, 287, 365, 365, "CID"], [314, 314, 11, 13, "CID"], [314, 314, 33, 35, "CID"], [314, 314, 37, 37, "CID"], [314, 314, 100, 100, "CID"], [314, 314, 123, 123, "CID"], [314, 314, 149, 149, "CID"], [314, 314, 193, 193, "CID"], [314, 314, 208, 208, "CID"], [314, 314, 274, 274, "CID"], [314, 314, 290, 290, "CID"], [314, 314, 317, 317, "CID"], [314, 314, 353, 353, "CID"], [314, 314, 365, 365, "CID"], [350, 350, 11, 13, "CID"], [350, 350, 33, 35, "CID"], [350, 350, 37, 37, "CID"], [350, 350, 100, 100, "CID"], [350, 350, 123, 123, "CID"], [350, 350, 149, 149, "CID"], [350, 350, 193, 193, "CID"], [350, 350, 208, 208, "CID"], [350, 350, 274, 274, "CID"], [350, 350, 290, 290, "CID"], [350, 350, 317, 317, "CID"], [350, 350, 353, 353, "CID"], [350, 350, 365, 365, "CID"], [362, 362, 11, 13, "CID"], [362, 362, 33, 35, "CID"], [362, 362, 37, 37, "CID"], [362, 362, 100, 100, "CID"], [362, 362, 123, 123, "CID"], [362, 362, 149, 149, "CID"], [362, 362, 193, 193, "CID"], [362, 362, 208, 208, "CID"], [362, 362, 274, 274, "CID"], [362, 362, 290, 290, "CID"], [362, 362, 317, 317, "CID"], [362, 362, 353, 353, "CID"], [362, 362, 365, 365, "CID"], [8, 8, 26, 26, "CID"], [23, 23, 26, 26, "CID"], [97, 97, 26, 26, "CID"], [120, 120, 26, 26, "CID"], [146, 146, 26, 26, "CID"], [190, 190, 26, 26, "CID"], [205, 205, 26, 26, "CID"], [271, 271, 26, 26, "CID"], [287, 287, 26, 26, "CID"], [314, 314, 26, 26, "CID"], [350, 350, 26, 26, "CID"], [362, 362, 26, 26, "CID"]]], "clusters": [], "translated": "因<0>对乙酰氨基酚</0>引起的<12>急性肝衰竭</12>移植患者的 医学和精神结果：病例对照研究。背景：<1>对乙酰氨基酚</1>引起的<25>肝毒性</25> 是英国<13>急性肝衰竭</13> (<14>ALF</14>) 的最常见原因。患者经常服用这种药物有自杀意图或有物质依赖的背景。目的和方法：我们比较了1999年至2004年间因<2>对乙酰氨基酚</2>诱导的<15>ALF</15> (n=36)、因非<3>对乙酰氨基酚</3>诱导的<16>ALF</16> (n=35) 和择期接受急诊LT用于<26>慢性肝病</26>(<27>CLD</27>, n=34) 年龄和性别匹配的患者。结果：<4>对乙酰氨基酚</4>诱发的<17>ALF</17>接受LT的患者有更严重的LT前疾病，反映在较高的急性生理学和慢性健康评估II评分和器官支持需求上另外两组。二十 (56%) <5>对乙酰氨基酚</5>诱发的<18>ALF</18>患者在LT前进行了正式的精神病学诊断(非<6>对乙酰氨基酚</6>-诱发的<19>ALF</19>=0/35，<28>CLD</28>=2/34；所有P<0.01)和九名(25%)曾有过自杀未遂。在随访期间(中位时间5年)，两组之间在排斥反应(急性和慢性)、移植物失败或存活率方面没有显着 差异，(<7>对乙酰氨基酚</7>-诱导的<20>ALF</20> 1年87%，5年75%; 非<8>对乙酰氨基酚</8>诱导的<21>ALF</21> 88%，78%；<29>CLD</29>93%，82%：P >0.6 对数秩)。两名<9>对乙酰氨基酚</9>诱发的<22>ALF</22>患者在LT后再次尝试自杀(一名在LT后8年 死亡)。结论:尽管存在精神障碍的高发病率，因<10>对乙酰氨基酚</10>诱导的<23>ALF</23>和非-<11>对乙酰氨基酚</11>诱导的<24>ALF</24>及选择性的<30>CLD</30>的LT患者的预后是可比的。具有长期精神病学随访的多学科方法可能有助于降低移植后自杀率和因不依从性而导致的移植物丢失率。", "revised": true}
{"doc_key": "20566328", "sentences": [["Mitochondrial", "impairment", "contributes", "to", "cocaine", "-", "induced", "cardiac", "dysfunction", ":", "Prevention", "by", "the", "targeted", "antioxidant", "MitoQ", ".", "The", "goal", "of", "this", "study", "was", "to", "assess", "mitochondrial", "function", "and", "ROS", "production", "in", "an", "experimental", "model", "of", "cocaine", "-", "induced", "cardiac", "dysfunction", ".", "We", "hypothesized", "that", "cocaine", "abuse", "may", "lead", "to", "altered", "mitochondrial", "function", "that", "in", "turn", "may", "cause", "left", "ventricular", "dysfunction", ".", "Seven", "days", "of", "cocaine", "administration", "to", "rats", "led", "to", "an", "increased", "oxygen", "consumption", "detected", "in", "cardiac", "fibers", ",", "specifically", "through", "complex", "I", "and", "complex", "III", ".", "ROS", "levels", "were", "increased", ",", "specifically", "in", "interfibrillar", "mitochondria", ".", "In", "parallel", "there", "was", "a", "decrease", "in", "ATP", "synthesis", ",", "whereas", "no", "difference", "was", "observed", "in", "subsarcolemmal", "mitochondria", ".", "This", "uncoupling", "effect", "on", "oxidative", "phosphorylation", "was", "not", "detectable", "after", "short", "-", "term", "exposure", "to", "cocaine", ",", "suggesting", "that", "these", "mitochondrial", "abnormalities", "were", "a", "late", "rather", "than", "a", "primary", "event", "in", "the", "pathological", "response", "to", "cocaine", ".", "MitoQ", ",", "a", "mitochondrial", "-", "targeted", "antioxidant", ",", "was", "shown", "to", "completely", "prevent", "these", "mitochondrial", "abnormalities", "as", "well", "as", "cardiac", "dysfunction", "characterized", "here", "by", "a", "diastolic", "dysfunction", "studied", "with", "a", "conductance", "catheter", "to", "obtain", "pressure", "-", "volume", "data", ".", "Taken", "together", ",", "these", "results", "extend", "previous", "studies", "and", "demonstrate", "that", "cocaine", "-", "induced", "cardiac", "dysfunction", "may", "be", "due", "to", "a", "mitochondrial", "defect", "."]], "ner": [[[4, 4, "Chemical"], [35, 35, "Chemical"], [64, 64, "Chemical"], [131, 131, "Chemical"], [151, 151, "Chemical"], [203, 203, "Chemical"], [7, 8, "Disease"], [38, 39, "Disease"], [172, 173, "Disease"], [206, 207, "Disease"], [0, 1, "Disease"], [136, 137, "Disease"], [167, 168, "Disease"], [213, 214, "Disease"], [15, 15, "Chemical"], [153, 153, "Chemical"], [72, 72, "Chemical"], [104, 104, "Chemical"], [44, 45, "Disease"], [57, 59, "Disease"]]], "relations": [[[4, 4, 7, 8, "CID"], [4, 4, 38, 39, "CID"], [4, 4, 172, 173, "CID"], [4, 4, 206, 207, "CID"], [35, 35, 7, 8, "CID"], [35, 35, 38, 39, "CID"], [35, 35, 172, 173, "CID"], [35, 35, 206, 207, "CID"], [64, 64, 7, 8, "CID"], [64, 64, 38, 39, "CID"], [64, 64, 172, 173, "CID"], [64, 64, 206, 207, "CID"], [131, 131, 7, 8, "CID"], [131, 131, 38, 39, "CID"], [131, 131, 172, 173, "CID"], [131, 131, 206, 207, "CID"], [151, 151, 7, 8, "CID"], [151, 151, 38, 39, "CID"], [151, 151, 172, 173, "CID"], [151, 151, 206, 207, "CID"], [203, 203, 7, 8, "CID"], [203, 203, 38, 39, "CID"], [203, 203, 172, 173, "CID"], [203, 203, 206, 207, "CID"]]], "clusters": [], "translated": " <10>线粒体损伤</10> 导致<0>可卡因</0>诱发<6>心脏功能障碍</6>：通过靶向抗氧化剂<14>MitoQ</14>进行预防。本研究的目的是在<1>可卡因</1>诱导的<7>心脏功能障碍</7>实验模型中评估线粒体功能和ROS产生。我们假设<18>可卡因滥用</18>可能导致线粒体功能改变，进而可能导致<19>左心室功能障碍</19>。对大鼠给予<2>可卡因</2>7天导致在心脏纤维中检测到的<16>耗氧量</16>增加，特别是通过复合物I和复合物III。 ROS水平增加，特别是在间质线粒体中。同时，<17>ATP</17>合成减少，而在亚肌膜线粒体中没有观察到差异。这种对氧化磷酸化的解偶联作用在短期接触<3>可卡因</3>后无法检测到，表明这些<11>线粒体异常</11>是对<4>可卡因</4>的一个迟发性反应，而非其主要病理反应。靶向线粒体的抗氧化剂<15>MitoQ</15>已被证明可以完全预防这些<12>线粒体异常</12>，以及<8>心脏功能障碍</8>，此处研究的特征是舒张功能障碍，使用传导导管获得压力-容积数据。总之，这些结果扩展了以前的研究，并证明<5>可卡因</5>诱发的<9>心脏功能障碍</9>可能是由于<13>线粒体缺陷</13>导致的。", "revised": true}
{"doc_key": "20495512", "sentences": [["Heparin", "-", "induced", "thrombocytopenia", ":", "a", "practical", "review", ".", "Heparin", "-", "induced", "thrombocytopenia", "(", "HIT", ")", "remains", "under", "-", "recognized", "despite", "its", "potentially", "devastating", "outcomes", ".", "It", "begins", "when", "heparin", "exposure", "stimulates", "the", "formation", "of", "heparin", "-", "platelet", "factor", "4", "antibodies", ",", "which", "in", "turn", "triggers", "the", "release", "of", "procoagulant", "platelet", "particles", ".", "Thrombosis", "and", "thrombocytopenia", "that", "follow", "comprise", "the", "2", "hallmark", "traits", "of", "HIT", ",", "with", "the", "former", "largely", "responsible", "for", "significant", "vascular", "complications", ".", "The", "prevalence", "of", "HIT", "varies", "among", "several", "subgroups", ",", "with", "greater", "incidence", "in", "surgical", "as", "compared", "with", "medical", "populations", ".", "HIT", "must", "be", "acknowledged", "for", "its", "intense", "predilection", "for", "thrombosis", "and", "suspected", "whenever", "thrombosis", "occurs", "after", "heparin", "exposure", ".", "Early", "recognition", "that", "incorporates", "the", "clinical", "and", "serologic", "clues", "is", "paramount", "to", "timely", "institution", "of", "treatment", ",", "as", "its", "delay", "may", "result", "in", "catastrophic", "outcomes", ".", "The", "treatment", "of", "HIT", "mandates", "an", "immediate", "cessation", "of", "all", "heparin", "exposure", "and", "the", "institution", "of", "an", "antithrombotic", "therapy", ",", "most", "commonly", "using", "a", "direct", "thrombin", "inhibitor", ".", "Current", "\"", "diagnostic", "\"", "tests", ",", "which", "primarily", "include", "functional", "and", "antigenic", "assays", ",", "have", "more", "of", "a", "confirmatory", "than", "diagnostic", "role", "in", "the", "management", "of", "HIT", ".", "Special", "attention", "must", "be", "paid", "to", "cardiac", "patients", "who", "are", "often", "exposed", "to", "heparin", "multiple", "times", "during", "their", "course", "of", "treatment", ".", "Direct", "thrombin", "inhibitors", "are", "appropriate", ",", "evidence", "-", "based", "alternatives", "to", "heparin", "in", "patients", "with", "a", "history", "of", "HIT", ",", "who", "need", "to", "undergo", "percutaneous", "coronary", "intervention", ".", "As", "heparin", "remains", "one", "of", "the", "most", "frequently", "used", "medications", "today", "with", "potential", "for", "HIT", "with", "every", "heparin", "exposure", ",", "a", "close", "vigilance", "of", "platelet", "counts", "must", "be", "practiced", "whenever", "heparin", "is", "initiated", "."]], "ner": [[[0, 0, "Chemical"], [9, 9, "Chemical"], [29, 29, "Chemical"], [35, 35, "Chemical"], [112, 112, "Chemical"], [151, 151, "Chemical"], [210, 210, "Chemical"], [230, 230, "Chemical"], [248, 248, "Chemical"], [264, 264, "Chemical"], [277, 277, "Chemical"], [3, 3, "Disease"], [12, 12, "Disease"], [14, 14, "Disease"], [55, 55, "Disease"], [64, 64, "Disease"], [79, 79, "Disease"], [96, 96, "Disease"], [144, 144, "Disease"], [195, 195, "Disease"], [237, 237, "Disease"], [261, 261, "Disease"], [53, 53, "Disease"], [105, 105, "Disease"], [109, 109, "Disease"], [165, 167, "Chemical"], [219, 221, "Chemical"]]], "relations": [[[0, 0, 3, 3, "CID"], [0, 0, 12, 12, "CID"], [0, 0, 14, 14, "CID"], [0, 0, 55, 55, "CID"], [0, 0, 64, 64, "CID"], [0, 0, 79, 79, "CID"], [0, 0, 96, 96, "CID"], [0, 0, 144, 144, "CID"], [0, 0, 195, 195, "CID"], [0, 0, 237, 237, "CID"], [0, 0, 261, 261, "CID"], [9, 9, 3, 3, "CID"], [9, 9, 12, 12, "CID"], [9, 9, 14, 14, "CID"], [9, 9, 55, 55, "CID"], [9, 9, 64, 64, "CID"], [9, 9, 79, 79, "CID"], [9, 9, 96, 96, "CID"], [9, 9, 144, 144, "CID"], [9, 9, 195, 195, "CID"], [9, 9, 237, 237, "CID"], [9, 9, 261, 261, "CID"], [29, 29, 3, 3, "CID"], [29, 29, 12, 12, "CID"], [29, 29, 14, 14, "CID"], [29, 29, 55, 55, "CID"], [29, 29, 64, 64, "CID"], [29, 29, 79, 79, "CID"], [29, 29, 96, 96, "CID"], [29, 29, 144, 144, "CID"], [29, 29, 195, 195, "CID"], [29, 29, 237, 237, "CID"], [29, 29, 261, 261, "CID"], [35, 35, 3, 3, "CID"], [35, 35, 12, 12, "CID"], [35, 35, 14, 14, "CID"], [35, 35, 55, 55, "CID"], [35, 35, 64, 64, "CID"], [35, 35, 79, 79, "CID"], [35, 35, 96, 96, "CID"], [35, 35, 144, 144, "CID"], [35, 35, 195, 195, "CID"], [35, 35, 237, 237, "CID"], [35, 35, 261, 261, "CID"], [112, 112, 3, 3, "CID"], [112, 112, 12, 12, "CID"], [112, 112, 14, 14, "CID"], [112, 112, 55, 55, "CID"], [112, 112, 64, 64, "CID"], [112, 112, 79, 79, "CID"], [112, 112, 96, 96, "CID"], [112, 112, 144, 144, "CID"], [112, 112, 195, 195, "CID"], [112, 112, 237, 237, "CID"], [112, 112, 261, 261, "CID"], [151, 151, 3, 3, "CID"], [151, 151, 12, 12, "CID"], [151, 151, 14, 14, "CID"], [151, 151, 55, 55, "CID"], [151, 151, 64, 64, "CID"], [151, 151, 79, 79, "CID"], [151, 151, 96, 96, "CID"], [151, 151, 144, 144, "CID"], [151, 151, 195, 195, "CID"], [151, 151, 237, 237, "CID"], [151, 151, 261, 261, "CID"], [210, 210, 3, 3, "CID"], [210, 210, 12, 12, "CID"], [210, 210, 14, 14, "CID"], [210, 210, 55, 55, "CID"], [210, 210, 64, 64, "CID"], [210, 210, 79, 79, "CID"], [210, 210, 96, 96, "CID"], [210, 210, 144, 144, "CID"], [210, 210, 195, 195, "CID"], [210, 210, 237, 237, "CID"], [210, 210, 261, 261, "CID"], [230, 230, 3, 3, "CID"], [230, 230, 12, 12, "CID"], [230, 230, 14, 14, "CID"], [230, 230, 55, 55, "CID"], [230, 230, 64, 64, "CID"], [230, 230, 79, 79, "CID"], [230, 230, 96, 96, "CID"], [230, 230, 144, 144, "CID"], [230, 230, 195, 195, "CID"], [230, 230, 237, 237, "CID"], [230, 230, 261, 261, "CID"], [248, 248, 3, 3, "CID"], [248, 248, 12, 12, "CID"], [248, 248, 14, 14, "CID"], [248, 248, 55, 55, "CID"], [248, 248, 64, 64, "CID"], [248, 248, 79, 79, "CID"], [248, 248, 96, 96, "CID"], [248, 248, 144, 144, "CID"], [248, 248, 195, 195, "CID"], [248, 248, 237, 237, "CID"], [248, 248, 261, 261, "CID"], [264, 264, 3, 3, "CID"], [264, 264, 12, 12, "CID"], [264, 264, 14, 14, "CID"], [264, 264, 55, 55, "CID"], [264, 264, 64, 64, "CID"], [264, 264, 79, 79, "CID"], [264, 264, 96, 96, "CID"], [264, 264, 144, 144, "CID"], [264, 264, 195, 195, "CID"], [264, 264, 237, 237, "CID"], [264, 264, 261, 261, "CID"], [277, 277, 3, 3, "CID"], [277, 277, 12, 12, "CID"], [277, 277, 14, 14, "CID"], [277, 277, 55, 55, "CID"], [277, 277, 64, 64, "CID"], [277, 277, 79, 79, "CID"], [277, 277, 96, 96, "CID"], [277, 277, 144, 144, "CID"], [277, 277, 195, 195, "CID"], [277, 277, 237, 237, "CID"], [277, 277, 261, 261, "CID"], [0, 0, 53, 53, "CID"], [0, 0, 105, 105, "CID"], [0, 0, 109, 109, "CID"], [9, 9, 53, 53, "CID"], [9, 9, 105, 105, "CID"], [9, 9, 109, 109, "CID"], [29, 29, 53, 53, "CID"], [29, 29, 105, 105, "CID"], [29, 29, 109, 109, "CID"], [35, 35, 53, 53, "CID"], [35, 35, 105, 105, "CID"], [35, 35, 109, 109, "CID"], [112, 112, 53, 53, "CID"], [112, 112, 105, 105, "CID"], [112, 112, 109, 109, "CID"], [151, 151, 53, 53, "CID"], [151, 151, 105, 105, "CID"], [151, 151, 109, 109, "CID"], [210, 210, 53, 53, "CID"], [210, 210, 105, 105, "CID"], [210, 210, 109, 109, "CID"], [230, 230, 53, 53, "CID"], [230, 230, 105, 105, "CID"], [230, 230, 109, 109, "CID"], [248, 248, 53, 53, "CID"], [248, 248, 105, 105, "CID"], [248, 248, 109, 109, "CID"], [264, 264, 53, 53, "CID"], [264, 264, 105, 105, "CID"], [264, 264, 109, 109, "CID"], [277, 277, 53, 53, "CID"], [277, 277, 105, 105, "CID"], [277, 277, 109, 109, "CID"]]], "clusters": [], "translated": "<0>肝素</0>诱导的<11>血小板减少症</11>：实践回顾。<1>肝素</1>诱导的<12>血小板减少症</12> (<13>HIT</13>) 尽管其潜在的破坏性后果仍未得到充分认识。它始于<2>肝素</2>暴露促使<3>肝素</3> - 血小板因子 4 抗体的形成，进而触发促凝血小板颗粒的释放。<22>血栓形成</22>和随后的<14>血小板减少症</14>构成了<15>HIT</15>的两个标志性特征，前者主要负责显着的血管并发症。<16>HIT</16>的患病率在几个亚组之间有所不同，与医学人群相比，外科人群的发病率更高。<17>HIT</17>必须承认其对<23>血栓形成</23>的强烈偏好，并且每当<4>肝素</4>暴露后发生<24>血栓形成</24>时应怀疑。结合临床和血清学线索的早期识别对于及时进行治疗至关重要，因为延误可能会导致灾难性后果。<18>HIT</18>的治疗要求立即停止所有<5>肝素</5>暴露并进行抗血栓治疗，最常见的是使用<25>直接凝血酶抑制剂</25>。当前的“诊断”测试主要包括功能和抗原检测，在<19>HIT</19>的管理中更多的是确认而不是诊断。必须特别注意在治疗过程中经常多次接触<6>肝素</6>的心脏病患者。<26>直接凝血酶抑制剂</26>是合适的、基于证据的<7>肝素</7>替代品，适用于有<20>HIT</20>病史且需要接受经皮冠状动脉介入治疗的患者。由于<8>肝素</8>仍然是当今最常用的药物之一，每次<9>肝素</9>暴露都可能导致<HIT<21>21</21>，因此必须密切注意血小板计数每当启动<10>肝素</10>时。", "revised": true}
{"doc_key": "20682692", "sentences": [["Blockade", "of", "endothelial", "-", "mesenchymal", "transition", "by", "a", "Smad3", "inhibitor", "delays", "the", "early", "development", "of", "streptozotocin", "-", "induced", "diabetic", "nephropathy", ".", "OBJECTIVE", ":", "A", "multicenter", ",", "controlled", "trial", "showed", "that", "early", "blockade", "of", "the", "renin", "-", "angiotensin", "system", "in", "patients", "with", "type", "1", "diabetes", "and", "normoalbuminuria", "did", "not", "retard", "the", "progression", "of", "nephropathy", ",", "suggesting", "that", "other", "mechanism", "(", "s", ")", "are", "involved", "in", "the", "pathogenesis", "of", "early", "diabetic", "nephropathy", "(", "diabetic", "nephropathy", ")", ".", "We", "have", "previously", "demonstrated", "that", "endothelial", "-", "mesenchymal", "-", "transition", "(", "EndoMT", ")", "contributes", "to", "the", "early", "development", "of", "renal", "interstitial", "fibrosis", "independently", "of", "microalbuminuria", "in", "mice", "with", "streptozotocin", "(", "STZ", ")", "-", "induced", "diabetes", ".", "In", "the", "present", "study", ",", "we", "hypothesized", "that", "blocking", "EndoMT", "reduces", "the", "early", "development", "of", "diabetic", "nephropathy", ".", "RESEARCH", "DESIGN", "AND", "METHODS", ":", "EndoMT", "was", "induced", "in", "a", "mouse", "pancreatic", "microvascular", "endothelial", "cell", "line", "(", "MMEC", ")", "in", "the", "presence", "of", "advanced", "glycation", "end", "products", "(", "AGEs", ")", "and", "in", "the", "endothelial", "lineage", "-", "traceble", "mouse", "line", "Tie2", "-", "Cre", ";", "Loxp", "-", "EGFP", "by", "administration", "of", "AGEs", ",", "with", "nonglycated", "mouse", "albumin", "serving", "as", "a", "control", ".", "Phosphorylated", "Smad3", "was", "detected", "by", "immunoprecipitation", "/", "Western", "blotting", "and", "confocal", "microscopy", ".", "Blocking", "studies", "using", "receptor", "for", "AGE", "siRNA", "and", "a", "specific", "inhibitor", "of", "Smad3", "(", "SIS3", ")", "were", "performed", "in", "MMECs", "and", "in", "STZ", "-", "induced", "diabetic", "nephropathy", "in", "Tie2", "-", "Cre", ";", "Loxp", "-", "EGFP", "mice", ".", "RESULTS", ":", "Confocal", "microscopy", "and", "real", "-", "time", "PCR", "demonstrated", "that", "AGEs", "induced", "EndoMT", "in", "MMECs", "and", "in", "Tie2", "-", "Cre", ";", "Loxp", "-", "EGFP", "mice", ".", "Immunoprecipitation", "/", "Western", "blotting", "showed", "that", "Smad3", "was", "activated", "by", "AGEs", "but", "was", "inhibited", "by", "SIS3", "in", "MMECs", "and", "in", "STZ", "-", "induced", "diabetic", "nephropathy", ".", "Confocal", "microscopy", "and", "real", "-", "time", "PCR", "further", "demonstrated", "that", "SIS3", "abrogated", "EndoMT", ",", "reduced", "renal", "fibrosis", ",", "and", "retarded", "progression", "of", "nephropathy", ".", "CONCLUSIONS", ":", "EndoMT", "is", "a", "novel", "pathway", "leading", "to", "early", "development", "of", "diabetic", "nephropathy", ".", "Blockade", "of", "EndoMT", "by", "SIS3", "may", "provide", "a", "new", "strategy", "to", "retard", "the", "progression", "of", "diabetic", "nephropathy", "and", "other", "diabetes", "complications", "."]], "ner": [[[15, 15, "Chemical"], [103, 103, "Chemical"], [105, 105, "Chemical"], [224, 224, "Chemical"], [286, 286, "Chemical"], [18, 19, "Disease"], [68, 69, "Disease"], [71, 72, "Disease"], [126, 127, "Disease"], [227, 228, "Disease"], [289, 290, "Disease"], [328, 329, "Disease"], [346, 347, "Disease"], [41, 43, "Disease"], [52, 52, "Disease"], [314, 314, "Disease"], [96, 96, "Disease"], [308, 308, "Disease"], [109, 109, "Disease"], [350, 351, "Disease"], [36, 36, "Chemical"]]], "relations": [[[15, 15, 18, 19, "CID"], [15, 15, 68, 69, "CID"], [15, 15, 71, 72, "CID"], [15, 15, 126, 127, "CID"], [15, 15, 227, 228, "CID"], [15, 15, 289, 290, "CID"], [15, 15, 328, 329, "CID"], [15, 15, 346, 347, "CID"], [103, 103, 18, 19, "CID"], [103, 103, 68, 69, "CID"], [103, 103, 71, 72, "CID"], [103, 103, 126, 127, "CID"], [103, 103, 227, 228, "CID"], [103, 103, 289, 290, "CID"], [103, 103, 328, 329, "CID"], [103, 103, 346, 347, "CID"], [105, 105, 18, 19, "CID"], [105, 105, 68, 69, "CID"], [105, 105, 71, 72, "CID"], [105, 105, 126, 127, "CID"], [105, 105, 227, 228, "CID"], [105, 105, 289, 290, "CID"], [105, 105, 328, 329, "CID"], [105, 105, 346, 347, "CID"], [224, 224, 18, 19, "CID"], [224, 224, 68, 69, "CID"], [224, 224, 71, 72, "CID"], [224, 224, 126, 127, "CID"], [224, 224, 227, 228, "CID"], [224, 224, 289, 290, "CID"], [224, 224, 328, 329, "CID"], [224, 224, 346, 347, "CID"], [286, 286, 18, 19, "CID"], [286, 286, 68, 69, "CID"], [286, 286, 71, 72, "CID"], [286, 286, 126, 127, "CID"], [286, 286, 227, 228, "CID"], [286, 286, 289, 290, "CID"], [286, 286, 328, 329, "CID"], [286, 286, 346, 347, "CID"]]], "clusters": [], "translated": "Smad3 抑制剂阻断内皮-间质转化可延缓<0>链脲佐菌素</0>诱导的<5>糖尿病肾病</5>的早期发展。目的：一项多中心对照试验表明，在<13>1型糖尿病</13>和正常白蛋白尿患者中早期阻断肾素-<20>血管紧张素</20>系统不会延缓<14>肾病</14>的进展，提示其他机制参与了早期<6>糖尿病肾病</6>（<7>糖尿病肾病</7>）的发病。我们之前已经证明内皮-间充质-转化（EndoMT）有助于肾间质<16>纤维化</16>的早期发展，与<1>链脲佐菌素</1>（<2>STZ</2>）-诱发的<18>糖尿病</18>小鼠的微量白蛋白尿无关。在本研究中，我们假设阻断EndoMT可减少<8>糖尿病肾病</8>的早期发展。研究设计和方法：在小鼠胰腺微血管内皮细胞系(MMEC)和内皮谱系可追踪小鼠系Tie2-Cre中诱导EndoMT；Loxp-EGFP通过施用晚期糖化终产物(AGEs)，以非糖化小鼠白蛋白作为对照。通过免疫沉淀/Western印迹和共聚焦显微镜检测磷酸化的Smad3。使用AGE siRNA受体和Smad3特异性抑制剂(SIS3)在MMEC和<3>STZ</3>诱导的Tie2-Cre中<9>糖尿病肾病</9>中进行阻断研究；Loxp-EGFP小鼠。结果：共聚焦显微镜和实时荧光定量PCR表明AGEs在MMEC和Tie2-Cre中诱导了EndoMT；Loxp-EGFP小鼠。免疫沉淀/Western blotting表明，在MMEC和<4>STZ</4>诱导的<10>糖尿病肾病</10>中，Smad3被AGEs激活，但被SIS3抑制。共聚焦显微镜和实时PCR进一步证明，SIS3可消除EndoMT，减少肾<17>纤维化</17>，并延缓<15>肾病</15>的进展。结论：EndoMT是导致<11>糖尿病肾病</11>早期发展的新途径。SIS3阻断EndoMT可能为延缓<12>糖尿病肾病</12>和其他<19>糖尿病并发症</19>的进展提供新的策略。", "revised": true}
{"doc_key": "17445520", "sentences": [["Caffeine", "challenge", "test", "in", "panic", "disorder", "and", "depression", "with", "panic", "attacks", ".", "Our", "aim", "was", "to", "observe", "if", "patients", "with", "panic", "disorder", "(", "PD", ")", "and", "patients", "with", "major", "depression", "with", "panic", "attacks", "(", "MDP", ")", "(", "Diagnostic", "and", "Statistical", "Manual", "of", "Mental", "Disorders", ",", "Fourth", "Edition", "criteria", ")", "respond", "in", "a", "similar", "way", "to", "the", "induction", "of", "panic", "attacks", "by", "an", "oral", "caffeine", "challenge", "test", ".", "We", "randomly", "selected", "29", "patients", "with", "PD", ",", "27", "with", "MDP", ",", "25", "with", "major", "depression", "without", "panic", "attacks", "(", "MD", ")", ",", "and", "28", "healthy", "volunteers", ".", "The", "patients", "had", "no", "psychotropic", "drug", "for", "at", "least", "a", "4", "-", "week", "period", ".", "In", "a", "randomized", "double", "-", "blind", "experiment", "performed", "in", "2", "occasions", "7", "days", "apart", ",", "480", "mg", "caffeine", "and", "a", "caffeine", "-", "free", "(", "placebo", ")", "solution", "were", "administered", "in", "a", "coffee", "form", "and", "anxiety", "scales", "were", "applied", "before", "and", "after", "each", "test", ".", "A", "total", "of", "58", ".", "6", "%", "(", "n", "=", "17", ")", "of", "patients", "with", "PD", ",", "44", ".", "4", "%", "(", "n", "=", "12", ")", "of", "patients", "with", "MDP", ",", "12", ".", "0", "%", "(", "n", "=", "3", ")", "of", "patients", "with", "MD", ",", "and", "7", ".", "1", "%", "(", "n", "=", "2", ")", "of", "control", "subjects", "had", "a", "panic", "attack", "after", "the", "480", "-", "mg", "caffeine", "challenge", "test", "(", "chi", "(", "2", ")", "(", "3", ")", "=", "16", ".", "22", ",", "P", "=", ".", "001", ")", ".", "The", "patients", "with", "PD", "and", "MDP", "were", "more", "sensitive", "to", "caffeine", "than", "were", "patients", "with", "MD", "and", "healthy", "volunteers", ".", "No", "panic", "attack", "was", "observed", "after", "the", "caffeine", "-", "free", "solution", "intake", ".", "The", "patients", "with", "MD", "had", "a", "lower", "heart", "rate", "response", "to", "the", "test", "than", "all", "the", "other", "groups", "(", "2", "-", "way", "analysis", "of", "variance", ",", "group", "by", "time", "interaction", "with", "Greenhouse", "-", "Geisser", "correction", ":", "F", "(", "3", ",", "762", ")", "=", "2", ".", "85", ",", "P", "=", ".", "026", ")", ".", "Our", "data", "suggest", "that", "there", "is", "an", "association", "between", "panic", "attacks", ",", "no", "matter", "if", "associated", "with", "PD", "or", "MDP", ",", "and", "hyperreactivity", "to", "an", "oral", "caffeine", "challenge", "test", "."]], "ner": [[[0, 0, "Chemical"], [63, 63, "Chemical"], [127, 127, "Chemical"], [130, 130, "Chemical"], [221, 221, "Chemical"], [253, 253, "Chemical"], [270, 270, "Chemical"], [355, 355, "Chemical"], [4, 5, "Disease"], [9, 10, "Disease"], [20, 21, "Disease"], [23, 23, "Disease"], [31, 32, "Disease"], [34, 34, "Disease"], [58, 59, "Disease"], [73, 73, "Disease"], [77, 77, "Disease"], [84, 85, "Disease"], [169, 169, "Disease"], [183, 183, "Disease"], [214, 215, "Disease"], [246, 246, "Disease"], [248, 248, "Disease"], [264, 265, "Disease"], [338, 339, "Disease"], [346, 346, "Disease"], [348, 348, "Disease"], [7, 7, "Disease"], [28, 29, "Disease"], [81, 82, "Disease"], [87, 87, "Disease"], [197, 197, "Disease"], [258, 258, "Disease"], [279, 279, "Disease"], [42, 43, "Disease"], [144, 144, "Disease"]]], "relations": [[[0, 0, 4, 5, "CID"], [0, 0, 9, 10, "CID"], [0, 0, 20, 21, "CID"], [0, 0, 23, 23, "CID"], [0, 0, 31, 32, "CID"], [0, 0, 34, 34, "CID"], [0, 0, 58, 59, "CID"], [0, 0, 73, 73, "CID"], [0, 0, 77, 77, "CID"], [0, 0, 84, 85, "CID"], [0, 0, 169, 169, "CID"], [0, 0, 183, 183, "CID"], [0, 0, 214, 215, "CID"], [0, 0, 246, 246, "CID"], [0, 0, 248, 248, "CID"], [0, 0, 264, 265, "CID"], [0, 0, 338, 339, "CID"], [0, 0, 346, 346, "CID"], [0, 0, 348, 348, "CID"], [63, 63, 4, 5, "CID"], [63, 63, 9, 10, "CID"], [63, 63, 20, 21, "CID"], [63, 63, 23, 23, "CID"], [63, 63, 31, 32, "CID"], [63, 63, 34, 34, "CID"], [63, 63, 58, 59, "CID"], [63, 63, 73, 73, "CID"], [63, 63, 77, 77, "CID"], [63, 63, 84, 85, "CID"], [63, 63, 169, 169, "CID"], [63, 63, 183, 183, "CID"], [63, 63, 214, 215, "CID"], [63, 63, 246, 246, "CID"], [63, 63, 248, 248, "CID"], [63, 63, 264, 265, "CID"], [63, 63, 338, 339, "CID"], [63, 63, 346, 346, "CID"], [63, 63, 348, 348, "CID"], [127, 127, 4, 5, "CID"], [127, 127, 9, 10, "CID"], [127, 127, 20, 21, "CID"], [127, 127, 23, 23, "CID"], [127, 127, 31, 32, "CID"], [127, 127, 34, 34, "CID"], [127, 127, 58, 59, "CID"], [127, 127, 73, 73, "CID"], [127, 127, 77, 77, "CID"], [127, 127, 84, 85, "CID"], [127, 127, 169, 169, "CID"], [127, 127, 183, 183, "CID"], [127, 127, 214, 215, "CID"], [127, 127, 246, 246, "CID"], [127, 127, 248, 248, "CID"], [127, 127, 264, 265, "CID"], [127, 127, 338, 339, "CID"], [127, 127, 346, 346, "CID"], [127, 127, 348, 348, "CID"], [130, 130, 4, 5, "CID"], [130, 130, 9, 10, "CID"], [130, 130, 20, 21, "CID"], [130, 130, 23, 23, "CID"], [130, 130, 31, 32, "CID"], [130, 130, 34, 34, "CID"], [130, 130, 58, 59, "CID"], [130, 130, 73, 73, "CID"], [130, 130, 77, 77, "CID"], [130, 130, 84, 85, "CID"], [130, 130, 169, 169, "CID"], [130, 130, 183, 183, "CID"], [130, 130, 214, 215, "CID"], [130, 130, 246, 246, "CID"], [130, 130, 248, 248, "CID"], [130, 130, 264, 265, "CID"], [130, 130, 338, 339, "CID"], [130, 130, 346, 346, "CID"], [130, 130, 348, 348, "CID"], [221, 221, 4, 5, "CID"], [221, 221, 9, 10, "CID"], [221, 221, 20, 21, "CID"], [221, 221, 23, 23, "CID"], [221, 221, 31, 32, "CID"], [221, 221, 34, 34, "CID"], [221, 221, 58, 59, "CID"], [221, 221, 73, 73, "CID"], [221, 221, 77, 77, "CID"], [221, 221, 84, 85, "CID"], [221, 221, 169, 169, "CID"], [221, 221, 183, 183, "CID"], [221, 221, 214, 215, "CID"], [221, 221, 246, 246, "CID"], [221, 221, 248, 248, "CID"], [221, 221, 264, 265, "CID"], [221, 221, 338, 339, "CID"], [221, 221, 346, 346, "CID"], [221, 221, 348, 348, "CID"], [253, 253, 4, 5, "CID"], [253, 253, 9, 10, "CID"], [253, 253, 20, 21, "CID"], [253, 253, 23, 23, "CID"], [253, 253, 31, 32, "CID"], [253, 253, 34, 34, "CID"], [253, 253, 58, 59, "CID"], [253, 253, 73, 73, "CID"], [253, 253, 77, 77, "CID"], [253, 253, 84, 85, "CID"], [253, 253, 169, 169, "CID"], [253, 253, 183, 183, "CID"], [253, 253, 214, 215, "CID"], [253, 253, 246, 246, "CID"], [253, 253, 248, 248, "CID"], [253, 253, 264, 265, "CID"], [253, 253, 338, 339, "CID"], [253, 253, 346, 346, "CID"], [253, 253, 348, 348, "CID"], [270, 270, 4, 5, "CID"], [270, 270, 9, 10, "CID"], [270, 270, 20, 21, "CID"], [270, 270, 23, 23, "CID"], [270, 270, 31, 32, "CID"], [270, 270, 34, 34, "CID"], [270, 270, 58, 59, "CID"], [270, 270, 73, 73, "CID"], [270, 270, 77, 77, "CID"], [270, 270, 84, 85, "CID"], [270, 270, 169, 169, "CID"], [270, 270, 183, 183, "CID"], [270, 270, 214, 215, "CID"], [270, 270, 246, 246, "CID"], [270, 270, 248, 248, "CID"], [270, 270, 264, 265, "CID"], [270, 270, 338, 339, "CID"], [270, 270, 346, 346, "CID"], [270, 270, 348, 348, "CID"], [355, 355, 4, 5, "CID"], [355, 355, 9, 10, "CID"], [355, 355, 20, 21, "CID"], [355, 355, 23, 23, "CID"], [355, 355, 31, 32, "CID"], [355, 355, 34, 34, "CID"], [355, 355, 58, 59, "CID"], [355, 355, 73, 73, "CID"], [355, 355, 77, 77, "CID"], [355, 355, 84, 85, "CID"], [355, 355, 169, 169, "CID"], [355, 355, 183, 183, "CID"], [355, 355, 214, 215, "CID"], [355, 355, 246, 246, "CID"], [355, 355, 248, 248, "CID"], [355, 355, 264, 265, "CID"], [355, 355, 338, 339, "CID"], [355, 355, 346, 346, "CID"], [355, 355, 348, 348, "CID"]]], "clusters": [], "translated": " <0>咖啡因</0>挑战测试在<8>惊恐障碍</8>和<27>抑郁症</27>伴<9>惊恐发作</9>中的应用。我们的目的是观察（用 Diagnostic and Statistical Manual of <34> Mental Disorders </34> , Fourth Edition criteria 诊断）患有<10>惊恐障碍</10> (<11>PD</11>) 的患者和（用 Diagnostic and Statistical Manual of <34> Mental Disorders </34>, Fourth Edition criteria 诊断）患有<28>重度抑郁症</28>并伴有<12>惊恐发作</12> (<13>MDP</13>) 的患者是否对口服诱导<14>惊恐</14>的<1>咖啡因</1>挑战试验有类似的反应。我们随机选择了29名<15>PD</15>患者、27名<16>MDP</16>患者、25名无<17>惊恐发作</17>（<30>MD</30>）的<29>抑郁症患者</29>和28名健康志愿者。患者在进入实验前至少4周没有使用任何精神药物。在随机双盲试验中，我们两次间隔七天分别用咖啡形式分别管饮480mg的<2>咖啡因</2>和不含<3>咖啡因</3>的溶液（安慰剂）并在每次试验前后应用焦虑<35>评价量表</35>。共有<18>PD</18>患者中的58.6%（n=17），<19>MDP</19>患者中的44.4%（n=12），<31>MD</31>患者中的12.0%（n=3）和对照组中的7.1%（n=2）在口服480mg的<4>咖啡因</4>挑战试验后出现了<20>惊恐发作</20>（χ (2) (3)=16.22，P=.001）。我们还发现<21>PD</21>和<22>MDP</22>患者的<5>咖啡因</5>敏感性高于<32>MD</32>患者和健康志愿者。摄入不含<6>咖啡因</6>的试验溶液后，未观测到<23>惊恐发作</23>。<33>MD</33>组患者对这种测试的心率反应低于所有其他组（2因素方差分析，按Greenhouse-Geisser校正的分组时间交互作用：F（3，762）=2.85，P=.026）。我们的数据表明，无论是否伴随着<25>PD</25>或<26>MDP</26>，在口服药物诱导的情况下出现了<24>惊恐发作</24>，与口服 <7>咖啡因</7>挑战试验的过度反应性有关。", "revised": true}
{"doc_key": "20959502", "sentences": [["Cerebrospinal", "fluid", "penetration", "of", "high", "-", "dose", "daptomycin", "in", "suspected", "Staphylococcus", "aureus", "meningitis", ".", "OBJECTIVE", ":", "To", "report", "a", "case", "of", "methicillin", "-", "sensitive", "Staphylococcus", "aureus", "(", "MSSA", ")", "bacteremia", "with", "suspected", "MSSA", "meningitis", "treated", "with", "high", "-", "dose", "daptomycin", "assessed", "with", "concurrent", "serum", "and", "cerebrospinal", "fluid", "(", "CSF", ")", "concentrations", ".", "CASE", "SUMMARY", ":", "A", "54", "-", "year", "-", "old", "male", "presented", "to", "the", "emergency", "department", "with", "generalized", "weakness", "and", "presumed", "health", "-", "care", "-", "associated", "pneumonia", "shown", "on", "chest", "radiograph", ".", "Treatment", "was", "empirically", "initiated", "with", "vancomycin", ",", "levofloxacin", ",", "and", "piperacillin", "/", "tazobactam", ".", "Blood", "cultures", "revealed", "S", ".", "aureus", "susceptible", "to", "oxacillin", ".", "Empiric", "antibiotic", "treatment", "was", "narrowed", "to", "nafcillin", "on", "day", "4", ".", "On", "day", "8", ",", "the", "patient", "developed", "acute", "renal", "failure", "(", "serum", "creatinine", "1", ".", "9", "mg", "/", "dL", ",", "increased", "from", "1", ".", "2", "mg", "/", "dL", "the", "previous", "day", "and", "0", ".", "8", "mg", "/", "dL", "on", "admission", ")", ".", "The", "patient", "'s", "Glasgow", "Coma", "Score", "was", "3", ",", "with", "normal", "findings", "shown", "on", "computed", "tomography", "scan", "of", "the", "head", "72", "hours", "following", "an", "episode", "of", "cardiac", "arrest", "on", "day", "10", ".", "The", "patient", "experienced", "relapsing", "MSSA", "bacteremia", "on", "day", "9", ",", "increasing", "the", "suspicion", "for", "a", "central", "nervous", "system", "(", "CNS", ")", "infection", ".", "Nafcillin", "was", "discontinued", "and", "daptomycin", "9", "mg", "/", "kg", "daily", "was", "initiated", "for", "suspected", "meningitis", "and", "was", "continued", "until", "the", "patient", "'s", "death", "on", "day", "16", ".", "Daptomycin", "serum", "and", "CSF", "trough", "concentrations", "were", "11", ".", "21", "ug", "/", "mL", "and", "0", ".", "52", "ug", "/", "mL", ",", "respectively", ",", "prior", "to", "the", "third", "dose", ".", "Lumbar", "puncture", "results", "were", "inconclusive", "and", "no", "further", "blood", "cultures", "were", "positive", "for", "MSSA", ".", "Creatine", "kinase", "levels", "were", "normal", "prior", "to", "daptomycin", "therapy", "and", "were", "not", "reassessed", ".", "DISCUSSION", ":", "Daptomycin", "was", "initiated", "in", "our", "patient", "secondary", "to", "possible", "nafcillin", "-", "induced", "acute", "interstitial", "nephritis", "and", "relapsing", "bacteremia", ".", "At", "a", "dose", "of", "9", "mg", "/", "kg", ",", "resultant", "penetration", "of", "5", "%", "was", "higher", "than", "in", "previous", "reports", ",", "more", "consistent", "with", "inflamed", "meninges", ".", "CONCLUSIONS", ":", "High", "-", "dose", "daptomycin", "may", "be", "an", "alternative", "option", "for", "MSSA", "bacteremia", "with", "or", "without", "a", "CNS", "source", "in", "patients", "who", "have", "failed", "or", "can", "not", "tolerate", "standard", "therapy", ".", "Further", "clinical", "evaluation", "in", "patients", "with", "confirmed", "meningitis", "is", "warranted", "."]], "ner": [[[113, 113, "Chemical"], [215, 215, "Chemical"], [311, 311, "Chemical"], [315, 316, "Disease"], [7, 7, "Chemical"], [39, 39, "Chemical"], [219, 219, "Chemical"], [242, 242, "Chemical"], [293, 293, "Chemical"], [302, 302, "Chemical"], [353, 353, "Chemical"], [12, 12, "Disease"], [33, 33, "Disease"], [229, 229, "Disease"], [387, 387, "Disease"], [29, 29, "Disease"], [197, 197, "Disease"], [319, 319, "Disease"], [361, 361, "Disease"], [69, 69, "Disease"], [77, 77, "Disease"], [125, 127, "Disease"], [186, 187, "Disease"], [213, 213, "Disease"], [21, 21, "Chemical"], [88, 88, "Chemical"], [90, 90, "Chemical"], [93, 93, "Chemical"], [95, 95, "Chemical"], [105, 105, "Chemical"], [130, 130, "Chemical"], [286, 286, "Chemical"]]], "relations": [[[113, 113, 315, 316, "CID"], [215, 215, 315, 316, "CID"], [311, 311, 315, 316, "CID"]]], "clusters": [], "translated": "大剂量<4>达托霉素</4><11>疑似金黄色葡萄球菌脑膜炎</11>的脑脊液穿透。目的：报告一例<24>甲氧西林</24>敏感的金黄色葡萄球菌（MSSA）<15>菌血症</15>，疑似MSSA<12>脑膜炎</12>，大剂量<5>达托霉素</5>治疗一例，同时评估血清和脑脊液 (CSF) 浓度。病例概要：一名54岁的男性因全身性<19>无力</19>和胸片显示与医疗保健相关的<20>肺炎</20>到急诊室就诊。根据经验开始使用<25>万古霉素</25>、<26>左氧氟沙星</26>和<27>哌拉西林</27>/<28>他唑巴坦</28>。血培养显示S.<29>苯唑西林</29>敏感的金黄色葡萄球菌。第4天，经验性抗生素治疗缩小至<0>萘夫西林</0>。第8天，患者出现<21>急性肾功能衰竭</21>（血清<30>肌酐</30>1.9mg/dL，从前一天的1.2mg/dL增加到0.8mg/入院时分升）。患者的格拉斯哥昏迷评分为3，在第10天<22>心脏骤停</22>发作后72小时，头部计算机断层扫描显示正常结果。患者在第9天出现复发性MSSA<16>菌血症</16>，增加了对中枢神经系统 (CNS)<23>感染</23>的怀疑。因疑似<13>脑膜炎</13>，<1>停用萘夫西林</1>，<6>达托霉素</6>每日9mg/kg，并持续至患者在第16天死亡。<7>达托霉素</7>的血清和脑脊液谷浓度均为11.21微克/毫升和0.52微克/毫升，在第三次给药前分别检测。腰椎穿刺结果尚无定论，并且没有进一步的血培养显示MSSA阳性。<31>肌酸</31>激酶水平在<8>达托霉素</8>治疗之前是正常的，并且没有被重新评估。讨论：<9>达托霉素</9>是继发于可能的<2>萘夫西林</2>诱发的急性<3>间质性肾炎</3>和复发性<17>菌血症</17>的患者。在9mg/kg的剂量下，5%的渗透率高于以前的报告，更符合发炎的脑膜。结论：大剂量<10>达托霉素</10>可能是MSSA<18>菌血症</18>的替代选择，适用于标准治疗失败或不能耐受标准治疗的患者，伴有或不伴有CNS来源。有必要对确诊的<14>脑膜炎</14>患者进行进一步的临床评估。", "revised": true}
{"doc_key": "21195121", "sentences": [["The", "role", "of", "nitric", "oxide", "in", "convulsions", "induced", "by", "lindane", "in", "rats", ".", "Lindane", "is", "an", "organochloride", "pesticide", "and", "scabicide", ".", "It", "evokes", "convulsions", "mainly", "trough", "the", "blockage", "of", "GABA", "(", "A", ")", "receptors", ".", "Nitric", "oxide", "(", "NO", ")", ",", "gaseous", "neurotransmitter", ",", "has", "contradictor", "role", "in", "epileptogenesis", "due", "to", "opposite", "effects", "of", "L", "-", "arginine", ",", "precursor", "of", "NO", "syntheses", "(", "NOS", ")", ",", "and", "L", "-", "NAME", "(", "NOS", "inhibitor", ")", "observed", "in", "different", "epilepsy", "models", ".", "The", "aim", "of", "the", "current", "study", "was", "to", "determine", "the", "effects", "of", "NO", "on", "the", "behavioral", "and", "EEG", "characteristics", "of", "lindane", "-", "induced", "epilepsy", "in", "male", "Wistar", "albino", "rats", ".", "The", "administration", "of", "L", "-", "arginine", "(", "600", ",", "800", "and", "1000", "mg", "/", "kg", ",", "i", ".", "p", ".", ")", "in", "dose", "-", "dependent", "manner", "significantly", "increased", "convulsion", "incidence", "and", "severity", "and", "shortened", "latency", "time", "to", "first", "convulsion", "elicited", "by", "lower", "lindane", "dose", "(", "4", "mg", "/", "kg", ",", "i", ".", "p", ".", ")", ".", "On", "the", "contrary", ",", "pretreatment", "with", "L", "-", "NAME", "(", "500", ",", "700", "and", "900", "mg", "/", "kg", ",", "i", ".", "p", ".", ")", "decreased", "convulsion", "incidence", "and", "severity", "and", "prolonged", "latency", "time", "to", "convulsion", "following", "injection", "with", "a", "convulsive", "dose", "of", "lindane", "(", "8", "mg", "/", "kg", ",", "i", ".", "p", ".", ")", ".", "EEG", "analyses", "showed", "increase", "of", "number", "and", "duration", "of", "ictal", "periods", "in", "EEG", "of", "rats", "receiving", "l", "-", "arginine", "prior", "to", "lindane", "and", "decrease", "of", "this", "number", "in", "rats", "pretreated", "with", "L", "-", "NAME", ".", "These", "results", "support", "the", "conclusion", "that", "NO", "plays", "a", "role", "of", "endogenous", "convulsant", "in", "rat", "model", "of", "lindane", "seizures", "."]], "ner": [[[9, 9, "Chemical"], [13, 13, "Chemical"], [100, 100, "Chemical"], [152, 152, "Chemical"], [208, 208, "Chemical"], [242, 242, "Chemical"], [273, 273, "Chemical"], [6, 6, "Disease"], [23, 23, "Disease"], [138, 138, "Disease"], [148, 148, "Disease"], [191, 191, "Disease"], [200, 200, "Disease"], [205, 205, "Disease"], [274, 274, "Disease"], [3, 4, "Chemical"], [35, 36, "Chemical"], [38, 38, "Chemical"], [60, 60, "Chemical"], [92, 92, "Chemical"], [262, 262, "Chemical"], [77, 77, "Disease"], [103, 103, "Disease"], [29, 29, "Chemical"], [54, 56, "Chemical"], [113, 115, "Chemical"], [237, 239, "Chemical"], [67, 69, "Chemical"], [172, 174, "Chemical"], [252, 254, "Chemical"]]], "relations": [[[9, 9, 6, 6, "CID"], [9, 9, 23, 23, "CID"], [9, 9, 138, 138, "CID"], [9, 9, 148, 148, "CID"], [9, 9, 191, 191, "CID"], [9, 9, 200, 200, "CID"], [9, 9, 205, 205, "CID"], [9, 9, 274, 274, "CID"], [13, 13, 6, 6, "CID"], [13, 13, 23, 23, "CID"], [13, 13, 138, 138, "CID"], [13, 13, 148, 148, "CID"], [13, 13, 191, 191, "CID"], [13, 13, 200, 200, "CID"], [13, 13, 205, 205, "CID"], [13, 13, 274, 274, "CID"], [100, 100, 6, 6, "CID"], [100, 100, 23, 23, "CID"], [100, 100, 138, 138, "CID"], [100, 100, 148, 148, "CID"], [100, 100, 191, 191, "CID"], [100, 100, 200, 200, "CID"], [100, 100, 205, 205, "CID"], [100, 100, 274, 274, "CID"], [152, 152, 6, 6, "CID"], [152, 152, 23, 23, "CID"], [152, 152, 138, 138, "CID"], [152, 152, 148, 148, "CID"], [152, 152, 191, 191, "CID"], [152, 152, 200, 200, "CID"], [152, 152, 205, 205, "CID"], [152, 152, 274, 274, "CID"], [208, 208, 6, 6, "CID"], [208, 208, 23, 23, "CID"], [208, 208, 138, 138, "CID"], [208, 208, 148, 148, "CID"], [208, 208, 191, 191, "CID"], [208, 208, 200, 200, "CID"], [208, 208, 205, 205, "CID"], [208, 208, 274, 274, "CID"], [242, 242, 6, 6, "CID"], [242, 242, 23, 23, "CID"], [242, 242, 138, 138, "CID"], [242, 242, 148, 148, "CID"], [242, 242, 191, 191, "CID"], [242, 242, 200, 200, "CID"], [242, 242, 205, 205, "CID"], [242, 242, 274, 274, "CID"], [273, 273, 6, 6, "CID"], [273, 273, 23, 23, "CID"], [273, 273, 138, 138, "CID"], [273, 273, 148, 148, "CID"], [273, 273, 191, 191, "CID"], [273, 273, 200, 200, "CID"], [273, 273, 205, 205, "CID"], [273, 273, 274, 274, "CID"]]], "clusters": [], "translated": "<15>一氧化氮</15> 在<0>林丹</0>致大鼠<7>惊厥</7>中的作用。 <1> 林丹 </1>是一种有机氯杀虫剂和杀螨剂。它主要通过阻断 <23> GABA </23> (A) 受体引起 <8> 抽搐 </8>。 <16> 一氧化氮 </16> (<17> NO </17>)，气态神经递质，由于 <24> L-精氨酸 </24> 的相反作用，在癫痫发生中具有矛盾作用，<18> NO </18> 的前体在不同的<21> 癫痫 </21>模型中观察到合成（NOS）和 <27> L-NAME </27>（NOS抑制剂）。本研究的目的是确定 <19>NO</19> 对雄性 Wistar 白化大鼠 <2>林丹</2>诱发的<22>癫痫</22>行为和脑电图特征的影响。<25> L-精氨酸 </25>(600，800和1000 mg/kg，i.p.)以剂量依赖方式显着增加<9>抽搐</9>发生率和严重程度，并缩短第一次 <10>抽搐</10> 的潜伏时间，由较低的 <3>林丹</3>剂量 ( 4 mg/kg，i.p. ) 引起。相反，用<28> L-NAME </28>( 500，700和900 mg/kg，i.p.) 预处理可降低 <11>抽搐</11>的发生率和严重程度，并将潜伏期延长至注射 <13>抽搐</13> 剂量的 <4>林丹</4> （8 mg/kg，i.p.）后的 <12>抽搐</12>。脑电图分析显示，在接受<5>林丹</5>之前接受<26> L-精氨酸 </26> 的大鼠脑电图中发作期的次数和持续时间增加，而接受<29> L-NAME </29>。这些结果支持了<20> NO </20>在<6>林丹</6><14>癫痫发作</14>大鼠模型中起内源性惊厥作用的结论。", "revised": true}
{"doc_key": "24055495", "sentences": [["Long", "-", "term", "oral", "galactose", "treatment", "prevents", "cognitive", "deficits", "in", "male", "Wistar", "rats", "treated", "intracerebroventricularly", "with", "streptozotocin", ".", "Basic", "and", "clinical", "research", "has", "demonstrated", "that", "dementia", "of", "sporadic", "Alzheimer", "'s", "disease", "(", "sAD", ")", "type", "is", "associated", "with", "dysfunction", "of", "the", "insulin", "-", "receptor", "(", "IR", ")", "system", "followed", "by", "decreased", "glucose", "transport", "via", "glucose", "transporter", "GLUT4", "and", "decreased", "glucose", "metabolism", "in", "brain", "cells", ".", "An", "alternative", "source", "of", "energy", "is", "d", "-", "galactose", "(", "the", "C", "-", "4", "-", "epimer", "of", "d", "-", "glucose", ")", "which", "is", "transported", "into", "the", "brain", "by", "insulin", "-", "independent", "GLUT3", "transporter", "where", "it", "might", "be", "metabolized", "to", "glucose", "via", "the", "Leloir", "pathway", ".", "Exclusively", "parenteral", "daily", "injections", "of", "galactose", "induce", "memory", "deterioration", "in", "rodents", "and", "are", "used", "to", "generate", "animal", "aging", "model", ",", "but", "the", "effects", "of", "oral", "galactose", "treatment", "on", "cognitive", "functions", "have", "never", "been", "tested", ".", "We", "have", "investigated", "the", "effects", "of", "continuous", "daily", "oral", "galactose", "(", "200", "mg", "/", "kg", "/", "day", ")", "treatment", "on", "cognitive", "deficits", "in", "streptozotocin", "-", "induced", "(", "STZ", "-", "icv", ")", "rat", "model", "of", "sAD", ",", "tested", "by", "Morris", "Water", "Maze", "and", "Passive", "Avoidance", "test", ",", "respectively", ".", "One", "month", "of", "oral", "galactose", "treatment", "initiated", "immediately", "after", "the", "STZ", "-", "icv", "administration", ",", "successfully", "prevented", "development", "of", "the", "STZ", "-", "icv", "-", "induced", "cognitive", "deficits", ".", "Beneficial", "effect", "of", "oral", "galactose", "was", "independent", "of", "the", "rat", "age", "and", "of", "the", "galactose", "dose", "ranging", "from", "100", "to", "300", "mg", "/", "kg", "/", "day", ".", "Additionally", ",", "oral", "galactose", "administration", "led", "to", "the", "appearance", "of", "galactose", "in", "the", "blood", ".", "The", "increase", "of", "galactose", "concentration", "in", "the", "cerebrospinal", "fluid", "was", "several", "times", "lower", "after", "oral", "than", "after", "parenteral", "administration", "of", "the", "same", "galactose", "dose", ".", "Oral", "galactose", "exposure", "might", "have", "beneficial", "effects", "on", "learning", "and", "memory", "ability", "and", "could", "be", "worth", "investigating", "for", "improvement", "of", "cognitive", "deficits", "associated", "with", "glucose", "hypometabolism", "in", "AD", "."]], "ner": [[[4, 4, "Chemical"], [71, 73, "Chemical"], [115, 115, "Chemical"], [135, 135, "Chemical"], [154, 154, "Chemical"], [197, 197, "Chemical"], [225, 225, "Chemical"], [235, 235, "Chemical"], [251, 251, "Chemical"], [258, 258, "Chemical"], [266, 266, "Chemical"], [285, 285, "Chemical"], [289, 289, "Chemical"], [7, 8, "Disease"], [165, 166, "Disease"], [218, 219, "Disease"], [308, 309, "Disease"], [16, 16, "Chemical"], [168, 168, "Chemical"], [172, 172, "Chemical"], [203, 203, "Chemical"], [213, 213, "Chemical"], [28, 30, "Disease"], [315, 315, "Disease"], [51, 51, "Chemical"], [54, 54, "Chemical"], [59, 59, "Chemical"], [82, 84, "Chemical"], [104, 104, "Chemical"], [25, 25, "Disease"], [117, 118, "Disease"], [312, 313, "Disease"]]], "relations": [[[4, 4, 7, 8, "CID"], [4, 4, 165, 166, "CID"], [4, 4, 218, 219, "CID"], [4, 4, 308, 309, "CID"], [71, 73, 7, 8, "CID"], [71, 73, 165, 166, "CID"], [71, 73, 218, 219, "CID"], [71, 73, 308, 309, "CID"], [115, 115, 7, 8, "CID"], [115, 115, 165, 166, "CID"], [115, 115, 218, 219, "CID"], [115, 115, 308, 309, "CID"], [135, 135, 7, 8, "CID"], [135, 135, 165, 166, "CID"], [135, 135, 218, 219, "CID"], [135, 135, 308, 309, "CID"], [154, 154, 7, 8, "CID"], [154, 154, 165, 166, "CID"], [154, 154, 218, 219, "CID"], [154, 154, 308, 309, "CID"], [197, 197, 7, 8, "CID"], [197, 197, 165, 166, "CID"], [197, 197, 218, 219, "CID"], [197, 197, 308, 309, "CID"], [225, 225, 7, 8, "CID"], [225, 225, 165, 166, "CID"], [225, 225, 218, 219, "CID"], [225, 225, 308, 309, "CID"], [235, 235, 7, 8, "CID"], [235, 235, 165, 166, "CID"], [235, 235, 218, 219, "CID"], [235, 235, 308, 309, "CID"], [251, 251, 7, 8, "CID"], [251, 251, 165, 166, "CID"], [251, 251, 218, 219, "CID"], [251, 251, 308, 309, "CID"], [258, 258, 7, 8, "CID"], [258, 258, 165, 166, "CID"], [258, 258, 218, 219, "CID"], [258, 258, 308, 309, "CID"], [266, 266, 7, 8, "CID"], [266, 266, 165, 166, "CID"], [266, 266, 218, 219, "CID"], [266, 266, 308, 309, "CID"], [285, 285, 7, 8, "CID"], [285, 285, 165, 166, "CID"], [285, 285, 218, 219, "CID"], [285, 285, 308, 309, "CID"], [289, 289, 7, 8, "CID"], [289, 289, 165, 166, "CID"], [289, 289, 218, 219, "CID"], [289, 289, 308, 309, "CID"], [16, 16, 7, 8, "CID"], [16, 16, 165, 166, "CID"], [16, 16, 218, 219, "CID"], [16, 16, 308, 309, "CID"], [168, 168, 7, 8, "CID"], [168, 168, 165, 166, "CID"], [168, 168, 218, 219, "CID"], [168, 168, 308, 309, "CID"], [172, 172, 7, 8, "CID"], [172, 172, 165, 166, "CID"], [172, 172, 218, 219, "CID"], [172, 172, 308, 309, "CID"], [203, 203, 7, 8, "CID"], [203, 203, 165, 166, "CID"], [203, 203, 218, 219, "CID"], [203, 203, 308, 309, "CID"], [213, 213, 7, 8, "CID"], [213, 213, 165, 166, "CID"], [213, 213, 218, 219, "CID"], [213, 213, 308, 309, "CID"], [16, 16, 28, 30, "CID"], [16, 16, 315, 315, "CID"], [168, 168, 28, 30, "CID"], [168, 168, 315, 315, "CID"], [172, 172, 28, 30, "CID"], [172, 172, 315, 315, "CID"], [203, 203, 28, 30, "CID"], [203, 203, 315, 315, "CID"], [213, 213, 28, 30, "CID"], [213, 213, 315, 315, "CID"], [51, 51, 28, 30, "CID"], [51, 51, 315, 315, "CID"], [54, 54, 28, 30, "CID"], [54, 54, 315, 315, "CID"], [59, 59, 28, 30, "CID"], [59, 59, 315, 315, "CID"], [82, 84, 28, 30, "CID"], [82, 84, 315, 315, "CID"], [104, 104, 28, 30, "CID"], [104, 104, 315, 315, "CID"]]], "clusters": [], "translated": "长期口服<0>半乳糖</0>治疗可预防<13>认知缺陷</13>，雄性Wistar大鼠脑室内注射<17>链脲佐菌素</17>。基础和临床研究表明，散发性<22>阿尔茨海默病</22>（sAD）类型的<29>痴呆</29>与胰岛素受体（IR）系统的功能障碍有关，随后<24>葡萄糖</24>通过<25>葡萄糖转运蛋白GLUT4</25>转运，降低脑细胞中的<26>葡萄糖</26>代谢。另一种能量来源是<1>d-半乳糖</1>（<27>d-葡萄糖</27>的C-4-差向异构体），它通过不依赖胰岛素的<25>GLUT3</25>转运蛋白转运到大脑中，在那里它可能通过Leloir途径代谢成<28>葡萄糖</28>。每日肠胃外独家注射<2>半乳糖</2>可诱导啮齿类动物<30>记忆衰退</30>并用于建立动物衰老模型，但从未测试过口服<3>半乳糖</3>治疗对认知能力的影响。我们研究了连续每日口服<4>半乳糖</4>（200mg/kg/天）治疗对<18>链脲佐菌素</18>诱导的<14>认知缺陷</14>的影响（<19>STZ</19>-icv大鼠sAD模型），分别采用Morris水迷宫和被动回避试验。在<20>STZ</20>-icv给药后立即开始口服<5>半乳糖</5>治疗一个月，成功地阻止了<21>STZ</21>-icv诱导的<15>认知缺陷</15>发展。口服<6>半乳糖</6>的有益效果与大鼠年龄和<7>半乳糖</7>剂量范围为100至300mg/kg/天无关。此外，口服<8>半乳糖</8>导致血液中出现<9>半乳糖</9>。口服相同剂量的<11>半乳糖</11>后，脑脊液中<10>半乳糖</10>浓度的增加比肠胃外给药后低数倍。口服<12>半乳糖</12>暴露可能对学习和记忆能力产生有益影响，值得研究以改善<23>AD</23>中与<31>葡萄糖代谢减退</31>相关的<16>认知缺陷</16>。", "revised": true}
{"doc_key": "20169779", "sentences": [["Neuropsychiatric", "behaviors", "in", "the", "MPTP", "marmoset", "model", "of", "Parkinson", "'s", "disease", ".", "OBJECTIVES", ":", "Neuropsychiatric", "symptoms", "are", "increasingly", "recognised", "as", "a", "significant", "problem", "in", "patients", "with", "Parkinson", "'s", "disease", "(", "PD", ")", ".", "These", "symptoms", "may", "be", "due", "to", "'", "sensitisation", "'", "following", "repeated", "levodopa", "treatment", "or", "a", "direct", "effect", "of", "dopamine", "on", "the", "disease", "state", ".", "The", "levodopa", "-", "treated", "MPTP", "-", "lesioned", "marmoset", "was", "used", "as", "a", "model", "of", "neuropsychiatric", "symptoms", "in", "PD", "patients", ".", "Here", "we", "compare", "the", "time", "course", "of", "levodopa", "-", "induced", "motor", "fluctuations", "and", "neuropsychiatric", "-", "like", "behaviors", "to", "determine", "the", "relationship", "between", "duration", "of", "treatment", "and", "onset", "of", "symptoms", ".", "METHODS", ":", "Marmosets", "were", "administered", "1", "-", "methyl", "-", "4", "-", "phenyl", "-", "1", ",", "2", ",", "3", ",", "6", "-", "tetrahydropyridine", "(", "2", ".", "0", "mg", "/", "kg", "s", ".", "c", ".", ")", "for", "five", "days", ",", "resulting", "in", "stable", "parkinsonism", ".", "Levodopa", "(", "15", "mg", "/", "kg", "and", "benserazide", ",", "3", ".", "75", "mg", "/", "kg", ")", "p", ".", "o", ".", "b", ".", "i", ".", "d", ",", "was", "administered", "for", "30", "days", ".", "Animals", "were", "evaluated", "for", "parkinsonian", "disability", ",", "dyskinesia", "and", "on", "-", "time", "(", "motor", "fluctuations", ")", "and", "neuropsychiatric", "-", "like", "behaviors", "on", "Day", "0", "(", "prior", "to", "levodopa", ")", "and", "on", "Days", "1", ",", "7", ",", "13", ",", "27", "and", "30", "of", "treatment", "using", "post", "hoc", "DVD", "analysis", "by", "a", "trained", "rater", ",", "blind", "to", "the", "treatment", "day", ".", "RESULTS", ":", "The", "neuropsychiatric", "-", "like", "behavior", "rating", "scale", "demonstrated", "high", "interrater", "reliability", "between", "three", "trained", "raters", "of", "differing", "professional", "backgrounds", ".", "As", "anticipated", ",", "animals", "exhibited", "a", "progressive", "increase", "in", "levodopa", "-", "induced", "motor", "fluctuations", ",", "dyskinesia", "and", "wearing", "-", "off", ",", "that", "correlated", "with", "the", "duration", "of", "levodopa", "therapy", ".", "In", "contrast", ",", "levodopa", "-", "induced", "neuropsychiatric", "-", "like", "behaviors", "were", "present", "on", "Day", "1", "of", "levodopa", "treatment", "and", "their", "severity", "did", "not", "correlate", "with", "duration", "of", "treatment", ".", "CONCLUSIONS", ":", "The", "data", "suggest", "that", "neuropsychiatric", "disorders", "in", "PD", "are", "more", "likely", "an", "interaction", "between", "levodopa", "and", "the", "disease", "state", "than", "a", "consequence", "of", "sensitisation", "to", "repeated", "dopaminergic", "therapy", "."]], "ner": [[[4, 4, "Chemical"], [61, 61, "Chemical"], [112, 128, "Chemical"], [186, 187, "Disease"], [44, 44, "Chemical"], [58, 58, "Chemical"], [84, 84, "Chemical"], [150, 150, "Chemical"], [209, 209, "Chemical"], [272, 272, "Chemical"], [290, 290, "Chemical"], [296, 296, "Chemical"], [309, 309, "Chemical"], [338, 338, "Chemical"], [189, 189, "Disease"], [278, 278, "Disease"], [8, 10, "Disease"], [26, 28, "Disease"], [30, 30, "Disease"], [74, 74, "Disease"], [148, 148, "Disease"], [331, 331, "Disease"], [71, 72, "Disease"], [90, 93, "Disease"], [199, 202, "Disease"], [244, 247, "Disease"], [299, 302, "Disease"], [328, 329, "Disease"], [51, 51, "Chemical"], [157, 157, "Chemical"]]], "relations": [[[4, 4, 186, 187, "CID"], [61, 61, 186, 187, "CID"], [112, 128, 186, 187, "CID"], [44, 44, 189, 189, "CID"], [44, 44, 278, 278, "CID"], [58, 58, 189, 189, "CID"], [58, 58, 278, 278, "CID"], [84, 84, 189, 189, "CID"], [84, 84, 278, 278, "CID"], [150, 150, 189, 189, "CID"], [150, 150, 278, 278, "CID"], [209, 209, 189, 189, "CID"], [209, 209, 278, 278, "CID"], [272, 272, 189, 189, "CID"], [272, 272, 278, 278, "CID"], [290, 290, 189, 189, "CID"], [290, 290, 278, 278, "CID"], [296, 296, 189, 189, "CID"], [296, 296, 278, 278, "CID"], [309, 309, 189, 189, "CID"], [309, 309, 278, 278, "CID"], [338, 338, 189, 189, "CID"], [338, 338, 278, 278, "CID"]]], "clusters": [], "translated": "在<16>帕金森病</16>狨猴<0>MPTP</0>模型中出现了神经精神行为。目的：神经精神症状越来越被认为是<17>帕金森病</17> (<18> PD </18>)患者的重要问题。这些症状可能是由于反复<4>左旋多巴</4>治疗或<28>多巴胺</28>对疾病状态的直接影响导致的“致敏”。以<5>左旋多巴</5>治疗的<1>MPTP</1>损伤的狨猴被用作<19>PD</19>患者<22>神经精神症状</22>的模型。在这里，我们比较了<6>左旋多巴</6>引起的运动波动和<23>神经精神病学样功</23>行为的时间进程，以确定治疗持续时间与症状发作之间的关系。方法：给狨猴施用<2>1 - 甲基 - 4 - 苯基 - 1 , 2 , 3 , 6 - 四氢吡啶</2> (2.0 mg/kg s.c.)五天，导致稳定的<20>帕金森症</20>。<7>左旋多巴</7> (15 mg/kg和<29>苄丝肼</29>, 3.75 mg/kg) p.o. b.i.d，给药30天。在治疗的第 0 天 (之前<8>左旋多巴</8>) 以及在第1、7、13、27和30天进行评估，评估者由训练有素的评估者盲评，评估包括<3>帕金森病残疾</3>、<14>运动障碍</14>和运动时间波动，以及<24>神经精神病学样行为</24>。结果：<25>神经精神病学样行为</25>评定量表表明，三位训练有素的评定者之间具有较高的评定者间信度。正如预期，动物表现出随<10>左旋多巴</10>治疗时间的增加而逐渐增加的<9>左旋多巴</9>引起的运动波动、<15>运动障碍</15>和消退。相比之下，<11>左旋多巴</11>诱导的<26>神经精神病学样行为</26>在<12>左旋多巴</12>治疗的第1天出现，其严重程度与治疗持续时间无关。结论:数据表明，<21>PD</21>中的<27>神经精神障碍</27>更可能是由<13>左旋多巴</13>与疾病状态之间的相互作用而不是对重复的多巴胺能治疗致敏的结果。", "revised": true}
{"doc_key": "11988250", "sentences": [["Pulmonary", "hypertension", "after", "ibuprofen", "prophylaxis", "in", "very", "preterm", "infants", ".", "We", "report", "three", "cases", "of", "severe", "hypoxaemia", "after", "ibuprofen", "administration", "during", "a", "randomised", "controlled", "trial", "of", "prophylactic", "treatment", "of", "patent", "ductus", "arteriosus", "with", "ibuprofen", "in", "premature", "infants", "born", "at", "less", "than", "28", "weeks", "of", "gestation", ".", "Echocardiography", "showed", "severely", "decreased", "pulmonary", "blood", "flow", ".", "Hypoxaemia", "resolved", "quickly", "on", "inhaled", "nitric", "oxide", "therapy", ".", "We", "suggest", "that", "investigators", "involved", "in", "similar", "trials", "pay", "close", "attention", "to", "pulmonary", "pressure", "if", "hypoxaemia", "occurs", "after", "prophylactic", "administration", "of", "ibuprofen", "."]], "ner": [[[3, 3, "Chemical"], [18, 18, "Chemical"], [33, 33, "Chemical"], [84, 84, "Chemical"], [0, 1, "Disease"], [16, 16, "Disease"], [54, 54, "Disease"], [78, 78, "Disease"], [59, 60, "Chemical"], [29, 31, "Disease"]]], "relations": [[[3, 3, 0, 1, "CID"], [18, 18, 0, 1, "CID"], [33, 33, 0, 1, "CID"], [84, 84, 0, 1, "CID"], [3, 3, 16, 16, "CID"], [3, 3, 54, 54, "CID"], [3, 3, 78, 78, "CID"], [18, 18, 16, 16, "CID"], [18, 18, 54, 54, "CID"], [18, 18, 78, 78, "CID"], [33, 33, 16, 16, "CID"], [33, 33, 54, 54, "CID"], [33, 33, 78, 78, "CID"], [84, 84, 16, 16, "CID"], [84, 84, 54, 54, "CID"], [84, 84, 78, 78, "CID"]]], "clusters": [], "translated": " <4> 极早产儿 </4><0>布洛芬</0>预防后的<4>肺动脉高压</4> 。我们报告了三例妊娠不足 28 周出生的早产儿，在预防性给予<1>布洛芬</1>的一项随机对照试验中出现<5>严重低氧血症</5>。<9>动脉导管未闭</9>用<2>布洛芬</2>进行预防性治疗。超声心动图显示肺血流量严重下降。<6>低氧血症</6>吸入<8>一氧化氮</8>疗法可迅速解决。如果在预防性给予<3>布洛芬</3>后发生<7>低氧血症</7>，我们建议参与类似试验的研究者密切关注肺压。", "revised": true}
{"doc_key": "24659727", "sentences": [["Tolerability", "of", "lomustine", "in", "combination", "with", "cyclophosphamide", "in", "dogs", "with", "lymphoma", ".", "This", "retrospective", "study", "describes", "toxicity", "associated", "with", "a", "protocol", "of", "lomustine", "(", "CCNU", ")", "and", "cyclophosphamide", "(", "CTX", ")", "in", "dogs", "with", "lymphoma", ".", "CCNU", "was", "administered", "per", "os", "(", "PO", ")", "at", "a", "targeted", "dosage", "of", "60", "mg", "/", "m", "(", "2", ")", "body", "surface", "area", "on", "day", "0", ",", "CTX", "was", "administered", "PO", "at", "a", "targeted", "dosage", "of", "250", "mg", "/", "m", "(", "2", ")", "divided", "over", "days", "0", "through", "4", ",", "and", "all", "dogs", "received", "prophylactic", "antibiotics", ".", "Ninety", "treatments", "were", "given", "to", "the", "57", "dogs", "included", "in", "the", "study", ".", "Neutropenia", "was", "the", "principal", "toxic", "effect", ",", "and", "the", "overall", "frequency", "of", "grade", "4", "neutropenia", "after", "the", "first", "treatment", "of", "CCNU", "/", "CTX", "was", "30", "%", "(", "95", "%", "confidence", "interval", ",", "19", "-", "43", "%", ")", ".", "The", "mean", "body", "weight", "of", "dogs", "with", "grade", "4", "neutropenia", "(", "19", ".", "7", "kg", "+", "13", ".", "4", "kg", ")", "was", "significantly", "less", "than", "the", "mean", "body", "weight", "of", "dogs", "that", "did", "not", "develop", "grade", "4", "neutropenia", "(", "31", ".", "7", "kg", "+", "12", ".", "4", "kg", ";", "P", "=", ".", "005", ")", ".", "One", "dog", "(", "3", "%", ")", "developed", "hematologic", "changes", "suggestive", "of", "hepatotoxicity", ".", "No", "dogs", "had", "evidence", "of", "either", "renal", "toxicity", "or", "hemorrhagic", "cystitis", ".", "Adverse", "gastrointestinal", "effects", "were", "uncommon", ".", "On", "the", "basis", "of", "the", "findings", "reported", "herein", ",", "a", "dose", "of", "60", "mg", "/", "m", "(", "2", ")", "of", "CCNU", "combined", "with", "250", "mg", "/", "m", "(", "2", ")", "of", "CTX", "(", "divided", "over", "5", "days", ")", "q", "4", "wk", "is", "tolerable", "in", "tumor", "-", "bearing", "dogs", "."]], "ner": [[[2, 2, "Chemical"], [22, 22, "Chemical"], [24, 24, "Chemical"], [36, 36, "Chemical"], [126, 126, "Chemical"], [250, 250, "Chemical"], [106, 106, "Disease"], [120, 120, "Disease"], [153, 153, "Disease"], [181, 181, "Disease"], [6, 6, "Chemical"], [27, 27, "Chemical"], [29, 29, "Chemical"], [63, 63, "Chemical"], [128, 128, "Chemical"], [261, 261, "Chemical"], [10, 10, "Disease"], [34, 34, "Disease"], [16, 16, "Disease"], [210, 210, "Disease"], [218, 219, "Disease"], [221, 222, "Disease"], [274, 274, "Disease"]]], "relations": [[[2, 2, 106, 106, "CID"], [2, 2, 120, 120, "CID"], [2, 2, 153, 153, "CID"], [2, 2, 181, 181, "CID"], [22, 22, 106, 106, "CID"], [22, 22, 120, 120, "CID"], [22, 22, 153, 153, "CID"], [22, 22, 181, 181, "CID"], [24, 24, 106, 106, "CID"], [24, 24, 120, 120, "CID"], [24, 24, 153, 153, "CID"], [24, 24, 181, 181, "CID"], [36, 36, 106, 106, "CID"], [36, 36, 120, 120, "CID"], [36, 36, 153, 153, "CID"], [36, 36, 181, 181, "CID"], [126, 126, 106, 106, "CID"], [126, 126, 120, 120, "CID"], [126, 126, 153, 153, "CID"], [126, 126, 181, 181, "CID"], [250, 250, 106, 106, "CID"], [250, 250, 120, 120, "CID"], [250, 250, 153, 153, "CID"], [250, 250, 181, 181, "CID"], [6, 6, 106, 106, "CID"], [6, 6, 120, 120, "CID"], [6, 6, 153, 153, "CID"], [6, 6, 181, 181, "CID"], [27, 27, 106, 106, "CID"], [27, 27, 120, 120, "CID"], [27, 27, 153, 153, "CID"], [27, 27, 181, 181, "CID"], [29, 29, 106, 106, "CID"], [29, 29, 120, 120, "CID"], [29, 29, 153, 153, "CID"], [29, 29, 181, 181, "CID"], [63, 63, 106, 106, "CID"], [63, 63, 120, 120, "CID"], [63, 63, 153, 153, "CID"], [63, 63, 181, 181, "CID"], [128, 128, 106, 106, "CID"], [128, 128, 120, 120, "CID"], [128, 128, 153, 153, "CID"], [128, 128, 181, 181, "CID"], [261, 261, 106, 106, "CID"], [261, 261, 120, 120, "CID"], [261, 261, 153, 153, "CID"], [261, 261, 181, 181, "CID"]]], "clusters": [], "translated": "<0> 洛莫司汀 </0> 与 <10> 环磷酰胺 </10> 在患有 <16> 淋巴瘤 </16> 的狗中的耐受性。这项回顾性研究描述了<18>毒性</18>与<1>洛莫司汀</1>（<2>CCNU</2>）和<11>环磷酰胺</11>（<12>CTX</12>）治疗<17>淋巴瘤</17>的方案相关。 <3> CCNU </3> 在第 0 天以 60 mg / m (2 ) 体表面积的目标剂量经口（ PO ）给药， <13> CTX </13> 以目标剂量 PO 给药250 mg/m (2) 在第 0 天到第 4 天分配，所有狗都接受了预防性抗生素。研究中包括的 57 只狗接受了 90 次治疗。 <6> 中性粒细胞减少 </6> 是主要的毒性作用，<4> CCNU </4> / <14> CTX </14> 首次治疗后 4 级 <7> 中性粒细胞减少 </7> 的总体频率> 为 30%（95% 置信区间，19-43%）。患有4级<8>中性粒细胞减少症</8>的狗的平均体重（19 . 7 kg + 13 . 4 kg）明显低于未发生4级<9>中性粒细胞减少症</9>的狗的平均体重 (31. 7 公斤 + 12. 4 公斤；P = .005)。一只狗 (3%) 出现了提示 <19> 肝毒性 </19> 的血液学变化。没有狗有 <20> 肾毒性 </20> 或 <21> 出血性膀胱炎 </21> 的证据。胃肠道不良反应并不常见。根据本文报告的发现，60 mg / m ( 2 ) 的 <5> CCNU </5> 与 250 mg / m ( 2 ) <15> CTX </15> 的组合（分为 5天) q 4 wk 在携带<22>肿瘤</22>的狗中是可以耐受的。", "revised": true}
{"doc_key": "1760851", "sentences": [["Reduced", "cardiotoxicity", "of", "doxorubicin", "given", "in", "the", "form", "of", "N", "-", "(", "2", "-", "hydroxypropyl", ")", "methacrylamide", "conjugates", ":", "and", "experimental", "study", "in", "the", "rat", ".", "A", "rat", "model", "was", "used", "to", "evaluate", "the", "general", "acute", "toxicity", "and", "the", "late", "cardiotoxicity", "of", "4", "mg", "/", "kg", "doxorubicin", "(", "DOX", ")", "given", "either", "as", "free", "drug", "or", "in", "the", "form", "of", "three", "N", "-", "(", "2", "-", "hydroxypropyl", ")", "methacrylamide", "(", "HPMA", ")", "copolymer", "conjugates", ".", "In", "these", "HPMA", "copolymers", ",", "DOX", "was", "covalently", "bound", "via", "peptide", "linkages", "that", "were", "either", "non", "-", "biodegradable", "(", "Gly", "-", "Gly", ")", "or", "degradable", "by", "lysosomal", "proteinases", "(", "Gly", "-", "Phe", "-", "Leu", "-", "Gly", ")", ".", "In", "addition", ",", "one", "biodegradable", "conjugate", "containing", "galactosamine", "was", "used", ";", "this", "residue", "was", "targeted", "to", "the", "liver", ".", "Over", "the", "first", "3", "weeks", "after", "the", "i", ".", "v", ".", "administration", "of", "free", "and", "polymer", "-", "bound", "DOX", ",", "all", "animals", "showed", "a", "transient", "reduction", "in", "body", "weight", ".", "However", ",", "the", "maximal", "reduction", "in", "body", "weight", "seen", "in", "animals", "that", "received", "polymer", "-", "bound", "DOX", "(", "4", "mg", "/", "kg", ")", "was", "significantly", "lower", "than", "that", "observed", "in", "those", "that", "received", "free", "DOX", "(", "4", "mg", "/", "kg", ")", "or", "a", "mixture", "of", "the", "unmodified", "parent", "HPMA", "copolymer", "and", "free", "DOX", "(", "4", "mg", "/", "kg", ";", "P", "less", "than", "0", ".", "01", ")", ".", "Throughout", "the", "study", "(", "20", "weeks", ")", ",", "deaths", "related", "to", "cardiotoxicity", "were", "observed", "only", "in", "animals", "that", "received", "either", "free", "DOX", "or", "the", "mixture", "of", "HPMA", "copolymer", "and", "free", "DOX", ";", "in", "these", "cases", ",", "histological", "investigations", "revealed", "marked", "changes", "in", "the", "heart", "that", "were", "consistent", "with", "DOX", "-", "induced", "cardiotoxicity", ".", "Sequential", "measurements", "of", "cardiac", "output", "in", "surviving", "animals", "that", "received", "either", "free", "DOX", "or", "the", "mixture", "of", "HPMA", "copolymer", "and", "free", "DOX", "showed", "a", "reduction", "of", "approximately", "30", "%", "in", "function", "beginning", "at", "the", "4th", "week", "after", "drug", "administration", ".", "The", "heart", "rate", "in", "these", "animals", "was", "approximately", "12", "%", "lower", "than", "that", "measured", "in", "age", "-", "matched", "control", "rats", "(", "P", "less", "than", "0", ".", "05", ")", ".", "Animals", "that", "were", "given", "the", "HPMA", "copolymer", "conjugates", "containing", "DOX", "exhibited", "no", "significant", "change", "in", "cardiac", "output", "throughout", "the", "study", "(", "P", "less", "than", "0", ".", "05", ")", ".", "In", "addition", ",", "no", "significant", "histological", "change", "was", "observed", "in", "the", "heart", "of", "animals", "that", "received", "DOX", "in", "the", "form", "of", "HPMA", "copolymer", "conjugates", "and", "were", "killed", "at", "the", "end", "of", "the", "study", ".", "However", ",", "these", "animals", "had", "shown", "a", "significant", "increase", "in", "heart", "rate", "beginning", "at", "8", "weeks", "after", "drug", "administration", "(", "P", "less", "than", "0", ".", "01", ")", ".", "(", "ABSTRACT", "TRUNCATED", "AT", "400", "WORDS", ")"]], "ner": [[[3, 3, "Chemical"], [46, 46, "Chemical"], [48, 48, "Chemical"], [80, 80, "Chemical"], [150, 150, "Chemical"], [178, 178, "Chemical"], [196, 196, "Chemical"], [214, 214, "Chemical"], [250, 250, "Chemical"], [259, 259, "Chemical"], [277, 277, "Chemical"], [294, 294, "Chemical"], [303, 303, "Chemical"], [360, 360, "Chemical"], [396, 396, "Chemical"], [1, 1, "Disease"], [40, 40, "Disease"], [240, 240, "Disease"], [280, 280, "Disease"], [9, 16, "Chemical"], [61, 68, "Chemical"], [70, 70, "Chemical"], [77, 77, "Chemical"], [210, 210, "Chemical"], [255, 255, "Chemical"], [299, 299, "Chemical"], [356, 356, "Chemical"], [401, 401, "Chemical"], [104, 110, "Chemical"], [120, 120, "Chemical"], [36, 36, "Disease"]]], "relations": [[[3, 3, 1, 1, "CID"], [3, 3, 40, 40, "CID"], [3, 3, 240, 240, "CID"], [3, 3, 280, 280, "CID"], [46, 46, 1, 1, "CID"], [46, 46, 40, 40, "CID"], [46, 46, 240, 240, "CID"], [46, 46, 280, 280, "CID"], [48, 48, 1, 1, "CID"], [48, 48, 40, 40, "CID"], [48, 48, 240, 240, "CID"], [48, 48, 280, 280, "CID"], [80, 80, 1, 1, "CID"], [80, 80, 40, 40, "CID"], [80, 80, 240, 240, "CID"], [80, 80, 280, 280, "CID"], [150, 150, 1, 1, "CID"], [150, 150, 40, 40, "CID"], [150, 150, 240, 240, "CID"], [150, 150, 280, 280, "CID"], [178, 178, 1, 1, "CID"], [178, 178, 40, 40, "CID"], [178, 178, 240, 240, "CID"], [178, 178, 280, 280, "CID"], [196, 196, 1, 1, "CID"], [196, 196, 40, 40, "CID"], [196, 196, 240, 240, "CID"], [196, 196, 280, 280, "CID"], [214, 214, 1, 1, "CID"], [214, 214, 40, 40, "CID"], [214, 214, 240, 240, "CID"], [214, 214, 280, 280, "CID"], [250, 250, 1, 1, "CID"], [250, 250, 40, 40, "CID"], [250, 250, 240, 240, "CID"], [250, 250, 280, 280, "CID"], [259, 259, 1, 1, "CID"], [259, 259, 40, 40, "CID"], [259, 259, 240, 240, "CID"], [259, 259, 280, 280, "CID"], [277, 277, 1, 1, "CID"], [277, 277, 40, 40, "CID"], [277, 277, 240, 240, "CID"], [277, 277, 280, 280, "CID"], [294, 294, 1, 1, "CID"], [294, 294, 40, 40, "CID"], [294, 294, 240, 240, "CID"], [294, 294, 280, 280, "CID"], [303, 303, 1, 1, "CID"], [303, 303, 40, 40, "CID"], [303, 303, 240, 240, "CID"], [303, 303, 280, 280, "CID"], [360, 360, 1, 1, "CID"], [360, 360, 40, 40, "CID"], [360, 360, 240, 240, "CID"], [360, 360, 280, 280, "CID"], [396, 396, 1, 1, "CID"], [396, 396, 40, 40, "CID"], [396, 396, 240, 240, "CID"], [396, 396, 280, 280, "CID"]]], "clusters": [], "translated": "以<19>N-(2-羟丙基)甲基丙烯酰胺</19>偶联物形式给予<0>多柔比星</0>可降低<15>心脏毒性</15>，并在大鼠中进行实验研究。大鼠模型用于评估4 mg/kg<1>阿霉素</1>（<2>DOX</2>）作为游离药物或以三种<20>N-（2-羟丙基）甲基丙烯酰胺</20>（<21>HPMA</21>）共聚物偶联物的形式给予的一般急性<30>毒性</30>和晚期<16>心脏毒性</16>。在这些 <22> HPMA </22> 共聚物中，<3> DOX </3> 通过不可生物降解 (Gly-Gly) 或可被溶酶体蛋白酶降解 (<28> Gly-Phe-亮氨酸-甘氨酸</28>)。此外，还使用了一种含有<29>半乳糖胺</29>的可生物降解结合物；这种残留物被靶向肝脏。在 i 之后的前 3 周内。诉。施用游离和聚合物结合的 <4> DOX </4> 后，所有动物的体重都出现了短暂的减轻。然而，在接受聚合物结合 <5> DOX </5> (4 mg / kg) 的动物中观察到的最大体重减轻明显低于接受游离 <6> DOX </6> 的动物（ 4 mg/kg)或未改性母体<23>HPMA</23>共聚物与游离<7>DOX</7>的混合物(4 mg/kg;P小于0. 01)。在整个研究过程中（20周），仅在接受<8>DOX</8>或<24>HPMA</24>共聚物和<9>DOX</9>混合物的动物中观察到与<17>心脏毒性</17>相关的死亡;在这些病例中，组织学研究显示心脏有明显变化，这与 <10>DOX</10> 引起的<18>心脏毒性</18> 一致。接受游离 <11> DOX </11> 或 <25> HPMA </25> 共聚物和游离 <12> DOX </12> 混合物的存活动物的心输出量的连续测量显示减少了大约 30%给药后第4周开始功能正常。这些动物的心率比年龄匹配的对照组大鼠的心率低大约 12%（P 小于 0. 05）。给予含有<13> DOX </13> 的<26> HPMA </26> 共聚物偶联物的动物在整个研究期间心输出量没有显着变化（P 小于 0. 05）。此外，接受 <27> HPMA </27> 共聚物缀合物形式的 <14> DOX </14> 并在研究结束时被杀死的动物的心脏没有观察到明显的组织学变化。然而，这些动物在给药后 8 周开始表现出心率显着增加（P 小于 0. 01）。 （摘要被截断为 400 个单词）", "revised": true}
{"doc_key": "19338378", "sentences": [["Reducing", "harm", "associated", "with", "anticoagulation", ":", "practical", "considerations", "of", "argatroban", "therapy", "in", "heparin", "-", "induced", "thrombocytopenia", ".", "Argatroban", "is", "a", "hepatically", "metabolized", ",", "direct", "thrombin", "inhibitor", "used", "for", "prophylaxis", "or", "treatment", "of", "thrombosis", "in", "heparin", "-", "induced", "thrombocytopenia", "(", "HIT", ")", "and", "for", "patients", "with", "or", "at", "risk", "of", "HIT", "undergoing", "percutaneous", "coronary", "intervention", "(", "PCI", ")", ".", "The", "objective", "of", "this", "review", "is", "to", "summarize", "practical", "considerations", "of", "argatroban", "therapy", "in", "HIT", ".", "The", "US", "FDA", "-", "recommended", "argatroban", "dose", "in", "HIT", "is", "2", "microg", "/", "kg", "/", "min", "(", "reduced", "in", "patients", "with", "hepatic", "impairment", "and", "in", "paediatric", "patients", ")", ",", "adjusted", "to", "achieve", "activated", "partial", "thromboplastin", "times", "(", "aPTTs", ")", "1", ".", "5", "-", "3", "times", "baseline", "(", "not", ">", "100", "seconds", ")", ".", "Contemporary", "experiences", "indicate", "that", "reduced", "doses", "are", "also", "needed", "in", "patients", "with", "conditions", "associated", "with", "hepatic", "hypoperfusion", ",", "e", ".", "g", ".", "heart", "failure", ",", "yet", "are", "unnecessary", "for", "renal", "dysfunction", ",", "adult", "age", ",", "sex", ",", "race", "/", "ethnicity", "or", "obesity", ".", "Argatroban", "0", ".", "5", "-", "1", ".", "2", "microg", "/", "kg", "/", "min", "typically", "supports", "therapeutic", "aPTTs", ".", "The", "FDA", "-", "recommended", "dose", "during", "PCI", "is", "25", "microg", "/", "kg", "/", "min", "(", "350", "microg", "/", "kg", "initial", "bolus", ")", ",", "adjusted", "to", "achieve", "activated", "clotting", "times", "(", "ACTs", ")", "of", "300", "-", "450", "sec", ".", "For", "PCI", ",", "argatroban", "has", "not", "been", "investigated", "in", "hepatically", "impaired", "patients", ";", "dose", "adjustment", "is", "unnecessary", "for", "adult", "age", ",", "sex", ",", "race", "/", "ethnicity", "or", "obesity", ",", "and", "lesser", "doses", "may", "be", "adequate", "with", "concurrent", "glycoprotein", "IIb", "/", "IIIa", "inhibition", ".", "Argatroban", "prolongs", "the", "International", "Normalized", "Ratio", ",", "and", "published", "approaches", "for", "monitoring", "the", "argatroban", "-", "to", "-", "warfarin", "transition", "should", "be", "followed", ".", "Major", "bleeding", "with", "argatroban", "is", "0", "-", "10", "%", "in", "the", "non", "-", "interventional", "setting", "and", "0", "-", "5", ".", "8", "%", "periprocedurally", ".", "Argatroban", "has", "no", "specific", "antidote", ",", "and", "if", "excessive", "anticoagulation", "occurs", ",", "argatroban", "infusion", "should", "be", "stopped", "or", "reduced", ".", "Improved", "familiarity", "of", "healthcare", "professionals", "with", "argatroban", "therapy", "in", "HIT", ",", "including", "in", "special", "populations", "and", "during", "PCI", ",", "may", "facilitate", "reduction", "of", "harm", "associated", "with", "HIT", "(", "e", ".", "g", ".", "fewer", "thromboses", ")", "or", "its", "treatment", "(", "e", ".", "g", ".", "fewer", "argatroban", "medication", "errors", ")", "."]], "ner": [[[9, 9, "Chemical"], [17, 17, "Chemical"], [69, 69, "Chemical"], [79, 79, "Chemical"], [170, 170, "Chemical"], [229, 229, "Chemical"], [269, 269, "Chemical"], [282, 282, "Chemical"], [295, 295, "Chemical"], [316, 316, "Chemical"], [328, 328, "Chemical"], [342, 342, "Chemical"], [380, 380, "Chemical"], [293, 293, "Disease"], [15, 15, "Disease"], [37, 37, "Disease"], [39, 39, "Disease"], [49, 49, "Disease"], [72, 72, "Disease"], [82, 82, "Disease"], [345, 345, "Disease"], [362, 362, "Disease"], [32, 32, "Disease"], [95, 96, "Disease"], [149, 150, "Disease"], [156, 157, "Disease"], [168, 168, "Disease"], [253, 253, "Disease"], [12, 12, "Chemical"], [34, 34, "Chemical"], [286, 286, "Chemical"]]], "relations": [[[9, 9, 293, 293, "CID"], [17, 17, 293, 293, "CID"], [69, 69, 293, 293, "CID"], [79, 79, 293, 293, "CID"], [170, 170, 293, 293, "CID"], [229, 229, 293, 293, "CID"], [269, 269, 293, 293, "CID"], [282, 282, 293, 293, "CID"], [295, 295, 293, 293, "CID"], [316, 316, 293, 293, "CID"], [328, 328, 293, 293, "CID"], [342, 342, 293, 293, "CID"], [380, 380, 293, 293, "CID"]]], "clusters": [], "translated": "减少与抗凝相关的危害：<0>阿加曲班</0>治疗<28>肝素</28>引起的<14>血小板减少症</14>的实际考虑。 <1>阿加曲班</1>是一种肝代谢的直接凝血酶抑制剂，用于预防或治疗<29>肝素</29>引起的<15>血小板减少症</15><22>血栓形成</22>（ <16>HIT</16>) 以及患有<17>HIT</17> 或有风险的患者接受经皮冠状动脉介入治疗 (PCI)。本综述的目的是总结 <18> HIT </18> 中 <2> 阿加曲班 </2> 治疗的实际考虑因素。美国 FDA 推荐的 <3> 阿加曲班 </3> 在 <19> HIT </19> 中的剂量为 2 微克/千克/分钟（<23> 肝功能不全</23> 患者和儿科患者减少），调整后达到活化部分凝血活酶时间（aPTTs） 1． 5-3 倍基线（不>100 秒）。当代经验表明，患有与肝脏低灌注相关的病症的患者也需要减少剂量，例如。 G 。 <24>心力衰竭</24>，但对于<25>肾功能不全</25>、成年年龄、性别、种族/族裔或<26>肥胖</26>是不必要的。 <4>阿加曲班</4> 0 . 5 - 1 。 2 微克/千克/分钟通常支持治疗性 aPTT。 FDA 推荐的 PCI 期间剂量为 25 微克/千克/分钟（初始剂量为 350 微克/千克），调整后可使活化凝血时间 (ACT) 达到 300-450 秒。对于 PCI，<5>阿加曲班</5>尚未在肝功能受损患者中进行过研究；对于成年年龄、性别、种族/族裔或<27>肥胖</27>，无需调整剂量，同时抑制糖蛋白 IIb/IIIa 时，较小的剂量可能就足够了。 <6>阿加曲班</6>延长国际标准化比值，应遵循已发表的监测<7>阿加曲班</7>到<30>华法林</30>转变的方法。 <8>阿加曲班</8>的主要<13>出血</13>在非干预环境中为0-10%，0-5。围手术期 8%。 <9>阿加曲班</9>无特异性解毒剂，如发生过度抗凝，应停止或减量<10>阿加曲班</10>输注。提高医疗保健专业人员对 <20> HIT </20> 中的 <11> 阿加曲班 </11> 治疗的熟悉程度，包括特殊人群和 PCI 期间，可能有助于减少与 <21> HIT </21> 相关的危害（ e .g. 更少的血栓形成）或其治疗（例如更少的<12>阿加曲班</12>用药错误）。", "revised": true}
